PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kurban, G; Duplan, E; Ramlal, N; Hudon, V; Sado, Y; Ninomiya, Y; Pause, A				Kurban, G.; Duplan, E.; Ramlal, N.; Hudon, V.; Sado, Y.; Ninomiya, Y.; Pause, A.			Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2	ONCOGENE			English	Article						VHL; collagen IV; extracellular matrix; renal cell carcinoma	FIBRONECTIN MATRIX; REGULATE HIF; TUMORIGENESIS; ANGIOGENESIS; INHIBITION; THERAPY; DISEASE; COMPLEX; GENE; IV	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene predisposes to vascular tumor formation in several organs. VHL regulates two evolutionary conserved pathways: the targeting of hydroxylated hypoxia-inducible factor-alpha (HIF-alpha) for proteasomal degradation and the remodeling of extracellular matrix (ECM). The biochemical mechanisms of the ECM assembly pathway remain poorly defined. Here, we provide evidence supporting a biochemical role for VHL in ECM assembly. We show that VHL directly binds to the collagen IV alpha 2 (COL4A2) chain and that this interaction is necessary for its assembly into the ECM. The VHL-COL4A2 interaction is dependent on endoplasmic reticulum (ER)mediated COL4A2 hydroxylation and independent of cytosolic, hypoxia regulated HIF-alpha-modifying enzymes. We find that the N-terminal tail of COL4A2 protrudes from the ER lumen into the cytosol where it is bound by VHL. Failure of VHL to interact with COL4A2 correlates with loss of collagen IV network formation in vitro and collagen IV remodeling in vivo. Our data suggest a HIF-alpha-independent role for the VHL-COL4A2 interaction in suppression of angiogenic tumor formation through collagen IV network assembly.	[Kurban, G.; Duplan, E.; Ramlal, N.; Hudon, V.; Pause, A.] McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Sado, Y.] Shigei Med Res Inst, Div Immunol, Okayama, Japan; [Ninomiya, Y.] Okayama Univ, Dept Mol Biol & Biochem, Grad Sch Med, Okayama, Japan	McGill University; Okayama University	Pause, A (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, McIntyre Bldg,3655 Sir William Osler Promenade,Ro, Montreal, PQ H3G 1Y6, Canada.	arnim.pause@mcgill.ca	Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507				Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Grosfeld A, 2007, J BIOL CHEM, V282, P13264, DOI 10.1074/jbc.M611648200; Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Soder S, 2004, BIOCHEM BIOPH RES CO, V325, P276, DOI 10.1016/j.bbrc.2004.10.034; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Zimmer M, 2004, MOL CANCER RES, V2, P89	21	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					1004	1012		10.1038/sj.onc.1210709	http://dx.doi.org/10.1038/sj.onc.1210709			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700531				2022-12-25	WOS:000252946300012
J	Mano, I; Straud, S; Driscoll, M				Mano, Itzhak; Straud, Sarah; Driscoll, Monica			Caenorhabditis elegans glutamate transporters influence synaptic function and behavior at sites distant from the synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; CHLORIDE CHANNEL; NERVOUS-SYSTEM; HOMOLOG; SUBUNIT; PROTEIN; CLONING; NEUROTRANSMISSION; SENSITIVITY; GENETICS	To ensure precise neurotransmission and prevent neurotoxic accumulation, L-glutamate (Glu), the major excitatory neurotransmitter in the brain, is cleared from the synapse by glutamate transporters (GluTs). The molecular components of Glu synapses are highly conserved between Caenorhabditis elegans and mammals, yet the absence of synaptic insulation in C. elegans raises fundamental questions about Glu clearance strategies in the nematode nervous system. To gain insight into how Glu clearance is accomplished and how GluTs impact neurotransmission, we probed expression and function of all 6 GluTs found in the C. elegans genome. Disruption of each GluT impacts multiple Glu-dependent behaviors, with GluT combinations commonly increasing the severity of behavioral deficits. Interestingly, the sole GluT that we find expressed in neurons is localized predominantly in presynaptic neurons, in contrast to the postsynaptic concentration of neuronal GluTs typical in mammals. Moreover, 3 of the 6 GluT genes appear strongly expressed on the capillary excretory canal cell, where they affect Glu-dependent behaviors from positions distal to glutamatergic circuits. Indeed, our focused study of GLT-3, one of the distally expressed GluTs, shows that despite this distance, GLT-3 function can balance the activity mediated by synaptic release and synaptic receptors. The effects of distal GluTs on glutamatergic circuits support that Glu diffusion outside the vicinity of the synapse is a critical factor in C. elegans neurotransmission. Together with the presynaptic localization of neuronal GluTs, these observations suggest an unusual strategy for Glu clearance in C. elegans.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	Rutgers State University New Brunswick; University of Texas System; University of Texas Southwestern Medical Center Dallas	Driscoll, M (corresponding author), 604 Allison Rd, Piscataway, NJ 08854 USA.	driscoll@biology.rutgers.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046154, R37HL046154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034435, R01NS041632] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46154] Funding Source: Medline; NINDS NIH HHS [NS 41632, NS 34435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; Arnth-Jensen N, 2002, NAT NEUROSCI, V5, P325, DOI 10.1038/nn825; Barger AJ, 1998, J NEUROSCI, V18, P2871; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; BIANCHI L, 2004, TRANSDUCTION CHANNEL, P1; Boulin Thomas, 2006, WormBook, P1, DOI 10.1895/wormbook.1.106.1; Brockie Penelope J, 2006, WormBook, P1; Brockie PJ, 2001, NEURON, V31, P617, DOI 10.1016/S0896-6273(01)00394-4; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chaudhry FA, 2002, J CELL BIOL, V157, P349, DOI 10.1083/jcb.200201070; Chen WZ, 2004, J NEUROSCI, V24, P1136, DOI 10.1523/JNEUROSCI.1586-03.2004; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Hasegawa J, 2006, NEURON, V50, P63, DOI 10.1016/j.neuron.2006.02.022; He Y, 2000, J COMP NEUROL, V418, P255; Hope IA, 2004, GENOME RES, V14, P2070, DOI 10.1101/gr.2463804; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Kanner BI, 2002, BBA-BIOENERGETICS, V1555, P92, DOI 10.1016/S0005-2728(02)00260-8; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kawano T, 1996, BIOCHEM BIOPH RES CO, V228, P415, DOI 10.1006/bbrc.1996.1676; Kawano T, 1997, BIOSCI BIOTECH BIOCH, V61, P927, DOI 10.1271/bbb.61.927; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Mellem JE, 2002, NEURON, V36, P933, DOI 10.1016/S0896-6273(02)01088-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Radice AD, 1996, MOL BIOCHEM PARASIT, V80, P41, DOI 10.1016/0166-6851(96)02667-9; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zheng Y, 1999, NEURON, V24, P347, DOI 10.1016/S0896-6273(00)80849-1; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	42	29	41	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2007	282	47					34412	34419		10.1074/jbc.M704134200	http://dx.doi.org/10.1074/jbc.M704134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234FI	17681948	hybrid			2022-12-25	WOS:000251145700057
J	Kypriotou, M; Beauchef, G; Chadjichristos, C; Widom, R; Renard, E; Jimenez, SA; Korn, J; Maquart, FX; Oddos, T; Von Stetten, O; Pujol, JP; Galera, P				Kypriotou, Magdalini; Beauchef, Gallic; Chadjichristos, Christos; Widom, Russell; Renard, Emmanuelle; Jimenez, Sergio A.; Korn, Joseph; Maquart, Francois-Xavier; Oddos, Thierry; Von Stetten, Otto; Pujol, Jean-Pierre; Galera, Philippe			Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and Sp3 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA 2(I) COLLAGEN; HUMAN COL2A1 GENE; C-KROX; FACTOR YY1; DERMAL FIBROBLASTS; PROMOTER ACTIVITY; DOWN-REGULATION; COL1A1; BINDING; ELEMENTS	Despite several investigations, the transcriptional mechanisms that regulate the expression of both type I collagen genes (COL1A1 and COL1A2) in either physiological or pathological situations, such as scleroderma, are not completely known. We have investigated the role of hc-Krox transcription factor on type I collagen expression by human dermal fibroblasts. hc-Krox exerted a stimulating effect on type I collagen protein synthesis and enhanced the corresponding mRNA steady-state levels of COL1A1 and COL1A2 in foreskin fibroblasts (FF), adult normal fibroblasts (ANF), and scleroderma fibroblasts (SF). Forced hc-Krox expression was found to up-regulate COL1A1 transcription through a -112/-61-bp sequence in FF, ANF, and SF. Knockdown of hc-Krox by short interfering RNA and decoy strategies confirmed the transactivating effect of hc-Krox and decreased substantially COL1A1 transcription levels in all fibroblast types. The -112/-61-bp sequence bound specifically hc-Krox but also Sp1 and CBF. Attempts to elucidate the potential interactions between hc-Krox, Sp1, and Sp3 revealed that all of them co-immunoprecipitate from FF cellular extracts when a c-Krox antibody was used and bind to the COL1A1 promoter in chromatin immunoprecipitation assays. Moreover, hc-Krox DNA binding activity to its COL1A1-responsive element is increased in SF, cells producing higher amounts of type I collagen compared with ANF and FF. These data suggest that the regulation of COL1A1 gene transcription in human dermal fibroblasts involves a complex machinery that implicates at least three transcription proteins, hc-Krox, Sp1, and Sp3, which could act in concert to up-regulate COL1A1 transcriptional activity and provide evidence for a pro-fibrotic role of hc-Krox.	Johnson & Johnson Consumer France, R & D Europe, F-27100 Val De Reuil, France; Univ Caen Basse Normandie, Lab Biochim Tissu Conjonctif, Fac Med, CHU Niveau 3, F-14032 Caen, France; Boston Univ, Sch Med, Dept Med, Ctr Arthritis, Boston, MA 02118 USA; Boston Vet Affairs Med Ctr, Boston, MA 02118 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19017 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Biol, Philadelphia, PA 19017 USA; UFR Med, IFR Biomol 53, CNRS, FRE 2534,Lab Biochim Med & Biol Mol, F-51095 Reims, France	Johnson & Johnson; CHU de Caen NORMANDIE; Universite de Caen Normandie; Boston University; Jefferson University; Jefferson University; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Galera, P (corresponding author), Johnson & Johnson Consumer France, R & D Europe, Campus Maigremont, F-27100 Val De Reuil, France.	philippe.galera@unicaen.fr	Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Jimenez, Sergio/0000-0001-5213-1203				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Artlett CM, 1998, MATRIX BIOL, V17, P425, DOI 10.1016/S0945-053X(98)90102-0; Beauchef G, 2005, BIOCHEM BIOPH RES CO, V333, P1123, DOI 10.1016/j.bbrc.2005.06.020; Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cicchillitti L, 2004, BIOCHEM J, V378, P609, DOI 10.1042/BJ20031110; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; FERRARINI M, 1990, CLIN EXP IMMUNOL, V79, P346; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GALERA P, 1994, M S-MED SCI, V10, P1253, DOI 10.4267/10608/2564; Garcia Ruiz Inmaculada, 2000, DNA and Cell Biology, V19, P167; Garcia-Ruiz I, 2002, J BIOL CHEM, V277, P30551, DOI 10.1074/jbc.M203368200; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; He X, 2005, NATURE, V433, P826, DOI 10.1038/nature03338; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ihn H, 2001, J INVEST DERMATOL, V117, P301, DOI 10.1046/j.0022-202x.2001.01371.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; LEE B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P173; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE TC, 1994, ONCOGENE, V9, P1047; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Rincon-Arano H, 2005, J MOL BIOL, V349, P961, DOI 10.1016/j.jmb.2005.04.040; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; Sorrell JM, 2004, J CELL SCI, V117, P667, DOI 10.1242/jcs.01005; Sun GP, 2005, NAT IMMUNOL, V6, P373, DOI 10.1038/ni1183; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Weill L, 2003, J VIROL, V77, P2903, DOI 10.1128/JVI.77.5.2903-2914.2003; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706	56	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					32000	32014		10.1074/jbc.M705197200	http://dx.doi.org/10.1074/jbc.M705197200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17698844	hybrid, Green Submitted			2022-12-25	WOS:000250480300021
J	Devos, JM; Tomanicek, SJ; Jones, CE; Nossal, NG; Mueser, TC				Devos, Juliette M.; Tomanicek, Stephen J.; Jones, Charles E.; Nossal, Nancy G.; Mueser, Timothy C.			Crystal structure of bacteriophage T4 5' nuclease in complex with a branched DNA reveals how flap endonuclease-1 family nucleases bind their substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATION PROTEIN-A; T4 RNASE-H; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; PCNA BINDING; FEN-1; STIMULATION; EXONUCLEASE; CATALYSIS	Bacteriophage T4 RNase H, a flap endonuclease- 1 family nuclease, removes RNA primers from lagging strand fragments. It has both 5' nuclease and flap endonuclease activities. Our previous structure of native T4 RNase H(PD B code 1TFR) revealed an active site composed of highly conserved Asp residues and two bound hydrated magnesium ions. Here, we report the crystal structure of T4 RNase H in complex with a fork DNA substrate bound in its active site. This is the first structure of a flap endonuclease- 1 family protein with its complete branched substrate. The fork duplex interacts with an extended loop of the helix-hairpin-helix motif class 2. The 5' armcrosses over the active site, extending below the bridge ( helical arch) region. Cleavage assays of this DNA substrate identify a primary cut site 7-bases in from the 5' arm. The scissile phosphate, the first bond in the duplex DNA adjacent to the 5' arm, lies above a magnesium binding site. The less ordered 3' arm reaches toward the C and N termini of the enzyme, which are binding sites for T432 protein and T445 clamp, respectively. In the crystal structure, the scissile bond is located within the double-stranded DNA, between the first two duplex nucleotides next to the 5' arm, and lies above a magnesium binding site. This complex provides important insight into substrate recognition and specificity of the flap endonuclease- 1 enzymes.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA; NIDDK, NIH, Mol & Cellular Biol Lab, Bethesda, MD 20892 USA	University System of Ohio; University of Toledo; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mueser, TC (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.	timothy.mueser@utoledo.edu	Jones, Charles/GVS-9497-2022		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057816] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Brosh RM, 2001, EMBO J, V20, P5791; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Cowan JA, 2002, BIOMETALS, V15, P225, DOI 10.1023/A:1016022730880; Dervan JJ, 2002, P NATL ACAD SCI USA, V99, P8542, DOI 10.1073/pnas.082241699; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Feng M, 2004, NAT STRUCT MOL BIOL, V11, P450, DOI 10.1038/nsmb754; Gangisetty O, 2005, J BIOL CHEM, V280, P12876, DOI 10.1074/jbc.M414025200; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Matsui E, 2002, J BIOL CHEM, V277, P37840, DOI 10.1074/jbc.M205235200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Qiu JZ, 2004, J BIOL CHEM, V279, P24394, DOI 10.1074/jbc.M401464200; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Sharma S, 2005, NUCLEIC ACIDS RES, V33, P6769, DOI 10.1093/nar/gki1002; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; Sun SY, 2003, J BIOL CHEM, V278, P3876, DOI 10.1074/jbc.M210497200; Tock MR, 2003, EMBO J, V22, P995, DOI 10.1093/emboj/cdg098; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Woodworth DL, 1996, GENETICS, V143, P1081; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013	55	43	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31713	31724		10.1074/jbc.M703209200	http://dx.doi.org/10.1074/jbc.M703209200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17693399	hybrid			2022-12-25	WOS:000250309200062
J	Rogers, K; Gao, GH; Simpson, L				Rogers, Kestrel; Gao, Guanghan; Simpson, Larry			Uridylate-specific 3 '-5 '-exoribonucleases involved in uridylate-deletion RNA editing in trypanosomatid mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; MESSENGER-RNA; DNA-REPAIR; LEISHMANIA-TARENTOLAE; U-DELETION; IN-VITRO; BRUCEI; COMPLEX; IDENTIFICATION; EXONUCLEASE	In kinetoplastid protists, maturation of mitochondrial pre-mRNAs involves the insertion and deletion of uridylates (Us) within coding regions, as specified by mitochondrial DNA-encoded guide RNAs. U-deletion editing involves endonucleolytic cleavage of the pre-mRNA at the editing site followed by U-specific 3'-5'-exonucleolytic removal of nonbase-paired Us prior to ligation of the two mRNA cleavage fragments. We showed previously that an exonuclease/endonuclease/phosphatase (EEP) motif protein from Leishmania major, designated RNA editing exonuclease 1 (REX1) (Kang, X., Rogers, K., Gao, G., Falick, A. M., Zhou, S.-L., and Simpson, L. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 1017-1022), exhibits 3'-5'-exonuclease activity. Two EEP motif proteins have also been identified in the Trypanosoma brucei editing complex. TbREX1 is a homologue of LmREX1, and TbREX2 shows homology to another editing protein in L. major, which lacks the EEP motif (LmREX2*). Here we have expressed the T. brucei EEP motif proteins in insect cells and purified them to homogeneity. We showed that these are U-specific 3'-5'-exonucleases that are inhibited by base pairing of 3' Us. The recombinant EEP motif alone also showed 3'-5'-U-specific exonuclease activity, and mutations of the REX EEP motifs greatly reduced exonuclease activity. The absence of enzymatic activity in LmREX2* was confirmed with a purified recombinant protein. We showed that pre-cleaved U-deletion editing could be reconstituted with either TbREX1 or TbREX2 in combination with either RNA ligase, LmREL1, or LmREL2. Down-regulation of TbREX2 expression by conditional RNA interference had little effect on parasite viability or sedimentation of the L-complex, suggesting either that TbREX2 is inactive in vivo or that TbREX1 can compensate for the loss of TbREX2 function in down-regulated cells.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Simpson, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, 1602 Mol Sci Bldg, Los Angeles, CA 90095 USA.	simpson@kdna.ucla.edu		Rogers, Kestrel/0000-0002-0233-3613	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aphasizhev R, 2003, P NATL ACAD SCI USA, V100, P10617, DOI 10.1073/pnas.1833120100; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Carnes J, 2005, P NATL ACAD SCI USA, V102, P16614, DOI 10.1073/pnas.0506133102; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; Gao GH, 2005, P NATL ACAD SCI USA, V102, P4712, DOI 10.1073/pnas.0500553102; Hutchings NR, 2002, J CELL BIOL, V156, P867, DOI 10.1083/jcb.200201036; Igo RP, 2002, EUKARYOT CELL, V1, P112, DOI 10.1128/EC.1.1.112-118.2002; Kang XD, 2005, P NATL ACAD SCI USA, V102, P1017, DOI 10.1073/pnas.0409275102; Kang XD, 2006, P NATL ACAD SCI USA, V103, P13944, DOI 10.1073/pnas.0604476103; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Mian IS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-305; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2006, RNA, V12, P1038, DOI 10.1261/rna.45506; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schimanski B, 2005, EUKARYOT CELL, V4, P1942, DOI 10.1128/EC.4.11.1942-1950.2005; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; Stuart K, 2002, PHILOS T ROY SOC B, V357, P71, DOI 10.1098/rstb.2001.0994; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; Stuart Kenneth, 2004, Methods Mol Biol, V265, P273; Trotter JR, 2005, MOL CELL, V20, P403, DOI 10.1016/j.molcel.2005.09.016; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P6392, DOI 10.1093/nar/gkg870; Zhelonkina AG, 2006, RNA, V12, P476, DOI 10.1261/rna.2243206	42	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29073	29080		10.1074/jbc.M704551200	http://dx.doi.org/10.1074/jbc.M704551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699520	hybrid			2022-12-25	WOS:000249788000002
J	Zimmermann, AK; Loucks, FA; Schroeder, EK; Bouchard, RJ; Tyler, KL; Linseman, DA				Zimmermann, Angela K.; Loucks, F. Alexandra; Schroeder, Emily K.; Bouchard, Ron J.; Tyler, Kenneth L.; Linseman, Daniel A.			Glutathione binding to the Bcl-2 homology-3 domain groove - A molecular basis for Bcl-2 antioxidant function at mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOUSE MODEL; SUPEROXIDE DISMUTASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; MOTOR-NEURONS; APOPTOSIS; DEATH; MICE; CELLS	Bcl-2 protects cells against mitochondrial oxidative stress and subsequent apoptosis. However, the mechanism underlying the antioxidant function of Bcl-2 is currently unknown. Recently, Bax and several Bcl-2 homology-3 domain (BH3)-only proteins (Bid, Puma, and Noxa) have been shown to induce a pro-oxidant state at mitochondria (1-4). Given the opposing effects of Bcl-2 and Bax/BH3-only proteins on the redox state of mitochondria, we hypothesized that the antioxidant function of Bcl-2 is antagonized by its interaction with the BH3 domains of pro-apoptotic family members. Here, we show that BH3 mimetics that bind to a hydrophobic surface (the BH3 groove) of Bcl-2 induce GSH-sensitive mitochondrial dysfunction and apoptosis in cerebellar granule neurons. BH3 mimetics displace a discrete mitochondrial GSH pool in neurons and suppress GSH transport into isolated rat brain mitochondria. Moreover, BH3 mimetics and the BH3-only protein, Bim, inhibit a novel interaction between Bcl-2 and GSH in vitro. These results suggest that Bcl-2 regulates an essential pool of mitochondrial GSH and that this regulation may depend upon Bcl-2 directly interacting with GSH via the BH3 groove. We conclude that this novel GSH binding property of Bcl-2 likely plays a central role in its antioxidant function at mitochondria.	Univ Denver, Eleanor Roosevelt Inst, Denver, CO 80208 USA; Univ Denver, Dept Biol Sci, Denver, CO 80208 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol & Immunol, Denver, CO 80262 USA	University of Denver; University of Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Linseman, DA (corresponding author), Univ Denver, Eleanor Roosevelt Inst, FW Olin Hall,Rm 102,2190 E Iliff Ave, Denver, CO 80208 USA.	daniel.linseman@du.edu	Linseman, Daniel/L-3846-2019; Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050138, R01NS051403] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS051403, R01 NS051403-03, 1R01 NS051403, R01 NS050138, R01 NS050138-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; Hochman A, 1998, J NEUROCHEM, V71, P741; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Kong JM, 1998, J NEUROSCI, V18, P3241; Lash LH, 2006, CHEM-BIOL INTERACT, V163, P54, DOI 10.1016/j.cbi.2006.03.001; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754; Merad-Saidoune M, 1999, EXP NEUROL, V158, P428, DOI 10.1006/exnr.1999.7108; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Petri S, 2006, J NEUROCHEM, V98, P1141, DOI 10.1111/j.1471-4159.2006.04018.x; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Sasaki E, 2003, HISTOCHEM CELL BIOL, V120, P327, DOI 10.1007/s00418-003-0572-x; TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Yang LC, 1998, J NEUROSCI, V18, P8145; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang J, 2000, J NEUROPATH EXP NEUR, V59, P53, DOI 10.1093/jnen/59.1.53	35	113	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29296	29304		10.1074/jbc.M702853200	http://dx.doi.org/10.1074/jbc.M702853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690097	Green Accepted, hybrid			2022-12-25	WOS:000249788000026
J	Carnes, CA; Janssen, PML; Ruehr, ML; Nakayama, H; Nakayama, T; Haase, H; Bauer, JA; Chung, MK; Fearon, IM; Gillinov, AM; Hamlin, RL; Van Wagoner, DR				Carnes, Cynthia A.; Janssen, Paul M. L.; Ruehr, Mary L.; Nakayama, Hitomi; Nakayama, Tomohiro; Haase, Hannelore; Bauer, John Anthony; Chung, Mina K.; Fearon, Ian M.; Gillinov, A. Marc; Hamlin, Robert L.; Van Wagoner, David R.			Atrial glutathione content, calcium current, and contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL ALPHA(1C) SUBUNITS; NITRIC-OXIDE; OXIDATIVE STRESS; CA2+ CHANNEL; RYANODINE RECEPTORS; MOLECULAR-MECHANISMS; VENTRICULAR MYOCYTES; REDOX MODULATION; S-NITROSYLATION; DOWN-REGULATION	Atrial fibrillation (AF) is characterized by decreased L-type calcium current (I-Ca,I-L) in atrial myocytes and decreased atrial contractility. Oxidant stress and redox modulation of calcium channels are implicated in these pathologic changes. We evaluated the relationship between glutathione content (the primary cellular reducing moiety) and I-Ca,I-L in atrial specimens from AF patients undergoing cardiac surgery. Left atrial glutathione content was significantly lower in patients with either paroxysmal or persistent AF relative to control patients with no history of AF. Incubation of atrial myocytes from AF patients (but not controls) with the glutathione precursor N-acetylcysteine caused a marked increase in I-Ca,I-L. To test the hypothesis that glutathione levels were mechanistically linked with the reduction in I-Ca,I-L, dogs were treated for 48 h with buthionine sulfoximine, an inhibitor of glutathione synthesis. Buthiontine sulfoximine treatment resulted in a 24% reduction in canine atrial glutathione content, a reduction in atrial contractility, and an attenuation Of I-Ca,I-L in the canine atrial myocytes. Incubation of these myocytes with exogenous glutathione also restored I-Ca,I-L to normal or greater than normal levels. To probe the mechanism linking decreased glutathione levels to down-regulation Of I-Ca, the biotin switch technique was used to evaluate S-nitrosylation of calcium channels. S-Nitrosylation was apparent in left atrial tissues from AF patients; the extent of S-nitrosylation was inversely related to tissue glutathione content. S-Nitrosylation was also detectable in HEK cells expressing recombinant human cardiac calcium channel subunits following exposure to nitrosoglutathione. S-Nitrosylation may contribute to the glutathione-sensitive attenuation of I-Ca,I-L observed in AF.	Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA; Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Max Delbruck Ctr Mol Med, Berlin, Germany; Ctr Cardiovasc Med, Res Inst, Columbus, OH 43205 USA; Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England	Cleveland Clinic Foundation; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University of Manchester	Van Wagoner, DR (corresponding author), Cleveland Clin, Dept Mol Cardiol, M-S NE-61,9500 Euclid Ave, Cleveland, OH 44195 USA.	vanwagd@ccf.org	Janssen, Paul ML/E-3307-2011; Carnes, Cynthia A/C-9540-2012; Nakayama, Tomohiro/GYU-0303-2022; Van Wagoner, David R/C-6783-2008	Carnes, Cynthia A/0000-0003-0420-6973; Van Wagoner, David R/0000-0001-8250-9828; Janssen, Paul/0000-0002-9682-3014	NHLBI NIH HHS [R01 HL-78316, R01 HL-65412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abete P, 1999, J MOL CELL CARDIOL, V31, P227, DOI 10.1006/jmcc.1998.0862; Adamy C, 2005, ARCH MAL COEUR VAISS, V98, P906; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Bosch RF, 1999, CARDIOVASC RES, V44, P121, DOI 10.1016/S0008-6363(99)00178-9; Bosch RF, 2003, J AM COLL CARDIOL, V41, P858, DOI 10.1016/S0735-1097(02)02922-4; Brundel BJJM, 2002, CARDIOVASC RES, V54, P380, DOI 10.1016/S0008-6363(02)00289-4; Burkard N, 2007, CIRC RES, V100, pE32, DOI 10.1161/01.RES.0000259042.04576.6a; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Cargnoni A, 2002, J MOL CELL CARDIOL, V34, P997, DOI 10.1006/jmcc.2002.2046; Carnes CA, 2001, CIRC RES, V89, pE32, DOI 10.1161/hh1801.097644; Cheong E, 2005, CELL CALCIUM, V38, P481, DOI 10.1016/j.ceca.2005.07.001; Christ T, 2004, CIRCULATION, V110, P2651, DOI 10.1161/01.CIR.0000145659.80212.6A; Chung MK, 2004, NAT CLIN PRACT CARD, V1, P56, DOI 10.1038/ncpcardio0027; CIA H, 2002, CIRCULATION, V106, P2854; De Vecchi E, 1998, HEART, V79, P242, DOI 10.1136/hrt.79.3.242; Dudley SC, 2005, CIRCULATION, V112, P1266, DOI 10.1161/CIRCULATIONAHA.105.538108; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Fearon IM, 2006, CARDIOVASC RES, V69, P855, DOI 10.1016/j.cardiores.2005.11.019; Fearon IM, 1999, J PHYSIOL-LONDON, V514, P629, DOI 10.1111/j.1469-7793.1999.629ad.x; Fukuda K, 2005, CIRC RES, V97, P1262, DOI 10.1161/01.RES.0000195844.31466.e9; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Han D, 2006, AM J PHYSIOL-GASTR L, V291, pG1, DOI 10.1152/ajpgi.00001.2006; Hidalgo C, 2005, IUBMB LIFE, V57, P315, DOI 10.1080/15216540500092328; Hool LC, 2002, CIRC RES, V91, P601, DOI 10.1161/01.RES.0000035528.00678.D5; Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200; Hudasek K, 2004, BIOCHEM BIOPH RES CO, V318, P135, DOI 10.1016/j.bbrc.2004.04.011; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAFFREY SR, 2001, SCI STKE 2001, P61; Janssen PML, 1999, J MOL CELL CARDIOL, V31, P1419, DOI 10.1006/jmcc.1999.0978; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; Leung JM, 2004, EUR HEART J, V25, P1836, DOI 10.1016/j.ehj.2004.07.014; Levy S, 1997, PACE, V20, P2670, DOI 10.1111/j.1540-8159.1997.tb06115.x; Li SM, 2003, J MOL CELL CARDIOL, V35, P1145, DOI 10.1016/S0022-2828(03)00230-X; Liu HJ, 2005, CIRC RES, V97, P967, DOI 10.1161/01.RES.0000188210.72062.10; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Martin-Gallan P, 2003, FREE RADICAL BIO MED, V34, P1563, DOI 10.1016/S0891-5849(03)00185-0; Mihm MJ, 2001, CIRCULATION, V104, P174, DOI 10.1161/01.CIR.104.2.174; Mueller CFH, 2005, CIRC RES, V97, P637, DOI 10.1161/01.RES.0000183734.21112.b7; Pacher P, 2006, CURR OPIN PHARMACOL, V6, P136, DOI 10.1016/j.coph.2006.01.001; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; Schotten U, 2003, J MOL CELL CARDIOL, V35, P437, DOI 10.1016/S0022-2828(03)00012-9; Schotten U, 2003, CIRCULATION, V107, P1433, DOI 10.1161/01.CIR.0000055314.10801.4F; Schotten U, 2001, CIRCULATION, V103, P691; Skasa M, 2001, BASIC RES CARDIOL, V96, P151, DOI 10.1007/s003950170065; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; STIO M, 1994, BIOCHEM CELL BIOL, V72, P58, DOI 10.1139/o94-010; Sun JH, 2006, CIRC RES, V98, P403, DOI 10.1161/01.RES.0000202707.79018.0a; Takimoto E, 2005, J CLIN INVEST, V115, P1221, DOI 10.1172/JCI200521968; Van Wagoner DR, 1999, CIRC RES, V85, P428, DOI 10.1161/01.RES.85.5.428; Van Wagoner DR, 2001, J CARDIOVASC ELECTR, V12, P183; Whiteman M, 2006, BIOCHEM BIOPH RES CO, V339, P255, DOI 10.1016/j.bbrc.2005.10.200; Xu Z, 2002, CARDIOVASC RES, V53, P80, DOI 10.1016/S0008-6363(01)00446-1; Yagi T, 2002, CARDIOVASC RES, V54, P405, DOI 10.1016/S0008-6363(02)00279-1; Yue LX, 1999, CIRC RES, V84, P776; Yue LX, 1997, CIRC RES, V81, P512, DOI 10.1161/01.RES.81.4.512	56	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28063	28073		10.1074/jbc.M704893200	http://dx.doi.org/10.1074/jbc.M704893200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656369	hybrid			2022-12-25	WOS:000249455600056
J	Valmsen, K; Boeglin, WE; Jarving, R; Jarving, I; Varvas, K; Brash, AR; Samel, N				Valmsen, Karin; Boeglin, William E.; Jarving, Reet; Jarving, Ivar; Varvas, Kuelliki; Brash, Alan R.; Samel, Nigulas			A critical role of non-active site residues on cyclooxygenase helices 5 and 6 in the control of prostaglandin stereochemistry at carbon 15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; CORAL PLEXAURA-HOMOMALLA; MOLECULAR-CLONING; ARACHIDONIC-ACID; MECHANISM; BINDING; BIOSYNTHESIS; OXYGENATION; EXPRESSION	The correct stereochemistry of prostaglandins is a prerequisite of their biological activity and thus is under a strict enzymatic control. Recently, we cloned and characterized two cyclooxygenase (COX) isoforms in the coral Plexaura homomalla that share 97% amino acid sequence identity, yet form prostaglandins with opposite stereochemistry at carbon 15. The difference in oxygenation specificity is only partially accounted for by the single amino acid substitution in the active site (Ile or Val at position 349). For further elucidation of residues involved in the C-15 stereocontrol, a series of sequence swapping and site-directed mutagenesis experiments between 15R- and 15S-COX were performed. Our results show that the change in stereochemistry at carbon 15 of prostaglandins relates mainly to five amino acid substitutions on helices 5 and 6 of the coral COX. In COX proteins, these helices form a helix-turn-helix motif that traverses through the entire protein, contributing to the second shell of residues around the oxygenase active site; it constitutes the, most highly conserved region where even slight changes result in loss of catalytic activity. The finding that this region is among the least conserved between the P. homomalla 15S- and 15R-specific COX further supports its significance in maintaining. the desired prostaglandin stereochernistry at C-15. The results are particularly remarkable because, based on its strong conservation, the conserved middle of helix 5 is considered as central to the core structure of peroxidases, of which COX proteiris are derivatives. Now we show that the same parts of the protein are involved in the control of oxygenation with 15R or 15S stereospecificity in the dioxygenase active site.	Tallinn Univ Technol, EE-12618 Tallinn, Estonia; Tallinn Univ Technol, Dept Chem, EE-12618 Tallinn, Estonia; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA	Tallinn University of Technology; Tallinn University of Technology; Vanderbilt University	Samel, N (corresponding author), Tallinn Univ Technol, Akadeemia tee 15, EE-12618 Tallinn, Estonia.	samel@chemnet.ee	Samel, Nigulas/A-1420-2019	Valmsen, Karin/0000-0001-5303-6654	NIGMS NIH HHS [GM-53638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Daiyasu H, 2000, J MOL EVOL, V51, P433, DOI 10.1007/s002390010106; Garavito RM, 2003, ANNU REV BIOPH BIOM, V32, P183, DOI 10.1146/annurev.biophys.32.110601.141906; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KENNEDY TA, 1994, J BIOL CHEM, V269, P27357; Koljak R, 2001, J BIOL CHEM, V276, P7033, DOI 10.1074/jbc.M009803200; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LIGHT RJ, 1972, EUR J BIOCHEM, V28, P232, DOI 10.1111/j.1432-1033.1972.tb01906.x; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NAKANO J, 1972, BRIT J PHARMACOL, V44, P63, DOI 10.1111/j.1476-5381.1972.tb07238.x; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; SCHNEIDER WP, 1972, J AM CHEM SOC, V94, P2122, DOI 10.1021/ja00761a060; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Valmsen K, 2004, EUR J BIOCHEM, V271, P3533, DOI 10.1111/j.0014-2956.2004.04289.x; Valmsen K, 2001, P NATL ACAD SCI USA, V98, P7700, DOI 10.1073/pnas.131022398; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; Varvas K, 1999, J BIOL CHEM, V274, P9923, DOI 10.1074/jbc.274.15.9923; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185	28	3	3	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28157	28163		10.1074/jbc.M704950200	http://dx.doi.org/10.1074/jbc.M704950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652088	hybrid			2022-12-25	WOS:000249455600065
J	Chang, EJ; Begum, R; Chait, BT; Gaasterland, T				Chang, Emmanuel J.; Begum, Rashida; Chait, Brian T.; Gaasterland, Terry			Prediction of Cyclin-Dependent Kinase Phosphorylation Substrates	PLOS ONE			English	Article							CDC28 PROTEIN-KINASE; HIDDEN MARKOV-MODELS; YEAST-CELL CYCLE; MASS-SPECTROMETRY; BUDDING YEAST; MULTISITE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; STRUCTURAL BASIS; DNA-REPLICATION	Protein phosphorylation, mediated by a family of enzymes called cyclin-dependent kinases (Cdks), plays a central role in the cell-division cycle of eukaryotes. Phosphorylation by Cdks directs the cell cycle by modifying the function of regulators of key processes such as DNA replication and mitotic progression. Here, we present a novel computational procedure to predict substrates of the cyclin-dependent kinase Cdc28 (Cdk1) in the Saccharomyces cerevisiae. Currently, most computational phosphorylation site prediction procedures focus solely on local sequence characteristics. In the present procedure, we model Cdk substrates based on both local and global characteristics of the substrates. Thus, we define the local sequence motifs that represent the Cdc28 phosphorylation sites and subsequently model clustering of these motifs within the protein sequences. This restraint reflects the observation that many known Cdk substrates contain multiple clustered phosphorylation sites. The present strategy defines a subset of the proteome that is highly enriched for Cdk substrates, as validated by comparing it to a set of bona fide, published, experimentally characterized Cdk substrates which was to our knowledge, comprehensive at the time of writing. To corroborate our model, we compared its predictions with three experimentally independent Cdk proteomic datasets and found significant overlap. Finally, we directly detected in vivo phosphorylation at Cdk motifs for selected putative substrates using mass spectrometry.	[Chang, Emmanuel J.; Begum, Rashida] CUNY York Coll, Dept Chem, Jamaica, NY 11451 USA; [Chang, Emmanuel J.; Chait, Brian T.] Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA; [Gaasterland, Terry] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	City University of New York (CUNY) System; York College NY (CUNY); Rockefeller University; University of California System; University of California San Diego; Scripps Institution of Oceanography	Chang, EJ (corresponding author), CUNY York Coll, Dept Chem, Jamaica, NY 11451 USA.	echang@york.cuny.edu			Burroughs-Wellcome Interfaces in Science; State of New York; National Institutes of Health [RR00862]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER	Burroughs-Wellcome Interfaces in Science(Burroughs Wellcome Fund); State of New York; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	EJC was supported in part by a Burroughs-Wellcome Interfaces in Science fellowship, and a Graduate Research Technology Initiative grant from the State of New York. BTC acknowledges support from the National Institutes of Health (Grant RR00862).	Agarwal R, 2002, GENE DEV, V16, P1371, DOI 10.1101/gad.971402; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; Archambault V, 2004, MOL CELL, V14, P699, DOI 10.1016/j.molcel.2004.05.025; Aubol BE, 2002, BIOCHEMISTRY-US, V41, P10002, DOI 10.1021/bi020233y; Azzam R, 2004, SCIENCE, V305, P516, DOI 10.1126/science.1099402; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Chang EJ, 2004, ANAL CHEM, V76, P4472, DOI 10.1021/ac049637h; Chen SL, 2002, MOL CELL PROTEOMICS, V1, P186, DOI 10.1074/mcp.M100032-MCP200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; Cross FR, 2002, MOL BIOL CELL, V13, P52, DOI 10.1091/mbc.01-05-0265; Doolin MT, 2001, MOL MICROBIOL, V40, P422, DOI 10.1046/j.1365-2958.2001.02388.x; ELASSER S, 1996, MOL BIOL CELL, V7, P1723; Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Ho W, 1999, MOL CELL BIOL, V19, P5267; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hollunder J, 2005, PROTEOMICS, V5, P2082, DOI 10.1002/pmic.200401121; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Holmes JK, 2001, EUR J BIOCHEM, V268, P4647, DOI 10.1046/j.1432-1327.2001.02392.x; Huang HD, 2005, NUCLEIC ACIDS RES, V33, pW226, DOI 10.1093/nar/gki471; Huang HD, 2005, J COMPUT CHEM, V26, P1032, DOI 10.1002/jcc.20235; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; JEFFERY D, 2001, J MOL BIOL, V306; Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731; Jones D T, 2001, Brief Bioinform, V2, P111, DOI 10.1093/bib/2.2.111; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McBride HJ, 1999, J BIOL CHEM, V274, P21029, DOI 10.1074/jbc.274.30.21029; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moses AM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r23; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393, DOI 10.1091/mbc.9.9.2393; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Senawongse P, 2005, J CHEM INF MODEL, V45, P1147, DOI 10.1021/ci050047+; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Velazquez-Dones A, 2005, J BIOL CHEM, V280, P41761, DOI 10.1074/jbc.M504156200; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wu CH, 1997, COMPUT CHEM, V21, P237, DOI 10.1016/S0097-8485(96)00038-1; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	67	23	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e656	10.1371/journal.pone.0000656	http://dx.doi.org/10.1371/journal.pone.0000656			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668044	Green Published, gold			2022-12-25	WOS:000207452300002
J	Cheeran, A; Kolli, NR; Sen, R				Cheeran, Anoop; Kolli, Nanci R.; Sen, Ranjan			The site of action of the antiterminator protein N from the lambdoid phage H-19B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; TRANSCRIPT CLEAVAGE FACTORS; 3.3 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; PHAGE-LAMBDA; ELONGATION COMPLEX; ALPHA-SUBUNIT; NASCENT RNA; DNA HYBRID	Transcription antitermination by N proteins of lambdoid phages involves specific interactions of the C-terminal domain of N with the elongation complex (EC). The interacting surface of N on the EC is unknown, knowledge of which is essential to understand the mechanism of antitermination. Specific cleavage patterns were generated near the active site Mg2+ of the RNA polymerase of an N-modified stalled EC using iron-(S)-1-(p-bromoacetamidobenzyl) ethylenediaminetetraacetate conjugated to the only cysteine residue in the C-terminal domain of N from a lambdoid phage H-19B. Modification of EC by N also induced conformational changes around the same region as revealed from the limited trypsin digestion and in situ Fe-dithiothreitol cleavage pattern of the same EC. These data, together with the previously obtained H-19B N-specific mutations in RNA polymerase, beta(G1045D), and beta '(P251S, P254L, G336S, and R270C) subunits, suggest that the active center cleft of the EC could be the site of action of this antiterminator. H-19B N induced altered interactions in this region of EC, prevented the backtracking of the stalled EC at the ops pause site and destabilized RNA hairpin-beta subunit flap domain interactions at the his pause site. We propose that the physical proximity of the C-terminal domain of H-19B N to the active center cleft of the EC is required for the process of transcription antitermination and that it involves both stabilization of the weak RNA-DNA hybrid at a terminator and destabilization of the interactions of terminator hairpin in the RNA exit channel.	Ctr DNA Fingerpriting & Diagnost, Lab Transcript Biol, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Sen, R (corresponding author), Ctr DNA Fingerpriting & Diagnost, Lab Transcript Biol, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.	rsen@cdfd.org.in	Sen, Ranjan/AAP-7075-2021		FOGARTY INTERNATIONAL CENTER [R01TW006185] Funding Source: NIH RePORTER; FIC NIH HHS [TW06185] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Banerjee S, 2006, J MICROBIOL, V44, P11; Bonin I, 2004, P NATL ACAD SCI USA, V101, P13762, DOI 10.1073/pnas.0405883101; Borukhov S, 2005, MOL MICROBIOL, V55, P1315, DOI 10.1111/j.1365-2958.2004.04481.x; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Cheeran A, 2005, J MOL BIOL, V352, P28, DOI 10.1016/j.jmb.2005.06.052; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; Das A, 1996, METHOD ENZYMOL, V274, P374; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GEORGOPO.CP, 1971, P NATL ACAD SCI USA, V68, P2977, DOI 10.1073/pnas.68.12.2977; GHYSEN A, 1972, J MOL BIOL, V65, P259, DOI 10.1016/0022-2836(72)90281-1; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Gusarov I, 2001, CELL, V107, P437, DOI 10.1016/S0092-8674(01)00582-7; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; King RA, 2003, METHOD ENZYMOL, V371, P207; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Meares CF, 2003, METHOD ENZYMOL, V371, P82; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; Nechaev S, 2002, J MOL BIOL, V320, P11, DOI 10.1016/S0022-2836(02)00420-5; Neely MN, 2000, MOL MICROBIOL, V38, P1074, DOI 10.1046/j.1365-2958.2000.02217.x; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Obuchowski M, 1997, MOL MICROBIOL, V23, P211, DOI 10.1046/j.1365-2958.1997.2101576.x; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; Schauer AT, 1996, MOL MICROBIOL, V21, P839, DOI 10.1046/j.1365-2958.1996.451409.x; Sen R, 2002, MOL MICROBIOL, V46, P215, DOI 10.1046/j.1365-2958.2002.03154.x; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; STERNBERG N, 1976, VIROLOGY, V73, P139, DOI 10.1016/0042-6822(76)90068-4; Szalewska-Palasz A, 2003, ARCH MICROBIOL, V180, P161, DOI 10.1007/s00203-003-0571-2; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toulokhonov I, 2003, MOL CELL, V12, P1125, DOI 10.1016/S1097-2765(03)00439-8; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Van Gilst MR, 2000, METHOD ENZYMOL, V323, P1; VanGilst MR, 1997, J MOL BIOL, V274, P160, DOI 10.1006/jmbi.1997.1389; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Watnick RS, 1999, SCIENCE, V286, P2337, DOI 10.1126/science.286.5448.2337; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WHALEN W A, 1990, New Biologist, V2, P975; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	54	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30997	31007		10.1074/jbc.M704864200	http://dx.doi.org/10.1074/jbc.M704864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17698847	hybrid			2022-12-25	WOS:000250136300067
J	Garstka, M; Borchert, B; Al-Balushi, M; Praveen, PVK; Kuehl, N; Majoul, I; Duden, R; Springer, S				Garstka, Malgorzata; Borchert, Britta; Al-Balushi, Mohammed; Praveen, P. V. K.; Kuehl, Nicole; Majoul, Irina; Duden, Rainer; Springer, Sebastian			Peptide-receptive major histocompatibility complex class I molecules cycle between endoplasmic reticulum and cis-golgi in wild-type lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; INTERMEDIATE COMPARTMENT; MONOCLONAL-ANTIBODIES; HEAVY-CHAINS; QUALITY-CONTROL; INTRACELLULAR-TRANSPORT; MEMBRANE GLYCOPROTEIN; RETROGRADE TRANSPORT; ANTIGEN PRESENTATION; PROTEIN-TRANSPORT	Prior to binding to a high affinity peptide and transporting it to the cell surface, major histocompatibility complex class I molecules are retained inside the cell by retention in the endoplasmic reticulum ( ER), recycling through the ER-Golgi intermediate compartment and possibly the cis-Golgi, or both. Using fluorescence microscopy and a novel in vitro COPII ( ER-to-ER-Golgi intermediate compartment) vesicle formation assay, we find that in both lymphocytes and fibroblasts that lack the functional transporter associated with antigen presentation, class I molecules exit the ER and reach the cis-Golgi. Intriguingly, in wild-type T1 lymphoma cells, peptide-occupied and peptide-receptive class I molecules are simultaneously exported from ER membranes with similar efficiencies. Our results suggest that binding of high affinity peptide and exit from the ER are not coupled, that the major histocompatibility complex class I quality control compartment extends into the Golgi apparatus under standard conditions, and that peptide loading onto class I molecules may occur in post-ER compartments.	Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany; Sultan Qaboos Univ, Dept Microbiol & Immunol, Muscat 123, Oman; Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	Jacobs University; Sultan Qaboos University; University of London; Royal Holloway University London	Springer, S (corresponding author), Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany.	s.springer@jacobs-university.de	Majoul, Irina V/K-5339-2013; Pvk, Praveen/C-3833-2013; Garstka, Malgorzata A./AAU-4401-2020; Duden, Rainer/C-8917-2011; Springer, Sebastian/AAJ-7036-2021	Garstka, Malgorzata A./0000-0003-2896-7275; Springer, Sebastian/0000-0002-5527-6149	Wellcome Trust [047578] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON KS, 1993, J IMMUNOL, V151, P3407; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Appenzeller-Herzog C, 2006, J CELL SCI, V119, P2173, DOI 10.1242/jcs.03019; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BALCH WE, 1986, J BIOL CHEM, V261, P4690; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Barre L, 2005, FEBS J, V272, P1063, DOI 10.1111/j.1742-4658.2005.04548.x; Boyle LH, 2006, J IMMUNOL, V176, P6464, DOI 10.4049/jimmunol.176.11.6464; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X; De Silva AD, 1999, J IMMUNOL, V163, P4413; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garbi N, 2007, CURR OPIN IMMUNOL, V19, P99, DOI 10.1016/j.coi.2006.11.013; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Glithero A, 2006, J BIOL CHEM, V281, P12699, DOI 10.1074/jbc.M511683200; Greenfield JJA, 1999, J CELL SCI, V112, P1477; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Groothuis T, 2005, CURR TOP MICROBIOL, V300, P127; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hermosilla R, 2004, TRAFFIC, V5, P993, DOI 10.1111/j.1600-0854.2004.00239.x; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Ito M, 2002, BIOCHEM J, V361, P473, DOI 10.1042/0264-6021:3610473; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kienast A, 2007, NAT IMMUNOL, V8, P864, DOI 10.1038/ni1483; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kincaid MM, 2007, MOL BIOL CELL, V18, P455, DOI 10.1091/mbc.E06-08-0696; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Koch J, 2006, CELL MOL LIFE SCI, V63, P653, DOI 10.1007/s00018-005-5462-z; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Moldovan L, 2004, HISTOCHEM CELL BIOL, V122, P395, DOI 10.1007/s00418-004-0676-y; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Murshid A, 2004, CELL MOL LIFE SCI, V61, P133, DOI 10.1007/s00018-003-3352-9; Neisig A, 1996, J IMMUNOL, V156, P3196; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nyfeler B, 2006, TRAFFIC, V7, P1473, DOI 10.1111/j.1600-0854.2006.00483.x; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Otsu M, 2006, ANTIOXID REDOX SIGN, V8, P274, DOI 10.1089/ars.2006.8.274; OZATO K, 1981, J IMMUNOL, V126, P317; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Park B, 2006, CELL, V127, P369, DOI 10.1016/j.cell.2006.08.041; Paulsson KM, 2002, J BIOL CHEM, V277, P18266, DOI 10.1074/jbc.M201388200; Paulsson KM, 2001, INT IMMUNOL, V13, P1063, DOI 10.1093/intimm/13.8.1063; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Shastri N, 2005, IMMUNOL REV, V207, P31, DOI 10.1111/j.0105-2896.2005.00321.x; Shugrue CA, 1999, J CELL SCI, V112, P4547; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Spear ED, 2003, MOL BIOL CELL, V14, P2756, DOI 10.1091/mbc.E02-11-0717; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; STAM NJ, 1986, J IMMUNOL, V137, P2299; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; Thammavongsa V, 2006, J IMMUNOL, V177, P3150, DOI 10.4049/jimmunol.177.5.3150; Tourdot S, 2005, J IMMUNOL, V174, P925, DOI 10.4049/jimmunol.174.2.925; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Wearsch PA, 2007, NAT IMMUNOL, V8, P873, DOI 10.1038/ni1485; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; Wright CA, 2004, BIOL CHEM, V385, P763, DOI 10.1515/BC.2004.100; Zernich D, 2004, J EXP MED, V200, P13, DOI 10.1084/jem.20031680; Zhang YN, 2006, IMMUNOL RES, V35, P151, DOI 10.1385/IR:35:1:151; ZUNIGA MC, 1983, CELL, V34, P535, DOI 10.1016/0092-8674(83)90386-0	83	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30680	30690		10.1074/jbc.M701721200	http://dx.doi.org/10.1074/jbc.M701721200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17656363	hybrid			2022-12-25	WOS:000250136300036
J	Barber, MA; Donald, S; Thelen, S; Anderson, KE; Thelen, M; Welch, HCE				Barber, Mark A.; Donald, Sarah; Thelen, Sylvia; Anderson, Karen E.; Thelen, Marcus; Welch, Heidi C. E.			Membrane translocation of P-Rex1 is mediated by G protein beta gamma subunits and phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; PLASMA-MEMBRANE; NEUTROPHIL FUNCTION; FACTOR TIAM1; RHO-GTPASES; ACTIVATION; RAC; RECRUITMENT; BINDING	P-Rex1 is a guanine-nucleotide exchange factor (GEF) for the small GTPase Rac that is directly activated by the beta gamma subunits of heterotrimeric G proteins and by the lipid second messenger phosphatidylinositol ( 3,4,5)-trisphosphate (PIP3), which is generated by phosphoinositide 3-kinase (PI3K). G beta gamma subunits and PIP3 are membrane-bound, whereas the intracellular localization of P-Rex1 in basal cells is cytosolic. Activation of PI3K alone is not sufficient to promote significant membrane translocation of P-Rex1. Here we investigated the subcellular localization of P-Rex1 by fractionation of Sf9 cells co-expressing P-Rex1 with G beta gamma and/or PI3K. In basal, serum-starved cells, P-Rex1 was mainly cytosolic, but 7% of the total was present in the 117,000 x g membrane fraction. Co-expression of P-Rex1 with either G beta gamma or PI3K caused only an insignificant increase in P-Rex1 membrane localization, whereas G beta gamma and PI3K together synergistically caused a robust increase in membrane-localized P-Rex1 to 23% of the total. PI3K-driven P-Rex1 membrane recruitment was wortmannin-sensitive. The use of P-Rex1 mutants showed that the isolated Dbl homology/pleckstrin homology domain tandem of P-Rex1 is sufficient for synergistic G beta gamma- and PI3K-driven membrane localization; that the enzymatic GEF activity of P-Rex1 is not required for membrane translocation; and that the other domains of P-Rex1 ( DEP, PDZ, and IP4P) contribute to keeping the enzyme localized in the cytosol of basal cells. In vitro Rac2-GEF activity assays showed that membrane-derived purified P-Rex1 has a higher basal activity than cytosol-derived P-Rex1, but both can be further activated by PIP3 and G beta gamma subunits.	Inst Res Biomed, CH-6500 Bellinzona, Switzerland; Babraham Inst, Inositide Lab, Cambridge CB22 3AT, England	Universita della Svizzera Italiana; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Welch, HCE (corresponding author), Babraham Inst, Inositide Lab, Babraham Res Campus, Cambridge CB22 3AT, England.	heidi.welch@bbsrc.ac.uk		Welch, Heidi/0000-0001-7865-7000; Anderson, Karen/0000-0002-7394-6660	Biotechnology and Biological Sciences Research Council [C19943, BBS/E/B/0000M090] Funding Source: Medline; Medical Research Council [G120/825] Funding Source: Medline; MRC [G120/825] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Baumeister MA, 2006, BIOCHEM J, V400, P563, DOI 10.1042/BJ20061020; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Dong XM, 2005, CURR BIOL, V15, P1874, DOI 10.1016/j.cub.2005.09.014; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fleming IN, 2004, BIOCHEM J, V382, P857, DOI 10.1042/BJ20040916; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Gaffney PRJ, 1997, BIOORG MED CHEM LETT, V7, P3171, DOI 10.1016/S0960-894X(97)10166-4; Hill K, 2006, METHOD ENZYMOL, V406, P26, DOI 10.1016/S0076-6879(06)06003-4; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Koh CG, 2001, J CELL SCI, V114, P4239; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li Z, 2005, PROSTAG OTH LIPID M, V76, P95, DOI 10.1016/j.prostaglandins.2005.02.002; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1913, DOI 10.1074/jbc.M506034200; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1921, DOI 10.1074/jbc.M506035200; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; PITTCHER JA, 1992, SCIENCE, V257, P1264; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sun YJ, 2006, MOL CELL BIOL, V26, P6923, DOI 10.1128/MCB.02474-05; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Vazquez-Prado J, 2004, J BIOL CHEM, V279, P54283, DOI 10.1074/jbc.M410594200; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yang L, 2006, NEURON, V52, P595, DOI 10.1016/j.neuron.2006.09.039; Yoshizawa M, 2005, J NEUROSCI, V25, P4406, DOI 10.1523/JNEUROSCI.4955-04.2005; Zegers MMP, 2003, EMBO J, V22, P4155, DOI 10.1093/emboj/cdg398; Zhao TM, 2007, J LEUKOCYTE BIOL, V81, P1127, DOI 10.1189/jlb.0406251	41	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29967	29976		10.1074/jbc.M701877200	http://dx.doi.org/10.1074/jbc.M701877200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698854	hybrid			2022-12-25	WOS:000249981200026
J	Bol, R; de Wit, JG; Driessen, AJM				Bol, Redmar; de Wit, Janny G.; Driessen, Arnold J. M.			The active protein-conducting channel of Escherichia coli contains an apolar patch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER MEMBRANE; TRANSLOCATION CHANNEL; PREPROTEIN TRANSLOCASE; PRECURSOR PROTEIN; PLASMA-MEMBRANE; CHAPERONE SECB; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; DISULFIDE BRIDGE; CATALYTIC CYCLE	Protein translocation across the cytoplasmic membrane of Escherichia coli is mediated by translocase, a complex of a protein conducting channel, SecYEG, and a peripheral motor domain, SecA. SecYEG has been proposed to constitute an aqueous path for proteins to pass the membrane in an unfolded state. To probe the solvation state of the active channel, the polarity sensitive fluorophore N-(( 2-( iodoacetoxy) ethyl)- N- methyl) amino- 7- nitrobenz- 2- oxa- 1,3- diazole was introduced at specific positions in the C- terminal region of the secretory protein proOmpA. Fluorescence measurements with defined proOmpA- DHFR translocation intermediates indicate mostly a water- exposed environment with a hydrophobic region in the center of the channel.	Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Groningen, Zernike Inst Adv Mat, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Institute, Zernike/W-7033-2019; Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cannon KS, 2005, J CELL BIOL, V169, P219, DOI 10.1083/jcb.200412019; Clemons WM, 2004, CURR OPIN STRUC BIOL, V14, P390, DOI 10.1016/j.sbi.2004.07.006; Crane JM, 2005, J MOL BIOL, V353, P295, DOI 10.1016/j.jmb.2005.08.022; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; Duong F, 1998, EMBO J, V17, P696, DOI 10.1093/emboj/17.3.696; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Gumbart J, 2006, BIOPHYS J, V90, P2356, DOI 10.1529/biophysj.105.075291; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HIRATSUKA T, 1987, J BIOL CHEM, V262, P6318; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Junne T, 2006, MOL BIOL CELL, V17, P4063, DOI 10.1091/mbc.E06-03-0200; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li WK, 2007, MOL CELL, V26, P511, DOI 10.1016/j.molcel.2007.05.002; MACINTYRE S, 1991, MOL GEN GENET, V227, P224; Maillard AP, 2007, J BIOL CHEM, V282, P1281, DOI 10.1074/jbc.M610060200; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; MITRA K, 2006, NAT STRUCT BIOL, V157, P262; Papanikou E, 2005, J BIOL CHEM, V280, P43209, DOI 10.1074/jbc.M509990200; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; Sato K, 1997, J BIOL CHEM, V272, P20082, DOI 10.1074/jbc.272.32.20082; Scheuring J, 2005, J MOL BIOL, V354, P258, DOI 10.1016/j.jmb.2005.09.058; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Tam PCK, 2005, EMBO J, V24, P3380, DOI 10.1038/sj.emboj.7600804; TANI K, 1991, FEBS LETT, V285, P127, DOI 10.1016/0014-5793(91)80741-K; TANI K, 1990, J BIOL CHEM, V265, P17341; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; VRONTOU E, 2004, BIOCHIM BIOPHYS ACTA, V11, P67; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Zhou JH, 2005, MOL MICROBIOL, V58, P349, DOI 10.1111/j.1365-2958.2005.04842.x	57	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29785	29793		10.1074/jbc.M702140200	http://dx.doi.org/10.1074/jbc.M702140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699162	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000249981200007
J	Greco, SJ; Smirnov, SV; Murthy, RG; Rameshwar, P				Greco, Steven J.; Smirnov, Sergey V.; Murthy, Raghav G.; Rameshwar, Pranela			Synergy between the RE-1 silencer of transcription and NF kappa B in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMERGING IMMUNE-SYSTEM; BREAST-CANCER CELLS; BONE-MARROW; EXPRESSION; REST; PLASTICITY; NEURONS; BIOLOGY; DIFFERENTIATION; NEUROGENESIS	The RE-1 silencer of transcription ( REST) is a transcriptional regulator that represses neuron-specific genes in non-neuronal tissues by remodeling chromatin structure. We have utilized human mesenchymal stem cells (MSCs) as a research tool to understand the molecular mechanisms that regulate a neurogenic program of differentiation in non-neuronal tissue. MSCs are mesoderm-derived cells that generate specialized cells such as stroma, fat, bone, and cartilage. We have reported previously the transdifferentiation of MSCs into functional neuronal cells (Cho, K. J., Trzaska, K. A., Greco, S. J., McArdle, J., Wang, F. S., Ye, J.-H., and Rameshwar, P. ( 2005) Stem Cells 23, 383-391). Expression of the neurotransmitter gene TAC1 was detected only in neuronal cells and thus served as a model to study transcriptional regulation of neuron-specific genes in undifferentiated MSCs. Bone marrow stromal cells are known to transiently express TAC1 following stimulation with the microenvironmental factor interleukin-1 alpha. We thus compared the effects of interleukin-1 alpha stimulation and neuronal induction of MSCs on TAC1 regulation. Transcription factor mapping of the 5'-flanking region of the TAC1 promoter predicted two REST-binding sites adjacent to one NF kappa B site within exon 1. Chromatin immunoprecipitation, mutagenesis, and loss-of-function studies showed that both transcription factors synergistically mediated repression of TAC1 in the neurogenic and microenvironmental models. Together, the results support the novel finding of synergism between REST and NF kappa B in the suppression of TAC1 in non-neuronal cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol,MSB, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rameshwar, P (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol,MSB, Rm E-579,185 S Orange Ave, Newark, NJ 07103 USA.	rameshwa@umdnj.edu						Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Baharvand H, 2006, DEV GROWTH DIFFER, V48, P323, DOI 10.1111/j.1440-169x.2006.00867.x; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corcoran KE, 2007, J IMMUNOL, V178, P2075, DOI 10.4049/jimmunol.178.4.2075; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Greco SJ, 2004, FRONT BIOSCI-LANDMRK, V9, P1782, DOI 10.2741/1373; Jiang WH, 2006, TRANSPL INT, V19, P570, DOI 10.1111/j.1432-2277.2006.00307.x; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Komarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535-7163.MCT-05-0334; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kuwahara K, 2001, MOL CELL BIOL, V21, P2085, DOI 10.1128/MCB.21.6.2085-2097.2001; Lerou PH, 2005, BLOOD REV, V19, P321, DOI 10.1016/j.blre.2005.01.005; Lotem J, 2006, ONCOGENE, V25, P7663, DOI 10.1038/sj.onc.1209816; Lunyak VV, 2005, CELL, V121, P499, DOI 10.1016/j.cell.2005.05.003; Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495; Potian JA, 2003, J IMMUNOL, V171, P3426, DOI 10.4049/jimmunol.171.7.3426; Qian J, 2001, J IMMUNOL, V166, P2553, DOI 10.4049/jimmunol.166.4.2553; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rao G, 2004, CANCER RES, V64, P2874, DOI 10.1158/0008-5472.CAN-03-3121; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; Snyder BJ, 2005, CURR OPIN NEUROL, V18, P376, DOI 10.1097/01.wco.0000174298.27765.91; Spencer EM, 2006, NEUROBIOL DIS, V24, P41, DOI 10.1016/j.nbd.2006.04.020; Sun YM, 2005, MOL BIOL CELL, V16, P5630, DOI 10.1091/mbc.E05-07-0687; Wang QH, 2006, J MED INVESTIG, V53, P61, DOI 10.2152/jmi.53.61; Yan J, 2006, STEM CELLS, V24, P1976, DOI 10.1634/stemcells.2005-0518	33	35	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30039	30050		10.1074/jbc.M703026200	http://dx.doi.org/10.1074/jbc.M703026200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709376	hybrid			2022-12-25	WOS:000249981200034
J	Kobayashi, A; Asano, M; Mohri, S; Kitamoto, T				Kobayashi, Atsushi; Asano, Masahiro; Mohri, Shirou; Kitamoto, Tetsuyuki			Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERSTMANN-STRAUSSLER SYNDROME; DURA-MATER GRAFT; FLORID PLAQUES; KNOCK-IN; VARIANT CJD; PROTEIN; MOUSE; SUSCEPTIBILITY; WOMAN; MICE	The genotype ( methionine or valine) at polymorphic codon 129 of the human prion protein (PrP) gene and the type ( type 1 or type 2) of abnormal isoform of PrP ( PrPSc) are major determinants of the clinicopathological phenotypes of sporadic Creutzfeldt-Jakob disease (sCJD). Here we found that the transmission of sCJD prions from a patient with valine homozygosity (129V/V) and type 2 PrPSc (sCJD-VV2 prions) to mice expressing human PrP with methionine homozygosity (129M/M) generated unusual PrPSc intermediate in size between type 1 and type 2. The intermediate type PrPSc was seen in all examined dura mater graft-associated CJD cases with 129M/M and plaque-type PrP deposits (p-dCJD). p-dCJD prions and sCJD-VV2 prions exhibited similar transmissibility and neuropathology, and the identical type of PrPSc when inoculated into PrP-humanized mice with 129M/M or 129V/V. These findings suggest that p-dCJD could be caused by cross-sequence transmission of sCJD-VV2 prions.	Tohoku Univ, Grad Sch Med, Dept Prion Res, Div CJD Sci & Technol,Aoba Ku, Sendai, Miyagi 9808575, Japan; Natl Inst Anim Hlth, Prion Dis Res Ctr, Tsukuba, Ibaraki 3050856, Japan	Tohoku University; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan	Kitamoto, T (corresponding author), Tohoku Univ, Grad Sch Med, Dept Prion Res, Div CJD Sci & Technol,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kitamoto@mail.tains.tohoku.ac.jp	Mohri, Shirou/AAK-1281-2020					Asano M, 2006, BIOCHEM BIOPH RES CO, V342, P293, DOI 10.1016/j.bbrc.2006.01.149; Belay ED, 2004, EMERG INFECT DIS, V10, P977, DOI 10.3201/eid1006.031082; Belay ED, 2001, ARCH NEUROL-CHICAGO, V58, P1673, DOI 10.1001/archneur.58.10.1673; Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; Brown P, 2006, NEUROLOGY, V67, P389, DOI 10.1212/01.wnl.0000231528.65069.3f; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1179; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; DELISLE MB, 1993, REV NEUROL, V149, P524; DESLYS JP, 1994, J GEN VIROL, V75, P23, DOI 10.1099/0022-1317-75-1-23; DEVILLEMEUR TB, 1994, NEUROPATH APPL NEURO, V20, P111; DOHURA K, 1991, NATURE, V353, P801, DOI 10.1038/353801b0; Grathwohl KUD, 1996, ARCH VIROL, V141, P1863, DOI 10.1007/BF01718200; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Hoshi K, 2000, NEUROLOGY, V55, P718, DOI 10.1212/WNL.55.5.718; Kimura K, 2001, J NEUROL NEUROSUR PS, V70, P696, DOI 10.1136/jnnp.70.5.696; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V191, P709, DOI 10.1006/bbrc.1993.1275; Kitamoto T, 1996, BIOCHEM BIOPH RES CO, V222, P742, DOI 10.1006/bbrc.1996.0814; Kitamoto T, 2002, BIOCHEM BIOPH RES CO, V294, P280, DOI 10.1016/S0006-291X(02)00476-X; KITAMOTO T, 1991, BRAIN RES, V545, P319, DOI 10.1016/0006-8993(91)91306-L; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; Kopp N, 1996, LANCET, V348, P1239, DOI 10.1016/S0140-6736(05)65510-9; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Kretzschmar HA, 2003, BRAIN PATHOL, V13, P245; LANE KL, 1994, NEUROSURGERY, V34, P737, DOI 10.1227/00006123-199404000-00026; Lee HS, 2001, J INFECT DIS, V183, P192, DOI 10.1086/317935; Mochizuki Y, 2003, NEUROPATHOLOGY, V23, P136, DOI 10.1046/j.1440-1789.2003.00489.x; PALMER MS, 1993, HUM MOL GENET, V2, P541, DOI 10.1093/hmg/2.5.541; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Satoh K, 2003, J GEN VIROL, V84, P2885, DOI 10.1099/vir.0.19236-0; Scott MR, 2005, J VIROL, V79, P5259, DOI 10.1128/JVI.79.9.5259-5271.2005; Shimizu S, 1999, ARCH NEUROL-CHICAGO, V56, P357, DOI 10.1001/archneur.56.3.357; Taguchi Y, 2003, AM J PATHOL, V163, P2585, DOI 10.1016/S0002-9440(10)63613-9; Takashima S, 1997, LANCET, V350, P865, DOI 10.1016/S0140-6736(05)62035-1; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; Zeidler M, 1997, LANCET, V350, P668, DOI 10.1016/S0140-6736(05)63366-1	41	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30022	30028		10.1074/jbc.M704597200	http://dx.doi.org/10.1074/jbc.M704597200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709374	hybrid			2022-12-25	WOS:000249981200032
J	Eisinger, AL; Nadauld, LD; Shelton, DN; Prescott, SM; Stafforini, DM; Jones, DA				Eisinger, Annie L.; Nadauld, Lincoln D.; Shelton, Dawne N.; Prescott, Stephen M.; Stafforini, Diana M.; Jones, David A.			Retinoic acid inhibits beta-catenin through suppression of Cox-2 - A role for truncated adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; NEGATIVE REGULATOR; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; INTESTINAL DEVELOPMENT; PROTEIN INTERACTIONS; 9-CIS-RETINOIC ACID; GROWTH-INHIBITION; BREAST-CANCER; GENE-PRODUCT; AXIN	Mutations in adenomatous polyposis coli (APC) underlie the earliest stages of colorectal carcinogenesis. Consequences of APC mutation include stabilization of beta-catenin, dysregulation of cyclooxygenase-2 (COX-2) expression, and loss of retinoic acid production, events with poorly defined interactions. Here we showed that treatment of zebrafish expressing a truncated form of Apc with either retinoic acid or a selective COX-2 inhibitor decreased beta-catenin protein levels and downstream signaling events. Interestingly, the destruction of beta-catenin in apc mutant embryos following Cox-2 inhibition required the presence of truncated Apc. These findings support roles for retinoic acid and Cox-2 in regulating the stability of beta-catenin following Apc loss. Furthermore, truncated Apc appears to retain the ability to target beta-catenin for destruction, but only in the absence of Cox-2 activity. This novel function of truncated Apc may provide a molecular basis for the efficacy of COX-2 inhibitors in the treatment of colon cancer.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu; david.jones@hci.utah.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANZANO MA, 1994, CANCER RES, V54, P4614; Begemann G, 2001, DEVELOPMENT, V128, P3081; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Blavier L, 2006, CANCER RES, V66, P2691, DOI 10.1158/0008-5472.CAN-05-2919; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Delaunay F, 2000, SCIENCE, V289, P297, DOI 10.1126/science.289.5477.297; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EDWARD M, 1992, CLIN EXP METASTAS, V10, P61, DOI 10.1007/BF00163577; Eisinger AL, 2006, J BIOL CHEM, V281, P20474, DOI 10.1074/jbc.M602859200; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fitzgerald P, 1997, CANCER RES, V57, P2642; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; HONG WK, 1994, LEUKEMIA BALTIMOR S3, V8, P33; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Li JJ, 1996, CANCER RES, V56, P483; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Nadauld LD, 2005, J BIOL CHEM, V280, P30490, DOI 10.1074/jbc.M504973200; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; Nadauld LD, 2006, J BIOL CHEM, V281, P37828, DOI 10.1074/jbc.M602119200; Nadauld LD, 2006, P NATL ACAD SCI USA, V103, P13409, DOI 10.1073/pnas.0601634103; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shih IM, 2000, CANCER RES, V60, P1671; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	43	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29394	29400		10.1074/jbc.M609768200	http://dx.doi.org/10.1074/jbc.M609768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17673467	hybrid			2022-12-25	WOS:000249788000036
J	Schneider, L; Essmann, F; Kletke, A; Rio, P; Hanenberg, H; Wetzel, W; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schneider, Leonid; Essmann, Frank; Kletke, Anja; Rio, Paula; Hanenberg, Helmut; Wetzel, Wiebke; Schulze-Osthoff, Klaus; Nuernberg, Bernd; Piekorz, Roland P.			The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC COILED-COIL; MESSENGER-RNA; CENTROSOME ABERRATIONS; ASSEMBLY CHECKPOINT; POLE ORGANIZATION; TUMOR-SUPPRESSOR; HUMAN CANCERS; GENE FAMILY; ZYG-9 FORM; CELL-DEATH	Cancer-associated centrosomal transforming acidic coiled coil (TACC) proteins are involved in mitotic spindle function. By employing gene targeting, we have recently described a non-redundant and essential role of TACC3 in regulating cell proliferation. In this study, we used an inducible RNA interference approach to characterize the molecular function of TACC3 and its role in mitotic progression and cell survival. Our data demonstrate that a TACC3 knockdown arrests G1 checkpoint-compromised HeLa cells prior to anaphase with aberrant spindle morphology and severely misaligned chromosomes. Interestingly, TACC3-depleted cells fail to accumulate the mitotic kinase Aurora B and the checkpoint protein BubR1 to normal levels at kinetochores. Moreover, localization of the structural protein Ndc80 at outer kinetochores is reduced, indicating a defective kinetochore-microtubule attachment in TACC3-deficient cells. As a consequence of prolonged TACC3 depletion, cells undergo caspase-dependent cell death that relies on a spindle checkpoint-dependent mitotic arrest. TACC3 knockdown cells that escape from this arrest by mitotic slippage become highly polyploid and accumulate supernumerary centrosomes. Similarly, deficiency of the post-mitotic cell cycle inhibitor p21(WAF) exacerbates the effects of TACC3 depletion. Our findings therefore point to an essential role of TACC3 in spindle assembly and cellular survival and identify TACC3 as a potential therapeutic target in cancer cells.	Univ Dusseldorf, Univ Klinikum, Inst BIochem & Mol Biol 2, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Univ Klinikum, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Univ Klinikum, Klin Kinder Onkol Hamatol & Klin Immunol, D-40225 Dusseldorf, Germany; Indiana Univ, Riley Hosp Children, Sch Med, Wells Ctr Pediat Res,Dept Pediat, Indianapolis, IN 46223 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Piekorz, RP (corresponding author), Univ Dusseldorf, Univ Klinikum, Inst BIochem & Mol Biol 2, D-40225 Dusseldorf, Germany.	Roland.Piekorz@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013; Rio, Paula/G-8681-2015; Schneider, Leonid/H-3275-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Rio, Paula/0000-0002-5424-5543; Schneider, Leonid/0000-0002-6204-9470; Nurnberg, Bernd/0000-0002-5995-6555				Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Ciferri C, 2007, FEBS LETT, V581, P2862, DOI 10.1016/j.febslet.2007.05.012; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Holmfeldt P, 2004, EMBO J, V23, P627, DOI 10.1038/sj.emboj.7600076; HU GY, 1995, CANCER GENE THER, V2, P19; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; Kline SL, 2006, J CELL BIOL, V173, P9, DOI 10.1083/jcb.200509158; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Leurs C, 2003, HUM GENE THER, V14, P509, DOI 10.1089/104303403764539305; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; Meek DW, 2000, PATHOL BIOL, V48, P246; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; SCHNEIDER L, 2007, ONCOGENE; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Sluder G, 2005, NAT REV MOL CELL BIO, V6, P743, DOI 10.1038/nrm1712; Srayko M, 2003, CURR BIOL, V13, P1506, DOI 10.1016/S0960-9822(03)00597-9; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-16; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	60	72	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29273	29283		10.1074/jbc.M704151200	http://dx.doi.org/10.1074/jbc.M704151200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675670	hybrid			2022-12-25	WOS:000249788000024
J	Thomas, NA; Deng, WY; Baker, N; Puente, J; Finlay, BB				Thomas, Nikhil A.; Deng, Wanyin; Baker, Noel; Puente, Jose; Finlay, B. Brett			Hierarchical delivery of an essential host colonization factor in enteropathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATED INTIMIN RECEPTOR; ACTIN PEDESTAL FORMATION; III SECRETION CHAPERONE; ENTEROCYTE EFFACEMENT; PATHOGENICITY ISLAND; BACTERIAL PATHOGENS; VIRULENCE FACTOR; YERSINIA-PESTIS; TIR BINDS; EPEC	Many significant bacterial pathogens use a type III secretion system to inject effector proteins into host cells to disrupt specific cellular functions, enabling disease progression. The injection of these effectors into host cells is often dependent on dedicated chaperones within the bacterial cell. In this report, we demonstrate that the enteropathogenic Escherichia coli (EPEC) chaperone CesT interacts with a variety of known and putative type III effector proteins. Using pull-down and secretion assays, a degenerate CesT binding domain was identified within multiple type III effectors. Domain exchange experiments between selected type III effector proteins revealed a modular nature for the CesT binding domain, as demonstrated by secretion, chaperone binding, and infection assays. The CesT-interacting type III effector Tir, which is crucial for in vivo intestinal colonization, had to be expressed and secreted for efficient secretion of other type III effectors. In contrast, the absence of other CesT-interacting type III effectors did not abrogate effector secretion, indicating an unexpected hierarchy with respect to Tir for type III effector delivery. Coordinating the expression of other type III effectors with cesT in the absence of tir partially restored total type III effector secretion, thereby implicating CesT in secretion events. Collectively, the results suggest a coordinated mechanism involving both Tir and CesT for type III effector injection into host cells.	Dalhousie Univ, Dept Immunol & Microbiol, Halifax, NS B3X 1H5, Canada; Dalhousie Univ, Dept Med, Halifax, NS B3X 1H5, Canada; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Microbiol, Cuernavaca 62210, Morelos, Mexico	Dalhousie University; Dalhousie University; University of British Columbia; Universidad Nacional Autonoma de Mexico	Thomas, NA (corresponding author), Dalhousie Univ, Dept Immunol & Microbiol, Halifax, NS B3X 1H5, Canada.	n.thomas@dal.ca		Thomas, Nikhil/0000-0003-3037-425X				Abe A, 1999, MOL MICROBIOL, V33, P1162, DOI 10.1046/j.1365-2958.1999.01558.x; Batchelor M, 2004, EMBO REP, V5, P104, DOI 10.1038/sj.embor.7400038; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Campellone KG, 2002, MOL MICROBIOL, V43, P1227, DOI 10.1046/j.1365-2958.2002.02817.x; Caron E, 2006, CURR OPIN MICROBIOL, V9, P40, DOI 10.1016/j.mib.2005.12.008; Crawford JA, 2002, MOL MICROBIOL, V46, P855, DOI 10.1046/j.1365-2958.2002.03214.x; Creasey EA, 2003, MICROBIOL-SGM, V149, P2093, DOI 10.1099/mic.0.26355-0; Creasey EA, 2003, MOL MICROBIOL, V47, P209, DOI 10.1046/j.1365-2958.2003.03290.x; Dean P, 2005, CURR OPIN MICROBIOL, V8, P28, DOI 10.1016/j.mib.2004.12.010; Deng WY, 2005, INFECT IMMUN, V73, P2135, DOI 10.1128/IAI.73.4.2135-2146.2005; Deng WY, 2003, MOL MICROBIOL, V48, P95, DOI 10.1046/j.1365-2958.2003.03429.x; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Elliott SJ, 2002, INFECT IMMUN, V70, P2271, DOI 10.1128/IAI.70.5.2271-2277.2002; Elliott SJ, 1999, MOL MICROBIOL, V33, P1176, DOI 10.1046/j.1365-2958.1999.01559.x; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; Garmendia J, 2005, INFECT IMMUN, V73, P2573, DOI 10.1128/IAI.73.5.2573-2585.2005; Gauthier A, 2003, J BACTERIOL, V185, P6747, DOI 10.1128/JB.185.23.6747-6755.2003; Goosney DL, 2000, CURR BIOL, V10, P735, DOI 10.1016/S0960-9822(00)00543-1; Gruenheid S, 2004, MOL MICROBIOL, V51, P1233, DOI 10.1046/j.1365-2958.2003.03911.x; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Kenny B, 2002, MOL MICROBIOL, V44, P1095, DOI 10.1046/j.1365-2958.2002.02952.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; LEVINE MM, 1978, LANCET, V1, P1119; Lilic M, 2006, MOL CELL, V21, P653, DOI 10.1016/j.molcel.2006.01.026; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Marches O, 2000, INFECT IMMUN, V68, P2171, DOI 10.1128/IAI.68.4.2171-2182.2000; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; Mellies JL, 2001, INFECT IMMUN, V69, P315, DOI 10.1128/IAI.69.1.315-324.2001; Nougayrede JP, 2004, CELL MICROBIOL, V6, P1097, DOI 10.1111/j.1462-5822.2004.00421.x; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; Patel A, 2006, CELL MICROBIOL, V8, P55, DOI 10.1111/j.1462-5822.2005.00600.x; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Phan J, 2004, ACTA CRYSTALLOGR D, V60, P1591, DOI 10.1107/S0907444904017597; Phillips N, 2004, NAT CELL BIOL, V6, P618, DOI 10.1038/ncb1148; Ritchie JM, 2003, INFECT IMMUN, V71, P7129, DOI 10.1128/IAI.71.12.7129-7139.2003; Sanchez-SanMartin C, 2001, J BACTERIOL, V183, P2823, DOI 10.1128/JB.183.9.2823-2833.2001; Sorg I, 2007, EMBO J, V26, P3015, DOI 10.1038/sj.emboj.7601731; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Thomas NA, 2005, MOL MICROBIOL, V57, P1762, DOI 10.1111/j.1365-2958.2005.04802.x; Tobe T, 2006, P NATL ACAD SCI USA, V103, P14941, DOI 10.1073/pnas.0604891103; Tomson FL, 2005, MOL MICROBIOL, V56, P447, DOI 10.1111/j.1365-2958.2005.04571.x; van Eerde A, 2004, EMBO REP, V5, P477, DOI 10.1038/sj.embor.7400144; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x	45	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29634	29645		10.1074/jbc.M706019200	http://dx.doi.org/10.1074/jbc.M706019200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681945	hybrid			2022-12-25	WOS:000249788000060
J	Teng, CH; Huang, WN; Meng, TC				Teng, Chun-Hung; Huang, Wen-Nin; Meng, Tzu-Ching			Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; TERMINAL KINASE ACTIVATION; MAP KINASE; C-JUN; REACTIVE OXYGEN; TRANSCRIPTIONAL ACTIVATION; INDUCED PHOSPHORYLATION; CELL-CYCLE; P53; TRANSDUCTION	Mitogen-activated protein kinases (MAPKs) are important mediators that integrate signaling from upstream pathways in response to various environmental cues. In order to control appropriate gene expression through phosphorylation of transcription factors, the activity of MAPKs must be tightly regulated by the actions coordinated between protein kinases and phosphatases. In this study, we explore the underlying mechanism through which the oxidative stress-activated c-Jun N-terminal kinases (JNKs), members of MAPKs, are regulated by dual specificity phosphatases (DUSPs). DUSPs are a group of enzymes that belong to the superfamily of protein-tyrosine phosphatases. They are able to recognize phospho-Ser/Thr and phospho-Tyr residues in substrates. Using quantitative real time PCR, we found that stimulation of human embryonic kidney 293T cells with H2O2 or xanthine/xanthine oxidase led to inducible expression of multiple DUSPs. We used RNA interference to characterize the functional role of these DUSPs and found rapid and transient induction of DUSP1 and DUSP10 to be essential for determining the appropriate magnitude of JNK activation in response to oxidative stress. The transcription factor ATF2, which is phosphorylated and activated by JNK, is a critical mediator for inducible expression of DUSP1 and DUSP10 in this signaling pathway. We further demonstrated that DUSP4 and DUSP16, both showing significant late phase induction, dephosphorylate JNK effectively, causing the down-regulation of the signaling cascade. Thus, this study provides new insights into the role of several DUSPs that coordinate with each other to control the magnitude and duration of JNK activity in response to oxidative stress.	Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Meng, TC (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	tcmeng@gate.sinica.edu.tw	Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cheng WH, 2003, BIOCHEM J, V370, P927, DOI 10.1042/BJ20021870; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fernandez-Sanchez ME, 2003, HUM MOL GENET, V12, P3161, DOI 10.1093/hmg/ddg340; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jeffrey KL, 2006, NAT IMMUNOL, V7, P274, DOI 10.1038/ni1310; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; KWAK SP, 1994, J BIOL CHEM, V269, P3596; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; TONKS NK, 2003, HDB CELL SIGNALLING, V108, P641; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; Worby CA, 2006, J BIOL CHEM, V281, P30412, DOI 10.1074/jbc.M606117200; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang T, 2006, J MOL ENDOCRINOL, V36, P41, DOI 10.1677/jme.1.01881	58	47	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28395	28407		10.1074/jbc.M705142200	http://dx.doi.org/10.1074/jbc.M705142200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681939	hybrid			2022-12-25	WOS:000249642100014
J	Zhao, ZF; Li, XH; Hao, JF; Winston, JH; Weinman, SA				Zhao, Zhifang; Li, Xinhua; Hao, Junfang; Winston, John H.; Weinman, Steven A.			The CIC-3 chloride transport protein traffics through the plasma membrane via interaction of an N-terminal dileucine cluster with clathrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOMAL ACIDIFICATION; RECEPTOR TRAFFICKING; GROWTH-FACTOR; CLC PROTEINS; KINASE-C; CHANNEL; CELLS; LOCALIZATION; DISRUPTION; EXPRESSION	ClC-3 is a ubiquitously expressed chloride transport protein that is present in synaptic vesicles and endosome/lysosome compartments. It is largely intracellular but has been observed at the plasma membrane as well. The aim of this study was to identify the pathways and regulation of ClC-3 trafficking to intracellular sites. At the steady state, similar to 94% of transfected ClC-3 was localized intracellularly, and only 6% was at the plasma membrane. Pulse labeling with [S-35]methionine and biotinylation demonstrated that about 25% of newly synthesized ClC-3 traffics through the plasma membrane. We used both immunofluorescence microscopy and biotinylation assays to assess the trafficking of ClC-3. Plasma membrane ClC-3 was rapidly endocytosed ( t1/2 similar to 9 min); a portion entered a recycling pool that returned to the cell surface after internalization, and the remainder trafficked to more distal intracellular compartments. ClC-3 associated with clathrin at the plasma membrane. Coimmunoprecipitation and glutathione S-transferase pulldown assays demonstrated that the N terminus of ClC-3 binds to clathrin. Alanine replacement of a dileucine acidic cluster within the cytosolic N terminus ( amino acids 13-19) resulted in a molecule that had decreased endocytosis and increased surface expression. This replacement also abolished interaction with clathrin as assessed both by coimmunoprecipitation and glutathione S-transferase pulldown assays. We conclude that ClC-3 is primarily an intracellular transport protein that is transiently inserted into the plasma membrane where it is rapidly endocytosed. Internalization of ClC-3 depends on the interaction between an N-terminal dileucine cluster and clathrin.	Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Cell Biol & Neurosci, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Weinman, Steven/E-7012-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042917, R01DK042917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK042917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Jentsch TJ, 2007, J PHYSIOL-LONDON, V578, P633, DOI 10.1113/jphysiol.2006.124719; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Salazar G, 2004, J BIOL CHEM, V279, P25430, DOI 10.1074/jbc.M402331200; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516; Wang T, 2004, GASTROENTEROLOGY, V126, P1157, DOI 10.1053/j.gastro.2004.01.015; Wang XQ, 2006, NEURON, V52, P321, DOI 10.1016/j.neuron.2006.08.035; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Yoshikawa M, 2002, GENES CELLS, V7, P597, DOI 10.1046/j.1365-2443.2002.00539.x	31	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29022	29031		10.1074/jbc.M703506200	http://dx.doi.org/10.1074/jbc.M703506200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652080	hybrid			2022-12-25	WOS:000249642100076
J	Harman, CA; Turman, MV; Kozak, KR; Marnett, LJ; Smith, WL; Garavito, RM				Harman, Christine A.; Turman, Melissa V.; Kozak, Kevin R.; Marnett, Lawrence J.; Smith, William L.; Garavito, R. Michael			Sturctural basis of enantioselective inhibition of cyclooxygenase-1 S-alpha-Substituted indomethacin ethanolamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPEROXIDE-H SYNTHASE-1; SELECTIVE-INHIBITION; ARACHIDONIC-ACID; ARGININE 120; ACTIVE-SITE; PROSTAGLANDIN; BINDING; FLUORESCENCE; PROTEOLYSIS	The modification of the nonselective nonsteroidal anti-inflammatory drug, indomethacin, by amidation presents a promising strategy for designing novel cyclooxygenase (COX)-2-selective inhibitors. A series of alpha-substituted indomethacin ethanolamides, which exist as R/S-enantiomeric pairs, provides a means to study the impact of stereochemistry on COX inhibition. Comparative studies revealed that the R- and S-enantiomers of the alpha-substituted analogs inhibit COX-2 with almost equal efficacy, whereas COX-1 is selectively inhibited by the S-enantiomers. Mutagenesis studies have not been able to identify residues that manifest the enantioselectivity in COX-1. In an effort to understand the structural impact of chirality on COX-1 selectivity, the crystal structures of ovine COX-1 in complexes with an enantiomeric pair of these indomethacin ethanolamides were determined at resolutions between 2.75 and 2.85 angstrom. These structures reveal unique, enantiomer-selective interactions within the COX-1 side pocket region that stabilize drug binding and account for the chiral selectivity observed with the (S)-alpha-substituted indomethacin ethanolamides. Kinetic analysis of binding demonstrates that both inhibitors bind quickly utilizing a two-step mechanism. However, the second binding step is readily reversible for the R-enantiomer, whereas for the S-enantiomer, it is not. These studies establish for the first time the structural and kinetic basis of high affinity binding of a neutral inhibitor to COX-I and demonstrate that the side pocket of COX-1, previously thought to be sterically inaccessible, can serve as a binding pocket for inhibitor association.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Inst Biol Chem, Nashville, TN 37232 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Michigan State University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Michigan System; University of Michigan	Garavito, RM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 513 Biochem,E Lansing, E Lansing, MI 48824 USA.	garavito@msu.edu		Vaught, Melissa/0000-0001-7627-8330	NATIONAL CANCER INSTITUTE [R01CA089450] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA89450] Funding Source: Medline; NHLBI NIH HHS [R01HL56773] Funding Source: Medline; NIDA NIH HHS [F31DA02014] Funding Source: Medline; NIEHS NIH HHS [T32ES07028] Funding Source: Medline; NIGMS NIH HHS [R01GM68868, P01GM57323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; Garavito RM, 1999, BBA-MOL CELL BIOL L, V1441, P278, DOI 10.1016/S1388-1981(99)00147-X; GARAVITO RM, 2001, HDB METALLOPROTEINS, P245; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; Kalgutkar AS, 1996, BIOCHEMISTRY-US, V35, P9076, DOI 10.1021/bi9605752; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kozak KR, 2002, BIOORG MED CHEM LETT, V12, P1315, DOI 10.1016/S0960-894X(02)00133-6; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lanzo CA, 2000, BIOCHEMISTRY-US, V39, P6228, DOI 10.1021/bi992761o; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2000, ARCH BIOCHEM BIOPHYS, V380, P39, DOI 10.1006/abbi.2000.1906; Moth CW, 2005, J MED CHEM, V48, P3613, DOI 10.1021/jm0494164; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Prusakiewicz JJ, 2004, BIOCHEMISTRY-US, V43, P15439, DOI 10.1021/bi048534q; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Seibold SA, 2004, J PHYS CHEM B, V108, P9297, DOI 10.1021/jp049844l; Seibold SA, 2003, J BIOL CHEM, V278, P46163, DOI 10.1074/jbc.M306319200; SMITH WL, 1971, J BIOL CHEM, V246, P6700; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Walker MC, 2001, BIOCHEM J, V357, P709, DOI 10.1042/0264-6021:3570709; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	32	73	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28096	28105		10.1074/jbc.M701335200	http://dx.doi.org/10.1074/jbc.M701335200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656360	hybrid			2022-12-25	WOS:000249455600059
J	Huttunen, HJ; Guenette, SY; Peach, C; Greco, C; Xia, WM; Kim, DY; Barren, C; Tanzi, RE; Kovacs, DM				Huttunen, Henri J.; Guenette, Suzanne Y.; Peach, Camilla; Greco, Christopher; Xia, Weiming; Kim, Doo Yeon; Barren, Cory; Tanzi, Rudolph E.; Kovacs, Dora M.			HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; LIPID RAFTS; CLEAVAGE; INHIBITOR; DOMAIN; PRESENILIN-1; OMI/HTRA2; STRESS	Alzheimer disease-associated beta-amyloid peptide is generated from its precursor protein APP. By using the yeast two-hybrid assay, here we identified HtrA2/Omi, a stress-responsive chaperone-protease as a protein binding to the N-terminal cysteine-rich region of APP. HtrA2 coimmunoprecipitates exclusively with immature APP from cell lysates as well as mouse brain extracts and degrades APP in vitro. A subpopulation of HtrA2 localizes to the cytosolic side of the endoplasmic reticulum (ER) membrane where it contributes to ER-associated degradation of APP together with the proteasome, Inhibition of the proteasome results in accumulation of retrotranslocated forms of APP and increased association of APP with HtrA2 and Derlin-1 in microsomal membranes. In cells lacking HtrA2, APP holoprotein is stabilized and accumulates in the early secretory pathway correlating with elevated levels of APP C-terminal fragments and increased All secretion. Inhibition of ER-associated degradation (either HtrA2 or proteasome) promotes binding of APP to the COPII protein Sec23 suggesting enhanced trafficking of APP out of the ER. Based on these results we suggest a novel function for HtrA2 as a regulator of APP metabolism through ER-associated degradation.	Massachusetts Gen Hosp, Harvard Med Sch, Neurobiol Dis Lab, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Harvard Med Sch, Massachussetts Gen Inst Nuerodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Harvard Med Sch, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kovacs, DM (corresponding author), Massachusetts Gen Hosp, Harvard Med Sch, Neurobiol Dis Lab, 114 16th St, Charlestown, MA 02129 USA.	Dora_Kovacs@hms.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; xia, weiming/E-5465-2016	Tanzi, Rudolph/0000-0002-7032-1454; xia, weiming/0000-0002-7463-3295; Huttunen, Henri/0000-0002-9867-4438				Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; d'Abramo C, 2005, BIOCHEM J, V391, P693, DOI 10.1042/BJ20050560; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Forster ML, 2006, J CELL BIOL, V173, P853, DOI 10.1083/jcb.200602046; Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hare JF, 2006, ARCH BIOCHEM BIOPHYS, V451, P79, DOI 10.1016/j.abb.2006.05.002; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hiltunen M, 2006, J BIOL CHEM, V281, P32240, DOI 10.1074/jbc.M603106200; Johnson RJ, 2001, NEUROBIOL AGING, V22, P387, DOI 10.1016/S0197-4580(00)00247-5; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kincaid MM, 2007, MOL BIOL CELL, V18, P455, DOI 10.1091/mbc.E06-08-0696; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kudo T, 2006, BIOCHEM BIOPH RES CO, V344, P525, DOI 10.1016/j.bbrc.2006.03.173; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Lott IT, 2005, NEUROBIOL AGING, V26, P383, DOI 10.1016/j.neurobiolaging.2004.08.005; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Park HJ, 2004, NEUROSCI LETT, V357, P63, DOI 10.1016/j.neulet.2003.11.068; Park HJ, 2006, J BIOL CHEM, V281, P34277, DOI 10.1074/jbc.M603443200; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Rechards M, 2006, TRAFFIC, V7, P354, DOI 10.1111/j.1600-0854.2006.00388.x; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-4; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; Wilken C, 2004, CELL, V117, P483, DOI 10.1016/S0092-8674(04)00454-4; Yang L, 2007, J BIOL CHEM, V282, P10981, DOI 10.1074/jbc.M700445200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	57	60	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28285	28295		10.1074/jbc.M702951200	http://dx.doi.org/10.1074/jbc.M702951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17684015	hybrid			2022-12-25	WOS:000249455600078
J	Green, RE; Taggart, MA; Senacha, KR; Raghavan, B; Pain, DJ; Jhala, Y; Cuthbert, R				Green, Rhys E.; Taggart, Mark A.; Senacha, Kalu Ram; Raghavan, Bindu; Pain, Deborah J.; Jhala, Yadvendradev; Cuthbert, Richard			Rate of Decline of the Oriental White-Backed Vulture Population in India Estimated from a Survey of Diclofenac Residues in Carcasses of Ungulates	PLOS ONE			English	Article								The non-steroidal anti-inflammatory drug diclofenac is a major cause of the rapid declines in the Indian subcontinent of three species of vultures endemic to South Asia. The drug causes kidney failure and death in vultures. Exposure probably arises through vultures feeding on carcasses of domesticated ungulates treated with the drug. However, before the study reported here, it had not been established from field surveys of ungulate carcasses that a sufficient proportion was contaminated to cause the observed declines. We surveyed diclofenac concentrations in samples of liver from carcasses of domesticated ungulates in India in 2004-2005. We estimated the concentration of diclofenac in tissues available to vultures, relative to that in liver, and the proportion of vultures killed after feeding on a carcass with a known level of contamination. We assessed the impact of this mortality on vulture population trend with a population model. We expected levels of diclofenac found in ungulate carcasses in 2004-2005 to cause oriental white-backed vulture population declines of 80-99% per year, depending upon the assumptions used in the model. This compares with an observed rate of decline, from road transect counts, of 48% per year in 2000-2003. The precision of the estimate based upon carcass surveys is low and the two types of estimate were not significantly different. Our analyses indicate that the level of diclofenac contamination found in carcasses of domesticated ungulates in 2004-2005 was sufficient to account for the observed rapid decline of the oriental white-backed vulture in India. The methods we describe could be used again to assess changes in the effect on vulture population trend of diclofenac and similar drugs. In this way, the effectiveness of the recent ban in India on the manufacture and importation of diclofenac for veterinary use could be monitored.	[Green, Rhys E.] Univ Cambridge, Dept Zool, Conservat Sci Grp, Cambridge, England; [Green, Rhys E.; Pain, Deborah J.; Cuthbert, Richard] Royal Soc Protect Birds, Sandy SG19 2DL, Beds, England; [Taggart, Mark A.] Univ Aberdeen, Dept Plant & Soil Sci, Sch Biol Sci, Aberdeen, Scotland; [Taggart, Mark A.] Univ Castilla La Mancha, Inst Invest Recursos Cineget, Ciudad Real, Spain; [Senacha, Kalu Ram; Raghavan, Bindu] Bombay Nat Hist Soc, Bombay, Maharashtra, India; [Jhala, Yadvendradev] Wildlife Inst India, Dehra Dun, Uttaranchal, India	University of Cambridge; Royal Society for Protection of Birds; University of Aberdeen; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigacion en Recursos Cinegeticos (IREC); Universidad de Castilla-La Mancha; Wildlife Institute of India	Green, RE (corresponding author), Univ Cambridge, Dept Zool, Conservat Sci Grp, Cambridge, England.	reg29@hermes.cam	Jhala, Yadvendradev/AAL-9711-2020	Taggart, Mark/0000-0002-0649-8490; Raghavan, Bindu/0000-0002-1819-5251	Darwin Initiative; Royal Society	Darwin Initiative; Royal Society(Royal Society of London)	The research is part of a programme on vulture conservation science co-funded by Darwin Initiative for the Survival of Species of the UK Government's Department for Environment, Food and Rural Affairs, the Royal Society for the Protection of Birds and the Zoological Society of London. The RSPB is a sponsor and also employs 3 of the authors of this paper as scientists who are members of its Conservation Science department. Other than that, sponsors have not been involved in any aspect of the preparation, review, approval or any other aspect of this paper.	Cuthbert R, 2007, BIOL LETTERS, V3, P90, DOI 10.1098/rsbl.2006.0554; Gilbert M, 2006, ORYX, V40, P388, DOI 10.1017/S0030605306001347; Green RE, 2004, J APPL ECOL, V41, P793, DOI 10.1111/j.0021-8901.2004.00954.x; Green RE, 2006, J APPL ECOL, V43, P949, DOI 10.1111/j.1365-2664.2006.01225.x; GRUBH RB, 1974, THESIS U BOMBAY MUMB; *IUCN, 2006, 2006 IUCN RED LIST T; Johnson JA, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-65; Kalbfleisch J. G., 1979, PROBABILITY STAT INF; Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317; Prakash V, 2003, BIOL CONSERV, V109, P381, DOI 10.1016/S0006-3207(02)00164-7; ROTHERY P, 1988, BIRD STUDY, V35, P219, DOI 10.1080/00063658809476992; Shultz S, 2004, P ROY SOC B-BIOL SCI, V271, pS458, DOI 10.1098/rsbl.2004.0223; Swan G, 2006, PLOS BIOL, V4, P395, DOI 10.1371/journal.pbio.0040066; Swan GE, 2006, BIOL LETT-UK, V2, P279, DOI 10.1098/rsbl.2005.0425; Taggart MA, 2007, ENVIRON INT, V33, P759, DOI 10.1016/j.envint.2007.02.010; White C.M., 1994, NEW WORLD VULTURES G	16	54	64	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e686	10.1371/journal.pone.0000686	http://dx.doi.org/10.1371/journal.pone.0000686			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668064	Green Published, gold			2022-12-25	WOS:000207452300022
J	Appenzeller, O; Qualls, C; Barbic, F; Furlan, R; Porta, A				Appenzeller, Otto; Qualls, Clifford; Barbic, Franca; Furlan, Raffaello; Porta, Alberto			Stable Isotope Ratios in Hair and Teeth Reflect Biologic Rhythms	PLOS ONE			English	Article								Biologic rhythms give insight into normal physiology and disease. They can be used as biomarkers for neuronal degenerations. We present a diverse data set to show that hair and teeth contain an extended record of biologic rhythms, and that analysis of these tissues could yield signals of neurodegenerations. We examined hair from mummified humans from South America, extinct mammals and modern animals and people, both healthy and diseased, and teeth of hominins. We also monitored heart-rate variability, a measure of a biologic rhythm, in some living subjects and analyzed it using power spectra. The samples were examined to determine variations in stable isotope ratios along the length of the hair and across growth-lines of the enamel in teeth. We found recurring circa-annual periods of slow and fast rhythms in hydrogen isotope ratios in hair and carbon and oxygen isotope ratios in teeth. The power spectra contained slow and fast frequency power, matching, in terms of normalized frequency, the spectra of heart rate variability found in our living subjects. Analysis of the power spectra of hydrogen isotope ratios in hair from a patient with neurodegeneration revealed the same spectral features seen in the patient's heart-rate variability. Our study shows that spectral analysis of stable isotope ratios in readily available tissues such as hair could become a powerful diagnostic tool when effective treatments and neuroprotective drugs for neurodegenerative diseases become available. It also suggests that similar analyses of archaeological specimens could give insight into the physiology of ancient people and animals.	[Appenzeller, Otto] New Mexico Hlth Enhancement & Marathon Clin Res F, Albuquerque, NM USA; [Qualls, Clifford] Univ New Mexico, Dept Math & Stat, Albuquerque, NM 87131 USA; [Barbic, Franca; Furlan, Raffaello] Univ Milan, Osped L Sacco, Milan, Italy; [Porta, Alberto] Univ Milan, IRCCS, Ist Ortoped Galeazzi, Dipartimento Tecnol Salute, Milan, Italy	University of New Mexico; University of Milan; Luigi Sacco Hospital; IRCCS Istituto Ortopedico Galeazzi; University of Milan	Appenzeller, O (corresponding author), New Mexico Hlth Enhancement & Marathon Clin Res F, Albuquerque, NM USA.	oarun@unm.edu	Porta, Alberto/K-4390-2016; Furlan, Raffaello/AAH-3167-2021; Barbic, Franca/S-2183-2019; Barbic, Franca/GLV-2669-2022	Porta, Alberto/0000-0002-6720-9824; Furlan, Raffaello/0000-0001-5209-6786; Barbic, Franca/0000-0002-8283-1988; 	NMHEMC Research Foundation, Albuquerque NM USA	NMHEMC Research Foundation, Albuquerque NM USA	Funding: Funded by NMHEMC Research Foundation, Albuquerque NM USA.	Barbic F, 2007, HYPERTENSION, V49, P120, DOI 10.1161/01.HYP.0000250939.71343.7c; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; BROMAGE TG, 1985, NATURE, V317, P525, DOI 10.1038/317525a0; Buijs RM, 2003, J ENDOCRINOL, V177, P17, DOI 10.1677/joe.0.1770017; CHESHIRE WP, 2000, AUTONOMIC NERVOUS 2, P105; Iranzo A, 2006, LANCET NEUROL, V5, P572, DOI 10.1016/S1474-4422(06)70476-8; Krause K, 2006, SEMIN CUTAN MED SURG, V25, P2, DOI 10.1016/j.sder.2006.01.002; Lincoln GA, 2006, SCIENCE, V314, P1941, DOI 10.1126/science.1132009; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McDearmon EL, 2006, SCIENCE, V314, P1304, DOI 10.1126/science.1132430; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Pregueiro AM, 2006, SCIENCE, V313, P644, DOI 10.1126/science.1121716; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Sharp ZD, 2003, J ARCHAEOL SCI, V30, P1709, DOI 10.1016/S0305-4403(03)00071-2; Sponheimer M, 2006, SCIENCE, V314, P980, DOI 10.1126/science.1133827; USGS MENLO PARK CALI; 2006, NATURE, V442, pR7	17	9	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e636	10.1371/journal.pone.0000636	http://dx.doi.org/10.1371/journal.pone.0000636			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653263	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452200005
J	Sharpee, T; Bialek, W				Sharpee, Tatyana; Bialek, William			Neural Decision Boundaries for Maximal Information Transmission	PLOS ONE			English	Article							NATURAL IMAGES; STATISTICS; FEATURES; NEURONS; EFFICIENCY; RESPONSES; CONTRAST	We consider here how to separate multidimensional signals into two categories, such that the binary decision transmits the maximum possible information about those signals. Our motivation comes from the nervous system, where neurons process multidimensional signals into a binary sequence of responses (spikes). In a small noise limit, we derive a general equation for the decision boundary that locally relates its curvature to the probability distribution of inputs. We show that for Gaussian inputs the optimal boundaries are planar, but for non-Gaussian inputs the curvature is nonzero. As an example, we consider exponentially distributed inputs, which are known to approximate a variety of signals from natural environment.	[Sharpee, Tatyana] Crick Jacobs Ctr Theoret Biol, La Jolla, CA USA; [Sharpee, Tatyana] Salk Inst Biol Studies, Lab Computat Neurobiol, La Jolla, CA 92037 USA; [Bialek, William] Princeton Univ, Joseph Henry Labs Phys, Lewis Sigler Inst Integrat Genom, Princeton Ctr Theoret Phys, Princeton, NJ 08544 USA	Salk Institute; Princeton University	Sharpee, T (corresponding author), Crick Jacobs Ctr Theoret Biol, La Jolla, CA USA.	sharpee@salk.edu	Sharpee, Tatyana/E-8663-2010	Sharpee, Tatyana/0000-0002-7483-5081	NIMH; Swartz Foundation	NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Swartz Foundation	Funding: This work was supported by the NIMH and the Swartz Foundation.	Arcas BAY, 2003, NEURAL COMPUT, V15, P1715, DOI 10.1162/08997660360675017; Atick JJ, 1990, NEURAL COMPUT, V2, P308, DOI 10.1162/neco.1990.2.3.308; ATTNEAVE F, 1954, PSYCHOL REV, V61, P183, DOI 10.1037/h0054663; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Balasubramanian V, 2001, NEURAL COMPUT, V13, P799, DOI 10.1162/089976601300014358; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; BARLOW HB, 1959, P S MECH THOUGHT PRO; Bialek W, 2005, FEATURES DIMENSIONS; Brenner N, 2000, NEURON, V26, P695, DOI 10.1016/S0896-6273(00)81205-2; BUCHSBAUM G, 1983, PROC R SOC SER B-BIO, V220, P89, DOI 10.1098/rspb.1983.0090; Cover T. M, 2006, ELEMENTS INFORM THEO, V2nd, DOI 10.1002/0471200611; David SV, 2004, J NEUROSCI, V24, P6991, DOI 10.1523/JNEUROSCI.1422-04.2004; DeWeese M, 1996, NETWORK-COMP NEURAL, V7, P325, DOI 10.1088/0954-898X/7/2/013; Escabi MA, 2003, J NEUROSCI, V23, P11489; Fairhall AL, 2006, J NEUROPHYSIOL, V96, P2724, DOI 10.1152/jn.00995.2005; Fairhall AL, 2001, NATURE, V412, P787, DOI 10.1038/35090500; Felsen G, 2005, PLOS BIOL, V3, P1819, DOI 10.1371/journal.pbio.0030342; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Hsu A, 2004, J NEUROSCI, V24, P9201, DOI 10.1523/JNEUROSCI.2449-04.2004; LAUGHLIN S, 1981, Z NATURFORSCH C, V36, P910; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Linsker R., 1989, ADV NEURAL INFORMATI, P186; Machens CK, 2003, NAT NEUROSCI, V6, P341, DOI 10.1038/nn1036; Maravall M, 2007, PLOS BIOL, V5, P323, DOI 10.1371/journal.pbio.0050019; MINSKY ML, 1969, PAPERT SA PERCEPTRON, P263; Nelken I, 1999, NATURE, V397, P154, DOI 10.1038/16456; Rieke F, 1995, P ROY SOC B-BIOL SCI, V262, P259, DOI 10.1098/rspb.1995.0204; RIEKE F, 1997, SPIKES EXPLORING NEU, P416; RUDERMAN DL, 1994, PHYS REV LETT, V73, P814, DOI 10.1103/PhysRevLett.73.814; RUDERMAN DL, 1994, NETWORK-COMP NEURAL, V5, P517, DOI 10.1088/0954-898X/5/4/006; Rust NC, 2005, NEURON, V46, P945, DOI 10.1016/j.neuron.2005.05.021; Sarpeshkar R, 1998, NEURAL COMPUT, V10, P1601, DOI 10.1162/089976698300017052; Sharpee T, 2004, NEURAL COMPUT, V16, P223, DOI 10.1162/089976604322742010; Sharpee TO, 2006, NATURE, V439, P936, DOI 10.1038/nature04519; Slee SJ, 2005, J NEUROSCI, V25, P9978, DOI 10.1523/JNEUROSCI.2666-05.2005; Smirnakis SM, 1997, NATURE, V386, P69, DOI 10.1038/386069a0; SRINIVASAN MV, 1982, PROC R SOC SER B-BIO, V216, P427, DOI 10.1098/rspb.1982.0085; STRUIK DJ, 1988, LECT CLASSICAL DIFFE, P240	38	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e646	10.1371/journal.pone.0000646	http://dx.doi.org/10.1371/journal.pone.0000646			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653273	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452200015
J	Muerkoster, SS; Rausch, AV; Isberner, A; Minkenberg, J; Blaszczuk, E; Witt, M; Folsch, UR; Schmitz, F; Schafer, H; Arlt, A				Mueerkoester, S. Sebens; Rausch, A. V.; Isberner, A.; Minkenberg, J.; Blaszczuk, E.; Witt, M.; Foelsch, U. R.; Schmitz, F.; Schaefer, H.; Arlt, A.			The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition	ONCOGENE			English	Article						early-response gene; gastrin receptor; loss of function mutation; apoptosis; colon cancer	EARLY-RESPONSE GENE; GLYCINE-EXTENDED GASTRIN; COLON-CANCER; CARCINOMA CELLS; TRANSGENIC MICE; MOUSE MODEL; CRYPT FOCI; IN-VIVO; PROGASTRIN; RECEPTORS	Addressing the puzzling role of amidated gastrin(17) ( G17) and the gastrin/ CCKB/ CCK2 receptor in colorectal carcinogenesis, we analysed potential candidate genes involved in G17-dependent NF-kappa B inhibition and apoptosis. The colorectal carcinoma cell line Colo320 over-expressing the wild-type CCK2 receptor ( Colo320wt) underwent G17-induced apoptosis along with suppressed NF-kappa B activation and decreased expression of the antiapoptotic NF-kappa B target genes cIAP1 and cIAP2, whereas G17 was without effect on Colo320 cells expressing a CCK2 receptor bearing a loss of function mutation ( Colo320mut). Gene microarray analysis revealed an elevated expression of the stress response gene IEX-1 in G17-treated Colo320wt but not Colo320mut cells. Quantitative real-time PCR and conventional RT-PCR confirmed this G17-dependent increase of IEX-1 expression in Colo320wt cells. If these cells were subjected to IEX-1 knockdown by small interfering RNA transfection, the apoptosis-inducing effect of G17 was abolished. Moreover, tumor necrosis factor alpha (TNF alpha)- or 5-FU-induced apoptosis that is greatly enhanced by G17 treatment in Colo320wt cells was prevented if IEX-1 expression was repressed. Under these conditions of blocked IEX-1 expression, the NF-kappa B activity remained unaffected by G17, in particular in Colo320wt cells co-treated with TNF alpha and also the suppressive effect of G17 on cIAP1 and cIAP2 expression was not observed anymore if IEX-1 expression was blocked. Conversely, IEX-1 overexpression in Colo320mut cells caused an increase of basal and TNF alpha- or 5-FU-induced apoptosis, an effect not further triggered by G17 treatment. Using a xenograft tumor model in severe combined immune deficiency mice, we could show that experimental systemic hypergastrinemia induced by the administration of omeprazole led to enhanced apoptosis as well as to a marked increase of IEX-1 expression in Colo320wt tumors, but not in Colo320mut tumors. These observations indicate that the proapoptotic effect of G17 on human colon cancer cells expressing the wild-type CCK2 receptor is mediated by IEX-1, which modulates NF-kappa B-dependent antiapoptotic protection and thereby exerts tumor-suppressive potential.	[Mueerkoester, S. Sebens; Rausch, A. V.; Isberner, A.; Minkenberg, J.; Blaszczuk, E.; Witt, M.; Foelsch, U. R.; Schmitz, F.; Schaefer, H.; Arlt, A.] Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; [Schmitz, F.] Klinikum Hildesheim, Dept Med 2, Hildesheim, Germany	University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Schmitz, Frank/ABB-6798-2021	Arlt, Alexander/0000-0002-6160-1059; 				Ahmed S, 2004, FEBS LETT, V556, P199, DOI 10.1016/S0014-5793(03)01408-X; Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Arlt A, 2007, BIOCHEM J, V402, P367, DOI 10.1042/BJ20061072; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Clerc P, 1997, INT J CANCER, V72, P931, DOI 10.1002/(SICI)1097-0215(19970917)72:6<931::AID-IJC2>3.0.CO;2-Q; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Cobb S, 2002, GASTROENTEROLOGY, V123, P516, DOI 10.1053/gast.2002.34754; Copps J, 2007, PEPTIDES, V28, P632, DOI 10.1016/j.peptides.2006.10.008; Corcoran JA, 2006, J VIROL, V80, P9720, DOI 10.1128/JVI.01216-06; Dilley WG, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-9; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Kondratyev AD, 1996, CANCER RES, V56, P1498; Muerkoster S, 2005, GASTROENTEROLOGY, V129, P952, DOI 10.1053/j.gastro.2005.06.059; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Osawa Y, 2003, J IMMUNOL, V170, P4053, DOI 10.4049/jimmunol.170.8.4053; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; Rooman I, 2001, GASTROENTEROLOGY, V121, P940, DOI 10.1053/gast.2001.27998; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1996, CANCER RES, V56, P2641; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Schmidt WE, 2004, GASTROENTEROLOGY, V126, P606, DOI 10.1053/j.gastro.2003.12.017; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; Singh P, 2007, ONCOGENE, V26, P425, DOI 10.1038/sj.onc.1209798; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Till A, 2005, J BIOL CHEM, V280, P5994, DOI 10.1074/jbc.M411541200; Watson SA, 2001, CANCER RES, V61, P625; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yu HG, 2005, CELL SIGNAL, V17, P1505, DOI 10.1016/j.cellsig.2005.03.009	40	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1122	1134		10.1038/sj.onc.1210728	http://dx.doi.org/10.1038/sj.onc.1210728			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704804				2022-12-25	WOS:000253136700012
J	Ogawa, E; Okuyama, R; Ikawa, S; Nagoshi, H; Egawa, T; Kurihara, A; Yabuki, M; Tagami, H; Obinata, M; Aiba, S				Ogawa, E.; Okuyama, R.; Ikawa, S.; Nagoshi, H.; Egawa, T.; Kurihara, A.; Yabuki, M.; Tagami, H.; Obinata, M.; Aiba, S.			P51/p63 inhibits ultraviolet B-induced apoptosis via Akt activation	ONCOGENE			English	Article						p51/p63; p53; apoptosis; UV; epidermis	SKIN-CANCER; P53 HOMOLOG; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; DOWN-REGULATION; P63; PATHWAY; DELTA-NP63-ALPHA; TRANSCRIPTION; DEGRADATION	The epidermis must be protected against excess apoptotic cell death in response to ultraviolet-B (UV-B) irradiation. p53 is known to be critical for this protection. Although the p53 family member Delta Np51B/Delta Np63a (an N terminal-deleted form of p51/p63) is abundantly expressed in keratinocytes, its contribution to UV-B-dependent apoptosis is largely unknown. We found that, after a transient increase, Delta Np51B is downregulated in UV-B-irradiated keratinocytes undergoing apoptosis, whereas p53 is upregulated with delayed kinetics. Furthermore, the reduction of Delta Np51B by small interfering RNAs augmented UV- B-dependent apoptosis in keratinocytes, indicating that Delta Np51B blocks keratinocyte apoptosis. Although the exogenous expression of Delta Np51B in keratinocytes did not further block the UV-B-dependent apoptosis, to our surprise the expression of TAp51B (an isoform with a full NH2-terminal transactivation domain that is structurally and functionally similar to p53) decreased apoptosis significantly. The blockade of keratinocyte apoptosis by the p51 was dependent on the phosphorylation of Akt, resulting in the activation of a survival pathway. Thus, in addition to its indispensable roles in epithelial development, p51 acts in adult cells to protect the epidermis against UV-B irradiation by preventing excess depletion of keratinocytes.	[Ogawa, E.; Okuyama, R.; Egawa, T.; Tagami, H.; Aiba, S.] Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Ikawa, S.; Nagoshi, H.; Kurihara, A.; Yabuki, M.; Obinata, M.] Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Ikawa, S.; Nagoshi, H.; Kurihara, A.; Yabuki, M.] Tohoku Univ, Interdisciplinary Res Ctr, Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University; Tohoku University	Okuyama, R (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	rokuyama@mail.tains.tohoku.ac.jp	井川, 俊太郎/L-5911-2015					Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CUI R, 2005, BIOCH BIOPHYS RES CO; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Koster MI, 2006, CANCER RES, V66, P3981, DOI 10.1158/0008-5472.CAN-06-0027; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Liefer KM, 2000, CANCER RES, V60, P4016; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Papoutsaki M, 2005, ONCOGENE, V24, P6970, DOI 10.1038/sj.onc.1208835; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	26	20	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					848	856		10.1038/sj.onc.1210682	http://dx.doi.org/10.1038/sj.onc.1210682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653081				2022-12-25	WOS:000252884500014
J	Voloboueva, LA; Killilea, DW; Atamna, H; Ames, BN				Voloboueva, Ludmila A.; Killilea, David W.; Atamna, Hani; Ames, Bruce N.			N-tert-butyl hydroxylamine, a mitochondrial antioxidant, protects human retinal pigment epithelial cells from iron overload: relevance to macular degeneration	FASEB JOURNAL			English	Article						calcitrol; cognition; depression; nutrition; brain development; cytokine theory	CYTOCHROME-C-OXIDASE; TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; INDUCED APOPTOSIS; FERRITIN; GLUTATHIONE; TOXICITY; DAMAGE; CERULOPLASMIN; ACCUMULATION	Age-related macular degeneration (AMD) is the leading cause of severe visual impairment in the elderly in developed countries. AMD patients have elevated levels of iron within the retinal pigment epithelia (RPE), which may lead to oxidative damage to mitochondria, disruption of retinal metabolism, and vision impairment or loss. As a possible model for iron-induced AMD, we investigated the effects of excess iron in cultured human fetal RPE cells on oxidant levels and mitochondrial cytochrome c oxidase (complex IV) function and tested for protection by N-tert-butyl hydroxylamine (Nt-BHA), a known mitochondrial antioxidant. RPE exposure to ferric ammonium citrate resulted in a time-and dose-dependent increase in intracellular iron, which increased oxidant production and decreased glutathione (GSH) levels and mitochondrial complex IV activity. NtBHA addition to iron-overloaded RPE cells led to a reduction of intracellular iron content, oxidative stress, and partial restoration of complex IV activity and GSH content. NtBHA might be useful in AMD due to its potential to reduce oxidative stress, mitochondrial damage, and age-related iron accumulation, which may damage normal RPE function and lead to loss of vision.-Voloboueva, L. A., Killilea, D. W., Atamna, H., Ames, B. N. N-tert-butyl hydroxylamine, a mitochondrial antioxidant, protects human retinal pigment epithelial cells from iron overload: relevance to macular degeneration.	Childrens Hosp Oakland, Res Inst, Nutr & Metabol Ctr, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Ames, BN (corresponding author), Childrens Hosp Oakland, Res Inst, Nutr & Metabol Ctr, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	bames@chori.org		Killilea, David/0000-0002-8929-6527	NEI NIH HHS [R21 EY016101-01, R21 EY016101-01A1, R01 EY002205-24, R01 EY002205, R21 EY016101, R21 EY016101-02, R37 EY002205, EY02205] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY016101, R01EY002205, R37EY002205] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011; Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Atamna H, 2002, ARCH BIOCHEM BIOPHYS, V397, P345, DOI 10.1006/abbi.2001.2671; Atamna H, 2001, FASEB J, V15, P2196, DOI 10.1096/fj.01-0134com; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Bishop GM, 2001, BRAIN RES, V907, P175, DOI 10.1016/S0006-8993(01)02303-4; Brubacher JL, 2001, J IMMUNOL METHODS, V251, P81, DOI 10.1016/S0022-1759(01)00308-8; Chen HY, 2006, INT J BIOCHEM CELL B, V38, P1402, DOI 10.1016/j.biocel.2006.02.006; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246; DAVIS KJA, 1991, OXIDATIVE DAMAGE REP; De Domenico I, 2006, EMBO J, V25, P5396, DOI 10.1038/sj.emboj.7601409; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029; Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003; Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; GUTTERIDGE JMC, 1989, CLIN HAEMATOL, V2, P195; Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101; Hahn P, 2004, MOL VIS, V10, P598; Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099; Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776; Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019; Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Hoepken HH, 2004, J NEUROCHEM, V88, P1194, DOI 10.1046/j.1471-4159.2003.02236.x; Huang XP, 2006, CHEM-BIOL INTERACT, V163, P68, DOI 10.1016/j.cbi.2006.05.007; HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; Killilea DW, 2003, ANTIOXID REDOX SIGN, V5, P507, DOI 10.1089/152308603770310158; Kim HJ, 2005, REDOX REP, V10, P287, DOI 10.1179/135100005X83662; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443; Lee JH, 2004, CARCINOGENESIS, V25, P1435, DOI 10.1093/carcin/bgh139; Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622; Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; RAPP LM, 1982, PROBLEMS NORMAL GENE, P109; Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73; Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226; VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2; Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098; Walter PB, 2002, P NATL ACAD SCI USA, V99, P2264, DOI 10.1073/pnas.261708798; Wang ZJ, 1998, INVEST OPHTH VIS SCI, V39, P631; Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547; Watts RN, 2006, P NATL ACAD SCI USA, V103, P7670, DOI 10.1073/pnas.0602515103; Wetli HA, 2006, CHEM BIOL, V13, P965, DOI 10.1016/j.chembiol.2006.08.005; Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537; Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343; [于健 Yu Jian], 2003, [第四军医大学学报, Journal of the Fourth Military Medical University], V24, P805	71	29	29	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4077	4086		10.1096/fj.07-8396com	http://dx.doi.org/10.1096/fj.07-8396com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17656467	Green Accepted			2022-12-25	WOS:000251283500032
J	Park, MJ; Kwak, HJ; Lee, HC; Yoo, DH; Park, IC; Kim, MS; Lee, SH; Rhee, CH; Hong, SI				Park, Myung-Jin; Kwak, Hee-Jin; Lee, Hyung-Chahn; Yoo, Doo-Hyun; Park, In-Chul; Kim, Mi-Suk; Lee, Seung-Hoon; Rhee, Chang Hun; Hong, Seok-Il			Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IN-VITRO ANGIOGENESIS; PHOSPHATASE GENE; PC12 CELLS; MIGRATION; PROLIFERATION; CANCER; AKT; IDENTIFICATION; NEUROTROPHINS	Nerve growth factor (NGF) is a well characterized neurotrophic agonist in the nervous system that triggers angiogenesis. In this study, we investigated the signaling mechanisms involved in NGF-induced angiogenesis. NGF stimulated endothelial cell invasion and cord formation on Matrigel in vitro but had marginal effect on proliferation and migration of these cells. NGF stimulated matrix metalloproteinase (MMP)-2 mRNA expression and protein secretion in human umbilical vein endothelial cells. Using synthetic and endogenous inhibitors of MMP-2 and MMP-2 small interfering RNA suppressed NGF-induced invasion and cord formation. We demonstrated that NGF-induced MMP-2 secretion, invasion, and cord formation are regulated via activation of the NGF receptor, TrkA, phosphatidylinositol 3-kinase (PI3K), and Akt using various pharmacological inhibitors. Specifically, NGF enhanced TrkA phosphorylation, PI3K activity, and Akt phosphorylation. Introduction of NGF-neutralizing antibodies, dominant-negative Akt, or wild-typePTEN effectively inhibited NGF-induced MMP-2 secretion and cord formation. Deletion and site-directed mutagenesis analysis of the MMP-2 promoter demonstrated that the AP-2-binding site is critical for NGF-induced MMP-2 promoter activity. NGF increased the DNA binding activity of AP-2, which was suppressed by inhibitors of TrkA and PI3K. Furthermore, transfection of AP-2 small interfering RNA effectively blocked NGF-induced MMP-2 secretion and cord formation. Finally, NGF promoted neovessel formation in Matrigel plugs in vivo, which was significantly inhibited by K252a and LY294002, but it failed to promote angiogenesis using MMP-2 knock-out mice. Our data collectively suggest that NGF stimulates endothelial cell invasion and cord formation by augmenting MMP-2 via the PI3K/Akt signaling pathway and AP-2 transcription factor, which may be responsible for triggering angiogenesis.	Korea Inst Radiol & Med Sci, Lab Funct Genom, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Dept Neurosurg, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Med & Clin Pathol, Seoul 139706, South Korea; Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; National Cancer Center - Korea (NCC)	Hong, SI (corresponding author), Korea Inst Radiol & Med Sci, Lab Funct Genom, 215-4 Gongneung Dong, Seoul 139706, South Korea.	hongsicp@kcch.re.kr						Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Choi YA, 2004, J BIOL CHEM, V279, P36579, DOI 10.1074/jbc.M314235200; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; Emanueli C, 2002, CIRCULATION, V106, P2257, DOI 10.1161/01.CIR.0000033971.56802.C5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giuliani R, 1999, J CELL SCI, V112, P2597; Graiani G, 2004, DIABETOLOGIA, V47, P1047, DOI 10.1007/s00125-004-1414-7; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Guccione M, 2002, AM J PHYSIOL-RENAL, V282, pF164, DOI 10.1152/ajprenal.0318.2000; Haas TL, 2005, CAN J PHYSIOL PHARM, V83, P1, DOI 10.1139/Y04-120; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Inoue K, 2006, J BIOL CHEM, V281, P33814, DOI 10.1074/jbc.M607290200; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kumar R, 1998, INT J ONCOL, V12, P749; Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056; Lee OH, 2000, BRIT J CANCER, V82, P385; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3; Nusser N, 2002, J BIOL CHEM, V277, P35840, DOI 10.1074/jbc.M203617200; Park MJ, 2002, CANCER RES, V62, P6318; Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rahbek UL, 2005, PFLUG ARCH EUR J PHY, V450, P355, DOI 10.1007/s00424-005-1436-0; Raychaudhuri SK, 2001, ARCH DERMATOL RES, V293, P291, DOI 10.1007/s004030100224; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Risinger GM, 2006, J BIOL CHEM, V281, P25915, DOI 10.1074/jbc.M513513200; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Schonhoff CM, 2001, J NEUROCHEM, V78, P631, DOI 10.1046/j.1471-4159.2001.00432.x; Seo K, 2001, J Vet Sci, V2, P125; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Steinle JJ, 2003, AUTON NEUROSCI-BASIC, V108, P57, DOI 10.1016/S1566-0702(03)00151-6; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	46	83	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30485	30496		10.1074/jbc.M701081200	http://dx.doi.org/10.1074/jbc.M701081200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17666398	hybrid			2022-12-25	WOS:000250136300016
J	Yao, Y; Nowak, S; Yochelis, A; Garfinkel, A; Bostroem, KI				Yao, Yucheng; Nowak, Sarah; Yochelis, Arik; Garfinkel, Alan; Bostroem, Kristina I.			Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BRANCHING MORPHOGENESIS; GENE-EXPRESSION; LUNG MORPHOGENESIS; ENDOTHELIAL-CELLS; MESENCHYMAL CELLS; PATTERN-FORMATION; EPITHELIAL-CELLS; KEUTEL-SYNDROME; MOUSE LUNG	Deficiency of matrix GLA protein (MGP), an inhibitor of bone morphogenetic protein (BMP)-2/4, is known to cause arterial calcification and peripheral pulmonary artery stenosis. Yet the vascular role of MGP remains poorly understood. To further investigate MGP, we created a new MGP transgenic mouse model with high expression of the transgene in the lungs. The excess MGP led to a disruption of the pulmonary pattern of BMP-4, and resulted in significant morphological defects in the pulmonary artery tree. Specifically, the vascular branching pattern lacked characteristic side branching, whereas control lungs had extensive side branching accounting for as much as 40% of the vascular endothelium. The vascular changes could be explained by a dramatic reduction of phosphorylated SMAD1/5/8 in the alveolar epithelium, and in epithelial expression of the activin-like kinase receptor 1 and vascular endothelial growth factor, both critical in vascular formation. Abnormalities were also found in the terminal airways and in lung cell differentiation; high levels of surfactant protein-B were distributed in an abnormal pattern suggesting lost coordination between vasculature and airways. Ex vivo, lung cells from MGP transgenic mice showed higher proliferation, in particular surfactant protein B-expressing cells, and conditioned medium from these cells poorly supported in vitro angiogenesis compared with normal lung cells. The vascular branching defect can be mechanistically explained by a computational model based on activator/inhibitor reaction-diffusion dynamics, where BMP-4 and MGP are considered as an activating and inhibitory morphogen, respectively, suggesting that morphogen interactions are important for vascular branching.	Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Bostroem, KI (corresponding author), Box 951679, Los Angeles, CA 90095 USA.	kbostrom@mednet.ucla.edu	Yochelis, Arik/AAF-8523-2019; Yochelis, Arik/C-6782-2013	Yochelis, Arik/0000-0002-1516-0766; Yochelis, Arik/0000-0002-1516-0766	NHLBI NIH HHS [HL78931, HL30568, HL81397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078931, P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acarregui MJ, 1999, AM J RESP CELL MOL, V20, P14, DOI 10.1165/ajrcmb.20.1.3251; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Bragg AD, 2001, MECH DEVELOP, V109, P13, DOI 10.1016/S0925-4773(01)00508-1; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Del Moral PM, 2006, DEV BIOL, V290, P177, DOI 10.1016/j.ydbio.2005.11.022; Dobens LL, 2000, DEVELOPMENT, V127, P745; Eblaghie MC, 2006, DEV BIOL, V291, P67, DOI 10.1016/j.ydbio.2005.12.006; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Fan CW, 2001, CANCER LETT, V165, P63, DOI 10.1016/S0304-3835(01)00416-5; Frank DB, 2005, CIRC RES, V97, P496, DOI 10.1161/01.RES.0000181152.65534.07; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; Furthauer M, 2004, DEVELOPMENT, V131, P2853, DOI 10.1242/dev.01156; Garfinkel A, 2004, P NATL ACAD SCI USA, V101, P9247, DOI 10.1073/pnas.0308436101; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gilbert KA, 2004, AM J PHYSIOL-LUNG C, V286, pL1179, DOI 10.1152/ajplung.00188.2003; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Harris MP, 2005, P NATL ACAD SCI USA, V102, P11734, DOI 10.1073/pnas.0500781102; Hossler FE, 2001, MICROSC MICROANAL, V7, P253, DOI 10.1017/S1431927601010261; Hur DJ, 2005, AM J MED GENET A, V135A, P36, DOI 10.1002/ajmg.a.30680; Jiang TX, 1999, DEVELOPMENT, V126, P4997; KONDO S, 1995, NATURE, V376, P765, DOI 10.1038/376765a0; Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Maini PK, 2006, SCIENCE, V314, P1397, DOI 10.1126/science.1136396; MARGRAF LR, 1993, AM J RESP CELL MOL, V9, P231, DOI 10.1165/ajrcmb/9.3.231; Marshall Vikki M, 2004, Methods Mol Biol, V256, P159; MEINHARDT H, 1976, DIFFERENTIATION, V6, P117, DOI 10.1111/j.1432-0436.1976.tb01478.x; Murray James D., 2002, MATH BIOL SPATIAL MO, V2; Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Painter KJ, 1999, P NATL ACAD SCI USA, V96, P5549, DOI 10.1073/pnas.96.10.5549; Panchenko MP, 1996, AM J PHYSIOL-LUNG C, V270, pL547, DOI 10.1152/ajplung.1996.270.4.L547; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; Parmar H, 2006, PEDIATR RADIOL, V36, P241, DOI 10.1007/s00247-005-0036-7; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Schachtner SK, 2000, AM J RESP CELL MOL, V22, P157, DOI 10.1165/ajrcmb.22.2.3766; Shin V, 2004, J VASC RES, V41, P193, DOI 10.1159/000077394; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Vincent S, 2001, NATURE, V411, P533, DOI 10.1038/35079214; Weaver M, 2003, DEV BIOL, V258, P169, DOI 10.1016/S0012-1606(03)00117-9; Weaver M, 2000, DEVELOPMENT, V127, P2695; Yao YC, 2007, CARDIOVASC RES, V74, P279, DOI 10.1016/j.cardiores.2006.09.014; Yao YC, 2006, J BIOL CHEM, V281, P33921, DOI 10.1074/jbc.M604239200; Yelon D, 2002, CURR BIOL, V12, pR707, DOI 10.1016/S0960-9822(02)01213-7; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhao JS, 1997, AM J PHYSIOL-LUNG C, V273, pL282, DOI 10.1152/ajplung.1997.273.1.L282; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	58	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30131	30142		10.1074/jbc.M704297200	http://dx.doi.org/10.1074/jbc.M704297200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17670744	hybrid			2022-12-25	WOS:000249981200043
J	Hamdan, FF; Rochdi, MD; Breton, B; Fessart, D; Michaud, DE; Charest, PG; Laporte, SA; Bouvier, M				Hamdan, Fadi F.; Rochdi, Moulay Driss; Breton, Billy; Fessart, Delphine; Michaud, Douce E.; Charest, Pascale G.; Laporte, Stephane A.; Bouvier, Michel			Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between beta-arrestins and AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; CLATHRIN-INDEPENDENT ENDOCYTOSIS; N-FORMYL PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; INDUCED INTERNALIZATION; VASOPRESSIN RECEPTORS; HUMAN ENDOTHELIN; VISUAL ARRESTIN; TYPE-1 RECEPTOR; C5A RECEPTOR	The most widely studied pathway underlying agonist-promoted internalization of G protein-coupled receptors (GPCRs) involves beta-arrestin and clathrin-coated pits. However, both beta-arrestin- and clathrin-independent processes have also been reported. Classically, the endocytic routes are characterized using pharmacological inhibitors and various dominant negative mutants, resulting sometimes in conflicting results and interpretational difficulties. Here, taking advantage of the fact that beta-arrestin binding to the beta 2 subunit of the clathrin adaptor AP-2 (beta 2-adaptin) is needed for the beta-arrestin-mediated targeting of GPCRs to clathrin-coated pits, we developed a bioluminescence resonance energy transfer-based approach directly assessing the molecular steps involved in the endocytosis of GPCRs in living cells. For 10 of the 12 receptors tested, including some that were previously suggested to internalize via clathrinin-dependent pathways, agonist stimulation promoted beta-arrestin 1 and 2 interaction with beta 2-adaptin, indicating a beta-arrestin- and clathrin-dependent endocytic process. Detailed analyses of beta-arrestin interactions with both the receptor and beta 2-adaptin also allowed us to demonstrate that recruitment of beta-arrestins to the receptor and the ensuing conformational changes are the leading events preceding AP-2 engagement and subsequent clathrin-mediated endocytosis. Among the receptors tested, only the endothelin A and B receptors failed to promote interaction between beta-arrestins and beta 2-adaptin. However, both receptors recruited beta-arrestins upon agonist stimulation, suggesting a beta-arrestin-dependent but clathrin-independent route of internalization for these two receptors. In addition to providing a new tool to dissect the molecular events involved in GPCR endocytosis, the bioluminescence resonance energy transfer-based beta-arrestin/beta 2-adaptin interaction assay represents a novel biosensor to assess receptor activation.	Univ Montreal, Inst Res Immunol & Canc, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Res Immunol & Canc, Grp Rech Univ Medicament, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	Universite de Montreal; Universite de Montreal; McGill University	Bouvier, M (corresponding author), Univ Montreal, St Justine Hosp, Res Ctr, Dept Genet, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014; Laporte, Stephane A/F-3282-2012; FESSART, Delphine/J-2784-2014; Laporte, Stephane/ABC-4228-2021	Bouvier, Michel/0000-0003-1128-0100; FESSART, Delphine/0000-0001-7566-5670; Laporte, Stephane/0000-0002-0633-543X				Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Benmerah A, 1999, J CELL SCI, V112, P1303; Bernier V, 2004, MOL ENDOCRINOL, V18, P2074, DOI 10.1210/me.2004-0080; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Charest PG, 2007, CELL SIGNAL, V19, P32, DOI 10.1016/j.cellsig.2006.05.020; Charest PG, 2005, EMBO REP, V6, P334, DOI 10.1038/sj.embor.7400373; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Desai S, 2001, FEBS LETT, V501, P156, DOI 10.1016/S0014-5793(01)02640-0; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Droese J, 2004, BIOCHEM BIOPH RES CO, V322, P42, DOI 10.1016/j.bbrc.2004.07.076; Edeling MA, 2006, DEV CELL, V10, P329, DOI 10.1016/j.devcel.2006.01.016; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fessart D, 2007, J CELL SCI, V120, P1723, DOI 10.1242/jcs.03444; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hamdan FF, 2005, J BIOMOL SCREEN, V10, P463, DOI 10.1177/1087057105275344; HAMDAN FF, 2006, CURR PROT NEUROSCI; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Neuschafer-Rube F, 2004, BIOCHEM J, V379, P573, DOI 10.1042/BJ20031820; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Orem NR, 2006, J CELL SCI, V119, P3141, DOI 10.1242/jcs.03052; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; PFLEGER KD, 2004, BIOCHEM J, V85, P625; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; Prossnitz ER, 2004, LIFE SCI, V75, P893, DOI 10.1016/j.lfs.2004.04.003; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Roseberry AG, 2001, J CELL SCI, V114, P739; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Shetzline MA, 2002, J BIOL CHEM, V277, P25519, DOI 10.1074/jbc.M201815200; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Simaan M, 2005, CELL SIGNAL, V17, P1074, DOI 10.1016/j.cellsig.2004.12.001; Suvorova ES, 2005, TRAFFIC, V6, P100, DOI 10.1111/j.1600-0854.2004.00256.x; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WILLIAMS DL, 1993, LIFE SCI, V53, P407, DOI 10.1016/0024-3205(93)90644-I; Zapata-Hommer O, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-5; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	72	61	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29089	29100		10.1074/jbc.M700577200	http://dx.doi.org/10.1074/jbc.M700577200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675294	hybrid			2022-12-25	WOS:000249788000004
J	Tocilescu, MA; Fendel, U; Zwicker, K; Kerscher, S; Brandt, U				Tocilescu, Maja A.; Fendel, Uta; Zwicker, Klaus; Kerscher, Stefan; Brandt, Ulrich			Exploring the ubiquinone binding cavity of respiratory complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-QUINONE OXIDOREDUCTASE; SULFUR CLUSTER N2; 49-KDA SUBUNIT; 3-DIMENSIONAL STRUCTURE; YARROWIA-LIPOLYTICA; MITOCHONDRIAL NADH; CATALYTIC CORE; RESIDUES; DOMAIN	Proton pumping respiratory complex I is a major player in mitochondrial energy conversion. Yet little is known about the molecular mechanism of this large membrane protein complex. Understanding the details of ubiquinone reduction will be prerequisite for elucidating this mechanism. Based on a recently published partial structure of the bacterial enzyme, we scanned the proposed ubiquinone binding cavity of complex I by site-directed mutagenesis in the strictly aerobic yeast Yarrowia lipolytica. The observed changes in catalytic activity and inhibitor sensitivity followed a consistent pattern and allowed us to define three functionally important regions near the ubiquinone-reducing iron-sulfur cluster N2. We identified a likely entry path for the substrate ubiquinone and defined a region involved in inhibitor binding within the cavity. Finally, we were able to highlight a functionally critical structural motif in the active site that consisted of Tyr-144 in the 49-kDa subunit, surrounded by three conserved hydrophobic residues.	Univ Frankfurt Klinikum, Zentrum Biol Chem Mol Bioenerget, Fachbereich Med, Ctr Excellence Frankfurt Macromol Complexes, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Brandt, U (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem Mol Bioenerget, Fachbereich Med, Ctr Excellence Frankfurt Macromol Complexes, Theodor Stern Kai 7,Haus 26, D-60590 Frankfurt, Germany.	brandt@zbc.kgu.de	Brandt, Ulrich/GLV-1242-2022; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539; Chen DC, 1997, APPL MICROBIOL BIOT, V48, P232, DOI 10.1007/s002530051043; CLASON T, 2007, IN PRESS J STRUCT BI; Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Eschemann A, 2005, J BIOL CHEM, V280, P3138, DOI 10.1074/jbc.M411217200; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kerscher S, 2005, RSC BIOMOLEC SCI, P156; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Prieur I, 2001, BBA-BIOENERGETICS, V1504, P173, DOI 10.1016/S0005-2728(01)00158-X; Radermacher M, 2006, J STRUCT BIOL, V154, P269, DOI 10.1016/j.jsb.2006.02.011; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Wittig I, 2007, MOL CELL PROTEOMICS, V6, P1215, DOI 10.1074/mcp.M700076-MCP200; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200; Zwicker K, 2006, J BIOL CHEM, V281, P23013, DOI 10.1074/jbc.M603442200	32	84	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29514	29520		10.1074/jbc.M704519200	http://dx.doi.org/10.1074/jbc.M704519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681940	hybrid			2022-12-25	WOS:000249788000048
J	Trouw, LA; Bengtsson, AA; Gelderman, KA; Dahlback, B; Sturfelt, G; Blom, AM				Trouw, Leendert A.; Bengtsson, Anders A.; Gelderman, Kyra A.; Dahlback, Bjorn; Sturfelt, Gunnar; Blom, Anna M.			C4b-binding protein and factor h compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; C-REACTIVE PROTEIN; BINDING LECTIN ENGAGEMENT; NECROTIC CELLS; ACTIVATES COMPLEMENT; IMPAIRED UPTAKE; RESIDUES 14-26; PLASMA-LEVELS; ALPHA-CHAIN; HUMAN C1Q	Apoptotic cells have been reported to down- regulate membrane-bound complement regulatory proteins ( m- C- Reg) and to activate complement. Nonetheless, most apoptotic cells do not undergo complement- mediated lysis. Therefore, we hypothesized that fluid phase complement inhibitors would bind to apoptotic cells and compensate functionally for the loss of m- C- Reg. We observed that m- C- Reg are down- regulated rapidly upon apoptosis but that complement activation follows only after a gap of several hours. Coinciding with, but independent from, complement activation, fluid phase complement inhibitors C4b- binding protein ( C4BP) and factorH( fH) bind to the cells. C4BP and fH do not entirely prevent complement activation but strongly limit C3 and C9 deposition. Late apoptotic cells, present in blood of healthy controls and systemic lupus erythematosus patients, are also positive for C4BP and fH. Upon culture, the percentage of late apoptotic cells increases, paralleled by increased C4BP binding. C4BP binds to dead cells mainly via phosphatidylserine, whereas fH binds via multiple interactions with CRP playing no major role for binding of C4BP or fH. In conclusion, during late apoptosis, cells acquire fluid phase complement inhibitors that compensate for the downregulation of m- C- Reg and protect against excessive complement activation and lysis.	Malmo Univ Hosp, Dept Lab Med, S-20502 Malmo, Sweden; Lund Univ, Dept Clin Sci Rheumatol, S-22184 Lund, Sweden; Lund Univ, Unit Med Inflammat Res, S-22184 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Lund University	Blom, AM (corresponding author), Lund Univ, Dept Lab Med, Wallenberg Lab, MAS Entrance 46,Floor 4, S-20502 Malmo, Sweden.	Anna.Blom@med.lu.se	Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022; Trouw, Leendert/AGK-5202-2022	Blom, Anna/0000-0002-1348-1734; Trouw, Leendert/0000-0001-5186-2290; Gelderman, Kyra/0000-0002-7815-032X; Dahlback, Bjorn/0000-0003-1546-0328				Agrawal A, 2005, MOL IMMUNOL, V42, P927, DOI 10.1016/j.molimm.2004.09.028; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; Bengtsson AA, 2004, CLIN EXP IMMUNOL, V135, P535, DOI 10.1111/j.1365-2249.2003.02386.x; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Carroll MC, 2004, NAT REV IMMUNOL, V4, P825, DOI 10.1038/nri1456; Ciurana CLF, 2004, EUR J IMMUNOL, V34, P2609, DOI 10.1002/eji.200425045; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Coombe DR, 2005, CELL MOL LIFE SCI, V62, P410, DOI 10.1007/s00018-004-4293-7; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005; DE FRUTOS PG, 1994, BLOOD, V84, P815; Denny MF, 2006, J IMMUNOL, V176, P2095, DOI 10.4049/jimmunol.176.4.2095; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Gaipl US, 2006, CURR DIRECT AUTOIMMU, V9, P173; Gaipl Udo S, 2004, Curr Rheumatol Rep, V6, P401, DOI 10.1007/s11926-004-0016-1; Gaipl US, 2001, CELL DEATH DIFFER, V8, P327, DOI 10.1038/sj.cdd.4400826; Gardai SJ, 2006, J LEUKOCYTE BIOL, V79, P896, DOI 10.1189/jlb.1005550; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Gladman DD, 2002, J RHEUMATOL, V29, P288; Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733; Hart Simon P, 2005, J Inflamm (Lond), V2, P5, DOI 10.1186/1476-9255-2-5; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Jarva H, 1999, J IMMUNOL, V163, P3957; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Jones J, 1995, IMMUNOLOGY, V86, P651; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; Leers MPG, 2002, CELL MOL LIFE SCI, V59, P1358, DOI 10.1007/s00018-002-8513-8; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549; MARCOVINA SM, 1991, INT J CLIN LAB RES, V21, P171; Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7; Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sheriff A, 2004, RHEUM DIS CLIN N AM, V30, P505, DOI 10.1016/j.rdc.2004.04.006; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; Tas SW, 2006, ANN RHEUM DIS, V65, P216, DOI 10.1136/ard.2005.037143; TENNER AJ, 1981, J IMMUNOL, V127, P648; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189; Walport MJ, 2002, ARTHRITIS RES THER, V4, pS279, DOI 10.1186/ar586; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Webb JH, 2003, BLOOD COAGUL FIBRIN, V14, P355, DOI 10.1097/00001721-200306000-00006; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580; WILCOX LA, 1991, BLOOD, V78, P820, DOI 10.1182/blood.V78.3.820.bloodjournal783820; Xu W, 2006, BLOOD, V107, P4930, DOI 10.1182/blood-2005-10-4144; Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015; Zwart B, 2004, AUTOIMMUNITY, V37, P95, DOI 10.1080/0891693042000196183	56	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28540	28548		10.1074/jbc.M704354200	http://dx.doi.org/10.1074/jbc.M704354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17699521	hybrid			2022-12-25	WOS:000249642100028
J	Tubb, MR; Silva, RAGD; Pearson, KJ; Tso, P; Liu, M; Davidson, WS				Tubb, Matthew R.; Silva, R. A. Gangani D.; Pearson, Kevin J.; Tso, Patrick; Liu, Min; Davidson, W. Sean			Modulation of apolipoprotein A-IV lipid binding by an interaction between the N and C termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; CORONARY-ARTERY-DISEASE; EXCHANGEABLE APOLIPOPROTEINS; CIRCULAR-DICHROISM; SLIDING CLAMP; APOA-IV; PLASMA; MICE; POLYMORPHISM; POLYMERASE	Apolipoprotein A-IV (apoA-IV) is a 376-amino acid exchangeable apolipoprotein made in the small intestine of humans. Although it has many proposed roles in vascular disease, satiety, and chylomicron metabolism, there is no known structural basis for these functions. The ability to associate with lipids may be a key step in apoA-IV functionality. We recently identified a single amino acid, Phe(334), which seems to inhibit the lipid binding capability of apoA-IV. We also found that an intact N terminus was necessary for increased lipid binding of Phe334 mutants. Here, we identify Trp(12) and Phe(15) as the N-terminal amino acids required for the fast lipid binding seen with the F334A mutant. Furthermore, we found that individual disruption of putative amphipathic alpha-helices 3-11 had little effect on lipid binding, suggesting that the N terminus of apoA-IV may be the operational site for initial lipid binding. We also provide three independent pieces of experimental evidence supporting a direct intramolecular interaction between sequences near amino acids 12/15 and 334. This interaction could represent a unique "switch" mechanism by which apoA-IV changes lipid avidity in vivo.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; NIA, Lab Exp Gerontol, NIH, Baltimore, MD 21224 USA	University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 2120 Galbraith Rd, Cincinnati, OH 45237 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989; Tubb, Matthew/0000-0002-4543-2742	NHLBI NIH HHS [HL67093, HL82734] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082734, R01HL067093] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alley SC, 1999, BIOCHEMISTRY-US, V38, P7696, DOI 10.1021/bi9827971; Bhattacharyya R, 2004, PROTEIN ENG DES SEL, V17, P795, DOI 10.1093/protein/gzh093; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Davidson WS, 2006, J LIPID RES, V47, P440, DOI 10.1194/jlr.D500034-JLR200; DIEPLINGER H, 1992, EUR J CLIN INVEST, V22, P166, DOI 10.1111/j.1365-2362.1992.tb01822.x; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Ezeh B, 2003, J LIPID RES, V44, P1523, DOI 10.1194/jlr.M300060-JLR200; Gallagher JW, 2004, J LIPID RES, V45, P1826, DOI 10.1194/jlr.M400188-JLR200; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; KALOGERIS TJ, 1997, J NUTR S, V127, P537; Kronenberg F, 2000, J AM COLL CARDIOL, V36, P751, DOI 10.1016/S0735-1097(00)00775-0; Kronenberg F, 2002, J AM SOC NEPHROL, V13, P461, DOI 10.1681/ASN.V132461; LAGROST L, 1989, J LIPID RES, V30, P1525; LOHSE P, 1991, J BIOL CHEM, V266, P13513; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lu S, 2006, J BIOL CHEM, V281, P3473, DOI 10.1074/jbc.M502501200; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Ostos MA, 2000, ATHEROSCLEROSIS, V153, P209, DOI 10.1016/S0021-9150(00)00400-7; Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pearson K, 2005, J BIOL CHEM, V280, P38576, DOI 10.1074/jbc.M506802200; Pearson K, 2004, BIOCHEMISTRY-US, V43, P10719, DOI 10.1021/bi048978m; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Sahoo D, 2002, J MOL BIOL, V321, P201, DOI 10.1016/S0022-2836(02)00618-6; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1992, J LIPID RES, V33, P141; Silva RAGD, 2007, J BIOL CHEM, V282, P9713, DOI 10.1074/jbc.M610380200; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Tanaka M, 2006, BIOCHEMISTRY-US, V45, P10351, DOI 10.1021/bi060726t; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Warner MM, 2001, CHINESE MED J-PEKING, V114, P275; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1988, BIOCHEMISTRY-US, V27, P1515, DOI 10.1021/bi00405a018; Weinstock PH, 1997, J LIPID RES, V38, P1782; WOODY RW, 1995, METHOD ENZYMOL, V246, P34	39	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28385	28394		10.1074/jbc.M704070200	http://dx.doi.org/10.1074/jbc.M704070200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686771	hybrid			2022-12-25	WOS:000249642100013
J	Dam, TK; Gerken, TA; Cavada, BS; Nascimento, KS; Moura, TR; Brewer, CF				Dam, Tarun K.; Gerken, Thomas A.; Cavada, Benildo S.; Nascimento, Kyria S.; Moura, Tales R.; Brewer, C. Fred			Binding studies of alpha-GaINAc-specific lectins to the alpha-GaINAc (Tn-antigen) form of porcine submaxillary mucin and its smaller fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMODYNAMIC ANALYSIS; CANCER; OLIGOSACCHARIDES; GLYCOSYLATION; PURIFICATION; ASIALOFETUIN; CONSTANTS; RESPONSES; SEQUENCE; RESIDUES	Isothermal titration microcalorimetry (ITC) and hemagglutination inhibition measurements demonstrate that a chemically and enzymatically prepared form of porcine submaxillary mucin that possesses a molecular mass of similar to 10(6) daltons and similar to 2300 alpha-GalNAc residues (Tn-PSM) binds to the soybean agglutinin (SBA) with a K-d of 0.2 nM, which is similar to 10(6) -fold enhanced affinity relative to GalNAc alpha 1-O-Ser (Tn), the pancarcinoma carbohydrate antigen. The enzymatically derived 81 amino acid tandem repeat domain of Tn-PSM containing similar to 23 alpha-GalNAc residues binds with similar to 10(3) -fold enhanced affinity, while the enzymatically derived 38/40 amino acid cleavage product(s) of Tn-PSM containing similar to 11-12 alpha-GaINAc residues shows similar to 10(2) -fold enhanced affinity. A natural carbohydrate decorated form of PSM (Fd-PSM) containing 40% of the core 1 blood group type A tetrasaccharide, and 58% peptide-linked GalNAc alpha 1-O-Ser/Thr residues, with 45% of the peptide-linked a-GaINAc residues linked alpha-(2,6) to N-glycolylneuraminic acid, shows similar to 10(4) enhanced affinity for SBA. Vatairea macrocarpa lectin (VML), which is also a GalNAc binding lectin, displays a similar pattern of binding to the four forms of PSM, although there are quantitative differences in its affinities as compared with SBA. The higher affinities of SBA and VML for Tn-PSM relative to Fd-PSM indicate the importance of carbohydrate composition and epitope density of mucins on their affinities for lectins. The higher affinities of SBA and VML for Tn-PSM relative to its two shorter chain analogs demonstrate that the length of a mucin polypeptide and hence total carbohydrate valence determines the affinities of the three Tn-PSM analogs. The results suggest a binding model in which lectin molecules "bind and jump" from alpha-GaINAc residue to alpha-GalNAc residue along the polypeptide chain of Tn-PSM before dissociating. The complete thermodynamic binding parameters for these mucins including their binding stoichiometries are presented. The results have important implications for the biological activities of mucins including those expressing the Tn cancer antigen.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Univ Fed Ceara, Dept Bioquim Biol Mol, Fortaleza, Ceara, Brazil; Case Western Reserve Univ, WA Bernbaum Ctr Cyst Fibrosis Res, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Federal do Ceara; Case Western Reserve University; Case Western Reserve University	Brewer, CF (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA.	brewer@aecom.yu.edu	Cavada, Benildo/CEA-4997-2022	Cavada, Benildo/0000-0002-5791-6170; Rocha de Moura, Tales/0000-0001-5492-8419	NATIONAL CANCER INSTITUTE [R01CA016054, R01CA078834, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078834, CA-16054, CA-78834, P30 CA-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Calvete JJ, 1998, FEBS LETT, V425, P286, DOI 10.1016/S0014-5793(98)00243-9; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Cavada BS, 1998, PHYTOCHEMISTRY, V49, P675, DOI 10.1016/S0031-9422(98)00144-7; Dam TK, 2005, BIOCHEMISTRY-US, V44, P12564, DOI 10.1021/bi051144z; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; Dam TK, 2002, BIOCHEMISTRY-US, V41, P1351, DOI 10.1021/bi015830j; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Daniels MA, 2002, NAT IMMUNOL, V3, P903, DOI 10.1038/ni1002-903; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; GERKEN TA, 1987, BIOCHEMISTRY-US, V26, P4689, DOI 10.1021/bi00389a015; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Gestwicki JE, 2002, CHEM BIOL, V9, P163, DOI 10.1016/S1074-5521(02)00102-3; Goldstein I.J., 1986, LECTINS; Lau KS, 2007, CELL, V129, P123, DOI 10.1016/j.cell.2007.01.049; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P8465, DOI 10.1021/bi00151a012; Osawa TMI, 1972, METHODS ENZYMOL B, V28, P323; Pace KE, 1999, J IMMUNOL, V163, P3801; Ramos MV, 1999, PROTEIN PEPTIDE LETT, V6, P163; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5526; SINGHAL A, 1991, CANCER RES, V51, P1406; Sorensen AL, 2006, GLYCOBIOLOGY, V16, P96, DOI 10.1093/glycob/cwj044; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; von Hippel PH, 2007, ANNU REV BIOPH BIOM, V36, P79, DOI 10.1146/annurev.biophys.34.040204.144521; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu AM, 2004, BIOCHIMIE, V86, P317, DOI 10.1016/j.biochi.2004.03.007; Yu LG, 2007, J BIOL CHEM, V282, P773, DOI 10.1074/jbc.M606862200	35	73	73	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28256	28263		10.1074/jbc.M704677200	http://dx.doi.org/10.1074/jbc.M704677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652089	hybrid			2022-12-25	WOS:000249455600075
J	Kuhn, JR; Pollard, TD				Kuhn, Jeffrey R.; Pollard, Thomas D.			Single molecule kinetic analysis of actin filament capping - Polyphosphoinositides do not dissociate capping proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; ARP2/3 COMPLEX; BARBED-END; FISSION YEAST; ADP-ACTIN; ENA/VASP PROTEINS; STRUCTURAL BASIS; POLYMERIZATION; LOCALIZATION; MYOSIN	We investigated how heterodimeric capping proteins bind to and dissociate from the barbed ends of actin filaments by observing single muscle actin filaments by total internal reflection fluorescence microscopy. The barbed end rate constants for mouse capping protein (CP) association of 2.6 x 10(6) M-1 s(-1) and dissociation of 0.0003 s(-1) agree with published values measured in bulk assays. The polyphosphoinositides (PPIs), phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-2), PI(4,5)P-2, and PI(3,4,5)P-3, prevent CP from binding to barbed ends, but three different assays showed that none of these lipids dissociate CP from filaments at concentrations that block CP binding to barbed ends. The affinity of fission yeast CP for barbed ends is a thousandfold less than mouse CP, because of a slower association rate constant (1.1 x 10(5) M-1 s(-1)) and a faster dissociation rate constant (0.004 s(-1)). PPIs do not inhibit binding of fission yeast CP to filament ends. Comparison of homology models revealed that fission yeast CP lacks a large patch of basic residues along the actin-binding surface on mouse CP. PPIs binding to this site might interfere sterically with capping, but this site would be inaccessible when CP is bound to the end of a filament.	Yale Univ, MCDB, KBT548, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University	Pollard, TD (corresponding author), Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA.	thomas.pollard@yale.edu			NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; BAUM LE, 1970, ANN MATH STAT, V41, P164, DOI 10.1214/aoms/1177697196; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; HARRIS HE, 1984, FEBS LETT, V177, P184, DOI 10.1016/0014-5793(84)81280-6; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; Kim K, 2007, J BIOL CHEM, V282, P5871, DOI 10.1074/jbc.M609850200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; Maly IV, 2001, P NATL ACAD SCI USA, V98, P11324, DOI 10.1073/pnas.181338798; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Narita A, 2006, EMBO J, V25, P5626, DOI 10.1038/sj.emboj.7601395; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Qin F, 2004, BIOPHYS J, V86, P1488, DOI 10.1016/S0006-3495(04)74217-4; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Sabanayagam CR, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e33; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sirotkin V, 2005, J CELL BIOL, V170, P637, DOI 10.1083/jcb.200502053; Smith J, 2006, THEOR BIOL MED MODEL, V3, DOI 10.1186/1742-4682-3-30; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Uruno T, 2006, J BIOL CHEM, V281, P10635, DOI 10.1074/jbc.M513186200; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167	43	63	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28014	28024		10.1074/jbc.M705287200	http://dx.doi.org/10.1074/jbc.M705287200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656356	hybrid			2022-12-25	WOS:000249455600051
J	Niwa, J; Yamada, S; Ishigaki, S; Sone, J; Takahashi, M; Katsuno, M; Tanaka, F; Doyu, M; Sobue, G				Niwa, Jun-ichi; Yamada, Shin-ichi; Ishigaki, Shinsuke; Sone, Jun; Takahashi, Miho; Katsuno, Masahisa; Tanaka, Fumiaki; Doyu, Manabu; Sobue, Gen			Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEATH; CU,ZN-SUPEROXIDE DISMUTASE; DISEASE PROGRESSION; TRANSGENIC MICE; MOUSE MODEL; PROTEIN; SUPEROXIDE-DISMUTASE-1; PROTEASOME	Mutations in the Cu/Zn-superoxide dismutase (SOD1) gene cause familial amyotrophic lateral sclerosis (ALS) through the gain of a toxic function; however, the nature of this toxic function remains largely unknown. Ubiquitylated aggregates of mutant SOD 1 proteins in affected brain lesions are pathological hallmarks of the disease and are suggested to be involved in several proposed mechanisms of motor neuron death. Recent studies suggest that mutant SODI readily forms an incorrect disulfide bond upon mild oxidative stress in vitro, and the insoluble SOD 1 aggregates in spinal cord of ALS model mice contain multimers cross-linked via intermolecular disulfide bonds. Here we show that a non-physiological intermolecular disulfide bond between cysteines at positions 6 and 111 of mutant SOD 1 is important for high molecular weight aggregate formation, ubliquitylation, and neurotoxicity, all of which were dramatically reduced when the pertinent cysteines were replaced in mutant SOD 1 expressed in Neuro-2a cells. Dorfin is a ubiquityl ligase that specifically binds familial ALS-linked mutant SOD 1 and ubiquitylates it, thereby promoting its degradation. We found that Dorfin ubiquitylated mutant SOD1 by recognizing the CYS6- and Cys(111)-disulfide cross-linked form and targeted it for proteasomal degradation.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 466, Japan; Aichi Med Univ, Ctr Stroke, Aichi 480, Japan	Nagoya University; Aichi Medical University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai cho, Nagoya, Aichi 466, Japan.	sobueg@med.nagoya-u.ac.jp	Sone, Jun/M-5027-2014; ISHIGAKI, Shinsuke/I-7305-2014; KATSUNO, MASAHISA/I-7502-2014	Sone, Jun/0000-0002-9057-7609; KATSUNO, MASAHISA/0000-0001-9453-9311; Ishigaki, Shinsuke/0000-0002-9555-0659				Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BRIGGS RG, 1978, BIOCHIM BIOPHYS ACTA, V537, P86, DOI 10.1016/0005-2795(78)90605-0; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cheroni C, 2005, NEUROBIOL DIS, V18, P509, DOI 10.1016/j.nbd.2004.12.007; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Di Noto L, 2005, J BIOL CHEM, V280, P39907, DOI 10.1074/jbc.M506247200; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; FISHER CL, 1994, PROTEINS, V19, P24, DOI 10.1002/prot.340190105; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee JP, 2002, J NEUROCHEM, V82, P1229, DOI 10.1046/j.1471-4159.2002.01056.x; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Lindenau J, 2000, GLIA, V29, P25, DOI 10.1002/(SICI)1098-1136(20000101)29:1<25::AID-GLIA3>3.0.CO;2-G; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCREE DE, 1990, J BIOL CHEM, V265, P14234; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2006, J NEUROCHEM, V96, P1277, DOI 10.1111/j.1471-4159.2005.03642.x; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443	48	127	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28087	28095		10.1074/jbc.M704465200	http://dx.doi.org/10.1074/jbc.M704465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17666395	hybrid			2022-12-25	WOS:000249455600058
J	Wakabayashi, K; Nakagawa, H; Tamura, A; Koshiba, S; Hoshijima, K; Komada, M; Ishikawa, T				Wakabayashi, Kanako; Nakagawa, Hiroshi; Tamura, Ai; Koshiba, Shoko; Hoshijima, Kazuyuki; Komada, Masayuki; Ishikawa, Toshihisa			Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; ENDOPLASMIC-RETICULUM STRESS; STEM-CELLS; IDENTIFICATION; POLYMORPHISMS; MITOXANTRONE; GLUTATHIONE; AGGRESOMES; PROTECTION; ENDOSOMES	Human ABCG2 belongs to the ATP-binding cassette (ABC) transporter family and plays an important role in various biological reactions, such as xenobiotic elimination and homeostasis of protoporphyrin. We previously reported that ABCG2 exists in the plasma membrane as a homodimer bound via a disulfide bond at Cys-603. In the present study, we examined the importance of an intramolecular disulfide bond for stability of the ABCG2 protein. Substitution of either Cys-592 or Cys-608 located in the extracellular loop to glycine resulted in a significant decrease in protein levels of ABCG2 when expressed in Flp-In-293 cells. Interestingly, the protein levels of those ABCG2 variants were remarkably enhanced by treatment with the proteasome inhibitor MG132. Concomitantly, increases in ubiquitinated forms of those variant proteins were detected by immunoprecipitation. In contrast, neither the protein level nor the ubiquitinated state of the ABCG2 wild-type (WT) was affected by MG132 treatment. Ubiquitin-mediated protein degradation is suggested to be involved in degradation, of misfolded ABCG2 proteins lacking the intramolecular disulfide bond. On the other hand, the protein level of ABCG2 WT increased more than 4-fold when cells were treated with bafilomycin A(1), which inhibits lysosomal degradation, whereas the C592G or C608G variant was little affected by the same treatment. These results strongly suggest that two distinct pathways exist for protein degradation of ABCG2 WT and mutants lacking the intramolecular disulfide bond. Namely, the WT ABCG2 is degraded in lysosomes, and the misfolded ABCG2 lacking intramolecular disulfide bond undergoes ubiquitin-mediated protein degradation in proteasomes.	Tokyo Inst Technol, Grad Sch BIosci & Biotechnol, Dept Biomol Engn, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology	Ishikawa, T (corresponding author), Tokyo Inst Technol, Grad Sch BIosci & Biotechnol, Dept Biomol Engn, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	tishikaw@bio.titech.ac.jp						Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Henriksen U, 2005, J BIOL CHEM, V280, P36926, DOI 10.1074/jbc.M502937200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kage K, 2005, CANCER SCI, V96, P866, DOI 10.1111/j.1349-7006.2005.00126.x; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Mitomo H, 2003, BIOCHEM J, V373, P767, DOI 10.1042/BJ20030150; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2006, TRAFFIC, V7, P1017, DOI 10.1111/j.1600-0854.2006.00452.x; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Tamura A, 2006, MOL PHARMACOL, V70, P287, DOI 10.1124/mol.106.023556; Tamura A, 2007, CANCER SCI, V98, P231, DOI 10.1111/j.1349-7006.2006.00371.x; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Wakabayashi K, 2006, J EXP THER ONCOL, V5, P205; Wakabayashi K, 2006, DRUG METAB REV, V38, P371, DOI 10.1080/03602530600727947; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	28	63	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27841	27846		10.1074/jbc.C700133200	http://dx.doi.org/10.1074/jbc.C700133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17686774	hybrid			2022-12-25	WOS:000249455600032
J	Waldmann, I; Walde, S; Kehlenbach, RH				Waldmann, Inga; Waelde, Sarah; Kehlenbach, Ralph H.			Nuclear import of c-Jun is mediated by multiple transport receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; TRANSCRIPTION FACTOR; LEUCINE-ZIPPER; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; MAMMALIAN-CELLS; BINDING DOMAIN; CORE HISTONES; EXPORT; FOS	c-Jun and c-Fos are major components of the transcriptional complex AP-1. Here, we investigate the nuclear import pathway(s) of the transcription factor c-Jun. c-Jun bound specifically to the nuclear import receptors importin 113, transportin, importin 5, importin 7, importin 9, and importin 13. In digitonin-permeabilized cells, importin 13, transportin, importin 7, and importin 9 promoted efficient import of c-Jun into the nucleus. Importin a, by contrast, inhibited nuclear import of c-Jun in vitro. A single basic region preceding the leucine zipper of c-Jun functions as a nuclear localization signal (NLS) and was required for interaction with all tested import receptors. In vivo, nuclear import of a c-Jun reporter protein lacking the leucine zipper strictly depended on this NLS. In a leucine zipper-dependent manner, c-Jun with mutations in its NLS was still imported into the nucleus in a complex with endogenous leucine zipper proteins or, for example, with cotransfected c-Fos. Together, these results explain the highly efficient nuclear import of the transcription factor c-Jun.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Kehlenbach, RH (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	rkehlen@gwdg.de		Kehlenbach, Ralph/0000-0003-4920-9916; Walde, Sarah/0000-0001-8544-2323				ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Arnold M, 2006, J BIOL CHEM, V281, P5492, DOI 10.1074/jbc.M513281200; Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Camuzeaux B, 2005, BIOCHEM BIOPH RES CO, V332, P1107, DOI 10.1016/j.bbrc.2005.05.057; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chida K, 1999, CELL MOL LIFE SCI, V55, P297, DOI 10.1007/s000180050291; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; Dean KA, 2001, J CELL SCI, V114, P3479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee BJ, 2006, CELL, V126, P543, DOI 10.1016/j.cell.2006.05.049; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MIKAELIAN I, 1993, J VIROL, V67, P734; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Muhlhausser P, 2001, EMBO REP, V2, P690, DOI 10.1093/embo-reports/kve168; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Plafker SM, 2000, EMBO J, V19, P5502, DOI 10.1093/emboj/19.20.5502; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wohlwend D, 2007, J BIOL CHEM, V282, P10707, DOI 10.1074/jbc.M610409200; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	48	61	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27685	27692		10.1074/jbc.M703301200	http://dx.doi.org/10.1074/jbc.M703301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652081	hybrid			2022-12-25	WOS:000249455600016
J	Patel, DN; King, CA; Bailey, SR; Holt, JW; Venkatachalam, K; Agrawal, A; Valente, AJ; Chandrasekar, B				Patel, Devang N.; King, Carter A.; Bailey, Steven R.; Holt, Jeffrey W.; Venkatachalam, Kaliyamurthi; Agrawal, Alok; Valente, Anthony J.; Chandrasekar, Bysani			Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappa B and C/EBP beta activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-HEART-DISEASE; NECROSIS-FACTOR-ALPHA; SERUM AMYLOID-A; CARDIOVASCULAR-DISEASE; NUCLEAR-FACTOR; TNF-ALPHA; ENDOTHELIAL-CELLS; INFLAMMATION; COMPLEMENT; CYTOKINE	Elevated systemic levels of the acute phase C-reactive protein (CRP) are predictors of future cardiovascular events. There is evidence that CRP may also play a direct role in atherogenesis. Here we determined whether the proinflammatory interleukin (IL)-17 stimulates CRP expression in hepatocytes (Hep3B cell line and primary hepatocytes) and coronary artery smooth muscle cells (CASMC). Our results demonstrate that IL-17 potently induces CRP expression in Hep3B cells independent of IL-1 beta and IL-6. IL-17 induced CRP promoter-driven reporter gene activity that could be attenuated by dominant negative I kappa B alpha or C/EBP beta knockdown and stimulated both NF-kappa B and C/EBP DNA binding and reporter gene activities. Targeting NF-kappa B and C/EBP beta activation by pharmacological inhibitors, small interfering RNA interference and adenoviral transduction of dominant negative expression vectors blocked IL-17-mediated CRP induction. Overexpression of wild type p50, p65, and C/EBP beta stimulated CRP transcription. IL-17 stimulated p38 MAPK and ERK1/2 activation, and SB203580 and PD98059 blunted IL-17-mediated NF-kappa B and C/EBP activation and CRP transcription. These results, confirmed in primary human hepatocytes and CASMC, demonstrate for the first time that IL-17 is a potent inducer of CRP expression via p38 MAPK and ERK1/2-dependent NF-kappa B and C/EBP beta activation and suggest that IL-17 may mediate chronic inflammation, atherosclerosis, and thrombosis.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; E Tennessee State Univ, Dept Pharmacol, Johnson City, TN 37614 USA; S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; East Tennessee State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Venkatachalam, Kaliyamurthi/GXM-4890-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020, R01HL071233] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071233, R01 HL068020, HL 68020] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal A, 2003, IMMUNOLOGY, V108, P539, DOI 10.1046/j.1365-2567.2003.01608.x; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Chandrasekar B, 2006, J BIOL CHEM, V281, P15099, DOI 10.1074/jbc.M600200200; Chen K, 2006, NAT MED, V12, P425, DOI 10.1038/nm1372; Clapp BR, 2005, CIRCULATION, V111, P1530, DOI 10.1161/01.CIR.0000159336.31613.31; Csiszar A, 2003, FASEB J, V17, P1183, DOI 10.1096/fj.02-1049fje; DEBEER FC, 1982, BRIT HEART J, V47, P239; Fujii H, 2006, ARTERIOSCL THROM VAS, V26, P2476, DOI 10.1161/01.ATV.0000242794.65541.02; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733; Hattori Y, 2003, CARDIOVASC RES, V58, P186, DOI 10.1016/S0008-6363(02)00855-6; Henness S, 2006, AM J PHYSIOL-LUNG C, V290, pL1283, DOI 10.1152/ajplung.00367.2005; HURLIMANN J, 1966, J EXP MED, V123, P365, DOI 10.1084/jem.123.2.365; Inoue Nobutaka, 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P227; Ivashchenko Y, 2005, ARTERIOSCL THROM VAS, V25, P186, DOI 10.1161/01.ATV.0000150041.81963.68; Jabs WJ, 2003, CIRCULATION, V108, P1428, DOI 10.1161/01.CIR.0000092184.43176.91; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Koenders MI, 2006, J IMMUNOL, V176, P6262, DOI 10.4049/jimmunol.176.10.6262; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; KUSHNER I, 1978, J EXP MED, V148, P466, DOI 10.1084/jem.148.2.466; Kwon WJ, 2004, MOL CELLS, V18, P200; Labbozzetta M, 2006, ANN NY ACAD SCI, V1089, P268, DOI 10.1196/annals.1386.014; Li SH, 2004, CIRCULATION, V109, P833, DOI 10.1161/01.CIR.0000117087.27524.0E; Liu XKK, 2004, J BIOL CHEM, V279, P52762, DOI 10.1074/jbc.M405764200; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Mazer SP, 2004, J THROMB THROMBOLYS, V17, P95, DOI 10.1023/B:THRO.0000037664.77460.d8; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Pasceri V, 2000, CIRCULATION, V102, P2165; Patel DN, 2006, BIOCHEM BIOPH RES CO, V347, P1113, DOI 10.1016/j.bbrc.2006.07.015; Paul A, 2004, CIRCULATION, V109, P647, DOI 10.1161/01.CIR.0000114526.50618.24; POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rifai N, 2001, CLIN CHEM, V47, P403; Rost NS, 2001, STROKE, V32, P2575, DOI 10.1161/hs1101.098151; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Shen F, 2006, J BIOL CHEM, V281, P24138, DOI 10.1074/jbc.M604597200; Sternik L, 2002, ARTERIOSCL THROM VAS, V22, P1865, DOI 10.1161/01.ATV.0000033821.96354.90; Torzewski J, 1998, ARTERIOSCL THROM VAS, V18, P1386, DOI 10.1161/01.ATV.18.9.1386; Venugopal SK, 2005, CURR OPIN NEPHROL HY, V14, P33, DOI 10.1097/00041552-200501000-00006; Voleti B, 2005, J IMMUNOL, V175, P3386, DOI 10.4049/jimmunol.175.5.3386; Wang CH, 2003, CIRCULATION, V107, P1783, DOI 10.1161/01.CIR.0000061916.95736.E5; Wu Y, 2003, ACTA CRYSTALLOGR D, V59, P922, DOI 10.1107/S0907444903004414; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Yeh TC, 2007, BIOCHEM PHARMACOL, V73, P782, DOI 10.1016/j.bcp.2006.11.027; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhong J, 2004, MOL CELL BIOL, V24, P9165, DOI 10.1128/MCB.24.20.9165-9175.2004; Zwaka TP, 2001, CIRCULATION, V103, P1194	58	157	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27229	27238		10.1074/jbc.M703250200	http://dx.doi.org/10.1074/jbc.M703250200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652082	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000249304900064
J	Thakur, NN; El-Gogo, S; Steer, B; Freimuller, K; Waha, A; Adler, H				Thakur, Nagendra N.; El-Gogo, Susanne; Steer, Beatrix; Freimueller, Klaus; Waha, Andreas; Adler, Heiko			A Gammaherpesviral Internal Repeat Contributes to Latency Amplification	PLOS ONE			English	Article								Background. Gammaherpesviruses cause important infections of humans, in particular in immunocompromised patients. The genomes of gammaherpesviruses contain variable numbers of internal repeats whose precise role for in vivo pathogenesis is not well understood. Methodology/Principal Findings. We used infection of laboratory mice with murine gammaherpesvirus 68 (MHV-68) to explore the biological role of the 40 bp internal repeat of MHV-68. We constructed several mutant viruses partially or completely lacking this repeat. Both in vitro and in vivo, the loss of the repeat did not substantially affect lytic replication of the mutant viruses. However, the extent of splenomegaly, which is associated with the establishment of latency, and the number of ex vivo reactivating and genome positive splenocytes were reduced. Since the 40 bp repeat is part of the hypothetical open reading frame (ORF) M6, it might function as part of M6 or as an independent structure. To differentiate between these two possibilities, we constructed an N-terminal M6STOP mutant, leaving the repeat structure intact but rendering ORF M6 unfunctional. Disruption of ORF M6 did neither affect lytic nor latent infection. In contrast to the situation in lytically infected NIH3T3 cells, the expression of the latency-associated genes K3 and ORF72 was reduced in the latently infected murine B cell line Ag8 in the absence of the 40 bp repeat. Conclusions/Significance. These data suggest that the 40 bp repeat contributes to latency amplification and might be involved in the regulation of viral gene expression.	[Thakur, Nagendra N.; Steer, Beatrix; Freimueller, Klaus; Adler, Heiko] GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Clin Cooperat Grp Hematopoiet Cell Transplantat, Munich, Germany; [Thakur, Nagendra N.; Steer, Beatrix] Univ Munich, Dept Med 3, Munich, Germany; [El-Gogo, Susanne] Tech Univ Munich, Inst Virol, Munich, Germany; [Waha, Andreas] Univ Bonn, Inst Neuropathol, D-5300 Bonn, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Technical University of Munich; University of Bonn	Adler, H (corresponding author), GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Clin Cooperat Grp Hematopoiet Cell Transplantat, Munich, Germany.	h.adler@gsf.de	Adler, Heiko/M-7355-2014	Adler, Heiko/0000-0002-6481-6709	Deutsche Forschungsgemeinschaft [Ad121/2-1, 2-2, 2-4]; BMBF [NGFN-2, FKZ 01GS0405]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF))	This work was supported by grants from the Deutsche Forschungsgemeinschaft (Ad121/2-1, 2-2 and 2-4) and the BMBF (NGFN-2, FKZ 01GS0405).	AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Adler H, 2001, J VIROL, V75, P5692, DOI 10.1128/JVI.75.12.5692-5696.2001; Adler H, 2007, J VIROL, V81, P7300, DOI 10.1128/JVI.02406-06; ALLAN GJ, 1989, VIROLOGY, V173, P489, DOI 10.1016/0042-6822(89)90561-8; Almqvist J, 2005, J GEN VIROL, V86, P1261, DOI 10.1099/vir.0.80620-0; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Boname JM, 2004, IMMUNITY, V20, P305, DOI 10.1016/S1074-7613(04)00047-0; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; Chambeyron S, 2004, CURR OPIN CELL BIOL, V16, P256, DOI 10.1016/j.ceb.2004.03.004; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Coleman HM, 2005, J GEN VIROL, V86, P561, DOI 10.1099/vir.0.80565-0; Coleman HM, 2003, J VIROL, V77, P13093, DOI 10.1128/JVI.77.24.13093-13105.2003; Cook PR, 2003, J CELL SCI, V116, P4483, DOI 10.1242/jcs.00819; COX MA, 1990, J VIROL, V64, P313, DOI 10.1128/JVI.64.1.313-321.1990; Dantuma NP, 2000, P NATL ACAD SCI USA, V97, P8381, DOI 10.1073/pnas.140217397; Dean A, 2006, TRENDS GENET, V22, P38, DOI 10.1016/j.tig.2005.11.001; DELUCA NA, 1988, J VIROL, V62, P732, DOI 10.1128/JVI.62.3.732-743.1988; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; Fowler P, 2003, J GEN VIROL, V84, P3405, DOI 10.1099/vir.0.19594-0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hoge AT, 2000, J VIROL, V74, P7016, DOI 10.1128/JVI.74.15.7016-7023.2000; JEANG KT, 1983, J VIROL, V48, P135, DOI 10.1128/JVI.48.1.135-148.1983; JONES MD, 1983, NUCLEIC ACIDS RES, V11, P3919, DOI 10.1093/nar/11.12.3919; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAUX G, 1985, J VIROL, V56, P987, DOI 10.1128/JVI.56.3.987-995.1985; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; Marques S, 2003, J VIROL, V77, P7308, DOI 10.1128/JVI.77.13.7308-7318.2003; McCormick C, 2006, J VIROL, V80, P6165, DOI 10.1128/JVI.02331-05; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759; Moorman NJ, 2003, J VIROL, V77, P10295, DOI 10.1128/JVI.77.19.10295-10303.2003; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Nash AA, 2001, PHILOS T R SOC B, V356, P569, DOI 10.1098/rstb.2000.0779; NUEBLING CM, 1989, J VIROL, V63, P4609, DOI 10.1128/JVI.63.11.4609-4615.1989; Oki M, 2002, CURR OPIN CELL BIOL, V14, P299, DOI 10.1016/S0955-0674(02)00327-7; Pearsall RS, 1999, GENOMICS, V55, P194, DOI 10.1006/geno.1998.5660; Rochford R, 2001, J VIROL, V75, P4955, DOI 10.1128/JVI.75.11.4955-4963.2001; Roizman B, 2001, FIELDS VIROL, P2381; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SHAPIRO A, 1998, NAT MED, V4, P939; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; Speck SH, 1999, CURR OPIN MICROBIOL, V2, P403; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Stevenson PG, 2004, CURR OPIN IMMUNOL, V16, P456, DOI 10.1016/j.coi.2004.05.002; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; Tao Q, 2003, CLIN IMMUNOL, V109, P53, DOI 10.1016/S1521-6616(03)00198-0; van Dyk LF, 2000, J VIROL, V74, P7451, DOI 10.1128/JVI.74.16.7451-7461.2000; Virgin HW, 1999, CURR OPIN IMMUNOL, V11, P371, DOI 10.1016/S0952-7915(99)80063-6; Virgin HW, 1999, J VIROL, V73, P2321, DOI 10.1128/JVI.73.3.2321-2332.1999; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Weinberg JB, 2004, VIRAL IMMUNOL, V17, P69, DOI 10.1089/088282404322875467; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	59	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e733	10.1371/journal.pone.0000733	http://dx.doi.org/10.1371/journal.pone.0000733			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710133	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200010
J	Lau, LMS; Nugent, JK; Zhao, X; Irwin, MS				Lau, L. M. S.; Nugent, J. K.; Zhao, X.; Irwin, M. S.			HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function	ONCOGENE			English	Article						Nutlin; p73; HDM2; apoptosis; p53	MOLECULE MDM2 ANTAGONISTS; SQUAMOUS-CELL CARCINOMA; CENTRAL DOMAIN; P53 PATHWAY; MUTANT P53; IN-VIVO; APOPTOSIS; FAMILY; SITE; P63	Nutlin-3, a small molecule inhibitor, activates p53 by disrupting p53-HDM2 association. In this study, we found that Nutlin-3 suppressed cell growth and induced apoptosis in the absence of wild-type p53, suggesting a p53-independent mechanism for Nutlin-3-induced cell death. Like p53, its homolog p73 transactivates proapoptotic genes and induces cell death. Since HDM2, a key negative regulator of p53, also binds to and inhibits p73, we asked whether p73 could mediate Nutlin-3-induced apoptosis. We demonstrate that Nutlin-3 inhibits endogenous binding between the proapoptotic p73 isoform TAp73 alpha and HDM2 in p53-null cells. Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with up regulation of p73 target genes noxa, puma and p21,as well as enhanced apoptosis. p73 knockdown by siRNA results in rescue of Nutlin-3-treated cells, indicating that Nutlin-3-induced apoptosis is, at least in part, p73 dependent. In addition, Nutlin-3 treatment increases TAp73 alpha protein levels with prolongation of p73 half-life. These results provide the first evidence that Nutlin-3 disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73 and thus, provides a rationale for the use of Nutlin-3 in the large number of human tumors in which p53 is inactivated.	[Lau, L. M. S.; Zhao, X.; Irwin, M. S.] Univ Toronto, Div Hematol Oncol, Dept Paediat, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Lau, L. M. S.; Nugent, J. K.; Irwin, M. S.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Irwin, MS (corresponding author), Univ Toronto, Div Hematol Oncol, Dept Paediat, Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970				Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Ma JH, 2006, BIOCHEMISTRY-US, V45, P9238, DOI 10.1021/bi060661u; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; VanderBorght A, 2006, ONCOGENE, V25, P6672, DOI 10.1038/sj.onc.1209667; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	30	147	153	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					997	1003		10.1038/sj.onc.1210707	http://dx.doi.org/10.1038/sj.onc.1210707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700533				2022-12-25	WOS:000252946300011
J	Cohen, L; Ilan, N; Gur, M; Stuhmer, W; Gordon, D; Gurevitz, M				Cohen, Lior; Ilan, Nitza; Gur, Maya; Stuhmer, Walter; Gordon, Dalia; Gurevitz, Michael			Design of a specific activator for skeletal muscle sodium channels uncovers channel architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODIC PARALYSIS TYPE-2; SCORPION BETA-TOXINS; GATED ION CHANNELS; VOLTAGE-SENSOR; ENHANCED INACTIVATION; FUNCTIONAL SURFACE; MUTATIONS; COMMON; INSECT; LOOP	Gating modifiers of voltage-gated sodium channels (Na(v)s) are important tools in neuroscience research and may have therapeutic potential in medicinal disorders. Analysis of the bioactive surface of the scorpion beta-toxin Css4 (from Centruroides suffusus suffusus) toward rat brain (rNa(v)1.2a) and skeletal muscle (rNa(v)1.4) channels using binding studies revealed commonality but also substantial differences, which were used to design a specific activator, Css4(F14A/E15A/E28R), of rNa(v)1.4 expressed in Xenopus oocytes. The therapeutic potential of Css4(F14A/E15A/E28R) was tested using an rNa(v)1.4 mutant carrying the same mutation present in the genetic disorder hypokalemic periodic paralysis. The activator restored the impaired gating properties of the mutant channel expressed in oocytes, thus offering a tentative new means for treatment of neuromuscular disorders with reduced muscle excitability. Mutant double cycle analysis employing toxin residues involved in the construction of Css4(F14A/E15A/E28R) and residues whose equivalents in the rat brain channel rNa(v)1.2a were shown to affect Css4 binding revealed significant coupling energy (> 1.3 kcal/mol) between F14A and E592A at Domain-2/voltage sensor segments 1-2 (D2/S1-S2), R27Q and E1251N at D3/SS2-S6, and E28R with both E650A at D2/S3-S4 and E1251N at D3/SS2-S6. These results show that despite the differences in interactions with the rat brain and skeletal muscle Navs, Css4 recognizes a similar region on both channel subtypes. Moreover, our data indicate that the S3-S4 loop of the voltage sensor module in Domain-2 is in very close proximity to the SS2-S6 segment of the pore module of Domain-3 in rNa(v)1.4. This is the first experimental evidence that the inter-domain spatial organization of mammalian Na(v)s resembles that of voltage-gated potassium channels.				dgordon@post.tau.ac.il; mamgur@post.tau.ac.il	Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764	NINDS NIH HHS [1 U01 NS058039-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS058039] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Bosmans F, 2007, TOXICOL APPL PHARM, V218, P45, DOI 10.1016/j.taap.2006.10.009; Cannon SC, 2002, NEUROMUSCULAR DISORD, V12, P533, DOI 10.1016/S0960-8966(02)00007-X; Cannon SC, 2001, CLIN NEUROSCI RES, V1, P104, DOI 10.1016/S1566-2772(00)00011-6; Carle T, 2006, BIOCHEM BIOPH RES CO, V348, P653, DOI 10.1016/j.bbrc.2006.07.101; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Chen H, 2001, J GEN PHYSIOL, V117, P505, DOI 10.1085/jgp.117.6.505; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; GERSHON E, 1992, J NEUROSCI, V12, P3743; Gilles N, 2001, BIOCHEMISTRY-US, V40, P14576, DOI 10.1021/bi010973r; Goldin AL, 1999, ANN NY ACAD SCI, V868, P38, DOI 10.1111/j.1749-6632.1999.tb11272.x; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; Jurkat-Rott K, 2002, J NEUROL, V249, P1493, DOI 10.1007/s00415-002-0871-5; Jurkat-Rott K, 2000, P NATL ACAD SCI USA, V97, P9549, DOI 10.1073/pnas.97.17.9549; Karbat I, 2007, J MOL BIOL, V366, P586, DOI 10.1016/j.jmb.2006.10.085; Kuzmenkin A, 2002, BRAIN, V125, P835, DOI 10.1093/brain/awf071; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Leipold E, 2006, MOL PHARMACOL, V70, P340, DOI 10.1124/mol.106.024034; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Richardson J, 2006, P NATL ACAD SCI USA, V103, P15865, DOI 10.1073/pnas.0607532103; Schiavon E, 2006, J BIOL CHEM, V281, P20326, DOI 10.1074/jbc.M600565200; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Sokolov S, 2007, NATURE, V446, P76, DOI 10.1038/nature05598; Sternberg D, 2001, BRAIN, V124, P1091, DOI 10.1093/brain/124.6.1091; Vicart S, 2005, NEUROL SCI, V26, P194, DOI 10.1007/s10072-005-0461-x; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q	35	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29424	29430		10.1074/jbc.M704651200	http://dx.doi.org/10.1074/jbc.M704651200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686768	hybrid			2022-12-25	WOS:000249788000039
J	Higgins, MJ; Graves, PR; Graves, LM				Higgins, Matthew J.; Graves, Paul R.; Graves, Lee M.			Regulation of human cytidine triphosphate synthetase 1 by glycogen synthase kinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEPENDENT PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; ATP-CITRATE-LYASE; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE SYNTHESIS; LYMPHOBLASTIC-LEUKEMIA; PHOSPHORYLASE-KINASE	Cytidine triphosphate synthetase (CTPS) catalyzes the rate-limiting step in the de novo synthesis of CTP, and both the yeast and human enzymes have been reported to be regulated by protein kinase A or protein kinase C phosphorylation. Here, we provide evidence that stimulation or inhibition of protein kinase A and protein kinase C does not alter the phosphorylation of endogenous human CTPS1 in human embryonic kidney 293 cells under the conditions tested. Unexpectedly, we found that low serum conditions increased phosphorylation of endogenous CTPS1 and this phosphorylation was inhibited by the glycogen synthase kinase 3 (GSK3) inhibitor indirubin-3'-monoxime and GSK3 beta short interfering RNAs, demonstrating the involvement of GSK3 in phosphorylation of endogenous human CTPS1. Separating tryptic peptides from [P-32] orthophosphate-labeled cells and analyzing the phosphopeptides by mass spectrometry identified Ser-574 and Ser-575 as phosphorylated residues. Mutation of Ser-571 demonstrated that Ser-571 was the major site phosphorylated by GSK3 in intact human embryonic kidney 293 cells by GSK3 in vitro. Furthermore, mutation of Ser-575 prevented the phosphorylation of Ser-571, suggesting that phosphorylation of Ser-575 was necessary for priming the GSK3 phosphorylation of Ser-571. Low serum was found to decrease CTPS1 activity, and incubation with the GSK3 inhibitor indirubin-3'-monoxime protected against this decrease in activity. Incubation with an alkaline phosphatase increased CTPS1 activity in a time-dependent manner, demonstrating that phosphorylation inhibits CTPS1 activity. This is the first study to investigate the phosphorylation and regulation of human CTPS1 in human cells and suggests that GSK3 is a novel regulator of CTPS activity.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	University of North Carolina; University of North Carolina Chapel Hill; Virginia Commonwealth University	Graves, LM (corresponding author), 116 Manning Dr,936A Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	lmg@med.unc.edu	Graves, Lee/AAG-5470-2021					Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chabes A, 2007, P NATL ACAD SCI USA, V104, P1183, DOI 10.1073/pnas.0610585104; Chandra D, 2006, CELL, V125, P1333, DOI 10.1016/j.cell.2006.05.026; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; DEKORTE D, 1987, INT J CANCER, V40, P192, DOI 10.1002/ijc.2910400211; DEKORTE D, 1987, CANCER RES, V47, P1841; DEKORTE D, 1985, ANAL BIOCHEM, V147, P197, DOI 10.1016/0003-2697(85)90028-4; DEKORTE D, 1986, LEUKEMIA RES, V10, P389, DOI 10.1016/0145-2126(86)90068-8; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; Han GS, 2005, J BIOL CHEM, V280, P38328, DOI 10.1074/jbc.M509622200; HARMENBERG J, 1990, J CHROMATOGR, V508, P75, DOI 10.1016/S0021-9673(00)91241-X; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Park TS, 2003, J BIOL CHEM, V278, P20785, DOI 10.1074/jbc.M301394200; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PULVERER BJ, 1994, ONCOGENE, V9, P59; Raska CS, 2002, J AM SOC MASS SPECTR, V13, P1034, DOI 10.1016/S1044-0305(02)00433-6; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SHEWACH DS, 1992, ANAL BIOCHEM, V206, P178, DOI 10.1016/S0003-2697(05)80030-2; SIDI Y, 1985, BRIT J HAEMATOL, V61, P125, DOI 10.1111/j.1365-2141.1985.tb04067.x; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P257; VANDENBERG AA, 1994, LEUKEMIA, V8, P1375; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	46	32	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29493	29503		10.1074/jbc.M703948200	http://dx.doi.org/10.1074/jbc.M703948200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681942	hybrid, Green Published			2022-12-25	WOS:000249788000046
J	Schietroma, C; Yu, HY; Wagner, MC; Umbach, JA; Bement, WM; Gundersen, CB				Schietroma, Cataldo; Yu, Hoi-Ying; Wagner, Mark C.; Umbach, Joy A.; Bement, William M.; Gundersen, Cameron B.			A role for myosin 1e in cortical granule exocytosis in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-STRING-PROTEIN; NEUROTRANSMITTER RELEASE; UNCONVENTIONAL MYOSINS; MEIOTIC MATURATION; LAEVIS OOCYTES; SUBCELLULAR-LOCALIZATION; COMPENSATORY ENDOCYTOSIS; ENDOPLASMIC-RETICULUM; VESICLE TRANSPORT; ACTIN	Xenopus oocytes undergo dynamic structural changes during maturation and fertilization. Among these, cortical granule exocytosis and compensatory endocytosis provide effective models to study membrane trafficking. This study documents an important role for myosin1e in cortical granule exocytosis. Myosin1e is expressed at the earliest stage that cortical granule exocytosis can be detected in oocytes. Prior to exocytosis, myosin1e relocates to the surface of cortical granules. Overexpression of myosin1e augments the kinetics of cortical granule exocytosis, whereas tail-derived fragments of myosin1e inhibit this secretory event (but not constitutive exocytosis). Finally, intracellular injection of myosin1e antibody inhibits cortical granule exocytosis. Further experiments identified cysteine string proteins as interacting partners for myosin1e. As constituents of the membrane of cortical granules, cysteine string proteins are also essential for cortical granule exocytosis. Future investigation of the link between myosin1e and cysteine string proteins should help to clarify basic mechanisms of regulated exocytosis.	Univ Calif Los Angeles, David Geffen UCLA Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Indiana University System; Indiana University-Purdue University Indianapolis; University of Wisconsin System; University of Wisconsin Madison	Gundersen, CB (corresponding author), Univ Calif Los Angeles, David Geffen UCLA Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	cgundersen@mednet.ucla.edu	Bement, William/AAA-5444-2021	Gundersen, Cameron/0000-0002-1552-6086; Schietroma, Cataldo/0000-0002-0865-9956	NIGMS NIH HHS [R01 GM052932-10, R01 GM052932, GM52932] Funding Source: Medline; NINDS NIH HHS [NS31934, R01 NS031934-06, R01 NS031934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barylko B, 2005, ACTA BIOCHIM POL, V52, P373; BEMENT WM, 1989, J CELL BIOL, V108, P885, DOI 10.1083/jcb.108.3.885; BEMENT WM, 1989, CELL TISSUE RES, V255, P183; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CAMPANELLA C, 1984, J EXP ZOOL, V229, P283, DOI 10.1002/jez.1402290214; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chang BY, 2004, COMP BIOCHEM PHYS A, V137, P115, DOI 10.1016/S1095-6433(03)00269-1; CHARBONNEAU M, 1984, DEV BIOL, V102, P90, DOI 10.1016/0012-1606(84)90177-5; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Dumont RA, 2002, JARO-J ASSOC RES OTO, V3, P375, DOI 10.1007/s101620020049; Gillespie PG, 2001, J CELL BIOL, V155, P703, DOI 10.1083/jcb.200110032; Gundersen CB, 2002, J CELL SCI, V115, P1313; Gundersen CB, 2001, CELL TISSUE RES, V303, P211, DOI 10.1007/s004410000314; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Hokanson DE, 2006, P NATL ACAD SCI USA, V103, P3118, DOI 10.1073/pnas.0505685103; Hubner K, 2002, INT REV CYTOL, V214, P103; Kohan SA, 2003, J EXP ZOOL PART A, V300A, P113, DOI 10.1002/jez.a.10317; Krendel M, 2007, FEBS LETT, V581, P644, DOI 10.1016/j.febslet.2007.01.021; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; LARABELL CA, 1988, CELL TISSUE RES, V251, P129, DOI 10.1007/BF00215457; MOZINGO NM, 1995, RAPID FREEZING FREEZ, P285; Neco P, 2004, J BIOL CHEM, V279, P27450, DOI 10.1074/jbc.M311462200; NISHIHARA T, 1986, BIOCHEMISTRY-US, V25, P6013, DOI 10.1021/bi00368a027; Oliver TN, 1999, CELL MOL LIFE SCI, V56, P243, DOI 10.1007/s000180050426; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Poage RE, 1999, J NEUROPHYSIOL, V82, P50, DOI 10.1152/jn.1999.82.1.50; Provance DW, 1999, CELL MOL LIFE SCI, V56, P233, DOI 10.1007/s000180050425; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Smith GB, 2005, J BIOL CHEM, V280, P32669, DOI 10.1074/jbc.M501806200; Sokac AM, 2000, INT REV CYTOL, V200, P197, DOI 10.1016/S0074-7696(00)00005-X; Sokac AM, 2003, NAT CELL BIOL, V5, P727, DOI 10.1038/ncb1025; Sokac AM, 2006, DEV CELL, V11, P629, DOI 10.1016/j.devcel.2006.09.002; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; Stoffler HE, 1998, J CELL SCI, V111, P2779; Sudhof TC, 2001, SYNAPSES, P177; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; Wu XF, 2000, CURR OPIN CELL BIOL, V12, P42, DOI 10.1016/S0955-0674(99)00055-1; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	50	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29504	29513		10.1074/jbc.M705825200	http://dx.doi.org/10.1074/jbc.M705825200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17702742	Green Accepted, hybrid			2022-12-25	WOS:000249788000047
J	Shin, N; Lee, S; Ahn, N; Kim, SA; Ahn, SG; YongPark, Z; Chang, S				Shin, Narae; Lee, Suho; Ahn, Namhui; Kim, Soo-A; Ahn, Sang-Gun; YongPark, Zee; Chang, Sunghoe			Sorting nexin 9 interacts with dynamin 1 and N-WASP and coordinates synaptic vesicle endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; MEDIATED ENDOCYTOSIS; SORTING NEXIN-9; SH3 DOMAINS; RECEPTOR; NCK; SYNAPTOJANIN-1; ASSOCIATION; KINETICS; ADAPTER	Sorting nexin 9 (SNX9) is a member of the sorting nexin family of proteins, each of which contains a characteristic Phox homology domain. SNX9 is widely expressed and plays a role in clathrin-mediated endocytosis, but it is not known if it is present in neuronal cells. We report that SNX9 is expressed in the presynaptic compartment of cultured hippocampal neurons, where it binds to dynamin-1 and N-WASP. Overexpression of full-length SNX9 or a C-terminal truncated version caused severe defects in synaptic vesicle endocytosis during, as well as after, stimulation. Knockdown of SNX9 with short interfering RNA also reduced synaptic vesicle endocytosis, and the W39A mutation of SNX9 abolished the inhibitory effect of SNX9 on endocytosis. Rescue experiments showed that most of the effect of SNX9 on endocytosis results from its interaction with dynamin 1, although its interaction with N-WASP contributes in some degree. We further showed that SNX9 dimerizes through its C-terminal domain, suggesting that it may interact simultaneously with dynamin 1 and N-WASP. We propose that SNX9 interacts with dynamin-1 and N-WASP in presynaptic terminals, where it links actin dynamics and synaptic vesicle endocytosis.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Dongguk Univ, Dept Biochem, Coll Oriental Med, Gyeongju 780714, South Korea; Chosun Univ, Coll Dent, Dept Pathol, Kwangju 501759, South Korea	Gwangju Institute of Science & Technology (GIST); Dongguk University; Chosun University	Chang, S (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong song, Kwangju 500712, South Korea.	sunghoe@gist.ac.kr	Chang, Sunghoe/J-2784-2012	Kim, Soo-A/0000-0001-6777-739X; chang, sunghoe/0000-0002-3446-7288				Chang S, 2001, NAT NEUROSCI, V4, P787, DOI 10.1038/90489; Childress C, 2006, BIOCHEM J, V394, P693, DOI 10.1042/BJ20050576; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Fernandez-Alfonso T, 2004, NEURON, V41, P943, DOI 10.1016/S0896-6273(04)00113-8; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim WT, 2002, P NATL ACAD SCI USA, V99, P17143, DOI 10.1073/pnas.222657399; Kim Y, 2005, J NEUROSCI, V25, P9515, DOI 10.1523/JNEUROSCI.1643-05.2005; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lundmark R, 2004, J BIOL CHEM, V279, P42694, DOI 10.1074/jbc.M407430200; Lundmark R, 2003, J BIOL CHEM, V278, P46772, DOI 10.1074/jbc.M307334200; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Micheva KD, 2003, NAT NEUROSCI, V6, P925, DOI 10.1038/nn1114; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Solomaha E, 2005, J BIOL CHEM, V280, P23147, DOI 10.1074/jbc.M501745200; Soulet F, 2005, MOL BIOL CELL, V16, P2058, DOI 10.1091/mbc.E04-11-1016; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Yeow-Fong L, 2005, FEBS LETT, V579, P5040, DOI 10.1016/j.febslet.2005.07.093; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	41	54	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28939	28950		10.1074/jbc.M700283200	http://dx.doi.org/10.1074/jbc.M700283200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681954	hybrid			2022-12-25	WOS:000249642100068
J	Tripathi, V; Ali, A; Bhat, R; Pati, U				Tripathi, Veenu; Ali, Amjad; Bhat, Rajiv; Pati, Uttam			CHIP chaperones wild type p53 tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; HEAT-SHOCK PROTEINS; MUTANT P53; TARGET; DEGRADATION; HSP90; IDENTIFICATION; CONFORMATION; RESCUE; CANCER	Wild type p53 exists in a constant state of equilibrium between wild type and mutant conformation and undergoes conformational changes at elevated temperature. We have demonstrated that the co-chaperone CHIP (carboxyl terminus of Hsp70-interacting protein), which suppressed aggregation of several misfolded substrates and induced the proteasomal degradation of both wild type and mutant p53, physically interacts with the amino terminus of WT53 and prevented it from irreversible thermal inactivation. CHIP preferentially binds to the p53 mutant phenotype and restored the DNA binding activity of heat-denatured p53 in an ATP-independent manner. In cells under elevated temperatures that contained a higher level of p53 mutant phenotype, CHIP restored the native-like conformation of p53 in the presence of geldanamycin, whereas CHIP-small interfering RNA considerably increased the mutant form. Further, under elevated temperatures, the levels of CHIP and p53 were higher in nucleus, and chromatin immunoprecipitation shows the presence of p53 and CHIP together upon the DNA binding site in the p21 and p53 promoters. We propose that CHIP might be a direct chaperone of wild type p53 that helps p53 in maintaining wild type conformation under physiological condition as well as help resurrect p53 mutant phenotype into a folded native state under stress condition.	Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Pati, U (corresponding author), Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.	uttam@mail.jnu.ac.in	Pati, Uttam/L-9345-2019					Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; BIAGOSKLONNY MV, 1996, P NATL ACAD SCI USA, V93, P8379; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; DIXIT P, 2007, BIOCHEM BIOPH RES CO, V357, P761; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Rosser MFN, 2007, J BIOL CHEM, V282, P22267, DOI 10.1074/jbc.M700513200; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	42	32	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28441	28454		10.1074/jbc.M703698200	http://dx.doi.org/10.1074/jbc.M703698200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666403	hybrid			2022-12-25	WOS:000249642100018
J	Xuan, CH; Qiao, WT; Gao, JM; Liu, M; Zhang, XH; Cao, YJ; Chen, QM; Geng, YQ; Zhou, J				Xuan, Chenghao; Qiao, Wentao; Gao, Jinmin; Liu, Min; Zhang, Xihui; Cao, Youjia; Chen, Qimin; Geng, Yunqi; Zhou, Jun			Regulation of microtubule assembly and stability by the transactivator of transcription protein of Jembrana disease virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT; APOPTOSIS; CELLS; DYNAMICS; PROLIFERATION; CYTOSKELETON; REPLICATION; SEQUENCE; PATHWAY; DRUGS	Microtubules are cytoskeletal polymers consisting of tubulin subunits that take part in diverse cell activities. Many viruses hijack cellular motor proteins to move on microtubules toward the cell interior during the entry process and toward the plasma membrane during the egress period. In addition, viruses often remodel microtubules to facilitate the generation of infectious progeny. In this study, we found that the transactivator of transcription protein of Jembrana disease virus (Jtat) bound tubulin and microtubules both in cells and in the purified system. Microtubule co-sedimentation and co-localization assays revealed a robust interaction of Jtat with microtubules. Tubulin turbidity assay further showed that Jtat promoted tubulin polymerization in vitro in a concentration-dependent manner. Moreover, Jtat promoted the partitioning of cellular tubulin toward the polymeric form, increased the level of tubulin acetylation, and significantly enhanced the cold stability of cellular microtubules. In addition, Jtat-mediated disruption of microtubule dynamics induced the release of Bim from microtubules, leading to profound apoptosis. These results not only identify Jtat as an important viral regulator of microtubule dynamics but also indicate that Jtat-induced apoptosis might contribute to Jembrana disease pathogenesis.	Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China	Nankai University	Geng, YQ (corresponding author), Nankai Univ, Coll Life Sci, 94 Weijin Rd, Tianjin 300071, Peoples R China.	gengyq@nankai.edu.cn	Zhou, Jun/D-4654-2017; Gao, Jinmin/J-8967-2015	Zhou, Jun/0000-0001-7858-8260; 				Amos LA, 2005, ADV PROTEIN CHEM, V71, P257, DOI 10.1016/S0065-3233(04)71007-4; Aneja R, 2006, BLOOD, V107, P2486, DOI 10.1182/blood-2005-08-3516; CHADWICK BJ, 1995, J GEN VIROL, V76, P189, DOI 10.1099/0022-1317-76-1-189; Chen HX, 2000, J VIROL, V74, P2703, DOI 10.1128/JVI.74.6.2703-2713.2000; Chen HX, 1999, J VIROL, V73, P658, DOI 10.1128/JVI.73.1.658-666.1999; Deng G, 2006, VIRUS RES, V121, P122, DOI 10.1016/j.virusres.2006.01.023; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; Gibellini D, 2005, NEW MICROBIOL, V28, P95; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matarrese P, 2005, CELL DEATH DIFFER, V12, P932, DOI 10.1038/sj.cdd.4401582; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; SOESANTO M, 1990, J COMP PATHOL, V103, P61, DOI 10.1016/S0021-9975(08)80135-1; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WILCOX GE, 1995, VET MICROBIOL, V46, P249, DOI 10.1016/0378-1135(95)00089-S; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Zagury J F, 1998, J Hum Virol, V1, P282; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zhou J, 2006, CANCER RES, V66, P445, DOI 10.1158/0008-5472.CAN-05-1779	31	15	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28800	28806		10.1074/jbc.M702823200	http://dx.doi.org/10.1074/jbc.M702823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656359	hybrid			2022-12-25	WOS:000249642100054
J	Noguchi, TQP; Kanzaki, N; Ueno, H; Hirose, K; Uyeda, TQP				Noguchi, Taro Q. P.; Kanzaki, Noriko; Ueno, Hironori; Hirose, Keiko; Uyeda, Taro Q. P.			A novel system for expressing toxic actin mutants in Dictyostelium and purification and characterization of a dominant lethal yeast actin mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; IN-VITRO; FUNCTIONAL INTERACTIONS; MOTOR DOMAIN; N-TERMINUS; MYOSIN; FILAMENT; BINDING; PROTEIN; CELLS	We have developed a novel system for expressing recombinant actin in Dictyostelium. In this system, the C terminus of actin is fused to thymosin 6 via a glycine-based linker. The fusion protein is purified using a His tag attached to the thymosin beta moiety and then cleaved by chymotrypsin immediately after the native final residue of actin to yield intact actin. Wildtype actin prepared in this way was functionally normal in terms of its polymerization kinetics and muscle myosin-mediated motility. We expected that this system would be particularly useful for expressing toxic actin mutants, because the actin moiety of the fusion protein is unlikely to interact with the actin cytoskeleton of the host cells. We therefore chose to express the E2016A/R207A/E208A mutant, which appears to be dominant lethal in yeast, as a model case of a toxic actin mutant that is difficult to express. We found that the E206A/R207A/E208A mutant could be expressed and purified with a yield comparable to the wild-type molecule (3-4 mg/20 g cells), even though green fluorescent protein-fused actin carrying the E206A/R207A/E208A mutation was expressed at a much lower level than wild-type actin. Purified E206A/R207A/E208A actin did not polymerize, even in the presence of muscle actin; however, it accelerated polymerization of muscle actin and inhibited the nucleating and severing activities of gelsolin. Given that the location of the substituted residues is near the pointed end face of the mutant, we suggest that E206A/R207A/E208A actin behaves like a weak pointed end-capping protein that perturbs the actin cytoskeleton of the host cells.	Univ Tsukuba, Res Inst Cell Engn, Tsukuba, Ibaraki 3058562, Japan; Univ Tsukuba, Inst Human Sci & Biomed Engn, Nalt Inst Adv Ind Sci & Technol Tsukuba Cent 4, Tsukuba, Ibaraki 3058562, Japan; Univ Tsukuba, Grad Sch Life Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; University of Tsukuba	Uyeda, TQP (corresponding author), Univ Tsukuba, Res Inst Cell Engn, 1-1-1 Highashi, Tsukuba, Ibaraki 3058562, Japan.	t-uyeda@aist.go.jp	Hirose, Keiko/M-5429-2018	Hirose, Keiko/0000-0003-4587-8346				Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; An HS, 1996, J MOL BIOL, V260, P492, DOI 10.1006/jmbi.1996.0417; ANSON M, 1995, BIOPHYS J, V68, P1991, DOI 10.1016/S0006-3495(95)80376-0; Asano Y, 2004, CELL MOTIL CYTOSKEL, V59, P17, DOI 10.1002/cm.20015; ASPENSTROM P, 1991, EUR J BIOCHEM, V200, P35, DOI 10.1111/j.1432-1033.1991.tb21045.x; COOK RK, 1992, J BIOL CHEM, V267, P9430; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; DRUMMOND DR, 1991, BIOCHEM J, V274, P301, DOI 10.1042/bj2740301; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; EGELMAN EH, 1995, CURR OPIN STRUC BIOL, V5, P172, DOI 10.1016/0959-440X(95)80072-7; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JACOBSON GR, 1976, P NATL ACAD SCI USA, V73, P2742, DOI 10.1073/pnas.73.8.2742; Joel PB, 2004, BIOCHEMISTRY-US, V43, P11554, DOI 10.1021/bi048899a; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LEE RJ, 1994, J CELL SCI, V107, P2875; Liu X, 1998, P NATL ACAD SCI USA, V95, P14124, DOI 10.1073/pnas.95.24.14124; MIKI M, 1982, BIOCHEMISTRY-US, V21, P3661, DOI 10.1021/bi00258a021; Oosawa F., 1972, COLD SPRING HARB SYM, V37, P277; Prochniewicz E, 1997, BIOCHEMISTRY-US, V36, P12845, DOI 10.1021/bi971201r; PROCHNIEWICZ E, 1993, BIOPHYS J, V65, P113, DOI 10.1016/S0006-3495(93)81057-9; ROMANS P, 1985, J MOL BIOL, V186, P321, DOI 10.1016/0022-2836(85)90108-1; RUBENSTEIN P, 1979, J BIOL CHEM, V254, P1142; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; Terada N, 2007, BIOPHYS J, V92, P2162, DOI 10.1529/biophysj.106.098871; VANDEKERCKHOVE J, 1980, NATURE, V284, P475, DOI 10.1038/284475a0; WERTMAN KF, 1992, GENETICS, V132, P337; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Yokoyama K, 2002, BIOCHEM BIOPH RES CO, V299, P825, DOI 10.1016/S0006-291X(02)02758-4	38	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27721	27727		10.1074/jbc.M703165200	http://dx.doi.org/10.1074/jbc.M703165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656358	hybrid			2022-12-25	WOS:000249455600020
J	Raybaud, A; Baspinar, EE; Dionne, F; Dodier, Y; Sauve, R; Parent, L				Raybaud, Alexandra; Baspinar, Ebru-Eylem; Dionne, Francois; Dodier, Yolaine; Sauve, Remy; Parent, Lucie			The role of distal s6 hydrophobic residues in the voltage-dependent Gating of Ca(v)2.3 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; GATED SODIUM-CHANNELS; CALCIUM-CHANNEL; CA2+ CHANNEL; K+ CHANNEL; BETA-SUBUNIT; MOLECULAR DETERMINANTS; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION GATE	The hydrophobic locus VAVIM is conserved in the S6 transmembrane segment of domain IV (IVS6) in Ca(V)1 and Ca(V)2 families. Herein we show that glycine substitution of the VAVIM motif in Ca(V)2.3 produced whole cell currents with inactivation kinetics that were either slower (A1719G approximate to V1720G), similar (V1718G), or faster (I1721G approximate to M1722G) than the wild-type channel. The fast kinetics of I1721G were observed with a approximate to + 10 mV shift in its voltage dependence of activation (E-0.5,E-act). In contrast, the slow kinetics of A1719G and V1720G were accompanied by a significant shift of approximate to-20 mV in their E-0.5,E-act indicating that the relative stability of the channel closed state was decreased in these mutants. Glycine scan performed with Val(349) in IS6, Ile(701) in IIS6, and Leu(1420) in IIIS6 at positions predicted to face Val(1720) in IVS6 also produced slow inactivating currents with hyperpolarizing shifts in the activation and inactivation potentials, again pointing out a decrease in the stability of the channel closed state. Mutations to other hydrophobic residues at these positions nearly restored the channel gating. Altogether these data indicate that residues at positions equivalent to 1720 exert a critical control upon the relative stability of the channel closed and open states and more specifically, that hydrophobic residues at these positions promote the channel closed state. We discuss a three-dimensional homology model of Ca(V)2.3 based upon Kv1.2 where hydrophobic residues at positions facing Val(1720) in IS6, IIS6, and IIIS6 play a critical role in stabilizing the closed state in Ca(V)2.3.	Univ Montreal, Dept Physiol, Membrane Protein Res Grp, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Parent, L (corresponding author), PO Box 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	lucie.parent@umontreal.ca						Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Armstrong Clay M, 2003, Sci STKE, V2003, pre10, DOI 10.1126/stke.2003.188.re10; Bernatchez G, 2001, BBA-BIOMEMBRANES, V1514, P217, DOI 10.1016/S0005-2736(01)00373-X; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; Beyl S, 2007, J BIOL CHEM, V282, P3864, DOI 10.1074/jbc.M609153200; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Cao YQ, 2005, P NATL ACAD SCI USA, V102, P2590, DOI 10.1073/pnas.0409896102; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dafi O, 2004, BIOPHYS J, V87, P3181, DOI 10.1529/biophysj.104.045559; Dodier Y, 2004, J BIOL CHEM, V279, P6853, DOI 10.1074/jbc.M310534200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ferrer T, 2006, J BIOL CHEM, V281, P12858, DOI 10.1074/jbc.M513518200; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Hans M, 1999, J NEUROSCI, V19, P1610; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hohaus A, 2005, J BIOL CHEM, V280, P38471, DOI 10.1074/jbc.M507013200; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jin TH, 2002, MOL CELL, V10, P469, DOI 10.1016/S1097-2765(02)00659-7; Kitaguchi T, 2004, J GEN PHYSIOL, V124, P319, DOI 10.1085/jgp.200409098; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lipkind GM, 2005, MOL PHARMACOL, V68, P1611, DOI 10.1124/mol.105.014803; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Meza U, 2007, MOL PHARMACOL, V71, P284, DOI 10.1124/mol.106.028530; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; Parent L, 1997, J MEMBRANE BIOL, V160, P127, DOI 10.1007/s002329900302; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; Raybaud A, 2006, J BIOL CHEM, V281, P39424, DOI 10.1074/jbc.M607405200; Scheib H, 2006, J MOL MODEL, V12, P813, DOI 10.1007/s00894-005-0066-y; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Scholle A, 2004, BIOPHYS J, V87, P873, DOI 10.1529/biophysj.104.040550; Serikov V, 2002, BIOCHEM BIOPH RES CO, V293, P1405, DOI 10.1016/S0006-291X(02)00396-0; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; Simoes M, 2002, J GEN PHYSIOL, V120, P99, DOI 10.1085/jgp.20028586; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Terwindt GM, 1998, EUR J HUM GENET, V6, P297, DOI 10.1038/sj.ejhg.5200206; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; Wang SY, 2007, PFLUG ARCH EUR J PHY, V454, P277, DOI 10.1007/s00424-006-0202-2; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Xie C, 2005, J GEN PHYSIOL, V126, P205, DOI 10.1085/jgp.200509293; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhen XG, 2005, J GEN PHYSIOL, V126, P193, DOI 10.1085/jgp.200509292	55	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27944	27952		10.1074/jbc.M703895200	http://dx.doi.org/10.1074/jbc.M703895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660294	hybrid			2022-12-25	WOS:000249455600043
J	Gillet, L; May, JS; Colaco, S; Stevenson, PG				Gillet, Laurent; May, Janet S.; Colaco, Susanna; Stevenson, Philip G.			The Murine Gammaherpesvirus-68 gp150 Acts as an Immunogenic Decoy to Limit Virion Neutralization	PLOS ONE			English	Article								Herpesviruses maintain long-term infectivity without marked antigenic variation. They must therefore evade neutralization by other means. Immune sera block murine gammaherpesvirus-68 (MHV-68) infection of fibroblasts, but fail to block and even enhance its infection of IgG Fc receptor-bearing cells, suggesting that the antibody response to infection is actually poor at ablating virion infectivity completely. Here we analyzed this effect further by quantitating the glycoprotein-specific antibody response of MHV-68 carrier mice. Gp150 was much the commonest glycoprotein target and played a predominant role in driving Fc receptor-dependent infection: when gp150-specific antibodies were boosted, Fc receptor-dependent infection increased; and when gp150-specific antibodies were removed, Fc receptor-dependent infection was largely lost. Neither gp150-specific monoclonal antibodies nor gp150-specific polyclonal sera gave significant virion neutralization. Gp150 therefore acts as an immunogenic decoy, distorting the MHV-68-specific antibody response to promote Fc receptor-dependent infection and so compromise virion neutralization. This immune evasion mechanism may be common to many non-essential herpesvirus glycoproteins.	[Gillet, Laurent; May, Janet S.; Colaco, Susanna; Stevenson, Philip G.] Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England	University of Cambridge	Stevenson, PG (corresponding author), Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England.	pgs27@cam.ac.uk	Stevenson, Philip g/F-9688-2014; Stevenson, Philip/F-6651-2011	Stevenson, Philip g/0000-0002-3520-5060; Gillet, Laurent/0000-0002-1047-2525	Fonds National Belge de la Recherche Scientifique (FNRS); Wellcome Trust [GR076956MA]; Medical Research Council [G0400427, G9800903]; CRUK [C19612/A6189]; Medical Research Council [G9800943] Funding Source: researchfish; MRC [G9800943, G0400427] Funding Source: UKRI	Fonds National Belge de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Laurent Gillet is a Postdoctoral Researcher of the Fonds National Belge de la Recherche Scientifique (FNRS). Philip Stevenson is a Wellcome Trust Senior Clinical Fellow (GR076956MA). This work was also supported by Medical Research Council grants G0400427 and G9800903 and a CRUK project grant (C19612/A6189).	Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Atalay R, 2002, J VIROL, V76, P8596, DOI 10.1128/JVI.76.17.8596-8608.2002; Belz GT, 2000, P NATL ACAD SCI USA, V97, P2725, DOI 10.1073/pnas.040575197; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Boname JM, 2005, J VIROL, V79, P3163, DOI 10.1128/JVI.79.5.3163-3168.2005; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Chandran B, 1998, VIROLOGY, V243, P208, DOI 10.1006/viro.1998.9055; Coleman HM, 2003, J VIROL, V77, P2410, DOI 10.1128/JVI.77.4.2410-2417.2003; Dal Conto AJ, 2000, J VIROL, V74, P11304, DOI 10.1128/JVI.74.23.11304-11310.2000; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; De Lima BD, 2004, J VIROL, V78, P5103, DOI 10.1128/JVI.78.10.5103-5112.2004; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; Fowler P, 2003, J GEN VIROL, V84, P3405, DOI 10.1099/vir.0.19594-0; Galfre G, 1981, Methods Enzymol, V73, P3; Gill MB, 2006, J GEN VIROL, V87, P1465, DOI 10.1099/vir.0.81760-0; Gillet L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000347; Gillet L, 2007, J VIROL, V81, P280, DOI 10.1128/JVI.01616-06; Gillet L, 2006, J GEN VIROL, V87, P3515, DOI 10.1099/vir.0.82313-0; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; KOHL S, 1982, J IMMUNOL, V129, P370; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; Lopes FB, 2004, J VIROL, V78, P13370, DOI 10.1128/JVI.78.23.13370-13375.2004; May JS, 2005, TRAFFIC, V6, P780, DOI 10.1111/j.1600-0854.2005.00316.x; May JS, 2005, J VIROL, V79, P5059, DOI 10.1128/JVI.79.8.5059-5068.2005; May JS, 2005, J GEN VIROL, V86, P919, DOI 10.1099/vir.0.80661-0; May JS, 2005, J VIROL, V79, P3459, DOI 10.1128/JVI.79.6.3459-3467.2005; May JS, 2004, J GEN VIROL, V85, P137, DOI 10.1099/vir.0.19599-0; Means RE, 2004, VIROLOGY, V326, P67, DOI 10.1016/j.virol.2004.05.015; MILLER N, 1988, J VIROL, V62, P2366, DOI 10.1128/JVI.62.7.2366-2372.1988; Mozdzanowska K, 2003, J VIROL, V77, P8322, DOI 10.1128/JVI.77.15.8322-8328.2003; PEETERS B, 1993, J VIROL, V67, P170, DOI 10.1128/JVI.67.1.170-177.1993; ROSA GT, 2007, PLOSONE IN PRESS; ROTH MG, 1980, J VIROL, V35, P547, DOI 10.1128/JVI.35.2.547-550.1980; SCHERLE PA, 1986, J EXP MED, V164, P1114, DOI 10.1084/jem.164.4.1114; Shannon-Lowe CD, 2006, P NATL ACAD SCI USA, V103, P7065, DOI 10.1073/pnas.0510512103; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; SISSONS JGP, 1980, J INFECT DIS, V142, P442, DOI 10.1093/infdis/142.3.442; Sitki-Green D, 2003, J VIROL, V77, P1840, DOI 10.1128/JVI.77.3.1840-1847.2003; Stevenson PG, 2005, VIRAL IMMUNOL, V18, P445, DOI 10.1089/vim.2005.18.445; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; Stevenson PG, 1999, P NATL ACAD SCI USA, V96, P9281, DOI 10.1073/pnas.96.16.9281; Stevenson PG, 1999, J VIROL, V73, P1075, DOI 10.1128/JVI.73.2.1075-1079.1999; Stevenson PG, 1998, J VIROL, V72, P943, DOI 10.1128/JVI.72.2.943-949.1998; Stewart JP, 2004, J VIROL, V78, P10449, DOI 10.1128/JVI.78.19.10449-10459.2004; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Tarlinton D, 2006, NAT REV IMMUNOL, V6, P785, DOI 10.1038/nri1938; THORLEYLAWSON DA, 1982, J VIROL, V43, P730, DOI 10.1128/JVI.43.2.730-736.1982; Turk SM, 2006, J VIROL, V80, P9628, DOI 10.1128/JVI.00622-06; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wang FZ, 2001, J VIROL, V75, P7517, DOI 10.1128/JVI.75.16.7517-7527.2001; WILDY P, 1985, BRIT MED BULL, V41, P86, DOI 10.1093/oxfordjournals.bmb.a072032; Xu JK, 1996, J GEN VIROL, V77, P49, DOI 10.1099/0022-1317-77-1-49; YAO QY, 1991, INT J CANCER, V48, P45; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; Zinkernagel RM, 2006, IMMUNOL REV, V211, P310, DOI 10.1111/j.0105-2896.2006.00402.x	58	40	40	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e705	10.1371/journal.pone.0000705	http://dx.doi.org/10.1371/journal.pone.0000705			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684552	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452400009
J	Emerson, D; Rentz, JA; Lilburn, TG; Davis, RE; Aldrich, H; Chan, C; Moyer, CL				Emerson, David; Rentz, Jeremy A.; Lilburn, Timothy G.; Davis, Richard E.; Aldrich, Henry; Chan, Clara; Moyer, Craig L.			A Novel Lineage of Proteobacteria Involved in Formation of Marine Fe-Oxidizing Microbial Mat Communities	PLOS ONE			English	Article							HYDROTHERMAL VENT SYSTEM; LOIHI SEAMOUNT; SP-NOV.; MINERAL DEPOSITION; IRON; DIVERSITY; BACTERIA; DEEP; OCEAN; OXIDE	Background. For decades it has been recognized that neutrophilic Fe-oxidizing bacteria (FeOB) are associated with hydrothermal venting of Fe(II)-rich fluids associated with seamounts in the world's oceans. The evidence was based almost entirely on the mineralogical remains of the microbes, which themselves had neither been brought into culture or been assigned to a specific phylogenetic clade. We have used both cultivation and cultivation-independent techniques to study Fe-rich microbial mats associated with hydrothermal venting at Loihi Seamount, a submarine volcano. Methodology/Principle Findings. Using gradient enrichment techniques, two iron-oxidizing bacteria, strains PV-1 and JV-1, were isolated. Chemolithotrophic growth was observed under microaerobic conditions; Fe(II) and Fe-0 were the only energy sources that supported growth. Both strains produced filamentous stalk-like structures composed of multiple nanometer sized fibrils of Fe-oxyhydroxide. These were consistent with mineralogical structures found in the iron mats. Phylogenetic analysis of the small subunit (SSU) rRNA gene demonstrated that strains PV-1 and JV-1 were identical and formed a monophyletic group deeply rooted within the Proteobacteria. The most similar sequence (85.3% similarity) from a cultivated isolate came from Methylophaga marina. Phylogenetic analysis of the RecA and GyrB protein sequences confirmed that these strains are distantly related to other members of the Proteobacteria. A cultivation-independent analysis of the SSU rRNA gene by terminal-restriction fragment (T-RF) profiling showed that this phylotype was most common in a variety of microbial mats collected at different times and locations at Loihi. Conclusions. On the basis of phylogenetic and physiological data, it is proposed that isolate PV-1(T) (= ATCC BAA-1019: JCM 14766) represents the type strain of a novel species in a new genus, Mariprofundus ferrooxydans gen. nov., sp. nov. Furthermore, the strain is the first cultured representative of a new candidatus class of the Proteobacteria that is widely distributed in deep-sea environments, Candidatus zeta (zeta)-Proteobacteria cl. nov.	[Emerson, David; Rentz, Jeremy A.; Lilburn, Timothy G.] Amer Type Culture Collect, Manassas, VA USA; [Aldrich, Henry] Univ Florida, Dept Microbiol, Gainesville, FL USA; [Chan, Clara] Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; [Davis, Richard E.; Moyer, Craig L.] Western Washington Univ, Dept Biol, Bellingham, WA 98225 USA	State University System of Florida; University of Florida; Woods Hole Oceanographic Institution; Western Washington University	Emerson, D (corresponding author), Amer Type Culture Collect, Manassas, VA USA.	demerson@gmu.edu	Chan, Clara S/B-6420-2011; Davis, Richard/AAC-8464-2019	Chan, Clara S/0000-0003-1810-4994; Davis, Richard/0000-0003-1601-6384	National Science Foundation [0348330]; NASA Astobiology Institute; Direct For Biological Sciences [0810973] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); NASA Astobiology Institute; Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	Funding was provided to DE and CLM by the National Science Foundation (0348330) and to DE through the NASA Astobiology Institute.	ALT JC, 1988, MAR GEOL, V81, P227, DOI 10.1016/0025-3227(88)90029-1; Amend JP, 2005, PALAEOGEOGR PALAEOCL, V219, P131, DOI 10.1016/j.palaeo.2004.10.018; Bach W, 2003, GEOCHIM COSMOCHIM AC, V67, P3871, DOI 10.1016/S0016-7037(03)00304-1; Bogan BW, 2003, INT J SYST EVOL MICR, V53, P1389, DOI 10.1099/ijs.0.02568-0; Chan CS, 2004, SCIENCE, V303, P1656, DOI 10.1126/science.1092098; CHAO LSL, 2007, MAR ECOL, V28, P1; DAVIS RE, 2005, EOS T AGU, V86; Delaney JR, 1998, SCIENCE, V281, P222, DOI 10.1126/science.281.5374.222; Dhillon A, 2003, APPL ENVIRON MICROB, V69, P2765, DOI 10.1128/AEM.69.5.2765-2772.2003; Dinh HT, 2004, NATURE, V427, P829, DOI 10.1038/nature02321; Eder W, 2001, APPL ENVIRON MICROB, V67, P3077, DOI 10.1128/AEM.67.7.3077-3085.2001; Edwards KJ, 2004, GEOMICROBIOL J, V21, P393, DOI 10.1080/01490450490485863; Edwards KJ, 2003, APPL ENVIRON MICROB, V69, P2906, DOI 10.1128/AEM.69.5.2906-2913.2003; Emerson D, 2005, METHOD ENZYMOL, V397, P112, DOI 10.1016/S0076-6879(05)97006-7; EMERSON D, 1993, J BACTERIOL, V175, P7808, DOI 10.1128/JB.175.24.7808-7818.1993; Emerson D, 1997, APPL ENVIRON MICROB, V63, P4784, DOI 10.1128/AEM.63.12.4784-4792.1997; Emerson D, 2002, APPL ENVIRON MICROB, V68, P3085, DOI 10.1128/AEM.68.6.3085-3093.2002; Emerson D, 2000, ENVIRONMENTAL MICROBE-METAL INTERACTIONS, P31; EMERSON D, 2007, INT J SYST IN PRESS; Engebretson JJ, 2003, APPL ENVIRON MICROB, V69, P4823, DOI 10.1128/AEM.69.8.4823-4829.2003; Fortin D, 2005, EARTH-SCI REV, V72, P1, DOI 10.1016/j.earscirev.2005.03.002; Garrity GM, 2001, BERGEYS MANUAL SYSTE, V1, P155; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; HALLBECK EL, 2005, BERGEYS MANUAL SYSTE, P880; HALLBECK L, 1993, J GEN MICROBIOL, V139, P1531, DOI 10.1099/00221287-139-7-1531; HANE BG, 1993, ELECTROPHORESIS, V14, P967, DOI 10.1002/elps.11501401154; Holland HD, 2006, PHILOS T R SOC B, V361, P903, DOI 10.1098/rstb.2006.1838; HOLM NG, 1987, CHEM GEOL, V63, P45, DOI 10.1016/0009-2541(87)90073-8; JANNASCH HW, 1985, SCIENCE, V229, P717, DOI 10.1126/science.229.4715.717; Juniper S. K., 1995, MICR EXTREM UNUSUAL, P219; JUNIPER SK, 1988, CAN MINERAL, V26, P859; Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198; Kennedy CB, 2003, GEOMICROBIOL J, V20, P199, DOI 10.1080/01490450303873; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Ludwig W, 2005, BERGEYS MANUAL SYSTE, V2, P49, DOI DOI 10.1007/978-0-387-21609-6_8; McCollom TM, 2000, DEEP-SEA RES PT I, V47, P85, DOI 10.1016/S0967-0637(99)00048-5; Mergaert J, 2003, INT J SYST EVOL MICR, V53, P1961, DOI 10.1099/ijs.0.02684-0; MOYER CL, 1994, APPL ENVIRON MICROB, V60, P871, DOI 10.1128/AEM.60.3.871-879.1994; MOYER CL, 1995, APPL ENVIRON MICROB, V61, P1555, DOI 10.1128/AEM.61.4.1555-1562.1995; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Pikuta EV, 2003, EXTREMOPHILES, V7, P327, DOI 10.1007/s00792-003-0326-7; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Sievert SM, 2007, ENVIRON MICROBIOL, V9, P271, DOI 10.1111/j.1462-2920.2006.01156.x; Sobolev D, 2004, GEOMICROBIOL J, V21, P1, DOI 10.1080/01490450490253310; Staudigel H, 2006, P NATL ACAD SCI USA, V103, P6448, DOI 10.1073/pnas.0600830103; Stead DE, 1998, PLANT CELL TISS ORG, V52, P17, DOI 10.1023/A:1005991706343; Taylor CD, 1999, APPL ENVIRON MICROB, V65, P2253; Thorseth IH, 2001, EARTH PLANET SC LETT, V194, P31, DOI 10.1016/S0012-821X(01)00537-4; Wallace IM, 2005, BIOINFORMATICS, V21, P1408, DOI 10.1093/bioinformatics/bti159; WEISS JV, 2007, GEOMICROBIO IN PRESS; YANG P, 1993, SYST APPL MICROBIOL, V16, P47, DOI 10.1016/S0723-2020(11)80250-X	53	279	292	7	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e667	10.1371/journal.pone.0000667	http://dx.doi.org/10.1371/journal.pone.0000667			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668050	Green Published, gold			2022-12-25	WOS:000207452300008
J	Yao, YG; Bandelt, HJ; Young, NS				Yao, Yong-Gang; Bandelt, Hans-Juergen; Young, Neal S.			External Contamination in Single Cell mtDNA Analysis	PLOS ONE			English	Article							MITOCHONDRIAL-DNA MUTATIONS; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; SEQUENCE; INHERITANCE; ACCUMULATION; PENETRANCE; PHYLOGENY; DELETIONS; ABUNDANT	Background. Mitochondrial DNA (mtDNA) variation in single hematopoietic cells, muscle fibers, oocytes, and from tiny amount of tumor tissues and degraded clinical specimens has been reported in many medical publications. External DNA contamination, notoriously difficult to avoid, threatens the integrity of such studies. Methodology/Principal Findings. Employing a phylogenetic approach, we analyzed the geographic origins of mtDNA sequence anomalies observed during multiple studies of mtDNA sequence variation in a total of 7094 single hematopoietic cells. 40 events with irregular mtDNA patterns were detected: eight instances (from seven different haplotypes) could be traced to laboratory personnel; six cases were caused by sample cross-contamination. The sources of the remaining events could not be identified, and the anomalous sequence variation referred to matrilines from East Asia, Africa, or West Eurasia, respectively. These mtDNA sequence anomalies could be best explained by contamination. Conclusions. Using the known world mtDNA phylogeny, we could distinguish the geographic origin of the anomalous mtDNA types, providing some useful information regarding the source of contamination. Our data suggest that routine mtDNA sequence analysis of laboratory personnel is insufficient to identify and eliminate all contaminants. A rate of 0.6% of external contamination in this study, while low, is not negligible: Unrecognized contaminants will be mistaken as evidence of remarkable somatic mutations associated with the development of cancer and other diseases. The effective contamination rate can increase by a factor of more than an order of magnitude in some studies that did not institute high standards. Our results are of particular relevance to mtDNA research in medicine, and such an approach should be adopted to maintain and improve quality control in single-cell analyses.	[Yao, Yong-Gang; Young, Neal S.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; [Bandelt, Hans-Juergen] Univ Hamburg, Dept Math, Hamburg, Germany	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Hamburg	Yao, YG (corresponding author), NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.	yaoy3@nhlbi.nih.gov	Yao, Yong-Gang/AAH-2303-2021	Yao, Yong-Gang/0000-0002-2955-0693	NIH; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002315, ZIAHL002315] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Intramural Research Program of the NIH.	Alonso A, 2005, J CLIN PATHOL, V58, P83, DOI 10.1136/jcp.2004.017673; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bandelt HJ, 2007, EUR J HUM GENET, V15, P400, DOI 10.1038/sj.ejhg.5201781; Bandelt HJ, 2007, BIOCHEM BIOPH RES CO, V352, P283, DOI 10.1016/j.bbrc.2006.10.131; Bandelt HJ, 2006, NUCL ACID M, V18, P117; Bandelt HJ, 2005, J MED GENET, V42, P957, DOI 10.1136/jmg.2005.033589; Bandelt HJ, 2005, BIOCHEM BIOPH RES CO, V333, P122, DOI 10.1016/j.bbrc.2005.04.055; Behar DM, 2006, AM J HUM GENET, V78, P487, DOI 10.1086/500307; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190; Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Chan CCW, 2005, MOL HUM REPROD, V11, P843, DOI 10.1093/molehr/gah243; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188; Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X; Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9; Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014; Czarnecka AM, 2006, J APPL GENET, V47, P67, DOI 10.1007/BF03194602; Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Durham SE, 2006, NEUROMUSCULAR DISORD, V16, P381, DOI 10.1016/j.nmd.2006.03.012; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Gilbert MTP, 2005, TRENDS ECOL EVOL, V20, P541, DOI 10.1016/j.tree.2005.07.005; Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103; Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071; Jakupciak JP, 2005, J MOL DIAGN, V7, P258, DOI 10.1016/S1525-1578(10)60553-3; Johns DR, 2003, ANN NEUROL, V54, P422, DOI 10.1002/ana.10771; Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375; Kong QP, 2006, HUM MOL GENET, V15, P2076, DOI 10.1093/hmg/ddl130; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; LEONARD JL, 2007, J ARCHAEOL IN PRESS, DOI DOI 10.1016/J.JAS.2006.1010.1023; Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504; Malmstrom H, 2005, MOL BIOL EVOL, V22, P2040, DOI 10.1093/molbev/msi195; MORAES CT, 1992, AM J HUM GENET, V50, P934; Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7; Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199; Ogasawara Y, 2005, BLOOD, V106, P3271, DOI 10.1182/blood-2005-01-0150; Olivieri A, 2006, SCIENCE, V314, P1767, DOI 10.1126/science.1135566; Paabo S, 2004, ANNU REV GENET, V38, P645, DOI 10.1146/annurev.genet.37.110801.143214; Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x; Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Reidla M, 2003, AM J HUM GENET, V73, P1178, DOI 10.1086/379380; Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296; Sampietro ML, 2006, MOL BIOL EVOL, V23, P1801, DOI 10.1093/molbev/msl047; Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350; Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724; Sun C, 2006, MOL BIOL EVOL, V23, P683, DOI 10.1093/molbev/msj078; Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74; Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001; Vega A, 2004, ONCOGENE, V23, P1314, DOI 10.1038/sj.onc.1207214; Verma Mukesh, 2007, Cancer Res, V67, P437, DOI 10.1158/0008-5472.CAN-06-4119; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wang CY, 2007, INT J CANCER, V121, P1253, DOI 10.1002/ijc.22822; Willerslev E, 2005, P ROY SOC B-BIOL SCI, V272, P3, DOI 10.1098/rspb.2004.2813; Yao YG, 2006, HUM GENET, V119, P505, DOI 10.1007/s00439-006-0154-9; Yao YG, 2007, BLOOD, V109, P756, DOI 10.1182/blood-2006-01-011007; Yao YG, 2007, HUM MOL GENET, V16, P286, DOI 10.1093/hmg/ddl457; Zanssen S, 2005, PLOS MED, V2, P1082, DOI 10.1371/journal.pmed.0020401	64	18	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e681	10.1371/journal.pone.0000681	http://dx.doi.org/10.1371/journal.pone.0000681			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668059	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452300017
J	Lee, JA; Park, JE; Lee, DH; Park, SG; Myung, PK; Park, BC; Cho, S				Lee, J. A.; Park, J. E.; Lee, D. H.; Park, S. G.; Myung, P. K.; Park, B. C.; Cho, S.			G(1) to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1	ONCOGENE			English	Article						apoptosis; apoptosis signal-regulating kinase 1; G(1) to S phase transition 1; mitogen-activated protein kinase	BINDING PROTEIN; TRANSLATION TERMINATION; CELL-DEATH; PROLIFERATION; THIOREDOXIN; INHIBITOR; STRESS; DAXX	Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase kinase kinase family, plays a critical role in mediating apoptosis signals initiated by a variety of death stimuli such as hydrogen peroxide and tumor necrosis factor-a. Owing to its critical role in inducing apoptosis, the activity of ASK1 is tightly regulated by various mechanisms such as post-translational modi. cations and protein-protein interactions. Here we describe the identification of G(1) to S phase transition protein 1 (GSPT1), which is associated with protein translation, as a regulator of ASK1. GSPT1 interacts with ASK1 and enhances ASK1-induced apoptotic activity through the activation of caspase-3. In vitro kinase assay data show that GSPT1 enhances ASK1 autophosphorylation and its kinase activity. Cell cycle-dependent GSPT1 induction and small interfering RNA analyses show that ASK1 autophosphorylation is dependent on the expression level of endogenous GSPT1 in cells. GSPT1 inhibits the binding of ASK1 to the 14-3-3 protein, an ASK1 inhibitor, while GSPT1 has no effect on the interaction between ASK1 and TRAF2, a C-terminal-binding activator of ASK1. Thus, our results reveal a novel role of GSPT1 in the regulation of ASK1-mediated apoptosis.	[Park, J. E.; Lee, D. H.; Park, S. G.; Park, B. C.] Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Proteome Res Lab, Taejon 305600, South Korea; [Lee, J. A.; Cho, S.] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; [Lee, J. A.; Cho, S.] Chung Ang Univ, Res Inst Translat Syst Biom, Seoul, South Korea; [Myung, P. K.] Chungnam Natl Univ, Coll Pharm, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Chung Ang University; Chungnam National University	Park, BC (corresponding author), Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Proteome Res Lab, POB 115 Yusong, Taejon 305600, South Korea.	parkbc@kribb.re.kr; sycho@cau.ac.kr						[Anonymous], 1999, HYBRID RICE; Bell R, 2004, EJC SUPPL, V2, P1, DOI 10.1016/J.EJCSUP.2004.01.001; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chauvin C, 2005, MOL CELL BIOL, V25, P5801, DOI 10.1128/MCB.25.14.5801-5811.2005; Cho SY, 2004, J BIOL CHEM, V279, P16050, DOI 10.1074/jbc.M305758200; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Malta-Vacas J, 2005, J CLIN PATHOL, V58, P621, DOI 10.1136/jcp.2004.021774; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	23	22	23	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1297	1305		10.1038/sj.onc.1210740	http://dx.doi.org/10.1038/sj.onc.1210740			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17700517				2022-12-25	WOS:000253407000012
J	Lee, OH; Xu, J; Fueyo, J; Alonso, MM; Liu, D; Martin, V; Jiang, H; Piao, Y; Liu, TJ; Gomez-Manzano, C				Lee, O-H; Xu, J.; Fueyo, J.; Alonso, M. M.; Liu, D.; Martin, V.; Jiang, H.; Piao, Y.; Liu, T. J.; Gomez-Manzano, C.			Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas	ONCOGENE			English	Article						Tie2; angiopoietin-2; HIF-1 alpha; VEGF; gliomas	RECEPTOR TYROSINE KINASE; VESSEL FORMATION; ANGIOGENESIS; TIE2; INTEGRIN; CANCER; CELLS; ADHESION; MATRIX; RAT	Angiogenesis is thought to depend on a perfectly coordinated balance between endogenous-positive and negative regulatory factors. Of these factors, the vascular endothelial growth factor (VEGF) and angiopoietins (Angs) seem to play an essential role. Recently, we reported the expression of the Ang-natural receptor, Tie2, in neoplastic astrocytic cells within gliomas. Because of the VEGF/Ang2 functional partnership together with the presence of Tie2 in gliomas, we hypothesized a role of Ang2 on the modulation of VEGF levels in these tumors. We examined the effect of Ang2 on VEGF expression in a panel of glioma cells, which showed that Ang2 inhibited VEGF expression at both mRNA and protein levels in Tie2-expressing cells, but not in Tie2-negative cells. VEGF promoter analysis showed that Ang2 regulated VEGF expression at the transcriptional level in relation to a decrease in HIF-1 alpha expression and HIF-DNA-binding activity. Tie2 silencing by siRNA rescued the Ang2-mediated downmodulation of VEGF, suggesting an essential role for Tie2 in this regulatory loop. To our knowledge, this is the first report on the role of Ang2/Tie2 in the regulation of HIF-1 alpha/VEGF expression, providing additional evidence of the intrinsic coordination that occurs among these factors during angiogenesis.	[Lee, O-H; Xu, J.; Fueyo, J.; Alonso, M. M.; Liu, D.; Martin, V.; Jiang, H.; Piao, Y.; Liu, T. J.; Gomez-Manzano, C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Gomez-Manzano, C (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cmanzano@mdanderson.org	MARTIN, VANESA/A-7312-2012; Alonso, Marta M/AAI-9457-2020	MARTIN, VANESA/0000-0001-6923-2529; Alonso, Marta M/0000-0002-7520-7351; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA083127] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA83127, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Goede V, 1998, LAB INVEST, V78, P1385; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Kukk E, 1997, BRIT J HAEMATOL, V98, P195, DOI 10.1046/j.1365-2141.1997.1732989.x; Lee OH, 2006, MOL CANCER RES, V4, P915, DOI 10.1158/1541-7786.MCR-06-0184; Lee OH, 2006, NEOPLASIA, V8, P419, DOI 10.1593/neo.06109; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005; Machein MR, 2004, AM J PATHOL, V165, P1557, DOI 10.1016/S0002-9440(10)63413-X; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Shirakawa K, 2002, INT J CANCER, V99, P344, DOI 10.1002/ijc.10336; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Wang J, 2005, BIOCHEM BIOPH RES CO, V337, P386, DOI 10.1016/j.bbrc.2005.09.051; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	18	15	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1310	1314		10.1038/sj.onc.1210731	http://dx.doi.org/10.1038/sj.onc.1210731			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704802				2022-12-25	WOS:000253407000014
J	Foijer, F; Simonis, M; van Vliet, M; Wessels, L; Kerkhoven, R; Sorger, PK; Riele, HT				Foijer, F.; Simonis, M.; van Vliet, M.; Wessels, L.; Kerkhoven, R.; Sorger, P. K.; Riele, H. te			Oncogenic pathways impinging on the G(2)-restriction point	ONCOGENE			English	Article						mitogenic signaling; G2 restriction point; retinoblastoma gene family; expression profiling; c-MYC; RAS	DNA-DAMAGE; MITOGEN REQUIREMENT; RESTRICTION POINT; KINASE-ACTIVITY; G(1) CONTROL; CELL; CYCLE; INHIBITOR; P21; PHOSPHORYLATION	In the absence of mitogenic stimuli, cells normally arrest in G(1/0), because they fail to pass the G(1)-restriction point. However, abrogation of the G(1)-restriction point ( by loss of the retinoblastoma gene family) reveals a second-restriction point that arrests cells in G(2). Serum-starvation-induced G(2) arrest is effectuated through inhibitory interactions of p27(KIP1) and p21(CIP1) with cyclins A and B1 and can be reversed through mitogen re-addition. In this study, we have investigated the pathways that allow cell cycle re-entry from this G(2) arrest. We provide evidence that recovery from G(2) arrest depends on the rat sarcoma viral oncogene ( RAS) and phosphatidylinositol-3 kinase pathways and show that oncogenic hits, such as overexpression of c-MYC or mutational activation of RAS can abrogate the G(2)-restriction point. Together, our results provide new mechanistic insight into multistep carcinogenesis.	[Foijer, F.; van Vliet, M.; Wessels, L.; Riele, H. te] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [Foijer, F.; Sorger, P. K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA; [Simonis, M.; Kerkhoven, R.] Netherlands Canc Inst, Cent Microarray Facil, NL-1066 CX Amsterdam, Netherlands; [van Vliet, M.; Wessels, L.] Delft Univ Technol, Fac Elect Engn Math & Comp Sci, Delft, Netherlands	Netherlands Cancer Institute; Harvard University; Harvard Medical School; Netherlands Cancer Institute; Delft University of Technology	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl		Sorger, Peter/0000-0002-3364-1838; Foijer, Floris/0000-0003-0989-3127				Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; D'Abaco GM, 2002, J CELL SCI, V115, P4607, DOI 10.1242/jcs.00161; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Foijer F, 2005, CANCER CELL, V8, P455, DOI 10.1016/j.ccr.2005.10.021; Foijer F, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-8; Foijer F, 2006, CELL CYCLE, V5, P831, DOI 10.4161/cc.5.8.2687; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARPER JW, 1993, CELL, V75, P805; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Theodosiou A, 2002, GENOME BIOL, V3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200	41	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1142	1154		10.1038/sj.onc.1210724	http://dx.doi.org/10.1038/sj.onc.1210724			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700522				2022-12-25	WOS:000253136700014
J	Brookes, MJ; Boult, J; Roberts, K; Cooper, BT; Hotchin, NA; Matthews, G; Iqbal, T; Tselepis, C				Brookes, M. J.; Boult, J.; Roberts, K.; Cooper, B. T.; Hotchin, N. A.; Matthews, G.; Iqbal, T.; Tselepis, C.			A role for iron in Wnt signalling	ONCOGENE			English	Article						Wnt; E-cadherin; iron; colon	COLORECTAL-CANCER RISK; C-MYC; COLON-CANCER; E-CADHERIN; HEME IRON; CARCINOGENESIS; GENE; APC; IDENTIFICATION; ACTIVATION	There is an emerging body of evidence implicating iron in carcinogenesis and in particular colorectal cancer, but whether this involves Wnt signalling, a major oncogenic signalling pathway has not been studied. We aimed to determine the effect of iron loading on Wnt signalling using mutant APC (Caco-2 and SW480) and wild-type APC (HEK-293 and human primary. broblasts) containing cell lines. Elevating cellular iron levels in Caco-2 and SW480 cells caused increased Wnt signalling as indicated by increased TOPFLASH reporter activity, increased mRNA expression of two known targets, c-myc and Nkd1, and increased cellular proliferation. In contrast wild-type APC and beta-catenin-containing lines, HEK-293 and human primary. broblasts were not responsive to iron loading. This was verified in SW480 cells that no longer induced iron-mediated Wnt signalling when transfected with wild-type APC. The cell line LS174T, wild type for APC but mutant for beta-catenin, was also responsive suggesting that the role of iron is to regulate beta-catenin. Furthermore, we show that E-cadherin status has no influence on iron-mediated Wnt signalling. We thus speculate that excess iron could exacerbate tumorigenesis in the background of APC loss, a common finding in cancers.	[Brookes, M. J.; Boult, J.; Roberts, K.; Iqbal, T.; Tselepis, C.] Univ Birmingham, CRUK Inst Canc Studies, Birmingham B32 1NX, W Midlands, England; [Brookes, M. J.; Cooper, B. T.] City Hosp, Birmingham, W Midlands, England; [Hotchin, N. A.] Univ Birmingham, Sch Biosci, Birmingham B32 1NX, W Midlands, England; [Matthews, G.] Univ Birmingham, Dept Med Sci, Birmingham B32 1NX, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Tselepis, C (corresponding author), Univ Birmingham, CRUK Inst Canc Studies, Vincent Dr, Birmingham B32 1NX, W Midlands, England.	c.tselepis@bham.ac.uk	Brookes, Matthew/ABE-6952-2020	Brookes, Matthew/0000-0002-8782-0292; iqbal, tariq/0000-0002-6681-9882; Hotchin, Neil/0000-0002-1844-7607				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brookes MJ, 2006, GUT, V55, P1449, DOI 10.1136/gut.2006.094060; Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habel ME, 2006, BIOCHEM BIOPH RES CO, V341, P1309, DOI 10.1016/j.bbrc.2006.01.097; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilsley JNM, 2004, NUTR CANCER, V49, P162, DOI 10.1207/s15327914nc4902_7; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latunde-Dada GO, 2006, TRENDS BIOCHEM SCI, V31, P182, DOI 10.1016/j.tibs.2006.01.005; Lee DH, 2004, JNCI-J NATL CANCER I, V96, P403, DOI 10.1093/jnci/djh047; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Mainous AG, 2005, ANN FAM MED, V3, P131, DOI 10.1370/afm.283; Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Munro SB, 1995, EXP MOL PATHOL, V62, P118, DOI 10.1006/exmp.1995.1013; Nelson RL, 2001, NUTR REV, V59, P140, DOI 10.1111/j.1753-4887.2001.tb07002.x; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Oates PS, 2006, WORLD J GASTROENTERO, V12, P4281, DOI 10.3748/wjg.v12.i27.4281; Orsulic S, 1999, J CELL SCI, V112, P1237; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Penman GA, 2005, J CELL SCI, V118, P4741, DOI 10.1242/jcs.02589; Pierre F, 2003, CARCINOGENESIS, V24, P1683, DOI 10.1093/carcin/bgg130; Rao AS, 2005, EUR J ENDOCRINOL, V153, P929, DOI 10.1530/eje.1.02038; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Seril DN, 2002, DIGEST DIS SCI, V47, P1266, DOI 10.1023/A:1015362228659; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; YOUNG GP, 1990, J GASTROEN HEPATOL, V5, P194, DOI 10.1111/j.1440-1746.1990.tb01824.x	38	98	101	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					966	975		10.1038/sj.onc.1210711	http://dx.doi.org/10.1038/sj.onc.1210711			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700530				2022-12-25	WOS:000252946300008
J	Ji, Y; Shah, S; Soanes, K; Islam, MN; Hoxter, B; Biffo, S; Heslip, T; Byers, S				Ji, Y.; Shah, S.; Soanes, K.; Islam, M. N.; Hoxter, B.; Biffo, S.; Heslip, T.; Byers, S.			Eukaryotic initiation factor 6 selectively regulates Wnt signaling and beta-catenin protein synthesis	ONCOGENE			English	Article						beta-catenin; eIF6; wnt; wingless; Drosophila; APC	SACCHAROMYCES-CEREVISIAE HOMOLOG; C-MYC; TRANSLATION; APC; PHOSPHORYLATION; UBIQUITINATION; P27(BBP); ADHESION; COMPLEX; BINDING	Eukaryotic initiation factor 6 ( eIF6), an essential protein important in ribosome biosynthesis and assembly, was identified as an interacting partner of the beta-catenin C terminus in the yeast two-hybrid assay. Independent studies identified Drosophila eIF6 ( DeIF6) in a genetic screen designed to detect new genes involved in the regulation of the Wnt/Wg ( wingless) pathway. Ectopic expression of DeIF6 in wing discs results in a Wg phenotype. Expression of eIF6 in adenomatous polyposis coli ( APC)-mutant colon cancer cells, which express high levels of active beta-catenin, showed that eIF6 selectively inhibits the Wnt pathway at the level of beta-catenin protein independently of proteasomal degradation. Incorporation of radiolabeled amino acids into beta-catenin was selectively decreased in cells that overexpressed eIF6. A similar inverse relationship of the two proteins was observed in the APC(min/+) mouse intestine, in which beta-catenin levels are very high. Taken together these data reveal a link between eIF6 and Wnt signaling, perhaps at the level of ribosome recycling on beta-catenin mRNA.	[Ji, Y.; Shah, S.; Islam, M. N.; Hoxter, B.; Byers, S.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Biffo, S.] DIBIT HSR, Mol Histol Unit, Milan, Italy; [Soanes, K.; Heslip, T.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada	Georgetown University; University of Calgary	Byers, S (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, E415 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	byerss@georgetown.edu	Ji, Yun/B-7245-2009; Waldmann, Thomas/AAT-5972-2021	Ji, Yun/0000-0001-6340-7009; Waldmann, Thomas/0000-0003-4500-6660; biffo, stefano/0000-0002-3780-1050				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Basu U, 2003, MOL CELL BIOL, V23, P6187, DOI 10.1128/MCB.23.17.6187-6199.2003; Basu U, 2001, MOL CELL BIOL, V21, P1453, DOI 10.1128/MCB.21.5.1453-1462.2001; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Biffo S, 1997, J BIOL CHEM, V272, P30314, DOI 10.1074/jbc.272.48.30314; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Donadini A, 2001, GENE, V266, P35, DOI 10.1016/S0378-1119(01)00370-5; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Greaves S, 1999, GENETICS, V153, P1753; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823; Si K, 1999, MOL CELL BIOL, V19, P1416; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wood LC, 1999, J BIOL CHEM, V274, P11653, DOI 10.1074/jbc.274.17.11653	30	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					755	762		10.1038/sj.onc.1210667	http://dx.doi.org/10.1038/sj.onc.1210667			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17667944				2022-12-25	WOS:000252884500004
J	Li, ZG; Yang, J; Vazquez, ES; Rose, D; Vakar-Lopez, F; Mathew, P; Lopez, A; Logothetis, CJ; Lin, SH; Navone, NM				Li, Z. G.; Yang, J.; Vazquez, E. S.; Rose, D.; Vakar-Lopez, F.; Mathew, P.; Lopez, A.; Logothetis, C. J.; Lin, S-H; Navone, N. M.			Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone	ONCOGENE			English	Article						WNT; WNT7b; prostate cancer; bone metastases; osteoblasts; DKK1	METASTASES; OSTEOBLASTS; DICKKOPF-1; PROTEINS; HEDGEHOG; CATENIN; LESIONS	The tendency of prostate cancer to produce osteoblastic bone metastases suggests that cancer cells and osteoblasts interact in ways that contribute to cancer progression. To identify factors that mediate these interactions, we compared gene expression patterns between two bone-derived prostate cancer cell lines that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3). Both cell lines expressed Wnt ligands, including WNT7b, a canonical Wnt implicated in osteogenesis. PC-3 cells expressed 50 times more Dickkopf-1 (DKK1), an inhibitor of Wnt pathways, than did MDA PCa 2b cells. Evaluation of the functional role of these factors (in cocultures of prostate cancer cells with primary mouse osteoblasts (PMOs) or in bone organ cultures) showed that MDA PCa 2b cells activated Wnt canonical signaling in PMOs and that DKK1 blocked osteoblast proliferation and new bone formation induced by MDA PCa 2b cells. MDA PCa 2b cells did not induce bone formation in calvaria from mice lacking the Wnt co-receptor Lrp5. In human specimens, WNT7b was not expressed in normal prostate but was expressed in areas of high-grade prostate intraepithelial neoplasia, in three of nine primary prostate tumor specimens and in 16 of 38 samples of bone metastases from prostate cancer. DKK1 was not expressed in normal or cancerous tissue but was expressed in two of three specimens of osteolytic bone metastases (P = 0.0119). We conclude that MDA PCa 2b induces new bone formation through Wnt canonical signaling, that LRP5 mediates this effect, and that DKK1 is involved in the balance between bone formation and resorption that determines lesion phenotype.	[Li, Z. G.; Yang, J.; Rose, D.; Mathew, P.; Logothetis, C. J.; Navone, N. M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77230 USA; [Vazquez, E. S.] Univ Buenos Aires, CONICET, Sch Sci, Dept Biol Chem, RA-1053 Buenos Aires, DF, Argentina; [Vakar-Lopez, F.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77230 USA; [Lopez, A.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77230 USA; [Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Navone, NM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd,POB 301439, Houston, TX 77230 USA.	nnavone@mdanderson.org	; Vazquez, Elba/D-5134-2019	Lopez, Adriana/0000-0001-9169-800X; Vazquez, Elba/0000-0002-0460-0236	NATIONAL CANCER INSTITUTE [R01CA096797, R01CA111479, P50CA090270] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA111479, R01CA096797, P50CA90270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; COOK GB, 1968, J UROLOGY, V99, P87, DOI 10.1016/S0022-5347(17)62647-8; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Ferrari SL, 2005, CURR OPIN LIPIDOL, V16, P207, DOI 10.1097/01.mol.0000162326.62419.e4; Fizazi K, 2003, CLIN CANCER RES, V9, P2587; Freshney RI, 1994, CULTURE ANIMAL CELLS; GARRETT R, 2003, METHODS MOL MED, P183; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; YANG BC, 2001, J E CHINA NORMAL U N, V1, P61; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	27	53	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					596	603		10.1038/sj.onc.1210694	http://dx.doi.org/10.1038/sj.onc.1210694			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17700537				2022-12-25	WOS:000252674900004
J	Shih, JW; Tsai, Y; Chao, CH; Lee, YHW				Shih, J-W; Tsai, Y.; Chao, C-H; Lee, Y-H Wu			Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein	ONCOGENE			English	Article						cap-dependent translation; HCVIRES; DEAD box RNA helicase; DDX3; eIF4E inhibitory protein; tumor suppressor	HEPATITIS-C VIRUS; MESSENGER-RNA; CORE PROTEIN; EUKARYOTIC TRANSLATION; CELL-GROWTH; BINDING-PROTEIN; INITIATION; TRANSFORMATION; REQUIREMENT; EXPRESSION	DDX3 is a human RNA helicase with plethoric functions. Our previous studies have indicated that DDX3 is a transcriptional regulator and functions as a tumor suppressor. In this study, we use a bicistronic reporter to demonstrate that DDX3 specifically represses cap-dependent translation but enhances hepatitis C virus internal ribosome entry site-mediated translation in vivo in a helicase activity-independent manner. To elucidate how DDX3 modulates translation, we identified translation initiation factor eukaryotic initiation factor 4E (eIF4E) as a DDX3-binding partner. Interestingly, DDX3 utilizes a consensus eIF4E-binding sequence YIPPHLR to interact with the functionally important dorsal surface of eIF4E in a similar manner to other eIF4E-binding proteins. Furthermore, cap affinity chromatography analysis suggests that DDX3 traps eIF4E in a translationally inactive complex by blocking interaction with eIF4G. Point mutations within the consensus eIF4E-binding motif in DDX3 impair its ability to bind eIF4E and result in a loss of DDX3's regulatory effects on translation. All these features together indicate that DDX3 is a new member of the eIF4E inhibitory proteins involved in translation initiation regulation. Most importantly, this DDX3-mediated translation regulation also confers the tumor suppressor function on DDX3. Altogether, this study demonstrates regulatory roles and action mechanisms for DDX3 in translation, cell growth and likely viral replication.	[Shih, J-W; Tsai, Y.; Chao, C-H; Lee, Y-H Wu] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Sect 2, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Sect 2, 155 Li Nong St, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; Lee Wu, Yan-Hwa/0000-0001-7299-7354; Chao, Chi-Hong/0000-0001-9890-4902				Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hwang LH, 1998, BIOCHEM BIOPH RES CO, V252, P455, DOI 10.1006/bbrc.1998.9673; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Linder P, 2003, BIOL CELL, V95, P157, DOI 10.1016/S0248-4900(03)00032-7; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Niessing D, 2002, GENE DEV, V16, P2576, DOI 10.1101/gad.240002; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rousseau D, 1996, ONCOGENE, V13, P2415; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; YANG HS, 2004, NAT STRUCT MOL BIOL, V23, P26; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	38	130	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					700	714		10.1038/sj.onc.1210687	http://dx.doi.org/10.1038/sj.onc.1210687			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667941				2022-12-25	WOS:000252674900014
J	Veverka, V; Crabbe, T; Bird, I; Lennie, G; Muskett, FW; Taylor, RJ; Carr, MD				Veverka, V.; Crabbe, T.; Bird, I.; Lennie, G.; Muskett, F. W.; Taylor, R. J.; Carr, M. D.			Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR	ONCOGENE			English	Article						mTOR; FRB; rapamycin; phosphatidic acid; NMR	N-TERMINAL DOMAIN; MAMMALIAN TARGET; TISSUE INHIBITOR; BINDING PARTNER; RAPAMYCIN MTOR; PROTEIN; CANCER; TOR; PATHWAY; GROWTH	The mammalian target of rapamycin (mTOR) is a large, multidomain protein kinase, which plays a central role in the regulation of cell growth and has recently emerged as an essential target of survival signals in many types of human cancer cells. Here, we report the solution structures of complexes formed between the FKBP12-rapamycin binding (FRB) domain of mTOR and phosphatidic acid, an important cellular activator of the kinase, and between the FRB domain and a novel inhibitor (HTS-1). The overall structure of the FRB domain is very similar to that seen in the ternary complex formed with FKBP12 and the immunosuppressive drug rapamycin; however, there are significant changes within the rapamycin-binding site with important consequences for rational drug design. The surface of the FRB domain contains a number of distinctive features that have previously escaped attention, including a potential new regulatory site on the opposite face to that involved in the binding of rapamycin, which displays the features expected for a specific binding site for a small molecule. The interaction sites for phosphatidic acid and HTS-1 were found to closely match the site responsible for rapamycin binding. In addition, the structures determined for the FRB phosphatidic acid and FRB-HTS-1 complexes revealed a striking similarity between the conformations of buried portions of the ligands and that seen for the rapamycin backbone in contact with the domain. Our findings further highlight the importance of the FRB domain in small molecule-mediated regulation of mTOR, demonstrate the ability to identify novel inhibitors of mTOR that bind tightly to the rapamycin-binding site in the absence of FKBP12, and identify a potential new regulatory site that may be exploited in the design of new anticancer drugs.	[Veverka, V.; Muskett, F. W.; Carr, M. D.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Crabbe, T.; Bird, I.; Lennie, G.; Taylor, R. J.] UCB R&D, Slough, Berks, England	University of Leicester	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk	Ward, Stephen/AAE-4341-2020; Veverka, Vaclav/P-5251-2019; Veverka, Vaclav/G-9174-2014	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Annis DA, 2004, INT J MASS SPECTROM, V238, P77, DOI 10.1016/j.ijms.2003.11.022; Avila-Flores A, 2005, J BIOL CHEM, V280, P10091, DOI 10.1074/jbc.M412296200; Banaszynski LA, 2005, J AM CHEM SOC, V127, P4715, DOI 10.1021/ja043277y; Bianco RB, 2006, EUR J CANCER, V42, P290, DOI 10.1016/j.ejca.2005.07.034; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Choi Jai-Pil, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8; DELANO WL, 2002, PYMOL MOL GRAPHICS; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; Koharudin LMI, 2003, J MAGN RESON, V163, P228, DOI 10.1016/S1090-7807(03)00149-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leone M, 2006, BIOCHEMISTRY-US, V45, P10294, DOI 10.1021/bi060976+; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Thomas GV, 2006, CURR OPIN GENET DEV, V16, P78, DOI 10.1016/j.gde.2005.12.003; Veverka V, 2006, J BIOMOL NMR, V36, P3, DOI 10.1007/s10858-005-4324-1; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	43	118	126	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					585	595		10.1038/sj.onc.1210693	http://dx.doi.org/10.1038/sj.onc.1210693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684489				2022-12-25	WOS:000252674900003
J	Fanelli, M; Caprodossi, S; Ricci-Vitiani, L; Porcellini, A; Tomassoni-Ardori, F; Amatori, S; Andreoni, F; Magnani, M; De Maria, R; Santoni, A; Minucci, S; Pelicci, PG				Fanelli, M.; Caprodossi, S.; Ricci-Vitiani, L.; Porcellini, A.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.; De Maria, R.; Santoni, A.; Minucci, S.; Pelicci, P. G.			Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment	ONCOGENE			English	Article						glioblastoma; DNA methyltransferases; DNA methylation; brain tumor; stem cells	CHROMOSOME INSTABILITY; DNMT3B; HYPOMETHYLATION; GENE; OVEREXPRESSION; FEATURES; REGIONS; CANCER; 3B	Cancer is generally characterized by loss of CG dinucleotides methylation resulting in a global hypomethylation and the consequent genomic instability. The major contribution to the general decreased methylation levels seems to be due to demethylation of heterochromatin repetitive DNA sequences. In human immunodeficiency, centromeric instability and facial anomalies syndrome, demethylation of pericentromeric satellite 2 DNA sequences has been correlated to functional mutations of the de novo DNA methyltransferase 3b (DNMT3b), but the mechanism responsible for the hypomethylated status in tumors is poorly known. Here, we report that human glioblastoma is affected by strong hypomethylation of satellite 2 pericentromeric sequences that involves the stem cell compartment. Concomitantly with the integrity of the DNMTs coding sequences, we report aberrations in DNA methyltrasferases expression showing upregulation of the DNA methyltransferase 1 (DNMT1) and downregulation of the de novo DNA methyltransferase 3a (DNMT3a). Moreover, we show that DNMT3a is the major de novo methyltransferase expressed in normal neural progenitor cells (NPCs) and its forced re-expression is sufficient to partially recover the methylation levels of satellite 2 repeats in glioblastoma cell lines. Thus, we speculate that DNMT3a decreased expression may be involved in the early post-natal inheritance of an epigenetically altered NPC population that could be responsible for glioblastoma development later in adult life.	[Fanelli, M.; Caprodossi, S.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.] Univ Urbino, Ctr Biotechnol, Mol Pathol Lab, I-61032 Urbino, Italy; [Caprodossi, S.; Minucci, S.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, Milan, Italy; [Ricci-Vitiani, L.; De Maria, R.] Inst Sup Sanita, Dept Hematol, Rome, Italy; [Porcellini, A.; Santoni, A.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; [Porcellini, A.; Santoni, A.] INM Neuromed, Dept Expt Med & Pathol, Rome, Italy	University of Urbino; IRCCS European Institute of Oncology (IEO); Istituto Superiore di Sanita (ISS); Sapienza University Rome; IRCCS Neuromed	Fanelli, M (corresponding author), Univ Urbino, Ctr Biotechnol, Mol Pathol Lab, Via Campanella 1, I-61032 Urbino, Italy.	mirco.fanelli@uniurb.it	Porcellini, Antonio/AAC-6097-2019; Ricci Vitiani, Lucia/J-8320-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; De Maria, Ruggero/S-6385-2019; Fanelli, Mirco/F-2665-2011; Porcellini, Antonio/E-1900-2011; Minucci, Saverio/J-9669-2012; santoni, angela/K-8997-2016; feng, jian/G-9313-2011; Francesca, Andreoni/G-7505-2012; Magnani, Mauro/A-1919-2008	Ricci Vitiani, Lucia/0000-0001-7336-5615; De Maria, Ruggero/0000-0003-2255-0583; Fanelli, Mirco/0000-0002-9649-8661; Porcellini, Antonio/0000-0001-6882-9518; santoni, angela/0000-0003-1206-7731; Francesca, Andreoni/0000-0002-4857-8210; Amatori, Stefano/0000-0003-3988-3480; Tomassoni Ardori, Francesco/0000-0002-8824-3693; Magnani, Mauro/0000-0001-6456-6626				Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Blanc JL, 2004, J NEURO-ONCOL, V68, P275, DOI 10.1023/B:NEON.0000033385.37098.85; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Caprodossi S, 2005, MOL BIOTECHNOL, V30, P231, DOI 10.1385/MB:30:3:231; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404; Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hassan KMA, 2001, HUM GENET, V109, P452; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PROSSER J, 1986, J MOL BIOL, V187, P145, DOI 10.1016/0022-2836(86)90224-X; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0; Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	30	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					358	365		10.1038/sj.onc.1210642	http://dx.doi.org/10.1038/sj.onc.1210642			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17653095				2022-12-25	WOS:000252256000012
J	Gomez, BP; Riggins, RB; Shajahan, AN; Klimach, U; Wang, A; Crawford, AC; Zhu, Y; Zwart, A; Wang, M; Clarke, R				Gomez, Bianca P.; Riggins, Rebecca B.; Shajahan, Ayesha N.; Klimach, Uwe; Wang, Aifen; Crawford, Anatasha C.; Zhu, Yuelin; Zwart, Alan; Wang, Mingyue; Clarke, Robert			Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines	FASEB JOURNAL			English	Article						apoptosis; aromatase; cell cycle; Faslodex; SERM; SERD; unfolded protein response; Tamoxifen; proliferation; XBPI	REGULATORY-FACTOR-I; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR XBP-1; GENE-EXPRESSION PROFILES; CYTOCHROME-C RELEASE; FALSE DISCOVERY RATE; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; AROMATASE INHIBITORS; TISSUE MICROARRAYS	Human X-box binding protein-1 (XBP1) is an alternatively spliced transcription factor that participates in the unfolded protein response (UPR), a stress-signaling pathway that allows cells to survive the accumulation of unfolded proteins in the endoplasmic reticulum lumen. We have previously demonstrated that XBP1 expression is increased in antiestrogen-resistant breast cancer cell lines and is coexpressed with estrogen receptor alpha (ER) in breast tumors. The purpose of this study is to investigate the role of XBP1 and the UPR in estrogen and antiestrogen responsiveness in breast cancer. Overexpression of spliced XBP1 [XBP1(S)] in ER-positive breast cancer cells leads to estrogen-independent growth and reduced sensitivity to growth inhibition induced by the antiestrogens Tamoxifen and Faslodex in a manner independent of functional p53. Data from gene expression microarray analyses imply that XBP1(S) acts through regulation of the expression of ER, the antiapoptotic gene BCL2, and several other genes associated with control of the cell cycle and apoptosis. Testing this hypothesis, we show that overexpression of XBP1(S) prevents cell cycle arrest and antiestrogen-induced cell death through the mitochondrial apoptotic pathway. XBP1 and/or the UPR may be a useful molecular target for the development of novel predictive and therapeutic strategies in breast cancer. -Gomez, B. P., Riggins, R. B., Shajahan, A., Klimach, U., Wang, A., Crawford, A. C., Zhu, Y., Zwart, A., Wang, M., Clarke, R. Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.	Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Physiol & Biophys, Washington, DC 20057 USA	Georgetown University; Georgetown University	Clarke, R (corresponding author), Georgetown Univ, Sch Med, Dept Oncol, W405A Res Bldg, 3970 Reservoir Rd, NW, Washington, DC 20057 USA.	clarker@georgetown.edu	Clarke, Robert/A-6485-2008; Zhu, Yuelin/ABD-5743-2021; Riggins, Rebecca/GQH-4466-2022	Clarke, Robert/0000-0002-9278-0854; Zhu, Yuelin/0000-0003-2762-0755; Shajahan-Haq, Ayesha/0000-0001-7616-320X; Zwart, Alan/0000-0001-6834-9290; Riggins, Rebecca/0000-0002-1555-4431	NATIONAL CANCER INSTITUTE [P30CA051008, R01CA096483] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA51008-14, R01-CA096483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 1998, LANCET, V352, P930; Auer H, 2003, NAT GENET, V35, P292, DOI 10.1038/ng1203-292; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Clarke M, 1998, LANCET, V351, P1451; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke R, 2001, PHARMACOL REV, V53, P25; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; Clauss IM, 1996, NUCLEIC ACIDS RES, V24, P1855, DOI 10.1093/nar/24.10.1855; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; DuRose JB, 2006, MOL BIOL CELL, V17, P3095, DOI 10.1091/mbc.E06-01-0055; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Frank D, 2002, P NATL ACAD SCI USA, V99, P7490, DOI 10.1073/pnas.122039999; Fu YP, 2003, CANCER RES, V63, P2440; Fujimoto Takashi, 2003, Breast Cancer, V10, P301, DOI 10.1007/BF02967649; Gu ZP, 2002, CANCER RES, V62, P3428; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jamerson MH, 2004, J MAMMARY GLAND BIOL, V9, P27, DOI 10.1023/B:JOMG.0000023586.69263.0b; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lee K, 2001, MRS INTERNET J N S R, V6, P1; Lee MP, 1998, CANCER RES, V58, P1052; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Mueller O., 2004, AGIL APPL NOTE, V2011, P1, DOI DOI 10.1186/1471-2199-7-3; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Real PJ, 2004, CANCER RES, V64, P7947, DOI 10.1158/0008-5472.CAN-04-0945; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Riggins RB, 2005, VITAM HORM, V71, P201, DOI 10.1016/S0083-6729(05)71007-4; Riggins RB, 2005, MOL CANCER THER, V4, P33; Sakamoto M, 2001, Hum Cell, V14, P305; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Scheid S, 2005, BIOINFORMATICS, V21, P2921, DOI 10.1093/bioinformatics/bti436; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; TAYLOR IW, 1983, CANCER RES, V43, P4007; TAYLOR IW, J BIOL CHEM, V16, P452; Taylor J, 2005, BIOSTATISTICS, V6, P111, DOI 10.1093/biostatistics/kxh021; Thiantanawat A, 2003, CANCER RES, V63, P8037; Tsai CA, 2003, BIOMETRICS, V59, P1071, DOI 10.1111/j.0006-341X.2003.00123.x; Venditti M, 2002, INT J CANCER, V99, P35, DOI 10.1002/ijc.10269; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang ZY, 2003, J VLSI SIG PROC SYST, V35, P255, DOI 10.1023/B:VLSI.0000003024.13494.40; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhu YL, 2006, INT J ONCOL, V28, P67; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; 2006, GENE CARD IRF 1	74	134	148	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					4013	4027		10.1096/fj.06-7990com	http://dx.doi.org/10.1096/fj.06-7990com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17660348				2022-12-25	WOS:000251283500026
J	Dzeja, PP; Bast, P; Pucar, D; Wieringa, B; Terzic, A				Dzeja, Petras P.; Bast, Peter; Pucar, Darko; Wieringa, Be; Terzic, Andre			Defective metabolic signaling in adenylate kinase AK1 gene knock-out hearts compromises post-ischemic coronary reflow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTACT SKELETAL-MUSCLE; O-18-ASSISTED P-31 NMR; SENSITIVE K+ CHANNELS; CREATINE-KINASE; ENDOTHELIAL-CELLS; ENERGY-METABOLISM; SMOOTH-MUSCLE; CATALYZED PHOSPHOTRANSFER; NITRIC-OXIDE	Matching blood flow to myocardial energy demand is vital for heart performance and recovery following ischemia. The molecular mechanisms responsible for transduction of myocardial energetic signals into reactive vasodilatation are, however, elusive. Adenylate kinase, associated with AMP signaling, is a sensitive reporter of the cellular energy state, yet the contribution of this phosphotransfer system in coupling myocardial metabolism with coronary flow has not been explored. Here, knock out of the major adenylate kinase isoform, AK1, disrupted the synchrony between inorganic phosphate Pi turnover at ATP-consuming sites and gamma-ATP exchange at ATP synthesis sites, as revealed by O-18-assisted P-31 NMR. This reduced energetic signal communication in the post-ischemic heart. AK1 gene deletion blunted vascular adenylate kinase phosphotransfer, compromised the contractility-coronary flow relationship, and precipitated inadequate coronary reflow following ischemia-reperfusion. Deficit in adenylate kinase activity abrogated AMP signal generation and reduced the vascular adenylate kinase/ creatine kinase activity ratio essential for the response of metabolic sensors. The sarcolemma-associated splice variant AK1 beta facilitated adenosine production, a function lost in the absence of adenylate kinase activity. Adenosine treatment bypassed AK1 deficiency and restored post-ischemic flow to wild-type levels, achieving phenotype rescue. AK1 phosphotransfer thus transduces stress signals into adequate vascular response, providing linkage between cell bioenergetics and coronary flow.	Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Radboud Univ Nijmegen Med Ctr, Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands	Mayo Clinic; Mayo Clinic; Mayo Clinic; Radboud University Nijmegen	Dzeja, PP (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	dzeja.petras@mayo.edu	Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085744] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL085744-02W1, R01 HL085744-02, R01 HL085744-01A1, R01 HL085744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 2002, J BIOL CHEM, V277, P24427, DOI 10.1074/jbc.M201777200; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; Brewster LM, 2006, CIRCULATION, V114, P2034, DOI 10.1161/CIRCULATIONAHA.105.584490; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; da Silva CG, 2006, CIRC RES, V98, pE39, DOI 10.1161/01.RES.0000215436.92414.1d; DAUT J, 1994, CARDIOVASC RES, V28, P811, DOI 10.1093/cvr/28.6.811; DAWIS SM, 1989, BIOPHYS J, V55, P79, DOI 10.1016/S0006-3495(89)82782-1; Decking UKM, 1997, CIRC RES, V81, P154, DOI 10.1161/01.RES.81.2.154; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 2004, MOL CELL BIOCHEM, V256, P13, DOI 10.1023/B:MCBI.0000009856.23646.38; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 2003, J EXP BIOL, V206, P2039, DOI 10.1242/jeb.00426; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; DZEJA PP, 2002, MAGMA, V14, P180; DZEJA PP, 2006, HDB NEUROCHEMISTRY M, P641; Evans AM, 2005, J BIOL CHEM, V280, P41504, DOI 10.1074/jbc.M510040200; Flood AJ, 2002, CARDIOVASC RES, V55, P161, DOI 10.1016/S0008-6363(02)00329-2; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Goirand F, 2007, J PHYSIOL-LONDON, V581, P1163, DOI 10.1113/jphysiol.2007.132589; Gumina RJ, 2003, AM J PHYSIOL-HEART C, V284, pH2106, DOI 10.1152/ajpheart.00057.2003; Guns PJDF, 2005, BRIT J PHARMACOL, V146, P288, DOI 10.1038/sj.bjp.0706326; Hancock CR, 2006, J APPL PHYSIOL, V100, P406, DOI 10.1152/japplphysiol.00885.2005; Hancock CR, 2005, AM J PHYSIOL-CELL PH, V288, pC1287, DOI 10.1152/ajpcell.00567.2004; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hodgson DM, 2003, EMBO J, V22, P1732, DOI 10.1093/emboj/cdg192; Ikeno F, 2007, CARDIOVASC RES, V73, P699, DOI 10.1016/j.cardiores.2006.12.011; Ingwall JS, 2004, J MOL CELL CARDIOL, V37, P613, DOI 10.1016/j.yjmcc.2004.05.020; Ishibashi Y, 1998, CIRC RES, V82, P346, DOI 10.1161/01.RES.82.3.346; ISHIDA Y, 1994, MOL CELL BIOCHEM, V133, P39, DOI 10.1007/BF01267946; Ito H, 2001, J Cardiol, V37 Suppl 1, P39; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Janssen E, 2004, MOL CELL BIOCHEM, V256, P59, DOI 10.1023/B:MCBI.0000009859.15267.db; Janssen E, 2003, J BIOL CHEM, V278, P30441, DOI 10.1074/jbc.M303150200; Janssen E, 2003, J BIOL CHEM, V278, P12937, DOI 10.1074/jbc.M211465200; JONES CJH, 1995, CIRCULATION, V91, P1807, DOI 10.1161/01.CIR.91.6.1807; Kakkar R, 2006, CIRC RES, V98, P682, DOI 10.1161/01.RES.0000207498.40005.e7; Kane GC, 2006, FASEB J, V20, P2271, DOI 10.1096/fj.06-6349com; KROLL K, 1993, CIRC RES, V73, P846, DOI 10.1161/01.RES.73.5.846; KUROKAWA Y, 1990, ENZYME, V43, P57, DOI 10.1159/000468708; Melchert PJ, 1999, AM J PHYSIOL-HEART C, V277, pH617, DOI 10.1152/ajpheart.1999.277.2.H617; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Morrison RR, 2002, AM J PHYSIOL-HEART C, V282, pH437, DOI 10.1152/ajpheart.00723.2001; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; NITENBERG A, 1995, EUR HEART J, V16, P7, DOI 10.1093/eurheartj/16.suppl_I.7; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; PAUL RJ, 1989, ANNU REV PHYSIOL, V51, P331, DOI 10.1146/annurev.physiol.51.1.331; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; Pucar D, 2004, MOL CELL BIOCHEM, V256, P281, DOI 10.1023/B:MCBI.0000009875.30308.7a; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Pucar D, 2001, J BIOL CHEM, V276, P44812, DOI 10.1074/jbc.M104425200; Rubin LJ, 2005, J APPL PHYSIOL, V98, P296, DOI 10.1152/japplphysiol.00075.2004; Saks V, 2006, J PHYSIOL-LONDON, V571, P253, DOI 10.1113/jphysiol.2005.101444; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; Seccia TM, 1998, CLIN EXP HYPERTENS, V20, P345, DOI 10.3109/10641969809052126; Selivanov VA, 2004, MOL CELL BIOCHEM, V256, P243, DOI 10.1023/B:MCBI.0000009872.35940.7d; Sutherland FJ, 2003, CLIN EXP PHARMACOL P, V30, P879, DOI 10.1046/j.1440-1681.2003.03926.x; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Tune JD, 2004, J APPL PHYSIOL, V97, P404, DOI 10.1152/japplphysiol.01345.2003; Vial C., 2006, CREATINE KINASE, P195; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110; Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98	67	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31366	31372		10.1074/jbc.M705268200	http://dx.doi.org/10.1074/jbc.M705268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17704060	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000250309200026
J	Arthur, JF; Shen, Y; Kahn, ML; Berndt, MC; Andrews, RK; Gardiner, EE				Arthur, Jane F.; Shen, Yang; Kahn, Mark L.; Berndt, Michael C.; Andrews, Robert K.; Gardiner, Elizabeth E.			Ligand binding rapidly induces disulfide-dependent dimerization of glycoprotein VI on the platelet plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GPVI DOWN-REGULATION; C-TYPE LECTIN; GPIB-IX-V; COLLAGEN RECEPTOR; FC-RECEPTOR; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; ACTIVATION	Thrombus formation in hemostasis or thrombotic disease is initiated by adhesion of circulating platelets to damaged blood vessel walls. Exposed subendothelial collagen interacting with platelet glycoprotein (GP) VI leads to platelet activation and integrin alpha(IIb)beta(3)-mediated aggregation. We previously showed that ligand binding to GPVI also induces metalloproteinase-dependent shedding, generating an similar to 55-kDa soluble ectodomain fragment and an similar to 10-kDa membrane-associated remnant. Here, treatment of platelets with collagen or the GPVI-targeting rattlesnake toxin convulxin also induces rapid (10-30 s) formation of a high molecular weight GPVI complex (GPVIc) under nonreducing conditions, as detected by immunoblotting with anti-GPVI antibodies. The appearance of an similar to 20-kDa remnant detectable using a polyclonal antibody against the GPVI cytoplasmic tail under nonreducing, but not reducing, conditions after ectodomain shedding and nonreduced/reduced two-dimensional SDS-polyacrylamide gel analysis of biotinylated platelets confirmed that that GPVIc was a homodimer. Formation of disulfide-linked GPVIc was prolonged in the presence of metalloproteinase inhibitor GM6001 and was independent of GPVI signaling because it was unaffected by inhibitors of Src kinases, Syk, or phosphoinositide 3-kinase. To identify the thiol involved in disulfide bond formation, wild-type or mutant GPVI, where two available sulfhydryls (Cys-274 and Cys-338) were individually mutated to serine, was expressed in rat basophilic leukemia cells. Dimerization of wild-type and C274S GPVI, but not the C338S mutant, was observed after treating cells with convulxin. We conclude that (i) a subpopulation of GPVI forms a constitutive dimer on the platelet surface, facilitating rapid disulfide cross-linking, (ii) convulxin or other GPVI agonists induce disulfide-linked GPVI dimerization independent of GPVI signaling, and (iii) the penultimate residue of the GPVI cytoplasmic tail, Cys338, mediates disulfide-dependent dimer formation.	Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Monash University; University of Pennsylvania	Gardiner, EE (corresponding author), Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.	elizabeth.gardiner@med.monash.edu.au	ARTHUR, JANE/AAW-9983-2020; Gardiner, Elizabeth/P-8716-2019; Gardiner, Elizabeth/E-7774-2011; Berndt, Michael C/D-5580-2012	Gardiner, Elizabeth/0000-0001-9453-9688; Andrews, Robert Keith/0000-0001-9577-8082				Andrews RK, 2004, IUBMB LIFE, V56, P13, DOI 10.1080/15216540310001649831; Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; Andrews RK, 2001, J BIOL CHEM, V276, P28092, DOI 10.1074/jbc.M011352200; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Arthur JF, 2005, THROMB HAEMOSTASIS, V93, P716, DOI 10.1160/TH04-09-0584; Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; Baker J, 2004, PLATELETS, V15, P207, DOI 10.1080/09537100410001701010; Batuwangala T, 2004, ACTA CRYSTALLOGR D, V60, P46, DOI 10.1107/S0907444903021620; Bergmeier W, 2004, CIRC RES, V95, P677, DOI 10.1161/01.RES.0000143899.73453.11; Bergmeier W, 2004, THROMB HAEMOSTASIS, V91, P951, DOI 10.1160/TH03-12-0795; Berlanga O, 2007, J THROMB HAEMOST, V5, P1026, DOI 10.1111/j.1538-7836.2007.02449.x; Berlanga O, 2002, EUR J BIOCHEM, V269, P2951, DOI 10.1046/j.1432-1033.2002.02969.x; Boylan B, 2006, BLOOD, V108, P908, DOI 10.1182/blood-2005-07-2937; Briant L, 1997, J BIOL CHEM, V272, P19441, DOI 10.1074/jbc.272.31.19441; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Gardiner EE, 2007, J THROMB HAEMOST, V5, P1530, DOI 10.1111/j.1538-7836.2007.02590.x; Gardiner EE, 2004, BLOOD, V104, P3611, DOI 10.1182/blood-2004-04-1549; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hisamitsu T, 2004, BIOCHEMISTRY-US, V43, P11135, DOI 10.1021/bi049367x; Horii K, 2006, BLOOD, V108, P936, DOI 10.1182/blood-2006-01-010215; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kato K, 2006, J THROMB HAEMOST, V4, P1107, DOI 10.1111/j.1538-7836.2006.01874.x; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kuijpers MJE, 2004, J PHYSIOL-LONDON, V558, P403, DOI 10.1113/jphysiol.2004.062414; Lecut C, 2004, J BIOL CHEM, V279, P52293, DOI 10.1074/jbc.M406342200; Locke D, 2003, J BIOL CHEM, V278, P15441, DOI 10.1074/jbc.M212338200; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Moroi M, 2004, THROMB RES, V114, P221, DOI 10.1016/j.thromres.2004.06.046; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Newton JP, 1999, BIOCHEM BIOPH RES CO, V261, P283, DOI 10.1006/bbrc.1999.1018; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Powell MS, 2006, J IMMUNOL, V176, P7489, DOI 10.4049/jimmunol.176.12.7489; Rabie T, 2005, J BIOL CHEM, V280, P14462, DOI 10.1074/jbc.M500041200; Rabie T, 2007, BLOOD, V110, P529, DOI 10.1182/blood-2006-11-058107; Sarratt KL, 2005, BLOOD, V106, P1268, DOI 10.1182/blood-2004-11-4434; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; Smethurst PA, 2007, J BIOL CHEM, V282, P1296, DOI 10.1074/jbc.M606479200; Stephens G, 2005, BLOOD, V105, P186, DOI 10.1182/blood-2004-07-2842; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; Takeda K, 2001, ANTIOXID REDOX SIGN, V3, P473, DOI 10.1089/15230860152409103	59	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30434	30441		10.1074/jbc.M701330200	http://dx.doi.org/10.1074/jbc.M701330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690106	hybrid			2022-12-25	WOS:000250136300011
J	de Vega, S; Iwamoto, T; Nakamura, T; Hozumi, K; McKnight, DA; Fisher, LW; Fukumoto, S; Yamada, Y				de Vega, Susana; Iwamoto, Tsutomu; Nakamura, Takashi; Hozumi, Kentaro; McKnight, Dianalee A.; Fisher, Larry W.; Fukumoto, Satoshi; Yamada, Yoshihiko			TM14 is a new member of the fibulin family (fibulin-7) that interacts with extracellular matrix molecules and is active for cell binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ODONTOBLAST DIFFERENTIATION; TOOTH DEVELOPMENT; TISSUE LOCALIZATION; MEMBRANE-PROTEIN; CARCINOMA CELLS; IN-VIVO; EXPRESSION; FIBRONECTIN; GENE; DOMAINS	We identified a new extracellular protein, TM14, by differential hybridization using mouse tooth germ cDNA microarrays. TM14 cDNA encodes 440 amino acids containing a signal peptide. The protein contains 3 EGF modules at the center, aC-terminal domain homologous to the fibulin module, and a unique Sushi domain at the N terminus. In situ hybridization revealed that TM14 mRNA was expressed by preodontoblasts and odontoblasts in developing teeth. TM14 mRNA was also expressed in cartilage, hair follicles, and extraembryonic tissues of the placenta. Immunostaining revealed that TM14 was localized at the apical pericellular regions of preodontoblasts. When the dentin matrix was fully formed and dentin mineralization occurred, TM14 was present in the predentin matrix and along the dentinal tubules. We found that the recombinant TM14 protein was glycosylated with N-linked oligosaccharides and interacted with heparin, fibronectin, fibulin-1, and dentin sialophosphoprotein. We also found that TM14 preferentially bound dental mesenchyme cells and odontoblasts but not dental epithelial cells or nondental cells such as HeLa, COS7, or NIH3T3 cells. Heparin, EDTA, and anti-integrin beta 1 antibody inhibited TM14 binding to dental mesenchyme cells, suggesting that both a heparan sulfate-containing cell surface receptor and an integrin are involved in TM14 cell binding. Our findings indicate that TM14 is a cell adhesion molecule that interacts with extracellular matrix molecules in teeth and suggest that TM14 plays important roles in both the differentiation and maintenance of odontoblasts as well as in dentin formation. Because of its protein characteristics, TM14 can be classified as a new member of the fibulin family: fibulin-7.	NIDCR, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA; NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA; Kyushu Univ, Fac Dent Sci, Dept Pediat Dent, Fukuoka 8128582, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Kyushu University	Yamada, Y (corresponding author), NIDCR, Lab Cell & Dev Biol, NIH, Bldg 30,Rm 407,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov	Iwamoto, Tsutomu/AAI-8952-2021; Iwamoto, Tsutomu/AAA-6597-2019; Nakamura, Takashi/A-8931-2012; Nakamura, Takashi/P-7796-2016; de Vega, Susana/AAH-4775-2020	Iwamoto, Tsutomu/0000-0001-8472-605X; Nakamura, Takashi/0000-0001-9904-1037; Nakamura, Takashi/0000-0001-9904-1037; Hozumi, Kentaro/0000-0002-6671-4386; Fukumoto, Satoshi/0000-0002-5046-6891	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000483, ZIADE000074, ZIADE000720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000720, Z01DE000483, Z01DE000074] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; BRONCKERS ALJJ, 1987, J HISTOCHEM CYTOCHEM, V35, P825, DOI 10.1177/35.8.3298423; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; Ehlermann J, 2003, GENE EXPR PATTERNS, V3, P441, DOI 10.1016/S1567-133X(03)00084-X; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FUJISAWA R, 1989, ARCH ORAL BIOL, V34, P89, DOI 10.1016/0003-9969(89)90131-3; Fukumoto S, 2005, CELLS TISSUES ORGANS, V181, P189, DOI 10.1159/000091380; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806; Hozumi K, 2006, J BIOL CHEM, V281, P32929, DOI 10.1074/jbc.M605708200; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; KLUBER MD, 1988, ROUX ARCH DEVEL BIOL, V197, P212; Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200; Kostka G, 2001, MOL CELL BIOL, V21, P7025, DOI 10.1128/MCB.21.20.7025-7034.2001; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; LESOT H, 1992, DIFFERENTIATION, V49, P109, DOI 10.1111/j.1432-0436.1992.tb00775.x; LESOT H, 1988, DIFFERENTIATION, V37, P62, DOI 10.1111/j.1432-0436.1988.tb00797.x; LESOT H, 1990, DIFFERENTIATION, V44, P25, DOI 10.1111/j.1432-0436.1990.tb00533.x; LESOT H, 1985, DIFFERENTIATION, V29, P176, DOI 10.1111/j.1432-0436.1985.tb00312.x; LESOT H, 1981, DEV BIOL, V82, P371, DOI 10.1016/0012-1606(81)90460-7; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; Matsuura T, 2001, MATRIX BIOL, V20, P367, DOI 10.1016/S0945-053X(01)00142-1; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Nakamura T, 2004, J BIOL CHEM, V279, P626, DOI 10.1074/jbc.M307502200; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; REICHERT T, 1992, CALCIFIED TISSUE INT, V50, P468, DOI 10.1007/BF00296779; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Ruch J V, 1987, Revis Biol Celular, V14, P1; Saito T, 2004, J ENDODONT, V30, P205, DOI 10.1097/00004770-200404000-00005; SAMBROOK J, 1989, EXTRACTION PURIFICAT; Singh U, 2006, PLACENTA, V27, P1014, DOI 10.1016/j.placenta.2005.10.009; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Tran H, 1997, J BIOL CHEM, V272, P22600, DOI 10.1074/jbc.272.36.22600; Utani A, 2003, J BIOL CHEM, V278, P34483, DOI 10.1074/jbc.M304827200; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Weigell-Weber M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1184, DOI 10.1001/archopht.121.8.1184; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0	55	73	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30878	30888		10.1074/jbc.M705847200	http://dx.doi.org/10.1074/jbc.M705847200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699513	hybrid			2022-12-25	WOS:000250136300056
J	Mohs, A; Silva, T; Yoshida, T; Amin, R; Lukomski, S; Inouye, M; Brodsky, B				Mohs, Angela; Silva, Teresita; Yoshida, Takeshi; Amin, Ravish; Lukomski, Slawomir; Inouye, Masayori; Brodsky, Barbara			Mechanism of stabilization of a bacterial collagen triple helix in the absence of hydroxyproline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; AMINO-ACID-SEQUENCE; GLY-X-Y; MOLECULAR-STRUCTURE; SURFACE PROTEIN; BACILLUS-ANTHRACIS; SCL2 PROTEINS; STABILITY; IDENTIFICATION; PEPTIDES	The Streptococcus pyogenes cell- surface protein Scl2 contains a globular N- terminal domain and a collagen- like domain, ( GlyXaa- X ' aa) 79, which forms a triple helix with a thermal stability close to that seen for mammalian collagens. Hyp is a major contributor to triple- helix stability in animal collagens, but is not present in bacteria, which lack prolyl hydroxylase. To explore the basis of bacterial collagen triple- helix stability in the absence of Hyp, biophysical studies were carried out on recombinant Scl2 protein, the isolated collagen- like domain from Scl2, and a set of peptides modeling the Scl2 highly charged repetitive ( GlyXaa- X ' aa) n sequences. At pH 7, CD spectroscopy, dynamic light scattering, and differential scanning calorimetry of the Scl2 protein all showed a very sharp thermal transition near 36 C, indicating a highly cooperative unfolding of both the globular and triple- helix domains. The collagen- like domain isolated by trypsin digestion showed a sharp transition at the same temperature, with an enthalpy of 12.5 kJ/ mol of tripeptide. At low pH, Scl2 and its isolated collagen- like domain showed substantial destabilization from the neutral pH value, with two thermal transitions at 24 and 27 C. A similar destabilization at low pH was seen for Scl2 charged model peptides, and the degree of destabilization was consistent with the strong pH dependence arising from the GKD tripeptide unit. The Scl2 protein contained twice as much charge as human fibril- forming collagens, and the degree of electrostatic stabilization observed for Scl2 was similar to the contribution Hyp makes to the stability of mammalian collagens. The high enthalpic contribution to the stability of the Scl2 collagenous domain supports the presence of a hydration network in the absence of Hyp.	Univ Med & Dent New Jersey, Dept Biochem, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; West Virginia University	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Dept Biochem, Robert Wood Johnson Med Sch, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu		Yoshida, Takeshi/0000-0003-0133-5067	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB007198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060048] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50666] Funding Source: Medline; NIBIB NIH HHS [R21EB007198] Funding Source: Medline; NIGMS NIH HHS [GM60048] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Beres SB, 2004, P NATL ACAD SCI USA, V101, P11833, DOI 10.1073/pnas.0404163101; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Boydston JA, 2005, J BACTERIOL, V187, P5310, DOI 10.1128/JB.187.15.5310-5317.2005; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; BURJANADZE TV, 1982, BIOPOLYMERS, V21, P1489, DOI 10.1002/bip.360210803; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Daubenspeck JM, 2004, J BIOL CHEM, V279, P30945, DOI 10.1074/jbc.M401613200; de Bruin Eric C., 2002, FEMS Yeast Research, V1, P291, DOI 10.1016/S1567-1356(01)00042-3; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; Han RL, 2006, APPL MICROBIOL BIOT, V72, P109, DOI 10.1007/s00253-006-0387-5; HAYASHI T, 1979, BIOCHEMISTRY-US, V18, P4182, DOI 10.1021/bi00586a022; Humtsoe JO, 2005, J BIOL CHEM, V280, P13848, DOI 10.1074/jbc.M410605200; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JIMENEZ S, 1973, BIOCHEM BIOPH RES CO, V52, P106, DOI 10.1016/0006-291X(73)90960-1; JOSSE J, 1964, J MOL BIOL, V9, P269, DOI 10.1016/S0022-2836(64)80207-2; Kar K, 2006, J BIOL CHEM, V281, P33283, DOI 10.1074/jbc.M605747200; KRAMER JM, 1994, FASEB J, V8, P329, DOI 10.1096/fasebj.8.3.8143939; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; MIGCHELS.C, 1973, J CHEM PHYS, V59, P296, DOI 10.1063/1.1679805; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Perret S, 2001, J BIOL CHEM, V276, P43693, DOI 10.1074/jbc.M105507200; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Qing GL, 2004, NAT BIOTECHNOL, V22, P877, DOI 10.1038/nbt984; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Rasmussen M, 2001, MOL MICROBIOL, V40, P1427, DOI 10.1046/j.1365-2958.2001.02493.x; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RIGBY BJ, 1968, NATURE, V219, P166, DOI 10.1038/219166a0; SUTOH K, 1974, BIOPOLYMERS, V13, P2477, DOI 10.1002/bip.1974.360131207; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Xu YJ, 2003, BIOCHEMISTRY-US, V42, P8696, DOI 10.1021/bi034006n	49	103	109	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29757	29765		10.1074/jbc.M703991200	http://dx.doi.org/10.1074/jbc.M703991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693404	hybrid, Green Published			2022-12-25	WOS:000249981200004
J	Xu, YC; Zhou, YL; Gonzalez, FJ; Snead, ML				Xu, Yucheng; Zhou, Yan Larry; Gonzalez, Frank J.; Snead, Malcolm L.			CCAAT/Enhancer-binding protein delta(C/EBP delta) maintains amelogenin expression in the absence of C/EBP alpha in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA; GENE-EXPRESSION; ADIPOSE-TISSUE; NF-Y; TRANSCRIPTION; DIFFERENTIATION; MORPHOGENESIS; DISRUPTION; LOCUS; LIVER	C/ EBP alpha is implicated to regulate mouse amelogenin gene expression during tooth enamel formation in vitro. Because enamel formation occurs during postnatal development and C/ EBP alpha- deficient mice die at birth, we used the Cre/ loxP recombination system to characterize amelogenin expression in C/ EBP alpha conditional knock- out mice. Mice carrying the Cre transgene under the control of the human keratin- 14 promoter show robust Cre expression in the ameloblast cell lineage. Mating between mice bearing the floxed C/ EBP alpha allele with keratin14- Cre mice generate C/ EBP alpha conditional knock- out mice. Real- time PCR analysis shows that removal of one C/EBP alpha allele from the molar enamel epithelial organ of 3- day postnatal mice results in dramatic decrease in endogenous C/EBP alpha mRNAlevels and coordinately altered amelogeninm RNA abundance. Conditional deletion of both C/ EBP alpha alleles further diminishes C/ EBP alpha mRNAlevels; however, rather than ablating amelogenin expression, we observe wild- type amelogenin mRNA abundance levels. We examined C/ EBP beta and nuclear factor YA expression, two transcription factors that had previously been shown to modestly participate in amelogenin expression, in vitro but found no significant changes in either of their mRNA abundance levels comparing conditional knock- out mice with wild- type counterparts. Although the abundance of C/ EBP delta is also unchanged in C/ EBP alpha\ conditional knock- out mice, in vitro we find that C/ EBP delta activates the mouse amelogenin promoter and synergistically cooperates with nuclear factor Y, suggesting that C/ EBP delta can functionally substitute for C/ EBP alpha to produce an enamel matrix competent to direct biomineralization.	Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; NCI, NIH, Lab Metab, Bethesda, MD 20892 USA	University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Snead, ML (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, CSA 142,2250 Alcazar St, Los Angeles, CA 90033 USA.	mlsnead@usc.edu			NIDCR NIH HHS [DE-06988, R01 DE006988] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Li M, 2001, DEVELOPMENT, V128, P675; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Mustonen T, 2004, DEVELOPMENT, V131, P4907, DOI 10.1242/dev.01377; Osada S, 1996, J BIOL CHEM, V271, P3891; Plikus MV, 2005, EVOL DEV, V7, P440, DOI 10.1111/j.1525-142X.2005.05048.x; SNEAD ML, 1988, DEVELOPMENT, V104, P77; SNEAD ML, 1984, DEV BIOL, V104, P255, DOI 10.1016/0012-1606(84)90053-8; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 2004, DEV DYNAM, V231, P98, DOI 10.1002/dvdy.20118; Xu YC, 2007, BIOCHEM BIOPH RES CO, V354, P56, DOI 10.1016/j.bbrc.2006.12.182; Xu YC, 2006, EUR J ORAL SCI, V114, P169, DOI 10.1111/j.1600-0722.2006.00319.x; Xu Y, 2006, J BIOL CHEM, V281, P16090, DOI 10.1074/jbc.M510514200; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273; Zhu QS, 2004, J BIOL CHEM, V279, P29902, DOI 10.1074/jbc.M400438200	22	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29882	29889		10.1074/jbc.M702097200	http://dx.doi.org/10.1074/jbc.M702097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17704518	Green Accepted, hybrid			2022-12-25	WOS:000249981200017
J	Friedrichs, J; Torkko, JM; Helenius, J; Teravainen, TP; Fullekrug, J; Muller, DJ; Simons, K; Manninen, A				Friedrichs, Jens; Torkko, Juha M.; Helenius, Jonne; Teravainen, Terhi P.; Fullekrug, Joachim; Muller, Daniel J.; Simons, Kai; Manninen, Aki			Contributions of galectin-3 and-9 to epithelial cell adhesion analyzed by single cell force spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS LECTIN; MEMBRANE; LAMININ; POLARIZATION; POLARITY; BINDING; PROTEIN; BETA-1-INTEGRINS; TUBULOGENESIS; EXPRESSION	Galectins are widely expressed in epithelial tissues and have been implicated in a variety of cellular processes, including adhesion and polarization. Here we studied the contributions of galectins in cell adhesion and cyst formation of Madin-Darby canine kidney cells. Quantitative single cell force spectroscopy and standard adhesion assays were employed to study both early (< 2 min) and long term (90 min) adhesion of cells to different extracellular matrix components. Inhibitors were used to examine the contribution of integrins and galectins in general and RNA interference to specifically address the role of two abundantly expressed galectins, galectin-3 and -9. We found that both galectin-3 and -9 were required for optimal long term cell adhesion to both collagen I and laminin-III. Early adhesion to laminin was found to be integrin-independent and was instead mediated by carbohydrate interactions and galectin-3 and -9. The opposite was observed for early adhesion to collagen. Although similar, the contributions of galectin-3 and -9 to adhesion appeared to be by distinct processes. These defects in adhesion of the two galectin knockdown cell lines may underlie the epithelial phenotypes observed in the cyst assays. Our findings emphasize the complex regulation of epithelial cell functions by galectins.	Oulu Univ, Bioctr Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Tech Univ Dresden, Biotechnol Ctr, D-01307 Dresden, Germany; Heidelberg Univ, Dept Internal Med Gastroenterol 4, D-69120 Heidelberg, Germany	University of Oulu; Max Planck Society; Technische Universitat Dresden; Ruprecht Karls University Heidelberg	Manninen, A (corresponding author), Oulu Univ, Bioctr Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.	aki.manninen@oulu.fi	Friedrichs, Jens/D-4833-2015; Manninen, Aki/AAC-8067-2019; Füllekrug, Joachim/A-6581-2008; Müller, Daniel J./A-5967-2010	Manninen, Aki/0000-0002-6263-8101; Müller, Daniel J./0000-0003-3075-0665; Simons, Kai/0000-0002-9231-9996				Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Bao Q, 1999, GLYCOBIOLOGY, V9, P489, DOI 10.1093/glycob/9.5.489; BAO Q, 1995, J CELL SCI, V108, P2791; Bullock SL, 2001, J AM SOC NEPHROL, V12, P515, DOI 10.1681/ASN.V123515; Carcamo C, 2006, EXP CELL RES, V312, P374, DOI 10.1016/j.yexcr.2005.10.025; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Delacour D, 2006, CURR BIOL, V16, P408, DOI 10.1016/j.cub.2005.12.046; Delacour D, 2005, J CELL BIOL, V169, P491, DOI 10.1083/jcb.200407073; Furtak V, 2001, BIOCHEM BIOPH RES CO, V289, P845, DOI 10.1006/bbrc.2001.6064; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GRANT DS, 1985, AM J ANAT, V174, P387, DOI 10.1002/aja.1001740403; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hughes RC, 2001, BIOCHIMIE, V83, P667; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang FZ, 2004, MICROSC RES TECHNIQ, V64, P435, DOI 10.1002/jemt.20101; Lagana A, 2006, MOL CELL BIOL, V26, P3181, DOI 10.1128/MCB.26.8.3181-3193.2006; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; Matlin KS, 2003, METHODS, V30, P235, DOI 10.1016/S1046-2023(03)00030-6; Meder D, 2005, J CELL BIOL, V168, P303, DOI 10.1083/jcb.200407072; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Nelson WJ, 2003, NEWS PHYSIOL SCI, V18, P143, DOI 10.1152/nips.01435.2002; Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Poirier F, 2002, BIOCHEM SOC SYMP, V69, P95; Puech PH, 2005, J CELL SCI, V118, P4199, DOI 10.1242/jcs.02547; Puech PH, 2006, ULTRAMICROSCOPY, V106, P637, DOI 10.1016/j.ultramic.2005.08.003; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Schuck S, 2004, P NATL ACAD SCI USA, V101, P4912, DOI 10.1073/pnas.0401285101; Taubenberger A, 2007, MOL BIOL CELL, V18, P1634, DOI 10.1091/mbc.E06-09-0777; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zinkl GM, 1996, J CELL BIOL, V133, P695, DOI 10.1083/jcb.133.3.695	41	69	69	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29375	29383		10.1074/jbc.M701867200	http://dx.doi.org/10.1074/jbc.M701867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675292	hybrid			2022-12-25	WOS:000249788000034
J	Bleijerveld, OB; Brouwers, JFHM; Vaandrager, AB; Helms, JB; Houweling, M				Bleijerveld, Onno B.; Brouwers, Jos F. H. M.; Vaandrager, Arie B.; Helms, J. Bernd; Houweling, Martin			The CDP-ethanolamine pathway and phosphatidylserine decarboxylation generate different phosphatidylethanolamine molecular species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE PHOSPHOLIPIDS; HAMSTER OVARY CELLS; ELECTROSPRAY-IONIZATION; QUANTITATIVE-ANALYSIS; BIOSYNTHETIC DEFECT; MASS-SPECTROMETRY; SERINE RACEMASE; MITOCHONDRIA; PHOSPHATIDYLCHOLINE; LIVER	In mammalian cells, phosphatidylethanolamine (PtdEtn) is mainly synthesized via the CDP-ethanolamine (Kennedy) pathway and by decarboxylation of phosphatidylserine (PtdSer). However, the extent to which these two pathways contribute to overall PtdEtn synthesis both quantitatively and qualitatively is still not clear. To assess their contributions, PtdEtn species synthesized by the two routes were labeled with pathway-specific stable isotope precursors, d(3)-serine and d(4)-ethanolamine, and analyzed by high performance liquid chromatography-mass spectrometry. The major conclusions from this study are that (i) in both McA-RH7777 and Chinese hamster ovary K1 cells, the CDP-ethanolamine pathway was favored over PtdSer decarboxylation, and (ii) both pathways for PtdEtn synthesis are able to produce all diacyl-PtdEtn species, but most of these species were preferentially made by one pathway. For example, the CDP-ethanolamine pathway preferentially synthesized phospholipids with mono- or di-unsaturated fatty acids on the sn-2 position (e. g. (16:0-18:2) PtdEtn and (18:1-18:2) PtdEtn), whereas PtdSer decarboxylation generated species with mainly polyunsaturated fatty acids on the sn-2 position (e. g. (18:0-20:4) PtdEtn and (18:0-20:5) PtdEtn in McArdle and (18: 0-20:4) PtdEtn and (18:0-22:6) PtdEtn in Chinese hamster ovary K1 cells). (iii) The main PtdEtn species newly synthesized from the Kennedy pathway in the microsomal fraction appeared to equilibrate rapidly between the endoplasmic reticulum and mitochondria. (iv) Newly synthesized PtdEtn species preferably formed in the mitochondria, which is at least in part due to the substrate specificity of the phosphatidylserine decarboxylase, seemed to be retained in this organelle. Our data suggest a potentially essential role of the PtdSer decarboxylation pathway in mitochondrial functioning.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3508 TD Utrecht, Netherlands	Utrecht University; Utrecht University	Houweling, M (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	M.Houweling@uu.nl	Brouwers, Jos F/AAH-1444-2019	Brouwers, Jos F/0000-0003-2924-3279; Vaandrager, Arie/0000-0001-9394-9239				ARTHUR G, 1987, BIOCHEM CELL BIOL, V65, P1016, DOI 10.1139/o87-133; ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN LF, 1961, J BIOL CHEM, V236, P28; Brouwers JFHM, 1999, J LIPID RES, V40, P164; Brouwers JFHM, 1998, J LIPID RES, V39, P344; DE BERNARDO S, 1974, ARCH BIOCHEM BIOPHYS, V163, P390, DOI 10.1016/0003-9861(74)90490-1; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; Foltyn VN, 2005, J BIOL CHEM, V280, P1754, DOI 10.1074/jbc.M405726200; Heikinheimo L, 2002, TRAFFIC, V3, P367, DOI 10.1034/j.1600-0854.2002.30506.x; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; Hsu FF, 2003, J MASS SPECTROM, V38, P752, DOI 10.1002/jms.491; Kevala JH, 2001, ANAL BIOCHEM, V292, P130, DOI 10.1006/abio.2001.5076; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1991, J BIOL CHEM, V266, P6370; Kuksis A, 2005, METHODS, V36, P172, DOI 10.1016/j.ymeth.2004.11.001; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MILLER MA, 1986, J BIOL CHEM, V261, P9753; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SCHMID PC, 1991, J BIOL CHEM, V266, P13690; Schmid PC, 1997, LIPIDS, V32, P1181, DOI 10.1007/s11745-997-0152-7; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Steenbergen R, 2005, J BIOL CHEM, V280, P40032, DOI 10.1074/jbc.M506510200; Steenbergen R, 2006, BBA-MOL CELL BIOL L, V1761, P313, DOI 10.1016/j.bbalip.2006.03.005; TIJBURG LBM, 1989, BIOCHEM BIOPH RES CO, V160, P1275, DOI 10.1016/S0006-291X(89)80141-X; Vance D.E., 1996, BIOCH LIPIDS LIPOPRO, P1; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; Vance JE, 2005, PROG LIPID RES, V44, P207, DOI 10.1016/j.plipres.2005.05.001; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; Xia MH, 2004, MOL BRAIN RES, V125, P96, DOI 10.1016/j.molbrainres.2004.03.007; Xu Y, 2003, J BIOL CHEM, V278, P51380, DOI 10.1074/jbc.M307382200; YAMANE T, 2003, Patent No. 6660504; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7	48	66	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28362	28372		10.1074/jbc.M703786200	http://dx.doi.org/10.1074/jbc.M703786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673461	hybrid, Green Published			2022-12-25	WOS:000249642100010
J	Dashti, N; Manchekar, M; Liu, YW; Sun, ZH; Segrest, JP				Dashti, Nassrin; Manchekar, Medha; Liu, Yanwen; Sun, Zhihuan; Segrest, Jere P.			Microsomal triglyceride transfer protein activity is not required for the initiation of apolipoprotein B-containing lipoprotein assembly in McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; TRIACYLGLYCEROL TRANSFER PROTEIN; RAT HEPATOMA MCA-RH7777; N-TERMINAL 17-PERCENT; APO-B; HEPG2 CELLS; PLASMA-LIPOPROTEINS; RICH LIPOPROTEINS; GENE-EXPRESSION; LIPID-BINDING	We previously demonstrated that the N-terminal 1000 amino acid residues of human apolipoprotein (apo) B (designated apoB: 1000) are competent to fold into a three-sided lipovitellin-like lipid binding cavity to form the apoB " lipid pocket" without a structural requirement for microsomal triglyceride transfer protein (MTP). Our results established that this primordial apoB-containing particle is phospholipid-rich (Manchekar, M., Richardson, P. E., Forte, T. M., Datta, G., Segrest, J. P., and Dashti, N. (2004) J. Biol. Chem. 279, 39757-39766). In this study we have investigated the putative functional role of MTP in the initial lipidation of apoB: 1000 in stable transformants of McA-RH7777 cells. Inhibition of MTP lipid transfer activity by 0.1 mu M BMS-197636 and 5, 10, and 20 mu M of BMS-200150 had no detectable effect on the synthesis, lipidation, and secretion of apoB: 1000-containing particles. Under identical experimental conditions, the synthesis, lipidation, and secretion of endogenous apoB100-containing particles in HepG2 and parental untransfected McARH7777 cells were inhibited by 86-94%. BMS-200150 at 40 mu M nearly abolished the secretion of endogenous apoB100-containing particles in HepG2 and parental McA-RH cells but caused only 15-20% inhibition in the secretion of apoB: 1000-containing particles. This modest decrease was attributable to the nonspecific effect of a high concentration of this compound on hepatic protein synthesis, as reflected in a similar (20-25%) reduction in albumin secretion. Suppression of MTP gene expression in stable transformants of McARH7777 cells by micro-interfering RNA led to 60-70% decrease in MTP mRNA and protein levels, but it had no detectable effect on the secretion of apoB: 1000. Our results provide a compelling argument that the initial addition of phospholipids to apoB: 1000 and initiation of apoB-containing lipoprotein assembly occur independently of MTP lipid transfer activity.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Basic Sci Sect, Atherosclerosis Res Unit, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Dashti, N (corresponding author), Univ Alabama Birmingham, Dept Med, 1808 7th Ave S,BDB-D680, Birmingham, AL 35292 USA.	ndashti@uab.edu			NHLBI NIH HHS [HL084685, P01 HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, R01HL084685] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1994, J BIOL CHEM, V269, P25879; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carraway M, 2000, BIOCHEMISTRY-US, V39, P9737, DOI 10.1021/bi000791h; Dashti N, 2004, J LIPID RES, V45, P1919, DOI 10.1194/jlr.M400251-JLR200; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Dashti N, 2002, J NUTR, V132, P2651, DOI 10.1093/jn/132.9.2651; DASHTI N, 1992, J BIOL CHEM, V267, P7160; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DECOURCELLES DDC, 1980, J BIOL CHEM, V255, P6727; Dixon JL, 2002, J HISTOCHEM CYTOCHEM, V50, P629, DOI 10.1177/002215540205000504; Du EZ, 1996, J LIPID RES, V37, P1309; ELOVSON J, 1988, J LIPID RES, V29, P1461; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FOLCH J, 1957, J BIOL CHEM, V226, P497; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Hamilton RL, 1998, J LIPID RES, V39, P1543; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Jiang ZHG, 2006, BIOCHEMISTRY-US, V45, P11799, DOI 10.1021/bi060600w; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson SL, 2004, J BIOL CHEM, V279, P831, DOI 10.1074/jbc.M303057200; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; LIN MCM, 1995, J LIPID RES, V36, P1073; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Nicodeme E, 1999, J BIOL CHEM, V274, P1986, DOI 10.1074/jbc.274.4.1986; OHLENDORF DH, 1977, J BIOL CHEM, V252, P7992; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; PEREZ LE, 1991, COMP BIOCHEM PHYS B, V100, P821, DOI 10.1016/0305-0491(91)90297-Q; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rava P, 2006, J BIOL CHEM, V281, P11019, DOI 10.1074/jbc.M512823200; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; STEYRER E, 1990, J BIOL CHEM, V265, P19575; Stillemark-Billton P, 2005, J LIPID RES, V46, P104, DOI 10.1194/jlr.M400296-JLR200; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; van Greevenbroek MMJ, 1998, J LIPID RES, V39, P173; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Yamaguchi J, 2006, J BIOL CHEM, V281, P27063, DOI 10.1074/jbc.M606809200; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YAO ZM, 1993, ARTERIOSCLER THROMB, V13, P1476, DOI 10.1161/01.ATV.13.10.1476; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175	69	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28597	28608		10.1074/jbc.M700229200	http://dx.doi.org/10.1074/jbc.M700229200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690102	hybrid			2022-12-25	WOS:000249642100034
J	Koenigsknecht, MJ; Ramos, I; Downs, DM				Koenigsknecht, Mark J.; Ramos, Itzel; Downs, Diana M.			Glutamine phosphoribosylpyrophosphate amidotransferase-independent phosphoribosyl amine synthesis from ribose 5-phosphate and glutamine or asparagine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MG1655; SALMONELLA-TYPHIMURIUM; PYRIMIDINE MOIETY; THIAMINE SYNTHESIS; ANTHRANILATE SYNTHASE; ACID-PHOSPHATASE; BIOSYNTHESIS; PATHWAY; INVOLVEMENT; PROTEINS	Phosphoribosylamine (PRA) is the first intermediate in the common pathway to purines and thiamine and is generated in bacteria by glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase (EC 2.4.2.14) from PRPP and glutamine. Genetic data have indicated that multiple, non-PRPP amidotransferase mechanisms exist to generate PRA sufficient for thiamine but not purine synthesis. Here we describe the purification and identification of an activity (present in both Escherichia coli and Salmonella enterica) that synthesizes PRA from ribose 5-phosphate and glutamine/asparagine. Apurification resulting in greater than a 625-fold increase in specific activity identified 8 candidate proteins. Of the candidates, overexpression of AphA (EC 3.1.3.2), a periplasmic class B nonspecific acid phosphatase, significantly increased activity in partially purified extracts. Native purification of AphA to >95% homogeneity determined that the periplasmic L-asparaginase II, AnsB (EC 3.5.1.1), co-purified with AphA and was also necessary for PRA formation. The potential physiological relevance of AphA and AnsB in contributing to thiamine biosynthesis in vivo is discussed.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, DM (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	downs@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne BA, 2006, J BACTERIOL, V188, P6786, DOI 10.1128/JB.00745-06; Downs DM, 2006, ANNU REV MICROBIOL, V60, P533, DOI 10.1146/annurev.micro.60.080805.142308; DOWNS DM, 1991, J BACTERIOL, V173, P6597, DOI 10.1128/jb.173.20.6597-6604.1991; Enos-Berlage JL, 1999, J BACTERIOL, V181, P841, DOI 10.1128/JB.181.3.841-848.1999; Enos-Berlage JL, 1998, J BACTERIOL, V180, P6519, DOI 10.1128/JB.180.24.6519-6528.1998; EnosBerlage JL, 1996, J BACTERIOL, V178, P1476, DOI 10.1128/jb.178.5.1476-1479.1996; ESTRAMAREIX B, 1984, J AM CHEM SOC, V106, P3857, DOI 10.1021/ja00325a025; LEGAL ML, 1967, BIOCHEM BIOPH RES CO, V27, P618, DOI 10.1016/S0006-291X(67)80079-2; MILLER HK, 1969, BIOCHEM PHARMACOL, V18, P2225, DOI 10.1016/0006-2952(69)90329-3; NEWELL PC, 1968, BIOCHEM J, V106, P271, DOI 10.1042/bj1060271; NEWELL PC, 1968, BIOCHEM J, V106, P279, DOI 10.1042/bj1060279; NIERLICH D, 1961, J BIOL CHEM, V236, pPC32; NIERLICH.DP, 1965, J BIOL CHEM, V240, P366; Passariello C, 2006, BBA-PROTEINS PROTEOM, V1764, P13, DOI 10.1016/j.bbapap.2005.08.028; Petersen L, 1996, GENETICS, V143, P37; Ramos I, 2003, J BACTERIOL, V185, P5125, DOI 10.1128/JB.185.17.5125-5132.2003; Reshetnyak E, 1999, MOL MICROBIOL, V31, P167, DOI 10.1046/j.1365-2958.1999.01156.x; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Thaller MC, 1997, FEMS MICROBIOL LETT, V146, P191, DOI 10.1016/S0378-1097(96)00474-0; Zilles JL, 1996, GENETICS, V144, P883	23	7	7	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28379	28384		10.1074/jbc.M704024200	http://dx.doi.org/10.1074/jbc.M704024200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686772	hybrid, Green Accepted			2022-12-25	WOS:000249642100012
J	Riekhof, WR; Wu, J; Jones, JL; Voelker, DR				Riekhof, Wayne R.; Wu, James; Jones, Jennifer L.; Voelker, Dennis R.			Identification and characterization of the major lysophosphatidylethanolamine acyltransferase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; ENDOPLASMIC-RETICULUM; II CELLS; YEAST; GENE; CLONING; ACID; PHOSPHATIDYLETHANOLAMINE; CYTIDYLYLTRANSFERASE; BIOSYNTHESIS	We recently demonstrated that yeast actively import lysophosphatidylethanolamine (lyso-PtdEtn) through the action of plasma membrane P-type ATPases and rapidly acylate it to form PtdEtn. The predominant lyso-PtdEtn acyltransferase (LPEAT) activity present in cellular extracts is acyl-CoA dependent, but the identity of the gene encoding this activity was unknown. We now demonstrate that a previously uncharacterized open reading frame, YOR175C, encodes the major acyl-CoA-dependent LPEAT activity in yeast and henceforth refer to it as ALE1 ((a) under bar cyltransferase for (l) under bar yso-Ptd (E) under bar tn). Ale1p is an integral membrane protein and is highly enriched in the mitochondria-associated endoplasmic reticulum membrane. It is a member of the membrane-bound O-acyltransferase family and possesses a dibasic motif at its C terminus that is likely responsible for Golgi retrieval and retention in the endoplasmic reticulum. An ale1 Delta strain retains only trace amounts of acyl-CoA-dependent LPEAT activity, and strains lacking the capacity for PtdEtn synthesis via the phosphatidylserine decarboxylase and Kennedy pathways show a stringent requirement for both exogenous lyso-PtdEtn and a functional ALE1 gene for viability. Ale1p catalytic activity has a pH optimum between pH 7 and 7.5 and a strong preference for unsaturated acyl-CoA substrates.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA.	voelkerd@njc.org			NIGMS NIH HHS [R01 GM081461, R01 GM032453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081461, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Bosson R, 2006, MOL BIOL CELL, V17, P2636, DOI 10.1091/mbc.E06-02-0104; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; Choi JY, 1996, J BIOL CHEM, V271, P3581; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; Nakashima A, 1997, J BIOL CHEM, V272, P9567; Riekhof WR, 2006, J BIOL CHEM, V281, P36588, DOI 10.1074/jbc.M608851200; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu Y, 2006, J BIOL CHEM, V281, P39217, DOI 10.1074/jbc.M606100200; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Zarini S, 2006, J BIOL CHEM, V281, P10134, DOI 10.1074/jbc.M510783200	27	118	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28344	28352		10.1074/jbc.M705256200	http://dx.doi.org/10.1074/jbc.M705256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652094	hybrid			2022-12-25	WOS:000249642100008
J	Selvendiran, K; Tong, L; Vishwanath, S; Bratasz, A; Trigg, NJ; Kutala, VK; Hideg, K; Kuppusamy, P				Selvendiran, Karuppaiyah; Tong, Liyue; Vishwanath, Shilpa; Bratasz, Anna; Trigg, Nancy J.; Kutala, Vijay K.; Hideg, Kalman; Kuppusamy, Periannan			EF24 induces G(2)/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; BREAST-CANCER; TRANSCRIPTIONAL INDUCTION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; KINASE PATHWAY; CYCLE ARREST; FAS LIGAND; AKT; P53	We report that EF24, a synthetic compound 3,5-bis( 2-flurobenzylidene) piperidin-4-one, greatly inhibits cisplatin-resistant ( CR) human ovarian cancer cell proliferation. The inhibitory effect of EF24 on cell proliferation is associated with G(2)/Mphase cell cycle arrest and increased G2/M checkpoint protein ( pp53, p53, and p21) levels. Within 24 h following treatment, EF24 induced apoptosis in CR cells. The apoptosis was partially blocked by the general caspase inhibitor z-VAD. Within 12 h, EF24 induced a membranous FasL expression, consistent with a substantial decrease in the Ser(473) and Thr(308) phosphorylation of Akt, a known negative regulator of FasL transcription. Also, EF24 activated the phosphorylated PTEN and marginally upregulated total PTEN expression through the inhibition of ubiquitin-mediated PTEN degradation. Suppression of PTEN expression with siRNA significantly reduced the p53 and p21 levels and activated Akt phosphorylation at Ser473 and Thr308, resulting in decreased apoptosis and increased cell survival. On the other hand, overexpression of PTEN markedly induced apoptosis. Our results clearly suggested that EF24 induced significant increase in PTEN expression. The up-regulation of PTEN inhibited Akt and MDM2, which enhanced the level of p53, thereby inducing G2/M arrest and apoptosis. Therefore, EF24 appears to have a potential therapeutic role in human ovarian cancer through the activation of PTEN.	Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Pecs, Inst Organ & Med Chem, H-7643 Pecs, Hungary	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Pecs	Kuppusamy, P (corresponding author), Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, 420 W 12th Ave, Columbus, OH 43210 USA.	kuppusamy.1@osu.edu		Kutala, Vijay Kumar/0000-0002-7253-8999	NATIONAL CANCER INSTITUTE [R01CA102264] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102264-04, CA102264, R01 CA102264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams BK, 2005, ANTI-CANCER DRUG, V16, P263, DOI 10.1097/00001813-200503000-00005; Adams BK, 2004, BIOORGAN MED CHEM, V12, P3871, DOI 10.1016/j.bmc.2004.05.006; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ANDREWS PA, 1990, CANCER COMMUN-US, V2, P93, DOI 10.3727/095535490820874641; Bratasz A, 2006, P NATL ACAD SCI USA, V103, P3914, DOI 10.1073/pnas.0511250103; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Garrison JB, 2006, CANCER RES, V66, P464, DOI 10.1158/0008-5472.CAN-05-2039; Honjo S, 2005, DNA CELL BIOL, V24, P141, DOI 10.1089/dna.2005.24.141; JOHNSON SW, 1993, CANCER-AM CANCER SOC, V71, P644; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee S, 2005, GYNECOL ONCOL, V97, P26, DOI 10.1016/j.ygyno.2004.11.051; Li J, 1998, CANCER RES, V58, P5667; Liu XS, 2006, MOL CANCER THER, V5, P494, DOI 10.1158/1535-7163.MCT-05-0049; MARKMAN M, 1984, J CLIN ONCOL, V2, P1321, DOI 10.1200/JCO.1984.2.12.1321; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McNeish IA, 2004, GENE THER, V11, P497, DOI 10.1038/sj.gt.3302238; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Orlowski RZ, 2003, BREAST CANCER RES, V5, P1, DOI 10.1186/bcr460; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Panka DJ, 2003, J BIOL CHEM, V278, P37632, DOI 10.1074/jbc.M307339200; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Saito Y, 2003, CANCER GENE THER, V10, P803, DOI 10.1038/sj.cgt.7700644; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Selvendiran K, 2006, CANCER RES, V66, P4826, DOI 10.1158/0008-5472.CAN-05-4062; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Uriarte SM, 2005, CELL DEATH DIFFER, V12, P233, DOI 10.1038/sj.cdd.4401549; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069; Weir NM, 2007, CANCER BIOL THER, V6, P178, DOI 10.4161/cbt.6.2.3577; Weng LP, 1999, CANCER RES, V59, P5808; Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Zhou MX, 2003, CANCER RES, V63, P6357	49	120	127	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28609	28618		10.1074/jbc.M703796200	http://dx.doi.org/10.1074/jbc.M703796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17684018	Green Accepted, hybrid			2022-12-25	WOS:000249642100035
J	Singh, A; Kaur, N; Kosman, DJ				Singh, Arvinder; Kaur, Navjot; Kosman, Daniel J.			The metalloreductase Fre6p in Fe-Efflux from the yeast vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR-MECHANISMS; METAL TRANSPORTERS; GENE-EXPRESSION; MODEL ORGANISM; COPPER; HOMEOSTASIS; MUTANTS; STORAGE	The yeast vacuole is the storage depot for cellular iron. In this report we quantify the import-export balance in the vacuole because of the import of iron by Ccc1p and to export by the combined activity of Smf3p and the ferroxidase, permease pair of proteins, Fet5p and Fth1p. Our data indicate that the two efflux pathways are equally efficient in trafficking iron out of the vacuole. A major focus of this work was to identify the ferrireductase( s) that supplies the FeII for efflux whether by Smf3p or the Fet5p-Fth1p complex. Using a combination of flameless atomic absorption spectrophotometry to quantify vacuolar and whole cell iron content and a reporter assay for cytoplasmic iron we demonstrate that Fre6p supplies FeII to both efflux systems, while Fre7p plays no role in Fe-efflux from the vacuole. Enzymatic assay shows the two fusions to have similar reductase activity, however. Confocal fluorescence microscopy demonstrates that Fre6: GFP localizes to the vacuolar membrane; in contrast, Fre7: GFP fusions exhibit a variable and diffuse cellular distribution. Demonstrating a role for a vacuolar metalloreductase in Fe-efflux supports the model that iron is stored in the vacuole in the ferric state.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@buffalo.edu			NIDDK NIH HHS [DK77826] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077826] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; Curie C, 2003, ANNU REV PLANT BIOL, V54, P183, DOI 10.1146/annurev.arplant.54.031902.135018; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; De Freitas JM, 2004, J BIOL CHEM, V279, P4450, DOI 10.1074/jbc.M212308200; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Hell R, 2003, PLANTA, V216, P541, DOI 10.1007/s00425-002-0920-4; Herman EM, 1999, PLANT CELL, V11, P601, DOI 10.1105/tpc.11.4.601; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Kucharczyk R, 2001, ACTA BIOCHIM POL, V48, P1025; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Mao XC, 2002, CURR MICROBIOL, V45, P37, DOI 10.1007/s00284-001-0046-0; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Miller JH., 1972, EXPT MOL GENETICS, P353; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681; Ohgami RS, 2005, NAT GENET, V37, P1264, DOI 10.1038/ng1658; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; Rees EM, 2007, J BIOL CHEM, V282, P21629, DOI 10.1074/jbc.M703397200; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schroder I, 2003, FEMS MICROBIOL REV, V27, P427, DOI 10.1016/S0168-6445(03)00043-3; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SIKORSKI RS, 1989, GENETICS, V122, P19; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wheeler GL, 2004, PHYSIOL PLANTARUM, V120, P12, DOI 10.1111/j.0031-9317.2004.0193.x; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200	43	60	65	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28619	28626		10.1074/jbc.M703398200	http://dx.doi.org/10.1074/jbc.M703398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681937	hybrid			2022-12-25	WOS:000249642100036
J	Craddock, RM; Lockstone, HE; Rider, DA; Wayland, MT; Harris, LJW; McKenna, PJ; Bahn, S				Craddock, Rachel M.; Lockstone, Helen E.; Rider, David A.; Wayland, Matthew T.; Harris, Laura J. W.; McKenna, Peter J.; Bahn, Sabine			Altered T-Cell Function in Schizophrenia: A Cellular Model to Investigate Molecular Disease Mechanisms	PLOS ONE			English	Article								Despite decades of research into the aetiology and pathophysiology of schizophrenia, our understanding of this devastating disorder remains incomplete, with adverse consequences for both diagnosis and treatment. Here we investigate whether differences between patients and controls can be observed in peripheral patient tissue, with a view of establishing a means for dynamic investigations into cell function. In vitro stimulation of peripheral blood CD3+ pan T cells with anti-CD3 (clone OKT3) was used to investigate disease-associated cell responses. T cells from both medicated (n = 39), unmedicated (n = 6) and minimally medicated (n = 5) schizophrenia patients were found to have significantly lower proliferative responses to stimulation, compared to well-matched controls (n = 32). Expression of CD3 and TCR (T cell receptor) ab chains was equivalent between patients and controls, ensuring equal stimulation with anti-CD3, and there was no significant difference in the proportions of CD4+ and CD8+ T cells between samples (n = 12). Lower T cell proliferation in schizophrenia patients was not found to result from deficient early tyrosine phosphorylation signalling or lower IL-2 (interleukin-2) production, as these parameters were similar between patients and controls, as was the expression of CD25, the IL-2 receptor a chain. Analysis of CD45 isoforms, however, revealed that patients had a significantly greater percentage of CD8+ and CD4+ CD45RA+ cells before stimulation and significantly higher fluorescence intensity of CD45RA on CD4+ and CD8+ cells before and after stimulation. There was significantly higher expression of CD45 RB on both CD4+ and CD8+ unstimulated cells, with a trend towards lower numbers of CD45RO+ T cells in patient blood. Gene expression analysis in freshly isolated T cells from six minimally treated or first onset patients and six controls was carried out using human whole-genome CodeLink microarrays to identify functional pathways that may affect the ability of patient cells to respond to stimulation. Functional profiling showed prominent transcript changes in categories pertaining to cell cycle machinery, intracellular signalling, oxidative stress and metabolism. Intriguingly, chromosomal location analysis of genes significantly altered between schizophrenia and controls revealed clusters at 1p36, 1q42 and 6p22, which have previously been identified as strong susceptibility loci for schizophrenia.	[Craddock, Rachel M.; Lockstone, Helen E.; Wayland, Matthew T.; Harris, Laura J. W.; Bahn, Sabine] Univ Cambridge, Inst Biotechnol, Cambridge, England; [Rider, David A.] Inst Mol & Cell Biol, Proteos, Singapore; [McKenna, Peter J.] Fulbourn Hosp, Cambridge, England	University of Cambridge; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Bahn, S (corresponding author), Univ Cambridge, Inst Biotechnol, Cambridge, England.	sb209@cam.ac.uk	Wayland, Matthew/V-6751-2019	Wayland, Matthew/0000-0002-8095-858X; McKenna, Peter/0000-0001-5474-1144; Rider, David/0000-0003-1972-2524	The Stanley Medical Research Institute (SMRI); National Alliance for Research into Schizophrenia and Depression (NARSAD)	The Stanley Medical Research Institute (SMRI); National Alliance for Research into Schizophrenia and Depression (NARSAD)(NARSAD)	This research was supported by The Stanley Medical Research Institute (SMRI) and the National Alliance for Research into Schizophrenia and Depression (NARSAD). SB is a NARSAD Essel Investigator. GE Healthcare UK, provided CodeLink (TM) Human Whole Genome Bioarrays.	AKBAR AN, 1988, J IMMUNOL, V140, P2171; ALLEN ME, 1995, EUR J IMMUNOL, V25, P1547, DOI 10.1002/eji.1830250612; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cazzullo CL, 1998, SCHIZOPHR RES, V31, P49, DOI 10.1016/S0920-9964(97)00153-9; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHENGAPPA KNR, 1992, SCHIZOPHR RES, V8, P75, DOI 10.1016/0920-9964(92)90063-B; CHENGAPPA KNR, 1992, SCHIZOPHR RES, V7, P49; CHENGAPPA KNR, 1991, BIOL PSYCHIAT, V30, P731, DOI 10.1016/0006-3223(91)90019-I; Cope AP, 2002, ARTHRITIS RES THER, V4, pS197, DOI 10.1186/ar557; DELISI LE, 1982, BIOL PSYCHIAT, V17, P1003; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Faint JM, 2001, J IMMUNOL, V167, P212, DOI 10.4049/jimmunol.167.1.212; Frommberger UH, 1997, EUR ARCH PSY CLIN N, V247, P228, DOI 10.1007/BF02900219; GANGULI R, 1987, ANN NY ACAD SCI, V496, P676, DOI 10.1111/j.1749-6632.1987.tb35829.x; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HENNEBERG AE, 1994, SCHIZOPHR RES, V14, P15, DOI 10.1016/0920-9964(94)90004-3; Lewis DA, 2002, NEUROPSYCHOPHARMACOL, V26, P143, DOI 10.1016/S0893-133X(01)00393-1; Ma CS, 2004, IMMUNOL CELL BIOL, V82, P67, DOI 10.1046/j.0818-9641.2003.01206.x; MULLER N, 1991, PSYCHIAT RES, V37, P147, DOI 10.1016/0165-1781(91)90072-W; Muller N, 1999, EUR ARCH PSY CLIN N, V249, P62; Muller N, 2000, World J Biol Psychiatry, V1, P173, DOI 10.3109/15622970009150588; POULTON TA, 1988, IMMUNOLOGY, V64, P419; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; Prabakaran S, 2007, J PROTEOME RES, V6, P141, DOI 10.1021/pr060308a; Reif A, 2006, MOL PSYCHIATR, V11, P514, DOI 10.1038/sj.mp.4001791; RIEDEL M, 2006, J PSYCHIAT RES; RUSSO R, 1994, LANCET, V343, P356, DOI 10.1016/S0140-6736(94)91193-2; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SALMON M, 1994, EUR J IMMUNOL, V24, P892, DOI 10.1002/eji.1830240417; SHINITZKY M, 1991, ANN NY ACAD SCI, V621, P205; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Torrey EF, 2001, BRAIN BEHAV IMMUN, V15, P401, DOI 10.1006/brbi.2001.0649; Wills MR, 2002, J IMMUNOL, V168, P5455, DOI 10.4049/jimmunol.168.11.5455; Zhang XY, 2002, J PSYCHIATR RES, V36, P331	37	68	73	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e692	10.1371/journal.pone.0000692	http://dx.doi.org/10.1371/journal.pone.0000692			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668069	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452300027
J	Ronald, J; Akey, JM				Ronald, James; Akey, Joshua M.			The Evolution of Gene Expression QTL in Saccharomyces cerevisiae	PLOS ONE			English	Article							NATURAL-SELECTION; LINKAGE ANALYSIS; RAPID EVOLUTION; POPULATION; REVEALS; RATES; IDENTIFICATION; MECHANISMS; GENEALOGY; ALIGNMENT	Understanding the evolutionary forces that influence patterns of gene expression variation will provide insights into the mechanisms of evolutionary change and the molecular basis of phenotypic diversity. To date, studies of gene expression evolution have primarily been made by analyzing how gene expression levels vary within and between species. However, the fundamental unit of heritable variation in transcript abundance is the underlying regulatory allele, and as a result it is necessary to understand gene expression evolution at the level of DNA sequence variation. Here we describe the evolutionary forces shaping patterns of genetic variation for 1206 cis-regulatory QTL identified in a cross between two divergent strains of Saccharomyces cerevisiae. We demonstrate that purifying selection against mildly deleterious alleles is the dominant force governing cis-regulatory evolution in S. cerevisiae and estimate the strength of selection. We also find that essential genes and genes with larger codon bias are subject to slightly stronger cis-regulatory constraint and that positive selection has played a role in the evolution of major trans-acting QTL.	[Ronald, James; Akey, Joshua M.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Akey, JM (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.	akeyj@u.washington.edu		Akey, Joshua/0000-0002-4411-1330	JMA	JMA	JMA is an Alfred P. Sloan research fellow. The sponsors played no role in any aspect of the project other than funding.	Bing N, 2005, GENETICS, V170, P533, DOI 10.1534/genetics.105.041103; Brem RB, 2005, P NATL ACAD SCI USA, V102, P1572, DOI 10.1073/pnas.0408709102; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Denver DR, 2005, NAT GENET, V37, P544, DOI 10.1038/ng1554; Doniger SW, 2005, GENOME RES, V15, P701, DOI 10.1101/gr.3578205; Fay JC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r26; Fay JC, 2001, GENETICS, V158, P1227; Gilad Y, 2006, NATURE, V440, P242, DOI 10.1038/nature04559; Gu ZL, 2005, P NATL ACAD SCI USA, V102, P1092, DOI 10.1073/pnas.0409159102; Hahn MW, 2007, GENETICA, V129, P7, DOI 10.1007/s10709-006-0029-y; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HEATON B, 1992, NUCLEIC ACIDS RES, V20, P5365, DOI 10.1093/nar/20.20.5365; Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522; Hughes AL, 2005, GENETICS, V169, P533, DOI 10.1534/genetics.104.036939; Hughes AL, 2003, P NATL ACAD SCI USA, V100, P15754, DOI 10.1073/pnas.2536718100; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Khaitovich P, 2005, SCIENCE, V309, P1850, DOI 10.1126/science.1108296; Khaitovich P, 2004, PLOS BIOL, V2, P682, DOI 10.1371/journal.pbio.0020132; Krone SM, 1997, THEOR POPUL BIOL, V51, P210, DOI 10.1006/tpbi.1997.1299; Lan H, 2006, PLOS GENET, V2, P51, DOI 10.1371/journal.pgen.0020006; Landry CR, 2005, GENETICS, V171, P1813, DOI 10.1534/genetics.105.047449; Lee SI, 2006, P NATL ACAD SCI USA, V103, P14062, DOI 10.1073/pnas.0601852103; Lemos B, 2005, EVOLUTION, V59, P126; Monks SA, 2004, AM J HUM GENET, V75, P1094, DOI 10.1086/426461; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; MORTIMER RK, 1986, GENETICS, V113, P35; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Neuhauser C, 1997, GENETICS, V145, P519; Ohta T, 2002, P NATL ACAD SCI USA, V99, P16134, DOI 10.1073/pnas.252626899; Petretto E, 2006, PLOS GENET, V2, P1625, DOI 10.1371/journal.pgen.0020172; Rifkin SA, 2005, NATURE, V438, P220, DOI 10.1038/nature04114; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; Ronald J, 2005, PLOS GENET, V1, P213, DOI 10.1371/journal.pgen.0010025; Ronald J, 2006, GENETICS, V174, P541, DOI 10.1534/genetics.106.060863; Ruderfer DM, 2006, NAT GENET, V38, P1077, DOI 10.1038/ng1859; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Storey JD, 2005, PLOS BIOL, V3, P1380, DOI 10.1371/journal.pbio.0030267; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Townsend JP, 2003, MOL BIOL EVOL, V20, P955, DOI 10.1093/molbev/msg106; Whitehead A, 2006, P NATL ACAD SCI USA, V103, P5425, DOI 10.1073/pnas.0507648103; Whitehead A, 2006, MOL ECOL, V15, P1197, DOI 10.1111/j.1365-294X.2006.02868.x; Wong WSW, 2004, GENETICS, V167, P949, DOI 10.1534/genetics.102.010959; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222	49	39	40	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e678	10.1371/journal.pone.0000678	http://dx.doi.org/10.1371/journal.pone.0000678			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668057	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452300015
J	Suzuki, M; McHugh, J; Tork, C; Shelley, B; Klein, SM; Aebischer, P; Svendsen, CN				Suzuki, Masatoshi; McHugh, Jacalyn; Tork, Craig; Shelley, Brandon; Klein, Sandra M.; Aebischer, Patrick; Svendsen, Clive N.			GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALS	PLOS ONE			English	Article								Background. Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disease characterized by rapid loss of muscle control and eventual paralysis due to the death of large motor neurons in the brain and spinal cord. Growth factors such as glial cell line derived neurotrophic factor (GDNF) are known to protect motor neurons from damage in a range of models. However, penetrance through the blood brain barrier and delivery to the spinal cord remains a serious challenge. Although there may be a primary dysfunction in the motor neuron itself, there is also increasing evidence that excitotoxicity due to glial dysfunction plays a crucial role in disease progression. Clearly it would be of great interest if wild type glial cells could ameliorate motor neuron loss in these models, perhaps in combination with the release of growth factors such as GDNF. Methodology/Principal Findings. Human neural progenitor cells can be expanded in culture for long periods and survive transplantation into the adult rodent central nervous system, in some cases making large numbers of GFAP positive astrocytes. They can also be genetically modified to release GDNF (hNPC(GDNF)) and thus act as long-term 'mini pumps' in specific regions of the rodent and primate brain. In the current study we genetically modified human neural stem cells to release GDNF and transplanted them into the spinal cord of rats over-expressing mutant SOD1 (SOD1(G93A)). Following unilateral transplantation into the spinal cord of SOD1(G93A) rats there was robust cellular migration into degenerating areas, efficient delivery of GDNF and remarkable preservation of motor neurons at early and end stages of the disease within chimeric regions. The progenitors retained immature markers, and those not secreting GDNF had no effect on motor neuron survival. Interestingly, this robust motor neuron survival was not accompanied by continued innervation of muscle end plates and thus resulted in no improvement in ipsilateral limb use. Conclusions/Significance. The potential to maintain dying motor neurons by delivering GDNF using neural progenitor cells represents a novel and powerful treatment strategy for ALS. While this approach represents a unique way to prevent motor neuron loss, our data also suggest that additional strategies may also be required for maintenance of neuromuscular connections and full functional recovery. However, simply maintaining motor neurons in patients would be the first step of a therapeutic advance for this devastating and incurable disease, while future strategies focus on the maintenance of the neuromuscular junction.	[Suzuki, Masatoshi; McHugh, Jacalyn; Tork, Craig; Shelley, Brandon; Klein, Sandra M.; Svendsen, Clive N.] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; [Svendsen, Clive N.] Univ Wisconsin, Dept Anat, Madison, WI 53706 USA; [Svendsen, Clive N.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; [Aebischer, Patrick] Ecole Polytech Fed Lausanne, Brain & Mind Inst, Lausanne, Switzerland	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Svendsen, CN (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.	svendsen@waisman.wisc.edu	Aebischer, Patrick/E-1387-2013		ALS association; University of Wisconsin Foundation	ALS association; University of Wisconsin Foundation	This work was supported by the grant from the ALS association and the University of Wisconsin Foundation.	Acsadi G, 2002, HUM GENE THER, V13, P1047, DOI 10.1089/104303402753812458; Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820310011700; Arvidsson A, 2003, NEUROBIOL DIS, V14, P542, DOI 10.1016/j.nbd.2003.08.002; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; Beers DR, 2006, P NATL ACAD SCI USA, V103, P16021, DOI 10.1073/pnas.0607423103; Behrstock S, 2006, GENE THER, V13, P379, DOI 10.1038/sj.gt.3302679; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Capowski EE, 2007, J NEUROSCI METH, V163, P338, DOI 10.1016/j.jneumeth.2007.02.022; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Deitch JS, 2002, J NEUROL SCI, V193, P117, DOI 10.1016/S0022-510X(01)00656-6; Deshpande DM, 2006, ANN NEUROL, V60, P32, DOI 10.1002/ana.20901; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Ganel R, 2006, NEUROBIOL DIS, V21, P556, DOI 10.1016/j.nbd.2005.08.014; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; Gould TW, 2006, J NEUROSCI, V26, P8774, DOI 10.1523/JNEUROSCI.2315-06.2006; Guillot S, 2004, NEUROBIOL DIS, V16, P139, DOI 10.1016/j.nbd.2004.01.017; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hemendinger R, 2005, EXP NEUROL, V196, P235, DOI 10.1016/j.expneurol.2005.07.025; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Herbik MA, 2006, FOLIA NEUROPATHOL, V44, P149; Hitoshi S, 2002, DEVELOPMENT, V129, P233; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Leitner ML, 1999, J NEUROSCI, V19, P9322; Li W, 2007, EXP NEUROL, V203, P457, DOI 10.1016/j.expneurol.2006.08.028; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mohajeri MH, 1999, HUM GENE THER, V10, P1853, DOI 10.1089/10430349950017536; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; NIKKHAH G, 1994, NEUROSCIENCE, V63, P57, DOI 10.1016/0306-4522(94)90007-8; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Ostenfeld T, 2002, DEV BRAIN RES, V134, P43, DOI 10.1016/S0165-3806(01)00291-7; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Perrelet D, 2002, NAT CELL BIOL, V4, P175, DOI 10.1038/ncb751; Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653; Rakowicz WP, 2002, J NEUROSCI, V22, P3953, DOI 10.1523/JNEUROSCI.22-10-03953.2002; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Sagot Y, 1996, J NEUROSCI, V16, P2335; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Suzuki M, 2007, AMYOTROPH LATERAL SC, V8, P20, DOI 10.1080/17482960600982447; Svendsen CN, 2004, NAT MED, V10, P224, DOI 10.1038/nm0304-224; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; van Damme P, 2005, NEURODEGENER DIS, V2, P147, DOI 10.1159/000089620; von Bartheld CS, 2001, MOL NEUROBIOL, V24, P1, DOI 10.1385/MN:24:1-3:001; Watanabe K, 2004, DEV NEUROSCI-BASEL, V26, P275, DOI 10.1159/000082144; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Xu LY, 2006, TRANSPLANTATION, V82, P865, DOI 10.1097/01.tp.0000235532.00920.7a	60	224	232	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e689	10.1371/journal.pone.0000689	http://dx.doi.org/10.1371/journal.pone.0000689			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668067	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452300025
J	Brommer, JE; Kirkpatrick, M; Qvarnstrom, A; Gustafsson, L				Brommer, Jon E.; Kirkpatrick, Mark; Qvarnstrom, Anna; Gustafsson, Lars			The Intersexual Genetic Correlation for Lifetime Fitness in the Wild and Its Implications for Sexual Selection	PLOS ONE			English	Article								Background. The genetic benefits of mate choice are limited by the degree to which male and female fitness are genetically correlated. If the intersexual correlation for fitness is small or negative, choosing a highly fit mate does not necessarily result in high fitness offspring. Methodology/Principal Finding. Using an animal-model approach on data from a pedigreed population of over 7,000 collared flycatchers (Ficedula albicollis), we estimate the intersexual genetic correlation in Lifetime Reproductive Success (LRS) in a natural population to be negative in sign (-0.85 +/- 0.6). Simulations show this estimate to be robust in sign to the effects of extra-pair parentage. The genetic benefits in this population are further limited by a low level of genetic variation for fitness in males. Conclusions/Significance. The potential for indirect sexual selection is nullified by sexual antagonistic fitness effects in this natural population. Our findings and the scarce evidence from other studies suggest that the intersexual genetic correlation for lifetime fitness may be very low in nature. We argue that this form of conflict can, in general, both constrain and maintain sexual selection, depending on the sex-specific additive genetic variances in lifetime fitness.	[Brommer, Jon E.] Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland; [Kirkpatrick, Mark] Univ Texas Austin, Sect Integrat Biol, Austin, TX 78712 USA; [Qvarnstrom, Anna; Gustafsson, Lars] Uppsala Univ, Dept Ecol & Evolut, Uppsala, Sweden	University of Helsinki; University of Texas System; University of Texas Austin; Uppsala University	Brommer, JE (corresponding author), Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland.	jon.brommer@helsinki.fi	Brommer, Jon E/C-3613-2008; Gustafsson, Lars/O-8056-2019; Gustafsson, Lars/A-7634-2012	Brommer, Jon E/0000-0002-2435-2612; Gustafsson, Lars/0000-0001-6566-2863; Gustafsson, Lars/0000-0001-6566-2863; Qvarnstrom, Anna/0000-0002-1178-4053	Academy of Finland (JEB); Swedish Research Council (LG, AQ); NSF [DEB-09973221, EF-0328594]	Academy of Finland (JEB)(Academy of Finland); Swedish Research Council (LG, AQ)(Swedish Research Council); NSF(National Science Foundation (NSF))	This work was financed by the Academy of Finland (JEB), The Swedish Research Council (LG, AQ), and NSF grants DEB-09973221 and EF-0328594 (MK).	Arnqvist Goran, 2005, pUnpaginated; Charmantier A, 2005, MOL ECOL, V14, P2839, DOI 10.1111/j.1365-294X.2005.02619.x; Chippindale AK, 2001, P NATL ACAD SCI USA, V98, P1671, DOI 10.1073/pnas.041378098; Csillery K, 2006, GENETICS, V173, P2091, DOI 10.1534/genetics.106.057331; Eshel I, 2000, EVOL ECOL RES, V2, P509; Fisher R.A., 1958, GENETICAL THEORY NAT; Foerster K, 2007, NATURE, V447, P1107, DOI 10.1038/nature05912; Gibson JR, 2002, P ROY SOC B-BIOL SCI, V269, P499, DOI 10.1098/rspb.2001.1863; Griffith SC, 2002, MOL ECOL, V11, P2195, DOI 10.1046/j.1365-294X.2002.01613.x; Holland B, 1999, P NATL ACAD SCI USA, V96, P5083, DOI 10.1073/pnas.96.9.5083; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; Kirkpatrick M, 2004, EVOLUTION, V58, P683; Kirkpatrick M, 1997, P NATL ACAD SCI USA, V94, P1282, DOI 10.1073/pnas.94.4.1282; Kokko H, 2003, P ROY SOC B-BIOL SCI, V270, P653, DOI 10.1098/rspb.2002.2235; Lynch M., 1998, GENETICS ANAL QUANTI; McCleery RH, 2004, AM NAT, V164, pE62, DOI 10.1086/422660; Merila J, 2000, AM NAT, V155, P301, DOI 10.1086/303330; Pischedda A, 2006, PLOS BIOL, V4, P2099, DOI 10.1371/journal.pbio.0040356; Qvarnstrom A, 2006, NATURE, V441, P84, DOI 10.1038/nature04564; Rice WR, 2000, P NATL ACAD SCI USA, V97, P12953, DOI 10.1073/pnas.97.24.12953; ROBERTSON A, 1966, ANIM PROD, V8, P95, DOI 10.1017/S0003356100037752; Roff D.A., 1997, EVOLUTIONARY QUANTIT; Sheldon BC, 2003, EVOLUTION, V57, P406; Sheldon BC, 1999, ANIM BEHAV, V57, P285, DOI 10.1006/anbe.1998.0968; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	25	97	97	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e744	10.1371/journal.pone.0000744	http://dx.doi.org/10.1371/journal.pone.0000744			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710144	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200021
J	Gardner, A; West, SA; Griffin, AS				Gardner, Andy; West, Stuart A.; Griffin, Ashleigh S.			Is Bacterial Persistence a Social Trait?	PLOS ONE			English	Article							NONINHERITED RESISTANCE; SEED DORMANCY; EVOLUTION; COOPERATION; BISTABILITY; COMPETITION; SURVIVAL; CONFLICT; ALTRUISM; BEHAVIOR	The ability of bacteria to evolve resistance to antibiotics has been much reported in recent years. It is less well-known that within populations of bacteria there are cells which are resistant due to a non-inherited phenotypic switch to a slow-growing state. Although such 'persister' cells are receiving increasing attention, the evolutionary forces involved have been relatively ignored. Persistence has a direct benefit to cells because it allows survival during catastrophes-a form of bet-hedging. However, persistence can also provide an indirect benefit to other individuals, because the reduced growth rate can reduce competition for limiting resources. This raises the possibility that persistence is a social trait, which can be influenced by kin selection. We develop a theoretical model to investigate the social consequences of persistence. We predict that selection for persistence is increased when: (a) cells are related (e. g. a single, clonal lineage); and (b) resources are scarce. Our model allows us to predict how the level of persistence should vary with time, across populations, in response to intervention strategies and the level of competition. More generally, our results clarify the links between persistence and other bet-hedging or social behaviours.	[Gardner, Andy] Univ Oxford, St Johns Coll, Oxford, England; [Gardner, Andy; West, Stuart A.; Griffin, Ashleigh S.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland	University of Oxford; University of Edinburgh	Gardner, A (corresponding author), Univ Oxford, St Johns Coll, Oxford, England.	andy.gardner@ed.ac.uk	West, Stuart A/M-3608-2014; Griffin, Ashleigh/C-6244-2014; Gardner, Andy/K-5353-2013	West, Stuart A/0000-0003-2152-3153; Griffin, Ashleigh/0000-0001-7674-9825; Gardner, Andy/0000-0002-1304-3734	Royal Society	Royal Society(Royal Society of London)	All three authors are supported by Royal Society fellowships.	Avery SV, 2006, NAT REV MICROBIOL, V4, P577, DOI 10.1038/nrmicro1460; Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Bigger JW, 1944, LANCET, V2, P497; COZENS RM, 1986, ANTIMICROB AGENTS CH, V29, P797, DOI 10.1128/AAC.29.5.797; Dubnau D, 2006, MOL MICROBIOL, V61, P564, DOI 10.1111/j.1365-2958.2006.05249.x; EAGLE H, 1949, J EXP MED, V90, P595, DOI 10.1084/jem.90.6.595; ELLNER S, 1986, J THEOR BIOL, V123, P173, DOI 10.1016/S0022-5193(86)80151-5; Finkel SE, 2006, NAT REV MICROBIOL, V4, P113, DOI 10.1038/nrmicro1340; Frank S. A., 1998, FDN SOCIAL EVOLUTION, DOI DOI 10.1515/9780691206820; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; Gardner A, 2006, J EVOLUTION BIOL, V19, P1707, DOI 10.1111/j.1420-9101.2006.01104.x; GODFRAY HCJ, 1987, ECOL ENTOMOL, V12, P251, DOI 10.1111/j.1365-2311.1987.tb01003.x; Graumann PL, 2006, MOL MICROBIOL, V61, P560, DOI 10.1111/j.1365-2958.2006.05264.x; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1970, NATURE, V228, P1218, DOI 10.1038/2281218a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90039-6; Keller L, 2006, NAT REV MICROBIOL, V4, P249, DOI 10.1038/nrmicro1383; Keren I, 2004, FEMS MICROBIOL LETT, V234, P187, DOI 10.1016/j.femsle.2004.03.006; Kolter R, 2006, NATURE, V441, P300, DOI 10.1038/441300a; Kussell E, 2005, GENETICS, V169, P1807, DOI 10.1534/genetics.104.035352; Lee SW, 1944, J BACTERIOL, V48, P393, DOI 10.1128/JB.48.4.393-399.1944; Levin BR, 2004, SCIENCE, V305, P1578, DOI 10.1126/science.1103077; Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445; Lewis K, 2000, MICROBIOL MOL BIOL R, V64, P503, DOI 10.1128/MMBR.64.3.503-514.2000; Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557; Massey RC, 2001, CURR BIOL, V11, P1810, DOI 10.1016/S0960-9822(01)00507-3; Palkova Z, 2004, EMBO REP, V5, P470, DOI 10.1038/sj.embor.7400145; Peters JM, 1999, P ROY SOC B-BIOL SCI, V266, P379, DOI 10.1098/rspb.1999.0648; PHILIPPI T, 1989, TRENDS ECOL EVOL, V4, P41, DOI 10.1016/0169-5347(89)90138-9; Ratnieks FLW, 2006, ANNU REV ENTOMOL, V51, P581, DOI 10.1146/annurev.ento.51.110104.151003; Rees M, 1996, PHILOS T R SOC B, V351, P1299, DOI 10.1098/rstb.1996.0113; Rees M, 2006, AM NAT, V168, pE53, DOI 10.1086/505762; Ringel MS, 1998, J THEOR BIOL, V194, P195, DOI 10.1006/jtbi.1998.0754; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Shapiro JA, 1997, BACTERIA MULTICELLUL; SMITH JM, 1973, NATURE, V246, P15, DOI 10.1038/246015a0; Strassmann JE, 2000, NATURE, V404, P555, DOI 10.1038/35007175; Sufya N, 2003, J APPL MICROBIOL, V95, P1261, DOI 10.1046/j.1365-2672.2003.02079.x; West SA, 2007, J EVOLUTION BIOL, V20, P415, DOI 10.1111/j.1420-9101.2006.01258.x; West SA, 2002, SCIENCE, V296, P72, DOI 10.1126/science.1065507; West SA, 2007, ANNU REV ECOL EVOL S, V38, P53, DOI 10.1146/annurev.ecolsys.38.091206.095740; West SA, 2006, NAT REV MICROBIOL, V4, P597, DOI 10.1038/nrmicro1461; Wingreen NS, 2006, PLOS BIOL, V4, P1486, DOI 10.1371/journal.pbio.0040299; Wiuff C, 2005, ANTIMICROB AGENTS CH, V49, P1483, DOI 10.1128/AAC.49.4.1483-1494.2005	45	65	65	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e752	10.1371/journal.pone.0000752	http://dx.doi.org/10.1371/journal.pone.0000752			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710151	Green Submitted, gold, Green Published			2022-12-25	WOS:000207455200028
J	Weinberger, M; Feng, L; Paul, A; Smith, DL; Hontz, RD; Smith, JS; Vujcic, M; Singh, KK; Huberman, JA; Burhans, WC				Weinberger, Martin; Feng, Li; Paul, Anita; Smith, Daniel L., Jr.; Hontz, Robert D.; Smith, Jeffrey S.; Vujcic, Marija; Singh, Keshav K.; Huberman, Joel A.; Burhans, William C.			DNA Replication Stress Is a Determinant of Chronological Lifespan in Budding Yeast	PLOS ONE			English	Article							DEPENDENT PROTEIN-KINASE; CDK INHIBITOR SIC1; CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; STATIONARY-PHASE; GENOMIC INSTABILITY; MITOCHONDRIAL BIOGENESIS; CHROMOSOME INSTABILITY; CHECKPOINT CONTROLS	The chronological lifespan of eukaryotic organisms is extended by the mutational inactivation of conserved growth-signaling pathways that regulate progression into and through the cell cycle. Here we show that in the budding yeast S. cerevisiae, these and other lifespan-extending conditions, including caloric restriction and osmotic stress, increase the efficiency with which nutrient-depleted cells establish or maintain a cell cycle arrest in G1. Proteins required for efficient G1 arrest and longevity when nutrients are limiting include the DNA replication stress response proteins Mec1 and Rad53. Ectopic expression of CLN3 encoding a G1 cyclin downregulated during nutrient depletion increases the frequency with which nutrient depleted cells arrest growth in S phase instead of G1. Ectopic expression of CLN3 also shortens chronological lifespan in concert with age-dependent increases in genome instability and apoptosis. These findings indicate that replication stress is an important determinant of chronological lifespan in budding yeast. Protection from replication stress by growth-inhibitory effects of caloric restriction, osmotic and other stresses may contribute to hormesis effects on lifespan. Replication stress also likely impacts the longevity of higher eukaryotes, including humans.	[Weinberger, Martin; Feng, Li; Burhans, William C.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Paul, Anita; Huberman, Joel A.] Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA; [Smith, Daniel L., Jr.; Hontz, Robert D.; Smith, Jeffrey S.] Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA USA; [Vujcic, Marija; Singh, Keshav K.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Virginia; Roswell Park Cancer Institute	Burhans, WC (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.	wburhans@buffalo.edu		Smith Jr, Daniel/0000-0002-1602-2023	NCI Cancer Center [P30 CA016056, CA121904, CA113655, GM075240, CA095908, GM070566]; NATIONAL CANCER INSTITUTE [R01CA121904, R01CA095908, R01CA113655, P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075240, R01GM070566] Funding Source: NIH RePORTER	NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported in part by a NCI Cancer Center Support Grant (P30 CA016056) to Roswell Park Cancer Institute, CA121904 and CA113655 to K. K. S., GM075240 to J. S. S., and CA095908 and GM070566 to J. A. H.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Admire A, 2006, GENE DEV, V20, P159, DOI 10.1101/gad.1392506; Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Allen C, 2006, J CELL BIOL, V174, P89, DOI 10.1083/jcb.200604072; Amberg DC., 2005, METHODS YEAST GENETI; Andalis AA, 2004, GENETICS, V167, P1109, DOI 10.1534/genetics.104.029256; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barbe E., 1996, MEDITERR POLIT, V1, P25; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Belli G, 2001, MOL MICROBIOL, V39, P1022, DOI 10.1046/j.1365-2958.2001.02297.x; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Bonawitz ND, 2007, CELL METAB, V5, P265, DOI 10.1016/j.cmet.2007.02.009; Cameroni E, 2004, CELL CYCLE, V3, P462; Carter CD, 2005, MOL CELL BIOL, V25, P10273, DOI 10.1128/MCB.25.23.10273-10285.2005; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Cobb JA, 2005, GENE DEV, V19, P3055, DOI 10.1101/gad.361805; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dohrmann PR, 2006, GENETICS, V174, P87, DOI 10.1534/genetics.106.060236; Escote X, 2004, NAT CELL BIOL, V6, P997, DOI 10.1038/ncb1174; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fabrizio P, 2004, FEBS LETT, V557, P136, DOI 10.1016/S0014-5793(03)01462-5; Fabrizio P, 2003, GENETICS, V163, P35; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Granot D, 2003, FEMS YEAST RES, V4, P7, DOI 10.1016/S1567-1356(03)00154-5; Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378; Gunjan A, 2003, CELL, V115, P537, DOI 10.1016/S0092-8674(03)00896-1; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Hoopes LLM, 2002, MOL CELL BIOL, V22, P4136, DOI 10.1128/MCB.22.12.4136-4146.2002; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; JOHNSTON GC, 1980, MOL GEN GENET, V178, P357, DOI 10.1007/BF00270484; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Khurana V, 2006, CURR BIOL, V16, P230, DOI 10.1016/j.cub.2005.12.042; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lemoine FJ, 2005, CELL, V120, P587, DOI 10.1016/j.cell.2004.12.039; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Longo VD, 2005, NAT REV GENET, V6, DOI 10.1038/nrg1706; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Mai B, 1997, MOL CELL BIOL, V17, P6491, DOI 10.1128/MCB.17.11.6491; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Miwa S, 2004, ANN NY ACAD SCI, V1019, P388, DOI 10.1196/annals.1297.069; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; OGURA M, 1989, P NATL ACAD SCI USA, V86, P5918, DOI 10.1073/pnas.86.15.5918; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Radonjic M, 2005, MOL CELL, V18, P171, DOI 10.1016/j.molcel.2005.03.010; Reinders A, 1998, GENE DEV, V12, P2943, DOI 10.1101/gad.12.18.2943; Roosen J, 2005, MOL MICROBIOL, V55, P862, DOI 10.1111/j.1365-2958.2004.04429.x; Santangelo GM, 2006, MICROBIOL MOL BIOL R, V70, P253, DOI 10.1128/MMBR.70.1.253-282.2006; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; SMITH DL, 2007, AGEING CELL IN PRESS; Swinnen E, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-3; T Burhans D, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-58; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Wang Y, 2004, PLOS BIOL, V2, P610, DOI 10.1371/journal.pbio.0020128; Wanke V, 2005, EMBO J, V24, P4271, DOI 10.1038/sj.emboj.7600889; Weinberger M, 2005, J CELL SCI, V118, P3543, DOI 10.1242/jcs.02477; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000; Zinzalla V, 2007, MOL MICROBIOL, V63, P1482, DOI 10.1111/j.1365-2958.2007.05599.x	88	84	86	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e748	10.1371/journal.pone.0000748	http://dx.doi.org/10.1371/journal.pone.0000748			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710147	Green Submitted, Green Published, gold			2022-12-25	WOS:000207455200024
J	Yoshida, K; Ozaki, T; Furuya, K; Nakanishi, M; Kikuchi, H; Yamamoto, H; Ono, S; Koda, T; Omura, K; Nakagawara, A				Yoshida, K.; Ozaki, T.; Furuya, K.; Nakanishi, M.; Kikuchi, H.; Yamamoto, H.; Ono, S.; Koda, T.; Omura, K.; Nakagawara, A.			ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin	ONCOGENE			English	Article						apoptosis; ATM; cisplatin; IKK; p73; ubiquitination	B-KINASE-ALPHA; MICE LACKING; LIVER DEGENERATION; KAPPA; PHOSPHORYLATION; ACTIVATION; SUBUNIT; SKIN	I kappa B kinase ( IKK) complex plays an important role in the regulation of signaling pathway that activates nuclear factor-kappa-B (NF-kappa B). Recently, we reported that cisplatin ( CDDP) treatment causes a remarkable nuclear accumulation of IKK-alpha in association with stabilization and activation of p73. However, underlying mechanisms of CDDP-induced nuclear accumulation of IKK-alpha are elusive. Here, we found that ataxia-telangiectasia mutated ( ATM) is one of upstream mediators of IKK-alpha during CDDP-induced apoptosis. In response to CDDP, ATM was phosphorylated at Ser-1981, which was accompanied with nuclear accumulation of IKK-alpha in HepG2 cells, whereas CDDP treatment had undetectable effects on IKK-alpha in ATM-deficient cells. Indirect immuno fluorescence experiments demonstrated that phosphorylated form of ATM colocalizes with nuclear IKK-alpha in response to CDDP. In vitro kinase assay indicated that ATM phosphorylates IKK-alpha at Ser-473. Moreover, IKK-alpha-deficient MEFs displayed CDDP-resistant phenotype as compared with wild-type MEFs. Taken together, our present results suggest that ATM-mediated phosphorylation of nuclear IKK-alpha, which stabilizes p73, is one of the main apoptotic pathways in response to CDDP.	[Yoshida, K.; Ozaki, T.; Furuya, K.; Nakanishi, M.; Kikuchi, H.; Yamamoto, H.; Nakagawara, A.] Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Yoshida, K.; Omura, K.] Tokyo Med & Dent Univ, Dept Oral & Maxillofacial Surg, Tokyo, Japan; [Ono, S.; Koda, T.] Hisamitsu Pharmaceut Co Inc, Res Ctr Funct Genom, Chiba, Japan	Chiba Cancer Center; Tokyo Medical & Dental University (TMDU); Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Furuya K, 2007, J BIOL CHEM, V282, P18365, DOI 10.1074/jbc.M610522200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saito H, 2002, GYNECOL OBSTET INVES, V53, P46, DOI 10.1159/000049424; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	21	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1183	1188		10.1038/sj.onc.1210722	http://dx.doi.org/10.1038/sj.onc.1210722			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700524				2022-12-25	WOS:000253136700019
J	Veeck, J; Chorovicer, M; Naami, A; Breuer, E; Zafrakas, M; Bektas, N; Durst, M; Kristiansen, G; Wild, PJ; Hartmann, A; Knuechel, R; Dahl, E				Veeck, J.; Chorovicer, M.; Naami, A.; Breuer, E.; Zafrakas, M.; Bektas, N.; Duerst, M.; Kristiansen, G.; Wild, P. J.; Hartmann, A.; Knuechel, R.; Dahl, E.			The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation	ONCOGENE			English	Article						inter-alpha-trypsin inhibitor heavy chain ( ITIH); breast cancer; prognostic marker; predictive marker; tumour invasion; metastasis	ALPHA-TRYPSIN INHIBITOR; FACTOR-STIMULATED GENE-6; SHAP-HYALURONAN COMPLEX; TUMOR-SUPPRESSOR GENES; DNA METHYLATION; HEAVY-CHAIN; OVARIAN-CANCER; FAMILY; BINDING; TISSUE	Inter-alpha-trypsin inhibitors (ITIs) are protease inhibitors stabilizing the extracellular matrix. ITIs consist of one light (bikunin) and two heavy chains (ITIHs). We have recently characterized ITIH5, a novel member of the ITIH gene family, and showed that its messenger RNA is lost in a high proportion of breast tumours. In the present study, an ITIH5-specific polyclonal antibody was generated, validated with western blot and used for immunohistochemical analysis on a tissue microarray; ITIH5 was strongly expressed in epithelial cells of normal breast (n = 11/15), while it was lost or strongly reduced in 42% (92/217) of invasive breast cancers. ITIH5 expression in invasive carcinomas was associated with positive expression of oestrogen receptor (P = 0.008) and histological grade (P = 0.024). Correlation of ITIH5 expression with clinical outcome revealed that patients with primary tumours retaining abundant ITIH5 expression had longer recurrence-free survival (RFS; P = 0.037) and overall survival (OS; P = 0.044), compared to those with reduced expression (mean RFS: 102 vs 78 months; mean OS: 120 vs 105 months). Methylation-specific PCR analysis frequently showed strong methylation of the ITIH5 promoter in primary breast tumours (41%, n = 109) and breast cancer cell lines (n = 6). Methylation was significantly associated with mRNA loss (P<0.001; n = 39), and ITIH5 expression was induced after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Moreover, ITIH5 promoter methylation was significantly associated with reduced OS (P = 0.008). The cellular function of ITIH5 was evaluated by forced expression of a full-length ITIH5 complementary DNA in the breast cancer cell line MDA-MB-231, which does not endogenously express ITIH5. ITIH5-expressing clones showed a 40% reduced proliferation rate compared to mock-transfected cells. Overall, these data show that promoter methylation-mediated loss of ITIH5 expression is associated with unfavourable outcome in breast cancer patients, and thus ITIH5 could be used as a prognostic marker, although this marker is not multivariate independent due to its close association with ER expression. Our data indicate that ITIH5 is a candidate class II tumour suppressor gene and could be involved in tumour progression, invasion and metastasis, as its absence is associated with increased proliferation rates and a prognostic value indicating poor clinical outcome.	[Veeck, J.; Chorovicer, M.; Naami, A.; Breuer, E.; Zafrakas, M.; Bektas, N.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany; [Duerst, M.] Univ Jena, Dept Gynecol & Obstet, Jena, Germany; [Kristiansen, G.] Univ Med Berlin, Inst Pathol, Berlin, Germany; [Wild, P. J.] Univ Zurich, Inst Pathol, Zurich, Switzerland; [Hartmann, A.] Univ Regensburg, Inst Pathol, Regensburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; University of Regensburg	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	, Zafrakas-M/ABA-8487-2021; Veeck, Jürgen/B-9256-2008	Veeck, Jürgen/0000-0002-2952-6159				Atmani F, 1999, UROL RES, V27, P57, DOI 10.1007/s002400050089; Bachman KE, 1999, CANCER RES, V59, P798; Balduyck M, 2000, J LAB CLIN MED, V135, P188, DOI 10.1067/mlc.2000.104462; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; Bourguignon J, 1999, J HISTOCHEM CYTOCHEM, V47, P1625, DOI 10.1177/002215549904701214; CHEN L, 1994, J BIOL CHEM, V269, P28282; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 1999, CANCER RES, V59, P67; Fujita Y, 2004, J HUM GENET, V49, P24, DOI 10.1007/s10038-003-0101-8; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011; HUANG L, 1993, J BIOL CHEM, V268, P26725; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; Onda H, 1999, J CEREBR BLOOD F MET, V19, P1279, DOI 10.1097/00004647-199911000-00013; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Pineiro M, 2004, INFECT IMMUN, V72, P3777, DOI 10.1128/IAI.72.7.3777-3782.2004; REMMELE W, 1987, PATHOLOGE, V8, P138; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Shao GZ, 2006, CANCER RES, V66, P4566, DOI 10.1158/0008-5472.CAN-05-2130; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	39	64	68	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					865	876		10.1038/sj.onc.1210669	http://dx.doi.org/10.1038/sj.onc.1210669			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653090				2022-12-25	WOS:000252884500016
J	Lee, KC; Goh, WLP; Xu, M; Kua, N; Lunny, D; Wong, JS; Coomber, D; Vojtesek, B; Lane, EB; Lane, DP				Lee, K-C; Goh, W. L. P.; Xu, M.; Kua, N.; Lunny, D.; Wong, J. S.; Coomber, D.; Vojtesek, B.; Lane, E. B.; Lane, D. P.			Detection of the p53 response in zebrafish embryos using new monoclonal antibodies	ONCOGENE			English	Article						zebrafish; p53; monoclonal antibody; immunohistochemistry; p53-activating agents	DANIO-RERIO; MUTANT P53; GENE; EXPRESSION; MUTATIONS; PROTEIN; IDENTIFICATION; ACTIVATION; INDUCTION; NEOPLASIA	The zebrafish has many advantages as a vertebrate model organism and has been extensively used in the studies of development. Its potential as a model in which to study tumour suppressor and oncogene function is now being realized. Whilst in situ hybridization of mRNA has been well developed in this species to study gene expression, antibody probes are in short supply. We have, therefore, generated a panel of anti-zebrafish p53 monoclonal antibodies and used these to study the p53 response in zebrafish embryos. By immunohistochemistry, we show that the exposure of zebrafish embryos to p53-activating agents such as R-roscovitine and c-irradiation results in the accumulation of p53 protein in the gut epithelium, liver and pancreas. A combination of R-roscovitine and gamma-irradiation results in massive p53 induction, not only in the pharyngeal arches, gut region and liver but also in brain tissues. Induction of apoptosis and expression of p53 response genes are seen in regions that correspond to sites of p53 protein accumulation. In contrast, although zebrafish tp53(M214K) mutant embryos showed a similar accumulation of p53 protein, a complete lack of a downstream p53-dependent response was observed. In this system the p53 gene is identified as a p53-responsive gene itself. Our results demonstrate that zebrafish p53 protein can readily be induced in embryos and detected using these new antibody tools, which will increase the usefulness of zebrafish as a model in compound-based screening for novel drugs in cancer research.	[Lee, K-C; Goh, W. L. P.; Xu, M.; Kua, N.; Wong, J. S.; Coomber, D.; Vojtesek, B.; Lane, D. P.] Inst Mol & Cell Biol, Control Pathway Lab P53, Proteos 138673, Singapore; [Lunny, D.; Lane, E. B.] Med Biol Inst, Epithelial Biol Programme, Proteos, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Lane, DP (corresponding author), Inst Mol & Cell Biol, Control Pathway Lab P53, 61 Biopolis Dr, Proteos 138673, Singapore.	d.p.lane@imcb.a-star.edu.sg	Lane, David P/C-4920-2008; Lee, Kian-Chung/AAP-9059-2021	Lane, David/0000-0003-0551-3545				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; BARTEK J, 1990, ONCOGENE, V5, P893; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Cheng R, 1997, MOL MAR BIOL BIOTECH, V6, P88; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1988, ANTIBODIES LAB MANUA, P186; HARLOW E, 1999, USING ANTIBODIES LAB, P395; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jowett T, 1999, METHOD CELL BIOL, V59, P63; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kotala V, 2001, CELL MOL LIFE SCI, V58, P1333, DOI 10.1007/PL00000944; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lu WG, 2001, ONCOGENE, V20, P3206, DOI 10.1038/sj.onc.1204412; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nickels A, 1997, J CLIN PATHOL, V50, P654, DOI 10.1136/jcp.50.8.654; Nusslein-Volhard C., 2002, ZEBRAFISH PRACTICAL; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Spitsbergen Jan M., 2003, Toxicologic Pathology, V31, P62, DOI 10.1080/01926230309774; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P716, DOI 10.1177/019262330002800512; STANTON MF, 1965, JNCI-J NATL CANCER I, V34, P117, DOI 10.1093/jnci/34.1.117; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Sutcliffe JE, 2004, FEBS LETT, V567, P86, DOI 10.1016/j.febslet.2004.03.122; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Zhao L, 2003, MOL CANCER RES, V1, P195	41	56	57	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					629	640		10.1038/sj.onc.1210695	http://dx.doi.org/10.1038/sj.onc.1210695			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684488				2022-12-25	WOS:000252674900007
J	Qahwash, IM; Boire, A; Lanning, J; Pytel, TKP; Meredith, SC				Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.			Site-specific effects of peptide lipidation on beta-Amyloid aggregation and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; EXPERIMENTAL CONSTRAINTS; ALZHEIMERS DEMENTIA; PROTEIN ADDUCTS; OXIDIZED LDL; FIBRILS; DISEASE; INJURY	beta-Amyloid (A beta) aggregates at low concentrations in vivo, and this may involve covalently modified forms of these peptides. Modification of A beta by 4-hydroxynonenal (4-HNE) initially increases the hydrophobicity of these peptides and subsequently leads to additional reactions, such as peptide cross-linking. To model these initial events, without confounding effects of subsequent reactions, we modified A beta at each of its amino groups using a chemically simpler, close analogue of 4-HNE, the octanoyl group: K16-octanoic acid (OA)-A beta, K28-OA-A beta, and N alpha-OA-A beta. Octanoylation of these sites on A beta-(1-40) had strikingly different effects on fibril formation. K16-OA-A beta and K28-OA-A beta, but not N alpha-OA-A beta, had increased propensity to aggregate. The type of aggregate ( electron microscopic appearance) differed with the site of modification. The ability of octanoyl-A beta peptides to cross-seed solutions of A beta was the inverse of their ability to form fibrils on their own (i.e. A approximate to N alpha-OA-A beta >> K16-OA-A beta >> K28-OA-A beta). By CD spectroscopy, K16-OA-A beta and K28-OA-A beta had increased beta-sheet propensity compared with A beta-(1-40) or N alpha-OA-A beta. K16-OA-A beta and K28-OA-A beta were more amphiphilic than A beta-(1-40) or N alpha-OA-A beta, as shown by lower "critical micelle concentrations" and higher monolayer collapse pressures. Finally, K16-OA-A beta and K28-OA-A beta are much more cytotoxic to N2A cells than A beta-(1-40) or N alpha-OA-A beta. The greater cytotoxicity of K16-OA-A beta and K28-OA-A beta may reflect their greater amphiphilicity. We conclude that lipidation can make A beta more prone to aggregation and more cytotoxic, but these effects are highly site-specific.	[Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; [Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.] Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Meredith, SC (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	scmeredi@uchicago.edu	Boire, Adrienne/AAA-3578-2022; Boire, Adrienne/AAJ-9352-2021	Boire, Adrienne/0000-0002-9029-1248; Boire, Adrienne/0000-0002-9029-1248	NINDS NIH HHS [R01 NS042852] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042852] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdi F, 2006, J ALZHEIMERS DIS, V9, P293; Aoyama K, 2006, EUR J NEUROL, V13, P89, DOI 10.1111/j.1468-1331.2006.01139.x; Bieschke J, 2006, ACCOUNTS CHEM RES, V39, P611, DOI 10.1021/ar0500766; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2; Dalfo E, 2005, J NEUROPATH EXP NEUR, V64, P816, DOI 10.1097/01.jnen.0000179050.54522.5a; Ding QX, 2007, CURR ALZHEIMER RES, V4, P73, DOI 10.2174/156720507779939788; Ege C, 2004, BIOPHYS J, V87, P1732, DOI 10.1529/biophysj.104.043265; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FUKUSHIMA D, 1979, J AM CHEM SOC, V101, P3703, DOI 10.1021/ja00507a068; Fukuyama R, 2000, EUR NEUROL, V43, P155, DOI 10.1159/000008156; Gordon DJ, 2004, BIOPHYS J, V86, P428, DOI 10.1016/S0006-3495(04)74119-3; Gustafson DR, 2007, J NEUROL NEUROSUR PS, V78, P461, DOI 10.1136/jnnp.2006.100529; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X; Kheterpal I, 2006, J MOL BIOL, V361, P785, DOI 10.1016/j.jmb.2006.06.066; Koppaka V, 2003, J BIOL CHEM, V278, P36277, DOI 10.1074/jbc.M301334200; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Lewczuk P, 2004, NEUROBIOL AGING, V25, P273, DOI 10.1016/S0197-4580(03)00086-1; LEWCZUK P, 2007, NEUROBIOL AGING; Leyvraz F., 1986, On Growth and Form - Fractal and Non-Fractal Patterns in Physics. Proceedings of the NATO Advanced Study Institute, P136; Li DY, 2005, CARDIOVASC RES, V68, P353, DOI 10.1016/j.cardiores.2005.09.009; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Markesbery WR, 1998, NEUROBIOL AGING, V19, P33, DOI 10.1016/S0197-4580(98)00009-8; MINAKATA H, 1989, J BIOL CHEM, V264, P7907; Murray IVJ, 2007, J BIOL CHEM, V282, P9335, DOI 10.1074/jbc.M608589200; Murray IVJ, 2005, BIOCHEMISTRY-US, V44, P12606, DOI 10.1021/bi050926p; O'Nuallain B, 2006, METHOD ENZYMOL, V413, P34, DOI 10.1016/S0076-6879(06)13003-7; Odetti P, 2000, J NEUROPATH EXP NEUR, V59, P393, DOI 10.1093/jnen/59.5.393; Olkkonen VM, 2004, ANN MED, V36, P562, DOI 10.1080/07853890410018907; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; Pasternack RF, 2000, BIOPHYS J, V79, P550, DOI 10.1016/S0006-3495(00)76316-8; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Qahwash I, 2003, J BIOL CHEM, V278, P23187, DOI 10.1074/jbc.M213298200; Qin ZJ, 2007, J BIOL CHEM, V282, P5862, DOI 10.1074/jbc.M608126200; Raby CA, 1998, J NEUROCHEM, V71, P2505; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Riemenschneider M, 2000, NEUROSCI LETT, V284, P85, DOI 10.1016/S0304-3940(00)00976-9; Salvayre R, 2002, BBA-MOL CELL BIOL L, V1585, P213, DOI 10.1016/S1388-1981(02)00343-8; Sayre LM, 2006, DRUG METAB REV, V38, P651, DOI 10.1080/03602530600959508; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Sciarretta KL, 2006, BIOCHEMISTRY-US, V45, P9485, DOI 10.1021/bi0605585; Sciarretta KL, 2005, BIOCHEMISTRY-US, V44, P6003, DOI 10.1021/bi0474867; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5; SHEN BW, 1973, CIRCULATION, V48, P218; Siegel SJ, 2007, BIOCHEMISTRY-US, V46, P1503, DOI 10.1021/bi061853s; Simonsen AH, 2007, DEMENT GERIATR COGN, V23, P246, DOI 10.1159/000100020; Simpson EP, 2004, NEUROLOGY, V62, P1758, DOI 10.1212/WNL.62.10.1758; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Teunissen CE, 2002, NEUROBIOL AGING, V23, P485, DOI 10.1016/S0197-4580(01)00328-1; Tycko R, 2006, Q REV BIOPHYS, V39, P1, DOI 10.1017/S0033583506004173; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; VANGOOL WA, 1994, NEUROSCI LETT, V172, P122, DOI 10.1016/0304-3940(94)90677-7; Whittemore NA, 2005, BIOCHEMISTRY-US, V44, P4434, DOI 10.1021/bi048292u; Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6; Yamashita T, 2000, J NEUROL SCI, V175, P107, DOI 10.1016/S0022-510X(00)00296-3; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101; Zhang XC, 1996, J BIOCHEM BIOPH METH, V31, P145, DOI 10.1016/0165-022X(95)00032-M; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200	74	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2007	282	51					36987	36997		10.1074/jbc.M702146200	http://dx.doi.org/10.1074/jbc.M702146200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241GX	17693400	hybrid			2022-12-25	WOS:000251646000025
J	Leuner, K; Kazanski, V; Muller, M; Essin, K; Henke, B; Gollasch, M; Harteneck, C; Muller, WE				Leuner, Kristina; Kazanski, Victor; Mueller, Margarethe; Essin, Kirill; Henke, Bettina; Gollasch, Maik; Harteneck, Christian; Mueller, Walter E.			Hyperforin - a key constituent of St. John's wort specifically activates TRPC6 channels	FASEB JOURNAL			English	Article						calcium; neurite outgrowth	NONSELECTIVE CATION CHANNELS; NERVE GROWTH CONES; DOUBLE-BLIND; PC12 CELLS; MAJOR DEPRESSION; EXTRACT WS-5570; BRAIN; EFFICACY; MOUSE; TRIAL	Hyperforin, a bicyclic polyprenylated acylphloroglucinol derivative, is the main active principle of St. John's wort extract responsible for its antidepressive profile. Hyperforin inhibits the neuronal serotonin and norepinephrine uptake comparable to synthetic antidepressants. In contrast to synthetic antidepressants directly blocking neuronal amine uptake, hyperforin increases synaptic serotonin and norepinephrine concentrations by an indirect and yet unknown mechanism. Our attempts to identify the molecular target of hyperforin resulted in the identification of TRPC6. Hyperforin induced sodium and calcium entry as well as currents in TRPC6-expressing cells. Sodium currents and the subsequent breakdown of the membrane sodium gradients may be the rationale for the inhibition of neuronal amine uptake. The hyper-forin-induced cation entry was highly specific and related to TRPC6 and was suppressed in cells expressing a dominant negative mutant of TRPC6, whereas phylogenetically related channels, i. e., TRPC3 remained unaffected. Furthermore, hyperforin induces neuronal axonal sprouting like nerve growth factor in a TRPC6-dependent manner. These findings support the role of TRPC channels in neurite extension and identify hyperforin as the first selective pharmacological tool to study TRPC6 function. Hyperforin integrates inhibition of neurotransmitter uptake and neurotrophic property by specific activation of TRPC6 and represents an interesting lead-structure for a new class of antidepressants. -Leuner, K., Kazanski, V., Muller, M., Essin, K., Henke, B., Gollasch, M., Harteneck, C., Muller, W. E. Hyperforin -a key constituent of St. John's wort specifically activates TRPC6 channels.	Pharmakol Inst Naturwissenschaftler, Bioctr Niederursel, Frankfurt, Germany; Univ Berlin, Mol Pharmakol & Zellbiol, Berlin, Germany; Charite, Franz Volhard Clin, Max Delbruck Ctr, Sect Nephrol Intens Care, Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Leuner, K (corresponding author), Pharmakol Inst Naturwissenschaftler, Max-von-Laue-Strasse 9, D-60438 Frankfurt, Germany.	pharmacolnat@em.uni-frankfurt.de	Friedland, Kristina/G-4651-2015	Friedland, Kristina/0000-0001-8603-5957; Muller, Werner E.G./0000-0002-8223-3689				Biber A, 1998, PHARMACOPSYCHIATRY, V31, P36, DOI 10.1055/s-2007-979344; Caraveo G, 2006, SCIENCE, V314, P122, DOI 10.1126/science.1127815; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; Harteneck C, 2005, N-S ARCH PHARMACOL, V371, pR54; Harteneck C, 2005, N-S ARCH PHARMACOL, V371, P307, DOI 10.1007/s00210-005-1034-x; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kasper S, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-14; Keller JH, 2003, ANAL CHEM, V75, P6084, DOI 10.1021/ac034520z; KIM JY, 2006, J BIOL CHEM, V314, P122; Kraft R, 2005, PFLUG ARCH EUR J PHY, V451, P204, DOI 10.1007/s00424-005-1428-0; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; KWAN CY, 1990, J BIOL CHEM, V265, P678; Large WA, 2002, J CARDIOVASC ELECTR, V13, P493, DOI 10.1046/j.1540-8167.2002.00493.x; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Linde K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000448.pub3; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Muller WE, 2003, PHARMACOL RES, V47, P101, DOI 10.1016/S1043-6618(02)00266-9; Mwanjewe J, 2004, BIOCHEM J, V378, P975, DOI 10.1042/BJ20031187; Ohta T, 2004, NEUROSCI LETT, V358, P161, DOI 10.1016/j.neulet.2004.01.028; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Singer A, 1999, J PHARMACOL EXP THER, V290, P1363; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Szegedi A, 2005, BMJ-BRIT MED J, V330, P503, DOI 10.1136/bmj.38356.655266.82; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Treiber K, 2005, BRIT J PHARMACOL, V145, P75, DOI 10.1038/sj.bjp.0706155; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Wang GX, 2005, NATURE, V434, P898, DOI 10.1038/nature03478; Williams John W Jr, 2005, BMJ, V330, pE350, DOI 10.1136/bmj.330.7500.E350; Wonnemann M, 2000, NEUROPSYCHOPHARMACOL, V23, P188, DOI 10.1016/S0893-133X(00)00102-0	39	184	190	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4101	4111		10.1096/fj.07-8110com	http://dx.doi.org/10.1096/fj.07-8110com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17666455				2022-12-25	WOS:000251283500035
J	Simoes, I; Faro, R; Bur, D; Faro, C				Simoes, Isaura; Faro, Rosario; Bur, Daniel; Faro, Carlos			Characterization of recombinant CDR1, an Arabidopsis aspartic proteinase involved in disease resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; SIGNALING PATHWAYS; CRYSTAL-STRUCTURE; HUMAN RENIN; CATHEPSIN-E; TOBACCO; ZINC; SPECIFICITY	The Arabidopsis thaliana constitutive disease resistance 1 (CDR1) gene product is an aspartic proteinase that has been implicated in disease resistance signaling (Xia, Y., Suzuki, H., Borevitz, J., Blount, J., Guo, Z., Patel, K., Dixon, R. A., and Lamb, C. (2004) EMBO J. 23, 980-988). This apoplastic enzyme is a member of the group of "atypical" plant aspartic proteinases. As for other enzymes of this subtype, CDR1 has remained elusive until recently as a result of its unusual properties and localization. Here we report on the heterologous expression and characterization of recombinant CDR1, which displays unique enzymatic properties among plant aspartic proteinases. The highly restricted specificity requirements, insensitivity toward the typical aspartic proteinase inhibitor pepstatin A, an unusually high optimal pH of 6.0-6.5, proteinase activity without irreversible prosegment removal, and dependence of catalytic activity on formation of a homo-dimer are some of the unusual properties observed for recombinant CDR1. These findings unveil a pattern of unprecedented functional complexity for Arabidopsis CDR1 and are consistent with a highly specific and regulated biological function.	Univ Coimbra, Ctr Neurosci & Biol Celular, Dept Mol Biol & Biotechnol, P-3000 Coimbra, Portugal; Actel Pharmaceut Ltd, CH-4123 Allschwil, Switzerland	Universidade de Coimbra; Actelion Pharmaceuticals Ltd	Faro, C (corresponding author), Univ Coimbra, Ctr Neurosci & Biol Celular, Dept Mol Biol & Biotechnol, Apt 3126, P-3000 Coimbra, Portugal.	cfaro@imagem.ibili.uc.pt	Simões, Isaura/N-4210-2019; Simões, Isaura I G/F-3239-2010	Simões, Isaura/0000-0002-9331-6340; Simões, Isaura I G/0000-0002-9331-6340; Faro, Carlos/0000-0002-0480-8379				Athauda SBP, 2004, BIOCHEM J, V381, P295, DOI 10.1042/BJ20031575; Beers EP, 2004, PHYTOCHEMISTRY, V65, P43, DOI 10.1016/j.phytochem.2003.09.005; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bi XZ, 2005, PLANT CELL PHYSIOL, V46, P87, DOI 10.1093/pcp/pci002; Castanheira P, 2005, J BIOL CHEM, V280, P13047, DOI 10.1074/jbc.M412076200; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; Durrant WE, 2004, ANNU REV PHYTOPATHOL, V42, P185, DOI 10.1146/annurev.phyto.42.040803.140421; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; EVANS DB, 1990, BIOTECHNOL APPL BIOC, V12, P161; Faro C, 2005, CURR PROTEIN PEPT SC, V6, P493, DOI 10.2174/138920305774933268; Fobert PR, 2005, CURR OPIN PLANT BIOL, V8, P378, DOI 10.1016/j.pbi.2005.05.003; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; Foyer CH, 2005, PLANT CELL, V17, P1866, DOI 10.1105/tpc.105.033589; Ge XC, 2005, EMBO REP, V6, P282, DOI 10.1038/sj.embor.7400357; Gerber PR, 1998, J COMPUT AID MOL DES, V12, P37, DOI 10.1023/A:1007902804814; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Kato Y, 2005, PLANTA, V222, P643, DOI 10.1007/s00425-005-0011-4; Kato Y, 2004, PLANTA, V220, P97, DOI 10.1007/s00425-004-1328-0; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Maldonado AM, 2002, NATURE, V419, P399, DOI 10.1038/nature00962; Maret W, 2005, J TRACE ELEM MED BIO, V19, P7, DOI 10.1016/j.jtemb.2005.02.003; Maret W, 2004, BIOCHEMISTRY-US, V43, P3301, DOI 10.1021/bi036340p; Murakami S, 2000, FEBS LETT, V468, P15, DOI 10.1016/S0014-5793(00)01186-8; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; Ostermann N, 2004, J MOL BIOL, V342, P889, DOI 10.1016/j.jmb.2004.07.073; Pieterse CM, 2004, CURR OPIN PLANT BIOL, V7, P456, DOI 10.1016/j.pbi.2004.05.006; PITARRESI TM, 1992, J BIOL CHEM, V267, P11753; Simoes I, 2004, EUR J BIOCHEM, V271, P2067, DOI 10.1111/j.1432-1033.2004.04136.x; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SLATER EE, 1981, J BIOL CHEM, V256, P8164; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Xia YJ, 2004, EMBO J, V23, P980, DOI 10.1038/sj.emboj.7600086; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	39	44	46	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31358	31365		10.1074/jbc.M702477200	http://dx.doi.org/10.1074/jbc.M702477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17650510	hybrid			2022-12-25	WOS:000250309200025
J	Lengyel, CSE; Willis, LJ; Mann, P; Baker, D; Kortemme, T; Strong, RK; McFarland, BJ				Lengyel, Candice S. E.; Willis, Lindsey J.; Mann, Patrick; Baker, David; Kortemme, Tanja; Strong, Roland K.; McFarland, Benjamin J.			Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING IMMUNORECEPTOR NKG2D; PROTEIN COMPLEXES; CRYSTAL-STRUCTURE; RATIONAL DESIGN; T-CELLS; BINDING; RECOGNITION; ANTIGEN; LIGAND; MICA	MICA is a major histocompatibility complex-like protein that undergoes a structural transition from disorder to order upon binding its immunoreceptor, NKG2D. We redesigned the disordered region of MICA with RosettaDesign to increase NKG2D binding. Mutations that stabilize this region were expected to increase association kinetics without changing dissociation kinetics, increase affinity of interaction, and reduce entropy loss upon binding. MICA mutants were stable in solution, and they were amenable to surface plasmon resonance evaluation of NKG2D binding kinetics and thermodynamics. Several MICA mutants bound NKG2D with enhanced affinity, kinetic changes were primarily observed during association, and thermodynamic changes in entropy were as expected. However, none of the 15 combinations of mutations predicted to stabilize the receptor-bound MICA conformation enhanced NKG2D affinity, whereas all 10 mutants predicted to be destabilized bound NKG2D with increased on-rates. Five of these had affinities enhanced by 0.9-1.8 kcal/ mol over wild type by one to three non-contacting substitutions. Therefore, in this case, mutations designed to mildly destabilize a protein enhanced association and affinity.	Seattle Pacific Univ, Dept Chem & Biochem, Seattle, WA 98119 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Fred Hutchinson Cancer Center	McFarland, BJ (corresponding author), 3307 3rd Ave W,Suite 205, Seattle, WA 98119 USA.	bjm@spu.edu	Baker, David/K-8941-2012; Kortemme, Tanja/AAN-3180-2021	Baker, David/0000-0001-7896-6217; Kortemme, Tanja/0000-0002-8494-680X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI058972] Funding Source: NIH RePORTER; NIAID NIH HHS [R15 AI058972-01, R15 AI058972-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Avbelj F, 2000, P NATL ACAD SCI USA, V97, P10786, DOI 10.1073/pnas.200343197; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; CALHOUN D B, 1986, Proteins Structure Function and Genetics, V1, P109, DOI 10.1002/prot.340010202; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1533, DOI 10.1021/bi00276a003; Clark LA, 2006, PROTEIN SCI, V15, P949, DOI 10.1110/ps.052030506; Dantas G, 2003, J MOL BIOL, V332, P449, DOI 10.1016/S0022-2836(03)00888-X; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Holmes MA, 2002, J IMMUNOL, V169, P1395, DOI 10.4049/jimmunol.169.3.1395; Horn JR, 2006, BIOCHEMISTRY-US, V45, P8488, DOI 10.1021/bi0604328; Keeble AH, 2006, BIOCHEMISTRY-US, V45, P3243, DOI 10.1021/bi052373o; Kiel C, 2004, P NATL ACAD SCI USA, V101, P9223, DOI 10.1073/pnas.0401160101; Kortemme T, 2003, J MOL BIOL, V326, P1239, DOI 10.1016/S0022-2836(03)00021-4; Krishnamurthy VM, 2006, J AM CHEM SOC, V128, P5802, DOI 10.1021/ja060070r; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Li YL, 2001, BIOCHEMISTRY-US, V40, P2011, DOI 10.1021/bi0014148; Lipschultz CA, 2002, J MOL RECOGNIT, V15, P44, DOI 10.1002/jmr.559; Lipschultz CA, 2000, METHODS, V20, P310, DOI 10.1006/meth.1999.0924; McFarland BJ, 2003, IMMUNITY, V19, P803, DOI 10.1016/S1074-7613(03)00320-0; McFarland BJ, 2003, STRUCTURE, V11, P411, DOI 10.1016/S0969-2126(03)00047-9; Miley MJ, 2004, J EXP MED, V200, P1445, DOI 10.1084/jem.20040217; Natarajan K, 2006, J MOL BIOL, V358, P157, DOI 10.1016/j.jmb.2006.01.068; Reichmann D, 2007, J MOL BIOL, V365, P663, DOI 10.1016/j.jmb.2006.09.076; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Song G, 2006, J BIOL CHEM, V281, P5042, DOI 10.1074/jbc.M510454200; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325	33	23	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30658	30666		10.1074/jbc.M704513200	http://dx.doi.org/10.1074/jbc.M704513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690100	hybrid			2022-12-25	WOS:000250136300033
J	Kitayama, K; Hayashida, Y; Nishida, K; Akama, TO				Kitayama, Kazuko; Hayashida, Yasutaka; Nishida, Kohji; Akama, Tomoya O.			Enzymes responsible for synthesis of corneal keratan sulfate glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDES; DYSTROPHY; GLYCOSYLATION; PROTEOGLYCAN; LUMICAN; CLONING; FAMILY; CELLS	Keratan sulfate glycosaminoglycans are among the most abundant carbohydrate components of the cornea and are suggested to play an important role in maintaining corneal extracellular matrix structure. Keratan sulfate carbohydrate chains consist of repeating N-acetyllactosamine disaccharides with sulfation on the 6-O positions of N-acetylglucosamine and galactose. Despite its importance for corneal function, the biosynthetic pathway of the carbohydrate chain and particularly the elongation steps are poorly understood. Here we analyzed enzymatic activity of two glycosyltransferases, beta 1,3-N-acetylglucosaminyltansferase-7 (beta 3GnT7) and beta 1,4-galactosyltransferase-4 (beta 4GalT4), in the production of keratan sulfate carbohydrate in vitro. These glycosyltransferases produced only short, elongated carbohydrates when they were reacted with substrate in the absence of a carbohydrate sulfotransferase; however, they produced extended GlcNAc-sulfated poly-N-acetyllactosamine structures with more than four repeats of the GlcNAc-sulfated N-acetyllactosamine unit in the presence of corneal N-acetylglucosamine 6-O sulfotransferase (CGn6ST). Moreover, we detected production of highly sulfated keratan sulfate by a two-step reaction in vitro with a mixture of beta 3GnT7/beta 4GalT4/CGn6ST followed by keratan sulfate galactose 6-O sulfotransferase treatment. We also observed that production of highly sulfated keratan sulfate in cultured human corneal epithelial cells was dramatically reduced when expression of beta 3GnT7 or beta 4GalT4 was suppressed by small interfering RNAs, indicating that these glycosyltransferases are responsible for elongation of the keratan sulfate carbohydrate backbone.	Burnham Inst Med Res, Glycobiol Program, La Jolla, CA 92037 USA; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan	Sanford Burnham Prebys Medical Discovery Institute; Osaka University	Akama, TO (corresponding author), Burnham Inst Med Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takama@burnham.org		Nishida, Kohji/0000-0001-9069-3610; Kitayama, Kazuko/0000-0003-2829-762X	NATIONAL EYE INSTITUTE [R01EY014620] Funding Source: NIH RePORTER; NEI NIH HHS [EY014620] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2002, J BIOL CHEM, V277, P42505, DOI 10.1074/jbc.M207412200; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; Connon CJ, 2004, EXP EYE RES, V78, P909, DOI 10.1016/j.exer.2004.01.005; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; DOANE KJ, 1992, EXP CELL RES, V202, P113, DOI 10.1016/0014-4827(92)90410-A; EDWARD DP, 1990, OPHTHALMOLOGY, V97, P1194; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; Funderburgh JL, 2002, IUBMB LIFE, V54, P187, DOI 10.1080/15216540214932; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; Greiling H, 1994, EXS, V70, P101; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; Hayashida Y, 2006, P NATL ACAD SCI USA, V103, P13333, DOI 10.1073/pnas.0605441103; Kataoka K, 2002, BIOCHEM BIOPH RES CO, V294, P843, DOI 10.1016/S0006-291X(02)00553-3; Klintworth GK, 2003, FRONT BIOSCI-LANDMRK, V8, pD687, DOI 10.2741/1018; KRESSE H, 1981, J BIOL CHEM, V256, P2926; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Musselmann K, 2006, EXP EYE RES, V83, P707, DOI 10.1016/j.exer.2005.11.020; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Seko A, 2004, FEBS LETT, V556, P216, DOI 10.1016/S0014-5793(03)01440-6; Seko A, 2003, J BIOL CHEM, V278, P9150, DOI 10.1074/jbc.M211480200; Tai GH, 1997, J BIOL CHEM, V272, P28227, DOI 10.1074/jbc.272.45.28227; TAI GH, 1993, BIOCHEM J, V291, P889, DOI 10.1042/bj2910889; THONAR EJMA, 1985, ARTHRITIS RHEUM, V28, P1367, DOI 10.1002/art.1780281209; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; YANG CJ, 1988, AM J OPHTHALMOL, V106, P65, DOI 10.1016/S0002-9394(14)76390-1	34	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30085	30096		10.1074/jbc.M703695200	http://dx.doi.org/10.1074/jbc.M703695200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17690104	hybrid			2022-12-25	WOS:000249981200039
J	Kotsyfakis, M; Karim, S; Andersen, JF; Mather, TN; Ribeiro, JMC				Kotsyfakis, Michalis; Karim, Shahid; Andersen, John F.; Mather, Thomas N.; Ribeiro, Jose M. C.			Selective cysteine protease inhibition contributes to blood-feeding success of the tick Ixodes scapularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGEN TRANSMISSION; CATHEPSIN-S; CYSTATIN; PROTEINASES; IMMUNITY; DISRUPTION; SIALOME	Ixodes scapularis is the main vector of Lyme disease in the eastern and central United States. Tick salivary secretion has been shown as important for both blood-meal completion and pathogen transmission. Here we report a duplication event of cystatin genes in its genome that results in a transcription-regulated boost of saliva inhibitory activity against a conserved and relatively limited number of vertebrate papain-like cysteine proteases during blood feeding. We further show that the polypeptide products of the two genes differ in their binding affinity for some enzyme targets, and they display different antigenicity. Moreover, our reverse genetic approach employing RNA interference uncovered a crucial mediation in tick-feeding success. Given the role of the targeted enzymes in vertebrate immunity, we also show that host immunomodulation is implicated in the deleterious phenotype of silenced ticks making I. scapularis cystatins attractive targets for development of antitick vaccines.	NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; Univ Rhode Isl, Ctr Vector Borne Dis, Kingston, RI 02881 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Rhode Island	Ribeiro, JMC (corresponding author), NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.	jribeiro@niaid.nih.gov	Kotsyfakis, Michail/G-9525-2014	Kotsyfakis, Michail/0000-0002-7526-1876; Karim, Shahid/0000-0001-5596-3304; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000810, R01AI037230, Z01AI001012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [5R01AI037230] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson JF, 2002, MED CLIN N AM, V86, P205, DOI 10.1016/S0025-7125(03)00083-X; Bjork I, 1996, BIOCHEMISTRY-US, V35, P10720, DOI 10.1021/bi960420u; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Estrada-Pena A, 1999, EXP APPL ACAROL, V23, P685, DOI 10.1023/A:1006241108739; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Grunclova L, 2006, BIOL CHEM, V387, P1635, DOI 10.1515/BC.2006.204; Hsing LC, 2005, IMMUNOL REV, V207, P229, DOI 10.1111/j.0105-2896.2005.00310.x; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Karim S, 2005, BIOCHEM BIOPH RES CO, V334, P1336, DOI 10.1016/j.bbrc.2005.07.036; Kotsyfakis M, 2006, J BIOL CHEM, V281, P26298, DOI 10.1074/jbc.M513010200; Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41; Narasimhan S, 2004, P NATL ACAD SCI USA, V101, P1141, DOI 10.1073/pnas.0307669100; Pedra JHF, 2006, AM J TROP MED HYG, V75, P677, DOI 10.4269/ajtmh.2006.75.677; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; SCHORDERET S, 1993, MED VET ENTOMOL, V7, P186, DOI 10.1111/j.1365-2915.1993.tb00673.x; Serveau-Avesque C, 2006, BIOL CELL, V98, P15, DOI 10.1042/BC20040512; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4; Wikel SK, 1999, INT J PARASITOL, V29, P851, DOI 10.1016/S0020-7519(99)00042-9; Wikel SK, 1997, PARASITOL TODAY, V13, P383, DOI 10.1016/S0169-4758(97)01126-5; Zavasnik-Bergant T, 2006, TISSUE ANTIGENS, V67, P349, DOI 10.1111/j.1399-0039.2006.00585.x; Zhou JL, 2006, INSECT BIOCHEM MOLEC, V36, P527, DOI 10.1016/j.ibmb.2006.03.003	28	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29256	29263		10.1074/jbc.M703143200	http://dx.doi.org/10.1074/jbc.M703143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698852	Green Published, hybrid			2022-12-25	WOS:000249788000022
J	Firulli, BA; Redick, BA; Conway, SJ; Firulli, AB				Firulli, Beth A.; Redick, Bradley A.; Conway, Simon J.; Firulli, Anthony B.			Mutations within helix I of twist1 result in distinct limb defects and variation of DNA binding affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH PROTEIN; TRANSCRIPTION; DIMERIZATION; IDENTIFICATION; DHAND; EXPRESSION; PARTNERS; HAND2; BUD	Twist1 is a basic helix-loop-helix ( bHLH) factor that plays an important role in limb development. Haploinsufficiency of Twist1 results in polydactyly via the inability of Twist1 to antagonistically regulate the related factor Hand2. The mechanism modulating Twist1-Hand2 antagonism is via phosphoregulation of conserved threonine and serine residues in helix I of the bHLH domain. Phosphoregulation alters the dimerization affinities for both proteins. Here we show that the expression of Twist1 and Twist1 phosphoregulation mutants results in distinct limb phenotypes in mice. In addition to dimer regulation, Twist1 phosphoregulation affects the DNA binding affinities of Twist1 in a partner-dependent and cis-element-dependent manner. In order to gain a better understanding of the specific Twist1 transcriptional complexes that function during limb morphogensis, we employ a series of Twist1-tethered dimers that include the known Twist1 partners, E12 and Hand2, as well as a tethered Twist1 homodimer. We show that these dimers behave in a manner similar to monomerically expressed bHLH factors and result in distinct limb phenotypes that correlate well with those observed from the limb expression of Twist1 and Twist1 phosphoregulation mutants. Taken together, this study shows that the Twist1 dimer affinity for a given partner can modulate the DNA binding affinity and that Twist1 dimer choice determines phenotypic outcome during limb development.	Indiana Med Sch, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Div Cardiol,Dept Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children	Firulli, AB (corresponding author), Indiana Med Sch, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Div Cardiol,Dept Pediat, 1044 W Walnut,R4 371, Indianapolis, IN 46202 USA.	tfirulli@iupui.edu		/0000-0001-6687-8949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085098, R01HL061677] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL085098-029002, P01 HL085098, R01 HL061677, P01 HL085098-01A10001, R01 HL061677-09, 2R01 HI 061677-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cai JL, 2005, BIOESSAYS, V27, P1102, DOI 10.1002/bies.20313; Castanon I, 2001, DEVELOPMENT, V128, P3145; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dickman ED, 1999, ANAT REC, V255, P353, DOI 10.1002/(SICI)1097-0185(19990701)255:3<353::AID-AR11>3.0.CO;2-H; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Firulli AB, 2003, GENE, V312, P27, DOI 10.1016/S0378-1119(03)00669-3; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Firulli Beth A., 2004, Biol Proced Online, V6, P16, DOI 10.1251/bpo69; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hornik C, 2004, ANAT EMBRYOL, V209, P31, DOI 10.1007/s00429-004-0412-3; Hu D, 2006, DEV BIOL, V295, P369, DOI 10.1016/j.ydbio.2006.04.134; Jabs Ethylin Wang, 2004, P401; Knofler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264-6021:3610641; Martin JF, 2000, GENESIS, V26, P225, DOI 10.1002/(SICI)1526-968X(200004)26:4<225::AID-GENE10>3.0.CO;2-F; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2002, DEVELOPMENT, V129, P3077; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; O'Rourke MP, 2002, INT J DEV BIOL, V46, P401; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Tavares AT, 2001, INT J DEV BIOL, V45, P707; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; Zuniga A, 2002, MECH DEVELOP, V114, P51, DOI 10.1016/S0925-4773(02)00048-5	24	68	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27536	27546		10.1074/jbc.M702613200	http://dx.doi.org/10.1074/jbc.M702613200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652084	Green Accepted, hybrid			2022-12-25	WOS:000249304900094
J	Franke, A; Hampe, J; Rosenstiel, P; Becker, C; Wagner, F; Hasler, R; Little, RD; Huse, K; Ruether, A; Balschun, T; Wittig, M; ElSharawy, A; Mayr, G; Albrecht, M; Prescott, NJ; Onnie, CM; Fournier, H; Keith, T; Radelof, U; Platzer, M; Mathew, CG; Stoll, M; Krawczak, M; Nurnberg, P; Schreiber, S				Franke, Andre; Hampe, Jochen; Rosenstiel, Philip; Becker, Christian; Wagner, Florian; Haesler, Robert; Little, Randall D.; Huse, Klaus; Ruether, Andreas; Balschun, Tobias; Wittig, Michael; ElSharawy, Abdou; Mayr, Gabriele; Albrecht, Mario; Prescott, Natalie J.; Onnie, Clive M.; Fournier, Helene; Keith, Tim; Radelof, Uwe; Platzer, Matthias; Mathew, Christopher G.; Stoll, Monika; Krawczak, Michael; Nuernberg, Peter; Schreiber, Stefan			Systematic Association Mapping Identifies NELL1 as a Novel IBD Disease Gene	PLOS ONE			English	Article								Crohn disease (CD), a sub-entity of inflammatory bowel disease (IBD), is a complex polygenic disorder. Although recent studies have successfully identified CD-associated genetic variants, these susceptibility loci explain only a fraction of the heritability of the disease. Here, we report on a multi-stage genome-wide scan of 393 German CD cases and 399 controls. Among the 116,161 single-nucleotide polymorphisms tested, an association with the known CD susceptibility gene NOD2, the 5q31 haplotype, and the recently reported CD locus at 5p13.1 was confirmed. In addition, SNP rs1793004 in the gene encoding nel-like 1 precursor (NELL1, chromosome 11p15.1) showed a consistent disease-association in independent German population- and family-based samples (942 cases, 1082 controls, 375 trios). Subsequent fine mapping and replication in an independent sample of 454 French/Canadian CD trios supported the authenticity of the NELL1 association. Further confirmation in a large German ulcerative colitis (UC) sample indicated that NELL1 is a ubiquitous IBD susceptibility locus (combined p < 10(-6); OR = 1.66, 95% CI: 1.30-2.11). The novel 5p13.1 locus was also replicated in the French/Canadian sample and in an independent UK CD patient panel (453 cases, 521 controls, combined p < 10(-6) for SNP rs1992660). Several associations were replicated in at least one independent sample, point to an involvement of ITGB6 (upstream), GRM8 (downstream), OR5V1 (downstream), PPP3R2 (downstream), NM_ 152575(upstream) and HNF4G (intron).	[Franke, Andre; Rosenstiel, Philip; Haesler, Robert; ElSharawy, Abdou; Schreiber, Stefan] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Hampe, Jochen; Schreiber, Stefan] Univ Hosp Schleswig Holstein, Dept Med 1, Kiel, Germany; [Becker, Christian; Nuernberg, Peter] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Becker, Christian; Wagner, Florian; Radelof, Uwe] RZPD German Resource Ctr Genome Res, Berlin, Germany; [Little, Randall D.; Keith, Tim] Genizon BioSciences5, Quebec City, PQ, Canada; [Huse, Klaus] Leibniz Inst Age Res, Genome Anal Grp, Jena, Germany; [Ruether, Andreas; Wittig, Michael; Krawczak, Michael; Schreiber, Stefan] Univ Kiel, PopGen Biobank, Kiel, Germany; [Mayr, Gabriele; Albrecht, Mario] Max Planck Inst Informat, Saarbrucken, Germany; [Prescott, Natalie J.; Onnie, Clive M.; Mathew, Christopher G.] Kings Coll London, Sch Med, Dept Med & Mol Genet, London WC2R 2LS, England; [Stoll, Monika] Univ Munster, Leibniz Inst Arteriosclerosis Res, Munster, Germany; [Krawczak, Michael] Univ Kiel, Inst Med Stat & Informat, Kiel, Germany; [Nuernberg, Peter] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Cologne; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); University of Kiel; Max Planck Society; University of London; King's College London; University of Munster; University of Kiel; University of Cologne	Schreiber, S (corresponding author), Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.	s.schreiber@mucosa.de	Prescott, Natalie J/F-6490-2011; Elsharawy, Abdou/C-9848-2010; Häsler, Robert/A-4908-2009; Krawczak, Michael/A-8964-2010; Hampe, Jochen/A-2555-2010; Franke, Andre/B-2151-2010; Mathew, Christopher G/G-3434-2015; Little, Randall/O-7172-2014; Balschun, Tobias/B-2356-2010; Albrecht, Mario/B-6694-2008; Rosenstiel, Philip/A-5137-2009	Prescott, Natalie J/0000-0002-5901-7371; Häsler, Robert/0000-0003-4174-8229; Krawczak, Michael/0000-0003-2603-1502; Hampe, Jochen/0000-0002-2421-6127; Franke, Andre/0000-0003-1530-5811; Mathew, Christopher G/0000-0003-4178-1838; Albrecht, Mario/0000-0002-3103-9624; Rosenstiel, Philip/0000-0002-9692-8828; Huse, Klaus/0000-0003-3854-1884; Elsharawy, Abdou/0000-0002-5089-9435	Medical Research Council [G0000934] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0000934] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABITBOL V, 1995, GASTROENTEROLOGY, V108, P417, DOI 10.1016/0016-5085(95)90068-3; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801; Biank V, 2007, AM J GASTROENTEROL, V102, P391, DOI 10.1111/j.1572-0241.2006.01011.x; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653; COMPSTON JE, 1987, GUT, V28, P410, DOI 10.1136/gut.28.4.410; Croucher PJP, 2003, EUR J HUM GENET, V11, P6, DOI 10.1038/sj.ejhg.5200897; CUMMINGS JRF, 2007, INFLAMM BOWEL DIS; Daly MJ, 2005, EUR J HUM GENET, V13, P835, DOI 10.1038/sj.ejhg.5201403; de Ridder L, 2007, INFLAMM BOWEL DIS, V13, P1083, DOI 10.1002/ibd.20171; Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Fingerlin TE, 2004, AM J HUM GENET, V74, P432, DOI 10.1086/381652; Fisher SA, 2006, HUM MUTAT, V27, P778, DOI 10.1002/humu.20358; Franke A, 2006, HUM MUTAT, V27, P583, DOI 10.1002/humu.20306; Friedrichs F, 2006, HUM GENET, V119, P305, DOI 10.1007/s00439-006-0133-1; Friedrichs F, 2006, WORLD J GASTROENTERO, V12, P3651, DOI 10.3748/wjg.v12.i23.3651; Hampe J, 2001, BIOINFORMATICS, V17, P654, DOI 10.1093/bioinformatics/17.7.654; Hampe J, 2002, LANCET, V359, P1661, DOI 10.1016/S0140-6736(02)08590-2; Hampe J, 1999, AM J HUM GENET, V64, P808, DOI 10.1086/302294; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183; Krawczak M, 2006, COMMUNITY GENET, V9, P55, DOI 10.1159/000090694; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P79, DOI 10.1006/bbrc.1999.1638; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P752, DOI 10.1006/bbrc.1999.1753; KUSTER W, 1989, AM J MED GENET, V32, P105, DOI 10.1002/ajmg.1320320122; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; Lin ZW, 2007, GASTROENTEROLOGY, V132, pA451; Lin ZW, 2007, GASTROENTEROLOGY, V132, pA450; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Luce MJ, 1999, GENE, V231, P121, DOI 10.1016/S0378-1119(99)00093-1; MATSUHASHI S, 1995, DEV DYNAM, V203, P212, DOI 10.1002/aja.1002030209; Matsuhashi S, 1996, DEV DYNAM, V207, P233; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; McIntyre LM, 2000, GENET EPIDEMIOL, V19, P18, DOI 10.1002/1098-2272(200007)19:1<18::AID-GEPI2>3.0.CO;2-Y; Monteleone G, 2005, GASTROENTEROLOGY, V129, P1420, DOI 10.1053/j.gastro.2005.09.005; Newman WG, 2006, HUM MUTAT, V27, P353, DOI 10.1002/humu.20301; Nicolae DL, 2006, PLOS GENET, V2, P665, DOI 10.1371/journal.pgen.0020067; Noble CL, 2005, GUT, V54, P1416, DOI 10.1136/gut.2005.066621; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Onnie CM, 2006, INFLAMM BOWEL DIS, V12, P263, DOI 10.1097/01.MIB.0000209791.98866.ba; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; PARKES M, 2007, NAT GENET; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Romeo S, 2007, NAT GENET, V39, P513, DOI 10.1038/ng1984; ROUX C, 1995, OSTEOPOROSIS INT, V5, P156, DOI 10.1007/BF02106094; Russell RK, 2007, J PEDIATR-US, V150, P268, DOI 10.1016/j.jpeds.2006.12.010; Schreiber S, 2005, NAT REV GENET, V6, P376, DOI 10.1038/nrg1607; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Steffens M, 2006, HUM HERED, V62, P20, DOI 10.1159/000095850; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; Tan K, 2006, STRUCTURE, V14, P33, DOI 10.1016/j.str.2005.09.017; TEUBER M, 2005, JALA-J ASSOC LAB AUT, V10, P43; Thompson NP, 1996, BRIT MED J, V312, P95; Torok HP, 2005, GUT, V54, P1421, DOI 10.1136/gut.2005.066340; TRUELOVE SC, 1976, GUT, V17, P192, DOI 10.1136/gut.17.3.192; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; Vermeire S, 2005, GASTROENTEROLOGY, V129, P1845, DOI 10.1053/j.gastro.2005.10.006; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Waetzig GH, 2004, FASEB J, V18, P91, DOI 10.1096/fj.04-2073fje; Weckx S, 2005, GENOME RES, V15, P436, DOI 10.1101/gr.2754005; Weersma RK, 2007, GASTROENTEROLOGY, V132, pA445; Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379; Yamazaki K, 2004, J HUM GENET, V49, P664, DOI 10.1007/s10038-004-0204-x; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375; NATURE, V447, P661	79	107	114	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e691	10.1371/journal.pone.0000691	http://dx.doi.org/10.1371/journal.pone.0000691			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684544	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000207452400001
J	Kaelin, CB; Cooper, GM; Sidow, A; Barsh, GS				Kaelin, Christopher B.; Cooper, Gregory M.; Sidow, Arend; Barsh, Gregory S.			Mammalian Comparative Sequence Analysis of the Agrp Locus	PLOS ONE			English	Article								Agouti-related protein encodes a neuropeptide that stimulates food intake. Agrp expression in the brain is restricted to neurons in the arcuate nucleus of the hypothalamus and is elevated by states of negative energy balance. The molecular mechanisms underlying Agrp regulation, however, remain poorly defined. Using a combination of transgenic and comparative sequence analysis, we have previously identified a 760 bp conserved region upstream of Agrp which contains STAT binding elements that participate in Agrp transcriptional regulation. In this study, we attempt to improve the specificity for detecting conserved elements in this region by comparing genomic sequences from 10 mammalian species. Our analysis reveals a symmetrical organization of conserved sequences upstream of Agrp, which cluster into two inverted repeat elements. Conserved sequences within these elements suggest a role for homeodomain proteins in the regulation of Agrp and provide additional targets for functional evaluation.	[Kaelin, Christopher B.; Sidow, Arend; Barsh, Gregory S.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Cooper, Gregory M.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Sidow, Arend] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Barsh, Gregory S.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA	Stanford University; University of Washington; University of Washington Seattle; Stanford University; Stanford University	Barsh, GS (corresponding author), Stanford Univ, Dept Genet, Stanford, CA 94305 USA.	gbarsh@stanford.edu	Cooper, Gregory/D-6914-2011	Cooper, Gregory/0000-0001-5509-9923	National Institutes of Health [DK-48506]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048506] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This investigation was supported by grants from the National Institutes of Health to GSB (DK-48506).	Boswell T, 2002, MOL BRAIN RES, V100, P31, DOI 10.1016/S0169-328X(02)00145-6; Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603; Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P4552, DOI 10.1210/en.2003-0453; Chen HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/en.2003-1596; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Cooper GM, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-192; Cooper GM, 2003, GENOME RES, V13, P813, DOI 10.1101/gr.1064503; de Souza FSJ, 2005, MOL CELL BIOL, V25, P3076, DOI 10.1128/MCB.25.8.3076-3086.2005; Doghman M, 2007, MOL CELL ENDOCRINOL, V265, P108, DOI 10.1016/j.mce.2006.12.025; Drazen DL, 2003, DIABETES, V52, P2928, DOI 10.2337/diabetes.52.12.2928; Foucher I, 2003, DEVELOPMENT, V130, P1867, DOI 10.1242/dev.00414; Foucher I, 2002, DEVELOPMENT, V129, P4065; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gao J, 2002, BRAIN RES, V936, P87, DOI 10.1016/S0006-8993(02)02493-9; Henry BA, 2001, BRAIN RES, V918, P40, DOI 10.1016/S0006-8993(01)02918-3; HISANO S, 1988, NEUROSCI LETT, V95, P13, DOI 10.1016/0304-3940(88)90624-6; Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956; Kaelin CB, 2006, MOL ENDOCRINOL, V20, P2591, DOI 10.1210/me.2006-0107; Kamegai J, 2000, ENDOCRINOLOGY, V141, P4797, DOI 10.1210/en.141.12.4797; Kelley CG, 2002, MOL ENDOCRINOL, V16, P2413, DOI 10.1210/me.2002-0189; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Makimura Hideo, 2003, BMC Physiol, V3, P5, DOI 10.1186/1472-6793-3-5; Mayer CM, 2003, BIOCHEM BIOPH RES CO, V307, P847, DOI 10.1016/S0006-291X(03)01289-0; Moriguchi T, 2002, J BIOL CHEM, V277, P16985, DOI 10.1074/jbc.M107962200; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Phillips-Singh D, 2003, CELL TISSUE RES, V313, P217, DOI 10.1007/s00441-003-0755-8; RAVEHAREL N, 2005, J BIOL CHEM; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; STANLEY BG, 1986, PEPTIDES, V7, P1189; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95	33	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e702	10.1371/journal.pone.0000702	http://dx.doi.org/10.1371/journal.pone.0000702			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684549	gold, Green Published			2022-12-25	WOS:000207452400006
J	Strating, JRPM; Bouw, G; Hafmans, TGM; Martens, GJM				Strating, Jeroen R. P. M.; Bouw, Gerrit; Hafmans, Theo G. M.; Martens, Gerard J. M.			Disparate Effects of p24 alpha and p24 delta on Secretory Protein Transport and Processing	PLOS ONE			English	Article								Background. The p24 family is thought to be somehow involved in endoplasmic reticulum (ER)-to-Golgi protein transport. A subset of the p24 proteins (p24 alpha(3), -beta(1), -gamma(3) and -delta(2)) is upregulated when Xenopus laevis intermediate pituitary melanotrope cells are physiologically activated to produce vast amounts of their major secretory cargo, the prohormone proopiomelanocortin (POMC). Methodology/Principal Findings. Here we find that transgene expression of p24 alpha(3) or p24 delta(2) specifically in the Xenopus melanotrope cells in both cases causes an effective displacement of the endogenous p24 proteins, resulting in severely distorted p24 systems and disparate melanotrope cell phenotypes. Transgene expression of p24 alpha(3) greatly reduces POMC transport and leads to accumulation of the prohormone in large, ER-localized electron-dense structures, whereas p24 delta(2)-transgenesis does not influence the overall ultrastructure of the cells nor POMC transport and cleavage, but affects the Golgi-based processes of POMC glycomaturation and sulfation. Conclusions/Significance. Transgenic expression of two distinct p24 family members has disparate effects on secretory pathway functioning, illustrating the specificity and non-redundancy of our transgenic approach. We conclude that members of the p24 family furnish subcompartments of the secretory pathway with specific sets of machinery cargo to provide the proper microenvironments for efficient and correct secretory protein transport and processing.	[Strating, Jeroen R. P. M.; Bouw, Gerrit; Hafmans, Theo G. M.; Martens, Gerard J. M.] Radboud Univ Nijmegen, Dept Mol Anim Physiol, Nijmegen Ctr Mol Life Sci, Inst Neurosci,Fac Sci, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Martens, GJM (corresponding author), Radboud Univ Nijmegen, Dept Mol Anim Physiol, Nijmegen Ctr Mol Life Sci, Inst Neurosci,Fac Sci, NL-6525 ED Nijmegen, Netherlands.	g.martens@ncmls.ru.nl	Strating, Jeroen/F-4399-2019; Martens, Gerard JM/D-1925-2010	Strating, Jeroen/0000-0003-2509-5213; 	Netherlands Organisation for Scientific Research-Earth and Life Sciences [811.38.002]	Netherlands Organisation for Scientific Research-Earth and Life Sciences(Netherlands Organization for Scientific Research (NWO))	This work was supported by grant 811.38.002 from The Netherlands Organisation for Scientific Research-Earth and Life Sciences (NWO-ALW).	Belden WJ, 2001, MOL BIOL CELL, V12, P957, DOI 10.1091/mbc.12.4.957; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bouw G, 2004, MOL BIOL CELL, V15, P1244, DOI 10.1091/mbc.E03-08-0600; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Carney GE, 2004, BIOL CELL, V96, P271, DOI 10.1016/j.biolcel.2004.01.004; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; Collin RWJ, 2005, J NEUROCHEM, V94, P1015, DOI 10.1111/j.1471-4159.2005.03243.x; Denzel A, 2000, CURR BIOL, V10, P55, DOI 10.1016/S0960-9822(99)00266-3; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Emery G, 1999, PROTOPLASMA, V207, P24, DOI 10.1007/BF01294710; Emery G, 2003, J CELL SCI, V116, P4821, DOI 10.1242/jcs.00802; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gupta V, 2006, J CELL SCI, V119, P1703, DOI 10.1242/jcs.02885; HOLTHUIS JCM, 1995, J CELL SCI, V108, P3295; Jansen EJR, 2002, FEBS LETT, V516, P201, DOI 10.1016/S0014-5793(02)02523-1; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kuiper RP, 2001, BIOCHEM J, V360, P421, DOI 10.1042/0264-6021:3600421; Kuiper RP, 2000, BIOCHEM CELL BIOL, V78, P289, DOI 10.1139/bcb-78-3-289; Kuiper RP, 2000, MOL BIOL CELL, V11, P131, DOI 10.1091/mbc.11.1.131; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; MARTENS GJM, 1982, EUR J BIOCHEM, V126, P17, DOI 10.1111/j.1432-1033.1982.tb06739.x; MARTENS GJM, 1986, NUCLEIC ACIDS RES, V14, P3791, DOI 10.1093/nar/14.9.3791; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Rojo M, 2000, J CELL SCI, V113, P1043; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Rotter J, 2002, J CELL SCI, V115, P1049; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Simpson JC, 2006, MOL BIOL CELL, V17, P723, DOI 10.1091/mbc.E05-06-0580; Sparrow D B, 2000, Nucleic Acids Res, V28, pE12, DOI 10.1093/nar/28.4.e12; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; van Kuppeveld FJM, 1997, MOL CELL ENDOCRINOL, V136, P29, DOI 10.1016/S0303-7207(97)00211-6; Vetrivel KS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-4; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165	44	16	16	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e704	10.1371/journal.pone.0000704	http://dx.doi.org/10.1371/journal.pone.0000704			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684551	gold, Green Published			2022-12-25	WOS:000207452400008
J	Efferth, T; Giaisi, M; Merling, A; Krammer, PH; Li-Weber, M				Efferth, Thomas; Giaisi, Marco; Merling, Annette; Krammer, Peter H.; Li-Weber, Min			Artesunate Induces ROS-Mediated Apoptosis in Doxorubicin-Resistant T Leukemia Cells	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; CANCER; DEATH; ANTIMALARIALS; ARTEMISININ; INHIBITION; QINGHAOSU; TOXICITY; MEDICINE; NECROSIS	Background. A major obstacle for successful cancer treatment often is the development of drug resistance in cancer cells during chemotherapy. Therefore, there is an urgent need for novel drugs with improved efficacy against tumor cells and with less toxicity on normal cells. Artesunate (ART), a powerful anti-malarial herbal compound, has been shown to inhibit growth of various tumor cell lines in vitro and of xenografted Kaposi's sarcoma in mice in vivo. However, the molecular mechanisms by which ART exerts its cytotoxicity have not been elucidated. The ART-class of anti-malarial compounds is attractive due to their activity against multidrug-resistant Plasmodium falciparum and Plasmodium vivax strains. Another salient feature of these compounds is the lack of severe side effects in malaria patients. Methodology and Principal Findings. In this study, we used T-cell leukemias as a model system to study the molecular mechanisms of ART-induced apoptosis. The most typical anticancer drugs are DNA intercalators such as Doxorubicin. To investigate drug sensitivity and resistance, we chose a Doxorubicin-resistant leukemia cell line and investigated the killing effect of ART on these cells. We show that ART induces apoptosis in leukemic T cells mainly through the mitochondrial pathway via generation of reactive oxygen species (ROS), a mechanism different from Doxorubicin. This is confirmed by the fact that the antioxidant N-Acetyle-Cysteine (NAC) could completely block ROS generation and, consequently, inhibited ART-induced apoptosis. Therefore, ART can overcome the Doxorubicin-resistance and induce the Doxorubicin-resistant leukemia cells to undergo apoptosis. We also show that ART can synergize with Doxorubicin to enhance apoptotic cell death in leukemic T cells. This synergistic effect can be largely explained by the fact that ART and Doxorubicin use different killing mechanisms. Conclusions. Our studies raise the possibility to develop ART in combination with other established anticancer drugs which induce apoptosis through the pathways or mechanisms different from ART.	[Giaisi, Marco; Merling, Annette; Krammer, Peter H.; Li-Weber, Min] German Canc Res Ctr, Tumor Immunol Program, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Li-Weber, M (corresponding author), German Canc Res Ctr, Tumor Immunol Program, D-6900 Heidelberg, Germany.	m.li-weber@dkfz-heidelberg.de		Efferth, Thomas/0000-0002-3096-3292	Deutsche Forschungsgemeinschaft; Tumor Center Heidelberg/Mannheim	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tumor Center Heidelberg/Mannheim	This work was supported by the Deutsche Forschungsgemeinschaft and the Tumor Center Heidelberg/Mannheim.	ABELSON PH, 1990, SCIENCE, V247, P513, DOI 10.1126/science.2300807; Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Boik J., 2001, J NAT PROD; Brana MF, 2001, CURR PHARM DESIGN, V7, P1745, DOI 10.2174/1381612013397113; BREWER TG, 1994, AM J TROP MED HYG, V51, P251, DOI 10.4269/ajtmh.1994.51.251; BUSTOS MDG, 1994, B WORLD HEALTH ORGAN, V72, P729; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Dell'Eva R, 2004, BIOCHEM PHARMACOL, V68, P2359, DOI 10.1016/j.bcp.2004.08.021; Efferth T, 2006, CURR DRUG TARGETS, V7, P407, DOI 10.2174/138945006776359412; Efferth T, 2005, IN VIVO, V19, P225; Efferth T, 2003, INT J ONCOL, V23, P1231; Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382; Efferth T, 2002, BLOOD CELL MOL DIS, V28, P160, DOI 10.1006/bcmd.2002.0492; Efferth T, 1996, ARZNEIMITTEL-FORSCH, V46, P196; Efferth T, 2001, INT J ONCOL, V18, P767; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Gordi T, 2004, TOXICOL LETT, V147, P99, DOI 10.1016/j.toxlet.2003.12.009; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8; KIMMIG A, 1990, CANCER RES, V50, P6793; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; KRUNGKRAI SR, 1987, T ROY SOC TROP MED H, V81, P710, DOI 10.1016/0035-9203(87)90003-4; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOSTEN F, 1995, DRUG SAFETY, V12, P264, DOI 10.2165/00002018-199512040-00006; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Price R, 1998, AM J TROP MED HYG, V59, P883, DOI 10.4269/ajtmh.1998.59.883; RHOADS CP, 1947, T ASSOC AM PHYSICIAN, V60, P110; Ribeiro I R, 1998, Med Trop (Mars), V58, P50; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Sugimoto K, 2002, BRIT J HAEMATOL, V118, P229, DOI 10.1046/j.1365-2141.2002.03577.x; UBEZIO P, 1994, FREE RADICAL BIO MED, V16, P509, DOI 10.1016/0891-5849(94)90129-5; Yokochi T, 2004, MOL PHARMACOL, V66, P1415, DOI 10.1124/mol.104.002634	38	187	206	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e693	10.1371/journal.pone.0000693	http://dx.doi.org/10.1371/journal.pone.0000693			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668070	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452300028
J	Mailloux, RJ; Beriault, R; Lemire, J; Singh, R; Chenier, DR; Hamel, RD; Appanna, VD				Mailloux, Ryan J.; Beriault, Robin; Lemire, Joseph; Singh, Ranji; Chenier, Daniel R.; Hamel, Robert D.; Appanna, Vasu D.			The Tricarboxylic Acid Cycle, an Ancient Metabolic Network with a Novel Twist	PLOS ONE			English	Article								The tricarboxylic acid (TCA) cycle is an essential metabolic network in all oxidative organisms and provides precursors for anabolic processes and reducing factors (NADH and FADH(2)) that drive the generation of energy. Here, we show that this metabolic network is also an integral part of the oxidative defence machinery in living organisms and alpha-ketoglutarate ( KG) is a key participant in the detoxification of reactive oxygen species (ROS). Its utilization as an anti-oxidant can effectively diminish ROS and curtail the formation of NADH, a situation that further impedes the release of ROS via oxidative phosphorylation. Thus, the increased production of KG mediated by NADP-dependent isocitrate dehydrogenase (NADP-ICDH) and its decreased utilization via the TCA cycle confer a unique strategy to modulate the cellular redox environment. Activities of alpha-ketoglutarate dehydrogenase (KGDH), NAD-dependent isocitrate dehydrogenase (NAD-ICDH), and succinate dehydrogenase (SDH) were sharply diminished in the cellular systems exposed to conditions conducive to oxidative stress. These findings uncover an intricate link between TCA cycle and ROS homeostasis and may help explain the ineffective TCA cycle that characterizes various pathological conditions and ageing.	[Mailloux, Ryan J.; Beriault, Robin; Lemire, Joseph; Singh, Ranji; Chenier, Daniel R.; Hamel, Robert D.; Appanna, Vasu D.] Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada	Laurentian University	Appanna, VD (corresponding author), Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada.	VAppanna@lauren-tian.ca		Mailloux, Ryan/0000-0003-3986-9830; Appanna, Vasu/0000-0002-0138-5665	Ontario Center of Excellence and Industry Canada	Ontario Center of Excellence and Industry Canada	This work was supported by funding from Ontario Center of Excellence and Industry Canada.	ANDERSON S, 1992, FEBS LETT, V308, P94, DOI 10.1016/0014-5793(92)81059-U; Aydin S, 2005, FOOD CHEM TOXICOL, V43, P1093, DOI 10.1016/j.fct.2005.02.014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bubber P, 2004, NEUROCHEM INT, V45, P1021, DOI 10.1016/j.neuint.2004.05.007; Bunik VI, 2003, EUR J BIOCHEM, V270, P1036, DOI 10.1046/j.1432-1033.2003.03470.x; Bunik VI, 2003, EUR J BIOCHEM, V270, P1035, DOI 10.1046/j.1432-1033.2003.03467.x; Calabrese V, 2005, J NEUROL SCI, V233, P145, DOI 10.1016/j.jns.2005.03.012; Das J, 2006, BIOESSAYS, V28, P890, DOI 10.1002/bies.20463; Devin A, 2007, AM J PHYSIOL-CELL PH, V292, pC52, DOI 10.1152/ajpcell.00208.2006; Exley C, 2004, FREE RADICAL BIO MED, V36, P380, DOI 10.1016/j.freeradbiomed.2003.11.017; Fernie AR, 2004, CURR OPIN PLANT BIOL, V7, P254, DOI 10.1016/j.pbi.2004.03.007; Frank J, 2000, FREE RADICAL BIO MED, V29, P1096, DOI 10.1016/S0891-5849(00)00395-6; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Johnson P, 2002, COMP BIOCHEM PHYS C, V133, P493, DOI 10.1016/S1532-0456(02)00120-5; Kwik-Uribe CL, 2003, BRAIN RES, V973, P1, DOI 10.1016/S0006-8993(03)02457-0; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Mailloux RJ, 2007, TOXICOL IN VITRO, V21, P16, DOI 10.1016/j.tiv.2006.07.013; Mailloux RJ, 2006, J BIOCHEM MOL TOXIC, V20, P198, DOI 10.1002/jbt.20137; Mailloux RJ, 2006, ANAL BIOCHEM, V359, P210, DOI 10.1016/j.ab.2006.09.019; Middaugh J, 2005, J BIOL CHEM, V280, P3159, DOI 10.1074/jbc.M411979200; Noctor G, 2006, PLANT CELL ENVIRON, V29, P409, DOI 10.1111/j.1365-3040.2005.01476.x; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Romanov V, 1999, ANAL BIOCHEM, V268, P49, DOI 10.1006/abio.1998.3033; Sadka A, 2000, PLANT SCI, V158, P173, DOI 10.1016/S0168-9452(00)00328-9; Sargazi M, 2006, J TRACE ELEM MED BIO, V19, P267, DOI 10.1016/j.jtemb.2005.11.002; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sgherri C, 2002, PLANT PHYSIOL BIOCH, V40, P591, DOI 10.1016/S0981-9428(02)01421-3; Singh R, 2005, J BIOCHEM BIOPH METH, V64, P189, DOI 10.1016/j.jbbm.2005.07.005; Singh R, 2005, EXTREMOPHILES, V9, P367, DOI 10.1007/s00792-005-0450-7; Tappia PS, 2006, FREE RADICAL BIO MED, V41, P349, DOI 10.1016/j.freeradbiomed.2006.03.025; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Urso ML, 2003, TOXICOLOGY, V189, P41, DOI 10.1016/S0300-483X(03)00151-3; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901; Yumoto I, 2000, J BACTERIOL, V182, P1903, DOI 10.1128/JB.182.7.1903-1909.2000; Zhu XW, 2004, BRAIN RES, V1000, P32, DOI 10.1016/j.brainres.2004.01.012	41	230	236	5	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e690	10.1371/journal.pone.0000690	http://dx.doi.org/10.1371/journal.pone.0000690			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668068	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452300026
J	Singh, K; Mogare, D; Giridharagopalan, RO; Gogiraju, R; Pande, G; Chattopadhyay, S				Singh, Kamini; Mogare, Devraj; Giridharagopalan, Ramprasad Obula; Gogiraju, Rajinikanth; Pande, Gopal; Chattopadhyay, Samit			p53 Target Gene SMAR1 Is Dysregulated in Breast Cancer: Its Role in Cancer Cell Migration and Invasion	PLOS ONE			English	Article								Tumor suppressor SMAR1 interacts and stabilizes p53 through phosphorylation at its serine-15 residue. We show that SMAR1 transcription is regulated by p53 through its response element present in the SMAR1 promoter. Upon Doxorubicin induced DNA damage, acetylated p53 is recruited on SMAR1 promoter that allows activation of its transcription. Once SMAR1 is induced, cell cycle arrest is observed that is correlated to increased phospho-ser-15-p53 and decreased p53 acetylation. Further we demonstrate that SMAR1 expression is drastically reduced during advancement of human breast cancer. This was correlated with defective p53 expression in breast cancer where acetylated p53 is sequestered into the heterochromatin region and become inaccessible to activate SMAR1 promoter. In a recent report we have shown that SMAR1 represses Cyclin D1 transcription through recruitment of HDAC1 dependent repressor complex at the MAR site of Cyclin D1 promoter. Here we show that downmodulation of SMAR1 in high grade breast carcinoma is correlated with upregulated Cyclin D1 expression. We also established that SMAR1 inhibits tumor cell migration and metastases through inhibition of TGF beta signaling and its downstream target genes including cutl1 and various focal adhesion molecules. Thus, we report that SMAR1 plays a central role in coordinating p53 and TGF beta pathways in human breast cancer.	[Singh, Kamini; Mogare, Devraj; Chattopadhyay, Samit] Pune Univ, Natl Ctr Cell Sci, Pune, Maharashtra, India; [Giridharagopalan, Ramprasad Obula; Gogiraju, Rajinikanth; Pande, Gopal] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Savitribai Phule Pune University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Chattopadhyay, S (corresponding author), Pune Univ, Natl Ctr Cell Sci, Pune, Maharashtra, India.	samit@nccs.res.in		Pande, Gopal/0000-0002-0730-1389; Gogiraju, Rajinikanth/0000-0003-1284-9338	National Centre for Cell Science (NCCS); Department of Biotechnology (DBT); Department of Science and Technology (DST); Indian Council of Medical Research (ICMR), Government of India	National Centre for Cell Science (NCCS); Department of Biotechnology (DBT)(Department of Biotechnology (DBT) India); Department of Science and Technology (DST)(Department of Science & Technology (India)); Indian Council of Medical Research (ICMR), Government of India(Indian Council of Medical Research (ICMR))	This work is supporter by National Centre for Cell Science (NCCS), Department of Biotechnology (DBT), Department of Science and Technology (DST) and Indian Council of Medical Research (ICMR), Government of India.	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Azuma H, 2005, JNCI-J NATL CANCER I, V97, P1734, DOI 10.1093/jnci/dji399; Bazzoni G, 2003, CURR OPIN CELL BIOL, V15, P525, DOI 10.1016/S0955-0674(03)00104-2; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Birot AM, 2000, GENE, V253, P189, DOI 10.1016/S0378-1119(00)00244-4; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chattopadhyay S, 2000, GENOMICS, V68, P93, DOI 10.1006/geno.2000.6279; Chen HB, 2005, J BIOL CHEM, V280, P21329, DOI 10.1074/jbc.M500362200; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Galande S, 2002, CURR CANCER DRUG TAR, V2, P157, DOI 10.2174/1568009023333917; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; Harkonen P, 2005, PROSTATE, V62, P267, DOI 10.1002/pros.20147; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HENDERSON IC, 1991, BREAST DIS, P504; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Jalota A, 2005, J BIOL CHEM, V280, P16019, DOI 10.1074/jbc.M413200200; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kaul R, 2003, INT J CANCER, V103, P606, DOI 10.1002/ijc.10881; Kaul-Ghanekar R, 2005, J BIOL CHEM, V280, P9450, DOI 10.1074/jbc.M412206200; Kaul-Ghanekar R, 2004, NUCLEIC ACIDS RES, V32, P4862, DOI 10.1093/nar/gkh807; Kochetkova M, 2002, CANCER RES, V62, P4599; Labat-Robert J, 2002, SEMIN CANCER BIOL, V12, P187, DOI 10.1016/S1044-579X(02)00022-6; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rampalli S, 2005, MOL CELL BIOL, V25, P8415, DOI 10.1128/MCB.25.19.8415-8429.2005; Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581; Sottile J, 1998, J CELL SCI, V111, P2933; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Suzui M, 2002, CANCER RES, V62, P3997; Vaghefi H, 2004, ONCOGENE, V23, P8078, DOI 10.1038/sj.onc.1207953; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yakmovych I, 2001, FASEB J, V15, P553; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhu Q, 2004, MOL CELL BIOL, V24, P4810, DOI 10.1128/MCB.24.11.4810-4823.2004; Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430	50	51	52	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e660	10.1371/journal.pone.0000660	http://dx.doi.org/10.1371/journal.pone.0000660			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668048	gold, Green Published			2022-12-25	WOS:000207452300006
J	Mochel, F; Charles, P; Seguin, F; Barritault, J; Coussieu, C; Perin, L; Le Bouc, Y; Gervais, C; Carcelain, G; Vassault, A; Feingold, J; Rabier, D; Durr, A				Mochel, Fanny; Charles, Perrine; Seguin, Francois; Barritault, Julie; Coussieu, Christiane; Perin, Laurence; Le Bouc, Yves; Gervais, Christiane; Carcelain, Guislaine; Vassault, Anne; Feingold, Josue; Rabier, Daniel; Durr, Alexandra			Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression	PLOS ONE			English	Article							CEREBROSPINAL-FLUID; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; TRANSGENIC MICE; AMINO-ACIDS; BODY-WEIGHT; DEFECTS; CELLS; PHOSPHORYLATION; ABNORMALITIES	Huntington disease (HD) is a fatal neurodegenerative disorder, with no effective treatment. The pathogenic mechanisms underlying HD have not been elucidated, but weight loss, associated with chorea and cognitive decline, is a characteristic feature of the disease that is accessible to investigation. We, therefore, performed a multiparametric study exploring body weight and the mechanisms of its loss in 32 presymptomatic carriers and HD patients in the early stages of the disease, compared to 21 controls. We combined this study with a multivariate statistical analysis of plasma components quantified by proton nuclear magnetic resonance (H-1 NMR) spectroscopy. We report evidence of an early hypermetabolic state in HD. Weight loss was observed in the HD group even in presymptomatic carriers, although their caloric intake was higher than that of controls. Inflammatory processes and primary hormonal dysfunction were excluded. H-1 NMR spectroscopy on plasma did, however, distinguish HD patients at different stages of the disease and presymptomatic carriers from controls. This distinction was attributable to low levels of the branched chain amino acids (BCAA), valine, leucine and isoleucine. BCAA levels were correlated with weight loss and, importantly, with disease progression and abnormal triplet repeat expansion size in the HD1 gene. Levels of IGF1, which is regulated by BCAA, were also significantly lower in the HD group. Therefore, early weight loss in HD is associated with a systemic metabolic defect, and BCAA levels may be used as a biomarker, indicative of disease onset and early progression. The decreased plasma levels of BCAA may correspond to a critical need for Krebs cycle energy substrates in the brain that increased metabolism in the periphery is trying to provide.	[Mochel, Fanny; Durr, Alexandra] Hop La Pitie Salpetriere, INSERM, UMR 679, Paris, France; [Charles, Perrine; Feingold, Josue; Durr, Alexandra] Hop La Pitie Salpetriere, AP HP, Dept Genet & Cytogenet, Paris, France; [Seguin, Francois; Barritault, Julie] Hop La Miletrie, Poitiers, France; [Seguin, Francois; Barritault, Julie] Fac Med & Pharm, INSERM, Poitiers, France; [Coussieu, Christiane] Hop La Pitie Salpetriere, AP HP, Lab Endocrinol, Paris, France; [Perin, Laurence; Le Bouc, Yves] Hop Enfants Armand Trousseau, AP HP, Paris, France; [Gervais, Christiane] Hop La Pitie Salpetriere, AP HP, Serv Dietet, Paris, France; [Carcelain, Guislaine] Hop La Pitie Salpetriere, AP HP, Immunol Lab, Paris, France; [Vassault, Anne; Rabier, Daniel] Hop Necker Enfants Malad, AP HP, Lab Biochim Metab, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Durr, A (corresponding author), Hop La Pitie Salpetriere, INSERM, UMR 679, Paris, France.	durr@ccr.jussieu.fr			Fondation pour la Recherche Medicale (France); Pitie-Salpetriere Hospital Paris (France) [17-06]	Fondation pour la Recherche Medicale (France)(Fondation pour la Recherche Medicale); Pitie-Salpetriere Hospital Paris (France)	Funding: Dr Mochel was supported by the Fondation pour la Recherche Medicale (France).; The authors gratefully acknowledge Alexis Brice, Merle Ruberg and Charles Roe for their helpful suggestions. They also acknowledge Anne Faudet for her expert technical assistance and Anne Desfarge for her help with the dietary assessment of both the controls and HD patients. This study was approved by the Committee de Protection des Personnes (CPP) from the Pitie-Salpetriere Hospital Paris (France) on October 18, 2006 (project n# 17-06).	Antonini A, 1996, BRAIN, V119, P2085, DOI 10.1093/brain/119.6.2085; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; Bixel MG, 2001, J HISTOCHEM CYTOCHEM, V49, P407, DOI 10.1177/002215540104900314; Browne SE, 2004, NEUROCHEM RES, V29, P531, DOI 10.1023/B:NERE.0000014824.04728.dd; Colin E, 2005, EUR J NEUROSCI, V21, P1478, DOI 10.1111/j.1460-9568.2005.03985.x; Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015; De Bandt JP, 2006, J NUTR, V136, p308S, DOI 10.1093/jn/136.1.308S; Djousse L, 2002, NEUROLOGY, V59, P1325, DOI 10.1212/01.WNL.0000031791.10922.CF; Engelke UFH, 2005, NMR BIOMED, V18, P331, DOI 10.1002/nbm.966; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Gines S, 2003, HUM MOL GENET, V12, P497, DOI 10.1093/hmg/ddg046; GRAFTON ST, 1992, ARCH NEUROL-CHICAGO, V49, P1161, DOI 10.1001/archneur.1992.00530350075022; Greenamyre JT, 2007, NEW ENGL J MED, V356, P518, DOI 10.1056/NEJMcibr067022; HARP JB, 1991, DIABETES, V40, P95, DOI 10.2337/diabetes.40.1.95; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Hutson SM, 2001, J NUTR, V131, p846S, DOI 10.1093/jn/131.3.846S; Joshi MA, 2006, BIOCHEM J, V400, P153, DOI 10.1042/BJ20060869; Klivenyi P, 2004, J NEUROCHEM, V88, P1352, DOI 10.1046/j.1471-4159.2003.02263.x; KREMER HPH, 1989, J NEUROL SCI, V90, P335, DOI 10.1016/0022-510X(89)90120-2; KUWERT T, 1993, J NEUROL, V241, P31, DOI 10.1007/BF00870669; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lodi R, 2000, ANN NEUROL, V48, P72; Marder K, 2000, NEUROLOGY, V54, P452, DOI 10.1212/WNL.54.2.452; Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003; Milakovic T, 2005, J BIOL CHEM, V280, P30773, DOI 10.1074/jbc.M504749200; Mochel F, 2005, J CLIN ENDOCR METAB, V90, P3780, DOI 10.1210/jc.2005-0009; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; PERRY TL, 1969, LANCET, V1, P806; PHILLIPSON OT, 1977, CLIN SCI MOL MED, V52, P311, DOI 10.1042/cs0520311; Popovic V, 2004, EUR J ENDOCRINOL, V151, P451, DOI 10.1530/eje.0.1510451; Rangone H, 2005, J BIOL CHEM, V280, P22021, DOI 10.1074/jbc.M407528200; Robbins AO, 2006, EUR J NEUROL, V13, pE7, DOI 10.1111/j.1468-1331.2006.01319.x; Roe CR, 1999, MOL GENET METAB, V68, P243, DOI 10.1006/mgme.1999.2911; SANBERG PR, 1981, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1981.tb135681.x; Siesling S, 1998, MOVEMENT DISORD, V13, P915, DOI 10.1002/mds.870130609; Strand AD, 2005, HUM MOL GENET, V14, P1863, DOI 10.1093/hmg/ddi192; STRAUS DS, 1988, BIOCHIM BIOPHYS ACTA, V972, P33; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Szpetnar Maria, 2004, Ann Univ Mariae Curie Sklodowska Med, V59, P91; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Teahan O, 2006, ANAL CHEM, V78, P4307, DOI 10.1021/ac051972y; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Trejo A, 2004, NUTRITION, V20, P192, DOI 10.1016/j.nut.2003.10.007; Underwood BR, 2006, BRAIN, V129, P877, DOI 10.1093/brain/awl027; Walsh MC, 2006, AM J CLIN NUTR, V84, P531, DOI 10.1093/ajcn/84.3.531; Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004	47	168	171	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e647	10.1371/journal.pone.0000647	http://dx.doi.org/10.1371/journal.pone.0000647			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653274	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452200016
J	Eckert, A; Bock, BC; Tagscherer, KE; Haas, TL; Grund, K; Sykora, J; Herold-Mende, C; Ehemann, V; Hollstein, M; Chneiweiss, H; Wiestler, OD; Walczak, H; Roth, W				Eckert, A.; Boeck, B. C.; Tagscherer, K. E.; Haas, T. L.; Grund, K.; Sykora, J.; Herold-Mende, C.; Ehemann, V.; Hollstein, M.; Chneiweiss, H.; Wiestler, O. D.; Walczak, H.; Roth, W.			The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway	ONCOGENE			English	Article						apoptosis; brain tumors; PEA-15/PED; glucose; MAP kinases; ERK1/2	DEATH EFFECTOR DOMAIN; CANCER-CELLS; CYTOPLASMIC SEQUESTRATION; INTEGRIN ACTIVATION; GLIOMA-CELLS; IN-VITRO; PED/PEA-15; EXPRESSION; ASTROCYTES; PHOSPHOPROTEIN	PEA-15 ( phosphoprotein enriched in astrocytes 15 kDa) is a death effector domain-containing protein, which is involved in the regulation of apoptotic cell death. Since PEA-15 is highly expressed in cells of glia l origin, we studied the role of PEA-15 in human malignant brain tumors. Immunohistochemical analysis of PEA-15 expression shows strong immunoreactivity in astrocytomas and glioblastomas. Phosphorylation of PEA-15 at Ser(116) is found in vivo in perinecrotic areas in glioblastomas and in vitro after glucose deprivation of glioblastoma cells. Overexpression of PEA-15 induces a marked resistance against glucose deprivation-induced apoptosis, whereas small interfering RNA (siRNA)-mediated downregulation of endogenous PEA-15 results in the sensitization to glucose withdrawal-mediated cell death. This antiapoptotic activity of PEA-15 under low glucose conditions depends on its phosphorylation at Ser116. Moreover, siRNA-mediated knockdown of PEA-15 abolishes the tumorigenicity of U87MG glioblastoma cells in vivo. PEA-15 regulates the level of phosphorylated extracellular-regulated kinase ( ERK) 1/ 2 in glioblastoma cells and the PEA-15-dependent protection from glucose deprivation-induced cell death requires ERK1/2 signaling. PEA-15 transcriptionally upregulates the Glucose Transporter 3, which is abrogated by the inhibition of ERK1/2 phosphorylation. Taken together, our findings suggest that Ser(116)-phosphorylated PEA-15 renders glioma cells resistant to glucose deprivation-mediated cell death as encountered in poor microenvironments, for example in perinecrotic areas of glioblastomas.	[Eckert, A.; Boeck, B. C.; Tagscherer, K. E.; Haas, T. L.; Grund, K.; Sykora, J.; Wiestler, O. D.; Walczak, H.; Roth, W.] German Canc Res Ctr, Div Apoptosis Regulat, D-69120 Heidelberg, Germany; [Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Ehemann, V.; Roth, W.] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Hollstein, M.] German Canc Res Ctr, Dept Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; [Chneiweiss, H.] INSERM, U752, Paris, France	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm)	Roth, W (corresponding author), German Canc Res Ctr, Div Apoptosis Regulat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Walczak, Henning/AAV-2214-2020; Tagscherer, Katrin/AAS-3809-2021; herve, chneiweiss/Q-6818-2019	Walczak, Henning/0000-0002-6312-4591; Tagscherer, Katrin/0000-0002-0657-6399; herve, chneiweiss/0000-0001-7675-5061; Haas, Tobias/0000-0003-2336-0263				ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Bartholomeusz C, 2006, ONCOGENE, V25, P79, DOI 10.1038/sj.onc.1209014; Boulos S, 2007, NEUROBIOL DIS, V25, P54, DOI 10.1016/j.nbd.2006.08.012; Chou FL, 2003, J BIOL CHEM, V278, P52587, DOI 10.1074/jbc.M309322200; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Dong G, 2001, CANCER RES, V61, P4797; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formisano P, 2005, ONCOGENE, V24, P7012, DOI 10.1038/sj.onc.1208871; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Hao CH, 2001, CANCER RES, V61, P1162; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Kubes M, 1998, J NEUROCHEM, V71, P1307; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; NISHIOKA T, 1992, CANCER RES, V52, P3972; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Renault-Mihara F, 2006, MOL BIOL CELL, V17, P5141, DOI 10.1091/mbc.E05-11-1072; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Stassi G, 2005, CANCER RES, V65, P6668, DOI 10.1158/0008-5472.CAN-04-4009; Todaro M, 2006, CANCER RES, V66, P1491, DOI 10.1158/0008-5472.CAN-05-2514; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Ziegler A, 2001, CANCER RES, V61, P5595	37	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1155	1166		10.1038/sj.onc.1210732	http://dx.doi.org/10.1038/sj.onc.1210732			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700518				2022-12-25	WOS:000253136700015
J	Scavelli, C; Nico, B; Cirulli, T; Ria, R; Di Pietro, G; Mangieri, D; Bacigalupo, A; Mangialardi, G; Coluccia, AML; Caravita, T; Molica, S; Ribatti, D; Dammacco, F; Vacca, A				Scavelli, C.; Nico, B.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangieri, D.; Bacigalupo, A.; Mangialardi, G.; Coluccia, A. M. L.; Caravita, T.; Molica, S.; Ribatti, D.; Dammacco, F.; Vacca, A.			Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma	ONCOGENE			English	Article						basic fibroblast growth factor; macrophages; multiple myeloma; vascular endothelial growth factor; vasculogenesis	ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; PROGENITOR CELLS; PERIPHERAL-BLOOD; HUMAN MONOCYTES; FACTOR VEGF; STEM-CELLS; ANGIOGENESIS; EXPRESSION; NEOVASCULARIZATION	Bone marrow macrophages of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies of undetermined significance (MGUS) and benign anemia (controls) were stimulated for 7 days with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and analysed for the expression of endothelial cell (EC) markers by reverse transcription (RT) - PCR, real- time RT - PCR, western blot and immunofluorescence. Their vasculogenic ability was investigated in vitro in a Matrigel assay and in vivo on bone marrow biopsies through dual immunofluorescence and confocal laser microscopy. Active MM macrophages exposed to VEGF and bFGF acquired EC markers and formed capillary-like structures mimicking paired bone marrow ECs (multiple myeloma patient-derived endothelial cells, MMECs), with major responsiveness compared to macrophages from nonactive MM, MGUS or controls. Bone marrow biopsies of active MM harbored 'mosaic' vessels, being formed by MMECs, EC-like macrophages and macrophages themselves. These figures were rare in nonactive MM and absent in MGUS or controls. Our data indicate that macrophages contribute to build neovessels in active MM through vasculogenic mimicry, and this ability proceeds parallel to progression of the plasma cell tumors. Macrophages may be a target for the MM antivascular treatment.	[Scavelli, C.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangialardi, G.; Coluccia, A. M. L.; Dammacco, F.; Vacca, A.] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70124 Bari, Italy; [Nico, B.; Mangieri, D.] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy; [Bacigalupo, A.] San Martino Hosp, Dept Hematooncol, Genoa, Italy; [Caravita, T.] Univ Roma Tor Vergata, Sch Med, Dept Hematol, S Eugenio Hosp, Rome, Italy; [Molica, S.] Azienda Osped Pugliese Ciaccio, Dept Med Oncol, Catanzaro, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Genoa; IRCCS AOU San Martino IST; Sant'Eugenio Hospital; University of Rome Tor Vergata	Vacca, A (corresponding author), Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Piazzi Giulio Cesare 11, I-70124 Bari, Italy.	a.vacca@dimo.uniba.it	Caravita, Tommaso/O-8929-2019; Dammacco, Franco/ABG-5728-2020; Vacca, Angelo/AAC-9558-2022; Ria, Roberto/I-4263-2015	Dammacco, Franco/0000-0003-2149-5471; Vacca, Angelo/0000-0002-4567-8216; Mangieri, Domenica/0000-0001-7350-9383; Ria, Roberto/0000-0002-1515-0090; Mangieri, Domenica/0000-0003-4871-1701	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Anghelina M, 2004, STEM CELLS DEV, V13, P665, DOI 10.1089/scd.2004.13.665; Anghelina M, 2006, AM J PATHOL, V168, P529, DOI 10.2353/ajpath.2006.050255; Anghelina M, 2006, J CELL MOL MED, V10, P708, DOI 10.2755/jcmm010.003.21; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BARONI CD, 1987, HISTOPATHOLOGY, V11, P1029; Bellamy WT, 1999, CANCER RES, V59, P728; Bender AT, 2004, CELL SIGNAL, V16, P365, DOI 10.1016/j.cellsig.2003.08.009; Bender CM, 1998, CANCER RES, V58, P95; Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; DURIE BGM, 1986, SEMIN ONCOL, V13, P300; Fehrenbach H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-60; Fernandez E, 2000, Gac Sanit, V14, P287; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujiyama S, 2003, CIRC RES, V93, P980, DOI 10.1161/01.RES.0000099245.08637.CE; Gendron RL, 1996, DEV BIOL, V177, P332, DOI 10.1006/dbio.1996.0167; GOTO F, 1993, LAB INVEST, V69, P508; Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; Moldovan NI, 2000, CIRC RES, V87, P378; Moldovan NI, 2005, STEM CELLS DEV, V14, P111, DOI 10.1089/scd.2005.14.111; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Rajkumar SV, 1999, LEUKEMIA, V13, P469, DOI 10.1038/sj.leu.2401336; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456; RISAU W, 1988, DEVELOPMENT, V102, P471; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vacca A, 1999, BLOOD, V93, P3064; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100	45	112	117	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					663	674		10.1038/sj.onc.1210691	http://dx.doi.org/10.1038/sj.onc.1210691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667938				2022-12-25	WOS:000252674900010
J	Shultz, T; Shmuel, M; Hyman, T; Altschuler, Y				Shultz, Tamar; Shmuel, Miriam; Hyman, Tehila; Altschuler, Yoram			beta-tubulin cofactor D and ARL2 take part in apical junctional complex disassembly and abrogate epithelial structure	FASEB JOURNAL			English	Article						MDCK; tight junction; adherens junctions	PROTEIN PHOSPHATASE 2A; TIGHT JUNCTION; FOLDING COFACTORS; MICROTUBULES; ORGANIZATION; CYTOSKELETON; OCCLUDIN; LOCALIZATION; MAINTENANCE; NUCLEATION	In epithelial cells, the apical junctional complex (AJC), composed of tight junctions (TJs) and adherens junctions (AJs), maintains cell-surface polarity by forming a fence that prevents lateral movement and diffusion of proteins and lipids between the apical and basolateral PM and holds the epithelial monolayer intact through cell-cell contacts. Disassembly of this complex is a prime event in development and cell transformation. Maintenance of the AJC has been shown to involve mainly the actin cytoskeleton. Recent findings also point to the involvement of the microtubule (MT) system. Here we show the first evidence that in polarized epithelial MDCK cells, ARF-like protein 2 (ARL2) and beta-tubulin cofactor D, known to be involved in MT dynamics, have a role in disassembly of the AJC followed by cell dissociation from the epithelial monolayer, which is not dependent on MT depolymerization. In addition, we show that beta-tubulin cofactor D is partially localized to the lateral PM through its 15 C-terminal amino acids and intact MTs. ARL2 inhibited beta-tubulin cofactor D-dependent cell dissociation from the monolayer and AJC disassembly. To our knowledge, this is the first evidence that beta-tubulin cofactor D plays a role in cells independent of its presumed role in folding tubulin heterodimers. We conclude that ARL2 and beta-tubulin cofactor D participate in AJC disassembly and epithelial depolarization. -Shultz, T., Shmuel, M., Hyman, T., and Altschuler, Y. beta-tubulin cofactor D and ARL2 take part in apical junctional complex disassembly and abrogate epithelial structure.	[Shultz, Tamar; Shmuel, Miriam; Hyman, Tehila; Altschuler, Yoram] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, Jerusalem, Israel	Hebrew University of Jerusalem	Altschuler, Y (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, Jerusalem, Israel.	yoram11@md.huji.ac.il						Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Antoshechkin I, 2002, DEV CELL, V2, P579, DOI 10.1016/S1534-5807(02)00146-6; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; Bowzard JB, 2005, METHOD ENZYMOL, V404, P453, DOI 10.1016/S0076-6879(05)04040-1; Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Chen N, 2003, NEUROSCIENCE, V120, P163, DOI 10.1016/S0306-4522(03)00259-8; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, pL1134, DOI 10.1152/ajplung.00022.2004; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978, DOI 10.1152/ajpcell.1990.259.6.C978; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hyman A, 1998, J CELL SCI, V111, P2077; Ivanov AI, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-12; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Kohler K, 2005, BIOL CELL, V97, P659; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; Lopez-Fanarraga M, 2001, J STRUCT BIOL, V135, P219, DOI 10.1006/jsbi.2001.4386; Luton F, 2004, MOL BIOL CELL, V15, P1134, DOI 10.1091/mbc.E03-10-0751; Martin L, 2000, FEBS LETT, V470, P93, DOI 10.1016/S0014-5793(00)01293-X; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Nunes FD, 2006, J CELL SCI, V119, P4819, DOI 10.1242/jcs.03233; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Shern JF, 2003, J BIOL CHEM, V278, P40829, DOI 10.1074/jbc.M308678200; Steinborn K, 2002, GENE DEV, V16, P959, DOI 10.1101/gad.221702; Takahashi K, 2006, J CELL PHYSIOL, V206, P814, DOI 10.1002/jcp.20524; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; Tzafrir I, 2002, PLANT PHYSIOL, V128, P38, DOI 10.1104/pp.010911; WANG AZ, 1990, J CELL SCI, V95, P153; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	43	17	20	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					168	182		10.1096/fj.06-7786com	http://dx.doi.org/10.1096/fj.06-7786com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17704193				2022-12-25	WOS:000252309900020
J	Beevers, AJ; Kukol, A				Beevers, Andrew J.; Kukol, Andreas			Phospholemman transmembrane structure reveals potential interactions with Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; MOLECULAR-DYNAMICS; SECONDARY STRUCTURE; FXYD PROTEINS; ION CURRENTS; INFRARED DICHROISM; NA+/CA2+ EXCHANGE; CHANNEL MOLECULES; LIPID-BILAYER; PHOSPHORYLATION	Phospholemman ( PLM) is a 72- residue bitopic cardiac transmembrane protein, which acts as a modulator of the Na+/K+-ATPase and the Na+/Ca2+ exchanger and possibly forms taurine channels in nonheart tissue. This work presents a high resolution structural model obtained from a combination of site- specific infrared spectroscopy and experimentally constrained high throughput molecular dynamics ( MD) simulations. Altogether, 37 experimental constraints, including nine long range orientational constraints, have been used during MD simulations in an explicit lipid bilayer/ water system. The resulting tetrameric alpha- helical bundle has an average helix tilt of 7.3 degrees and a crossing angle close to 0 degrees. It does not reveal a hydrophilic pore, but instead strong interactions between various residues occlude any pore. The helix- helix packing is unusual, with Gly(19) and Gly(20) pointing to the outside of the helical bundle, facilitating potential interaction with other transmembrane proteins, thus providing a structural basis for the modulatory effect of PLM on the Na+/K+-ATPase. A two- stage model of interaction between PLM and the Na+/K+- ATPase is discussed involving PLM- ATPase interaction and subsequent formation of an unstable PLM trimer, which readily interacts with surrounding ATPase molecules. Further unconstrained MD simulations identified other packing models of PLM, one of which could potentially undergo a conformational transition to an open pore.	Univ Hertfordshire, Sch Life Sci, Hatfield AL10 9AB, Herts, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England	University of Hertfordshire; University of Warwick	Kukol, A (corresponding author), Univ Hertfordshire, Sch Life Sci, Hatfield AL10 9AB, Herts, England.	a.kukol@herts.ac.uk	Kukol, Andreas/AAR-4569-2020	Kukol, Andreas/0000-0002-8859-010X				Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arkin IT, 1997, J AM CHEM SOC, V119, P8973, DOI 10.1021/ja964253x; Beevers AJ, 2006, PROTEIN SCI, V15, P1127, DOI 10.1110/ps.051899406; Beevers AJ, 2006, J MOL BIOL, V361, P945, DOI 10.1016/j.jmb.2006.07.004; Beevers AJ, 2006, J MOL GRAPH MODEL, V25, P226, DOI 10.1016/j.jmgm.2005.12.008; Bogaev RC, 2001, GENE, V271, P69, DOI 10.1016/S0378-1119(01)00497-8; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; Chen ZH, 1999, RECEPTOR CHANNEL, V6, P435; Dalskov SM, 2005, NEUROCHEM INT, V46, P489, DOI 10.1016/j.neuint.2004.11.010; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 2005, J BIOENERG BIOMEMBR, V37, P387, DOI 10.1007/s10863-005-9476-x; Gurtovenko AA, 2004, BIOPHYS J, V86, P3461, DOI 10.1529/biophysj.103.038760; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Kass I, 2004, BIOPHYS J, V86, P2502, DOI 10.1016/S0006-3495(04)74305-2; Kortenaar P. B. W. T., 1986, INT J PEPT PROT RES, V27, P398; Kukol A, 1999, BIOPHYS J, V77, P1594, DOI 10.1016/S0006-3495(99)77007-4; Kukol A, 2005, SPECTROSC-INT J, V19, P1; Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lindzen M, 2006, J BIOL CHEM, V281, P5947, DOI 10.1074/jbc.M512063200; Marsh D, 2000, BIOPHYS J, V78, P2499, DOI 10.1016/S0006-3495(00)76795-6; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; Mounsey JP, 1999, BBA-MOL CELL RES, V1451, P305, DOI 10.1016/S0167-4889(99)00102-0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Song JL, 2005, AM J PHYSIOL-HEART C, V288, pH2342, DOI 10.1152/ajpheart.01133.2004; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Torres J, 2000, J MOL BIOL, V300, P677, DOI 10.1006/jmbi.2000.3885; Torres J, 2001, BIOPOLYMERS, V59, P396, DOI 10.1002/1097-0282(200111)59:6<396::AID-BIP1044>3.3.CO;2-P; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002	41	13	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32742	32748		10.1074/jbc.M703676200	http://dx.doi.org/10.1074/jbc.M703676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17698851	hybrid, Green Submitted			2022-12-25	WOS:000250625400022
J	Ueda, Y; Yamaguchi, R; Ikawa, M; Okabe, M; Morii, E; Maeda, Y; Kinoshita, T				Ueda, Yasutaka; Yamaguchi, Ryo; Ikawa, Masahito; Okabe, Masaru; Morii, Eiichi; Maeda, Yusuke; Kinoshita, Taroh			PGAP1 knock-out mice show otocephaly and male infertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; GPI-ANCHORED PROTEINS; WINGLESS MORPHOGEN GRADIENT; DALLY-LIKE PROTEIN; CELL-SURFACE; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHOR; DECAPACITATION FACTOR; VISCERAL ENDODERM; MONOCLONAL-ANTIBODIES; SPERM FERTILITY	A palmitate linked to the inositol in glycosylphosphatidylinositol (GPI) is removed in the endoplasmic reticulum immediately after the conjugation of GPI with proteins in most cells. Previously, we identified PGAP1 (post GPI attachment to proteins 1) as a GPI inositoldeacylase that removes the palmitate from inositol. A defect in PGAP1 caused a delay in the transport of GPI-anchored proteins (GPI-APs) from the endoplasmic reticulum to the cell surface in Chinese hamster ovary cells, although the cell-surface expression of GPI-APs in the steady state was normal. Nevertheless, in most cells, GPI-APs undergo deacylation. To elucidate the biological significance of PGAP1 in vivo, we established PGAP1 knock-out mice. Most PGAP1 knock-out mice showed otocephaly, a developmental defect, and died right after birth. However, some survived with growth retardation. Male knock-out mice showed severely reduced fertility despite the capability of ejaculation. Their spermatozoa were normal in number, motility, and ability to ascend the uterus, but were unable to go into the oviduct. In vitro, PGAP1-deficient spermatozoa showed weak attachment to the zona pellucida and a severely diminished rate of fertilization. Therefore, an extra acyl chain in GPI anchors caused severe deleterious effects to development and sperm function.	Osaka Univ, Dept Immunoregulat, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Dept Immunoregulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	ikawa, masahito/A-5315-2009; Kinoshita, Taroh/C-7353-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044; Ueda, Yutaka/0000-0001-8760-6379				AUSTIN CR, 1952, NATURE, V170, P326, DOI 10.1038/170326a0; Baba D, 2002, J BIOL CHEM, V277, P30310, DOI 10.1074/jbc.M204596200; Baeg GH, 2001, DEVELOPMENT, V128, P87; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; BEDFORD JM, 1962, AM J PHYSIOL, V202, P179, DOI 10.1152/ajplegacy.1962.202.1.179; BIXLER D, 1985, J CRAN GENET DEV BIO, P241; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; DEEG MA, 1992, J BIOL CHEM, V267, P18573; deLamirande E, 1997, MOL HUM REPROD, V3, P175, DOI 10.1093/molehr/3.3.175; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Franch-Marro X, 2005, DEVELOPMENT, V132, P659, DOI 10.1242/dev.01639; FRASER LR, 1984, J REPROD FERTIL, V72, P373, DOI 10.1530/jrf.0.0720373; Fraser LR, 1998, MOL REPROD DEV, V51, P193, DOI 10.1002/(SICI)1098-2795(199810)51:2&lt;193::AID-MRD9&gt;3.0.CO;2-L; Gibbons R, 2005, REPRODUCTION, V130, P497, DOI 10.1530/rep.1.00792; Giraldez AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Han C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/dev.01636; Harris CL, 2003, IMMUNOLOGY, V109, P117, DOI 10.1046/j.1365-2567.2003.01628.x; Hide T, 2002, DEVELOPMENT, V129, P4347; Hufnagel L, 2006, DEV BIOL, V300, P512, DOI 10.1016/j.ydbio.2006.08.076; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; JURILOFF DM, 1985, J CRAN GENET DEV BIO, V5, P121; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Khare N, 2000, MECH DEVELOP, V99, P199, DOI 10.1016/S0925-4773(00)00502-5; Kimura C, 2000, DEV BIOL, V225, P304, DOI 10.1006/dbio.2000.9835; Kimura C, 2001, DEV BIOL, V235, P12, DOI 10.1006/dbio.2001.0289; Kimura-Yoshida C, 2005, DEV CELL, V9, P639, DOI 10.1016/j.devcel.2005.09.011; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; Kirkpatrick CA, 2004, DEV CELL, V7, P513, DOI 10.1016/j.devcel.2004.08.004; Kondoh G, 2005, NAT MED, V11, P160, DOI 10.1038/nm1179; Kravets FG, 2000, PROSTATE, V43, P169, DOI 10.1002/(SICI)1097-0045(20000515)43:3<169::AID-PROS2>3.0.CO;2-D; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Kreuger J, 2004, DEV CELL, V7, P503, DOI 10.1016/j.devcel.2004.08.005; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maeda Y, 2007, MOL BIOL CELL, V18, P1497, DOI 10.1091/mbc.E06-10-0885; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; Murakami Y, 2003, MOL BIOL CELL, V14, P4285, DOI 10.1091/mbc.E03-03-0193; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Nozaki M, 1999, LAB INVEST, V79, P293; Ohta R, 1999, MICROBIOL IMMUNOL, V43, P1045, DOI 10.1111/j.1348-0421.1999.tb01234.x; Perea-Gomez A, 2001, DEVELOPMENT, V128, P753; Rooney IA, 1996, J CLIN INVEST, V97, P1675, DOI 10.1172/JCI118594; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Saez F, 2003, J ANDROL, V24, P149; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Suda Y, 1996, GENES CELLS, V1, P1031, DOI 10.1046/j.1365-2443.1996.900288.x; Tanaka S, 2004, J BIOL CHEM, V279, P14256, DOI 10.1074/jbc.M313755200; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Wallis D, 2000, HUM MUTAT, V16, P99, DOI 10.1002/1098-1004(200008)16:2<99::AID-HUMU2>3.0.CO;2-0; WALTER EI, 1990, J IMMUNOL, V144, P1030; Winter RM, 1996, NAT GENET, V12, P124, DOI 10.1038/ng0296-124; Yamagata K, 2002, DEV BIOL, V250, P348, DOI 10.1006/dbio.2002.0803; Yamaguchi R, 2006, BIOL REPROD, V75, P760, DOI 10.1095/biolreprod.106.052977; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Zakin L, 2000, P NATL ACAD SCI USA, V97, P14388, DOI 10.1073/pnas.011513398; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	78	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30373	30380		10.1074/jbc.M705601200	http://dx.doi.org/10.1074/jbc.M705601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17711852	hybrid			2022-12-25	WOS:000250136300005
J	Xiao, F; Giavalisco, P; Martin, GB				Xiao, Fangming; Giavalisco, Patrick; Martin, Gregory B.			Pseudomonas syringae type III effector AvrPtoB is phosphorylated in plant cells on serine 258, promoting its virulence activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; PTO-MEDIATED RESISTANCE; RHIZOBIUM SP NGR234; PV. TOMATO; DISEASE RESISTANCE; INNATE IMMUNITY; SECRETION SYSTEM; PLASMA-MEMBRANE; PROTEIN-KINASE; DEATH	The Pseudomonas syringae pv. tomato protein AvrPtoB is translocated into plant cells via the bacterial type III secretion system. In resistant tomato leaves, AvrPtoB acts as an avirulence protein by interacting with the host Pto kinase and eliciting the host immune response. Pto-mediated immunity requires Prf, a Pto-interacting protein with a putative nucleotide-binding site and a region of leucine-rich repeats. In susceptible tomato plants, which lack either Pto or Prf, AvrPtoB acts as a virulence protein by promoting P. syringae pv. tomato growth and enhancing symptoms associated with bacterial speck disease. The N-terminal 307 amino acids of AvrPtoB ( designated AvrPtoB(1-307)) are sufficient for these virulence activities and for Pto-mediated avirulence. We report that AvrPtoB is phosphorylated by a Pto- and Prf-independent kinase activity that is conserved in several plant species, including tomato ( Solanum lycopersicum), Nicotiana benthamiana, and Arabidopsis thaliana. AvrPtoB(1-307) was phosphorylated in tomato protoplasts, and mass spectrometry identified serine 258 as the major in vivo phosphorylation site of this protein. An alanine substitution of Ser(258) resulted in the loss of virulence and the diminution of avirulence activity of AvrPtoB(1-307), whereas a phosphomimetic S258D mutant had activities similar to wild type AvrPtoB(1-307). These observations suggest that AvrPtoB has evolved to mimic a substrate of a conserved plant kinase, leading to enhancement of its virulence and avirulence activities in the host cell.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research; Cornell University	Martin, GB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	gbm7@cornell.edu	Martin, Gregory B/F-6262-2011	Martin, Gregory B/0000-0003-0044-6830	NIGMS NIH HHS [R01GM078021, R01 GM078021-02, R01 GM078021] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078021] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitch RB, 2006, P NATL ACAD SCI USA, V103, P2851, DOI 10.1073/pnas.0507892103; Abramovitch RB, 2004, CURR OPIN PLANT BIOL, V7, P356, DOI 10.1016/j.pbi.2004.05.002; Abramovitch RB, 2003, EMBO J, V22, P60, DOI 10.1093/emboj/cdg006; Abramovitch RB, 2006, NAT REV MOL CELL BIO, V7, P601, DOI 10.1038/nrm1984; Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; Anderson JC, 2006, PLANT CELL, V18, P502, DOI 10.1105/tpc.105.036590; Angot A, 2007, PLOS PATHOG, V3, P1, DOI 10.1371/journal.ppat.0030003; Bartsev AV, 2004, PLANT PHYSIOL, V134, P871, DOI 10.1104/pp.103.031740; Bartsev AV, 2003, FEBS LETT, V554, P271, DOI 10.1016/S0014-5793(03)01145-1; Chang JH, 2000, MOL PLANT MICROBE IN, V13, P568, DOI 10.1094/MPMI.2000.13.5.568; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; Cohn JR, 2005, PLANT J, V44, P139, DOI 10.1111/j.1365-313X.2005.02516.x; Desveaux D., 2007, PLOS PATHOG, V3, P0456; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grant SR, 2006, ANNU REV MICROBIOL, V60, P425, DOI 10.1146/annurev.micro.60.080805.142251; Greenberg JT, 2004, CELL MICROBIOL, V6, P201, DOI 10.1111/j.1462-5822.2004.00361.x; He P, 2006, CELL, V125, P563, DOI 10.1016/j.cell.2006.02.047; Jamir Y, 2004, PLANT J, V37, P554, DOI 10.1046/j.1365-313X.2003.01982.x; Janjusevic R, 2006, SCIENCE, V311, P222, DOI 10.1126/science.1120131; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; Li XY, 2005, P NATL ACAD SCI USA, V102, P12990, DOI 10.1073/pnas.0502425102; Lin NC, 2006, APPL ENVIRON MICROB, V72, P702, DOI 10.1128/AEM.72.1.702-712.2006; Lin NC, 2005, MOL PLANT MICROBE IN, V18, P43, DOI 10.1094/MPMI-18-0043; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Mucyn TS, 2006, PLANT CELL, V18, P2792, DOI 10.1105/tpc.106.044016; Mudgett MB, 2005, ANNU REV PLANT BIOL, V56, P509, DOI 10.1146/annurev.arplant.56.032604.144218; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Petnicki-Ocwieja T, 2002, P NATL ACAD SCI USA, V99, P7652, DOI 10.1073/pnas.112183899; Rosebrock TR, 2007, NATURE, V448, P370, DOI 10.1038/nature05966; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Shan LB, 2000, MOL PLANT MICROBE IN, V13, P592, DOI 10.1094/MPMI.2000.13.6.592; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Skorpil P, 2005, MOL MICROBIOL, V57, P1304, DOI 10.1111/j.1365-2958.2005.04768.x; Wulf' J, 2004, STRUCTURE, V12, P1257, DOI 10.1016/j.str.2004.04.017; XIAO F, 2007, PLANT J; Xiao FM, 2003, PLANT PHYSIOL, V131, P1239, DOI 10.1104/pp.016113; Zipfel C, 2005, CURR OPIN PLANT BIOL, V8, P353, DOI 10.1016/j.pbi.2005.05.004	39	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30737	30744		10.1074/jbc.M705565200	http://dx.doi.org/10.1074/jbc.M705565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17711844	Green Accepted, hybrid			2022-12-25	WOS:000250136300042
J	Ma, H; Jiang, WR; Robledo, N; Leveque, V; Ali, S; Lara-Jaime, T; Masjedizadeh, M; Smith, DB; Cammack, N; Klumpp, K; Symons, J				Ma, Han; Jiang, Wen-Rong; Robledo, Nicole; Leveque, Vincent; Ali, Samir; Lara-Jaime, Teresa; Masjedizadeh, Mohammad; Smith, David B.; Cammack, Nick; Klumpp, Klaus; Symons, Julian			Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2 '-Deoxy-2 '-fluoro-2 '-C-methylcytidine (PSI-6130) and identification of a novel active 5 '-triphosphate species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-SYNTHESIS; DEOXYCYTIDYLATE DEAMINASE; POTENT INHIBITOR; REPLICATION; RIBONUCLEOSIDES; NUCLEOTIDE; RIBAVIRIN; ANALOGS; DESIGN	beta- D- 2'- Deoxy- 2'- fluoro- 2'- C- methylcytidine ( PSI- 6130) is a potent inhibitor of hepatitis C virus ( HCV) replication in the subgenomic HCV replicon system, and its corresponding 5 '- triphosphate is a potent inhibitor of the HCV RNA polymerase in vitro. In this study the formation of PSI- 6130- triphosphate was characterized in primary human hepatocytes. PSI6130 and its 5 '- phosphorylated derivatives were identified, and the intracellular concentrations were determined. In addition, the deaminated derivative of PSI- 6130, '- D- 2 '- deoxy- 2 '- fluoro2 '- C- methyluridine ( RO2433, PSI- 6026) and its corresponding phosphorylated metabolites were identified in human hepatocytes after incubation with PSI- 6130. The formation of the 5 '- triphosphate ( TP) of PSI- 6130 ( PSI- 6130- TP) and RO2433 ( RO2433- TP) increased with time and reached steady state levels at 48 h. The formation of both PSI- 6130- TP and RO2433- TP demonstrated a linear relationship with the extracellular concentrations of PSI- 6130 up to 100 mu M, suggesting a high capacity of human hepatocytes to generate the two triphosphates. The mean half- lives of PSI- 6130- TP and RO2433- TP were 4.7 and 38 h, respectively. RO2433- TP also inhibited RNA synthesis by the native HCV replicase isolated from HCV replicon cells and the recombinantHCVpolymerase NS5B with potencies comparable with those of PSI- 6130- TP. Incorporation of RO2433- 5 'monophosphate ( MP) into nascent RNA by NS5B led to chain termination similar to that of PSI- 6130- MP. These results demonstrate that PSI- 6130 is metabolized to two pharmacologically active species in primary human hepatocytes.	Roche Palo Alto LLC, Palo Alto, CA 94304 USA	Roche Holding	Ma, H (corresponding author), Roche Palo Alto LLC, 3431 Hillview Ave, Palo Alto, CA 94304 USA.	han.ma@roche.com						AFDHAL N, 2005, 40 ANN M EUR ASS STU; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Carroll S. S., 2006, Infectious Disorders - Drug Targets, V6, P17, DOI 10.2174/187152606776056698; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Clark JL, 2005, J MED CHEM, V48, P5504, DOI 10.1021/jm0502788; DUARTE MIS, 1989, J SUBMICR CYTOL PATH, V21, P275; Eldrup AB, 2004, J MED CHEM, V47, P5284, DOI 10.1021/jm040068f; FRIED, 2002, NEJM, V347, P975; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Hardy RW, 2003, J VIROL, V77, P2029, DOI 10.1128/JVI.77.3.2029-2037.2003; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; Klumpp K, 2006, J BIOL CHEM, V281, P3793, DOI 10.1074/jbc.M510195200; Le Pogam S, 2006, VIROLOGY, V351, P349, DOI 10.1016/j.virol.2006.03.045; Ma H, 2005, VIROLOGY, V332, P8, DOI 10.1016/j.virol.2004.11.024; MANCINI WR, 1983, MOL PHARMACOL, V23, P159; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Murakami E, 2007, ANTIMICROB AGENTS CH, V51, P503, DOI 10.1128/AAC.00400-06; Perrone P, 2007, J MED CHEM, V50, P1840, DOI 10.1021/jm0613370; Roberts S, 2006, HEPATOLOGY, V44, p692A; Smith DB, 2007, BIOORG MED CHEM LETT, V17, P2570, DOI 10.1016/j.bmcl.2007.02.004; Stuyver Lieven J., 2006, Antiviral Chemistry & Chemotherapy, V17, P79; Tomassini JE, 2005, ANTIMICROB AGENTS CH, V49, P2050, DOI 10.1128/AAC.49.5.2050-2058.2005; Van Rompay AR, 2000, PHARMACOL THERAPEUT, V87, P189, DOI 10.1016/S0163-7258(00)00048-6; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x	25	91	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29812	29820		10.1074/jbc.M705274200	http://dx.doi.org/10.1074/jbc.M705274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698842	hybrid			2022-12-25	WOS:000249981200010
J	Wiegert, JS; Bengtson, CP; Bading, H				Wiegert, J. Simon; Bengtson, C. Peter; Bading, Hilmar			Diffusion and not active transport underlies and limits ERK1/2 synapse-to-nucleus signaling in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE PATHWAY; MAP KINASE; REGULATED KINASE; NMDA RECEPTORS; LATE-PHASE; NUCLEOCYTOPLASMIC TRANSPORT; RETROGRADE TRANSPORT; RESPONSE ELEMENT; GENE-EXPRESSION	The propagation of signals from synapses and dendrites to the nucleus is crucial for long lasting adaptive changes in the nervous system. The ERK-MAPK pathway can link neuronal activity and cell surface receptor activation to the regulation of gene transcription, and it is often considered the principal mediator of synapse-to-nucleus communication in late-phase plasticity and learning. However, the mechanisms underlying ERK1/2 trafficking in dendrites and nuclear translocation in neurons remain to be determined leaving it unclear whether ERK1/2 activated at the synapse can contribute to nuclear signaling and transcriptional regulation. Using the photobleachable and photoactivable fluorescent tag Dronpa on ERK1 and ERK2, we show here that ERK1/2 translocation to the nucleus of hippocampal neurons is induced by the stimulation of N-methyl-D-aspartate receptors or TrkB stimulation and is apparently mediated by facilitated diffusion. In contrast, ERK1/2 trafficking within dendrites is not signal-regulated and is mediated by passive diffusion. Within dendrites, the reach of a locally activated pool of ERK1/2 is very limited and follows an exponential decay with distance. These results indicate that successful signal propagation to the nucleus by the ERK-MAPK pathway depends on the distance of the nucleus from the site of ERK1/2 activation. ERK1/2 activated within or near the soma may rapidly reach the nucleus to induce gene expression, whereas ERK1/2 activated at distal synapses may only contribute to local signaling.	Univ Heidelberg, Interdisciplinary Ctr Neurosci, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bading, H (corresponding author), Univ Heidelberg, Interdisciplinary Ctr Neurosci, Dept Neurobiol, Bergheimer Str 58, D-69120 Heidelberg, Germany.	Hilmar.Bading@uni-hd.de	Wiegert, J. Simon/ABE-4199-2020	Wiegert, J. Simon/0000-0003-0893-9349; Bengtson, C Peter/0000-0002-8245-3323				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi N, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-42; Adams JP, 2005, NAT REV NEUROSCI, V6, P737, DOI 10.1038/nrn1749; Akashi M, 2000, GENE DEV, V14, P645; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; Arnold FJL, 2005, J PHYSIOL-LONDON, V564, P3, DOI 10.1113/jphysiol.2004.077446; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Chen RH, 1996, ONCOGENE, V12, P1493; Costa M, 2006, J CELL SCI, V119, P4952, DOI 10.1242/jcs.03272; Deisseroth K, 2003, CURR OPIN NEUROBIOL, V13, P354, DOI 10.1016/S0959-4388(03)00076-X; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dudek SM, 2002, P NATL ACAD SCI USA, V99, P3962, DOI 10.1073/pnas.062510599; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Fujioka A, 2006, J BIOL CHEM, V281, P8917, DOI 10.1074/jbc.M509344200; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Futter M, 2005, P NATL ACAD SCI USA, V102, P3489, DOI 10.1073/pnas.0409802102; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Horiuchi KY, 1998, BIOCHEMISTRY-US, V37, P8879, DOI 10.1021/bi972731q; Howe CL, 2005, CURR OPIN NEUROBIOL, V15, P40, DOI 10.1016/j.conb.2005.01.010; Hu HJ, 2006, NEURON, V50, P89, DOI 10.1016/j.neuron.2006.03.010; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Limback-Stokin K, 2004, J NEUROSCI, V24, P10858, DOI 10.1523/JNEUROSCI.1022-04.2004; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nakamura T, 1996, ONCOGENE, V13, P1111; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Osawa M, 2004, J BIOL CHEM, V279, P29691, DOI 10.1074/jbc.M309371200; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PETERS R, 1986, BIOCHEM SOC T, V14, P821, DOI 10.1042/bst0140821; Raymond CR, 2006, J PHYSIOL-LONDON, V570, P97, DOI 10.1113/jphysiol.2005.098947; Reynolds AJ, 2001, NEUROSCIENCE, V105, P761, DOI 10.1016/S0306-4522(01)00235-4; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sindreu CB, 2007, NEURON, V53, P79, DOI 10.1016/j.neuron.2006.11.024; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Thiels E, 2001, REV NEUROSCIENCE, V12, P327; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Valjent E, 2000, J NEUROSCI, V20, P8701; Wellmann H, 2001, J BIOL CHEM, V276, P11821, DOI 10.1074/jbc.M009253200; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhao ML, 2005, J NEUROSCI, V25, P7032, DOI 10.1523/JNEUROSCI.1579-05.2005; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	70	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29621	29633		10.1074/jbc.M701448200	http://dx.doi.org/10.1074/jbc.M701448200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675293	hybrid			2022-12-25	WOS:000249788000059
J	Belevich, I; Borisov, VB; Verkhovsky, MI				Belevich, Ilya; Borisov, Vitaliy B.; Verkhovsky, Michael I.			Discovery of the true peroxy intermediate in the catalytic cycle of terminal oxidases by real-time measurement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; RESONANCE RAMAN-SPECTROSCOPY; BD UBIQUINOL OXIDASE; COMPOUND-I FORMATION; HEME ACTIVE-SITE; ESCHERICHIA-COLI; CARBON-MONOXIDE; QUINOL OXIDASE; HORSERADISH-PEROXIDASE; OXYGENATED COMPLEX	The sequence of the catalytic intermediates in the reaction of cytochrome bd terminal oxidases from Escherichia coli and Azotobacter vinelandii with oxygen was monitored in real time by absorption spectroscopy and electrometry. The initial binding of O-2 to the fully reduced enzyme is followed by the fast (5 mu s) conversion of the oxy complex to a novel, previously unresolved intermediate. In this transition, low spin heme b(558) remains reduced while high spin heme b(595) is oxidized with formation of a new heme d-oxygen species with an absorption maximum at 635 nm. Reduction of O-2 by two electrons is sufficient to produce ( hydro) peroxide bound to ferric heme d. In this case, the O-O bond is left intact and the newly detected intermediate must be a peroxy complex of heme d (Fe-d(3+)-O-O-( H)) corresponding to compound 0 in peroxidases. The alternative scenario where the O-O bond is broken as in the P-M intermediate of heme-copper oxidases and compound I of peroxidases is not very likely, because it would require oxidation of a nearby amino acid residue or the porphyrin ring that is energetically unfavorable in the presence of the reduced heme b558 in the proximity of the catalytic center. The formation of the peroxy intermediate is not coupled to membrane potential generation, indicating that hemes d and b595 are located at the same depth of the membrane dielectric. The lifetime of the new intermediate is 47 mu s; it decays into oxoferryl species due to oxidation of low spin heme b558 that is linked to significant charge translocation across the membrane.	Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, FI-00014 Helsinki, Finland; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Dept Mol Energet Microorganisms, Moscow 119991, Russia	University of Helsinki; Lomonosov Moscow State University	Verkhovsky, MI (corresponding author), Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, POB 65,Viikinkaari 1, FI-00014 Helsinki, Finland.	michael.verkhovsky@helsinki.fi	Borisov, Vitaliy B/C-9504-2012	Borisov, Vitaliy B/0000-0002-3400-9068; Belevich, Ilya/0000-0003-2190-4909				ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; Belevich I, 2005, P NATL ACAD SCI USA, V102, P3657, DOI 10.1073/pnas.0405683102; Belevich I, 2005, FEBS LETT, V579, P4567, DOI 10.1016/j.febslet.2005.07.011; BELEVICH I, 2007, IN PRESS BIOCHEMISTR; Belevich I, 2007, P NATL ACAD SCI USA, V104, P2685, DOI 10.1073/pnas.0608794104; Borisov V, 1999, BIOCHEMISTRY-US, V38, P740, DOI 10.1021/bi981908t; Borisov V, 1995, BIOCHEM MOL BIOL INT, V37, P975; Borisov VB, 2002, BIOCHEMISTRY-US, V41, P1654, DOI 10.1021/bi0158019; Borisov VB, 2001, J BIOL CHEM, V276, P22095, DOI 10.1074/jbc.M011542200; BORISOV VB, 1995, BIOCHEMISTRY-MOSCOW+, V60, P231; Borisov VB, 1996, BIOCHEMISTRY-MOSCOW+, V61, P565; Borisov VB, 2007, BIOCHEM BIOPH RES CO, V355, P97, DOI 10.1016/j.bbrc.2007.01.118; Borisov VB, 2006, FEBS LETT, V580, P4823, DOI 10.1016/j.febslet.2006.07.072; Brunori M, 2005, J INORG BIOCHEM, V99, P324, DOI 10.1016/j.jinorgbio.2004.10.011; Brzezinski P, 2004, TRENDS BIOCHEM SCI, V29, P380, DOI 10.1016/j.tibs.2004.05.008; Fabian M, 1999, P NATL ACAD SCI USA, V96, P13114, DOI 10.1073/pnas.96.23.13114; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; GREENWOOD C, 1974, BIOCHEM J, V137, P205, DOI 10.1042/bj1370205; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HILL BC, 1994, BIOCHEMISTRY-US, V33, P15110, DOI 10.1021/bi00254a021; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL BC, 1994, J BIOL CHEM, V269, P2419; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; Hosler JP, 2006, ANNU REV BIOCHEM, V75, P165, DOI 10.1146/annurev.biochem.75.062003.101730; Iwaki M, 2006, BIOCHEMISTRY-US, V45, P10873, DOI 10.1021/bi061114b; Jasaitis A, 2000, BIOCHEMISTRY-US, V39, P13800, DOI 10.1021/bi001165n; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Jones P, 2005, J INORG BIOCHEM, V99, P2292, DOI 10.1016/j.jinorgbio.2005.08.009; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; KAHLOW MA, 1991, BIOCHEMISTRY-US, V30, P11485, DOI 10.1021/bi00113a001; KAHLOW MA, 1993, J AM CHEM SOC, V115, P5845, DOI 10.1021/ja00066a071; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P14664, DOI 10.1021/bi0013748; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P1051, DOI 10.1021/bi00301a003; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; LORENCE RM, 1989, J BIOL CHEM, V264, P7135; MILLER MJ, 1986, METHOD ENZYMOL, V126, P87; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Morgan JE, 2001, BIOCHEMISTRY-US, V40, P6882, DOI 10.1021/bi010246w; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Shintaku M, 2005, J BIOL CHEM, V280, P40934, DOI 10.1074/jbc.M503472200; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sucheta A, 1998, BIOCHEMISTRY-US, V37, P17905, DOI 10.1021/bi981092w; TAKAHASHI S, 1995, J BIOL CHEM, V270, P8405, DOI 10.1074/jbc.270.15.8405; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; Vos MH, 2000, P NATL ACAD SCI USA, V97, P1554, DOI 10.1073/pnas.030528197; Yoshikawa S, 2006, BBA-BIOENERGETICS, V1757, P395, DOI 10.1016/j.bbabio.2006.04.028; Zhang J, 2001, BIOCHEMISTRY-US, V40, P8548, DOI 10.1021/bi010469m	58	44	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28514	28519		10.1074/jbc.M705562200	http://dx.doi.org/10.1074/jbc.M705562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690093	hybrid			2022-12-25	WOS:000249642100025
J	Ma, L; Wang, HY				Ma, Li; Wang, Hsien-Yu			Mitogen-activated protein kinase p38 regulates the Wnt/Cyclic GMP/Ca2+ non-canonical pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PROTEIN-KINASE; WNT; WINGLESS; CA2+; JNK; CGMP	The non-canonical Wnt/cyclic GMP/Ca2+/ NF-AT pathway operates via Frizzled-2, a member of the superfamily of G protein-coupled receptors. In scanning for signaling events downstream of the Frizzled-2/G alpha t2/PDE6 triad activated in response to Wnt5a, we observed a strong activation of the mitogen-activated protein kinase p38 in mouse F9 teratocarcinoma embryonal cells. The activation of p38 is essential for NF-AT transcriptional activation mediated via Frizzled2. Wnt5a-stimulated p38 activation was rapid, sensitive to pertussis toxin, to siRNA against either G alpha t2 or p38 alpha, and to the p38 inhibitor SB203580. Real-time analysis of intracellular cyclic GMP using the Cygnet2 biosensor revealed p38 to act at the level of cyclic GMP, upstream of the mobilization of intracellular Ca2+. Fluorescence resonance energy transfer (FRET) imaging reveals the changes in cyclic GMP in response to Wnt5a predominate about the cell membrane, and likewise sensitive to either siRNA targeting p38 or to treatment with SB203580. Dishevelled is not required for Wnt5a activation of p38; siRNAs targeting Dishevelleds and expression of the Dishevelled antagonist Dapper-1 do not suppress the p38 response to Wnt5a stimulation. These novel results are the first to detail a Dishevelled-independent Wnt response, demonstrating a critical role of the mitogen-activated protein kinase p38 in regulating the Wnt non-canonical pathway.	SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Physiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	wangh@pharm.stonybrook.edu	Ma, Li/AAG-4109-2020	Ma, Li/0000-0001-8470-0378	NIGMS NIH HHS [GM069375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen CM, 1999, DEVELOPMENT, V126, P5441; Chen LY, 1997, AM J PHYSIOL-HEART C, V273, pH1854, DOI 10.1152/ajpheart.1997.273.4.H1854; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Honda Akira, 2005, V307, P27; Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200; Katanaev VL, 2006, P NATL ACAD SCI USA, V103, P6524, DOI 10.1073/pnas.0601853103; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma L, 2006, J BIOL CHEM, V281, P30990, DOI 10.1074/jbc.M603603200; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Wang H, 2004, BIOCHEM SOC T, V32, P792, DOI 10.1042/BST0320792; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; WOLFE L, 1987, J BIOL CHEM, V262, P16906; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008	32	63	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28980	28990		10.1074/jbc.M702840200	http://dx.doi.org/10.1074/jbc.M702840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17684012	hybrid			2022-12-25	WOS:000249642100072
J	Mah, AK; Armstrong, KR; Chew, DS; Chu, JS; Tu, DK; Johnsen, RC; Chen, N; Chamberlin, HM; Baillie, DL				Mah, Allan K.; Armstrong, Kristin R.; Chew, Derek S.; Chu, Jeffrey S.; Tu, Dornena K.; Johnsen, Robert C.; Chen, Nansheng; Chamberlin, Helen M.; Baillie, David L.			Transcriptional regulation of AQP-8, a Caenorhabditis elegans aquaporin exclusively expressed in the excretory system, by the POU homeobox transcription factor CEH-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL; FUNCTIONAL-CHARACTERIZATION; NERVOUS-SYSTEM; GENE; CELL; IDENTIFICATION; PROTEIN; NEMATODE; DOMAIN; MEMBRANE	Due to the ever changing environmental conditions in soil, regulation of osmotic homeostasis in the soil-dwelling nematode Caenorhabditis elegans is critical. AQP-8 is a C. elegans aquaporin that is expressed in the excretory cell, a renal equivalent tissue, where the protein participates in maintaining water balance. To better understand the regulation of AQP-8, we undertook a promoter analysis to identify the aqp-8 cis-regulatory elements. Using progressive 5' deletions of upstream sequence, we have mapped an essential regulatory region to roughly 300 bp upstream of the translational start site of aqp-8. Analysis of this region revealed a sequence corresponding to a known DNA functional element (octamer motif), which interacts with POU homeobox transcription factors. Phylogenetic footprinting showed that this site is perfectly conserved in four nematode species. The octamer site's function was further confirmed by deletion analyses, mutagenesis, functional studies, and electrophoretic mobility shift assays. Of the three POU homeobox proteins encoded in the C. elegans genome, CEH-6 is the only member that is expressed in the excretory cell. We show that expression of AQP-8 is regulated by CEH-6 by performing RNA interference experiments. CEH-6's mammalian ortholog, Brn1, is expressed both in the kidney and the central nervous system and binds to the same octamer consensus binding site to drive gene expression. These parallels in transcriptional control between Brn1 and CEH-6 suggest that C. elegans may well be an appropriate model for determining gene-regulatory networks in the developing vertebrate kidney.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Simon Fraser University; University System of Ohio; Ohio State University	Mah, AK (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	amaha@sfu.ca	Chamberlin, Helen/L-4206-2019; Chen, Nansheng/E-6450-2012	Chamberlin, Helen/0000-0001-7203-2691; Chew, Derek/0000-0003-3539-7485				AGRE P, 1993, AM J PHYSIOL, V265, pF463; Baranek C, 2005, NUCLEIC ACIDS RES, V33, P6277, DOI 10.1093/nar/gki947; Blacque OE, 2005, CURR BIOL, V15, P935, DOI 10.1016/j.cub.2005.04.059; BRENNER S, 1974, GENETICS, V77, P71; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; Buechner M, 2002, TRENDS CELL BIOL, V12, P479, DOI 10.1016/S0962-8924(02)02364-4; Burglin TR, 2001, DEVELOPMENT, V128, P779; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Castle NA, 2005, DRUG DISCOV TODAY, V10, P485, DOI 10.1016/S1359-6446(05)03390-8; Chavez M, 1999, MECH DEVELOP, V87, P207, DOI 10.1016/S0925-4773(99)00152-5; Coates JC, 2002, NATURE, V419, P925, DOI 10.1038/nature01170; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Frand AR, 2005, PLOS BIOL, V3, P1719, DOI 10.1371/journal.pbio.0030312; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Gazzarrini S, 2006, P NATL ACAD SCI USA, V103, P5355, DOI 10.1073/pnas.0600848103; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; Hauptmann G, 2000, DEV DYNAM, V218, P345, DOI 10.1002/(SICI)1097-0177(200006)218:2<345::AID-DVDY8>3.0.CO;2-V; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Huang CG, 2007, AM J PHYSIOL-CELL PH, V292, pC1867, DOI 10.1152/ajpcell.00514.2006; Ishibashi K, 2002, BBA-GENE STRUCT EXPR, V1576, P335, DOI 10.1016/S0167-4781(02)00393-7; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; KALDENHOFF R, 1995, PLANT J, V7, P87, DOI 10.1046/j.1365-313X.1995.07010087.x; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kuwahara M, 2000, BBA-GENE STRUCT EXPR, V1517, P107, DOI 10.1016/S0167-4781(00)00268-2; Kuwahara M, 1998, AM J PHYSIOL-CELL PH, V275, pC1459, DOI 10.1152/ajpcell.1998.275.6.C1459; Lan L, 2006, DEV DYNAM, V235, P1107, DOI 10.1002/dvdy.20703; Li HP, 2005, BIOL CELL, V97, P823, DOI 10.1042/BC20040091; McCarroll SA, 2005, CURR BIOL, V15, P347, DOI 10.1016/j.cub.2005.02.023; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Nakai S, 2003, DEVELOPMENT, V130, P4751, DOI 10.1242/dev.00666; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Rai T, 1997, AM J PHYSIOL-RENAL, V273, pF264, DOI 10.1152/ajprenal.1997.273.2.F264; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rose KL, 1997, DEV BIOL, V192, P59, DOI 10.1006/dbio.1997.8728; Ross DA, 1998, J IMMUNOL, V160, P3874; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; Spaniol P, 1996, NUCLEIC ACIDS RES, V24, P4874, DOI 10.1093/nar/24.24.4874; Stein LD, 2002, GENOME RES, V12, P1599, DOI 10.1101/gr.403602; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Sze JY, 2003, P NATL ACAD SCI USA, V100, P9560, DOI 10.1073/pnas.1530752100; Thacker C, 2006, CELL MOL LIFE SCI, V63, P1193, DOI 10.1007/s00018-006-6012-z; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Wang LL, 1996, MECH DEVELOP, V56, P183, DOI 10.1016/0925-4773(96)00523-0; Yuh CH, 2005, DEV BIOL, V281, P286, DOI 10.1016/j.ydbio.2005.02.034; Zhang TY, 2004, BIOCHEM J, V380, P255, DOI 10.1042/BJ20031482; Zhao ZY, 2005, J BIOL CHEM, V280, P38787, DOI 10.1074/jbc.M505701200	64	23	26	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28074	28086		10.1074/jbc.M703305200	http://dx.doi.org/10.1074/jbc.M703305200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660295	hybrid			2022-12-25	WOS:000249455600057
J	Wang, ZX; Wu, JW				Wang, Zhi-Xin; Wu, Jia-Wei			The complete pathway for ERK2-catalyzed reaction - Evidence for an iso random BiBi mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; KINETIC MECHANISM; SUBSTRATE; PHOSPHORYLATION; EQUILIBRIUM	In the present study, the enzymatic mechanism of ERK2 is re-examined by a combination of steady-state kinetic studies in the absence and presence of viscosogenic agents. Kinetic studies carried out in various concentrations of sucrose revealed that both k(cat) and k(cat)/K-m for either ATP or Ets Delta 138 were highly sensitive to solvent viscosity, suggesting that the rapid equilibrium assumption is not valid for the phosphorylation of protein substrate by ERK2. Furthermore, the kinetic analysis with the minimal random Bi Bi reaction mechanism is shown to be inconsistent with the principle of the detailed balance. This inconsistent calculation strongly suggests that there is isomerization of the enzyme-substrate ternary complex. The viscosity-dependent steady-state kinetic data are combined to establish a kinetic mechanism for the ERK2-catalyzed reaction that predicts initial reaction velocities under varying concentrations of ATP and substrate. These results complement previous structure-function studies of mitogen-activated protein kinases and provide important insight for mechanistic interpretation of the kinase functions.	Tsinghua Univ, Dept Biol Sci, Beijing 100084, Peoples R China; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100080, Peoples R China	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, ZX (corresponding author), Tsinghua Univ, Dept Biol Sci, Beijing 100084, Peoples R China.	zxwang@sun5.ibp.ac.cn; Jiaweiwu@mail.tsinghua.edu.cn	wang, zhixin/GZH-2500-2022					ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; [Anonymous], 1982, PHYS BIOCH APPL BIOC; CHA S, 1968, J BIOL CHEM, V243, P820; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DALZIEL K, 1958, T FARADAY SOC, V54, P1247, DOI 10.1039/tf9585401247; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FRIEDEN C, 1976, BIOCHEM BIOPH RES CO, V68, P914, DOI 10.1016/0006-291X(76)91232-8; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; GUTFREUND H, 1995, KINETICS LIFE SCI, P248; HAMMES GG, 1995, THERMODYNAMICS KINET; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Madhusudan, 2002, NAT STRUCT BIOL, V9, P273, DOI 10.1038/nsb780; PETTERSSON G, 1969, ACTA CHEM SCAND, V23, P2717, DOI 10.3891/acta.chem.scand.23-2717; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; SEUBERT PA, 1985, ARCH BIOCHEM BIOPHYS, V240, P509, DOI 10.1016/0003-9861(85)90057-8; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Waas WF, 2002, J BIOL CHEM, V277, P12532, DOI 10.1074/jbc.M110523200; Waas WF, 2001, PROTEIN EXPRES PURIF, V23, P191, DOI 10.1006/prep.2001.1491; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilsbacher JL, 2001, METHOD ENZYMOL, V332, P387	26	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27678	27684		10.1074/jbc.M703161200	http://dx.doi.org/10.1074/jbc.M703161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652083	hybrid			2022-12-25	WOS:000249455600015
J	Lee, WS; Payne, BJ; Gelfman, CM; Vogel, P; Kornfeld, S				Lee, Wang-Sik; Payne, Bobby Joe; Gelfman, Claire M.; Vogel, Peter; Kornfeld, Stuart			Murine UDP-GlcNAc : Lysosomal enzyme N-acetylglucosamine-1-phosphotransferase lacking the gamma-subunit retains substantial activity toward acid hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-HURLER POLYDYSTROPHY; PHOSPHOTRANSFERASE ALPHA/BETA-SUBUNITS; I-CELL DISEASE; N-ACETYLGLUCOSAMINE; MUCOLIPIDOSIS-III; PROCATHEPSIN-D; PHOSPHORYLATION; MUTATIONS; IDENTIFICATION; RECOGNITION	UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase) mediates the first step in the synthesis of the mannose 6-phosphate recognition marker on acid hydrolases. The transferase exists as an alpha(2)beta(2)gamma(2) hexameric complex with the alpha- and beta-subunits derived from a single precursor molecule. The catalytic function of the transferase is attributed to the alpha- and beta-subunits, whereas the gamma-subunit is believed to be involved in the recognition of a conformation-dependent protein determinant common to acid hydrolases. Using knock-out mice with mutations in either the alpha/beta gene or the gamma gene, we show that disruption of the alpha/beta gene completely abolishes phosphorylation of high mannose oligosaccharides on acid hydrolases whereas knock-out of the gamma gene results in only a partial loss of phosphorylation. These findings demonstrate that the alpha/beta-subunits, in addition to their catalytic function, have some ability to recognize acid hydrolases as specific substrates. This process is enhanced by the gamma-subunit.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Lexicon Pharmaceut Inc, The Woodlands, TX 77381 USA	Washington University (WUSTL); Lexicon Pharmaceuticals	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.	skornfel@wustl.edu	Vogel, Peter/N-2490-2018	Vogel, Peter/0000-0002-7535-0545	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AERTS JMFG, 1988, BIOCHIM BIOPHYS ACTA, V964, P303, DOI 10.1016/0304-4165(88)90030-X; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bargal R, 2006, MOL GENET METAB, V88, P359, DOI 10.1016/j.ymgme.2006.03.003; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; GELFMAN C, 2007, IN PRESS INVEST OPHT; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Joyner AL, 2000, GENE TARGETING PRACT; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; Kornfeld S., 2001, METABOLIC MOL BASES, P3469; Kudo M, 2006, AM J HUM GENET, V78, P451, DOI 10.1086/500849; Kudo M, 2005, J BIOL CHEM, V280, P36141, DOI 10.1074/jbc.m509008200; LANG L, 1984, J BIOL CHEM, V259, P4663; LANG L, 1985, J CLIN INVEST, V76, P2191, DOI 10.1172/JCI112227; LITTLE LE, 1986, J BIOL CHEM, V261, P733; Mazrier H, 2003, J HERED, V94, P363, DOI 10.1093/jhered/esg080; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; Paik KH, 2005, HUM MUTAT, V26, P308, DOI 10.1002/humu.20205; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; Schierau A, 1999, J BIOL CHEM, V274, P3651, DOI 10.1074/jbc.274.6.3651; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; Steet R, 2005, J BIOL CHEM, V280, P33318, DOI 10.1074/jbc.M505994200; Steet RA, 2005, AM J MED GENET A, V132A, P369, DOI 10.1002/ajmg.a.30498; Steet R, 2007, BIOCHEM PHARMACOL, V73, P1376, DOI 10.1016/j.bcp.2006.12.015; Tiede S, 2005, AM J MED GENET A, V137A, P235, DOI 10.1002/ajmg.a.30868; Tiede S, 2005, NAT MED, V11, P1109, DOI 10.1038/nm1305; Tiede Stephan, 2004, Hum Mutat, V24, P535, DOI 10.1002/humu.9293; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; VARKI A, 1982, AM J HUM GENET, V34, P717; VARKI AP, 1981, P NATL ACAD SCI-BIOL, V78, P7773, DOI 10.1073/pnas.78.12.7773; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; Yaghootfam A, 2003, J BIOL CHEM, V278, P32653, DOI 10.1074/jbc.M304865200; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27198	27203		10.1074/jbc.M704067200	http://dx.doi.org/10.1074/jbc.M704067200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652091	hybrid			2022-12-25	WOS:000249304900061
J	Jun, JK; Jin, DZZ				Jun, Joseph K.; Jin, Dezhe Z.			Development of Neural Circuitry for Precise Temporal Sequences through Spontaneous Activity, Axon Remodeling, and Synaptic Plasticity	PLOS ONE			English	Article							NEURONAL REPLACEMENT; SILENT SYNAPSES; SYNFIRE CHAINS; IN-VIVO; PROPAGATION; GENERATION; SYNCHRONY; DYNAMICS; PATTERNS; SPIKING	Temporally precise sequences of neuronal spikes that span hundreds of milliseconds are observed in many brain areas, including songbird premotor nucleus, cat visual cortex, and primary motor cortex. Synfire chains-networks in which groups of neurons are connected via excitatory synapses into a unidirectional chain-are thought to underlie the generation of such sequences. It is unknown, however, how synfire chains can form in local neural circuits, especially for long chains. Here, we show through computer simulation that long synfire chains can develop through spike-time dependent synaptic plasticity and axon remodeling-the pruning of prolific weak connections that follows the emergence of a finite number of strong connections. The formation process begins with a random network. A subset of neurons, called training neurons, intermittently receive superthreshold external input. Gradually, a synfire chain emerges through a recruiting process, in which neurons within the network connect to the tail of the chain started by the training neurons. The model is robust to varying parameters, as well as natural events like neuronal turnover and massive lesions. Our model suggests that long synfire chain can form during the development through self-organization, and axon remodeling, ubiquitous in developing neural circuits, is essential in the process.	[Jun, Joseph K.; Jin, Dezhe Z.] Penn State Univ, Dept Phys, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Jin, DZZ (corresponding author), Penn State Univ, Dept Phys, 104 Davey Lab, University Pk, PA 16802 USA.	djin@phys.psu.edu	Jin, Dezhe/AAE-6788-2020		Huck Institute of Life Sciences; Pennsylvania State University; A.P. Sloan Research Fellowship; ONR [N000140410208]	Huck Institute of Life Sciences; Pennsylvania State University; A.P. Sloan Research Fellowship(Alfred P. Sloan Foundation); ONR(Office of Naval Research)	Research supported by the Huck Institute of Life Sciences, The Pennsylvania State University; A.P. Sloan Research Fellowship; and ONR grant N000140410208.	Abeles M., 1982, LOCAL CORTICAL CIRCU; Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; Airey DC, 2000, NEUROREPORT, V11, P1749, DOI 10.1097/00001756-200006050-00030; ALVAREZBUYLLA A, 1990, SCIENCE, V249, P1444, DOI 10.1126/science.1698312; AMARI SI, 1972, IEEE T COMPUT, VC 21, P1197, DOI 10.1109/T-C.1972.223477; Atasoy D, 2006, NEURON, V50, P345, DOI 10.1016/j.neuron.2006.04.018; Atwood HL, 1999, LEARN MEMORY, V6, P542, DOI 10.1101/lm.6.6.542; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Buonomano DV, 2005, J NEUROPHYSIOL, V94, P2275, DOI 10.1152/jn.01250.2004; Diesmann M, 1999, NATURE, V402, P529, DOI 10.1038/990101; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; FLADBY T, 1987, ACTA PHYSIOL SCAND, V129, P239, DOI 10.1111/j.1748-1716.1987.tb08064.x; Fonseca R, 2004, NEURON, V44, P1011, DOI 10.1016/j.neuron.2004.10.033; Hahnloser RHR, 2002, NATURE, V419, P65, DOI 10.1038/nature00974; Hertz J, 1996, NETWORK-COMP NEURAL, V7, P357, DOI 10.1088/0954-898X/7/2/017; Hua JY, 2005, NATURE, V434, P1022, DOI 10.1038/nature03409; Ikegaya Y, 2004, SCIENCE, V304, P559, DOI 10.1126/science.1093173; Immelmann K., 1969, P61; Innocenti GM, 2005, NAT REV NEUROSCI, V6, P955, DOI 10.1038/nrn1790; Jarvis ED, 1998, NEURON, V21, P775, DOI 10.1016/S0896-6273(00)80594-2; Jin DZ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208102; JIN DZ, 2007, J COMP NEUR IN PRESS; Kasthuri N, 2003, NATURE, V424, P426, DOI 10.1038/nature01836; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kitano K, 2002, NEUROREPORT, V13, P795, DOI 10.1097/00001756-200205070-00012; KLEINFELD D, 1988, BIOPHYS J, V54, P1039, DOI 10.1016/S0006-3495(88)83041-8; Kozhevnikov AA, 2007, J NEUROPHYSIOL, V97, P4271, DOI 10.1152/jn.00952.2006; Levy N, 2001, NEURAL NETWORKS, V14, P815, DOI 10.1016/S0893-6080(01)00044-2; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Meyer MP, 2006, J NEUROSCI, V26, P3604, DOI 10.1523/JNEUROSCI.0223-06.2006; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; Nottebohm F, 2002, J NEUROSCI, V22, P624, DOI 10.1523/JNEUROSCI.22-03-00624.2002; Nowotny T, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.011908; Prut Y, 1998, J NEUROPHYSIOL, V79, P2857, DOI 10.1152/jn.1998.79.6.2857; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; Reyes AD, 2003, NAT NEUROSCI, V6, P593, DOI 10.1038/nn1056; Ruthazer ES, 2006, J NEUROSCI, V26, P3594, DOI 10.1523/JNEUROSCI.0069-06.2006; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Shen WH, 2006, NEURON, V50, P401, DOI 10.1016/j.neuron.2006.03.017; SOMPOLINSKY H, 1986, PHYS REV LETT, V57, P2861, DOI 10.1103/PhysRevLett.57.2861; Song S, 2000, NAT NEUROSCI, V3, P919, DOI 10.1038/78829; THOMPSON JA, 2006, J NEUROBIOL, V66, P1; THOMPSON W, 1977, NEUROSCIENCE, V2, P523, DOI 10.1016/0306-4522(77)90049-5; van Rossum MCW, 2000, J NEUROSCI, V20, P8812	46	61	63	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e723	10.1371/journal.pone.0000723	http://dx.doi.org/10.1371/journal.pone.0000723			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684568	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452400025
J	Brynedal, B; Duvefelt, K; Jonasdottir, G; Roos, IM; Akesson, E; Palmgren, J; Hillert, J				Brynedal, Boel; Duvefelt, Kristina; Jonasdottir, Gudrun; Roos, Izaura M.; Akesson, Eva; Palmgren, Juni; Hillert, Jan			HLA-A Confers an HLA-DRB1 Independent Influence on the Risk of Multiple Sclerosis	PLOS ONE			English	Article								A recent high-density linkage screen confirmed that the HLA complex contains the strongest genetic factor for the risk of multiple sclerosis (MS). In parallel, a linkage disequilibrium analysis using 650 single nucleotide polymorphisms (SNP) markers of the HLA complex mapped the entire genetic effect to the HLA-DR-DQ subregion, reflected by the well-established risk haplotype HLA-DRB1*15, DQB1*06. Contrary to this, in a cohort of 1,084 MS patients and 1,347 controls, we show that the HLA-A gene confers an HLA-DRB1 independent influence on the risk of MS (P = 8.4 x 10(-10)). This supports the opposing view, that genes in the HLA class I region indeed exert an additional influence on the risk of MS, and confirms that the class I allele HLA-A*02 is negatively associated with the risk of MS (OR = 0.63, P = 7610 212) not explained by linkage disequilibrium with class II. The combination of HLA-A and HLA-DRB1 alleles, as represented by HLA-A*02 and HLA-DRB1*15, was found to influence the risk of MS 23-fold. These findings imply complex autoimmune mechanisms involving both the regulatory and the effector arms of the immune system in the triggering of MS.	[Brynedal, Boel; Duvefelt, Kristina; Roos, Izaura M.; Akesson, Eva; Hillert, Jan] Karolinska Inst, Dept Clin Neurosci, Div Neurol, Stockholm, Sweden; [Duvefelt, Kristina; Palmgren, Juni] Karolinska Univ Hosp, Clin Res Ctr, Mutat Anal Facil, Stockholm, Sweden; [Jonasdottir, Gudrun] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Brynedal, B (corresponding author), Karolinska Inst, Dept Clin Neurosci, Div Neurol, Stockholm, Sweden.	boel.brynedal@ki.se	Lima Bomfim, Izaura/J-3462-2012	Palmgren, Juni/0000-0002-9031-8615; Lima Bomfim, Izaura/0000-0003-0890-3872	Swedish Research Council [11220]; Swedish society of Neurologically Disabled, Bibbi & Nils Jensens Foundation; Swedish Foundation for Strategic Research and Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish society of Neurologically Disabled, Bibbi & Nils Jensens Foundation; Swedish Foundation for Strategic Research and Karolinska Institutet	This study was supported by grants from the Swedish Research Council (project number 11220), the Swedish society of Neurologically Disabled, Bibbi & Nils Jensens Foundation, the Swedish Foundation for Strategic Research and Karolinska Institutet.	Barcellos LF, 2003, AM J HUM GENET, V72, P710, DOI 10.1086/367781; Barcellos LF, 2006, HUM MOL GENET, V15, P2813, DOI 10.1093/hmg/ddl223; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; Dyment DA, 2005, HUM MOL GENET, V14, P2019, DOI 10.1093/hmg/ddi206; Fogdell-Hahn A, 2000, TISSUE ANTIGENS, V55, P140, DOI 10.1034/j.1399-0039.2000.550205.x; Friese MA, 2005, BRAIN, V128, P1747, DOI 10.1093/brain/awh578; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Harbo HF, 2004, TISSUE ANTIGENS, V63, P237, DOI 10.1111/j.0001-2815.2004.00173.x; HILLERT J, 1994, ANN NEUROL, V36, pS15, DOI 10.1002/ana.410360706; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; JERSILD C, 1973, LANCET, V2, P1221; JERSILD C, 1972, ACTA NEUROL SCAND, V48, P377; Lincoln MR, 2005, NAT GENET, V37, P1108, DOI 10.1038/ng1647; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Modin H, 2004, AM J HUM GENET, V74, P1321, DOI 10.1086/420977; NAITO S, 1972, TISSUE ANTIGENS, V2, P1; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; Sawcer S, 2005, AM J HUM GENET, V77, P454; YEO TW, 2007, ANN NEUROL; J NEUROIMMUNOL, V143, P39	20	127	130	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e664	10.1371/journal.pone.0000664	http://dx.doi.org/10.1371/journal.pone.0000664			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653284	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452200026
J	Heimesaat, MM; Fischer, A; Siegmund, B; Kupz, A; Niebergall, J; Fuchs, D; Jahn, HK; Freudenberg, M; Loddenkemper, C; Batra, A; Lehr, HA; Liesenfeld, O; Blaut, M; Gobel, UB; Schumann, RR; Bereswill, S				Heimesaat, Markus M.; Fischer, Andre; Siegmund, Britta; Kupz, Andreas; Niebergall, Julia; Fuchs, David; Jahn, Hannah-Katharina; Freudenberg, Marina; Loddenkemper, Christoph; Batra, Arvind; Lehr, Hans-Anton; Liesenfeld, Oliver; Blaut, Michael; Goebel, Ulf B.; Schumann, Ralf R.; Bereswill, Stefan			Shift Towards Pro-inflammatory Intestinal Bacteria Aggravates Acute Murine Colitis via Toll-like Receptors 2 and 4	PLOS ONE			English	Article							ESCHERICHIA-COLI; MUCOSAL FLORA; MODELS; CELLS; TLR4; LIPOPOLYSACCHARIDE; EXPRESSION; GENE	Background. Gut bacteria trigger colitis in animal models and are suspected to aggravate inflammatory bowel diseases. We have recently reported that Escherichia coli accumulates in murine ileitis and exacerbates small intestinal inflammation via Toll-like receptor (TLR) signaling. Methodology and Principal Findings. Because knowledge on shifts in the intestinal microflora during colitis is limited, we performed a global survey of the colon flora of C57BL/10 wild-type (wt), TLR2(-/-), TLR4(-/-), and TLR2/4(-/-) mice treated for seven days with 3.5% dextrane-sulfate-sodium (DSS). As compared to wt animals, TLR2(-/-), TLR4(-/-), and TLR2/4(-/-) mice displayed reduced macroscopic signs of acute colitis and the amelioration of inflammation was associated with reduced IFN-gamma levels in mesenteric lymph nodes, lower amounts of neutrophils, and less FOXP3-positive T-cells in the colon in situ. During acute colitis E. coli increased in wt and TLR-deficient mice (P<0.05), but the final numbers reached were significantly lower in TLR2(-/-), TLR4(-/-) and TLR2/4(-/-) animals, as compared to wt controls (P<0.01). Concentrations of Bacteroides/Prevotella spp., and enterococci did not increase during colitis, but their numbers were significantly reduced in the colon of DSS-treated TLR2/4(-/-) animals (P<0.01). Numbers of lactobacilli and clostridia remained unaffected by colitis, irrespective of the TLR-genotype of mice. Culture-independent molecular analyses confirmed the microflora shifts towards enterobacteria during colitis and showed that the gut flora composition was similar in both, healthy wt and TLR-deficient animals. Conclusions and Significance. DSS-induced colitis is characterized by a shift in the intestinal microflora towards pro-inflammatory Gram-negative bacteria. Bacterial products exacerbate acute inflammation via TLR2- and TLR4-signaling and direct the recruitment of neutrophils and regulatory T-cells to intestinal sites. E. coli may serve as a biomarker for colitis severity and DSS-induced barrier damage seems to be a valuable model to further identify bacterial factors involved in maintaining intestinal homeostasis and to test therapeutic interventions based upon anti-TLR strategies.	[Heimesaat, Markus M.; Fischer, Andre; Kupz, Andreas; Niebergall, Julia; Fuchs, David; Jahn, Hannah-Katharina; Liesenfeld, Oliver; Goebel, Ulf B.; Schumann, Ralf R.; Bereswill, Stefan] Charite Univ Med Berlin, Inst Mikrobiol & Hyg, Berlin, Germany; [Siegmund, Britta; Batra, Arvind] Charite Univ Med Berlin, Med Klin 1, Berlin, Germany; [Freudenberg, Marina] Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; [Loddenkemper, Christoph] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Lehr, Hans-Anton] Ctr Univ Hosp Vaudois, Inst Univ Pathol, Lausanne, Switzerland; [Blaut, Michael] Deutsch Inst Ernahrungsforsch, Abt Gastrointestinale Mikrobiol, Potsdam, Nuthetal, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Bereswill, S (corresponding author), Charite Univ Med Berlin, Inst Mikrobiol & Hyg, Charite Campus Mitte, Berlin, Germany.	stefan.bereswill@charite.de	Siegmund, Britta/E-6929-2018; Kupz, Andreas/J-3844-2014; Eckhardt, Erik/G-1567-2010	Siegmund, Britta/0000-0002-0055-958X; Kupz, Andreas/0000-0002-9259-7873; Freudenberg, Marina Alexandra/0000-0001-5894-1805; Heimesaat, Markus/0000-0001-6399-651X	Sonnenfeld Foundation Berlin, Germany	Sonnenfeld Foundation Berlin, Germany	Funding: This work was supported by grants from the Deutsche Forschungsgemeinschaft to U.B. G., O.L., R.R.S., C.L. (KFO104/project 6; SFB633/ projects A7, B6, Z1), to B. S. (Emmy-Noether-Programm of the DFG, 749/3-4, 749/5-1) and to M. F. (DFG-SPP1110/ project Fr448/4-3). A.F. is supported by a grant from the Sonnenfeld Foundation Berlin, Germany.	Aebischer T, 2006, FEMS IMMUNOL MED MIC, V46, P221, DOI 10.1111/rp10.1016-j.femsim.2004.05.008; Araki A, 2005, J GASTROENTEROL, V40, P16, DOI 10.1007/s00535-004-1492-9; Basset Christelle, 2002, Science Progress, V85, P33, DOI 10.3184/003685002783238861; Beelen DW, 1999, BLOOD, V93, P3267, DOI 10.1182/blood.V93.10.3267.410k22_3267_3275; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Fort MM, 2005, J IMMUNOL, V174, P6416, DOI 10.4049/jimmunol.174.10.6416; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Hans W, 2000, EUR J GASTROEN HEPAT, V12, P267, DOI 10.1097/00042737-200012030-00002; Hart AL, 2005, GASTROENTEROLOGY, V129, P50, DOI 10.1053/j.gastro.2005.05.013; Heimesaat MM, 2007, GUT, V56, P941, DOI 10.1136/gut.2006.104497; Heimesaat MM, 2006, J IMMUNOL, V177, P8785, DOI 10.4049/jimmunol.177.12.8785; Husebye E, 2005, CHEMOTHERAPY, V51, P1, DOI 10.1159/000081988; Kim SC, 2005, GASTROENTEROLOGY, V128, P891, DOI 10.1053/j.gastro.2005.02.009; Lange S, 1996, APMIS, V104, P823, DOI 10.1111/j.1699-0463.1996.tb04948.x; Lodes MJ, 2004, J CLIN INVEST, V113, P1296, DOI 10.1172/JCI200420295; Maul J, 2005, GASTROENTEROLOGY, V128, P1868, DOI 10.1053/j.gastro.2005.03.043; Ortega-Cava CF, 2003, J IMMUNOL, V170, P3977, DOI 10.4049/jimmunol.170.8.3977; Pizarro TT, 2003, TRENDS MOL MED, V9, P218, DOI 10.1016/S1471-4914(03)00052-2; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Rath HC, 2001, INFECT IMMUN, V69, P2277, DOI 10.1128/IAI.69.4.2277-2285.2001; Ruiz PA, 2005, J IMMUNOL, V174, P2990, DOI 10.4049/jimmunol.174.5.2990; Schuppler M, 2004, INFECT IMMUN, V72, P1983, DOI 10.1128/IAI.72.4.1983-1990.2004; Siegmund B, 2001, J PHARMACOL EXP THER, V296, P99; Stevceva L, 1999, J GASTROEN HEPATOL, V14, P54, DOI 10.1046/j.1440-1746.1999.01806.x; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Swidsinski A, 2005, J CLIN MICROBIOL, V43, P3380, DOI 10.1128/JCM.43.7.3380-3389.2005; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Tlaskalova-Hogenova H, 2005, ANN NY ACAD SCI, V1051, P787, DOI 10.1196/annals.1361.122; Vowinkel T, 2007, GASTROENTEROLOGY, V132, P955, DOI 10.1053/j.gastro.2006.12.027; Waidmann M, 2003, GASTROENTEROLOGY, V125, P162, DOI 10.1016/S0016-5085(03)00672-3	34	160	167	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e662	10.1371/journal.pone.0000662	http://dx.doi.org/10.1371/journal.pone.0000662			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653282	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000207452200024
J	Liu, PY; Vikis, H; Lu, Y; Wang, DL; You, M				Liu, Pengyuan; Vikis, Haris; Lu, Yan; Wang, Daolong; You, Ming			Large-Scale In Silico Mapping of Complex Quantitative Traits in Inbred Mice	PLOS ONE			English	Article								Understanding the genetic basis of common disease and disease-related quantitative traits will aid in the development of diagnostics and therapeutics. The processs of gene discovery can be sped up by rapid and effective integration of well-defined mouse genome and phenome data resources. We describe here an in silico gene-discovery strategy through genome-wide association (GWA) scans in inbred mice with a wide range of genetic variation. We identified 937 quantitative trait loci (QTLs) from a survey of 173 mouse phenotypes, which include models of human disease (atherosclerosis, cardiovascular disease, cancer and obesity) as well as behavioral, hematological, immunological, metabolic, and neurological traits. 67% of QTLs were refined into genomic regions <0.5 Mb with similar to 40-fold increase in mapping precision as compared with classical linkage analysis. This makes for more efficient identification of the genes that underlie disease. We have identified two QTL genes, Adam12 and Cdh2, as causal genetic variants for atherogenic diet-induced obesity. Our findings demonstrate that GWA analysis in mice has the potential to resolve multiple tightly linked QTLs and achieve single-gene resolution. These high-resolution QTL data can serve as a primary resource for positional cloning and gene identification in the research community.	[You, Ming] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.	youm@wudosis.wustl.edu			US National Institutes of Health [CA099187, CA099147, ES012063, ES013340]; NATIONAL CANCER INSTITUTE [R01CA099147, R01CA099187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013340, R01ES012063] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Funding: Our research was supported by grants from the US National Institutes of Health (CA099187, CA099147, ES012063 and ES013340).	Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Altman D.G., 1991, PRACTICAL STATISTIC; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bale TL, 2003, ENDOCRINOLOGY, V144, P2580, DOI 10.1210/en.2002-0091; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Brewer H., 2005, ATHEROTHROMBOSIS COR, P55; Brockmann GA, 1998, GENETICS, V150, P369; Brockmann GA, 2000, GENOME RES, V10, P1941, DOI 10.1101/gr.GR1499R; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Bymaster FP, 2003, NEUROCHEM RES, V28, P437, DOI 10.1023/A:1022844517200; Castro CHM, 2004, J CELL SCI, V117, P2853, DOI 10.1242/jcs.01133; Chartrel N, 2007, SCIENCE, V315, DOI 10.1126/science.1135047; Cheverud JM, 2001, MAMM GENOME, V12, P3, DOI 10.1007/s003350010218; Christians JK, 2004, MAMM GENOME, V15, P482, DOI 10.1007/s00335-004-3046-0; Christians JK, 2003, MAMM GENOME, V14, P175, DOI 10.1007/s00335-002-3041-2; Christians JK, 2006, GENETICS, V173, P1547, DOI 10.1534/genetics.106.057513; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; de Mora JF, 2003, EMBO J, V22, P3039, DOI 10.1093/emboj/cdg280; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Flaherty L, 2005, GENOME RES, V15, P1741, DOI 10.1101/gr.3841405; Goudriaan JR, 2003, J LIPID RES, V44, P2270, DOI 10.1194/jlr.M300143-JLR200; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; HEDRICK PW, 1987, GENETICS, V117, P331; Hollander M., 1973, NONPARAMETRIC STAT, P68; Holst B, 2007, ENDOCRINOLOGY, V148, P13, DOI 10.1210/en.2006-0933; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Lauwers E, 2006, BIOCHEM BIOPH RES CO, V351, P21, DOI 10.1016/j.bbrc.2006.09.141; Liao GC, 2004, SCIENCE, V306, P690, DOI 10.1126/science.1100636; Liu PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Mao J, 2006, P NATL ACAD SCI USA, V103, P8552, DOI 10.1073/pnas.0603115103; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Masaki M, 2005, ENDOCRINOLOGY, V146, P1752, DOI 10.1210/en.2004-1082; Miyasaka K, 2002, J GASTROENTEROL, V37, P102, DOI 10.1007/BF03326426; Moechars D, 2006, GASTROENTEROLOGY, V131, P1131, DOI 10.1053/j.gastro.2006.07.009; Morris KH, 1999, MAMM GENOME, V10, P225, DOI 10.1007/s003359900977; Naaz A, 2004, FASEB J, V18, P1925, DOI 10.1096/fj.04-2631fje; Nadeau JH, 2000, NAT GENET, V25, P381, DOI 10.1038/78051; Patel HR, 2006, DIABETES, V55, P3091, DOI 10.2337/db05-0624; Payseur BA, 2007, GENETICS, V175, P1999, DOI 10.1534/genetics.106.067868; Peters LL, 2007, NAT REV GENET, V8, P58, DOI 10.1038/nrg2025; Pletcher MT, 2004, PLOS BIOL, V2, P2159, DOI 10.1371/journal.pbio.0020393; Pritchard JK, 2000, GENETICS, V155, P945; Rankinen T, 2006, OBESITY, V14, P529, DOI 10.1038/oby.2006.71; Rollins J, 2006, TRENDS CARDIOVAS MED, V16, P220, DOI 10.1016/j.tcm.2006.04.003; Tremblay F, 2007, ENDOCRINOLOGY, V148, P501, DOI 10.1210/en.2006-1275; Tuncman G, 2006, P NATL ACAD SCI USA, V103, P10741, DOI 10.1073/pnas.0603509103; Valdar W, 2006, NAT GENET, V38, P879, DOI 10.1038/ng1840; Vaughn TT, 1999, GENET RES, V74, P313, DOI 10.1017/S0016672399004103; Wade CM, 2005, NAT GENET, V37, P1175, DOI 10.1038/ng1666; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Yamada M, 2001, NATURE, V410, P207, DOI 10.1038/35065604; Yu JM, 2006, NAT GENET, V38, P203, DOI 10.1038/ng1702; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100; Zhao KY, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030004; [No title captured]	61	29	29	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e651	10.1371/journal.pone.0000651	http://dx.doi.org/10.1371/journal.pone.0000651			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653278	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452200020
J	Blais, J; Rico, C; van Oosterhout, C; Cable, J; Turner, GF; Bernatchez, L				Blais, Jonatan; Rico, Ciro; van Oosterhout, Cock; Cable, Joanne; Turner, George F.; Bernatchez, Louis			MHC Adaptive Divergence between Closely Related and Sympatric African Cichlids	PLOS ONE			English	Article							MAJOR-HISTOCOMPATIBILITY-COMPLEX; MATE CHOICE; CLASS-I; SEXUAL SELECTION; LAKE MALAWI; ANTIGEN PRESENTATION; BALANCING SELECTION; CLASS-IIB; EVOLUTION; SPECIATION	Background. The haplochromine cichlid species assemblages of Lake Malawi and Victoria represent some of the most important study systems in evolutionary biology. Identifying adaptive divergence between closely-related species can provide important insights into the processes that may have contributed to these spectacular radiations. Here, we studied a pair of sympatric Lake Malawi species, Pseudotropheus fainzilberi and P. emmiltos, whose reproductive isolation depends on olfactory communication. We tested the hypothesis that these species have undergone divergent selection at MHC class II genes, which are known to contribute to olfactory-based mate choice in other taxa. Methodology/Principal Findings. Divergent selection on functional alleles was inferred from the higher genetic divergence at putative antigen binding sites (ABS) amino acid sequences than at putatively neutrally evolving sites at intron 1, exon 2 synonymous sequences and exon 2 amino acid residues outside the putative ABS. In addition, sympatric populations of these fish species differed significantly in communities of eukaryotic parasites. Conclusions/Significance. We propose that local host-parasite coevolutionary dynamics may have driven adaptive divergence in MHC alleles, influencing odor-mediated mate choice and leading to reproductive isolation. These results provide the first evidence for a novel mechanism of adaptive speciation and the first evidence of adaptive divergence at the MHC in closely related African cichlid fishes.	[Blais, Jonatan; Bernatchez, Louis] Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada; [Blais, Jonatan; Rico, Ciro] CSIC, Estac Biol Donana, E-41080 Seville, Spain; [Blais, Jonatan; van Oosterhout, Cock; Turner, George F.] Univ Hull, Dept Biol Sci, Kingston Upon Hull HU6 7RX, N Humberside, England; [Cable, Joanne] Cardiff Univ, Sch Biol Sci, Cardiff, S Glam, Wales	Laval University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); University of Hull; Cardiff University	Bernatchez, L (corresponding author), Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada.	Louis.Bernatchez@bio.ulaval.ca	Cable, Joanne/A-4360-2010; Rico, Ciro/P-9750-2019; Rico, Ciro/K-5725-2015	Cable, Joanne/0000-0002-8510-7055; Rico, Ciro/0000-0002-0822-336X; Rico, Ciro/0000-0002-0822-336X; Bernatchez, Louis/0000-0002-8085-9709; Turner, George/0000-0003-0099-7261; van Oosterhout, Cock/0000-0002-5653-738X	Natural Science and Engineering Research Council of Canada; Fond Quebecois pour la Nature et les Technologies of Quebec; Natural and Environment Research Council [NER/J/S/2002/00706]; British Ecological Society; Consejo Superior de Investigacion Scientifica of Spain; Biotechnology and Biological Sciences Research Council of the UK	Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Fond Quebecois pour la Nature et les Technologies of Quebec; Natural and Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); British Ecological Society; Consejo Superior de Investigacion Scientifica of Spain; Biotechnology and Biological Sciences Research Council of the UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	JB was supported by a post-graduate scholarship from the Natural Science and Engineering Research Council of Canada and Fond Quebecois pour la Nature et les Technologies of Quebec. JC was funded by an Advanced Research Fellowship from the Natural and Environment Research Council (NER/J/S/2002/00706) of the UK. Field work by CvO., JB, and JC was funded by the British Ecological Society. CR was supported by the Consejo Superior de Investigacion Scientifica of Spain. GFT was funded by the Biotechnology and Biological Sciences Research Council of the UK and field work by the Natural and Environment Research Council of the UK. LB was funded by the Natural Science and Engineering Research Council of Canada (Discovery Grant Program).	Aguilar A, 2004, P NATL ACAD SCI USA, V101, P3490, DOI 10.1073/pnas.0306582101; Albertson RC, 1999, P NATL ACAD SCI USA, V96, P5107, DOI 10.1073/pnas.96.9.5107; Allender CJ, 2003, P NATL ACAD SCI USA, V100, P14074, DOI 10.1073/pnas.2332665100; Anzai T, 2003, P NATL ACAD SCI USA, V100, P7708, DOI 10.1073/pnas.1230533100; Bernatchez L, 2003, J EVOLUTION BIOL, V16, P363, DOI 10.1046/j.1420-9101.2003.00531.x; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Blais J, 2004, EVOLUTION, V58, P2498; Borghans JAM, 2003, EUR J IMMUNOL, V33, P3353, DOI 10.1002/eji.200324365; Buckling A, 2002, NATURE, V420, P496, DOI 10.1038/nature01164; Carroll LS, 2002, P NATL ACAD SCI USA, V99, P2187, DOI 10.1073/pnas.042244899; Cohen S, 2002, MOL BIOL EVOL, V19, P1870, DOI 10.1093/oxfordjournals.molbev.a004011; Deutsch JC, 1997, BIOL J LINN SOC, V62, P1; DOMINEY WJ, 1984, EVOLUTION FISH SPECI, P231; Emes RD, 2004, GENOME RES, V14, P591, DOI 10.1101/gr.1940604; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Fenton A, 2002, J ANIM ECOL, V71, P893, DOI 10.1046/j.1365-2656.2002.00656.x; FRANK SA, 1994, PHILOS T R SOC B, V346, P283, DOI 10.1098/rstb.1994.0145; Garamszegi LZ, 2003, EVOLUTION, V57, P905, DOI 10.1554/0014-3820(2003)057[0905:TEOIDA]2.0.CO;2; Genner MJ, 2005, FISH FISH, V6, P1, DOI 10.1111/j.1467-2679.2005.00173.x; Getty T, 2002, AM NAT, V159, P363, DOI 10.1086/338992; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Haldane J. B. S., 1949, Ricerca Scientifica Suppl, P68; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; Hedrick PW, 1999, EVOLUTION, V53, P313, DOI 10.1111/j.1558-5646.1999.tb03767.x; Hudson RR, 2000, GENETICS, V155, P2011; HUDSON RR, 1992, GENETICS, V132, P583; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Hughes AL, 2000, IMMUNOGENETICS, V51, P473, DOI 10.1007/s002510050646; Jacob S, 2002, NAT GENET, V30, P175, DOI 10.1038/ng830; Kocher TD, 2004, NAT REV GENET, V5, P288, DOI 10.1038/nrg1316; KONINGS A, 2001, MALAWI CICHLIDS THEI, P352; Kornfield I, 2000, ANNU REV ECOL SYST, V31, P163, DOI 10.1146/annurev.ecolsys.31.1.163; Pond SLK, 2006, PLOS COMPUT BIOL, V2, P530, DOI 10.1371/journal.pcbi.0020062; Pond SLK, 2006, MOL BIOL EVOL, V23, P1891, DOI 10.1093/molbev/msl051; Krasnov BR, 2004, J BIOGEOGR, V31, P1857, DOI 10.1111/j.1365-2699.2004.01132.x; Kruiswijk CP, 2005, IMMUNOGENETICS, V56, P894, DOI 10.1007/s00251-005-0767-5; Landry C, 2001, P ROY SOC B-BIOL SCI, V268, P1279, DOI 10.1098/rspb.2001.1659; Lederberg J, 1999, GENETICS, V153, P1; Legendre P, 2001, OECOLOGIA, V129, P271, DOI 10.1007/s004420100716; Maan ME, 2006, BEHAV ECOL, V17, P691, DOI 10.1093/beheco/ark020; Malaga-Trillo E, 1998, GENETICS, V149, P1527; Milinski M, 2005, P NATL ACAD SCI USA, V102, P4414, DOI 10.1073/pnas.0408264102; Moore SL, 2002, SCIENCE, V297, P2015, DOI 10.1126/science.1074196; NEI M, 1973, P NATL ACAD SCI USA, V70, P3321, DOI 10.1073/pnas.70.12.3321; Nielsen R, 2001, GENETICS, V158, P885; NOWAK MA, 1992, P NATL ACAD SCI USA, V89, P10896, DOI 10.1073/pnas.89.22.10896; Nunn CL, 2004, AM NAT, V164, pS90, DOI 10.1086/424608; ONO H, 1993, MOL BIOL EVOL, V10, P1060; ONO H, 1992, P NATL ACAD SCI USA, V89, P11886, DOI 10.1073/pnas.89.24.11886; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Plenderleith M, 2005, BIOL LETT-UK, V1, P411, DOI 10.1098/rsbl.2005.0355; Pond SK, 2005, MOL BIOL EVOL, V22, P2375, DOI 10.1093/molbev/msi232; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Posada D, 2001, P NATL ACAD SCI USA, V98, P13757, DOI 10.1073/pnas.241370698; Reusch TBH, 2001, NATURE, V414, P300, DOI 10.1038/35104547; Reusch TBH, 2005, J MOL EVOL, V61, P531, DOI 10.1007/s00239-004-0340-0; RIBBINK AJ, 1983, S AFR J ZOOL, V18, P149; Rico C, 2002, MOL ECOL, V11, P1585, DOI 10.1046/j.1365-294X.2002.01537.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schierup MH, 2000, GENET RES, V76, P63, DOI 10.1017/S0016672300004547; Schluter D, 2001, TRENDS ECOL EVOL, V16, P372, DOI 10.1016/S0169-5347(01)02198-X; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Seehausen O, 1999, ECOL LETT, V2, P262; Skarstein F, 2005, J FISH BIOL, V67, P969, DOI 10.1111/j.0022-1112.2005.00796.x; Sommer S, 2005, BEHAV ECOL SOCIOBIOL, V58, P181, DOI 10.1007/s00265-005-0909-7; Sorhannus U, 2006, J MOL EVOL, V63, P231, DOI 10.1007/s00239-006-0016-z; Summers K, 2003, BIOL REV, V78, P639, DOI 10.1017/S146479310300616X; Switzer WM, 2005, NATURE, V434, P376, DOI 10.1038/nature03341; Taylor MI, 1998, ANIM BEHAV, V56, P379, DOI 10.1006/anbe.1998.0795; Terai Y, 2006, PLOS BIOL, V4, P2244, DOI 10.1371/journal.pbio.0040433; Thompson J. N., 2005, INTERSPEC INTERACT; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Turelli M, 2001, TRENDS ECOL EVOL, V16, P330, DOI 10.1016/S0169-5347(01)02177-2; Turner GT, 1999, EVOLUTION OF BIOLOGICAL DIVERSITY, P113; van den Berg HA, 2003, J THEOR BIOL, V224, P249, DOI 10.1016/S0022-5193(03)00162-0; van Oosterhout C, 2006, EVOLUTION, V60, P2562, DOI 10.1111/j.0014-3820.2006.tb01890.x; vonSchantz T, 1996, P ROY SOC B-BIOL SCI, V263, P265, DOI 10.1098/rspb.1996.0041; Wang TH, 2001, J VIROL, V75, P11686, DOI 10.1128/JVI.75.23.11686-11699.2001; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Westneat DF, 1998, P ROY SOC B-BIOL SCI, V265, P1065, DOI 10.1098/rspb.1998.0400; Willig MR, 2003, ANNU REV ECOL EVOL S, V34, P273, DOI 10.1146/annurev.ecolsys.34.012103.144032; Yampolsky LY, 2005, GENETICS, V170, P1459, DOI 10.1534/genetics.104.039107; Yang ZH, 2002, MOL BIOL EVOL, V19, P49, DOI 10.1093/oxfordjournals.molbev.a003981	84	86	87	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e734	10.1371/journal.pone.0000734	http://dx.doi.org/10.1371/journal.pone.0000734			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710134	gold, Green Published			2022-12-25	WOS:000207455200011
J	Knapen, T; van Ee, R; Blake, R				Knapen, Tomas; van Ee, Raymond; Blake, Randolph			Stimulus Motion Propels Traveling Waves in Binocular Rivalry	PLOS ONE			English	Article							VISUAL-CORTEX; INTEGRATION; DIRECTION; DYNAMICS; FEEDBACK; DEPTH	State transitions in the nervous system often take shape as traveling waves, whereby one neural state is replaced by another across space in a wave-like manner. In visual perception, transitions between the two mutually exclusive percepts that alternate when the two eyes view conflicting stimuli (binocular rivalry) may also take shape as traveling waves. The properties of these waves point to a neural substrate of binocular rivalry alternations that have the hallmark signs of lower cortical areas. In a series of experiments, we show a potent interaction between traveling waves in binocular rivalry and stimulus motion. The course of the traveling wave is biased in the motion direction of the suppressed stimulus that gains dominance by means of the wave-like transition. Thus, stimulus motion may propel the traveling wave across the stimulus to the extent that the stimulus motion dictates the traveling wave's direction completely. Using a computational model, we show that a speed-dependent asymmetry in lateral inhibitory connections between retinotopically organized and motion-sensitive neurons can explain our results. We argue that such a change in suppressive connections may play a vital role in the resolution of dynamic occlusion situations.	[Knapen, Tomas; van Ee, Raymond] Univ Utrecht, Helmholtz Inst, Utrecht, Netherlands; [Blake, Randolph] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA	Utrecht University; Vanderbilt University	Knapen, T (corresponding author), Univ Utrecht, Helmholtz Inst, Utrecht, Netherlands.	t.h.j.knapen@phys.uu.nl; r.vanee@phys.uu.nl		van Ee, Raymond/0000-0002-1134-8665	NIH [EY016752, EY13358]; National Academy of Science (KNAW); Netherlands Organization for Scientific Research (NWO); Utrecht University; NATIONAL EYE INSTITUTE [R01EY016752, R01EY013358, P30EY008126] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Academy of Science (KNAW); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Utrecht University; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Part of this work has been conducted during a research visit of TK at Vanderbilt University made possible by grants NIH EY016752 and NIH EY13358 to RB and grants from the National Academy of Science (KNAW) to RvE. RvE was supported by a grant from The Netherlands Organization for Scientific Research (NWO) as well as by a High Potential grant from Utrecht University.	Alais D, 2006, NEURON, V52, P911, DOI 10.1016/j.neuron.2006.10.027; Andrews TJ, 2002, VISION RES, V42, P301, DOI 10.1016/S0042-6989(01)00286-3; Andrews TJ, 1999, NAT NEUROSCI, V2, P405, DOI 10.1038/8068; BLAKE R, 1985, BIOL CYBERN, V52, P391, DOI 10.1007/BF00449596; Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701; BRADLEY DC, 1995, NATURE, V373, P609, DOI 10.1038/373609a0; Brooks KR, 2006, VISION RES, V46, P605, DOI 10.1016/j.visres.2005.06.015; DeAngelis GC, 2003, J NEUROPHYSIOL, V89, P1094, DOI 10.1152/jn.00717.2002; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; Grunewald A, 2004, J NEUROSCI, V24, P9185, DOI 10.1523/JNEUROSCI.1884-04.2004; Lee SH, 2005, NAT NEUROSCI, V8, P22, DOI 10.1038/nn1365; Livingstone MS, 1998, NEURON, V20, P509, DOI 10.1016/S0896-6273(00)80991-5; Muckli L, 2005, PLOS BIOL, V3, P1501, DOI 10.1371/journal.pbio.0030265; Nguyen VA, 2003, VISION RES, V43, P2003, DOI 10.1016/S0042-6989(03)00314-6; Rees G, 2002, NAT REV NEUROSCI, V3, P261, DOI 10.1038/nrn783; Rinzel J, 1998, SCIENCE, V279, P1351, DOI 10.1126/science.279.5355.1351; SHIMOJO S, 1988, NATURE, V333, P265, DOI 10.1038/333265a0; Sillito AM, 2006, TRENDS NEUROSCI, V29, P307, DOI 10.1016/j.tins.2006.05.001; SILLITO AM, 1977, J PHYSIOL-LONDON, V273, P791, DOI 10.1113/jphysiol.1977.sp012124; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; van Ee R, 2001, NATURE, V410, P690, DOI 10.1038/35070569; WADE NJ, 1984, PERCEPT PSYCHOPHYS, V35, P111, DOI 10.3758/BF03203891; Wilson HR, 2001, NATURE, V412, P907, DOI 10.1038/35091066; Xie XH, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051904	24	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e739	10.1371/journal.pone.0000739	http://dx.doi.org/10.1371/journal.pone.0000739			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710139	Green Published, Green Submitted, gold			2022-12-25	WOS:000207455200016
J	Mangold, U; Hayakawa, H; Coughlin, M; Munger, K; Zetter, BR				Mangold, U.; Hayakawa, H.; Coughlin, M.; Munger, K.; Zetter, B. R.			Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification	ONCOGENE			English	Article						antizyme; antizyme inhibitor; centrosome; proteasome; genomic instability; cancer	ORNITHINE DECARBOXYLASE-ANTIZYME; CELL-CYCLE; PROTEIN; GROWTH; OVEREXPRESSION; DUPLICATION; CANCER; IDENTIFICATION; POLYAMINES; ANEUPLOIDY	The potential tumor suppressor antizyme and its endogenous inhibitor (antizyme inhibitor, AZI) have been implicated in the ubiquitin-independent proteasomal degradation of proteins involved in cell proliferation as well as in the regulation of polyamine levels. We show here that both antizyme and AZI concentrate at centrosomes and that antizyme preferentially associates with the maternal centriole. Interestingly, alterations in the levels of these proteins have opposing effects on centrosomes. Depletion of antizyme in various cell lines and primary cells leads to centrosome overduplication, whereas overexpression of antizyme reduces numerical centrosome abnormalities. Conversely, silencing of the antizyme inhibitor, AZI, results in a decrease of numerical centrosome abnormalities, whereas overexpression of AZI leads to centrosome overduplication. We further show that the numerical centrosome abnormalities are due to daughter centriole amplification. In summary, our results demonstrate that alterations in the antizyme/AZI balance cause numerical centrosomal defects and suggest a role for ubiquitin-independent proteasomal degradation in centrosome duplication.	[Mangold, U.; Zetter, B. R.] Childrens Hosp Boston, Program Vasc Biol, Boston, MA USA; [Mangold, U.; Zetter, B. R.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Hayakawa, H.; Munger, K.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Coughlin, M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zetter, BR (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, 1 Blackfan Circle, Boston, MA 02115 USA.	bruce.zetter@childrens.harvard.edu	Loizides-Mangold, Ursula/I-9061-2014	Loizides-Mangold, Ursula/0000-0001-9233-2974; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA037393, R01CA066980, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA066980, CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fong LYY, 2003, CANCER RES, V63, P3945; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Keren-Paz A, 2006, ONCOGENE, V25, P5163, DOI 10.1038/sj.onc.1209521; Kim SW, 2006, J CELL SCI, V119, P2853, DOI 10.1242/jcs.02966; Koike C, 1999, CANCER RES, V59, P6109; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Mitchell JLA, 1998, BIOCHEM J, V329, P453; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; Sluder G, 2005, NAT REV MOL CELL BIO, V6, P743, DOI 10.1038/nrm1712; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Tsuji T, 2001, ONCOGENE, V20, P24, DOI 10.1038/sj.onc.1204051; Zou CZ, 2005, J CELL BIOL, V171, P437, DOI 10.1083/jcb.200506185	33	35	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					604	613		10.1038/sj.onc.1210685	http://dx.doi.org/10.1038/sj.onc.1210685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667942				2022-12-25	WOS:000252674900005
J	Wu, A; Chen, J; Baserga, R				Wu, A.; Chen, J.; Baserga, R.			Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes	ONCOGENE			English	Article						IRS-1; c-myc; cyclin D1; rRNS	SIMIAN-VIRUS-40 T-ANTIGEN; GROWTH-FACTOR RECEPTOR; IGF-I RECEPTOR; BETA-CATENIN; TRANSLOCATION; IRS-1; TRANSFORMATION; INSULIN-RECEPTOR-SUBSTRATE-1; PATHWAY	The insulin receptor substrate-1 (IRS-1) is a docking protein of the insulin-like growth factor-1 (IGF-1) receptor and of the insulin receptor. IRS-1 sends a strong mitogenic, anti-apoptotic signal and plays an important role in cell transformation and cancer. IRS-1 translocates to nuclei of cells, where it increases the activity of the rDNA, c-myc and cyclin D1 promoters. We show, by chromatin immunoprecipitation, occupancy by IRS-1 of the same promoters. Both promoter activation and promoter occupancy are IGF-1-dependent. In cells that respond to IGF-1 but in which IRS-1 does not translocate to nuclei, promoter occupancy is absent and promoter activation is absent or much reduced. Transcriptional activation of c-myc and cyclin D1 promoters by nuclear IRS-1 does not occur with a mutant, inactive IRS-1 protein ( deletion of the phosphotyrosine-binding domain, PTB) and does not require PI3- kinase activity. Taken together, these results indicate a novel mechanism by which nuclear IRS-1 activates cell cycle genes.	[Wu, A.; Chen, J.; Baserga, R.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NCI NIH HHS [CA08640, CA78890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Chang Q, 2002, CANCER RES, V62, P6035; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DeAngelis T, 2006, ONCOGENE, V25, P32, DOI 10.1038/sj.onc.1209013; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; del Rincon SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104; Drakas R, 2005, PROTEOMICS, V5, P132, DOI 10.1002/pmic.200400919; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Rowlands TM, 2003, P NATL ACAD SCI USA, V100, P11400, DOI 10.1073/pnas.1534601100; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wu A, 2005, J BIOL CHEM, V280, P2863, DOI 10.1074/jbc.M406138200	20	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					397	403		10.1038/sj.onc.1210636	http://dx.doi.org/10.1038/sj.onc.1210636			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17700539				2022-12-25	WOS:000252256000016
J	Bernatchez, PN; Acevedo, L; Fernandez-Hernando, C; Murata, T; Chalouni, C; Kim, J; Erdjument-Bromage, H; Shah, V; Gratton, JP; Mcnally, EM; Tempst, P; Sessa, WC				Bernatchez, Pascal N.; Acevedo, Lisette; Fernandez-Hernando, Carlos; Murata, Takahisa; Chalouni, Cecile; Kim, Jiae; Erdjument-Bromage, Hediye; Shah, Vijay; Gratton, Jean-Philippe; Mcnally, Elizabeth M.; Tempst, Paul; Sessa, William C.			Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; MEMBRANE REPAIR; MUSCULAR-DYSTROPHY; IN-VIVO; FUSION; CELLS; DYSFERLIN; PATHWAYS; PROTEIN; GENE	Myoferlin and dysferlin are members of the ferlin family of membrane proteins. Recent studies have shown that mutation or genetic disruption of myoferlin or dysferlin promotes muscular dystrophy-related phenotypes in mice, which are the result of impaired plasma membrane integrity. However, no biological functions have been ascribed to myoferlin in non-muscle tissues. Herein, using a proteomic analysis of endothelial cell ( EC) caveolae/lipid raft microdomains we identified myoferlin in these domains and show that myoferlin is highly expressed in ECs and vascular tissues. The loss of myoferlin results in lack of proliferation, migration, and nitric oxide ( NO) release in response to vascular endothelial growth factor ( VEGF). Western blotting and surface biotinylation experiments show that loss of myoferlin reduces the expression level and autophosphorylation of VEGF receptor-2 ( VEGFR-2) in native ECs. In a reconstituted cell system, transfection of myoferlin increases VEGFR-2 membrane expression and autophosphorylation in response to VEGF. In vivo, VEGFR-2 levels and VEGF-induced permeability are impaired in myoferlin-deficient mice. Mechanistically, myoferlin forms a complex with dynamin-2 and VEGFR-2, which prevents CBL-dependent VEGFR-2 polyubiquitination and proteasomal degradation. These data are the first to report novel biological activities for myoferlin and reveal the role of membrane integrity to VEGF signaling.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol & Vasc Biol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Transplantat Program, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Genet, Chicago, IL 60637 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Mayo Clin, GI Res Unit, Rochester, MN 55905 USA; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	Yale University; Yale University; Yale University; University of Chicago; University of Chicago; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol & Vasc Biol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	McNally, Elizabeth/W-4909-2019; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520; McNally, Elizabeth/0000-0002-1221-719X; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987; Murata, Takahisa/0000-0002-3328-0796	NHLBI NIH HHS [HL64793, R01 HL61371, N01-HV-28186, P01 HL 70295, R01 HL 57665] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295, R01HL061371, R01HL064793, R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Achanzar WE, 1997, J CELL SCI, V110, P1073; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Bhattacharya R, 2005, FASEB J, V19, P1692, DOI 10.1096/fj.05-3889fje; Britton S, 2000, GENOMICS, V68, P313, DOI 10.1006/geno.2000.6290; Cenacchi G, 2005, J CLIN PATHOL, V58, P190, DOI 10.1136/jcp.2004.018978; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Dubois C, 2006, BLOOD, V107, P3902, DOI 10.1182/blood-2005-09-3687; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Karsan A, 2005, J PROTEOME RES, V4, P349, DOI 10.1021/pr049824w; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; Murata T, 2007, J BIOL CHEM, V282, P16631, DOI 10.1074/jbc.M607948200; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Peplowska K, 2005, NAT CELL BIOL, V7, P103, DOI 10.1038/ncb0205-103; Washington NL, 2006, J CELL SCI, V119, P2552, DOI 10.1242/jcs.02980; ZARRINPAR A, 2003, SCI STKE 2003	21	84	90	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30745	30753		10.1074/jbc.M704798200	http://dx.doi.org/10.1074/jbc.M704798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702744	hybrid			2022-12-25	WOS:000250136300043
J	Cantin, L; Faucher, F; Couture, JF; de Jesus-Tran, KP; Legrand, P; Ciobanu, LC; Frechette, Y; Labrecque, R; Singh, SM; Labrie, F; Breton, R				Cantin, Line; Faucher, Frederick; Couture, Jean-Francois; de Jesus-Tran, Karine Pereira; Legrand, Pierre; Ciobanu, Liviu C.; Frechette, Yvon; Labrecque, Richard; Singh, Shankar Mohan; Labrie, Fernand; Breton, Rock			Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; CRYSTAL-STRUCTURES; HORMONE AGONISTS; COACTIVATOR; PROTEIN; MOTIFS; FXXLF; TETRAHYDROGESTRINONE; TRANSACTIVATION; SUPERFAMILY	Antiandrogens are commonly used to treat androgen-dependent disorders. The currently used drugs unfortunately possess very weak affinity for the human AR (hAR), thus indicating the need to develop new high-affinity steroidal antiandrogens. Our compounds are specially designed to impede repositioning of the mobile carboxyl-terminal helix 12, which blocks the ligand-dependent transactivation function (AF-2) located in the AR ligand-binding domain (ARLBD). Using crystal structures of the hARLBD, we first found that H12 could be directly reached from the ligand-binding pocket (LBP) by a chain positioned on the C18 atom of an androgen steroid nucleus. A set of 5 alpha-dihydrotestosterone- derived molecules bearing various C18 chains were thus synthesized and tested for their capacity to bind hAR and act as antagonists. Although most of those having very high affinity for hAR were agonists, several very potent antagonists were obtained, confirming the structural importance of the C18 chain. To understand the role of the C18 chain in their agonistic/antagonistic properties, the structure of the hARLBD complexed with one of these agonists, EM5744, was determined at a 1.65-angstrom resolution. We have identified new interactions involving Gln(738), Met(742), and His(874) that explain both the high affinity of this compound and the inability of its bulky chain to prevent the repositioning of H12. This structural information will be helpful to refine the structure of the chains placed on the C18 atom to obtain efficient H12-directed steroidal antiandrogens.	CHU Laval, Ctr Rech Endocrinol Mol & Oncol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Ste Foy, PQ G1V 4G2, Canada; Ottawa Inst Syst Biol, Ottawa, ON K1H 8M5, Canada; Synchroton SOLEIL, F-91192 Gif Sur Yvette, France	Laval University; Laval University; University of Ottawa; SOLEIL Synchrotron	Breton, R (corresponding author), CHU Laval, Ctr Rech Endocrinol Mol & Oncol, 2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	rock.breton@crchul.ulaval.ca	LEGRAND, Pierre/G-7709-2011	LEGRAND, Pierre/0000-0003-2431-2255				ASSELIN J, 1980, CANCER RES, V40, P1612; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; De Jesus-Tran KP, 2006, PROTEIN SCI, V15, P987, DOI 10.1110/ps.051905906; Death AK, 2004, J CLIN ENDOCR METAB, V89, P2498, DOI 10.1210/jc.2004-0033; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; GINSBURG J, 1976, BRIT MED J, V2, P737, DOI 10.1136/bmj.2.6038.737; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMMOND GL, 1978, J ENDOCRINOL, V78, P7, DOI 10.1677/joe.0.0780007; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Huang XF, 2001, J STEROID BIOCHEM, V77, P129, DOI 10.1016/S0960-0760(01)00038-3; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIEG M, 1979, J STEROID BIOCHEM, V11, P615, DOI 10.1016/0022-4731(79)90090-6; LABRIE C, 1988, ENDOCRINOLOGY, V123, P1412, DOI 10.1210/endo-123-3-1412; Labrie F, 2005, ENDOCR REV, V26, P361, DOI 10.1210/er.2004-0017; Labrie F, 2005, J ENDOCRINOL, V184, P427, DOI 10.1677/joe.1.05997; LABRIE F, 1986, PROSTATE, V8, P293, DOI 10.1002/pros.2990080309; LABRIE F, 1985, BMJ-BRIT MED J, V291, P369, DOI 10.1136/bmj.291.6492.369; LABRIE F, 1988, JNCI-J NATL CANCER I, V80, P1138, DOI 10.1093/jnci/80.14.1138; LABRIE L, 2005, Patent No. 20050250749; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ONATE SA, 1995, SCIENCE, V270, P1354; Rager KM, 2006, THESCIENTIFICWORLDJO, V6, P116, DOI 10.1100/tsw.2006.23; Roy AK, 1999, VITAM HORM, V55, P309; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wirth MP, 2007, EUR UROL, V51, P306, DOI 10.1016/j.eururo.2006.08.043	47	45	51	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30910	30919		10.1074/jbc.M705524200	http://dx.doi.org/10.1074/jbc.M705524200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17711855	hybrid			2022-12-25	WOS:000250136300059
J	Kanno, K; Wu, MK; Agate, DS; Fanelli, BJ; Wagle, N; Scapa, EF; Ukomadu, C; Cohen, DE				Kanno, Keishi; Wu, Michele K.; Agate, Diana S.; Fanelli, Brandon J.; Wagle, Neil; Scapa, Erez F.; Ukomadu, Chinweike; Cohen, David E.			Interacting proteins dictate function of the minimal START domain phosphatidylcholine transfer protein/StarD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA HYDROLASE; THIOESTERASE SUPERFAMILY MEMBER-2; INTRACELLULAR LIPID-METABOLISM; PHOSPHOLIPID TRANSFER PROTEINS; TISSUE-SPECIFIC EXPRESSION; BROWN ADIPOSE-TISSUE; BINDING DOMAIN; CDNA CLONING; RAT-LIVER; C-RET	The Star ( steroidogenic acute regulatory protein)-related transfer ( START) domain superfamily is characterized by a distinctive lipid-binding motif. START domains typically reside in multidomain proteins, suggesting their function as lipid sensors that trigger biological activities. Phosphatidylcholine transfer protein ( PC-TP, also known as StarD2) is an example of a START domain minimal protein that consists only of the lipid-binding motif. PC-TP, which binds phosphatidylcholine exclusively, is expressed during embryonic development and in several tissues of the adult mouse, including liver. Although it catalyzes the intermembrane exchange of phosphatidylcholines in vitro, this activity does not appear to explain the various metabolic alterations observed in mice lacking PC-TP. Here we demonstrate that PC-TP function may be mediated via interacting proteins. Yeast two-hybrid screening using libraries prepared from mouse liver and embryo identified Them2 ( thioesterase superfamily member 2) and the homeodomain transcription factor Pax3 ( paired box gene 3), respectively, as PC-TP-interacting proteins. These were notable because the START domain superfamily contains multidomain proteins in which the START domain coexists with thioesterase domains in mammals and with homeodomain transcription factors in plants. Interactions were verified in pulldown assays, and colocalization with PC-TP was confirmed within tissues and intracellularly. The acyl-CoA thioesterase activity of purified recombinant Them2 was markedly enhanced by recombinant PC-TP. In tissue culture, PC-TP coactivated the transcriptional activity of Pax3. These findings suggest that PC-TP functions as a phosphatidylcholine-sensing molecule that engages in diverse regulatory activities that depend upon the cellular expression of distinct interacting proteins.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol,Dept Med, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA; Harvard Univ, MIT, Div Hlth & Sci & Technol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Massachusetts Institute of Technology (MIT)	Cohen, DE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol,Dept Med, 75 Francis St, Boston, MA 02115 USA.	dcohen@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, R01DK048873, R01DK056626, R29DK048873, R37DK048873] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34854, DK56626, DK48873] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams SH, 2001, BIOCHEM J, V360, P135, DOI 10.1042/bj3600135; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Baez JM, 2002, J BIOL CHEM, V277, P6198, DOI 10.1074/jbc.M106799200; Berger UV, 2000, J COMP NEUROL, V421, P385, DOI 10.1002/(SICI)1096-9861(20000605)421:3<385::AID-CNE7>3.0.CO;2-S; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Cheng ZJ, 2006, BIOCHEM BIOPH RES CO, V350, P850, DOI 10.1016/j.bbrc.2006.09.105; Cheng ZJ, 2006, BIOCHEM BIOPH RES CO, V349, P172, DOI 10.1016/j.bbrc.2006.08.025; Cohen DE, 1999, BBA-GENE STRUCT EXPR, V1447, P265, DOI 10.1016/S0167-4781(99)00163-3; de Brouwer APM, 2002, EXP CELL RES, V274, P100, DOI 10.1006/excr.2001.5460; Epstein JA, 2000, METH MOL B, V137, P459; Feng L, 2000, BIOCHEMISTRY-US, V39, P15399, DOI 10.1021/bi001076a; Geijtenbeek TBH, 1996, BIOCHEM J, V316, P49; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hunt MC, 2005, J LIPID RES, V46, P2029, DOI 10.1194/jlr.E500003-JLR200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; ISOHASHI F, 1983, EUR J BIOCHEM, V134, P447, DOI 10.1111/j.1432-1033.1983.tb07587.x; Kanno K, 2007, BBA-MOL CELL BIOL L, V1771, P654, DOI 10.1016/j.bbalip.2007.04.003; Lang D, 2003, HUM MOL GENET, V12, P937, DOI 10.1093/hmg/ddg107; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Machado AF, 2001, CURR PHARM DESIGN, V7, P751, DOI 10.2174/1381612013397726; MATSUNAGA T, 1985, EUR J BIOCHEM, V152, P331, DOI 10.1111/j.1432-1033.1985.tb09202.x; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; Pan HJ, 2006, FEBS LETT, V580, P5953, DOI 10.1016/j.febslet.2006.09.066; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Schrick K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r41; Shoda J, 2001, HEPATOLOGY, V33, P1194, DOI 10.1053/jhep.2001.23936; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Suematsu N, 2002, ACTA BIOCHIM POL, V49, P937; Suematsu N, 2001, EUR J BIOCHEM, V268, P2700, DOI 10.1046/j.1432-1327.2001.02162.x; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wirtz KWA, 2006, FEBS LETT, V580, P5436, DOI 10.1016/j.febslet.2006.06.065; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200; ZUCKER SD, 1992, BIOCHEMISTRY-US, V31, P3184, DOI 10.1021/bi00127a020	41	56	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30728	30736		10.1074/jbc.M703745200	http://dx.doi.org/10.1074/jbc.M703745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704541	hybrid			2022-12-25	WOS:000250136300041
J	Gong, M; Hay, S; Marshall, KR; Munro, AW; Scrutton, NS				Gong, Min; Hay, Sam; Marshall, Ker R.; Munro, Andrew W.; Scrutton, Nigel S.			DNA binding suppresses human AIF-M2 activity and provides a connection between redox chemistry, reactive oxygen species, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; RIG-I; INFECTION; ACTIVATION; PROTEIN; INDUCTION; HOMOLOG; CANCER; STRESS; STATE	Human AIF-M2 is an unusual flavoprotein oxidoreductase that binds DNA, nicotinamide coenzyme, and the modified flavin 6-hydroxy- FAD. Using multiple solution methods to investigate the redox chemistry and binding interactions of AIF-M2, we demonstrate that binding of DNA and coenzyme to AIF-M2 is mutually exclusive. We also show that DNA binding does not perturb the redox chemistry of AIF-M2, but it has significant effects on the reduction kinetics of the 6-hydroxy- FAD cofactor by NAD(P)H. Based on quantitative analysis of ligand binding and redox chemistry, we propose a model for the function of AIF-M2. In this model, DNA binding suppresses the redox activity of AIF-M2 by preventing the binding of the reducing coenzyme NAD(P) H. This DNA- mediated suppression of AIF-M2 activity is expected to lower cellular levels of superoxide and peroxide, thereby lessening survival signaling by Ras, NF-kappa B, or AP-1, as suggested from knock-out studies of the related AIF in human colon cancer cell lines. We show marked differences between AIF-M2 and AIF. DNA and coenzyme binding activity is retained in the C-terminal deletion mutant AIF-M2-(Delta 319-613), whereas DNA binds to the C-terminal D3 domain of AIF. Our work provides the first analysis of AIF-M2 ligand interactions and redox chemistry and identifies an important mechanistic connection between coenzyme and DNA binding, redox activity, and the apoptotic function of AIF-M2. Through its DNA binding activity, we suggest that AIF-M2 lessens survival cell signaling in the presence of foreign ( e. g. bacterial and ( retro) viral) cytosolic DNA, thus contributing to the onset of apoptosis.	Univ Manchester, Fac Life Sci, Manchester M1 7DN, Lancs, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Manchester, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England	University of Manchester; University of Leicester; University of Manchester	Scrutton, NS (corresponding author), Univ Manchester, Manchester Interdisciplinary Bioctr, 131 Princess St, Manchester M1 7DN, Lancs, England.	nigel.scrutton@manchester.ac.uk	Hay, Sam/D-5974-2012; Munro, Andrew/G-5639-2019	Hay, Sam/0000-0003-3274-0938; Munro, Andrew/0000-0002-4642-180X	Biotechnology and Biological Sciences Research Council [BB/D01963X/1] Funding Source: Medline; BBSRC [BB/D01963X/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allsopp TE, 1998, CELL DEATH DIFFER, V5, P50, DOI 10.1038/sj.cdd.4400298; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Delhalle S, 2003, ANN NY ACAD SCI, V1010, P1, DOI 10.1196/annals.1299.001; Delhon GA, 2002, J GEN VIROL, V83, P2257, DOI 10.1099/0022-1317-83-9-2257; Despres P, 1998, J VIROL, V72, P823; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dutton P L, 1978, Methods Enzymol, V54, P411; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; Horikoshi N, 1999, BIOCHEM BIOPH RES CO, V261, P864, DOI 10.1006/bbrc.1999.1123; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kim YB, 2007, BIOCHEMISTRY-US, V46, P1423, DOI 10.1021/bi0617308; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Koyama AH, 1998, ARCH VIROL, V143, P2435, DOI 10.1007/s007050050473; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Marshall KR, 2005, J BIOL CHEM, V280, P30735, DOI 10.1074/jbc.M414018200; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Mei J, 2006, ONCOGENE, V25, P849, DOI 10.1038/sj.onc.1209121; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Ojcius DM, 1998, J IMMUNOL, V161, P4220; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Shigemori K, 1996, AM J PHYSIOL-LUNG C, V270, pL803, DOI 10.1152/ajplung.1996.270.5.L803; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang QH, 2002, SCIENCE, V295, P1895	46	25	28	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30331	30340		10.1074/jbc.M703713200	http://dx.doi.org/10.1074/jbc.M703713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711848	hybrid			2022-12-25	WOS:000249981200064
J	Tanaka, T; Suh, KS; Lo, AM; De Luca, LM				Tanaka, Takemi; Suh, Kwang S.; Lo, Angela M.; De Luca, Luigi M.			P21(WAF1/CIP1) is a common transcriptional target of retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; X-RECEPTOR; BREAST-CANCER; RESPONSE ELEMENT; 9-CIS-RETINOIC ACID; HORMONE-RECEPTORS; OVARIAN-CARCINOMA; PROSTATE-CANCER; MOUSE SKIN; VITAMIN-A	The divergent response and the molecular mechanisms underlying the anti-cancer effects of retinoid X receptor (RXR) ligand (rexinoid) therapy are poorly understood. This study demonstrates that ligand-activated RXR homodimer facilitated G(1) arrest by up-regulation of p21 in vitro and in vivo but failed to induce G1 arrest when p21 expression was blocked by p21 small interfering RNA. RXR ligand-dependent p21 up-regulation was transcriptionally controlled through the direct binding of RXR homodimers to two consecutive retinoid X response elements in the p21 promoter. Structural overlap of a retinoic acid response element with these retinoid X response elements led to a high affinity binding of retinoic acid receptor/RXR heterodimer to the retinoic acid response element, resulting in the prevention of RXR ligand-mediated p21 transactivation. These data show that p21 is a potential and novel molecular target for RXR ligand-mediated anti-cancer therapy and that the expression level of retinoic acid receptor and RXR in tumors may be crucial to induce p21-mediated cell growth arrest in RXR ligand therapy.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tanaka, T (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med, 1825 Herman Pressler,Rm 537C, Houston, TX 77030 USA.	Takemi.Tanaka@uth.tmc.edu			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], 2005, CLIN LUNG CANCER, V7, P17, DOI 10.1016/S1525-7304(11)70385-0; Balasubramanian S, 2004, CARCINOGENESIS, V25, P1377, DOI 10.1093/carcin/bgh122; Barger PM, 1997, J BIOL CHEM, V272, P2722, DOI 10.1074/jbc.272.5.2722; Cheng SX, 2001, ARCH DERMATOL, V137, P649; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; Didierjean L, 1996, J INVEST DERMATOL, V107, P714, DOI 10.1111/1523-1747.ep12365603; Disdier B, 2000, SKIN PHARMACOL APPL, V13, P9, DOI 10.1159/000029904; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Friedrich M, 2002, HISTOCHEM J, V34, P35, DOI 10.1023/A:1021343825552; Geisler HE, 2001, CANCER-AM CANCER SOC, V92, P781, DOI 10.1002/1097-0142(20010815)92:4<781::AID-CNCR1383>3.0.CO;2-P; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Huang JP, 2002, CANCER RES, V62, P4812; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LANCILLOTTI F, 1992, CANCER RES, V52, P6144; Lawrence JA, 1998, CANCER EPIDEM BIOMAR, V7, P29; LEE MO, 1995, MOL CELL BIOL, V15, P4194; Li M, 2001, DEVELOPMENT, V128, P675; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Mao GE, 2004, CANCER EPIDEM BIOMAR, V13, P383; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Naka K, 1997, DIFFERENTIATION, V61, P313, DOI 10.1046/j.1432-0436.1997.6150313.x; Rose SL, 2003, CLIN CANCER RES, V9, P1028; Schondorf T, 2004, PATHOBIOLOGY, V71, P217, DOI 10.1159/000078676; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Tanaka T, 2004, MOL CELL BIOL, V24, P3972, DOI 10.1128/MCB.24.9.3972-3982.2004; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wan HS, 1998, J BIOL CHEM, V273, P26915, DOI 10.1074/jbc.273.41.26915; Weinberg WC, 1999, CANCER RES, V59, P2050; Wu KD, 2002, CANCER RES, V62, P6376; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	43	54	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29987	29997		10.1074/jbc.M701700200	http://dx.doi.org/10.1074/jbc.M701700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17656367	hybrid			2022-12-25	WOS:000249981200028
J	Vong, L; D'Acquisto, F; Pederzoli-Ribeil, M; Lavagno, L; Flower, RJ; Witko-Sarsat, R; Perretti, M				Vong, Linda; D'Acquisto, Fulvio; Pederzoli-Ribeil, Magali; Lavagno, Luisa; Flower, Roderick J.; Witko-Sarsat, Ronique; Perretti, Mauro			Annexin 1 cleavage in activated neutrophils - A pivotal role for proteinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; LAVAGE FLUID; LIPOCORTIN 1; DEGRADATION; PHOSPHORYLATION; DIFFERENTIATION; EXPRESSION; MECHANISM; ELASTASE; GRANULES	Annexin 1 is an anti-inflammatory protein that plays a key role in innate immunity by modulating the activation of several types of cells, including neutrophils. Here we have developed a cleavage assay using tagged annexin 1 and observed marked activity in the membrane fraction of activated neutrophils. A combination of inhibitors, transfected cells, and proteomic analyses allowed us to identify proteinase 3 as the main enzyme responsible for this cleavage in the N terminus region of the protein, at least in the context of neutrophil activation. Because annexin 1 is an important endogenous anti-inflammatory mediator, blocking its cleavage by proteinase 3 would augment its homeostatic pro-resolving actions and could represent an opportunity for innovative anti-inflammatory drug discovery.	Barts & London, William Harvey Res Inst, London EC1M 6BQ, England; INSERM, U845, F-75015 Paris, France; Univ Paris 05, Necker Hosp, F-75015 Paris, France	University of London; Queen Mary University London; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Perretti, M (corresponding author), Barts & London, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	M.Perretti@qmul.ac.uk	D'Acquisto, Fulvio/E-7204-2018; Witko-Sarsat, Veronique/L-9714-2017	D'Acquisto, Fulvio/0000-0002-4513-1608; Witko-Sarsat, Veronique/0000-0002-5296-9601	Arthritis Research UK [15755] Funding Source: Medline; British Heart Foundation [PG/06/153/22042] Funding Source: Medline; Medical Research Council [G0400327] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400327] Funding Source: UKRI	Arthritis Research UK(Versus Arthritis); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Dublet B, 2005, J BIOL CHEM, V280, P30242, DOI 10.1074/jbc.M414609200; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hajjar E, 2006, J MED CHEM, V49, P1248, DOI 10.1021/jm051018t; Harper L, 2000, J PATHOL, V190, P349, DOI 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A; HUANG KS, 1987, J BIOL CHEM, V262, P7639; Korkmaz B, 2007, J BIOL CHEM, V282, P1989, DOI 10.1074/jbc.M608700200; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Movitz C, 1999, BBA-BIOMEMBRANES, V1416, P101, DOI 10.1016/S0005-2736(98)00212-0; Mulla A, 2004, CLIN ENDOCRINOL, V60, P107, DOI 10.1111/j.1365-2265.2004.01936.x; Pederzoli M, 2005, J IMMUNOL, V174, P6381, DOI 10.4049/jimmunol.174.10.6381; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; Perretti M, 2004, J LEUKOCYTE BIOL, V76, P25, DOI 10.1189/jlb.1103552; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Rescher U, 2006, BBA-MOL CELL RES, V1763, P1320, DOI 10.1016/j.bbamcr.2006.08.041; Rosales JL, 1997, J IMMUNOL, V159, P6195; Schreiber A, 2003, J AM SOC NEPHROL, V14, P68, DOI 10.1097/01.ASN.0000040751.83734.D1; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Solito E, 2006, FASEB J, V20, P1498, DOI 10.1096/fj.05-5319fje; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; van der Geld YM, 2001, J LEUKOCYTE BIOL, V69, P177; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Vishwanatha JK, 1998, CLIN CANCER RES, V4, P2559; Wiesner O, 2005, FEBS LETT, V579, P5305, DOI 10.1016/j.febslet.2005.08.056; Witko-Sarsat V, 1999, BLOOD, V94, P2487, DOI 10.1182/blood.V94.7.2487.419k07_2487_2496; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Witko-Sarsat V, 1999, J AM SOC NEPHROL, V10, P1224; Witko-Sarsat V, 2002, J BIOL CHEM, V277, P47338, DOI 10.1074/jbc.M202789200	35	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29998	30004		10.1074/jbc.M702876200	http://dx.doi.org/10.1074/jbc.M702876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17681950	Green Accepted, hybrid			2022-12-25	WOS:000249981200029
J	Hakansson, AP; Smith, AW				Hakansson, Anders P.; Smith, Alexander W.			Enzymatic characterization of dihydrolipoamide dehydrogenase from Streptococcus pneumoniae harboring its own substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEPENDENT TRANSPORT; REFINED CRYSTAL-STRUCTURE; COMPLETE GENOME SEQUENCE; LIPOIC ACID METABOLISM; LIPOAMIDE DEHYDROGENASE; ESCHERICHIA-COLI; PYRUVATE-DEHYDROGENASE; AZOTOBACTER-VINELANDII; MOLECULAR-CLONING; IDENTIFICATION	This study describes the enzymatic characterization of dihydrolipoamide dehydrogenase (DLDH) from Streptococcus pneumoniae and is the first characterization of a DLDH that carries its own substrate (a lipoic acid covalently attached to a lipoyl protein domain) within its own sequence. Full-length recombinant DLDH (rDLDH) was expressed and compared with enzyme expressed in the absence of lipoic acid (rDLDH(-LA)) or with enzyme lacking the first 112 amino acids constituting the lipoyl protein domain (rDLDH(-LIPOYL)). All three proteins contained 1 mol of FAD/mol of protein, had a higher activity for the conversion of NAD(+) to NADH than for the reaction in the reverse direction, and were unable to use NADP(+) and NADPH as substrates. The enzymes had similar substrate specificities, with the K-m for NAD(+) being similar to 20 times higher than that for dihydrolipoamide. The kinetic pattern suggested a Ping Pong Bi Bi mechanism, which was verified by product inhibition studies. The protein expressed without lipoic acid was indistinguishable from the wild-type protein in all analyses. On the other hand, the protein without a lipoyl protein domain had a 2-3-fold higher turnover number, a lower K-I for NADH, and a higher K-I for lipoamide compared with the other two enzymes. The results suggest that the lipoyl protein domain (but not lipoic acid alone) plays a regulatory role in the enzymatic characteristics of pneumococcal DLDH.	SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA; New York State Ctr Excellence Bioinformat & Life, Buffalo, NY 14203 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Alabama System; University of Alabama Birmingham	Hakansson, AP (corresponding author), SUNY Buffalo, Dept Microbiol & Immunol, 145 Biomed Res Bldg,3435 Main St, Buffalo, NY 14214 USA.	andersh@buffalo.edu	Hakansson, Anders/H-8190-2014; Hakansson, Anders P/AAX-1225-2020	Hakansson, Anders/0000-0002-2834-6009; Hakansson, Anders P/0000-0002-2834-6009	NHLBI NIH HHS [HL54818] Funding Source: Medline; NIAID NIH HHS [AI07051, AI21548, T32 AI007051] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021548, T32AI007051, R56AI021548] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; Argyrou A, 2001, BIOCHEMISTRY-US, V40, P11353, DOI 10.1021/bi010575o; BRINGAS R, 1995, PROTEINS, V21, P303, DOI 10.1002/prot.340210404; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DANSON MJ, 1988, BIOCHEM SOC T, V16, P87, DOI 10.1042/bst0160087; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; delaSierra IL, 1997, J MOL BIOL, V269, P129, DOI 10.1006/jmbi.1997.1009; DIETRICHS D, 1990, J BACTERIOL, V172, P243, DOI 10.1128/JB.172.1.243-251.1990; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Jang YJ, 1997, BBA-MOL CELL RES, V1358, P229, DOI 10.1016/S0167-4889(97)00078-5; KRUGER N, 1994, J BACTERIOL, V176, P3614; Marcinkeviciene J, 1997, ARCH BIOCHEM BIOPHYS, V340, P168, DOI 10.1006/abbi.1997.9926; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; NAKAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V267, P249, DOI 10.1016/0005-2728(72)90113-2; OPPERMANN FB, 1991, J BACTERIOL, V173, P757, DOI 10.1128/jb.173.2.757-767.1991; OWEN P, 1980, FEMS MICROBIOL LETT, V7, P345, DOI 10.1111/j.1574-6941.1980.tb01619.x; Palmer JM, 1999, HEPATOLOGY, V30, P21, DOI 10.1002/hep.510300106; PERHAM RN, 1987, BIOCHEM SOC SYMP, P67; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; Raya NE, 1999, BIOTECHNOL APPL BIOC, V29, P113; REED JK, 1973, J BIOL CHEM, V248, P4834; REED LJ, 1958, J BIOL CHEM, V232, P143; RICHARME G, 1989, J BACTERIOL, V171, P6580, DOI 10.1128/jb.171.12.6580-6585.1989; RICHARME G, 1985, J BACTERIOL, V162, P286, DOI 10.1128/JB.162.1.286-293.1985; RICHARME G, 1987, BIOCHIM BIOPHYS ACTA, V893, P373, DOI 10.1016/0005-2728(87)90058-2; RICHARME G, 1986, EUR J BIOCHEM, V156, P399, DOI 10.1111/j.1432-1033.1986.tb09596.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAHLMAN L, 1989, J BIOL CHEM, V264, P8039; Smith AW, 2002, MOL MICROBIOL, V44, P431, DOI 10.1046/j.1365-2958.2002.02883.x; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; VETTAKKORUMAKANKAV NN, 1992, BIOCHEM CELL BIOL, V70, P656, DOI 10.1139/o92-101; VIENOZINSKIS J, 1990, BIOCHEM J, V269, P101, DOI 10.1042/bj2690101; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Williams Jr C.H., 1989, ANN N Y ACAD SCI, V573, P55; WREN A, 1966, BIOCHIM BIOPHYS ACTA, V122, P436, DOI 10.1016/0926-6593(66)90036-1; Youn H, 1998, BBA-PROTEIN STRUCT M, V1388, P405, DOI 10.1016/S0167-4838(98)00200-3; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016; Zhu PP, 1996, PROTEIN SCI, V5, P1719, DOI 10.1002/pro.5560050825	47	15	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29521	29530		10.1074/jbc.M703144200	http://dx.doi.org/10.1074/jbc.M703144200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690105	hybrid			2022-12-25	WOS:000249788000049
J	Yogev, O; Karniely, S; Pines, O				Yogev, Ohad; Karniely, Sharon; Pines, Ophry			Translation-coupled translocation of yeast fumarase into mitochondria in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PROTEIN IMPORT; ADENYLATE KINASE; COMPLEX; RIBOSOMES; SEQUENCE; CHANNEL; CYTOSOL; TOM40	Fumarase represents proteins that cannot be imported into mitochondria after the termination of translation (post-translationally). Utilizing mitochondrial and cytosolic versions of the tobacco etch virus (TEV) protease, we show that mitochondrially targeted fumarase harboring a TEV protease recognition sequence is efficiently cleaved by the mitochondrial but not by the cytosolic TEV protease. Nonetheless, fumarase was readily cleaved by cytosolic TEV when its import into mitochondria was slowed down by either (i) disrupting the activity of the TOM complex, (ii) lowering the growth temperature, or (iii) reducing the inner membrane electrochemical potential. Accessibility of the fumarase nascent chain to TEV protease under such conditions was prevented by low cycloheximide concentrations, which impede translation. In addition, depletion of the ribosome-associated nascent polypeptide-associated complex (NAC) reduced the fumarase rate of translocation into mitochondria and exposed it to TEV cleavage in the cytosol. These results indicate that cytosolic exposure of the fumarase nascent chain depends on both translocation and translation rates, allowing us to discuss the possibility that import of fumarase into mitochondria occurs while the ribosome is still attached to the nascent chain.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.	ophryp@ekmd.huji.ac.il	Karniely, Sharon/AAY-5499-2020; Karniely, Sharon/AAN-7886-2021; pines, ophry/C-4086-2011	Yogev, Ohad/0000-0001-8216-6386; pines, ophry/0000-0001-7126-2575				ADES IZ, 1980, J BIOL CHEM, V255, P9925; ADES IZ, 1980, J BIOL CHEM, V255, P9918; Angermayr M, 2001, FEBS LETT, V508, P427, DOI 10.1016/S0014-5793(01)03122-2; BANDLOW W, 1988, EUR J BIOCHEM, V178, P451, DOI 10.1111/j.1432-1033.1988.tb14469.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; HARMEY MA, 1977, EUR J BIOCHEM, V81, P533, DOI 10.1111/j.1432-1033.1977.tb11979.x; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Karniely S, 2006, J MOL BIOL, V358, P396, DOI 10.1016/j.jmb.2006.02.023; KARNIELY S, 2006, THESIS HEBREW U JERU; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KELLEMS RE, 1974, J BIOL CHEM, V249, P3297; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Luk E, 2005, J BIOL CHEM, V280, P22715, DOI 10.1074/jbc.M504257200; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; Mokranjac D, 2005, BIOCHEM SOC T, V33, P1019, DOI 10.1042/BST0331019; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Phan J, 2002, J BIOL CHEM, V277, P50564, DOI 10.1074/jbc.M207224200; Regev-Rudzki N, 2005, MOL BIOL CELL, V16, P4163, DOI 10.1091/mbc.e04-11-1028; Sagot I, 1999, FEBS LETT, V447, P53, DOI 10.1016/S0014-5793(99)00258-6; Sass E, 2003, J BIOL CHEM, V278, P45109, DOI 10.1074/jbc.M302344200; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Waizengger T, 2005, EMBO REP, V6, P57, DOI 10.1038/sj.embor.7400318; Weaver T, 1998, J MOL BIOL, V280, P431, DOI 10.1006/jmbi.1998.1862; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200	36	61	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29222	29229		10.1074/jbc.M704201200	http://dx.doi.org/10.1074/jbc.M704201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17666392	hybrid			2022-12-25	WOS:000249788000018
J	Gao, YT; Roman, LJ; Martasek, P; Panda, SP; Ishimura, Y; Masters, BSS				Gao, Ying Tong; Roman, Linda J.; Martasek, Pavel; Panda, Satya Prakash; Ishimura, Yuzuru; Masters, Bettie Sue S.			Oxygen metabolism by endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; TETRAHYDROBIOPTERIN RADICAL FORMATION; HEME-DIOXY REDUCTION; L-ARGININE; SUPEROXIDE GENERATION; NO SYNTHASE; ISOCITRATE DEHYDROGENASE; SUBSTRATE-ANALOGS; ESCHERICHIA-COLI; MECHANISM	Nitric- oxide synthase ( NOS) catalyzes both coupled and uncoupled reactions that generate nitric oxide and reactive oxygen species. Oxygen is often the overlooked substrate, and the oxygen metabolism catalyzed by NOS has been poorly defined. In this paper we focus on the oxygen stoichiometry and effects of substrate/ cofactor binding on the endothelial NOS isoform ( eNOS). In the presence of both L- arginine and tetrahydrobiopterin, eNOS is highly coupled (> 90%), and the measured stoichiometry of O-2/ NADPH is very close to the theoretical value. We report for the first time that the presence of L- arginine stimulates oxygen uptake by eNOS. The fact that nonhydrolyzable L- arginine analogs are not stimulatory indicates that the occurrence of the coupled reaction, rather than the accelerated uncoupled reaction, is responsible for the L- arginine- dependent stimulation. The presence of 5,6,7,8- tetrahydrobiopterin quenched the uncoupled reactions and resulted in much less reactive oxygen species formation, whereas the presence of redox- incompetent 7,8- dihydrobiopterin demonstrates little quenching effect. These results reveal different mechanisms for oxygen metabolism for eNOS as opposed to nNOS and, perhaps, partially explain their functional differences.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Charles Univ Prague, Sch Med 1, Dept Pediat, Prague 12808, Czech Republic; Keio Univ, Sch Med, Dept Biochem & Integrated Biol, Tokyo 1608582, Japan	University of Texas System; University of Texas Health San Antonio; Charles University Prague; Keio University	Masters, BSS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	masters@uthscsa.edu	Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Alp NJ, 2004, ARTERIOSCL THROM VAS, V24, P413, DOI 10.1161/01.ATV.0000110785.96039.f6; Barua RS, 2003, CIRCULATION, V107, P2342, DOI 10.1161/01.CIR.0000066691.52789.BE; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bendall JK, 2005, CIRC RES, V97, P864, DOI 10.1161/01.RES.0000187447.03525.72; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Bevers LM, 2006, HYPERTENSION, V47, P87, DOI 10.1161/01.HYP.0000196735.85398.0e; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Cunningham MA, 1998, BIOPHYS J, V74, pA133; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; Dixon LJ, 2005, AM J HYPERTENS, V18, P839, DOI 10.1016/j.amjhyper.2005.01.004; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; Gao YT, 2007, J BIOL CHEM, V282, P7921, DOI 10.1074/jbc.M609814200; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2005, METHOD ENZYMOL, V396, P456, DOI 10.1016/S0076-6879(05)96038-2; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Higman DJ, 1996, ARTERIOSCL THROM VAS, V16, P546, DOI 10.1161/01.ATV.16.4.546; Kawashima S, 2004, ARTERIOSCL THROM VAS, V24, P998, DOI 10.1161/01.ATV.0000125114.88079.96; Khoo JP, 2005, CIRCULATION, V111, P2126, DOI 10.1161/01.CIR.0000162470.26840.89; KORTH HG, 1994, J BIOL CHEM, V269, P17776; KWON NS, 1989, J BIOL CHEM, V264, P20496; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li D, 2007, J AM CHEM SOC, V129, P6943, DOI 10.1021/ja070683j; Lowe ER, 2005, DRUG METAB DISPOS, V33, P131, DOI 10.1124/dmd.104.001891; Madeddu P, 2005, J HYPERTENS, V23, P1335, DOI 10.1097/01.hjh.0000173513.37740.7c; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MAKINO R, 1972, J BIOCHEM-TOKYO, V72, P655, DOI 10.1093/oxfordjournals.jbchem.a129943; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1991, FASEB J, V5, pA864; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; McMillan K, 1996, METHOD ENZYMOL, V268, P460; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NAKAMURA Y, 1989, J BIOL CHEM, V264, P4759; Porasuphatana S, 2003, COMP BIOCHEM PHYS C, V134, P281, DOI 10.1016/S1532-0456(02)00271-5; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, BIOCHEMISTRY-US, V36, P11821, DOI 10.1021/bi963003q; Satoh M, 2005, AM J PHYSIOL-RENAL, V288, pF1144, DOI 10.1152/ajprenal.00221.2004; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Sullivan JC, 2006, CIRC RES, V98, P717, DOI 10.1161/01.RES.0000217594.97174.c2; Takaya T, 2007, ARTERIOSCL THROM VAS, V27, P1632, DOI 10.1161/ATVBAHA.107.142182; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Tierney DL, 1999, J INORG BIOCHEM, V74, P32; Tierney DL, 1999, J INORG BIOCHEM, V74, P314; Tierney DL, 2000, J AM CHEM SOC, V122, P5405, DOI 10.1021/ja993685f; Tierney DL, 1999, BIOCHEMISTRY-US, V38, P3704, DOI 10.1021/bi982904r; Tierney DL, 1998, J AM CHEM SOC, V120, P2983, DOI 10.1021/ja973648t; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 2003, FREE RADICAL RES, V37, P121, DOI 10.1080/1071576021000040655; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; WANG JL, 1993, J BIOL CHEM, V268, P22255; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wang X, 2007, EUR J PHARMACOL, V555, P48, DOI 10.1016/j.ejphar.2006.10.017; Wei CC, 2005, J BIOL CHEM, V280, P8929, DOI 10.1074/jbc.M409737200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	77	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28557	28565		10.1074/jbc.M704890200	http://dx.doi.org/10.1074/jbc.M704890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17698846	hybrid			2022-12-25	WOS:000249642100030
J	Ye, XC; Paroo, Z; Liu, QH				Ye, Xuecheng; Paroo, Zain; Liu, Qinghua			Functional anatomy of the Drosophila MicroRNA- generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NUCLEAR EXPORT; MICROPROCESSOR COMPLEX; INTERFERENCE; DICER; MATURATION; PATHWAY; PROTEIN; SIRNA; MIRNA	In Drosophila melanogaster, the multidomain RNase III Dicer-1 (Dcr-1) functions in tandem with the doublestranded (ds) RNA-binding protein Loquacious (Loqs) to catalyze the maturation of microRNAs (miRNAs) from precursor (pre)-miRNAs. Here we dissect the molecular mechanism of pre-miRNA processing by the Dcr-1-Loqs complex. The tandem RNase III (RIII) domains of Dcr-1 form an intramolecular dimer such that one RIII domain cleaves the 3' strand, whereas the other cuts the 5' strand of pre-miRNA. We show that the functional core of Dcr-1 consists of a DUF283 domain, a PAZ domain, and two RIII domains. Dcr-1 preferentially associates with the Loqs-PB splice isoform. Loqs-PB uses the second dsRNA-binding domain to bind pre-miRNA and the third dsRNA-binding domain to interact with Dcr-1. Both domains of Loqs-PB are required for efficient miRNA production by enhancing the affinity of Dcr-1 for pre-miRNA. Thus, our results provide further insights into the functional anatomy of the Drosophila miRNA-generating enzyme.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ye, XC (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd,K3-219, Dallas, TX 75390 USA.	Qinghua.Liu@UTsouthwestern.edu			NIGMS NIH HHS [GM078163] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078163] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Dlakic M, 2006, BIOINFORMATICS, V22, P2711, DOI 10.1093/bioinformatics/btl468; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; LEE Y, 2007, EMBO J, V25, P533; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Liu X, 2006, RNA, V12, P1514, DOI 10.1261/rna.101606; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Park JK, 2007, CURR BIOL, V17, P533, DOI 10.1016/j.cub.2007.01.060; Pham JW, 2005, J BIOL CHEM, V280, P39278, DOI 10.1074/jbc.M509202200; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Tang GL, 2005, TRENDS BIOCHEM SCI, V30, P106, DOI 10.1016/j.tibs.2004.12.007; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017	32	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28373	28378		10.1074/jbc.M705208200	http://dx.doi.org/10.1074/jbc.M705208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666393	hybrid			2022-12-25	WOS:000249642100011
J	Popescu, F; Fazli, S; Badower, Y; Blankertz, B; Muller, KR				Popescu, Florin; Fazli, Siamac; Badower, Yakob; Blankertz, Benjamin; Mueller, Klaus-R.			Single Trial Classification of Motor Imagination Using 6 Dry EEG Electrodes	PLOS ONE			English	Article								Background. Brain computer interfaces (BCI) based on electro-encephalography (EEG) have been shown to detect mental states accurately and non-invasively, but the equipment required so far is cumbersome and the resulting signal is difficult to analyze. BCI requires accurate classification of small amplitude brain signal components in single trials from recordings which can be compromised by currents induced by muscle activity. Methodology/Principal Findings. A novel EEG cap based on dry electrodes was developed which does not need time-consuming gel application and uses far fewer electrodes than on a standard EEG cap set-up. After optimizing the placement of the 6 dry electrodes through off-line analysis of standard cap experiments, dry cap performance was tested in the context of a well established BCI cursor control paradigm in 5 healthy subjects using analysis methods which do not necessitate user training. The resulting information transfer rate was on average about 30% slower than the standard cap. The potential contribution of involuntary muscle activity artifact to the BCI control signal was found to be inconsequential, while the detected signal was consistent with brain activity originating near the motor cortex. Conclusions/Significance. Our study shows that a surprisingly simple and convenient method of brain activity imaging is possible, and that simple and robust analysis techniques exist which discriminate among mental states in single trials. Within 15 minutes the dry BCI device is set-up, calibrated and ready to use. Peak performance matched reported EEG BCI state of the art in one subject. The results promise a practical non-invasive BCI solution for severely paralyzed patients, without the bottleneck of setup effort and limited recording duration that hampers current EEG recording technique. The presented recording method itself, BCI not considered, could significantly widen the use of EEG for emerging applications requiring longterm brain activity and mental state monitoring.	[Popescu, Florin; Fazli, Siamac; Badower, Yakob; Blankertz, Benjamin; Mueller, Klaus-R.] Fraunhofer Inst FIRST, Intelligent Data Anal Lab, Berlin, Germany; [Blankertz, Benjamin; Mueller, Klaus-R.] Tech Univ Berlin, Machine Learning Lab, Berlin, Germany	Fraunhofer Gesellschaft; Technical University of Berlin	Popescu, F (corresponding author), Fraunhofer Inst FIRST, Intelligent Data Anal Lab, Berlin, Germany.	florin.popescu@first.fhg.de	Mueller, Klaus-Robert/Y-3547-2019; Muller, Klaus R/C-3196-2013; Fazli, Siamac/GYQ-9627-2022; Fazli, Siamac/D-7720-2013	Mueller, Klaus-Robert/0000-0002-3861-7685; Fazli, Siamac/0000-0003-3397-0647; Blankertz, Benjamin/0000-0002-2437-4846	European Union's Marie Curie Excellence Team [MEXT-CT-2004-014194]	European Union's Marie Curie Excellence Team	Funding: This work was supported by the European Union's Marie Curie Excellence Team project MEXT-CT-2004-014194, entitled "BRAIN2ROBOT"	Birbaumer N, 2003, IEEE T NEUR SYS REH, V11, P120, DOI 10.1109/TNSRE.2003.814439; Birbaumer N, 1999, NATURE, V398, P297, DOI 10.1038/18581; BLANKERTZ B, 2007, NEUROIMAGE IN PRESS; Blankertz B, 2006, J UNIVERS COMPUT SCI, V12, P581; Blankertz B, 2006, IEEE T NEUR SYS REH, V14, P153, DOI 10.1109/TNSRE.2006.875642; Blankertz B, 2006, IEEE T NEUR SYS REH, V14, P147, DOI 10.1109/TNSRE.2006.875557; Bonnet MH, 2001, PHYSIOL BEHAV, V74, P291, DOI 10.1016/S0031-9384(01)00581-9; Dornhege G., 2007, BRAIN COMPUTER INTER; Falco C, 2005, CLIN NEUROPHYSIOL, V116, P1771, DOI 10.1016/j.clinph.2005.04.012; FARQUHAR J, 2006, REGULARISED CSP SENS, P14; Koles ZJ, 1998, ELECTROEN CLIN NEURO, V107, P343, DOI 10.1016/S0013-4694(98)00084-4; KRAULEDAT M, 2007, ADV NEURAL INF PROC; Lemm S, 2005, IEEE T BIO-MED ENG, V52, P1541, DOI 10.1109/TBME.2005.851521; Niedermeyer E., 1999, ELECTROENCEPHALOGRAP; Pfurtscheller G, 2006, NEUROIMAGE, V31, P153, DOI 10.1016/j.neuroimage.2005.12.003; WENTRUP MG, 2005, NEUR ENG 2005 C P 2, P128; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3	17	133	142	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e637	10.1371/journal.pone.0000637	http://dx.doi.org/10.1371/journal.pone.0000637			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653264	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452200006
J	Sugaya, K; Matsubara, S; Kagamihara, Y; Kawata, A; Hayashi, H				Sugaya, Keizo; Matsubara, Shiro; Kagamihara, Yasuhiro; Kawata, Akihiro; Hayashi, Hideaki			Polyglutamine Expansion Mutation Yields a Pathological Epitope Linked to Nucleation of Protein Aggregate: Determinant of Huntington's Disease Onset	PLOS ONE			English	Article								Polyglutamine (polyQ) expansion mutation causes conformational, neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These diseases are characterized by the aggregation of misfolded proteins, such as amyloid fibrils, which are toxic to cells. Amyloid fibrils are formed by a nucleated growth polymerization reaction. Unexpectedly, the critical nucleus of polyQ aggregation was found to be a monomer, suggesting that the rate-limiting nucleation process of polyQ aggregation involves the folding of mutated protein monomers. The monoclonal antibody 1C2 selectively recognizes expanded pathogenic and aggregate-prone glutamine repeats in polyQ diseases, including Huntington's disease (HD), as well as binding to polyleucine. We have therefore assayed the in vitro and in vivo aggregation kinetics of these monomeric proteins. We found that the repeat-length-dependent differences in aggregation lag times of variable lengths of polyQ and polyleucine tracts were consistently related to the integration of the length-dependent intensity of anti-1C2 signal on soluble monomers of these proteins. Surprisingly, the correlation between the aggregation lag times of polyQ tracts and the intensity of anti-1C2 signal on soluble monomers of huntingtin precisely reflected the repeat-length dependent age-of-onset of HD patients. These data suggest that the alterations in protein surface structure due to polyQ expansion mutation in soluble monomers of the mutated proteins act as an amyloid-precursor epitope. This, in turn, leads to nucleation, a key process in protein aggregation, thereby determining HD onset. These findings provide new insight into the gain-of-function mechanisms of polyQ diseases, in which polyQ expansion leads to nucleation rather than having toxic effects on the cells.	[Sugaya, Keizo; Matsubara, Shiro; Kagamihara, Yasuhiro; Kawata, Akihiro; Hayashi, Hideaki] Tokyo Metropolitan Neurol Hosp, Dept Neurol, Tokyo, Japan	Tokyo Metropolitan Institute for Neuroscience	Sugaya, K (corresponding author), Tokyo Metropolitan Neurol Hosp, Dept Neurol, Tokyo, Japan.	keizo_sugaya@member.metro.tokyo.jp		Sugaya, Kiminobu/0000-0002-2788-5457	Tokyo Metropolitan Government	Tokyo Metropolitan Government(Tokyo Metropolitan Government)	Funding: This study was funded by the Tokyo Metropolitan Government.	Bates G, 1996, BIOESSAYS, V18, P175, DOI 10.1002/bies.950180303; Brinkman RR, 1997, AM J HUM GENET, V60, P1202; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Dorsman JC, 2002, HUM MOL GENET, V11, P1487, DOI 10.1093/hmg/11.13.1487; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lunkes A, 1999, PHILOS T R SOC B, V354, P1013, DOI 10.1098/rstb.1999.0453; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Nagai Y, 2003, HUM MOL GENET, V12, P1253, DOI 10.1093/hmg/ddg144; Page KJ, 1998, EUR J NEUROSCI, V10, P1835, DOI 10.1046/j.1460-9568.1998.00185.x; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Rong J, 2006, J NEUROSCI, V26, P6019, DOI 10.1523/JNEUROSCI.1251-06.2006; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Thompson AJ, 2002, CURR MED CHEM, V9, P1751; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	32	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e635	10.1371/journal.pone.0000635	http://dx.doi.org/10.1371/journal.pone.0000635			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653262	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452200004
J	Maekawa, T; Sano, Y; Shinagawa, T; Rahman, Z; Sakuma, T; Nomura, S; Licht, JD; Ishii, S				Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Sakuma, T.; Nomura, S.; Licht, J. D.; Ishii, S.			ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors	ONCOGENE			English	Article						ATF-2; GADD45 alpha; Maspin; p53; BRCA1; tumor suppressors	BRCA1; EXPRESSION; ELEMENT; BINDING; OCT-1; MICE	The activating transcription factor, ATF-2, is a target of p38 and JNK that are involved in stress-induced apoptosis. Heterozygous Atf-2 mutant ( Atf-2(+/-)) mice are highly prone to mammary tumors. The apoptosis-regulated gene GADD45 alpha and the breast cancer suppressor gene Maspin, both of which are known to be p53 target genes, are downregulated in the mammary tumors arisen in Atf-2(+/-) mice. Here, we have analysed how ATF-2 controls the transcription of GADD45a and Maspin. ATF-2 and p53 independently activate the GADD45a transcription. ATF-2 does not directly bind to the GADD45a promoter; instead, it is recruited via Oct-1 and NF-I. ATF-2 simultaneously binds to Oct-1, NF-I and breast cancer suppressor BRCA1 to activate transcription. With regard to Maspin, ATF-2 and p53 directly bind to different sites in the Maspin promoter to independently activate its transcription. Consistent with the observation that ATF-2 and p53 independently activate the transcription of Maspin and GADD45a is that the loss of one copy of p53 shortened the period required for mammary tumor development in Atf-2(+/-) mice. These studies suggest the functional link between the ATF-2 and the two tumor suppressors BRCA1 and p53.	[Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Ishii, S.] RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; [Sakuma, T.; Nomura, S.] Osaka Univ, Dept Pathol, Grad Sch Med, Suita, Osaka, Japan; [Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	RIKEN; Osaka University; Northwestern University; Feinberg School of Medicine	Maekawa, T (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	maekawa@rtc.riken.jp; sishii@rtc.riken.jp	Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020; Ishii, Shunsuke/A-5271-2016	Licht, Jonathan/0000-0002-3942-1369; Ishii, Shunsuke/0000-0002-6530-2478; Sakuma, Takahiko/0000-0002-9477-2196				Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Osada S, 1996, J BIOL CHEM, V271, P3891; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	23	57	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1045	1054		10.1038/sj.onc.1210727	http://dx.doi.org/10.1038/sj.onc.1210727			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700520				2022-12-25	WOS:000253136700003
J	Davis, E; Teng, H; Bilican, B; Parker, MI; Liu, B; Carriera, S; Goding, CR; Prince, S				Davis, E.; Teng, H.; Bilican, B.; Parker, M. I.; Liu, B.; Carriera, S.; Goding, C. R.; Prince, S.			Ectopic Tbx2 expression results in polyploidy and cisplatin resistance	ONCOGENE			English	Article						Tbx2; T-box factor; polyploidy; chromosomal instability	CELL-CYCLE; MITOTIC CATASTROPHE; DNA-DAMAGE; SENESCENCE; GENE; P53; REPRESSES; SUBSET; ARREST; DOMAIN	T-box factors play critical roles in embryonic development and have been implicated in cell cycle regulation and cancer. For example, Tbx2 can suppress senescence through a mechanism involving the repression of the cyclin-dependent kinase inhibitors, p19ARF and p21(WAF1/CIP1/SDII), and the Tbx2 gene is deregulated in melanoma, breast and pancreatic cancers. In this study, several transformed human lung. broblast cell lines were shown to downregulate Tbx2. To further investigate the role of Tbx2 in oncogenesis we therefore stably reexpressed Tbx2 in one such cell line. Compared to their parental cells, the resulting Tbx2-expressing cells are larger, with binucleate and lobular nuclei containing double the number of chromosomes. Moreover, these cells had an increase in frequency of several features of genomic instability such as chromosome missegregation, chromosomal rearrangements and polyploidy. While grossly abnormal, these cells still divide and give rise to cells that are resistant to the chemotherapeutic drug cisplatin. Furthermore, this is shown to be neither species nor cell type dependent, as ectopically expressing Tbx2 in a murine melanoma cell line also induce mitotic defects and polyploidy. These results have important implications for our understanding of the role of Tbx2 in tumorigenesis because polyploidy frequently precedes aneuploidy, which is associated with high malignancy and poor prognosis.	[Davis, E.; Prince, S.] Univ Cape Town, Dept Human Biol, Fac Hlth Sci,Div Cell Biol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, Western Prov, South Africa; [Teng, H.; Parker, M. I.] Univ Cape Town, Fac Hlth Sci, Div Med Biochem, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, Western Prov, South Africa; [Bilican, B.; Liu, B.; Carriera, S.; Goding, C. R.] Marie Curie Res Inst, Signalling & Dev Lab, Surrey, England	University of Cape Town; University of Cape Town	Prince, S (corresponding author), Univ Cape Town, Dept Human Biol, Fac Hlth Sci,Div Cell Biol, Inst Infect Dis & Mol Med, Anzio Rd, ZA-7925 Cape Town, Western Prov, South Africa.	sharon.prince@uct.ac.za	Prince, Sharon/AFU-4911-2022	Prince, Sharon/0000-0002-6975-5255; Goding, Colin/0000-0002-1614-3909; Carreira, Suzanne/0000-0002-5077-5379				Andreassen PR, 2001, CANCER RES, V61, P7660; Baroja A, 1998, LIFE SCI, V62, P2275, DOI 10.1016/S0024-3205(98)00208-2; Bilican B, 2006, EXP CELL RES, V312, P2358, DOI 10.1016/j.yexcr.2006.03.033; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butz NV, 2004, GENE, V342, P67, DOI 10.1016/j.gene.2004.07.024; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Danesi R, 2003, PHARMACOL REV, V55, P57, DOI 10.1124/pr.55.1.4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Huang XX, 2005, P NATL ACAD SCI USA, V102, P1065, DOI 10.1073/pnas.0409130102; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jerome-Majewska LA, 2005, DEV DYNAM, V234, P922, DOI 10.1002/dvdy.20575; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Naiche LA, 2005, ANNU REV GENET, V39, P219, DOI 10.1146/annurev.genet.39.073003.105925; NAMBA M, 1980, GANN, V71, P300; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Packham EA, 2003, HUM MOL GENET, V12, pR37, DOI 10.1093/hmg/ddg077; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PRIEST JH, 1977, MED CYTOGENETICS CEL, P118; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Prince S, 2003, PIGM CELL RES, V16, P26, DOI 10.1034/j.1600-0749.2003.00008.x; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; ROTHENBERG M, 1989, JNCI-J NATL CANCER I, V81, P907, DOI 10.1093/jnci/81.12.907; Sinclair CS, 2002, CANCER RES, V62, P3587; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; TENG H, 2007, J CELL BIOCH; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	31	38	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					976	984		10.1038/sj.onc.1210701	http://dx.doi.org/10.1038/sj.onc.1210701			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700536				2022-12-25	WOS:000252946300009
J	Kramer, OH; Knauer, SK; Zimmermann, D; Stauber, RH; Heinzel, T				Kraemer, O. H.; Knauer, S. K.; Zimmermann, D.; Stauber, R. H.; Heinzel, T.			Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis	ONCOGENE			English	Article						VPA; HDAC inhibitor; hydroxyurea; caspase-3; CDKI p21/p27; chemotherapy resistance	ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; VALPROIC ACID; MEDIATED APOPTOSIS; DRUG-RESISTANCE; RECURRENT MENINGIOMAS; TUMOR-CELLS; P27(KIP1); MELANOMA; EXPRESSION	Therapy resistance represents a major problem for disease management in oncology. Histone deacetylase inhibitors (HDACi) have been shown to modulate the cell cycle, to induce apoptosis and to sensitize cancer cells for other chemotherapeutics. Our study shows that the HDACi valproic acid (VPA) and the ribonucleotide reductase inhibitor hydroxyurea (HU) potentiate the pro-apoptotic effects of each other towards several cancer cell lines. This correlates with the HU-induced degradation of the cyclin-dependent kinase inhibitors (CDKI) p21 and p27, mediated by the proteasome or caspase-3. Moreover, we found that caspase-3 activation is required for VPA induced apoptosis. Remarkably, p21 and p27 can confer resistance against VPA and HU. Both CDKI interact with caspase-3 and compete with other caspase-3 substrates. Hence, p21 and p27 may contribute to chemotherapy resistance as apoptosis inhibitors. Since the biological effects of VPA and HU could be achieved at concentrations used in current treatment protocols, the combined application of these compounds might be considered as a potential strategy for cancer treatment.	[Kraemer, O. H.; Heinzel, T.] Univ Jena, Inst Biochem & Biophys, Jena, Germany; [Knauer, S. K.; Stauber, R. H.] Univ Hosp Mainz, Mainz, Germany; [Zimmermann, D.] Inst Biomed Res, Frankfurt, Germany	Friedrich Schiller University of Jena; University Hospital Mainz	Kramer, OH (corresponding author), Univ Jena, Inst Biochem & Biophys, Jena, Germany.	Oliver.Kraemer@uni-jena.de; t.heinzel@uni-jena.de	Krämer, Oliver H/L-9266-2015; Heinzel, Thorsten/B-1013-2015; Knauer, Shirley K/E-7931-2012	Krämer, Oliver H/0000-0003-3973-045X; Knauer, Shirley K/0000-0003-4321-0924; Stauber, Roland/0000-0002-1341-4523				Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Drexler HCA, 2003, CELL DEATH DIFFER, V10, P290, DOI 10.1038/sj.cdd.4401159; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AL, 1985, INT J RADIAT BIOL, V48, P675, DOI 10.1080/09553008514551781; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Koon HB, 2007, EXPERT REV ANTICANC, V7, P79, DOI 10.1586/14737140.7.1.79; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; La Porta CAM, 2007, CURR MED CHEM, V14, P387; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631; Montefusco E, 2001, LEUKEMIA LYMPHOMA, V40, P671, DOI 10.3109/10428190109097666; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; Rosato RR, 2003, CANCER RES, V63, P3637; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Schrell UMH, 1997, J NEUROSURG, V86, P840, DOI 10.3171/jns.1997.86.5.0840; Schrell UMH, 1997, J NEUROSURG, V86, P845, DOI 10.3171/jns.1997.86.5.0845; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; StCroix B, 1996, NAT MED, V2, P1204; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; Van den Berg C, 1995, Cancer Treat Res, V78, P95; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	37	66	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					732	740		10.1038/sj.onc.1210677	http://dx.doi.org/10.1038/sj.onc.1210677			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653085				2022-12-25	WOS:000252884500002
J	Deniaud, A; el Dein, OS; Maillier, E; Poncet, D; Kroemer, G; Lemaire, C; Brenner, C				Deniaud, A.; el dein, O. Sharaf; Maillier, E.; Poncet, D.; Kroemer, G.; Lemaire, C.; Brenner, C.			Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis	ONCOGENE			English	Article						permeability transition; mitochondrion; cell death	ADENINE-NUCLEOTIDE TRANSLOCATOR; CELL-DEATH; INTRACELLULAR CA2+; RAT-LIVER; PORE; BAX; RECEPTOR; MECHANISM; CHANNEL; DRIVEN	The accumulation of Ca2+ in the mitochondrial matrix can stimulate oxidative phosphorylation, but can also, at high Ca2+ concentrations, transmit and amplify an apoptotic signal. Here, we characterized the capacity of physiological stimuli (for example, histamine and inositol-1,4,5-triphosphate) and inducers of endoplasmic reticulum (ER) stress (for example, A23187, thapsigargin and tunicamycin) to release Ca2+ from ER stores, induce mitochondrial Ca2+ accumulation, and trigger cell death in human cervix and colon carcinoma cell lines. Sustained Ca2+ accumulation in the mitochondrial matrix induced by ER stress triggered signs of proapoptotic mitochondrial alteration, namely permeability transition, dissipation of the electrochemical potential, matrix swelling, relocalization of Bax to mitochondria and the release of cytochrome c and apoptosis-inducing factor from mitochondria. In contrast, rapid and transient accumulation of Ca2+ induced by physiological stimuli failed to promote mitochondrial permeability transition and to affect cell viability. The specificity of this apoptosis pathway was validated in cells using a panel of pharmacological agents that chelate Ca2+ (BAPTA-AM) or inhibit inositol-1,4,5-trisphosphate receptor (IP3R; 2-aminoethoxydiphenyl borate), voltage-dependent anion channel (VDAC) (4,4'-diisothiocyanatostilbene-2,2'-disulfonate, NADH), the permeability transition pore (cyclosporin A and bongk-rekic acid), caspases (z-VAD-fmk) and protein synthesis (cycloheximide). Finally, we designed an original cell-free system in which we confronted purified mitochondria and ER vesicles, and identified IP3R, VDAC and the permeability transition pore as key proteins in the ER-triggered proapoptotic mitochondrial membrane permeabilization process.	[Deniaud, A.; el dein, O. Sharaf; Maillier, E.; Lemaire, C.; Brenner, C.] Univ Versailles, SQY, CNRS, UMR 8159, F-78035 Versailles, France; [Poncet, D.; Kroemer, G.] IGR, CNRS, UMR 8125, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Brenner, C (corresponding author), Univ Versailles, SQY, CNRS, UMR 8159, 45 Ave Etas Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Poncet, Delphine A/A-7190-2016; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Deniaud, Aurelien/L-5093-2019	Poncet, Delphine A/0000-0003-0446-5262; KROEMER, Guido/0000-0002-9334-4405; Lemaire, Christophe/0000-0001-6316-8781				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bathori G, 2006, J BIOL CHEM, V281, P17347, DOI 10.1074/jbc.M600906200; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bhanumathy CD, 2006, J BIOL CHEM, V281, P3722, DOI 10.1074/jbc.M509966200; BOCHNING D, 2003, NAT CELL BIOL, V5, P1051; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cianchi F, 2005, CLIN CANCER RES, V11, P6807, DOI 10.1158/1078-0432.CCR-05-0675; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; LAUQUIN GJM, 1976, BIOCHEMISTRY-US, V15, P2316, DOI 10.1021/bi00656a011; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407; LEE AC, 1994, J BIOL CHEM, V269, P30974; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Luo X, 2005, CELL DEATH DIFFER, V12, P1310, DOI 10.1038/sj.cdd.4401659; Madesh M, 2005, J CELL BIOL, V170, P1079, DOI 10.1083/jcb.200505022; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCDOWELL W, 1988, BIOCHIMIE, V70, P1535, DOI 10.1016/0300-9084(88)90290-8; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; PAULIK M, 1988, J BIOL CHEM, V263, P17738; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	59	437	450	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					285	299		10.1038/sj.onc.1210638	http://dx.doi.org/10.1038/sj.onc.1210638			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17700538				2022-12-25	WOS:000252256000004
J	Pennington, SR; Foster, BJ; Hawley, SR; Jenkins, RE; Zolle, O; White, MRH; McNamee, CJ; Sheterline, P; Simpson, AWM				Pennington, Stephen R.; Foster, Brian J.; Hawley, Shaun R.; Jenkins, Rosalind E.; Zolle, Olga; White, Michael R. H.; McNamee, Christine J.; Sheterline, Peter; Simpson, Alec W. M.			Cell shape-dependent control of Ca2+ influx and cell cycle progression in swiss 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CALCIUM-ENTRY; PROTEIN-KINASE ACTIVITY; SERUM RESPONSE FACTOR; SMOOTH-MUSCLE-CELLS; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; PHOSPHATASE-1 EXPRESSION; TRANSFORMED-CELLS; ENDOTHELIAL-CELLS; CHANNEL FUNCTION	The ability of adherent cells such as fibroblasts to enter the cell cycle and progress to S phase is strictly dependent on the extent to which individual cells can attach to and spread on a substratum. Here we have used microengineered adhesive islands of 22 and 45 mu m diameter surrounded by a nonadhesive substratum of polyhydroxyl methacrylate to accurately control the extent to which individual Swiss 3T3 fibroblasts may spread. The effect of cell shape on mitogen-evoked Ca2+ signaling events that accompany entry into the cell cycle was investigated. In unrestricted cells, the mitogens bombesin and fetal calf serum evoked a typical biphasic change in the cytoplasmic free Ca2+ concentration. However, when the spreading of individual cells was restricted, such that progression to S phase was substantially reduced, both bombesin and fetal calf serum caused a rapid transient rise in the cytoplasmic free Ca2+ concentration but failed to elicit the normal sustained influx of Ca2+ that follows Ca2+ release. As expected, restricting cell spreading led to the loss of actin stress fibers and the formation of a ring of cortical actin. Restricting cell shape did not appear to influence mitogen-receptor interactions, nor did it influence the presence of focal adhesions. Because Ca2+ signaling is an essential component of mitogen responses, these findings implicate Ca2+ influx as a necessary component of cell shape-dependent control of the cell cycle.	Univ Liverpool, Sch Biomed Sci, Dept Human Anat & Cell Biol, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Sch Biol Sci, Ctr Cell Imaging, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	Simpson, AWM (corresponding author), Univ Liverpool, Sch Biomed Sci, Dept Human Anat & Cell Biol, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	awms@liv.ac.uk	Pennington, Stephen R/C-7505-2015	White, Michael/0000-0002-3617-3232; Pennington, Stephen/0000-0001-7529-1015	BBSRC [BB/E012965/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E012965/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BROOKS RF, 1976, NATURE, V260, P248, DOI 10.1038/260248a0; Burrell HE, 2005, J BIOL CHEM, V280, P29667, DOI 10.1074/jbc.M505381200; Conant AR, 1998, BRIT J PHARMACOL, V125, P357, DOI 10.1038/sj.bjp.0702082; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Cook SJ, 2000, BIOCHEM SOC T, V28, P233, DOI 10.1042/bst0280233; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Green AK, 2002, GASTROENTEROLOGY, V123, P1291, DOI 10.1053/gast.2002.35994; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hawley SR, 2000, CELL SIGNAL, V12, P619, DOI 10.1016/S0898-6568(00)00104-2; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; IRELAND GW, 1989, CELL BIOL INT REP, V13, P781, DOI 10.1016/0309-1651(89)90055-6; IRELAND GW, 1987, J CELL SCI, P19; IWIG M, 1995, EUR J CELL BIOL, V67, P145; Jenkins RE, 2001, PROTEOMICS, V1, P1092, DOI 10.1002/1615-9861(200109)1:9<1092::AID-PROT1092>3.0.CO;2-S; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Krishan A, 1990, Methods Cell Biol, V33, P121; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lipskaia L, 2004, BIOL CELL, V96, P55, DOI 10.1016/j.biolcel.2003.11.001; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; Lopez JJ, 2006, J BIOL CHEM, V281, P28254, DOI 10.1074/jbc.M604272200; Mammoto A, 2004, J BIOL CHEM, V279, P26323, DOI 10.1074/jbc.M402725200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MCNAMEE CJ, 1995, CELL BIOL INT, V19, P769, DOI 10.1006/cbir.1995.1128; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MINETT TW, 1984, CELL BIOL INT REP, V8, P151, DOI 10.1016/0309-1651(84)90082-1; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Morales S, 2005, CELL SIGNAL, V17, P635, DOI 10.1016/j.cellsig.2004.10.002; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Munaron L, 2004, J CELL MOL MED, V8, P161, DOI 10.1111/j.1582-4934.2004.tb00271.x; Nelson CM, 2003, J CELL SCI, V116, P3571, DOI 10.1242/jcs.00680; ONEILL C, 1986, CELL, V44, P489, DOI 10.1016/0092-8674(86)90470-8; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Peppiatt CM, 2004, BIOCHEM J, V381, P929, DOI 10.1042/BJ20040097; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2004, J BIOL CHEM, V279, P29231, DOI 10.1074/jbc.M403509200; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; See V, 2004, J CELL BIOL, V166, P661, DOI 10.1083/jcb.200402136; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shuttleworth TJ, 2003, BIOCHEM SOC T, V31, P916; SIMPSON AWM, 1990, BIOCHEM J, V267, P277, DOI 10.1042/bj2670277; STOKER MGP, 1966, J CELL SCI, V1, P297; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	75	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					32112	32120		10.1074/jbc.M705067200	http://dx.doi.org/10.1074/jbc.M705067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17711856	hybrid			2022-12-25	WOS:000250480300032
J	Malnou, CE; Salem, T; Brockly, F; Wodrich, H; Piechaczyk, M; Jariel-Encontre, I				Malnou, Cecile E.; Salem, Tamara; Brockly, Frederique; Wodrich, Harald; Piechaczyk, Marc; Jariel-Encontre, Isabelle			Heterodimerization with jun family members regulates c-fos nucleocytoplasmic traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED NUCLEAR IMPORT; CELL-CYCLE PROGRESSION; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTORS; G0-TO-G1 TRANSITION; PROTO-ONCOPROTEIN; MOUSE FIBROBLASTS; LEUCINE-ZIPPER; PROTEINS; AP-1	c-Fos proto-oncoprotein forms AP-1 transcription complexes with heterodimerization partners such as c-Jun, JunB, and JunD. Thereby, it controls essential cell functions and exerts tumorigenic actions. The dynamics of c-Fos intracellular distribution is poorly understood. Hence, we have combined genetic, cell biology, and microscopic approaches to investigate this issue. In addition to a previously characterized basic nuclear localization signal (NLS) located within the central DNA-binding domain, we identified a second NLS within the c-Fos N-terminal region. This NLS is non-classic and its activity depends on transportin 1 in vivo. Under conditions of prominent nuclear localization, c-Fos can undergo nucleocytoplasmic shuttling through an active Crm-1 exportin-independent mechanism. Dimerization with the Jun proteins inhibits c-Fos nuclear exit. The strongest effect is observed with c-Jun probably in accordance with the relative stabilities of the different c-Fos: Jun dimers. Retrotransport inhibition is not caused by binding of dimers to DNA and, therefore, is not induced by indirect effects linked to activation of c-Fos target genes. Monomeric, but not dimeric, Jun proteins also shuttle actively. Thus, our work unveils a novel regulation operating on AP-1 by demonstrating that dimerization is crucial, not only for active transcription complex formation, but also for keeping them in the compartment where they exert their transcriptional function.	CNRS, Inst Genet Mol Montpellier, UMR 5535, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Jariel-Encontre, I (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, 1919 Route Mende, F-34293 Montpellier, France.	isabelle.jariel@igmm.cnrs.fr	Wodrich, Harald/P-1777-2019; PIECHACZYK, Marc/E-7896-2013; MALNOU, Cécile/O-9970-2019; MALNOU, Cécile E/K-1569-2014	Wodrich, Harald/0000-0002-4764-1708; PIECHACZYK, Marc/0000-0003-1367-2597; MALNOU, Cécile/0000-0002-1223-0247; MALNOU, Cécile E/0000-0002-1223-0247				Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Arnold M, 2006, J BIOL CHEM, V281, P5492, DOI 10.1074/jbc.M513281200; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BASBOUS J, 2007, IN PRESS BIOCHIMIE P; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Bussolino DF, 2001, FASEB J, V15, P556; Campos MAS, 1999, CELL BIOL INT, V23, P81, DOI 10.1006/cbir.1998.0323; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Chida K, 1999, CELL MOL LIFE SCI, V55, P297, DOI 10.1007/s000180050291; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.e03-09-0705; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; JARIELENCONTRE I, 2007, IN PRESS TARGETED PR; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Mason JM, 2006, P NATL ACAD SCI USA, V103, P8989, DOI 10.1073/pnas.0509880103; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Sambrook J, 1989, MOL CLONNING; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; TRATNER I, 1991, ONCOGENE, V6, P2049; Verhagen J, 2006, J VIROL, V80, P10021, DOI 10.1128/JVI.01322-06; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; YOUNG JS, 1979, SCI DIG, V1, P11	56	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31046	31059		10.1074/jbc.M702833200	http://dx.doi.org/10.1074/jbc.M702833200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17681951	Green Published, hybrid			2022-12-25	WOS:000250136300072
J	Butler, MP; Hanly, JA; Moynagh, PN				Butler, Marion P.; Hanly, Jennifer A.; Moynagh, Paul N.			Kinase-active interleukin-1 receptor-associated kinases promote polyubiquitination and degradation of the Pellino family - Direct evidence for pellino proteins being ubiquitin-protein isopeptide ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; MICE LACKING; IRAK FAMILY; IL-1; MEMBER; ACTIVATION; COMPLEX; TRAF6; EXPRESSION; REGULATOR	Members of the Pellino family are interleukin- 1 receptor- associated kinase ( IRAK)- interacting proteins that possess RINGlike domains. The presence of these domains led to the suggestion that Pellino proteins are ubiquitin- protein isopeptide ligases ( E3). However, no conclusive data currently exist to prove this proposal. This study provides the first direct evidence that Pellino proteins possess E3 activity. Recombinant forms of Pellino1 and Pellino2 and both spliced variants of Pellino3 are shown in an in vitro ubiquitination assay to be E3 ligases that catalyze Lys(63)- linked polyubiquitination, with Pellino3 exhibiting the greatest ligase activity. Whereas the Pellino proteins cause polyubiquitination of IRAK- 1, we also show that kinaseactive members of the IRAK family ( IRAK- 1 and IRAK- 4) promote reciprocal polyubiquitination of the Pellino proteins and that this is associated with IRAK- induced degradation of the Pellino family. In contrast, IRAK- 2 ( which lacks a functional kinase domain) and kinase- dead forms of IRAK- 1 and IRAK- 4 fail to degrade the Pellino proteins. We show that these kinaseinactive IRAK proteins can associate with Pellino proteins, thus excluding the possibility that their inability to regulate Pellino degradation is due to lack of association with the Pellino proteins. The physiological relevance of IRAK- induced degradation of Pellino proteins is confirmed by the demonstration that lipopolysaccharide causes degradation of endogenous forms of Pellino3 in peripheral blood mononuclear cells. In summary, this study not only demonstrates Pellino proteins to be E3 ligases that can catalyze Lys(63)- linked polyubiquitination but also shows bidirectional signaling between the IRAK and Pellino families and highlights a novel function for IRAK kinase activity.	Natl Univ Ireland, Inst Immunol, Maynooth, Kildare, Ireland	Maynooth University	Moynagh, PN (corresponding author), Natl Univ Ireland, Inst Immunol, Maynooth, Kildare, Ireland.	Paul.Moynagh@nuim.ie		Moynagh, Paul/0000-0002-4139-3061; Hanly, Jennifer/0000-0002-1553-7228				Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fukushima T, 2007, P NATL ACAD SCI USA, V104, P6371, DOI 10.1073/pnas.0700548104; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kim TW, 2007, J EXP MED, V204, P1025, DOI 10.1084/jem.20061825; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Koziczak-Holbro M, 2007, J BIOL CHEM, V282, P13552, DOI 10.1074/jbc.M700548200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Thomas JA, 1999, J IMMUNOL, V163, P978; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075	29	64	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29729	29737		10.1074/jbc.M704558200	http://dx.doi.org/10.1074/jbc.M704558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17675297	hybrid			2022-12-25	WOS:000249981200001
J	Meng, XW; Lee, SH; Dai, HM; Loegering, D; Yu, C; Flatten, K; Schneider, P; Dai, NT; Kumar, SK; Smith, BD; Karp, JE; Adjei, AA; Kaufmann, SH				Meng, Xue Wei; Lee, Sun-Hee; Dai, Haiming; Loegering, David; Yu, Chunrong; Flatten, Karen; Schneider, Paula; Dai, Nga T.; Kumar, Shaji K.; Smith, B. Douglas; Karp, Judith E.; Adjei, Alex A.; Kaufmann, Scott H.			MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR INHIBITOR; CYTOCHROME-C RELEASE; X-LINKED INHIBITOR; N-TERMINAL KINASE; CANCER-CELLS; TUMOR-CELLS; MOLECULAR DETERMINANTS; CLINICAL-TRIALS; TARGETING DEATH; DOWN-REGULATION	Previous studies have suggested that Mcl- 1, an antiapoptotic Bcl- 2 homolog that does not exhibit appreciable affinity for the caspase 8- generated C- terminal Bid fragment ( tBid), diminishes sensitivity to tumor necrosis factor- alpha related apoptosis- inducing ligand ( TRAIL). This study was performed to determine the mechanism by which Mcl- 1 confers TRAIL resistance and to evaluate methods for overcoming this resistance. Affinity purification/ immunoblotting assays using K562 human leukemia cells, which contain Mcl- 1 and Bcl- x(L) as the predominant antiapoptotic Bcl- 2 homologs, demonstrated that TRAIL treatment resulted in binding of tBid to Bcl- xL but not Mcl- 1. In contrast, TRAIL caused increased binding between Mcl- 1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-( N-alpha- acetylisoleucylglutamylthreonyl) asparticacid( O- methylester)- fluoromethylketone ( IETD( OMe)- fmk) or the c- Jun N- terminal kinase inhibitor SP600125. In addition, TRAIL caused increased binding of Bim and Puma to Mcl- 1 that was inhibited by IETD( OMe)- fmk but not SP600125. Further experiments demonstrated that down- regulation of Mcl- 1 by short hairpin RNA or the kinase inhibitor sorafenib increased TRAIL- induced Bak activation and death ligand- induced apoptosis in a wide variety of neoplastic cell lines as well as clinical acute myelogenous leukemia specimens. Collectively, these observations not only suggest a model in which Mcl- 1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity.	Mayo Clin, Div Oncol Res, Dept Oncol, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Div Med Oncol, Dept Oncol, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Div Hematol, Coll Med, Rochester, MN 55905 USA; Johns Hopkins Univ Hosp, Sidney Kimmel Canc Ctr, Adult Leukemia Program, Baltimore, MD 21287 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine	Kaufmann, SH (corresponding author), Mayo Clin, Div Oncol Res, Dept Oncol, Coll Med, Guggenheim 1342 C,200 1rst St,SW, Rochester, MN 55905 USA.	Kaufmann.scott@mayo.edu	Kumar, Shaji K/A-9853-2008	Kumar, Shaji K/0000-0001-5392-9284; Kaufmann, Scott/0000-0002-4900-7145; Dai, Haiming/0000-0002-0484-7407	NCI NIH HHS [R01 CA69008, R01 CA069008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Arnt CR, 2003, CELL DEATH DIFFER, V10, P1118, DOI 10.1038/sj.cdd.4401294; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Burns TF, 2001, J BIOL CHEM, V276, P37879; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clark JW, 2005, CLIN CANCER RES, V11, P5472, DOI 10.1158/1078-0432.CCR-04-2658; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Jurewicz A, 2006, GLIA, V53, P158, DOI 10.1002/glia.20249; Kandasamy K, 2003, CANCER RES, V63, P1712; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; Kaufmann SH, 2005, LEUKEMIA, V19, P2195, DOI 10.1038/sj.leu.2403946; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lamothe B, 2002, J INTERF CYTOK RES, V22, P269, DOI 10.1089/107999002753536248; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MCCULLOCH EA, 1983, BLOOD, V62, P1; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Meng XW, 2006, CURR OPIN CELL BIOL, V18, P668, DOI 10.1016/j.ceb.2006.10.008; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; Puduvalli VK, 2005, APOPTOSIS, V10, P233, DOI 10.1007/s10495-005-6078-3; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Ravi R, 2004, CANCER RES, V64, P9105, DOI 10.1158/0008-5472.CAN-04-2488; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; ROSATO RR, 2007, IN PRESS CANC RES, V67; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Szczepankiewicz BG, 2006, J MED CHEM, V49, P3563, DOI 10.1021/jm060199b; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tong FK, 2006, CYTOM PART B-CLIN CY, V70B, P107, DOI 10.1002/cyto.b.20092; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wirth T, 2005, CANCER RES, V65, P7393, DOI 10.1158/0008-5472.CAN-04-3664; Wright JJ, 2005, ONCOLOGY-NY, V19, P499; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang XD, 2001, CANCER RES, V61, P7339	98	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29831	29846		10.1074/jbc.M706110200	http://dx.doi.org/10.1074/jbc.M706110200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698840	hybrid			2022-12-25	WOS:000249981200012
J	Gupta, SK; Guo, X; Durkin, SS; Fryrear, KF; Ward, MD; Semmes, OJ				Gupta, Saurabh K.; Guo, Xin; Durkin, Sarah S.; Fryrear, Kimberly F.; Ward, Michael D.; Semmes, O. John			Human T-cell leukemia virus type 1 tax oncoprotein prevents DNA damage-induced chromatin egress of hyperphosphorylated Chk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I TAX; PROTEIN-KINASE; GENETIC INSTABILITY; TRANSACTIVATOR TAX; CYCLE CHECKPOINTS; MUTATION ANALYSIS; MAMMALIAN-CELLS; PHOSPHORYLATION; ACTIVATION; P53	De novo expression of human T-cell leukemia virus type 1 Tax results in cellular genomic instability. We demonstrated previously that Tax associates with the cell cycle check point regulator Chk2 and proposed that the inappropriate activation of Chk2 provides a model for Tax-induced loss of genetic integrity (Haoudi, A., Daniels, R. C., Wong, E., Kupfer, G., and Semmes, O. J. (2003) J. Biol. Chem. 278, 37736-37744). Here we provide an explanation for how Tax induces some Chk2 activities but represses others. We show that Tax interaction with Chk2 generates two activation signals in Chk2, oligomerization and autophosphorylation. However, egress of Chk2 from chromatin, normally observed in response to ionizing radiation, was repressed in Tax-expressing cells. Analysis of chromatin-bound Chk2 from Tax-expressing cells revealed phosphorylation at Thr(378), Ser(379), Thr(383), Thr(387), and Thr(389). In contrast, chromatin-bound Chk2 in the absence of Tax was phosphorylated at Thr(383) and Thr(387) in response to ionizing radiation. We further establish that Tax binds to the kinase domain of Chk2. Confocal microscopy revealed a redistribution of Chk2 to colocalize with Tax in Tax speckled structures, which we have shown previously to coincide with interchromatin granules. We propose that Tax binding via the Chk2 kinase domain sequesters phosphorylated Chk2 within chromatin, thus hindering chromatin egress and appropriate response to DNA damage.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23507 USA	Eastern Virginia Medical School	Semmes, OJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Lewis Hall,700 W Olney Rd, Norfolk, VA 23507 USA.	Semmesoj@evms.edu	Semmes, Oliver/GQA-5179-2022		NATIONAL CANCER INSTITUTE [R01CA076595] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA076595, CA076595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Coleman WB, 2006, EXP SUPPL, V96, P321; Durkin SS, 2006, J BIOL CHEM, V281, P31705, DOI 10.1074/jbc.M607011200; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; Gaspar M, 2006, P NATL ACAD SCI USA, V103, P2821, DOI 10.1073/pnas.0511148103; GESSAIN A, 1985, LANCET, V2, P407; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Ishikawa K, 2006, DNA CELL BIOL, V25, P406, DOI 10.1089/dna.2006.25.406; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Li J, 2005, J BIOL CHEM, V280, P37948, DOI 10.1074/jbc.M509299200; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; MARUYAMA K, 1992, LEUKEMIA, V6, pS60; Matsuoka S, 2001, CANCER RES, V61, P5362; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Oliver AW, 2006, EMBO J, V25, P3179, DOI 10.1038/sj.emboj.7601209; OSAME M, 1986, LANCET, V1, P1031; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Raptis S, 2006, EXP SUPPL, V96, P303; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Semmes OJ, 2006, J CLIN INVEST, V116, P858, DOI 10.1172/JCI28140; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shieh SY, 2000, GENE DEV, V14, P289; Sibon D, 2006, J CLIN INVEST, V116, P974, DOI 10.1172/JCI27198; Sieber O, 2005, SEMIN CANCER BIOL, V15, P61, DOI 10.1016/j.semcancer.2004.09.005; Strom L, 2005, CELL CYCLE, V4, P536, DOI 10.4161/cc.4.4.1613; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang XA, 2006, ENVIRON TOXICOL CHEM, V25, P3035, DOI 10.1897/05-706R.1; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	61	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29431	29440		10.1074/jbc.M704110200	http://dx.doi.org/10.1074/jbc.M704110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698850	hybrid			2022-12-25	WOS:000249788000040
J	Jacobs, MT; Zhang, YW; Campbell, SD; Rudnick, G				Jacobs, Miriam T.; Zhang, Yuan-Wei; Campbell, Scott D.; Rudnick, Gary			Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; ANTI-ADDICTIVE DRUG; PLATELET 5-HYDROXYTRYPTAMINE; ION DEPENDENCE; LIGAND-BINDING; KINETICS; CONFORMATION; EQUILIBRIA; EXPRESSION; POTASSIUM	Ibogaine, a hallucinogenic alkaloid with purported anti-addiction properties, inhibited serotonin transporter (SERT) noncompetitively by decreasing V-max with little change in the K-m for serotonin (5-HT). Ibogaine also inhibited binding to SERT of the cocaine analog 2 beta-2-carbomethoxy-3-(4[I-125] iodophenyl) tropane. However, inhibition of binding was competitive, increasing the apparent K-D without much change in B-max. Ibogaine increased the reactivity of cysteine residues positioned in the proposed cytoplasmic permeation pathway of SERT but not at nearby positions out of that pathway. In contrast, cysteines placed at positions in the extracellular permeation pathway reacted at slower rates in the presence of ibogaine. These results are consistent with the proposal that ibogaine binds to and stabilizes the state of SERT from which 5-HT dissociates to the cytoplasm, in contrast with cocaine, which stabilizes the state that binds extracellular 5-HT.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	gary.rudnick@yale.edu		ZHANG, YUAN-WEI/0000-0002-4276-9251; Jacobs, Miriam/0000-0002-8831-7592	NIDA NIH HHS [DA012408] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BOWEN WD, 1995, EUR J PHARMACOL, V279, pR1, DOI 10.1016/0014-2999(95)00247-I; BUCHANAN BB, 1976, P NATL ACAD SCI USA, V73, P2280, DOI 10.1073/pnas.73.7.2280; Forrest LR, 2007, P NATL ACAD SCI USA, V104, P12761, DOI 10.1073/pnas.0705600104; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GU H, 1994, J BIOL CHEM, V269, P7124; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; MACH RH, 1995, LIFE SCI, V57, P57; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MASH DC, 1995, LIFE SCI, V57, P45; Mitchell SM, 2004, J BIOL CHEM, V279, P24089, DOI 10.1074/jbc.M311173200; NELSON PJ, 1979, J BIOL CHEM, V254, P84; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; POPIK P, 1995, PHARMACOL REV, V47, P235; POPIK P, 1994, PSYCHOPHARMACOLOGY, V114, P672, DOI 10.1007/BF02245000; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Staley JK, 1996, PSYCHOPHARMACOLOGY, V127, P10, DOI 10.1007/BF02805969; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; SWEETNAM PM, 1995, PSYCHOPHARMACOLOGY, V118, P369, DOI 10.1007/BF02245936; Toll L, 1998, NIDA Res Monogr, V178, P440; Vastag B, 2005, SCIENCE, V308, P345, DOI 10.1126/science.308.5720.345; WALL SC, 1993, MOL PHARMACOL, V43, P264; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhang YW, 2005, J BIOL CHEM, V280, P30807, DOI 10.1074/jbc.M504087200	30	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29441	29447		10.1074/jbc.M704456200	http://dx.doi.org/10.1074/jbc.M704456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698848	hybrid			2022-12-25	WOS:000249788000041
J	Lou, H; Kaplowitz, N				Lou, Huan; Kaplowitz, Neil			Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappa B activity via I kappa B kinase-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; OXIDATIVE STRESS; CYSTEINE RESIDUE; TNF RECEPTOR; ACTIVATION; UBIQUITINATION; COMPLEX; PROTEIN; IKK	Reduced glutathione (GSH) plays a crucial role in hepatocyte function, and GSH depletion by diethyl maleate was shown previously to inhibit expression of NF-beta B target genes induced by tumor necrosis factor alpha(TNF alpha) and sensitize primary cultured mouse hepatocytes to TNF-mediated apoptotic killing. Here we demonstrate in the same system that GSH depletion down-regulates TNF-induced NF-kappa B transactivation via two mechanisms, depending on the extent of the depletion. With moderate GSH depletion (similar to 50%), the down-regulation is I kappa B kinase (IKK)-independent and likely acts on NF-kappa B transcriptional activity because TNF-induced IKK activation, I kappa B alpha phosphorylation and degradation, NF-kappa B nuclear translocation, NF-kappa B DNA binding in vitro, and NF-kappa B subunit RelA(p65) recruitment to kappa B sites of target gene promoters all appear unaltered. On the other hand, with profound GSH depletion (similar to 80%), the down-regulation also is IKK-dependent, and a timeline is established linking the inhibition of polyubiquitination of receptor-interacting protein 1 in TNF receptor 1 complex to partial blockage of IKK activation, I kappa B alpha phosphorylation and degradation, and NF-kappa B nuclear translocation. Of note, pretreatment with antioxidant trolox protects against the inhibitory effect of profound GSH depletion on IKK activation and NF-kappa B nuclear translocation but fails to restore expression of NF-kappa B target genes, revealing both IKK-dependent and -independent inhibition. These findings provide new insights into the complex effects of oxidative stress and redox perturbations on the NF-kappa B pathway.	Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Kaplowitz, N (corresponding author), Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, 2011 Zonal Ave,HMR 101, Los Angeles, CA 90033 USA.	kaplowit@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522, R01DK067215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48522, DK067215] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albano E, 2006, P NUTR SOC, V65, P278, DOI 10.1079/PNS2006496; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BOYLAND E, 1967, BIOCHEM J, V104, P95, DOI 10.1042/bj1040095; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Feng GP, 2002, AM J PHYSIOL-GASTR L, V282, pG825, DOI 10.1152/ajpgi.00467.2001; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glineur C, 2000, BIOCHEM J, V352, P583, DOI 10.1042/0264-6021:3520583; Han D, 2006, FREE RADICAL BIO MED, V41, P627, DOI 10.1016/j.freeradbiomed.2006.05.002; Han D, 2006, AM J PHYSIOL-GASTR L, V291, pG1, DOI 10.1152/ajpgi.00001.2006; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Kaplowitz N, 2005, NAT REV DRUG DISCOV, V4, P489, DOI 10.1038/nrd1750; KUBAL G, 1995, CHEM RES TOXICOL, V8, P780, DOI 10.1021/tx00047a019; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Ma H, 2003, METHOD ENZYMOL, V364, P284; Matsumaru K, 2003, HEPATOLOGY, V37, P1425, DOI 10.1053/jhep.2003.50230; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nagai H, 2002, HEPATOLOGY, V36, P55, DOI 10.1053/jhep.2002.33995; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Panopoulos A, 2005, J BIOL CHEM, V280, P2912, DOI 10.1074/jbc.M409524200; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	41	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29470	29481		10.1074/jbc.M706145200	http://dx.doi.org/10.1074/jbc.M706145200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690092	hybrid			2022-12-25	WOS:000249788000044
J	Sullivan, SM; Lee, A; Bjorkman, ST; Miller, SM; Sullivan, RKP; Poronnik, P; Colditz, PB; Pow, DV				Sullivan, Susan M.; Lee, Aven; Bjorkman, S. Tracey; Miller, Stephanie M.; Sullivan, Robert K. P.; Poronnik, Philip; Colditz, Paul B.; Pow, David V.			Cytoskeletal anchoring of GLAST determines susceptibility to brain damage - An identified role for GFAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIAL GLUTAMATE TRANSPORTER; AMYOTROPHIC-LATERAL-SCLEROSIS; RAT-BRAIN; HYPOXIA-ISCHEMIA; EXPRESSION; INJURY; HIPPOCAMPUS; WIDESPREAD; ASTROCYTES; MECHANISMS	Glial fibrillary acidic protein (GFAP) is an enigmatic protein; it currently has no unambiguously defined role. It is expressed in the cytoskeleton of astrocytes in the mammalian brain. We have used co-immunoprecipitation to identify in vivo binding partners for GFAP in the rat and pig brain. We demonstrate interactions between GFAP, the glutamate transporter GLAST, the PDZ-binding protein NHERF1, and ezrin. These interactions are physiologically relevant; we demonstrate in vitro that transport of D-aspartate (a glutamate analogue) is significantly increased in the presence of GFAP and NHERF1. Moreover, we demonstrate in vivo that expression of GFAP is essential in retaining GLAST in the plasma membranes of astrocytes after an hypoxic insult. These data indicate that the cytoskeleton of the astrocyte plays an important role in protecting the brain against glutamate-mediated excitotoxicity.	Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Queensland, Perinatal Res Ctr, Royal Brisbane & Womens Hosp, Brisbane, Qld 4029, Australia	University of Newcastle; University of Queensland; Royal Brisbane & Women's Hospital; University of Queensland	Pow, DV (corresponding author), Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia.	d.pow@eaats.org	Bjorkman, Stella/C-9589-2011; Sullivan, Susan/C-7489-2011; Lee, Aven/M-2416-2016; Pow, David/F-8198-2010; Sullivan, Robert KP/A-8639-2012; Pow, David V/A-2064-2016; Colditz, Paul B/F-6772-2010; Miller, Stephanie M./F-9815-2011	Bjorkman, Stella/0000-0002-6545-3962; Sullivan, Susan/0000-0002-4601-8420; Lee, Aven/0000-0002-4171-8532; Sullivan, Robert KP/0000-0003-3414-2448; Pow, David V/0000-0001-8522-4465; Colditz, Paul B/0000-0002-6408-8238; Miller, Stephanie M./0000-0002-5565-2001; Poronnik, Philip/0000-0002-6246-528X				Bjorkman ST, 2006, BRAIN RES, V1100, P110, DOI 10.1016/j.brainres.2006.04.119; Bruhn T, 2000, NEUROCHEM INT, V37, P277, DOI 10.1016/S0197-0186(00)00029-2; Chengyun D, 2006, NEUROL SCI, V27, P245, DOI 10.1007/s10072-006-0678-8; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Derouiche A, 2001, GLIA, V36, P330, DOI 10.1002/glia.1120; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021; JENSEN FE, 1991, ANN NEUROL, V29, P629, DOI 10.1002/ana.410290610; Jensen FE, 1999, EPILEPSIA, V40, pS51, DOI 10.1111/j.1528-1157.1999.tb00879.x; Johnston MV, 2002, NEUROSCIENTIST, V8, P212, DOI 10.1177/1073858402008003007; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; KANNER BI, 1978, FEBS LETT, V94, P245, DOI 10.1016/0014-5793(78)80947-8; KUSHNER PD, 1991, J NEUROPATH EXP NEUR, V50, P263, DOI 10.1097/00005072-199105000-00008; Lee A, 2007, GLIA, V55, P119, DOI 10.1002/glia.20439; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Messing A, 2003, GLIA, V43, P87, DOI 10.1002/glia.10219; Mishra OP, 1999, BRAIN RES BULL, V48, P233, DOI 10.1016/S0361-9230(98)00170-1; NAGY D, 1994, J NEUROSCI RES, V38, P336, DOI 10.1002/jnr.490380312; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pow DV, 2004, DEV BRAIN RES, V153, P1, DOI 10.1016/j.devbrainres.2004.06.019; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; SULLIVAN RKP, 1994, GLIA, V45, P155; Tao F, 2001, NEUROSCIENCE, V102, P503, DOI 10.1016/S0306-4522(00)00485-1; Tessler S, 1999, NEUROSCIENCE, V88, P1083, DOI 10.1016/S0306-4522(98)00301-7; TORP R, 1995, EXP BRAIN RES, V103, P51; Vessal M, 2005, BRAIN RES, V1044, P190, DOI 10.1016/j.brainres.2005.02.058; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	35	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29414	29423		10.1074/jbc.M704152200	http://dx.doi.org/10.1074/jbc.M704152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684014	hybrid			2022-12-25	WOS:000249788000038
J	Abudula, A; Grabbe, A; Brechmann, M; Polaschegg, C; Herrmann, N; Goldbeck, I; Dittmann, K; Wienands, J				Abudula, Abulizi; Grabbe, Annika; Brechmann, Markus; Polaschegg, Christian; Herrmann, Nadine; Goldbeck, Ingo; Dittmann, Kai; Wienands, Juergen			SLP-65 signal transduction requires Src homology 2 domain-mediated membrane anchoring and a kinase-independent adaptor function of Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; NON-ITAM TYROSINE; T-CELL; B-LYMPHOCYTES; CUTTING EDGE; MOLECULAR-CLONING; LINKER PROTEIN; SH2 DOMAIN; IG-ALPHA; KAPPA-B	The family of SLPs ((S) under bar rc homology 2 domain-containing (l) under bar eukocyte adaptor (p) under bar roteins) are cytoplasmic signal effectors of lymphocyte antigen receptors. A main function of SLP is to orchestrate the assembly of Ca2+-mobilizing enzymes at the inner leaflet of the plasma membrane. For this purpose, SLP-76 in T cells utilizes the transmembrane adaptor LAT, but the mechanism of SLP-65 membrane anchoring in B cells remains an enigma. We now employed two genetic reconstitution systems to unravel structural requirements of SLP-65 for the initiation of Ca2+ mobilization and subsequent activation of gene transcription. First, mutational analysis of SLP-65 in DT40 B cells revealed that its C-terminal Src homology 2 domain controls efficient tyrosine phosphorylation by the kinase Syk, plasma membrane recruitment, as well as downstream signaling to NFAT activation. Second, we dissected these processes by expressing SLP-65 in SLP-76-deficient T cells and found that a kinase-independent adaptor function of Syk is required to link phosphorylated SLP-65 to Ca2+ mobilization. These approaches unmask a mechanistic complexity of SLP-65 activation and coupling to signaling cascades in that Syk is upstream as well as downstream of SLP-65. Moreover, membrane anchoring of the SLP-65-assembled Ca2+ initiation complex, which appears to be fundamentally different from that of closely related SLP-76, does not necessarily involve a B cell-specific component.	Univ Gottingen, Inst Cell & Mol Immunol, D-37073 Gottingen, Germany	University of Gottingen	Wienands, J (corresponding author), Univ Gottingen, Inst Cell & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	jwienan@uni-goettingen.de	Herrmann, Nadine/L-3362-2019	Herrmann, Nadine/0000-0003-4924-2281				Boerth NJ, 2000, J BIOL CHEM, V275, P5143, DOI 10.1074/jbc.275.7.5143; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; Coppolino MG, 2001, J CELL SCI, V114, P4307; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Engels N, 2001, EUR J IMMUNOL, V31, P2126, DOI 10.1002/1521-4141(200107)31:7<2126::AID-IMMU2126>3.0.CO;2-O; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Geng LP, 1999, J IMMUNOL, V163, P5753; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Grabbe A, 2006, BLOOD, V108, P3761, DOI 10.1182/blood-2006-02-005397; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; Kabak S, 2002, MOL CELL BIOL, V22, P2524, DOI 10.1128/MCB.22.8.2524-2535.2002; Kohler F, 2005, NAT IMMUNOL, V6, P204, DOI 10.1038/ni1163; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Patterson HCK, 2006, IMMUNITY, V25, P55, DOI 10.1016/j.immuni.2006.04.014; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Sayegh CE, 2000, IMMUNOL REV, V175, P187, DOI 10.1034/j.1600-065X.2000.017507.x; Stork B, 2004, IMMUNITY, V21, P681, DOI 10.1016/j.immuni.2004.09.007; Stork B, 2007, EMBO J, V26, P1140, DOI 10.1038/sj.emboj.7601557; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Swamy M, 2006, IMMUNOL LETT, V104, P131, DOI 10.1016/j.imlet.2005.11.004; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamamoto T, 2001, FEBS LETT, V491, P272, DOI 10.1016/S0014-5793(01)02208-6; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	43	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29059	29066		10.1074/jbc.M704043200	http://dx.doi.org/10.1074/jbc.M704043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681949	hybrid			2022-12-25	WOS:000249642100080
J	Correll, RN; Pang, C; Finlin, BS; Dailey, AM; Satin, J; Andres, DA				Correll, Robert N.; Pang, Chunyan; Finlin, Brian S.; Dailey, Alexandria M.; Satin, Jonathan; Andres, Douglas A.			Plasma membrane targeting is essential for Rem-mediated Ca2+ channel inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING; BETA-SUBUNITS; CALMODULIN BINDS; RGK FAMILY; RAS; MEMBER; PHOSPHORYLATION; GEM; EXPRESSION; SURFACE	The small GTPase Rem is a potent negative regulator of high voltage-activated Ca2+ channels and a known interacting partner for Ca2+ channel accessory beta subunits. The mechanism for Rem-mediated channel inhibition remains controversial, although it has been proposed that Ca-V beta association is required. Previous work has shown that a C-terminal truncation of Rem (Rem-(1-265)) displays reduced in vivo binding to membrane-localized beta 2a and lacks channel regulatory function. In this paper, we describe a role for the Rem C terminus in plasma membrane localization through association with phosphatidylinositol lipids. Moreover, Rem-(1-265) can associate with beta 2a in vitro and beta 1b in vivo, suggesting that the C terminus does not directly participate in Ca-V beta association. Despite demonstrated beta 1b binding, Rem-(1-265) was not capable of regulating a CaV1.2-beta 1b channel complex, indicating that beta subunit binding is not sufficient for channel regulation. However, fusion of the CAAX domain from K-Ras4B or H-Ras to the Rem-(1-265) C terminus restored membrane localization and Ca2+ channel regulation, suggesting that beta binding and membrane localization are independent events required for channel inhibition.	Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, BBSRB Rm B-179,741 S Limestone St, Lexington, KY 40536 USA.	dandres@uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL072743, R56HL074091, R01HL072936, R01HL074091] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR020171, P20 RR20171] Funding Source: Medline; NHLBI NIH HHS [R01 HL074091, HL074091, HL072936, R01 HL072936-04, T32 HL072743, R01 HL072936, R56 HL074091] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres DA, 2006, METHOD ENZYMOL, V407, P484, DOI 10.1016/S0076-6879(05)07039-4; Beguin P, 2006, J MOL BIOL, V355, P34, DOI 10.1016/j.jmb.2005.10.013; Beguin P, 2005, BIOCHEM J, V390, P67, DOI 10.1042/BJ20050414; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Crump SM, 2006, AM J PHYSIOL-HEART C, V291, pH1959, DOI 10.1152/ajpheart.00956.2005; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Finlin BS, 2006, J BIOL CHEM, V281, P23557, DOI 10.1074/jbc.M604867200; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Opatowsky Y, 2006, FEBS LETT, V580, P5959, DOI 10.1016/j.febslet.2006.09.067; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richards MW, 2004, TRENDS PHARMACOL SCI, V25, P626, DOI 10.1016/j.tips.2004.10.008; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; Seu L, 2006, J GEN PHYSIOL, V128, P605, DOI 10.1085/jgp.200609631; Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28431	28440		10.1074/jbc.M706176200	http://dx.doi.org/10.1074/jbc.M706176200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686775	Green Accepted, hybrid			2022-12-25	WOS:000249642100017
J	Li, MH; Jang, JH; Na, HK; Cha, YN; Surh, YJ				Li, Mei-Hua; Jang, Jung-Hee; Na, Hye-Kyung; Cha, Young-Nam; Surh, Young-Joon			Carbon monoxide produced by heme oxygenase-1 in response to nitrosative stress induces expression of glutamate-cysteine ligase in PC12 cells via activation of phosphatidylinositol 3-kinase and Nrf2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HUMAN NEUROBLASTOMA-CELLS; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; OXIDATIVE STRESS; NITRIC-OXIDE; GENE-EXPRESSION; INTRACELLULAR GLUTATHIONE; NF-E2-RELATED FACTOR-2; TRANSCRIPTION FACTOR	Induction of heme oxygenase-1 (HO-1) expression has been associated with adaptive cytoprotection against a wide array of toxic insults, but the underlying molecular mechanisms remain largely unresolved. In this study, we investigated the potential role of carbon monoxide(CO), one of the by-products of the HO-1reaction, in the adaptive survival response to peroxynitrite-induced PC12 cell death. Upon treatment of rat pheochromocytoma (PC12) cells with the peroxynitrite generator 3-morpholinosydnonimine hydrochloride (SIN-1), the cellular GSH level decreased initially, but was gradually restored to the basal level. This was accompanied by increased expression of the catalytic subunit of glutamate-cysteine ligase (GCLC), the rate-limiting enzyme in GSH biosynthesis. The SIN-1-induced GCLC up-regulation was preceded by induction of HO-1 and subsequent CO production. Inhibition of HO activity by zinc protoporphyrin IX or knockdown of HO-1 gene expression by small interfering RNA abrogated the up-regulation of GCLC expression and the subsequent GSH restoration induced by SIN-1. In contrast, additional exposure to the CO-releasing molecule (CO-RM) restored the GSH level previously reduced by inhibition of CO production using zinc protoporphyrin IX. Furthermore, CO-RM treatment up-regulated GCLC expression through activation of Nrf2. The CO-RM-induced activation of Nrf2 was under the control of the phosphatidylinositol 3-kinase/Akt signaling pathway. In conclusion, CO produced by HO-1 rescues PC12 cells from nitrosative stress through induction of GCLC, which is mediated by activation of phosphatidylinositol 3-kinase/Akt and subsequently Nrf2 signaling.	Seoul Natl Univ, Coll Pharm, Natl Res Lab Mol Carcinogenesis & Chemoprevent, Seoul 151742, South Korea; Seoul Natl Univ, Inst Canc Res, Seoul 110799, South Korea; Inha Univ, Coll Med, Dept Pharmacol & Toxicol, Inchon 382751, South Korea	Seoul National University (SNU); Seoul National University (SNU); Inha University	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab Mol Carcinogenesis & Chemoprevent, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr	li, meihua/D-7286-2013					Abraham NG, 2003, CIRC RES, V93, P507, DOI 10.1161/01.RES.0000091828.36599.34; Anwar AA, 2005, FREE RADICAL BIO MED, V39, P227, DOI 10.1016/j.freeradbiomed.2005.03.012; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Botta D, 2004, FREE RADICAL BIO MED, V37, P632, DOI 10.1016/j.freeradbiomed.2004.05.027; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Choi BM, 2003, FREE RADICAL BIO MED, V34, P1136, DOI 10.1016/S0891-5849(03)00064-9; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Iles KE, 2005, FREE RADICAL BIO MED, V38, P547, DOI 10.1016/j.freeradbiomed.2004.11.012; Jackson RM, 1998, FREE RADICAL BIO MED, V25, P463, DOI 10.1016/S0891-5849(98)00101-4; Kang KW, 2002, NITRIC OXIDE-BIOL CH, V7, P244, DOI 10.1016/S1089-8603(02)00117-9; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Lee BS, 2006, BIOCHEM BIOPH RES CO, V343, P965, DOI 10.1016/j.bbrc.2006.03.058; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Li MH, 2006, FREE RADICAL BIO MED, V41, P1079, DOI 10.1016/j.freeradbiomed.2006.06.010; Li MH, 2006, BIOCHEM BIOPH RES CO, V342, P984, DOI 10.1016/j.bbrc.2006.02.046; Li MH, 2005, FREE RADICAL BIO MED, V39, P890, DOI 10.1016/j.freeradbiomed.2005.05.015; Li WG, 2006, J BIOL CHEM, V281, P27251, DOI 10.1074/jbc.M602746200; Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Matsumoto H, 2006, MOL CELL BIOCHEM, V291, P21, DOI 10.1007/s11010-006-9190-y; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Salvemini D, 1998, DRUG NEWS PERSPECT, V11, P204; Srisook K, 2006, BIOCHEM PHARMACOL, V71, P307, DOI 10.1016/j.bcp.2005.10.042; Srisook K, 2004, BIOCHEM PHARMACOL, V68, P1709, DOI 10.1016/j.bcp.2004.07.001; Srisook K, 2005, NITRIC OXIDE-BIOL CH, V12, P70, DOI 10.1016/j.niox.2004.12.002; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; Tian L, 1997, ARCH BIOCHEM BIOPHYS, V342, P126, DOI 10.1006/abbi.1997.9997; TROCINO RA, 1995, DIABETES, V44, P992, DOI 10.2337/diabetes.44.8.992; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhu H, 2005, FEBS LETT, V579, P3029, DOI 10.1016/j.febslet.2005.04.058; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	54	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28577	28586		10.1074/jbc.M701916200	http://dx.doi.org/10.1074/jbc.M701916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681938	hybrid			2022-12-25	WOS:000249642100032
J	Sun, JP; Luo, Y; Yu, X; Wang, WQ; Zhou, B; Liang, FB; Zhang, ZY				Sun, Jin-Peng; Luo, Yong; Yu, Xiao; Wang, Wei-Qing; Zhou, Bo; Liang, Fubo; Zhang, Zhong-Yin			Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; PLASMA-MEMBRANE; COLORECTAL-CANCER; DOWN-REGULATION; CAAX MOTIF; PRL-1; INVASION; METASTASIS; EXPRESSION; PIP2	The phosphatase of regenerating liver ( PRL) phosphatases are implicated in a number of tumorigenesis and metastasis processes. The PRLs are unique among protein-tyrosine phosphatases in that they have extremely low phosphatase activity, a high propensity for trimer formation, and a polybasic region that precedes the C-terminal prenylation motif. To investigate the functional significance of these distinctive biochemical and structural features, we established a cell-based system in which ectopic PRL1 expression increased cell proliferation and migration, whereas knockdown of endogenous PRL1 abrogated these cellular activities. We showed that the intrinsic PRL1 phosphatase activity is obligatory for its biological function. We provided evidence that trimerization may be a general property for all PRL enzymes, and that PRL1 trimer formation is essential for the PRL1-mediated cell growth and migration. This finding indicates a novel mechanism for phosphatase regulation. We further demonstrated that the conserved C-terminal polybasic region is important for specific phosphoinositide recognition by PRL1. Both the polybasic residues and the adjacent prenylation motif are required for proper PRL1 subcellular localization and full biological activity.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Zhang, ZY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	zyzhang@iupui.edu	sun, Jinpeng/AAR-9196-2020; SUN, JINPENG/F-9551-2013	Yu, Xiao/0000-0003-1119-8334	NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achiwa H, 2007, CANCER RES, V67, P643, DOI 10.1158/0008-5472.CAN-06-2436; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arena S, 2005, CELL MOL LIFE SCI, V62, P2092, DOI 10.1007/s00018-005-5205-1; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chenette EJ, 2006, MOL BIOL CELL, V17, P3108, DOI 10.1091/mbc.E05-09-0896; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Diamond RH, 1996, AM J PHYSIOL-GASTR L, V271, pG121, DOI 10.1152/ajpgi.1996.271.1.G121; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Jeong DG, 2005, J MOL BIOL, V345, P401, DOI 10.1016/j.jmb.2004.10.061; Kaadige MR, 2006, J BIOL CHEM, V281, P28831, DOI 10.1074/jbc.M605624200; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Kozlov G, 2004, J BIOL CHEM, V279, P11882, DOI 10.1074/jbc.M312905200; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Rouleau C, 2006, MOL CANCER THER, V5, P219, DOI 10.1158/1535-7163.MCT-05-0289; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Sun JP, 2005, BIOCHEMISTRY-US, V44, P12009, DOI 10.1021/bi0509191; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Wang WQ, 2004, J BIOL CHEM, V279, P30459, DOI 10.1074/jbc.M402217200; Werner SR, 2003, CANCER LETT, V202, P201, DOI 10.1016/S0304-3835(03)00517-2; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4	46	60	63	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29043	29051		10.1074/jbc.M703537200	http://dx.doi.org/10.1074/jbc.M703537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656357	hybrid			2022-12-25	WOS:000249642100078
J	Luo, J; Kintner, DB; Shull, GE; Sun, D				Luo, Jing; Kintner, Douglas B.; Shull, Gary E.; Sun, Dandan			ERK1/2-p90(RSK)-mediated phosphorylation of Na+/H+ exchanger isoform 1 - A role in ischemic neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; RIBOSOMAL S6 KINASE; MEK1 PROTEIN-KINASE; INTRACELLULAR PH; DEPENDENT ACTIVATION; MEDIATED REGULATION; REPERFUSION INJURY; OXIDATIVE TOXICITY; RAT MYOCARDIUM	The function and regulation of Na+/H+ exchanger isoform 1 (NHE1) following cerebral ischemia are not well understood. In this study, we demonstrate that extracellular signal-related kinases (ERK1/2) play a role in stimulation of neuronal NHE1 following in vitro ischemia. NHE1 activity was significantly increased during 10-60 min reoxygenation (REOX) after 2-h oxygen and glucose deprivation (OGD). OGD/REOX not only increased the V-max for NHE1 but also shifted the K-m toward decreased [H+](i). These changes in NHE1 kinetics were absent when MAPK/ERK kinase (MEK) was inhibited by the MEK inhibitor U0126. There were no changes in the levels of phosphorylated ERK1/2 (p-ERK1/2) after 2 h OGD. The p-ERK1/2 level was significantly increased during 10 - 60 min REOX, which was accompanied by nuclear translocation. U0126 abolished REOX-induced elevation and translocation of p-ERK1/2. We further examined the ERK/90-kDa ribosomal S6 kinase (p90(RSK)) signaling pathways. At 10 min REOX, phosphorylated NHE1 was increased with a concurrent elevation of phosphorylation of p90(RSK), a known NHE1 kinase. Inhibition of MEK activity with U0126 abolished phosphorylation of both NHE1 and p90RSK. Moreover, neuroprotection was observed with U0126 or genetic ablation or pharmacological inhibition of NHE1 following OGD/REOX. Taken together, these results suggest that activation of ERK1/2-p90(RSK) pathways following in vitro ischemia phosphorylates NHE1 and increases its activity, which subsequently contributes to neuronal damage.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Physiol, Madison, WI 53792 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; University of Cincinnati	Sun, D (corresponding author), Univ Wisconsin, Clin Hlth Ctr, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.	sun@neurosurg.wisc.edu	sun, dandan/GZG-6540-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048216] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS48216] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Cuello F, 2007, MOL PHARMACOL, V71, P799, DOI 10.1124/mol.106.029900; Diarra A, 1999, NEUROSCIENCE, V93, P1003, DOI 10.1016/S0306-4522(99)00230-4; Haworth RS, 2006, BIOCHEM J, V399, P493, DOI 10.1042/BJ20051628; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Kelly MP, 1997, CIRC RES, V80, P853; Kintner DB, 2005, AM J PHYSIOL-CELL PH, V289, pC934, DOI 10.1152/ajpcell.00092.2005; Kintner DB, 2004, AM J PHYSIOL-CELL PH, V287, pC12, DOI 10.1152/ajpcell.00560.2003; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Levinthal DJ, 2005, J BIOL CHEM, V280, P5875, DOI 10.1074/jbc.M410771200; Luo J, 2005, J NEUROSCI, V25, P11256, DOI 10.1523/JNEUROSCI.3271-05.2005; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; MABE H, 1983, J CEREBR BLOOD F MET, V3, P109, DOI 10.1038/jcbfm.1983.13; Maekawa N, 2006, CIRCULATION, V113, P2516, DOI 10.1161/CIRCULATIONAHA.105.563486; Malo ME, 2007, J BIOL CHEM, V282, P6292, DOI 10.1074/jbc.M611073200; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Moor AN, 2001, J BIOL CHEM, V276, P16113, DOI 10.1074/jbc.M100519200; Mukhin YV, 2004, J BIOL CHEM, V279, P1845, DOI 10.1074/jbc.M304907200; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Noshita N, 2002, J NEUROSCI, V22, P7923; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Shackelford DA, 2003, MOL BRAIN RES, V115, P173, DOI 10.1016/S0169-328X(03)00206-7; Snabaitis AK, 2006, J BIOL CHEM, V281, P20252, DOI 10.1074/jbc.M600268200; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takeishi Y, 1999, CIRC RES, V85, P1164; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Yao H, 2001, AM J PHYSIOL-CELL PH, V281, pC1205, DOI 10.1152/ajpcell.2001.281.4.C1205	40	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28274	28284		10.1074/jbc.M702373200	http://dx.doi.org/10.1074/jbc.M702373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17664275	hybrid			2022-12-25	WOS:000249455600077
J	Tao, H; Berno, AJ; Cox, DR; Frazer, KA				Tao, Heng; Berno, Anthony J.; Cox, David R.; Frazer, Kelly A.			In Vitro Human Keratinocyte Migration Rates Are Associated with SNPs in the KRT1 Interval	PLOS ONE			English	Article								Efforts to develop effective therapeutic treatments for promoting fast wound healing after injury to the epidermis are hindered by a lack of understanding of the factors involved. Re-epithelialization is an essential step of wound healing involving the migration of epidermal keratinocytes over the wound site. Here, we examine genetic variants in the keratin-1 (KRT1) locus for association with migration rates of human epidermal keratinocytes (HEK) isolated from different individuals. Although the role of intermediate filament genes, including KRT1, in wound activated keratinocytes is well established, this is the first study to examine if genetic variants in humans contribute to differences in the migration rates of these cells. Using an in vitro scratch wound assay we observe quantifiable variation in HEK migration rates in two independent sets of samples; 24 samples in the first set and 17 samples in the second set. We analyze genetic variants in the KRT1 interval and identify SNPs significantly associated with HEK migration rates in both samples sets. Additionally, we show in the first set of samples that the average migration rate of HEK cells homozygous for one common haplotype pattern in the KRT1 interval is significantly faster than that of HEK cells homozygous for a second common haplotype pattern. Our study demonstrates that genetic variants in the KRT1 interval contribute to quantifiable differences in the migration rates of keratinocytes isolated from different individuals. Furthermore we show that in vitro cell assays can successfully be used to deconstruct complex traits into simple biological model systems for genetic association studies.	[Tao, Heng; Berno, Anthony J.; Cox, David R.; Frazer, Kelly A.] Perlegen Sci, Mountain View, CA USA		Frazer, KA (corresponding author), Perlegen Sci, Mountain View, CA USA.	kfrazer@scripps.edu		Frazer, Kelly/0000-0002-6060-8902	NHGRI [5 R44 HG002638-03]	NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by an NHGRI grant (5 R44 HG002638-03) to K. A. Frazer.	BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; BRANDHORST BP, 1974, J MOL BIOL, V85, P451, DOI 10.1016/0022-2836(74)90444-6; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Germer S, 2000, GENOME RES, V10, P258, DOI 10.1101/gr.10.2.258; HOLLAND CA, 1980, J MOL BIOL, V138, P755, DOI 10.1016/0022-2836(80)90064-9; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Li XM, 2001, HEREDITY, V86, P668, DOI 10.1046/j.1365-2540.2001.00879.x; Mahr S, 2006, AM J HUM GENET, V78, P793, DOI 10.1086/503849; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Masinde GL, 2001, GENOME RES, V11, P2027, DOI 10.1101/gr.203701; MASINDE GL, 2005, FUNCT INTEGR GENOMIC, P1; McBrearty BA, 1998, P NATL ACAD SCI USA, V95, P11792, DOI 10.1073/pnas.95.20.11792; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; Pant PVK, 2006, GENOME RES, V16, P331, DOI 10.1101/gr.4559106; Porter RM, 2003, TRENDS GENET, V19, P278, DOI 10.1016/S0168-9525(03)00071-4; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; Rogers MA, 2005, J INVEST DERMATOL, V124, P536, DOI 10.1111/j.0022-202X.2004.23530.x; Sambrook J., 2002, MOL CLONING LAB MANU; Spurzem JR, 2002, AM J PHYSIOL-LUNG C, V282, pL1108, DOI 10.1152/ajplung.00148.2001; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; Tao H, 2006, PLOS GENET, V2, P848, DOI 10.1371/journal.pgen.0020093; Vaitomaa J, 2003, APPL ENVIRON MICROB, V69, P7289, DOI 10.1128/AEM.69.12.7289-7297.2003; Wong P, 2003, J CELL BIOL, V163, P327, DOI 10.1083/jcb.200305032; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zegers MMP, 2003, EMBO J, V22, P4155, DOI 10.1093/emboj/cdg398	31	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e697	10.1371/journal.pone.0000697	http://dx.doi.org/10.1371/journal.pone.0000697			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668073	Green Published, gold			2022-12-25	WOS:000207452300031
J	Hansen, ABE; Lohse, N; Gerstoft, J; Kronborg, G; Laursen, A; Pedersen, C; Sorensen, HT; Obel, N				Hansen, Ann-Brit Eg; Lohse, Nicolai; Gerstoft, Jan; Kronborg, Gitte; Laursen, Alex; Pedersen, Court; Sorensen, Henrik Toft; Obel, Niels			Cause-Specific Excess Mortality in Siblings of Patients Co-Infected with HIV and Hepatitis C Virus	PLOS ONE			English	Article								Background. Co-infection with hepatitis C in HIV-infected individuals is associated with 3- to 4-fold higher mortality among these patients' siblings, compared with siblings of mono-infected HIV-patients or population controls. This indicates that risk factors shared by family members partially account for the excess mortality of HIV/HCV-co-infected patients. We aimed to explore the causes of death contributing to the excess sibling mortality. Methodology and Principal Findings. We retrieved causes of death from the Danish National Registry of Deaths and estimated cause-specific excess mortality rates (EMR) for siblings of HIV/HCV-co-infected individuals (n = 436) and siblings of HIV mono-infected individuals (n = 1837) compared with siblings of population controls (n = 281,221). Siblings of HIV/HCV-co-infected individuals had an all-cause EMR of 3.03 (95% CI, 1.56-4.50) per 1,000 person-years, compared with siblings of matched population controls. Substance abuse-related deaths contributed most to the elevated mortality among siblings [EMR = 2.25 (1.09-3.40)] followed by unnatural deaths [EMR = 0.67 (20.05-1.39)]. No siblings of HIV/HCV co-infected patients had a liver-related diagnosis as underlying cause of death. Siblings of HIV-mono-infected individuals had an all-cause EMR of 0.60 (0.16-1.05) compared with siblings of controls. This modest excess mortality was due to deaths from an unknown cause [EMR = 0.28 (0.07-0.48)], deaths from substance abuse [EMR = 0.19 (-0.04-0.43)], and unnatural deaths [EMR = 0.18 (-0.06-0.42)]. Conclusions. HCV co-infection among HIV-infected patients was a strong marker for family-related mortality due to substance abuse and other unnatural causes. To reduce morbidity and mortality in HIV/HCV-co-infected patients, the advances in antiviral treatment of HCV should be accompanied by continued focus on interventions targeted at substance abuse-related risk factors.	[Hansen, Ann-Brit Eg; Pedersen, Court] Odense Univ Hosp, Dept Infect Dis, DK-5000 Odense, Denmark; [Hansen, Ann-Brit Eg] Univ So Denmark, Odense, Denmark; [Hansen, Ann-Brit Eg] Rigshosp, Danish HIV Cohort Study, DK-2100 Copenhagen, Denmark; [Lohse, Nicolai; Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark; [Gerstoft, Jan; Obel, Niels] Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; [Kronborg, Gitte] Hvidovre Univ Hosp, Dept Infect Dis, Copenhagen, Denmark; [Laursen, Alex] Aarhus Univ Hosp Skejby, Dept Infect Dis, Aarhus, Denmark; [Sorensen, Henrik Toft] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Rigshospitalet; University of Copenhagen; Aarhus University; Rigshospitalet; University of Copenhagen; University of Copenhagen; Aarhus University; Boston University	Hansen, ABE (corresponding author), Odense Univ Hosp, Dept Infect Dis, DK-5000 Odense, Denmark.	ann-brit.eg.hansen@rh.regionh.dk	Kronborg, Gitte/E-4757-2010; Hansen, Ann-Brit/ABA-1921-2020; Lohse, Nicolai/ABE-5884-2020; Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Lohse, Nicolai/0000-0001-8403-8759; Hansen, Ann-Brit Eg/0000-0003-4228-3822; Laursen, Alex Lund/0000-0002-1206-156X	Danish AIDS Foundation, Odense University Hospital, Preben; Anna Simonsen's Foundation; Foundation of the Danish Association of Pharmacists; Clinical Institute at the University of Southern Denmark	Danish AIDS Foundation, Odense University Hospital, Preben; Anna Simonsen's Foundation; Foundation of the Danish Association of Pharmacists; Clinical Institute at the University of Southern Denmark	The Danish HIV Cohort Study receives funding from the Danish AIDS Foundation, Odense University Hospital, Preben and Anna Simonsen's Foundation, the Foundation of the Danish Association of Pharmacists, and the Clinical Institute at the University of Southern Denmark. No funding sources were involved in study design, data collection, analysis, report writing or approval of the manuscript.	Amin J, 2006, LANCET, V368, P938, DOI 10.1016/S0140-6736(06)69374-4; [Anonymous], CIVIL REGISTRATION S; Antonucci G, 2005, CLIN INFECT DIS, V40, pE101, DOI 10.1086/430445; Backus LI, 2005, AIDS, V19, pS13, DOI 10.1097/01.aids.0000192065.09281.01; CADORET RJ, 1995, ARCH GEN PSYCHIAT, V52, P42; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; GWAMZI N, 2007, 14 C RETR OPP INF LO; Hansen ABE, 2007, J INFECT DIS, V195, P230, DOI 10.1086/510246; Juel K, 2001, UGESKRIFT LAEGER, V163, P4190; Juel K, 1999, DAN MED BULL, V46, P354; Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687; Lohse N, 2005, SCAND J INFECT DIS, V37, P338, DOI 10.1080/00365540510031692; MABECH CE, 1980, UGESKRIFT LAEGER, V142, P256; Miller MF, 2005, CLIN INFECT DIS, V41, P713, DOI 10.1086/432618; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHULZSCHAEFFER W, 1993, FORENSIC SCI INT, V62, P157, DOI 10.1016/0379-0738(93)90062-F; Sulkowski MS, 2005, AIDS, V19, pS8, DOI 10.1097/01.aids.0000192064.09281.48; Sullivan PS, 2006, AIDS, V20, P1171, DOI 10.1097/01.aids.0000226958.87471.48; Wahren CA, 1997, SUBST USE MISUSE, V32, P2163, DOI 10.3109/10826089709035627; Weis N, 2006, CLIN INFECT DIS, V42, P1481, DOI 10.1086/503569; SURVIVAL ANAL EPIDEM	22	17	18	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e738	10.1371/journal.pone.0000738	http://dx.doi.org/10.1371/journal.pone.0000738			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710138	Green Published, gold			2022-12-25	WOS:000207455200015
J	Chan, BL; Ching, AK; To, KF; Leung, JK; Chen, S; Li, Q; Lai, PS; Tang, NS; Shaw, PC; Chan, JH; James, A; Lai, KN; Lim, PL; Lee, KH; Chui, YL				Chan, BC-L; Ching, AK-K; To, K-F; Leung, JC-K; Chen, S.; Li, Q.; Lai, PB-S; Tang, NL-S; Shaw, P-C; Chan, JY-H; James, A. E.; Lai, K-N; Lim, P-L; Lee, KK-H; Chui, Y-L			BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma	ONCOGENE			English	Article						BRE; antiapoptosis; tumorigenesis; human hepatocellular carcinoma; BRE-specific monoclonal antibody; Fas-mediated acute liver failure	ANTI-FAS ANTIBODY; CELL-CYCLE ENTRY; TRANSGENIC MICE; HEPATIC CARCINOGENESIS; SIGNALING PATHWAYS; BCL-2 FAMILY; APOPTOSIS; DEATH; EXPRESSION; PROLIFERATION	BRE binds to the cytoplasmic domains of tumor necrosis factor receptor-1 and Fas, and in cell lines can attenuate death receptor-initiated apoptosis by inhibiting t-BID-induced activation of the mitochondrial apoptotic pathway. Overexpression of BRE by transfection can also attenuate intrinsic apoptosis and promote growth of the transfected Lewis lung carcinoma line in mice. There is, however, a complete lack of in vivo data about the protein. Here, we report that by using our BRE-specific monoclonal antibody on the immunohistochemistry of 123 specimens of human hepatocellular carcinoma (HCC), significant differences in BRE expression levels between the paired tumoral and non-tumoral regions (P<2.2e-16) were found. Marked overexpression of BRE was detected in majority of the tumors, whereas most non-tumoral regions expressed the same low level of the protein as in normal livers. To investigate whether BRE overexpression could promote cell survival in vivo, liver-specific transgenic BRE mice were generated and found to be significantly resistant to Fas-mediated lethal hepatic apoptosis. The transgenic model also revealed post-transcriptional regulation of Bre level in the liver, which was not observed in HCC and non-HCC cell lines. Indeed, all cell lines analysed express high levels of BRE. In conclusion, BRE is antiapoptotic in vivo, and may promote tumorigenesis when overexpressed.	[Chan, BC-L; Ching, AK-K; Chen, S.; Li, Q.; Lim, P-L; Chui, Y-L] Chinese Univ Hong Kong, Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China; [Chan, BC-L; Ching, AK-K; Chen, S.; Li, Q.; Lim, P-L; Chui, Y-L] Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China; [To, K-F] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, JC-K; Lai, K-N] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; [Lai, PB-S] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Tang, NL-S] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China; [Shaw, P-C] Chinese Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; [Chan, JY-H] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [James, A. E.] Chinese Univ Hong Kong, Lab Anim Serv Ctr, Hong Kong, Hong Kong, Peoples R China; [Lee, KK-H] Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Chui, Y-L] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital	Chui, YL (corresponding author), Chinese Univ Hong Kong, Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China.	yiuloonchui@cuhk.edu.hk	Lai, Kar Neng/C-4300-2009; Leung, Joseph Chi Kam/C-4338-2009; Lee, Kenneth Ka Ho/H-6698-2013; Tang, Nelson L/P-5018-2017; Lai, Paul BS/K-8556-2015	Lee, Kenneth Ka Ho/0000-0002-6520-304X; Tang, Nelson L/0000-0002-3607-5819; Lai, Paul BS/0000-0002-9469-6728; Chui, Yiu-Loon/0000-0002-3441-9729				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Chan BCL, 2005, BIOCHEM BIOPH RES CO, V326, P268, DOI 10.1016/j.bbrc.2004.11.013; Chan BCL, 2002, INT J CANCER, V102, P492, DOI 10.1002/ijc.10773; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Ching AKK, 2000, INT IMMUNOL, V12, P1245, DOI 10.1093/intimm/12.9.1245; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; de la Coste A, 1999, CANCER RES, V59, P5017; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Dive C, 1992, Semin Cancer Biol, V3, P417; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu CH, 1998, FASEB J, V12, P1101, DOI 10.1096/fasebj.12.12.1101; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; KOHLER G, 1975, NATURE, V256, P497; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; Li Q, 2004, J BIOL CHEM, V279, P52106, DOI 10.1074/jbc.M408678200; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pierce RH, 2002, AM J PATHOL, V160, P1555, DOI 10.1016/S0002-9440(10)61101-7; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tang MK, 2006, PROTEOMICS, V6, P2376, DOI 10.1002/pmic.200500603; Vail ME, 2001, CANCER RES, V61, P594; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2007, GUT, V56, P991, DOI 10.1136/gut.2006.097923; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhivotovsky B, 2006, CARCINOGENESIS, V27, P1939, DOI 10.1093/carcin/bgl035	39	34	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1208	1217		10.1038/sj.onc.1210733	http://dx.doi.org/10.1038/sj.onc.1210733			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704801				2022-12-25	WOS:000253407000003
J	Ying, H; Willingham, MC; Cheng, SY				Ying, H.; Willingham, M. C.; Cheng, S-Y			The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer	ONCOGENE			English	Article						thyroid carcinogenesis; SRC-3; apoptosis; cell cycles; thyroid hormone receptor mutant; mouse model of thyroid cancer	TRANSCRIPTIONAL ACTIVITY; HORMONE RESISTANCE; CELL-PROLIFERATION; SIGNALING PATHWAY; LIGAND-BINDING; BETA-RECEPTOR; GENE; CARCINOGENESIS; GROWTH; SRC-3	The molecular genetic events underlying thyroid carcinogenesis are not well understood. Mice harboring a dominant-negative mutant thyroid hormone receptor-beta (TR beta(PV/PV) mice) spontaneously develop follicular thyroid carcinoma similar to human cancer. The present study aimed to elucidate the role of the steroid receptor coactivator-3 (SRC-3) in thyroid carcinogenesis in vivo by using the offspring from the cross of TR beta(PV/PV) and SRC-3(-/-) mice. TR beta PV/PV mice deficient in SRC-3 (TRb beta(SRC)-S-PV/PV-3(-/-) mice) had significantly increased survival, decreased thyroid tumor growth, delayed tumor progression and lower incidence of distant metastasis as compared with TR beta(PV/PV) mice with SRC-3 (TR beta(SRC)-S-PV/PV-3(-/-) mice). Further, in vivo nd in vitro analyses of multiple signaling pathways indicated that SRC-3 deficiency could lead to (1) inhibition of cell cycle progression at the G(1)/S transition via controlling the expression of cell cycle regulators, such as E2F1; (2) induction of apoptosis by controlling the expression of the Bcl-2 and caspase-3 genes and (3) suppression of neovascularization and metastasis, at least in part, through modulating the vascular endothelial growth factor gene expression. Taken together, SRC-3 could play important roles through regulating multiple target genes and signaling pathways during thyroid carcinogenesis, understanding of which should direct future therapeutic options for thyroid cancer.	[Ying, H.; Cheng, S-Y] NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bldg 37,Room 5128,37 Convent Dr, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008752, ZIABC008752] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Gillenwater A M, 1997, Cancer Treat Res, V90, P149; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Liao L, 2002, J STEROID BIOCHEM, V83, P3, DOI 10.1016/S0960-0760(02)00254-6; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Louie MC, 2006, MOL CELL BIOL, V26, P3810, DOI 10.1128/MCB.26.10.3810-3823.2006; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Olateju TO, 2006, ANN CLIN BIOCHEM, V43, P431, DOI 10.1258/000456306778904678; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Ying H, 2005, MOL CELL BIOL, V25, P7687, DOI 10.1128/MCB.25.17.7687-7695.2005; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	24	22	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					823	830		10.1038/sj.onc.1210680	http://dx.doi.org/10.1038/sj.onc.1210680			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653082				2022-12-25	WOS:000252884500011
J	Kirsch, M; Kemp-Harper, B; Weissmann, N; Grimminger, F; Schmidt, HHHW				Kirsch, Mark; Kemp-Harper, Barbara; Weissmann, Norbert; Grimminger, Friedrich; Schmidt, Harald H. H. W.			Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling	FASEB JOURNAL			English	Article						vascular disease; PH; lung perfusate	NITRIC-OXIDE SYNTHASE; SOLUBLE GUANYLATE-CYCLASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; VASCULAR SMOOTH-MUSCLE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ENDOTHELIUM-DEPENDENT RELAXATION; RAT LUNG; ARTERIAL-HYPERTENSION; GENE-EXPRESSION; RELAXING FACTOR	The availability of inhibitors of cGMP-specific phosphodiesterase 5 (PDE 5), such as sildenafil, has revolutionized the treatment of pulmonary hypertension (PH). Sildenafil may exert its protective effects in a mechanism-based fashion by targeting a pathophysiologically attenuated NO-cGMP signaling pathway. To elucidate this, we analyzed changes in the pulmonary expression and activity of key enzymes of NO-cGMP signaling as well as the functional pulmonary responses to sildenafil in the 5 or 21 day hypoxia mouse model of PH. Surprisingly, we found doubled NO synthase ( NOS) II and III levels, no evidence for attenuated NO bioaviability as evidenced by the nitro-sative/oxidative stress marker protein nitro tyrosine, and no changes in the expression and activity of the NO receptor, soluble guanylyl cyclase (sGC). PDE 5 was either unchanged at day 5 or, after 21 days of hypoxia, even significantly decreased along with unchanged activity. Biochemically, these changes were mirrored by increased cGMP spillover into the lung perfusate and cGMP-dependent phosphorylation of the vasodilator-stimulated phosphoprotein, VASP. Sildenafil further augmented cGMP and phospho-VASP levels in lungs of mice exposed for 5 or 21 days and decreased pulmonary arterial pressure in mice after 5 days but not 21 days of hypoxia. In conclusion, NO-cGMP signaling is compensatorily up-regulated in the hypoxic mouse model of PH, and sildenafil further augments this pathway to functionally alleviate pulmonary vasoconstriction. -Kirsch, M., Kemp-Harper, B., Weissmann, N., Grimminger, F., Schmidt, H. H. H. W. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO- cGMP signaling.	[Kemp-Harper, Barbara; Schmidt, Harald H. H. W.] Monash Univ, Dept Pharmacol, Melbourne, Vic 3800, Australia; [Kemp-Harper, Barbara; Schmidt, Harald H. H. W.] Monash Univ, Ctr Vasc Hlth, Melbourne, Vic 3800, Australia; [Kirsch, Mark] Univ Giessen, Rudolf Buchheim Inst Pharmacol, Giessen, Germany; [Weissmann, Norbert; Grimminger, Friedrich] Univ Giessen, Lung Ctr, Med Clin 2 5, Giessen, Germany	Monash University; Monash University; Justus Liebig University Giessen; Justus Liebig University Giessen	Schmidt, HHHW (corresponding author), Monash Univ, Dept Pharmacol, Wellington Rd,Bldg 13E,Rm 116, Melbourne, Vic 3800, Australia.	harald.schmidt@med.monash.edu.au	Schmidt, Harald HHW/B-1549-2008; Kemp-Harper, Barbara K/A-7882-2008	Schmidt, Harald HHW/0000-0003-0419-5549; Grimminger, Friedrich/0000-0001-8725-6276; Weissmann, Norbert/0000-0003-2675-3871				ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BHARANI A, 2003, INDIAN HEART J, V55, P285; Cohen AH, 1996, J CLIN INVEST, V97, P172, DOI 10.1172/JCI118386; CRAWLEY DE, 1992, AM J PHYSIOL, V263, pL325, DOI 10.1152/ajplung.1992.263.3.L325; Demiryurek MR, 2000, PULM PHARMACOL THER, V13, P157, DOI 10.1006/pupt.2000.0238; Dumitrascu R, 2006, CIRCULATION, V113, P286, DOI 10.1161/CIRCULATIONAHA.105.581405; Evgenov OV, 2004, CIRCULATION, V110, P2253, DOI 10.1161/01.CIR.0000144469.01521.8A; Fagan KA, 1999, AM J PHYSIOL-LUNG C, V277, pL472, DOI 10.1152/ajplung.1999.277.3.L472; Feil R, 2006, EMBO REP, V7, P149, DOI 10.1038/sj.embor.7400627; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Frank DU, 1998, J APPL PHYSIOL, V85, P1070, DOI 10.1152/jappl.1998.85.3.1070; Fukumoto Y, 2007, TOHOKU J EXP MED, V211, P309, DOI 10.1620/tjem.211.309; Galle J, 1999, BRIT J PHARMACOL, V127, P195, DOI 10.1038/sj.bjp.0702495; Ghofrani HA, 2002, LANCET, V360, P895, DOI 10.1016/S0140-6736(02)11024-5; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; GRIMMINGER F, 1995, J APPL PHYSIOL, V78, P1509, DOI 10.1152/jappl.1995.78.4.1509; Hanasato N, 1999, AM J PHYSIOL-LUNG C, V277, pL225, DOI 10.1152/ajplung.1999.277.2.L225; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Ibarra-Alvarado C, 2002, MOL PHARMACOL, V61, P312, DOI 10.1124/mol.61.2.312; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; ISAACSON TC, 1994, J APPL PHYSIOL, V76, P933, DOI 10.1152/jappl.1994.76.2.933; Jernigan NL, 2003, AM J PHYSIOL-LUNG C, V285, pL634, DOI 10.1152/ajplung.00328.2002; Jernigan NL, 2002, AM J PHYSIOL-LUNG C, V282, pL1366, DOI 10.1152/ajplung.00273.2001; JOHNS RA, 1989, CIRC RES, V65, P1508, DOI 10.1161/01.RES.65.6.1508; Kahl KG, 2003, J NEUROSCI RES, V73, P198, DOI 10.1002/jnr.10649; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; Kotera J, 2000, J HISTOCHEM CYTOCHEM, V48, P685, DOI 10.1177/002215540004800512; Krick S, 2005, FASEB J, V19, P857, DOI 10.1096/fj.04-2890fje; LeCras TD, 1996, AM J PHYSIOL-LUNG C, V270, pL164, DOI 10.1152/ajplung.1996.270.1.L164; Li DC, 1999, AM J PHYSIOL-LUNG C, V277, pL841, DOI 10.1152/ajplung.1999.277.4.L841; Li DC, 2001, AM J PHYSIOL-LUNG C, V281, pL369, DOI 10.1152/ajplung.2001.281.2.L369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lugnier C, 1999, J PHYSIOL PHARMACOL, V50, P639; MacLean MR, 1997, J PHARMACOL EXP THER, V283, P619; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Muramatsu M, 1996, J APPL PHYSIOL, V80, P1336, DOI 10.1152/jappl.1996.80.4.1336; Murata T, 2002, J BIOL CHEM, V277, P44085, DOI 10.1074/jbc.M205934200; Murray F, 2002, BRIT J PHARMACOL, V137, P1187, DOI 10.1038/sj.bjp.0704984; Murray F, 2007, AM J PHYSIOL-LUNG C, V292, pL294, DOI 10.1152/ajplung.00190.2006; Muzaffar S, 2005, THORAX, V60, P305, DOI 10.1136/thx.2003.018796; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; Pauvert O, 2004, AM J PHYSIOL-LUNG C, V287, pL577, DOI 10.1152/ajplung.00449.2003; Petkov V, 2003, J CLIN INVEST, V111, P1339, DOI 10.1172/JCI200317500; Phillips PG, 2005, AM J PHYSIOL-LUNG C, V288, pL103, DOI 10.1152/ajplung.00095.2004; Polson JB, 1996, ANNU REV PHARMACOL, V36, P403, DOI 10.1146/annurev.pa.36.040196.002155; Preston IR, 2004, EXP BIOL MED, V229, P920, DOI 10.1177/153537020422900908; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; RODMAN DM, 1990, AM J PHYSIOL, V258, pL207, DOI 10.1152/ajplung.1990.258.4.L207; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; Sauzeau V, 2003, CIRC RES, V93, P630, DOI 10.1161/01.RES.0000093220.90027.D9; Schermuly RT, 2007, CIRCULATION, V115, P2331, DOI 10.1161/CIRCULATIONAHA.106.676809; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Sebkhi A, 2003, CIRCULATION, V107, P3230, DOI 10.1161/01.CIR.0000074226.20466.B1; SHAUL PW, 1995, AM J RESP CELL MOL, V13, P167, DOI 10.1165/ajrcmb.13.2.7542896; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Turley JE, 2003, AM J PHYSIOL-LUNG C, V284, pL489, DOI 10.1152/ajplung.00246.2002; Valencia A, 2006, FREE RADICAL BIO MED, V41, P1704, DOI 10.1016/j.freeradbiomed.2006.09.006; WARNHOLTZ A, 2007, IN PRESS ARTHERSCLER; Weissmann N, 2005, THROMB HAEMOSTASIS, V94, P630, DOI 10.1160/TH05-02-0104; Weissmann N, 2004, RESP PHYSIOL NEUROBI, V139, P191, DOI 10.1016/j.resp.2003.10.003; Weissmann N, 2003, AM J PHYSIOL-HEART C, V284, pH931, DOI 10.1152/ajpheart.00376.2002; Weissmann N, 2006, P NATL ACAD SCI USA, V103, P19093, DOI 10.1073/pnas.0606728103; Wingler M, 2001, FREE RADICAL BIO MED, V31, P1456, DOI 10.1016/S0891-5849(01)00727-4; XIA XD, 2003, NEI KE ZA ZHI, V42, P628; Xue C, 1996, HYPERTENSION, V28, P743, DOI 10.1161/01.HYP.28.5.743; XUE C, 1994, AM J PHYSIOL-LUNG C, V267, pL667, DOI 10.1152/ajplung.1994.267.6.L667; ZABEL U, 1998, BIOCHEM J, V127, P195; Zhao L, 2003, CIRCULATION, V107, P234, DOI 10.1161/01.CIR.0000050653.10758.6B; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	72	32	34	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					30	40		10.1096/fj.06-7526com	http://dx.doi.org/10.1096/fj.06-7526com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17679609				2022-12-25	WOS:000252309900006
J	Osei-Owusu, P; Sun, XG; Drenan, RM; Steinberg, TH; Blumer, KJ				Osei-Owusu, Patrick; Sun, Xiaoguang; Drenan, Ryan M.; Steinberg, Thomas H.; Blumer, Kendall J.			Regulation of RGS2 and second messenger signaling in vascular smooth muscle cells by cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; TERMINAL CYSTEINE RESIDUES; GTPASE-ACTIVATING PROTEINS; END RULE PATHWAY; ADENYLYL-CYCLASE; PLASMA-MEMBRANE; 3RD-INTRACELLULAR LOOP; RECIPROCAL REGULATION; CELLULAR MECHANISM; ANGIOTENSIN-II	RGS2, a GTPase-activating protein (GAP) for G(q)alpha, regulates vascular relaxation and blood pressure. RGS2 can be phosphorylated by type I alpha cGMP-dependent protein kinase (cGKI alpha), increasing its GAP activity. To understand how RGS2 and cGKI alpha regulate vascular smooth muscle signaling and function, we identified signaling pathways that are controlled by cGMP in an RGS2-dependent manner and discovered new mechanisms whereby cGK activity regulates RGS2. We show that RGS2 regulates vasoconstrictor-stimulated Ca2+ store release, capacitative Ca2+ entry, and noncapacitative Ca2+ entry and that RGS2 is required for cGMP-mediated inhibition of vasoconstrictor-elicited phospholipase C beta activation, Ca2+ store release, and capacitative Ca2+ entry. RGS2 is degraded in vascular smooth muscle cells via the proteasome. Inhibition of cGK activity blunts RGS2 degradation. However, inactivation of the cGKI alpha phosphorylation sites in RGS2 does not stabilize the protein, suggesting that cGK activity regulates RGS2 degradation by other mechanisms. cGK activation promotes association of RGS2 with the plasma membrane by a mechanism requiring its cGKI alpha phosphorylation sites. By regulating GAP activity, plasma membrane association, and degradation, cGKI alpha therefore may control a cycle of RGS2 activation and inactivation. By diminishing cGK activity, endothelial dysfunction may impair RGS2 activation, thereby blunting vascular relaxation and contributing to hypertension.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	kblumer@cellbiology.wustl.edu	Osei-Owusu, Patrick/AAH-9063-2019; Blumer, Kendall J/C-5268-2012; Osei-Owusu, Patrick/L-9104-2018		NHLBI NIH HHS [HL075632] Funding Source: Medline; NIGMS NIH HHS [GM44592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bodenstein J, 2007, MOL PHARMACOL, V71, P1040, DOI 10.1124/mol.106.029397; Brueggemann LI, 2006, J PHARMACOL EXP THER, V317, P488, DOI 10.1124/jpet.105.095067; Brueggemann LI, 2005, BIOCHEM J, V388, P237, DOI 10.1042/BJ20041360; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; Derrien A, 2001, J BIOL CHEM, V276, P48532, DOI 10.1074/jbc.M108862200; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GILL DL, 2004, SCI STKE, pE39; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Hu RG, 2005, NATURE, V437, P981, DOI 10.1038/nature04027; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Jerius H, 1998, SURGERY, V123, P46, DOI 10.1067/msy.1998.82476; Kanaide H, 2003, CIRC RES, V93, P1015, DOI 10.1161/01.RES.0000105920.33926.60; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Luker GD, 2003, CANCER RES, V63, P1780; Moneer Z, 2005, BIOCHEM J, V389, P821, DOI 10.1042/BJ20050145; Moneer Z, 2003, BIOCHEM J, V370, P439, DOI 10.1042/BJ20021104; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Osterhout JL, 2003, J BIOL CHEM, V278, P19309, DOI 10.1074/jbc.M210124200; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Roy AA, 2006, CELL SIGNAL, V18, P336, DOI 10.1016/j.cellsig.2005.05.004; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Schoeber JP, 2006, J BIOL CHEM, V281, P29669, DOI 10.1074/jbc.M606233200; SIDEROVSKI DP, 2004, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A000028.01; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sun XG, 2005, MOL PHARMACOL, V67, P631, DOI 10.1124/mol.104.007724; TAKATA S, 1990, AM J HYPERTENS, V3, pS227, DOI 10.1093/ajh/3.8.227; Takida S, 2005, MOL PHARMACOL, V67, P132, DOI 10.1124/mol.104.003418; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taylor Colin W, 2002, Novartis Found Symp, V246, P91; Taylor CW, 2004, BIOL RES, V37, P641, DOI 10.4067/s0716-97602004000400020; Thuillez C, 2005, J HUM HYPERTENS, V19, pS21, DOI 10.1038/sj.jhh.1001889; Tikhonova IG, 2006, BIOCHEM BIOPH RES CO, V341, P715, DOI 10.1016/j.bbrc.2005.12.221; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2004, METHOD ENZYMOL, V389, P89; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wang X, 2007, EMBO J, V26, P2768, DOI 10.1038/sj.emboj.7601701; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0	73	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31656	31665		10.1074/jbc.M706360200	http://dx.doi.org/10.1074/jbc.M706360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17681944	hybrid			2022-12-25	WOS:000250309200057
J	Chang, YF; Chan, WK; Imam, JS; Wilkinson, MF				Chang, Yao-Fu; Chan, Wai-Kin; Imam, J. Saadi; Wilkinson, Miles F.			Alternatively spliced T-cell receptor transcripts are up-regulated in response to disruption of either splicing elements or reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA-DECAY; NONSENSE-MEDIATED DECAY; PREMATURE TERMINATION CODON; EXON-JUNCTION COMPLEX; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; DEPENDENT MANNER; MAMMALIAN-CELLS; SITE SELECTION; HUMAN SMG-1	Nonsense mutations create premature termination codons ( PTCs), leading to the generation of truncated proteins, some of which have deleterious gain-of-function or dominant-negative activity. Protecting cells from such aberrant proteins is nonsensemediated decay ( NMD), an RNA surveillance pathway that degrades transcripts harboring PTCs. Asecond response to nonsense mutations is the up-regulation of alternatively spliced transcripts that skip the PTC. This nonsense-associated altered splicing ( NAS) response has the potential to rescue protein function, but the mechanism by which it is triggered has been controversial. Some studies suggest that, like NMD, NAS is triggered as a result of nonsense mutations disrupting reading frame, whereas other studies suggest thatNASis triggered when nonsense mutations disrupt exonic splicing enhancers ( ESEs). Using T-cell receptor-beta( TCR beta), which naturally acquires PTCs at high frequency, we provide evidence that both mechanisms act on a single type of mRNA. Mutations that disrupt consensus ESE sites up-regulated an alternatively spliced TCR beta transcript that skipped the mutations independently of reading frame disruption and the NMD factor UPF1. In contrast, reading frame disrupting mutations that did not disrupt consensus ESE sites elicited UPF1-dependent up-regulation of the alternatively spliced TCR beta transcript. Restoration of reading frame prevented this up-regulation. Our results suggest that the response of an mRNA to a nonsense mutation depends on its context.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Unit 1000, Houston, TX 77030 USA.	mwilkins@mdanderson.org	Chan, Waikin/AAI-4995-2020	Imam, J Saadi/0000-0003-3463-838X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-058595] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker KE, 2006, RNA, V12, P1441, DOI 10.1261/rna.92706; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Brogna S, 2002, MOL CELL, V10, P93, DOI 10.1016/S1097-2765(02)00565-8; Buhler M, 2005, RNA, V11, P139, DOI 10.1261/rna.7183805; Buhler M, 2002, EMBO REP, V3, P646, DOI 10.1093/embo-reports/kvf129; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Caputi M, 2002, GENE DEV, V16, P1754, DOI 10.1101/gad.997502; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Chan WK, 2007, EMBO J, V26, P1820, DOI 10.1038/sj.emboj.7601628; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; Chin SY, 2004, GENE DEV, V18, P745, DOI 10.1101/gad.1170204; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Dahlberg JE, 2003, RNA, V9, P1, DOI 10.1261/rna.2121703; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; Di Blasi C, 2001, BRAIN, V124, P698, DOI 10.1093/brain/124.4.698; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Gehring NH, 2005, MOL CELL, V20, P65, DOI 10.1016/j.molcel.2005.08.012; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Gersappe A, 1999, J BIOL CHEM, V274, P22452, DOI 10.1074/jbc.274.32.22452; Ginjaar IB, 2000, EUR J HUM GENET, V8, P793, DOI 10.1038/sj.ejhg.5200535; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grimson A, 2004, MOL CELL BIOL, V24, P7483, DOI 10.1128/MCB.24.17.7483-7490.2004; Gudikote JP, 2002, EMBO J, V21, P125, DOI 10.1093/emboj/21.1.125; Gudikote JP, 2005, NAT STRUCT MOL BIOL, V12, P801, DOI 10.1038/nsmb980; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Kunz JB, 2006, RNA, V12, P1015, DOI 10.1261/rna.12506; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Longman D, 2007, GENE DEV, V21, P1075, DOI 10.1101/gad.417707; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Mangiarotti G, 1999, BIOCHEMISTRY-US, V38, P3996, DOI 10.1021/bi9822022; Maquat LE, 2002, GENE DEV, V16, P1743, DOI 10.1101/gad.1014502; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Metzstein MM, 2006, PLOS GENET, V2, P2143, DOI 10.1371/journal.pgen.0020180; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Mohn F, 2005, RNA, V11, P147, DOI 10.1261/rna.7182905; Moore MJ, 2002, CELL, V108, P431, DOI 10.1016/S0092-8674(02)00645-1; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Nathanson L, 2003, RNA, V9, P9, DOI 10.1261/rna.2990203; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Schell T, 2002, GENOME BIOL, V3; Singh G, 2003, TRENDS BIOCHEM SCI, V28, P464, DOI 10.1016/S0968-0004(03)00176-2; Stroupe ME, 2006, J MOL BIOL, V360, P743, DOI 10.1016/j.jmb.2006.05.049; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Usuki F, 2006, MOL THER, V14, P351, DOI 10.1016/j.ymthe.2006.04.011; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; van Deutekom JCT, 2001, HUM MOL GENET, V10, P1547, DOI 10.1093/hmg/10.15.1547; Wachtel C, 2004, RNA, V10, P1740, DOI 10.1261/rna.7480804; Wang J, 2002, MOL CELL, V10, P951, DOI 10.1016/S1097-2765(02)00635-4; Wang J, 2002, J BIOL CHEM, V277, P18489, DOI 10.1074/jbc.M111781200; Wang J, 2002, SCIENCE, V297, P108, DOI 10.1126/science.1069757; Wilkinson MF, 2005, TRENDS GENET, V21, P143, DOI 10.1016/j.tig.2005.01.007; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001	67	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29738	29747		10.1074/jbc.M704372200	http://dx.doi.org/10.1074/jbc.M704372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693403	hybrid			2022-12-25	WOS:000249981200002
J	Echevarria, M; Munoz-Cabello, AM; Sanchez-Silva, R; Toledo-Aral, JJ; Lopez-Barneo, J				Echevarria, Miriam; Munoz-Cabello, Ana M.; Sanchez-Silva, Rocio; Toledo-Aral, Juan J.; Lopez-Barneo, Jose			Development of cytosolic hypoxia and hypoxia-inducible factor stabilization are facilitated by aquaporin-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; WATER CHANNEL; XENOPUS OOCYTES; CO2 PERMEABILITY; MESSENGER-RNA; RAT-KIDNEY; PC12 CELLS; OXYGEN; MEMBRANE; INDUCTION	O-2 is essential for aerobic life, and the classic view is that it diffuses freely across the plasma membrane. However, measurements of O-2 permeability of lipid bilayers have indicated that it is much lower than previously thought, and therefore, the existence of membrane O-2 channels has been suggested. Wehypothesized that, besides its role as a water channel, aquaporin-1 (AQP-1) could also work as an O-2 transporter, because this transmembrane protein appears to be CO2-permeable and is highly expressed in cells with rapid O2 turnover (erythrocytes and microvessel endothelium). Here we show that in mammalian cells overexpressing AQP-1 and exposed to hypoxia, the loss of cytosolic O-2, as well as stabilization of the O-2-dependent hypoxia-inducible transcription factor and expression of its target genes, is accelerated. In normoxic endothelial cells, knocking down AQP-1 produces induction of hypoxia-inducible genes. Moreover, lung AQP-1 is markedly up-regulated in animals exposed to hypoxia. These data suggest that AQP-1 has O-2 permeability and thus could facilitate O-2 diffusion across the cell membrane.	Univ Seville, Hosp Univ Virgen Rocio, Dept Fisiol Med & Bioffis, Lab Invest Biomed,Edificio Labs, Seville 41013, Spain	University of Sevilla; Virgen del Rocio University Hospital	Lopez-Barneo, J (corresponding author), Univ Seville, Hosp Univ Virgen Rocio, Dept Fisiol Med & Bioffis, Lab Invest Biomed,Edificio Labs, 2 Planta,Ave Manuel Siurot S-N, Seville 41013, Spain.	lbarneo@us.es	Cabello, Ana Maria Muñoz/E-5292-2016; Toledo-Aral, Juan J/F-2613-2015; IBIS, NEUROBIOLOGIA/O-9922-2015; Echevarría, Miriam/E-6682-2010; IBIS, TERAPIA CELULA/P-3297-2015	Cabello, Ana Maria Muñoz/0000-0002-8047-768X; Toledo-Aral, Juan J/0000-0001-7512-7135; Echevarría, Miriam/0000-0002-4758-9428; 				Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Carter EP, 1998, BIOPHYS J, V74, P2121, DOI 10.1016/S0006-3495(98)77919-6; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAPMAN JD, 1981, BRIT J CANCER, V43, P546, DOI 10.1038/bjc.1981.79; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Del Toro R, 2003, J BIOL CHEM, V278, P22316, DOI 10.1074/jbc.M212576200; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; FISCHKOFF S, 1975, J GEN PHYSIOL, V65, P663, DOI 10.1085/jgp.65.5.663; Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Herrera M, 2007, AM J PHYSIOL-RENAL, V292, pF1443, DOI 10.1152/ajprenal.00353.2006; Herrera M, 2006, HYPERTENSION, V48, P157, DOI 10.1161/01.HYP.0000223652.29338.77; Ivanov II, 2004, BIOCHEM BIOPH RES CO, V322, P746, DOI 10.1016/j.bbrc.2004.07.187; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Murillo-Carretero MI, 1999, J AM SOC NEPHROL, V10, P696; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; OBESO J, 1990, LAB INVEST, V63, P259; Piruat JI, 2005, J BIOL CHEM, V280, P42676, DOI 10.1074/jbc.M507044200; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RALEIGH JA, 1987, BRIT J CANCER, V56, P395, DOI 10.1038/bjc.1987.213; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; SUBCZYNSKI WK, 1992, J GEN PHYSIOL, V100, P69, DOI 10.1085/jgp.100.1.69; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; Vacca A, 2001, BRIT J HAEMATOL, V113, P415, DOI 10.1046/j.1365-2141.2001.02738.x; Wang Y, 2007, J STRUCT BIOL, V157, P534, DOI 10.1016/j.jsb.2006.11.008; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Zhou BY, 2007, AM J PHYSIOL-CELL PH, V292, pC1280, DOI 10.1152/ajpcell.00070.2006	44	95	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30207	30215		10.1074/jbc.M702639200	http://dx.doi.org/10.1074/jbc.M702639200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17673462	hybrid			2022-12-25	WOS:000249981200051
J	Brower, JV; Rodic, N; Seki, T; Jorgensen, M; Fliess, N; Yachnis, AT; McCarrey, JR; Oh, SP; Terada, N				Brower, Jeffrey V.; Rodic, Nemanja; Seki, Tsugio; Jorgensen, Marda; Fliess, Naime; Yachnis, Anthony T.; McCarrey, John R.; Oh, S. Paul; Terada, Naohiro			Evolutionarily conserved mammalian adenine nucleotide translocase 4 is essential for spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						t	ADENINE-NUCLEOTIDE TRANSLOCATOR; MITOCHONDRIAL PERMEABILITY TRANSITION; ADP/ATP CARRIER; PSEUDOAUTOSOMAL-REGION; GERM-CELLS; MOUSE; GENE; EXPRESSION; INACTIVATION; CHROMOSOMES	The adenine nucleotide translocases (Ant) facilitate the transport of ADP and ATP by an antiport mechanism across the inner mitochondrial membrane, thus playing an essential role in cellular energy metabolism. We recently identified a novel member of the Ant family in mouse, Ant4, of which gene configuration as well as amino acid homology is well conserved among mammals. The conservation of Ant4 in mammals, along with the absence of Ant4 in nonmammalian species, suggests a unique and indispensable role for this ADP/ATP carrier in mammalian development. Of interest, in contrast to its paralog Ant2, which is encoded by the X chromosome and ubiquitously expressed in somatic cells, Ant4 is encoded by an autosome and selectively expressed in testicular germ cells. Immunohistochemical examination as well as RNA expression analysis using separated spermatogenic cell types revealed that Ant4 expression was particularly high in spermatocytes. When we generated Ant4-deficient mice by targeted disruption, a significant reduction in testicular size was observed without any other distinguishable abnormalities in the mice. Histological examination as well as stage-specific gene expression analysis in adult and neonatal testes revealed a severe reduction of spermatocytes accompanied by increased apoptosis. Subsequently, the Ant4-deficient male mice were infertile. Taken together, these data elucidated the indispensable role of Ant4 in murine spermatogenesis. Considering the unique conservation and chromosomal location of the Ant family genes in mammals, the Ant4 gene may have arisen in mammalian ancestors and been conserved in mammals to serve as the sole and essential mitochondrial ADP/ATP carrier during spermatogenesis where the sex chromosome-linked Ant2 gene is inactivated.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA; Univ Texas, Dept Biol, San Antonio, TX 78249 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, POB 100275, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu		Yachnis, Anthony/0000-0002-6971-0698	NCRR NIH HHS [RR17001] Funding Source: Medline; NIDDK NIH HHS [DK59699] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR017001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY J, 2005, SYNOPSIS, V26, P678; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Bradley J, 2004, NAT GENET, V36, P872, DOI 10.1038/ng1390; Carra E, 2004, BIOCHEM BIOPH RES CO, V322, P333, DOI 10.1016/j.bbrc.2004.07.112; CECI JD, 1994, MAMM GENOME, V5, pS124; Charchar FJ, 2003, GENOME RES, V13, P281, DOI 10.1101/gr.390503; Chen KF, 2004, MAMM GENOME, V15, P996, DOI 10.1007/s00335-004-2405-1; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Ellison JW, 1996, GENOMICS, V36, P369, DOI 10.1006/geno.1996.0478; Emerson JJ, 2004, SCIENCE, V303, P537, DOI 10.1126/science.1090042; ERICKSON RP, 1980, P NATL ACAD SCI-BIOL, V77, P6086, DOI 10.1073/pnas.77.10.6086; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; FOLGERO T, 1993, HUM REPROD, V8, P1863, DOI 10.1093/oxfordjournals.humrep.a137950; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Graves JAM, 2006, CELL, V124, P901, DOI 10.1016/j.cell.2006.02.024; Guo R, 2004, MOL REPROD DEV, V67, P264, DOI 10.1002/mrd.20026; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163; KAO SH, 1995, BIOL REPROD, V52, P729, DOI 10.1095/biolreprod52.4.729; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KHALIL S, 2004, AFR J MATH PHYS, V1, P101; Kim YH, 2007, DEV BIOL, V302, P463, DOI 10.1016/j.ydbio.2006.10.004; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Lestienne P, 1997, MOL HUM REPROD, V3, P811, DOI 10.1093/molehr/3.9.811; Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3; Lodi T, 2006, BIOCHEM BIOPH RES CO, V341, P810, DOI 10.1016/j.bbrc.2006.01.034; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; McCarrey JR, 2005, ANN NY ACAD SCI, V1061, P226, DOI 10.1196/annals.1336.025; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; METTUS RV, 1994, ONCOGENE, V9, P3077; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103; Namekawa SH, 2006, CURR BIOL, V16, P660, DOI 10.1016/j.cub.2006.01.066; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ohta H, 2001, INT J ANDROL, V24, P15, DOI 10.1046/j.1365-2605.2001.00257.x; Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341; Richardson LL, 2000, BIOL REPROD, V62, P789, DOI 10.1095/biolreprod62.3.789; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; Santamaria M, 2004, GENE, V333, P51, DOI 10.1016/j.gene.2004.02.013; Spiropoulos J, 2002, MOL HUM REPROD, V8, P719, DOI 10.1093/molehr/8.8.719; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Sweeney C, 1996, DEVELOPMENT, V122, P53; Toder R, 1998, MAMM GENOME, V9, P373, DOI 10.1007/s003359900772; Turner JMA, 2006, DEV CELL, V10, P521, DOI 10.1016/j.devcel.2006.02.009; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Wang PJ, 2004, TRENDS ENDOCRIN MET, V15, P79, DOI 10.1016/j.tem.2004.01.007; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	54	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29658	29666		10.1074/jbc.M704386200	http://dx.doi.org/10.1074/jbc.M704386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681941	hybrid			2022-12-25	WOS:000249788000062
J	Huang, XD; Masselli, A; Frisch, SM; Hunton, IC; Jiang, Y; Wang, JYJ				Huang, XiaoDong; Masselli, Anja; Frisch, Steven M.; Hunton, Irina C.; Jiang, Yong; Wang, Jean Y. J.			Blockade of tumor necrosis factor-induced bid cleavage by caspase-resistant Rb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RETINOBLASTOMA PROTEIN FUNCTION; CELL-DEATH; INDUCED APOPTOSIS; C-ABL; INTERACTING PROTEIN; TNF RECEPTOR-1; ACTIVATION; PATHWAY; INDUCTION	Tumor necrosis factor-alpha (TNF) activates caspase-8 to cleave effector caspases or Bid, resulting in type-1 or type-2 apoptosis, respectively. We show here that TNF also induces caspase-8-dependent C-terminal cleavage of the retinoblastoma protein (Rb). Interestingly, fibroblasts from Rb-MI/MI mice, in which the C-terminal caspase cleavage site is mutated, exhibit a defect in Bid cleavage despite caspase-8 activation. Recent results suggest that TNF receptor endocytosis is required for the activation of caspase-8. Consistent with this notion, inhibition of V-ATPase, which plays an essential role in acidification and degradation of endosomes, specifically restores Bid cleavage in Rb-MI/MI cells. Inhibition of V-ATPase sensitizes Rb-MI/MI but not wild-type fibroblasts to TNF-induced apoptosis and stimulates inflammation-associated colonic apoptosis in Rb-MI/MI but not wild-type mice. These results suggest that Rb cleavage is required for Bid cleavage in TNF-induced type-2 apoptosis, and this requirement can be supplanted by the inhibition of V-ATPase.	Univ Calif San Diego, Ctr Canc, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Moores Canc Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Div Hematol Oncol, Dept Med, La Jolla, CA 92093 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; West Virginia University; West Virginia University	Wang, JYJ (corresponding author), Univ Calif San Diego, Ctr Canc, Div Biol Sci, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; BEG AA, 1996, SCIENCE, V274, P784; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Borges HL, 2005, P NATL ACAD SCI USA, V102, P15587, DOI 10.1073/pnas.0503925102; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382; Helfer B, 2006, CANCER RES, V66, P4273, DOI 10.1158/0008-5472.CAN-05-4183; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Inoue T, 2005, J BIOENERG BIOMEMBR, V37, P393, DOI 10.1007/s10863-005-9478-8; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Park SM, 2005, CURR OPIN CELL BIOL, V17, P610, DOI 10.1016/j.ceb.2005.09.010; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2006, J CLIN INVEST, V116, P2901, DOI 10.1172/JCI23771; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Tu S, 2006, NAT CELL BIOL, V8, P72, DOI 10.1038/ncb1340; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Vella V, 2003, J BIOL CHEM, V278, P25151, DOI 10.1074/jbc.M301962200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	64	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29401	29413		10.1074/jbc.M702261200	http://dx.doi.org/10.1074/jbc.M702261200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686781	Green Published, hybrid			2022-12-25	WOS:000249788000037
J	Koh, CY; Kazimirova, M; Trimnell, A; Takac, P; Labuda, M; Nuttall, PA; Kini, RM				Koh, Cho Yeow; Kazimirova, Maria; Trimnell, Adama; Takac, Peter; Labuda, Milan; Nuttall, Patricia A.; Kini, R. Manjunatha			Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; RECOMBINANT HUMAN PRETHROMBIN-2; GLOSSINA-MORSITANS-MORSITANS; CRYSTAL-STRUCTURE; SALIVARY-GLANDS; ACTIVE-SITE; ANTICOAGULANT PEPTIDE; SLOW-BINDING; HIRUDIN; COMPLEX	Tick saliva contains potent antihemostatic molecules that help ticks obtain their enormous blood meal during prolonged feeding. We isolated thrombin inhibitors present in the salivary gland extract from partially fed female Amblyomma variegatum, the tropical bont tick, and characterized the most potent, variegin, one of the smallest (32 residues) thrombin inhibitors found in nature. Full-length variegin and two truncated variants were chemically synthesized. Despite its small size and flexible structure, variegin binds thrombin with strong affinity (K-i similar to 10.4 pM) and high specificity. Results using the truncated variants indicated that the seven residues at the N terminus affected the binding kinetics; when removed, the binding characteristics changed from fast to slow. Further, the thrombin active site binding moiety of variegin is in the region of residues 8-14, and the exosite-I binding moiety is within residues 15-32. Our results show that variegin is structurally and functionally similar to the rationally designed thrombin inhibitor, hirulog. However, compared with hirulog, variegin is a more potent inhibitor, and its inhibitory activity is largely retained after cleavage by thrombin.	Natl Univ Singapore, Fac Sci, Dept Biol Sci, Prot Sci Lab, Singapore 117543, Singapore; Slovak Acad Sci, Inst Zool, SK-84506 Bratislava, Slovakia; Seattle Biomed Res Inst, Seattle, WA 98109 USA; NERC, Ctr Ecol & Hydrol, Oxford OX1 3SR, England; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA USA	National University of Singapore; Slovak Academy of Sciences; Center for Infectious Disease Research; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, Prot Sci Lab, Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Kazimirova, Maria/U-8222-2017; Kini, Manjunatha/H-8029-2012; Koh, Cho Yeow/J-4635-2019; Nuttall, Pat A/I-6142-2012	Kazimirova, Maria/0000-0001-6904-8342; Koh, Cho Yeow/0000-0003-0002-4603; Nuttall, Pat A/0000-0002-0385-8294; Kini, Manjunatha/0000-0002-6100-3251	Natural Environment Research Council [CEH010021] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200; Bates SM, 2006, BRIT J HAEMATOL, V134, P3, DOI 10.1111/j.1365-2141.2006.06134.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cappello M, 1998, P NATL ACAD SCI USA, V95, P14290, DOI 10.1073/pnas.95.24.14290; Cappello M, 1996, AM J TROP MED HYG, V54, P475, DOI 10.4269/ajtmh.1996.54.475; Champagne DE, 2005, PATHOPHYSIOL HAEMO T, V34, P221, DOI 10.1159/000092428; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Davie EW, 2003, J BIOL CHEM, V278, P50819, DOI 10.1074/jbc.X300009200; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Gurm HS, 2005, AM HEART J, V149, pS43, DOI 10.1016/j.ahj.2004.10.022; Hirsh J, 2005, BLOOD, V105, P453, DOI 10.1182/blood-2003-12-4195; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; Ibrahim MA, 2001, EXP APPL ACAROL, V25, P675, DOI 10.1023/A:1016136207308; Kazimirova M, 2002, EXP APPL ACAROL, V28, P97, DOI 10.1023/A:1025398100044; Kazimirova M, 2002, MED VET ENTOMOL, V16, P301, DOI 10.1046/j.1365-2915.2002.00379.x; Lane DA, 2005, BLOOD, V106, P2605, DOI 10.1182/blood-2005-04-1710; Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NOESKEJUNGBLUT C, 1995, J BIOL CHEM, V270, P28629, DOI 10.1074/jbc.270.48.28629; Page MJ, 2005, J THROMB HAEMOST, V3, P2401, DOI 10.1111/j.1538-7836.2005.01456.x; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P3368, DOI 10.1021/bi036177y; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Salzet M, 2000, J BIOL CHEM, V275, P30774, DOI 10.1074/jbc.M000787200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schwienhorst A, 2006, CELL MOL LIFE SCI, V63, P2773, DOI 10.1007/s00018-006-6219-z; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; Soejima K, 2001, J BIOCHEM, V130, P269, DOI 10.1093/oxfordjournals.jbchem.a002982; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STRUBE KH, 1993, J BIOL CHEM, V268, P8590; Subburaju S, 1997, TOXICON, V35, P1239, DOI 10.1016/S0041-0101(97)00014-7; van de L. A., 1996, EMBO J, V15, P6011; VANDE LA, 1995, EMBO J, V14, P5149; WITTING JI, 1992, BIOCHEM J, V283, P737, DOI 10.1042/bj2830737; Yonemura H, 2004, J BIOCHEM, V135, P577, DOI 10.1093/jb/mvh070; ZINGALI RB, 1993, BIOCHEMISTRY-US, V32, P10794, DOI 10.1021/bi00091a034	47	76	83	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29101	29113		10.1074/jbc.M705600200	http://dx.doi.org/10.1074/jbc.M705600200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684009	hybrid			2022-12-25	WOS:000249788000005
J	Sot, B; Freund, SMV; Fersht, AR				Sot, Begona; Freund, Stefan M. V.; Fersht, Alan R.			Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR P53; FULL-LENGTH P53; CORE DOMAIN; STRUCTURAL BASIS; IN-VIVO; COMPLEX; MITOCHONDRIA; DEATH; MUTATIONS	The p53 transcription-independent apoptosis in mitochondria, mediated by its interaction with the pro-apoptotic and the anti-apoptotic members of the Bcl2 family of proteins, has been described in vivo, especially in radiosensitive tissues. We have characterized the interaction of p53 with both the pro-apoptotic Bak and the anti-apoptotic Bcl-x(L) proteins, comparing their affinity and their interaction surfaces, using biophysical techniques such as fluorescence anisotropy, analytical ultracentrifugation, and NMR. We have shown that both proteins interact with only the p53 core domain and not with its N- and C-terminal regions. Further, p53 has a higher affinity for Bcl-x(L) than for Bak, which is consistent with the previously described sequential binding of Bcl-x(L) and Bak by p53. Interestingly, although the interaction with both proteins is electrostatic in character, they have different binding sites. Using NMR spectroscopy, we have determined that Bcl-x(L) interacts with the DNA binding site of p53, but Bak does not interact with this site. A new potential interaction surface for Bak is proposed.	MRC, Ctr Prot Engn, Cambridge CB2 0QH, England	University of Cambridge	Fersht, AR (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 0QH, England.	arf25@cam.ac.uk	Sot, Begoña/H-2882-2015; Fersht, Alan R/B-2189-2008	Sot, Begoña/0000-0001-8763-0651; 	Medical Research Council [MC_U105474168] Funding Source: Medline; MRC [MC_U105474168] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bauer JH, 2006, AGING CELL, V5, P437, DOI 10.1111/j.1474-9726.2006.00228.x; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chan SL, 2004, CLIN EXP PHARMACOL P, V31, P119, DOI 10.1111/j.1440-1681.2004.03975.x; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Hainaut P, 2000, ADV CANCER RES, V77, P81; Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liebermann DA, 2007, CELL CYCLE, V6, P166, DOI 10.4161/cc.6.2.3789; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; Palacios G, 2006, ONCOGENE, V25, P6133, DOI 10.1038/sj.onc.1209641; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tidow H, 2007, P NATL ACAD SCI USA, V104, P12324, DOI 10.1073/pnas.0705069104; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Vaynberg J, 2005, MOL CELL, V17, P513, DOI 10.1016/j.molcel.2004.12.031; Veprintsev DB, 2006, P NATL ACAD SCI USA, V103, P2115, DOI 10.1073/pnas.0511130103; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Xu HB, 2006, BIOCHEM BIOPH RES CO, V341, P938, DOI 10.1016/j.bbrc.2005.12.227; Yamada Y, 2005, ACTA CRYSTALLOGR D, V61, P731, DOI 10.1107/S0907444905009595; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103	41	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29193	29200		10.1074/jbc.M705544200	http://dx.doi.org/10.1074/jbc.M705544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699158	hybrid			2022-12-25	WOS:000249788000015
J	Eshaghi, M; Karuturi, RKM; Li, JT; Chu, ZQ; Liu, ET; Liu, JH				Eshaghi, Majid; Karuturi, R. Krishna M.; Li, Juntao; Chu, Zhaoqing; Liu, Edison T.; Liu, Jianhua			Global Profiling of DNA Replication Timing and Efficiency Reveals that Efficient Replication/Firing Occurs Late during S-Phase in S. pombe	PLOS ONE			English	Article								Background. During S. pombe S-phase, initiation of DNA replication occurs at multiple sites (origins) that are enriched with AT-rich sequences, at various times. Current studies of genome-wide DNA replication profiles have focused on the DNA replication timing and origin location. However, the replication and/or firing efficiency of the individual origins on the genomic scale remain unclear. Methodology/Principal Findings. Using the genome-wide ORF-specific DNA microarray analysis, we show that in S. pombe, individual origins fire with varying efficiencies and at different times during S-phase. The increase in DNA copy number plotted as a function of time is approximated to the near-sigmoidal model, when considering the replication start and end timings at individual loci in cells released from HU-arrest. Replication efficiencies differ from origin to origin, depending on the origin's firing efficiency. We have found that DNA replication is inefficient early in S-phase, due to inefficient firing at origins. Efficient replication occurs later, attributed to efficient but late-firing origins. Furthermore, profiles of replication timing in cds1 Delta cells are abnormal, due to the failure in resuming replication at the collapsed forks. The majority of the inefficient origins, but not the efficient ones, are found to fire in cds1 Delta cells after HU removal, owing to the firing at the remaining unused (inefficient) origins during HU treatment. Conclusions/Significance. Taken together, our results indicate that efficient DNA replication/firing occurs late in S-phase progression in cells after HU removal, due to efficient late-firing origins. Additionally, checkpoint kinase Cds1p is required for maintaining the efficient replication/firing late in S-phase. We further propose that efficient late-firing origins are essential for ensuring completion of DNA duplication by the end of S-phase.	[Eshaghi, Majid; Karuturi, R. Krishna M.; Li, Juntao; Chu, Zhaoqing; Liu, Edison T.; Liu, Jianhua] Genome Inst Singapore, Singapore, Singapore; [Liu, Jianhua] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Liu, JH (corresponding author), Genome Inst Singapore, Singapore, Singapore.	liujh@gis.a-star.edu.sg	Liu, Edison/C-4141-2008	Liu, Jianhua/0000-0003-1165-9348; ?, ??/0000-0002-3982-9858	Agency for Science, Technology and Research (A-STAR), Singapore	Agency for Science, Technology and Research (A-STAR), Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by the Agency for Science, Technology and Research (A-STAR), Singapore.	ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Dai JL, 2005, P NATL ACAD SCI USA, V102, P337, DOI 10.1073/pnas.0408811102; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Feng WY, 2006, NAT CELL BIOL, V8, P148, DOI 10.1038/ncb1358; Gilbert DM, 2001, J CELL BIOL, V152, pF11, DOI 10.1083/jcb.152.2.F11; Glynn EF, 2004, PLOS BIOL, V2, P1325, DOI 10.1371/journal.pbio.0020259; Hayashi M, 2007, EMBO J, V26, P1327, DOI 10.1038/sj.emboj.7601585; Heichinger C, 2006, EMBO J, V25, P5171, DOI 10.1038/sj.emboj.7601390; Jeon Y, 2005, P NATL ACAD SCI USA, V102, P6419, DOI 10.1073/pnas.0405088102; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Legouras I, 2006, YEAST, V23, P951, DOI 10.1002/yea.1416; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MacAlpine D, 2005, CHROMOSOME RES, V13, P309, DOI 10.1007/s10577-005-1508-1; MacNeill SA, 1997, METHOD ENZYMOL, V283, P440; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Patel PK, 2006, MOL BIOL CELL, V17, P308, DOI 10.1091/mbc.E05-07-0657; Peng X, 2005, MOL BIOL CELL, V16, P1026, DOI 10.1091/mbc.E04-04-0299; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Rhind N, 2006, NAT CELL BIOL, V8, P1313, DOI 10.1038/ncb1206-1313; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yabuki N, 2002, GENES CELLS, V7, P781, DOI 10.1046/j.1365-2443.2002.00559.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	32	20	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e722	10.1371/journal.pone.0000722	http://dx.doi.org/10.1371/journal.pone.0000722			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684567	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452400024
J	Hossler, P; Mulukutla, BC; Hu, WS				Hossler, Patrick; Mulukutla, Bhanu Chandra; Hu, Wei-Shou			Systems Analysis of N-Glycan Processing in Mammalian Cells	PLOS ONE			English	Article								N-glycosylation plays a key role in the quality of many therapeutic glycoprotein biologics. The biosynthesis reactions of these oligosaccharides are a type of network in which a relatively small number of enzymes give rise to a large number of N-glycans as the reaction intermediates and terminal products. Multiple glycans appear on the glycoprotein molecules and give rise to a heterogeneous product. Controlling the glycan distribution is critical to the quality control of the product. Understanding N-glycan biosynthesis and the etiology of microheterogeneity would provide physiological insights, and facilitate cellular engineering to enhance glycoprotein quality. We developed a mathematical model of glycan biosynthesis in the Golgi and analyzed the various reaction variables on the resulting glycan distribution. The Golgi model was modeled as four compartments in series. The mechanism of protein transport across the Golgi is still controversial. From the viewpoint of their holding time distribution characteristics, the two main hypothesized mechanisms, vesicular transport and Golgi maturation models, resemble four continuous mixing-tanks (4CSTR) and four plug-flow reactors (4PFR) in series, respectively. The two hypotheses were modeled accordingly and compared. The intrinsic reaction kinetics were first evaluated using a batch (or single PFR) reactor. A sufficient holding time is needed to produce terminally-processed glycans. Altering enzyme concentrations has a complex effect on the final glycan distribution, as the changes often affect many reaction steps in the network. Comparison of the glycan profiles predicted by the 4CSTR and 4PFR models points to the 4PFR system as more likely to be the true mechanism. To assess whether glycan heterogeneity can be eliminated in the biosynthesis of biotherapeutics the 4PFR model was further used to assess whether a homogeneous glycan profile can be created through metabolic engineering. We demonstrate by the spatial localization of enzymes to specific compartments all terminally processed N-glycans can be synthesized as homogeneous products with a sufficient holding time in the Golgi compartments. The model developed may serve as a guide to future engineering of glycoproteins.	[Hossler, Patrick; Mulukutla, Bhanu Chandra; Hu, Wei-Shou] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hu, WS (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	acre@cems.umn.edu			NIH [GM08347]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	P.H. was supported by an NIH Biotechnology Training Grant (GM08347).	Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BENDIAK B, 1987, J BIOL CHEM, V262, P5784; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; CHANDRASEKARAN EV, 1984, CANCER RES, V44, P4059; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; Elsner M, 2003, MOL MEMBR BIOL, V20, P221, DOI 10.1080/0968768031000114024; Ferrara C, 2006, BIOTECHNOL BIOENG, V93, P851, DOI 10.1002/bit.20777; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hooker AD, 1999, BIOTECHNOL BIOENG, V63, P559, DOI 10.1002/(SICI)1097-0290(19990605)63:5<559::AID-BIT6>3.0.CO;2-L; Hossler P, 2006, BIOTECHNOL BIOENG, V95, P946, DOI 10.1002/bit.21062; Ikeda Y, 2001, TRENDS GLYCOSCI GLYC, V13, P167, DOI 10.4052/tigg.13.167; Jost F, 2005, GLYCOBIOLOGY, V15, P165, DOI 10.1093/glycob/cwh157; Kindt T.J., 1984, ANTIBODY ENIGMA; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Krambeck FJ, 2005, BIOTECHNOL BIOENG, V92, P711, DOI 10.1002/bit.20645; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Losev E, 2006, NATURE, V441, P1002, DOI 10.1038/nature04717; Malhotra V, 2006, NATURE, V441, P939, DOI 10.1038/441939a; Marsh BJ, 2002, NAT REV MOL CELL BIO, V3, P789, DOI 10.1038/nrm933; Matsuura-Tokita K, 2006, NATURE, V441, P1007, DOI 10.1038/nature04737; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; Mironov A, 1998, FASEB J, V12, P249; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; NISHIU J, 1995, BIOSCI BIOTECH BIOCH, V59, P1750, DOI 10.1271/bbb.59.1750; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; PAQUET MR, 1984, J BIOL CHEM, V259, P4716; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RAO AK, 1976, BIOCHEMISTRY-US, V15, P5001, DOI 10.1021/bi00668a009; Seth G, 2006, ADV BIOCHEM ENG BIOT, V101, P119, DOI 10.1007/10_017; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Sinclair AM, 2005, J PHARM SCI-US, V94, P1626, DOI 10.1002/jps.20319; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; Stephens DJ, 2001, J CELL SCI, V114, P1053; TABAS I, 1979, J BIOL CHEM, V254, P1655; TULSIANI DRP, 1989, METHOD ENZYMOL, V179, P446; Umana P, 1997, BIOTECHNOL BIOENG, V55, P890, DOI 10.1002/(SICI)1097-0290(19970920)55:6<890::AID-BIT7>3.0.CO;2-B; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Wildt S, 2005, NAT REV MICROBIOL, V3, P119, DOI 10.1038/nrmicro1087; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151; YEO KT, 1985, J BIOL CHEM, V260, P7896	54	82	87	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e713	10.1371/journal.pone.0000713	http://dx.doi.org/10.1371/journal.pone.0000713			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684559	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452400016
J	Stoddart, CA; Bales, CA; Bare, JC; Chkhenkeli, G; Galkina, SA; Kinkade, AN; Moreno, ME; Rivera, JM; Ronquillo, RE; Sloan, B; Black, PL				Stoddart, Cheryl A.; Bales, Cheryl A.; Bare, Jennifer C.; Chkhenkeli, George; Galkina, Sofiya A.; Kinkade, April N.; Moreno, Mary E.; Rivera, Jose M.; Ronquillo, Rollie E.; Sloan, Barbara; Black, Paul L.			Validation of the SCID-hu Thy/Liv Mouse Model with Four Classes of Licensed Antiretrovirals	PLOS ONE			English	Article								Background. The SCID-hu Thy/Liv mouse model of HIV-1 infection is a useful platform for the preclinical evaluation of antiviral efficacy in vivo. We performed this study to validate the model with representatives of all four classes of licensed antiretrovirals. Methodology/Principal Findings. Endpoint analyses for quantification of Thy/Liv implant viral load included ELISA for cell-associated p24, branched DNA assay for HIV-1 RNA, and detection of infected thymocytes by intracellular staining for Gag-p24. Antiviral protection from HIV-1-mediated thymocyte depletion was assessed by multicolor flow cytometric analysis of thymocyte subpopulations based on surface expression of CD3, CD4, and CD8. These mice can be productively infected with molecular clones of HIV-1 (e. g., the X4 clone NL4-3) as well as with primary R5 and R5X4 isolates. To determine whether results in this model are concordant with those found in humans, we performed direct comparisons of two drugs in the same class, each of which has known potency and dosing levels in humans. Here we show that second-generation antiretrovirals were, as expected, more potent than their first-generation predecessors: emtricitabine was more potent than lamivudine, efavirenz was more potent than nevirapine, and atazanavir was more potent than indinavir. After interspecies pharmacodynamic scaling, the dose ranges found to inhibit viral replication in the SCID-hu Thy/Liv mouse were similar to those used in humans. Moreover, HIV-1 replication in these mice was genetically stable; treatment of the mice with lamivudine did not result in the M184V substitution in reverse transcriptase, and the multidrug-resistant NY index case HIV-1 retained its drug-resistance substitutions. Conclusion. Given the fidelity of such comparisons, we conclude that this highly reproducible mouse model is likely to predict clinical antiviral efficacy in humans.	[Stoddart, Cheryl A.] Univ Calif San Francisco, Dept Med, Div Expt Med, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; [Black, Paul L.] NIAID, Div Aids, Targeted Intervent Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Stoddart, CA (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.	cheryl.stoddart@ucsf.edu			NIAID, NIH [N01-AI-05418]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005418] Funding Source: NIH RePORTER	NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with Federal funds from NIAID, NIH, under contract no. N01-AI-05418.	ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aldrovandi GM, 1996, J VIROL, V70, P1505, DOI 10.1128/JVI.70.3.1505-1511.1996; ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; Aldrovandi GM, 1998, J VIROL, V72, P7032, DOI 10.1128/JVI.72.9.7032-7039.1998; Amado RG, 1999, J VIROL, V73, P6361, DOI 10.1128/JVI.73.8.6361-6369.1999; Baenziger S, 2006, P NATL ACAD SCI USA, V103, P15951, DOI 10.1073/pnas.0604493103; BAST RC, 2000, CANC MED E 5 ONLINE; Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76; Berkowitz RD, 2000, AIDS RES HUM RETROV, V16, P1039, DOI 10.1089/08892220050075291; Berkowitz RD, 1999, J VIROL, V73, P7817, DOI 10.1128/JVI.73.9.7817-7822.1999; Berkowitz RD, 1998, J IMMUNOL, V161, P3702; Berkowitz RD, 1998, J VIROL, V72, P10108, DOI 10.1128/JVI.72.12.10108-10117.1998; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; Datema R, 1996, ANTIMICROB AGENTS CH, V40, P750, DOI 10.1128/AAC.40.3.750; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; Fenger J, 1999, ENVIRONM POLLUT SER, V1, P3; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06; Greenberg ML, 2004, J ANTIMICROB CHEMOTH, V54, P333, DOI 10.1093/jac/dkh330; JAMIESON BD, 1995, J VIROL, V69, P6259, DOI 10.1128/JVI.69.10.6259-6264.1995; Jamieson BD, 1997, J VIROL, V71, P8245, DOI 10.1128/JVI.71.11.8245-8253.1997; KANESHIMA H, 1991, P NATL ACAD SCI USA, V88, P4523, DOI 10.1073/pnas.88.10.4523; KANESHIMA H, 1994, J VIROL, V68, P8188, DOI 10.1128/JVI.68.12.8188-8192.1994; Keir ME, 2002, J IMMUNOL, V168, P325, DOI 10.4049/jimmunol.168.1.325; Kitchen SG, 1998, AIDS RES HUM RETROV, V14, pS235; Kitchen SG, 1997, J VIROL, V71, P6928, DOI 10.1128/JVI.71.9.6928-6934.1997; Koka PS, 1998, J VIROL, V72, P5121, DOI 10.1128/JVI.72.6.5121-5127.1998; Kovalev G, 1999, J IMMUNOL, V162, P7555; KROWKA JF, 1991, J IMMUNOL, V146, P3751; Manz MG, 2007, IMMUNITY, V26, P537, DOI 10.1016/j.immuni.2007.05.001; Markowitz M, 2005, LANCET, V365, P1031, DOI 10.1016/S0140-6736(05)74227-6; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; McCune JM, 1997, SCIENCE, V278, P2141, DOI 10.1126/science.278.5346.2141; McCutchen D, 1996, EDUC PSYCHOL REV, V8, P187, DOI 10.1007/BF01464072; Miller ED, 2001, J VIROL, V75, P8498, DOI 10.1128/JVI.75.18.8498-8506.2001; MORDENTI J, 1986, J PHARM SCI, V75, P1028, DOI 10.1002/jps.2600751104; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; Rabin L, 1996, ANTIMICROB AGENTS CH, V40, P755, DOI 10.1128/AAC.40.3.755; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; Stoddart CA, 2000, ANTIMICROB AGENTS CH, V44, P783, DOI 10.1128/AAC.44.3.783-786.2000; Stoddart CA, 1998, ANTIMICROB AGENTS CH, V42, P2113, DOI 10.1128/AAC.42.8.2113; Stoddart CA, 2003, J VIROL, V77, P2124, DOI 10.1128/JVI.77.3.2124-2133.2003; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; Su LS, 1997, VIROLOGY, V227, P45, DOI 10.1006/viro.1996.8338; Sun ZF, 2007, J EXP MED, V204, P705, DOI 10.1084/jem.20062411; Valentin A, 1997, J VIROL, V71, P9817, DOI 10.1128/JVI.71.12.9817-9822.1997; WithersWard ES, 1997, NAT MED, V3, P1102, DOI 10.1038/nm1097-1102; YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602; Zhang LG, 2007, BLOOD, V109, P2978, DOI 10.1182/blood-2006-07-033159	56	43	44	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e655	10.1371/journal.pone.0000655	http://dx.doi.org/10.1371/journal.pone.0000655			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668043	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452300001
J	Supp, GG; Schlogl, A; Trujillo-Barreto, N; Muller, MM; Gruber, T				Supp, Gernot G.; Schloegl, Alois; Trujillo-Barreto, Nelson; Mueller, Matthias M.; Gruber, Thomas			Directed Cortical Information Flow during Human Object Recognition: Analyzing Induced EEG Gamma-Band Responses in Brain's Source Space	PLOS ONE			English	Article							REPETITION PRIMING TASK; HIGH-RESOLUTION EEG; FUNCTIONAL CONNECTIVITY; OSCILLATORY SYNCHRONY; NEURONAL MECHANISMS; EVOKED-POTENTIALS; CAUSAL RELATIONS; PARIETAL CORTEX; PHASE SYNCHRONY; NEURAL ACTIVITY	The increase of induced gamma-band responses (iGBRs; oscillations >30 Hz) elicited by familiar (meaningful) objects is well established in electroencephalogram (EEG) research. This frequency-specific change at distinct locations is thought to indicate the dynamic formation of local neuronal assemblies during the activation of cortical object representations. As analytically power increase is just a property of a single location, phase-synchrony was introduced to investigate the formation of large-scale networks between spatially distant brain sites. However, classical phase-synchrony reveals symmetric, pair-wise correlations and is not suited to uncover the directionality of interactions. Here, we investigated the neural mechanism of visual object processing by means of directional coupling analysis going beyond recording sites, but rather assessing the directionality of oscillatory interactions between brain areas directly. This study is the first to identify the directionality of oscillatory brain interactions in source space during human object recognition and suggests that familiar, but not unfamiliar, objects engage widespread reciprocal information flow. Directionality of cortical information-flow was calculated based upon an established Granger-Causality coupling-measure (partial-directed coherence; PDC) using autoregressive modeling. To enable comparison with previous coupling studies lacking directional information, phase-locking analysis was applied, using wavelet-based signal decompositions. Both, autoregressive modeling and wavelet analysis, revealed an augmentation of iGBRs during the presentation of familiar objects relative to unfamiliar controls, which was localized to inferior-temporal, superior-parietal and frontal brain areas by means of distributed source reconstruction. The multivariate analysis of PDC evaluated each possible direction of brain interaction and revealed widespread reciprocal information-transfer during familiar object processing. In contrast, unfamiliar objects entailed a sparse number of only unidirectional connections converging to parietal areas. Considering the directionality of brain interactions, the current results might indicate that successful activation of object representations is realized through reciprocal (feed-forward and feed-backward) information-transfer of oscillatory connections between distant, functionally specific brain areas.	[Mueller, Matthias M.; Gruber, Thomas] Univ Leipzig, Inst Psychol 1, Leipzig, Germany; [Supp, Gernot G.] Univ Hamburg, Dept Neurophysiol & Pathophysiol, Ctr Med Expt, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Supp, Gernot G.] Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany; [Schloegl, Alois] Graz Univ Technol, Inst Human Comp Interfaces, A-8010 Graz, Austria; [Schloegl, Alois] Inst Comp Architecture & Software Technol, Fraunhofer Inst FIRST, Intelligent Data Anal Grp, Berlin, Germany; [Trujillo-Barreto, Nelson] Cuban Neurosci Ctr, Havana, Cuba	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; Graz University of Technology; Fraunhofer Gesellschaft	Gruber, T (corresponding author), Univ Leipzig, Inst Psychol 1, Leipzig, Germany.	gruber@rz.uni-leipzig.de	Trujillo-Barreto, Nelson J/G-3764-2013	Trujillo-Barreto, Nelson J/0000-0001-6581-7503; Schlogl, Alois/0000-0002-5621-8100	Max Planck Society; Deutsche-Forschungsgemeinschaft (DFG)	Max Planck Society(Max Planck SocietyFoundation CELLEX); Deutsche-Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was in part supported by a Post-Doctoral Fellowship of the Max Planck Society to G. S. and by a grant of the Deutsche-Forschungsgemeinschaft (DFG).	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Astolfi L, 2005, CLIN NEUROPHYSIOL, V116, P920, DOI 10.1016/j.clinph.2004.10.012; Astolfi L, 2007, HUM BRAIN MAPP, V28, P143, DOI 10.1002/hbm.20263; Astolfi L, 2006, IEEE T BIO-MED ENG, V53, P1802, DOI 10.1109/TBME.2006.873692; Babiloni F, 2005, NEUROIMAGE, V24, P118, DOI 10.1016/j.neuroimage.2004.09.036; Baccala L A, 2001, Prog Brain Res, V130, P33; Baccala LA, 2001, BIOL CYBERN, V84, P463, DOI 10.1007/PL00007990; Baccala LA, 2006, BIOL CYBERN, V95, P135, DOI 10.1007/s00422-006-0075-7; Bar M, 2003, NEURON, V38, P347, DOI 10.1016/S0896-6273(03)00167-3; Bar M, 2004, NAT REV NEUROSCI, V5, P617, DOI 10.1038/nrn1476; Bertrand O, 2000, INT J PSYCHOPHYSIOL, V38, P211, DOI 10.1016/S0167-8760(00)00166-5; BERTRAND O, 1994, NATO ADV SCI INST SE, V271, P231; Blinowska KJ, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.050902; Bosch-Bayard J, 2001, CLIN ELECTROENCEPHAL, V32, P47, DOI 10.1177/155005940103200203; Bressler SL, 2001, TRENDS COGN SCI, V5, P26, DOI 10.1016/S1364-6613(00)01564-3; Brovelli A, 2004, P NATL ACAD SCI USA, V101, P9849, DOI 10.1073/pnas.0308538101; Brovelli A, 2005, NEUROIMAGE, V28, P154, DOI 10.1016/j.neuroimage.2005.05.045; Busch NA, 2006, NEUROIMAGE, V33, P1169, DOI 10.1016/j.neuroimage.2006.07.034; COOPER R, 1965, ELECTROEN CLIN NEURO, V18, P217, DOI 10.1016/0013-4694(65)90088-X; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; David O, 2004, NEUROIMAGE, V21, P659, DOI 10.1016/j.neuroimage.2003.10.006; Ding MZ, 2000, BIOL CYBERN, V83, P35, DOI 10.1007/s004229900137; Eckhorn R, 1990, NEURAL COMPUT, V2, P293, DOI 10.1162/neco.1990.2.3.293; EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.1093/biomet/68.3.589; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Engel AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0; EVANS AC, 1993, STAT NEUROANATOMICAL; Fenske MJ, 2006, PROG BRAIN RES, V155, P3, DOI 10.1016/S0079-6123(06)55001-0; Fiebach CJ, 2005, J NEUROSCI, V25, P3414, DOI 10.1523/JNEUROSCI.4107-04.2005; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Fuster JM, 1997, TRENDS NEUROSCI, V20, P451, DOI 10.1016/S0166-2236(97)01128-4; Fuster JM, 2006, INT J PSYCHOPHYSIOL, V60, P125, DOI 10.1016/j.ijpsycho.2005.12.015; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; Gross J, 2004, P NATL ACAD SCI USA, V101, P13050, DOI 10.1073/pnas.0404944101; Gross J, 2001, P NATL ACAD SCI USA, V98, P694, DOI 10.1073/pnas.98.2.694; Gruber T, 1999, CLIN NEUROPHYSIOL, V110, P2074, DOI 10.1016/S1388-2457(99)00176-5; Gruber T, 2006, NEUROIMAGE, V29, P888, DOI 10.1016/j.neuroimage.2005.09.004; Gruber T, 2005, CEREB CORTEX, V15, P109, DOI 10.1093/cercor/bhh113; Gruber T, 2004, EUR J NEUROSCI, V19, P1073, DOI 10.1111/j.0953-816X.2004.03176.x; Gruber T, 2002, J COGNITIVE NEUROSCI, V14, P732, DOI 10.1162/08989290260138636; Gruber T, 2002, COGNITIVE BRAIN RES, V13, P377, DOI 10.1016/S0926-6410(01)00130-6; Gruber T, 2006, EUR J NEUROSCI, V24, P2654, DOI 10.1111/j.1460-9568.2006.05130.x; Gruber T, 2006, BRAIN RES, V1097, P194, DOI 10.1016/j.brainres.2006.04.069; JENSEN O, TRENDS NEUR IN PRESS; Jerbi K, 2007, P NATL ACAD SCI USA, V104, P7676, DOI 10.1073/pnas.0609632104; Junghofer M, 2000, PSYCHOPHYSIOLOGY, V37, P523, DOI 10.1111/1469-8986.3740523; Kaiser J, 2003, NEUROSCIENTIST, V9, P475, DOI 10.1177/1073858403259137; Kaminski M, 2001, BIOL CYBERN, V85, P145, DOI 10.1007/s004220000235; Kaminski M, 1997, ELECTROEN CLIN NEURO, V102, P216, DOI 10.1016/S0013-4694(96)95721-5; Keil A, 2001, NEUROSCI BIOBEHAV R, V25, P527, DOI 10.1016/S0149-7634(01)00031-8; Konig P, 2006, BIOL CYBERN, V94, P325, DOI [10.1007/s00422-006-0050-3, 10.1007/S00422-006-0050-3]; Kus R, 2004, IEEE T BIO-MED ENG, V51, P1501, DOI 10.1109/TBME.2004.827929; Lachaux JP, 2006, NEUROIMAGE, V30, P1302, DOI 10.1016/j.neuroimage.2005.11.023; Lachaux JP, 2003, J PHYSIOLOGY-PARIS, V97, P613, DOI 10.1016/j.jphysparis.2004.01.018; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Mainy N, 2007, HUM BRAIN MAPP, V28, P183, DOI 10.1002/hbm.20264; Martinovic J, 2007, J COGNITIVE NEUROSCI, V19, P921, DOI 10.1162/jocn.2007.19.6.921; Melloni L, 2007, J NEUROSCI, V27, P2858, DOI 10.1523/JNEUROSCI.4623-06.2007; Muller MM, 2004, J COGNITIVE NEUROSCI, V16, P503, DOI 10.1162/089892904322926827; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; PEISSIG JJ, 2006, ANN REV PSYCHOL; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Pfurtscheller G, 1999, J CLIN NEUROPHYSIOL, V16, P512, DOI 10.1097/00004691-199911000-00003; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; Salazar RF, 2004, EUR J NEUROSCI, V20, P1391, DOI 10.1111/j.1460-9568.2004.03579.x; Sameshima K, 1999, J NEUROSCI METH, V94, P93, DOI 10.1016/S0165-0270(99)00128-4; Schlogl A, 2006, PROG BRAIN RES, V159, P135, DOI 10.1016/S0079-6123(06)59009-0; Schlogl A, 2006, SIGNAL PROCESS, V86, P2426, DOI 10.1016/j.sigpro.2005.11.007; SCHLOGL A, 2007, BIOSIG PROJECT; Schneider T, 2001, ACM T MATH SOFTWARE, V27, P58, DOI 10.1145/382043.382316; Schnitzler M, 2005, INT REV NEUROBIOL, V68, P173, DOI 10.1016/S0074-7742(05)68007-5; Shafritz KM, 2002, P NATL ACAD SCI USA, V99, P10917, DOI 10.1073/pnas.152694799; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; Snijders Tom A. B., 1999, CONNECTIONS, V22, P161; Sporns O, 2002, BEHAV BRAIN RES, V135, P69, DOI 10.1016/S0166-4328(02)00157-2; Supp GG, 2005, EUR J NEUROSCI, V21, P1139, DOI 10.1111/j.1460-9568.2005.03906.x; Supp GG, 2004, NEUROREPORT, V15, P1209, DOI 10.1097/00001756-200405190-00026; Tallon-Baudry C, 2003, J PHYSIOL-PARIS, V97, P355, DOI 10.1016/j.jphysparis.2003.09.009; Tallon-Baudry C, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-20-j0008.2001; Tallon-Baudry C, 1999, TRENDS COGN SCI, V3, P151, DOI 10.1016/S1364-6613(99)01299-1; TallonBaudry C, 1996, J NEUROSCI, V16, P4240; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; Treisman A, 1998, PHILOS T ROY SOC B, V353, P1295, DOI 10.1098/rstb.1998.0284; Trujillo-Barreto NJ, 2004, NEUROIMAGE, V21, P1300, DOI 10.1016/j.neuroimage.2003.11.008; Uhlhaas PJ, 2006, J NEUROSCI, V26, P8168, DOI 10.1523/JNEUROSCI.2002-06.2006; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P74, DOI 10.1002/(SICI)1097-0193(1996)4:1<74::AID-HBM5>3.0.CO;2-M; Wright JJ, 1996, BEHAV BRAIN SCI, V19, P285, DOI 10.1017/S0140525X00042679; ZETTERBERG L H, 1969, Mathematical Biosciences, V5, P227, DOI 10.1016/0025-5564(69)90044-3; ZIONGOLUMBIC E, 2006, CEREB CORTEX	96	106	110	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e684	10.1371/journal.pone.0000684	http://dx.doi.org/10.1371/journal.pone.0000684			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668062	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452300020
J	Lucas, M; Ulsenheimer, A; Pfafferot, K; Heeg, MHJ; Gaudieri, S; Gruner, N; Rauch, A; Gerlach, JT; Jung, MC; Zachoval, R; Pape, GR; Schraut, W; Santantonio, T; Nitschko, H; Obermeier, M; Phillips, R; Scriba, TJ; Semmo, N; Day, C; Weber, JN; Fidler, S; Thimme, R; Haberstroh, A; Baumert, TF; Klenerman, P; Diepolder, HM				Lucas, Michaela; Ulsenheimer, Axel; Pfafferot, Katja; Heeg, Malte H. J.; Gaudieri, Silvana; Gruener, Norbert; Rauch, Andri; Gerlach, J. Tilman; Jung, Maria-Christina; Zachoval, Reinhart; Pape, Gerd R.; Schraut, Winfried; Santantonio, Teresa; Nitschko, Hans; Obermeier, Martin; Phillips, Rodney; Scriba, Thomas J.; Semmo, Nasser; Day, Cheryl; Weber, Jonathan N.; Fidler, Sarah; Thimme, Robert; Haberstroh, Anita; Baumert, Thomas F.; Klenerman, Paul; Diepolder, Helmut M.			Tracking Virus-Specific CD4+T Cells during and after Acute Hepatitis C Virus Infection	PLOS ONE			English	Article								Background. CD4+ T cell help is critical in maintaining antiviral immune responses and such help has been shown to be sustained in acute resolving hepatitis C. In contrast, in evolving chronic hepatitis C CD4+ T cell helper responses appear to be absent or short-lived, using functional assays. Methodology/Principal Findings. Here we used a novel HLA-DR1 tetramer containing a highly targeted CD4+ T cell epitope from the hepatitis C virus non-structural protein 4 to track number and phenotype of hepatitis C virus specific CD4+ T cells in a cohort of seven HLA-DR1 positive patients with acute hepatitis C in comparison to patients with chronic or resolved hepatitis C. We observed peptide-specific T cells in all seven patients with acute hepatitis C regardless of outcome at frequencies up to 0.65% of CD4+ T cells. Among patients who transiently controlled virus replication we observed loss of function, and/or physical deletion of tetramer+ CD4+ T cells before viral recrudescence. In some patients with chronic hepatitis C very low numbers of tetramer+ cells were detectable in peripheral blood, compared to robust responses detected in spontaneous resolvers. Importantly we did not observe escape mutations in this key CD4+ T cell epitope in patients with evolving chronic hepatitis C. Conclusions/Significance. During acute hepatitis C a CD4+ T cell response against this epitope is readily induced in most, if not all, HLA-DR1+ patients. This antiviral T cell population becomes functionally impaired or is deleted early in the course of disease in those where viremia persists.	[Ulsenheimer, Axel; Heeg, Malte H. J.; Gruener, Norbert; Gerlach, J. Tilman; Jung, Maria-Christina; Zachoval, Reinhart; Pape, Gerd R.; Schraut, Winfried; Diepolder, Helmut M.] Univ Munich, Dept Med 2, Munich, Germany; [Ulsenheimer, Axel; Heeg, Malte H. J.; Gruener, Norbert; Gerlach, J. Tilman; Jung, Maria-Christina; Zachoval, Reinhart; Pape, Gerd R.; Schraut, Winfried; Diepolder, Helmut M.] Univ Munich, Inst Immunol, D-8000 Munich, Germany; [Lucas, Michaela; Phillips, Rodney; Scriba, Thomas J.; Semmo, Nasser; Day, Cheryl; Klenerman, Paul] Univ Oxford, Nuffield Dept Clin Med, Peter Medawar Bldg Pathogen Res, Oxford, England; [Lucas, Michaela; Pfafferot, Katja; Gaudieri, Silvana; Rauch, Andri] Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia; [Lucas, Michaela; Pfafferot, Katja; Gaudieri, Silvana; Rauch, Andri] Murdoch Univ, Perth, WA, Australia; [Gaudieri, Silvana] Univ Western Australia, Ctr Forens Sci, Sch Anat & Human Biol, Nedlands, WA 6009, Australia; [Rauch, Andri] Univ Hosp, Div Infect Dis, Bern, Switzerland; [Santantonio, Teresa] Univ Bari, Clin Malattie Infett, Bari, Italy; [Nitschko, Hans; Obermeier, Martin] Univ Munich, Max Von Pettenkofer Inst, Dept Virol, Munich, Germany; [Weber, Jonathan N.; Fidler, Sarah] Univ London Imperial Coll Sci Technol & Med, Dept Med, St Marys Hosp, London, England; [Thimme, Robert; Haberstroh, Anita] Univ Freiburg, Freiburg, Germany; [Baumert, Thomas F.] Univ Strasbourg 1, INSERM, U748, Strasbourg, France	University of Munich; University of Munich; University of Oxford; Royal Perth Hospital; University of Western Australia; Murdoch University; University of Western Australia; University of Bern; University Hospital of Bern; Universita degli Studi di Bari Aldo Moro; University of Munich; Imperial College London; University of Freiburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Diepolder, HM (corresponding author), Univ Munich, Dept Med 2, Munich, Germany.	hdiepold@med.uni-muenchen.de	Day, Cheryl L/J-9844-2012; Day, Cheryl/GQQ-9720-2022; Scriba, Thomas/AAH-9413-2020; Baumert, Thomas/ABF-4718-2020; Rauch, Andri/E-9948-2017; Scriba, Thomas/H-3633-2013; Scriba, Thomas/GPX-2573-2022	Day, Cheryl L/0000-0002-6497-4846; Baumert, Thomas/0000-0002-8864-2168; Rauch, Andri/0000-0001-5297-6062; Scriba, Thomas/0000-0002-0641-1359; Lucas, Michaela/0000-0001-8881-9990; , Silvana/0000-0001-6873-0198; klenerman, paul/0000-0003-4307-9161	Wellcome Trust; James Martin School of the 21st Century, Oxford; Kompetenznetz Hepatitis HepNet [10.2.1]; Priority 1 "Life Sciences, Genomics and Biotechnology for Health" programme in the 6th Framework Programme of the EU [LSHM-CT-2004-503359]	Wellcome Trust(Wellcome TrustEuropean Commission); James Martin School of the 21st Century, Oxford; Kompetenznetz Hepatitis HepNet; Priority 1 "Life Sciences, Genomics and Biotechnology for Health" programme in the 6th Framework Programme of the EU	Funding: This work was supported by funding from the Wellcome Trust, the James Martin School of the 21st Century, Oxford and the Kompetenznetz Hepatitis HepNet (Teilprojekt 10.2.1). This work is part of the activities of the VIRGIL European Network of Excellence on Antiviral Drug Resistance supported by a grant (LSHM-CT-2004-503359) from the Priority 1 "Life Sciences, Genomics and Biotechnology for Health" programme in the 6th Framework Programme of the EU.	Butt Adeel A, 2005, Expert Rev Anti Infect Ther, V3, P241, DOI 10.1586/14787210.3.2.241; Cox AL, 2005, J EXP MED, V201, P1741, DOI 10.1084/jem.20050121; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Gerlach JT, 2005, J VIROL, V79, P12425, DOI 10.1128/JVI.79.19.12425-12433.2005; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Kasprowicz V, 2006, J VIROL, V80, P11209, DOI 10.1128/JVI.01173-06; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lucas M, 2004, J VIROL, V78, P7284, DOI 10.1128/JVI.78.13.7284-7287.2004; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; Neumann-Haefelin C, 2006, HEPATOLOGY, V43, P563, DOI 10.1002/hep.21049; Scriba TJ, 2005, J IMMUNOL, V175, P6334, DOI 10.4049/jimmunol.175.10.6334; Scriba TJ, 2005, J CLIN INVEST, V115, P443, DOI 10.1172/JCI200523084; Seth N, 2005, J IMMUNOL, V175, P6948, DOI 10.4049/jimmunol.175.10.6948; Spangenberg HC, 2005, HEPATOLOGY, V42, P828, DOI 10.1002/hep.20856; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; Timm J, 2004, J EXP MED, V200, P1593, DOI 10.1084/jem.20041006; Ulsenheimer A, 2006, J VIRAL HEPATITIS, V13, P708, DOI 10.1111/j.1365-2893.2006.00747.x; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; Witt CS, 2002, TISSUE ANTIGENS, V60, P474, DOI 10.1034/j.1399-0039.2002.600602.x; zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603	24	61	62	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e649	10.1371/journal.pone.0000649	http://dx.doi.org/10.1371/journal.pone.0000649			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653276	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200018
J	Beppu, H; Mwizerwa, ON; Beppu, Y; Dattwyler, MP; Lauwers, GY; Bloch, KD; Goldstein, AM				Beppu, H.; Mwizerwa, O. N.; Beppu, Y.; Dattwyler, M. P.; Lauwers, G. Y.; Bloch, K. D.; Goldstein, A. M.			Stromal inactivation of BMPRII leads to colorectal epithelial overgrowth and polyp formation	ONCOGENE			English	Article						bone morphogenetic proteins; BMPRII; nestin hamartomatous polyps; colorectal polyps; stromal-epithelial interactions	JUVENILE POLYPOSIS; CELLS; MYOFIBROBLASTS; SUPPRESSION; FIBROBLASTS; MUTATIONS; SIGNALS; GENE	Stromal - epithelial interactions play a central role in development and tumorigenesis. Bone morphogenetic protein ( BMP) signaling in the intestine is involved in both of these processes. Inactivation of BMP pathway genes in the epithelium is known to cause intestinal polyposis. However, the role of the intestinal stroma in polyp initiation is incompletely understood. We observed that conditional inactivation of the BMP type II receptor ( BMPRII) in the stroma leads to epithelial hyperplasia throughout the colon with increased epithelial cell proliferation. Mutant mice developed rectal bleeding and hamartomatous polyps in the colorectum. The polyps demonstrated increased proliferation of epithelial and mesenchymal cells in the mucosa with an expansion of the myofibroblast cell population. These results demonstrate that genetic mutations altering the BMP signaling pathway in the stromal microenvironment can lead to epithelial tumors in the colon.	[Mwizerwa, O. N.; Goldstein, A. M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; [Beppu, H.; Beppu, Y.; Dattwyler, M. P.; Bloch, K. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Lauwers, G. Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Goldstein, AM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, 55 Fruit St,Warren 1153, Boston, MA 02114 USA.	agoldstein@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL074352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adegboyega PA, 2002, ARCH PATHOL LAB MED, V126, P829; Batts LE, 2006, DEV DYNAM, V235, P1563, DOI 10.1002/dvdy.20741; Beppu H, 2005, GENESIS, V41, P133, DOI 10.1002/gene.20099; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chen AL, 2005, SURGERY, V138, P382, DOI 10.1016/j.surg.2005.04.012; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Hogan B, 1994, MANIPULATING MOUSE E; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; LIU D, IN PRESS BLOOD; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; van den Brink GR, 2004, NAT GENET, V36, P1038, DOI 10.1038/ng1004-1038; Wirtzfeld DA, 2001, ANN SURG ONCOL, V8, P319, DOI 10.1245/aso.2001.8.4.319	26	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1063	1070		10.1038/sj.onc.1210720	http://dx.doi.org/10.1038/sj.onc.1210720			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700526				2022-12-25	WOS:000253136700005
J	Faucherre, A; Taylor, GS; Overvoorde, J; Dixon, JE; den Hertog, J				Faucherre, A.; Taylor, G. S.; Overvoorde, J.; Dixon, J. E.; den Hertog, J.			Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development	ONCOGENE			English	Article						pten; zebrafish; tumorigenesis; development; proliferation; survival	LIPID PHOSPHATASE-ACTIVITY; LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE B; SIGNALING PATHWAY; NEGATIVE REGULATION; GERMLINE MUTATIONS; CELL-SURVIVAL; CANCER-CELLS; PTEN/MMAC1	In human cancer, PTEN ( Phosphatase and TENsin homolog on chromosome 10, also referred to as MMAC1 and TEP1) is a frequently mutated tumor suppressor gene. We have used the zebrafish as a model to investigate the role of Pten in embryonic development and tumorigenesis. The zebrafish genome encodes two pten genes, ptena and ptenb. Here, we report that both Pten gene products from zebrafish are functional. Target-selected inactivation of ptena and ptenb revealed that Ptena and Ptenb have redundant functions in embryonic development, in that ptena-/- and ptenb-/- mutants did not show embryonic phenotypes. Homozygous single mutants survived as adults and they were viable and fertile. Double homozygous ptena-/- ptenb-/- mutants died at 5 days post fertilization with pleiotropic defects. These defects were rescued by treatment with the phosphatidylinositol-3-kinase inhibitor, LY294002. Double homozygous embryos showed enhanced cellular proliferation. In addition, cell survival was dramatically enhanced in embryos that lack functional Pten upon gamma-irradiation. Surprisingly, adult ptenb-/- zebrafish developed ocular tumors later in life, despite the expression of ptena in adult eyes. We conclude that whereas Ptena and Ptenb have redundant functions in embryonic development, they apparently do not have completely overlapping functions later in life. These pten mutant zebrafish represent a unique model to screen for genetic and/ or chemical suppressors of Pten loss-of-function.	[Faucherre, A.; Overvoorde, J.; den Hertog, J.] Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	j.denhertog@niob.knaw.nl		Faucherre, Adele/0000-0002-6099-3898				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Croushore JA, 2005, DEV DYNAM, V234, P911, DOI 10.1002/dvdy.20576; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marcus RC, 1999, VISUAL NEUROSCI, V16, P417, DOI 10.1017/S095252389916303X; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Westerfield M., 1995, GUIDE LAB USE ZEBRAF; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Wu ZX, 2007, TUMOR BIOL, V28, P9, DOI 10.1159/000097041; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382	32	86	89	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1079	1086		10.1038/sj.onc.1210730	http://dx.doi.org/10.1038/sj.onc.1210730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704803				2022-12-25	WOS:000253136700007
J	Tam, J; Trembovler, V; Di Marzo, V; Petrosino, S; Leo, G; Alexandrovich, A; Regev, E; Casap, N; Shteyer, A; Ledent, C; Karsak, M; Zimmer, A; Mechoulam, R; Yirmiya, R; Shohami, E; Bab, I				Tam, Joseph; Trembovler, Victoria; Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella; Alexandrovich, Alex; Regev, Eran; Casap, Nardy; Shteyer, Arie; Ledent, Catherine; Karsak, Meliha; Zimmer, Andreas; Mechoulam, Raphael; Yirmiya, Raz; Shohami, Esther; Bab, Itai			The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling	FASEB JOURNAL			English	Article						2-arachidonoylglycerol; norepinephrine; sympathetic nervous system; traumatic brain injury	SYMPATHETIC-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; NORADRENALINE RELEASE; MEDIATED INHIBITION; VAS-DEFERENS; ANANDAMIDE; MICE; PATHOGENESIS; PROTEIN	We have recently reported that in bone the cannabinoid CB1 receptor is present in sympathetic terminals. Here we show that traumatic brain injury (TBI), which in humans enhances peripheral osteogenesis and fracture healing, acutely stimulates bone formation in a distant skeletal site. At this site we demonstrate i) a high level of the main endocannabinoid, 2-arachidonoylglycerol (2-AG), and expression of diacylglycerol lipases, enzymes essential for 2-AG synthesis; ii) that the TBI-induced increase in bone formation is preceded by elevation of the 2-AG and a decrease in norepinephrine (NE) levels. The TBI stimulation of bone formation was absent in CB1-null mice. In wild-type animals it could be mimicked, including the suppression of NE levels, by 2-AG administration. The TBI- and 2-AG-induced stimulation of osteogenesis was restrained by the beta-adrenergic receptor agonist isoproterenol. NE from sympathetic terminals is known to tonically inhibit bone formation by activating osteoblastic beta 2- adrenergic receptors. The present findings further demonstrate that the sympathetic control of bone formation is regulated through 2-AG activation of prejunctional CB1. Elevation of bone 2-AG apparently suppresses NE release from bone sympathetic terminals, thus alleviating the inhibition of bone formation. The involvement of osteoblastic CB2 signaling in this process is minimal, if any.	[Tam, Joseph; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; [Trembovler, Victoria; Alexandrovich, Alex] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Regev, Eran; Casap, Nardy; Shteyer, Arie] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral & Maxillofacial Surg, IL-91120 Jerusalem, Israel; [Mechoulam, Raphael] Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; [Yirmiya, Raz] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella] Inst Biomol Chem, Consiglio Nazl Ric, Endocannabinoid Res Grp, Pozzilli, Italy; [Petrosino, Stefania] Univ Salerno, Dipartimento Sci Farmaceut, Fisciano, Italy; [Ledent, Catherine] Univ Libre Bruxelles, Inst Rech Interdisciplinaire & Biol Humaine & Mol, Brussels, Belgium; [Karsak, Meliha; Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Consiglio Nazionale delle Ricerche (CNR); University of Salerno; Universite Libre de Bruxelles; University of Bonn	Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il	Di Marzo, Vincenzo/AAD-7742-2019; Yirmiya, Raz/D-1090-2014; Zimmer, Andreas/B-8357-2009	Di Marzo, Vincenzo/0000-0002-1490-3070; Yirmiya, Raz/0000-0002-4009-7316; Tam, Joseph/0000-0002-0948-0093; Karsak, Meliha/0000-0001-6612-6317				Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Contractor A, 2003, J NEUROSCI, V23, P422, DOI 10.1523/JNEUROSCI.23-02-00422.2003; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; FRIED A, 1993, J CELL PHYSIOL, V155, P472, DOI 10.1002/jcp.1041550306; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Malinowska B, 1997, N-S ARCH PHARMACOL, V356, P197, DOI 10.1007/PL00005041; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Monteleone P, 2005, NEUROPSYCHOPHARMACOL, V30, P1216, DOI 10.1038/sj.npp.1300695; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Niederhoffer N, 2003, N-S ARCH PHARMACOL, V367, P434, DOI 10.1007/s00210-003-0755-y; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Rhee MH, 1997, J MED CHEM, V40, P3228, DOI 10.1021/jm970126f; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Rouzer CA, 2002, CHEM PHYS LIPIDS, V119, P69, DOI 10.1016/S0009-3084(02)00068-3; Schlicker E, 2003, BRIT J PHARMACOL, V140, P323, DOI 10.1038/sj.bjp.0705449; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Szabo B, 2005, HANDB EXP PHARMACOL, V168, P327; Szabo B, 2001, J PHARMACOL EXP THER, V297, P819; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435; Vizi ES, 2001, EUR J PHARMACOL, V431, P237, DOI 10.1016/S0014-2999(01)01413-3; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Yao M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P319; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	57	137	147	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					285	294		10.1096/fj.06-7957com	http://dx.doi.org/10.1096/fj.06-7957com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17704191				2022-12-25	WOS:000252309900030
J	Li, X; Liu, H; Qin, L; Tamasi, J; Bergenstock, M; Shapses, S; Feyen, JHM; Notterman, DA; Partridge, NC				Li, Xin; Liu, Hao; Qin, Ling; Tamasi, Joseph; Bergenstock, Marika; Shapses, Sue; Feyen, Jean H. M.; Notterman, Daniel A.; Partridge, Nicola C.			Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; TRABECULAR BONE; RECEPTOR; CELLS; PTH; OSTEOBLASTS; FRAGMENT; FAMILY; HISTOMORPHOMETRY; OSTEOPOROSIS	Parathyroid hormone ( PTH) stimulates bone formation when injected daily but causes severe bone loss with continuous infusion. The mechanism of its paradoxical effects is still elusive. In this study, we compared changes in the gene expression profile in bone induced by intermittent or continuous treatment with three different PTH peptides, PTH-(1-34), -(1-31), and -(3-34), in Sprague-Dawley female rats. PTH-( 1 - 34) regulated numerous genes (similar to 1,000), but differentially, in both regimes. PTH-( 1 - 31) regulated a similar number of genes in the intermittent regimen but fewer in the continuous regimen, consistent with its less potent catabolic effect. PTH-( 3 - 34) regulated very few genes in both regimes, which suggests the protein kinase C pathway plays a limited role in mediating the dual effects of PTH, whereas the cAMP-ependent protein kinase A pathway appears to predominate. In the intermittent treatment, many genes encoding signaling mediators, transcription factors, cytokines, and proteases/ protease inhibitors are regulated rapidly and cyclically with each PTH injection; genes associated with skeletal development show a slowly accruing pattern of expression. With continuous treatment, some genes are regulated from 6 h, and the mRNA levels are sustained with a longer infusion, whereas others show a kinetic decrease and then increase later. Significant up-regulation of genes stimulating osteoclastogenesis in the anabolic regime suggests a provocative and paradoxical theme for the anabolic effect of PTH that a full anabolic response requires a transient up-regulation of genes classically associated with a resorptive response. Ingenuity pathway analysis was performed on the microarray data. A novel signaling network was established that is differentially regulated in the two PTH treatment regimes. Key regulators are suggested to be AREG, CCL2, WNT4, and cAMP-responsive element modulator.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Core Express Facil Canc Inst New Jersey, Dept Pediat, New Brunswick, NJ 08901 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat Mol Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Bristol-Myers Squibb; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln,Res Tower 561, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Shapses, Sue/0000-0002-3128-2325; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brauner-Osborne H, 2001, BBA-GENE STRUCT EXPR, V1518, P237, DOI 10.1016/S0167-4781(01)00197-X; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353; CIVITELLI R, 1994, J BONE MINER RES, V9, P1407; Eriksen EF, 2002, J BONE MINER RES, V17, pN95; Fraher LJ, 1999, J CLIN ENDOCR METAB, V84, P2739, DOI 10.1210/jc.84.8.2739; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gay CV, 2000, CRIT REV EUKAR GENE, V10, P213; Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683; Gunness M. E., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P321; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; Inoue S, 2004, J INVEST DERMATOL, V122, P565, DOI 10.1046/j.0022-202X.2004.12628.x; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200; Li XQ, 2005, J BIOL CHEM, V280, P38317, DOI 10.1074/jbc.M505853200; Marks Sandy C. Jr., 1996, P3; Mayburd AL, 2006, CLIN CANCER RES, V12, P1820, DOI 10.1158/1078-0432.CCR-05-2149; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349; Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003-0024; Nagel DE, 2004, J CELL BIOCHEM, V93, P1107, DOI 10.1002/jcb.20249; Onyia JE, 2005, J CELL BIOCHEM, V95, P403, DOI 10.1002/jcb.20438; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood-2004-12-4940; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Robbins MJ, 2002, MOL BRAIN RES, V106, P136, DOI 10.1016/S0169-328X(02)00420-5; ROSENBLATT, 1981, CALCIF TISSUE INT, V33, P153; Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330; Satoh W, 2006, DEVELOPMENT, V133, P989, DOI 10.1242/dev.02274; Slegtenhorst-Eegdeman KE, 1998, MOL HUM REPROD, V4, P649, DOI 10.1093/molehr/4.7.649; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF792, DOI 10.1152/ajprenal.2000.278.5.F792; Tsingotjidou A, 2002, BONE, V30, P677, DOI 10.1016/S8756-3282(02)00698-1; Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001; von Stechow D, 2004, J CELL BIOCHEM, V93, P476, DOI 10.1002/jcb.20174; Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021; YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275	42	136	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					33086	33097		10.1074/jbc.M705194200	http://dx.doi.org/10.1074/jbc.M705194200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17690103	hybrid			2022-12-25	WOS:000250625400057
J	Shenoy, SK; Barak, LS; Xiao, KH; Ahn, S; Berthouze, M; Shukla, AK; Luttrell, LM; Lefkowitz, RJ				Shenoy, Sudha K.; Barak, Larry S.; Xiao, Kunhong; Ahn, Seungkirl; Berthouze, Magali; Shukla, Arun K.; Luttrell, Louis M.; Lefkowitz, Robert J.			Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; DEPENDENT ENDOCYTOSIS; CLATHRIN ADAPTER; VISUAL ARRESTIN; CELL; BETA-ARRESTIN2; KINASE; MONOUBIQUITINATION	beta-Arrestin2 and its ubiquitination play crucial roles in both internalization and signaling of seven-transmembrane receptors (7TMRs). To understand the connection between ubiquitination and the endocytic and signaling functions of beta-arrestin, we generated a beta-arrestin2 mutant that is defective in ubiquitination (beta-arrestin2(OK)), by mutating all of the ubiquitin acceptor lysines to arginines and compared its properties with the wild type and a stably ubiquitinated beta-arrestin2-ubiquitin (Ub) chimera. In vitro translated beta-arrestin2 and beta-arrestin2(OK) displayed equivalent binding to recombinant beta(2)-adrenergic receptor (beta(2)AR) reconstituted in vesicles, whereas beta-arrestin2-Ub bound similar to 4-fold more. In cellular coimmunoprecipitation assays, beta-arrestin2(OK) bound nonreceptor partners, such as AP-2 and c-Raf and scaffolded phosphorylated ERK robustly but displayed weak binding to clathrin. Moreover, beta-arrestin2(OK) was recruited only transiently to activated receptors at the membrane, did not enhance receptor internalization, and decreased the amount of phosphorylated ERK assimilated into isolated beta(2)AR complexes. Although the wild type beta-arrestin2 formed ERK signaling complexes with the beta(2)AR at the membrane, a stably ubiquitinated beta-arrestin2-Ub chimera not only stabilized the ERK signalosomes but also led to their endosomal targeting. Interestingly, in cellular fractionation assays, the ubiquitination state of beta-arrestin2 favors its distribution in membrane fractions, suggesting that ubiquitination increases the propensity of beta-arrestin for membrane association. Our findings suggest that although beta-arrestin ubiquitination is dispensable for beta-arrestin cytosol to membrane translocation and its "constitutive" interactions with some cytosolic proteins, it nevertheless is a prerequisite both for the formation of tight complexes with 7TMRs in vivo and for membrane compartment interactions that are crucial for downstream endocytic and signaling processes.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Med Univ S Carolina, Dept Med Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Shenoy, SK (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	sudha@receptor-biol.duke.edu	Shenoy, Sudha/AAN-4075-2021; Lefkowitz, Robert/AAW-2649-2021; Xiao, Kunhong/AAG-4275-2020	Shenoy, Sudha/0000-0002-2565-4663; Xiao, Kunhong/0000-0002-1069-1226; Luttrell, Louis/0000-0003-2805-6949; shukla, arun/0000-0003-2910-8288	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080525, R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, R56DK055524] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037, R01 HL016037, R01 HL080525, HL080525, R01 HL080525-02] Funding Source: Medline; NIDDK NIH HHS [R56 DK055524, DK55524, R01 DK055524] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2007, ANNU REV PHYSIOL, V69, P535, DOI 10.1146/annurev.physiol.69.022405.154804; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Jafri F, 2006, J BIOL CHEM, V281, P19346, DOI 10.1074/jbc.M512643200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Milano SK, 2006, J BIOL CHEM, V281, P9812, DOI 10.1074/jbc.M512703200; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Scott MGH, 2006, MOL CELL BIOL, V26, P3432, DOI 10.1128/MCB.26.9.3432-3445.2006; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shenoy SK, 2007, CIRC RES, V100, P1142, DOI 10.1161/01.RES.0000261939.88744.5a; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700	45	98	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29549	29562		10.1074/jbc.M700852200	http://dx.doi.org/10.1074/jbc.M700852200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17666399	Green Accepted, hybrid			2022-12-25	WOS:000249788000052
J	Todi, SV; Laco, MN; Winborn, BJ; Travis, SM; Wen, HM; Paulson, HL				Todi, Sokol V.; Laco, Mario N.; Winborn, Brett J.; Travis, Sue M.; Wen, Hsiang M.; Paulson, Henry L.			Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACHADO-JOSEPH-DISEASE; VALOSIN-CONTAINING PROTEIN; TRANSITIONAL ENDOPLASMIC-RETICULUM; UBIQUITIN-MEDIATED PROTEOLYSIS; BULBAR MUSCULAR-ATROPHY; DEUBIQUITINATING ENZYMES; INTRANUCLEAR INCLUSIONS; NUCLEAR-LOCALIZATION; BRAZILIAN FAMILIES; CAG REPEAT	Ataxin-3, a deubiquitinating enzyme, is the disease protein in spinocerebellar ataxia type 3, one of many neurodegenerative disorders caused by polyglutamine expansion. Little is known about the cellular regulation of ataxin-3. This is an important issue, since growing evidence links disease protein context to pathogenesis in polyglutamine disorders. Expanded ataxin-3, for example, is more neurotoxic in fruit fly models when its active site cysteine is mutated (1). We therefore sought to determine the influence of ataxin-3 enzymatic activity on various cellular properties. Here we present evidence that the catalytic activity of ataxin-3 regulates its cellular turnover, ubiquitination, and subcellular distribution. Cellular protein levels of catalytically inactive ataxin-3 were much higher than those of active ataxin-3, in part reflecting slower degradation. In vitro studies revealed that inactive ataxin-3 was more slowly degraded by the proteasome and that this degradation occurred independent of ubiquitination. Slower degradation of inactive ataxin-3 correlated with reduced interaction with the proteasome shuttle protein, VCP/p97. Enzymatically active ataxin-3 also showed a greater tendency to concentrate in the nucleus, where it colocalized with the proteasome in subnuclear foci. Taken together, these and other findings suggest that the catalytic activity of this disease-linked deubiquitinating enzyme regulates several of its cellular properties, which in turn may influence disease pathogenesis.	Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Grad Program Mol Biol, Iowa City, IA 52242 USA; Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal; Univ Coimbra, Fac Med, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal	University of Iowa; University of Iowa; Universidade de Coimbra; Universidade de Coimbra	Paulson, HL (corresponding author), Univ Iowa, Dept Neurol, EMRB Rm 240B, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu		TODI, SOKOL/0000-0003-4399-5549; Noro Laco, Mario/0000-0003-4823-3340	NINDS NIH HHS [R01 NS38712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038712] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Berke SJS, 2005, J BIOL CHEM, V280, P32026, DOI 10.1074/jbc.M506084200; Bichelmeier U, 2007, J NEUROSCI, V27, P7418, DOI 10.1523/JNEUROSCI.4540-06.2007; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Fujigasaki H, 2000, EXP NEUROL, V165, P248, DOI 10.1006/exnr.2000.7479; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Katsuno M, 2006, EXP NEUROL, V200, P8, DOI 10.1016/j.expneurol.2006.01.021; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koeppen AH, 2005, CEREBELLUM, V4, P62, DOI 10.1080/14734220510007950; Kordasiewicz HB, 2006, HUM MOL GENET, V15, P1587, DOI 10.1093/hmg/ddl080; Lerer I, 1996, EUR J HUM GENET, V4, P3; Mao Y, 2005, P NATL ACAD SCI USA, V102, P12700, DOI 10.1073/pnas.0506344102; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Paulson HL, 2000, P NATL ACAD SCI USA, V97, P12957, DOI 10.1073/pnas.210395797; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Sakai T, 1996, NEUROLOGY, V46, P846; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Seilhean D, 2004, ACTA NEUROPATHOL, V108, P81, DOI 10.1007/s00401-004-0855-x; STEVANIN G, 1995, AM J HUM GENET, V57, P1247; STEVANIN G, 1995, J MED GENET, V32, P827, DOI 10.1136/jmg.32.10.827; Takahashi J, 2001, J NEUROPATH EXP NEUR, V60, P369, DOI 10.1093/jnen/60.4.369; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	43	41	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29348	29358		10.1074/jbc.M704126200	http://dx.doi.org/10.1074/jbc.M704126200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693639	hybrid			2022-12-25	WOS:000249788000031
J	Wang, JL; Liu, X; Hande, MP; Wong, AC; Jin, YJ; Yin, YX				Wang, Jianli; Liu, Xin; Hande, M. Prakash; Wong, Alan C.; Jin, Y. Jenny; Yin, Yuxin			TAp73 is a downstream target of p53 in controlling the cellular defense against stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; P73 GENE; CYCLE CONTROL; P53-INDUCED APOPTOSIS; TRANSCRIPTION TARGET; POTENTIAL MEDIATOR; SPONTANEOUS TUMORS; OXIDATIVE STRESS	TAp73 is a p53 tumor suppressor gene homologue that is known to be mainly involved in apoptosis. We report here that TAp73 is necessary for the cellular response to oxidative stress and that TAp73 functions as a downstream target of p53 in this process. We show that p53 physically interacts with the TAp73 promoter under stress conditions that lead to cell death. Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription. TAp73 expression is highly increased under oxidative stress in a p53-dependent manner. Furthermore, knockdown of TAp73 expression inhibits the cellular apoptotic response to oxidative damage. In contrast, the ectopic expression of TAp73 in p53(-/-) mouse embryonic fibroblasts induces oxidative cell death. Our findings demonstrate that p53 is a direct transcriptional regulator of TAp73. Our data reveal a new pathway for cellular protection against oxidative damage and provide evidence that TAp73 is a stress-response gene and a downstream effector in the p53 pathway.	Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117579, Singapore	Columbia University; National University of Singapore	Yin, YX (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, VC-11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu	Hande, M. Prakash/B-1645-2008	Hande, M. Prakash/0000-0002-4511-6256	NCI NIH HHS [R01 CA093677, R01 CA102447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102447, R01CA093677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Catani MV, 2002, BIOCHEM J, V364, P441, DOI 10.1042/BJ20011713; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Coates PJ, 2006, J PATHOL, V210, P385, DOI 10.1002/path.2080; Corn PG, 1999, CANCER RES, V59, P3352; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mai M, 1998, CANCER RES, V58, P2347; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schwartz DI, 1999, BREAST CANCER RES TR, V58, P25, DOI 10.1023/A:1006237031070; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Stirewalt DL, 1999, LEUKEMIA, V13, P985, DOI 10.1038/sj.leu.2401418; Stoffel A, 2004, LEUKEMIA RES, V28, P1341, DOI 10.1016/j.leukres.2004.04.010; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yokomizo A, 1999, PROSTATE, V39, P94; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhao RB, 2000, GENE DEV, V14, P981	60	26	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29152	29162		10.1074/jbc.M703408200	http://dx.doi.org/10.1074/jbc.M703408200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693405	hybrid			2022-12-25	WOS:000249788000010
J	Butcher, NJ; Broadhurst, GM; Minchin, RF				Butcher, Neville J.; Broadhurst, Gysell M.; Minchin, Rodney F.			Polyamine-dependent regulation of spermidine-spermine N-1-acetyltransferase mRNA translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CODING REGION; HUMAN-MELANOMA CELLS; CANCER-CELLS; POSTTRANSCRIPTIONAL REGULATION; DIFFERENTIAL INDUCTION; GENE-EXPRESSION; ANALOGS; N1-ACETYLTRANSFERASE; ELEMENT; N-1,N-11-DIETHYLNORSPERMINE	Spermidine-spermine N-1-acetyltransferase (SSAT) is induced in response to an elevation in intracellular polyamine pools. The increased enzyme activity is the result of an increase in gene transcription, mRNA translation, and protein stability. Induction of SSAT by polyamine analogues can lead to intracellular polyamine depletion and apoptosis. The mechanism by which polyamines alter the translational efficiency of SSAT mRNA is not well understood. In this study, we investigated the regulation of SSAT translation by the polyamine analogue N-1,N-11-diethylnorspermine ( DENSPM). DENSPM induced expression of both FLAG-tagged SSAT and SSAT fused to Renilla luciferase in a time- and concentration-dependent manner. This effect was not inhibited by actinomycin D indicating that changes in gene transcription did not explain the enhanced expression in the presence of DENSPM. Furthermore, because FLAG-SSAT did not contain the 5'- or 3'-untranslated regions of SSAT, translational regulation involved the coding sequence only. By contrast, cycloheximide completely inhibited induction by DENSPM, indicating a requirement for new protein synthesis. Deletion constructs identified two regions of the SSAT protein-coding RNA sequence that conferred polyamine responsiveness. Using these regions as probes in RNA electrophoretic mobility shift assays, we observed specific binding of a cytoplasmic protein. In addition, we found that the interaction between the RNA probes and the binding protein could be inhibited by DENSPM in a concentration-dependent manner. These results suggest that polyamines regulate SSAT mRNA translational efficiency by inhibiting a repressor protein from binding to regions of the coding sequence of the SSAT transcript.	Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, St Lucia, Qld 4072, Australia	University of Queensland	Butcher, NJ (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	n.butcher@uq.edu.au		Minchin, Rodney/0000-0002-3178-4835; Butcher, Neville/0000-0002-0709-5589				BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chopra S, 1998, BIOCHEM PHARMACOL, V55, P1119, DOI 10.1016/S0006-2952(97)00601-1; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; Coleman CS, 2001, BIOCHEM J, V358, P137, DOI 10.1042/0264-6021:3580137; Creaven PJ, 1997, INVEST NEW DRUG, V15, P227, DOI 10.1023/A:1005827231849; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GERNER EW, 1993, BIOCHEM J, V294, P491, DOI 10.1042/bj2940491; Green ML, 1998, BIOL REPROD, V59, P1251, DOI 10.1095/biolreprod59.5.1251; Hector S, 2004, MOL CANCER THER, V3, P813; Ichimura S, 2004, INT J RADIAT BIOL, V80, P369, DOI 10.1080/09553000410001695886; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; Kramer DL, 1998, BIOCHEM SOC T, V26, P609, DOI 10.1042/bst0260609; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Marverti G, 2001, EUR J CANCER, V37, P281, DOI 10.1016/S0959-8049(00)00389-0; Minchin RF, 2006, INT J CANCER, V118, P509, DOI 10.1002/ijc.21359; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PORTER CW, 1994, CANCER RES, V54, P5917; REDMAN B, 1999, P AM SOC CLIN ON ATL; Spencer CM, 1999, DNA CELL BIOL, V18, P39, DOI 10.1089/104454999315600; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; Streiff RR, 2001, INVEST NEW DRUG, V19, P29, DOI 10.1023/A:1006448516938; Tai NW, 2004, BIOCHEM J, V378, P999, DOI 10.1042/BJ20031396; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Tierney MJ, 2001, J BIOL CHEM, V276, P13675, DOI 10.1074/jbc.M010627200; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wallace HM, 2003, BIOCHEM SOC T, V31, P393, DOI 10.1042/BST0310393; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wolff JC, 2003, CLIN CANCER RES, V9, P5922; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	37	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28530	28539		10.1074/jbc.M701265200	http://dx.doi.org/10.1074/jbc.M701265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690107	hybrid			2022-12-25	WOS:000249642100027
J	Chen, XM; Splinter, PL; O'Hara, SP; LaRusso, NF				Chen, Xian-Ming; Splinter, Patrick L.; O'Hara, Steven P.; LaRusso, Nicholas F.			A cellular Micro-RNA, let-7i, regulates toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR; NF-KAPPA-B; EPITHELIAL-CELLS; DOWN-REGULATION; DEFENSE; PATHWAY; DIFFERENTIATION; APOPTOSIS; PROTEINS; TLR4	Toll-like receptors (TLRs) are important pathogen recognition molecules and are key to epithelial immune responses to microbial infection. However, the molecular mechanisms that regulate TLR expression in epithelia are obscure. Micro-RNAs play important roles in a wide range of biological events through post-transcriptional suppression of target mRNAs. Here we report that human biliary epithelial cells (cholangiocytes) express let-7 family members, micro-RNAs with complementarity to TLR4 mRNA. We found that let-7 regulates TLR4 expression via post-transcriptional suppression in cultured human cholangiocytes. Infection of cultured human cholangiocytes with Cryptosporidium parvum, a parasite that causes intestinal and biliary disease, results in decreased expression of primary let-7i and mature let-7 in a MyD88/NF-kappa B-dependent manner. The decreased let-7 expression is associated with C. parvum-induced up-regulation of TLR4 in infected cells. Moreover, experimentally induced suppression or forced expression of let-7i causes reciprocal alterations in C. parvum-induced TLR4 protein expression, and consequently, infection dynamics of C. parvum in vitro. These results indicate that let-7i regulates TLR4 expression in cholangiocytes and contributes to epithelial immune responses against C. parvum infection. Furthermore, the data raise the possibility that micro-RNA-mediated post-transcriptional pathways may be critical to host-cell regulatory responses to microbial infection in general.	Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Miles & Shirley Fiterman Ctr Digest Dis, Rochester, MN 55905 USA	Mayo Clinic	Chen, XM (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA.	xianmingchen@creighton.edu; larusso.nicholas@mayo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024031, R37DK024031, R01DK057993] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI071321-02, AI071321, R01 AI071321, R01 AI071321-01, R01 AI071321-03] Funding Source: Medline; NIDDK NIH HHS [DK24031, R01 DK057993, R01 DK024031, DK57993] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brandenburg K, 2003, EUR J BIOCHEM, V270, P3271, DOI 10.1046/j.1432-1033.2003.03719.x; Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102; Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen XM, 2005, J IMMUNOL, V175, P7447, DOI 10.4049/jimmunol.175.11.7447; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Eckmann L, 2005, SPRINGER SEMIN IMMUN, V27, P181, DOI 10.1007/s00281-005-0207-5; Eun CS, 2006, DIGEST DIS SCI, V51, P693, DOI 10.1007/s10620-006-3193-0; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Gatti G, 2006, J LEUKOCYTE BIOL, V79, P989, DOI 10.1189/jlb.1005597; Guerrant RL, 1997, EMERG INFECT DIS, V3, P51, DOI 10.3201/eid0301.970106; Harada K, 2004, HEPATOLOGY, V40, P925, DOI 10.1002/hep.20379; Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jo YJ, 2004, GASTROENTEROLOGY, V126, pA171; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Modlin RL, 2004, NAT MED, V10, P1173, DOI 10.1038/nm1104-1173; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Strober W, 2004, NAT MED, V10, P898, DOI 10.1038/nm0904-898; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tzipori S, 2002, MICROBES INFECT, V4, P1047, DOI 10.1016/S1286-4579(02)01629-5; Viswanathan VK, 2004, ADV DRUG DELIVER REV, V56, P727, DOI 10.1016/j.addr.2003.09.005; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	38	366	401	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28929	28938		10.1074/jbc.M702633200	http://dx.doi.org/10.1074/jbc.M702633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17660297	Green Accepted, hybrid			2022-12-25	WOS:000249642100067
J	Gu, L; Husain-Ponnampalam, R; Hoffmann-Benning, S; Henry, RW				Gu, Liping; Husain-Ponnampalam, Rhonda; Hoffmann-Benning, Susanne; Henry, R. William			The protein kinase CK2 phosphorylates SNAP190 to negatively regulate SNAP(c) DNA binding and human U6 transcription by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL SEQUENCE ELEMENT; SNRNA GENE-TRANSCRIPTION; OCT-1 POU DOMAIN; COMPLEX SNAP(C); ACTIVATING PROTEIN; CASEIN KINASE-2; BETA-SUBUNIT; HUMAN-CELLS; PROMOTER; RESIDUES	Human U6 small nuclear RNA gene transcription by RNA polymerase III requires the general transcription factor SNAP(C), which binds to human small nuclear RNA core promoter elements and nucleates pre-initiation complex assembly with the Brf2-TFIIIB complex. Multiple components in this pathway are phosphorylated by the protein kinase CK2, including the Bdp1 subunit of the Brf2-TFIIIB complex, and RNA polymerase III, with negative and positive outcomes for U6 transcription, respectively. However, a role for CK2 phosphorylation of SNAPC in U6 transcription has not been defined. In this report, we investigated the role of CK2 in modulating the transcriptional properties of SNAPC and demonstrate that within SNAP(C), CK2 phosphorylates the N-terminal half of the SNAP190 subunit at two regions (amino acids 20 - 63 and 514-545) that each contain multiple CK2. consensus sites. SNAP190 phosphorylation by CK2 inhibits both SNAPC DNA binding and U6 transcription activity. Mutational analyses of SNAP190 support a model wherein CK2 phosphorylation triggers an allosteric inhibition. of the SNAP190 Myb DNA binding domain.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Henry, RW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	henryrw@msu.edu			NIGMS NIH HHS [R01-GM59805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai L, 1996, MOL CELL BIOL, V16, P5419; BYFORD MF, 1991, BIOCHEM J, V280, P261, DOI 10.1042/bj2800261; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; Ghavidel A, 1999, MOL CELL BIOCHEM, V191, P143, DOI 10.1023/A:1006885522221; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Gridasova AA, 2005, MOL CELL BIOL, V25, P3247, DOI 10.1128/MCB.25.8.3247-3260.2005; Gu LP, 2005, J BIOL CHEM, V280, P27697, DOI 10.1074/jbc.M503206200; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hinkley CS, 2003, J BIOL CHEM, V278, P18649, DOI 10.1074/jbc.M204247200; Hovde S, 2002, GENE DEV, V16, P2772, DOI 10.1101/gad.1021002; Hu P, 2004, MOL CELL, V16, P81, DOI 10.1016/j.molcel.2004.09.008; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Jawdekar GW, 2006, J BIOL CHEM, V281, P31050, DOI 10.1074/jbc.M603810200; Jiang XZ, 2004, BIOCHEMISTRY-US, V43, P15567, DOI 10.1021/bi0483965; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; Ma BC, 2002, MOL CELL BIOL, V22, P8067, DOI 10.1128/MCB.22.22.8067-8078.2002; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Reina JH, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000134; RESING KA, 1995, BIOCHEMISTRY-US, V34, P9477, DOI 10.1021/bi00029a024; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Sarno S, 1999, MOL CELL BIOCHEM, V191, P13, DOI 10.1023/A:1006857016712; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1	40	12	12	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27887	27896		10.1074/jbc.M702269200	http://dx.doi.org/10.1074/jbc.M702269200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17670747	hybrid			2022-12-25	WOS:000249455600037
J	Hou, W; Yap, JSF; Wu, S; Liu, T; Cheverud, JM; Wu, RL				Hou, Wei; Yap, John Stephen F.; Wu, Song; Liu, Tian; Cheverud, James M.; Wu, Rongling			Haplotyping a Quantitative Trait with a High-Density Map in Experimental Crosses	PLOS ONE			English	Article								Background. The ultimate goal of genetic mapping of quantitative trait loci (QTL) is the positional cloning of genes involved in any agriculturally or medically important phenotype. However, only a small portion (<= 1%) of the QTL detected have been characterized at the molecular level, despite the report of hundreds of thousands of QTL for different traits and populations. Methods/Results. We develop a statistical model for detecting and characterizing the nucleotide structure and organization of haplotypes that underlie QTL responsible for a quantitative trait in an F-2 pedigree. The discovery of such haplotypes by the new model will facilitate the molecular cloning of a QTL. Our model is founded on population genetic properties of genes that are segregating in a pedigree, constructed with the mixture-based maximum likelihood context and implemented with the EM algorithm. The closed forms have been derived to estimate the linkage and linkage disequilibria among different molecular markers, such as single nucleotide polymorphisms, and quantitative genetic effects of haplotypes constructed by non-alleles of these markers. Results from the analysis of a real example in mouse have validated the usefulness and utilization of the model proposed. Conclusion. The model is flexible to be extended to model a complex network of genetic regulation that includes the interactions between different haplotypes and between haplotypes and environments.	[Yap, John Stephen F.; Wu, Song; Liu, Tian; Wu, Rongling] Univ Florida, Dept Stat, Gainesville, FL 32611 USA; [Hou, Wei] Univ Florida, Dept Epidemiol & Hlth Policy Res, Gainesville, FL 32611 USA; [Cheverud, James M.] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Washington University (WUSTL)	Wu, RL (corresponding author), Univ Florida, Dept Stat, Gainesville, FL 32611 USA.	rwu@mail.ifas.ufl.edu	hou, wei/GWM-4800-2022		NSF [0540745]	NSF(National Science Foundation (NSF))	The preparation of this manuscript is supported by NSF grant (0540745) to RW.	Bader JS, 2001, PHARMACOGENOMICS, V2, P11, DOI 10.1517/14622416.2.1.11; Burnham K. P., 1998, MODEL SELECTION INFE; CHURCHILL GA, 1994, GENETICS, V138, P963; Eyheramendy S, 2007, GENOME RES, V17, P88, DOI 10.1101/gr.5675406; Flint J, 2005, NAT REV GENET, V6, P271, DOI 10.1038/nrg1576; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; JANSEN RC, 1994, GENETICS, V136, P1447; Judson R, 2000, Pharmacogenomics, V1, P15, DOI 10.1517/14622416.1.1.15; Kao CH, 1999, GENETICS, V152, P1203; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Li CB, 2006, SCIENCE, V311, P1936, DOI 10.1126/science.1123604; Lin M, 2006, CURR GENOMICS, V7, P59, DOI 10.2174/138920206776389775; Lou XY, 2003, GENETICS, V163, P1533; LOUIS TA, 1982, J ROY STAT SOC B MET, V44, P226; Lynch M., 1998, GENETICS ANAL QUANTI; Mackay TFC, 2001, NAT REV GENET, V2, P11, DOI 10.1038/35047544; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Sebastiani P, 2003, P NATL ACAD SCI USA, V100, P9900, DOI 10.1073/pnas.1633613100; Tian L, 2004, GENETICS, V168, P503, DOI 10.1534/genetics.104.029603; Vaughn TT, 1999, GENET RES, V74, P313, DOI 10.1017/S0016672399004103; ZENG ZB, 1994, GENETICS, V136, P1457; Zhang K, 2002, P NATL ACAD SCI USA, V99, P7335, DOI 10.1073/pnas.102186799	23	3	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e732	10.1371/journal.pone.0000732	http://dx.doi.org/10.1371/journal.pone.0000732			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710132	Green Published, Green Submitted, gold			2022-12-25	WOS:000207455200009
J	Kretschmer, B; Luthje, K; Guse, AH; Ehrlich, S; Koch-Nolte, F; Haag, F; Fleischer, B; Breloer, M				Kretschmer, Birte; Luethje, Katja; Guse, Andreas H.; Ehrlich, Svenja; Koch-Nolte, Friedrich; Haag, Friedrich; Fleischer, Bernhard; Breloer, Minka			CD83 Modulates B Cell Function In Vitro: Increased IL-10 and Reduced Ig Secretion by CD83Tg B Cells	PLOS ONE			English	Article								The murine transmembrane glycoprotein CD83 is an important regulator for both thymic T cell maturation and peripheral T cell responses. Recently, we reported that CD83 also has a function on B cells: Ubiquitous transgenic (Tg) expression of CD83 interfered with the immunoglobulin (Ig) response to infectious agents and to T cell dependent as well as T cell independent model antigen immunization. Here we compare the function of CD83Tg B cells that overexpress CD83 and CD83 mutant (CD83mu) B cells that display a drastically reduced CD83 expression. Correlating with CD83 expression, the basic as well as the lipopolysaccharide (LPS) induced expression of the activation markers CD86 and MHC-II are significantly increased in CD83Tg B cells and reciprocally decreased in CD83mu B cells. Wild-type B cells rapidly upregulate CD83 within three hours post BCR or TLR engagement by de novo protein synthesis. The forced premature overexpression of CD83 on the CD83Tg B cells results in reduced calcium signaling, reduced Ig secretion and a reciprocally increased IL-10 production upon in vitro activation. This altered phenotype is mediated by CD83 expressed on the B cells themselves, since it is observed in the absence of accessory cells. In line with this finding, purified CD83mu B cells displayed a reduced IL-10 production and slightly increased Ig secretion upon LPS stimulation in vitro. Taken together, our data strongly suggest that CD83 is expressed by B cells upon activation and contributes to the regulation of B cell function.	[Kretschmer, Birte; Luethje, Katja; Ehrlich, Svenja; Fleischer, Bernhard; Breloer, Minka] Bernhard Nocht Inst Trop Med, Dept Immunol, Hamburg, Germany; [Guse, Andreas H.] Univ Med Ctr Hamburg Eppendorf, Inst Biochem & Mol Biol 1, Hamburg, Germany; [Koch-Nolte, Friedrich; Haag, Friedrich; Fleischer, Bernhard] Univ Med Ctr Hamburg Eppendorf, Inst Immunol, Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Breloer, M (corresponding author), Bernhard Nocht Inst Trop Med, Dept Immunol, Hamburg, Germany.	Breloer@bni-hamburg.de	Breloer, Minka/F-3999-2018	Breloer, Minka/0000-0001-6199-4908; Koch-Nolte, Friedrich/0000-0003-1730-6674	Deutsche Forschungsgemeinschaft [FL129/5-1, 5-2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the "Deutsche Forschungsgemeinschaft" (FL129/5-1, 5-2).	Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388; Berchtold S, 2002, IMMUNOBIOLOGY, V205, P231, DOI 10.1078/0171-2985-00128; Berchtold S, 1999, FEBS LETT, V461, P211, DOI 10.1016/S0014-5793(99)01465-9; Breloer M, 2007, EUR J IMMUNOL, V37, P634, DOI 10.1002/eji.200636852; BURDIN N, 1995, J IMMUNOL, V154, P2533; Cao WP, 2005, BIOCHEM J, V385, P85, DOI 10.1042/BJ20040741; Cramer SO, 2000, INT IMMUNOL, V12, P1347, DOI 10.1093/intimm/12.9.1347; Dudziak D, 2005, J IMMUNOL, V174, P6672, DOI 10.4049/jimmunol.174.11.6672; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Fujimoto Y, 2002, CELL, V108, P755, DOI 10.1016/S0092-8674(02)00673-6; Fujimoto Yoko, 2006, Journal of Medical and Dental Sciences, V53, P85; Garcia-Martinez LF, 2004, J IMMUNOL, V173, P2995, DOI 10.4049/jimmunol.173.5.2995; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Hirano N, 2006, BLOOD, V107, P1528, DOI 10.1182/blood-2005-05-2073; Klein E, 2005, INT IMMUNOL, V17, P477, DOI 10.1093/intimm/dxh228; KOZLOW EJ, 1993, BLOOD, V81, P454, DOI 10.1182/blood.V81.2.454.454; Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; Luthje K, 2006, EUR J IMMUNOL, V36, P2035, DOI 10.1002/eji.200636068; Lund Frances E., 2005, V8, P25; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; Mizoguchi A, 2006, J IMMUNOL, V176, P705, DOI 10.4049/jimmunol.176.2.705; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nitschke L, 2005, CURR OPIN IMMUNOL, V17, P290, DOI 10.1016/j.coi.2005.03.005; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Pan C, 1999, IMMUNITY, V11, P495, DOI 10.1016/S1074-7613(00)80124-7; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Prechtel AT, 2007, J IMMUNOL, V178, P5454, DOI 10.4049/jimmunol.178.9.5454; Senechal B, 2004, BLOOD, V103, P4207, DOI 10.1182/blood-2003-12-4350; Serra P, 2006, TRENDS IMMUNOL, V27, P7, DOI 10.1016/j.it.2005.11.003; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Twist CJ, 1998, IMMUNOGENETICS, V48, P383, DOI 10.1007/s002510050449; Wolenski M, 2003, SCAND J IMMUNOL, V58, P306, DOI 10.1046/j.1365-3083.2003.01303.x; ZHOU LJ, 1992, J IMMUNOL, V149, P735; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588; ZHOU LJ, 1995, J IMMUNOL, V154, P3821; Zinser E, 2004, J EXP MED, V200, P345, DOI 10.1084/jem.20030973	40	36	37	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e755	10.1371/journal.pone.0000755	http://dx.doi.org/10.1371/journal.pone.0000755			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710154	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200031
J	Myatt, SS; Burchill, SA				Myatt, S. S.; Burchill, S. A.			The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38MAPK activity	ONCOGENE			English	Article						p38MAPK; EWS-Fli1; ROS; fenretinide; apoptosis; ESFT	PHASE-I TRIAL; RNA INTERFERENCE; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; SUSTAINED-ACTIVATION; ORAL FENRETINIDE; CANCER-CELLS; SOLID TUMORS; GROWTH; NEUROBLASTOMA; PHENOTYPE	The Ewing's sarcoma family of tumours (ESFT) are small round cell tumours characterized by the non-random EWS-ETS gene rearrangements. We have previously demonstrated that ESFT are highly sensitive to fenretinide-induced death, effected in part through a reactive oxygen species (ROS)-dependent pathway. Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG. This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWSFli1-dependent modulation of p38(MAPK) activity. Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide- induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells. These data demonstrate that expression of EWS-Fli1 enhances fenretinide-induced cell death in ESFT and that this is effected at least in part through modulation of p38(MAPK) activity.	[Myatt, S. S.; Burchill, S. A.] St James Hosp, Candlelighters Childrens Can Res Lab, Canc Res UK Cllin Care, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Burchill, SA (corresponding author), St James Hosp, Candlelighters Childrens Can Res Lab, Canc Res UK Cllin Care, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	s.a.burchill@leeds.ac.uk						Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; BURCHILL SA, 1994, INT J CANCER, V57, P671, DOI 10.1002/ijc.2910570510; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Chiesa F, 2005, INT J CANCER, V115, P625, DOI 10.1002/ijc.20923; Corazzari M, 2005, BIOCHEM BIOPH RES CO, V331, P810, DOI 10.1016/j.bbrc.2005.03.184; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang SL, 2004, J BIOL CHEM, V279, P36490, DOI 10.1074/jbc.M401208200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/eoid.12.11.1829.21882; Matsunobu T, 2006, CANCER RES, V66, P803, DOI 10.1158/0008-5472.CAN-05-1972; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; O'Donnell PH, 2002, LEUKEMIA, V16, P902, DOI 10.1038/sj.leu.2402485; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Pienta KJ, 1997, AM J CLIN ONCOL-CANC, V20, P36, DOI 10.1097/00000421-199702000-00008; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Simeone AM, 2005, CARCINOGENESIS, V26, P1000, DOI 10.1093/carcin/bgi038; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Villablanca JG, 2006, J CLIN ONCOL, V24, P3423, DOI 10.1200/JCO.2005.03.9271; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Won JS, 2006, FREE RADICAL BIO MED, V40, P1875, DOI 10.1016/j.freeradbiomed.2006.01.035; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zanardi S, 2006, ENDOCR-RELAT CANCER, V13, P51, DOI 10.1677/erc.1.00938	41	18	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					985	996		10.1038/sj.onc.1210705	http://dx.doi.org/10.1038/sj.onc.1210705			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700534				2022-12-25	WOS:000252946300010
J	Mohr, A; Buneker, C; Gough, RP; Zwacka, RM				Mohr, A.; Bueneker, C.; Gough, R. P.; Zwacka, R. M.			MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release	ONCOGENE			English	Article						apoptosis; MnSOD; TRAIL; XIAP; Smac/DIABLO; colon cancer	MANGANESE SUPEROXIDE-DISMUTASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; REDOX GENE-THERAPY; PANCREATIC ADENOCARCINOMA; MATRIX METALLOPROTEINASES; ANTIOXIDANT ENZYMES; CONFERS RESISTANCE; OVEREXPRESSION; EXPRESSION	The mitochondrial enzyme manganese superoxide dismutase (MnSOD) has been shown to have two faces with regard to its role in tumor development. On the one side, it is well documented that overexpression of MnSOD slows down cancer cell growth, whereas on the other side MnSOD also has a metastasis-promoting activity. We set out to examine the role of MnSOD in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, thought to be a first-line tumor surveillance mechanism and failure to undergo apoptosis might contribute to metastasis formation. We show that overexpression of MnSOD at moderate levels is able to protect cells from TRAIL-induced apoptosis. While caspase-8 activation and Bid cleavage were not affected by MnSOD, we detected a marked decrease in caspase-3 activation pointing to a mitochondrial resistance mechanism. Indeed, we found that MnSOD-overexpressing cells showed reduced cytochrome c and no Smac/DIABLO release into the cytosol. The resulting lack of X-linked inhibitor of apoptosis (XIAP) inhibition by cytosolic Smac/DIABLO most likely caused the TRAIL resistance as RNAi against XIAP-rescued caspase-3 activity and TRAIL sensitivity. Our results show that reactive oxygen species are involved in TRAIL-induced Smac/DIABLO release and in TRAIL-triggered apoptosis. Hence, high levels of MnSOD, which decompose and neutralize these reactive oxygen species, might contribute to metastasis formation by allowing disseminated tumor cells to escape from TRAIL-mediated tumor surveillance. As part of TRAIL regimens, adjuvant treatment with XIAP inhibitors in the form of Smac/DIABLO mimetics or MnSOD inhibitors might be able to break TRAIL resistance of malignant tumor cells.	[Mohr, A.; Bueneker, C.; Gough, R. P.; Zwacka, R. M.] Natl Univ Ireland Univ Coll Galway, Mol Therapeut Grp, Natl Ctr Biomed Engn Sci, Galway, Ireland; [Bueneker, C.] Univ Ulm, Div Gene Therapy, Ulm, Germany	Ollscoil na Gaillimhe-University of Galway; Ulm University	Mohr, A (corresponding author), Natl Univ Ireland Univ Coll Galway, Mol Therapeut Grp, Natl Ctr Biomed Engn Sci, Univ Rd, Galway, Ireland.	andrea.mohr@nuigalway.ie; ralf.zwacka@nuigalway.ie		Zwacka, Ralf/0000-0003-2821-0387; Mohr, Andrea/0000-0002-4295-0341				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behrend L, 2005, MOL CELL BIOL, V25, P7758, DOI 10.1128/MCB.25.17.7758-7769.2005; Braeuer SJ, 2006, MOL CANCER RES, V4, P715, DOI 10.1158/1541-7786.MCR-05-0231; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cullen JJ, 2003, CANCER RES, V63, P1297; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; Davis AR, 2001, MOL BIOTECHNOL, V18, P63, DOI 10.1385/MB:18:1:63; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Duiker EW, 2006, EUR J CANCER, V42, P2233, DOI 10.1016/j.ejca.2006.03.018; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Izeradjene K, 2005, CANCER RES, V65, P7436, DOI 10.1158/0008-5472.CAN-04-2628; Izutani R, 1998, J GASTROENTEROL, V33, P816, DOI 10.1007/s005350050181; Janssen AML, 1999, J CANCER RES CLIN, V125, P327, DOI 10.1007/s004320050282; Kahl R, 2004, DRUG METAB REV, V36, P747, DOI 10.1081/DMR-200033488; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lam EWN, 1997, CANCER RES, V57, P5550; Lee MW, 2002, CANCER LETT, V182, P75; Lewis A, 2005, CLIN EXP METASTAS, V22, P523, DOI 10.1007/s10585-005-4919-7; Li JJ, 1997, CANCER RES, V57, P1991; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Liotta L A, 1990, Semin Cancer Biol, V1, P99; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; Mohr A, 2005, ONCOGENE, V24, P2421, DOI 10.1038/sj.onc.1208432; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nozoe T, 2003, ONCOL REP, V10, P39; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Toh Y, 2000, INT J ONCOL, V17, P107; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Vigneswaran N, 2005, INT J ONCOL, V26, P103; Wajant H, 2006, CANC TREAT, V130, P141; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	46	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					763	774		10.1038/sj.onc.1210673	http://dx.doi.org/10.1038/sj.onc.1210673			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653087				2022-12-25	WOS:000252884500005
J	Siddiqui, K; Del Valle, L; Morellet, N; Cui, J; Ghafouri, M; Mukerjee, R; Urbanska, K; Fan, S; Pattillo, CB; Deshmane, SL; Kiani, MF; Ansari, R; Khalili, K; Roques, BP; Reiss, K; Bouaziz, S; Amini, S; Srinivasan, A; Sawaya, BE				Siddiqui, K.; Del Valle, L.; Morellet, N.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Pattillo, C. B.; Deshmane, S. L.; Kiani, M. F.; Ansari, R.; Khalili, K.; Roques, B. P.; Reiss, K.; Bouaziz, S.; Amini, S.; Srinivasan, A.; Sawaya, B. E.			Molecular mimicry in inducing DNA damage between HIV-1Vpr and the anticancer agent, cisplatin	ONCOGENE			English	Article						HIV-1; Vpr; DNA damage; chromosomal aberrations; cisplatin; necrosis	IMMUNODEFICIENCY-VIRUS TYPE-1; HISTONE H3 PHOSPHORYLATION; REGULATORY PROTEIN VPR; CELL-CYCLE; NMR STRUCTURE; TERMINAL DOMAIN; MICRONUCLEI FORMATION; VIRION INCORPORATION; GENE-EXPRESSION; ACCESSORY GENE	The human immunodeficiency virus type 1(HIV-1) viral protein R (vpr) gene is an evolutionarily conserved gene among the primate lentiviruses. Several functions are attributed to Vpr including the ability to cause cell death, cell cycle arrest, apoptosis and DNA damage. The Vpr domain responsible for DNA damage as well as the mechanism(s) through which Vpr induces this damage is unknown. Using site-directed mutagenesis, we identified the helical domain II within Vpr (aa 37-50) as the region responsible for causing DNA damage. Interestingly, Vpr D(37-50) failed to cause cell cycle arrest or apoptosis, to induce Ku70 or Ku80 and to suppress tumor growth, but maintained its capability to activate the HIV-1 LTR, to localize to the nucleus and to promote nonhomologous end-joining. In addition, our cytogenetic data indicated that helical domain II induced chromosomal aberrations, which mimicked those induced by cisplatin, an anticancer agent. This novel molecular mimicry function of Vpr might lead to its potential therapeutic use as a tumor suppressor.	[Del Valle, L.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Deshmane, S. L.; Khalili, K.; Reiss, K.; Sawaya, B. E.] Temple Univ, Sch Med, Dept Neurosci, Philadelphia, PA 19122 USA; [Del Valle, L.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Deshmane, S. L.; Khalili, K.; Reiss, K.; Sawaya, B. E.] Temple Univ, Sch Med, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Siddiqui, K.; Amini, S.] Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; [Morellet, N.; Roques, B. P.; Bouaziz, S.] INSERM, Unite Pharmacol Chim & Genet, Paris 06, France; [Urbanska, K.] Jagiellonian Univ, Fac Biotechnol, Dept Cell Biol, Krakow, Poland; [Pattillo, C. B.; Kiani, M. F.; Ansari, R.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Srinivasan, A.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Institut National de la Sante et de la Recherche Medicale (Inserm); Jagiellonian University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Sawaya, BE (corresponding author), Temple Univ, Sch Med, Dept Neurosci, 1900 N 12th St, Philadelphia, PA 19122 USA.	sawaya@temple.edu	Del Valle, Luis/J-4085-2015; Pattillo, Christopher/J-9517-2012	Del Valle, Luis/0000-0003-3894-9206; Pattillo, Christopher/0000-0002-8017-067X; morellet, nelly/0000-0001-5076-8884; bouaziz, serge/0000-0001-7792-8307	NATIONAL CANCER INSTITUTE [R01CA095518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466, R01NS040673] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095518] Funding Source: Medline; NINDS NIH HHS [R01 NS040673-05, P01 NS036466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amini S, 2005, MOL CELL BIOL, V25, P8126, DOI 10.1128/MCB.25.18.8126-8138.2005; Amini S, 2004, J BIOL CHEM, V279, P46046, DOI 10.1074/jbc.M403792200; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Baumgartner BL, 2005, GENE DEV, V19, P2522, DOI 10.1101/gad.1373205; Claudio PP, 2006, J CELL PHYSIOL, V208, P602, DOI 10.1002/jcp.20698; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gaynor EM, 2001, EXP CELL RES, V267, P243, DOI 10.1006/excr.2001.5247; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Kino T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Le Rouzic E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-11; Mahalingam S, 1995, VIROLOGY, V214, P647, DOI 10.1006/viro.1995.0079; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Mameli G, 2007, J GEN VIROL, V88, P631, DOI 10.1099/vir.0.82487-0; McCray AN, 2006, MOL THER, V14, P647, DOI 10.1016/j.ymthe.2006.06.010; Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Nakamura T, 2002, VIRUS RES, V90, P263, DOI 10.1016/S0168-1702(02)00230-7; Nishizawa M, 1999, VIROLOGY, V263, P313, DOI 10.1006/viro.1999.9905; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Pang S, 2001, CLIN CANCER RES, V7, P3567; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Shimura M, 1999, CANCER RES, V59, P2259; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; SIDDIQUI KM, 1988, MUTAT RES, V207, P179; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Zhou Y, 2000, J VIROL, V74, P6520, DOI 10.1128/JVI.74.14.6520-6527.2000; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028; Zhu QZ, 2001, CANCER RES, V61, P64; [No title captured]	53	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					32	43		10.1038/sj.onc.1210632	http://dx.doi.org/10.1038/sj.onc.1210632			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17653096				2022-12-25	WOS:000252118700004
J	Sher, D; Fishman, Y; Melamed-Book, N; Zhang, ML; Zlotkin, E				Sher, Daniel; Fishman, Yelena; Melamed-Book, Naomi; Zhang, Mingliang; Zlotkin, Eliahu			Osmotically driven prey disintegration in the gastrovascular cavity of the green hydra by a pore-forming protein	FASEB JOURNAL			English	Article						chemical ecology; toxin; digestion; cnidaria	SEA-ANEMONES; CHIRONEX-FLECKERI; NEMATOCYST VENOM; GLAND-CELLS; TOXINS; POLYPEPTIDES; TENTACLES; MEMBRANE; CNIDARIA; EXTRACT	Pore-forming proteins (PFPs) are watersoluble proteins able to integrate into target membranes to form transmembrane pores. They are common determinants of bacterial pathogenicity and are often found in animal venoms. We recently isolated and characterized Hydralysins (Hlns), paralytic PFPs from the venomous green hydra Chlorohydra viridissima that are not found within the nematocytes, suggesting they are not involved in prey capture. The present study aimed to decipher the biological role of Hlns. Using in situ hybridization and immunohistochemistry, we show that Hlns are expressed by digestive cells surrounding the gastrovascular cavity (GVC) of Chlorohydra and secreted onto the prey during feeding. At biologically relevant concentrations, Hlns bind prey membranes and form pores, lysing the cells and disintegrating the prey tissue. Hlns are unable to bind Chlorohydra membranes, thus protecting the producing animal from the destructive effect of its own cytolytic protein. We suggest that osmotic disintegration of the prey within the GVC by Hlns, followed by phagocytosis and intracellular digestion, allows the soft-bodied green hydra to feed on hard, cuticle-covered prey while lacking the physical means to mechanically disintegrate it. Our results extend the biological significance of PFPs beyond the commonly expected offensive or defensive roles. -Sher, D., Fishman, Y., Melamed-Book, N., Zhang, M., Zlotkin, E. Osmotically driven prey disintegration in the gastrovascular cavity of the green hydra by a pore-forming protein.	[Sher, Daniel; Fishman, Yelena; Zhang, Mingliang; Zlotkin, Eliahu] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel; [Melamed-Book, Naomi] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Confocal Microscopy Unit, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Sher, D (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.	dsher@pob.huji.ac.il						Amimoto Y, 2006, MECH DEVELOP, V123, P352, DOI 10.1016/j.mod.2006.03.002; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Bassler BL, 2006, CELL, V125, P237, DOI 10.1016/j.cell.2006.04.001; Basulto A, 2006, J EXP ZOOL PART A, V305A, P253, DOI 10.1002/jez.a.256; BENOS DJ, 1977, TISSUE CELL, V9, P11, DOI 10.1016/0040-8166(77)90045-3; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BODE HR, 1987, DEV BIOL, V122, P577, DOI 10.1016/0012-1606(87)90321-6; Bosch TCG, 2007, DEV BIOL, V303, P421, DOI 10.1016/j.ydbio.2006.12.012; CASTE JD, 2004, CURRENT PROTOCOLS PR; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; Don TA, 2004, INT J PARASITOL, V34, P1029, DOI 10.1016/j.ijpara.2004.04.013; Edwards L, 2000, TOXICON, V38, P1015, DOI 10.1016/S0041-0101(99)00213-5; ENDEAN R, 1971, TOXICON, V9, P255, DOI 10.1016/0041-0101(71)90078-X; GORDON D, 1982, BIOCHIM BIOPHYS ACTA, V688, P229, DOI 10.1016/0005-2736(82)90598-3; HAYNES J. F., 1973, BIOL HYDRA; Hermo L, 2002, MOL REPROD DEV, V63, P394, DOI 10.1002/mrd.90023; HOLSTEIN TW, 1992, FEBS LETT, V309, P288, DOI 10.1016/0014-5793(92)80791-E; Honma T, 2003, BBA-PROTEINS PROTEOM, V1652, P103, DOI 10.1016/j.bbapap.2003.08.007; Horibata Y, 2004, J BIOL CHEM, V279, P33379, DOI 10.1074/jbc.M401460200; Kanaev LI, 1952, HYDRA; Lee JY, 2002, BIOCHEM BIOPH RES CO, V296, P1238, DOI 10.1016/S0006-291X(02)02062-4; Leippe M, 2004, J EUKARYOT MICROBIOL, V51, P516, DOI 10.1111/j.1550-7408.2004.tb00286.x; Lenhoff H.M., 1983, P29; LENTZ T, 1966, CELL BIOL HYDRA; LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0; Martinez DE, 1997, DEV BIOL, V192, P523, DOI 10.1006/dbio.1997.8715; MCNEIL PL, 1981, J CELL SCI, V49, P311; MEINARDI E, 1994, COMP BIOCHEM PHYS B, V109, P153, DOI 10.1016/0305-0491(94)90152-X; Miller DJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r59; Nagai H, 2002, BIOSCI BIOTECH BIOCH, V66, P2621, DOI 10.1271/bbb.66.2621; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P589, DOI 10.1006/bbrc.2000.3352; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P582, DOI 10.1006/bbrc.2000.3353; PARDY RL, 1983, HYDRA RES METHODS; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Purves W. K., 2004, LIFE SCI BIOL; Ramasamy S, 2005, TOXICOL LETT, V155, P219, DOI 10.1016/j.toxlet.2004.09.018; Ramasamy S, 2005, TOXICOL LETT, V155, P135, DOI 10.1016/j.toxlet.2004.09.004; Ruppert EE, 1994, INVERTEBRATE ZOOLOGY; SCHMIDT T, 1986, J CELL SCI, V85, P197; Sher D, 2005, TOXICON, V45, P865, DOI 10.1016/j.toxicon.2005.02.004; Sher D, 2005, J BIOL CHEM, V280, P22847, DOI 10.1074/jbc.M503242200; Shimizu H, 2004, J COMP PHYSIOL A, V190, P623, DOI 10.1007/s00359-004-0518-3; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; THOMAS RG, 1979, TOXICON, V17, P221, DOI 10.1016/0041-0101(79)90211-3; VANPRAET M, 1985, ADV MAR BIOL, V22, P65, DOI 10.1016/S0065-2881(08)60050-4; Weber J., 1988, P427; Zhang ML, 2003, BIOCHEMISTRY-US, V42, P8939, DOI 10.1021/bi0343929	49	29	29	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					207	214		10.1096/fj.07-9133com	http://dx.doi.org/10.1096/fj.07-9133com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17679608				2022-12-25	WOS:000252309900023
J	Barrett, D; Wang, TSA; Yuan, Y; Zhang, Y; Kahne, D; Walker, S				Barrett, Dianah; Wang, Tsung-Shing Andrew; Yuan, Yanqiu; Zhang, Yi; Kahne, Daniel; Walker, Suzanne			Analysis of glycan polymers produced by peptidoglycan glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; CELL-WALL BIOSYNTHESIS; ESCHERICHIA-COLI; MOENOMYCIN-A; LIPID-II; BACTERIAL TRANSGLYCOSYLASE; KINETIC CHARACTERIZATION; STAPHYLOCOCCUS-AUREUS; ANTIBIOTICS	Bacterial cells are surrounded by a cross-linked polymer called peptidoglycan, the integrity of which is necessary for cell survival. The carbohydrate chains that form the backbone of peptidoglycan are made by peptidoglycan glycosyltransferases (PGTs), highly conserved membrane-bound enzymes that are thought to be excellent targets for the development of new antibacterials. Although structural information on these enzymes recently became available, their mechanism is not well understood because of a dearth of methods to monitor PGT activity. Here we describe a direct, sensitive, and quantitative SDS-PAGE method to analyze PGT reactions. We apply this method to characterize the substrate specificity and product length profile for two different PGT domains, PBP1A from Aquifex aeolicus and PBP1A from Escherichia coli. We show that both disaccharide and tetrasaccharide diphospholipids (Lipid II and Lipid IV) serve as substrates for these PGTs, but the product distributions differ significantly depending on which substrate is used as the starting material. Reactions using the disaccharide substrate are more processive and yield much longer glycan products than reactions using the tetrasaccharide substrate. We also show that the SDS-PAGE method can be applied to provide information on the roles of invariant residues in catalysis. A comprehensive mutational analysis shows that the biggest contributor to turnover of 14 mutated residues is an invariant glutamate located in the center of the active site cleft. The assay and results described provide new information about the process by which PGTs assemble bacterial cell walls.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Kahne, D (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	kahne@chemistry.harvard.edu	Wang, Tsung-Shing/AAF-4974-2019	Wang, Tsung-Shing/0000-0002-4690-3438	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076710] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM076710, GM076710] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2006, J AM CHEM SOC, V128, P14012, DOI 10.1021/ja065905c; ANDERSON JS, 1966, ARCH BIOCHEM BIOPHYS, V116, P487, DOI 10.1016/0003-9861(66)90056-7; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Chen L, 2003, P NATL ACAD SCI USA, V100, P5658, DOI 10.1073/pnas.0931492100; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; Lovering AL, 2007, SCIENCE, V315, P1402, DOI 10.1126/science.1136611; Macheboeuf P, 2006, FEMS MICROBIOL REV, V30, P673, DOI 10.1111/j.1574-6976.2006.00024.x; Offant J, 2006, BBA-PROTEINS PROTEOM, V1764, P1036, DOI 10.1016/j.bbapap.2006.03.012; Ostash B, 2005, CURR OPIN CHEM BIOL, V9, P459, DOI 10.1016/j.cbpa.2005.08.014; Ostash B, 2007, CHEM BIOL, V14, P257, DOI 10.1016/j.chembiol.2007.01.008; PERLSTEIN DL, 2007, IN PRESS J AM CHEM S; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schiffer G, 1999, J BIOL CHEM, V274, P32031, DOI 10.1074/jbc.274.45.32031; Schwartz B, 2001, J AM CHEM SOC, V123, P11638, DOI 10.1021/ja0166848; Schwartz B, 2002, BIOCHEMISTRY-US, V41, P12552, DOI 10.1021/bi026205x; Spratt BG, 1996, MOL MICROBIOL, V19, P639, DOI 10.1046/j.1365-2958.1996.442924.x; Taylor JG, 2006, J AM CHEM SOC, V128, P15084, DOI 10.1021/ja065907x; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; Terrak M, 2006, J BACTERIOL, V188, P2528, DOI 10.1128/JB.188.7.2528-2532.2006; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VanNieuwenhze MS, 2002, J AM CHEM SOC, V124, P3656, DOI 10.1021/ja017386d; Vollmer W, 2004, J BACTERIOL, V186, P5978, DOI 10.1128/jb.186.18.5978-5987.2004; Welzel P, 2005, CHEM REV, V105, P4610, DOI 10.1021/cr040634e; Ye XY, 2001, J AM CHEM SOC, V123, P3155, DOI 10.1021/ja010028q; Yuan YQ, 2007, P NATL ACAD SCI USA, V104, P5348, DOI 10.1073/pnas.0701160104; Zhang Y, 2007, J AM CHEM SOC, V129, P3080, DOI 10.1021/ja069060g	32	60	62	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					31964	31971		10.1074/jbc.M705440200	http://dx.doi.org/10.1074/jbc.M705440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17704540	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000250480300017
J	Wu, H; Kao, SC; Barrientos, T; Baldwin, SH; Olson, EN; Crabtree, GR; Zhou, B; Chang, CP				Wu, Hai; Kao, Shih-Chu; Barrientos, Tomasa; Baldwin, Scott H.; Olson, Eric N.; Crabtree, Gerald R.; Zhou, Bin; Chang, Ching-Pin			Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-VALVE FORMATION; IN-VIVO; GENE-EXPRESSION; FETAL LOSS; NF-ATC; CALCINEURIN; CELLS; DSCR1; MORPHOGENESIS; HYPERTROPHY	Patients with Down syndrome have characteristic heart valve lesions resulting from endocardial cushion defects. The Down syndrome critical region 1 ( DSCR1) gene, identified at the conserved trisomic 21 region in those patients, encodes a calcineurin inhibitor that inactivates nuclear factor of activated T cells ( NFATc) activity. Here, we identify a regulatory sequence in the promoter region of human DSCR1 that dictates specific expression of a reporter gene in the endocardium, defined by the temporal and spatial expression of Nfatc1 during heart valve development. Activation of this evolutionally conserved DSCR1 regulatory sequence requires calcineurin and NFATc1 signaling in the endocardium. NFATc1 proteins bind to the regulatory sequence and trigger its enhancer activity. NFATc1 is sufficient to induce the expression of Dscr1 in cells that normally have undetectable or minimal NFATc1 or DSCR1. Pharmacologic inhibition of calcineurin or genetic Nfatc1 null mutation in mice abolishes the endocardial activity of this DSCR1 enhancer. Furthermore, in mice lacking endocardial NFATc1, the endogenous Dscr1 expression is specifically inhibited in the endocardium but not in the myocardium. Thus, our studies indicate that the DSCR1 gene is a direct transcriptional target of NFATc1 proteins within the endocardium during a critical window of heart valve formation.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Vanderbilt Univ, Dept Pediat Cardiol, Nashville, TN 37232 USA	Stanford University; Stanford University; Stanford University; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University	Chang, CP (corresponding author), CCSR Bldg,Rm 3115-C,269 Campus Dr, Stanford, CA 94305 USA.	chingpin@stanford.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078881] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL078881, R01 HL078881-01A2, R01 HL078881-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Chang CP, 2004, J CLIN INVEST, V113, P1051, DOI 10.1172/JCI200420049; Chang CP, 2003, GENESIS, V36, P7, DOI 10.1002/gene.10186; Chang CP, 2004, CELL, V118, P649, DOI 10.1016/j.cell.2004.08.010; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; EPSTEIN CJ, 1990, AM J MED GENET, P31; FERENCZ C, 1989, J PEDIATR-US, V114, P79, DOI 10.1016/S0022-3476(89)80605-5; GEGGEL RL, 1993, J PEDIATR-US, V122, P821, DOI 10.1016/S0022-3476(06)80036-3; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Lange AW, 2005, DEV DYNAM, V233, P954, DOI 10.1002/dvdy.20433; Lange AW, 2004, DEV BIOL, V266, P346, DOI 10.1016/j.ydbio.2003.10.036; Morris JK, 1999, PRENATAL DIAG, V19, P142, DOI 10.1002/(SICI)1097-0223(199902)19:2<142::AID-PD486>3.3.CO;2-Z; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Roper RJ, 2006, PLOS GENET, V2, P231, DOI 10.1371/journal.pgen.0020050; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sanna B, 2006, P NATL ACAD SCI USA, V103, P7327, DOI 10.1073/pnas.0509340103; Spencer K, 2001, PRENATAL DIAG, V21, P788, DOI 10.1002/pd.134; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhou B, 2005, DEVELOPMENT, V132, P1137, DOI 10.1242/dev.01640	31	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30673	30679		10.1074/jbc.M703622200	http://dx.doi.org/10.1074/jbc.M703622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17693409	Green Accepted, hybrid			2022-12-25	WOS:000250136300035
J	Anghel, SI; Bedu, E; Vivier, CD; Descombes, P; Desvergne, B; Wahli, W				Anghel, Silvia I.; Bedu, Elodie; Vivier, Celine Delucinge; Descombes, Patrick; Desvergne, Beatrice; Wahli, Walter			Adipose tissue integrity as a prerequisite for systemic energy balance - A critical role for peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PPAR-GAMMA; GENE-EXPRESSION; INSULIN-RESISTANCE; IGF-I; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MICE; MUSCLE; GLYCERONEOGENESIS; DIFFERENTIATION	Peroxisome proliferator- activated receptor gamma ( PPAR gamma) is an essential regulator of adipocyte differentiation, maintenance, and survival. Deregulations of its functions are associated with metabolic diseases. We show here that deletion of one PPAR gamma allele not only affected lipid storage but, more surprisingly, also the expression of genes involved in glucose uptake and utilization, the pentose phosphate pathway, fatty acid synthesis, lipolysis, and glycerol export as well as in IR/ IGF- 1 signaling. These deregulations led to reduced circulating adiponectin levels and an energy crisis in theWAT, reflected in a decrease to nearly half of its intracellular ATP content. In addition, there was a decrease in the metabolic rate and physical activity of the PPAR gamma(+/-) mice, which was abolished by thiazolidinedione treatment, thereby linking regulation of the metabolic rate and physical activity to PPAR gamma. It is likely that the PPAR gamma(+/-) phenotype was due to the observed WAT dysfunction, since the gene expression profiles associated with metabolic pathways were not affected either in the liver or the skeletal muscle. These findings highlight novel roles of PPAR gamma in the adipose tissue and underscore the multifaceted action of this receptor in the functional fine tuning of a tissue that is crucial for maintaining the organism in good health.	Univ Lausanne, Natl Res Ctr Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Geneva, Sch Med, Natl Res Ctr Frontiers Genet, CH-1211 Geneva, Switzerland	University of Lausanne; University of Geneva	Wahli, W (corresponding author), Univ Lausanne, Natl Res Ctr Frontiers Genet, Ctr Integrat Genom, Genopode Bldg, CH-1015 Lausanne, Switzerland.	walter.wahli@unil.ch	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Agostini M, 2004, ENDOCRINOLOGY, V145, P1527, DOI 10.1210/en.2003-1271; Allen T, 2006, DIABETES, V55, P2523, DOI 10.2337/db06-0618; Anghel SI, 2007, CELL RES, V17, P486, DOI 10.1038/cr.2007.48; Atsumi T, 2005, DIABETES, V54, P3349, DOI 10.2337/diabetes.54.12.3349; Beale EG, 2003, TRENDS BIOCHEM SCI, V28, P402, DOI 10.1016/S0968-0004(03)00163-4; Boden G, 2005, DIABETES, V54, P880, DOI 10.2337/diabetes.54.3.880; Cadoudal T, 2005, BIOCHIMIE, V87, P27, DOI 10.1016/j.biochi.2004.12.005; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010; Clement K, 2000, INT J OBESITY, V24, P391, DOI 10.1038/sj.ijo.0801191; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Duan SZ, 2007, J CLIN INVEST, V117, P812, DOI 10.1172/JCI28859; Feige JN, 2007, J BIOL CHEM, V282, P19152, DOI 10.1074/jbc.M702724200; Frick F, 2000, AM J PHYSIOL-ENDOC M, V278, pE729, DOI 10.1152/ajpendo.2000.278.4.E729; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Gerfault V, 1999, GEN COMP ENDOCR, V114, P396, DOI 10.1006/gcen.1999.7271; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Gosmain Y, 2005, J LIPID RES, V46, P697, DOI 10.1194/jlr.M400261-JLR200; Gosmain Y, 2004, DIABETES, V53, P321, DOI 10.2337/diabetes.53.2.321; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Hanson RW, 2003, BIOCHIMIE, V85, P1199, DOI 10.1016/j.biochi.2003.10.022; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hegele RA, 2000, GENOME RES, V10, P652, DOI 10.1101/gr.10.5.652; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Ioudina M, 2004, BRAIN RES, V1004, P188, DOI 10.1016/j.brainres.2003.12.046; Jan V, 2004, ANTIVIR THER, V9, P555; Jitrapakdee S, 2005, J BIOL CHEM, V280, P27466, DOI 10.1074/jbc.M503836200; Jo SH, 2006, J IMMUNOL, V177, P3737, DOI 10.4049/jimmunol.177.6.3737; Juge-Aubry CE, 2003, DIABETES, V52, P1104, DOI 10.2337/diabetes.52.5.1104; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; Koutnikova H, 2003, P NATL ACAD SCI USA, V100, P14457, DOI 10.1073/pnas.2336090100; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemasters JJ, 2005, GASTROENTEROLOGY, V129, P351, DOI 10.1053/j.gastro.2005.06.006; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Miyazaki Y, 2002, J CLIN ENDOCR METAB, V87, P2784, DOI 10.1210/jc.87.6.2784; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Ogura T, 2003, FEBS LETT, V542, P65, DOI 10.1016/S0014-5793(03)00339-9; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; Patsouris D, 2004, J CLIN INVEST, V114, P94, DOI 10.1172/JC1200420468; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Rieusset J, 2004, MOL ENDOCRINOL, V18, P2363, DOI 10.1210/me.2003-0325; Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; SAITO K, 2006, BIOCHIM BIOPHYS ACTA, V1761, P7093; Simha V, 2006, CURR OPIN LIPIDOL, V17, P162, DOI 10.1097/01.mol.0000217898.52197.18; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vickers MH, 2001, ENDOCRINOLOGY, V142, P3964, DOI 10.1210/en.142.9.3964; VOET D, 1990, BIOCHEMISTRY-US, P577; Wang T, 2006, ANNU REV PHYSIOL, V68, P223, DOI 10.1146/annurev.physiol.68.040104.105739; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	70	40	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29946	29957		10.1074/jbc.M702490200	http://dx.doi.org/10.1074/jbc.M702490200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699161	hybrid			2022-12-25	WOS:000249981200024
J	Lee, HHC; Walker, JA; Williams, JR; Goodier, RJ; Payne, JA; Moss, SJ				Lee, Henry H. C.; Walker, Joshua A.; Williams, Jeffery R.; Goodier, Richard J.; Payne, John A.; Moss, Stephen J.			Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL LOCALIZATION; INTRACELLULAR DOMAINS; NEURONAL MATURATION; MOUSE CEREBELLUM; EXPRESSION; TRANSMISSION; MODULATION; RECEPTORS; TERMINUS; SUBUNITS	The potassium chloride cotransporter KCC2 plays a major role inthemaintenanceoftransmembranechloridepotentialinmature neurons; thus KCC2 activity is critical for hyperpolarizing membrane currents generated upon the activation of gamma aminobutyric acid type A and glycine ( Gly) receptors that underlie fast synaptic inhibition in the adult central nervous system. However, to date an understanding of the cellular mechanism that neurons use to modulate the functional expression of KCC2 remains rudimentary. Using Escherichia coli expression coupled with in vitro kinase assays, we first established that protein kinaseC( PKC) can directly phosphorylate serine (940) ( Ser(940)) within the C- terminal cytoplasmic domain of KCC2. We further demonstrated that Ser(940) is the major site for PKC- dependent phosphorylation for full- length KCC2 molecules when expressed in HEK- 293 cells. Phosphorylation of Ser(940) increased the cell surface stability of KCC2 in this system by decreasing its rate of internalization from the plasma membrane. Coincident phosphorylation of Ser(940) increased the rate of ion transport by KCC2. It was further evident that phosphorylation of endogenous KCC2 in cultured hippocampal neurons is regulated by PKC- dependent activity. Moreover, in keeping with our recombinant studies, enhancing PKC- dependent phosphorylation increased the targeting of KCC2 to the neuronal cell surface. Our studies thus suggest that PKC- dependent phosphorylation of KCC2 may play a central role in modulating both the functional expression of this critical transporter in the brain and the strength of synaptic inhibition.	Univ Penn, Dept Neurosci, Sch Med, Philadelphia, PA 19104 USA; Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA; UCL, Dept Pharmacol, London WC1E 6BT, England	University of Pennsylvania; University of California System; University of California Davis; University of London; University College London	Moss, SJ (corresponding author), Univ Penn, Dept Neurosci, Sch Med, 215 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu	Lee, Henry/GVS-2114-2022; Lee, Henry HC/S-6014-2016	Lee, Henry HC/0000-0003-4975-7330	NINDS NIH HHS [NS-047478, NS-036296, NS-048045] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036296, R01NS048045, R01NS047478, R29NS036296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adragna NC, 2004, J MEMBRANE BIOL, V201, P109, DOI 10.1007/s00232-004-0695-6; Bergeron MJ, 2006, J BIOL CHEM, V281, P15959, DOI 10.1074/jbc.M600015200; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Couve A, 2002, NAT NEUROSCI, V5, P415, DOI 10.1038/nn833; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Fiumelli H, 2005, NEURON, V48, P773, DOI 10.1016/j.neuron.2005.10.025; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Karadsheh MF, 2001, J NEUROPHYSIOL, V85, P995, DOI 10.1152/jn.2001.85.2.995; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Lee H, 2005, EUR J NEUROSCI, V21, P2593, DOI 10.1111/j.1460-9568.2005.04084.x; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; McDonald BJ, 1997, NEUROPHARMACOLOGY, V36, P1377, DOI 10.1016/S0028-3908(97)00111-1; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Price TJ, 2005, CURR TOP MED CHEM, V5, P547, DOI 10.2174/1568026054367629; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Senawongse P, 2005, J CHEM INF MODEL, V45, P1147, DOI 10.1021/ci050047+; Staley KJ, 2004, ADV EXP MED BIOL, V548, P104; Stein V, 2004, J COMP NEUROL, V468, P57, DOI 10.1002/cne.10983; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Takayama C, 2006, NEUROSCIENCE, V143, P757, DOI 10.1016/j.neuroscience.2006.08.044; Takayama C, 2007, NEUROSCI RES, V57, P322, DOI 10.1016/j.neures.2006.10.016; Uvarov P, 2005, J NEUROCHEM, V95, P1144, DOI 10.1111/j.1471-4159.2005.03434.x; Wake H, 2007, J NEUROSCI, V27, P1642, DOI 10.1523/JNEUROSCI.3104-06.2007; Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656	28	198	201	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29777	29784		10.1074/jbc.M705053200	http://dx.doi.org/10.1074/jbc.M705053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693402	hybrid			2022-12-25	WOS:000249981200006
J	Im, E; Kazlauskas, A				Im, Eunok; Kazlauskas, Andrius			Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR-BETA-RECEPTOR; CELLULAR-TRANSFORMATION; MACULAR DEGENERATION; ANGIOGENESIS; ACTIVATION; RHO; DISEASE; CELLS; REQUIREMENT	Src family kinases (SFKs) are one of the signaling enzymes that contribute to angiogenesis, but their precise input to the various phases of the angiogenic program has not been defined. Using an in vitro model system, we discovered that SFKs promoted the formation of tubes and prevented their regression. They suppressed regression by activating the ERK pathway that antagonized the Rho/ROCK pathway, which was essential for regression. These studies reveal that SFKs contribute to several phases of the angiogenic program and identify the downstream effectors by which SFKs stabilize tubes.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	ak@eri.harvard.edu			NATIONAL EYE INSTITUTE [R03EY016385, R01EY018344] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY018344, EY016385] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Arcaro A, 2007, CELL SIGNAL, V19, P1081, DOI 10.1016/j.cellsig.2006.12.003; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004; Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GITLIN JD, 1983, MICROVASC RES, V26, P74, DOI 10.1016/0026-2862(83)90056-0; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Halstead JR, 2006, CURR BIOL, V16, P1850, DOI 10.1016/j.cub.2006.07.066; Halstead JR, 2005, TRENDS PHARMACOL SCI, V26, P654, DOI 10.1016/j.tips.2005.10.004; Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029; Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100; Im E, 2006, CELL CYCLE, V5, P2057, DOI 10.4161/cc.5.18.3210; Janiak A, 2006, MOL BIOL CELL, V17, P1606, DOI 10.1091/mbc.E05-06-0549; Jin W, 2007, CANCER RES, V67, P3192, DOI 10.1158/0008-5472.CAN-06-3526; Knott RM, 1999, DIABETOLOGIA, V42, P870, DOI 10.1007/s001250051240; LANG R, 1994, DEVELOPMENT, V120, P3395; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje; Qiao YF, 2006, SCIENCE, V311, P1293, DOI 10.1126/science.1122224; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Thamilselvan V, 2007, FASEB J, V21, P1730, DOI 10.1096/fj.06-6545com; Tolloczko B, 2002, AM J PHYSIOL-LUNG C, V282, pL1305, DOI 10.1152/ajplung.00304.2001; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Werdich Xiang Q., 2005, Angiogenesis, V8, P315	38	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29122	29129		10.1074/jbc.M702637200	http://dx.doi.org/10.1074/jbc.M702637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684019	hybrid			2022-12-25	WOS:000249788000007
J	Morten, IJ; Gosal, WS; Radford, SE; Hewitt, EW				Morten, Isobel J.; Gosal, Walraj S.; Radford, Sheena E.; Hewitt, Eric W.			Investigation into the role of macrophages in the formation and degradation of beta(2)-microglobulin amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS; DISULFIDE BOND; CELL-CULTURE; BETA-2-MICROGLOBULIN; PROTEIN; AGGREGATION; PATHOGENESIS; DEPOLYMERIZATION; PHAGOCYTOSIS	Dialysis related amyloidosis is a serious complication of longterm hemodialysis in which beta(2)-microglobulin (beta(2)m) forms amyloid fibrils that deposit predominantly in cartilaginous tissues. How these fibrils form in vivo, however, is poorly understood. Here we perform a systematic investigation into the role of macrophages in the formation and degradation of beta(2)m amyloid fibrils, building on observations that macrophages are found in association with beta(2)m amyloid deposits in vivo and that these cells contain intra-lysosomal beta(2)m amyloid. In live cell imaging experiments we demonstrate that macrophages internalize monomeric beta(2)m, whereupon it is sorted to lysosomes. At lysosomal pH beta(2)m self-associates in vitro to form amyloid-like fibrils with an array of morphologies as visualized by atomic force microscopy. Cleavage of the monomeric protein by both macrophages and lysosomal proteases isolated from these cells results in the rapid degradation of the monomeric protein, preventing amyloid formation. Incubation of macrophages with preformed fibrils revealed that macrophages internalize amyloid-like fibrils formed extracellularly, but in marked contrast with the monomeric protein, the fibrils were not degraded within macrophage lysosomes. Correspondingly beta(2)m fibrils were highly resistant to degradation by high concentrations of lysosomal proteases isolated from macrophages. Despite their enormous degradative capacity, therefore, macrophage lysosomes cannot ameliorate dialysis-related amyloidosis by degrading pre-existing amyloid fibrils, but lysosomal proteases may play a protective role by eliminating amyloid precursors before beta(2)m fibrils can accumulate in what may represent an otherwise fibrillogenic environment.	Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Hewitt, EW (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England.	e.w.hewitt@leeds.ac.uk	Gosal, Walraj/J-5260-2012	Gosal, Walraj/0000-0003-3396-1505; Radford, Sheena/0000-0002-3079-8039; Hewitt, Eric/0000-0002-6238-6303	Biotechnology and Biological Sciences Research Council [SF16972] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ARGILES A, 1994, NEPHROL DIAL TRANSPL, V9, P662, DOI 10.1093/ndt/9.6.662; Argiles A, 2002, NEPHROL DIAL TRANSPL, V17, P1136, DOI 10.1093/ndt/17.6.1136; Badman MK, 1998, CELL TISSUE RES, V291, P285, DOI 10.1007/s004410050998; Borysik AJ, 2007, KIDNEY INT, V72, P174, DOI 10.1038/sj.ki.5002270; CAMPISTOL JM, 1992, AM J PATHOL, V141, P241; Chen CS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-21; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DeLano W, 2000, PYMOL MOL GRAPHICS S; Elimova E, 2004, FASEB J, V18, P1749, DOI 10.1096/fj.03-1436fje; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Floege J, 1996, NEPHRON, V72, P9, DOI 10.1159/000188801; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Garcia-Garcia M, 1999, KIDNEY INT, V55, P899, DOI 10.1046/j.1523-1755.1999.055003899.x; Gargar C, 1999, KIDNEY INT, V55, P1983, DOI 10.1046/j.1523-1755.1999.00430.x; GEJYO F, 1986, NEW ENGL J MED, V314, P585; Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040; Heegaard NHH, 2005, BIOCHEMISTRY-US, V44, P4397, DOI 10.1021/bi047594t; IIDA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1235, DOI 10.1006/bbrc.1994.1837; INOUE H, 1995, NEPHROL DIAL TRANSPL, V10, P2077; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kluve-Beckerman B, 1999, AM J PATHOL, V155, P123, DOI 10.1016/S0002-9440(10)65107-3; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; LeVine H, 1997, ARCH BIOCHEM BIOPHYS, V342, P306, DOI 10.1006/abbi.1997.0137; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Mimmi MC, 2006, FEBS J, V273, P2461, DOI 10.1111/J.1742-4658.2006.05254.x; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYATA T, 1994, J CLIN INVEST, V93, P521, DOI 10.1172/JCI117002; MIYATA T, 1994, BIOCHEMISTRY-US, V33, P12215, DOI 10.1021/bi00206a026; Monti M, 2004, J MOL BIOL, V336, P253, DOI 10.1016/j.jmb.2003.10.082; Morten I. J., 2007, PROTEIN REV PROTEI B, V6, P217; MORTEN IJ, 2007, THESIS U LEEDS; Myers SL, 2006, BIOCHEMISTRY-US, V45, P2311, DOI 10.1021/bi052434i; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; O'Neill KD, 2003, NEPHROL DIAL TRANSPL, V18, P46, DOI 10.1093/ndt/18.1.46; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; OHASHI K, 1992, KIDNEY INT, V41, P1646, DOI 10.1038/ki.1992.237; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Relini A, 2006, J BIOL CHEM, V281, P16521, DOI 10.1074/jbc.M513827200; SARGENT MA, 1989, CLIN RADIOL, V40, P277, DOI 10.1016/S0009-9260(89)80201-6; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Stoppini M, 2005, BBA-PROTEINS PROTEOM, V1753, P23, DOI 10.1016/j.bbapap.2005.07.019; Stoppini M, 2000, KIDNEY INT, V57, P349, DOI 10.1046/j.1523-1755.2000.00851.x; Tagouri YM, 1996, LAB INVEST, V74, P290; Tennent GA, 1999, METHOD ENZYMOL, V309, P26; Tjelle TE, 2000, BIOESSAYS, V22, P255, DOI 10.1002/(SICI)1521-1878(200003)22:3<255::AID-BIES7>3.0.CO;2-R; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Yamaguchi I, 2003, KIDNEY INT, V64, P1080, DOI 10.1046/j.1523-1755.2003.00167.x; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com	60	27	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29691	29700		10.1074/jbc.M705004200	http://dx.doi.org/10.1074/jbc.M705004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686767	hybrid			2022-12-25	WOS:000249788000065
J	Zhong, ZH; Jiang, WQ; Cesare, AJ; Neumann, AA; Wadhwa, R; Reddel, RR				Zhong, Ze-Huai; Jiang, Wei-Qin; Cesare, Anthony J.; Neumann, Axel A.; Wadhwa, Renu; Reddel, Roger R.			Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; PROMYELOCYTIC LEUKEMIA BODIES; TELANGIECTASIA-LIKE DISORDER; DNA-REPAIR; ATAXIA-TELANGIECTASIA; HOMOLOGOUS RECOMBINATION; TARGETED DISRUPTION; CATALYTIC SUBUNIT; SYNDROME GENE; NBS1	Immortalized human cells are able to maintain their telomeres by telomerase or by a recombination-mediated DNA replication mechanism known as alternative lengthening of telomeres (ALT). We showed previously that overexpression of Sp100 protein can suppress ALT and that this was associated with sequestration of the MRE11/RAD50/NBS1 (MRN) recombination protein complex by Sp100. In the present study, we determined whether MRN proteins are required for ALT activity. ALT cells were depleted of MRN proteins by small hairpin RNA-mediated knockdown, which was maintained for up to 100 population doublings. Knockdown of NBS1 had no effect on the level of RAD50 or MRE11, but knockdown of RAD50 also depleted cells of NBS1, and knockdown of MRE11 depleted cells of all three MRN proteins. Depletion of NBS1, with or without depletion of other members of the complex, resulted in inhibition of ALT-mediated telomere maintenance, as evidenced by decreased numbers of ALT-associated promyelocytic leukemia bodies and decreased telomere length. In some clones there was an initial period of rapid shortening followed by stabilization of telomere length, whereas in others there was continuous shortening at a rate within the reported range for normal human somatic cells lacking a telomere maintenance mechanism. In contrast, depletion of NBS1 in telomerase-positive cells did not result in telomere shortening. A recent study showed that NBS1 was required for the formation of extrachromosomal telomeric circles (Compton, S. A., Choi, J. H., Cesare, A. J., Ozgur, S., and Griffith, J. D. (2007) Cancer Res. 67, 1513-1519), also a marker for ALT. We conclude that the MRN complex, and especially NBS1, is required for the ALT mechanism.	Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Natl Inst Adv Ind Sci & Technol, Cell Proliferat Res Grp, Res Inst Cell Engn, Tsukuba, Ibaraki 3058562, Japan	Children's Medical Research Institute - Australia; University of Sydney; National Institute of Advanced Industrial Science & Technology (AIST)	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Cesare, Anthony J/F-4691-2010; Reddel, Roger R/A-6635-2014; Neumann, Axel/D-3319-2012; Wadhwa, Renu/L-8898-2018; Cesare, Anthony/N-7415-2019	Cesare, Anthony J/0000-0002-0864-1254; Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192; Cesare, Anthony/0000-0002-0864-1254				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Compton SA, 2007, CANCER RES, V67, P1513, DOI 10.1158/0008-5472.CAN-06-3672; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; Gallego ME, 2001, P NATL ACAD SCI USA, V98, P1711, DOI 10.1073/pnas.98.4.1711; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Jiang WQ, 2007, ONCOGENE, V26, P4635, DOI 10.1038/sj.onc.1210260; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Ueno M, 2003, MOL CELL BIOL, V23, P6553, DOI 10.1128/MCB.23.18.6553-6563.2003; van Engelen BGM, 2001, HUM IMMUNOL, V62, P1324, DOI 10.1016/S0198-8859(01)00345-7; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	49	114	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29314	29322		10.1074/jbc.M701413200	http://dx.doi.org/10.1074/jbc.M701413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693401	hybrid			2022-12-25	WOS:000249788000028
J	Perez-Pinera, P; Zhang, W; Chang, YC; Vega, JA; Deuel, TF				Perez-Pinera, Pablo; Zhang, Wei; Chang, Yunchao; Antonio Vega, Jose; Deuel, Thomas F.			Anaplastic lymphoma kinase is activated through the Pleiotrophin/Receptor protein-tyrosine phosphatase beta/zeta signaling pathway - An alternative mechanism of receptor tyrosine kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; NON-HODGKINS-LYMPHOMA; NEURITE OUTGROWTH; BETA-ADDUCIN; ALK; GROWTH; PHOSPHORYLATION; GENE; IDENTIFICATION; EXPRESSION	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) first discovered as the constitutively active nucleophosmin ALK oncoprotein in anaplastic large cell lymphomas (ALCL). Fulllength ALK has a critical role in normal development and differentiation. Activated full-length ALK also is found in different malignant cancers. Nevertheless, the ligand to activate ALK remained unknown until recently, when ALK was proposed to be the physiological receptor of the cytokine pleiotrophin (PTN, Ptn). However, earlier studies had demonstrated that receptor protein tyrosine phosphatase (RPTP) beta/zeta is a physiological PTN receptor. We now demonstrate that phosphorylation of ALK in PTN-stimulated cells is mediated through the PTN/ RPTP beta/zeta signaling pathway. ALK is phosphorylated independently of a direct interaction of PTN with ALK. The data thus support a unique model of ALK activation. In cells not stimulated by PTN, RPTP beta/zeta dephosphorylates ALK at the site(s) in ALK that is undergoing autophosphorylation through autoactivation. In contrast, when RPTP beta/zeta is inactivated in PTN-stimulated cells, the sites that are autophosphorylated in ALK no longer can be dephosphorylated by RPTP beta/zeta; thus, autoactivation and tyrosine phosphorylation of ALK rapidly increase. The data indicate that the PTN/ RPTP beta/zeta signaling pathway is a critical regulator of the steady state levels of tyrosine phosphorylation and activation of ALK; the data support the conclusion that ALK phosphorylation and activation in PTN-stimulated cells are increased through a unique " alternative mechanism of RTK activation."	Scripps Res Inst, La Jolla, CA 92037 USA; Univ San Pablo CEU, Madrid, Spain	Scripps Research Institute; San Pablo CEU University	Deuel, TF (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tfdeuel@scripps.edu	Vega, Jose A/AAG-3209-2021	Perez-Pinera, Pablo/0000-0002-9167-0004	NCI NIH HHS [CA84400] Funding Source: Medline; NIDDK NIH HHS [2 T32 DK007022-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Dewang PM, 2005, CURR MED CHEM, V12, P1; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; Fukada M, 2006, FEBS LETT, V580, P4051, DOI 10.1016/j.febslet.2006.06.041; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; LEBEAU MM, 1989, LEUKEMIA, V3, P866; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Pariser H, 2005, P NATL ACAD SCI USA, V102, P12407, DOI 10.1073/pnas.0505901102; Pariser H, 2005, BIOCHEM BIOPH RES CO, V335, P232, DOI 10.1016/j.bbrc.2005.07.060; Pariser H, 2005, BIOCHEM BIOPH RES CO, V332, P664, DOI 10.1016/j.bbrc.2005.05.007; Perez-Pinera P, 2006, P NATL ACAD SCI USA, V103, P17795, DOI 10.1073/pnas.0607299103; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Schlessinger J, 1993, Harvey Lect, V89, P105; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Tamura H, 2006, NEUROSCI LETT, V399, P33, DOI 10.1016/j.neulet.2006.01.045; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Zhang N, 2006, BIOCHEM BIOPH RES CO, V343, P653, DOI 10.1016/j.bbrc.2006.03.006	33	107	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28683	28690		10.1074/jbc.M704505200	http://dx.doi.org/10.1074/jbc.M704505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681947	hybrid			2022-12-25	WOS:000249642100042
J	Schoenwaelder, SM; Ono, A; Sturgeon, S; Chan, SM; Mangin, P; Maxwell, MJ; Turnbull, S; Mulchandani, M; Anderson, K; Kauffenstein, G; Rewcastle, GW; Kendall, J; Gachet, C; Salem, HH; Jackson, SP				Schoenwaelder, Simone M.; Ono, Akiko; Sturgeon, Sharelle; Chan, Siew Mei; Mangin, Pierre; Maxwell, Mhairi J.; Turnbull, Shannon; Mulchandani, Megha; Anderson, Karen; Kauffenstein, Gilles; Rewcastle, Gordon W.; Kendall, Jackie; Gachet, Christian; Salem, Hatem H.; Jackson, Shaun P.			Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha(IIb)beta(3) adhesive function in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; BETA-GAMMA-SUBUNITS; CLASS-IA PI3K; CELL-ADHESION; COUPLED RECEPTORS; P2 RECEPTORS; ACTIVATION; AGGREGATION; 3-KINASE; KINASE	Phosphoinositide (PI) 3-kinases play an important role in regulating the adhesive function of a variety of cell types through affinity modulation of integrins. Two type IPI3-kinase isoforms(p110 beta and p110 gamma) have been implicated in G(i)-dependent integrin alpha IIb beta 3 regulation in platelets, however, the mechanisms by which they coordinate their signaling function remains unknown. By employing isoform-selective PI 3-kinase inhibitors and knock-out mouse models we have identified a unique mechanism of PI 3-kinase signaling co-operativity in platelets. We demonstrate that p110 beta is primarily responsible for Gi-dependent phosphatidylinositol 3,4-bisphosphate (PI(3,4) P-2) production in ADP-stimulated platelets and is linked to the activation of Rap1b and AKT. In contrast, defective integrin alpha(IIb)beta(3) activation in p110 gamma(-/)-platelets was not associated with alterations in the levels of PI(3,4) P2 or active Rap1b/ AKT. Analysis of the effects of active site pharmacological inhibitors confirmed that p110 gamma principally regulated integrin alpha(IIb)beta(3) activation through a non-catalytic signaling mechanism. Inhibitionof the kinase function of PI 3-kinases, combined with deletion of p110 gamma, led to a major reduction in integrin alpha(IIb)beta(3) activation, resulting in a profound defect in platelet aggregation, hemostatic plug formation, and arterial thrombosis. These studies demonstrate a kinaseindependent signaling function for p110 gamma in platelets. Moreover, they demonstrate that the combined catalytic and non-catalytic signaling function of p110 beta and p110 gamma is critical for P2Y(12)/ Gi-dependent integrin alpha(IIb)beta(3) regulation. These findings have potentially important implications for the rationale design of novel antiplatelet therapies targeting PI 3-kinase signaling pathways.	Monash Univ, Alfred Med Res & Educ Precint, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; EFS Alsace, INSERM U 311, Strasbourg, France; Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland 1020, New Zealand	Monash University; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Auckland	Jackson, SP (corresponding author), Monash Univ, Alfred Med Res & Educ Precint, Australian Ctr Blood Dis, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	Shaun.Jackson@med.monash.edu.au	Kauffenstein, Gilles/K-2867-2015; Maxwell, Mhairi/G-5492-2011; Schoenwaelder, Simone/E-9506-2011; Gachet, Christian/H-9156-2016; Mangin, Pierre/H-9354-2016	Kauffenstein, Gilles/0000-0003-4994-8305; Jackson, Shaun/0000-0002-4750-1991; Anderson, Karen/0000-0002-7394-6660; Schoenwaelder, Simone/0000-0003-0465-5840				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cosemans JMEM, 2006, BLOOD, V108, P3045, DOI 10.1182/blood-2006-03-006338; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; Eltit JM, 2006, J BIOL CHEM, V281, P12143, DOI 10.1074/jbc.M511218200; Feigelson SW, 2003, J BIOL CHEM, V278, P51203, DOI 10.1074/jbc.M303601200; Fergus GJ, 2007, NAT CELL BIOL, V9, P86, DOI 10.1038/ncb1517; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gachet C, 2005, PHARMACOL THERAPEUT, V108, P180, DOI 10.1016/j.pharmthera.2005.03.009; Gachet C, 2005, SEMIN THROMB HEMOST, V31, P162, DOI 10.1055/s-2005-869521; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Gukovsky I, 2004, GASTROENTEROLOGY, V126, P554, DOI 10.1053/j.gastro.2003.11.017; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Kauffenstein G, 2001, FEBS LETT, V505, P281, DOI 10.1016/S0014-5793(01)02824-1; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Lian LR, 2005, BLOOD, V106, P110, DOI 10.1182/blood-2004-05-2005; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Mangin P, 2006, BLOOD, V107, P4346, DOI 10.1182/blood-2005-10-4244; Maxwell MJ, 2007, BLOOD, V109, P566, DOI 10.1182/blood-2006-07-028282; Maxwell MJ, 2004, J BIOL CHEM, V279, P32196, DOI 10.1074/jbc.M400746200; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Paul BZS, 2003, J THROMB HAEMOST, V1, P814, DOI 10.1046/j.1538-7836.2003.00099.x; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Piccio L, 2002, J IMMUNOL, V168, P1940, DOI 10.4049/jimmunol.168.4.1940; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; SADHU C, 2003, Patent No. 20040266780; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Shankar H, 2004, BLOOD, V104, P1335, DOI 10.1182/blood-2004-01-0069; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Van Kolen K, 2004, J NEUROCHEM, V89, P442, DOI 10.1111/j.1471-4159.2004.02339.x; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang J, 2007, MOL CANCER THER, V6, P1143, DOI 10.1158/1535-7163.MCT-06-0555; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103; ZHAO JJ, 2006, SCI STKE	69	71	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28648	28658		10.1074/jbc.M704358200	http://dx.doi.org/10.1074/jbc.M704358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673465	hybrid			2022-12-25	WOS:000249642100039
J	Nielsen, HB; Mundy, J; Willenbrock, H				Nielsen, Henrik Bjorn; Mundy, John; Willenbrock, Hanni			Functional Associations by Response Overlap (FARO), a Functional Genomics Approach Matching Gene Expression Phenotypes	PLOS ONE			English	Article							ARABIDOPSIS-THALIANA; SIGNAL-TRANSDUCTION; MICROARRAY; REGULATOR; STRESS; MUTANT; MAP; CONNECTIVITY; SUMMARIES; PATHWAYS	The systematic comparison of transcriptional responses of organisms is a powerful tool in functional genomics. For example, mutants may be characterized by comparing their transcript profiles to those obtained in other experiments querying the effects on gene expression of many experimental factors including treatments, mutations and pathogen infections. Similarly, drugs may be discovered by the relationship between the transcript profiles effectuated or impacted by a candidate drug and by the target disease. The integration of such data enables systems biology to predict the interplay between experimental factors affecting a biological system. Unfortunately, direct comparisons of gene expression profiles obtained in independent, publicly available microarray experiments are typically compromised by substantial, experiment-specific biases. Here we suggest a novel yet conceptually simple approach for deriving 'Functional Association(s) by Response Overlap' (FARO) between microarray gene expression studies. The transcriptional response is defined by the set of differentially expressed genes independent from the magnitude or direction of the change. This approach overcomes the limited comparability between studies that is typical for methods that rely on correlation in gene expression. We apply FARO to a compendium of 242 diverse Arabidopsis microarray experimental factors, including phyto-hormones, stresses and pathogens, growth conditions/stages, tissue types and mutants. We also use FARO to confirm and further delineate the functions of Arabidopsis MAP kinase 4 in disease and stress responses. Furthermore, we find that a large, well-defined set of genes responds in opposing directions to different stress conditions and predict the effects of different stress combinations. This demonstrates the usefulness of our approach for exploiting public microarray data to derive biologically meaningful associations between experimental factors. Finally, our results indicate that FARO is more powerful in associating mutants in common pathways than existing methods such as co-expression analysis.	[Nielsen, Henrik Bjorn; Willenbrock, Hanni] Tech Univ Denmark, Bioctr, Ctr Biol Sequence Anal, Kongens Lyngby, Denmark; [Mundy, John] Univ Copenhagen, Bioctr, Inst Mol Biol, Copenhagen, Denmark	Technical University of Denmark; University of Copenhagen	Nielsen, HB (corresponding author), Tech Univ Denmark, Bioctr, Ctr Biol Sequence Anal, Kongens Lyngby, Denmark.	hbjorn@cbs.dtu.dk	mundy, john/A-2361-2013; Nielsen, Henrik Bjorn/B-8961-2019	mundy, john/0000-0001-7490-4588; Nielsen, Henrik Bjorn/0000-0003-2281-5713	Danish Center for Scientific Computing [LSHB-CT-2005-511977]; Danish Technical and Agricultural and Veterinary Research Councils	Danish Center for Scientific Computing; Danish Technical and Agricultural and Veterinary Research Councils	This study was supported financially by The Danish Center for Scientific Computing; EU, ADIT (IP), FP6, contract no.: LSHB-CT-2005-511977; and The Danish Technical and Agricultural and Veterinary Research Councils, in part via the STF program.	Andreasson E, 2005, EMBO J, V24, P2579, DOI 10.1038/sj.emboj.7600737; *ATGENEXPRESS, 2006, ATGENEXPRESS MULT CO; Blangiardo M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r54; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; BRODERSEN P, 2006, PLANT J; Buchanan-Wollaston V, 2005, PLANT J, V42, P567, DOI 10.1111/j.1365-313X.2005.02399.x; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Carlson MRJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-40; Conover WJ, 1971, PRACTICAL NONPARAMET, P97; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; de Lichtenberg U, 2005, BIOINFORMATICS, V21, P1164, DOI 10.1093/bioinformatics/bti093; Droillard MJ, 2004, FEBS LETT, V574, P42, DOI 10.1016/j.febslet.2004.08.001; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P15; Horak J, 2003, PLANT BIOLOGY, V5, P245, DOI 10.1055/s-2003-40789; Huang DS, 2006, BIOINFORMATICS, V22, P1259, DOI 10.1093/bioinformatics/btl065; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kiba T, 2005, PLANT CELL PHYSIOL, V46, P339, DOI 10.1093/pcp/pci033; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lee HK, 2004, GENOME RES, V14, P1085, DOI 10.1101/gr.1910904; Lottaz C, 2006, BIOINFORMATICS, V22, P2315, DOI 10.1093/bioinformatics/btl385; Marshall E, 2004, SCIENCE, V306, P630, DOI 10.1126/science.306.5696.630; Martinez C, 2004, PLANT J, V37, P209, DOI 10.1046/j.1365-313X.2003.01954.x; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Miklos GLG, 2004, NAT BIOTECHNOL, V22, P615, DOI 10.1038/nbt965; Mittler R, 2006, TRENDS PLANT SCI, V11, P15, DOI 10.1016/j.tplants.2005.11.002; Mizuno T, 2004, CURR OPIN PLANT BIOL, V7, P499, DOI 10.1016/j.pbi.2004.07.015; Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tajima Y, 2004, PLANT CELL PHYSIOL, V45, P28, DOI 10.1093/pcp/pcg154; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Teige M, 2004, MOL CELL, V15, P141, DOI 10.1016/j.molcel.2004.06.023; Thilmony R, 2006, PLANT J, V46, P34, DOI 10.1111/j.1365-313X.2006.02725.x; Van Driessche N, 2005, NAT GENET, V37, P471, DOI 10.1038/ng1545; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	44	14	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e676	10.1371/journal.pone.0000676	http://dx.doi.org/10.1371/journal.pone.0000676			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668056	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452300014
J	Santos, JG; Vomel, M; Struck, R; Homberg, U; Nassel, DR; Wegener, C				Santos, Jonathan G.; Voemel, Matthias; Struck, Rafael; Homberg, Uwe; Nassel, Dick R.; Wegener, Christian			Neuroarchitecture of Peptidergic Systems in the Larval Ventral Ganglion of Drosophila melanogaster	PLOS ONE			English	Article							PIGMENT-DISPERSING FACTOR; CENTRAL-NERVOUS-SYSTEM; CRUSTACEAN CARDIOACTIVE PEPTIDE; FMRFAMIDE NEUROPEPTIDE GENE; IMMUNOREACTIVE VPLI NEURONS; TACHYKININ-RELATED PEPTIDES; VASOPRESSIN-LIKE; CLOCK NEURONS; FRUIT-FLY; IMMUNOCYTOCHEMICAL LOCALIZATION	Recent studies on Drosophila melanogaster and other insects have revealed important insights into the functions and evolution of neuropeptide signaling. In contrast, in- and output connections of insect peptidergic circuits are largely unexplored. Existing morphological descriptions typically do not determine the exact spatial location of peptidergic axonal pathways and arborizations within the neuropil, and do not identify peptidergic in- and output compartments. Such information is however fundamental to screen for possible peptidergic network connections, a prerequisite to understand how the CNS controls the activity of peptidergic neurons at the synaptic level. We provide a precise 3D morphological description of peptidergic neurons in the thoracic and abdominal neuromeres of the Drosophila larva based on fasciclin-2 (Fas2) immunopositive tracts as landmarks. Comparing the Fas2 "coordinates'' of projections of sensory or other neurons with those of peptidergic neurons, it is possible to identify candidate in-and output connections of specific peptidergic systems. These connections can subsequently be more rigorously tested. By immunolabeling and GAL4-directed expression of marker proteins, we analyzed the projections and compartmentalization of neurons expressing 12 different peptide genes, encoding approximately 75% of the neuropeptides chemically identified within the Drosophila CNS. Results are assembled into standardized plates which provide a guide to identify candidate afferent or target neurons with overlapping projections. In general, we found that putative dendritic compartments of peptidergic neurons are concentrated around the median Fas2 tracts and the terminal plexus. Putative peptide release sites in the ventral nerve cord were also more laterally situated. Our results suggest that i) peptidergic neurons in the Drosophila ventral nerve cord have separated in- and output compartments in specific areas, and ii) volume transmission is a prevailing way of peptidergic communication within the CNS. The data can further be useful to identify colocalized transmitters and receptors, and develop peptidergic neurons as new landmarks.	[Santos, Jonathan G.; Voemel, Matthias; Struck, Rafael; Wegener, Christian] Univ Marburg, Dept Biol, Emmy Noether Neuropeptide Grp, Marburg, Germany; [Nassel, Dick R.] Stockholm Univ, Dept Zool, S-10691 Stockholm, Sweden	Philipps University Marburg; Stockholm University	Wegener, C (corresponding author), Univ Marburg, Dept Biol, Emmy Noether Neuropeptide Grp, Marburg, Germany.	wegener@staff.uni-marburg.de	Homberg, Uwe/AFH-8214-2022	Homberg, Uwe/0000-0002-8229-7236; Wegener, Christian/0000-0003-4481-3567	Deutsche Forschungsgemeinschaft (DFG) [We 2652/2-1,2]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft (DFG We 2652/2-1,2) to CW.	AGNATI LF, 1995, NEUROSCIENCE, V69, P711, DOI 10.1016/0306-4522(95)00308-6; AGRICOLA H, 1985, CELL TISSUE RES, V239, P203, DOI 10.1007/BF00214920; AGRICOLA H. J., 1995, NERVOUS SYSTEMS INVE, P303; Allan DW, 2003, CELL, V113, P73, DOI 10.1016/S0092-8674(03)00204-6; ANDERSON MS, 1988, J NEUROSCI, V8, P242; Baggerman G, 2005, J MASS SPECTROM, V40, P250, DOI 10.1002/jms.744; Baraban SC, 2004, TRENDS NEUROSCI, V27, P135, DOI 10.1016/j.tins.2004.01.008; Bate Michael, 1993, P1013; Baumgardt M, 2007, PLOS BIOL, V5, P295, DOI 10.1371/journal.pbio.0050037; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CANTERA R, 1992, CELL TISSUE RES, V269, P459, DOI 10.1007/BF00353901; CHIN AC, 1990, DNA CELL BIOL, V9, P263, DOI 10.1089/dna.1990.9.263; Choi MY, 2001, CELL TISSUE RES, V306, P459, DOI 10.1007/s00441-001-0467-x; Choi YJ, 2005, J COMP NEUROL, V482, P372, DOI 10.1002/cne.20419; Claeys I, 2002, PEPTIDES, V23, P807, DOI 10.1016/S0196-9781(01)00666-0; DIRCKSEN H, 1988, CELL TISSUE RES, V254, P347; DIRCKSEN H, 1987, CELL TISSUE RES, V250, P377; Dulcis D, 2005, J NEUROBIOL, V64, P259, DOI 10.1002/neu.20136; East PD, 1997, TISSUE CELL, V29, P347, DOI 10.1016/S0040-8166(97)80010-9; ECKERT M, 1981, CELL TISSUE RES, V217, P633; Eckert M, 2002, J COMP NEUROL, V452, P264, DOI 10.1002/cne.10382; Estes PS, 2000, J NEUROGENET, V13, P233, DOI 10.3109/01677060009084496; Ewer J, 2005, HORM BEHAV, V48, P418, DOI 10.1016/j.yhbeh.2005.05.018; Ewer J, 1996, J COMP NEUROL, V370, P330; Gade G, 1997, PHYSIOL REV, V77, P963, DOI 10.1152/physrev.1997.77.4.963; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Grueber WB, 2007, DEVELOPMENT, V134, P55, DOI 10.1242/dev.02666; Hamasaka Y, 2006, J COMP NEUROL, V494, P314, DOI 10.1002/cne.20807; Hamasaka Y, 2005, J NEUROBIOL, V65, P225, DOI 10.1002/neu.20184; Hamasaka Y, 2005, J INSECT SCI, V5, DOI 10.1093/jis/5.1.43; Hartenstein V, 2006, J ENDOCRINOL, V190, P555, DOI 10.1677/joe.1.06964; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; Hewes RS, 2003, DEVELOPMENT, V130, P1771, DOI 10.1242/dev.00404; Hewes RS, 1998, J NEUROSCI, V18, P7138; HORODYSKI FM, 1993, EUR J BIOCHEM, V215, P221, DOI 10.1111/j.1432-1033.1993.tb18026.x; Husain QM, 2004, J NEUROBIOL, V59, P181, DOI 10.1002/neu.10309; Hyun S, 2005, NEURON, V48, P267, DOI 10.1016/j.neuron.2005.08.025; Ito K, 2003, MICROSC RES TECHNIQ, V62, P170, DOI 10.1002/jemt.10369; Johnson E, 2000, J INSECT PHYSIOL, V46, P1229, DOI 10.1016/S0022-1910(00)00043-3; Johnson E. C., 2006, Invertebrate neuropeptides and hormones: basic knowledge and recent advances, P179; Johnson EC, 2005, J EXP BIOL, V208, P1239, DOI 10.1242/jeb.01529; Katz PS, 1996, TRENDS NEUROSCI, V19, P54, DOI 10.1016/0166-2236(96)89621-4; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; Kim YJ, 2004, P NATL ACAD SCI USA, V101, P6704, DOI 10.1073/pnas.0305291101; Kim YJ, 2006, CURR BIOL, V16, P1395, DOI 10.1016/j.cub.2006.06.027; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; KUTSCH W, 1994, ADV INSECT PHYSIOL, V24, P1, DOI 10.1016/S0065-2806(08)60082-X; Landgraf M, 2003, DEV BIOL, V260, P207, DOI 10.1016/S0012-1606(03)00215-X; Lee D, 2003, J NEUROSCI, V23, P4625; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P1126, DOI 10.1006/bbrc.2000.3062; Lohr R, 2002, J NEUROSCI, V22, P10357; Luan HJ, 2006, J NEUROSCI, V26, P573, DOI 10.1523/JNEUROSCI.3916-05.2006; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; MADDRELL SH, 1964, J EXP BIOL, V41, P459; MARDER E, 1987, J COMP NEUROL, V259, P150, DOI 10.1002/cne.902590111; McIver S.B., 1985, P71; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; Melcher C, 2006, PLOS BIOL, V4, P316, DOI 10.1371/journal.pbio.0040068; Melcher C, 2005, PLOS BIOL, V3, P1618, DOI 10.1371/journal.pbio.0030305; Meng XJ, 2002, MECH DEVELOP, V117, P5, DOI 10.1016/S0925-4773(02)00175-2; Mertens I, 2005, NEURON, V48, P213, DOI 10.1016/j.neuron.2005.09.009; Monastirioti M, 1999, MICROSC RES TECHNIQ, V45, P106, DOI 10.1002/(SICI)1097-0029(19990415)45:2<106::AID-JEMT5>3.3.CO;2-V; Mulloney B, 2003, MICROSC RES TECHNIQ, V60, P253, DOI 10.1002/jemt.10265; MURPHEY RK, 1985, J COMP PHYSIOL A, V156, P381, DOI 10.1007/BF00610730; Nassel DR, 2006, CELL TISSUE RES, V326, P1, DOI 10.1007/s00441-006-0210-8; NASSEL DR, 1992, J COMP NEUROL, V322, P45, DOI 10.1002/cne.903220105; NASSEL DR, 1989, J COMP NEUROL, V283, P450, DOI 10.1002/cne.902830312; Nassel DR, 2002, PROG NEUROBIOL, V68, P1, DOI 10.1016/S0301-0082(02)00057-6; Nassel DR, 1996, PROG NEUROBIOL, V48, P325, DOI 10.1016/0301-0082(95)00048-8; NEUPERT S, 2006, P INV NEUR C GUAN ME; Nijhout H, 2003, DEV BIOL, V261, P1, DOI 10.1016/S0012-1606(03)00276-8; Nusbaum MP, 2001, TRENDS NEUROSCI, V24, P146, DOI 10.1016/S0166-2236(00)01723-9; O'Brien MA, 1998, J EXP BIOL, V201, P193; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Park JH, 2003, DEVELOPMENT, V130, P2645, DOI 10.1242/dev.00503; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Persson MGS, 2001, J NEUROBIOL, V48, P19, DOI 10.1002/neu.1040; PFLUGER HJ, 1988, PHILOS T R SOC B, V321, P1, DOI 10.1098/rstb.1988.0090; Predel R, 2004, J COMP NEUROL, V474, P379, DOI 10.1002/cne.20145; Predel R, 2001, J COMP NEUROL, V436, P363; Predel R, 2001, PEPTIDES, V22, P199, DOI 10.1016/S0196-9781(00)00383-1; Predel R, 2007, J COMP NEUROL, V500, P498, DOI 10.1002/cne.21183; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Sanchez-Soriano N, 2005, DEV BIOL, V288, P126, DOI 10.1016/j.ydbio.2005.09.026; Santos JG, 2006, CELL TISSUE RES, V326, P187, DOI 10.1007/s00441-006-0211-7; SCHNEIDER LE, 1993, J COMP NEUROL, V337, P446, DOI 10.1002/cne.903370308; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHNEIDER LE, 1991, J COMP NEUROL, V304, P608, DOI 10.1002/cne.903040408; Schrader S, 2000, J COMP NEUROL, V425, P34; Siviter RJ, 2000, J BIOL CHEM, V275, P23273, DOI 10.1074/jbc.M002875200; Strand P., 1999, P 4 INT C ENV RAD AR; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; Suster ML, 2003, J NEUROBIOL, V55, P233, DOI 10.1002/neu.10202; TAGHERT PH, 1990, J NEUROSCI, V10, P1929; Taghert PH, 2003, ADV GENET, V49, P1, DOI 10.1016/S0065-2660(03)01001-0; Taylor CAM, 2004, J NEUROBIOL, V58, P379, DOI 10.1002/neu.10301; Terhzaz S, 1999, J EXP BIOL, V202, P3667; Terhzaz S, 2007, BIOCHEM BIOPH RES CO, V352, P305, DOI 10.1016/j.bbrc.2006.11.030; THOMPSON KSJ, 1991, J COMP PHYSIOL A, V168, P605, DOI 10.1007/BF00215083; THOMPSON KSJ, 1991, J COMP PHYSIOL A, V168, P619, DOI 10.1007/BF00215084; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V204, P292, DOI 10.1006/bbrc.1994.2458; VEENSTRA JA, 1991, PEPTIDES, V12, P1285, DOI 10.1016/0196-9781(91)90208-7; Verleyen P, 2004, BIOCHEM BIOPH RES CO, V320, P334, DOI 10.1016/j.bbrc.2004.05.173; Verleyen P, 2004, J NEUROCHEM, V88, P311, DOI 10.1046/j.1471-4159.2003.02161.x; Vitzthum H, 1996, J COMP NEUROL, V369, P419, DOI 10.1002/(SICI)1096-9861(19960603)369:3&lt;419::AID-CNE7&gt;3.0.CO;2-8; Vomel M, 2007, DEV NEUROBIOL, V67, P792, DOI 10.1002/dneu.20392; Wegener C, 2006, J NEUROCHEM, V96, P1362, DOI 10.1111/j.1471-4159.2005.03634.x; Wegener C, 2004, J NEUROPHYSIOL, V91, P912, DOI 10.1152/jn.00678.2003; WHITE K, 1986, J COMP NEUROL, V247, P430, DOI 10.1002/cne.902470403; Williamson M, 2001, BIOCHEM BIOPH RES CO, V281, P544, DOI 10.1006/bbrc.2001.4402; Winther AME, 2006, MOL CELL NEUROSCI, V31, P399, DOI 10.1016/j.mcn.2005.10.010; Winther AME, 2003, J COMP NEUROL, V464, P180, DOI 10.1002/cne.10790; Winther AME, 2001, J EXP BIOL, V204, P1269; Wu Q, 2003, NEURON, V39, P147, DOI 10.1016/S0896-6273(03)00396-9; Yoon JG, 1995, J COMP NEUROL, V363, P475, DOI 10.1002/cne.903630310; Zawarzin A, 1924, Z WISS ZOOL ABT A, V122, P323; Zitnan D, 2004, COMPREHENSIVE MOL IN, P1; Zlatic M, 2003, NEURON, V37, P41, DOI 10.1016/S0896-6273(02)01131-5	121	51	51	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e695	10.1371/journal.pone.0000695	http://dx.doi.org/10.1371/journal.pone.0000695			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668072	gold, Green Published			2022-12-25	WOS:000207452300030
J	Suga, K; Welch, DM; Tanaka, Y; Sakakura, Y; Hagiwara, A				Suga, Koushirou; Welch, David Mark; Tanaka, Yukari; Sakakura, Yoshitaka; Hagiwara, Atsushi			Analysis of Expressed Sequence Tags of the Cyclically Parthenogenetic Rotifer Brachionus plicatilis	PLOS ONE			English	Article							POPULATION-GROWTH; GENE-EXPRESSION; SEXUAL REPRODUCTION; SPECIES COMPLEX; GENERATION; EVOLUTION; PATTERNS; DIFFERENTIATION; SPECIATION; PHYLOGENY	Background. Rotifers are among the most common non-arthropod animals and are the most experimentally tractable members of the basal assemblage of metazoan phyla known as Gnathifera. The monogonont rotifer Brachionus plicatilis is a developing model system for ecotoxicology, aquatic ecology, cryptic speciation, and the evolution of sex, and is an important food source for finfish aquaculture. However, basic knowledge of the genome and transcriptome of any rotifer species has been lacking. Methodology/Principal Findings. We generated and partially sequenced a cDNA library from B. plicatilis and constructed a database of over 2300 expressed sequence tags corresponding to more than 450 transcripts. About 20% of the transcripts had no significant similarity to database sequences by BLAST; most of these contained open reading frames of significant length but few had recognized Pfam motifs. Sixteen transcripts accounted for 25% of the ESTs; four of these had no significant similarity to BLAST or Pfam databases. Putative up-and downstream untranslated regions are relatively short and AT rich. In contrast to bdelloid rotifers, there was no evidence of a conserved trans-spliced leader sequence among the transcripts and most genes were single-copy. Conclusions/Significance. Despite the small size of this EST project it revealed several important features of the rotifer transcriptome and of individual monogonont genes. Because there is little genomic data for Gnathifera, the transcripts we found with no known function may represent genes that are species-, class-, phylum-or even superphylum-specific; the fact that some are among the most highly expressed indicates their importance. The absence of trans-spliced leader exons in this monogonont species contrasts with their abundance in bdelloid rotifers and indicates that the presence of this phenomenon can vary at the subphylum level. Our EST database provides a relatively large quantity of transcript-level data for B. plicatilis, and more generally of rotifers and other gnathiferan phyla, and can be browsed and searched at gmod.mbl.edu.	[Welch, David Mark] Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA; [Suga, Koushirou; Tanaka, Yukari] Nagasaki Ind Promot Fdn, Omura, Japan; [Sakakura, Yoshitaka] Nagasaki Univ, Fac Fisheries, Nagasaki 852, Japan; [Hagiwara, Atsushi] Nagasaki Univ, Grad Sch Sci & Technol, Nagasaki 852, Japan	Marine Biological Laboratory - Woods Hole; Nagasaki University; Nagasaki University	Welch, DM (corresponding author), Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA.	dmarkwelch@mbl.edu	Hagiwara, Atsushi/O-3606-2018; Sakakura, Yoshitaka/AAL-9491-2020	Hagiwara, Atsushi/0000-0001-7514-8737; Sakakura, Yoshitaka/0000-0003-0205-8364; Mark Welch, David/0000-0001-9774-4580	Nagasaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, Japan Science and Technology Agency; US NSF [EF-0412674, MCB-0544199]	Nagasaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); US NSF(National Science Foundation (NSF))	This research was supported by the Nagasaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, Japan Science and Technology Agency to KS, YT, YS and AH, and US NSF grants EF-0412674 and MCB-0544199 to DMW.	Allen E J, 1910, J MAR BIOL ASS, V8, P421, DOI [DOI 10.1017/50025315400073690, DOI 10.1017/S0025315400073690]; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASAMIZU E, 1999, DNA RES, V6; Birney E, 2004, GENOME RES, V14, P988, DOI 10.1101/gr.1865504; CAIN GD, 1970, ARCH BIOCHEM BIOPHYS, V141, P264, DOI 10.1016/0003-9861(70)90131-1; Campillo S, 2005, HYDROBIOLOGIA, V546, P181, DOI 10.1007/s10750-005-4120-7; Caprioli M, 2004, COMP BIOCHEM PHYS A, V139, P527, DOI 10.1016/j.cbpb.2004.10.019; CHAO A, 1984, SCAND J STAT, V11, P265; Chen L, 2005, PLANT SCI, V168, P359, DOI 10.1016/j.plantsci.2004.08.009; Chou HH, 2001, BIOINFORMATICS, V17, P1093, DOI 10.1093/bioinformatics/17.12.1093; CLEMENT P, 1993, HYDROBIOLOGIA, V255, P527, DOI 10.1007/BF00025882; Derry AM, 2003, LIMNOL OCEANOGR, V48, P675, DOI 10.4319/lo.2003.48.2.0675; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gallardo WG, 1997, HYDROBIOLOGIA, V358, P113, DOI 10.1023/A:1003124205002; Gallardo WG, 1999, J EXP MAR BIOL ECOL, V240, P179, DOI 10.1016/S0022-0981(99)00055-6; Giribet G, 2000, SYST BIOL, V49, P539, DOI 10.1080/10635159950127385; Gomez A, 2005, HYDROBIOLOGIA, V546, P83, DOI 10.1007/s10750-005-4104-7; Gomez A, 2002, EVOLUTION, V56, P1431; Gomez A, 2002, J EVOLUTION BIOL, V15, P158, DOI 10.1046/j.1420-9101.2002.00368.x; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HAGIWARA A, 1993, NIPPON SUISAN GAKK, V59, P93, DOI 10.2331/suisan.59.93; Hagiwara A, 2001, AQUACULTURE, V200, P111, DOI 10.1016/S0044-8486(01)00696-2; HAGIWARA A, 1994, ISR J AQUACULT-BAMID, V46, P13; Harcus YM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r39; Hastings KEM, 2005, TRENDS GENET, V21, P240, DOI 10.1016/j.tig.2005.02.005; HIRAYAMA K, 1983, B JPN SOC SCI FISH, V49, P505; Hutchinson G. E., 1957, TREATISE LIMNOLOGY, VI; Kaneko G, 2005, HYDROBIOLOGIA, V546, P117, DOI 10.1007/s10750-005-4107-4; Kaneko G, 2002, FISHERIES SCI, V68, P1317, DOI 10.1046/j.1444-2906.2002.00570.x; Lapinski J, 2003, FEBS LETT, V553, P387, DOI 10.1016/S0014-5793(03)01062-7; Lee YM, 2005, MAR POLLUT BULL, V51, P757, DOI 10.1016/j.marpolbul.2005.02.014; Lehane MJ, 1997, ANNU REV ENTOMOL, V42, P525, DOI 10.1146/annurev.ento.42.1.525; Marcial HS, 2005, HYDROBIOLOGIA, V546, P569, DOI 10.1007/s10750-005-4302-3; Markus R, 2005, IMMUNOL LETT, V101, P108, DOI 10.1016/j.imlet.2005.03.021; Miyakawa M., 1988, Suisan Zoshoku, V35, P237; Nakamura Kazuyo, 1994, Mycoscience, V35, P383, DOI 10.1007/BF02268509; Ortells R, 2003, FRESHWATER BIOL, V48, P2194, DOI 10.1046/j.1365-2427.2003.01159.x; Ortells R, 2000, ARCH HYDROBIOL, V149, P529; Papakostas S, 2005, MAR BIOL, V147, P1129, DOI 10.1007/s00227-005-0012-7; Pouchkina-Stantcheva NN, 2005, MOL BIOL EVOL, V22, P1482, DOI 10.1093/molbev/msi139; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Sawbridge T, 2003, PLANT SCI, V165, P1077, DOI 10.1016/S0168-9452(03)00303-0; SCOTT JM, 1983, HYDROBIOLOGIA, V104, P155, DOI 10.1007/BF00045963; Serrano MG, 2002, EQUINE VET J, V34, P135; Snell TW, 2006, MAR BIOL, V149, P763, DOI 10.1007/s00227-006-0251-2; Snell TW, 2003, ECOTOXICOLOGY, V12, P475, DOI 10.1023/B:ECTX.0000003033.09923.a8; Snell TW, 1995, HYDROBIOLOGIA, V313, P231, DOI 10.1007/BF00025956; Snell TW, 1999, CUR TOP ECOTOX ENVIR, P169; Stelzer CP, 2003, LIMNOL OCEANOGR, V48, P939, DOI 10.4319/lo.2003.48.2.0939; Suatoni E, 2006, MOL PHYLOGENET EVOL, V41, P86, DOI 10.1016/j.ympev.2006.04.025; Wallace R.L., 2001, ECOLOGY CLASSIFICATI, P187; Watanabe H, 2005, GENOME, V48, P606, DOI 10.1139/G05-038; Welch DBM, 2000, INVERTEBR BIOL, V119, P17; Welch DBM, 2001, HYDROBIOLOGIA, V446, P315, DOI 10.1023/A:1017502923286; Welch DBM, 2001, HYDROBIOLOGIA, V446, P333, DOI 10.1023/A:1017511108265; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211; Yang YZ, 2003, FEBS LETT, V538, P183, DOI 10.1016/S0014-5793(03)00164-9; Yoshinaga T, 2003, J EXP MAR BIOL ECOL, V287, P261, DOI 10.1016/S0022-0981(02)00574-9	60	50	50	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e671	10.1371/journal.pone.0000671	http://dx.doi.org/10.1371/journal.pone.0000671			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668053	Green Published, gold			2022-12-25	WOS:000207452300011
J	Barzon, L; Trevisan, M; Masi, G; Pacenti, M; Sinigaglia, A; Macchi, V; Porzionato, A; De Caro, R; Favia, G; Iacobone, M; Palu, G				Barzon, L.; Trevisan, M.; Masi, G.; Pacenti, M.; Sinigaglia, A.; Macchi, V.; Porzionato, A.; De Caro, R.; Favia, G.; Iacobone, M.; Palu, G.			Detection of polyomaviruses and herpesviruses in human adrenal tumors	ONCOGENE			English	Article						adrenal gland neoplasms; herpesviruses; polyomaviruses; pheochromocytoma; adrenocortical carcinoma; hypercortisolism	EPSTEIN-BARR-VIRUS; GLUCOCORTICOID-RESPONSIVE ELEMENT; SARCOMA-ASSOCIATED HERPESVIRUS; TRANSGENIC MICE; CELL-LINES; JC VIRUS; HUMAN CYTOMEGALOVIRUS; CONTROL REGION; T-ANTIGEN; INFECTION	The presence of polyomaviruses and herpesviruses in adrenal tumors and their role in adrenal tumorigenesis has never been investigated, even though the adrenal gland seems to be a preferential site of infection by these viruses and adrenal steroid hormones have been shown to activate their replication. We examined in a large series of normal adrenal gland tissues (n = 20) and adrenal tumors (n = 107) the presence of herpesviruses and polyomaviruses sequences and gene expression, which were detected in a high proportion of both normal and neoplastic adrenal samples (overall, viruses were found in 15% normal adrenals, 27.8% benign adrenal tumors and 35.3% malignant tumors). The polyomaviruses SV40 and BK virus were more frequently found in malignant adrenal tumors, whereas herpesviruses, especially Epstein-Barr virus and human cytomegalovirus, were more frequently detected in functioning benign adrenocortical tumors, often as coinfection. Moreover, tumors from patients with severe hypercortisolism frequently showed herpesvirus coinfections at high viral genome copy number. Our study suggests that the adrenal gland could be a reservoir of infection for these viruses and that hormone overproduction by the adrenal gland could represent a trigger for virus reactivation. On the other hand, these viruses could also contribute to adrenal cell proliferation and tumorigenesis.	[Barzon, L.; Trevisan, M.; Masi, G.; Pacenti, M.; Sinigaglia, A.; Palu, G.] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy; [Macchi, V.; Porzionato, A.; De Caro, R.] Univ Padua, Dept Human Anat & Physiol, Padua, Italy; [Favia, G.; Iacobone, M.] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy	University of Padua; University of Padua; University of Padua	Barzon, L (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via A Gabelli 63, I-35121 Padua, Italy.	luisa.barzon@unipd.it; giorgio.palu@unipd.it	Barzon, Luisa/K-7961-2016; Masi, Giulia/K-1577-2016; Iacobone, Maurizio/K-8714-2016; Macchi, Veronica/AAV-4514-2020; TREVISAN, MARTA/K-6591-2016	Barzon, Luisa/0000-0003-0720-8456; Masi, Giulia/0000-0001-9138-9186; Macchi, Veronica/0000-0003-2335-6897; Pacenti, Monia/0000-0002-9792-9195; TREVISAN, MARTA/0000-0002-3148-7240; sinigaglia, alessandro/0000-0002-2386-1757; Iacobone, Maurizio/0000-0002-6057-4642				Aita K, 2001, ARCH VIROL, V146, P2009, DOI 10.1007/s007050170048; AMSTEY MS, 1977, AM J OBSTET GYNECOL, V15, P159; Barzon I, 2005, EUR J ENDOCRINOL, V153, P629, DOI 10.1530/eje.1.02011; Barzon L, 2003, EUR J ENDOCRINOL, V149, P273, DOI 10.1530/eje.0.1490273; Barzon L, 2004, ENDOCR REV, V25, P1, DOI 10.1210/er.2002-0035; BAUER G, 1983, INT J CANCER, V31, P291, DOI 10.1002/ijc.2910310307; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Biasolo MA, 2003, J MED VIROL, V69, P220, DOI 10.1002/jmv.10285; Bloom DC, 1997, VIROLOGY, V236, P202, DOI 10.1006/viro.1997.8723; Boldorini R, 2005, AM J CLIN PATHOL, V124, P303, DOI 10.1309/RLB1PMV33RK7CGAX; Carbone M, 2005, CANCER RES, V65, P10120, DOI 10.1158/0008-5472.CAN-05-1911; Carbone M, 2003, CANCER RES, V63, P6125; Chang M, 2005, J VIROL, V79, P13538, DOI 10.1128/JVI.79.21.13538-13547.2005; Correa RM, 2004, J MED VIROL, V73, P583, DOI 10.1002/jmv.20129; Dahia PLM, 2006, CURR OPIN ONCOL, V18, P1, DOI 10.1097/01.cco.0000198017.45982.06; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Flaegstad T, 1999, CANCER RES, V59, P1160; GLASER R, 1995, NEUROENDOCRINOLOGY, V62, P356, DOI 10.1159/000127025; Gratama JW, 1995, ADV CANCER RES, V67, P197, DOI 10.1016/S0065-230X(08)60714-9; Hornsby PJ, 2002, ENDOCR RES, V28, P777, DOI 10.1081/ERC-120017072; Hoshino Y, 1997, AIDS, V11, P1719, DOI 10.1097/00002030-199714000-00008; Isobe Y, 2004, CANCER RES, V64, P2167, DOI 10.1158/0008-5472.CAN-03-1562; KNECHT H, 1993, BLOOD, V82, P2937; KUPFER SR, 1990, J VIROL, V64, P1984, DOI 10.1128/JVI.64.5.1984-1990.1990; LATHEY JL, 1991, J VIROL, V65, P6371, DOI 10.1128/JVI.65.11.6371-6375.1991; Lee HS, 2004, CLIN CANCER RES, V10, P1698, DOI 10.1158/1078-0432.CCR-1122-3; Libe R, 2005, EUR J ENDOCRINOL, V153, P477, DOI 10.1530/eje.1.02004; Lopez-Rios F, 2004, LANCET, V364, P1157, DOI 10.1016/S0140-6736(04)17102-X; McNeese T, 2005, AM HIST, V40, P52; Mengoli C, 2004, J MED VIROL, V74, P78, DOI 10.1002/jmv.20149; MOENS U, 1994, J VIROL, V68, P2398, DOI 10.1128/JVI.68.4.2398-2408.1994; Moens U, 1999, J GEN VIROL, V80, P585, DOI 10.1099/0022-1317-80-3-585; MORHENN V, 1973, P NATL ACAD SCI USA, V70, P1088, DOI 10.1073/pnas.70.4.1088; NISHIYAMA Y, 1979, J VIROL, V31, P841, DOI 10.1128/JVI.31.3.841-844.1979; Podlech J, 1996, ARCH VIROL, V141, P1999, DOI 10.1007/BF01718210; Pomara G, 2006, EUR J HISTOCHEM, V50, P131; PULAKHANDAM U, 1990, AM J CLIN PATHOL, V93, P651, DOI 10.1093/ajcp/93.5.651; Razzaq F, 2002, HIV Med, V3, P212, DOI 10.1046/j.1468-1293.2002.00114.x; Ressetar HG, 1997, J NEUROVIROL, V3, P66, DOI 10.3109/13550289709015794; RESSETAR HG, 1993, MOL CHEM NEUROPATHOL, V20, P59, DOI 10.1007/BF03160070; SCHUSTER C, 1991, FEBS LETT, V284, P82, DOI 10.1016/0014-5793(91)80767-W; SCHUSTER C, 1991, MOL ENDOCRINOL, V5, P267, DOI 10.1210/mend-5-2-267; SERVENIUS B, 1994, CANCER RES, V54, P5198; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TANAKA J, 1984, VIROLOGY, V136, P448, DOI 10.1016/0042-6822(84)90182-X; TANAKA J, 1984, J GEN VIROL, V65, P1757; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; TISCHLER AS, 1993, LAB INVEST, V68, P541; Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004; Zoeteweij JP, 2002, J MED VIROL, V66, P378, DOI 10.1002/jmv.2155; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	51	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					857	864		10.1038/sj.onc.1210699	http://dx.doi.org/10.1038/sj.onc.1210699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684484				2022-12-25	WOS:000252884500015
J	Miele, C; Paturzo, F; Teperino, R; Sakane, F; Fiory, F; Oriente, F; Ungaro, P; Valentino, R; Beguinot, F; Formisano, P				Miele, Claudia; Paturzo, Flora; Teperino, Raffaele; Sakane, Fumio; Fiory, Francesca; Oriente, Francesco; Ungaro, Paola; Valentino, Rossella; Beguinot, Francesco; Formisano, Pietro			Glucose regulates diacylglycerol intracellular levels and protein kinase C activity by modulating diacylglycerol kinase subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; SKELETAL-MUSCLE; TYROSINE PHOSPHORYLATION; DIABETES-MELLITUS; MOLECULAR-CLONING; HYPERGLYCEMIA; ACTIVATION; ALPHA; TRANSPORT; ZETA	Although chronic hyperglycemia reduces insulin sensitivity and leads to impaired glucose utilization, short term exposure to high glucose causes cellular responses positively regulating its own metabolism. We show that exposure of L6 myotubes overexpressing human insulin receptors to 25 mM glucose for 5 min decreased the intracellular levels of diacylglycerol (DAG). This was paralleled by transient activation of diacylglycerol kinase (DGK) and of insulin receptor signaling. Following 30- min exposure, however, both DAG levels and DGK activity returned close to basal levels. Moreover, the acute effect of glucose on DAG removal was inhibited by > 85% by the DGK inhibitor R59949. DGK inhibition was also accompanied by increased protein kinase C-alpha (PKC alpha) activity, reduced glucose- induced insulin receptor activation, and GLUT4 translocation. Glucose exposure transiently redistributed DGK isoforms alpha and delta, from the prevalent cytosolic localization to the plasma membrane fraction. However, antisense silencing of DGK alpha, but not of DGK alpha expression, was sufficient to prevent the effect of high glucose on PKC alpha activity, insulin receptor signaling, and glucose uptake. Thus, the short term exposure of skeletal muscle cells to glucose causes a rapid induction of DGK, followed by a reduction of PKC alpha activity and transactivation of the insulin receptor signaling. The latter may mediate, at least in part, glucose induction of its own metabolism.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Sapporo Medical University	Formisano, P (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; Sakane, Fumio/H-2693-2017; ORIENTE, Francesco/J-6652-2018	Sakane, Fumio/0000-0003-0857-0377; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526; Teperino, Raffaele/0000-0001-8815-1409	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Bagnato C, 2003, J BIOL CHEM, V278, P52203, DOI 10.1074/jbc.M305760200; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bregoli L, 2001, J BIOL CHEM, V276, P23288, DOI 10.1074/jbc.M101501200; CAPALDO B, 1986, J CLIN INVEST, V77, P1285, DOI 10.1172/JCI112432; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; Ceolotto G, 1999, DIABETES, V48, P1316, DOI 10.2337/diabetes.48.6.1316; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; Crotty T, 2006, P NATL ACAD SCI USA, V103, P15485, DOI 10.1073/pnas.0604104103; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Fiory F, 2005, MOL CELL BIOL, V25, P10803, DOI 10.1128/MCB.25.24.10803-10814.2005; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Fukunaga-Takenaka R, 2005, GENES CELLS, V10, P311, DOI 10.1111/j.1365-2443.2005.00842.x; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Hou W, 1996, CELL SIGNAL, V8, P487, DOI 10.1016/S0898-6568(96)00104-0; Imai S, 2005, J BIOL CHEM, V280, P39870, DOI 10.1074/jbc.M500669200; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1986, J BIOL CHEM, V261, P5597; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Liu LZ, 2006, MOL BIOL CELL, V17, P2322, DOI 10.1091/mbc.E05-10-0969; Miele C, 2003, J BIOL CHEM, V278, P47376, DOI 10.1074/jbc.M301088200; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLTE LA, 1995, DIABETES, V44, P1345, DOI 10.2337/diabetes.44.11.1345; PREISS J, 1986, J BIOL CHEM, V261, P8597; REVERS RR, 1984, J CLIN INVEST, V73, P664, DOI 10.1172/JCI111258; SACCA L, 1981, METABOLISM, V30, P457, DOI 10.1016/0026-0495(81)90180-3; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stenina OI, 2005, CURR PHARM DESIGN, V11, P2367, DOI 10.2174/1381612054367283; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Takahashi N, 2007, BIOCHEM BIOPH RES CO, V360, P244, DOI 10.1016/j.bbrc.2007.06.040; Tomas E, 2002, ANN NY ACAD SCI, V967, P43; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; Yki-Jarvinen H, 1998, DIABETES METAB REV, V14, pS45, DOI 10.1002/(SICI)1099-0895(199809)14:1+<S45::AID-DMR230>3.3.CO;2-Z; Zulian SE, 2006, J NEUROSCI RES, V84, P1012, DOI 10.1002/jnr.21010	46	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					31835	31843		10.1074/jbc.M702481200	http://dx.doi.org/10.1074/jbc.M702481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17675299	hybrid			2022-12-25	WOS:000250480300003
J	Abad, M; Menendez, C; Fuchtbauer, A; Serrano, M; Fuchtbauer, EM; Palmero, I				Abad, Maria; Menendez, Camino; Fuchtbauer, Annette; Serrano, Manuel; Fuchtbauer, Ernst-Martin; Palmero, Ignacio			Ing1 mediates p53 accumulation and chromatin modification in response to oncogenic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERICENTRIC HETEROCHROMATIN; PREMATURE SENESCENCE; HISTONE MODIFICATION; CELL-PROLIFERATION; PLANT HOMEODOMAIN; MAMMALIAN-CELLS; PHD FINGER; RAS; ACETYLATION; PROTEINS	ING proteins are putative tumor suppressor proteins linked to the p53 pathway and to the chromatin modification machinery. Here we have analyzed the role of the products of the murine Ing1 locus in cellular tumor-protective responses, using mouse primary fibroblasts where the Ing1 locus has been inactivated by the integration of a beta geo cassette. We show that Ing1-deficient mouse embryonic fibroblasts display a defective senescence-like antiproliferative response against oncogenic Ras, affecting several senescence-specific markers. This phenotype is accompanied by a reduced accumulation of p53, which can be explained by the reduced basal p53 protein stability in the Ing1-deficient background. Ing1 deficiency also results in defects in the appearance of heterochromatic marks upon expression of oncogenic Ras, suggestive of impaired heterochromatin formation during oncogene-induced senescence. Our results support an important role for the Ing1 locus in protection against oncogenic stress in vivo, both as a mediator of p53 activation and as a regulator of chromatin remodeling processes.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Aarhus University	Palmero, I (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Serrano, Manuel/H-2634-2015; Abad, Maria/I-3911-2015; Palmero, Ignacio/B-4346-2013; Abad, Maria/AAI-2366-2019; Vivancos, Ana/AAG-8331-2019	Serrano, Manuel/0000-0001-7177-9312; Abad, Maria/0000-0002-1462-2498; Abad, Maria/0000-0002-1462-2498; Vivancos, Ana/0000-0003-2888-6512; Menendez, Maria del Camino/0000-0002-3535-2490				Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Coles AH, 2007, CANCER RES, V67, P2054, DOI 10.1158/0008-5472.CAN-06-3558; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Ferbeyre G, 2000, GENE DEV, V14, P2015; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gonzalez L, 2006, ONCOGENE, V25, P5173, DOI 10.1038/sj.onc.1209526; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Groth A, 2000, J BIOL CHEM, V275, P27473; Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100; Kataoka H, 2003, CANCER RES, V63, P5785; Kichina JV, 2006, ONCOGENE, V25, P857, DOI 10.1038/sj.onc.1209118; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nouman GS, 2003, J CLIN PATHOL, V56, P491, DOI 10.1136/jcp.56.7.491; Palacios A, 2006, FEBS LETT, V580, P6903, DOI 10.1016/j.febslet.2006.11.055; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi XB, 2005, J CELL BIOCHEM, V96, P1127, DOI 10.1002/jcb.20625; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172	43	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31060	31067		10.1074/jbc.M701639200	http://dx.doi.org/10.1074/jbc.M701639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17693408	hybrid			2022-12-25	WOS:000250136300073
J	Kim, BJ; Kim, SY; Lee, H				Kim, Byung Ju; Kim, So-Young; Lee, Hoyun			Identification and characterization of human Cdc7 nuclear retention and export sequences in the context of chromatin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; CELL-CYCLE; PROTEIN-KINASE; S-PHASE; CYTOPLASMIC LOCALIZATION; MAMMALIAN-CELLS; LEPTOMYCIN B; INITIATION; COMPLEX; SIGNAL	The Cdc7 serine/threonine kinase activates the initiation of DNA replication by phosphorylating MCM proteins that are bound to the origins of DNA replication. We reported previously that human Cdc7 nuclear import is mediated directly by importin-beta through its binding to the Cdc7 nuclear localization sequence (NLS). Here, we report that human Cdc7 nuclear localization is regulated by two additional elements: nuclear retention (NRS) and export sequences (NES). Cdc7 proteins imported into the nucleus are retained in the nucleus by associating with chromatin, for which NRS-(306-326) is essential. Importantly, this binding appears to be specific to the origin of DNA replication, because the binding of wild-type Cdc7 to origin is 2.4-fold higher than to non-origin DNA. Furthermore, an NRS- defective Cdc7 mutant could not be retained in the nucleus, although it was imported into the nucleus normally. Together, our data suggest that NRS plays an important role in the activation of DNA replication by Cdc7. The Cdc7 proteins unassociated with chromatin are bound by CRM1 via two NES elements: NES1 at 458 467 within kinase insert III, and NES2 at 545-554 within the kinase IX domain. The primary function of the Cdc7-CRM1 association may be to translocate nuclear Cdc7 to the cytoplasm. However, the binding of CRM1 with Cdc7 at NES2 raises an interesting possibility that CRM1 may also down-regulate Cdc7 by masking its kinase domain.	Sudbury Reg Hosp, NE Ontario Reg Canc Program, Tumour Biol Grp, Sudbury, ON P3E 5J1, Canada; Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1M 8M5, Canada; No Ontario Sch Med, Dept Med Sci, Sudbury, ON P3E 2C6, Canada	Health Sciences North; University of Ottawa; Northern Ontario School of Medicine	Lee, H (corresponding author), Sudbury Reg Hosp, NE Ontario Reg Canc Program, Tumour Biol Grp, Sudbury, ON P3E 5J1, Canada.	hlee@hrsrh.on.ca						Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Cho WH, 2006, P NATL ACAD SCI USA, V103, P11521, DOI 10.1073/pnas.0604990103; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Guo BQ, 1999, SOMAT CELL MOLEC GEN, V25, P159, DOI 10.1023/A:1018841506868; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Ishimi Y, 2001, J BIOL CHEM, V276, P42744, DOI 10.1074/jbc.M106861200; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Kanwal C, 2002, AAPS PHARMSCI, V4; Kim BJ, 2006, J BIOL CHEM, V281, P12041, DOI 10.1074/jbc.M512630200; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Macfarlan T, 2005, J BIOL CHEM, V280, P7346, DOI 10.1074/jbc.M411675200; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H., 1999, FRONT BIOSCI, V4, pD834; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	49	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30029	30038		10.1074/jbc.M703705200	http://dx.doi.org/10.1074/jbc.M703705200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711849	hybrid			2022-12-25	WOS:000249981200033
J	Kojic, LD; Joshi, B; Lajoie, P; Le, PU; Cox, ME; Turbin, DA; Wiseman, SM; Nabi, IR				Kojic, Liliana D.; Joshi, Bharat; Lajoie, Patrick; Le, Phuong U.; Cox, Michael E.; Turbin, Dmitry A.; Wiseman, Sam M.; Nabi, Ivan R.			Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EXPRESSION; CAVEOLAE; INTERNALIZATION; CANCER; MACROPINOCYTOSIS; LOCALIZATION; ESTROGEN; PATHWAY; KINASE	Autocrine motility factor (AMF) is internalized via a receptor-mediated, dynamin-dependent, cholesterol-sensitive raft pathway to the smooth endoplasmic reticulum that is negatively regulated by caveolin-1. Expression of AMF and its receptor (AMFR) is associated with tumor progression and malignancy; however, the extent to which the raft-dependent uptake of AMF is tumor cell-specific has yet to be addressed. By Western blot and cell surface fluorescence-activated cell sorter (FACS) analysis, AMFR expression is increased in tumorigenic MCF7 and metastatic MDA-231 and MDA-435 breast cancer cell lines relative to dysplastic MCF10A mammary epithelial cells. AMF uptake, determined by FACS measurement of protease-insensitive internalized fluorescein-conjugated AMF, was increased in MCF7 and MDA-435 cells relative to MCF-10A and caveolin-1-expressing MDA-231 cells. Uptake of fluorescein-conjugated AMF was dynamin-dependent, methyl-beta-cyclodextrin- and genistein-sensitive, reduced upon overexpression of caveolin-1 in MDA-435 cells, and increased upon short hairpin RNA reduction of caveolin-1 in MDA-231 cells. Tissue microarray analysis of invasive primary human breast carcinomas showed that AMFR expression had no impact on survival but did correlate significantly with expression of phospho-Akt. Phospho-Akt expression was increased in AMF-internalizing MCF7 and MDA-435 breast carcinoma cells. AMF-uptake in these cells was reduced by phosphatidylinositol 3-kinase inhibition but not by regulators of macropinocytosis such as amiloride, phorbol ester, or actin cytoskeleton disruption by cytochalasin D. The raft-dependent endocytosis of AMF therefore follows a distinct phosphatidylinositol 3-kinase-dependent pathway that is up-regulated in more aggressive tumor cells.	Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; British Columbia Canc Agcy, Prostate Res Ctr, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver Gen Hosp, Dept Pathol, Genet Pathol Evaluat Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, St Pauls Hosp, Dept Surg, Vancouver, BC V6T NZ, Canada	University of British Columbia; National Research Council Canada; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Nabi, IR (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	irnabi@interchange.ubc.ca	Nabi, Ivan/GWZ-5144-2022; Nabi, Ivan R/C-5493-2009	Nabi, Ivan/0000-0002-0670-0513; Lajoie, Patrick/0000-0002-1614-176X				Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Araki N, 2003, J CELL SCI, V116, P247, DOI 10.1242/jcs.00235; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Goetz JG, 2006, BIOCHEM SOC T, V34, P370, DOI 10.1042/BST0340370; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; Jiang WG, 2006, J HISTOCHEM CYTOCHEM, V54, P231, DOI 10.1369/jhc.5A6785.2005; Joshi B, 2005, ONCOGENE, V24, P2204, DOI 10.1038/sj.onc.1208206; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lajoie P, 2007, J CELL MOL MED, V11, P644, DOI 10.1111/j.1582-4934.2007.00083.x; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; MARUYAMA K, 1995, INT J CANCER, V64, P316, DOI 10.1002/ijc.2910640506; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; NABI IR, 1990, CANCER RES, V50, P409; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nagai Y, 1996, DERMATOLOGY, V192, P8, DOI 10.1159/000246304; NAKAMORI S, 1994, CANCER-AM CANCER SOC, V74, P1855, DOI 10.1002/1097-0142(19941001)74:7<1855::AID-CNCR2820740705>3.0.CO;2-1; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; OTTO T, 1994, CANCER RES, V54, P3120; Parker RL, 2002, AM J CLIN PATHOL, V117, P723; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; REINER A, 1990, CANCER RES, V50, P7057; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Takanami I, 1998, TUMOR BIOL, V19, P384, DOI 10.1159/000030031; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Tsutsumi S, 2003, CANCER RES, V63, P242; Watanabe H, 1996, CANCER RES, V56, P2960; WATANABE H, 1991, CANCER RES, V51, P2699; Wiseman SM, 2005, CANCER-AM CANCER SOC, V103, P1770, DOI 10.1002/cncr.20970; Yu D, 2004, PROSTATE, V59, P370, DOI 10.1002/pros.20010; Zhou KM, 1998, J CELL SCI, V111, P283	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29305	29313		10.1074/jbc.M704069200	http://dx.doi.org/10.1074/jbc.M704069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690101	hybrid			2022-12-25	WOS:000249788000027
J	Li, ZZ; Lu, JZ; Xu, PY; Xie, XY; Chen, LY; Xu, T				Li, Zhengzheng; Lu, Jingze; Xu, Pingyong; Xie, Xiangyang; Chen, Liangyi; Xu, Tao			Mapping the interacting domains of STIM1 and Orai1 in Ca2+ release-activated Ca2+ channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL INTERACTION MOLECULE-1; CRAC CHANNEL; STORE; DEPLETION; SENSOR; ENTRY; OLIGOMERIZATION; IDENTIFICATION; PROTEIN	STIM1 and Orai1 are essential components of Ca2+ release-activated Ca2+ channels (CRACs). After endoplasmic reticulum Ca2+ store depletion, STIM1 in the endoplasmic reticulum aggregates and migrates toward the cell periphery to co-localize with Orai1 on the opposing plasma membrane. Little is known about the roles of different domains of STIM1 and Orai1 in protein clustering, migration, interaction, and, ultimately, opening CRAC channels. Here we demonstrate that the coiled-coil domain in the C terminus of STIM1 is crucial for its aggregation. Amino acids 425-671 of STIM1, which contain a serine-proline-rich region, are important for the correct targeting of the STIM1 cluster to the cell periphery after calcium store depletion. The polycationic region in the C-terminal tail of STIM1 also helps STIM1 targeting but is not essential for CRAC channel activation. The cytoplasmic C terminus but not the N terminus of Orai1 is required for its interaction with STIM1. We further identify a highly conserved region in the N terminus of Orai1 (amino acids 74-90) that is necessary for CRAC channel opening. Finally, we show that the transmembrane domain of Orai1 participates in Orai1-Orai1 interactions.	Chinese Acad Sci, Natl Key Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Chen, LY (corresponding author), Chinese Acad Sci, Natl Key Lab Biomacromol, Inst Biophys, Datun Rd 15,Chaoyang Dist, Beijing 100101, Peoples R China.	chen_liangyi@yahoo.com	Li, Zhengzheng/N-1415-2013; Xu, Pingyong/G-5472-2010; Xu, Tao/G-5474-2010; Chen, Liangyi/F-1352-2010	Chen, Liangyi/0000-0003-1270-7321				Baba Y, 2006, P NATL ACAD SCI USA, V103, P16704, DOI 10.1073/pnas.0608358103; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chen LY, 2003, DIABETES, V52, P1723, DOI 10.2337/diabetes.52.7.1723; DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200; Draber P, 2005, TRENDS IMMUNOL, V26, P621, DOI 10.1016/j.it.2005.09.006; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Lis A, 2007, CURR BIOL, V17, P794, DOI 10.1016/j.cub.2007.03.065; Lorin-Nebel C, 2007, J PHYSIOL-LONDON, V580, P67, DOI 10.1113/jphysiol.2006.124883; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, J GEN PHYSIOL, V128, P373, DOI 10.1085/jgp.200609588; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Stathopulos PB, 2006, J BIOL CHEM, V281, P35855, DOI 10.1074/jbc.M608247200; Takahashi Y, 2007, BIOCHEM BIOPH RES CO, V356, P45, DOI 10.1016/j.bbrc.2007.02.107; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Williams RT, 2002, BBA-PROTEIN STRUCT M, V1596, P131, DOI 10.1016/S0167-4838(02)00211-X; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yang XF, 2006, J BIOL CHEM, V281, P15457, DOI 10.1074/jbc.M513246200; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	37	195	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29448	29456		10.1074/jbc.M703573200	http://dx.doi.org/10.1074/jbc.M703573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17702753	hybrid			2022-12-25	WOS:000249788000042
J	Erdogan, M; Pozzi, A; Bhowmick, N; Moses, HL; Zent, R				Erdogan, Mete; Pozzi, Ambra; Bhowmick, Neil; Moses, Harold L.; Zent, Roy			Signaling pathways regulating TC21-induced tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; H-RAS; PROTEIN; TC21; ACTIVATION; KINASE; TARGET; GROWTH; IDENTIFICATION; TRANSFORMATION	TC21(R-Ras2), a Ras-related GTPase with transforming potential similar to H-, K- and N-Ras, is implicated in the pathogenesis of human cancers. Transforming growth factor beta (TGF-beta), a cytokine that plays a significant role in modulating tumorigenesis, normally prevents uncontrolled cell proliferation but paradoxically induces proliferation in H-Ras-transformed cancer cells. Although TC21 activates some pathways that mediate cellular transformation by the classical Ras proteins, the mechanisms through which TC21 induces tumor formation and how TGF-beta regulates TC21 transformed cells is not known. To better understand the role of TC21 in cancer progression, we overexpressed an activated G23V mutant of TC21 in a nontumorigenic murine mammary epithelial (EpH4) cell line. Mutant TC21-expressing cells were significantly more oncogenic than cells expressing activated G12V H-Ras both in vivo and in vitro. TC21-induced transformation and proliferation required activation of p38 MApK, mTOR (the mammalian target of rapamycin), and phosphoinositide 3-kinase but not Akt/PKB. Transformation by TC21 rendered EpH4 cells insensitive to the growth inhibitory effects of TGF-beta, and the soft agar growth of these cells was increased upon TGF-beta stimulation. Despite losing responsiveness to TGF-beta-mediated growth inhibition, both Smad-dependent and independent pathways remained intact in TC21-transformed cells. Thus, overexpression of active TC21 in EpH4 cells induces tumorigenicity through the phosphoinositide 3-kinase, p38 MAPK, and mTOR pathways, and these cells lose their sensitivity to the normal growth inhibitory role of TGF-beta.	Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA; Vet Affairs Hosp, Dept Med, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Zent, R (corresponding author), Vanderbilt Univ, Med Ctr, Rm C3210, Nashville, TN 37232 USA.	roy.zent@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	NCI NIH HHS [CA 102162, R01-CA94849, CA 085492] Funding Source: Medline; NIDDK NIH HHS [R01-DK 69921, R01-DK074359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094849, R01CA102162, R01CA085492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069921, R01DK074359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Barker KT, 1998, BRIT J CANCER, V78, P296, DOI 10.1038/bjc.1998.490; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; HUANG Y, 1995, ONCOGENE, V11, P1255; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pozzi A, 2006, MOL BIOL CELL, V17, P2046, DOI 10.1091/mbc.E05-08-0800; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Sharma R, 2005, ONCOLOGY-BASEL, V69, P10, DOI 10.1159/000087283; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420	31	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27713	27720		10.1074/jbc.M703037200	http://dx.doi.org/10.1074/jbc.M703037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656362	hybrid			2022-12-25	WOS:000249455600019
J	Park, MY; Moon, JH; Lee, KS; Choi, HI; Chung, J; Hong, HJ; Kim, E				Park, Min-Young; Moon, Ji-Hyun; Lee, Ki-Sung; Choi, Hye-In; Chung, Jongkyeong; Hong, Hyo Jeong; Kim, Eunhee			FAF1 suppresses I kappa B kinase (IKK) activation by disrupting the IKK complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-ASSOCIATED FACTOR-1; NECROSIS-FACTOR-ALPHA; MEDIATED APOPTOSIS; PROTEIN; BETA; TRANSCRIPTION; ASSOCIATION; GAMMA; PHOSPHORYLATION; IDENTIFICATION	This study presents a molecular inhibitory mechanism by Fas-associated factor 1 (FAF1) on I kappa B kinase (IKK) activation, where divergent NF-kappa B-activating stimuli converge. FAF1 interacts with IKK beta in response to proinflammatory stimuli (such as tumor necrosis factor-a, interleukin-1 beta, and lipopolysaccharide) and suppresses IKK activation. Interaction of the leucine-zipper domain of IKK beta with FAF1 affected the IKK heterocomplex (IKK alpha/beta) and homocomplex (IKK alpha/alpha, IKK beta/beta) formations and attenuated IKK gamma recruitment to IKK beta. Overexpression of FAF1 reduced the level of IKK,13 activity, whereas FAF1 depletion increased the activity. These results indicate that FAF1 inhibits IKK activation and its downstream signaling by interrupting the IKK complex assembly through physical interaction with IKK beta. Taken together, FAF1 robustly suppresses NF-kappa B activation through the inhibition of IKK activation in combination with previously reported cytoplasmic retention of NF-kappa B p65 (Park, M. Y., Jang, H. D., Lee, S. Y., Lee, K. J., and Kim, E. (2004) J. Biol. Chem. 279, 2544-2549). Such redundant suppression would prevent inadvertent activation of the NF-kappa B pathway.	Chungnam Natl Univ, Sch Biosci & Biotechnol, Dept Biol, Taejon 305764, South Korea; PaiChai Univ, Res Ctr Biomed Resources, Taejon 302835, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Natl Creat Res Initiat Ctr Cell Growth Regulat, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Lab Antibody Engn, Taejon 305333, South Korea	Chungnam National University; Pai Chai University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Kim, E (corresponding author), Chungnam Natl Univ, Sch Biosci & Biotechnol, Dept Biol, 220 Gungdong,Yuseong-gu, Taejon 305764, South Korea.	eunhee@cnu.ac.kr		Choi, Hye-In/0000-0003-4348-0780				Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Frohlich T, 1998, J CELL SCI, V111, P2353; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Kim HJ, 2005, J BIOL CHEM, V280, P8125, DOI 10.1074/jbc.M406297200; Kim M, 2006, P NATL ACAD SCI USA, V103, P16358, DOI 10.1073/pnas.0603238103; Kim S, 2006, J NEUROSCI, V26, P2403, DOI 10.1523/JNEUROSCI.4691-05.2006; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Olsen BB, 2003, FEBS LETT, V546, P218, DOI 10.1016/S0014-5793(03)00575-1; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Park MY, 2005, INT J CANCER, V115, P412, DOI 10.1002/ijc.20857; Park MY, 2004, J BIOL CHEM, V279, P2544, DOI 10.1074/jbc.M304565200; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Ryu SW, 1999, BIOCHEM BIOPH RES CO, V262, P388, DOI 10.1006/bbrc.1999.1217; Ryu SW, 2003, J BIOL CHEM, V278, P24003, DOI 10.1074/jbc.M302200200; Ryu SW, 2001, BIOCHEM BIOPH RES CO, V286, P1027, DOI 10.1006/bbrc.2001.5505; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Song EJ, 2005, MOL CELL BIOL, V25, P2511, DOI 10.1128/MCB.25.6.2511-2524.2005; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Tanji T, 2005, TRENDS IMMUNOL, V26, P193, DOI 10.1016/j.it.2005.02.006; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	31	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27572	27577		10.1074/jbc.C700106200	http://dx.doi.org/10.1074/jbc.C700106200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17684021	hybrid			2022-12-25	WOS:000249455600004
J	Faye, A; Esnous, C; Price, NT; Onfray, MA; Girard, J; Prip-Buus, C				Faye, Audrey; Esnous, Catherine; Price, Nigel T.; Onfray, Marie Anne; Girard, Jean; Prip-Buus, Carina			Rat liver carnitine palmitoyltransferase 1 forms an oligomeric complex within the outer mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; MALONYL-COA SENSITIVITY; FATTY-ACID OXIDATION; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; SUBSTRATE SELECTIVITY; STRUCTURAL MODEL; CPT I; ACETYLTRANSFERASE; OCTANOYLTRANSFERASE	Carnitine palmitoyltransferase (CPT) 1A catalyzes the rate-limiting step in the transport of long chain acyl-CoAs from cytoplasm to the mitochondrial matrix by converting them to acyl-carnitines. Located within the outer mitochondrial membrane, CPT1A activity is inhibited by malonyl-CoA, its allosteric inhibitor. In this study, we investigate for the first time the quaternary structure of rat CPT1A. Chemical cross-linking studies using intact mitochondria isolated from fed rat liver or from Saccharomyces cerevisiae expressing CPT1A show that CPT1A self-assembles into an oligomeric complex. Size exclusion chromatography experiments using solubilized mitochondrial extracts suggest that the fundamental unit of its quaternary structure is a trimer. When studied in blue native-PAGE, the CPT1A hexamer could be observed, however, suggesting that under these native conditions CPT1A trimers might be arranged as dimers. Moreover, the oligomeric state of CPT1A was found unchanged by starvation and by streptozotocin-induced diabetes, conditions characterized by changes in malonyl-CoA sensitivity of CPT1A. Finally, gel filtration analysis of several yeast-expressed chimeric CPTs demonstrates that the first 147 N-terminal residues of CPT1A, encompassing its two transmembrane segments, trigger trimerization independently of its catalytic C-terminal domain. Deletion of residues 1 - 82, including transmembrane 1, did not abrogate oligomerization, but the latter is limited to a trimer by the presence of the large catalytic C-terminal domain on the cytosolic face of mitochondria. Based on these findings, we proposed that the oligomeric structure of CPT1A would allow the newly formed acylcarnitines to gain direct access into the intermembrane space, hence facilitating substrate channeling.	Univ Paris 05, Inst Cochin, Dept Endocrinol, Metab Ctr,Fac Med,UMR 8104, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; Hannah Res Inst, Dept Cell Biochem, Ayr KA6 5HL, Scotland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Prip-Buus, C (corresponding author), Univ Paris 05, Inst Cochin, Dept Endocrinol, Metab Ctr,Fac Med,UMR 8104, 24,Rue Faubourg St, F-75014 Paris, France.	prip-buus@cochin.inserm.fr	PRIP-BUUS, Carina/P-9084-2017	Prip-Buus, Carina/0000-0002-2153-7857				Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Barycki JJ, 2001, J BIOL CHEM, V276, P36718, DOI 10.1074/jbc.M104839200; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; Borthwick K, 2006, J BIOL CHEM, V281, P32946, DOI 10.1074/jbc.M600843200; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1987, J BIOL CHEM, V262, P4968; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; ESSER V, 1993, J BIOL CHEM, V268, P5817; Faye A, 2005, BIOCHEM J, V387, P67, DOI 10.1042/BJ20041533; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Gobin S, 2003, J BIOL CHEM, V278, P50428, DOI 10.1074/jbc.M310130200; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Hsiao YS, 2006, J BIOL CHEM, V281, P28480, DOI 10.1074/jbc.M602622200; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jogl G, 2005, J BIOL CHEM, V280, P738, DOI 10.1074/jbc.M409894200; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Lopez-Vinas E, 2007, J BIOL CHEM, V282, P18212, DOI 10.1074/jbc.M700885200; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; McGarry JD, 2000, BIOCHEM J, V349, P179, DOI 10.1042/0264-6021:3490179; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Pan Y, 2002, J BIOL CHEM, V277, P47184, DOI 10.1074/jbc.M208055200; PAULY DF, 1988, J BIOL CHEM, V263, P18160; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Rufer AC, 2006, STRUCTURE, V14, P713, DOI 10.1016/j.str.2006.01.008; SAGGERSON ED, 1981, FEBS LETT, V132, P166, DOI 10.1016/0014-5793(81)81152-0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Shiloff BA, 1996, EUR J BIOCHEM, V242, P41, DOI 10.1111/j.1432-1033.1996.0041r.x; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Turkaly P, 1999, FEBS LETT, V460, P241, DOI 10.1016/S0014-5793(99)01354-X; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; Wolfgang MJ, 2006, J BIOL CHEM, V281, P37265, DOI 10.1074/jbc.R600016200; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7	51	25	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26908	26916		10.1074/jbc.M705418200	http://dx.doi.org/10.1074/jbc.M705418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650509	hybrid			2022-12-25	WOS:000249304900030
J	Vucinic, D; Sejnowski, TJ				Vucinic, Dejan; Sejnowski, Terrence J.			A Compact Multiphoton 3D Imaging System for Recording Fast Neuronal Activity	PLOS ONE			English	Article							2-PHOTON EXCITATION; SCANNING MICROSCOPY; SATURABLE ABSORBER; LASER; FLUORESCENCE; FEMTOSECOND; GENERATION; DENDRITES; COMPENSATION; DISPERSION	We constructed a simple and compact imaging system designed specifically for the recording of fast neuronal activity in a 3D volume. The system uses an Yb:KYW femtosecond laser we designed for use with acousto-optic deflection. An integrated two-axis acousto-optic deflector, driven by digitally synthesized signals, can target locations in three dimensions. Data acquisition and the control of scanning are performed by a LeCroy digital oscilloscope. The total cost of construction was one order of magnitude lower than that of a typical Ti:sapphire system. The entire imaging apparatus, including the laser, fits comfortably onto a small rig for electrophysiology. Despite the low cost and simplicity, the convergence of several new technologies allowed us to achieve the following capabilities: i) full-frame acquisition at video rates suitable for patch clamping; ii) random access in under ten microseconds with dwelling ability in the nominal focal plane; iii) three-dimensional random access with the ability to perform fast volume sweeps at kilohertz rates; and iv) fluorescence lifetime imaging. We demonstrate the ability to record action potentials with high temporal resolution using intracellularly loaded potentiometric dye di-2-ANEPEQ. Our design proffers easy integration with electrophysiology and promises a more widespread adoption of functional two-photon imaging as a tool for the study of neuronal activity. The software and firmware we developed is available for download at http://neurospy.org/ under an open source license.	[Vucinic, Dejan; Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, Computat Neurobiol Lab, La Jolla, CA 92037 USA; [Sejnowski, Terrence J.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Vucinic, D (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Computat Neurobiol Lab, La Jolla, CA 92037 USA.	dejan@salk.edu	Sejnowski, Terrence/AAV-5558-2021		Howard Hughes Medical Institute; National Institutes of Health	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the Howard Hughes Medical Institute and by the National Institutes of Health.	ANTIC S, 1995, J NEUROSCI, V15, P1392; Antic SD, 2003, J PHYSIOL-LONDON, V550, P35, DOI 10.1113/jphysiol.2002.033746; Becker W, 2004, MICROSC RES TECHNIQ, V63, P58, DOI 10.1002/jemt.10421; Bewersdorf J, 1998, J MICROSC-OXFORD, V191, P28; Brunner F, 2000, OPT LETT, V25, P1119, DOI 10.1364/OL.25.001119; DAVILA HV, 1973, NATURE-NEW BIOL, V241, P159, DOI 10.1038/newbio241159a0; Deisseroth K, 2006, J NEUROSCI, V26, P10380, DOI 10.1523/JNEUROSCI.3863-06.2006; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dimitrov D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000440; Djurisic M, 2004, J NEUROSCI, V24, P6703, DOI 10.1523/JNEUROSCI.0307-04.2004; Dombeck DA, 2005, J NEUROPHYSIOL, V94, P3628, DOI 10.1152/jn.00416.2005; EVELETH JH, 1974, Patent No. 3851951; FLUHLER E, 1985, BIOCHEMISTRY-US, V24, P5749, DOI 10.1021/bi00342a010; Gobel W, 2004, OPT LETT, V29, P1285, DOI 10.1364/OL.29.001285; Griesinger CB, 2005, NATURE, V435, P212, DOI 10.1038/nature03567; Hellstrom JE, 2006, APPL PHYS B-LASERS O, V83, P235, DOI 10.1007/s00340-006-2171-8; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Hubener G, 2003, J PHYS CHEM B, V107, P7896, DOI 10.1021/jp0345809; Iyer V, 2006, J NEUROPHYSIOL, V95, P535, DOI 10.1152/jn.00865.2005; Iyer V, 2003, J BIOMED OPT, V8, P460, DOI 10.1117/1.1580827; Jaque D, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2345828; Jung JC, 2003, OPT LETT, V28, P902, DOI 10.1364/OL.28.000902; Kano H., 1996, Bioimaging, V4, P187, DOI 10.1002/1361-6374(199609)4:3<187::AID-BIO9>3.3.CO;2-V; KELLER U, 1992, OPT LETT, V17, P505, DOI 10.1364/OL.17.000505; Keller U, 1996, IEEE J SEL TOP QUANT, V2, P435, DOI 10.1109/2944.571743; Klopp P, 2002, OPT EXPRESS, V10, P108, DOI 10.1364/OE.10.000108; Koester HJ, 2005, SCIENCE, V308, P863, DOI 10.1126/science.1100815; Koester HJ, 1999, BIOPHYS J, V77, P2226, DOI 10.1016/S0006-3495(99)77063-3; Kuhn B, 2004, BIOPHYS J, V87, P631, DOI 10.1529/biophysj.104.040477; Lagatsky AA, 2003, ELECTRON LETT, V39, P1108, DOI 10.1049/el:20030735; Lechleiter JD, 2002, BIOPHYS J, V83, P2292, DOI 10.1016/S0006-3495(02)73989-1; Levene MJ, 2004, J NEUROPHYSIOL, V91, P1908, DOI 10.1152/jn.01007.2003; Liu H, 2001, OPT LETT, V26, P1723, DOI 10.1364/OL.26.001723; Martinez-Corral M, 2003, PROC SPIE, V5182, P112; Ngoi BKA, 2001, OPT EXPRESS, V9, P200, DOI 10.1364/OE.9.000200; Nimchinsky EA, 2004, J NEUROSCI, V24, P2054, DOI 10.1523/JNEUROSCI.5066-03.2004; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Palmer LM, 2006, J NEUROSCI, V26, P1854, DOI 10.1523/JNEUROSCI.4812-05.2006; Patterson GH, 2000, BIOPHYS J, V78, P2159, DOI 10.1016/S0006-3495(00)76762-2; Paunescu G, 2004, APPL PHYS B-LASERS O, V79, P555, DOI 10.1007/s00340-004-1561-z; Reddy GD, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2141504; Roorda RD, 2004, J NEUROPHYSIOL, V92, P609, DOI 10.1152/jn.00087.2004; Salome R, 2006, J NEUROSCI METH, V154, P161, DOI 10.1016/j.jneumeth.2005.12.010; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Svoboda K, 1996, OPT LETT, V21, P1411, DOI 10.1364/OL.21.001411; Theer P, 2003, OPT LETT, V28, P1022, DOI 10.1364/OL.28.001022; Tsai PS, 2003, NEURON, V39, P27, DOI 10.1016/S0896-6273(03)00370-2; Vucinic D, 2006, OPT LETT, V31, P2447, DOI 10.1364/OL.31.002447; Yasuda R, 2006, NAT NEUROSCI, V9, P283, DOI 10.1038/nn1635; Zaouter Y, 2006, OPT LETT, V31, P119, DOI 10.1364/OL.31.000119	50	50	51	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e699	10.1371/journal.pone.0000699	http://dx.doi.org/10.1371/journal.pone.0000699			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684546	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452400003
J	Miyake, K; Tanaka, T; McNeil, PL				Miyake, Katsuya; Tanaka, Toru; McNeil, Paul L.			Lectin-Based Food Poisoning: A New Mechanism of Protein Toxicity	PLOS ONE			English	Article								Background. Ingestion of the lectins present in certain improperly cooked vegetables can result in acute GI tract distress, but the mechanism of toxicity is unknown. In vivo, gut epithelial cells are constantly exposed to mechanical and other stresses and consequently individual cells frequently experience plasma membrane disruptions. Repair of these cell surface disruptions allows the wounded cell to survive: failure results in necrotic cell death. Plasma membrane repair is mediated, in part, by an exocytotic event that adds a patch of internal membrane to the defect site. Lectins are known to inhibit exocytosis. We therefore tested the novel hypothesis that lectin toxicity is due to an inhibitory effect on plasma membrane repair. Methods and Findings. Repair of plasma membrane disruptions and exocytosis of mucus was assessed after treatment of cultured cell models and excised segments of the GI tract with lectins. Plasma membrane disruptions were produced by focal irradiation of individual cells, using a microscope-based laser, or by mechanical abrasion of multiple cells, using a syringe needle. Repair was then assessed by monitoring the cytosolic penetration of dyes incapable of crossing the intact plasma membrane. We found that cell surface-bound lectins potently inhibited plasma membrane repair, and the exocytosis of mucus that normally accompanies the repair response. Conclusions. Lectins potently inhibit plasma membrane repair, and hence are toxic to wounded cells. This represents a novel form of protein-based toxicity, one that, we propose, is the basis of plant lectin food poisoning.	[Miyake, Katsuya; McNeil, Paul L.] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; [Tanaka, Toru] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 35002, Japan; [McNeil, Paul L.] Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Josai University; University System of Georgia; Augusta University	McNeil, PL (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.	pmcneil@mcg.edu			NASA; Marine Biological Laboratory	NASA(National Aeronautics & Space Administration (NASA)); Marine Biological Laboratory	L. M. was supported by a grant from NASA; K. M. by summer fellowships (Marine Biological Laboratory).	Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Boehm S, 1998, J NEUROCHEM, V71, P2421; EDELSON PJ, 1974, J EXP MED, V140, P1364, DOI 10.1084/jem.140.5.1364; Evans RC, 2002, GASTROENTEROLOGY, V122, P1784, DOI 10.1053/gast.2002.33659; HART CA, 1988, SCAND J GASTROENTERO, V23, P1153, DOI 10.3109/00365528809090184; Kilpatrick DC, 1999, MOL BIOTECHNOL, V11, P55, DOI 10.1007/BF02789176; LORENZSONN V, 1982, GASTROENTEROLOGY, V82, P838; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; Miyake K, 2006, PLOS BIOL, V4, P1525, DOI 10.1371/journal.pbio.0040276; NACHBAR MS, 1980, AM J CLIN NUTR, V33, P2338, DOI 10.1093/ajcn/33.11.2338; Sauvion N, 2004, J INSECT PHYSIOL, V50, P1137, DOI 10.1016/j.jinsphys.2004.10.006; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Steinhardt RA, 2005, ANN NY ACAD SCI, V1066, P152, DOI 10.1196/annals.1363.017; SWANSON JA, 1987, SCIENCE, V238, P548, DOI 10.1126/science.2443981; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Vasconcelos IM, 2004, TOXICON, V44, P385, DOI 10.1016/j.toxicon.2004.05.005; WEISER MM, 1976, LANCET, V1, P567	19	58	59	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e687	10.1371/journal.pone.0000687	http://dx.doi.org/10.1371/journal.pone.0000687			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668065	gold, Green Published			2022-12-25	WOS:000207452300023
J	Gold, JA; Hoshino, Y; Jones, MB; Hoshino, S; Nolan, A; Weiden, MD				Gold, Jeffrey A.; Hoshino, Yoshihiko; Jones, Marcus B.; Hoshino, Satomi; Nolan, Anna; Weiden, Michael D.			Exogenous Interferon-alpha and Interferon-gamma Increase Lethality of Murine Inhalational Anthrax	PLOS ONE			English	Article								Background. Bacillus anthracis, the etiologic agent of inhalational anthrax, is a facultative intracellular pathogen. Despite appropriate antimicrobial therapy, the mortality from inhalational anthrax approaches 45%, underscoring the need for better adjuvant therapies. The variable latency between exposure and development of disease suggests an important role for the host's innate immune response. Type I and Type II Interferons (IFN) are prominent members of the host innate immune response and are required for control of intracellular pathogens. We have previously described a protective role for exogenous Type I and Type II IFNs in attenuating intracellular B. anthracis germination and macrophage cell death in vitro. Methodology and Principal Findings. We sought to extend these findings in an in vivo model of inhalational anthrax, utilizing the Sterne strain (34F(2)) of B. anthracis. Mice devoid of STAT1, a component of IFN-alpha and IFN-gamma signaling, had a trend towards increased mortality, bacterial germination and extrapulmonary spread of B. anthracis at 24 hrs. This was associated with impaired IL-6, IL-10 and IL-12 production. However, administration of exogenous IFN-gamma, and to a lesser extent IFN-alpha, at the time of infection, markedly increased lethality. While IFNs were able to reduce the fraction of germinated spores within the lung, they increased both the local and systemic inflammatory response manifest by increases in IL-12 and reductions in IL-10. This was associated with an increase in extrapulmonary dissemination. The mechanism of IFN mediated inflammation appears to be in part due to STAT1 independent signaling. Conclusions. In conclusion, while endogenous IFNs are essential for control of B. anthracis germination and lethality, administration of exogenous IFNs appear to increase the local inflammatory response, thereby increasing mortality.	[Gold, Jeffrey A.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA; [Hoshino, Yoshihiko; Hoshino, Satomi; Nolan, Anna; Weiden, Michael D.] NYU, Sch Med, Div Pulm & Crit Care, New York, NY USA; [Jones, Marcus B.] J Craig Venter Inst, Rockville, MD USA	Oregon Health & Science University; New York University; J. Craig Venter Institute	Gold, JA (corresponding author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.	goldje@ohsu.edu	Hoshino, Yoshihiko/B-5159-2019; Nolan, Anna/C-2796-2012	Hoshino, Yoshihiko/0000-0002-3132-0715; Nolan, Anna/0000-0002-0631-1171; gold, jeffrey/0000-0001-6683-9907	NIH NCRR GCRC [MO1 RR0096, K08 HL070710, RO1 HL57879]; UNCF/MERCK Graduate Science Research Dissertation Fellowship;  [RO1 GM 63270]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057879, K23HL084191, K08HL070710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER	NIH NCRR GCRC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); UNCF/MERCK Graduate Science Research Dissertation Fellowship; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	NIH NCRR GCRC MO1 RR0096, K08 HL070710, RO1 HL57879, UNCF/MERCK Graduate Science Research Dissertation Fellowship, David and Lucile Packard Foundation and RO1 GM 63270	ANTHONY LSD, 1989, MICROB PATHOGENESIS, V7, P421, DOI 10.1016/0882-4010(89)90022-3; Chung MP, 2003, AM J RESP CELL MOL, V29, P375, DOI 10.1165/rcmb.2003-0029OC; Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X; Cui XZ, 2006, J INFECT DIS, V193, P829, DOI 10.1086/500468; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Dang O, 2004, J IMMUNOL, V172, P747, DOI 10.4049/jimmunol.172.2.747; Drysdale M, 2007, INFECT IMMUN, V75, P1757, DOI 10.1128/IAI.01712-06; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; GARNER RE, 1989, INFECT IMMUN, V57, P1800, DOI 10.1128/IAI.57.6.1800-1808.1989; Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156, DOI 10.1164/ajrccm.158.4.9803065; Giosue S, 2000, EUR CYTOKINE NETW, V11, P99; Glomski IJ, 2007, J IMMUNOL, V178, P2646, DOI 10.4049/jimmunol.178.5.2646; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gold JA, 2004, INFECT IMMUN, V72, P1291, DOI 10.1128/IAI.72.3.1291-1297.2004; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353; Johnson Christopher P, 2005, Surg Infect (Larchmt), V6, P397, DOI 10.1089/sur.2005.6.397; Lavigne LM, 1998, J IMMUNOL, V160, P284; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lyons CR, 2004, INFECT IMMUN, V72, P4801, DOI 10.1128/IAI.72.8.4801-4809.2004; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Palmero D, 1999, INT J TUBERC LUNG D, V3, P214; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Popov SG, 2002, FEBS LETT, V527, P211, DOI 10.1016/S0014-5793(02)03228-3; Remoli ME, 2002, J IMMUNOL, V169, P366, DOI 10.4049/jimmunol.169.1.366; Roy SK, 2005, J BIOL CHEM, V280, P24462, DOI 10.1074/jbc.M413661200; Stoiber D, 2001, J IMMUNOL, V166, P466, DOI 10.4049/jimmunol.166.1.466; Sugawara I, 2004, TOHOKU J EXP MED, V202, P41, DOI 10.1620/tjem.202.41; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Weiden M, 2000, J IMMUNOL, V165, P2028, DOI 10.4049/jimmunol.165.4.2028	34	8	8	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e736	10.1371/journal.pone.0000736	http://dx.doi.org/10.1371/journal.pone.0000736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710136	Green Published, gold			2022-12-25	WOS:000207455200013
J	Martin, TG; Chades, I; Arcese, P; Marra, PP; Possingham, HP; Norris, DR				Martin, Tara G.; Chades, Iadine; Arcese, Peter; Marra, Peter P.; Possingham, Hugh P.; Norris, D. Ryan			Optimal Conservation of Migratory Species	PLOS ONE			English	Article							WINTER	Background. Migratory animals comprise a significant portion of biodiversity worldwide with annual investment for their conservation exceeding several billion dollars. Designing effective conservation plans presents enormous challenges. Migratory species are influenced by multiple events across land and sea-regions that are often separated by thousands of kilometres and span international borders. To date, conservation strategies for migratory species fail to take into account how migratory animals are spatially connected between different periods of the annual cycle (i.e. migratory connectivity) bringing into question the utility and efficiency of current conservation efforts. Methodology/Principal Findings. Here, we report the first framework for determining an optimal conservation strategy for a migratory species. Employing a decision theoretic approach using dynamic optimization, we address the problem of how to allocate resources for habitat conservation for a Neotropical-Nearctic migratory bird, the American redstart Setophaga ruticilla, whose winter habitat is under threat. Our first conservation strategy used the acquisition of winter habitat based on land cost, relative bird density, and the rate of habitat loss to maximize the abundance of birds on the wintering grounds. Our second strategy maximized bird abundance across the entire range of the species by adding the constraint of maintaining a minimum percentage of birds within each breeding region in North America using information on migratory connectivity as estimated from stable-hydrogen isotopes in feathers. We show that failure to take into account migratory connectivity may doom some regional populations to extinction, whereas including information on migratory connectivity results in the protection of the species across its entire range. Conclusions/Significance. We demonstrate that conservation strategies for migratory animals depend critically upon two factors: knowledge of migratory connectivity and the correct statement of the conservation problem. Our framework can be used to identify efficient conservation strategies for migratory taxa worldwide, including insects, birds, mammals, and marine organisms.	[Martin, Tara G.; Arcese, Peter; Norris, D. Ryan] Univ British Columbia, Ctr Appl Conservat Res, Vancouver, BC V5Z 1M9, Canada; [Chades, Iadine] INRA, UR875, Unite Biometrie & Intelligence Artificielle, F-31931 Toulouse, France; [Marra, Peter P.] Smithsonian Migratory Bird Ctr, Washington, DC USA; [Possingham, Hugh P.] Univ Queensland, Ctr Ecol, Brisbane, Qld 4072, Australia; [Possingham, Hugh P.] Univ Queensland, Dept Math, Brisbane, Qld 4072, Australia; [Norris, D. Ryan] Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada	University of British Columbia; INRAE; Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute; University of Queensland; University of Queensland; University of Guelph	Martin, TG (corresponding author), Univ British Columbia, Ctr Appl Conservat Res, Vancouver, BC V5Z 1M9, Canada.	Tara.Martin@ubc.ca	Chades, iadine/A-4052-2011; Norris, Ryan/F-4720-2011; Martin, Tara/M-1897-2016; POSSINGHAM, HUGH/R-8310-2019; Possingham, Hugh/B-1337-2008	Chades, iadine/0000-0002-7442-2850; Norris, Ryan/0000-0003-4874-1425; Martin, Tara/0000-0001-7165-9812; POSSINGHAM, HUGH/0000-0001-7755-996X; Possingham, Hugh/0000-0001-7755-996X; Marra, Peter/0000-0002-0508-7577	NSERC; Killam Memorial Foundation; Centre for Applied Conservation Research; Smithsonian Institution; National Science Foundation; Institut National de la Recherche Agronomique; Australian Research Council	NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Killam Memorial Foundation; Centre for Applied Conservation Research; Smithsonian Institution(Smithsonian Institution); National Science Foundation(National Science Foundation (NSF)); Institut National de la Recherche Agronomique; Australian Research Council(Australian Research Council)	This work was supported by NSERC ( R.N., P. A., T. G. M.), Killam Memorial Foundation ( R.N.), Centre for Applied Conservation Research ( T. G. M), Smithsonian Institution ( P. P. M., R.N.), National Science Foundation ( P. P. M.), Institut National de la Recherche Agronomique ( I. C.), and the Australian Research Council ( H. P. P).	Cormen T. H., 2001, DIJKSTRAS ALGORITHM, P595, DOI DOI 10.1515/9783110522013; CORMEN TH, 2001, INTRO ALGORITHMS, P595; Costello C, 2004, RESOUR ENERGY ECON, V26, P157, DOI 10.1016/j.reseneeco.2003.11.005; Davis FW, 2006, ECOL SOC, V11; Haight RG, 2004, BIOL CONSERV, V117, P61, DOI 10.1016/S0006-3207(03)00263-5; Marra PP, 2001, AUK, V118, P92, DOI 10.1642/0004-8038(2001)118[0092:CODMHS]2.0.CO;2; Marra PP, 1998, SCIENCE, V282, P1884, DOI 10.1126/science.282.5395.1884; MARRA PP, MAINTAINING CONNECTI; *MATH WORKS INC, 2002, MATLAB 7 0; Moore J, 2004, BIOL CONSERV, V117, P343, DOI 10.1016/j.biocon.2003.12.013; Nicholson E, 2006, CONSERV BIOL, V20, P871, DOI 10.1111/j.1523-1739.2006.00369.x; Norris D. Ryan, 2006, Ornithological Monographs, V61, P14; Norris DR, 2004, P ROY SOC B-BIOL SCI, V271, P59, DOI 10.1098/rspb.2003.2569; Possingham HP, 2001, CONSERVATION BIOLOGY: RESEARCH PRIORITIES FOR THE NEXT DECADE, P225; Rappole JH., 1995, ECOLOGY MIGRANT BIRD; Sherry TW, 1997, BIRDS N AM; Studds CE, 2005, ECOLOGY, V86, P2380, DOI 10.1890/04-1145; Webster MS, 2002, TRENDS ECOL EVOL, V17, P76, DOI 10.1016/S0169-5347(01)02380-1; Williams PH, 2000, P ROY SOC B-BIOL SCI, V267, P1959, DOI 10.1098/rspb.2000.1236; Wilson KA, 2006, NATURE, V440, P337, DOI 10.1038/nature04366; WILSON KA, PLOS BIOL IN PRESS; 2006, 2005 ANN REPORT MIGR; 2003, CONVENTION CONSERVAT	23	253	262	7	140	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e751	10.1371/journal.pone.0000751	http://dx.doi.org/10.1371/journal.pone.0000751			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710150	Green Published, gold			2022-12-25	WOS:000207455200027
J	Wesolowska, A; Kwiatkowska, A; Slomnicki, L; Dembinski, M; Master, A; Sliwa, M; Franciszkiewicz, K; Chouaib, S; Kaminska, B				Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Franciszkiewicz, K.; Chouaib, S.; Kaminska, B.			Microglia-derived TGF-beta as an important regulator of glioblastoma invasion - an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor	ONCOGENE			English	Article						gliomas; TGF-beta signaling; RNA interference; invasion/cell motility; tumor-host interactions; microglia	GROWTH-FACTOR-BETA; HUMAN GLIOMA-CELLS; RNA INTERFERENCE; MESSENGER-RNA; IN-VIVO; TARGETED DISRUPTION; INDUCIBLE ELEMENTS; TUMOR PROGRESSION; MAMMALIAN-CELLS; CYCLOSPORINE-A	The invasion of tumor cells into brain tissue is a pathologic hallmark of malignant gliomas and contributes to treatment failures. Diffuse glioblastomas contain numerous microglial cells, which enhance the progression of gliomas; however, factors responsible for invasion-promoting role of microglia are unknown. Transforming growth factor-beta (TGF-beta) can enhance tumor growth, invasion, angiogenesis and immunosuppression. Antagonizing TGF-beta activity has been shown to inhibit tumor invasion in vitro and tumorigenicity, but a systemic inhibition or lack of TGF-beta signaling results in acute inflammation and disruption of immune system homeostasis. We developed plasmid-transcribed small hairpin RNAs (shRNAs) to downregulate the TGF-beta type II receptor (T beta IIR) expression, which effectively inhibited cytokine-induced signaling pathways and transcriptional responses in transiently transfected human glioblastoma cells. Silencing of T beta IIR abolished TGF-beta-induced glioblastoma invasiveness and migratory responses in vitro. Moreover, tumorigenicity of glioblastoma cells stably expressing T beta IIR shRNAs in nude mice was reduced by 50%. Microglia strongly enhanced glioma invasiveness in the co-culture system, but this invasion-promoting activity was lost in glioma cells stably expressing shT beta RII, indicating a crucial role of microglia-derived TGF-beta in tumor-host interactions. Our results demonstrate a successful targeting of TGF-beta-dependent invasiveness and tumorigenicity of glioblastoma cells by RNAi-mediated gene silencing.	[Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Kaminska, B.] M Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, PL-002093 Warsaw, Poland; [Franciszkiewicz, K.; Chouaib, S.] Inst Gustave Roussy, Human Tumor Cytokines Lab, Villejuif, France	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; UNICANCER; Gustave Roussy	Kaminska, B (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, 3 Pasteur St, PL-002093 Warsaw, Poland.	bozenakk@nencki.gov.pl	Chouaib, Salem/F-7939-2016; Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014	Kaminska, Bozena/0000-0002-2642-4616; Master, Adam/0000-0001-9391-8846				ALBINI A, 1987, CANCER RES, V47, P3239; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Badie B, 2001, MICROSC RES TECHNIQ, V54, P106, DOI 10.1002/jemt.1125; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Jazag A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni130; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIEFER R, 1994, NEUROSCI LETT, V166, P161, DOI 10.1016/0304-3940(94)90475-8; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ogorelkova M, 2006, OLIGONUCLEOTIDES, V16, P2, DOI 10.1089/oli.2006.16.2; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Pardridge WM, 2004, EXPERT OPIN BIOL TH, V4, P1103, DOI 10.1517/14712598.4.7.1103; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Platten M, 2001, MICROSC RES TECHNIQ, V52, P401, DOI 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Praus M, 1999, GENE THER, V6, P227, DOI 10.1038/sj.gt.3300802; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Schlingensiepen KH, 2006, CYTOKINE GROWTH F R, V17, P129, DOI 10.1016/j.cytogfr.2005.09.002; Shah AH, 2002, CANCER RES, V62, P7135; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Teicher BA, 2001, CANCER METAST REV, V20, P133, DOI 10.1023/A:1013177011767; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Won JW, 1999, CANCER RES, V59, P1273; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; YAMAMOTO M, 1994, CANCER RES, V54, P3329; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Ye L, 2006, INT J ONCOL, V29, P1149; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zawadzka M, 2005, GLIA, V49, P36, DOI 10.1002/glia.20092; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	61	183	188	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					918	930		10.1038/sj.onc.1210683	http://dx.doi.org/10.1038/sj.onc.1210683			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17684491				2022-12-25	WOS:000252946300004
J	Chen, YH; Harvey, BK; Hoffman, AF; Wang, Y; Chiang, YH; Lupica, CR				Chen, Yuan-Hao; Harvey, Brandon K.; Hoffman, Alexander F.; Wang, Yun; Chiang, Yung-Hsiao; Lupica, Carl R.			MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector	FASEB JOURNAL			English	Article						cyclic voltammetry; gene therapy; LTD; LTP; Parkinson's disease	METABOTROPIC GLUTAMATE RECEPTORS; LONG-TERM POTENTIATION; RAT NUCLEUS-ACCUMBENS; PARKINSONS-DISEASE; IN-VIVO; CAUDATE-PUTAMEN; 6-HYDROXYDOPAMINE LESION; CORTICOSTRIATAL SYNAPSES; DOPAMINE DENERVATION; NIGROSTRIATAL SYSTEM	This study determined the consequences of dopamine denervation of the striatum on synaptic plasticity and prevention of these changes with gene therapy using an adeno-associated viral vector (AAV) expressing glial cell line-derived neurotrophic factor (GDNF). C57BL6/J mice were injected with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); long-term depression (LTD) or potentiation (LTP) were measured in vitro. Fast-scan cyclic voltammetry measured electrically released dopamine from a functionally relevant pool in these same striatal slices. After MPTP, dopamine release and uptake were greatly diminished, and LTP and LTD were blocked in the striatal slices. The loss of plasticity resulted directly from the loss of dopamine since its application rescued synaptic plasticity. Striatal GDNF expression via AAV, before MPTP, significantly protected against the loss of dopamine and prevented the blockade of corticostriatal LTP. These data demonstrate that dopamine plays a role in supporting several forms of striatal plasticity and that GDNF expression via AAV prevents the loss of dopamine and striatal plasticity caused by MPTP. We propose that impairment of striatal plasticity after dopamine denervation plays a role in the symptomology of Parkinson's disease and that AAV expression of neurotrophic factors represents a tenable approach to protecting against or slowing these neurobiological deficits.	[Chen, Yuan-Hao; Chiang, Yung-Hsiao] Triserv Gen Hosp, Dept Neurol Surg, Taipei 114, Taiwan; [Chen, Yuan-Hao; Chiang, Yung-Hsiao] Natl Def Med Ctr, Grad Inst Med Sci, Program Clin Med, Taipei, Taiwan; [Chen, Yuan-Hao; Harvey, Brandon K.; Hoffman, Alexander F.; Wang, Yun; Lupica, Carl R.] Natl Inst Drug Abuse, Natl Inst Hlth, Intramural Res Program, Dept Hlth & Human Serv, Baltimore, MD USA	Tri-Service General Hospital; National Defense Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Chiang, YH (corresponding author), Triserv Gen Hosp, Dept Neurol Surg, 325 Sect 2,Cheng Kung Rd,Neihu Dist, Taipei 114, Taiwan.	ychiang@mac.com; clupica@intra.nida.nih.gov	Harvey, Brandon Keith/AAY-4080-2021; Harvey, Brandon K/A-5559-2010; Hoffman, Alex/AIF-4544-2022; Lupica, Carl/AAY-3193-2021; Hoffman, Alex/H-3035-2012	Harvey, Brandon Keith/0000-0002-4036-1383; Hoffman, Alex/0000-0002-2676-0628; Lupica, Carl/0000-0002-5375-3263; Hoffman, Alex/0000-0002-2676-0628	NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000516, Z01DA000443, ZIADA000443, Z01DA000516, ZIADA000429, Z01DA000429, ZIADA000461, Z01DA000461] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abarca J, 1999, NEUROCHEM INT, V35, P19, DOI 10.1016/S0197-0186(99)00029-7; Araki T, 2000, EUR NEUROPSYCHOPHARM, V10, P365, DOI 10.1016/S0924-977X(00)00094-8; Arbuthnott GW, 2000, J ANAT, V196, P587, DOI 10.1046/j.1469-7580.2000.19640587.x; Barnes TD, 2005, NATURE, V437, P1158, DOI 10.1038/nature04053; Bensadoun JC, 2000, EXP NEUROL, V164, P15, DOI 10.1006/exnr.2000.7409; Cahill PS, 1996, ANAL CHEM, V68, P3180, DOI 10.1021/ac960347d; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; CALABRESI P, 1992, EUR J NEUROSCI, V4, P929, DOI 10.1111/j.1460-9568.1992.tb00119.x; Calabresi P, 2007, TRENDS NEUROSCI, V30, P211, DOI 10.1016/j.tins.2007.03.001; Capozzo A, 1997, EXP NEUROL, V146, P142, DOI 10.1006/exnr.1997.6494; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Cheng FC, 1998, NEUROSCI LETT, V252, P87, DOI 10.1016/S0304-3940(98)00554-0; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Eslamboli A, 2005, J NEUROSCI, V25, P769, DOI 10.1523/JNEUROSCI.4421-04.2005; FLORIO T, 1993, BRAIN RES, V619, P180, DOI 10.1016/0006-8993(93)91610-5; Ganguly A, 2001, NEUROSCIENCE, V103, P405, DOI 10.1016/S0306-4522(01)00005-7; Gasmi M, 2007, NEUROBIOL DIS, V27, P67, DOI 10.1016/j.nbd.2007.04.003; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; Gubellini P, 2004, PROG NEUROBIOL, V74, P271, DOI 10.1016/j.pneurobio.2004.09.005; Heien MLAV, 2004, ANAL CHEM, V76, P5697, DOI 10.1021/ac0491509; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Hoffman AF, 2003, J NEUROSCI, V23, P4815; Ingham CA, 1998, J NEUROSCI, V18, P4732; JONES SR, 1995, J PHARMACOL EXP THER, V274, P396; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; Kerr JND, 2001, J NEUROPHYSIOL, V85, P117, DOI 10.1152/jn.2001.85.1.117; Kirik D, 2004, NAT NEUROSCI, V7, P105, DOI 10.1038/nn1175; Kirik D, 2000, J NEUROSCI, V20, P4686, DOI 10.1523/JNEUROSCI.20-12-04686.2000; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Kurosaki R, 2004, PHARMACOL BIOCHEM BE, V78, P143, DOI 10.1016/j.pbb.2004.03.006; Lai SK, 2003, NEUROCHEM INT, V43, P639, DOI 10.1016/S0197-0186(03)00080-9; LINDEFORS N, 1990, NEUROSCI LETT, V115, P248, DOI 10.1016/0304-3940(90)90463-J; LOVINGER DM, 1995, J NEUROPHYSIOL, V73, P1076, DOI 10.1152/jn.1995.73.3.1076; Mahon S, 2004, TRENDS NEUROSCI, V27, P460, DOI 10.1016/j.tins.2004.06.010; Meshul CK, 2000, EXP NEUROL, V165, P191, DOI 10.1006/exnr.2000.7467; Meshul CK, 1999, NEUROSCIENCE, V88, P1, DOI 10.1016/S0306-4522(98)00189-4; PARENT A, 1990, TRENDS NEUROSCI, V13, P254, DOI 10.1016/0166-2236(90)90105-J; Partridge JG, 2000, J NEUROPHYSIOL, V84, P1422, DOI 10.1152/jn.2000.84.3.1422; PENNARTZ CMA, 1990, BRAIN RES, V529, P30, DOI 10.1016/0006-8993(90)90808-O; PENNARTZ CMA, 1993, EUR J NEUROSCI, V5, P107, DOI 10.1111/j.1460-9568.1993.tb00475.x; Picconi B, 2005, NEUROTOXICOLOGY, V26, P779, DOI 10.1016/j.neuro.2005.02.002; Price CJ, 1999, J NEUROCHEM, V73, P2441, DOI 10.1046/j.1471-4159.1999.0732441.x; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; Stephens B, 2005, NEUROSCIENCE, V132, P741, DOI 10.1016/j.neuroscience.2005.01.007; Tang KC, 2001, P NATL ACAD SCI USA, V98, P1255, DOI 10.1073/pnas.031374698; Tarazi FI, 2000, BRAIN RES, V881, P69, DOI 10.1016/S0006-8993(00)02812-2; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; WALSH JP, 1993, BRAIN RES, V608, P123, DOI 10.1016/0006-8993(93)90782-I; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Wickens JR, 1996, NEUROSCIENCE, V70, P1, DOI 10.1016/0306-4522(95)00436-M; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Zhang H, 2003, J NEUROSCI, V23, P10585	60	42	44	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					261	275		10.1096/fj.07-8797com	http://dx.doi.org/10.1096/fj.07-8797com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17690153				2022-12-25	WOS:000252309900028
J	Deng, YQ; Li, B; Liu, F; Iqbal, K; Grundke-Iqbal, I; Brandt, R; Gong, CX				Deng, Yanqiu; Li, Bin; Liu, Fei; Iqbal, Khalid; Grundke-Iqbal, Inge; Brandt, Roland; Gong, Cheng-Xin			Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease	FASEB JOURNAL			English	Article						glycosylation; cytoskeleton; glucose metabolism	CYCLIN-DEPENDENT KINASE-5; PROTEIN PHOSPHATASE 2A; RAT BRAIN-SLICES; N-ACETYLGLUCOSAMINE; NEUROFIBRILLARY DEGENERATION; MAMMALIAN NEUROFILAMENTS; GLUCOSE-METABOLISM; DYNAMIC INTERPLAY; TAIL DOMAIN; IN-VIVO	The medium subunit of neurofilament (NF-M) is extensively modified by phosphate and O-linked beta-N-acetylglucosamine (O-GlcNAc). Phosphorylation of NF-M plays a critical role in regulating its translocation, filament formation, and function. However, the regulation of NF-M phosphorylation and the role of NF-M O-GlcNAcylation (a modification by which GlcNAc is attached to the serine/threonine residues of a protein via an O-linked glycosidic bond) are largely unknown. Here, we demonstrate that O-GlcNAcylation and phosphorylation of NF-M regulate each other reciprocally in cultured neuroblastoma cells and in metabolically active rat brain slices. In animal models of fasting rats, which mimicked the decreased glucose uptake/metabolism observed in brains of individuals with Alzheimer disease (AD), we found a decrease in O-GlcNAcylation and increase in phosphorylation of NF-M. We also observed decreased O-GlcNAcylation and an increased phosphorylation of NF-M in AD brain. These results suggest that O-GlcNAcylation and phosphorylation of NF-M are regulated reciprocally and that the hyperphosphorylation and accumulation of NF-M in AD brain might be caused by impaired brain glucose uptake/metabolism via down-regulation of NF-M O-GlcNAcylation. -Deng, Y., Li, B., Liu, F., Iqbal, K., Grundke-Iqbal, I., Brandt, R., Gong, C.-X. Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease.	[Deng, Yanqiu; Li, Bin; Liu, Fei; Iqbal, Khalid; Grundke-Iqbal, Inge; Gong, Cheng-Xin] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; [Brandt, Roland] Univ Osnabruck, Dept Neurobiol, Osnabruck, Germany	Institute for Basic Research in Developmental Disabilities; University Osnabruck	Gong, CX (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	cxgong@mail.csi.cuny.edu		Brandt, Roland/0000-0003-0101-1257	NATIONAL INSTITUTE ON AGING [R01AG019158, P30AG019610, R01AG027429] Funding Source: NIH RePORTER; NIA NIH HHS [AG027429, P30 AG019610, P30 AG19610, AG019158, R01 AG019158, R01 AG027429-01, R01 AG027429, R01 AG027429-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexander GE, 2002, AM J PSYCHIAT, V159, P738, DOI 10.1176/appi.ajp.159.5.738; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; Elder GA, 1998, J CELL BIOL, V141, P727, DOI 10.1083/jcb.141.3.727; Elder GA, 1999, J NEUROSCI RES, V57, P23, DOI 10.1002/(SICI)1097-4547(19990701)57:1<23::AID-JNR3>3.3.CO;2-1; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Garcia ML, 2003, J CELL BIOL, V163, P1011, DOI 10.1083/jcb.200308159; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; Gong CX, 2006, J ALZHEIMERS DIS, V9, P1; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; Gong CX, 2003, NEUROSCI LETT, V340, P107, DOI 10.1016/S0304-3940(03)00096-X; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Gong CX, 2001, BRAIN RES PROTOC, V6, P134, DOI 10.1016/S1385-299X(00)00046-5; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hoyer S, 2004, ADV EXP MED BIOL, V541, P135; Hoyer S, 2000, EXP GERONTOL, V35, P1363, DOI 10.1016/S0531-5565(00)00156-X; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kesavapany S, 2003, NEUROSIGNALS, V12, P252, DOI 10.1159/000074627; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; Li BS, 2001, J NEUROCHEM, V76, P703, DOI 10.1046/j.1471-4159.2001.00064.x; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; Li X, 2006, EUR J NEUROSCI, V23, P2078, DOI 10.1111/j.1460-9568.2006.04735.x; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Ludemann N, 2005, J BIOL CHEM, V280, P31648, DOI 10.1074/jbc.M504395200; MCLEAN WG, 1992, MOL NEUROBIOL, V6, P225, DOI 10.1007/BF02780555; PERRY G, 1985, P NATL ACAD SCI USA, V82, P3916, DOI 10.1073/pnas.82.11.3916; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Reiman EM, 2001, P NATL ACAD SCI USA, V98, P3334, DOI 10.1073/pnas.061509598; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Sanchez I, 2000, J CELL BIOL, V151, P1013, DOI 10.1083/jcb.151.5.1013; Schechter R, 2005, BIOCHEM BIOPH RES CO, V334, P979, DOI 10.1016/j.bbrc.2005.07.001; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; Trimpin S, 2004, BIOCHEMISTRY-US, V43, P2091, DOI 10.1021/bi030196q; Veeranna, 1998, J NEUROSCI, V18, P4008; VEERANNA, 1995, J NEUROCHEM, V64, P2681; Wang JZ, 2001, FEBS LETT, V507, P81, DOI 10.1016/S0014-5793(01)02944-1; XU ZS, 1992, J BIOL CHEM, V267, P4467	49	68	89	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					138	145		10.1096/fj.07-8309com	http://dx.doi.org/10.1096/fj.07-8309com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17687114	Green Accepted			2022-12-25	WOS:000252309900017
J	Tuttle, SW; Maity, A; Oprysko, PR; Kachur, AV; Ayene, IS; Biaglow, JE; Koch, CJ				Tuttle, Stephen W.; Maity, Amit; Oprysko, Patricia R.; Kachur, Alexander V.; Ayene, Iraimoudi S.; Biaglow, John E.; Koch, Cameron J.			Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration - Implications for the mechanism of HIF-1 alpha stabilization under moderate hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; HIF-ALPHA; HYDROGEN-PEROXIDE; INDUCIBLE FACTOR; MAMMALIAN-CELLS; DEFICIENT CELLS; CYTOCHROME-C; DNA-DAMAGE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; APOPTOSIS	The oxidative pentose phosphate cycle (OPPC) is necessary to maintain cellular reducing capacity during periods of increased oxidative stress. Metabolic flux through the OPPC increases stoichiometrically in response to a broad range of chemical oxidants, including those that generate reactive oxygen species (ROS). Here we show that OPPC sensitivity is sufficient to detect low levels of ROS produced metabolically as a function of the percentage of O-2. We observe a significant decrease in OPPC activity in cells incubated under severe and moderate hypoxia (ranging from <0.01 to 4% O-2), whereas hyperoxia (95% O-2) results in a significant increase in OPPC activity. These data indicate that metabolic ROS production is directly dependent on oxygen concentration. Moreover, we have found no evidence to suggest that ROS, produced by mitochondria, are needed to stabilize hypoxia-inducible factor 1 alpha(HIF-1 alpha) under moderate hypoxia. Myxothiazol, an inhibitor of mitochondrial electron transfer, did not prevent HIF-1 alpha stabilization under moderate hypoxia. Moreover, the levels of HIF-1 alpha that we observed after exposure to moderate hypoxia were comparable between rho(0) cells, which lack functional mitochondria, and the wild-type cells. Finally, we find no evidence for stabilization of HIF-1 alpha in response to the non-toxic levels of H2O2 generated by the enzyme glucose oxidase. Therefore, we conclude that the oxygen dependence of the prolyl hydroxylase reaction is sufficient to mediate HIF-1 alpha stability under moderate as well as severe hypoxia.	[Tuttle, Stephen W.; Maity, Amit; Oprysko, Patricia R.; Kachur, Alexander V.; Biaglow, John E.; Koch, Cameron J.] Univ Penn, Dept Radiat Oncol, Sch Med, Philadelphia, PA 19104 USA; [Ayene, Iraimoudi S.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA	University of Pennsylvania; Lankenau Medical Center; Lankenau Institute for Medical Research	Tuttle, SW (corresponding author), Univ Penn, Dept Radiat Oncol, Sch Med, 195 John Morgan Bldg, Philadelphia, PA 19104 USA.	tuttle@xrt.upenn.edu		Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA092108, R01CA091053, R01CA044982, R37CA044982, R01CA109604, R01CA074071, R01CA093638] Funding Source: NIH RePORTER; NCI NIH HHS [CA109604, CA44982, CA74071, CA91053, CA92108, CA93638] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Au SWN, 2000, STRUCTURE, V8, P293, DOI 10.1016/S0969-2126(00)00104-0; Biaglow JE, 2000, BIOCHEM BIOPH RES CO, V273, P846, DOI 10.1006/bbrc.2000.3024; BIAGLOW JE, 1992, INT J RADIAT ONCOL, V22, P665, DOI 10.1016/0360-3016(92)90499-8; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Cheng ML, 2004, FREE RADICAL BIO MED, V36, P580, DOI 10.1016/j.freeradbiomed.2003.11.031; Cosgrove MS, 1998, BIOCHEMISTRY-US, V37, P2759, DOI 10.1021/bi972069y; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; Efferth T, 2001, J LEUKOCYTE BIOL, V69, P340; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; EVANS SM, 1995, BRIT J CANCER, V72, P875, DOI 10.1038/bjc.1995.427; Fico A, 2004, CELL DEATH DIFFER, V11, P823, DOI 10.1038/sj.cdd.4401420; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giandomenico AR, 1997, FREE RADICAL BIO MED, V23, P426, DOI 10.1016/S0891-5849(97)00113-5; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Horan AD, 1999, RADIAT RES, V152, P144, DOI 10.2307/3580087; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koch CJ, 2002, METHOD ENZYMOL, V352, P3; KOCH CJ, 1995, BRIT J CANCER, V72, P869, DOI 10.1038/bjc.1995.426; KOCH CJ, 1984, RADIAT RES, V97, P434, DOI 10.2307/3576294; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee J, 1996, INT J CANCER, V67, P372, DOI 10.1002/(SICI)1097-0215(19960729)67:3<372::AID-IJC11>3.0.CO;2-A; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Tuttle S, 2000, RADIAT RES, V153, P781, DOI 10.1667/0033-7587(2000)153[0781:GPDATO]2.0.CO;2; TUTTLE SW, 1994, INT J RADIAT ONCOL, V29, P357, DOI 10.1016/0360-3016(94)90289-5; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; VARNES ME, 1984, BIOCHEM PHARMACOL, V33, P1671, DOI 10.1016/0006-2952(84)90290-9; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	42	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2007	282	51					36790	36796		10.1074/jbc.M700327200	http://dx.doi.org/10.1074/jbc.M700327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241GX	17666400	hybrid			2022-12-25	WOS:000251646000003
J	Bennetts, B; Parker, MW; Cromer, BA				Bennetts, Brett; Parker, Michael W.; Cromer, Brett A.			Inhibition of skeletal muscle ClC-1 chloride channels by low intracellular pH and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW GATING RELAXATIONS; TEMPERATURE-DEPENDENCE; CYTOPLASMIC DOMAIN; DYNAMIC EXERCISE; RAT DIAPHRAGM; CL-CHANNEL; FIBERS; CONDUCTANCE; FATIGUE; DOMINANT	Skeletal muscle acidosis during exercise has long been thought to be a cause of fatigue, but recent studies have shown that acidosis maintains muscle excitability and opposes fatigue by decreasing the sarcolemmal chloride conductance. ClC-1 is the primary sarcolemmal chloride channel and has a clear role in controlling muscle excitability, but recombinant ClC- 1 has been reported to be activated by acidosis. Following our recent finding that intracellular ATP inhibits ClC- 1, we investigated here the interaction between pH and ATP regulation of ClC-1. We found that, in the absence of ATP, intracellular acidosis from pH 7.2to 6.2 inhibited ClC- 1 slightly by shifting the voltage dependence of common gating to more positive potentials, similar to the effect of ATP. Importantly, the effects of ATP and acidosis were cooperative, such that ATP greatly potentiated the effect of acidosis. Adenosine had a similar effect to ATP at pH 7.2, but acidosis did not potentiate this effect, indicating that the phosphates of ATP are important for this cooperativity, possibly due to electrostatic interactions with protonatable residues of ClC-1. A protonatable residue identified by molecular modeling, His- 847, was found to be critical for both pH and ATP modulation and may be involved in such electrostatic interactions. These findings are now consistent with, and provide a molecular explanation for, acidosis opposing fatigue by decreasing the chloride conductance of skeletal muscle via inhibition of ClC-1. The modulation of ClC- 1 by ATP is a key component of this molecular mechanism.	St Vincents Inst, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Cromer, BA (corresponding author), Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia.	brett.cromer@florey.edu.au	Parker, Michael W/F-9069-2013; Cromer, Brett/AAQ-6533-2020	Parker, Michael W/0000-0002-3101-1138; Cromer, Brett/0000-0003-0743-1535				Accardi A, 2000, J GEN PHYSIOL, V116, P433, DOI 10.1085/jgp.116.3.433; Aromataris EC, 2001, MOL PHARMACOL, V60, P200, DOI 10.1124/mol.60.1.200; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; Bennetts B, 2001, J PHYSIOL-LONDON, V535, P83, DOI 10.1111/j.1469-7793.2001.t01-1-00083.x; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; Chen MF, 1997, J PHYSIOL-LONDON, V504, P75, DOI 10.1111/j.1469-7793.1997.075bf.x; Chen TY, 1998, J GEN PHYSIOL, V112, P715, DOI 10.1085/jgp.112.6.715; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; CORFU NA, 1991, EUR J BIOCHEM, V199, P659, DOI 10.1111/j.1432-1033.1991.tb16168.x; Duffield M, 2003, J GEN PHYSIOL, V121, P149, DOI 10.1085/jgp.20028741; Dutka TL, 2004, J PHYSIOL-LONDON, V560, P451, DOI 10.1113/jphysiol.2004.069112; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Estevez R, 2004, J PHYSIOL-LONDON, V557, P363, DOI 10.1113/jphysiol.2003.058453; FITTS RH, 1994, PHYSIOL REV, V74, P49, DOI 10.1152/physrev.1994.74.1.49; Hebeisen S, 2005, BIOPHYS J, V89, P1710, DOI 10.1529/biophysj.104.056093; HERMANSEN L, 1972, J APPL PHYSIOL, V32, P304, DOI 10.1152/jappl.1972.32.3.304; HUTTER OF, 1967, J PHYSIOL-LONDON, V189, P403, DOI 10.1113/jphysiol.1967.sp008176; Karatzaferi C, 2001, PFLUG ARCH EUR J PHY, V442, P467, DOI 10.1007/s004240100552; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; METZGER JM, 1987, J APPL PHYSIOL, V62, P1392, DOI 10.1152/jappl.1987.62.4.1392; Meyer S, 2006, STRUCTURE, V14, P299, DOI 10.1016/j.str.2005.10.008; Meyer S, 2007, NAT STRUCT MOL BIOL, V14, P60, DOI 10.1038/nsmb1188; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Nielsen OB, 2001, J PHYSIOL-LONDON, V536, P161, DOI 10.1111/j.1469-7793.2001.t01-1-00161.x; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; Papponen H, 2005, EXP NEUROL, V191, P163, DOI 10.1016/j.expneurol.2004.07.018; Pedersen TH, 2005, J GEN PHYSIOL, V125, P237, DOI 10.1085/jgp.200409173; Pedersen TH, 2004, SCIENCE, V305, P1144, DOI 10.1126/science.1101141; Pusch M, 1997, J GEN PHYSIOL, V109, P105, DOI 10.1085/jgp.109.1.105; Pusch M, 2002, HUM MUTAT, V19, P423, DOI 10.1002/humu.10063; ROOS A, 1978, AM J PHYSIOL, V235, pC49, DOI 10.1152/ajpcell.1978.235.1.C49; Ruff RL, 1996, ACTA PHYSIOL SCAND, V156, P159, DOI 10.1046/j.1365-201X.1996.189000.x; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Rychkov GY, 2001, J PHYSIOL-LONDON, V530, P379, DOI 10.1111/j.1469-7793.2001.0379k.x; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; SAHLIN K, 1978, J APPL PHYSIOL, V45, P474, DOI 10.1152/jappl.1978.45.3.474; SAHLIN K, 1976, PFLUG ARCH EUR J PHY, V367, P143, DOI 10.1007/BF00585150; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Sejersted OM, 2000, PHYSIOL REV, V80, P1411, DOI 10.1152/physrev.2000.80.4.1411; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THOMPSON LV, 1992, AM J PHYSIOL, V262, pC1507, DOI 10.1152/ajpcell.1992.262.6.C1507; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; WILSON JR, 1988, J APPL PHYSIOL, V64, P2333, DOI 10.1152/jappl.1988.64.6.2333	47	54	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32780	32791		10.1074/jbc.M703259200	http://dx.doi.org/10.1074/jbc.M703259200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17693413	hybrid, Green Accepted			2022-12-25	WOS:000250625400027
J	Messens, J; Collet, JF; Van Belle, K; Brosens, E; Loris, R; Wyns, L				Messens, Joris; Collet, Jean-Francois; Van Belle, Karolien; Brosens, Elke; Loris, Remy; Wyns, Lode			The oxidase DsbA folds a protein with a nonconsecutive disulfide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHYTASE; BOND FORMATION; IN-VIVO; PERIPLASMIC PROTEIN; RIBONUCLEASE; ISOMERASE; ENZYME; GENE; OXIDOREDUCTASES; IDENTIFICATION	One of the last unsolved problems of molecular biology is how the sequential amino acid information leads to a functional protein. Correct disulfide formation within a protein is hereby essential. We present periplasmic ribonuclease I (RNase I) from Escherichia coli as a new endogenous substrate for the study of oxidative protein folding. One of its four disulfides is between nonconsecutive cysteines. In general view, the folding of proteins with nonconsecutive disulfides requires the protein disulfide isomerase DsbC. In contrast, our study with RNase I shows that DsbA is a sufficient catalyst for correct disulfide formation in vivo and in vitro. DsbA is therefore more specific than generally assumed. Further, we show that the redox potential of the periplasm depends on the presence of glutathione and the Dsb proteins to maintain it at -165 mV. We determined the influence of this redox potential on the folding of RNase I. Under the more oxidizing conditions of dsb(-) strains, DsbC becomes necessary to correct non-native disulfides, but it cannot substitute for DsbA. Altogether, DsbA folds a protein with a nonconsecutive disulfide as long as no incorrect disulfides are formed.	Vrije Univ Brussel VIB, Ultrastrutture Lab, B-1050 Brussels, Belgium; Vlaams Inst Biotechnol, Dept Mol & Cellular Interact, Brussels, Belgium; Univ Catholique Louvain, Duve Inst, B-1200 Brussels, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Universite Catholique Louvain	Messens, J (corresponding author), Vrije Univ Brussel VIB, Ultrastrutture Lab, Pleinlaan 2, B-1050 Brussels, Belgium.	joris.messens@vub.ac.be	Loris, Remy/GPG-0894-2022; Messens, Joris/AAH-3008-2020; Collet, Jean Francois/F-2105-2010	Messens, Joris/0000-0002-2128-8264; Collet, Jean-Francois/0000-0001-8069-7036; Loris, Remy/0000-0002-8862-3338				Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Berkmen M, 2005, J BIOL CHEM, V280, P11387, DOI 10.1074/jbc.M411774200; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; Ewis HE, 2005, FEMS MICROBIOL LETT, V253, P295, DOI 10.1016/j.femsle.2005.09.046; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; GreinerStoeffele T, 1996, ANAL BIOCHEM, V240, P24, DOI 10.1006/abio.1996.0326; HABER E, 1961, J BIOL CHEM, V236, P422; Hiniker A, 2005, J BIOL CHEM, V280, P33785, DOI 10.1074/jbc.M505742200; Hiniker A, 2004, TRENDS BIOCHEM SCI, V29, P516, DOI 10.1016/j.tibs.2004.08.002; Hiniker A, 2004, J BIOL CHEM, V279, P12967, DOI 10.1074/jbc.M311391200; Ida K, 2001, J MOL BIOL, V314, P103, DOI 10.1006/jmbi.2001.5127; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; Lim D, 2000, NAT STRUCT BIOL, V7, P108; Marcyjaniak M, 2004, J BIOL CHEM, V279, P43982, DOI 10.1074/jbc.M406735200; Messens J, 2006, INT J BIOCHEM CELL B, V38, P1050, DOI 10.1016/j.biocel.2005.12.011; MILLER JH, 1972, EXP MOL GENETICS; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan S, 2001, ARCH BIOCHEM BIOPHYS, V390, P42, DOI 10.1006/abbi.2001.2359; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; Pittman MS, 2005, J BIOL CHEM, V280, P32254, DOI 10.1074/jbc.M503075200; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	33	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31302	31307		10.1074/jbc.M705236200	http://dx.doi.org/10.1074/jbc.M705236200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17702751	hybrid			2022-12-25	WOS:000250309200019
J	Choi, JH; Williams, J; Cho, J; Falck, JR; Shears, SB				Choi, Jae H.; Williams, Jason; Cho, Jaiesoon; Falck, J. R.; Shears, Stephen B.			Purification, sequencing, and molecular identification of a mammalian PP-InsP(5) kinase that is activated when cells are exposed to hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIS-DIPHOSPHOINOSITOL TETRAKISPHOSPHATE; INOSITOL HEXAKISPHOSPHATE KINASE-2; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; PYROPHOSPHATES; PENTAKISPHOSPHATE; METABOLISM; PROTEIN; FAMILY; 1,4,5-TRISPHOSPHATE	Mammalian cells utilize multiple signaling mechanisms to protect against the osmotic stress that accompanies plasma membrane ion transport, solute uptake, and turnover of protein and carbohydrates (Schliess, F., and Haussinger, D. (2002) Biol. Chem. 383, 577-583). Recently, osmotic stress was found to increase synthesis of bisdiphosphoinositol tetrakisphosphate ((PP)(2)-InsP(4)), a high energy inositol pyrophosphate (Pesesse, X., Choi, K., Zhang, T., and Shears, S. B. (2004) J. Biol. Chem. 279, 43378-43381). Here, we describe the purification from rat brain of a diphosphoinositol pentakisphosphate kinase (PPIP5K) that synthesizes (PP)(2)-InsP(4). Partial amino acid sequence, obtained by mass spectrometry, matched the sequence of a 160-kDa rat protein containing a putative ATP-grasp kinase domain. BLAST searches uncovered two human isoforms (PPIP5K1 (160 kDa) and PPIP5K2 (138 kDa)). Recombinant human PPIP5K1, expressed in Escherichia coli, was found to phosphorylate diphosphoinositol pentakisphosphate (PP-InsP(5)) to (PP)(2)-InsP(4) (V-max = 8.3 nmol/mg of protein/min; K-m = 0.34 mu M). Overexpression in human embryonic kidney cells of either PPIP5K1 or PPIP5K2 substantially increased levels of (PP)(2)-InsP(4), whereas overexpression of a catalytically dead PPIP5K1(D332A) mutant had no effect. PPIP5K1 and PPIP5K2 were more active against PP-InsP5 than InsP6, both in vitro and in vivo. Analysis by confocal immunofluorescence showed PPIP5K1 to be distributed throughout the cytoplasm but excluded from the nucleus. Immunopurification of overexpressed PPIP5K1 from osmotically stressed HEK cells (0.2 M sorbitol; 30 min) revealed a persistent, 3.9 +/- 0.4-fold activation when compared with control cells. PPIP5Ks are likely to be important signaling enzymes.	NIEHS, Inositide Siganling Grp, Lab Signal Transduct, NIH,DHHS, Res Triangle Pk, NC 27709 USA; NIEHS, Prot Microcharacterizat Core Facil, Struct Biol Lab, NIH,DHHS, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shears, SB (corresponding author), NIEHS, Inositide Siganling Grp, Lab Signal Transduct, NIH,DHHS, POB 12233, Res Triangle Pk, NC 27709 USA.	shears@niehs.nih.gov	shears, stephen/C-6335-2019	shears, stephen/0000-0001-7309-8916; Falck, John/0000-0002-9219-7845	Intramural NIH HHS [Z01 ES080046-19] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101564, Z01ES080046] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; Alcazar-Roman AR, 2006, NAT CELL BIOL, V8, P711, DOI 10.1038/ncb1427; Alfieri RR, 2007, PFLUG ARCH EUR J PHY, V454, P173, DOI 10.1007/s00424-006-0195-x; Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Cho J, 2006, J BIOTECHNOL, V126, P248, DOI 10.1016/j.jbiotec.2006.04.028; Choi K, 2005, CELL SIGNAL, V17, P1533, DOI 10.1016/j.cellsig.2005.03.021; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; El Alami M, 2003, MOL MICROBIOL, V49, P457, DOI 10.1046/j.1365-2958.2003.03562.x; Fridy PC, 2007, J BIOL CHEM, V282, P30754, DOI 10.1074/jbc.M704656200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hand CE, 2007, BIOORG MED CHEM LETT, V17, P183, DOI 10.1016/j.bmcl.2006.09.066; Hidaka K, 2002, J BIOL CHEM, V277, P32730, DOI 10.1074/jbc.M205476200; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Miller GJ, 2005, MOL CELL, V18, P201, DOI 10.1016/j.molcel.2005.03.016; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Mullaney EJ, 2003, BIOCHEM BIOPH RES CO, V312, P179, DOI 10.1016/j.bbrc.2003.09.176; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Pattni K, 2004, CELL SIGNAL, V16, P643, DOI 10.1016/j.cellsig.2003.10.009; Pesesse X, 2005, BIOCHEM BIOPH RES CO, V336, P157, DOI 10.1016/j.bbrc.2005.08.049; Pesesse X, 2004, J BIOL CHEM, V279, P43378, DOI 10.1074/jbc.C400286200; Riley AM, 2006, CHEMBIOCHEM, V7, P1114, DOI 10.1002/cbic.200600037; Safrany ST, 2004, MOL PHARMACOL, V66, P1585, DOI 10.1124/mol.104.002667; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Seeds AM, 2007, BIOCHEM SOC SYMP, V74, P183, DOI 10.1042/BSS2007c16; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 2007, BIOCHEM SOC SYMP, V74, P211, DOI 10.1042/BSS2007c18; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zhang T, 2001, FEBS LETT, V494, P208, DOI 10.1016/S0014-5793(01)02351-1	57	84	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30763	30775		10.1074/jbc.M704655200	http://dx.doi.org/10.1074/jbc.M704655200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702752	Green Accepted, hybrid			2022-12-25	WOS:000250136300045
J	Voigt, J; Woestemeyer, J; Frank, R				Voigt, Juergen; Woestemeyer, Johannes; Frank, Ronald			The chaotrope-soluble glycoprotein GP2 is a precursor of the insoluble glycoprotein framework of the Chlamydomonas cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYPROLINE-RICH GLYCOPROTEINS; VOLVOX-CARTERI; CROSS-LINKING; CONSTITUENT GLYCOPROTEINS; MOLECULAR-ORGANIZATION; EXTRACELLULAR-MATRIX; POLYACRYLAMIDE-GELS; PROLYL HYDROXYLASE; MASS-SPECTROMETRY; AMINO-ACID	The cell wall of the unicellular green alga Chlamydomonas reinhardtii consists of an insoluble, hydroxyproline-rich glycoprotein framework and several chaotrope-soluble, hydroxyproline-containing glycoproteins. Up to now, there have been no data concerning the amino acid sequences of the hydroxyproline-containing polypeptides of the insoluble wall fraction. Matrix-assisted laser desorption ionization time-of-flight analyses of peptides released from the insoluble cell wall fraction by trypsin treatment revealed the presence of 14 peptide fragments that could be attributed to non-glycosylated domains of the chaotrope-soluble cell wall glycoprotein GP2. However, these peptides cover only 15% of the GP2 polypeptide backbone. Considerably more information concerning the presence of GP2 in the insoluble cell wall fraction was obtained by an immunochemical approach. For this purpose, 407 overlapping pentadecapeptides covering the whole known amino acid sequence of GP2 were chemically synthesized and probed with a polyclonal antibody raised against the deglycosylated, insoluble cell wall fraction. This particular antibody reacted with 297 of the 407 GP2-derived peptides. The peptides that were recognized by this antibody are distributed over the whole known GP2 sequence. The epitopes recognized by polyclonal antibodies raised against the 64- and 45-kDa constituents purified from the deglycosylation products of the insoluble cell wall fraction are also distributed over the whole GP2 backbone, although the corresponding antigens are considerably smaller than GP2. The significance of the latter results for the structure of the insoluble cell wall fraction is discussed.	Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany; Univ Jena, Inst Microbiol, D-07743 Jena, Germany; Helmholtz Ctr Infect Res, Dept Biol Chem, D-38124 Braunschweig, Germany	Leipzig University; Friedrich Schiller University of Jena; Helmholtz Association; Helmholtz-Center for Infection Research	Voigt, J (corresponding author), Univ Leipzig, Inst Biochem, Johannisallee 30, D-04103 Leipzig, Germany.	juergen.voigt@medizin.uni-leipzig.de	Voigt, Juergen/H-2163-2011	Voigt, Juergen/0000-0002-8104-6443				ADAIR WS, 1987, J CELL BIOL, V105, P2373, DOI 10.1083/jcb.105.5.2373; ADAIR WS, 1990, P NATL ACAD SCI USA, V87, P7355, DOI 10.1073/pnas.87.19.7355; Arnott D, 1998, ANAL BIOCHEM, V258, P1, DOI 10.1006/abio.1998.2566; BALDWIN TC, 1992, PLANT J, V2, P733, DOI 10.1046/j.1365-313X.1992.t01-14-00999.x; BIGGS KJ, 1990, PLANT PHYSIOL, V92, P197, DOI 10.1104/pp.92.1.197; BLANKENSTEIN P, 1986, PLANTA, V169, P238, DOI 10.1007/BF00392320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; EPSTEIN L, 1984, PHYTOCHEMISTRY, V23, P1241, DOI 10.1016/S0031-9422(00)80433-1; ERTL H, 1992, EMBO J, V11, P2055, DOI 10.1002/j.1460-2075.1992.tb05263.x; Estevez JM, 2006, PLANT PHYSIOL, V142, P458, DOI 10.1104/pp.106.084244; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GOLDMAN MHD, 1992, PLANT CELL, V4, P1041, DOI 10.1105/tpc.4.9.1041; Goodenough U.W., 1986, J CELL BIOL, V103, P924; GOODENOUGH UW, 1985, J CELL BIOL, V101, P1550, DOI 10.1083/jcb.101.4.1550; GOODENOUGH UW, 1988, J CELL SCI, V90, P717; GOODENOUGH UW, 1988, J CELL SCI, V90, P735; Grossman AR, 2003, EUKARYOT CELL, V2, P1137, DOI 10.1128/EC.2.6.1137-1150.2003; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HILLS GJ, 1975, J MOL BIOL, V96, P431, DOI 10.1016/0022-2836(75)90170-9; Hoffmann XK, 2005, PLANT PHYSIOL, V139, P999, DOI 10.1104/pp.105.065037; HOLST O, 1989, EUR J BIOCHEM, V181, P345, DOI 10.1111/j.1432-1033.1989.tb14730.x; IMAM SH, 1985, J CELL BIOL, V101, P1599, DOI 10.1083/jcb.101.4.1599; Keskiaho K, 2007, PLANT CELL, V19, P256, DOI 10.1105/tpc.106.042739; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kilz S, 2002, J MASS SPECTROM, V37, P331, DOI 10.1002/jms.287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPORT DTA, 1967, NATURE, V216, P1322, DOI 10.1038/2161322a0; Liu XN, 2001, PLANT MOL BIOL REP, V19, P261, DOI 10.1007/BF02772898; Maniatis T., 1982, MOL CLONING LAB MANU; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; ROBERTS K, 1972, J ULTRA MOL STRUCT R, V40, P599, DOI 10.1016/S0022-5320(72)80046-7; ROBERTS K, 1974, PHILOS T R SOC B, V268, P129, DOI 10.1098/rstb.1974.0021; ROBERTS K, 1985, J CELL SCI, P105; RUBENSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086; RUBENSTEIN AL, 1995, PLANT CELL, V7, P2211; SAUER A, 1985, PLANTA, V164, P287, DOI 10.1007/BF00396094; Schnabelrauch LS, 1996, PLANT J, V9, P477, DOI 10.1046/j.1365-313X.1996.09040477.x; Serpe MD, 1999, ADV BOT RES, V30, P207; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Shrager J, 2003, PLANT PHYSIOL, V131, P401, DOI 10.1104/pp.016899; Sommer-Knudsen J, 1998, PHYTOCHEMISTRY, V47, P483, DOI 10.1016/S0031-9422(97)00724-3; Sumper M, 1998, INT REV CYTOL, V180, P51; TANAKA M, 1981, J BIOL CHEM, V256, P1397; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA H, 1993, CURR GENET, V24, P296, DOI 10.1007/BF00336779; VOGELER HP, 1990, PLANT SCI, V71, P119, DOI 10.1016/0168-9452(90)90075-Y; Voigt J, 1996, PLANT CELL PHYSIOL, V37, P91, DOI 10.1093/oxfordjournals.pcp.a028919; VOIGT J, 1987, PLANTA, V172, P463, DOI 10.1007/BF00393861; Voigt J, 2004, BBA-GENE STRUCT EXPR, V1679, P180, DOI 10.1016/j.bbaexp.2004.06.007; VOIGT J, 1985, PLANTA, V164, P379, DOI 10.1007/BF00402950; VOIGT J, 1985, BIOCHEM J, V226, P259, DOI 10.1042/bj2260259; Voigt J, 2003, PLANT CELL, V15, P1399, DOI 10.1105/tpc.010611; Voigt J, 2001, EUR J BIOCHEM, V268, P6449, DOI 10.1046/j.0014-2956.2001.02593.x; VOIGT J, 1986, Z NATURFORSCH C, V41, P885; Waffenschmidt S, 1999, PLANT PHYSIOL, V121, P1003, DOI 10.1104/pp.121.3.1003; WAFFENSCHMIDT S, 1993, PLANT CELL, V5, P809, DOI 10.1105/tpc.5.7.809; WOESSNER JP, 1994, PLANT MOL BIOL, V26, P947, DOI 10.1007/BF00028861; WOESSNER JP, 1994, PROTOPLASMA, V181, P245, DOI 10.1007/BF01666399; WOESSNER JP, 1989, PLANT CELL, V1, P901; WU HM, 1993, P NATL ACAD SCI USA, V90, P6829, DOI 10.1073/pnas.90.14.6829	66	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30381	30392		10.1074/jbc.M701673200	http://dx.doi.org/10.1074/jbc.M701673200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17673458	hybrid			2022-12-25	WOS:000250136300006
J	Zhang, Y; Sawada, T; Jing, XF; Yokote, H; Yan, XM; Sakaguchi, K				Zhang, Yueqiang; Sawada, Takahiro; Jing, Xuefeng; Yokote, Hideyuki; Yan, Xiaomei; Sakaguchi, Kazushige			Regulation of ephexin1, a guanine nucleotide exchange factor of Rho family GTPases, by fibroblast growth factor receptor-mediated tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P85 BETA-PIX; TARGET RECOGNITION; EPHA4; MORPHOGENESIS; SPECIFICITY; INHIBITION; ACTIVATION; COLLAPSE; PATHWAY; EMBRYOS	Fibroblast growth factor (FGF) signal is implicated in not only cell proliferation, but cell migration and morphological changes. Several different Rho family GTPases downstream of the Ras/ERK pathway are postulated to mediate the latter functions. However, none have been recognized to be directly coupled to FGF receptors (FGFRs). We have previously reported that EphA4 and FGFRs hetero-oligomerize through their cytoplasmic domains, trans-activate each other, and transduce a signal for cell proliferation through a docking protein, FRS2 alpha (Yokote, H., Fujita, K., Jing, X., Sawada, T., Liang, S., Yao, L., Yan, X., Zhang, Y., Schlessinger, J., and Sakaguchi, K. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 18866-18871). Here, we have found that ephexin1, a guanine nucleotide exchange factor for Rho family GTPases, constitutes another downstream component of the receptor complex. Ephexin1 directly binds to the kinase domain of FGFR mainly through its DH and PH domains. The binding appears to become weaker and limited to the DH domain when FGFRs become activated. FGFR-mediated phosphorylation of ephexin1 enhances the guanine nucleotide exchange activity toward RhoA without affecting the activity to Rac1 or Cdc42. The FGFR-mediated tyrosine phosphorylation includes, but is not limited to, the residue (Tyr-87) phosphorylated by Src family kinase, which is known to be activated following EphA4 activation. The Tyr-to-Asp mutations that mimic the tyrosine phosphorylation in some of the putative FGFR-mediated phosphorylation sites increase the nucleotide exchange activity for RhoA without changing the activity for Rac1 or Cdc42. From these results, we conclude that ephexin1 is located immediately downstream of the EphA4-FGFR complex and the function is altered by the FGFR-mediated tyrosine phosphorylation at multiple sites.	Wakayama Med Univ, Inst Adv Med, Dept Mol Cell Biol, Wakayama 6418509, Japan	Wakayama Medical University	Sakaguchi, K (corresponding author), Wakayama Med Univ, Inst Adv Med, Dept Mol Cell Biol, 811-1 Kimiidera, Wakayama 6418509, Japan.	ksaka@wakayama-med.ac.jp	ZHANG, YUEQIANG/C-1742-2012; Zhang, Yueqiang/AAE-9649-2020					Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Knoll B, 2004, J NEUROSCI, V24, P6248, DOI 10.1523/JNEUROSCI.0985-04.2004; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; McFarlane S, 1996, NEURON, V17, P245, DOI 10.1016/S0896-6273(00)80156-7; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Watabe-Uchida M, 2006, NEURON, V51, P727, DOI 10.1016/j.neuron.2006.07.020; Winning RS, 2002, DIFFERENTIATION, V70, P46, DOI 10.1046/j.1432-0436.2002.700105.x; Yokote H, 2005, P NATL ACAD SCI USA, V102, P18866, DOI 10.1073/pnas.0509741102; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	21	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31103	31112		10.1074/jbc.M704430200	http://dx.doi.org/10.1074/jbc.M704430200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702745	hybrid			2022-12-25	WOS:000250136300078
J	Brown, MD; Bry, L; Li, ZG; Sacks, DB				Brown, Matthew D.; Bry, Lynn; Li, Zhigang; Sacks, David B.			IQGAP1 regulates Salmonella invasion through interactions with actin, Rac1, and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL; NUCLEOTIDE EXCHANGE; BACTERIAL INVASION; RHO GTPASES; IDENTIFICATION; TYPHIMURIUM; PROTEIN; CYTOSKELETAL; CALMODULIN; SOPE2	To infect host cells, Salmonella utilizes an intricate system to manipulate the actin cytoskeleton and promote bacterial uptake. Proteins injected into the host cell by Salmonella activate the Rho GTPases, Rac1 and Cdc42, to induce actin polymerization. Following uptake, a different set of proteins inactivates Rac1 and Cdc42, returning the cytoskeleton to normal. Although the signaling pathways allowing Salmonella to invade host cells are beginning to be understood, many of the contributing factors remain to be elucidated. IQGAP1 is a multidomain protein that influences numerous cellular functions, including modulation of Rac1/Cdc42 signaling and actin polymerization. Here, we report that IQGAP1 regulates Salmonella invasion. Through its interaction with actin, IQGAP1 co-localizes with Rac1, Cdc42, and actin at sites of bacterial uptake, whereas infection promotes the interaction of IQGAP1 with both Rac1 and Cdc42. Knockdown of IQGAP1 significantly reduces Salmonella invasion and abrogates activation of Cdc42 and Rac1 by Salmonella. Overexpression of IQGAP1 significantly increases the ability of Salmonella to enter host cells and required interaction with both actin and Cdc42/Rac1. Together, these data identify IQGAP1 as a novel regulator of Salmonella invasion.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sacks, DB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735; Bry, Lynn/0000-0002-8792-8527				Bakshi CS, 2000, J BACTERIOL, V182, P2341, DOI 10.1128/JB.182.8.2341-2344.2000; Bensenor LB, 2007, J CELL SCI, V120, P658, DOI 10.1242/jcs.03376; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Brown MD, 2006, TRENDS CELL BIOL, V16, P242, DOI 10.1016/j.tcb.2006.03.002; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; Friebel A, 2001, J BIOL CHEM, V276, P34035, DOI 10.1074/jbc.M100609200; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Jeong HW, 2007, J BIOL CHEM, V282, P20752, DOI 10.1074/jbc.M700487200; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Le Clainche C, 2007, J BIOL CHEM, V282, P426, DOI 10.1074/jbc.M607711200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mataraza JM, 2007, CELL SIGNAL, V19, P1857, DOI 10.1016/j.cellsig.2007.04.011; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Patel JC, 2006, J CELL BIOL, V175, P453, DOI 10.1083/jcb.200605144; Patel JC, 2005, TRENDS PHARMACOL SCI, V26, P564, DOI 10.1016/j.tips.2005.09.005; Pizarro-Cerda J, 2006, CELL, V124, P715, DOI 10.1016/j.cell.2006.02.012; Raffatellu M, 2005, INFECT IMMUN, V73, P146, DOI 10.1128/IAI.73.1.146-154.2005; Ren JG, 2005, J BIOL CHEM, V280, P34548, DOI 10.1074/jbc.M507321200; Ren JG, 2007, P NATL ACAD SCI USA, V104, P10465, DOI 10.1073/pnas.0611308104; Roy M, 2005, MOL CELL BIOL, V25, P7940, DOI 10.1128/MCB.25.18.7940-7952.2005; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schlumberger MC, 2003, J BIOL CHEM, V278, P27149, DOI 10.1074/jbc.M302475200; SHI J, 2006, MOL BIOL, P4698; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	44	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30265	30272		10.1074/jbc.M702537200	http://dx.doi.org/10.1074/jbc.M702537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693642	hybrid			2022-12-25	WOS:000249981200057
J	Tsukamoto, H; Takakura, Y; Yamamoto, T				Tsukamoto, Hiroshi; Takakura, Yoshimitsu; Yamamoto, Takeshi			Purification, cloning, and expression of an alpha/beta-galactoside alpha-2,3-sialyltransferase from a luminous marine bacterium, Photobacterium phosphoreum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPYLOBACTER-JEJUNI; CHEMOENZYMATIC SYNTHESIS; ENZYMATIC-SYNTHESIS; SIGNAL PEPTIDES; SIALIC-ACID; SIALYLTRANSFERASE; ALPHA-2,6-SIALYLTRANSFERASE; IDENTIFICATION; CONSTRUCTION; LIPOPROTEIN	A novel sialyltransferase, alpha/beta- galactoside alpha- 2,3- sialyltransferase, was purified from the cell lysate of a luminous marine bacterium, Photobacterium phosphoreum JT- ISH- 467, isolated from the Japanese common squid ( Todarodes pacificus). The gene encoding the enzyme was cloned from the genomic library of the bacterium using probes derived from the NH2- terminal and internal amino acid sequences. An open reading frame of 409 amino acids was identified, and the sequence had 32% identity with that of beta- galactoside alpha- 2,6- sialyltrasferase in Photobacterium damselae JT0160. DNA fragments that encoded the full- length protein and a protein that lacked the sequence between the 2nd and 24th residues at the NH2 terminus were amplified by polymerase chain reactions and cloned into an expression vector. The full- length and truncated proteins were expressed in Escherichia coli, producing active enzymes of 0.25 and 305 milliunits, respectively, per milliliter of the medium in the lysate of E. coli. The truncated enzyme was much more soluble without detergent than the full- length enzyme. The enzyme catalyzed the transfer of N- acetylneuraminic acid from CMP- N- acetylneuraminic acid to disaccharides, such as lactose and N- acetyllactosamine, with low apparent Km and to monosaccharides, such as alpha- methyl- galactopyranoside and beta- methylgalactopyranoside, with much lower apparent Km. Thus, this sialyltransferase is unique and should be very useful for achieving high productivity in E. coli with a wide substrate range.	Japan Tobacco Inc, Glycotechnol Business Unit, Shizuoka 4380802, Japan	Japan Tobacco Inc.	Yamamoto, T (corresponding author), Japan Tobacco Inc, Glycotechnol Business Unit, Shizuoka 4380802, Japan.	takeshi.yamamoto@ims.jti.co.jp		Yamamoto, Takeshi/0000-0002-0525-6481				Babu MM, 2006, J BACTERIOL, V188, P2761, DOI 10.1128/JB.188.8.2761-2773.2006; Babu MM, 2002, BIOINFORMATICS, V18, P641, DOI 10.1093/bioinformatics/18.4.641; Blixt O, 2005, CARBOHYD RES, V340, P1963, DOI 10.1016/j.carres.2005.06.008; Bozue JA, 1999, J BIOL CHEM, V274, P4106, DOI 10.1074/jbc.274.7.4106; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Disney MD, 2004, CHEM BIOL, V11, P1701, DOI 10.1016/j.chembiol.2004.10.011; Elliott S, 2003, NAT BIOTECHNOL, V21, P414, DOI 10.1038/nbt799; Fukae K, 2004, GLYCOCONJUGATE J, V21, P243, DOI 10.1023/B:GLYC.0000045096.89408.50; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Guerry P, 2002, INFECT IMMUN, V70, P787, DOI 10.1128/IAI.70.2.787-793.2002; HAYGOOD MG, 1993, CRIT REV MICROBIOL, V19, P191, DOI 10.3109/10408419309113529; Izumi M, 2001, J AM CHEM SOC, V123, P10909, DOI 10.1021/ja011382r; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; Kajihara Y, 1996, J ORG CHEM, V61, P8632, DOI 10.1021/jo961214v; LAI JS, 1980, J BIOL CHEM, V255, P5384; Maniatis T., 1982, MOL CLONING LAB MANU; Narimatsu H, 2004, GLYCOCONJUGATE J, V21, P17, DOI 10.1023/B:GLYC.0000043742.99482.01; Ni LS, 2006, BIOCHEMISTRY-US, V45, P2139, DOI 10.1021/bi0524013; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; Paarup T, 2002, J APPL MICROBIOL, V92, P941, DOI 10.1046/j.1365-2672.2002.01604.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Regan T, 1999, ANTON LEEUW INT J G, V75, P369, DOI 10.1023/A:1002019420453; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; Thyssen A., 2005, BERGEYS MANUAL SYSTE, V2, P546; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Verez-Bencomo V, 2004, SCIENCE, V305, P522, DOI 10.1126/science.1095209; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Werz DB, 2005, CHEM-EUR J, V11, P3194, DOI 10.1002/chem.200500025; Yamamoto T, 1998, J BIOCHEM-TOKYO, V123, P94; Yamamoto T, 1996, J BIOCHEM-TOKYO, V120, P104; Yamamoto T, 1998, BIOSCI BIOTECH BIOCH, V62, P210, DOI 10.1271/bbb.62.210; Yu H, 2005, J AM CHEM SOC, V127, P17618, DOI 10.1021/ja0561690; Yu H, 2006, ANGEW CHEM INT EDIT, V45, P3938, DOI 10.1002/anie.200600572	42	35	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29794	29802		10.1074/jbc.M701907200	http://dx.doi.org/10.1074/jbc.M701907200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702755	hybrid			2022-12-25	WOS:000249981200008
J	Janz, JM; Sakmar, TP; Min, KC				Janz, Jay M.; Sakmar, Thomas P.; Min, K. Christopher			A novel interaction between atrophin-interacting protein 4 and beta-p21-activated kinase-interactive exchange factor is mediated by an SH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; BETA-PIX-A; DOWN-REGULATION; C-CBL; GENE-PRODUCT; SH3 DOMAIN; BINDING; FAMILY; PAK; ACTIVATION	Cross-talk between G protein-coupled receptors and receptor tyrosine kinase signaling pathways is crucial to the efficient relay and integration of cellular information. Here we identify and define the novel binding interaction of the E3 ubiquitin ligase atrophin-interacting protein 4 (AIP4) with the GTP exchange factor beta-p21-activated kinase-interactive exchange factor (beta PIX). We demonstrate that this interaction is mediated in part by the beta PIX-SH3 domain binding to a proline-rich stretch of AIP4. Analysis of the interaction by isothermal calorimetry is consistent with a heterotrimeric complex with one AIP4-derived peptide binding to two beta PIX-SH3 domains. We determined the crystal structure of the beta PIX-SH3 center dot AIP4 complex to 2.0-angstrom resolution. In contrast to the calorimetry results, the crystal structure shows a monomeric complex in which AIP4 peptide binds the beta PIX-SH3 domain as a canonical Class I ligand with an additional type II polyproline helix that makes extensive contacts with another face of beta PIX. Taken together, the novel interaction between AIP4 and beta PIX represents a new regulatory node for G protein-coupled receptor and receptor tyrosine kinase signal integration. Our structure of the beta PIX-SH3 center dot AIP4 complex provides important insight into the mechanistic basis for beta PIX scaffolding of signaling components, especially those involved in cross-talk.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Ellison Med Fdn, Bethesda, MD 20814 USA	Rockefeller University; Columbia University	Janz, JM (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave,Box 187, New York, NY 10021 USA.	jjanz@rockefeller.edu	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NEI NIH HHS [K08-EY015540] Funding Source: Medline; PHS HHS [T3ZEY007138] Funding Source: Medline; NATIONAL EYE INSTITUTE [K08EY015540] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn SJ, 2003, CANCER LETT, V193, P99, DOI 10.1016/S0304-3835(03)00004-1; Bae JY, 2005, J CELL BIOCHEM, V94, P1010, DOI 10.1002/jcb.20357; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Feng QY, 2006, NAT CELL BIOL, V8, P945, DOI 10.1038/ncb1453; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Gu CP, 2006, P NATL ACAD SCI USA, V103, P14447, DOI 10.1073/pnas.0606624103; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hoefen RJ, 2006, J CELL SCI, V119, P1469, DOI 10.1242/jcs.02925; Hoelz A, 2006, J MOL BIOL, V358, P509, DOI 10.1016/j.jmb.2006.02.027; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Natarajan Kanchana, 2006, V332, P51; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Schmidt MHH, 2006, ONCOGENE, V25, P3071, DOI 10.1038/sj.onc.1209329; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stofega MR, 2004, MOL BIOL CELL, V15, P2965, DOI 10.1091/mbc.E03-08-0604; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Volinsky N, 2006, BIOCHEM J, V397, P213, DOI 10.1042/BJ20051655; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	52	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28893	28903		10.1074/jbc.M702678200	http://dx.doi.org/10.1074/jbc.M702678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652093	hybrid			2022-12-25	WOS:000249642100064
J	Philippe, H; Brinkmann, H; Martinez, P; Riutort, M; Baguna, J				Philippe, Herve; Brinkmann, Henner; Martinez, Pedro; Riutort, Marta; Baguna, Jaume			Acoel Flatworms Are Not Platyhelminthes: Evidence from Phylogenomics	PLOS ONE			English	Article								Acoel flatworms are small marine worms traditionally considered to belong to the phylum Platyhelminthes. However, molecular phylogenetic analyses suggest that acoels are not members of Platyhelminthes, but are rather extant members of the earliest diverging Bilateria. This result has been called into question, under suspicions of a long branch attraction (LBA) artefact. Here we re-examine this problem through a phylogenomic approach using 68 different protein-coding genes from the acoel Convoluta pulchra and 51 metazoan species belonging to 15 different phyla. We employ a mixture model, named CAT, previously found to overcome LBA artefacts where classical models fail. Our results unequivocally show that acoels are not part of the classically defined Platyhelminthes, making the latter polyphyletic. Moreover, they indicate a deuterostome affinity for acoels, potentially as a sister group to all deuterostomes, to Xenoturbellida, to Ambulacraria, or even to chordates. However, the weak support found for most deuterostome nodes, together with the very fast evolutionary rate of the acoel Convoluta pulchra, call for more data from slowly evolving acoels (or from its sister-group, the Nemertodermatida) to solve this challenging phylogenetic problem.	[Philippe, Herve; Brinkmann, Henner] Univ Montreal, Dept Biochim, Canadian Inst Adv Res, Ctr Robert Cedergren, Montreal, PQ H3C 3J7, Canada; [Martinez, Pedro; Riutort, Marta; Baguna, Jaume] Univ Barcelona, Fac Biol, Dept Genet, Barcelona, Spain	Canadian Institute for Advanced Research (CIFAR); Universite de Montreal; University of Barcelona	Philippe, H (corresponding author), Univ Montreal, Dept Biochim, Canadian Inst Adv Res, Ctr Robert Cedergren, Montreal, PQ H3C 3J7, Canada.	herve.philippe@umontreal.ca; jbaguna@ub.edu	Martinez, Pedro/O-5025-2014; Riutort, Marta/B-6441-2009	Martinez, Pedro/0000-0003-3956-7541; Riutort, Marta/0000-0002-2134-7674	Genome Quebec; Canadian Research Chair; Universite de Montreal; ICREA; Generalitat de Catalunya; Ministerio de Educacion y Ciencia	Genome Quebec; Canadian Research Chair(Canada Research Chairs); Universite de Montreal; ICREA(ICREA); Generalitat de Catalunya(Generalitat de Catalunya); Ministerio de Educacion y Ciencia(Spanish Government)	HP acknowledges Genome Quebec, the Canadian Research Chair and the Universite de Montreal for financial support, PM, MR and JB are supported by grants from ICREA, Generalitat de Catalunya and the Ministerio de Educacion y Ciencia.	Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; AX P, 1996, MULTICELLULAR ANIMAL, V1, P225; Baguna J, 2004, BIOESSAYS, V26, P1046, DOI 10.1002/bies.20113; Baurain D, 2007, MOL BIOL EVOL, V24, P6, DOI 10.1093/molbev/msl137; Bourlat SJ, 2006, NATURE, V444, P85, DOI 10.1038/nature05241; Brinkmann H, 2005, SYST BIOL, V54, P743, DOI 10.1080/10635150500234609; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Delsuc F, 2005, NAT REV GENET, V6, P361, DOI 10.1038/nrg1603; Ehlers U., 1985, Das Phylogenetische System der Plathelminthes.; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Felsenstein J, 2001, PHYLIP PHYLOGENE INF; Halanych KM, 2004, ANNU REV ECOL EVOL S, V35, P229, DOI 10.1146/annurev.ecolsys.35.112202.130124; Hyman L., 1951, INVERTEBRATES, VII; Jondelius U, 2002, ZOOL SCR, V31, P201, DOI 10.1046/j.1463-6409.2002.00090.x; Lartillot N, 2004, MOL BIOL EVOL, V21, P1095, DOI 10.1093/molbev/msh112; Lartillot N, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S4; Lundin K, 1998, ZOOL SCR, V27, P263, DOI 10.1111/j.1463-6409.1998.tb00440.x; Marletaz F, 2006, CURR BIOL, V16, pR577, DOI 10.1016/j.cub.2006.07.016; Matus DQ, 2006, CURR BIOL, V16, pR575, DOI 10.1016/j.cub.2006.07.017; Peterson KJ, 2001, EVOL DEV, V3, P170, DOI 10.1046/j.1525-142x.2001.003003170.x; Philippe H, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-50; Philippe H, 2005, MOL BIOL EVOL, V22, P1246, DOI 10.1093/molbev/msi111; Philippe H, 2004, MOL BIOL EVOL, V21, P1740, DOI 10.1093/molbev/msh182; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; Philippe H, 2006, TRENDS ECOL EVOL, V21, P614, DOI 10.1016/j.tree.2006.08.004; Roure B, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S2; Ruiz-Trillo I, 2004, MOL PHYLOGENET EVOL, V33, P321, DOI 10.1016/j.ympev.2004.06.002; Ruiz-Trillo I, 2002, P NATL ACAD SCI USA, V99, P11246, DOI 10.1073/pnas.172390199; Ruiz-Trillo I, 1999, SCIENCE, V283, P1919, DOI 10.1126/science.283.5409.1919; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Shimodaira H, 2001, BIOINFORMATICS, V17, P1246, DOI 10.1093/bioinformatics/17.12.1246; SMITH JPS, 1986, HYDROBIOLOGIA, V132, P71, DOI 10.1007/BF00046231; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Telford MJ, 2003, P ROY SOC B-BIOL SCI, V270, P1077, DOI 10.1098/rspb.2003.2342; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	37	102	105	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e717	10.1371/journal.pone.0000717	http://dx.doi.org/10.1371/journal.pone.0000717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684563	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452400020
J	Telschow, A; Flor, M; Kobayashi, Y; Hammerstein, P; Werren, JH				Telschow, Arndt; Flor, Matthias; Kobayashi, Yutaka; Hammerstein, Peter; Werren, John H.			Wolbachia-Induced Unidirectional Cytoplasmic Incompatibility and Speciation: Mainland-Island Model	PLOS ONE			English	Article							REPRODUCTIVE ISOLATION; GENETIC-DIVERGENCE; REINFORCEMENT; POPULATIONS; EVOLUTION; INFECTION; VARIABILITY; PATTERNS; STRAINS; FLOW	Bacteria of the genus Wolbachia are among the most common endosymbionts in the world. In many insect species these bacteria induce a sperm-egg incompatibility between the gametes of infected males and uninfected females, commonly called unidirectional cytoplasmic incompatibility (CI). It is generally believed that unidirectional CI cannot promote speciation in hosts because infection differences between populations will be unstable and subsequent gene flow will eliminate genetic differences between diverging populations. In the present study we investigate this question theoretically in a mainland-island model with migration from mainland to island. Our analysis shows that (a) the infection polymorphism is stable below a critical migration rate, (b) an (initially) uninfected "island'' can better maintain divergence at a selected locus (e.g. can adapt locally) in the presence of CI, and (c) unidirectional CI selects for premating isolation in (initially) uninfected island populations if they receive migration from a Wolbachia-infected mainland. Interestingly, premating isolation is most likely to evolve if levels of incompatibility are intermediate and if either the infection causes fecundity reductions or Wolbachia transmission is incomplete. This is because under these circumstances an infection pattern with an infected mainland and a mostly uninfected island can persist in the face of comparably high migration. We present analytical results for all three findings: (a) a lower estimation of the critical migration rate in the presence of local adaptation, (b) an analytical approximation for the gene flow reduction caused by unidirectional CI, and (c) a heuristic formula describing the invasion success of mutants at a mate preference locus. These findings generally suggest that Wolbachia-induced unidirectional CI can be a factor in divergence and speciation of hosts.	[Telschow, Arndt; Kobayashi, Yutaka] Kyoto Univ, Ctr Ecol Res, Kyoto, Japan; [Telschow, Arndt; Flor, Matthias; Hammerstein, Peter] Humboldt Univ, Inst Theoret Biol, Berlin, Germany; [Werren, John H.] Univ Rochester, Dept Biol, Rochester, NY 14627 USA	Kyoto University; Humboldt University of Berlin; University of Rochester	Telschow, A (corresponding author), Kyoto Univ, Ctr Ecol Res, Kyoto, Japan.	a.telschow@ecology.kyoto-u.ac.jp	Flor, Matthias/C-4953-2008; Kobayashi, Yutaka/G-5424-2010	Flor, Matthias/0000-0003-0429-7457; Werren, John/0000-0001-9353-2070	Deutsche Forschungsgemeinschaft [SFB 618]; National Science Foundation [NSF: EF-0328363]; Biodiversity Research [21COE (A14)]; Japanese Society for the Promotion of Science (JSPS)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Science Foundation(National Science Foundation (NSF)); Biodiversity Research; Japanese Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The study was funded by the Deutsche Forschungsgemeinschaft (SFB 618), the National Science Foundation (NSF: EF-0328363), the Grant of Biodiversity Research 21COE (A14), and the Japanese Society for the Promotion of Science (JSPS).	BARTON N, 1986, HEREDITY, V57, P357, DOI 10.1038/hdy.1986.135; Baudry E, 2003, MOL ECOL, V12, P1843, DOI 10.1046/j.1365-294X.2003.01855.x; Bordenstein SR, 2001, NATURE, V409, P707, DOI 10.1038/35055543; Bordenstein Sr, 2003, CONT T ENT, P283; Bourtzis K, 2003, CONT T ENT, P217; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; Clancy DJ, 1996, TRENDS ECOL EVOL, V11, P145, DOI 10.1016/0169-5347(96)30006-2; COYNE JA, 1989, EVOLUTION, V43, P362, DOI 10.1111/j.1558-5646.1989.tb04233.x; Coyne JA, 1997, EVOLUTION, V51, P295, DOI 10.1111/j.1558-5646.1997.tb02412.x; Coyne JA, 2004, SPECIATION, V37; De Crespigny FEC, 2005, J EVOLUTION BIOL, V18, P967, DOI 10.1111/j.1420-9101.2005.00909.x; Dobzhansky T, 1940, AM NAT, V74, P312, DOI 10.1086/280899; Engelstadter J, 2004, J THEOR BIOL, V231, P345, DOI 10.1016/j.jtbi.2004.06.029; FINE PEM, 1978, J INVERTEBR PATHOL, V31, P10, DOI 10.1016/0022-2011(78)90102-7; Flor M, 2007, J EVOLUTION BIOL, V20, P696, DOI 10.1111/j.1420-9101.2006.01252.x; GAVRILETS S, 2004, MONOGRAPHS POPULATIO, V41; Guillemaud T, 1997, P ROY SOC B-BIOL SCI, V264, P245, DOI 10.1098/rspb.1997.0035; Hartl D., 1989, PRINCIPLES POPULATIO; Hoffmann AA, 1997, INFLUENTIAL PASSENGERS, P42; Hurst GDD, 1998, HEREDITY, V80, P2, DOI 10.1046/j.1365-2540.1998.00337.x; Jaenike J, 2006, PLOS BIOL, V4, P1852, DOI 10.1371/journal.pbio.0040325; Jeyaprakash A, 2000, INSECT MOL BIOL, V9, P393, DOI 10.1046/j.1365-2583.2000.00203.x; Keller GP, 2004, MOL ECOL, V13, P2405, DOI 10.1111/j.1365-294X.2004.02213.x; Kirkpatrick M, 1999, GENETICS, V151, P865; LAVEN H, 1959, COLD SPRING HARB SYM, V24, P166, DOI 10.1101/SQB.1959.024.01.017; Laven H, 1967, GENETICS INSECT VECT, P251; LIOU LW, 1994, EVOLUTION, V48, P1451, DOI 10.1111/j.1558-5646.1994.tb02187.x; Mayr E., 1963, ANIMAL SPECIES EVOLU, P797; MERCOT H, 1995, GENETICS, V141, P1015; PerrotMinnot MJ, 1996, GENETICS, V143, P961; Rasgon JL, 2006, P ROY SOC B-BIOL SCI, V273, P1603, DOI 10.1098/rspb.2006.3493; SANDERSON N, 1989, EVOLUTION, V43, P1223, DOI [10.2307/2409358, 10.1111/j.1558-5646.1989.tb02570.x]; Servedio MR, 2000, EVOLUTION, V54, P21, DOI 10.1111/j.0014-3820.2000.tb00003.x; Shoemaker DD, 2000, INSECT MOL BIOL, V9, P661, DOI 10.1046/j.1365-2583.2000.00233.x; Shoemaker DD, 2003, ENVIRON ENTOMOL, V32, P1329, DOI 10.1603/0046-225X-32.6.1329; Shoemaker DD, 1999, EVOLUTION, V53, P1157, DOI [10.2307/2640819, 10.1111/j.1558-5646.1999.tb04529.x]; SPENCER HG, 1986, AM NAT, V128, P241, DOI 10.1086/284557; Telschow A, 2006, J EVOLUTION BIOL, V19, P869, DOI 10.1111/j.1420-9101.2005.01049.x; Telschow A, 2005, EVOLUTION, V59, P1607, DOI 10.1111/j.0014-3820.2005.tb01812.x; Telschow A, 2005, J THEOR BIOL, V235, P265, DOI 10.1016/j.jtbi.2005.01.008; Telschow A, 2002, INTEGR COMP BIOL, V42, P340, DOI 10.1093/icb/42.2.340; Telschow A, 2002, AM NAT, V160, pS54, DOI 10.1086/342153; TELSCHOW A, 2004, THESIS HUMBOLDT U BE; Turelli M, 2001, TRENDS ECOL EVOL, V16, P330, DOI 10.1016/S0169-5347(01)02177-2; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; Vala F, 2004, J EVOLUTION BIOL, V17, P692, DOI 10.1046/j.1420-9101.2003.00679.x; Wade MJ, 2001, NATURE, V409, P675, DOI 10.1038/35055648; WEEKS AR, 2002, WOLBACHIA DYNAMICS H; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587; WERREN JH, 1995, P ROY SOC B-BIOL SCI, V261, P55, DOI 10.1098/rspb.1995.0117; Werren JH, 2000, P ROY SOC B-BIOL SCI, V267, P1277, DOI 10.1098/rspb.2000.1139; Werren JH, 1998, ENDLESS FORMS, P245	52	60	62	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e701	10.1371/journal.pone.0000701	http://dx.doi.org/10.1371/journal.pone.0000701			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684548	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452400005
J	Arkhipov, SN; Maly, IV				Arkhipov, Sergey N.; Maly, Ivan V.			A Model for the Interplay of Receptor Recycling and Receptor-Mediated Contact in T Cells	PLOS ONE			English	Article								Orientation of organelles inside T cells (TC) toward antigen-presenting cells (APC) ensures that the immune response is properly directed, but the orientation mechanisms remain largely unknown. Structural dynamics of TC are coupled to dynamics of T-cell receptor (TCR), which recognizes antigen on the APC surface. Engagement of the TCR triggers its internalization followed by delayed polarized recycling to the plasma membrane through the submembrane recycling compartment (RC), which organelle shares intracellular location with the TC effector apparatus. TCR engagement also triggers TC-APC interface expansion enabling further receptor engagement. To analyze the interplay of the cell-cell contact and receptor dynamics, we constructed a new numerical model. The new model displays the experimentally observed selective stabilization of the contact initiated next to the RC, and only transient formation of contact diametrically opposed to the RC. In the general case wherein the TC-APC contact is initiated in an arbitrary orientation to the RC, the modeling predicts that the contact dynamics and receptor recycling can interact, resulting effectively in migration of the contact to the TC surface domain adjacent to the submembrane RC. Using three-dimensional live-cell confocal microscopy, we obtain data consistent with this unexpected behavior. We conclude that a TC can stabilize its contact with an APC by aligning it with the polarized intracellular traffic of TCR. The results also suggest that the orientation of TC organelles, such as the RC and the effector apparatus, toward the APC can be achieved without any intracellular translocation of the organelles.	[Arkhipov, Sergey N.; Maly, Ivan V.] Univ Pittsburgh, Sch Med, Dept Computat Biol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Maly, IV (corresponding author), Univ Pittsburgh, Sch Med, Dept Computat Biol, Pittsburgh, PA 15260 USA.	maly@ccbb.pitt.edu	Arkhipov, Sergey/M-6858-2019; Arkhipov, Sergey/E-6293-2014	Arkhipov, Sergey/0000-0003-4707-902X	NIH [GM078332]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078332] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grant GM078332.	ALBERTS B, 1989, MOL BIOL CELL, P1219; Arkhipov SN, 2006, BIOPHYS J, V91, P4306, DOI 10.1529/biophysj.106.083204; Borroto A, 2000, EUR J IMMUNOL, V30, P3403, DOI 10.1002/1521-4141(2000012)30:12<3403::AID-IMMU3403>3.0.CO;2-H; Bray D., 2001, CELL MOVEMENTS MOL M, V2nd, P372; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; BUNNELL SC, 2003, SCI STKE, pPL8; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Burroughs NJ, 2002, BIOPHYS J, V83, P1784, DOI 10.1016/S0006-3495(02)73944-1; Cai YF, 2006, BIOPHYS J, V91, P3907, DOI 10.1529/biophysj.106.084806; Combs J, 2006, P NATL ACAD SCI USA, V103, P14883, DOI 10.1073/pnas.0600914103; Coombs D, 2002, NAT IMMUNOL, V3, P926, DOI 10.1038/ni838; Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DUNN GA, 1995, J CELL SCI, V108, P1239; Favier B, 2001, INT IMMUNOL, V13, P1525, DOI 10.1093/intimm/13.12.1525; Gakamsky DM, 2005, BIOPHYS J, V89, P2121, DOI 10.1529/biophysj.105.061671; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; Gonzalez PA, 2005, P NATL ACAD SCI USA, V102, P4824, DOI 10.1073/pnas.0500922102; HAMMER DA, 1987, BIOPHYS J, V52, P475, DOI 10.1016/S0006-3495(87)83236-8; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Kuhne MR, 2003, J IMMUNOL, V171, P860, DOI 10.4049/jimmunol.171.2.860; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1984, J IMMUNOL, V133, P2762; KUPFER A, 1985, J MOL CELL IMMUNOL, V2, P37; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN, P365; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; McGavern DB, 2002, NAT IMMUNOL, V3, P918, DOI 10.1038/ni843; Menne C, 2002, EUR J IMMUNOL, V32, P616, DOI 10.1002/1521-4141(200203)32:3<616::AID-IMMU616>3.3.CO;2-0; MOGILNER A, 2001, PATTERN FORMATION MO, P269; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Moss WC, 2002, P NATL ACAD SCI USA, V99, P15024, DOI 10.1073/pnas.192573999; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; PARSEY MV, 1993, J IMMUNOL, V151, P1881; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Reichert P, 2001, J IMMUNOL, V166, P4278, DOI 10.4049/jimmunol.166.7.4278; Sancho D, 2002, IMMUNOL REV, V189, P84, DOI 10.1034/j.1600-065X.2002.18908.x; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Wofsy C, 2001, BIOPHYS J, V80, P606, DOI 10.1016/S0006-3495(01)76041-9; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	42	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e633	10.1371/journal.pone.0000633	http://dx.doi.org/10.1371/journal.pone.0000633			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653260	Green Published, gold, Green Accepted			2022-12-25	WOS:000207452200002
J	Bakkali, M				Bakkali, Mohammed			Genome Dynamics of Short Oligonucleotides: The Example of Bacterial DNA Uptake Enhancing Sequences	PLOS ONE			English	Article								Among the many bacteria naturally competent for transformation by DNA uptake-a phenomenon with significant clinical and financial implications-Pasteurellaceae and Neisseriaceae species preferentially take up DNA containing specific short sequences. The genomic overrepresentation of these DNA uptake enhancing sequences (DUES) causes preferential uptake of conspecific DNA, but the function(s) behind this overrepresentation and its evolution are still a matter for discovery. Here I analyze DUES genome dynamics and evolution and test the validity of the results to other selectively constrained oligonucleotides. I use statistical methods and computer simulations to examine DUESs accumulation in Haemophilus influenzae and Neisseria gonorrhoeae genomes. I analyze DUESs sequence and nucleotide frequencies, as well as those of all their mismatched forms, and prove the dependence of DUESs genomic overrepresentation on their preferential uptake by quantifying and correlating both characteristics. I then argue that mutation, uptake bias, and weak selection against DUESs in less constrained parts of the genome combined are sufficient enough to cause DUESs accumulation in susceptible parts of the genome with no need for other DUES function. The distribution of overrepresentation values across sequences with different mismatch loads compared to the DUES suggests a gradual yet not linear molecular drive of DNA sequences depending on their similarity to the DUES. Other genomically overrepresented sequences, both pro-and eukaryotic, show similar distribution of frequencies suggesting that the molecular drive reported above applies to other frequent oligonucleotides. Rare oligonucleotides, however, seem to be gradually drawn to genomic underrepresentation, thus, suggesting a molecular drag. To my knowledge this work provides the first clear evidence of the gradual evolution of selectively constrained oligonucleotides, including repeated, palindromic and protein/transcription factor-binding DNAs.	Univ Nottingham, Inst Genet, Queens Med Ctr, Nottingham NG7 2RD, England	University of Nottingham	Bakkali, M (corresponding author), Univ Nottingham, Inst Genet, Queens Med Ctr, Nottingham NG7 2RD, England.	mbakkali@gmail.com	Sandstedt, Sara A/A-3001-2010; Bakkali, Mohammed/M-1267-2014	Bakkali, Mohammed/0000-0002-9079-8452				Ahmad S, 2006, NUCLEIC ACIDS RES, V34, pW124, DOI 10.1093/nar/gkl104; ALBRITTON WL, 1984, MOL GEN GENET, V193, P358, DOI 10.1007/BF00330693; Bakkali M, 2004, P NATL ACAD SCI USA, V101, P4513, DOI 10.1073/pnas.0306366101; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bigas A, 2005, VET MICROBIOL, V105, P223, DOI 10.1016/j.vetmic.2004.10.015; BISWAS GD, 1977, J BACTERIOL, V129, P983, DOI 10.1128/JB.129.2.983-992.1977; BISWAS GD, 1981, J BACTERIOL, V145, P638, DOI 10.1128/JB.145.1.638-640.1981; BoyleVavra S, 1996, MICROBIOL-SGM, V142, P2839, DOI 10.1099/13500872-142-10-2839; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; Chen I, 2005, SCIENCE, V310, P1456, DOI 10.1126/science.1114021; Chen I, 2004, NAT REV MICROBIOL, V2, P241, DOI 10.1038/nrmicro844; Chen I, 2003, FRONT BIOSCI, V8, pS544; Chu D, 2006, J THEOR BIOL, V238, P157, DOI 10.1016/j.jtbi.2005.05.024; Chu D, 2005, ARTIF LIFE, V11, P317, DOI 10.1162/1064546054407176; Cohan FM, 2002, ANNU REV MICROBIOL, V56, P457, DOI 10.1146/annurev.micro.56.012302.160634; Cohan FM, 2001, SYST BIOL, V50, P513, DOI 10.1080/10635150118398; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; Davidsen T, 2004, NUCLEIC ACIDS RES, V32, P1050, DOI 10.1093/nar/gkh255; Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217; Elemento O, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r18; ELKINS C, 1991, J BACTERIOL, V173, P3911, DOI 10.1128/JB.173.12.3911-3913.1991; Finkel SE, 2001, J BACTERIOL, V183, P6288, DOI 10.1128/JB.183.21.6288-6293.2001; Gerland U, 2002, J MOL EVOL, V55, P386, DOI 10.1007/s00239-002-2335-z; Gilsdorf JR, 1997, INFECT IMMUN, V65, P2997, DOI 10.1128/IAI.65.8.2997-3002.1997; Gioia J, 2006, J BACTERIOL, V188, P7257, DOI 10.1128/JB.00675-06; GOODGAL SH, 1984, J BACTERIOL, V157, P785, DOI 10.1128/JB.157.3.785-788.1984; GOODGAL SH, 1961, J GEN PHYSIOL, V44, P1201, DOI 10.1085/jgp.44.6.1201; GOODGAL SH, 1982, ANNU REV GENET, V16, P169, DOI 10.1146/annurev.ge.16.120182.001125; GOODGAL SH, 1990, J BACTERIOL, V172, P5924, DOI 10.1128/jb.172.10.5924-5928.1990; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; GRAVES JF, 1982, J BACTERIOL, V152, P1071; Hanage WP, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-6; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; Karlin S, 1998, ANNU REV GENET, V32, P185, DOI 10.1146/annurev.genet.32.1.185; Karlin S, 1996, NUCLEIC ACIDS RES, V24, P4263, DOI 10.1093/nar/24.21.4263; Karlin S, 1997, J BACTERIOL, V179, P3899, DOI 10.1128/jb.179.12.3899-3913.1997; Konstantinidis KT, 2006, PHILOS T R SOC B, V361, P1929, DOI 10.1098/rstb.2006.1920; LORENZ MG, 1994, MICROBIOL REV, V58, P563, DOI 10.1128/MMBR.58.3.563-602.1994; MATHIS LS, 1982, J GEN MICROBIOL, V128, P1159; MCCREA KW, 1994, INFECT IMMUN, V62, P4922, DOI 10.1128/IAI.62.11.4922-4928.1994; McCrea KW, 1997, J BACTERIOL, V179, P4227, DOI 10.1128/jb.179.13.4227-4231.1997; Moreno E, 1997, REV BIOL TROP, V45, P753; Palchevskiy V, 2006, J BACTERIOL, V188, P3902, DOI 10.1128/JB.01974-05; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; Poje Grant, 2003, Methods Mol Med, V71, P57; REDFIELD RJ, 1993, J HERED, V84, P400, DOI 10.1093/oxfordjournals.jhered.a111361; Redfield RJ, 2001, NAT REV GENET, V2, P634, DOI 10.1038/35084593; REDFIELD RJ, 1991, NATURE, V352, P25, DOI 10.1038/352025b0; Redfield RJ, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-82; ROBINSON NJ, 1995, NUCLEIC ACIDS RES, V23, P729, DOI 10.1093/nar/23.5.729; RUDEL T, 1995, P NATL ACAD SCI USA, V92, P7986, DOI 10.1073/pnas.92.17.7986; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Scharnagl M, 1998, J BACTERIOL, V180, P4116, DOI 10.1128/JB.180.16.4116-4122.1998; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SCOCCA JJ, 1974, J BACTERIOL, V118, P369, DOI 10.1128/JB.118.2.369-373.1974; Sengupta AM, 2002, P NATL ACAD SCI USA, V99, P2072, DOI 10.1073/pnas.022388499; Sinha S, 2003, NUCLEIC ACIDS RES, V31, P3586, DOI 10.1093/nar/gkg618; Sinha S, 2002, NUCLEIC ACIDS RES, V30, P5549, DOI 10.1093/nar/gkf669; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; Smith HO, 1999, RES MICROBIOL, V150, P603, DOI 10.1016/S0923-2508(99)00130-8; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; StGeme JW, 1996, P NATL ACAD SCI USA, V93, P11913, DOI 10.1073/pnas.93.21.11913; Stormo GD, 1998, TRENDS BIOCHEM SCI, V23, P109, DOI 10.1016/S0968-0004(98)01187-6; STUMPH WE, 1981, NUCLEIC ACIDS RES, V9, P5383, DOI 10.1093/nar/9.20.5383; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; VANHAM SM, 1994, MOL MICROBIOL, V13, P673; Wang Y, 2002, J BACTERIOL, V184, P3442, DOI 10.1128/JB.184.13.3442-3449.2002; Wang Y, 2006, MICROBIOL-SGM, V152, P3319, DOI 10.1099/mic.0.29018-0; Woegerbauer M, 2002, APPL ENVIRON MICROB, V68, P440, DOI 10.1128/AEM.68.1.440-443.2002	72	14	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e741	10.1371/journal.pone.0000741	http://dx.doi.org/10.1371/journal.pone.0000741			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710141	Green Published, gold			2022-12-25	WOS:000207455200018
J	Fievez, L; Desmet, C; Henry, E; Pajak, B; Hegenbarth, S; Garze, V; Bex, F; Jaspar, F; Boutet, P; Gillet, L; Vanderplasschen, A; Knolle, PA; Leo, O; Moser, M; Lekeux, P; Bureau, F				Fievez, Laurence; Desmet, Christophe; Henry, Emmanuelle; Pajak, Bernard; Hegenbarth, Silke; Garze, Virginie; Bex, Francoise; Jaspar, Fabrice; Boutet, Philippe; Gillet, Laurent; Vanderplasschen, Alain; Knolle, Percy A.; Leo, Oberdan; Moser, Muriel; Lekeux, Pierre; Bureau, Fabrice			STAT5 Is an Ambivalent Regulator of Neutrophil Homeostasis	PLOS ONE			English	Article								Background. Although STAT5 promotes survival of hematopoietic progenitors, STAT5(-/-) mice develop mild neutrophilia. Methodology/Principal findings. Here, we show that in STAT5(-/-) mice, liver endothelial cells (LECs) autonomously secrete high amounts of G-CSF, allowing myeloid progenitors to overcompensate for their intrinsic survival defect. However, when injected with pro-inflammatory cytokines, mutant mice cannot further increase neutrophil production, display a severe deficiency in peripheral neutrophil survival, and are therefore unable to maintain neutrophil homeostasis. In wild-type mice, inflammatory stimulation induces rapid STAT5 degradation in LECs, G-CSF production by LECs and other cell types, and then sustained mobilization and expansion of long-lived neutrophils. Conclusion. We conclude that STAT5 is an ambivalent factor. In cells of the granulocytic lineage, it exerts an antiapoptotic function that is required for maintenance of neutrophil homeostasis, especially during the inflammatory response. In LECs, STAT5 negatively regulates granulopoiesis by directly or indirectly repressing G-CSF expression. Removal of this STAT5-imposed brake contributes to induction of emergency granulopoiesis.	[Fievez, Laurence; Desmet, Christophe; Jaspar, Fabrice; Boutet, Philippe; Lekeux, Pierre; Bureau, Fabrice] Univ Liege, Lab Cellular & Mol Physiol, GIGA Res, Liege, Belgium; [Henry, Emmanuelle; Pajak, Bernard; Garze, Virginie; Leo, Oberdan; Moser, Muriel; Bureau, Fabrice] Univ Libre Bruxelles, Inst Mol Biol & Med, Physiol Anim Lab, Gosselies, Belgium; [Hegenbarth, Silke; Knolle, Percy A.] Univ Bonn, Inst Mol Med & Expt Immunol, D-5300 Bonn, Germany; [Bex, Francoise] Univ Libre Bruxelles, Microbiol Lab, Inst Microbiol Res JM Wiame, Brussels, Belgium; [Vanderplasschen, Alain] Univ Liege, Fac Vet Med, Lab Immunol & Vaccinol, Liege, Belgium	University of Liege; Universite Libre de Bruxelles; University of Bonn; Universite Libre de Bruxelles; University of Liege	Bureau, F (corresponding author), Univ Liege, Lab Cellular & Mol Physiol, GIGA Res, Liege, Belgium.	fabrice.bureau@ulg.ac.be		Gillet, Laurent/0000-0002-1047-2525; Knolle, Percy A./0000-0003-2983-0414	Fonds National de la Recherche Scientifique", FNRS; Fonds de la Formation a la Recherche dans l'Industrie et l'Agriculture", FRIA, Belgium	Fonds National de la Recherche Scientifique", FNRS(Fonds de la Recherche Scientifique - FNRS); Fonds de la Formation a la Recherche dans l'Industrie et l'Agriculture", FRIA, Belgium	This work has been funded by the "Fonds National de la Recherche Scientifique", FNRS, and the "Fonds de la Formation a la Recherche dans l'Industrie et l'Agriculture", FRIA, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Basu S, 2000, BLOOD, V95, P3725; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; CHATTA GS, 1994, BLOOD, V84, P2923; COLOTTA F, 1992, BLOOD, V80, P2012; Coxon A, 1999, J EXP MED, V190, P923, DOI 10.1084/jem.190.7.923; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Edwards SW, 2003, CHEM IMMUNOL, V83, P204; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kieslinger M, 2000, GENE DEV, V14, P232; Knolle PA, 1999, GASTROENTEROLOGY, V116, P1428, DOI 10.1016/S0016-5085(99)70508-1; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; LORD BI, 1989, P NATL ACAD SCI USA, V86, P9499, DOI 10.1073/pnas.86.23.9499; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Pajak B, 2000, J CLIN PATHOL, V53, P518, DOI 10.1136/jcp.53.7.518; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; ULICH TR, 1991, BLOOD, V78, P1954; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Yao ZJ, 2006, P NATL ACAD SCI USA, V103, P1000, DOI 10.1073/pnas.0507350103	41	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e727	10.1371/journal.pone.0000727	http://dx.doi.org/10.1371/journal.pone.0000727			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710127	Green Published, Green Submitted, gold			2022-12-25	WOS:000207455200004
J	Gauthier, BR; Duhamel, DL; Iezzi, M; Theander, S; Saltel, F; Fukuda, M; Wehrle-Haller, B; Wollheim, CB				Gauthier, Benoit R.; Duhamel, Dominique L.; Iezzi, Mariella; Theander, Sten; Saltel, Frederic; Fukuda, Mitsunori; Wehrle-Haller, Bernhard; Wollheim, Claes B.			Synaptotagmin VII splice variants alpha,beta, and delta are expressed in pancreatic beta-cells and regulate insulin exocytosis	FASEB JOURNAL			English	Article						islet beta-cells; calcium-induced exocytosis; INS-1E cells; membrane capacitance; RNAi	DENSE-CORE VESICLES; CALCIUM-DEPENDENT EXOCYTOSIS; SYNAPTIC-LIKE MICROVESICLES; PC12 CELLS; CA2+-DEPENDENT EXOCYTOSIS; C2 DOMAINS; SECRETION; MEMBRANE; PROTEIN; FUSION	Synaptotagmins (SYT) are calcium-binding proteins that participate in regulated exocytosis. Although SYTI to IX isoforms are expressed in insulin-producing cell lines, hitherto only SYTIX has been associated with native beta-cell insulin granules and implicated in exocytosis. SYTVII was also proposed to regulate insulin exocytosis, but its subcellular location and number of alternative splice variants produced remain controversial. Only transcripts of SYTVII alpha,beta, and a novel splice variant delta are expressed in beta-cells and INS-1E cells. Western blotting revealed that INS-1E cells predominantly produced SYTVII alpha and low levels of SYTVII beta, whereas SYTVII delta was undectable. The protein colocalized with insulin granules but not with synaptic-like microvesicles. Overexpression of SYTVII alpha resulted in decreased insulin granule content with a concomitant translocation of the variant to the plasma membrane, while SYTVII beta retained largely a granular pattern. Overexpressed SYTVII delta exhibited a distribution different to that of insulin granules and inhibited exocytosis when assessed by whole cell patch clamp capacitance recording. Silencing of SYTVII alpha by targeted RNA interference suppressed secretion, while repression of beta slightly increased release. Our results demonstrate that SYTVII is expressed on insulin granules and that only SYTVII alpha is implicated in exocytosis under physiological conditions. -Gauthier, B. R., Duhamel, D. L., Iezzi, M., Theander, S., Saltel, F., Fukuda, M., Wehrle-Haller, B., Wollheim. C. B. The synaptotagmin VII splice variants alpha, beta, and delta are expressed in pancreatic beta-cells and regulate insulin exocytosis.	[Gauthier, Benoit R.; Duhamel, Dominique L.; Iezzi, Mariella; Theander, Sten; Saltel, Frederic; Wehrle-Haller, Bernhard; Wollheim, Claes B.] Ctr Med Univ Geneva, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; [Fukuda, Mitsunori] Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 980, Japan	University of Geneva; Tohoku University	Gauthier, BR (corresponding author), Ctr Med Univ Geneva, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	benoit.gauthier@medecine.unige.ch	Fukuda, MItsunori/I-1511-2015; Gauthier, Benoit R/C-3138-2017	Fukuda, MItsunori/0000-0002-8620-5853; Gauthier, Benoit R/0000-0001-8146-7486; saltel, frederic/0000-0002-0724-9680				Andrews NW, 2005, TRENDS CELL BIOL, V15, P626, DOI 10.1016/j.tcb.2005.09.001; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; Barg S, 2001, J CELL SCI, V114, P2145; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Czibener C, 2006, J CELL BIOL, V174, P997, DOI 10.1083/jcb.200605004; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2004, J BIOL CHEM, V279, P52677, DOI 10.1074/jbc.M409241200; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; GEPPERT M, 1994, EMBO J, V13, P3720, DOI 10.1002/j.1460-2075.1994.tb06681.x; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gut A, 2001, J CELL SCI, V114, P1709; Han WP, 2005, J BIOL CHEM, V280, P5089, DOI 10.1074/jbc.M408757200; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Hui EF, 2005, P NATL ACAD SCI USA, V102, P5210, DOI 10.1073/pnas.0500941102; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Iezzi M, 2005, FEBS LETT, V579, P5241, DOI 10.1016/j.febslet.2005.08.047; Iezzi M, 2004, J CELL SCI, V117, P3119, DOI 10.1242/jcs.01179; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lezzi M, 2005, J CELL SCI, V118, P5647, DOI 10.1242/jcs.02658; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; MacDonald PE, 2005, DIABETES, V54, P736, DOI 10.2337/diabetes.54.3.736; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Meldolesi J, 2004, NAT CELL BIOL, V6, P476, DOI 10.1038/ncb0604-476; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Missler M, 1998, J NEUROCHEM, V71, P1339; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Monterrat C, 2006, BBA-MOL CELL RES, V1763, P73, DOI 10.1016/j.bbamcr.2005.11.008; Monterrat C, 2007, HISTOCHEM CELL BIOL, V127, P625, DOI 10.1007/s00418-007-0271-0; Nicholson-Tomishima K, 2004, P NATL ACAD SCI USA, V101, P16648, DOI 10.1073/pnas.0406968101; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tsuboi T, 2007, GENES CELLS, V12, P511, DOI 10.1111/j.1365-2443.2007.01070.x; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; VALLEE BL, 1987, METALLOTHIONEIN, V2, P5; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; Virmani T, 2003, EMBO J, V22, P5347, DOI 10.1093/emboj/cdg514; Wang H, 2005, DIABETOLOGIA, V48, P720, DOI 10.1007/s00125-005-1692-8; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; [No title captured]	61	40	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					194	206		10.1096/fj.07-8333com	http://dx.doi.org/10.1096/fj.07-8333com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17709608				2022-12-25	WOS:000252309900022
J	Caposio, P; Gugliesi, F; Zannetti, C; Sponza, S; Mondini, M; Medico, E; Hiscott, J; Young, HA; Gribaudo, G; Gariglio, M; Landolfo, S				Caposio, Patrizia; Gugliesi, Francesca; Zannetti, Claudia; Sponza, Simone; Mondini, Michele; Medico, Enzo; Hiscott, John; Young, Howard A.; Gribaudo, Giorgio; Gariglio, Marisa; Landolfo, Santo			A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; EPITHELIAL ICAM-1 EXPRESSION; GENE-EXPRESSION; HIN-200 FAMILY; ACTIVATION; TRANSCRIPTION; ALPHA; SP1; INFLAMMATION	The human IFI16 gene is an interferon-inducible gene implicated in the regulation of endothelial cell proliferation and tube morphogenesis. Immunohistochemical analysis has demonstrated that this gene is highly expressed in endothelial cells in addition to hematopoietic tissues. In this study, gene array analysis of human umbilical vein endothelial cells overexpressing IFI16 revealed an increased expression of genes involved in immunomodulation, cell growth, and apoptosis. Consistent with these observations, IFI16 triggered expression of adhesion molecules such as ICAM-1 and E-selectin or chemokines such as interleukin-8 or MCP-1. Treatment of cells with short hairpin RNA targeting IFI16 significantly inhibited ICAM-1 induction by interferon (IFN)-gamma demonstrating that IFI16 is required for proinflammatory gene stimulation. Moreover, functional analysis of the ICAM-1 promoter by deletion- or site-specific mutation demonstrated that NF-kappa B is the main mediator of IFI16-driven gene induction. NF-kappa B activation appears to be triggered by IFI16 through a novel mechanism involving suppression of I kappa B alpha mRNA and protein expression. Support for this finding comes from the observation that IFI16 targeting with specific short hairpin RNA down-regulates NF-kappa B binding activity to its cognate DNA and inhibits ICAM-1 expression induced by IFN-gamma. Using transient transfection and luciferase assay, electrophoretic mobility shift assay, and chromatin immunoprecipitation, we demonstrate indeed that activation of the NF-kappa B response is mediated by IFI16-induced block of Sp1-like factor recruitment to the promoter of the I kappa B alpha gene, encoding the main NF-kappa B inhibitor. Activation of NF-kappa B accompanied by induction of proinflammatory molecules was also observed when I kappa B alpha expression was down-regulated by specific small interfering RNA, resulting in an outcome similar to that observed with IFI16 overexpression. Taken together, these data implicate IFI16 as a novel regulator of endothelial proinflammatory activity and provide new insights into the physiological functions of the IFN-inducible gene IFI16.	Univ Turin, Sch Med, Dept Publ Hlth & Microbiol, Lab Viral Pathogenesis, I-10126 Turin, Italy; Univ Turin, Inst Canc Res & Treatment, I-10126 Turin, Italy; McGill Univ, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; NCI, Canc Res Ctr, Expt Immunol Lab, Natl Inst Hlth, Frederick, MD 21702 USA; Univ Piemonte Orientale, Dept Clin & Expt Med, I-28100 Novara, Italy	University of Turin; University of Turin; Lady Davis Institute; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Eastern Piedmont Amedeo Avogadro	Landolfo, S (corresponding author), Univ Turin, Sch Med, Dept Publ Hlth & Microbiol, Lab Viral Pathogenesis, Via Santena 9, I-10126 Turin, Italy.	santo.landolfo@unito.it	Mondini, Michele/T-4568-2019; Medico, Enzo/AAC-3185-2021; Gribaudo, Giorgio/A-8872-2011; Young, Howard/A-6350-2008	Mondini, Michele/0000-0001-5803-0083; Medico, Enzo/0000-0002-3917-2438; Gariglio, Marisa/0000-0002-5187-0140; Gribaudo, Giorgio/0000-0002-1583-9146; /0000-0001-6389-5129; Young, Howard/0000-0002-3118-5111				Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Albrecht M, 2005, BIOCHEM BIOPH RES CO, V327, P679, DOI 10.1016/j.bbrc.2004.12.056; Algarte M, 1999, MOL CELL BIOL, V19, P6140; Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002; Bekisz J, 2004, GROWTH FACTORS, V22, P243, DOI 10.1080/08977190400000833; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Caposio P, 2004, J VIROL, V78, P3190, DOI 10.1128/JVI.78.6.3190-3195.2004; Chang YJ, 2004, MOL PHARMACOL, V65, P589, DOI 10.1124/mol.65.3.589; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Fujiuchi N, 2004, J BIOL CHEM, V279, P20339, DOI 10.1074/jbc.M400344200; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Gugliesi F, 2005, J LEUKOCYTE BIOL, V77, P820, DOI 10.1189/jlb.0904507; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kempe S, 2005, NUCLEIC ACIDS RES, V33, P5308, DOI 10.1093/nar/gki836; Kong JSW, 2006, AUTOIMMUN REV, V5, P471, DOI 10.1016/j.autrev.2006.02.014; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Ludlow LEA, 2005, EXP CELL RES, V308, P1, DOI 10.1016/j.yexcr.2005.03.032; Luu P, 1997, J VIROL, V71, P6683, DOI 10.1128/JVI.71.9.6683-6691.1997; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Mondini M, 2007, ANN NY ACAD SCI, V1110, P47, DOI 10.1196/annals.1423.006; Mondini M, 2006, ARTHRITIS RHEUM, V54, P3939, DOI 10.1002/art.22266; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Parmar S, 2005, CANC TREAT, V126, P45, DOI 10.1007/0-387-24361-5_3; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Rozzo SJ, 2001, IMMUNITY, V15, P435, DOI 10.1016/S1074-7613(01)00196-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SEELIG HP, 1994, ARTHRITIS RHEUM-US, V37, P1672, DOI 10.1002/art.1780371117; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Uchida K, 2005, IMMUNOLOGY, V116, P53, DOI 10.1111/j.1365-2567.2005.02197.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0	47	59	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2007	282	46							33515	10.1074/jbc.M701846200	http://dx.doi.org/10.1074/jbc.M701846200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229XP	17699163	hybrid			2022-12-25	WOS:000250840200032
J	Fridy, PC; Otto, JC; Dollins, DE; York, JD				Fridy, Peter C.; Otto, James C.; Dollins, D. Eric; York, John D.			Cloning and characterization of two human VIP1-like inositol hexakisphosphate and diphosphoinositol pentakisphosphate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC ACID-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; POLYPHOSPHATE KINASES; TELOMERE LENGTH; ACTIVE-SITE; PYROPHOSPHATES; TETRAKISPHOSPHATE; IDENTIFICATION; DICTYOSTELIUM; METABOLISM	Eukaryotes possess numerous inositol phosphate ( IP) and diphosphoinositol phosphate ( PP-IPs or inositol pyrophosphates) species that act as chemical codes important for intracellular signaling pathways. Production of IP and PP-IP molecules occurs through several classes of evolutionarily conserved inositol phosphate kinases. Here we report the characterization of a human inositol hexakisphosphate ( IP6) and diphosphoinositol pentakisphosphate ( PP-IP5 or IP7) kinase with similarity to the yeast enzyme Vip1, a recently identified IP6/IP7 kinase ( Mulugu, S., Bai, W., Fridy, P. C., Bastidas, R. J., Otto, J. C., Dollins, D. E., Haystead, T. A., Ribeiro, A. A., and York, J. D. ( 2007) Science 316, 106-109). Recombinant human VIP1 exhibits in vitro IP6 and IP7 kinase activities and restores IP7 synthesis when expressed in mutant yeast. Expression of human VIP1 in HEK293T cells engineered to produce high levels of IP7 results in dramatic increases in bisdiphosphoinositol tetrakisphosphate ( PP2-IP4 or IP8). Northern blot analysis indicates that human VIP1 is expressed in a variety of tissues and is enriched in skeletal muscle, heart, and brain. The subcellular distribution of tagged human VIP1 is indicative of a cytoplasmic non-membrane localization pattern. We also characterized human and mouse VIP2, an additional gene product with nearly 90% similarity to VIP1 in the kinase domain, and observed both IP6 and IP7 kinase activities. Our data demonstrate that human VIP1 and VIP2 function as IP6 and IP7 kinases that act along with the IP6K/Kcs1-class of kinases to convert IP6 to IP8 in mammalian cells, a process that has been found to occur in response to various stimuli and signaling events.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, DUMC Box 3813, Durham, NC 27710 USA.	yorkj@duke.edu		Fridy, Peter/0000-0002-8208-9154	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070272] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-55672] Funding Source: Medline; NIDDK NIH HHS [R33 DK070272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Caffrey JJ, 1999, FEBS LETT, V442, P99, DOI 10.1016/S0014-5793(98)01636-6; Choi JH, 2007, J BIOL CHEM, V282, P30763, DOI 10.1074/jbc.M704655200; Choi K, 2005, CELL SIGNAL, V17, P1533, DOI 10.1016/j.cellsig.2005.03.021; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; EUROPEFINNER GN, 1991, BIOCHEM BIOPH RES CO, V181, P191, DOI 10.1016/S0006-291X(05)81400-7; Feoktistova A, 1999, GENETICS, V152, P895; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Ingram SW, 2003, BIOCHEM J, V369, P519, DOI 10.1042/BJ20020733; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Irvine R, 2007, SCIENCE, V316, P845, DOI 10.1126/science.1143339; Laussmann T, 2000, EUR J BIOCHEM, V267, P2447, DOI 10.1046/j.1432-1327.2000.01264.x; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Lim D, 2000, NAT STRUCT BIOL, V7, P108; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Mullaney EJ, 2003, BIOCHEM BIOPH RES CO, V312, P179, DOI 10.1016/j.bbrc.2003.09.176; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OSTANIN K, 1994, J BIOL CHEM, V269, P8971; OTTO JC, 2007, IN PRESS P NATL ACAD; Pesesse X, 2004, J BIOL CHEM, V279, P43378, DOI 10.1074/jbc.C400286200; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2006, BBA-MOL CELL BIOL L, V1761, P552, DOI 10.1016/j.bbalip.2006.04.014; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200	49	85	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30754	30762		10.1074/jbc.M704656200	http://dx.doi.org/10.1074/jbc.M704656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690096	hybrid			2022-12-25	WOS:000250136300044
J	Vorup-Jensen, T; Chi, LL; Gjelstrup, LC; Jensen, UB; Jewett, CA; Xie, C; Shimaoka, M; Linhardt, RJ; Springer, TA				Vorup-Jensen, Thomas; Chi, Lianli; Gjelstrup, Louise C.; Jensen, Uffe B.; Jewett, Craig A.; Xie, Can; Shimaoka, Motomu; Linhardt, Robert J.; Springer, Timothy A.			Binding between the Integrin alpha X beta 2 (CD11c/CD18) and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; PROTEIN INTERACTIONS; MAC-1 CD11B/CD18; ACTIVATION; AFFINITY; CONFORMATION; RECOGNITION; DERIVATIVES; ADHESION; LIGAND	The interactions between cell surface receptors and sulfated glucosamineglycans serve ubiquitous roles in cell adhesion and receptor signaling. Heparin, a highly sulfated polymer of uronic acids and glucosamine, binds strongly to the integrin receptor alpha X beta 2 (p150,95, CD11c/CD18). Here, we analyze the structural motifs within heparin that constitute high affinity binding sites for the I domain of integrin alpha X beta 2. Heparin oligomers with chain lengths of 10 saccharide residues or higher provide strong inhibition of the binding by the alpha X I domain to the complement fragment iC3b. By contrast, smaller oligomers or the synthetic heparinoid fondaparinux were not able to block the binding. Semipurified heparin oligomers with 12 saccharide residues identified the fully sulfated species as the most potent antagonist of iC3b, with a 1.3 mu M affinity for the alpha XI domain. In studies of direct binding by the alpha XI domain to immobilized heparin, we found that the interaction is conformationally regulated and requires Mg2+. Furthermore, the fully sulfated heparin fragment induced conformational change in the ectodomain of the alpha X beta 2 receptor, also demonstrating allosteric linkage between heparin binding and integrin conformation.	Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Univ Aarhus, Inst Med Microbiol & Immunol, Biophys Immunol Lab, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Human Genet, DK-8000 Aarhus C, Denmark; Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Dept Chem & Chem Biol, Troy, NY 12180 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Aarhus University; Aarhus University; Rensselaer Polytechnic Institute	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@idi.harvard.edu	Chi, Lianli/B-9149-2015; Jensen, Uffe Birk/E-6066-2017; Jensen, Uffe Birk/ABA-8306-2021; Vorup-Jensen, Thomas/N-9082-2016	Chi, Lianli/0000-0003-1126-1022; Jensen, Uffe Birk/0000-0002-6205-6355; Jensen, Uffe Birk/0000-0002-6205-6355; Vorup-Jensen, Thomas/0000-0002-4140-6563; Xie, Can/0000-0002-7412-3236	NHLBI NIH HHS [R01 HL052622-09, R01 HL052622, HL52622, R01 HL062244, R01 HL062244-05A1] Funding Source: Medline; NIAID NIH HHS [R01 AI072765, AI72765] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060, R01 GM038060-19, GM038060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200; COOMBE DR, 1994, BLOOD, V84, P739; de Kort M, 2005, DRUG DISCOV TODAY, V10, P769, DOI 10.1016/S1359-6446(05)03457-4; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HOFFMAN J, 1983, CARBOHYD RES, V117, P328, DOI 10.1016/0008-6215(83)88103-8; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Karlsson R, 1999, J MOL RECOGNIT, V12, P285, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<285::AID-JMR469>3.0.CO;2-Y; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Pavlov G, 2003, EUR BIOPHYS J BIOPHY, V32, P437, DOI 10.1007/s00249-003-0316-9; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vorup-Jensen T, 2005, P NATL ACAD SCI USA, V102, P1614, DOI 10.1073/pnas.0409057102; Vorup-Jensen T, 2003, P NATL ACAD SCI USA, V100, P1873, DOI 10.1073/pnas.0237387100; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101; Zhang FM, 2004, CLIN APPL THROMB-HEM, V10, P249, DOI 10.1177/107602960401000307	28	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30869	30877		10.1074/jbc.M706114200	http://dx.doi.org/10.1074/jbc.M706114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699512	Green Accepted, hybrid			2022-12-25	WOS:000250136300055
J	Garrity, J; Gardner, JG; Hawse, W; Wolberger, C; Escalante-Semerena, JC				Garrity, Jane; Gardner, Jeffrey G.; Hawse, William; Wolberger, Cynthia; Escalante-Semerena, Jorge C.			N-Lysine propionylation controls the activity of propionyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-ENTERICA; POSTTRANSLATIONAL MODIFICATIONS; CALORIE RESTRICTION; ESCHERICHIA-COLI; ACID CYCLE; IN-VIVO; PROTEIN; ENZYME; ACETYLATION; NAD(+)	Reversible protein acetylation is a ubiquitous means for the rapid control of diverse cellular processes. Acetyltransferase enzymes transfer the acetyl group from acetyl-CoA to lysine residues, while deacetylase enzymes catalyze removal of the acetyl group by hydrolysis or by an NAD(+)-dependent reaction. Propionylcoenzyme A (CoA), like acetyl-CoA, is a high energy product of fatty acid metabolism and is produced through a similar chemical reaction. Because acetyl-CoA is the donor molecule for protein acetylation, we investigated whether proteins can be propionylated in vivo, using propionyl-CoA as the donor molecule. We report that the Salmonella enterica propionyl-CoA synthetase enzyme PrpE is propionylated in vivo at lysine 592; propionylation inactivates PrpE. The propionyl-lysine modification is introduced by bacterial Gcn-5- related N-acetyltransferase enzymes and can be removed by bacterial and human Sir2 enzymes (sirtuins). Like the sirtuin deacetylation reaction, sirtuincatalyzed depropionylation is NAD(+)-dependent and produces a byproduct, O-propionyl ADP-ribose, analogous to the O-acetyl ADP-ribose sirtuin product of deacetylation. Only a subset of the human sirtuins with deacetylase activity could also depropionylate substrate. The regulation of cellular propionyl-CoA by propionylation of PrpE parallels regulation of acetylCoA by acetylation of acetyl-CoA synthetase and raises the possibility that propionylation may serve as a regulatory modification in higher organisms.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	escalante@bact.wisc.edu		Wolberger, Cynthia/0000-0001-8578-2969; Garrity, Jane/0000-0003-2266-6463	NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, R01GM062203] Funding Source: NIH RePORTER; NCRR NIH HHS [U54 RR020839.] Funding Source: Medline; NIGMS NIH HHS [T32 GM08349, R01 GM062203, GM62203] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Bertani G, 2004, J BACTERIOL, V186, P595, DOI 10.1128/JB.186.3.595-600.2004; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BRASS EP, 1990, J NUTR, V120, P290, DOI 10.1093/jn/120.3.290; Brinsmade SR, 2007, J BIOL CHEM, V282, P12629, DOI 10.1074/jbc.M611439200; Brock M, 2004, EUR J BIOCHEM, V271, P3227, DOI 10.1111/j.1432-1033.2004.04255.x; Chen Y, 2007, MOL CELL PROTEOMICS, V6, P812, DOI 10.1074/mcp.M700021-MCP200; Clark RSB, 2005, CRIT CARE MED, V33, pS407, DOI 10.1097/01.CCM.0000191712.96336.51; DAWSON RMC, 1986, DATA BIOCH RES, P122; Gardner JG, 2006, J BACTERIOL, V188, P5460, DOI 10.1128/JB.00215-06; Grubisha O, 2006, J BIOL CHEM, V281, P14057, DOI 10.1074/jbc.M513741200; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Haller T, 2000, BIOCHEMISTRY-US, V39, P4622, DOI 10.1021/bi992888d; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hoff KG, 2006, STRUCTURE, V14, P1231, DOI 10.1016/j.str.2006.06.006; Horswill AR, 2001, J BIOL CHEM, V276, P19094, DOI 10.1074/jbc.M100244200; Horswill AR, 2002, BIOCHEMISTRY-US, V41, P2379, DOI 10.1021/bi015647q; Horswill AR, 1999, MICROBIOL-UK, V145, P1381, DOI 10.1099/13500872-145-6-1381; Horswill AR, 2001, BIOCHEMISTRY-US, V40, P4703, DOI 10.1021/bi015503b; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; MIYAKOSHI S, 1987, AGR BIOL CHEM TOKYO, V51, P2381; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Sambrook J, 2001, MOL CLONING LAB MANU; SASSE J, 1991, CURRENT PROTOCOLS MO; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Sawers G, 2001, MOL MICROBIOL, V39, P1285, DOI 10.1046/j.1365-2958.2001.02316.x; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Shih YP, 2005, PROTEIN SCI, V14, P936, DOI 10.1110/ps.041129605; Smith BC, 2007, J AM CHEM SOC, V129, P5802, DOI 10.1021/ja070162w; Smith JS, 2002, METHOD ENZYMOL, V353, P282; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Starai VJ, 2003, GENETICS, V163, P545; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; STUMPF DA, 1980, PEDIATR RES, V14, P1127, DOI 10.1203/00006450-198010000-00008; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Walsh CT, 2005, ANGEW CHEM INT EDIT, V44, P7342, DOI 10.1002/anie.200501023; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	44	153	159	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30239	30245		10.1074/jbc.M704409200	http://dx.doi.org/10.1074/jbc.M704409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17684016	hybrid			2022-12-25	WOS:000249981200054
J	Woeller, CF; Fox, JT; Perry, C; Stover, PJ				Woeller, Collynn F.; Fox, Jennifer T.; Perry, Cheryll; Stover, Patrick J.			A ferritin-responsive internal ribosome entry site regulates folate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SERINE HYDROXYMETHYLTRANSFERASE; MESSENGER-RNA SEQUENCES; BINDING PROTEIN-BETA; HEAVY-CHAIN; 3'-UNTRANSLATED REGION; TRANSLATIONAL REGULATION; INCREASES TRANSLATION; POLY(A) TAIL; INITIATION; SUBUNIT	Cytoplasmic serine hydroxymethyltransferase ( cSHMT) enzyme levels are elevated by the expression of the heavy chain ferritin ( H ferritin) cDNA in cultured cells without corresponding changes in mRNA levels, resulting in enhanced folate- dependent de novo thymidylate biosynthesis and impaired homocysteine remethylation. In this study, the mechanism wherebyH ferritin regulates cSHMT expression was determined. cSHMT translation is shown to be regulated by an H ferritin- responsive internal ribosome entry site ( IRES) located within the cSHMT mRNA 5'- untranslated region ( 5'- UTR). The cSHMT 5'-UTR exhibited IRES activity during in vitro translation of bicistronic mRNAtemplates, and in MCF- 7 and HeLa cells transfected with bicistronic mRNAs. IRES activity was depressed in H ferritindeficient mouse embryonic fibroblasts and elevated in cells expressing theHferritin cDNA. Hferritin was shown to interact with the mRNA- binding protein CUGBP1, a protein known to interact with the alpha and beta subunits of eukaryotic initiation factor eIF2. Small interference RNA- mediated depletion of CUGBP1 decreased IRES activity from bicistronic templates that included the cSHMT 3'- UTR in the bicistronic construct. The identification of this H ferritin- responsive IRES represents a mechanism that accounts for previous observations that H ferritin regulates folate metabolism.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.	pjs13@cornell.edu	Woeller, Collynn/U-3877-2019	Woeller, Collynn/0000-0001-7197-5057	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058144] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58144] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abalea V, 1998, CARCINOGENESIS, V19, P1053, DOI 10.1093/carcin/19.6.1053; ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Bradrick SS, 2006, NUCLEIC ACIDS RES, V34, P1293, DOI 10.1093/nar/gkl019; Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69; Christensen KE, 2006, BIOESSAYS, V28, P595, DOI 10.1002/bies.20420; DORMOYRACLET V, 2005, RNA BIOL, V2, P112; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Ghosh B, 2000, MOL CELL BIOCHEM, V209, P9, DOI 10.1023/A:1007024119640; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; Hensley LL, 2003, J BIOL CHEM, V278, P32702, DOI 10.1074/jbc.M304200200; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Izquierdo JM, 2000, BIOCHEM J, V346, P849, DOI 10.1042/0264-6021:3460849; Jackson RJ, 2005, BIOCHEM SOC T, V33, P1231, DOI 10.1042/BST0331231; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Kim YK, 2002, BIOCHEM BIOPH RES CO, V297, P224, DOI 10.1016/S0006-291X(02)02154-X; Koh DCY, 2003, J BIOL CHEM, V278, P20565, DOI 10.1074/jbc.M210212200; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; Lie YS, 1999, DEVELOPMENT, V126, P4989; Liu XW, 2000, BIOCHEMISTRY-US, V39, P11523, DOI 10.1021/bi000665d; LOO D, 1994, CELL BIOL LAB HDB, P45; Lopez-Lastra M, 2005, BIOL RES, V38, P121, DOI 10.4067/S0716-97602005000200003; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MACEJAK DG, 1990, ENZYME, V44, P310, DOI 10.1159/000468767; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Miyazaki E, 2002, GUT, V50, P413, DOI 10.1136/gut.50.3.413; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Oltean S, 2005, J BIOL CHEM, V280, P32662, DOI 10.1074/jbc.M501964200; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Seydoux G, 1996, CURR OPIN GENET DEV, V6, P555, DOI 10.1016/S0959-437X(96)80083-9; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Simandan T, 1998, BIOCHEM J, V335, P233, DOI 10.1042/bj3350233; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2005, J BIOL CHEM, V280, P20549, DOI 10.1074/jbc.M409563200; Westerman DA, 1999, BRIT J HAEMATOL, V107, P512; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Xing J, 2004, J MOL BIOL, V344, P675, DOI 10.1016/j.jmb.2004.09.058; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; ZHU LJ, 1995, ENDOCRINOLOGY, V136, P4106, DOI 10.1210/en.136.9.4106	55	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29927	29935		10.1074/jbc.M706264200	http://dx.doi.org/10.1074/jbc.M706264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702748	hybrid			2022-12-25	WOS:000249981200022
J	Janssen, BJC; Halff, EF; Lambris, JD; Gros, P				Janssen, Bert J. C.; Halff, Els F.; Lambris, John D.; Gros, Piet			Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE INHIBITOR; ACTIVATION; INSIGHTS; ANALOGS; BINDING; DESIGN; FRAGMENT; SYSTEM	Undesired complement activation is a major cause of tissue injury in various pathological conditions and contributes to several immune complex diseases. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 and thus blocks a central and crucial step in the complement cascade. The precise binding site on C3, the structure in the bound form, and the exact mode of action of compstatin are unknown. Here we present the crystal structure of compstatin in complex with C3c, a major proteolytic fragment of C3. The structure reveals that the compstatin-binding site is formed by the macroglobulin (MG) domains 4 and 5. This binding site is part of the structurally stable MG-ring formed by domains MG1-6 and is far away from any other known binding site on C3. Compstatin does not alter the conformation of C3c, whereas compstatin itself undergoes a large conformational change upon binding. We propose a model in which compstatin sterically hinders the access of the substrate C3 to the convertase complexes, thus blocking complement activation and amplification. These insights are instrumental for further development of compstatin as a potential therapeutic.	Univ Utrecht, Fac Sci, Bijvoet Ctr Biomol Res, Dept Chem, NL-3584 CH Utrecht, Netherlands; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Utrecht University; University of Pennsylvania	Gros, P (corresponding author), Univ Utrecht, Fac Sci, Bijvoet Ctr Biomol Res, Dept Chem, NL-3584 CH Utrecht, Netherlands.	p.gros@chem.uu.nl	Janssen, Bert/I-3338-2016; Gros, Piet/I-5569-2016; Gros, Piet/AAD-6452-2019; Lambris, John/Q-5633-2018; Halff, Els F/M-9110-2015	Janssen, Bert/0000-0002-8101-8370; Gros, Piet/0000-0002-7782-2585; Gros, Piet/0000-0002-7782-2585; Lambris, John/0000-0002-9370-5776; Halff, Els F/0000-0001-5814-0899	NIAID NIH HHS [AI30040] Funding Source: Medline; NIGMS NIH HHS [GM069736, GM62134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM069736, R01GM062134] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; Bureeva S, 2005, DRUG DISCOV TODAY, V10, P1535, DOI 10.1016/S1359-6446(05)03592-0; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiane AE, 1999, XENOTRANSPLANTATION, V6, P52, DOI 10.1034/j.1399-3089.1999.00007.x; Fredslund F, 2006, J MOL BIOL, V361, P115, DOI 10.1016/j.jmb.2006.06.009; Furlong ST, 2000, IMMUNOPHARMACOLOGY, V48, P199, DOI 10.1016/S0162-3109(00)00205-8; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164; Janssen BJC, 2007, MOL IMMUNOL, V44, P3, DOI 10.1016/j.molimm.2006.06.017; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Katragadda M, 2004, J BIOL CHEM, V279, P54987, DOI 10.1074/jbc.M409963200; Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311; Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028; Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200; Nilsson B, 1998, BLOOD, V92, P1661, DOI 10.1182/blood.V92.5.1661; Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104; Ponnuraj K, 2004, MOL CELL, V14, P17, DOI 10.1016/S1097-2765(04)00160-1; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 2003, MOL IMMUNOL, V39, P557, DOI 10.1016/S0161-5890(02)00212-2; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; Soulika AM, 2000, CLIN IMMUNOL, V96, P212, DOI 10.1006/clim.2000.4903; Soulika AM, 2003, J IMMUNOL, V171, P1881, DOI 10.4049/jimmunol.171.4.1881; Soulika AM, 2006, MOL IMMUNOL, V43, P2023, DOI 10.1016/j.molimm.2005.12.002; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263	33	99	110	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29241	29247		10.1074/jbc.M704587200	http://dx.doi.org/10.1074/jbc.M704587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684013	hybrid, Green Published			2022-12-25	WOS:000249788000020
J	Grigg, JC; Vermeiren, CL; Heinrichs, DE; Murphy, MEP				Grigg, Jason C.; Vermeiren, Christie L.; Heinrichs, David E.; Murphy, Michael E. P.			Heme coordination by Staphylococcus aureus IsdE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEIN; OUTER-MEMBRANE PROTEIN; HEMOGLOBIN RECEPTOR; CONFORMATIONAL-CHANGE; DEGRADING ENZYMES; CRYSTAL-STRUCTURE; BINDING-PROTEIN; IRON; IDENTIFICATION; TRANSPORT	Staphylococcus aureus is a Gram-positive bacterial pathogen and a leading cause of hospital acquired infections. Because the free iron concentration in the human body is too low to support growth, S. aureus must acquire iron from host sources. Heme iron is the most prevalent iron reservoir in the human body and a predominant source of iron for S. aureus. The iron-regulated surface determinant (Isd) system removes heme from host heme proteins and transfers it to IsdE, the cognate substrate-binding lipoprotein of an ATP-binding cassette transporter, for import and subsequent degradation. Herein, we report the crystal structure of the soluble portion of the IsdE lipoprotein in complex with heme. The structure reveals a bi-lobed topology formed by an N- and C-terminal domain bridged by a single alpha-helix. The structure places IsdE as a member of the helical backbone metal receptor superfamily. A six-coordinate heme molecule is bound in the groove established at the domain interface, and the heme iron is coordinated in a novel fashion for heme transporters by Met(78) and His(229). Both heme propionate groups are secured by H-bonds to IsdE main chain and side chain groups. Of these residues, His(229) is essential for IsdE-mediated heme uptake by S. aureus when growth on heme as a sole iron source is measured. Multiple sequence alignments of homologues from several other Gram-positive bacteria, including the human pathogens pyogenes, Bacillus anthracis, and Listeria monocytogenes, suggest that these other systems function equivalently to S. aureus IsdE with respect to heme binding and transport.	Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	University of British Columbia; Western University (University of Western Ontario)	Murphy, MEP (corresponding author), Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada.	Michael.Murphy@ubc.ca	Heinrichs, David/ABD-5702-2021; Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014; Heinrichs, David/0000-0002-7217-2456				Ahn SH, 2005, INFECT IMMUN, V73, P722, DOI 10.1128/IAI.73.2.722-729.2005; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrade MA, 2002, GENOME BIOL, V3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; Bertini I, 2006, CHEM REV, V106, P90, DOI 10.1021/cr050241v; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Chan ACK, 2006, J MOL BIOL, V362, P1108, DOI 10.1016/j.jmb.2006.08.001; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Deresinski S, 2005, CLIN INFECT DIS, V40, P562, DOI 10.1086/427701; Deurenberg RH, 2007, CLIN MICROBIOL INFEC, V13, P222, DOI 10.1111/j.1469-0691.2006.01573.x; Dryla A, 2003, MOL MICROBIOL, V49, P37, DOI 10.1046/j.1365-2958.2003.03542.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Muller A, 2006, ANGEW CHEM INT EDIT, V45, P5132, DOI 10.1002/anie.200601198; Murphy ER, 2002, INFECT IMMUN, V70, P5390, DOI 10.1128/IAI.70.10.5390-5403.2002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nygaard TK, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-82; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Pilpa RM, 2006, J MOL BIOL, V360, P435, DOI 10.1016/j.jmb.2006.05.019; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Radtke AL, 2006, CELL MICROBIOL, V8, P1720, DOI 10.1111/j.1462-5822.2006.00795.x; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Schneider S, 2006, J BIOL CHEM, V281, P32606, DOI 10.1074/jbc.M607516200; Sebulsky MT, 2004, J BIOL CHEM, V279, P53152, DOI 10.1074/jbc.M409793200; Sebulsky MT, 2003, J BIOL CHEM, V278, P49890, DOI 10.1074/jbc.M305073200; Sharp KH, 2007, J BIOL CHEM, V282, P10625, DOI 10.1074/jbc.M700234200; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; Speziali CD, 2006, J BACTERIOL, V188, P2048, DOI 10.1128/JB.188.6.2048-2055.2006; Stojiljkovic I, 2002, DNA CELL BIOL, V21, P281, DOI 10.1089/104454902753759708; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Tenover FC, 2004, EMERG INFECT DIS, V10, P2052, DOI 10.3201/eid1011.040797_10; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vermeiren CL, 2006, BIOCHEMISTRY-US, V45, P12867, DOI 10.1021/bi0607711; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Weems JJ, 2001, POSTGRAD MED, V110, P24, DOI 10.3810/pgm.2001.10.1042; Wu RY, 2005, J BIOL CHEM, V280, P2840, DOI 10.1074/jbc.M409526200	60	79	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28815	28822		10.1074/jbc.M704602200	http://dx.doi.org/10.1074/jbc.M704602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666394	hybrid			2022-12-25	WOS:000249642100056
J	Kawamata, Y; Imamura, T; Babendure, JL; Lu, JC; Yoshizaki, T; Olefsky, JM				Kawamata, Yuji; Imamura, Takeshi; Babendure, Jennie L.; Lu, Juu-Chin; Yoshizaki, Takeshi; Olefsky, Jerrold M.			Tumor necrosis factor receptor-1 can function through a G alpha(q/11)-beta-arrestin-1 signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTORS; PROTEIN-COUPLED RECEPTOR; 3RD INTRACELLULAR LOOP; NF-KAPPA-B; 3T3-L1 ADIPOCYTES; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; TNF-ALPHA; HETEROLOGOUS DESENSITIZATION; PHOSPHOLIPASE-C	Tumor necrosis factor-alpha ( TNF alpha) is a proinflammatory cytokine secreted from macrophages and adipocytes. It is well known that chronic TNF alpha exposure can lead to insulin resistance both in vitro and in vivo and that elevated blood levels of TNF alpha are observed in obese and/or diabetic individuals. TNF alpha has many acute biologic effects, mediated by a complex intracellular signaling pathway. In these studies we have identified new G-protein signaling components to this pathway in 3T3-L1 adipocytes. We found that beta-arrestin-1 is associated with TRAF2 ( TNFreceptor-associated factor 2), an adaptor protein of TNF receptors, and that TNF alpha acutely stimulates tyrosine phosphorylation of G alpha(q/11) with an increase in G alpha(q/11) activity. Small interfering RNA-mediated knockdown of beta-arrestin-1 inhibits TNF alpha-induced tyrosine phosphorylation of G alpha(q/11) by interruption of Src kinase activation. TNF alpha stimulates lipolysis in 3T3-L1 adipocytes, and beta-arrestin-1 knockdown blocks the effects of TNF alpha to stimulate ERK activation and glycerol release. TNF alpha also led to activation of JNK with increased expression of the proinflammatory gene, monocyte chemoattractant protein-1 and matrix metalloproteinase 3, and beta-arrestin-1 knockdown inhibited both of these effects. Taken together these results reveal novel elements of TNF alpha action; 1) the trimeric G-protein component G alpha(q/11) and the adapter protein beta-arrestin-1 can function as signaling molecules in the TNF alpha action cascade; 2) beta-arrestin-1 can couple TNF alpha stimulation to ERK activation and lipolysis; 3) beta-arrestin-1 and G alpha(q/11) can mediate TNF alpha-induced phosphatidylinositol 3-kinase activation and inflammatory gene expression.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Lu, Juu-Chin/ABB-3198-2020	Lu, Juu-Chin/0000-0001-8523-6992; Kawamata, Yuji/0000-0001-5652-4899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; Doan JES, 2004, J IMMUNOL, V172, P7654, DOI 10.4049/jimmunol.172.12.7654; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hupfeld CJ, 2003, P NATL ACAD SCI USA, V100, P161, DOI 10.1073/pnas.0235674100; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Laurencikiene J, 2007, J LIPID RES, V48, P1069, DOI 10.1194/jlr.M600471-JLR200; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liao W, 2006, ENDOCRINOLOGY, V147, P2245, DOI 10.1210/en.2005-1638; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Puls A, 1999, J CELL SCI, V112, P2983; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Usui I, 2005, MOL ENDOCRINOL, V19, P2760, DOI 10.1210/me.2004-0429; Usui I, 2004, EMBO J, V23, P2821, DOI 10.1038/sj.emboj.7600297; Usui I, 2003, J BIOL CHEM, V278, P13765, DOI 10.1074/jbc.M208904200; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; Wang HL, 1997, J NEUROCHEM, V68, P1728; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	44	26	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28549	28556		10.1074/jbc.M705869200	http://dx.doi.org/10.1074/jbc.M705869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17664271	hybrid			2022-12-25	WOS:000249642100029
J	Neumann, M; Stocklein, W; Leimkuhler, S				Neumann, Meina; Stoecklein, Walter; Leimkuehler, Silke			Transfer of the molybdenum cofactor synthesized by Rhodobacter capsulatus MoeA to XdhC and MobA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; TRIMETHYLAMINE-N-OXIDE; ESCHERICHIA-COLI; XANTHINE DEHYDROGENASE; DIMETHYLSULFOXIDE REDUCTASE; RHODOPSEUDOMONAS-CAPSULATA; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; GENE-PRODUCTS; BIOSYNTHESIS	The molybdenum cofactor (Moco) exists in different variants in the cell and can be directly inserted into molybdoenzymes utilizing the molybdopterin (MPT) form of Moco. In bacteria such as Rhodobacter capsulatus and Escherichia coli, MPT is further modified by attachment of a GMP nucleotide, forming MPT guanine dinucleotide (MGD). In this work, we analyzed the distribution and targeting of different forms of Moco to their respective user enzymes by proteins that bind Moco and are involved in its further modification. The R. capsulatus proteins MogA, MoeA, MobA, and XdhC were purified, and their specific interactions were analyzed. Interactions between the protein pairs MogA-MoeA, MoeA-XdhC, MoeA-MobA, and XdhC-MobA were identified by surface plasmon resonance measurements. In addition, the transfer of Moco produced by the MogA-MoeA complex to XdhC was investigated. A direct competition of MobA and XdhC for Moco binding was determined. In vitro analyses showed that XdhC bound to MobA, prevented the binding of Moco to MobA, and thereby inhibited MGD biosynthesis. The data were confirmed by in vivo studies in R. capsulatus cells showing that overproduction of XdhC resulted in a 50% decrease in the activity of bis-MGD-containing Me2SO reductase. We propose that, in bacteria, the distribution of Moco in the cell and targeting to the respective user enzymes are accomplished by specific proteins involved in Moco binding and modification.	Univ Potsdam, Inst Biochem & Biol, Dept Prot Analyt, D-14476 Potsdam, Germany; Univ Potsdam, Inst Biochem & Biol, Dept Analyt Biochem, D-14476 Potsdam, Germany	University of Potsdam; University of Potsdam	Leimkuhler, S (corresponding author), Univ Potsdam, Inst Biochem & Biol, Dept Prot Analyt, D-14476 Potsdam, Germany.	sleim@uni-potsdam.de	Neumann-Schaal, Meina/AAM-6389-2021	Leimkuhler, Silke/0000-0003-3238-2122				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Genes O, 2005, J BIOL CHEM, V280, P15644, DOI 10.1074/jbc.M501119200; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOSHI MS, 1994, ARCH BIOCHEM BIOPHYS, V308, P331, DOI 10.1006/abbi.1994.1047; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KLIPP W, 1988, J BACTERIOL, V170, P693, DOI 10.1128/jb.170.2.693-699.1988; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Leimkuhler S, 1999, J BACTERIOL, V181, P5930; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Leimkuhler S, 1999, FEMS MICROBIOL LETT, V174, P239, DOI 10.1016/S0378-1097(99)00147-0; Llamas A, 2004, J BIOL CHEM, V279, P55241, DOI 10.1074/jbc.M409862200; Llamas A, 2006, J BIOL CHEM, V281, P18343, DOI 10.1074/jbc.M601415200; Loschi L, 2004, J BIOL CHEM, V279, P50391, DOI 10.1074/jbc.M408876200; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; MCEWAN AG, 1985, BIOCHIM BIOPHYS ACTA, V806, P410, DOI 10.1016/0005-2728(85)90248-8; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; MCEWAN AG, 1983, ARCH MICROBIOL, V136, P300, DOI 10.1007/BF00425221; McLuskey K, 2003, J BIOL CHEM, V278, P23706, DOI 10.1074/jbc.M301485200; MILLER JB, 1987, J BACTERIOL, V169, P1853, DOI 10.1128/jb.169.5.1853-1860.1987; Neumann M, 2007, BIOCHEMISTRY-US, V46, P9586, DOI 10.1021/bi700630p; Neumann M, 2006, J BIOL CHEM, V281, P15701, DOI 10.1074/jbc.M601617200; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Nichols JD, 2005, J BIOL CHEM, V280, P7817, DOI 10.1074/jbc.M413783200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; POLLOCK D, 1988, GENE, V65, P269, DOI 10.1016/0378-1119(88)90463-5; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; Solomon PS, 1999, MICROBIOL-UK, V145, P1421, DOI 10.1099/13500872-145-6-1421; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Vergnes A, 2006, J BIOL CHEM, V281, P2170, DOI 10.1074/jbc.M505902200; WANG G, 1993, J BACTERIOL, V175, P3031, DOI 10.1128/JB.175.10.3031-3042.1993; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	42	33	34	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28493	28500		10.1074/jbc.M704020200	http://dx.doi.org/10.1074/jbc.M704020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686778	hybrid			2022-12-25	WOS:000249642100023
J	Sato, T; Furukawa, K				Sato, Takeshi; Furukawa, Kiyoshi			Sequential action of Ets-1 and Sp1 in the activation of the human beta-1,4-galactosyltransferase v gene involved in abnormal glycosylation characteristic of cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; TRANSCRIPTION FACTOR SP1; HAMSTER-KIDNEY CELLS; LINKED OLIGOSACCHARIDES; GALACTOSYLTRANSFERASE GENE; HEPATOCELLULAR-CARCINOMA; COOPERATIVE INTERACTIONS; GROWTH-FACTOR; T-CELLS; EXPRESSION	\Malignant transformation is associated with increased gene expression of beta-1,4-galactosyltransferase (beta-1,4-GaIT) V, which contributes to the biosynthesis of highly branched N-linked oligosaccharides characteristic of cancer cells. Our previous study showed that expression of the human beta-1,4-GaIT V gene is regulated by Spl (Sato, T., and Furukawa, K. (2004) J. BioL Chem. 279, 39574-39583), and a subsequent study showed that the gene expression is also activated by Ets-1, a product of the oncogene (Sato, T., and Furukawa, K. (2005) Glycoconj. J. 22, 365). Herein we report the mechanism of beta-1,4-GaIT V gene activation by these transcription factors. The gene expression and promoter activity of beta-1,4-GaIT V increased when the ets-1 cDNA was transfected into A549 cells, which contain a small amount of Ets-1, but decreased dramatically when the dominant-negative ets-1 cDNA was transfected into HepG2 cells, which contain a large amount of Ets-1. Luciferase assays using deletion constructs of the beta-1,4-GaIT V gene promoter showed that promoter region - 116 to + 22 is critical for the transcriptional activation of the gene by Ets-1. Despite the presence of one Ets-1-binding site, which overlapped the Sp1-binding site, electrophoretic mobility shift assays showed that the region bound preferentially to Spl rather than to Ets-1. To solve this problem, we examined the transcriptional regulation of the human Spl gene by Ets-1 and found that the gene expression and promoter activity of Sp1 are regulated by Ets-1 in cancer cells. Functional analyses of two Ets-1-binding sites in the Sp1 gene promoter showed that only Ets-1-binding site -413 to -404 is involved in the activation of the gene by Ets-1. These results indicate that Ets-1 enhances expression of the beta-1,4-GaIT V gene through activation of the Sp1 gene in cancer cells.	Nagaoka Univ Technol, Dept Bioengn, Lab Glycobiol, Nagaoka, Niigata 94021, Japan	Nagaoka University of Technology	Sato, T (corresponding author), Nagaoka Univ Technol, Dept Bioengn, Lab Glycobiol, Kamitomioka 1603-1, Nagaoka, Niigata 94021, Japan.	taksato@vos.nagaokaut.ac.jp						Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Asada M, 1997, CANCER RES, V57, P1073; BHAT NK, 1989, J IMMUNOL, V142, P672; BOLON I, 1995, AM J PATHOL, V147, P1298; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Charron M, 1999, MOL CELL BIOL, V19, P5823; Davidson B, 2001, CLIN CANCER RES, V7, P551; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; Granovsky M, 2000, NAT MED, V6, P306; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Jiang JH, 2006, J BIOL CHEM, V281, P9482, DOI 10.1074/jbc.M504489200; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kita D, 2001, CANCER RES, V61, P7985; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lietard J, 1997, AM J PATHOL, V151, P1663; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nakayama T, 1996, AM J PATHOL, V149, P1931; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; PIERCE M, 1986, J BIOL CHEM, V261, P772; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raimondi LP, 2004, FEBS LETT, V576, P487, DOI 10.1016/j.febslet.2004.09.066; Santiago FS, 2004, CIRC RES, V95, P479, DOI 10.1161/01.RES.0000141135.36279.67; Sato T, 2000, BIOCHEM BIOPH RES CO, V276, P1019, DOI 10.1006/bbrc.2000.3594; Sato T, 2005, EUR J PHARM SCI, V25, P221, DOI 10.1016/j.ejps.2005.02.011; SATO T, 1993, J BIOCHEM-TOKYO, V114, P890, DOI 10.1093/oxfordjournals.jbchem.a124273; Sato T, 2004, J BIOL CHEM, V279, P39574, DOI 10.1074/jbc.M405805200; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SATO T, 2005, GLYCOCONJ J, V22, P365; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1990, ONCOGENE, V5, P1761; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Withers DA, 2000, J BIOL CHEM, V275, P40588, DOI 10.1074/jbc.M007262200; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; Zhang W, 2000, BIOCHEM J, V347, P511, DOI 10.1042/0264-6021:3470511; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	47	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27702	27712		10.1074/jbc.M611862200	http://dx.doi.org/10.1074/jbc.M611862200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656364	hybrid			2022-12-25	WOS:000249455600018
J	Hu, D; Bertozzi, SM; Gakidou, E; Sweet, S; Goldie, SJ				Hu, Delphine; Bertozzi, Stefano M.; Gakidou, Emmanuela; Sweet, Steve; Goldie, Sue J.			The Costs, Benefits, and Cost-Effectiveness of Interventions to Reduce Maternal Morbidity and Mortality in Mexico	PLOS ONE			English	Article							LAPAROSCOPY; STRATEGIES; AFGHANISTAN; HEALTH; DEATH; CARE; 2ND	Background. In Mexico, the lifetime risk of dying from maternal causes is 1 in 370 compared to 1 in 2,500 in the U. S. Although national efforts have been made to improve maternal services in the last decade, it is unclear if Millennium Development Goal 5 - to reduce maternal mortality by three-quarters by 2015 - will be met. Methodology/Principal Findings. We developed an empirically calibrated model that simulates the natural history of pregnancy and pregnancy-related complications in a cohort of 15-year-old women followed over their lifetime. After synthesizing national and sub-national trends in maternal mortality, the model was calibrated to current intervention-specific coverage levels and validated by comparing model-projected life expectancy, total fertility rate, crude birth rate and maternal mortality ratio with Mexico-specific data. Using both published and primary data, we assessed the comparative health and economic outcomes of alternative strategies to reduce maternal morbidity and mortality. A dual approach that increased coverage of family planning by 15%, and assured access to safe abortion for all women desiring elective termination of pregnancy, reduced mortality by 43% and was cost saving compared to current practice. The most effective strategy added a third component, enhanced access to comprehensive emergency obstetric care for at least 90% of women requiring referral. At a national level, this strategy reduced mortality by 75%, cost less than current practice, and had an incremental cost-effectiveness ratio of $300 per DALY relative to the next best strategy. Analyses conducted at the state level yielded similar results. Conclusions/Significance. Increasing the provision of family planning and assuring access to safe abortion are feasible, complementary and cost-effective strategies that would provide the greatest benefit within a short-time frame. Incremental improvements in access to high-quality intrapartum and emergency obstetric care will further reduce maternal deaths and disability.	[Hu, Delphine; Sweet, Steve; Goldie, Sue J.] Harvard Univ, Sch Publ Hlth, Program Hlth Decis Sci, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Bertozzi, Stefano M.] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico; [Gakidou, Emmanuela; Goldie, Sue J.] Harvard Initiat Global Hlth, Cambridge, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Instituto Nacional de Salud Publica; Harvard University	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Program Hlth Decis Sci, Dept Hlth Policy & Management, Boston, MA 02115 USA.	sue_goldie@harvard.edu		Bertozzi, Stefano M/0000-0002-1723-7085	John D. and Catherine T. MacArthur Foundation	John D. and Catherine T. MacArthur Foundation	This work was supported by a grant from the John D. and Catherine T. MacArthur Foundation. The MacArthur Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.	ABOUZAHR C, 2004, MATERNAL MORTALITY 2, P24; Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; *AL GUTTMA I, 1996, OV CLAND ABORT LAT A, P4; *AL GUTTMA I, 1999, FACTS BRIEF IND ABOR, P1; Amowitz LL, 2002, JAMA-J AM MED ASSOC, V288, P1284, DOI 10.1001/jama.288.10.1284; [Anonymous], 2000, COCHRANE DATABASE SY; AVILA JL, 2002, INDICE MARGINACION N; Bartlett LA, 2005, LANCET, V365, P864, DOI 10.1016/S0140-6736(05)71044-8; BRIHMER C, 1989, EUR J OBSTET GYN R B, V30, P263, DOI 10.1016/0028-2243(89)90011-7; Cahuana-Hurtado L, 2004, SALUD PUBLICA MEXICO, V46, P316, DOI 10.1590/S0036-36342004000400006; CAHUANAHURTADO L, 2004, APPL MOTHER BAY PACK; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; DRUMMOND M, EC EV HLTH CAR MERG; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; DULEY L, COCHRANE DATABASE SY, V2; DULEY L, COCHRANE DATABASE SY, V2; Ehrnborg C, 2000, PHARMACOECONOMICS, V17, P621, DOI 10.2165/00019053-200017060-00008; *ENG, 2003, OBST FIST NEEDS ASS; French L.M., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001067.PUB2; FRENCH LM, 2003, CURR WOMENS HLTH REP, V4, P274; Gold MR, 1996, COST EFFECTIVENESS H; Graham WJ, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P499; Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4; Healy J, 2006, INT J GYNECOL OBSTET, V95, P209, DOI 10.1016/j.ijgo.2006.08.002; Hofmeyr GJ, 2000, COCHRANE DB SYST REV, V2; HOFMEYR GJ, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000166; Horton R, 2006, LANCET, V368, P1129, DOI 10.1016/S0140-6736(06)69389-6; Hu D, 2004, ANN INTERN MED, V141, P501, DOI 10.7326/0003-4819-141-7-200410050-00006; JAMISON DT, COST EFFECTIVENESS A, P39; Jha P, 1998, HEALTH POLICY PLANN, V13, P249, DOI 10.1093/heapol/13.3.249; KENT KC, 1995, JAMA-J AM MED ASSOC, V274, P888, DOI 10.1001/jama.274.11.888; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Lau CY, 2002, SEX TRANSM DIS, V29, P497, DOI 10.1097/00007435-200209000-00001; Lozano R, 2006, LANCET, V368, P1729, DOI 10.1016/S0140-6736(06)69566-4; MAINE D, 1981, SAF MOTH PROGR OPT I; Max W, VALUING HUMAN LIFE E; MENKEN J, 2006, INT PUBLIC HLTH DIS, P71; *MIN HLTH, 2001, MORT 2001 CONT ACT A; *MIN HLTH, 1998, CONT ACT ASP REL MEX; MURRAY CJ, HLTH DIMENSIONS SEX; MURRAY CJL, 2004, HLTH DIMENSIONS SEX; Ojha Kamal, 2003, Hum Fertil (Camb), V6, P169, DOI 10.1080/1464770312331369443; *POP REF BUR, 2005, 2005 WOM OUR WORLD; Porter Ian, 1980, HUMAN EMBRYONIC FETA; Prata N, 2004, 2004 POP ASS AM M BO; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Schuitemaker N, 1997, ACTA OBSTET GYN SCAN, V76, P332, DOI 10.1111/j.1600-0412.1997.tb07987.x; SOMMERFELT AE, 2003, REDUCE WORKSH ADD AB; TEISALA K, 1987, OBSTET GYNECOL, V69, P343; UNICEF A, 2007, GLAN MEX STAT; *WHO, 2004, UNS ABORT; *WHO CHOICE, CHOOSING INT COST EF; WOLNERHANSSEN P, 1983, OBSTET GYNECOL, V61, P702; *WORLD BANK, WDI ONL; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2001, MACR HLTH INV HLTH E; [No title captured]; WKLY EPIDEMIOL REC, V68, P305	58	31	32	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e750	10.1371/journal.pone.0000750	http://dx.doi.org/10.1371/journal.pone.0000750			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710149	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200026
J	Suen, G; Goldman, BS; Welch, RD				Suen, Garret; Goldman, Barry S.; Welch, Roy D.			Predicting Prokaryotic Ecological Niches Using Genome Sequence Analysis	PLOS ONE			English	Article							LATERAL GENE-TRANSFER; BURKHOLDERIA-CEPACIA; EVOLUTION; DATABASE; TAXONOMY; PROPOSAL; SYSTEM; TREE	Automated DNA sequencing technology is so rapid that analysis has become the rate-limiting step. Hundreds of prokaryotic genome sequences are publicly available, with new genomes uploaded at the rate of approximately 20 per month. As a result, this growing body of genome sequences will include microorganisms not previously identified, isolated, or observed. We hypothesize that evolutionary pressure exerted by an ecological niche selects for a similar genetic repertoire in those prokaryotes that occupy the same niche, and that this is due to both vertical and horizontal transmission. To test this, we have developed a novel method to classify prokaryotes, by calculating their Pfam protein domain distributions and clustering them with all other sequenced prokaryotic species. Clusters of organisms are visualized in two dimensions as 'mountains' on a topological map. When compared to a phylogenetic map constructed using 16S rRNA, this map more accurately clusters prokaryotes according to functional and environmental attributes. We demonstrate the ability of this map, which we term a "niche map", to cluster according to ecological niche both quantitatively and qualitatively, and propose that this method be used to associate uncharacterized prokaryotes with their ecological niche as a means of predicting their functional role directly from their genome sequence.	[Suen, Garret; Welch, Roy D.] Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; [Goldman, Barry S.] Monsanto Co, St Louis, MO USA	Syracuse University; Monsanto	Welch, RD (corresponding author), Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA.	rowelch@syr.edu	Suen, Garret/AAF-2080-2019	Suen, Garret/0000-0002-6170-711X; Welch, Roy/0000-0002-9946-108X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apic G, 2001, J MOL BIOL, V310, P311, DOI 10.1006/jmbi.2001.4776; Badger JH, 2005, INT J SYST EVOL MICR, V55, P1021, DOI 10.1099/ijs.0.63510-0; Boucher Y, 2003, ANNU REV GENET, V37, P283, DOI 10.1146/annurev.genet.37.050503.084247; Chen K, 2005, PLOS COMPUT BIOL, V1, P106, DOI 10.1371/journal.pcbi.0010024; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; COHAN FM, 2004, INFEC DIS S, P175; Cole JR, 2007, NUCLEIC ACIDS RES, V35, pD169, DOI 10.1093/nar/gkl889; Dale C, 2006, CELL, V126, P453, DOI 10.1016/j.cell.2006.07.014; DAVIDSON GS, 2001, CLUSTER STABILITY US, P23; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Elton C. S., 1927, ANIMAL ECOLOGY; FELENSTEIN J, 2006, PHYLIP PHYLOGENY INF; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Garrity G. M., 2001, BERGEYS MANUAL SYSTE, V2; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Goldenfeld N, 2007, NATURE, V445, P369, DOI 10.1038/445369a; Grinnell J., 1917, Auk Cambridge Mass, V34; Gupta RS, 2002, THEOR POPUL BIOL, V61, P423, DOI 10.1006/tpbi.2002.1589; Harrison F, 2007, MICROBIOL-SGM, V153, P917, DOI 10.1099/mic.0.2006/004077-0; Hugenholtz P, 2002, GENOME BIOL, V3; Konstantinidis KT, 2005, J BACTERIOL, V187, P6258, DOI 10.1128/JB.187.18.6258-6264.2005; Lerat E, 2005, PLOS BIOL, V3, P807, DOI 10.1371/journal.pbio.0030130; Lerat E, 2003, PLOS BIOL, V1, P101, DOI 10.1371/journal.pbio.0000019; Lin J, 2000, GENOME RES, V10, P808, DOI 10.1101/gr.10.6.808; Marchler-Bauer A, 2007, NUCLEIC ACIDS RES, V35, pD237, DOI 10.1093/nar/gkl951; Markowitz VM, 2006, NUCLEIC ACIDS RES, V34, pD344, DOI 10.1093/nar/gkj024; Martiny JBH, 2006, NAT REV MICROBIOL, V4, P102, DOI 10.1038/nrmicro1341; Martiny JBH, 2005, ECOL LETT, V8, P1334, DOI 10.1111/j.1461-0248.2005.00837.x; Moran NA, 2002, CELL, V108, P583, DOI 10.1016/S0092-8674(02)00665-7; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Ochman H, 2001, SCIENCE, V292, P1096, DOI 10.1126/science.1058543; Ochman H, 2005, P NATL ACAD SCI USA, V102, P6595, DOI 10.1073/pnas.0502035102; Ohno S., 1970, EVOLUTION GENE DUPLI; Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165; Orengo CA, 2005, ANNU REV BIOCHEM, V74, P867, DOI 10.1146/annurev.biochem.74.082803.133029; PATTEN BC, 1981, AM NAT, V117, P893, DOI 10.1086/283777; Riedel K, 2001, MICROBIOL-SGM, V147, P3249, DOI 10.1099/00221287-147-12-3249; Riesenfeld CS, 2004, ANNU REV GENET, V38, P525, DOI 10.1146/annurev.genet.38.072902.091216; Simonson AB, 2005, P NATL ACAD SCI USA, V102, P6608, DOI 10.1073/pnas.0501996102; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Tekaia F, 2005, PLOS COMPUT BIOL, V1, P604, DOI 10.1371/journal.pcbi.0010075; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YABUUCHI E, 1992, MICROBIOL IMMUNOL, V36, P1251, DOI 10.1111/j.1348-0421.1992.tb02129.x; Yang S, 2005, P NATL ACAD SCI USA, V102, P373, DOI 10.1073/pnas.0408810102	49	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e743	10.1371/journal.pone.0000743	http://dx.doi.org/10.1371/journal.pone.0000743			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710143	gold, Green Published, Green Submitted			2022-12-25	WOS:000207455200020
J	Dobbyn, HC; Hill, K; Hamilton, TL; Spriggs, KA; Pickering, BM; Coldwell, MJ; de Moor, CH; Bushell, M; Willis, AE				Dobbyn, H. C.; Hill, K.; Hamilton, T. L.; Spriggs, K. A.; Pickering, B. M.; Coldwell, M. J.; de Moor, C. H.; Bushell, M.; Willis, A. E.			Regulation of BAG-1 IRES-mediated translation following chemotoxic stress	ONCOGENE			English	Article						BAG-1; translation; IRES; internal ribosome entry; polypyrimidine tract binding protein	INTERNAL RIBOSOME ENTRY; TRACT-BINDING-PROTEIN; CELL-DEATH; HEAT-SHOCK; BREAST-CANCER; MESSENGER-RNA; EXPRESSION; INITIATION; GROWTH; APOPTOSIS	There are three major isoforms of BAG-1 in mammalian cells, termed BAG-1L ( p50), BAG-1M ( p46) and BAG-1S ( p36) that function as pro-survival proteins and are associated with tumorigenesis and chemoresistance. Initiation of BAG-1 protein synthesis can occur by both cap-dependent and cap-independent mechanisms and it has been shown that synthesis of BAG-1S is dependent upon the presence of an internal ribosome entry segment ( IRES) in the 5'-UTR of BAG-1 mRNA. We have shown previously that BAG-1 IRES-meditated initiation of translation requires two trans-acting factors poly ( rC) binding protein 1 ( PCBP1) and polypyrimidine tract binding protein ( PTB) for function. The former protein allows BAG-1 IRES RNA to attain a structure that permits binding of the ribosome, while the latter protein appears to be involved in ribosome recruitment. Here, we show that the BAG-1 IRES maintains synthesis of BAG-1 protein following exposure of cells to the chemotoxic drug vincristine but not to cisplatin and that this is brought about, in part, by the relocalization of PTB and PCBP1 from the nucleus to the cytoplasm.	[Dobbyn, H. C.; Hill, K.; Hamilton, T. L.; Spriggs, K. A.; Pickering, B. M.; Coldwell, M. J.; de Moor, C. H.; Bushell, M.; Willis, A. E.] Univ Nottingham, Sch Pharm, Chair Canc Cell Biol, Nottingham NG7 2RD, England	University of Nottingham	Willis, AE (corresponding author), Univ Nottingham, Sch Pharm, Chair Canc Cell Biol, Univ Pk, Nottingham NG7 2RD, England.	anne.willis@nottingham.ac.uk	de Moor, Cornelia/AAE-8043-2020	de Moor, Cornelia/0000-0001-8776-0085; Willis, Anne/0000-0002-1470-8531	Biotechnology and Biological Sciences Research Council [C14959, BBS/B/03556] Funding Source: Medline; Wellcome Trust [075802] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Back SH, 2002, J VIROL, V76, P2529, DOI 10.1128/JVI.76.5.2529-2542.2002; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Cato ACB, 2001, J STEROID BIOCHEM, V78, P379, DOI 10.1016/S0960-0760(01)00114-5; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Hague A, 2002, J PATHOL, V197, P60, DOI 10.1002/path.1076; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamath RV, 2001, MOL BIOL CELL, V12, P3808, DOI 10.1091/mbc.12.12.3808; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Takahashi A, 1997, BRAIN RES PROTOC, V1, P70, DOI 10.1016/S1385-299X(96)00013-X; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Wang C, 2003, MOL BIOL CELL, V14, P2425, DOI 10.1091/mbc.E02-12-0818; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	34	52	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1167	1174		10.1038/sj.onc.1210723	http://dx.doi.org/10.1038/sj.onc.1210723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700523	Green Accepted			2022-12-25	WOS:000253136700016
J	Kurata, K; Yanagisawa, R; Ohira, M; Kitagawa, M; Nakagawara, A; Kamijo, T				Kurata, K.; Yanagisawa, R.; Ohira, M.; Kitagawa, M.; Nakagawara, A.; Kamijo, T.			Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; p53; noxa; mitochondria; apoptosis	WILD-TYPE P53; DNA-DAMAGE; IN-VIVO; P53-DEPENDENT APOPTOSIS; CYTOPLASMIC SEQUESTRATION; MOLECULAR-CLONING; EXPRESSION; DEATH; PROTEINS; GENE	In this study, we employed a panel of cell lines to determine whether p53-dependent cell death in neuroblastoma (NB) cells is caused by apoptotic cellular function, and we further studied the molecular mechanism of apoptosis induced via the p53-dependent pathway. We obtained evidence that a type of p53-dependent stress, doxorubicin (Doxo) administration, causes accumulation of p53 in the nucleus of NB cells and phosphorylation of several serine residues in both Doxo-sensitive and -resistant cell lines. Upregulation of p53-downstream molecules in cells and upregulation of Noxa in the mitochondrial fraction were observed only in Doxo-sensitive NB cells. Significance of Noxa in the Doxo-induced NB cell death was confirmed by Noxa-knockdown experiments. Mitochondrial dysfunction, including cytochrome-c release and membrane potential disregulation, occurred and resulted in the activation of the intrinsic caspase pathway. However, in the Doxo-resistant cells, the accumulation in the nucleus and phosphorylation of p53 did not induce p53-downstream p21(Cip1/Waf1) expression and the Noxa upregulation, resulting in the retention of the mitochondrial homeostasis. Taken together, these findings indicate that the p53 pathway seems to play a crucial role in NB cell death by Noxa regulation in mitochondria, and inhibition of the induction of p53-downstream effectors may regulate drug resistance of NB cells.	[Ohira, M.; Nakagawara, A.; Kamijo, T.] Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Kurata, K.; Yanagisawa, R.; Kamijo, T.] Shinshu Univ, Sch Med, Dept Pediat, Nagano, Japan; [Kitagawa, M.] Hamamatsu Univ Sch Med, Dept Biochem, Shizuoka, Japan	Chiba Cancer Center; Shinshu University; Hamamatsu University School of Medicine	Kamijo, T (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp						Aleyasin H, 2004, J NEUROSCI, V24, P2963, DOI 10.1523/JNEUROSCI.0155-04.2004; Bell E, 2006, CELL CYCLE, V5, P2639, DOI 10.4161/cc.5.22.3443; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hempel G, 2002, CANCER CHEMOTH PHARM, V49, P133, DOI 10.1007/s00280-001-0392-4; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; Keshelava N, 2001, CANCER RES, V61, P6185; Kiryu-Seo S, 2005, J NEUROSCI, V25, P1442, DOI 10.1523/JNEUROSCI.4041-04.2005; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee SJ, 2005, J BIOL CHEM, V280, P5781, DOI 10.1074/jbc.M411224200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Machida T, 2006, ONCOGENE, V25, P1931, DOI 10.1038/sj.onc.1209225; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakazawa Y, 2003, J BIOL CHEM, V278, P27888, DOI 10.1074/jbc.M300510200; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; ODA E, 2003, SCIENCE, V17, P1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohtani S, 2004, MOL CANCER THER, V3, P93; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Paull A, 2005, MOL VIS, V11, P328; Qin JZ, 2004, MOL CANCER THER, V3, P895; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200	37	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					741	754		10.1038/sj.onc.1210672	http://dx.doi.org/10.1038/sj.onc.1210672			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653088				2022-12-25	WOS:000252884500003
J	Borczuk, AC; Papanikolaou, N; Toonkel, RL; Sole, M; Gorenstein, LA; Ginsburg, ME; Sonett, JR; Friedman, RA; Powell, CA				Borczuk, A. C.; Papanikolaou, N.; Toonkel, R. L.; Sole, M.; Gorenstein, L. A.; Ginsburg, M. E.; Sonett, J. R.; Friedman, R. A.; Powell, C. A.			Lung adenocarcinoma invasion in TGFbRII-deficient cells is mediated by CCL5/RANTES	ONCOGENE			English	Article						lung adenocarcinoma; bronchioloalveolar carcinoma; neoplasm invasiveness; RANTES; TGF-beta; disease progression	FACTOR-BETA RECEPTOR; BREAST-CARCINOMA; GENE-EXPRESSION; CCL5 RANTES; CANCER; CCR5; METASTASIS; PROGRESSION; ANTAGONIST; ACTIVATION	Recently, we identified a lung adenocarcinoma signature that segregated tumors into three clades distinguished by histological invasiveness. Among the genes differentially expressed was the type II transforming growth factor-beta receptor (TGF beta RII), which was lower in adenocarcinoma mixed subtype and solid invasive subtype tumors compared with bronchioloalveolar carcinoma. We used a tumor cell invasion system to identify the chemokine CCL5 (RANTES, regulated on activation, normal T-cell expressed and presumably secreted) as a potential downstream mediator of TGF-beta signaling important for lung adenocarcinoma invasion. We specifically hypothesized that RANTES is required for lung cancer invasion and progression in TGFbRII-repressed cells. We examined invasion in TGFbRII-deficient cells treated with two inhibitors of RANTES activity, Met-RANTES and a CCR5 receptor-blocking antibody. Both treatments blocked invasion induced by TGFbRII knockdown. In addition, we examined the clinical relevance of the RANTES-CCR5 pathway by establishing an association of RANTES and CCR5 immunostaining with invasion and outcome in human lung adenocarcinoma specimens. Moderate or high expression of both RANTES and CCR5 was associated with an increased risk for death, P = 0.014 and 0.002, respectively. In conclusion, our studies indicate RANTES signaling is required for invasion in TGFbRII-deficient cells and suggest a role for CCR5 inhibition in lung adenocarcinoma prevention and treatment.	[Borczuk, A. C.] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; [Papanikolaou, N.; Toonkel, R. L.; Sole, M.; Powell, C. A.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Gorenstein, L. A.; Ginsburg, M. E.; Sonett, J. R.] Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Friedman, R. A.] Columbia Univ Coll Phys & Surg, Dept Biomed Informat, New York, NY 10032 USA; [Friedman, R. A.; Powell, C. A.] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Powell, CA (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, 630 W,168th St,Box 91, New York, NY 10032 USA.	cap6@columbia.edu	BORCZUK, alain/AHA-5172-2022; Powell, Charles A/C-8663-2011; Borczuk, Alain/AAI-8226-2021; Borczuk, Alain/AFU-5278-2022	Powell, Charles A/0000-0003-3509-891X; Borczuk, Alain/0000-0001-6807-8064; Borczuk, Alain/0000-0001-6807-8064; toonkel, rebecca/0000-0001-8339-2107	NATIONAL CANCER INSTITUTE [R01CA120174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA120174-02, 1R01CA120174, R01 CA120174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azenshtein E, 2002, CANCER RES, V62, P1093; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Biswas S, 2004, CANCER RES, V64, P4687, DOI 10.1158/0008-5472.CAN-03-3255; Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Culley FJ, 2006, J VIROL, V80, P8151, DOI 10.1128/JVI.00496-06; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gustin JA, 2004, AM J PHYSIOL-CELL PH, V286, pC547, DOI 10.1152/ajpcell.00332.2002; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Jang SB, 2002, MOL CELLS, V14, P35; Luboshits G, 1999, CANCER RES, V59, P4681; Ma B, 2005, J CLIN INVEST, V115, P3460, DOI 10.1172/JCI24858; Moran CJ, 2002, CLIN CANCER RES, V8, P3803; Nakazaki Y, 2006, MOL THER, V14, P599, DOI 10.1016/j.ymthe.2006.04.014; Nissinen R, 2003, J RHEUMATOL, V30, P1928; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Remmelink M, 2005, INT J ONCOL, V26, P247; Sakurai H, 2004, AM J SURG PATHOL, V28, P198, DOI 10.1097/00000478-200402000-00007; Schwabe RF, 2003, AM J PHYSIOL-GASTR L, V285, pG949, DOI 10.1152/ajpgi.00215.2003; Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306; van Deventer HW, 2005, CANCER RES, V65, P3374, DOI 10.1158/0008-5472.CAN-04-2616	24	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					557	564		10.1038/sj.onc.1210662	http://dx.doi.org/10.1038/sj.onc.1210662			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653092	Green Accepted			2022-12-25	WOS:000252426100016
J	Jackson, AA; Cronin, KR; Zachariah, R; Carew, JA				Jackson, Audrey A.; Cronin, Katherine R.; Zachariah, Roshini; Carew, Josephine A.			CCAAT/enhancer-binding protein-beta participates in insulin-responsive expression of the factor VII gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VII; ASPARAGINE SYNTHETASE GENE; AMINO-ACID LIMITATION; ACTIVATING TRANSCRIPTION FACTOR-3; FACTOR PROCOAGULANT ACTIVITY; CORONARY-HEART-DISEASE; STRESS-INDUCIBLE GENE; NUCLEAR FACTOR 4; TISSUE FACTOR; MYOCARDIAL-INFARCTION	Expression of the human coagulation factor VII (FVII) gene by hepatoma cells was modulated in concert with levels of glucose and insulin in the culture medium. In low glucose medium without insulin, amounts of both FVII mRNA and secreted FVII protein were coordinately increased; in the presence of glucose with insulin, both were decreased. Analysis of the FVII promoter showed that these effects could be reproduced in a reporter-gene system, and a small promoter element immediately upstream of the translation start site of the gene, which mediated these effects, was identified. Mutation of this element largely abrogated the glucose/insulin-responsive change in expression of the reporter gene. Several members of the CCAAT/enhancer-binding protein family were found to be capable of binding the identified sequence element but not the mutated element. The expression of a FVII minigene directed by a segment of the native FVII promoter responded to co-expressed activating and inhibiting forms of CCAAT/enhancer-binding protein beta.	Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School	Carew, JA (corresponding author), Vet Affairs Boston Healthcare Syst, 1400 VFW Pkwy,W Roxbury, Boston, MA 02132 USA.	josephine_carew@hms.harvard.edu						Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713; Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; Bach RR, 2006, ARTERIOSCL THROM VAS, V26, P456, DOI 10.1161/01.ATV.0000202656.53964.04; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; Bozzini C, 2004, THROMB HAEMOSTASIS, V92, P541, DOI 10.1160/Th04-02-0130; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; Butenas S, 2004, NAT MED, V10, P1155, DOI 10.1038/nm1104-1155b; Carew JA, 1998, BLOOD, V92, P1639, DOI 10.1182/blood.V92.5.1639.417k10_1639_1645; Carew JA, 2000, BLOOD, V96, P4370; Carew JA, 2003, J THROMB HAEMOST, V1, P2179, DOI 10.1046/j.1538-7836.2003.00424.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Carr ME, 2001, J DIABETES COMPLICAT, V15, P44, DOI 10.1016/S1056-8727(00)00132-X; Chen C, 2005, BIOCHEM J, V391, P649, DOI 10.1042/BJ20050882; Chen VM, 2006, BIOCHEMISTRY-US, V45, P12020, DOI 10.1021/bi061271a; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; De Stavola BL, 2007, J THROMB HAEMOST, V5, P461, DOI 10.1111/j.1538-7836.2007.02330.x; Dietzen DJ, 2004, BLOOD, V103, P3038, DOI 10.1182/blood-2003-07-2399; Doggen CJM, 1998, THROMB HAEMOSTASIS, V80, P281, DOI 10.1055/s-0037-1615188; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FAIR DS, 1983, J LAB CLIN MED, V101, P372; Fernandez J, 2003, J BIOL CHEM, V278, P50000, DOI 10.1074/jbc.M305903200; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Funk M, 2006, CLIN CHEM, V52, P1190, DOI 10.1373/clinchem.2005.059360; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Girelli D, 2000, NEW ENGL J MED, V343, P774, DOI 10.1056/NEJM200009143431104; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; Hunault M, 1999, BLOOD, V93, P1237, DOI 10.1182/blood.V93.4.1237.404k02_1237_1244; Hunault M, 1997, ARTERIOSCL THROM VAS, V17, P2825, DOI 10.1161/01.ATV.17.11.2825; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kavlie A, 2003, THROMB HAEMOSTASIS, V90, P194, DOI 10.1160/TH02-09-0050; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Mackman N, 2005, ARTERIOSCL THROM VAS, V25, P2273, DOI 10.1161/01.ATV.0000183884.06371.52; Marcinkowska E, 2006, EXP CELL RES, V312, P2054, DOI 10.1016/j.yexcr.2006.03.003; McGlynn LK, 1996, MOL CELL BIOL, V16, P1936; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1989, ATHEROSCLEROSIS, V78, P19, DOI 10.1016/0021-9150(89)90154-8; MOHROE DM, 2007, J THROMB HAEMOST, V5, P1097; Moneva MH, 2002, CURR DRUG TARGETS, V3, P203, DOI 10.2174/1389450023347803; Nagaizumi K, 2002, BRIT J HAEMATOL, V119, P1052, DOI 10.1046/j.1365-2141.2002.03933.x; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Persson E, 2006, BIOCHEM BIOPH RES CO, V341, P28, DOI 10.1016/j.bbrc.2005.12.146; Peyvandi F, 2005, J THROMB HAEMOST, V3, P803, DOI 10.1111/j.1538-7836.2005.01232.x; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; REIJNEN MJ, 1994, BLOOD COAGUL FIBRIN, V5, P341; Reiner AP, 2007, J THROMB HAEMOST, V5, P42, DOI 10.1111/j.1538-7836.2006.02279.x; Romisch J, 1999, BLOOD COAGUL FIBRIN, V10, P471; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato H, 2004, BIOCHEM BIOPH RES CO, V325, P109, DOI 10.1016/j.bbrc.2004.10.009; SCHREIBER E, 1989, SOMAT CELL MOLEC GEN, V15, P591, DOI 10.1007/BF01534920; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Stauffer DR, 1998, J BIOL CHEM, V273, P2277, DOI 10.1074/jbc.273.4.2277; TIDD T, 1999, THROMB HAEMOST S, V476, P1476; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; van't Hooft FM, 1999, BLOOD, V93, P3432, DOI 10.1182/blood.V93.10.3432.410k16_3432_3441; Wolberg AS, 1999, BLOOD COAGUL FIBRIN, V10, P201, DOI 10.1097/00001721-199906000-00007; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	77	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31156	31165		10.1074/jbc.M704694200	http://dx.doi.org/10.1074/jbc.M704694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17675296	hybrid			2022-12-25	WOS:000250309200005
J	Sridharan, R; Smale, ST				Sridharan, Rupa; Smale, Stephen T.			Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; CENTROMERIC HETEROCHROMATIN; REMODELING COMPLEXES; TRANSCRIPTION FACTOR; GENE ENCODES; CHROMATIN; FAMILY; REPRESSION; MECHANISM; PURIFICATION	Ikaros is the founding member of a small family of C2H2 zinc-finger DNA-binding proteins that carry out critical functions during lymphocyte development. Although interactions between Ikaros and various proteins have been reported, Ikaros-containing complexes have not been purified to determine their composition and identify the predominant interacting partners. In this study, a tandem affinity purification-mass spectrometry strategy was developed for the isolation of complexes formed by Ikaros and by Helios, a T-cell-restricted member of the Ikaros family that remains largely uncharacterized. This strategy, which appears to be well suited for general use in mammalian cells, relies on an N-terminal polypeptide containing a double FLAG epitope, followed by a tobacco etch virus protease cleavage site and calmodulin binding peptide. In extracts from a murine thymocyte line, Ikaros and Helios associated under moderate stringency conditions only with other members of the Ikaros family. However, under low stringency conditions, both tagged proteins assembled into higher molecular weight complexes. Mass spectrometry revealed that both proteins associated predominantly with subunits of NuRD, an ATP-dependent nucleosome remodeling complex implicated in transcriptional repression and activation and previously reported to associate with Ikaros. Further analysis of the affinity-purified Ikaros revealed that several serines and threonines are phosphorylated in the thymocyte line, with apparent changes upon thymocyte maturation. These results support the hypothesis that the NuRD complex makes major contributions to the functions of both Ikaros and Helios and that the activities of these proteins may be regulated in part by changes in phosphorylation.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Smale, ST (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 6-730 MRL,675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	smale@mednet.ucla.edu			NIDDK NIH HHS [R01 DK43736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gomez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004; GROVES T, 1995, J IMMUNOL, V154, P5011; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Harker N, 2002, MOL CELL, V10, P1403, DOI 10.1016/S1097-2765(02)00711-6; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kellum R, 2003, CURR TOP MICROBIOL, V274, P53; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Koipally J, 2002, J BIOL CHEM, V277, P27697, DOI 10.1074/jbc.M201694200; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Smale ST, 2006, NAT IMMUNOL, V7, P367, DOI 10.1038/ni0406-367; Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Westman BJ, 2003, J BIOL CHEM, V278, P42419, DOI 10.1074/jbc.M306817200; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314	46	88	90	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30227	30238		10.1074/jbc.M702541200	http://dx.doi.org/10.1074/jbc.M702541200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17681952	hybrid			2022-12-25	WOS:000249981200053
J	Chen, ZP; Knutson, E; Wang, S; Martinez, LA; Albrecht, T				Chen, Zhenping; Knutson, Eugene; Wang, Shuo; Martinez, Luis A.; Albrecht, Thomas			Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEINS; DNA-DAMAGE; INFECTED FIBROBLASTS; ONCOPROTEIN MDM2; GENE-EXPRESSION; DEGRADATION; VIRUS; LIGASE; ACTIVATION; PATHWAYS	Human cytomegalovirus (HCMV) induces serum- or density-arrested human lung (LU) cells to traverse the cell cycle, providing it with a strategy to replicate in post-mitotic cells that are its cellular substrate in vivo. HCMV infection also induces high cellular levels of p53, seemingly in contradiction to the observed cell cycle progression. This study was undertaken to examine the mechanism(s) of the increased p53 abundance. HCMV infection caused a 4-fold increase in p53 that preceded a substantial increase in p53 transcripts by more than 24 h. p53 was stabilized in HCMV-infected cells (from a half-life of less than 30 min to about 8 h) and was less sensitive to proteasome-mediated degradation. Ubiquitination of p53 in mock-infected LU cells was sensitive to inhibition by trans-4-iodo, 4'-boranylchalcone, consistent with HDM2-catalyzing ubiquitination of p53. In HCMV-infected cells, ubiquitination of p53 was essentially undetectable. Although HDM2 had a nuclear distribution in mock-infected LU cells, in HCMV-infected cells HDM2 was translocated to the cytoplasm beginning at 12 h and demonstrated decreased cellular abundance thereafter. HDM2 was stabilized in the HCMV-infected cells by MG132, indicating a shift from p53 to HDM2 ubiquitination. p53 demonstrated a predominantly nuclear distribution in HCMV-infected cells through 48 h, resulting in p53 and HDM2 in distinct subcellular compartments. The principal mechanism responsible for increased p53 stabilization was nuclear export and degradation of HDM2. Thus, HCMV uses a shift from p53 to HDM2 ubiquitination and destabilization to obtain protracted high levels of p53, while promoting cell cycle traverse.	Univ Texas, Med Branch, Infect Dis & Toxicol Opt Imaging Ctr, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Otolaryngol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Albrecht, T (corresponding author), Univ Texas, Med Branch, Infect Dis & Toxicol Opt Imaging Ctr, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	talbrech@utmb.edu			NCRR NIH HHS [RR14712] Funding Source: Medline; NIDCR NIH HHS [DE11389] Funding Source: Medline; NIEHS NIH HHS [ES06676, ES10018] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABUBAKAR S, 1990, BIOCHEM BIOPH RES CO, V166, P953, DOI 10.1016/0006-291X(90)90903-Z; ALBRECHT T, 1980, J GEN VIROL, V51, P83, DOI 10.1099/0022-1317-51-1-83; ALBRECHT T, 1980, LAB INVEST, V42, P1; Albrecht T, 1989, Subcell Biochem, V15, P157; ALBRECHT T, 1992, J INVEST DERMATOL, V98, pS29, DOI 10.1111/1523-1747.ep12462169; ALBRECHT T, 1980, AM J CLIN PATHOL, V73, P648, DOI 10.1093/ajcp/73.5.648; BOLDOGH I, 1990, SCIENCE, V247, P561, DOI 10.1126/science.1689075; BOLDOGH I, 1991, ARCH VIROL, V118, P163, DOI 10.1007/BF01314027; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; Bresnahan WA, 1998, J BIOL CHEM, V273, P22075, DOI 10.1074/jbc.273.34.22075; Bresnahan WA, 1997, J GEN VIROL, V78, P1993, DOI 10.1099/0022-1317-78-8-1993; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Castillo JP, 2002, GENE, V290, P19, DOI 10.1016/S0378-1119(02)00566-8; CAVALLO T, 1981, J GEN VIROL, V56, P97, DOI 10.1099/0022-1317-56-1-97; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen ZP, 2001, J VIROL, V75, P3613, DOI 10.1128/JVI.75.8.3613-3625.2001; Chi SW, 2005, J BIOL CHEM, V280, P38795, DOI 10.1074/jbc.M508578200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Collot-Teixeira S, 2004, REV MED VIROL, V14, P301, DOI 10.1002/rmv.431; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Deb SP, 2003, MOL CANCER RES, V1, P1009; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Evers DL, 2004, MICROBES INFECT, V6, P1084, DOI 10.1016/j.micinf.2004.05.026; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gandhi MK, 2004, LANCET INFECT DIS, V4, P725, DOI 10.1016/S1473-3099(04)01202-2; Gaspar M, 2006, P NATL ACAD SCI USA, V103, P2821, DOI 10.1073/pnas.0511148103; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; HORODNICEANU F, 1977, NATURE, V270, P615, DOI 10.1038/270615a0; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; Kumar SK, 2003, J MED CHEM, V46, P2813, DOI 10.1021/jm030213+; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine A J, 1989, Princess Takamatsu Symp, V20, P221; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MUGANDA P, 1994, J VIROL, V68, P8028, DOI 10.1128/JVI.68.12.8028-8034.1994; Muganda P, 1998, CELL MOL BIOL, V44, P321; NOKTA M, 1987, VIROLOGY, V157, P259, DOI 10.1016/0042-6822(87)90268-6; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Rawlinson William, 2003, Aust Fam Physician, V32, P789; RIMSZA LM, 1996, MOL DIAGN, V1, P291; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SAITO Y, 1990, NEUROSCI LETT, V120, P1, DOI 10.1016/0304-3940(90)90153-Z; Shen YH, 2004, CIRC RES, V94, P1310, DOI 10.1161/01.RES.0000129180.13992.43; Song YJ, 2005, J VIROL, V79, P2597, DOI 10.1128/JVI.79.4.2597-2603.2005; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Speir E, 1995, SCAND J INFECT DIS, P78; STANTON GJ, 1977, P SOC EXP BIOL MED, V156, P109; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang J, 2000, FEBS LETT, V474, P213, DOI 10.1016/S0014-5793(00)01604-5; Wang X, 2005, NAT MED, V11, P515, DOI 10.1038/nm1236; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang ZG, 2006, J VIROL, V80, P3833, DOI 10.1128/JVI.80.8.3833-3843.2006; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	75	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29284	29295		10.1074/jbc.M705349200	http://dx.doi.org/10.1074/jbc.M705349200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698841	hybrid			2022-12-25	WOS:000249788000025
J	McEwen, DP; Schumacher, SM; Li, QJ; Benson, MD; Iniguez-Lluhi, JA; Van Genderen, KM; Martens, JR				McEwen, Dyke P.; Schumacher, Sarah M.; Li, Qiuju; Benson, Mark D.; Iniguez-Lluhi, Jorge A.; Van Genderen, Kristin M.; Martens, Jeffrey R.			Rab-GTPase-dependent endocytic recycling of KV1.5 in atrial myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; POTASSIUM CHANNEL; TYROSINE KINASE; EXPRESSION; TRAFFICKING; INTERNALIZATION; DYNACTIN; RECEPTOR; PROTEIN; OVEREXPRESSION	The number of ion channels expressed on the cell surface shapes the complex electrical response of excitable cells. Maintaining a balance between anterograde and retrograde trafficking of channel proteins is vital in regulating steady-state cell surface expression. Kv1.5 is an important voltage-gated K+ channel in the cardiovascular system underlying the ultra-rapid rectifying potassium current (Ik(ur)), a major repolarizing current in atrial myocytes, and regulating the resting membrane potential and excitability of smooth muscle cells. Defects in the expression of Kv1.5 are associated with pathological states such as chronic atrial fibrillation and hypoxic pulmonary hypertension. There is, thus, substantial interest in understanding the mechanisms regulating cell surface channel levels. Here, we investigated the internalization and recycling of Kv1.5 in the HL-1 immortalized mouse atrial myocytes. Kinetic studies indicate that Kv1.5 is rapidly internalized to a perinuclear region where it co-localizes with the early endosomal marker, EEA1. Importantly, we identified that a population of Kv1.5, originating on the cell surface, internalized and recycled back to the plasma membrane. Notably, Kv1.5 recycling processes are driven by specific Rab-dependent endosomal compartments. Thus, co-expression of GDP-locked Rab4S22N and Rab11S25N dominant-negative mutants decreased the steady-state Kv1.5 surface levels, whereas GTPase-deficient Rab4Q67L and Rab11Q70L mutants increased steady-state Kv1.5 surface levels. These data reveal an unexpected dynamic trafficking of Kv1.5 at the myocyte plasma membrane and demonstrate a role for recycling in the maintenance of steady-state ion channel surface levels.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Martens, JR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRBIII,1500 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	martensj@umich.edu		Schumacher, Sarah/0000-0002-4941-7267; Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NHLBI NIH HHS [HL0270973] Funding Source: Medline; NIDDK NIH HHS [R01 DK061656-02, R01 DK061656, R01 DK061656-01, R01 DK061656-04, R01 DK061656-05, R01 DK061656-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; Benson MD, 2007, P NATL ACAD SCI USA, V104, P1805, DOI 10.1073/pnas.0606702104; Brundel BJJM, 2001, J AM COLL CARDIOL, V37, P926, DOI 10.1016/S0735-1097(00)01195-5; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Choi WS, 2005, CIRC RES, V97, P363, DOI 10.1161/01.RES.0000179535.06458.f8; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; Feng JL, 1997, CIRC RES, V80, P572, DOI 10.1161/01.RES.80.4.572; Filipeanu CM, 2006, J BIOL CHEM, V281, P11097, DOI 10.1074/jbc.M511460200; Gong Q, 2007, J BIOL CHEM, V282, P13087, DOI 10.1074/jbc.M700767200; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kato M, 2005, BIOCHEM BIOPH RES CO, V337, P343, DOI 10.1016/j.bbrc.2005.09.053; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Moudgil R, 2006, MICROCIRCULATION, V13, P615, DOI 10.1080/10739680600930222; Neel NF, 2005, CYTOKINE GROWTH F R, V16, P637, DOI 10.1016/j.cytogfr.2005.05.008; Nesti E, 2004, MOL BIOL CELL, V15, P4073, DOI 10.1091/mbc.E03-11-0788; O'Connell KMS, 2005, J CELL SCI, V118, P2155, DOI 10.1242/jcs.02348; Olson TM, 2006, HUM MOL GENET, V15, P2185, DOI 10.1093/hmg/ddl143; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris Rytis, 2003, ScientificWorldJournal, V3, P870; Rolf S, 2000, N-S ARCH PHARMACOL, V362, P22, DOI 10.1007/s002100000257; Saxena SK, 2006, BIOCHEM BIOPH RES CO, V340, P726, DOI 10.1016/j.bbrc.2005.12.036; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seebohm G, 2007, CIRC RES, V100, P686, DOI 10.1161/01.RES.0000260250.83824.8f; Soldati T, 2006, NAT REV MOL CELL BIO, V7, P897, DOI 10.1038/nrm2060; Tanabe Y, 2006, BIOCHEM BIOPH RES CO, V345, P1116, DOI 10.1016/j.bbrc.2006.05.030; Uhlig M, 2005, MOL CELL ENDOCRINOL, V235, P1, DOI 10.1016/j.mce.2005.02.004; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; van der Sluijs P, 2001, METHOD ENZYMOL, V329, P111; VanWagoner DR, 1997, CIRC RES, V80, P772; Wakabayashi Y, 2005, P NATL ACAD SCI USA, V102, P15087, DOI 10.1073/pnas.0503702102; Weir EK, 2005, NEW ENGL J MED, V353, P2042, DOI 10.1056/NEJMra050002; White SM, 2004, AM J PHYSIOL-HEART C, V286, pH823, DOI 10.1152/ajpheart.00986.2003; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Yuan XJ, 1998, AM J PHYSIOL-LUNG C, V274, pL621, DOI 10.1152/ajplung.1998.274.4.L621; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang L, 2007, AM J PHYSIOL-CELL PH, V293, pC152, DOI 10.1152/ajpcell.00480.2006	45	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29612	29620		10.1074/jbc.M704402200	http://dx.doi.org/10.1074/jbc.M704402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17673464	hybrid			2022-12-25	WOS:000249788000058
J	Wielputz, MO; Lee, IH; Dinudom, A; Boulkroun, S; Farman, N; Cook, DI; Korbmacher, C; Rauh, R				Wielpuetz, Mark O.; Lee, Il-Ha; Dinudom, Anuwat; Boulkroun, Sheerazed; Farman, Nicolette; Cook, David I.; Korbmacher, Christoph; Rauh, Robert			(NDRG2) stimulates amiloride-sensitive Na+ currents in Xenopus laevis oocytes and fisher rat thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; RENAL COLLECTING DUCT; INDUCIBLE KINASE SGK; SURFACE EXPRESSION; LIDDLES-SYNDROME; CYSTIC-FIBROSIS; N-MYC; ENAC; ALDOSTERONE; SERUM	Regulation of the epithelial sodium channel (ENaC) is highly complex and may involve several aldosterone-induced regulatory proteins. The N-Myc downstream-regulated gene 2 (NDRG2) has been identified as an early aldosterone-induced gene. Therefore, we hypothesized that NDRG2 may affect ENaC function. To test this hypothesis we measured the amiloride-sensitive (2 mu m) whole cell current (Delta I-ami) in Xenopus laevis oocytes expressing ENaC alone or co-expressing ENaC and NDRG2. Co-expression of NDRG2 significantly increased Delta I-ami in some, but not, all batches of oocytes tested. An inhibitory effect of NDRG2 was never observed. Using a chemiluminescence assay we demonstrated that the NDRG2-induced increase in ENaC currents was accompanied by a similar increase in channel surface expression. The stimulatory effect of NDRG2 was preserved in oocytes maintained in a low sodium bath solution to prevent sodium feedback inhibition. These findings suggest that the stimulatory effect of NDRG2 is independent of sodium feedback regulation. Furthermore, the stimulatory effect of NDRG2 on ENaC was at least in part additive to that of Sgk1. A short isoform of NDRG2 also stimulated Delta I-ami. Overexpression of NDRG2 and ENaC in Fisher rat thyroid cells confirmed the stimulatory effect of NDRG2 on ENaC-mediated short-circuit current (Isc-ami). In addition, small interference RNA against NDRG2 largely reduced ISC-ami in Fisher rat thyroid cells. Our results indicate that NDRG2 is a likely candidate to contribute to aldosterone-mediated ENaC regulation.	Univ Erlangen Nurnberg, Inst Zellular & Mol Physiol, D-91054 Erlangen, Germany; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Coll France, INSERM, U772, F-75231 Paris, France	University of Erlangen Nuremberg; University of Sydney; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Korbmacher, C (corresponding author), Univ Erlangen Nurnberg, Inst Zellular & Mol Physiol, Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de	Boulkroun, Sheerazed/M-4459-2017; Rauh, Robert/F-4129-2014; Wielpuetz, Mark/ABE-1790-2020; Boulkroun, Sheerazed/AAX-8348-2021; Wielpütz, Mark Oliver/ADP-0499-2022	Boulkroun, Sheerazed/0000-0002-8796-7534; Rauh, Robert/0000-0002-9406-3939; Wielpuetz, Mark/0000-0001-6962-037X; Boulkroun, Sheerazed/0000-0002-8796-7534; Wielpütz, Mark Oliver/0000-0001-6962-037X				Boulkroun S, 2005, PFLUG ARCH EUR J PHY, V451, P388, DOI 10.1007/s00424-005-1410-x; Boulkroun S, 2002, J BIOL CHEM, V277, P31506, DOI 10.1074/jbc.M200272200; Burchfield JG, 2004, J BIOL CHEM, V279, P18623, DOI 10.1074/jbc.M401504200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Drummond HA, 2006, AM J PHYSIOL-CELL PH, V290, pC404, DOI 10.1152/ajpcell.00210.2005; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hongo S, 2006, J CELL BIOCHEM, V98, P185, DOI 10.1002/jcb.20763; Hu XL, 2006, CELL TISSUE RES, V325, P67, DOI 10.1007/s00441-005-0137-5; Huang AM, 2000, GENETICS, V156, P1219; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Konstas AA, 2003, PFLUG ARCH EUR J PHY, V445, P513, DOI 10.1007/s00424-002-0957-z; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Kraus C, 2007, CELL PHYSIOL BIOCHEM, V19, P239, DOI 10.1159/000100643; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Rauh R, 2006, PFLUG ARCH EUR J PHY, V452, P290, DOI 10.1007/s00424-005-0026-5; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Verrey F, 2003, CELL PHYSIOL BIOCHEM, V13, P21, DOI 10.1159/000070246; Wagner CA, 2000, J PHYSIOL-LONDON, V526, P35, DOI 10.1111/j.1469-7793.2000.00035.x; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	49	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28264	28273		10.1074/jbc.M702168200	http://dx.doi.org/10.1074/jbc.M702168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652085	hybrid			2022-12-25	WOS:000249455600076
J	Wang, YL; Stieglitz, KA; Bubunenko, M; Court, DL; Stec, B; Roberts, MF				Wang, Yanling; Stieglitz, Kimberly A.; Bubunenko, Mikhail; Court, Donald L.; Stec, Boguslaw; Roberts, Mary F.			The structure of the R184A mutant of the inositol monophosphatase encoded by suhB and implications for its functional interactions in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SENSITIVE GROWTH; GENE-PRODUCT; PROTEIN; MUTATION; DOCKING; RECOMBINATION; REPLACEMENT; SUPPRESSES; BACTERIAL	The Escherichia coli product of the suhB gene, SuhB, is an inositol monophosphatase (IMPase) that is best known as a suppressor of temperature-sensitive growth phenotypes in E. coli. To gain insights into these biological diverse effects, we determined the structure of the SuhB R184A mutant protein. The structure showed a dimer organization similar to other IMPases, but with an altered interface suggesting that the presence of Arg-184 in the wild-type protein could shift the monomer-dimer equilibrium toward monomer. In parallel, a gel shift assay showed that SuhB forms a tight complex with RNA polymerase (RNA pol) that inhibits the IMPase catalytic activity of SuhB. A variety of SuhB mutant proteins designed to stabilize the dimer interface did not show a clear correlation with the ability of a specific mutant protein to complement the Delta suhB mutation when introduced extragenically despite being active IMPases. However, the loss of sensitivity to RNA pol binding, i.e. in G173V, R184I, and L96F/R184I, did correlate strongly with loss of complementation of Delta suhB. Because residue 184 forms the core of the SuhB dimer, it is likely that the interaction with RNA polymerase requires monomeric SuhB. The exposure of specific residues facilitates the interaction of SuhB with RNA pol (or another target with a similar binding surface) and it is this heterodimer formation that is critical to the ability of SuhB to rescue temperature-sensitive phenotypes in E. coli.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; NIH, NCI, Ctr Canc Res, Gene Regulat & Chrosome Biol Lab, Ft Detrick, MD 21702 USA; SAIC Frederick, Basic Res Program, Chestnut Hill, MA 02467 USA; Burnham Inst, Med Res, La Jolla, CA 92037 USA	Boston College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Sanford Burnham Prebys Medical Discovery Institute	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, 2609 Beacon St, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu		Stec, Boguslaw/0000-0002-8696-0349; Stieglitz, Kimberly/0000-0001-6086-3682	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline; NIGMS NIH HHS [GM 64481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064481] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arifuzzaman M, 2006, GENOME RES, V16, P686, DOI 10.1101/gr.4527806; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; Bubunenko M, 2007, J BACTERIOL, V189, P2844, DOI 10.1128/JB.01713-06; CHANG SF, 1991, J BIOL CHEM, V266, P3654; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P4145, DOI 10.1021/bi992424f; Chen LJ, 1999, APPL ENVIRON MICROB, V65, P4559; Court DL, 2002, ANNU REV GENET, V36, P361, DOI 10.1146/annurev.genet.36.061102.093104; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; INADA T, 1995, BIOCHIMIE, V77, P294, DOI 10.1016/0300-9084(96)88139-9; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Johnson KA, 2001, BIOCHEMISTRY-US, V40, P618, DOI 10.1021/bi0016422; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KOZLOFF LM, 1991, J BACTERIOL, V173, P2053, DOI 10.1128/jb.173.6.2053-2060.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MATSUHISA A, 1995, J BACTERIOL, V177, P200, DOI 10.1128/jb.177.1.200-205.1995; Morgan AJ, 2004, J AM CHEM SOC, V126, P15370, DOI 10.1021/ja047360x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Salwinski L, 2003, CURR OPIN STRUC BIOL, V13, P377, DOI 10.1016/S0959-440X(03)00070-8; SHIBA K, 1984, J BACTERIOL, V160, P696, DOI 10.1128/JB.160.2.696-701.1984; Stieglitz KA, 2002, J BIOL CHEM, V277, P22863, DOI 10.1074/jbc.M201042200; THOMASON LC, 2005, CURRENT PROTOCOLS MO; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; YANO R, 1990, J BACTERIOL, V172, P2124, DOI 10.1128/jb.172.4.2124-2130.1990; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	29	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26989	26996		10.1074/jbc.M701210200	http://dx.doi.org/10.1074/jbc.M701210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652087	hybrid			2022-12-25	WOS:000249304900039
J	Schousboe, JT; Wilson, KE; Hangartner, TN				Schousboe, John T.; Wilson, Kevin E.; Hangartner, Thomas N.			Detection of Aortic Calcification during Vertebral Fracture Assessment (VFA) Compared to Digital Radiography	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; COMPUTED-TOMOGRAPHY; RISK-FACTORS; ATHEROSCLEROSIS; OSTEOPOROSIS; ASSOCIATION; DEPOSITS; STROKE; ARTERY	Background. Cardiovascular disease is the most common cause of mortality among post-menopausal women. Our objective was to determine whether or not lateral spine images obtained on a bone densitometer to detect prevalent vertebral fracture can also accurately detect radiographic abdominal aortic calcification (AAC), an important risk factor for cardiovascular disease independent of clinical risk factors. Methodology/Principal Findings. One hundred seventy four postmenopausal women had bone densitometry, lateral spine densitometry imaging (called vertebral fracture assessment, or VFA), and lateral spine digital radiographs. Radiographs and VFA images were scored for AAC using a previously validated 24 point scale and a simplified, new 8 point scale (AAC-8). One hundred fifty six (90%) of the VFA images were evaluable for AAC. The non-parametric intraclass correlation coefficient between VFA and radiographic 24 point and AAC-8 readings, respectively, were 0.80 (95% C.I. 0.68-0.87) and 0.76 (95% C.I. 0.65-0.84). Areas under receiver operating characteristics (ROC) curves for VFA to detect those with a radiographic 24-point AAC score >= 5 were 0.86 (95% C.I. 0.77-0.94) using the 24 point scale and 0.84 (95% C.I. 0.76-0.92) using the AAC-8 scale. Conclusion/Significance. VFA imaging intended to detect prevalent vertebral fracture can also detect radiographic AAC, an important cardiovascular disease risk factor. Since bone densitometry is recommended for all women age 65 and older, VFA imaging at the time of bone densitometry offers an opportunity to assess this risk factor in the post-menopausal female population at very little incremental time and expense.	[Schousboe, John T.] Pk Nicollet Hlth Serv, Minneapolis, MN USA; [Schousboe, John T.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA; [Wilson, Kevin E.] Hologic, Bedford, MA USA; [Hangartner, Thomas N.] Wright State Univ, BioMed Imaging Lab, Dayton, OH 45435 USA; [Hangartner, Thomas N.] Miami Valley Hosp, Dayton, OH USA	University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Wright State University Dayton; Miami Valley Hospital	Schousboe, JT (corresponding author), Pk Nicollet Hlth Serv, Minneapolis, MN USA.	john.schousboe@parknicollet.com	Hangartner, Thomas/AAG-4479-2020		Hologic, Inc	Hologic, Inc	Hologic, Inc., funded this study. Kevin Wilson PhD., of Hologic, contributed to study design and manuscript preparation but had no role in data collection or analysis.	American College of Obstetricians and Gynecologists Women's Health Care Physicians, 2004, Obstet Gynecol, V103, P203; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; Blake GM, 2006, BONE, V38, P935, DOI 10.1016/j.bone.2005.11.007; Brown JP, 2002, CAN MED ASSOC J, V167, pS1; Greenland P, 2003, NEW ENGL J MED, V349, P465, DOI 10.1056/NEJMcp023197; Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891; Greenland P, 2000, CIRCULATION, V101, P723; Greenland P, 2001, CIRCULATION, V104, P1863, DOI 10.1161/hc4201.097189; Hodgson Stephen F, 2003, Endocr Pract, V9, P544; Hollander M, 2003, STROKE, V34, P2367, DOI 10.1161/01.STR.0000091393.32060.0E; Jayalath RW, 2005, EUR J VASC ENDOVASC, V30, P476, DOI 10.1016/j.ejvs.2005.04.030; Kauppila LI, 1997, ATHEROSCLEROSIS, V132, P245, DOI 10.1016/S0021-9150(97)00106-8; Kochanek K.D., 2004, NATL VITAL STAT REP, V52, P1; Kuller Lewis H., 1999, Cardiology Clinics, V17, P51, DOI 10.1016/S0733-8651(05)70056-4; Levitzky YS, 2006, CIRCULATION, V113, pE359; NEAL DJ, 2000, STATA TECHNICAL B RE, V10, P149; *NIH, NIH IM; O'Malley PG, 2003, CIRCULATION, V108, pE169, DOI 10.1161/01.CIR.0000108164.52246.89; Oei HHS, 2002, J AM COLL CARDIOL, V39, P1745, DOI 10.1016/S0735-1097(02)01853-3; Reaven PD, 2005, DIABETOLOGIA, V48, P379, DOI 10.1007/s00125-004-1640-z; Schousboe JT, 2006, J CLIN DENSITOM, V9, P302, DOI 10.1016/j.jocd.2006.05.007; Schousboe JT, 2006, J CLIN DENSITOM, V9, P133, DOI 10.1016/j.jocd.2005.11.004; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tanko LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; van der Meer IM, 2004, CIRCULATION, V109, P1089, DOI 10.1161/01.CIR.0000120708.59903.1B; Vogt TM, 2000, MAYO CLIN PROC, V75, P888, DOI 10.4065/75.9.888; Vokes T, 2006, J CLIN DENSITOM, V9, P37, DOI 10.1016/j.jocd.2006.05.006; Walsh CR, 2002, AM HEART J, V144, P733, DOI 10.1067/mhj.2002.124404; Wenger NK, 2003, PROG CARDIOVASC DIS, V46, P199, DOI 10.1016/j.pcad.2003.08.003; Wilson PWF, 2001, CIRCULATION, V103, P1529, DOI 10.1161/01.cir.103.11.1529	31	55	55	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e715	10.1371/journal.pone.0000715	http://dx.doi.org/10.1371/journal.pone.0000715			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684561	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452400018
J	Chan, KS; Sano, S; Kataoka, K; Abel, E; Carbajal, S; Beltran, L; Clifford, J; Peavey, M; Shen, J; DiGiovanni, J				Chan, K. S.; Sano, S.; Kataoka, K.; Abel, E.; Carbajal, S.; Beltran, L.; Clifford, J.; Peavey, M.; Shen, J.; DiGiovanni, J.			Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis	ONCOGENE			English	Article						stat3; epithelial carcinogenesis; malignant progression; angiogenesis and epithelial mesenchymal transition	GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; ALTERED EXPRESSION; P-CADHERIN; MICE; ONCOGENESIS; METASTASIS; INITIATION; CANCER	Recently, our laboratory demonstrated that Stat3 is required for the de novo development of chemically-induced skin tumors. We have further investigated the role of Stat3 in epithelial carcinogenesis using mice in which the expression of a constitutively active/ dimerized form of Stat3 ( Stat3C) is targeted to the proliferative compartment of epidermis ( referred to as K5.Stat3C transgenic mice). Keratinocytes from K5. Stat3C mice showed increased survival following exposure to 7,12-dimethyl-benz[ a] anthracene ( DMBA) and enhanced proliferation following exposure to 12-O-tetradecanoylphorbol-13-acetate ( TPA). In two-stage chemical carcinogenesis experiments using DMBA as the tumor initiator and TPA as the promoter, K5. Stat3C mice developed skin tumors witha shorter latency and in much greater number compared to non-transgenic littermates. Remarkably, 100% of the skin tumors that developed in K5. Stat3C transgenic mice bypassed the premalignant stage and were initially diagnosed as carcinoma in situ which rapidly progressed to squamous cell carcinoma ( SCC). These tumors were highly vascularized, poorly differentiated and invasive and loss of expression of K10, filaggrin and E-cadherin was observed by 20 weeks. Finally, overexpression of Stat3C in a papilloma cell line led to enhanced cell migration and enhanced invasion through Matrigel in both the absence and presence of growth factors. In addition to its critical role in early stages of epithelial carcinogenesis, the current study reveals a novel role for Stat3 in driving malignant progression of skin tumors in vivo.	[Chan, K. S.; Sano, S.; Kataoka, K.; Abel, E.; Carbajal, S.; Beltran, L.; Peavey, M.; Shen, J.; DiGiovanni, J.] Univ Texas Dallas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; [Clifford, J.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem, Shreveport, LA 71105 USA	University of Texas System; University of Texas Dallas; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	DiGiovanni, J (corresponding author), Univ Texas Dallas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	jdigiova@mdanderson.org	KATAOKA, Ken/B-1607-2011	Abel, Erika/0000-0001-8791-825X	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA05345, CA16672] Funding Source: Medline; NHLBI NIH HHS [R01 HL074352] Funding Source: Medline; NIEHS NIH HHS [ES07784, U01 ES11047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cai SQ, 2005, J DERMATOL, V32, P354, DOI 10.1111/j.1346-8138.2005.tb00906.x; Cano A, 1996, INT J CANCER, V65, P254; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Fuchs E, 1994, Princess Takamatsu Symp, V24, P290; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; MILLER DR, 1987, CANCER RES, V47, P1935; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RUGGERI B, 1992, AM J PATHOL, V140, P1179; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Tang MS, 2000, CANCER RES, V60, P5688; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; YUSPA SH, 1994, CANCER RES, V54, P1178; Zeigler ME, 1996, INVAS METAST, V16, P3	29	85	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1087	1094		10.1038/sj.onc.1210726	http://dx.doi.org/10.1038/sj.onc.1210726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700521				2022-12-25	WOS:000253136700008
J	Williams, C; Edvardsson, K; Lewandowski, SA; Strom, A; Gustafsson, JA				Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Stroem, A.; Gustafsson, J-A			A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; microarray; breast cancer; gene regulation	GENE-EXPRESSION; DOWN-REGULATION; IN-VITRO; ER-BETA; TARGET; PROLIFERATION; INTERLEUKIN-20; TRANSCRIPTION; ANGIOGENESIS; ESTRADIOL	Transcriptional effects of estrogen result from its activation of two estrogen receptor (ER) isoforms; ER alpha that drives proliferation and ER beta that is antiproliferative. Expression of ERb in xenograft tumors from the T47D breast cancer cell line reduces tumor growth and angiogenesis. If ERb can halt tumor growth, its introduction into cancers may be a novel therapeutic approach to the treatment of estrogen-responsive cancers. To assess the complete impact of ER beta on transcription, we have made a full transcriptome analysis of ER alpha- and ER beta-mediated gene regulation in T47D cell line with Tet-Off regulated ERb expression. Of the 35 000 genes and transcripts analysed, 4.1% (1434) were altered by ERa activation. Tet withdrawal and subsequent ER beta expression inhibited the ERa regulation of 998 genes and, in addition, altered expression of 152 non-ER alpha-regulated genes. ER alpha-induced and ER beta-repressed genes were involved in proliferation, steroid/xenobiotic metabolism and ion transport. The ER beta repressive effect was further confirmed by proliferation assays, where ER beta was shown to completely oppose the ER alpha-E2 induced proliferation. Additional analysis of ER beta with a mutated DNA-binding domain revealed that this mutant, at least for a quantity of genes, antagonizes ER alpha even more strongly than ER beta wt. From an examination of the genes regulated by ER alpha and ER beta, we suggest that introduction of ER beta may be an alternative therapeutic approach to the treatment of certain cancers.	[Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Stroem, A.; Gustafsson, J-A] Karolinska Inst, Novum, Dept Biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Williams, C (corresponding author), Karolinska Inst, Novum, Dept Biosci & Nutr, Halsovagen 7-9, S-14157 Huddinge, Sweden.	cecilia.williams@biosci.ki.se	Williams, Cecilia/A-6677-2009; Lewandowski, Sebastian A./K-2492-2019	Williams, Cecilia/0000-0002-0602-2062; Lewandowski, Sebastian A./0000-0002-5935-0211				Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI [10.1093/carcin/bci339, 10.1093/carcin/bgi339]; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chen WY, 2006, ARTERIOSCL THROM VAS, V26, P2090, DOI 10.1161/01.ATV.0000232502.88144.6f; Esslimani-Sahla M, 2005, CLIN CANCER RES, V11, P3170, DOI 10.1158/1078-0432.CCR-04-2298; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gougelet A, 2007, J STEROID BIOCHEM, V104, P110, DOI 10.1016/j.jsbmb.2007.03.002; Gustafsson JA, 2006, CLIMACTERIC, V9, P156, DOI 10.1080/14689360600734328; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hsieh MY, 2006, GENES IMMUN, V7, P234, DOI 10.1038/sj.gene.6364291; Hsu YH, 2006, ARTHRITIS RHEUM-US, V54, P2722, DOI 10.1002/art.22039; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Lo YL, 2005, INT J CANCER, V115, P276, DOI 10.1002/ijc.20855; Marshburn PB, 2004, AM J OBSTET GYNECOL, V191, P626, DOI 10.1016/j.ajog.2004.05.082; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Nikolova Z, 1998, J CELL SCI, V111, P2741; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Poola I, 2001, J STEROID BIOCHEM, V78, P459, DOI 10.1016/S0960-0760(01)00118-2; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Ricci MS, 1999, J BIOL CHEM, V274, P3430, DOI 10.1074/jbc.274.6.3430; Richter K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-75; ROBERTS M, 1988, BIOCHEM BIOPH RES CO, V151, P306, DOI 10.1016/0006-291X(88)90594-3; Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Tomasini R, 2005, ONCOGENE, V24, P8093, DOI 10.1038/sj.onc.1208951; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Wang F, 2006, J INVEST DERMATOL, V126, P1590, DOI 10.1038/sj.jid.5700310; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975	49	182	187	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					1019	1032		10.1038/sj.onc.1210712	http://dx.doi.org/10.1038/sj.onc.1210712			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700529				2022-12-25	WOS:000252946300014
J	Okawa, ER; Gotoh, T; Manne, J; Igarashi, J; Fujita, T; Silverman, KA; Xhao, H; Mosse, YP; White, PS; Brodeur, GM				Okawa, E. R.; Gotoh, T.; Manne, J.; Igarashi, J.; Fujita, T.; Silverman, K. A.; Xhao, H.; Mosse, Y. P.; White, P. S.; Brodeur, G. M.			Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas	ONCOGENE			English	Article						neuroblastoma; 1p36; tumor suppressor gene; gene expression; CHD5; mutation	N-MYC AMPLIFICATION; HOMOZYGOUS DELETION; NERVOUS-SYSTEM; CHROMOSOME 1P; CELL-LINES; REGION; LOCI; IDENTIFICATION; CAMTA1; RIBOSOMAL-PROTEIN-L22	Neuroblastomas are characterized by 1p deletions, suggesting that a tumor suppressor gene (TSG) resides in this region. We have mapped the smallest region of deletion (SRD) to a 2Mb region of 1p36.31 using microsatellite and single nucleotide polymorphisms. We have identified 23 genes in this region, and we have analysed these genes for mutations and RNA expression patterns to identify candidate TSGs. W e sequenced the coding exons of these genes in 30 neuroblastoma cell lines. Although rare mutations were found in 10 of the 23 genes, none showed a pattern of genetic change consistent with homozygous inactivation. We examined the expression of these 23 genes in 20 neuroblastoma cell lines, and most showed readily detectable expression, and no correlation with 1p deletion. How ever, 7 genes showed uniformly low expression in the lines, and 2 genes (CHD5, RNF207) had virtually absent expression, consistent with the expected pattern for a TSG. Our mutation and expression analysis in neuroblastoma cell lines, combined with expression analysis in normal tissues, putative function and prior implication in neuroblastoma pathogenesis, suggests that the most promising TSG deleted from the 1p36 SRD is CHD5, but TNFRSF25, CAMTA1 and AJAP1 are also viable candidates.	[Okawa, E. R.; Gotoh, T.; Manne, J.; Igarashi, J.; Fujita, T.; Silverman, K. A.; Mosse, Y. P.; White, P. S.; Brodeur, G. M.] Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Dept Pediat, Philadelphia, PA 19104 USA; [Xhao, H.] Childrens Hosp Philadelphia, Dept Pediat, Div Biostat & Data Management Core, Philadelphia, PA 19104 USA; [Xhao, H.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 3615 Civic Ctr Blvd,ARC Rm 902D, Philadelphia, PA 19104 USA.	brodeur@email.chop.edu			NCI NIH HHS [R01-CA039771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Brodeur G. M., 2006, PRINCIPLES PRACTICE, P933; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Chen YZ, 2001, GENE CHROMOSOME CANC, V31, P326, DOI 10.1002/gcc.1151; CHENG NC, 1995, ONCOGENE, V10, P291; Eggert A, 2002, EUR J CANCER, V38, P92, DOI 10.1016/S0959-8049(01)00347-1; Elia A, 2004, EUR J BIOCHEM, V271, P1895, DOI 10.1111/j.1432-1033.2004.04099.x; Fok V, 2006, RNA, V12, P872, DOI 10.1261/rna.2339606; GEHRING M, 1995, CANCER RES, V55, P5366; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Henrich KO, 2007, EUR J CANCER, V43, P607, DOI 10.1016/j.ejca.2006.09.023; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Katoh M, 2003, INT J ONCOL, V23, P1219; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; McDonald JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-35; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; OLIPHANT A, 2002, BIOTECHNIQUES S, V56, P60; Rozen S, 2000, Methods Mol Biol, V132, P365; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Steemers FJ, 2006, NAT METHODS, V3, P31, DOI 10.1038/NMETH842; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Thompson PM, 2001, CANCER RES, V61, P679; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102	40	69	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					803	810		10.1038/sj.onc.1210675	http://dx.doi.org/10.1038/sj.onc.1210675			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17667943				2022-12-25	WOS:000252884500009
J	Wang, XD; Hayes, JJ				Wang, Xiaodong; Hayes, Jeffrey J.			Site-specific binding affinities within the H2B tail domain indicate specific effects of lysine acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; NUCLEOSOME CORE PARTICLES; HIGHER-ORDER STRUCTURE; HISTONE ACETYLATION; CHROMATIN FIBER; THERMAL-DENATURATION; MAGNETIC-RESONANCE; DNA INTERACTIONS; GENE-REGULATION; MODEL SYSTEM	Acetylation of specific lysines within the core histone tail domains plays a critical role in regulating chromatin-based activities. However, the structures and interactions of the tail domains and the molecular mechanisms by which acetylation directly alters chromatin structures are not well understood. To address these issues we developed a chemical method to quantitatively determine binding affinities of specific regions within the individual tail domains in model chromatin complexes. Examinations of specific sites within the H2B tail domain indicate that this tail contains distinct structural elements and binds within nucleosomes with affinities that would reduce the activity of tail-binding proteins 10-50-fold from that deduced from peptide binding studies. Moreover, we find that mutations mimicking lysine acetylation do not cause a global weakening of tail-DNA interactions but rather the results suggest that acetylation leads to a much more subtle and specific alteration in tail interactions than has been assumed. In addition, we provide evidence that acetylation at specific sites in the tail is not additive with several events resulting in similar, localized changes in tail binding.			Hayes, JJ (corresponding author), Univ Rochester, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	Jeffrey_Hayes@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Angelov D, 2001, P NATL ACAD SCI USA, V98, P6599, DOI 10.1073/pnas.121171498; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Ballestar E, 1997, BIOCHEMISTRY-US, V36, P5963, DOI 10.1021/bi9626620; Baneres JL, 1997, J MOL BIOL, V273, P503, DOI 10.1006/jmbi.1997.1297; Becker PB, 2006, NATURE, V442, P31, DOI 10.1038/442031a; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Berndsen CE, 2007, BIOCHEMISTRY-US, V46, P2091, DOI 10.1021/bi602366n; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; Bonenfant D, 2006, MOL CELL PROTEOMICS, V5, P541, DOI 10.1074/mcp.M500288-MCP200; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CARY PD, 1978, EUR J BIOCHEM, V89, P475, DOI 10.1111/j.1432-1033.1978.tb12551.x; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gloss LM, 2002, BIOCHEMISTRY-US, V41, P14951, DOI 10.1021/bi026282s; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HILLIARD PR, 1986, J BIOL CHEM, V261, P5992; HONG L, 1993, J BIOL CHEM, V268, P305; Kan PY, 2007, MOL CELL BIOL, V27, P2084, DOI 10.1128/MCB.02181-06; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; Lee KM, 1998, BIOCHEMISTRY-US, V37, P8622, DOI 10.1021/bi980499y; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mangenot S, 2002, BIOPHYS J, V82, P345, DOI 10.1016/S0006-3495(02)75399-X; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; Schalch T, 2005, NATURE, V436, P138, DOI 10.1038/nature03686; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH RM, 1989, J BIOL CHEM, V264, P10574; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; van Holde KE., 1989, SPRINGER SERIES MOL; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WALKER IO, 1984, BIOCHIM BIOPHYS ACTA, V785, P97, DOI 10.1016/0167-4838(84)90132-8; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; Wang XD, 2006, BIOCHEM CELL BIOL, V84, P578, DOI 10.1139/O06-076; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Zheng CY, 2005, J BIOL CHEM, V280, P33552, DOI 10.1074/jbc.M507241200; Zheng CY, 2003, J BIOL CHEM, V278, P24217, DOI 10.1074/jbc.M302817200; Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303	60	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32867	32876		10.1074/jbc.M706035200	http://dx.doi.org/10.1074/jbc.M706035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17711854	hybrid			2022-12-25	WOS:000250625400036
J	Lee, HR; Johnson, KA				Lee, Harold R.; Johnson, Kenneth A.			Fidelity and processivity of reverse transcription by the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC CHARACTERIZATION; STRAND ORIGIN; GAMMA; EXONUCLEASE; MECHANISM; SUBUNIT; HYBRIDS; SITES	We have characterized, by transient-state kinetic methods, the polymerase and exonuclease activities of the human mitochondrialDNApolymerase (pol gamma) during reverse transcription, employing a synthetic oligonucleotide consisting of a DNA primer and an RNA template. In comparison with the kinetic parameters observed with a DNA template, the rate of correct deoxynucleotide incorporation was reduced 25-fold (5.5 +/- 0.2 s(-1)), whereas the dissociation constant ( Kd) for nucleotide binding was increased 4-fold (12 +/- 1 M). In addition, discrimination against mismatches was reduced similar to 20-fold to only 15,000 on average. The proofreading exonuclease favored the removal of an incorrect nucleotide (0.0021 +/- 0.0002 s(-1) for correct versus 0.034 +/- 0.004 s(-1) for incorrect), and the partitioning between incorporation beyond a mismatch (5.5 x 10(-5) +/- 0.4 x 10(-5) s(-1)), and exonuclease removal of that mismatch favors removal of the mismatch. These data suggest that the "reverse transcriptase activity" of mitochondrial polymerase could be physiologically relevant. However, the enzyme stalls and is unable to efficiently incorporate beyond a single nucleotide with an RNA template. Additionally, we present a refined method for calculating net discrimination, which more accurately describes the contributions of correct and incorrect incorporation. The biological and biotechnological significance of these results are discussed.	Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, 2500 Speedway, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 044613] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Gyi JI, 1998, BIOCHEMISTRY-US, V37, P73, DOI 10.1021/bi9719713; ITO K, 1975, J VIROL, V15, P1507, DOI 10.1128/JVI.15.6.1507-1510.1975; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Xu BJ, 1996, EMBO J, V15, P3135, DOI 10.1002/j.1460-2075.1996.tb00676.x; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	25	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					31982	31989		10.1074/jbc.M705392200	http://dx.doi.org/10.1074/jbc.M705392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17711845	hybrid			2022-12-25	WOS:000250480300019
J	Benach, J; Wang, LL; Chen, Y; Ho, CK; Lee, SY; Seetharaman, J; Xiao, R; Acton, TB; Montelione, GT; Deng, HY; Sun, R; Tong, L				Benach, Jordi; Wang, Lili; Chen, Yang; Ho, Chi Kent; Lee, Shaoying; Seetharaman, Jayaraman; Xiao, Rong; Acton, Thomas B.; Montelione, Gaetano T.; Deng, Hongyu; Sun, Ren; Tong, Liang			Structural and functional studies of the abundant tegument protein ORF52 from murine gammaherpesvirus 68	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; PSEUDORABIES VIRUS; VIRAL GENES; HERPESVIRUS; IDENTIFICATION; INFECTION; CLONING; MOUSE; MODEL; CONSTRUCTION	The tegument is a layer of proteins between the nucleocapsid and the envelope of herpesviruses. The functions of most tegument proteins are still poorly understood. In murine gammaherpesvirus 68, ORF52 is an abundant tegument protein of 135 residues that is required for the assembly and release of infectious virus particles. To help understand the molecular basis for the function of this protein, we have determined its crystal structure at 2.1 angstrom resolution. The structure reveals a dimeric association of this protein. Interestingly, an N-terminal alpha-helix that assumes different conformation in the two monomers of the dimer mediates the formation of an asymmetrical tetramer and contains many highly conserved residues. Structural and sequence analyses suggest that this helix is more likely involved in interactions with other components of the tegument or nucleocapsid of the virus and that ORF52 functions as a symmetrical dimer. The asymmetrical tetramer of ORF52 may be a "latent" form of the protein, when it is not involved in virion assembly. The self-association of ORF52 has been confirmed by co-immunoprecipitation and fluorescence resonance energy transfer experiments. Deletion of the N-terminal alpha-helix, as well as mutation of the conserved Arg(95) residue, abolished the function of ORF52. The results of the functional studies are fully consistent with the structural observations and indicate that the N-terminal alpha-helix is a crucial site of interaction for ORF52.	Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA; Chinese Acad Sci, Ctr Infect & Immun, Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China; Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ USA; Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Columbia University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Rutgers State University New Brunswick; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sun, R (corresponding author), Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA.	rsun@mednet.ucla.edu; ltong@columbia.edu	Wang, Lili/AAJ-8511-2020	Wang, Lili/0000-0002-8315-531X; Tong, Liang/0000-0002-0563-6468; Montelione, Gaetano/0000-0002-9440-3059	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074958] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE015752] Funding Source: Medline; NIGMS NIH HHS [U54 GM074958] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton TB, 2005, METHOD ENZYMOL, V394, P210, DOI 10.1016/S0076-6879(05)94008-1; Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Blasdell K, 2003, J GEN VIROL, V84, P111, DOI 10.1099/vir.0.18731-0; Borst EM, 1999, J VIROL, V73, P8320, DOI 10.1128/JVI.73.10.8320-8329.1999; Bortz E, 2003, J VIROL, V77, P13425, DOI 10.1128/JVI.77.24.13425-13432.2003; Bortz E, 2007, J VIROL, V81, P10137, DOI 10.1128/JVI.01233-06; Bresnahan WA, 2000, P NATL ACAD SCI USA, V97, P14506, DOI 10.1073/pnas.97.26.14506; Britt WJ, 2004, HUM IMMUNOL, V65, P395, DOI 10.1016/j.humimm.2004.02.008; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castillo JP, 2002, GENE, V290, P19, DOI 10.1016/S0378-1119(02)00566-8; DeLano W.L., 2002, PYMOL MANUAL; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; Ebrahimi B, 2003, J GEN VIROL, V84, P99, DOI 10.1099/vir.0.18639-0; EFSTATHIOU S, 1990, J GEN VIROL, V71, P1365, DOI 10.1099/0022-1317-71-6-1365; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fuchs W, 2002, J VIROL, V76, P6729, DOI 10.1128/JVI.76.13.6729-6742.2002; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Ishov AM, 2002, J VIROL, V76, P7705, DOI 10.1128/JVI.76.15.7705-7712.2002; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; Johannsen E, 2004, P NATL ACAD SCI USA, V101, P16286, DOI 10.1073/pnas.0407320101; Kattenhorn LM, 2004, J VIROL, V78, P11187, DOI 10.1128/JVI.78.20.11187-11197.2004; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Martinez-Guzman D, 2003, J VIROL, V77, P10488, DOI 10.1128/JVI.77.19.10488-10503.2003; Mettenleiter TC, 2004, VIRUS RES, V106, P167, DOI 10.1016/j.virusres.2004.08.013; Mettenleiter TC, 2002, J VIROL, V76, P1537, DOI 10.1128/JVI.76.4.1537-1547.2002; MISTRIKOVA J, 1985, ACTA VIROL, V29, P312; Nash AA, 1996, SEMIN VIROL, V7, P125, DOI 10.1006/smvy.1996.0016; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Connor CM, 2006, J VIROL, V80, P1574, DOI 10.1128/JVI.80.3.1574-1583.2006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAJCANI J, 1985, ACTA VIROL, V29, P51; ROLZMAN B, 2001, FIELDS VIROLOGY, P2399; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; Smith GA, 1999, J VIROL, V73, P6405, DOI 10.1128/JVI.73.8.6405-6414.1999; Song MJ, 2005, P NATL ACAD SCI USA, V102, P3805, DOI 10.1073/pnas.0404521102; Speck SH, 1999, CURR OPIN MICROBIOL, V2, P403; Subak-Sharpe JH, 1998, VIRUS GENES, V16, P239, DOI 10.1023/A:1008068902673; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Varnum SM, 2004, J VIROL, V78, P10960, DOI 10.1128/JVI.78.20.10960-10966.2004; Weeks CM, 2003, METHOD ENZYMOL, V374, P37, DOI 10.1016/S0076-6879(03)74003-8; Zhu FX, 2002, P NATL ACAD SCI USA, V99, P5573, DOI 10.1073/pnas.082420599	45	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31534	31541		10.1074/jbc.M705637200	http://dx.doi.org/10.1074/jbc.M705637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17699518	hybrid			2022-12-25	WOS:000250309200045
J	Mistry, AC; Mallick, R; Frohlich, O; Klein, JD; Rehm, A; Chen, G; Sands, JM				Mistry, Abinash C.; Mallick, Rickta; Frohlich, Otto; Klein, Janet D.; Rehm, Armin; Chen, Guangping; Sands, Jeff M.			The UT-A1 urea transporter interacts with snapin, a SNARE-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; BINDING PROTEIN; SYNTAXIN; SNAP-25; IDENTIFICATION; SPECIFICITY; COLOCALIZATION; SYNAPTOTAGMIN; AQUAPORIN-2; EXOCYTOSIS	The UT-A1 urea transporter mediates rapid transepithelial urea transport across the inner medullary collecting duct and plays a major role in the urinary concentrating mechanism. To transport urea, UT-A1 must be present in the plasma membrane. The purpose of this study was to screen for UT-A1-interacting proteins and to study the interactions of one of the identified potential binding partners with UT-A1. Using a yeast two-hybrid screen of a human kidney cDNA library with the UT-A1 intracellular loop (residues 409-594) as bait, we identified snapin, a ubiquitously expressed SNARE-associated protein, as a novel UT-A1 binding partner. Deletion analysis indicated that the C-terminal coiled-coil domain (H2) of snapin is required for UT-A1 interaction. Snapin binds to the intracellular loop of UT-A1 but not to the N- or C-terminal fragments. Glutathione S-transferase pulldown experiments and co-immunoprecipitation studies verified that snapin interacts with native UT-A1, SNAP23, and syntaxin-4 (t-SNARE partners), indicating that UT-A1 participates with the SNARE machinery in rat kidney inner medulla. Confocal microscopic analysis of immunofluorescent UT-A1 and snapin showed co-localization in both the cytoplasm and in the plasma membrane. When we co-injected UT-A1 with snapin cRNA in Xenopus oocytes, urea influx was significantly increased. In the absence of snapin, the influx was decreased when UT-A1 was combined with t- SNARE components syntaxin-4 and SNAP23. Weconclude that UT-A1 may be linked to the SNARE machinery via snapin and that this interaction may be functionally and physiologically important for urea transport.	Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Max Delbruck Ctr Mol Med, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Emory University; Emory University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sands, JM (corresponding author), Emory Univ, Sch Med, Dept Med, Div Renal, WMRB Rm 338,1639 Pierce Dr NE, Atlanta, GA 30322 USA.	jsands@emory.edu			NIDDK NIH HHS [R01-DK63657, P01 DK61521, R01 DK41707, R01 DK041707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041707, P01DK061521, R01DK063657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2005, PFLUG ARCH EUR J PHY, V450, P217, DOI 10.1007/s00424-005-1403-9; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chen GP, 2006, J BIOL CHEM, V281, P27436, DOI 10.1074/jbc.M605525200; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chou JL, 2004, J BIOL CHEM, V279, P46271, DOI 10.1074/jbc.M407206200; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Frohlich O, 2004, AM J PHYSIOL-CELL PH, V286, pC1264, DOI 10.1152/ajpcell.00499.2003; Hunt RA, 2003, BIOCHEM BIOPH RES CO, V303, P594, DOI 10.1016/S0006-291X(03)00400-5; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue T, 1998, AM J PHYSIOL-RENAL, V275, pF752, DOI 10.1152/ajprenal.1998.275.5.F752; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Klein JD, 2006, J AM SOC NEPHROL, V17, P2680, DOI 10.1681/ASN.2006030246; Klein JD, 1997, AM J PHYSIOL-RENAL, V273, pF949, DOI 10.1152/ajprenal.1997.273.6.F949; Mandon B, 1997, AM J PHYSIOL-RENAL, V273, pF718, DOI 10.1152/ajprenal.1997.273.5.F718; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mistry AC, 2005, AM J PHYSIOL-RENAL, V288, pF455, DOI 10.1152/ajprenal.00296.2004; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Ruder C, 2005, MOL BIOL CELL, V16, P1245, DOI 10.1091/mbc.E04-09-0817; Sands JM, 2004, CURR OPIN NEPHROL HY, V13, P525, DOI 10.1097/00041552-200409000-00008; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; Starcevic M, 2004, J BIOL CHEM, V279, P28393, DOI 10.1074/jbc.M402513200; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	37	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30097	30106		10.1074/jbc.M705866200	http://dx.doi.org/10.1074/jbc.M705866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702749	hybrid			2022-12-25	WOS:000249981200040
J	Hasdemir, B; Bunnett, NW; Cottrell, GS				Hasdemir, Burcu; Bunnett, Nigel W.; Cottrell, Graeme S.			Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) mediates post-endocytic trafficking of protease-activated receptor 2 and calcitonin receptor-like receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; ACTIVITY-MODIFYING PROTEIN-1; COUPLED RECEPTOR; DOWN-REGULATION; EARLY ENDOSOMES; MOLECULAR-CLONING; UBIQUITIN; RESENSITIZATION; CLATHRIN; LYSOSOMES	The E3 ligase c-Cbl ubiquitinates protease-activated receptor 2 (PAR(2)), which is required for post-endocytic sorting of PAR(2) to lysosomes, where degradation arrests signaling. The mechanisms of post-endocytic sorting of ubiquitinated receptors are incompletely understood. Here, we investigated the role of hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), in post-endocytic sorting and signaling of PAR(2). In HEK-PAR(2) cells, PAR(2) activating peptide (PAR(2)-AP) induced PAR(2) trafficking from the cell surface to early endosomes containing endogenous HRS, and then to lysosomes. HRS overexpression or knockdown with small interfering RNA caused formation of enlarged HRS-positive endosomes, where activated PAR(2) and c-Cbl accumulated, and PAR(2) failed to traffic to lysosomes. Overexpression of HRS prevented PAR(2)-AP-induced degradation of PAR(2), as determined by Western blotting. Overexpression of HRS mutant lacking an ubiquitin-binding motif similarly caused retention of PAR(2) in enlarged endosomes. Moreover, HRS overexpression or knockdown caused retention of ubiquitin-resistant PAR(2)Delta 14K/R in enlarged HRS-containing endosomes, preventing recycling and resensitization of PAR(2)Delta 14K/R. HRS overexpression or knockdown similarly prevented lysosomal trafficking and recycling of calcitonin receptor-like receptor, a non-ubiquitinated receptor that traffics to lysosomes after sustained activation and recycles after transient activation. Thus, HRS plays a critically important role in the post-endocytic sorting of single receptors, PAR(2) and CLR, to both degradative and recycling pathways. This sorting role for HRS is independent of its ubiquitin-interacting motif, and it can regulate trafficking of both ubiquitinated and non-ubiquitinated PAR(2) and non-ubiquitinated CLR. The ultimate sorting decision to degradative or recycling pathways appears to occur downstream from HRS.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), 513 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu		Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057840, R37DK039957, R56DK043207, R01DK043207, R01DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57840, DK39957, DK43207] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; Clague MJ, 2002, CURR BIOL, V12, pR529, DOI 10.1016/S0960-9822(02)01030-8; Cottrell GS, 2007, J BIOL CHEM, V282, P12260, DOI 10.1074/jbc.M606338200; Cottrell GS, 2005, J COMP NEUROL, V490, P239, DOI 10.1002/cne.20669; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Hanyaloglu AC, 2005, EMBO J, V24, P2265, DOI 10.1038/sj.emboj.7600688; Hanyaloglu AC, 2007, J BIOL CHEM, V282, P3095, DOI 10.1074/jbc.M605398200; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; Lavezzari G, 2007, NEUROPHARMACOLOGY, V52, P100, DOI 10.1016/j.neuropharm.2006.07.011; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Morino C, 2004, EXP CELL RES, V297, P380, DOI 10.1016/j.yexcr.2004.03.038; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, J CELL SCI, V114, P2255; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Scaife RM, 2000, J CELL SCI, V113, P215; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stern KA, 2007, MOL CELL BIOL, V27, P888, DOI 10.1128/MCB.02356-05; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Urbe S, 2005, ESSAYS BIOCHEM, V41, P81, DOI 10.1042/EB0410081; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200	44	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29646	29657		10.1074/jbc.M702974200	http://dx.doi.org/10.1074/jbc.M702974200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675298	hybrid			2022-12-25	WOS:000249788000061
J	Pau, VPT; Zhu, YF; Yuchi, ZG; Hoang, QQ; Yang, DSC				Pau, Victor P. T.; Zhu, Yongfang; Yuchi, Zhiguang; Hoang, Quyen Q.; Yang, Daniel S. C.			Characterization of the C-terminal domain of a potassium channel from Streptomyces lividans (KcsA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; ACTIVATION; RECONSTITUTION; REARRANGEMENTS; PURIFICATION; SELECTIVITY; STABILITY	KcsA, a potassium channel from Streptomyces lividans, is a good model for probing the general working mechanism of potassium channels. To date, the physiological activator of KcsA is still unknown, but in vitro studies showed that it could be opened by lowering the pH of the cytoplasmic compartment to 4. The C-terminal domain (CTD, residues 112-160) was proposed to be the modulator for this pH-responsive event. Here, we support this proposal by examining the pH profiles of: (a) thermal stability of KcsA with and without its CTD and (b) aggregation properties of a recombinant fragment of CTD. We found that the presence of the CTD weakened and enhanced the stability of KcsA at acidic and basic pH values, respectively. In addition, the CTD fragment oligomerized at basic pH values with a transition profile close to that of channel opening. Our results are consistent with the CTD being a pH modulator. We propose herein a mechanism on how this domain may contribute to the pH-dependent opening of KcsA.	McMaster Univ, Fac Hlth Sci, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; Brandeis Univ, Rosenstiel Basic Med Res Ctr, Waltham, MA 02454 USA	McMaster University; Brandeis University	Yang, DSC (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Biochem & Biomed Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	yang@mcmaster.ca	Yuchi, Zhiguang/N-5184-2016	Yuchi, Zhiguang/0000-0003-2595-9106; Pau, Victor/0000-0002-3093-2330				Clapham DE, 1998, NAT STRUCT BIOL, V5, P342, DOI 10.1038/nsb0598-342; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B, 2001, ION CHANNELS EXCITAB, P1; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; Iwamoto M, 2006, J BIOL CHEM, V281, P28379, DOI 10.1074/jbc.M602018200; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Li J, 2002, P NATL ACAD SCI USA, V99, P11605, DOI 10.1073/pnas.192439299; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; NORDENMAN B, 1977, THROMB RES, V11, P799, DOI 10.1016/0049-3848(77)90108-6; Noskov SY, 2006, BIOPHYS CHEM, V124, P279, DOI 10.1016/j.bpc.2006.05.033; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Ruta V, 2004, BIOCHEMISTRY-US, V43, P10071, DOI 10.1021/bi049463y; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Takeuchi K, 2007, J BIOL CHEM, V282, P15179, DOI 10.1074/jbc.M608264200; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	25	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29163	29169		10.1074/jbc.M703277200	http://dx.doi.org/10.1074/jbc.M703277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693406	hybrid			2022-12-25	WOS:000249788000011
J	Saska, I; Gillon, AD; Hatsugai, N; Dietzgen, RG; Hara-Nishimura, I; Anderson, MA; Craik, DJ				Saska, Ivana; Gillon, Amanda D.; Hatsugai, Noriyuki; Dietzgen, Ralf G.; Hara-Nishimura, Ikuko; Anderson, Marilyn A.; Craik, David J.			An asparaginyl endopeptidase mediates in vivo protein backbone cyclization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOTIDE KALATA B1; CIRCULAR PROTEINS; CYSTINE KNOT; MACROCYCLIC PEPTIDES; OLDENLANDIA-AFFINIS; FOLDING PATHWAYS; CONCANAVALIN-A; CELL-DEATH; PLANTS; BIOSYNTHESIS	Proteases can catalyze both peptide bond cleavage and formation, yet the hydrolysis reaction dominates in nature. This presents an interesting challenge for the biosynthesis of backbone cyclized (circular) proteins, which are encoded as part of precursor proteins and require post-translational peptide bond formation to reach their mature form. The largest family of circular proteins are the plant-produced cyclotides; extremely stable proteins with applications as bioengineering scaffolds. Little is known about the mechanism by which they are cyclized in vivo but a highly conserved Asn (occasionally Asp) residue at the C terminus of the cyclotide domain suggests that an enzyme with specificity for Asn (asparaginyl endopeptidase; AEP) is involved in the process. Nicotiana benthamiana does not endogenously produce circular proteins but when cDNA encoding the precursor of the cyclotide kalata B1 was transiently expressed in the plants they produced the cyclotide, together with linear forms not commonly observed in cyclotide-containing plants. Observation of these species over time showed that in vivo asparaginyl bond hydrolysis is necessary for cyclization. When AEP activity was suppressed, either by decreasing AEP gene expression or using a specific inhibitor, the amount of cyclic cyclotide in the plants was reduced compared with controls and was accompanied by the accumulation of extended linear species. These results suggest that an AEP is responsible for catalyzing both peptide bond cleavage and ligation of cyclotides in a single processing event.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; Univ Queensland, Queensland Dept Primary Ind & Fisheries, Brisbane, Qld 4072, Australia	University of Queensland; La Trobe University; Kyoto University; Queensland Department of Agriculture & Fisheries; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Anderson, Marilyn A/A-4259-2012; Craik, David/B-1695-2010; Hatsugai, Noriyuki/O-9156-2015; Dietzgen, Ralf Georg/A-5565-2010	Anderson, Marilyn A/0000-0002-8257-5128; Craik, David/0000-0003-0007-6796; Hatsugai, Noriyuki/0000-0002-5708-4263; Dietzgen, Ralf Georg/0000-0002-7772-2250				BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Basse CW, 2005, PLANT PHYSIOL, V138, P1774, DOI 10.1104/pp.105.061200; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CHAPMAN S, 1992, PLANT J, V2, P549; Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102; Cobos ES, 2002, BBA-PROTEINS PROTEOM, V1598, P98, DOI 10.1016/S0167-4838(02)00341-2; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q; Craik DJ, 2006, CURR OPIN DRUG DISC, V9, P251; Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Goodin MM, 2002, PLANT J, V31, P375, DOI 10.1046/j.1365-313X.2002.01360.x; Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719; GRAN L, 1973, LLOYDIA, V36, P174; Gran L., 1970, MEDDELELSER NORSK FA, V12, P173; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; HARLOW E, 1999, USING ANTIBODIES LAB, P267; Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Jung R, 1998, PLANT CELL, V10, P343, DOI 10.1105/tpc.10.3.343; Kimura RH, 2006, ANGEW CHEM INT EDIT, V45, P973, DOI 10.1002/anie.200503882; Kuroyanagi M, 2005, J BIOL CHEM, V280, P32914, DOI 10.1074/jbc.M504476200; Lindholm P, 2002, MOL CANCER THER, V1, P365; Mulvenna JP, 2006, PLANT CELL, V18, P2134, DOI 10.1105/tpc.106.042812; Muntz K, 2002, J PLANT PHYSIOL, V159, P1281, DOI 10.1078/0176-1617-00853; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678; Tam JP, 2000, EUR J BIOCHEM, V267, P3289, DOI 10.1046/j.1432-1327.2000.01359.x; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Warren EH, 2006, SCIENCE, V313, P1444, DOI 10.1126/science.1130660; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	42	180	194	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29721	29728		10.1074/jbc.M705185200	http://dx.doi.org/10.1074/jbc.M705185200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698845	hybrid, Green Accepted			2022-12-25	WOS:000249788000068
J	Tsukumo, Y; Tomida, A; Kitahara, O; Nakamura, Y; Asada, S; Mori, K; Tsuruo, T				Tsukumo, Yoshinori; Tomida, Akihiro; Kitahara, Osamu; Nakamura, Yusuke; Asada, Shinichi; Mori, Kazutoshi; Tsuruo, Takashi			Nucleobindin 1 controls the unfolded protein response by inhibiting ATF6 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR ATF6; ER STRESS; BINDING-PROTEIN; MESSENGER-RNA; NF-Y; ELEMENT; GOLGI; CLEAVAGE; CALNUC	In response to endoplasmic reticulum (ER) stress, activating transcription factor 6 (ATF6), an ER membrane-anchored transcription factor, is transported to the Golgi apparatus and cleaved by site-1 protease (S1P) to activate the unfolded protein response (UPR). Here, we identified nucleobindin 1 (NUCB1) as a novel repressor of the S1P-mediated ATF6 activation. NUCB1 is an ER stress-inducible gene with the promoter region having functional cis-elements for transcriptional activation by ATF6. Overexpression of NUCB1 inhibits S1P-mediated ATF6 cleavage without affecting ER-to-Golgi transport of ATF6, whereas knock-down of NUCB1 by siRNA accelerates ATF6 cleavage during ER stress. NUCB1 protein localizes in the Golgi apparatus, and disruption of the Golgi localization results in loss of the ATF6-inhibitiory activity. Consistent with these observations, NUCB1 can suppress physical interaction of S1P-ATF6 during ER stress. Together, our results demonstrate that NUCB1 is the first-identified, Golgi-localized negative feedback regulator in the ATF6-mediated branch of the UPR.	Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan; Univ Tokyo, Inst Mol & Cellular BIosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan	Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo; Kyoto University	Tomida, A (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan.	akihiro.tomida@jfcr.or.jp	Mori, Kazutoshi/K-6106-2015					Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; KANAI Y, 1992, IMMUNOL LETT, V32, P43; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213; Lavoie C, 2002, MOL ENDOCRINOL, V16, P2462, DOI 10.1210/me.2002-0079; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; Miura K, 1996, GENOMICS, V34, P181, DOI 10.1006/geno.1996.0263; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Park HR, 2004, JNCI-J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243; Petersson U, 2004, BONE, V34, P949, DOI 10.1016/j.bone.2004.01.019; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; WENDEL M, 1995, J BIOL CHEM, V270, P6125, DOI 10.1074/jbc.270.11.6125; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040	35	58	58	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29264	29272		10.1074/jbc.M705038200	http://dx.doi.org/10.1074/jbc.M705038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686766	hybrid			2022-12-25	WOS:000249788000023
J	Varnai, P; Toth, B; Toth, DJ; Hunyady, L; Balla, T				Varnai, Peter; Toth, Balazs; Toth, Daniel J.; Hunyady, Laszlo; Balla, Tamas			Visualization and manipulation of plasma membrane-endoplasmic reticulum contact sites indicates the presence of additional molecular components within the STIM1-Orai1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL INTERACTION MOLECULE-1; CA2+ STORE DEPLETION; CHANNEL FUNCTION; CRAC CHANNEL; CALCIUM-ENTRY; ORAI PROTEINS; STIM1; SENSOR; IDENTIFICATION; TRANSLOCATION	STIM1, a recently identified endoplasmic reticulum (ER) protein, rapidly translocates to a plasma membrane-adjacent ER compartment upon depletion of the ER Ca2+ stores. Here we use a novel means, namely a chemically inducible bridge formation between the plasma and ER membranes, to highlight the plasma membrane-adjacent ER compartment and show that this is the site where STIM1 and its Ca2+ channel partner, Orai1, form a productive interaction upon store depletion. By changing the length of the linkers connecting the plasma and ER membranes, we show that Orai1 requires a larger space than STIM1 between the two membranes. This finding suggests that Orai1 is part of a larger macromolecular cluster with an estimated 11-14-nm protrusion to the cytoplasm, whereas the cytoplasmic domain of STIM1 fits in a space calculated to be less than 6 nm. We finally show that agonist-induced translocation of STIM1 is rapidly reversible and only partially affects STIM1 in the juxtanuclear ER compartment. These studies are the first to detect juxtaposed areas between the ER and the plasma membrane in live cells, revealing novel details of STIM1-Orai1 interactions.	NIH, Sect Mol Signal Transduct, NICHD, Bethesda, MD 20892 USA; Semmelweis Univ, Sch Med, Dept Physiol, H-1086 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Semmelweis University	Balla, T (corresponding author), NIH, Sect Mol Signal Transduct, NICHD, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.	ballat@mail.nih.gov	Toth, Balazs/B-4252-2012; Tóth, Dániel/M-7105-2019	Tóth, Dániel/0000-0001-6670-3348; Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Hauser CT, 2007, P NATL ACAD SCI USA, V104, P3693, DOI 10.1073/pnas.0611713104; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Inoue T, 2005, NAT METHODS, V2, P415, DOI 10.1038/NMETH763; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Mignen O, 2007, J PHYSIOL-LONDON, V579, P703, DOI 10.1113/jphysiol.2006.122432; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; ONG HL, 2007, J BIOL CHEM; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, BBA-MOL CELL RES, V1763, P1161, DOI 10.1016/j.bbamcr.2006.09.023; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Varnai P, 2006, J CELL BIOL, V175, P377, DOI 10.1083/jcb.200607116; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wedel B, 2007, J PHYSIOL-LONDON, V579, P679, DOI 10.1113/jphysiol.2006.125641; Williams RT, 2002, BBA-PROTEIN STRUCT M, V1596, P131, DOI 10.1016/S0167-4838(02)00211-X; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	33	197	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29678	29690		10.1074/jbc.M704339200	http://dx.doi.org/10.1074/jbc.M704339200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684017	hybrid			2022-12-25	WOS:000249788000064
J	Arce, JDC; Gockel-Krzikalla, E; Rosl, F				Arce, Johanna De-Castro; Goeckel-Krzikalla, Elke; Roesl, Frank			Retinoic acid receptor beta silences human papillomavirus-18 oncogene expression by induction of de Novo methylation and heterochromatinization of the viral control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; CPG-BINDING PROTEINS; DNA METHYLATION; CANCER-CELLS; TRANSCRIPTIONAL CONTROL; AP-1 TRANSCRIPTION; GROWTH-INHIBITION; TYPE-16 DNA; GENE; CHROMATIN	Retinoic acid receptor beta 2 ( RAR beta 2) is often down-regulated during the multistep process to cervical cancer. In that way, its inhibitory function on the transcription factor AP-1, indispensable to maintain human papillomavirus (HPV) gene expression is relieved. Using HPV-18 positive HeLa cells as a model system, we show that ectopic expression of RAR beta 2 is able to down-regulate HPV-18 transcription by selectively abrogating the binding of AP-1 to the viral regulatory region in a ligand-independent manner. This resulted in down-regulation of the viral mRNAs at the level of initiation of transcription. Decreased oncogene expression was accompanied by a re-induction of cell cycle inhibitory proteins such as p53, p21(CIP1), and p27(KIP) as well as by a cessation of cellular growth. Reduced transcriptional activity as a consequence of AP-1 reduction by selective c-Jun degradation apparently targets the HPV-18 regulatory region for epigenetic modification such as de novo methylation and nucleosomal condensation. This mechanism is otherwise counterbalanced by active and abundant viral transcription in malignant cells, because RAR beta 2 itself becomes inactivated during cervical carcinogenesis. Hence, our study shows that the temporal co-existence of a potential repressor and viral oncoproteins is mutually exclusive and provides evidence of a cross-talk between nuclear receptor, AP-1, and the epigenetic machinery.	Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@dkfz.de						Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Badal S, 2004, VIROLOGY, V324, P483, DOI 10.1016/j.virol.2004.04.002; Badal V, 2003, J VIROL, V77, P6227, DOI 10.1128/JVI.77.11.6227-6234.2003; Berger J, 2002, J STEROID BIOCHEM, V80, P1, DOI 10.1016/S0960-0760(01)00179-0; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; BERNARD HU, 1994, ARCH DERMATOL, V130, P210, DOI 10.1001/archderm.130.2.210; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Brero A, 2005, J CELL BIOL, V169, P733, DOI 10.1083/jcb.200502062; BRUGERS WA, 2006, ONCOGENE, V26, P1650; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Carbone Michele, 2004, Cancer Res, V64, P5518, DOI 10.1158/0008-5472.CAN-04-0255; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; DECASTRO AJ, 2004, J BIOL CHEM, V279, P45408; Dedieu S, 2006, CELL SIGNAL, V18, P889, DOI 10.1016/j.cellsig.2005.08.001; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Geisen C, 1997, CANCER RES, V57, P1460; Geisen C, 2000, INT J CANCER, V85, P289, DOI 10.1002/(SICI)1097-0215(20000115)85:2<289::AID-IJC22>3.0.CO;2-T; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; Han L, 2001, MOL CELL BIOL, V21, P3416, DOI 10.1128/MCB.21.10.3416-3424.2001; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Kalantari M, 2004, J VIROL, V78, P12762, DOI 10.1128/JVI.78.23.12762-12772.2004; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim K, 2003, J VIROL, V77, P12450, DOI 10.1128/JVI.77.23.12450-12459.2003; Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin F, 2000, CANCER RES, V60, P3271; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; MINCHEVA A, 1987, MED MICROBIOL IMMUN, V176, P245, DOI 10.1007/bf00190531; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; NAFZ J, 1988, BIOCHEM J, V403, P4780; Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; O'Neill LP, 2003, METHODS, V31, P76, DOI 10.1016/S1046-2023(03)00090-2; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; Pavan B, 2006, CURR MED CHEM, V13, P3553, DOI 10.2174/092986706779026183; Pietrobono R, 2002, NUCLEIC ACIDS RES, V30, P3278, DOI 10.1093/nar/gkf434; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; ROSL F, 1993, J GEN VIROL, V74, P791, DOI 10.1099/0022-1317-74-5-791; Rosl F, 1997, J VIROL, V71, P362; Sandoval J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh091; Sato N, 2006, BIOCHEM BIOPH RES CO, V344, P845, DOI 10.1016/j.bbrc.2006.04.007; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Suzukawa K, 2002, ONCOGENE, V21, P2181, DOI 10.1038/sj.onc.1205281; Thain A, 1996, J VIROL, V70, P7233, DOI 10.1128/JVI.70.10.7233-7235.1996; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; Van Tine BA, 2004, J VIROL, V78, P11172, DOI 10.1128/JVI.78.20.11172-11186.2004; Wade PA, 2005, NAT GENET, V37, P212, DOI 10.1038/ng0305-212; Zhang Z, 2006, ONCOGENE, V25, P5436, DOI 10.1038/sj.onc.1209530; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	74	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28520	28529		10.1074/jbc.M702870200	http://dx.doi.org/10.1074/jbc.M702870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686773	hybrid			2022-12-25	WOS:000249642100026
J	Das, S; Chattopadhyay, R; Bhakat, KK; Boldogh, I; Kohno, K; Prasad, R; Wilson, SH; Hazra, TK				Das, Soumita; Chattopadhyay, Ranajoy; Bhakat, Kishor K.; Boldogh, Istvan; Kohno, Kimitoshi; Prasad, Rajendra; Wilson, Samuel H.; Hazra, Tapas K.			Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; TRANSCRIPTION FACTOR YB-1; HUMAN DNA GLYCOSYLASES; CELL NUCLEAR ANTIGEN; Y-BOX; ULTRAVIOLET-LIGHT; ENDONUCLEASE-VIII; MAMMALIAN-CELLS; MESSENGER-RNA; UVA RADIATION	The recently characterized enzyme NEIL2 (Nei-like-2), one of the four oxidized base-specific DNA glycosylases (OGG1, NTH1, NEIL1, and NEIL2) in mammalian cells, has poor base excision activity from duplex DNA. To test the possibility that one or more proteins modulate its activity in vivo, we performed mass spectrometric analysis of the NEIL2 immunocomplex and identified Y box-binding (YB-1) protein as a stably interacting partner of NEIL2. We show here that YB-1 not only interacts physically with NEIL2, but it also cooperates functionally by stimulating its base excision activity by 7-fold. Moreover, YB-1 interacts with the other NEIL2-associated BER proteins, namely, DNA ligase III alpha and DNA polymerase beta and thus could form a large multiprotein complex. YB-1, normally present in the cytoplasm, translocates to the nucleus during UVA-induced oxidative stress, concomitant with its increased association with and activation of NEIL2. NEIL2-initiated base excision activity is significantly reduced in YB-1-depleted cells. YB-1 thus appears to have a novel regulatory role in NEIL2-mediated repair under oxidative stress.	Univ Texas, Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Occupational & Environmental Health - Japan	Hazra, TK (corresponding author), 6-136 Med Res Bldg,Route 1079, Galveston, TX 77555 USA.	tkhazra@utmb.edu	Wilson, Samuel H/E-6644-2019; Bhakat, Kishor/C-8072-2012	Wilson, Samuel H/0000-0002-1702-5293; 	NATIONAL CANCER INSTITUTE [R01CA102271, R01CA081063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, Z01ES050158, Z01ES050159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021830] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES050159-11, Z01 ES050158-11] Funding Source: Medline; NCI NIH HHS [CA102271, CA81063, R01 CA081063, R01 CA102271] Funding Source: Medline; NIA NIH HHS [P01 AG021830] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, P01 ES06676] Funding Source: Medline; PHS HHS [E508457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bhakat KK, 2006, MOL CELL BIOL, V26, P1654, DOI 10.1128/MCB.26.5.1654-1665.2006; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Campalans A, 2007, J CELL SCI, V120, P23, DOI 10.1242/jcs.03312; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; Das A, 2006, DNA REPAIR, V5, P1439, DOI 10.1016/j.dnarep.2006.07.003; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hayakawa H, 2002, BIOCHEMISTRY-US, V41, P12739, DOI 10.1021/bi0201872; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Ise T, 1999, CANCER RES, V59, P342; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kappes UP, 2005, RADIAT RES, V164, P440, DOI 10.1667/RR3434.1; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kozmin S, 2005, P NATL ACAD SCI USA, V102, P13538, DOI 10.1073/pnas.0504497102; Kvam E, 1999, J INVEST DERMATOL, V113, P209, DOI 10.1046/j.1523-1747.1999.00653.x; LOWE NJ, 1995, J INVEST DERMATOL, V105, P739, DOI 10.1111/1523-1747.ep12325517; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Mitra S, 1997, MOL CELLS, V7, P305; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ogawa Y, 2003, INT J MOL MED, V11, P149; Ohga T, 1996, CANCER RES, V56, P4224; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; Petersen AB, 2000, J PHOTOCH PHOTOBIO B, V59, P123, DOI 10.1016/S1011-1344(00)00149-4; Pouget JP, 2000, CHEM RES TOXICOL, V13, P541, DOI 10.1021/tx000020e; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	56	105	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28474	28484		10.1074/jbc.M704672200	http://dx.doi.org/10.1074/jbc.M704672200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686777	hybrid, Green Accepted			2022-12-25	WOS:000249642100021
J	Pertusa, M; Morenilla-Palao, C; Carteron, C; Viana, F; Cabedo, H				Pertusa, Maria; Morenilla-Palao, Cruz; Carteron, Christelle; Viana, Felix; Cabedo, Hugo			Transcriptional control of cholesterol biosynthesis in Schwann cells by axonal neuregulin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; NEURON-DERIVED FACTOR; NERVOUS-SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; MEVALONATE PATHWAY; STRIATAL NEURONS; PLASMA-MEMBRANE; REDUCTASE; EXPRESSION; GROWTH	A characteristic feature of many vertebrate axons is their wrapping by a lamellar stack of glially derived membranes known as the myelin sheath. Myelin is a cholesterol-rich membrane that allows for rapid saltatory nerve impulse conduction. Axonal neuregulins instruct glial cells on when and how much myelin they should produce. However, how neuregulin regulates myelin sheath development and thickness is unknown. Here we show that neuregulin receptors are activated by drops in plasma membrane cholesterol, suggesting that they can sense sterol levels. In Schwann cells neuregulin-1 increases the transcription of the 3-hydroxy-3-methylglutarylcoenzyme A reductase, the rate-limiting enzyme for cholesterol biosynthesis. Neuregulin activity is mediated by the phosphatidylinositol 3-kinase pathway and a cAMP-response element located on the reductase promoter. We propose that by activating neuregulin receptors, neurons exploit a cholesterol homeostatic mechanism forcing Schwann cells to produce new membranes for the myelin sheath. We also show that a strong phylogenetic correlation exists between myelination and cholesterol biosynthesis, and we propose that the absence of the sterol branch of the mevalonate pathway in invertebrates precluded the myelination of their nervous system.	UMH CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain; Hosp St Joan Alacant, Unidad Invest, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Cabedo, H (corresponding author), UMH CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain.	hugo.cabedo@umh.es	Viana, Felix/U-8533-2017; Cabedo, Hugo/F-9404-2016	Viana, Felix/0000-0003-1439-949X; Cabedo, Hugo/0000-0002-1322-6290; Pertusa, Maria/0000-0003-3856-9019; Morenilla-Palao, Cruz/0000-0002-8159-1206				Asslan R, 1999, BIOCHEM BIOPH RES CO, V260, P699, DOI 10.1006/bbrc.1999.0945; Belles X, 2005, ANNU REV ENTOMOL, V50, P181, DOI 10.1146/annurev.ento.50.071803.130356; BIFULCO M, 1995, J BIOL CHEM, V270, P15231, DOI 10.1074/jbc.270.25.15231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cabedo H, 2002, J BIOL CHEM, V277, P19905, DOI 10.1074/jbc.M201587200; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; Clayton RB, 1964, J LIPID RES, V15, P3; Di Croce L, 1999, MOL ENDOCRINOL, V13, P1225, DOI 10.1210/me.13.8.1225; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Du XM, 2006, MOL BIOL CELL, V17, P2735, DOI 10.1091/mbc.E05-11-1094; Edenfeld G, 2005, CURR OPIN NEUROBIOL, V15, P34, DOI 10.1016/j.conb.2005.01.007; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Freeman MR, 2006, TRENDS NEUROSCI, V29, P82, DOI 10.1016/j.tins.2005.12.002; Fu Q, 1998, J NEUROCHEM, V71, P549; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gould RM, 2005, BIOL BULL-US, V209, P49, DOI 10.2307/3593141; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Kanazawa A, 2001, FISHERIES SCI, V67, P997, DOI 10.1046/j.1444-2906.2001.00354.x; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Santos AC, 2004, DEV CELL, V6, P283, DOI 10.1016/S1534-5807(04)00023-1; Schweigreiter R, 2006, INT REV NEUROBIOL, V73, P219, DOI 10.1016/S0074-7742(06)73007-0; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942	45	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28768	28778		10.1074/jbc.M701878200	http://dx.doi.org/10.1074/jbc.M701878200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652086	hybrid			2022-12-25	WOS:000249642100051
J	Stensman, H; Larsson, C				Stensman, Helena; Larsson, Christer			Identification of acidic amino acid residues in the protein kinase C alpha V5 domain that contribute to its insensitivity to diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-ALPHA; CATALYTIC DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CYTOPLASMIC DOMAIN; REGULATORY DOMAIN; HYDROPHOBIC MOTIF; PLASMA-MEMBRANE; LIVING CELLS; ACTIVATION; BINDING	The protein kinase C (PKC) isoforms are maintained in an inactive and closed conformation by intramolecular interactions. Upon activation these are disrupted by activators, binding proteins and cellular membrane. We have seen that autophosphorylation of two sites in the C-terminal V5 domain is crucial to keep PKC alpha insensitive to the activator diacylglycerol, which presumably is caused by a masking of the diacylglycerol-binding C1a domain. Here we demonstrate that the diacylglycerol sensitivity of the PKC beta isoforms also is suppressed by autophosphorylation of the V5 sites. To analyze conformational differences, a fusion protein ECFP-PKC alpha-EYFP was expressed in cells and the FRET signal was analyzed. The analogous mutant with autophosphorylation sites exchanged for alanine gave rise to a substantially lower FRET signal than wild-type PKC alpha indicating a conformational difference elicited by the mutations. Expression of the isolated PKC alpha V5 domain led to increased diacylglycerol sensitivity of PKC alpha. We identified acidic residues in the V5 domain that, when mutated to alanines or lysines, rendered PKC alpha sensitive to diacylglycerol. Furthermore, mutation to glutamate of four lysines in a lysine-rich cluster in the C2 domain gave a similar effect. Simultaneous reversal of the charges of the acidic residues in the V5 and the lysines in the C2 domain gave rise to a PKC alpha that was insensitive to diacylglycerol. We propose that these structures participate in an intramolecular interaction that maintains PKC alpha in a closed conformation. The disruption of this interaction leads to an unmasking of the C1a domain and thereby increased diacylglycerol sensitivity of PKC alpha.	Lund Univ, Malmo Univ Hosp, Ctr Mol Pathol, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Larsson, C (corresponding author), Lund Univ, Ctr Mol Pathol, Entrance 78,3rd Floor, SE-20502 Malmo, Sweden.	Christer.Larsson@med.lu.se						Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Banci L, 2002, J BIOL CHEM, V277, P12988, DOI 10.1074/jbc.M106875200; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bolsover SR, 2003, J BIOL CHEM, V278, P10282, DOI 10.1074/jbc.M212145200; Braun DC, 2005, J BIOL CHEM, V280, P8164, DOI 10.1074/jbc.M413896200; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; Corbalan-Garcia S, 2006, BBA-MOL CELL BIOL L, V1761, P633, DOI 10.1016/j.bbalip.2006.04.015; Dries DR, 2007, J BIOL CHEM, V282, P826, DOI 10.1074/jbc.C600268200; Evans JH, 2006, MOL BIOL CELL, V17, P56, DOI 10.1091/mbc.e05-06-0499; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Grodsky N, 2006, BIOCHEMISTRY-US, V45, P13970, DOI 10.1021/bi061128h; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kolkova K, 2005, J NEUROCHEM, V92, P886, DOI 10.1111/j.1471-4159.2004.02919.x; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Leitges M, 2004, NEURON, V44, P585, DOI 10.1016/j.neuron.2004.10.024; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Lim ST, 2003, J BIOL CHEM, V278, P13795, DOI 10.1074/jbc.M208300200; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; Marin-Vicente C, 2005, MOL BIOL CELL, V16, P2848, DOI 10.1091/mbc.E05-01-0067; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Rodriguez-Alfaro JA, 2004, J MOL BIOL, V335, P1117, DOI 10.1016/j.jmb.2003.10.080; Sanchez-Bautista S, 2006, J MOL BIOL, V362, P901, DOI 10.1016/j.jmb.2006.07.093; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Stensman H, 2004, J BIOL CHEM, V279, P40576, DOI 10.1074/jbc.M405560200; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Wang QMJ, 2004, MOL CANCER RES, V2, P129; Yeong SS, 2006, J BIOL CHEM, V281, P30768, DOI 10.1074/jbc.M511278200; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	45	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28627	28638		10.1074/jbc.M702248200	http://dx.doi.org/10.1074/jbc.M702248200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673466	hybrid			2022-12-25	WOS:000249642100037
J	Kashlan, OB; Mueller, GM; Qamar, MZ; Poland, PA; Ahner, A; Rubenstein, RC; Hughey, RP; Brodsky, JL; Kleyman, TR				Kashlan, Ossama B.; Mueller, Gunhild M.; Qamar, Mohammad Z.; Poland, Paul A.; Ahner, Annette; Rubenstein, Ronald C.; Hughey, Rebecca P.; Brodsky, Jeffrey L.; Kleyman, Thomas R.			Small heat shock protein alpha A-crystallin regulates epithelial sodium channel expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; SUBUNIT STOICHIOMETRY; CHAPERONE FUNCTION; CYSTIC-FIBROSIS; ION CHANNELS; MEMBRANE; CELL; TRAFFICKING; TRANSPORT; PATHWAY	Integral membrane proteins are synthesized on the cytoplasmic face of the endoplasmic reticulum (ER). After being translocated or inserted into the ER, they fold and undergo post-translational modifications. Within the ER, proteins are also subjected to quality control checkpoints, during which misfolded proteins may be degraded by proteasomes via a process known as ER-associated degradation. Molecular chaperones, including the small heat shock protein alpha A-crystallin, have recently been shown to play a role in this process. We have now found that aA-crystallin is expressed in cultured mouse collecting duct cells, where apical Na+ transport is mediated by epithelial Na+ channels (ENaC). ENaC-mediated Na+ currents in Xenopus oocytes were reduced by co-expression of alpha A-crystallin.. This reduction in ENaC activity reflected a decrease in the number of channels expressed at the cell surface. Furthermore we observed that the rate of ENaC delivery to the cell surface of Xenopus oocytes was significantly reduced by co-expression of alpha A-crystallin, whereas the rate of channel retrieval remained unchanged. We also observed that aA-crystallin and ENaC co-immunoprecipitate. These data are consistent with the hypothesis that small heat shock proteins recognize ENaC subunits at ER. quality control checkpoints and can target ENaC subunits for ER-associated degradation.	Univ Pittsburgh, Dept Med, Div Renal & Electrolyte, Pittsburgh, PA 15216 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Hughey, RP (corresponding author), 933 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hughey@dom.pitt.edu		Rubenstein, Ronald/0000-0002-3138-4006	NIDDK NIH HHS [DK065161, DK58046, F32 DK066883, R56 DK065161, R01 DK065161, R01 DK058046, DK066883, DK061296] Funding Source: Medline; NIGMS NIH HHS [R01 GM075061, GM75061, R01 GM075061-01A1, R01 GM075061-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065161, R56DK065161, T32DK061296, R01DK058046, F32DK066883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075061] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Ahner A, 2007, MOL BIOL CELL, V18, P806, DOI 10.1091/mbc.E06-05-0458; Bens M, 1999, J AM SOC NEPHROL, V10, P923; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Cashikar AG, 2005, J BIOL CHEM, V280, P23869, DOI 10.1074/jbc.M502854200; Ciampolillo F, 1996, AM J PHYSIOL-CELL PH, V271, pC1303, DOI 10.1152/ajpcell.1996.271.4.C1303; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goldfarb SB, 2006, P NATL ACAD SCI USA, V103, P5817, DOI 10.1073/pnas.0507903103; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Haslbeck M, 2005, J BIOL CHEM, V280, P23861, DOI 10.1074/jbc.M502697200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; Jentsch S, 2007, TRENDS BIOCHEM SCI, V32, P6, DOI 10.1016/j.tibs.2006.11.005; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KNOWLES MR, 1995, CHEST, V107, pS71, DOI 10.1378/chest.107.2_Supplement.71S; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lentze N, 2004, EUR J BIOCHEM, V271, P2494, DOI 10.1111/j.1432-1033.2004.04180.x; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Pasta SY, 2004, MOL VIS, V10, P655; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Sun Y, 2005, CELL MOL LIFE SCI, V62, P2460, DOI 10.1007/s00018-005-5190-4; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang Yimao, 2002, Methods Mol Med, V70, P257	48	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28149	28156		10.1074/jbc.M703409200	http://dx.doi.org/10.1074/jbc.M703409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17664274	Green Accepted, hybrid			2022-12-25	WOS:000249455600064
J	Rexroth, S; Wong, CCL; Park, JH; Yates, JR; Barry, BA				Rexroth, Sascha; Wong, Catherine C. L.; Park, Jessica H.; Yates, John R., III; Barry, Bridgette A.			An activated glutamate residue identified in photosystern II at the interface between the manganese-stabilizing subunit and the D2 polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SITE-DIRECTED MUTANTS; MASS-SPECTROMETRY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; POSTTRANSLATIONAL MODIFICATIONS; WATER OXIDATION; REDOX COFACTOR; BINDING	Photosystem II (PSII) catalyzes the oxidation of water during oxygenic photosynthesis. PSII is composed both of intrinsic subunits, such as D1, D2, and CP47, and extrinsic subunits, such as the manganese-stabilizing subunit (MSP). Previous work has shown that amines covalently bind to amino acid residues in the CP47, D1, and D2 subunits of plant and cyanobacterial PSII, and that these covalent reactions are prevented by the addition of chloride in plant preparations depleted of the 18- and 24-kDa extrinsic subunits. It has been proposed that these reactive groups are carbonyl-containing, post-translationally modified amino acid side chains (Ouellette, A. J. A., Anderson, L. B., and Barry, B. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2204-2209 and Anderson, L. B., Ouellette, A. J. A., and Barry, B. A. (2000) J. Biol. Chem. 275, 4920-4927). To identify the amino acid binding site in the spinach D2 subunit, we have employed a biotin-amine labeling reagent, which can be used in conjunction with avidin affinity chromatography to purify biotinylated peptides from the PSII complex. Multidimensional chromatographic separation and multistage mass spectrometry localizes a novel post-translational modification in the D2 subunit to glutamate 303. We propose that this glutamate is activated for amine reaction by post-translational modification. Because the modified glutamate is located at a contact site between the D2 and manganese-stabilizing subunits, we suggest that the modification is important in vivo in stabilizing the interaction between these two PSII subunits. Consistent with this conclusion, mutations at the modified glutamate alter the steady-state rate of photosynthetic oxygen evolution.	Georgia Inst Technol, Sch Chem & Biochem, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University System of Georgia; Georgia Institute of Technology; Scripps Research Institute	Barry, BA (corresponding author), Georgia Inst Technol, Petit Inst Bioengn, 315 Ferst Dr, Atlanta, GA 30332 USA.	bridgette.barry@chemistry.gatech.edu	Rexroth, Sascha/H-3702-2011	Rexroth, Sascha/0000-0003-3819-2127; Wong, Catherine CL/0000-0001-7270-980X				ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Anderson LB, 2004, J AM CHEM SOC, V126, P8399, DOI 10.1021/ja0478781; Anderson LB, 2000, J BIOL CHEM, V275, P4920, DOI 10.1074/jbc.275.7.4920; Anderson LB, 2002, P NATL ACAD SCI USA, V99, P14676, DOI 10.1073/pnas.232591599; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARRY BA, 1995, METHOD ENZYMOL, V258, P303; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BOERNER RJ, 1994, J BIOL CHEM, V269, P134; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; Cooper IB, 2007, PHOTOSYNTH RES, V92, P345, DOI 10.1007/s11120-007-9147-3; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ermakova-Gerdes S, 2001, J BACTERIOL, V183, P145, DOI 10.1128/JB.183.1.145-154.2001; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GHANOTAKIS DF, 1984, FEBS LETT, V170, P169, DOI 10.1016/0014-5793(84)81393-9; Grabolle M, 2006, J BIOL CHEM, V281, P4580, DOI 10.1074/jbc.M509724200; Han Yonghua, 2005, Journal of Bioinformatics and Computational Biology, V3, P697; Hurst GB, 2004, J AM SOC MASS SPECTR, V15, P832, DOI 10.1016/S1044-0305(04)00154-0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Krause F, 2004, J BIOL CHEM, V279, P48369, DOI 10.1074/jbc.M406085200; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; Lindorff-Larsen K, 2001, J BIOL CHEM, V276, P33547, DOI 10.1074/jbc.M104841200; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Ma CL, 1996, BIOPHYS J, V71, P1961, DOI 10.1016/S0006-3495(96)79394-3; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MIYAO M, 1983, BIOCHIM BIOPHYS ACTA, V725, P87, DOI 10.1016/0005-2728(83)90227-X; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; Ouellette AJA, 1998, P NATL ACAD SCI USA, V95, P2204, DOI 10.1073/pnas.95.5.2204; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pevzner PA, 2001, GENOME RES, V11, P290, DOI 10.1101/gr.154101; Pevzner PA, 2000, J COMPUT BIOL, V7, P777, DOI 10.1089/10665270050514927; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Rhee KH, 1998, NATURE, V396, P283, DOI 10.1038/24421; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sachs RK, 2003, J BIOL CHEM, V278, P44222, DOI 10.1074/jbc.M307148200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Searle BC, 2004, ANAL CHEM, V76, P2220, DOI 10.1021/ac035258x; Sharma J, 1997, J BIOL CHEM, V272, P33158, DOI 10.1074/jbc.272.52.33158; Shi LX, 2004, BBA-BIOENERGETICS, V1608, P75, DOI 10.1016/j.bbabio.2003.12.004; Sinz A, 2005, J AM SOC MASS SPECTR, V16, P1921, DOI 10.1016/j.jasms.2005.07.020; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsur D, 2005, NAT BIOTECHNOL, V23, P1562, DOI 10.1038/nbt1168; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wincencjusz H, 1999, BIOCHEMISTRY-US, V38, P3719, DOI 10.1021/bi982295n; YAMAMOTO Y, 1981, FEBS LETT, V133, P265, DOI 10.1016/0014-5793(81)80520-0; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Yi XP, 2005, J BIOL CHEM, V280, P16170, DOI 10.1074/jbc.M501550200; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	63	4	4	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27802	27809		10.1074/jbc.M704394200	http://dx.doi.org/10.1074/jbc.M704394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17666402	hybrid			2022-12-25	WOS:000249455600029
J	Sanchez-Sanchez, F; Martinez-Redondo, F; Aroca-Aguilar, JD; Coca-Prados, M; Escribano, J				Sanchez-Sanchez, Francisco; Martinez-Redondo, Francisco; Aroca-Aguilar, J. Daniel; Coca-Prados, Miguel; Escribano, Julio			Characterization of the intracellular proteolytic cleavage of myocilin and identification of calpain II as a myocilin-processing protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN-ANGLE GLAUCOMA; INCREASES OUTFLOW RESISTANCE; OLFACTOMEDIN-HOMOLOGY DOMAIN; HUMAN CILIARY BODY; ENDOPLASMIC-RETICULUM; AQUEOUS-HUMOR; PHYSIOLOGICAL-FUNCTION; TIGR/MYOCILIN PROTEIN; EXTRACELLULAR-MATRIX; NEUTRAL PROTEASE	MYOC, a gene involved in different types of glaucoma, encodes myocilin, a secreted glycoprotein of unknown function, consisting of an N-terminal leucine-zipper-like domain, a central linker region, and a C-terminal olfactomedin-like domain. Recently, we have shown that myocilin undergoes an intracellular endoproteolytic processing. We show herein that the proteolytic cleavage in the linker region splits the two terminal domains. The C-terminal domain is secreted to the culture medium, whereas the N-terminal domain mainly remains intra-cellularly retained. In transiently transfected 293T cells, the cleavage was prevented by calpain inhibitors, such as calpeptin, calpain inhibitor IV, and calpastatin. Since calpains are calcium-activated proteases, we analyzed how changes in either intra- or extracellular calcium affected the cleavage of myocilin. Intracellular ionomycin-induced calcium uptake enhanced myocilin cleavage, whereas chelation of extracellular calcium by EGTA inhibited the proteolytic processing. Calpains I and II cleaved myocilin in vitro. However, in cells in culture, only RNA interference knockdown of calpain II reduced myocilin processing. Subcellular fractionation and digestion of the obtained fractions with proteinase K showed that full-length myocilin resides in the lumen of the endoplasmic reticulum together with a sub-population of calpain II. These data revealed that calpain II is responsible for the intracellular processing of myocilin in the lumen of the endoplasmic reticulum. We propose that this cleavage might regulate extracellular interactions of myocilin, contributing to the control of intraocular pressure.	Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Area Genet, E-02006 Albacete, Spain; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA	Universidad de Castilla-La Mancha; Yale University	Escribano, J (corresponding author), Fac Med, Area Genet, Avda de Almansa,No 14, E-02006 Albacete, Spain.	julio.escribano@uclm.es	Escribano, Julio/D-9742-2015; , francisco/ABF-7718-2021; Aroca-Aguilar, Jose Daniel/R-5513-2019; Aroca-Aguilar, J.Daniel/B-7842-2008	Escribano, Julio/0000-0002-8919-8134; Aroca-Aguilar, Jose Daniel/0000-0001-6487-1612; Aroca-Aguilar, J.Daniel/0000-0001-6487-1612	NATIONAL EYE INSTITUTE [R01EY004873] Funding Source: NIH RePORTER; NEI NIH HHS [EY001785, EY04873] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503; Aroca-Aguilar JD, 2005, J BIOL CHEM, V280, P21043, DOI 10.1074/jbc.M501340200; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Bhatt A, 2002, J CELL SCI, V115, P3415; Branca D, 2004, BIOCHEM BIOPH RES CO, V322, P1098, DOI 10.1016/j.bbrc.2004.07.126; Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; COCAPRADOS M, 1986, P NATL ACAD SCI USA, V83, P8754, DOI 10.1073/pnas.83.22.8754; Croall DE, 1996, BBA-PROTEIN STRUCT M, V1298, P276, DOI 10.1016/S0167-4838(96)00138-0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; ELAMRANI N, 1993, BIOCHIMIE, V75, P849, DOI 10.1016/0300-9084(93)90038-T; Elbein A D, 1981, Ciba Found Symp, V80, P270; Escribano J, 2002, MOL VIS, V8, P315; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; Fautsch MP, 2000, INVEST OPHTH VIS SCI, V41, P4163; Fautsch MP, 2006, INVEST OPHTH VIS SCI, V47, P213, DOI 10.1167/iovs.05-0334; Filla MS, 2002, INVEST OPHTH VIS SCI, V43, P151; Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899; Furutani Y, 2005, BIOCHEM J, V389, P675, DOI 10.1042/BJ20050120; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Gobeil S, 2006, EXP EYE RES, V82, P1017, DOI 10.1016/j.exer.2005.11.002; Goldwich A, 2003, INVEST OPHTH VIS SCI, V44, P1953, DOI 10.1167/iovs.02-0863; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gong G, 2004, HUM MOL GENET, V13, pR91, DOI 10.1093/hmg/ddh074; Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Huang W, 2005, P NATL ACAD SCI USA, V102, P12242, DOI 10.1073/pnas.0505138102; Huang W, 2000, Ophthalmic Genet, V21, P155, DOI 10.1076/1381-6810(200009)21:3;1-Z;FT155; Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117; Karali A, 2000, INVEST OPHTH VIS SCI, V41, P729; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YX, 2006, BIOCHEM BIOPH RES CO, V339, P797, DOI 10.1016/j.bbrc.2005.11.082; Lindsey JD, 2001, INVEST OPHTH VIS SCI, V42, P1781; Maertens B, 2007, J BIOL CHEM, V282, P10647, DOI 10.1074/jbc.M611339200; Oka T, 2006, J NEUROSCI RES, V83, P1342, DOI 10.1002/jnr.20827; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; PEMRICK SM, 1984, J CELL BIOL, V99, P2297, DOI 10.1083/jcb.99.6.2297; PERSSON H, 1993, BRAIN RES, V611, P272, DOI 10.1016/0006-8993(93)90513-M; PLUMB JA, 1989, CANCER RES, V49, P4435; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Russell P, 2001, INVEST OPHTH VIS SCI, V42, P983; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sakamoto Y, 2000, CURR EYE RES, V21, P571, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT571; Sarfarazi M, 1997, HUM MOL GENET, V6, P1667, DOI 10.1093/hmg/6.10.1667; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Sorimachi H, 2000, ADV EXP MED BIOL, V481, P383; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Stamer WD, 2006, EXP EYE RES, V83, P1386, DOI 10.1016/j.exer.2006.07.018; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048; Tamm ER, 2002, PROG RETIN EYE RES, V21, P395, DOI 10.1016/S1350-9462(02)00010-1; TAYLOR RG, 1995, J ANIM SCI, V73, P1351; Tekirian TL, 2001, MOL BRAIN RES, V96, P14, DOI 10.1016/S0169-328X(01)00250-9; Ueda J, 2002, INVEST OPHTH VIS SCI, V43, P1068; Vollrath D, 2006, EXP EYE RES, V82, P1030, DOI 10.1016/j.exer.2005.10.007	65	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27810	27824		10.1074/jbc.M609608200	http://dx.doi.org/10.1074/jbc.M609608200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650508	hybrid			2022-12-25	WOS:000249455600030
J	Grieco, JP; Achee, NL; Chareonviriyaphap, T; Suwonkerd, W; Chauhan, K; Sardelis, MR; Roberts, DR				Grieco, John P.; Achee, Nicole L.; Chareonviriyaphap, Theeraphap; Suwonkerd, Wannapa; Chauhan, Kamal; Sardelis, Michael R.; Roberts, Donald R.			A New Classification System for the Actions of IRS Chemicals Traditionally Used For Malaria Control	PLOS ONE			English	Article							BEHAVIOR; MOSQUITOS; DDT; INSECTICIDES; RESPONSES; DIPTERA; VECTOR	Knowledge of how mosquitoes respond to insecticides is of paramount importance in understanding how an insecticide functions to prevent disease transmission. A suite of laboratory assays was used to quantitatively characterize mosquito responses to toxic, contact irritant, and non-contact spatial repellent actions of standard insecticides. Highly replicated tests of these compounds over a range of concentrations proved that all were toxic, some were contact irritants, and even fewer were non-contact repellents. Of many chemicals tested, three were selected for testing in experimental huts to confirm that chemical actions documented in laboratory tests are also expressed in the field. The laboratory tests showed the primary action of DDT is repellent, alphacypermethrin is irritant, and dieldrin is only toxic. These tests were followed with hut studies in Thailand against marked-released populations. DDT exhibited a highly protective level of repellency that kept mosquitoes outside of huts. Alphacypermethrin did not keep mosquitoes out, but its strong irritant action caused them to prematurely exit the treated house. Dieldrin was highly toxic but showed no irritant or repellent action. Based on the combination of laboratory and confirmatory field data, we propose a new paradigm for classifying chemicals used for vector control according to how the chemicals actually function to prevent disease transmission inside houses. The new classification scheme will characterize chemicals on the basis of spatial repellent, contact irritant and toxic actions.	[Grieco, John P.; Achee, Nicole L.; Sardelis, Michael R.; Roberts, Donald R.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Chareonviriyaphap, Theeraphap] Kasetsart Univ, Dept Entomol, Bangkok, Thailand; [Suwonkerd, Wannapa] Minist Publ Hlth, Off Dis Prevent & Control, Chiang Mai, Thailand; [Chauhan, Kamal] USDA, Chem Affecting Insect Behav Lab, Beltsville, MD 20705 USA	Uniformed Services University of the Health Sciences - USA; Kasetsart University; Ministry of Public Health - Thailand; United States Department of Agriculture (USDA)	Grieco, JP (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA.	jgrieco@usuhs.mil		Achee, Nicole/0000-0001-6939-2055; Grieco, John/0000-0002-2080-8598; Chareonviriyaphap, Theeraphap/0000-0002-7362-5621	National Institutes of Health [5U01AI054777-02]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI054777] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work is supported by a grant from the National Institutes of Health entitled "Behavior modifying compounds for disease vector control''(grant no. 5U01AI054777-02).	Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; ASCHER K. R. S., 1955, Rivista di Parassitologia, V16, P31; Brogdon WG, 1998, J AM MOSQUITO CONTR, V14, P159; BROWN AWA, 1958, WHO MONOGRAPH SERIES, V38; Chareonviriyaphap T, 1997, J AM MOSQUITO CONTR, V13, P171; DETHIER VG, 1960, J ECON ENTOMOL, V53, P134, DOI 10.1093/jee/53.1.134; DEZULUETA J, 1963, NATURE, V200, P860, DOI [10.1038/200860a0, 10.1038/200861a0]; Grieco JP, 2000, J VECTOR ECOL, V25, P62; Grieco JP, 2005, J AM MOSQUITO CONTR, V21, P404, DOI 10.2987/8756-971X(2006)21[404:ANHSST]2.0.CO;2; KENNEDY JS, 1947, B ENTOMOL RES, V37, P593, DOI 10.1017/S0007485300030091; KRAMER WL, 1979, ENVIRON ENTOMOL, V8, P1111, DOI 10.1093/ee/8.6.1111; MUELLER PH, 1948, NOBEL LECT, P227; MUIRHEADTHOMSON RC, 1953, MOSQUITO BEHAV RELAT, P219; Roberts D R, 1991, Bull Pan Am Health Organ, V25, P210; Roberts DR, 2000, J VECTOR ECOL, V25, P48; *SAS I INC, 1999, BAS SAS SOFTW SAS ON; *SAS I INC, 1999, SAS STAT SOFTW SAS O; SCHRECK CE, 1989, J AM MOSQUITO CONTR, V5, P247; SMITH A, 1969, B ENTOMOL RES, V59, P33, DOI 10.1017/S000748530000300X; TARZWELL CM, 1947, PUBLIC HEALTH REP, V62, P84, DOI 10.2307/4585983; WHO, 2006, WHO TECH REP SER, V936, P1; WHO, 1998, WHOCDSCPCMAL9812	22	163	168	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e716	10.1371/journal.pone.0000716	http://dx.doi.org/10.1371/journal.pone.0000716			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684562	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452400019
J	Zhao, W; Pahar, B; Borda, JT; Alvarez, X; Sestak, K				Zhao, Wei; Pahar, Bapi; Borda, Juan T.; Alvarez, Xavier; Sestak, Karol			A Decline in CCL3-5 Chemokine Gene Expression during Primary Simian-Human Immunodeficiency Virus Infection	PLOS ONE			English	Article								Background. The CC-chemokines CCL3, CCL4 and CCL5 have been found to block the entry of CCR5-tropic HIV into host cells and to suppress the viral replication in vitro, but the in vivo role of endogenous CC-chemokines in HIV-1 infection is still incompletely understood. Methodology/Principle Findings. In this study, the primate host CCL3, CCL4 and CCL5 gene expression was evaluated in response to simian-human immunodeficiency virus (SHIV) infection in rhesus macaque model. Five rhesus macaques were inoculated with CCR5-tropic SHIVSF162P4. The mRNA levels of CCL3, CCL4 and CCL5 were measured by real-time PCR at post inoculation day (PID) 0, 7, 14, 21, 35, 56 and 180 in peripheral blood. In addition, a selected subset of samples from CXCR4-tropic SHIVKu1-infected macaques was included with objective to compare the differences in CC-chemokine down-regulation caused by the two SHIVs. Gut-associated lymphoid tissues (GALT) collected from SHIVSF162P4-infected animals were also tested by flow cytometry and confocal microscopy to corroborate the gene expression results. Predictably, higher viral loads and CD4+ T cell losses were observed at PID 14 in macaques infected with SHIVKu1 than with SHIVSF162P4. A decline in CC-chemokine gene expression was also found during primary (PID 7-21), but not chronic (PID 180) stage of infection. Conclusions. It was determined that A) SHIVSF162P4 down-regulated the CC-chemokine gene expression during acute stage of infection to a greater extent (p<0.05) than SHIVKu1, and B) such down-regulation was not paralleled with the CD4+ T cell depletion. Evaluation of CC-chemokine enhancing immunomodulators such as synthetic CpG-oligonucleotides could be explored in future HIV vaccine studies.	[Zhao, Wei; Pahar, Bapi; Borda, Juan T.; Alvarez, Xavier; Sestak, Karol] Tulane Natl Primate Res Ctr, Covington, LA USA; [Alvarez, Xavier; Sestak, Karol] Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Tulane University; Tulane University	Sestak, K (corresponding author), Tulane Natl Primate Res Ctr, Covington, LA USA.	ksestak@tulane.edu	Pahar, Bapi/AFM-3129-2022	Pahar, Bapi/0000-0003-1949-973X; Zhao, Wei/0000-0003-1516-9493	National Institutes of Health [AI54146, RR00164]; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054146] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants AI54146 and RR00164 from the National Institutes of Health.	Ahmed RKS, 2002, CLIN EXP IMMUNOL, V129, P11, DOI 10.1046/j.1365-2249.2002.01894.x; Ahmed RKS, 2001, SCAND J IMMUNOL, V53, P245, DOI 10.1046/j.1365-3083.2001.00865.x; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Cline AN, 2005, J MED PRIMATOL, V34, P303; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Decrion AZ, 2005, CURR HIV RES, V3, P243, DOI 10.2174/1570162054368057; Dorner BG, 2002, P NATL ACAD SCI USA, V99, P6181, DOI 10.1073/pnas.092141999; Fantuzzi L, 2001, EUR CYTOKINE NETW, V12, P597; Gauduin MC, 1998, J VIROL, V72, P6315, DOI 10.1128/JVI.72.8.6315-6324.1998; Harouse JM, 1998, J MED PRIMATOL, V27, P81, DOI 10.1111/j.1600-0684.1998.tb00230.x; Hofmann-Lehmann R, 2002, AIDS RES HUM RETROV, V18, P627, DOI 10.1089/088922202760019329; Hsu M, 2003, J VIROL, V77, P989, DOI 10.1128/JVI.77.2.989-998.2003; Jennes W, 2002, AIDS RES HUM RETROV, V18, P171, DOI 10.1089/08892220252781220; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; LaFranco-Scheuch L, 2004, J VIROL, V78, P6399, DOI 10.1128/JVI.78.12.6399-6408.2004; Lehner T, 2000, IMMUNOLOGY, V99, P569, DOI 10.1046/j.1365-2567.2000.00993.x; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Mackewicz CE, 1996, SCIENCE, V274, P1393, DOI 10.1126/science.274.5291.1393; Mattapallil JJ, 1998, J VIROL, V72, P6421, DOI 10.1128/JVI.72.8.6421-6429.1998; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Moser B, 1997, TRENDS MICROBIOL, V5, P88, DOI 10.1016/S0966-842X(97)01019-6; Muthumani K, 2000, J LEUKOCYTE BIOL, V68, P366; Paxton WA, 1999, IMMUNOL LETT, V66, P71, DOI 10.1016/S0165-2478(98)00154-0; Paxton WA, 1998, VIROLOGY, V244, P66, DOI 10.1006/viro.1998.9082; Ramesh G, 2005, CLIN DIAGN LAB IMMUN, V12, P192, DOI 10.1128/CDLI.12.1.192-197.2005; Rottman JB, 1997, AM J PATHOL, V151, P1341; Stantchev TS, 2001, CYTOKINE GROWTH F R, V12, P219, DOI 10.1016/S1359-6101(00)00033-2; Stein JV, 2005, IMMUNOLOGY, V116, P1, DOI 10.1111/j.1365-2567.2005.02183.x; Veazey RS, 2003, J EXP MED, V198, P1551, DOI 10.1084/jem.20031266; Wen WR, 2005, VIRUS RES, V113, P26, DOI 10.1016/j.virusres.2005.04.002; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zhang LQ, 1998, J VIROL, V72, P5035, DOI 10.1128/JVI.72.6.5035-5045.1998; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	38	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e726	10.1371/journal.pone.0000726	http://dx.doi.org/10.1371/journal.pone.0000726			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684570	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452400027
J	Levesque, D; Briere, FP; Perreault, JP				Levesque, Dominique; Briere, Francis P.; Perreault, Jean-Pierre			A Modern Mode of Activation for Nucleic Acid Enzymes	PLOS ONE			English	Article							IN-VITRO SELECTION; RNA; CATALYSIS; RIBOZYMES	Through evolution, enzymes have developed subtle modes of activation in order to ensure the sufficiently high substrate specificity required by modern cellular metabolism. One of these modes is the use of a target-dependent module (i.e. a docking domain) such as those found in signalling kinases. Upon the binding of the target to a docking domain, the substrate is positioned within the catalytic site. The prodomain acts as a target-dependent module switching the kinase from an off state to an on state. As compared to the allosteric mode of activation, there is no need for the presence of a third partner. None of the ribozymes discovered to date have such a mode of activation, nor does any other known RNA. Starting from a specific on/off adaptor for the hepatitis delta virus ribozyme, that differs but has a mechanism reminiscent of this signalling kinase, we have adapted this mode of activation, using the techniques of molecular engineering, to both catalytic RNAs and DNAs exhibiting various activities. Specifically, we adapted three cleaving ribozymes (hepatitis delta virus, hammerhead and hairpin ribozymes), a cleaving 10-23 deoxyribozyme, a ligating hairpin ribozyme and an artificially selected capping ribozyme. In each case, there was a significant gain in terms of substrate specificity. Even if this mode of control is unreported for natural catalytic nucleic acids, its use needs not be limited to proteinous enzymes. We suggest that the complexity of the modern cellular metabolism might have been an important selective pressure in this evolutionary process.	[Levesque, Dominique; Briere, Francis P.; Perreault, Jean-Pierre] Univ Sherbrooke, RNA Grp Grp ARN, Dept Biochim, Fac Med & Sci Sante, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Perreault, JP (corresponding author), Univ Sherbrooke, RNA Grp Grp ARN, Dept Biochim, Fac Med & Sci Sante, Sherbrooke, PQ J1K 2R1, Canada.	Jean-Pierre.Perreault@usherbrooke.ca			This work was supported by grants from the Canadian Institute of Health Research (CIHR) [MOP-44002, EOP-38322, PRG-80169]; Universite de Sherbrooke	This work was supported by grants from the Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Universite de Sherbrooke	This work was supported by grants from the Canadian Institute of Health Research (CIHR; MOP-44002 and EOP-38322) to J.P.P. The RNA group is supported by grants from the Universite de Sherbrooke and the CIHR (PRG-80169).	Alaoui-Ismaili MH, 2000, ANTIVIR RES, V46, P181, DOI 10.1016/S0166-3542(00)00085-1; BEAUDRY D, 1995, NUCLEIC ACIDS RES, V23, P745, DOI 10.1093/nar/23.5.745; Bergeron LJ, 2005, RNA, V11, P1858, DOI 10.1261/rna.2112705; Bergeron LJ, 2005, NUCLEIC ACIDS RES, V33, P1240, DOI 10.1093/nar/gki278; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Blount KE, 2005, ANNU REV BIOPH BIOM, V34, P415, DOI 10.1146/annurev.biophys.34.122004.184428; Davidson EA, 2007, NAT CHEM BIOL, V3, P23, DOI 10.1038/nchembio846; FERSHT A, 1999, STRUCTURE MECH PROTE, P289; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Jansen JA, 2006, NAT STRUCT MOL BIOL, V13, P517, DOI 10.1038/nsmb1094; Komatsu Y, 1997, BIOORGAN MED CHEM, V5, P1063, DOI 10.1016/S0968-0896(97)00042-4; Levesque D, 2002, RNA, V8, P464, DOI 10.1017/S1355838202020289; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Penchovsky R, 2005, NAT BIOTECHNOL, V23, P1424, DOI 10.1038/nbt1155; Sakamoto N, 1996, J CLIN INVEST, V98, P2720, DOI 10.1172/JCI119097; Sargueil B, 2003, J BIOL CHEM, V278, P52783, DOI 10.1074/jbc.M306703200; Schubert S, 2004, J MOL BIOL, V339, P355, DOI 10.1016/j.jmb.2004.03.064; Silverman SK, 2005, NUCLEIC ACIDS RES, V33, P6151, DOI 10.1093/nar/gki930; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; Wilson TJ, 2005, BIOCHEM SOC T, V33, P461, DOI 10.1042/BST0330461; Winkler WC, 2004, NATURE, V428, P281, DOI 10.1038/nature02362; Zaher HS, 2006, RNA, V12, P1949, DOI 10.1261/rna.131306	24	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e673	10.1371/journal.pone.0000673	http://dx.doi.org/10.1371/journal.pone.0000673			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653287	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452200029
J	Cowling, VH; Cole, MD				Cowling, V. H.; Cole, M. D.			An N-Myc truncation analogous to c-Myc-S induces cell proliferation independently of transactivation but dependent on Myc homology box II	ONCOGENE			English	Article						c-Myc-S; Myc; transcriptional repression; transactivation; cell proliferation	TRANSFORMATION; TRANSCRIPTION; ASSOCIATION; RECRUITMENT; INHIBITORS; REPRESSES; MECHANISM; APOPTOSIS; COFACTOR; GROWTH	Myc promotes both normal cell proliferation and oncogenic transformation through the activation and repression of target genes. The c-Myc-S protein is a truncated form of c-Myc that is produced in some cells from translation initiation at an internal AUG codon. We report that c-Myc-S and a similar truncated form of N-MycWT can fully rescue the proliferation defect in myc-null fibroblasts, but rescue is dependent on the highly conserved Myc homology box II (MBII). Global gene expression studies show that the N-Myc equivalent of c-Myc-S is defective for virtually all transcriptional activation of Myc target genes but remains active for the majority of transcriptional repression. Repression by Myc-S is dependent on MBII, but it does not bind to several known nuclear cofactors. These data suggest that repression by Myc involves recruitment of a novel MBII-dependent cofactor.	[Cowling, V. H.; Cole, M. D.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; [Cowling, V. H.; Cole, M. D.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, 1 Med Ctr Dr,Rubin 6, Lebanon, NH 03756 USA.	mcole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	MRC [G0700240] Funding Source: UKRI; Medical Research Council [G0700240] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cole MD, 2006, SEMIN CANCER BIOL, V16, P241, DOI 10.1016/j.semcancer.2006.08.003; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Eisenman R N, 2000, Harvey Lect, V96, P1; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Malynn BA, 2000, GENE DEV, V14, P1390; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	25	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1327	1332		10.1038/sj.onc.1210734	http://dx.doi.org/10.1038/sj.onc.1210734			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704800				2022-12-25	WOS:000253407000017
J	Bae, SI; Cheriyath, V; Jacobs, BS; Reu, FJ; Borden, EC				Bae, S. I.; Cheriyath, V.; Jacobs, B. S.; Reu, F. J.; Borden, E. C.			Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL	ONCOGENE			English	Article						apoptosis; 5-AZAdC; IFNs; DR4; melanoma	TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; CUTANEOUS MELANOMA; STIMULATED GENES; APOPTOSIS; HYPERMETHYLATION; IDENTIFICATION; XIAP; INHIBITOR; CARCINOMA	Human melanoma cell lines, SK-MEL-3 and SK-MEL-28, despite induction of the proapoptotic cytokine, Apo2L/TRAIL, did not undergo apoptosis in response to interferons ( IFN-alpha 2b or IFN-beta). Postulating that genes important for apoptosis induction by IFNs might be silenced by methylation, the DNA demethylating agent 5-aza-2'-deoxycytidine ( 5-AZAdC) was assessed. DR4 ( TRAIL-R1) was identified as one of the genes reactivated by 5-AZAdC with a > 3-fold increase in 8 of 10 melanoma cell lines. Pretreatment with 5-AZAdC sensitized SK-MEL-3 and SK-MEL-28 cells to apoptosis induced by IFN-a2b and IFN-b; methylation-specific PCR and bisulfite sequencing confirmed demethylation of 5'CpG islands of DR4 and flow cytometry showed an increase in DR4 protein on the cell surface. In cells with reactivated DR4, neutralizing mAB to TRAIL reduced apoptosis in response to IFN-b or Apo2L/TRAIL. To further confirm the role of DR4, it was expressed by retroviral vector in SK-MEL-3 and SK-MEL-28 cells with reversal of resistance to IFN-b and Apo2L/TRAIL. Thus, reexpressing DR4 by 5-AZAdC or retroviral transfection in melanoma cell in which promoter methylation had suppressed its expression, potentiated apoptosis by IFN-alpha 2b, IFN-beta and Apo2L/TRAIL. Reactivation of silenced proapoptotic genes by inhibitors of DNA methylation may enhance clinical response to IFNs or Apo2L/TRAIL.	[Bae, S. I.; Cheriyath, V.; Jacobs, B. S.; Reu, F. J.; Borden, E. C.] Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Borden, EC (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, 9500 Euclid Ave,R 40, Cleveland, OH 44195 USA.	bordene@ccf.org		Reu, Frederic/0000-0003-1160-8030	NATIONAL CANCER INSTITUTE [R01CA090914] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 90914] Funding Source: Medline; NCRR NIH HHS [M01 RR-018390] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BORDEN EC, 2003, CANC MED, P830; Byun DS, 2003, CANCER RES, V63, P7068; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2001, CANCER RES, V61, P3225; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Pfeffer LM, 1998, CANCER RES, V58, P2489; Reu FJ, 2006, CANCER RES, V66, P2785, DOI 10.1158/0008-5472.CAN-05-2303; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Spugnardi M, 2003, CANCER RES, V63, P1639; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227	23	55	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					490	498		10.1038/sj.onc.1210655	http://dx.doi.org/10.1038/sj.onc.1210655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653094				2022-12-25	WOS:000252426100009
J	Xu, Z; Lam, LSM; Lam, LH; Chau, SF; Ng, TB; Au, SWN				Xu, Zheng; Lam, Levina Suk Mi; Lam, Lok Hei; Chau, So Fun; Ng, Tzi Bun; Au, Shannon Wing Ngor			Molecular basis of the redox regulation of SUMO proteases: a protective mechanism of intermolecular disulfide linkage against irreversible sulfhydryl oxidation	FASEB JOURNAL			English	Article						deconjugation; cysteine protease; oxidative stress	TRANSCRIPTION FACTOR FOXO3A; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN SUMOYLATION; RESIDUES; COMPLEX; STRESS; GROWTH	Sumoylation has emerged as an indispensable post-translational modification that modulates the functions of a broad spectrum of proteins. Recent studies have demonstrated that reactive oxygen species influence the equilibrium of sumoylation-desumoylation. We show herein that H2O2 induces formation of an intermolecular disulfide linkage of human SUMO protease SENP1 via the active-site Cys 603 and a unique residue Cys 613. Such reversible modification confers a higher recovery of enzyme activity, which is also observed in yeast Ulp1, but not in human SENP2, suggesting its protective role against irreversible sulfhydryl oxidation. In vivo formation of a disulfide-linked dimer of SENP1 is also detected in cultured cells in response to oxidative stress. The modifications are further elucidated by the crystal structures of Ulp1 with the catalytic cysteine oxidized to sulfenic, sulfinic, and sulfonic acids. Our findings suggest that, in addition to SUMO conjugating enzymes, SUMO proteases may act as redox sensors and effectors modulating the desumoylation pathway and specific cellular responses to oxidative stress.-Xu, Z., Lam, L. S. M., Lam, L. H., Chau, S. F., Ng, T. B., Au, S. W. N. Molecular basis of the redox regulation of SUMO proteases: a protective mechanism of intermolecular disulfide linkage against irreversible sulfhydryl oxidation.	[Xu, Zheng; Lam, Levina Suk Mi; Lam, Lok Hei; Chau, So Fun; Ng, Tzi Bun; Au, Shannon Wing Ngor] Chinese Univ Hong Kong, Fac Sci, Ctr Prot Sci & Crystallog, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Au, SWN (corresponding author), Chinese Univ Hong Kong, Fac Sci, Ctr Prot Sci & Crystallog, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.	shannon-au@cuhk.edu.hk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barford D, 2004, CURR OPIN STRUC BIOL, V14, P679, DOI 10.1016/j.sbi.2004.09.012; Bergmann EM, 1997, J VIROL, V71, P2436, DOI 10.1128/JVI.71.3.2436-2448.1997; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Holm L, 1996, METHOD ENZYMOL, V266, P653; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LASKOWSKI RA, CURR OPIN STRUCT BIO, V8, P631; LESLIE A, 1995, MOSFLM USERS GUIDE; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Manza LL, 2004, CHEM RES TOXICOL, V17, P1706, DOI 10.1021/tx049767l; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Salmeen A, 2005, ANTIOXID REDOX SIGN, V7, P560, DOI 10.1089/ars.2005.7.560; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Shen LN, 2006, BIOCHEM J, V397, P279, DOI 10.1042/BJ20052030; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P3168, DOI 10.1021/bi026861x; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xu Z, 2005, BIOCHEM J, V386, P325, DOI 10.1042/BJ20041210; Xu Z, 2006, BIOCHEM J, V398, P345, DOI 10.1042/BJ20060526; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	41	90	93	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					127	137		10.1096/fj.06-7871com	http://dx.doi.org/10.1096/fj.06-7871com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17704192				2022-12-25	WOS:000252309900016
J	Bendz, H; Ruhland, SC; Pandya, MJ; Hainzl, O; Riegelsberger, S; Brauchle, C; Mayer, MP; Buchner, J; Issels, RD; Noessner, E				Bendz, Henriette; Ruhland, Sibylle C.; Pandya, Maya J.; Hainzl, Otmar; Riegelsberger, Stefan; Braeuchle, Christoph; Mayer, Matthias P.; Buchner, Johannes; Issels, Rolf D.; Noessner, Elfriede			Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN DENDRITIC CELLS; CLASS-I MOLECULES; CD8(+) T-CELLS; CROSS-PRESENTATION; MURINE MACROPHAGES; EXOGENOUS ANTIGENS; PEPTIDE COMPLEXES; INFILTRATING LYMPHOCYTES; PRESENTATION PATHWAY	Heat shock proteins (HSPs) have shown promise for the optimization of protein-based vaccines because they can transfer exogenous antigens to dendritic cells and at the same time induce their maturation. Great care must be exercised in interpretating HSP-driven studies, as by-products linked to the recombinant generation of these proteins have been shown to mediate immunological effects. We generated highly purified human recombinant Hsp70 and demonstrated that it strongly enhances the cross-presentation of exogenous antigens resulting in better antigen-specific T cell stimulation. Augmentation of T cell stimulation was a direct function of the degree of complex formation between Hsp70 and peptides and correlated with improved antigen delivery to endosomal compartments. The Hsp70 activity was independent of TAP proteins and was not inhibited by exotoxin A or endosomal acidification. Consequently, Hsp70 enhanced cross-presentation of various antigenic sequences, even when they required different post-uptake processing and trafficking, as exemplified by the tumor antigens tyrosinase and Melan-A/MART-1. Furthermore, Hsp70 enhanced cross-presentation by different antigen-presenting cells (APCs), including dendritic cells and B cells. Importantly, enhanced cross-presentation and antigen-specific T cell activation were observed in the absence of innate signals transmitted by Hsp70. As Hsp70 supports the cross- presentation of different antigens and APCs and is inert to APC function, it may show efficacy in various settings of immune modulation, including induction of antigen-specific immunity or tolerance.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Munich, GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, Clin Cooperat grp, D-81377 Munich, Germany; Tech Univ Munich, Dept Chem, Lehrstuhl Biotechnol 4, D-85747 Garching, Germany; Univ Munich, Dept Chem & Biochem, Munich, Germany; Univ Munich, Ctr Nanosci, D-80539 Munich, Germany; Univ Heidelberg, ZMBH, D-6900 Heidelberg, Germany	University of Sheffield; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Technical University of Munich; University of Munich; University of Munich; Ruprecht Karls University Heidelberg	Bendz, H (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	henriette.bendz@gsf.de; noessner@gsf.de	Buchner, Johannes/A-2651-2010; Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Buchner, Johannes/0000-0003-1282-7737; Issels, Rolf/0000-0002-3494-6561				Ackerman AL, 2006, IMMUNITY, V25, P607, DOI 10.1016/j.immuni.2006.08.017; Amoscato AA, 1998, J IMMUNOL, V161, P4023; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Binder RJ, 2004, TISSUE ANTIGENS, V64, P442, DOI 10.1111/j.1399-0039.2004.00299.x; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Breloer M, 2001, EUR J IMMUNOL, V31, P2051, DOI 10.1002/1521-4141(200107)31:7<2051::AID-IMMU2051>3.0.CO;2-H; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Calderwood SK, 2005, EUR J IMMUNOL, V35, P2518, DOI 10.1002/eji.200535002; Calderwood SK, 2007, FEBS LETT, V581, P3689, DOI 10.1016/j.febslet.2007.04.044; Castelli C, 2001, CANCER RES, V61, P222; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Chow AY, 2005, TRENDS IMMUNOL, V26, P72, DOI 10.1016/j.it.2004.11.008; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Flechtner JB, 2006, J IMMUNOL, V177, P1017, DOI 10.4049/jimmunol.177.2.1017; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Goletz TJ, 1997, HUM IMMUNOL, V54, P129, DOI 10.1016/S0198-8859(97)00081-5; Grundler W, 2001, CYTOMETRY, V44, P45, DOI 10.1002/1097-0320(20010501)44:1<45::AID-CYTO1081>3.3.CO;2-P; Guermonprez P, 2005, SPRINGER SEMIN IMMUN, V26, P257, DOI 10.1007/s00281-004-0176-0; Heit A, 2004, J IMMUNOL, V172, P1501, DOI 10.4049/jimmunol.172.3.1501; HIRAYAMA K, 1990, BIOCHEM BIOPH RES CO, V173, P639, DOI 10.1016/S0006-291X(05)80083-X; Hunter AC, 2002, DRUG DISCOV TODAY, V7, P998, DOI 10.1016/S1359-6446(02)02444-3; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kim DT, 1997, J IMMUNOL, V159, P1666; Kuppner MC, 2001, EUR J IMMUNOL, V31, P1602, DOI 10.1002/1521-4141(200105)31:5<1602::AID-IMMU1602>3.0.CO;2-W; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; Lang A, 2005, J AM SOC NEPHROL, V16, P383, DOI 10.1681/ASN.2004040276; Li Z, 2004, METHODS, V32, P25, DOI 10.1016/S1046-2023(03)00183-X; Maecker HT, 2001, J IMMUNOL, V166, P7268, DOI 10.4049/jimmunol.166.12.7268; Marteau F, 2004, J LEUKOCYTE BIOL, V76, P796, DOI 10.1189/jlb.0104032; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCMICHAEL AJ, 1980, HUM IMMUNOL, V1, P121, DOI 10.1016/0198-8859(80)90099-3; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Milani V, 2002, INT J HYPERTHER, V18, P563, DOI 10.1080/02656730210166140; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Noakes KL, 1999, FEBS LETT, V453, P95, DOI 10.1016/S0014-5793(99)00609-2; Noessner E, 2002, J IMMUNOL, V169, P5424, DOI 10.4049/jimmunol.169.10.5424; Norbury CC, 2006, IMMUNOLOGY, V117, P443, DOI 10.1111/j.1365-2567.2006.02335.x; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; Palliser D, 2005, J IMMUNOL, V174, P1879, DOI 10.4049/jimmunol.174.4.1879; Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Rock KL, 2006, IMMUNITY, V25, P523, DOI 10.1016/j.immuni.2006.09.003; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Shen LJ, 2006, CURR OPIN IMMUNOL, V18, P85, DOI 10.1016/j.coi.2005.11.003; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theriault JR, 2005, FEBS LETT, V579, P1951, DOI 10.1016/j.febslet.2005.02.046; Tobian AAR, 2004, J IMMUNOL, V172, P5277, DOI 10.4049/jimmunol.172.9.5277; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; VISSEREN MJW, 1995, J IMMUNOL, V154, P3991; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang RB, 2006, BLOOD, V107, P1636, DOI 10.1182/blood-2005-06-2559; Wang XH, 2005, WORLD J GASTROENTERO, V11, P5614, DOI 10.3748/wjg.v11.i36.5614; Wassenberg JJ, 1999, J CELL SCI, V112, P2167; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Ye ZY, 2007, J BIOL CHEM, V282, P4479, DOI 10.1074/jbc.M606802200	81	103	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31688	31702		10.1074/jbc.M704129200	http://dx.doi.org/10.1074/jbc.M704129200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17684010	hybrid			2022-12-25	WOS:000250309200060
J	Fan, DW; Chen, ZQ; Chen, YP; Shang, YF				Fan, Dongwei; Chen, Zhongqiang; Chen, Yupeng; Shang, Yongfeng			Mechanistic roles of leptin in osteogenic stimulation in thoracic ligament Flavum cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTERIOR LONGITUDINAL LIGAMENT; RECEPTOR-REGULATED TRANSCRIPTION; BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; ENDOMETRIAL CARCINOGENESIS; MOLECULAR-MECHANISMS; STAT3 ACTIVATION; OSTEOCALCIN GENE; SPINAL LIGAMENTS; YELLOW LIGAMENT	Obesity is a risk factor for thoracic ossification of ligament flavum ( TOLF) that is characterized by ectopic bone formation in the spinal ligaments. Hyperleptinemia is a common feature of obese people, and leptin, an adipocyte- derived cytokine with proliferative and osteogenic effects in several cell types, is believed to be an important factor in the pathogenesis of TOLF. However, how leptin might stimulate cell osteogenic differentiation in TOLF is not totally understood. We reported here that leptin- induced osteogenic effect inTOLFcells is associated with activation of signaling molecules STAT3, JNK, and ERK1/ 2 but not p38. Blocking STAT3 phosphorylation with a selective inhibitor, AG490, significantly abolished leptin- induced osteogenic differentiation of TOLF cells, whereas blocking ERK1/ 2 and JNK phosphorylation with their selective inhibitors PD98059 and SP600125, respectively, had only marginal effects. In addition, we showed that STAT3 interacted with Runt- related transcription factor 2 ( Runx2) in the nucleus, and STAT3, Runx2, and steroid receptor coactivator steroid receptor coactivator- 1 were components of the transcription complex recruitedon Runx2 target gene promoters in response to leptin treatment. Our experiments identified STAT3, Runx2, and steroid receptor coactivator1 as critical molecules in mediating leptin- stimulated cell osteogenesis in TOLF.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Peking Univ Third Hosp, Dept Orthoped, Beijing 100083, Peoples R China	Peking University; Peking University	Shang, YF (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	yshang@hsc.pku.edu.cn	Chen, Yupeng/T-5275-2019	Chen, Yupeng/0000-0001-8887-9547				Akhaddar A, 2002, JOINT BONE SPINE, V69, P319, DOI 10.1016/S1297-319X(02)00400-1; Al-Orainy IA, 1998, EUR J RADIOL, V29, P76, DOI 10.1016/S0720-048X(98)00030-8; Aleffi S, 2005, HEPATOLOGY, V42, P1339, DOI 10.1002/hep.20965; Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Ben Hamouda K, 2003, J NEUROSURG, V99, P157, DOI 10.3171/spi.2003.99.2.0157; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Ciancaglini P, 2006, BRAZ J MED BIOL RES, V39, P603, DOI 10.1590/S0100-879X2006000500006; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Epstein N, 1996, J SPINAL DISORD, V9, P446; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Hegyi K, 2004, CELL BIOL INT, V28, P159, DOI 10.1016/j.cellbi.2003.12.003; Hess R, 2005, J CELL BIOCHEM, V94, P50, DOI 10.1002/jcb.20330; Huitema LFA, 2006, CALCIFIED TISSUE INT, V78, P171, DOI 10.1007/s00223-005-1233-y; Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074; Iwamoto I, 2004, GYNECOL ENDOCRINOL, V19, P97, DOI 10.1080/09513590412331284389; Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014-5793(02)02889-2; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; MIYAMOTO S, 1993, SPINE, V18, P2267, DOI 10.1097/00007632-199311000-00021; NAKAMURA T, 1990, J SPINAL DISORD, V3, P288; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; Okano T, 1997, J ORTHOPAED RES, V15, P820, DOI 10.1002/jor.1100150606; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847-8861.2004; Parhami F, 2001, CIRC RES, V88, P954, DOI 10.1161/hh0901.090975; Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469; Salingcarnboriboon R, 2006, ENDOCRINOLOGY, V147, P2296, DOI 10.1210/en.2005-1020; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Shirakura Y, 2000, BIOCHEM BIOPH RES CO, V267, P752, DOI 10.1006/bbrc.1999.2027; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Specchia N, 2001, J ORTHOP RES, V19, P294, DOI 10.1016/S0736-0266(00)00026-7; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Theilhaber J, 2002, GENOME RES, V12, P165, DOI 10.1101/gr.182601; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Vasudevan A, 2002, J CLIN NEUROSCI, V9, P311, DOI 10.1054/jocn.2001.0962; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Yin N, 2004, CANCER RES, V64, P5870, DOI 10.1158/0008-5472.CAN-04-0655; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang FM, 2005, VITAM HORM, V71, P345, DOI 10.1016/S0083-6729(05)71012-8; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306	48	35	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29958	29966		10.1074/jbc.M611779200	http://dx.doi.org/10.1074/jbc.M611779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702747	hybrid			2022-12-25	WOS:000249981200025
J	Jennings, MD; Blankley, RT; Baron, M; Golovanov, AP; Avis, JM				Jennings, Martin D.; Blankley, Richard T.; Baron, Martin; Golovanov, Alexander P.; Avis, Johanna M.			Specificity and autoregulation of notch binding by tandem WW domains in Suppressor of Deltex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; NEDD4 FAMILY; REGULATOR; RECOGNITION; LIGAND; GENE; SH3; AUTOINHIBITION	WW domains target proline-tyrosine (PY) motifs and frequently function as tandem pairs. When studied in isolation, single WW domains are notably promiscuous and regulatory mechanisms are undoubtedly required to ensure selective interactions. Here, we show that the fourth WW domain (WW4) of Suppressor of Deltex, a modular Nedd4-like protein that down-regulates the Notch receptor, is the primary mediator of a direct interaction with a Notch-PY motif. A natural Trp to Phe substitution in WW4 reduces its affinity for general PY sequences and enhances selective interaction with the Notch-PY motif via compensatory specificity-determining interactions with PY-flanking residues. When WW4 is paired with WW3, domain-domain association, impeding proper folding, competes with Notch-PY binding to WW4. This novel mode of autoinhibition is relieved by binding of another ligand to WW3. Such cooper-ativity may facilitate the transient regulatory interactions observed in vivo between Su(dx) and Notch in the endocytic pathway. The highly conserved tandem arrangement of WW domains in Nedd4 proteins, and similar arrangements in more diverse proteins, suggests domain-domain communication may be integral to regulation of their associated cellular activities.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England	University of Manchester; University of Manchester	Avis, JM (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	mbaron@manchester.ac.uk; a.golovanov@manchester.ac.uk; j.avis@manchester.ac.uk	Golovanov, Alexander P./ABN-0572-2022; Jennings, martin/E-5240-2010	Golovanov, Alexander P./0000-0002-8592-3984; Jennings, Martin/0000-0001-6173-0988	Wellcome Trust [074379] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; BUSSEAU I, 1994, GENETICS, V136, P585; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chong PA, 2006, J BIOL CHEM, V281, P17069, DOI 10.1074/jbc.M601493200; Cornell M, 1999, GENETICS, V152, P567; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fedoroff OY, 2004, J BIOL CHEM, V279, P34991, DOI 10.1074/jbc.M404987200; Flasza M, 2006, MOL MEMBR BIOL, V23, P269, DOI 10.1080/09687860600665010; Fostier M, 1998, GENETICS, V150, P1477; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Gao YG, 2006, STRUCTURE, V14, P1755, DOI 10.1016/j.str.2006.09.014; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Leykauf K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Long JF, 2005, NAT STRUCT MOL BIOL, V12, P722, DOI 10.1038/nsmb958; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Morvan J, 2004, TRAFFIC, V5, P383, DOI 10.1111/j.1398-9219.2004.00183.x; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Wilkin MB, 2005, MOL MEMBR BIOL, V22, P279, DOI 10.1080/09687860500129778; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	51	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29032	29042		10.1074/jbc.M703453200	http://dx.doi.org/10.1074/jbc.M703453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656366	hybrid, Green Accepted			2022-12-25	WOS:000249642100077
J	Bin, L; Thorburn, J; Thomas, LR; Clark, PE; Humphreys, R; Thorburn, A				Bin, Lianghua; Thorburn, Jacqueline; Thomas, Lance R.; Clark, Peter E.; Humphreys, Robin; Thorburn, Andrew			Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; DEATH DOMAIN FADD; IN-VIVO; TUMORICIDAL ACTIVITY; MONOCLONAL-ANTIBODY; SELECTIVE MUTANTS; DECOY RECEPTORS; TARGETING DEATH; CELL-DEATH; CANCER	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a cytokine that preferentially induces apoptosis in tumor cells compared with normal cells through two receptors (DR4 and DR5). Somatic mutations in these receptors have been found in different kinds of cancer; however, it is poorly understood how the mutations affect signaling. We found that point mutations (L334F, E326K, E338K, and K386N) that were identified in human tumors result in the DRS receptor losing its ability to form a functional death-inducing signaling complex and induce apoptosis. The mutant receptors also have a "dominant negative" effect whereby they inhibit the ability of TRAIL to induce apoptosis through functional DR4 receptors. This dominant negative mechanism is achieved through competition for TRAIL binding as shown by experiments where the ability of the mutant DR5 receptor to bind with the ligand was abolished, thus restoring TRAIL signaling through DR4. The inhibitory effect on signaling through the wild-type DR4 protein can be overcome if the inhibitory mechanism is bypassed by using a DR4-agonistic antibody that is not subject to this competition. This study provides a molecular basis for the use of specific therapeutic agonists of TRAIL receptors in people whose tumors harbor somatic DR5 mutations.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Urol, Nashville, TN 37232 USA; Human Genome Sci, Oncol Res Dept, Rockville, MD 20850 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University; Vanderbilt University; GlaxoSmithKline; Human Genome Sciences Inc	Thorburn, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Fitzsimos Campus,Mail Stop 8303, RC1 S Tower 6100, Aurora, CO 80045 USA.	Andrew.Thorburn@uchsc.edu	Clark, Peter/E-1423-2011	Clark, Peter/0000-0002-8006-7015	NCI NIH HHS [K08 CA113452, CA11421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA113452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Liao Q, 2001, ANTICANCER RES, V21, P3153; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; McDonald ER, 2001, J BIOL CHEM, V276, P14939, DOI 10.1074/jbc.M100399200; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Park WS, 2001, GASTROENTEROLOGY, V121, P1219, DOI 10.1053/gast.2001.28663; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Seki N, 2003, CANCER RES, V63, P207; Shin MS, 2001, CANCER RES, V61, P4942; Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041; Spierings DC, 2004, J HISTOCHEM CYTOCHEM, V52, P821, DOI 10.1369/jhc.3A6112.2004; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Thomas LR, 2004, J BIOL CHEM, V279, P52479, DOI 10.1074/jbc.M409578200; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; TOLCHER AW, 2004, J CLIN ONCOL, V22, P3060; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586	37	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28189	28194		10.1074/jbc.M704210200	http://dx.doi.org/10.1074/jbc.M704210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17666396	hybrid			2022-12-25	WOS:000249455600068
J	Marshall, JL				Marshall, Jeremy L.			Rapid Evolution of Spermathecal Duct Length in the Allonemobius socius Complex of Crickets: Species, Population and Wolbachia Effects	PLOS ONE			English	Article							REPRODUCTIVE ISOLATION; SPERM; ZONE; HYBRIDIZATION; COADAPTATION; COEVOLUTION; SPECIATION; PIPIENTIS; DYNAMICS; FEMALES	The three species in the Allonemobius socius complex of crickets have recently diverged and radiated across North America. Interestingly, the only barriers to gene flow between these species in zones of secondary contact appear to be associated with fertilization traits - e.g., conspecific sperm precedence and the ability of males to induce females to lay eggs. Other traits, such as the length of female's reproductive tract, may also influence fertilization success and be associated with species boundaries. However, the underlying variation in this duct has not been assessed across populations and species. Moreover, the effects of reproductive parasites like Wolbachia on these morphological features have yet to be addressed, even though its infections are concentrated in reproductive tissues. I evaluated both the natural variation in and the effects of Wolbachia infection on spermathecal duct length among several populations of two species in the Allonemobius socius complex. My results suggest the following: (1) spermathecal duct length varies between species and is associated with species boundaries, (2) there is considerable variation among populations within species, (3) there is a Wolbachia infection-by-population interaction effect on the length of the spermathecal duct, and (4) experimental curing of Wolbachia recovers the uninfected morphology. These findings suggest the following hypotheses: (1) spermathecal duct length, like other fertilization traits in Allonemobius, is evolving rapidly and influences reproductive isolation and (2) Wolbachia-induced modifications of this duct could influence the dynamics of male-female coevolution. Further experiments are needed, however, to explicitly test these latter two hypotheses.	Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA	Kansas State University	Marshall, JL (corresponding author), Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA.	cricket@ksu.edu	Marshall, Jeremy/D-1436-2013		Texas [ARP 003656-0067-2001]; Kansas Agricultural Experiment Station [07-242-J]	Texas; Kansas Agricultural Experiment Station	This work was supported by a grant from the Advanced Research Program of Texas (ARP 003656-0067-2001) and the Kansas Agricultural Experiment Station (contribution # 07-242-J)	BANDI C, 1994, P ROY SOC B-BIOL SCI, V257, P43, DOI 10.1098/rspb.1994.0092; BIRKHEAD TR, 1993, J THEOR BIOL, V161, P51, DOI 10.1006/jtbi.1993.1039; BIRKHEAD TR, 2000, PROMISCUITY, P272; Braswell WE, 2006, GENOME, V49, P1069, DOI 10.1139/G06-061; Briskie JV, 1997, EVOLUTION, V51, P937, DOI 10.1111/j.1558-5646.1997.tb03674.x; Britch SC, 2001, MOL ECOL, V10, P627, DOI 10.1046/j.1365-294x.2001.01215.x; Broughton RE, 2003, GENETICS, V163, P1389; Casiraghi M, 2001, PARASITOLOGY, V122, P93, DOI 10.1017/S0031182000007149; Coyne JA, 2004, SPECIATION; Dobson SL, 1999, INSECT BIOCHEM MOLEC, V29, P153, DOI 10.1016/S0965-1748(98)00119-2; Doherty JA, 1996, ANIM BEHAV, V51, P981, DOI 10.1006/anbe.1996.0101; DYBAS LK, 1981, EVOLUTION, V35, P168, DOI 10.1111/j.1558-5646.1981.tb04869.x; EBERHARD WG, 1996, FEMALE CONTROL SEXUA, P472; GREGORY PG, 1994, EVOLUTION, V48, P705, DOI [10.2307/2410480, 10.1111/j.1558-5646.1994.tb01355.x]; Gregory PG, 1998, ENTOMOL EXP APPL, V87, P263, DOI 10.1023/A:1003280322549; HOWARD DJ, 1991, EVOLUTION, V45, P1120, DOI 10.1111/j.1558-5646.1991.tb04379.x; Howard DJ, 1998, EVOLUTION, V52, P511, DOI 10.1111/j.1558-5646.1998.tb01650.x; HOWARD DJ, 1986, EVOLUTION, V40, P34, DOI 10.1111/j.1558-5646.1986.tb05715.x; Howard DJ, 1998, ENDLESS FORMS, P439; Ilango K, 2000, J MED ENTOMOL, V37, P653, DOI 10.1603/0022-2585-37.5.653; Jeyaprakash A, 2000, INSECT MOL BIOL, V9, P393, DOI 10.1046/j.1365-2583.2000.00203.x; KELLER L, 1995, ADV STUD BEHAV, V24, P291, DOI 10.1016/S0065-3454(08)60397-6; Marshall JL, 2004, EVOLUTION, V58, P2409, DOI 10.1111/j.0014-3820.2004.tb00871.x; McGraw EA, 2004, CURR OPIN MICROBIOL, V7, P67, DOI 10.1016/j.mib.2003.12.003; Miller GT, 2002, SCIENCE, V298, P1230, DOI 10.1126/science.1076968; Miller GT, 2003, J EVOLUTION BIOL, V16, P114, DOI 10.1046/j.1420-9101.2003.00476.x; Morrow EH, 2000, P ROY SOC B-BIOL SCI, V267, P307, DOI 10.1098/rspb.2000.1001; Pitnick S, 1999, EVOLUTION, V53, P1804, DOI [10.2307/2640442, 10.1111/j.1558-5646.1999.tb04564.x]; Presgraves DC, 1999, P ROY SOC B-BIOL SCI, V266, P1041, DOI 10.1098/rspb.1999.0741; Simmons LW, 1999, AM NAT, V153, P302, DOI 10.1086/303171; Sokal R. R., 1995, BIOMETRY; Stouthamer R, 1999, ANNU REV MICROBIOL, V53, P71, DOI 10.1146/annurev.micro.53.1.71; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; Vacquier VD, 1993, ZYGOTE, V1, P181, DOI 10.1017/S0967199400001465; Weeks AR, 2002, TRENDS ECOL EVOL, V17, P257, DOI 10.1016/S0169-5347(02)02480-1; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587	36	17	17	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e720	10.1371/journal.pone.0000720	http://dx.doi.org/10.1371/journal.pone.0000720			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684565	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452400022
J	Ramachandran, S; Xie, LH; John, SA; Subramaniam, S; Lal, R				Ramachandran, Srinivasan; Xie, Lai-Hua; John, Scott A.; Subramaniam, Shankar; Lal, Ratnesh			A Novel Role for Connexin Hemichannel in Oxidative Stress and Smoking-Induced Cell Injury	PLOS ONE			English	Article							GAP-JUNCTIONAL HEMICHANNELS; HORIZONTAL CELLS; PLASMA-MEMBRANE; CHANNELS; APOPTOSIS; PERMEABILITY; PROTEIN; MECHANISMS; TRANSPORT; PATHWAYS	Oxidative stress is linked to many pathological conditions, including ischemia, atherosclerosis and neurodegenerative disorders. The molecular mechanisms of oxidative stress induced pathophysiology and cell death are currently poorly understood. Our present work demonstrates that oxidative stress induced by reactive oxygen species and cigarette smoke extract depolarize the cell membrane and open connexin hemichannels. Under oxidative stress, connexin expression and connexin silencing resulted in increased and reduced cell deaths, respectively. Morphological and live/dead assays indicate that cell death is likely through apoptosis. Our studies provide new insights into the mechanistic role of hemichannels in oxidative stress induced cell injury.	[Subramaniam, Shankar] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Ramachandran, Srinivasan; Lal, Ratnesh] Univ Chicago, Ctr Nanomed, Chicago, IL 60637 USA; [Xie, Lai-Hua; John, Scott A.] Univ Calif Los Angeles, Cardiovasc Res Lab, Los Angeles, CA USA	University of California System; University of California San Diego; University of Chicago; University of California System; University of California Los Angeles	Subramaniam, S (corresponding author), Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.	shankar@sdsc.edu; rlal@uchicago.edu	Lal, Ratnesh/AAG-5424-2019; Ramachandran, Srinivasan/G-5300-2010	Ramachandran, Srinivasan/0000-0002-6155-4002; John, Scott/0000-0002-1232-9140; Xie, Lai-Hua/0000-0003-0613-6286	NIH; Philip Morris	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Philip Morris	The work was supported by grants from NIH and Philip Morris External Grant Program.	Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bruzzone S, 2001, FASEB J, V15, P10; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Das Sarma J, 2002, J BIOL CHEM, V277, P20911, DOI 10.1074/jbc.M111498200; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; Ek-Vitorin JF, 2005, AM J PHYSIOL-CELL PH, V289, pC1535, DOI 10.1152/ajpcell.00182.2005; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; George CH, 1999, J BIOL CHEM, V274, P8678, DOI 10.1074/jbc.274.13.8678; Gomes P, 2005, INVEST OPHTH VIS SCI, V46, P1208, DOI 10.1167/iovs.04-1181; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hirsch T, 1998, CELL BIOL TOXICOL, V14, P141, DOI 10.1023/A:1007486022411; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Kalvelyte A, 2003, BIOCHEM PHARMACOL, V66, P1661, DOI 10.1016/S0006-2952(03)00540-9; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Liu PL, 2005, AM J PHYSIOL-LUNG C, V289, pL739, DOI 10.1152/ajplung.00099.2005; Locke D, 2004, EXP CELL RES, V298, P643, DOI 10.1016/j.yexcr.2004.05.003; MALCHOW RP, 1993, J NEUROSCI RES, V35, P237, DOI 10.1002/jnr.490350303; Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Napoli C, 2005, NEUROBIOL AGING, V26, P293, DOI 10.1016/j.neurobiolaging.2004.02.031; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49; Saez JC, 2003, ACTA PHYSIOL SCAND, V179, P9, DOI 10.1046/j.1365-201X.2003.01196.x; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; VanSlyke JK, 2000, METHODS, V20, P156, DOI 10.1006/meth.1999.0933; Vayssier-Taussat M, 2001, AM J PHYSIOL-HEART C, V280, pH1293, DOI 10.1152/ajpheart.2001.280.3.H1293; Verselis VK, 2000, BRAZ J MED BIOL RES, V33, P379, DOI 10.1590/S0100-879X2000000400003; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; Zhao HB, 2005, EUR J NEUROSCI, V21, P1859, DOI 10.1111/j.1460-9568.2005.04031.x	51	122	124	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e712	10.1371/journal.pone.0000712	http://dx.doi.org/10.1371/journal.pone.0000712			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684558	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452400015
J	Scheer, FAJL; Wright, KP; Kronauer, RE; Czeisler, CA				Scheer, Frank A. J. L.; Wright, Kenneth P., Jr.; Kronauer, Richard E.; Czeisler, Charles A.			Plasticity of the Intrinsic Period of the Human Circadian Timing System	PLOS ONE			English	Article							SLEEP-PHASE SYNDROME; BRIGHT LIGHT; MELATONIN SUPPRESSION; RHYTHMS; ENTRAINMENT; PACEMAKER; CLOCK; WAKEFULNESS; ADAPTATION; ASSOCIATION	Human expeditions to Mars will require adaptation to the 24.65-h Martian solar day-night cycle (sol), which is outside the range of entrainment of the human circadian pacemaker under lighting intensities to which astronauts are typically exposed. Failure to entrain the circadian time-keeping system to the desired rest-activity cycle disturbs sleep and impairs cognitive function. Furthermore, differences between the intrinsic circadian period and Earth's 24-h light-dark cycle underlie human circadian rhythm sleep disorders, such as advanced sleep phase disorder and non-24-hour sleep-wake disorders. Therefore, first, we tested whether exposure to a model-based lighting regimen would entrain the human circadian pacemaker at a normal phase angle to the 24.65-h Martian sol and to the 23.5-h day length often required of astronauts during short duration space exploration. Second, we tested here whether such prior entrainment to non-24-h light-dark cycles would lead to subsequent modification of the intrinsic period of the human circadian timing system. Here we show that exposure to moderately bright light (similar to 450 lux; similar to 1.2 W/m(2)) for the second or first half of the scheduled wake episode is effective for entraining individuals to the 24.65-h Martian sol and a 23.5-h day length, respectively. Estimations of the circadian periods of plasma melatonin, plasma cortisol, and core body temperature rhythms collected under forced desynchrony protocols revealed that the intrinsic circadian period of the human circadian pacemaker was significantly longer following entrainment to the Martian sol as compared to following entrainment to the 23.5-h day. The latter finding of after-effects of entrainment reveals for the first time plasticity of the period of the human circadian timing system. Both findings have important implications for the treatment of circadian rhythm sleep disorders and human space exploration.	[Scheer, Frank A. J. L.] Harvard Univ, Brigham & Womens Hosp, Div Sleep Med, Sch Med,Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Scheer, FAJL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Div Sleep Med, Sch Med,Dept Med, Boston, MA 02115 USA.	fscheer@rics.bwh.harvard.edu	Scheer, Frank A.J.L./C-2795-2012	Scheer, Frank A.J.L./0000-0002-2014-7582; Czeisler, Charles Andrew/0000-0002-7408-1849	National Institute of Neurological Disorders and Stroke [R01-NS41886]; National Centers for Research Resources [M01-RR02635]; National Sleep Foundation; NASA [NCC 9-58];  [R01 HL081761]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041886] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Centers for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Sleep Foundation; NASA(National Aeronautics & Space Administration (NASA)); ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by grants from the National Institute of Neurological Disorders and Stroke (R01-NS41886) and the National Centers for Research Resources (M01-RR02635). FAJLS is supported by a Pickwick Fellowship from the National Sleep Foundation. KPW is supported by R01 HL081761. CAC is supported by NASA Cooperation Agreement NCC 9-58 with the National Space Biomedical Research Institute. The sponsors or funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Archer SN, 2003, SLEEP, V26, P413, DOI 10.1093/sleep/26.4.413; ASCHOFF J, 1962, NATURWISSENSCHAFTEN, V49, P337; Aton SJ, 2004, J BIOL RHYTHM, V19, P198, DOI 10.1177/0748730404264156; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Boivin DB, 1996, NATURE, V379, P540, DOI 10.1038/379540a0; Borbely A A, 1982, Hum Neurobiol, V1, P195; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; Czeisler CA, 1999, SCIENCE, V284, P2177, DOI 10.1126/science.284.5423.2177; DeCoursey PJ, 1989, CIRCADIAN CLOCKS ECO, P187; DIJK DJ, 1994, NEUROSCI LETT, V166, P63, DOI 10.1016/0304-3940(94)90841-9; Dijk DJ, 2001, AM J PHYSIOL-REG I, V281, pR1647, DOI 10.1152/ajpregu.2001.281.5.R1647; Duffy JF, 2001, BEHAV NEUROSCI, V115, P895, DOI 10.1037//0735-7044.115.4.895; EASTMAN CI, 1990, AM J PHYSIOL, V259, pR1189, DOI 10.1152/ajpregu.1990.259.6.R1189; Ebisawa T, 2001, EMBO REP, V2, P342, DOI 10.1093/embo-reports/kve070; ESKINA, 1971, BIOCHRONOMETRY, P55; Gronfier C, 2007, P NATL ACAD SCI USA, V104, P9081, DOI 10.1073/pnas.0702835104; Hebert M, 2002, J PINEAL RES, V33, P198, DOI 10.1034/j.1600-079X.2002.01885.x; HONMA KI, 1992, AM J PHYSIOL, V262, pR885, DOI 10.1152/ajpregu.1992.262.5.R885; IBUKA N, 1975, BRAIN RES, V96, P76, DOI 10.1016/0006-8993(75)90574-0; Jasser SA, 2006, J BIOL RHYTHM, V21, P394, DOI 10.1177/0748730406292391; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Kelly TL, 1999, J BIOL RHYTHM, V14, P190, DOI 10.1177/074873099129000597; Khalsa SBS, 2003, J PHYSIOL-LONDON, V549, P945, DOI 10.1113/jphysiol.2003.040477; KLEIN T, 1993, SLEEP, V16, P333, DOI 10.1093/sleep/16.4.333; Klerman EB, 1999, J BIOL RHYTHM, V14, P260, DOI 10.1177/074873099129000678; Kronauer RE, 1999, J BIOL RHYTHM, V14, P500, DOI 10.1177/074873099129001073; Lockley SW, 2000, J ENDOCRINOL, V164, pR1, DOI 10.1677/joe.0.164R001; Lockley SW, 1997, J BIOL RHYTHM, V12, P16, DOI 10.1177/074873049701200104; Lockley SW, 1997, J CLIN ENDOCR METAB, V82, P3763, DOI 10.1210/jc.82.11.3763; Lockley SW, 2003, J CLIN ENDOCR METAB, V88, P4502, DOI 10.1210/jc.2003-030570; Nelson DE, 1999, AM J PHYSIOL-REG I, V277, pR1351, DOI 10.1152/ajpregu.1999.277.5.R1351; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P223, DOI 10.1007/BF01417856; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Richter C. P., 1968, Communications in Behavioral Biology (Ser A), V1, P305; Sack RL, 2000, NEW ENGL J MED, V343, P1070, DOI 10.1056/NEJM200010123431503; Shen HM, 1997, J NEUROSCI, V17, P5221; Smith KA, 2004, J CLIN ENDOCR METAB, V89, P3610, DOI 10.1210/jc.2003-032100; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; vandenPol AN, 1996, J NEUROSCI, V16, P5883; WEVER RA, 1989, J BIOL RHYTHM, V4, P161; WEVER RA, 1979, CIRCADIAN SYSTEM MAN, P276; White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243; Wong KY, 2005, NEURON, V48, P1001, DOI 10.1016/j.neuron.2005.11.016; Wright KP, 2006, J COGNITIVE NEUROSCI, V18, P508, DOI 10.1162/jocn.2006.18.4.508; Wright KP, 2001, P NATL ACAD SCI USA, V98, P14027, DOI 10.1073/pnas.201530198; Xu Y, 2007, CELL, V128, P59, DOI 10.1016/j.cell.2006.11.043; Zeitzer JM, 2000, J PHYSIOL-LONDON, V526, P695, DOI 10.1111/j.1469-7793.2000.00695.x	48	88	102	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e721	10.1371/journal.pone.0000721	http://dx.doi.org/10.1371/journal.pone.0000721			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684566	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452400023
J	Zumdieck, A; Kruse, K; Bringmann, H; Hyman, AA; Julicher, F				Zumdieck, Alexander; Kruse, Karsten; Bringmann, Henrik; Hyman, Anthony A.; Juelicher, Frank			Stress Generation and Filament Turnover during Actin Ring Constriction	PLOS ONE			English	Article								We present a physical analysis of the dynamics and mechanics of contractile actin rings. In particular, we analyze the dynamics of ring contraction during cytokinesis in the Caenorhabditis elegans embryo. We present a general analysis of force balances and material exchange and estimate the relevant parameter values. We show that on a microscopic level contractile stresses can result from both the action of motor proteins, which cross-link filaments, and from the polymerization and depolymerization of filaments in the presence of end-tracking cross-linkers.	[Zumdieck, Alexander; Kruse, Karsten; Juelicher, Frank] Max Planck Inst Phys Komplexer Syst, Dresden, Germany; [Bringmann, Henrik; Hyman, Anthony A.] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany	Max Planck Society; Max Planck Society	Julicher, F (corresponding author), Max Planck Inst Phys Komplexer Syst, Dresden, Germany.	julicher@pks.mpg.de	Julicher, Frank/B-1828-2009; Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011; Kruse, Karsten/GOG-8298-2022	Julicher, Frank/0000-0003-4731-9185; Hyman, Anthony A/0000-0003-3664-154X; Kruse, Karsten/0000-0001-8665-2349	Max Planck Society	Max Planck Society(Max Planck Society)	This work was funded by the Max Planck Society.	Biron D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.098102; BRENNER S, 1974, GENETICS, V77, P71; Bringmann H, 2005, NATURE, V436, P731, DOI 10.1038/nature03823; Dickinson RB, 2004, BIOPHYS J, V87, P2838, DOI 10.1529/biophysj.104.045211; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; Gerisch G, 2000, CURR OPIN CELL BIOL, V12, P126, DOI 10.1016/S0955-0674(99)00066-6; He XY, 1997, EXP CELL RES, V233, P252, DOI 10.1006/excr.1997.3585; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; KANBE T, 1989, J CELL SCI, V94, P647; Kruse K, 2000, PHYS REV LETT, V85, P1778, DOI 10.1103/PhysRevLett.85.1778; Kruse K, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051913; Kruse K, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.031904; Kruse K, 2003, EUROPHYS LETT, V64, P716, DOI 10.1209/epl/i2003-00618-2; Kruse K, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.138101; Kruse K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.078101; Kruse K, 2005, EUR PHYS J E, V16, P5, DOI 10.1140/epje/e2005-00002-5; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; Matzke R, 2001, NAT CELL BIOL, V3, P607, DOI 10.1038/35078583; MAUPIN P, 1986, J ULTRA MOL STRUCT R, V94, P92, DOI 10.1016/0889-1605(86)90055-8; Mogilner A, 2003, BIOPHYS J, V84, P1591, DOI 10.1016/S0006-3495(03)74969-8; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Park S, 2005, BIOPHYS J, V89, P4330, DOI 10.1529/biophysj.104.053462; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; RAPPAPORT R, 1967, SCIENCE, V156, P1241, DOI 10.1126/science.156.3779.1241; Rappaport R., 1996, CYTOKINESIS ANIMAL C; Schroeder T E, 1975, Soc Gen Physiol Ser, V30, P305; SCHROEDER TE, 1990, ANN NY ACAD SCI, V582, P78; TAKIGUCHI K, 1991, J BIOCHEM-TOKYO, V109, P520, DOI 10.1093/oxfordjournals.jbchem.a123414; Tanaka-Takiguchi Y, 2004, J MOL BIOL, V341, P467, DOI 10.1016/j.jmb.2004.06.019; Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230; Zhang WD, 2005, P NATL ACAD SCI USA, V102, P7186, DOI 10.1073/pnas.0502545102	32	85	85	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e696	10.1371/journal.pone.0000696	http://dx.doi.org/10.1371/journal.pone.0000696			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684545	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452400002
J	Merrin, J; Leibler, S; Chuang, JS				Merrin, Jack; Leibler, Stanislas; Chuang, John S.			Printing Multistrain Bacterial Patterns with a Piezoelectric Inkjet Printer	PLOS ONE			English	Article								Many studies involving interacting microorganisms would benefit from simple devices able to deposit cells in precisely defined patterns. We describe an inexpensive bacterial piezoelectric inkjet printer (adapted from the design of the POSaM oligonucleotide microarrayer) that can be used to "print out" different strains of bacteria or chemicals in small droplets onto a flat surface at high resolution. The capabilities of this device are demonstrated by printing ordered arrays comprising two bacterial strains labeled with different fluorescent proteins. We also characterized several properties of this piezoelectric printer, such as the droplet volume (of the order of tens of pl), the distribution of number of cells in each droplet, and the dependence of droplet volume on printing frequency. We established the limits of the printing resolution, and determined that the printed viability of Escherichia coli exceeded 98.5%.	[Chuang, John S.] Rockefeller Univ, Lab Living Matter, New York, NY 10021 USA; Rockefeller Univ, Ctr Phys & Biol, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Chuang, JS (corresponding author), Rockefeller Univ, Lab Living Matter, 1230 York Ave, New York, NY 10021 USA.	chuangj@mail.rockefeller.edu			NIH [F32]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding: JSC was supported by an NIH F32 postdoctoral fellowship.	Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Basu S, 2005, NATURE, V434, P1130, DOI 10.1038/nature03461; Hasman H, 2000, J BACTERIOL, V182, P1089, DOI 10.1128/JB.182.4.1089-1095.2000; Lausted C, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r58; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; NAGELMAEKER PM, 2006, THESIS EINDHOVEN U T; Pardo L, 2003, LANGMUIR, V19, P1462, DOI 10.1021/la026171u; Roth EA, 2004, BIOMATERIALS, V25, P3707, DOI 10.1016/j.biomaterials.2003.10.052; Sanjana NE, 2004, J NEUROSCI METH, V136, P151, DOI 10.1016/j.jneumeth.2004.01.011; Shimoda T, 2003, MRS BULL, V28, P821, DOI 10.1557/mrs2003.231; Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123; Wang Y, 2004, P SOC PHOTO-OPT INS, V5374, P628, DOI 10.1117/12.541711; Watanabe K, 2003, ZOOL SCI, V20, P429, DOI 10.2108/zsj.20.429; Xu T, 2005, BIOMATERIALS, V26, P93, DOI 10.1016/j.biomaterials.2004.04.011; Xu T, 2004, BIOTECHNOL BIOENG, V85, P29, DOI 10.1002/bit.10768	15	49	50	7	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e663	10.1371/journal.pone.0000663	http://dx.doi.org/10.1371/journal.pone.0000663			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653283	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452200025
J	Datta, A; Nicot, C				Datta, A.; Nicot, C.			Telomere attrition induces a DNA double-strand break damage signal that reactivates p53 transcription in HTLV-I leukemic cells	ONCOGENE			English	Article						telomere; p53; MDMX; HTLV-I; ATM; senescence	HOMOLOGOUS RECOMBINATION; INTERFERON-ALFA; MDMX; PHOSPHORYLATION; ZIDOVUDINE; LYMPHOMA; TAX; ATM; INACTIVATION; COMBINATION	Persistent inhibition of telomerase induces a severe telomere shortening in human T-cell leukemia virus type-1-infected cells which signals a DNA double-strand break damage response, formation of telomere dysfunction-induced foci and activates the ATM pathway. In turn, activation of ATM and its downstream effectors led to an increased phosphorylation and acetylation on specific residues of p53 known to be involved in transcriptional activation. Disruption of Mdm2-p53 complexes coupled with increased proteasomal degradation of MDMX further enhanced reactivation of p53 transcription, ultimately leading to senescence of tumor cells. Induction of senescence in these T-cells was associated with an increased expression of p21, p16 and activation of GSK3 beta. Our results support the cancer - aging model and demonstrate that the halt of aging in cancer cells can be reversed through reactivation of p53.	[Datta, A.; Nicot, C.] Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66103 USA.	cnicot@kumc.edu		Datta, Abhik/0000-0002-3442-5774	NCI NIH HHS [R01 CA106258, R01CA106258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002/ijc.22026; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Chehab NH, 2000, GENE DEV, V14, P278; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046/j.1365-2141.2001.02794.x; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ramos YFM, 2001, CANCER RES, V61, P1839; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; White JD, 2001, LEUKEMIA LYMPHOMA, V40, P287, DOI 10.3109/10428190109057927	29	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1135	1141		10.1038/sj.onc.1210718	http://dx.doi.org/10.1038/sj.onc.1210718			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704807				2022-12-25	WOS:000253136700013
J	Elia, A; Constantinou, C; Clemens, MJ				Elia, A.; Constantinou, C.; Clemens, M. J.			Effects of protein phosphorylation on ubiquitination and stability of the translational inhibitor protein 4E-BP1	ONCOGENE			English	Article						calyculin A; eIF4E; protein degradation; protein phosphatases; protein synthesis	INITIATION-FACTOR 4E; NF-KAPPA-B; DNA-DAMAGING AGENT; MESSENGER-RNA; PHAS-I; DEPENDENT DEGRADATION; REPRESSOR 4E-BP1; CALYCULIN-A; CYCLIN D1; KINASE	The availability of the eukaryotic polypeptide chain initiation factor 4E (eIF4E) for protein synthesis is regulated by the 4E-binding proteins (4E-BPs), which act as inhibitors of cap-dependent mRNA translation. The ability of the 4E-BPs to sequester eIF4E is regulated by reversible phosphorylation at multiple sites. We show here that, in addition, 4E-BP1 is a substrate for polyubiquitination and that some forms of 4E-BP1 are simultaneously polyubiquitinated and phosphorylated. In Jurkat cells inhibition of proteasomal activity by MG132 enhances the level of hypophosphorylated, unmodified 4E-BP1 but only modestly increases the accumulation of high-molecular-weight, phosphorylated forms of 4E-BP1. In contrast, inhibition of protein phosphatase activity with calyculin A reduces the level of unmodified 4E-BP1 but strongly enhances the amount of phosphorylated, high-molecular-weight 4E-BP1. Turnover measurements in the presence of cycloheximide show that, whereas 4E-BP1 is normally a very stable protein, calyculin A decreases the apparent half-life of the normal-sized protein. Affinity chromatography on m(7)GTP-Sepharose indicates that the larger forms of 4E-BP1 bind very poorly to eIF4E. We suggest that the phosphorylation of 4E-BP1 may play a dual role in the regulation of protein synthesis, both reducing the affinity of 4E-BP1 for eIF4E and promoting the conversion of 4E-BP1 to alternative, polyubiquitinated forms.	[Elia, A.; Constantinou, C.; Clemens, M. J.] Univ London, Ctr Mol & Metab Signalling, Div Basic Med Sci, Translat Control Grp, London SW17 0RE, England	University of London	Clemens, MJ (corresponding author), Univ London, Ctr Mol & Metab Signalling, Div Basic Med Sci, Translat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sgul.ac.uk	Elia, Androulla/AAE-6854-2021					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Carroll M, 2006, MOL CELL BIOL, V26, P8586, DOI 10.1128/MCB.00955-06; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Fawcett J, 2001, J BIOL CHEM, V276, P11552, DOI 10.1074/jbc.M007988200; Fawcett J, 2001, ARCH BIOCHEM BIOPHYS, V385, P357, DOI 10.1006/abbi.2000.2160; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Graham B, 2005, CELL CYCLE, V4, P1342, DOI 10.4161/cc.4.10.2047; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Jeffrey IW, 2002, CANCER RES, V62, P2272; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Le Bouffant R, 2006, J CELL BIOCHEM, V99, P126, DOI 10.1002/jcb.20856; Li BG, 2000, INT J BIOCHEM CELL B, V32, P677, DOI 10.1016/S1357-2725(00)00010-8; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Lin SS, 2006, J BIOL CHEM, V281, P23003, DOI 10.1074/jbc.M602648200; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nimmanapalli R, 2003, CANCER RES, V63, P7950; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Othumpangat S, 2005, MOL CELL BIOCHEM, V279, P123, DOI 10.1007/s11010-005-8284-2; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ren Q, 2006, CANCER RES, V66, P5209, DOI 10.1158/0008-5472.CAN-05-4158; ROSENTHAL K, 1995, SEMIN AVIAN EXOT PET, V4, P1; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schneider R, 2005, INT J RADIAT ONCOL, V63, pS146, DOI 10.1016/j.ijrobp.2005.07.249; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tilleray V, 2006, FEBS LETT, V580, P1766, DOI 10.1016/j.febslet.2006.02.030; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135	74	52	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					811	822		10.1038/sj.onc.1210678	http://dx.doi.org/10.1038/sj.onc.1210678			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653084				2022-12-25	WOS:000252884500010
J	Anderton, E; Yee, J; Smith, P; Crook, T; White, RE; Allday, MJ				Anderton, E.; Yee, J.; Smith, P.; Crook, T.; White, R. E.; Allday, M. J.			Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma	ONCOGENE			English	Article						apoptosis; Bim; Burkitt's lymphoma; EBV; EBNA3A; EBNA3C; MYC	NUCLEAR ANTIGEN 3C; HUMAN B-CELLS; HOMOZYGOUS DELETIONS; HISTONE DEACETYLASE; BH3-ONLY PROTEIN; DOWN-REGULATION; C-MYC; APOPTOSIS; P53; CTBP	Epstein-Barr virus (EBV) contributes to the development of several human cancers including the endemic form of Burkitt's lymphoma (BL). In culture, EBV induces the continuous proliferation of primary B cells as lymphoblastoid cell lines (LCLs) and if EBV-negative BL-derived cells are infected with EBV, latency-associated viral factors confer resistance to various inducers of apoptosis. Nuclear proteins EBNA3A and EBNA3C (but not EBNA3B) are necessary to establish LCLs and their expression may be involved in the resistance of BL cells to cytotoxic agents. We have therefore created recombinant EBVs from which each of the EBNA3 genes has been independently deleted, and revertant viruses in which the genes have been re-introduced into the viral genome. Infection of EBV-negative BL cells with this panel of EBVs and challenge with various cytotoxic drugs showed that EBNA3A and EBNA3C cooperate as the main determinants of both drug resistance and the downregulation of the proapoptotic Bcl-2- family member Bcl-2-interacting mediator of cell death (Bim). The regulation of Bim is predominantly at the level of RNA, with little evidence of post-translational Bim stabilization by EBV. In the absence of Bim, EBNA3A and EBNA3C appear to provide no survival advantage. The level of Bim is a critical regulator of B cell survival and reduced expression is a major determinant of lymphoproliferative disease in mice and humans; moreover, Bim is uniquely important in the pathogenesis of BL. By targeting this tumour-suppressor for repression, EBV significantly increases the likelihood of B lymphomagenesis in general, and BL in particular. Our results may also explain the selection pressure that gives rise to a subset of BL that retain expression of the EBNA3 proteins.	[Anderton, E.; Yee, J.; White, R. E.; Allday, M. J.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; [Smith, P.; Crook, T.] Toby Robins Breast Canc Res Ctr, Inst Canc Res Breakthrough, London, England	Imperial College London; University of London; Institute of Cancer Research - UK	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England.	m.allday@imperial.ac.uk		White, Robert/0000-0002-5115-2173	Wellcome Trust Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now		ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood-2004-07-2713; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bourillot PY, 1998, J GEN VIROL, V79, P363, DOI 10.1099/0022-1317-79-2-363; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Epeldegui M, 2007, MOL IMMUNOL, V44, P934, DOI 10.1016/j.molimm.2006.03.018; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hickabottom M, 2002, J BIOL CHEM, V277, P47197, DOI 10.1074/jbc.M208116200; Jimenez-Ramirez C, 2006, J VIROL, V80, P11200, DOI 10.1128/JVI.00897-06; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; Kelly GL, 2005, J VIROL, V79, P10709, DOI 10.1128/JVI.79.16.10709-10717.2005; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Leao M, 2007, J VIROL, V81, P248, DOI 10.1128/JVI.01096-06; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; O'Nions F, 2004, ADV CANCER RES, V92, P119; O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838; O'Nions J, 2006, J VIROL, V80, P12408, DOI 10.1128/JVI.01363-06; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; White RE, 2003, J GEN VIROL, V84, P3393, DOI 10.1099/vir.0.19387-0; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	46	140	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					421	433		10.1038/sj.onc.1210668	http://dx.doi.org/10.1038/sj.onc.1210668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653091				2022-12-25	WOS:000252426100002
J	Kramarova, TV; Shabalina, IG; Andersson, U; Westerberg, R; Carlberg, I; Houstek, J; Nedergaard, J; Cannon, B				Kramarova, Tatiana V.; Shabalina, Irina G.; Andersson, Ulf; Westerberg, Rolf; Carlberg, Inger; Houstek, Josef; Nedergaard, Jan; Cannon, Barbara			Mitochondrial ATP synthase levels in brown adipose tissue are governed by the c-Fo subunit P1 isoform	FASEB JOURNAL			English	Article						biogenesis; assembly; UCP1 promoter; transgenic mice	UNCOUPLING PROTEIN; EXPRESSION; GENE; ELECTROPHORESIS; PURIFICATION; SEQUENCES; F1-ATPASE; DOMAIN; UCP1; FAT	Despite the significance of mitochondrial ATP synthase for mammalian metabolism, the regulation of the amount of ATP synthase in mammalian systems is not understood. As brown adipose tissue mitochondria contain very low amounts of ATP synthase, relative to respiratory chain components, they constitute a physiological system that allows for examination of the control of ATP synthase assembly. To examine the role of the expression of the P1-isoform of the c-F-o subunit in the biogenesis of ATP synthase, we made transgenic mice that express the P1-c subunit isoform under the promoter of the brown adipose tissue-specific protein UCP1. In the resulting UCP1p1 transgenic mice, total P1-c subunit mRNA levels were increased; mRNA levels of other F1F(o)-ATPase subunits were unchanged. In isolated brown-fat mitochondria, protein levels of the total c-Fo subunit were increased. Remarkably, protein levels of ATP synthase subunits that are part of the F-1-ATPase complex were also increased, as was the entire Complex V. Increased ATPase and ATP synthase activities demonstrated an increased functional activity of the F1Fo-ATPase. Thus, the levels of the c-F-o subunit P1-isoform are crucial for defining the final content of the ATP synthase in brown adipose tissue. The level of c-F-o subunit may be a determining factor for F1Fo-ATPase assembly in all higher eukaryotes.-Kramarova, T. V., Shabalina, I. G., Andersson, U., Westerberg, R., Carlberg, I., Houstek, J., Nedergaard, J., Cannon, B. Mitochondrial ATP synthase levels in brown adipose tissue are governed by the c-F-o subunit P1 isoform.	[Kramarova, Tatiana V.; Shabalina, Irina G.; Andersson, Ulf; Westerberg, Rolf; Nedergaard, Jan; Cannon, Barbara] Stockholm Univ, Wenner Gren Inst, Arrhenius Lab, SE-10691 Stockholm, Sweden; [Carlberg, Inger] Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; [Houstek, Josef] Acad Sci Czech Republ, Inst Physiol, Dept Bioenerget, Prague, Czech Republic; [Houstek, Josef] Ctr Appl Genom, Prague, Czech Republic	Stockholm University; Stockholm University; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Cannon, B (corresponding author), Stockholm Univ, Wenner Gren Inst, Arrhenius Lab, SE-10691 Stockholm, Sweden.	barbara.cannon@wgi.su.se	Shabalina, Irina G/A-4225-2011; Andersson, Ulf/ABD-5162-2021; Shabalina, Irina/AAC-3720-2019; Nedergaard, Jan/A-1706-2010; Nedergaard, Jan/Q-8286-2019; Houstek, Josef/C-5019-2012; Cannon, Barbara/B-3089-2016	Shabalina, Irina G/0000-0002-2915-6450; Andersson, Ulf/0000-0003-0316-3860; Shabalina, Irina/0000-0002-2915-6450; Houstek, Josef/0000-0002-8413-4772; Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; Andersson U, 1997, BIOCHEM J, V323, P379, DOI 10.1042/bj3230379; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2000, METH MOL B, V155, P295; CANNON B, 1977, FEBS LETT, V76, P284, DOI 10.1016/0014-5793(77)80169-5; Carbajo RJ, 2005, J MOL BIOL, V351, P824, DOI 10.1016/j.jmb.2005.06.012; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; De Grassi A, 2006, GENE, V371, P224, DOI 10.1016/j.gene.2005.11.022; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; Golozoubova V, 2006, AM J PHYSIOL-ENDOC M, V291, pE350, DOI 10.1152/ajpendo.00387.2005; HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689; HOUSTEK J, 1991, FEBS LETT, V294, P191, DOI 10.1016/0014-5793(91)80666-Q; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; LINDBERG O, 1967, J CELL BIOL, V34, P293, DOI 10.1083/jcb.34.1.293; PALMER DN, 1995, AM J MED GENET, V57, P260, DOI 10.1002/ajmg.1320570230; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	24	57	57	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					55	63		10.1096/fj.07-8581com	http://dx.doi.org/10.1096/fj.07-8581com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17666453				2022-12-25	WOS:000252309900009
J	Zhou, Y; Suram, A; Venugopal, C; Prakasam, A; Lin, SZ; Su, Y; Li, BL; Paul, SM; Sambamurti, K				Zhou, Yan; Suram, Anitha; Venugopal, Chitra; Prakasam, Annamalai; Lin, Suizhen; Su, Yuan; Li, Baolin; Paul, Steven M.; Sambamurti, Kumar			Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of A beta and APP-CTF gamma	FASEB JOURNAL			English	Article						Alzheimer's disease; statins; mevalonic acid; amyloid precursor protein; AICD; isoprenoid	AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; TYPE-4 ALLELE; CHOLESTEROL; PATHOLOGY; ASSOCIATION; SIMVASTATIN; STATINS	Cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases results in generation of the amyloid-beta protein (A beta), which is characteristically deposited in the brain of Alzheimer's disease patients. Inhibitors of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase (the statins) reduce levels of cholesterol and isoprenoids such as geranylgeranyl pyrophosphate (GGPP). Previous studies have demonstrated that cholesterol increases and statins reduce A beta levels mostly by regulating gamma-secretase activity. In this study, we focused on the role of geranylgeranyl isoprenoids GGPP and geranylgeraniol (GGOH) in regulating A beta production. Our data show that the inhibition of GGPP synthesis by statins plays an important role in statin-mediated reduction of A beta secretion. Consistent with this finding, the geranylgeranyl isoprenoids preferentially increase the yield of A beta of 42 residues (A beta 42) in a dose-dependent manner. Our studies further demonstrated that geranylgeranyl isoprenoids increase the yield of APP-CTF gamma (a. k. a. AICD) as well as A beta by stimulating gamma-secretase-mediated cleavage of APP-CTF beta and APP-CTF beta in vitro. Furthermore, GGOH increases the levels of the active gamma-secretase complex in the detergent-insoluble membrane fraction along with its substrates, APP-CTF alpha and APP-CTF beta. Our results indicate that geranylgeranyl isoprenoids may be an important physiological facilitator of gamma-secretase activity that can foster production of the pathologically important A beta 42. -Zhou, Y., Suram, A., Venugopal, C., Prakasam, A., Lin, S., Su, Y., Li, B., Paul, S. M., Sambamurti, K. Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of A beta and APP-CTF gamma.	[Zhou, Yan; Sambamurti, Kumar] Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Lin, Suizhen; Su, Yuan; Li, Baolin; Paul, Steven M.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Zhou, Yan; Suram, Anitha; Venugopal, Chitra; Prakasam, Annamalai; Sambamurti, Kumar] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Medical University of South Carolina	Zhou, Y (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, R4-331,1044 W Walnut, Indianapolis, IN 46202 USA.	Zhou2@iupui.edu; paul_steven_m@lilly.com; sambak@musc.edu	Paul, Steve/ABE-5400-2020; Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214	NIA NIH HHS [AG028544, R01 AG023055-02, AG023055, R01 AG023055-04, R01 AG023055, R03 AG028544, R01 AG023055-03, R01 AG023055-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG023055, R03AG028544] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURKE JR, 1991, INT J NEUROL, V26, P41; Buxbaum JD, 2002, FRONT BIOSCI, V7, pA50, DOI 10.2741/buxbaum; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fagan AM, 2004, AM J PATHOL, V165, P1413, DOI 10.1016/S0002-9440(10)63399-8; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; George AJ, 2004, NEUROBIOL DIS, V16, P124, DOI 10.1016/j.nbd.2004.01.009; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652; Ohnuma S, 1996, J BIOCHEM-TOKYO, V119, P541; Ownby SE, 2003, LIPIDS, V38, P751, DOI 10.1007/s11745-003-1123-8; Parsons RB, 2006, BIOCHEM J, V399, P205, DOI 10.1042/BJ20060655; Parvathy S, 2004, J NEUROCHEM, V90, P1005, DOI 10.1111/j.1471-4159.2004.02521.x; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Sambamurti K, 2004, CURR DRUG TARGETS, V5, P517, DOI 10.2174/1389450043345335; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Sambamurti Kumar, 2006, Current Alzheimer Research, V3, P81, DOI 10.2174/156720506775697142; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sjogren M, 2003, DEMENT GERIATR COGN, V16, P25, DOI 10.1159/000069989; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; Sparks DL, 2000, ANN NY ACAD SCI, V903, P335, DOI 10.1111/j.1749-6632.2000.tb06384.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wada S, 2003, BIOCHEMISTRY-US, V42, P13977, DOI 10.1021/bi034904j; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2002, BIOCHEM SOC T, V30, P525, DOI 10.1042/bst0300525; Zamrini E, 2004, NEUROEPIDEMIOLOGY, V23, P94, DOI 10.1159/000073981; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	44	45	46	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					47	54		10.1096/fj.07-8175com	http://dx.doi.org/10.1096/fj.07-8175com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17666454	Green Accepted			2022-12-25	WOS:000252309900008
J	Curreli, S; Arany, Z; Gerardy-Schahn, R; Mann, D; Stamatos, NM				Curreli, Sabrina; Arany, Zita; Gerardy-Schahn, Rita; Mann, Dean; Stamatos, Nicholas M.			Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ADHESION MOLECULE; N-CAM; SECRETED SEMAPHORINS; HUMAN MONOCYTES; IN-VIVO; ACID; RECEPTOR; GLYCOPROTEINS; UNITS	Polysialic acid (PSA) is a unique linear homopolymer of alpha 2,8-linked sialic acid that has been identified as a posttranslational modification on only five mammalian proteins. Studied predominantly on neural cell adhesion molecule (NCAM) during development of the vertebrate nervous system, PSA modulates cell interactions mediated by NCAM and other adhesion molecules. An isoform of NCAM (CD56) on natural killer (NK) cells is the only protein known to be polysialylated in cells of the immune system, yet the function of PSA in NK cells remains unclear. Weshow here that neuropilin-2 (NRP-2), a receptor for the semaphorin and vascular endothelial growth factor families in neurons and endothelial cells, respectively, is expressed on the surface of human dendritic cells and is polysialylated. Expression of NRP-2 is up-regulated during dendritic cell maturation, coincident with increased expression of ST8Sia IV, one of the key enzymes of PSA biosynthesis, and with the appearance of PSA on the cell surface. PSA on NRP-2 is resistant to digestion with peptide N-glycosidase F but is sensitive to release under alkaline conditions, suggesting that PSA chains are added to O-linked glycans of NRP-2. Removal of polysialic acid from the surface of dendritic cells or binding of NRP-2 with specific IgG promoted dendritic cell-induced activation and proliferation of T lymphocytes. Thus, this newly recognized polysialylated protein on the surface of dendritic cells influences dendritic cell-T lymphocyte interactions through one or more of its distinct extracellular domains.	Univ Maryland, Med Syst, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, Med Syst, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Med Syst, Div Infect Dis, Dept Med, Baltimore, MD 21201 USA; Hannover Med Sch, Zentrum Biochem, Abt Zellulare Chem, D-30625 Hannover, Germany	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Hannover Medical School	Stamatos, NM (corresponding author), Univ Maryland, Med Syst, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.	stamatos@umbi.umd.edu	Curreli, Sabrina/AAA-1380-2021	Curreli, Sabrina/0000-0003-1912-9608	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL072176] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL72176-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Bourbie-Vaudaine S, 2006, J IMMUNOL, V177, P1460, DOI 10.4049/jimmunol.177.3.1460; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Chen CY, 2005, WORLD J SURG, V29, P271, DOI 10.1007/s00268-004-7818-1; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Cohen T, 2002, J PATHOL, V198, P77, DOI 10.1002/path.1179; Cohen T, 2001, BIOCHEM BIOPH RES CO, V284, P395, DOI 10.1006/bbrc.2001.4958; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1982, J BIOL CHEM, V257, P1966; Friedl P, 2005, NAT REV IMMUNOL, V5, P532, DOI 10.1038/nri1647; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Galuska SP, 2006, J BIOL CHEM, V281, P31605, DOI 10.1074/jbc.M606516200; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P29922; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kikutani H, 2003, NAT REV IMMUNOL, V3, P159, DOI 10.1038/nri1003; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LACKIE PM, 1991, DIFFERENTIATION, V47, P85, DOI 10.1111/j.1432-0436.1991.tb00226.x; Lajaunias F, 2005, EUR J IMMUNOL, V35, P243, DOI 10.1002/eji.200425273; MANZI AE, 1994, J BIOL CHEM, V269, P23617; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mendiratta SS, 2006, J BIOL CHEM, V281, P36052, DOI 10.1074/jbc.M608073200; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Nakata D, 2005, J BIOL CHEM, V280, P38305, DOI 10.1074/jbc.M508762200; Renzi MJ, 1999, J NEUROSCI, V19, P7870; RIEGER F, 1985, J CELL BIOL, V101, P285, DOI 10.1083/jcb.101.1.285; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stamatos NM, 2005, FEBS J, V272, P2545, DOI 10.1111/j.1742-4658.2005.04679.x; Stamatos NM, 2004, J LEUKOCYTE BIOL, V75, P307, DOI 10.1189/jlb.0503241; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211; Yuan L, 2002, DEVELOPMENT, V129, P4797; ZUBER C, 1992, J BIOL CHEM, V267, P9965	49	143	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30346	30356		10.1074/jbc.M702965200	http://dx.doi.org/10.1074/jbc.M702965200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699524	hybrid			2022-12-25	WOS:000250136300002
J	Wu, H; Dombrovsky, L; Tempel, W; Martin, F; Loppnau, P; Goodfellow, GH; Grant, DM; Plotnikov, AN				Wu, Hong; Dombrovsky, Ludmila; Tempel, Wolfram; Martin, Fernando; Loppnau, Peter; Goodfellow, Geoffrey H.; Grant, Denis M.; Plotnikov, Alexander N.			Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CANCER; MOLECULAR-GENETICS; NAT1; POLYMORPHISMS; PROTEIN; RISK; PHARMACOGENETICS; IDENTIFICATION; EPIDEMIOLOGY; REVEALS	The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9- A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes.	Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; Structural Genomics Consortium; University of Toronto; University of Toronto	Plotnikov, AN (corresponding author), Univ Toronto, Struct Genom Consortium, 100 Coll St, Toronto, ON M5G 1L5, Canada.	alexander.plotnikov@utoronto.ca			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brockmoller J, 1996, CANCER RES, V56, P3915; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Filiadis IF, 1999, J UROLOGY, V161, P1672, DOI 10.1016/S0022-5347(05)69002-7; Goodfellow GH, 2000, BIOCHEM J, V348, P159, DOI 10.1042/0264-6021:3480159; Grant DM, 2000, PHARMACOLOGY, V61, P204, DOI 10.1159/000028402; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; Gu J, 2005, MUTAT RES-GEN TOX EN, V581, P97, DOI 10.1016/j.mrgentox.2004.11.012; GUENGERICH FP, 1992, PHARMACOL THERAPEUT, V54, P17; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Hein DW, 2000, DRUG METAB DISPOS, V28, P1425; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hughes NC, 1998, PHARMACOGENETICS, V8, P55, DOI 10.1097/00008571-199802000-00008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin HJ, 1998, PHARMACOGENETICS, V8, P269, DOI 10.1097/00008571-199806000-00009; Liu F, 2006, J MOL BIOL, V361, P482, DOI 10.1016/j.jmb.2006.06.029; LOWER GM, 1979, ENVIRON HEALTH PERSP, V29, P71, DOI 10.2307/3429048; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okkels H, 1997, CANCER EPIDEM BIOMAR, V6, P225; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RIDDLE B, 1971, J BIOL CHEM, V246, P3250; Sandy J, 2005, PROTEIN SCI, V14, P775, DOI 10.1110/ps.041163505; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walraven JM, 2007, DRUG METAB DISPOS, V35, P1001, DOI 10.1124/dmd.107.015040; WEBER WW, 1985, PHARMACOL REV, V37, P25; Zhang NX, 2006, J MOL BIOL, V363, P188, DOI 10.1016/j.jmb.2006.08.026	37	98	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30189	30197		10.1074/jbc.M704138200	http://dx.doi.org/10.1074/jbc.M704138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17656365	hybrid			2022-12-25	WOS:000249981200049
J	Yamasaki, S; Stoecklin, G; Kedersha, N; Simarro, M; Anderson, P				Yamasaki, Satoshi; Stoecklin, Georg; Kedersha, Nancy; Simarro, Maria; Anderson, Paul			T-cell intracellular antigen-1 (TIA-1)-induced translational silencing promotes the decay of selected mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BINDING PROTEIN TIAR; CYCLOOXYGENASE-2 EXPRESSION; STRESS GRANULES; IDENTIFICATION; REPRESSION; TRISTETRAPROLIN; MECHANISMS; COMPLEXES; ARTHRITIS	Gene array analysis revealed that a subset of mRNAs overexpressed in macrophages lacking the destabilizing factor TTP are also overexpressed in macrophages lacking the translational silencer TIA-1. We confirmed that a representative transcript, apobec-1, is significantly stabilized in cells lacking TIA-1. Tethering TIA-1 to a reporter transcript also promotes mRNA decay, suggesting that TIA-1- mediated translational silencing can render mRNA susceptible to the decay machinery. TIA-1- mediated decay is inhibited by small interfering RNAs targeting components of either the 5 '-3 ' ( e. g. DCP2) or the 3 '-5 ' ( e. g. exosome component Rrp46) decay pathways, suggesting that TIA-1 renders mRNA susceptible to both major decay pathways. TIA-1 mediated decay is inhibited by cycloheximide and emetine, drugs that stabilize polysomes, but is unaffected by puromycin, a drug that disassembles polysomes. These results suggest that TIA-1-induced polysome disassembly is required for enhanced mRNA decay and that TIA-1-induced translational silencing promotes the decay of selected mRNAs.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Helmholtz Association; German Cancer Research Center (DKFZ)	Anderson, P (corresponding author), Smith 652,1 Jimmy Fund Way, Boston, MA 02115 USA.	panderson@rics.bwh.harvard.edu	; Simarro, Maria/M-3947-2015	Stoecklin, Georg/0000-0001-9284-9834; Simarro, Maria/0000-0001-8917-7328	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI065858, R56AI033600, R01AI033600] Funding Source: NIH RePORTER; NIAID NIH HHS [AI033600, AI065858] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Anderson P, 2002, J CELL SCI, V115, P3227; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Buttner K, 2006, MOL MICROBIOL, V61, P1372, DOI 10.1111/j.1365-2958.2006.05331.x; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Fechir M, 2005, CELL MOL BIOL, V51, P299, DOI 10.1170/T631; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Gu MG, 2004, MOL CELL, V14, P67, DOI 10.1016/S1097-2765(04)00180-7; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Holmes LEA, 2004, MOL CELL BIOL, V24, P2998, DOI 10.1128/MCB.24.7.2998-3010.2004; Izquierdo JM, 2005, MOL CELL, V19, P475, DOI 10.1016/j.molcel.2005.06.015; Kandasamy K, 2005, J BIOL CHEM, V280, P1931, DOI 10.1074/jbc.M405937200; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Le Guiner C, 2003, J BIOL CHEM, V278, P10465, DOI 10.1074/jbc.M212378200; Liu HD, 2005, MOL CELL BIOL, V25, P9764, DOI 10.1128/MCB.25.22.9764-9772.2005; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Stoecklin G, 2006, ADV IMMUNOL, V89, P1, DOI 10.1016/S0065-2776(05)89001-7; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Tong X, 2007, MOL CELL BIOL, V27, P283, DOI 10.1128/MCB.01282-06; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Yang F, 2006, MOL CELL BIOL, V26, P8803, DOI 10.1128/MCB.00090-06; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200	41	58	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30070	30077		10.1074/jbc.M706273200	http://dx.doi.org/10.1074/jbc.M706273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711853	hybrid			2022-12-25	WOS:000249981200037
J	Yuan, WH; Pan, W; Kong, J; Zheng, W; Szeto, FL; Wong, KE; Cohen, R; Klopot, A; Zhang, Z; Li, YC				Yuan, Weihua; Pan, Wei; Kong, Juan; Zheng, Wei; Szeto, Frances L.; Wong, Kari E.; Cohen, Ronald; Klopot, Anna; Zhang, Zhongyi; Li, Yan Chun			1,25-dihydroxyvitamin D-3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; NUCLEAR RECEPTOR; DNA ELEMENT; EXPRESSION; ACTIVATION; ENHANCER; BINDING; CELLS; BETA; MICE	We have shown that 1,25- dihydroxyvitamin D-3 ( 1,25( OH) 2D(3)) down- regulates renin expression. To explore the molecular mechanism, we analyzed the mouse Ren- 1c gene promoter by luciferase reporter assays. Deletion analysis revealed two DNA fragments from - 2725 to - 2647 ( distal fragment) and from - 117 to - 6 ( proximal fragment) that are sufficient to mediate the repression. Mutation of the cAMP response element ( CRE) in the distal fragment blunted forskolin stimulation as well as 1,25( OH) D-2(3) inhibition of the transcriptional activity, suggesting the involvement of CRE in 1,25( OH) D-2(3)- induced suppression. EMSA revealed that 1,25( OH)(2)D-3 markedly inhibited nuclear protein binding to the CRE in the promoter. ChIP and GSTpull- down assays demonstrated that ligandedVDRblocked the binding of CREB to the CRE by directly interacting with CREB with the ligand- binding domain, and the VDR- mediated repression can be rescued by CREB, CBP, or p300 overexpression. These data indicate that 1,25( OH)(2)D-3 suppresses renin gene expression at least in part by blocking the formation of CRE- CREB- CBP complex.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Div Biol Sci, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Li, YC (corresponding author), Univ Chicago, Dept Med, MC 4080,5841 S Maryland Ave, Chicago, IL 60637 USA.	cyan@medicine.bsd.uchicago.edu			NHLBI NIH HHS [HL085793] Funding Source: Medline; NIDDK NIH HHS [DK062072] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062072] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEL KJ, 1990, GENETICS, V124, P937; Adams DJ, 2006, J BIOL CHEM, V281, P31753, DOI 10.1074/jbc.M605720200; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Ausubel F. M, 1994, CURRENT PROTOCOLS MO; Bader M, 2000, J MOL MED, V78, P130, DOI 10.1007/s001090000089; DE CD, 1999, TRENDS BIOCHEM SCI, V24, P281; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kim S, 2006, MOL CELL BIOL, V26, P6469, DOI 10.1128/MCB.00353-06; Klar J, 2002, PFLUG ARCH EUR J PHY, V444, P335, DOI 10.1007/s00424-002-0818-9; Kong J, 2003, AM J PHYSIOL-REG I, V285, pR255, DOI 10.1152/ajpregu.00517.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XB, 2003, CIRC RES, V92, P1033, DOI 10.1161/01.RES.0000071355.82009.43; Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MOFFETT DF, 1993, HUMAN PHYSL FDN FRON, P420; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Morello F, 2005, J CLIN INVEST, V115, P1913, DOI 10.1172/JCI24594; Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157; Nishishita T, 1998, J BIOL CHEM, V273, P10901, DOI 10.1074/jbc.273.18.10901; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pan L, 2005, J BIOL CHEM, V280, P20860, DOI 10.1074/jbc.M414618200; Pan L, 2005, HYPERTENSION, V45, P3, DOI 10.1161/01.HYP.0000149717.55920.45; Pan L, 2003, BBA-GENE STRUCT EXPR, V1625, P280, DOI 10.1016/S0167-4781(03)00016-2; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Qiao GL, 2005, J STEROID BIOCHEM, V96, P59, DOI 10.1016/j.jsbmb.2005.02.008; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Shah S, 2006, MOL CELL, V21, P799, DOI 10.1016/j.molcel.2006.01.037; Shi Q, 2001, HYPERTENSION, V38, P332, DOI 10.1161/01.HYP.38.3.332; Shi Q, 2001, J BIOL CHEM, V276, P3597, DOI 10.1074/jbc.M008361200; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Sun J, 2006, AM J PHYSIOL-ENDOC M, V291, pE315, DOI 10.1152/ajpendo.00590.2005; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; Xiang W, 2005, AM J PHYSIOL-ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Ying LH, 1997, J BIOL CHEM, V272, P2412	48	345	369	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29821	29830		10.1074/jbc.M705495200	http://dx.doi.org/10.1074/jbc.M705495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17690094	hybrid			2022-12-25	WOS:000249981200011
J	Averbeck, N; Keppler-Ross, S; Dean, N				Averbeck, Nicole; Keppler-Ross, Sabine; Dean, Neta			Membrane topology of the Alg14 endoplasmic reticulum UDP-GlcNAc transferase subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE TRANSPORTER; N-LINKED GLYCOSYLATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PEPTIDOGLYCAN BIOSYNTHESIS; CAMPYLOBACTER-JEJUNI; CRYSTAL-STRUCTURE; DOLICHOL PATHWAY; GENE DELETION; YEAST	N-linked glycosylation begins in the endoplasmic reticulum with the synthesis of a highly conserved dolichol-linked oligosaccharide precursor. The UDP-GlcNAc glycosyltransferase catalyzing the second sugar addition of this precursor consists in most eukaryotes of at least two subunits, Alg14 and Alg13. Alg14 is a membrane protein that recruits the soluble Alg13 catalytic subunit from the cytosol to the face of the endoplasmic reticulum ( ER) membrane where this reaction occurs. Here, we investigated the membrane topology of Saccharomyces cerevisiae Alg14 and its requirements for ER membrane association. Alg14 is predicted by most algorithms to contain one or more transmembrane spanning helices (transmembrane domains (TMDs)). We provide evidence that Alg14 contains a C-terminal cytosolic tail and an N terminus that resides within the ER lumen. However, we also demonstrate that Alg14 lacking this TMD is functional and remains peripherally associated with ER membranes, suggesting that additional domains can mediate ER association. These conclusions are based on the functional analysis of Alg13/Alg14 chimeras containing Alg13 fused at either end of Alg14 or truncated Alg14 variants lacking the predicted TMD; protease protection assays of Alg14 in intact ER membranes; and extraction of Alg14-containing ER membranes with high pH. These yeast Alg13-Alg14 chimeras recapitulate the phylogenetic diversity of Alg13-Alg14 domain arrangements that evolved in some protozoa. They encode single polypeptides containing an Alg13 domain fused to Alg14 domain in either orientation, including those lacking the Alg14 TMD. Thus, this Alg13-Alg14 UDP-GlcNAc transferase represents an unprecedented example of a bipartite glycosyltransferase that evolved by both fission and fusion.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dean, N (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Neta.Dean@stonybrook.edu			NIGMS NIH HHS [R01-GM48467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Bickel T, 2005, J BIOL CHEM, V280, P34500, DOI 10.1074/jbc.M506358200; BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199; BUPP K, 1993, J BACTERIOL, V175, P1841, DOI 10.1128/JB.175.6.1841-1843.1993; Chantret I, 2005, J BIOL CHEM, V280, P9236, DOI 10.1074/jbc.M413941200; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2005, J BIOL CHEM, V280, P36254, DOI 10.1074/jbc.M507569200; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; IKEDA M, 1990, NUCLEIC ACIDS RES, V18, P4014, DOI 10.1093/nar/18.13.4014; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; SIKORSKI RS, 1989, GENETICS, V122, P19; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; Tai VWF, 2001, BIOORGAN MED CHEM, V9, P1133, DOI 10.1016/S0968-0896(00)00334-5; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Weerapana E, 2006, GLYCOBIOLOGY, V16, p91R, DOI 10.1093/glycob/cwj099; Yoko-O T, 1998, EUR J BIOCHEM, V257, P630, DOI 10.1046/j.1432-1327.1998.2570630.x; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	28	17	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29081	29088		10.1074/jbc.M704410200	http://dx.doi.org/10.1074/jbc.M704410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686769	hybrid			2022-12-25	WOS:000249788000003
J	Plaza-Menacho, I; Mologni, L; Sala, E; Gambacorti-Passerini, C; Magee, AI; Links, TP; Hofstra, RMW; Barford, D; Isacke, CM				Plaza-Menacho, Ivan; Mologni, Luca; Sala, Elisa; Gambacorti-Passerini, Carlo; Magee, Anthony I.; Links, Thera P.; Hofstra, Robert M. W.; Barford, David; Isacke, Clare M.			Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY-THYROID CARCINOMA; ONCOGENIC RET; STI-571 INHIBITION; ANTITUMOR-ACTIVITY; CANCER-CELLS; B-RAF; RECEPTOR; MUTATIONS; NEOPLASIA; IMATINIB	Germ line missense mutations in the RET (rearranged during transfection) oncogene are the cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only treatment available for MEN2 patients. In this study, the ability of Sorafenib (BAY 43-9006) to act as a RET inhibitor was investigated. Sorafenib inhibited the activity of purified recombinant kinase domain of wild type RET and RETV804M with IC50 values of 5.9 and 7.9 nM, respectively. Interestingly, these values were 6-7-fold lower than the IC50 for the inhibition of B-RAF(V600E). In cell-based assays, Sorafenib inhibited the kinase activity and signaling of wild type and oncogenic RET in MEN2 tumor and established cell lines at a concentration between 15 and 150 nM. In contrast, inhibition of oncogenic B-RAF- or epidermal growth factor-induced ERK1/2 phosphorylation required micromolar concentrations of Sorafenib demonstrating the high specificity of this drug in targeting RET. Moreover, prolonged exposure to Sorafenib resulted in inhibition of cell proliferation and RET protein degradation. Using lysosomal and proteasomal inhibitors, we demonstrate that Sorafenib induces RET lysosomal degradation independent of proteasomal targeting. Furthermore, we provide a structural model of the Sorafenib center dot RETcomplex in which Sorafenib binds to and induces the DFG(out) conformation of the RET kinase domain. These results strengthen the argument that Sorafenib may be effective in the treatment of MEN2 patients. In addition, because inhibition of RET is not impaired by mutation of the Val(804) gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Univ Milan, Dept Clin & Prevent Med, I-20052 Milan, Italy; Univ London Imperial Coll Sci Technol & Med, Sect Mol & Cellular Med, London SW7 2AZ, England; Univ Groningen, Med Ctr, Dept Endocrinol, NL-9700 RB Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Genet, NL-9700 RB Groningen, Netherlands; Inst Canc Res, Sect Struct Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Milan; Imperial College London; University of Groningen; University of Groningen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk	Magee, Anthony/V-8345-2019; Piris, Alejandro/D-3830-2014; Mologni, Luca/AAC-1065-2022; Sala, Elisa/GQA-3928-2022; Plaza-Menacho, Ivan/K-8517-2017	Mologni, Luca/0000-0002-6365-5149; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; Isacke, Clare/0000-0002-9222-3345; Plaza-Menacho, Ivan/0000-0003-4666-9431; sala, elisa/0000-0001-8603-3839; Hofstra, Robert/0000-0001-7498-3829	Medical Research Council [G0100471] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline; MRC [G0100471] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Akeno-Stuart N, 2007, CANCER RES, V67, P6956, DOI 10.1158/0008-5472.CAN-06-4605; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2004, ONCOGENE, V23, P6056, DOI 10.1038/sj.onc.1207810; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; Carniti C, 2003, CANCER RES, V63, P2234; Cranston AN, 2006, CANCER RES, V66, P10179, DOI 10.1158/0008-5472.CAN-06-0884; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; de Groot JWB, 2006, SURGERY, V139, P806, DOI 10.1016/j.surg.2005.10.019; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; Drosten M, 2006, NAT CLIN PRACT ONCOL, V3, P564, DOI 10.1038/ncponc0610; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Knowles PP, 2006, J BIOL CHEM, V281, P33577, DOI 10.1074/jbc.M605604200; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lierman E, 2006, BLOOD, V108, P1374, DOI 10.1182/blood-2006-02-004457; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Mologni L, 2005, PROTEIN EXPRES PURIF, V41, P177, DOI 10.1016/j.pep.2005.01.002; Mologni L, 2006, J MOL ENDOCRINOL, V37, P199, DOI 10.1677/jme.1.01999; Nagar B, 2002, CANCER RES, V62, P4236; Niculescu-Duvaz I, 2006, J MED CHEM, V49, P407, DOI 10.1021/jm050983g; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Pierchala BA, 2006, J NEUROSCI, V26, P2777, DOI 10.1523/JNEUROSCI.3420-05.2006; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Scott RP, 2005, J BIOL CHEM, V280, P13442, DOI 10.1074/jbc.M500507200; Strock CJ, 2003, CANCER RES, V63, P5559; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443	36	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29230	29240		10.1074/jbc.M703461200	http://dx.doi.org/10.1074/jbc.M703461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17664273	hybrid			2022-12-25	WOS:000249788000019
J	Satoh, T; Cowieson, NP; Hakamata, W; Ideo, H; Fukushima, K; Kurihara, M; Kato, R; Yamashita, K; Wakatsuki, S				Satoh, Tadashi; Cowieson, Nathan P.; Hakamata, Wataru; Ideo, Hiroko; Fukushima, Keiko; Kurihara, Masaaki; Kato, Ryuichi; Yamashita, Katsuko; Wakatsuki, Soichi			Structural basis for recognition of high mannose type glycoproteins by mammalian transport lectin VIP36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; PROTEIN; ERGIC-53; BINDING; RECEPTOR; LOCALIZATION; VESICLES; COMPLEX; DOMAIN	VIP36 functions as a transport lectin for trafficking certain high mannose type glycoproteins in the secretory pathway. Here we report the crystal structure of VIP36 exoplasmic/luminal domain comprising a carbohydrate recognition domain and a stalk domain. The structures of VIP36 in complex with Ca2+ and mannosyl ligands are also described. The carbohydrate recognition domain is composed of a 17-stranded antiparallel beta-sandwich and binds one Ca2+ adjoining the carbohydrate-binding site. The structure reveals that a coordinated Ca2+ ion orients the side chains of Asp(131), Asn(166), and His(190) for carbohydrate binding. This result explains the Ca2+-dependent carbohydrate binding of this protein. The Man-alpha-1,2-Man-alpha-1,2-Man, which corresponds to the D1 arm of high mannose type glycan, is recognized by eight residues through extensive hydrogen bonds. The complex structures reveal the structural basis for high mannose type glycoprotein recognition by VIP36 in a Ca2+-dependent and D1 arm-specific manner.	Struct Biol Res Ctr, Photon Factory Inst Mat Struct Sci, High Energy Accelerator Res Organizat, Tsukuba, Ibaraki 305, Japan; Univ Queensland, Insy Mol Biosci, Brisbane, Qld 4072, Australia; Natl Inst Hlth Sci, Div Organ Chem, Tokyo 158, Japan; Tokyo Inst Technol, Innovat Res Initiat, Yokohama, Kanagawa 227, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Tokyo 101, Japan	High Energy Accelerator Research Organization (KEK); University of Queensland; National Institute of Health Sciences - Japan; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Wakatsuki, S (corresponding author), Struct Biol Res Ctr, Photon Factory Inst Mat Struct Sci, High Energy Accelerator Res Organizat, Tsukuba, Ibaraki 305, Japan.	soichi.wakatsuki@kek.jp	Hakamata, Wataru/T-6211-2019; Satoh, Tadashi/M-5157-2017	Satoh, Tadashi/0000-0002-4493-4978; Kato, Ryuichi/0000-0003-2087-2896; Wakatsuki, Soichi/0000-0001-5896-7968				ALLERHAND A, 1984, J AM CHEM SOC, V106, P2412, DOI 10.1021/ja00320a031; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; Appenzeller-Herzog C, 2005, MOL BIOL CELL, V16, P1258, DOI 10.1091/mbc.E04-08-0708; Beignet J, 2004, J ORG CHEM, V69, P6341, DOI 10.1021/jo049061w; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dahm T, 2001, MOL BIOL CELL, V12, P1481, DOI 10.1091/mbc.12.5.1481; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dromer F, 2002, ANTIMICROB AGENTS CH, V46, P3869, DOI 10.1128/AAC.46.12.3869-3876.2002; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fullekrug J, 1999, J CELL SCI, V112, P2813; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2004, GLYCOBIOLOGY, V14, P739, DOI 10.1093/glycob/cwh082; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hauri HP, 2000, J CELL SCI, V113, P587; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hiraki M, 2006, ACTA CRYSTALLOGR D, V62, P1058, DOI 10.1107/S0907444906023821; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; Kamiya Y, 2005, J BIOL CHEM, V280, P37178, DOI 10.1074/jbc.M505757200; Kawasaki N, 2007, J BIOCHEM, V141, P221, DOI 10.1093/jh/mvm024; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MEUWLY R, 1986, HELV CHIM ACTA, V69, P25, DOI 10.1002/hlca.19860690105; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Neve EPA, 2005, J MOL BIOL, V354, P556, DOI 10.1016/j.jmb.2005.09.077; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERS T, 1991, LIEBIGS ANN CHEM, P135; RINI JM, 1993, J BIOL CHEM, V268, P10126; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Satoh T, 2006, J BIOL CHEM, V281, P10410, DOI 10.1074/jbc.M512258200; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Shimada O, 2003, CELL STRUCT FUNCT, V28, P155; Shimada O, 2003, J HISTOCHEM CYTOCHEM, V51, P1057, DOI 10.1177/002215540305100809; TAI T, 1975, J BIOL CHEM, V250, P8569; Tanimoto T, 2002, CHEM PHARM BULL, V50, P280, DOI 10.1248/cpb.50.280; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	50	42	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28246	28255		10.1074/jbc.M703064200	http://dx.doi.org/10.1074/jbc.M703064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652092	hybrid			2022-12-25	WOS:000249455600074
J	Reig, R; Sanchez-Vives, MV				Reig, Ramon; Sanchez-Vives, Maria V.			Synaptic Transmission and Plasticity in an Active Cortical Network	PLOS ONE			English	Article								Background. The cerebral cortex is permanently active during both awake and sleep states. This ongoing cortical activity has an impact on synaptic transmission and short-term plasticity. An activity pattern generated by the cortical network is a slow rhythmic activity that alternates up (active) and down (silent) states, a pattern occurring during slow wave sleep, anesthesia and even in vitro. Here we have studied 1) how network activity affects short term synaptic plasticity and, 2) how synaptic transmission varies in up versus down states. Methodology/Principal Findings. Intracellular recordings obtained from cortex in vitro and in vivo were used to record synaptic potentials, while presynaptic activation was achieved either with electrical or natural stimulation. Repetitive activation of layer 4 to layer 2/3 synaptic connections from ferret visual cortex slices displayed synaptic augmentation that was larger and longer lasting in active than in silent slices. Paired-pulse facilitation was also significantly larger in an active network and it persisted for longer intervals (up to 200 ms) than in silent slices. Intracortical synaptic potentials occurring during up states in vitro increased their amplitude while paired-pulse facilitation disappeared. Both intracortical and thalamocortical synaptic potentials were also significantly larger in up than in down states in the cat visual cortex in vivo. These enhanced synaptic potentials did not further facilitate when pairs of stimuli were given, thus paired-pulse facilitation during up states in vivo was virtually absent. Visually induced synaptic responses displayed larger amplitudes when occurring during up versus down states. This was further tested in rat barrel cortex, where a sensory activated synaptic potential was also larger in up states. Conclusions/Significance. These results imply that synaptic transmission in an active cortical network is more secure and efficient due to larger amplitude of synaptic potentials and lesser short term plasticity.	[Reig, Ramon; Sanchez-Vives, Maria V.] Univ Miguel Hernandez, CSIC, Inst Neurociencias Alicante, Alacant, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Sanchez-Vives, MV (corresponding author), Univ Miguel Hernandez, CSIC, Inst Neurociencias Alicante, Alacant, Spain.	mavi.sanchez@umh.es	Sanchez-Vives, Maria/J-8526-2014; Reig, Ramon/A-6925-2017	Sanchez-Vives, Maria/0000-0002-8437-9083; Reig, Ramon/0000-0002-6475-4181	Ministerio de Educacion y Ciencia de Espana; Human Frontier Science Program	Ministerio de Educacion y Ciencia de Espana(Spanish Government); Human Frontier Science Program(Human Frontier Science Program)	This work has been sponsored by Ministerio de Educacion y Ciencia de Espana and Human Frontier Science Program to MVSV. No role in the study played by the sponsors.	AGHAJANIAN GK, 1989, SYNAPSE, V3, P331, DOI 10.1002/syn.890030406; Andersen P., 1968, PHYSIOLOGICAL BASIS; Anderson J, 2000, NAT NEUROSCI, V3, P617, DOI 10.1038/75797; Azouz R, 1999, J NEUROSCI, V19, P2209; Bazhenov M, 2002, J NEUROSCI, V22, P8691; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; Boudreau CE, 2005, J NEUROSCI, V25, P7179, DOI 10.1523/JNEUROSCI.1445-05.2005; Castro-Alamancos MA, 2002, J PHYSIOL-LONDON, V539, P567, DOI 10.1113/jphysiol.2001.013283; CastroAlamancos MA, 1996, J NEUROSCI, V16, P7742; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Chen DF, 2005, J NEUROPHYSIOL, V94, P2713, DOI 10.1152/jn.00024.2005; COMPTE A, 2003, FAST SYNCHRONIZED OS; Crochet S, 2006, CEREB CORTEX, V16, P618, DOI 10.1093/cercor/bhj008; Crochet S, 2005, EUR J NEUROSCI, V21, P1030, DOI 10.1111/j.1460-9568.2005.03932.x; De No RL, 1938, J NEUROPHYSIOL, V1, P207; Destexhe A, 2003, NAT REV NEUROSCI, V4, P739, DOI 10.1038/nrn1198; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; EVARTS EV, 1964, J NEUROPHYSIOL, V27, P152, DOI 10.1152/jn.1964.27.2.152; Fuentealba P, 2004, J NEUROPHYSIOL, V91, P1990, DOI 10.1152/jn.01105.2003; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; HAIDER B, 2007, J NEUROPHYSIOL; HOBSON JA, 1971, ELECTROEN CLIN NEURO, V30, P97, DOI 10.1016/0013-4694(71)90271-9; Kerr JND, 2002, J NEUROSCI, V22, P1499, DOI 10.1523/JNEUROSCI.22-05-01499.2002; KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813; Lampl I, 1999, NEURON, V22, P361, DOI 10.1016/S0896-6273(00)81096-X; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Massimini M, 2001, J NEUROPHYSIOL, V85, P1346, DOI 10.1152/jn.2001.85.3.1346; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; Nowak LG, 1998, EXP BRAIN RES, V118, P477, DOI 10.1007/s002210050304; Pare D, 1998, J NEUROPHYSIOL, V79, P1450, DOI 10.1152/jn.1998.79.3.1450; Paxinos G., 2005, RAT BRAIN STEREOTAXI, Vxliii; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Reig R, 2006, CEREB CORTEX, V16, P688, DOI 10.1093/cercor/bhj014; Rudolph M, 2005, J NEUROPHYSIOL, V94, P2805, DOI 10.1152/jn.01313.2004; Sachdev RNS, 2004, J NEUROPHYSIOL, V92, P3511, DOI 10.1152/jn.00347.2004; Sanchez-Vives MV, 2000, J NEUROSCI, V20, P4267; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027, DOI 10.1038/79848; SANCHEZVIVES MV, 1998, IS SYNAPTIC DEPRESSI, P896; Shu YS, 2006, NATURE, V441, P761, DOI 10.1038/nature04720; Shu YS, 2003, J NEUROSCI, V23, P10388; Steriade M, 2003, NEURON, V37, P563, DOI 10.1016/S0896-6273(03)00065-5; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; STERIADE M, 1993, J NEUROSCI, V13, P3284; Steriade M, 2001, J NEUROPHYSIOL, V86, P1, DOI 10.1152/jn.2001.86.1.1; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Thomson AM, 1997, J PHYSIOL-LONDON, V502, P131, DOI 10.1111/j.1469-7793.1997.131bl.x; Timofeev I, 1996, J PHYSIOL-LONDON, V494, P265, DOI 10.1113/jphysiol.1996.sp021489; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; Varela JA, 1997, J NEUROSCI, V17, P7926; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Waters J, 2006, J NEUROSCI, V26, P8267, DOI 10.1523/JNEUROSCI.2152-06.2006; Wilson CJ, 1996, J NEUROSCI, V16, P2397; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	56	37	37	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e670	10.1371/journal.pone.0000670	http://dx.doi.org/10.1371/journal.pone.0000670			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668052	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452300010
J	Thedieck, C; Kalbacher, H; Kuczyk, M; Muller, GA; Muller, CA; Klein, G				Thedieck, Cornelia; Kalbacher, Hubert; Kuczyk, Markus; Mueller, Gerhard A.; Mueller, Claudia A.; Klein, Gerd			Cadherin-9 Is a Novel Cell Surface Marker for the Heterogeneous Pool of Renal Fibroblasts	PLOS ONE			English	Article								Background. Interstitial fibroblasts are a minor, but nevertheless very important, component of the kidney. They secrete and remodel extracellular matrix and they produce active compounds such as erythropoietin. However, studying human renal fibroblasts has been hampered by the lack of appropriate surface markers. Methods and Findings. The expression of cadherin-9 in various human renal cell lines and tissues was studied on the mRNA level by RT-PCR and on the protein level with the help of newly generated cadherin-9 antibodies. The classical type II cadherin-9, so far only described in the neural system, was identified as a reliable surface marker for renal fibroblasts. Compared to FSP1, a widely-used cytosolic renal fibroblast marker, cadherin-9 showed a more restricted expression pattern in human kidney. Under pathological conditions, cadherin-9 was expressed in the stroma of renal cell carcinoma, but not in the tumor cells themselves, and in renal fibrosis the percentage of cadherin-9-positive cells was clearly elevated 3 to 5 times compared to healthy kidney tissue. Induction of epithelial mesenchymal transition in renal epithelial cells with cyclosporin-A, which causes renal fibrosis as a side effect, induced cadherin-9 expression. Functional studies following siRNA-mediated knockdown of cadherin-9 revealed that it acts in the kidney like a typical classical cadherin. It was found to be associated with catenins and to mediate homophilic but not heterophilic cell interactions. Conclusions. Cadherin-9 represents a novel and reliable cell surface marker for fibroblasts in healthy and diseased kidneys. Together with the established marker molecules FSP1, CD45 and alpha smooth muscle actin, cadherin-9 can now be used to differentiate the heterogenic pool of renal fibroblasts into resident and activated fibroblasts, immigrated bone marrow derived fibroblast precursors and cells in different stages of epithelial mesenchymal transition.	[Thedieck, Cornelia; Mueller, Claudia A.; Klein, Gerd] Univ Med Clin, Sect Transplantat Immunol & Immunohematol, Med Res Ctr, Tubingen, Germany; [Kalbacher, Hubert] Univ Tubingen, Med & Nat Sci Res Ctr, Tubingen, Germany; [Kuczyk, Markus] Univ Med Clin, Dept Urol, Tubingen, Germany; [Mueller, Gerhard A.] Univ Gottingen, Dept Nephrol & Rheumatol, Med Ctr, Gottingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Gottingen	Klein, G (corresponding author), Univ Med Clin, Sect Transplantat Immunol & Immunohematol, Med Res Ctr, Tubingen, Germany.	gerd.klein@uni-tuebingen.de	Klein, Gerd/C-8499-2013; Lee-Thedieck, Cornelia/H-2835-2013	Lee-Thedieck, Cornelia/0000-0001-8863-5403	DFG (German Research Society) [GK 794]	DFG (German Research Society)(German Research Foundation (DFG))	This project was supported by a grant of the Doctoral Program GK 794 of the DFG (German Research Society) and in part by institutional funding.	Angst BD, 2001, J CELL SCI, V114, P629; BACHMANN S, 1993, J HISTOCHEM CYTOCHEM, V41, P335, DOI 10.1177/41.3.8429197; Bekirov IH, 2002, NEUROSCIENCE, V115, P213, DOI 10.1016/S0306-4522(02)00375-5; Blaschke S, 2002, INT J CANCER, V101, P327, DOI 10.1002/ijc.10623; BOHLE A, 1994, NEPHROL DIAL TRANSPL, V9, P4; Dahl U, 2002, MOL CELL BIOL, V22, P1474, DOI 10.1128/MCB.22.5.1474-1487.2002; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Dekel B, 2006, J AM SOC NEPHROL, V17, P3300, DOI 10.1681/ASN.2005020195; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; Forino M, 2006, INT J EXP PATHOL, V87, P197, DOI 10.1111/j.1365-2613.2006.00479.x; Gooch JL, 2007, TRANSPLANTATION, V83, P439, DOI 10.1097/01.tp.0000251423.78124.51; Goto S, 1998, J AM SOC NEPHROL, V9, P1234; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Igarashi P, 2003, NEPHRON EXP NEPHROL, V94, pE1, DOI 10.1159/000070812; Inoue T, 2005, KIDNEY INT, V67, P2488, DOI 10.1111/j.1523-1755.2005.00358.x; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Le Hir M, 2005, KIDNEY INT, V68, P2400, DOI 10.1111/j.1523-1755.2005.00704_1.x; Le Hir M, 2005, HISTOCHEM CELL BIOL, V123, P335, DOI 10.1007/s00418-005-0788-z; LONNEMANN G, 1995, KIDNEY INT, V47, P845, DOI 10.1038/ki.1995.127; MAXWELL PH, 1993, KIDNEY INT, V44, P1149, DOI 10.1038/ki.1993.362; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; McMorrow T, 2005, NEPHROL DIAL TRANSPL, V20, P2215, DOI 10.1093/ndt/gfh967; MULLER GA, 1995, EXP NEPHROL, V3, P127; Munro SB, 1996, CELL IMMUNOL, V169, P309, DOI 10.1006/cimm.1996.0123; Munro SB, 1996, BIOL REPROD, V55, P822, DOI 10.1095/biolreprod55.4.822; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOUWEN EJ, 1993, KIDNEY INT, V44, P147, DOI 10.1038/ki.1993.225; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Paul R, 1997, CANCER RES, V57, P2741; Plotkin MD, 2006, AM J PHYSIOL-RENAL, V291, pF902, DOI 10.1152/ajprenal.00396.2005; Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Sariola H, 1998, BIOCHEM CELL BIOL, V76, P1009, DOI 10.1139/bcb-76-6-1009; Schuttert JB, 2003, PFLUG ARCH EUR J PHY, V446, P387, DOI 10.1007/s00424-003-1026-y; SCHWINZER R, 1989, LEUKOCYTE TYPING, V4, P628; Shimoyama Y, 2000, BIOCHEM J, V349, P159, DOI 10.1042/0264-6021:3490159; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Strutz F, 1996, EXP NEPHROL, V4, P267; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; Thedieck C, 2005, BRIT J CANCER, V92, P2010, DOI 10.1038/sj.bjc.6602597; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	47	17	17	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e657	10.1371/journal.pone.0000657	http://dx.doi.org/10.1371/journal.pone.0000657			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668045	Green Published, gold			2022-12-25	WOS:000207452300003
J	Hsiau, THC; Diaconu, C; Myers, CA; Lee, J; Cepko, CL; Corbo, JC				Hsiau, Timothy H. -C.; Diaconu, Claudiu; Myers, Connie A.; Lee, Jongwoo; Cepko, Constance L.; Corbo, Joseph C.			The Cis-regulatory Logic of the Mammalian Photoreceptor Transcriptional Network	PLOS ONE			English	Article								The photoreceptor cells of the retina are subject to a greater number of genetic diseases than any other cell type in the human body. The majority of more than 120 cloned human blindness genes are highly expressed in photoreceptors. In order to establish an integrative framework in which to understand these diseases, we have undertaken an experimental and computational analysis of the network controlled by the mammalian photoreceptor transcription factors, Crx, Nrl, and Nr2e3. Using microarray and in situ hybridization datasets we have produced a model of this network which contains over 600 genes, including numerous retinal disease loci as well as previously uncharacterized photoreceptor transcription factors. To elucidate the connectivity of this network, we devised a computational algorithm to identify the photoreceptor-specific cis-regulatory elements (CREs) mediating the interactions between these transcription factors and their target genes. In vivo validation of our computational predictions resulted in the discovery of 19 novel photoreceptor-specific CREs near retinal disease genes. Examination of these CREs permitted the definition of a simple cis-regulatory grammar rule associated with high-level expression. To test the generality of this rule, we used an expanded form of it as a selection filter to evolve photoreceptor CREs from random DNA sequences in silico. When fused to fluorescent reporters, these evolved CREs drove strong, photoreceptor-specific expression in vivo. This study represents the first systematic identification and in vivo validation of CREs in a mammalian neuronal cell type and lays the groundwork for a systems biology of photoreceptor transcriptional regulation.	[Cepko, Constance L.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; [Hsiau, Timothy H. -C.; Diaconu, Claudiu; Myers, Connie A.; Lee, Jongwoo; Corbo, Joseph C.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL)	Cepko, CL (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.	cepko@genetics.harvard.edu; jcorbo@pathology.wustl.edu		Corbo, Joseph/0000-0002-9323-7140	NIH [K08EY014822, R01EY009676]; Foundation for Retina Research, Howard Hughes Medical Institute; NATIONAL EYE INSTITUTE [K08EY014822, R01EY009676] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for Retina Research, Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Funding: This work was supported by funds from NIH grant, K08EY014822, to JCC and by funds from the Foundation for Retina Research, Howard Hughes Medical Institute and an NIH grant, R01EY009676, to CLC.	Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; AHMAD I, 1994, J NEUROCHEM, V62, P396; Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103; Alfano G, 2005, HUM MOL GENET, V14, P913, DOI 10.1093/hmg/ddi084; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Blanchette M, 2006, GENOME RES, V16, P656, DOI 10.1101/gr.4866006; Chang LW, 2006, GENOME RES, V16, P405, DOI 10.1101/gr.4303406; Chen CMA, 2000, MECH DEVELOP, V90, P293; CHEN J, 1994, P NATL ACAD SCI USA, V91, P2611, DOI 10.1073/pnas.91.7.2611; Chen JC, 2005, J NEUROSCI, V25, P118, DOI 10.1523/JNEUROSCI.3571-04.2005; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Corbo JC, 2005, PLOS GENET, V1, P140, DOI 10.1371/journal.pgen.0010011; CORBO JC, 2007, P NATL AC A IN PRESS; Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427; De-Leon SBT, 2007, ANNU REV BIOPH BIOM, V36, P191, DOI 10.1146/annurev.biophys.35.040405.102002; Dlakic M, 2001, EMBO J, V20, P828, DOI 10.1093/emboj/20.4.828; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa A, 2002, J NEUROSCI, V22, P1640, DOI 10.1523/JNEUROSCI.22-05-01640.2002; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619; Huber BR, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-229; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Lenhard B, 2002, BIOINFORMATICS, V18, P1135, DOI 10.1093/bioinformatics/18.8.1135; Lerner LE, 2002, J BIOL CHEM, V277, P25877, DOI 10.1074/jbc.M201407200; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Mitsunaga K, 2004, MECH DEVELOP, V121, P237, DOI 10.1016/j.mod.2004.01.006; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Morris TA, 1997, INVEST OPHTH VIS SCI, V38, P196; Moses AM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-r98; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Pawlyk BS, 2005, INVEST OPHTH VIS SCI, V46, P3039, DOI 10.1167/iovs.05-0371; Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Pennesi ME, 2003, J NEUROSCI, V23, P453; Pittler SJ, 2004, J BIOL CHEM, V279, P19800, DOI 10.1074/jbc.M401864200; Prud'homme B, 2006, NATURE, V440, P1050, DOI 10.1038/nature04597; Qian J, 2005, NUCLEIC ACIDS RES, V33, P3479, DOI 10.1093/nar/gki658; Roberts MR, 2005, INVEST OPHTH VIS SCI, V46, P2897, DOI 10.1167/iovs.05-0093; Rozen S, 2000, Methods Mol Biol, V132, P365; Schneider TD, 2000, NUCLEIC ACIDS RES, V28, P2794, DOI 10.1093/nar/28.14.2794; Schroeder MD, 2004, PLOS BIOL, V2, P1396, DOI 10.1371/journal.pbio.0020271; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Shimada N, 2003, MECH DEVELOP, V120, P455, DOI 10.1016/S0925-4773(03)00002-9; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; SRINIVAS M, 2006, MOL ENDOCRINOL; Stajich JE, 2002, GENOME RES, V12, P1611, DOI 10.1101/gr.361602; Vincent SD, 2005, DEVELOPMENT, V132, P1315, DOI 10.1242/dev.01711; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160; Young JE, 2003, INVEST OPHTH VIS SCI, V44, P4076, DOI 10.1167/iovs.03-0197; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	70	107	109	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e643	10.1371/journal.pone.0000643	http://dx.doi.org/10.1371/journal.pone.0000643			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653270	gold, Green Published			2022-12-25	WOS:000207452200012
J	Lee, SG; Su, ZZ; Emdad, L; Sarkar, D; Franke, TF; Fisher, PB				Lee, S-G; Su, Z-Z; Emdad, L.; Sarkar, D.; Franke, T. F.; Fisher, P. B.			Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling	ONCOGENE			English	Article						AEG-1; Ras; PI3K; Akt; apoptosis	RAPID SUBTRACTION HYBRIDIZATION; NF-KAPPA-B; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR PROGRESSION; HUMAN CANCER; AKT; APOPTOSIS; KINASE; PROTEIN	Astrocyte elevated gene-1 ( AEG-1) displays oncogenic properties. Its expression is elevated in diverse neoplastic states and it cooperates with Ha-ras to promote cellular transformation. Overexpression of AEG-1 augments invasion and anchorage-independent growth of transformed cells, while AEG-1 siRNA inhibits Ha-ras-mediated colony formation, supporting a potential functional role in tumorigenesis. Additionally, oncogenic Ha-ras induces AEG-1 expression through the phosphatidylinositol 3-kinase ( PI3K)-Akt signaling pathway. In the present study, we investigated whether AEG-1 could induce serum-independent cell growth, another property of oncogenes. Overexpression of AEG-1 inhibited serum starvation-induced apoptosis through activation of PI3K-Akt signaling, one of the effector pathways induced by activated Ras. AEG-1 also affected the phosphorylation state of Akt substrates that are implicated in apoptosis suppression, including glycogen synthase kinase 3 beta, c-Myc, murine double minute 2, p53, p21/ mda-6 and Bad. Additionally, AEG-1 blocked the activity of serum starvation-induced caspases. Taken together, these observations provide evidence that AEG-1 is an oncogene cooperating with Ha-ras as well as functioning as a downstream target gene of Ha-ras and may perform a central role in Ha-ras-mediated carcinogenesis. Activation of survival pathways may be one mechanism by which AEG-1 exerts its oncogenic properties.	[Lee, S-G; Su, Z-Z; Emdad, L.; Sarkar, D.; Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Urol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Emdad, L.; Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Neurosurg, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Franke, T. F.] NYU, Sch Med, Dept Psychiat, New York, NY USA; [Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Pathol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; New York University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Urol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.	pbf1@columbia.edu	Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777	NINDS NIH HHS [5 P01 NS31492] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Britt DE, 2004, EXP CELL RES, V300, P134, DOI 10.1016/j.yexcr.2004.06.026; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1984, MECHANISMS TUMOR PRO, P57; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lebedeva IV, 2007, ONCOGENE, V26, P733, DOI 10.1038/sj.onc.1209813; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Rich JN, 2001, CANCER RES, V61, P3556; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WHITE JA, 1992, EXP CELL RES, V203, P157, DOI 10.1016/0014-4827(92)90051-9; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	196	211	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1114	1121		10.1038/sj.onc.1210713	http://dx.doi.org/10.1038/sj.onc.1210713			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704808				2022-12-25	WOS:000253136700011
J	Gurzov, EN; Bakiri, L; Alfaro, JM; Wagner, EF; Izquierdo, M				Gurzov, E. N.; Bakiri, L.; Alfaro, J. M.; Wagner, E. F.; Izquierdo, M.			Targeting c-Jun and JunB proteins as potential anticancer cell therapy	ONCOGENE			English	Article						B16-F10 cancer cells; c-Jun; JunB; RNA interference; SP600125	APOPTOSIS-INDUCING FACTOR; N-TERMINAL KINASE; TRANSCRIPTION FACTOR AP-1; CHRONIC MYELOID-LEUKEMIA; OSTEO-SARCOMA VIRUS; DNA-BINDING; RNA INTERFERENCE; BREAST-CANCER; TUMOR-GROWTH; PROLIFERATION	The activating protein-1 transcription factor, in particular the Jun proteins play critical roles in the regulation of cell proliferation and tumor progression. To study the potential clinical relevance of interfering with JunB expression, we generated retroviruses expressing short hairpin RNA. Reduction of JunB levels causes increased proliferation and tumorigenicity in wild-type murine fibroblasts, whereas in c-Jun knockout cells p53-independent cell cycle arrest and apoptosis are induced. Using melanoma-derived B16-F10 cancer cells the combination of JunB knockdown and c-Jun/JNK inactivation leads to cell cycle arrest and apoptosis-inducing factor-dependent apoptosis. Furthermore, the combined treatment extends survival of mice inoculated with the tumor cells. These results indicate that in the absence of c-Jun, JunB can act as a tumor promoter and inactivation of both, c-Jun and JunB, could provide a valuable strategy for antitumor intervention.	[Gurzov, E. N.; Alfaro, J. M.; Izquierdo, M.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Dept Mol Biol, E-28049 Madrid, Spain; [Bakiri, L.; Wagner, E. F.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Izquierdo, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Dept Mol Biol, E-28049 Madrid, Spain.	mizquierdo@cbm.uam.es	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Wagner, Erwin F/0000-0001-7872-0196; bakiri, latifa/0000-0002-6300-2420; Gurzov, Esteban/0000-0003-4642-0273				Artus C, 2006, ONCOGENE, V25, P5741, DOI 10.1038/sj.onc.1209581; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Marchetti P, 1996, J IMMUNOL, V157, P4830; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szremska AP, 2003, BLOOD, V102, P4159, DOI 10.1182/blood-2003-03-0915; Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Xia HHX, 2006, CANCER LETT, V241, P268, DOI 10.1016/j.canlet.2005.10.031; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN	41	30	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					641	652		10.1038/sj.onc.1210690	http://dx.doi.org/10.1038/sj.onc.1210690			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667939				2022-12-25	WOS:000252674900008
J	Limmon, GV; Arredouani, M; McCann, KL; Minor, RAC; Kobzik, L; Imani, F				Limmon, Gino V.; Arredouani, Mohamed; McCann, Kelly L.; Minor, Radiah A. Corn; Kobzik, Lester; Imani, Farhad			Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA	FASEB JOURNAL			English	Article						lung; epithelium; inflammation; virus infection	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; HUMAN EPITHELIAL-CELLS; DENSITY-LIPOPROTEIN; BINDING-SITE; LIPID UPTAKE; VIRAL-RNA; SR-AI/II; VIRUS; PKR	Double-stranded RNA (dsRNA) is a potent signal to the host immune system for the presence of an ongoing viral infection. The presence of dsRNA, intracellularly or extracellularly, leads to the induction of innate inflammatory cytokines in many cell types including epithelial cells. However, the cell surface receptor for recognition of extracellular dsRNA is not yet determined. Here, we report that extracellular dsRNA is recognized and internalized by scavenger receptor class-A (SR-A). Treatment of human epithelial cells with specific antagonists of SR-A or with an anti-SR-A antibody significantly inhibited dsRNA induction of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and regulated on activation normal T-cell expressed and secreted (RANTES). Furthermore, intranasal dsRNA treatment of SR-A-deficient (SR-A(-/-)) mice showed a significant decrease in the expression of inflammatory cytokines and a corresponding decrease in the accumulation of polymorphonuclear leukocytes (PMNs) in lungs. These data provide direct evidence that SR-A is a novel cell surface receptor for dsRNA, and therefore, SR-A may play a role in antiviral immune responses.-Limmon, G. V., Arredouani, M., McCann, K. L., Corn Minor, R. A., Kobzik, L., Imani, L. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA.	[Limmon, Gino V.; McCann, Kelly L.; Minor, Radiah A. Corn; Imani, Farhad] NIEHS, NIH, Lab Resp Biol, Durham, NC 27709 USA; [Arredouani, Mohamed; Kobzik, Lester] Harvard Univ, Dept Environm Hlth, Cambridge, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University	Imani, F (corresponding author), NIEHS, NIH, Lab Resp Biol, MD 2-01,111 T-W Alexander Dr, Durham, NC 27709 USA.	imani@niehs.nih.gov	Limmon, Gino/X-5913-2019; minor, radiah AC/B-6412-2012	Limmon, Gino/0000-0003-3030-7022; 	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101784, ZIAES101784] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arredouani MS, 2006, AM J RESP CELL MOL, V35, P474, DOI 10.1165/rcmb.2006-0128OC; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; DECKER T, 1992, J INTERFERON RES, V12, P445, DOI 10.1089/jir.1992.12.445; DECLERCQ E, 1969, NATURE, V222, P1148, DOI 10.1038/2221148a0; DOUKAS J, 1994, AM J PATHOL, V145, P137; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Jiang Y, 2006, J BIOL CHEM, V281, P9058, DOI 10.1074/jbc.M507874200; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jozefowski S, 2005, J IMMUNOL, V175, P8032, DOI 10.4049/jimmunol.175.12.8032; Jozefowski S, 2006, J LEUKOCYTE BIOL, V80, P870, DOI 10.1189/jlb.0705357; KOLIAIS SI, 1981, EXPERIENTIA, V37, P971, DOI 10.1007/BF01971785; Konno S, 2002, AM J RESP CELL MOL, V26, P594, DOI 10.1165/ajrcmb.26.5.4438; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LEE JY, 1994, VIROLOGY, V200, P307, DOI 10.1006/viro.1994.1192; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu B, 2002, J BIOL CHEM, V277, P34125, DOI 10.1074/jbc.M204265200; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; Majde JA, 1998, ARCH VIROL, V143, P2371, DOI 10.1007/s007050050467; Meusel TR, 2003, J IMMUNOL, V171, P3768, DOI 10.4049/jimmunol.171.7.3768; Meusel TR, 2002, J IMMUNOL, V168, P6429, DOI 10.4049/jimmunol.168.12.6429; Moore KJ, 2006, ARTERIOSCL THROM VAS, V26, P1702, DOI 10.1161/01.ATV.0000229218.97976.43; Murphy JE, 2005, ATHEROSCLEROSIS, V182, P1, DOI 10.1016/j.atherosclerosis.2005.03.036; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Paludan SR, 2002, EUR CYTOKINE NETW, V13, P306; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Sen GC, 2005, CYTOKINE GROWTH F R, V16, P1, DOI 10.1016/j.cytogfr.2005.01.006; Stringer B, 1996, EXP LUNG RES, V22, P495, DOI 10.3109/01902149609046038; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Wyatt TA, 2005, ALCOHOL, V36, P31, DOI 10.1016/j.alcohol.2005.06.002; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhou HR, 2003, TOXICOL SCI, V74, P335, DOI 10.1093/toxsci/kfg148	45	114	115	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					159	167		10.1096/fj.07-8348com	http://dx.doi.org/10.1096/fj.07-8348com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17709607				2022-12-25	WOS:000252309900019
J	Benghezal, M; Roubaty, C; Veepuri, V; Knudsen, J; Conzelmann, A				Benghezal, Mohammed; Roubaty, Carole; Veepuri, Vijayanath; Knudsen, Jens; Conzelmann, Andreas			SLC1 and SLC4 encode partially redundant acyl-coenzyme A 1-acylglycerol-3-phosphate O-acyltransferases of budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-D; PHOSPHATIDIC-ACID; GPI ANCHOR; GENE; EXPRESSION; MEMBRANE; IDENTIFICATION; SPHINGOLIPIDS; PHOSPHATIDYLCHOLINE	Phosphatidic acid is the intermediate, from which all glycerophospholipids are synthesized. In yeast, it is generated from lysophosphatidic acid, which is acylated by Slc1p, an sn-2-specific, acyl-coenzyme A-dependent 1-acylglycerol-3-phosphate O-acyltransferase. Deletion of SLC1 is not lethal and does not eliminate all microsomal 1-acylglycerol-3-phosphate O-acyltransferase activity, suggesting that an additional enzyme may exist. Here we show that SLC4 (Yor175c), a gene of hitherto unknown function, encodes a second 1-acyl-sn-glycerol-3phosphate acyltransferase. SLC4 harbors a membrane-bound O-acyltransferase motif and down-regulation of SLC4 strongly reduces 1-acyl-sn-glycerol-3-phosphate acyltransferase activity in microsomes from slc1 Delta cells. The simultaneous deletion of SLC1 and SLC4 is lethal. Mass spectrometric analysis of lipids from slc1 Delta and slc4 Delta cells demonstrates that in vivo Slc1p and Slc4p generate almost the same glycerophospholipid profile. Microsomes from slc1 Delta and slc4 Delta cells incubated with [ C-14] oleoyl-coenzyme A in the absence of lysophosphatidic acid and without CTP still incorporate the label into glycerophospholipids, indicating that Slc1p and Slc4p can also use endogenous lysoglycerophospholipids as substrates. However, the lipid profiles generated by microsomes from slc1 Delta and slc4 Delta cells are different, and this suggests that Slc1p and Slc4p have a different substrate specificity or have access to different lyso-glycerophospholipid substrates because of a different subcellular location. Indeed, affinity-purified Slc1p displays Mg2+ - dependent acyltransferase activity not only toward lysophosphatidic acid but also lyso forms of phosphatidylserine and phosphatidylinositol. Thus, Slc1p and Slc4p may not only be active as 1-acylglycerol-3-phosphate O-acyltransferases but also be involved in fatty acid exchange at the sn-2position of mature glycerophospholipids.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Univ So Denmark, DK-5230 Odense M, Denmark	University of Fribourg; University of Southern Denmark	Conzelmann, A (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	andreas.conzelmann@unifr.ch		Benghezal, Mohammed/0000-0002-4207-0192				Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Bosson R, 2006, MOL BIOL CELL, V17, P2636, DOI 10.1091/mbc.E06-02-0104; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Coon M, 2003, MOL CANCER THER, V2, P1067; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DEKROON AI, 2006, BIOCHIM BIOPHYS ACTA, V1771, P343; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Guan XL, 2006, YEAST, V23, P465, DOI 10.1002/yea.1362; HANSON BA, 1980, J LIPID RES, V21, P309; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Jansen G, 2005, GENE, V344, P43, DOI 10.1016/j.gene.2004.10.016; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; LEE KS, 1994, J BIOL CHEM, V269, P19725; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nebauer R, 2004, TOP CURR GENET, V6, P125; Noiriel A, 2004, EUR J BIOCHEM, V271, P3752, DOI 10.1111/j.1432-1033.2004.04317.x; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Richard MG, 1998, LIPIDS, V33, P1229, DOI 10.1007/s11745-998-0328-1; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Sergeant S, 2001, J BIOL CHEM, V276, P4737, DOI 10.1074/jbc.M006571200; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Waksman M, 1997, J BIOL CHEM, V272, P36; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200; Zou JT, 1997, PLANT CELL, V9, P909, DOI 10.1105/tpc.9.6.909	37	82	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30845	30855		10.1074/jbc.M702719200	http://dx.doi.org/10.1074/jbc.M702719200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17675291	Green Submitted, hybrid			2022-12-25	WOS:000250136300053
J	Hammel, M; Sfyroera, G; Pyrpassopoulos, S; Ricklin, D; Ramyar, KX; Pop, M; Jin, Z; Lambris, JD; Geisbrecht, BV				Hammel, Michal; Sfyroera, Georgia; Pyrpassopoulos, Serapion; Ricklin, Daniel; Ramyar, Kasra X.; Pop, Mihai; Jin, Zhongmin; Lambris, John D.; Geisbrecht, Brian V.			Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN-BINDING PROTEIN; CONFORMATIONAL-CHANGES; IMMUNE EVASION; COMPONENT C3; FACTOR-H; ACTIVATION; INNATE; PEPTIDOGLYCAN; RECOGNITION; COMPSTATIN	We report here the discovery and characterization of Ehp, a new secreted Staphylococcus aureus protein that potently inhibits the alternative complement activation pathway. Ehp was identified through a genomic scan as an uncharacterized secreted protein from S. aureus, and immunoblotting of conditioned S. aureus culture medium revealed that the Ehp protein was secreted at the highest levels during log-phase bacterial growth. The mature Ehp polypeptide is composed of 80 residues and is 44% identical to the complement inhibitory domain of S. aureus Efb ( extracellular fibrinogen-binding protein). We observed preferential binding by Ehp to native and hydrolyzed C3 relative to fully active C3b and found that Ehp formed a subnanomolar affinity complex with these various forms of C3 by binding to its thioester-containing C3d domain. Site-directed mutagenesis demonstrated that Arg(75) and Asn(82) are important in forming the Ehp.C3d complex, but loss of these side chains did not completely disrupt Ehp/C3dbinding. This suggested the presence of a second C3d-binding site in Ehp, which was mapped to the proximity of Ehp Asn(63). Further molecular level details of the Ehp/C3d interaction were revealed by solving the 2.7-angstrom crystal structure of an Ehp.C3d complex in which the low affinity site had been mutationally inactivated. Ehp potently inhibited C3b deposition onto sensitized surfaces by the alternative complement activation pathway. This inhibition was directly related to Ehp/C3d binding and was more potent than that seen for Efb-C. An altered conformation in Ehp-bound C3 was detected by monoclonal antibody C3-9, which is specific for a neoantigen exposed in activated forms of C3. Our results suggest that increased inhibitory potency of Ehp relative to Efb-C is derived from the second C3-binding site in this new protein.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19105 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA; Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA	University of Missouri System; University of Missouri Kansas City; University of Pennsylvania; Johns Hopkins University; University System of Maryland; University of Maryland College Park; United States Department of Energy (DOE); Argonne National Laboratory	Geisbrecht, BV (corresponding author), Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, 5100 Rockhill Rd, Kansas City, MO 64110 USA.	GeisbrechtB@umkc.edu	Pop, Mihai/A-7987-2013; Pyrpassopoulos, Serapion/GWZ-1415-2022; Ricklin, Daniel/F-5104-2011; Lambris, John/Q-5633-2018	Pop, Mihai/0000-0001-9617-5304; Pyrpassopoulos, Serapion/0000-0002-9728-9239; Ricklin, Daniel/0000-0001-6140-0233; Lambris, John/0000-0002-9370-5776; Hammel, Michal/0000-0002-5610-9289	NIAID NIH HHS [AI30040] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins JN, 2002, MOL CELL PROTEOMICS, V1, P947, DOI 10.1074/mcp.M200066-MCP200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029; BODEN MK, 1992, MICROB PATHOGENESIS, V12, P289, DOI 10.1016/0882-4010(92)90047-R; BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x; BREDIUS RGM, 1992, INFECT IMMUN, V60, P4838, DOI 10.1128/IAI.60.11.4838-4847.1992; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; Geisbrecht BV, 2006, PROTEIN EXPRES PURIF, V46, P23, DOI 10.1016/j.pep.2005.09.003; Geisbrecht BV, 2003, J BIOL CHEM, V278, P32561, DOI 10.1074/jbc.M302943200; Guthridge JM, 2001, BIOCHEMISTRY-US, V40, P5931, DOI 10.1021/bi0101749; HACK CE, 1988, J IMMUNOL, V141, P1602; Hammel M, 2006, ACTA CRYSTALLOGR F, V62, P285, DOI 10.1107/S1744309106005926; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x; Hornef MW, 2002, NAT IMMUNOL, V3, P1033, DOI 10.1038/ni1102-1033; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, J BIOL CHEM, V258, P4238; ISENMAN DE, 1981, MOL IMMUNOL, V18, P331, DOI 10.1016/0161-5890(81)90057-2; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419; KAWASAKI A, 1987, MICROBIOL IMMUNOL, V31, P551, DOI 10.1111/j.1348-0421.1987.tb03117.x; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Kraus D, 1998, INFECT IMMUN, V66, P399, DOI 10.1128/IAI.66.2.399-405.1998; Kronvall G, 1999, J MOL RECOGNIT, V12, P38, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<38::AID-JMR378>3.0.CO;2-Q; Lachmann PJ, 2002, P NATL ACAD SCI USA, V99, P8461, DOI 10.1073/pnas.132284499; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; Lee LYL, 2004, J INFECT DIS, V190, P571, DOI 10.1086/422259; Lee LYL, 2004, J BIOL CHEM, V279, P50710, DOI 10.1074/jbc.M408570200; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531; Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028; MORIKIS D, 2005, STRUCTURE DYNAMICS A; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Neth O, 2002, J IMMUNOL, V169, P4430, DOI 10.4049/jimmunol.169.8.4430; Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Rooijakkers SHM, 2005, TRENDS MICROBIOL, V13, P596, DOI 10.1016/j.tim.2005.10.002; Rooijakkers SHM, 2005, NAT IMMUNOL, V6, P920, DOI 10.1038/ni1235; Rooijakkers SHM, 2006, CELL MICROBIOL, V8, P1282, DOI 10.1111/j.1462-5822.2006.00709.x; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; SAKAR G, 1990, BIOTECHNIQUES, V8, P404; Sakiniene E, 1999, CLIN EXP IMMUNOL, V115, P95; SCHUHARD M, 2005, PROTEOMIC TECHNOLOGI; Sfyroera G, 2005, J IMMUNOL, V174, P2143, DOI 10.4049/jimmunol.174.4.2143; VERBRUGH HA, 1979, IMMUNOLOGY, V37, P615; WILKINSON BJ, 1978, INFECT IMMUN, V20, P388, DOI 10.1128/IAI.20.2.388-392.1978; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wurzner R, 1999, MOL IMMUNOL, V36, P249, DOI 10.1016/S0161-5890(99)00049-8; Zemla A, 2003, NUCLEIC ACIDS RES, V31, P3370, DOI 10.1093/nar/gkg571; Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971	57	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30051	30061		10.1074/jbc.M704247200	http://dx.doi.org/10.1074/jbc.M704247200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699522	hybrid			2022-12-25	WOS:000249981200035
J	Petroski, MD; Zhou, XL; Dong, GQ; Daniel-Issakani, S; Payan, DG; Huang, JN				Petroski, Matthew D.; Zhou, Xiulan; Dong, GuoQiang; Daniel-Issakani, Sarkiz; Payan, Donald G.; Huang, Jianing			Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitin-conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; POLYUBIQUITIN CHAIN; STRUCTURAL BASIS; DNA-REPAIR; COMPLEX; TRAF6; ACTIVATION; PROTEIN; LIGASE; DEGRADATION	Protein modification with lysine 63- linked ubiquitin chains has been implicated in the non- proteolytic regulation of signaling pathways. To understand the molecular mechanisms underlying this process, we have developed an in vitro system to examine the activity of the ubiquitin- conjugating enzyme UBC13- UEV1A with TRAF6 in which TRAF6 serves as both a ubiquitin ligase and substrate for modification. Although TRAF6 potently stimulates the activity of UBC13- UEV1A to synthesize ubiquitin chains, it is not appreciably ubiquitinated. We have determined that the presentation of Lys(63) of ubiquitin by UEV1A suppresses TRAF6 modification. Based on our observations, we propose that the modification of proteins with Lys(63)- linked ubiquitin chains occurs through a UEV1A- independent substrate modification and UEV1A- dependent Lys(63)- linked ubiquitin chain synthesis mechanism.	Rigel Pharmaceut Inc, San Francisco, CA 94080 USA		Petroski, MD (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	matt.petroski@yahoo.com						Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Brzovic PS, 2006, CELL CYCLE, V5, P2867, DOI 10.4161/cc.5.24.3592; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Pastushok L, 2005, J BIOL CHEM, V280, P17891, DOI 10.1074/jbc.M410469200; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rodrigo-Brenni MC, 2007, CELL, V130, P127, DOI 10.1016/j.cell.2007.05.027; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038	28	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29936	29945		10.1074/jbc.M703911200	http://dx.doi.org/10.1074/jbc.M703911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709375	hybrid			2022-12-25	WOS:000249981200023
J	Sum, CS; Tikhonova, IG; Neumann, S; Engel, S; Raaka, BM; Costanzi, S; Gershengorn, MC				Sum, Chi Shing; Tikhonova, Irina G.; Neumann, Susanne; Engel, Stanislav; Raaka, Bruce M.; Costanzi, Stefano; Gershengorn, Marvin C.			Identification of residues important for agonist recognition and activation in GPR40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR GPR40; PANCREATIC BETA-CELLS; INSULIN-SECRETION; CRYSTAL-STRUCTURE; FATTY-ACIDS; BINDING	GPR40 was formerly an orphan G protein-coupled receptor whose endogenous ligands have recently been identified as free fatty acids (FFAs). The receptor, now named FFA receptor 1, has been implicated in the pathophysiology of type 2 diabetes and is a drug target because of its role in FFA-mediated enhancement of glucose-stimulated insulin release. Guided by molecular modeling, we investigated the molecular determinants contributing to binding of linoleic acid, a C18 polyunsaturated FFA, and GW9508, a synthetic small molecule agonist. Twelve residues within the putative GPR40-binding pocket including hydrophilic/positively charged, aromatic, and hydrophobic residues were identified and were subjected to site-directed mutagenesis. Our results suggest that linoleic acid and GW9508 are anchored on their carboxylate groups by Arg183, Asn244, and Arg258. Moreover, His86, Tyr91, and His137 may contribute to aromatic and/or hydrophobic interactions with GW9508 that are not present, or relatively weak, with linoleic acid. The anchor residues, as well as the residues Tyr12, Tyr91, His137, and Leu186, appear to be important for receptor activation also. Interestingly, His137 and particularly His86 may interact with GW9508 in a manner dependent on its protonation status. The greater number of putative interactions between GPR40 and GW9508 compared with linoleic acid may explain the higher potency of GW9508.	NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biol Modelling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gershengorn, MC (corresponding author), 50 South Dr,Rm 4134, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov	Costanzi, Stefano/G-8990-2013; Neumann, Susanne/GPK-6035-2022; Engel, Stanislav/G-2799-2013	Engel, Stanislav/0000-0001-5916-5190; Costanzi, Stefano/0000-0003-3183-7332	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK011006, ZIADK013025, Z01DK011006, Z01DK047045, Z01DK013025] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2005, DNA CELL BIOL, V24, P54, DOI 10.1089/dna.2005.24.54; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Feng DD, 2006, ENDOCRINOLOGY, V147, P674, DOI 10.1210/en.2005-0225; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Fujiwara K, 2005, AM J PHYSIOL-ENDOC M, V289, pE670, DOI 10.1152/ajpendo.00035.2005; Garrido DM, 2006, BIOORG MED CHEM LETT, V16, P1840, DOI 10.1016/j.bmcl.2006.01.007; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jaschke H, 2006, J BIOL CHEM, V281, P9841, DOI 10.1074/jbc.C600014200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Latour MG, 2007, DIABETES, V56, P1087, DOI 10.2337/db06-1532; *LLC, 2005, MACR; McKeown SC, 2007, BIOORG MED CHEM LETT, V17, P1584, DOI 10.1016/j.bmcl.2006.12.084; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nolan CJ, 2006, DIABETES, V55, pS16, DOI 10.2337/db06-S003; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Poitout V, 2003, TRENDS ENDOCRIN MET, V14, P201, DOI 10.1016/S1043-2760(03)00086-9; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; Shapiro H, 2005, BIOCHEM BIOPH RES CO, V335, P97, DOI 10.1016/j.bbrc.2005.07.042; Song FB, 2007, J MED CHEM, V50, P2807, DOI 10.1021/jm070130j; Steneberg R, 2005, CELL METAB, V1, P245, DOI 10.1016/j.cmet.2005.03.007; Stoddart LA, 2007, MOL PHARMACOL, V71, P994, DOI 10.1124/mol.106.031534; Surgand JS, 2006, PROTEINS, V62, P509, DOI 10.1002/prot.20768; Tikhonova IG, 2007, J MED CHEM, V50, P2981, DOI 10.1021/jm0614782; *TRIPOS ASS INC, 2006, SYBYL	29	95	101	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29248	29255		10.1074/jbc.M705077200	http://dx.doi.org/10.1074/jbc.M705077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699519	hybrid			2022-12-25	WOS:000249788000021
J	Lee, C; Kramer, G; Graham, DE; Appling, DR				Lee, Changkeun; Kramer, Gisela; Graham, David E.; Appling, Dean R.			Yeast mitochondrial initiator tRNA is methylated at guanosine 37 by the Trm5-encoded tRNA (guanine-N1-)-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; C-1-TETRAHYDROFOLATE SYNTHASE; MESSENGER-RNAS; METHYLTRANSFERASE; TRANSLATION; GENE; PROTEIN; DNA; IDENTIFICATION; MECHANISM	The TRM5 gene encodes a tRNA (guanine-N1-)-methyttransferase (Trm5p) that methylates guanosine at position 37 (m(1)G37) in cytoplasmic tRNAs in Saccharomyces cerevisiae. Here we show that Trm5p is also responsible for m(1)G37 methylation of mitochondrial tRNAs. The TRMS open reading frame encodes 499 amino acids containing four potential initiator codons within the first 48 codons. Full-length Trm5p, purified as a fusion protein with maltose-binding protein, exhibited robust methyltransferase activity with tRNA isolated from a Delta trm5 mutant strain, as well as with a synthetic mitochondrial initiator tRNA (tRNA(f)(Met)). Primer extension demonstrated that the site of methylation was guanosine 37 in both mitochondrial tRNA(f)(Met) and tRNA(Ph). High pressure liquid chromatography analysis showed the methylated product to be m(1)G. Subcellular fractionation and immunoblotting of a strain expressing a green fluorescent protein-tagged version of the TRMS gene revealed that the enzyme was localized to both cytoplasm and mitochondria. The slightly larger mitochondrial form was protected from protease digestion, indicating a matrix localization. Analysis of N-terminal truncation mutants revealed that a Trm5p active in the cytoplasm could be obtained with a construct lacking amino acids 1-33 (Delta 1-33), whereas production of a Trm5p active in the mitochondria required these first 33 amino acids. Yeast expressing the Delta 1-33 construct exhibited a significantly lower rate of oxygen consumption, indicating that efficiency or accuracy of mitochondrial protein synthesis is decreased in cells lacking m(1)G37 methylation of mitochondrial tRNAs. These data suggest that this tRNA modification plays an important role in reading frame maintenance in mitochondrial protein synthesis.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.	dappling@mail.utexas.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				BJORK GR, 1989, SCIENCE, V244, P986, DOI 10.1126/science.2471265; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; BROOM AD, 1964, BIOCHEMISTRY-US, V3, P494, DOI 10.1021/bi00892a005; Brule H, 2004, BIOCHEMISTRY-US, V43, P9243, DOI 10.1021/bi049671q; CANADAY J, 1980, NUCLEIC ACIDS RES, V8, P1445, DOI 10.1093/nar/8.7.1445; Chan SY, 2003, J BIOL CHEM, V278, P43051, DOI 10.1074/jbc.M308696200; Chang KJ, 2006, J BIOL CHEM, V281, P7775, DOI 10.1074/jbc.M511265200; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; Christian T, 2004, J MOL BIOL, V339, P707, DOI 10.1016/j.jmb.2004.04.025; CIGAN AM, 1987, GENE, V59, P1; DAUM G, 1982, J BIOL CHEM, V257, P3028; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Dunin-Horkawicz S, 2006, NUCLEIC ACIDS RES, V34, pD145, DOI 10.1093/nar/gkj084; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Garcia M, 2007, MOL BIOL CELL, V18, P362, DOI 10.1091/mbc.E06-09-0827; Graham DE, 2007, METHOD ENZYMOL, V425, P185; Hiley SL, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni002; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hou YM, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj018; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jackman JE, 2003, RNA, V9, P574, DOI 10.1261/rna.5070303; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; Kristelly R, 2004, J BIOL CHEM, V279, P47352, DOI 10.1074/jbc.M406056200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li MZ, 2007, NAT METHODS, V4, P251, DOI 10.1038/NMETH1010; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MARTIN RP, 1978, NUCLEIC ACIDS RES, V5, P4579, DOI 10.1093/nar/5.12.4579; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200; SIKORSKI RS, 1989, GENETICS, V122, P19; SINDHUPHAK T, 1985, BIOCHIM BIOPHYS ACTA, V824, P66, DOI 10.1016/0167-4781(85)90030-2; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SMITH JD, 1959, BIOCHEM J, V72, P294, DOI 10.1042/bj0720294; SMOLAR N, 1975, NUCLEIC ACIDS RES, V2, P993, DOI 10.1093/nar/2.6.993; Spencer AC, 2004, BIOCHEMISTRY-US, V43, P9743, DOI 10.1021/bi049639w; Takeda H, 2006, GENES CELLS, V11, P1353, DOI 10.1111/j.1365-2443.2006.01022.x; THOMAS RC, 1982, INTRACELLULAR PH ITS, P189; Tibbetts AS, 2003, J BIOL CHEM, V278, P31774, DOI 10.1074/jbc.M304962200; Tibbetts AS, 2000, J BIOL CHEM, V275, P20920, DOI 10.1074/jbc.M909851199; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Walkup AS, 2005, ARCH BIOCHEM BIOPHYS, V442, P196, DOI 10.1016/j.abb.2005.08.007; WOLFE CL, 1994, J BIOL CHEM, V269, P13361	44	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27744	27753		10.1074/jbc.M704572200	http://dx.doi.org/10.1074/jbc.M704572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652090	hybrid			2022-12-25	WOS:000249455600023
J	Funicello, M; Novelli, M; Ragni, M; Vottari, T; Cocuzza, C; Soriano-Lopez, J; Chiellini, C; Boschi, F; Marzola, P; Masiello, P; Saftig, P; Santini, F; St-Jacques, R; Desmarais, S; Morin, N; Mancini, J; Percival, MD; Pinchera, A; Maffei, M				Funicello, Marcella; Novelli, Michela; Ragni, Maurizio; Vottari, Teresa; Cocuzza, Cesare; Soriano-Lopez, Joaquin; Chiellini, Chiara; Boschi, Federico; Marzola, Pasquina; Masiello, Pellegrino; Saftig, Paul; Santini, Ferruccio; St-Jacques, Rene; Desmarais, Sylvie; Morin, Nicolas; Mancini, Joseph; Percival, M. David; Pinchera, Aldo; Maffei, Margherita			Cathepsin K Null Mice Show Reduced Adiposity during the Rapid Accumulation of Fat Stores	PLOS ONE			English	Article								Growing evidences indicate that proteases are implicated in adipogenesis and in the onset of obesity. We previously reported that the cysteine protease cathepsin K (ctsk) is overexpressed in the white adipose tissue (WAT) of obese individuals. We herein characterized the WAT and the metabolic phenotype of ctsk deficient animals (ctsk-/-). When the growth rate of ctsk-/- was compared to that of the wild type animals (WT), we could establish a time window (5-8 weeks of age) within which ctsk-/- display significantly lower body weight and WAT size as compared to WT. Such a difference was not observable in older mice. Upon treatment with high fat diet (HFD) for 12 weeks ctsk-/- gained significantly less weight than WT and showed reduced brown adipose tissue, liver mass and a lower percentage of body fat. Plasma triglycerides, cholesterol and leptin were significantly lower in HFD-fed-ctsk-/- as compared to HFD-fed WT animals. Adipocyte lipolysis rates were increased in both young and HFD-fed-ctsk-/-, as compared to WT. Carnitine palmitoyl transferase-1 activity, was higher in mitochondria isolated from the WAT of HFD treated ctsk-/- as compared to WT. Together, these data indicate that ctsk ablation in mice results in reduced body fat content under conditions requiring a rapid accumulation of fat stores. This observation could be partly explained by an increased release and/or utilization of FFA and by an augmented ratio of lipolysis/lipogenesis. These results also demonstrate that under a HFD, ctsk deficiency confers a partial resistance to the development of dyslipidemia.	[Funicello, Marcella; Ragni, Maurizio; Vottari, Teresa; Cocuzza, Cesare; Soriano-Lopez, Joaquin; Chiellini, Chiara; Maffei, Margherita] Univ Hosp Pisa, Dulbecco Telethon Inst, Dept Endocrinol & Metab, Pisa, Italy; [Novelli, Michela; Masiello, Pellegrino] Univ Pisa, Dept Expt Pathol Med Biotechnol Infectivol & Epid, Pisa, Italy; [Boschi, Federico; Marzola, Pasquina] Univ Verona, Fac Med, Dept Morphol Biomed Sci, Human Anat & Histol Sect, I-37100 Verona, Italy; [Saftig, Paul] Univ Kiel, Inst Biochem, D-2300 Kiel, Germany; [St-Jacques, Rene] Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Kirkland, PQ, Canada; [Desmarais, Sylvie; Morin, Nicolas; Mancini, Joseph; Percival, M. David] Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ, Canada	Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Pisa; Azienda Ospedaliero Universitaria Pisana; University of Pisa; University of Verona; University of Kiel; Merck & Company; Merck & Company	Maffei, M (corresponding author), Univ Hosp Pisa, Dulbecco Telethon Inst, Dept Endocrinol & Metab, Pisa, Italy.	mmaffei@dti.telethon.it	Saftig, Paul/A-7966-2010; Ragni, Maurizio/AAB-1527-2020; Santini, Ferruccio/J-9272-2018	Ragni, Maurizio/0000-0001-6548-741X; Santini, Ferruccio/0000-0002-1706-0822; MARZOLA, Pasquina/0000-0001-6936-8901	Telethon Foundation [TCP99016]; Compagnia di San Paolo	Telethon Foundation(Fondazione Telethon); Compagnia di San Paolo(Compagnia di San Paolo)	Margherita Maffei is an Assistant Telethon Scientist. MF, MR, TV, CC, JSL were supported by a Telethon fellowship. This work was supported by Telethon Foundation (grant TCP99016) and Compagnia di San Paolo.	BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; Boord JB, 2002, CURR OPIN LIPIDOL, V13, P141, DOI 10.1097/00041433-200204000-00005; Bouloumie A, 2001, DIABETES, V50, P2080, DOI 10.2337/diabetes.50.9.2080; Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222; Buhling F, 2001, J PATHOL, V195, P375; Buhling F, 2000, ADV EXP MED BIOL, V477, P281; CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046-8177(94)90003-5; Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200; Chiellini C, 2003, J CELL PHYSIOL, V195, P309, DOI 10.1002/jcp.10253; Cock TA, 2003, LANCET, V362, P1572, DOI 10.1016/S0140-6736(03)14747-2; Corisdeo S, 2001, BIOCHEM BIOPH RES CO, V285, P335, DOI 10.1006/bbrc.2001.5127; Dodds RA, 1999, ARTHRITIS RHEUM, V42, P1588, DOI 10.1002/1529-0131(199908)42:8<1588::AID-ANR4>3.0.CO;2-S; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; FOLCH J, 1957, J BIOL CHEM, V226, P497; Friedrichs B, 2003, J CLIN INVEST, V111, P1733, DOI 10.1172/JCI200315990; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; Herrera E, 2000, DIABETES-METAB RES, V16, P202, DOI 10.1002/1520-7560(200005/06)16:3<202::AID-DMRR116>3.3.CO;2-R; Hummel KM, 1998, J RHEUMATOL, V25, P1887; Lazner F, 1999, MOL MED TODAY, V5, P413, DOI 10.1016/S1357-4310(99)01563-4; Lecaille F, 2002, BIOCHEMISTRY-US, V41, P8447, DOI 10.1021/bi025638x; Levine JA, 1998, J CLIN INVEST, V101, P1557, DOI 10.1172/JCI2293; Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313; Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522; Lipton A, 2005, EXPERT OPIN BIOL TH, V5, P817, DOI 10.1517/14712598.5.6.817; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449; Maquoi E, 2002, DIABETES, V51, P1093, DOI 10.2337/diabetes.51.4.1093; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rodgers KJ, 2006, ARTERIOSCL THROM VAS, V26, P851, DOI 10.1161/01.ATV.0000203526.75772.4b; RUNGER TM, 2006, J INVEST DERMATOL; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sell H, 2004, INT J BIOCHEM CELL B, V36, P2098, DOI 10.1016/j.biocel.2004.04.003; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Taleb S, 2005, FASEB J, V19, P1540, DOI 10.1096/fj.05-3673fje; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Turk S, 2003, BIOCHEM SOC SYMP, V70, P15; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013; Xiao Y, 2006, J CLIN ENDOCR METAB, V91, P4520, DOI 10.1210/jc.2005-2486	43	45	49	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e683	10.1371/journal.pone.0000683	http://dx.doi.org/10.1371/journal.pone.0000683			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668061	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452300019
J	Lenoir, M; Serre, F; Cantin, L; Ahmed, SH				Lenoir, Magalie; Serre, Fuschia; Cantin, Lauriane; Ahmed, Serge H.			Intense Sweetness Surpasses Cocaine Reward	PLOS ONE			English	Article							EXTRACELLULAR DOPAMINE CONCENTRATIONS; NUCLEUS-ACCUMBENS; DRUG-ADDICTION; INTRAVENOUS COCAINE; RHESUS-MONKEYS; FOOD-INTAKE; CHOICE; MORPHINE; OBESITY; SUGAR	Background. Refined sugars (e.g., sucrose, fructose) were absent in the diet of most people until very recently in human history. Today overconsumption of diets rich in sugars contributes together with other factors to drive the current obesity epidemic. Overconsumption of sugar-dense foods or beverages is initially motivated by the pleasure of sweet taste and is often compared to drug addiction. Though there are many biological commonalities between sweetened diets and drugs of abuse, the addictive potential of the former relative to the latter is currently unknown. Methodology/Principal findings. Here we report that when rats were allowed to choose mutually-exclusively between water sweetened with saccharin-an intense calorie-free sweetener-and intravenous cocaine-a highly addictive and harmful substance-the large majority of animals (94%) preferred the sweet taste of saccharin. The preference for saccharin was not attributable to its unnatural ability to induce sweetness without calories because the same preference was also observed with sucrose, a natural sugar. Finally, the preference for saccharin was not surmountable by increasing doses of cocaine and was observed despite either cocaine intoxication, sensitization or intake escalation-the latter being a hallmark of drug addiction. Conclusions. Our findings clearly demonstrate that intense sweetness can surpass cocaine reward, even in drug-sensitized and -addicted individuals. We speculate that the addictive potential of intense sweetness results from an inborn hypersensitivity to sweet tastants. In most mammals, including rats and humans, sweet receptors evolved in ancestral environments poor in sugars and are thus not adapted to high concentrations of sweet tastants. The supranormal stimulation of these receptors by sugar-rich diets, such as those now widely available in modern societies, would generate a supranormal reward signal in the brain, with the potential to override self-control mechanisms and thus to lead to addiction.	[Lenoir, Magalie; Serre, Fuschia; Cantin, Lauriane; Ahmed, Serge H.] Univ Bordeaux 2, CNRS, Univ Bordeaux 1, UMR 5227, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Ahmed, SH (corresponding author), Univ Bordeaux 2, CNRS, Univ Bordeaux 1, UMR 5227, F-33076 Bordeaux, France.	sahmed@u--bordeaux2.fr	Lenoir, Magalie/E-5797-2019; SERRE, Fuschia/AAU-3161-2020; AHMED, Serge H/D-5236-2014	Lenoir, Magalie/0000-0001-7983-1824; SERRE, Fuschia/0000-0002-0228-3572; Ahmed, Serge/0000-0002-1225-9234	Universite Victor-Segalen Bordeaux 2; French Research Council (CNRS); Conseil Regional Aquitaine; National Research Agency (ANR); Fondation pour la Recherche Medicale (FRM)	Universite Victor-Segalen Bordeaux 2; French Research Council (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Conseil Regional Aquitaine(Region Nouvelle-Aquitaine); National Research Agency (ANR)(French National Research Agency (ANR)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	This work was supported by grants from the Universite Victor-Segalen Bordeaux 2, the French Research Council (CNRS), the Conseil Regional Aquitaine, the National Research Agency (ANR) and the Fondation pour la Recherche Medicale (FRM).	Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298; Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872; AIGNER TG, 1978, SCIENCE, V201, P534, DOI 10.1126/science.96531; Avena NM, 2006, NEUROSCIENCE, V139, P813, DOI 10.1016/j.neuroscience.2005.12.037; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; Berthoud HR, 2004, PHYSIOL BEHAV, V81, P781, DOI 10.1016/j.physbeh.2004.04.034; Blundell JE, 2001, OBES RES, V9, p263S, DOI 10.1038/oby.2001.129; CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407; CARROLL ME, 1993, PSYCHOPHARMACOLOGY, V110, P5, DOI 10.1007/BF02246944; Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401; Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66; Collier G, 1967, J Comp Physiol Psychol, V64, P401; DAnci KE, 1996, PHARMACOL BIOCHEM BE, V54, P693, DOI 10.1016/0091-3057(96)00016-0; Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICIANO P, 1995, BEHAV PHARMACOL, V6, P311; Doyon WM, 2004, ALCOHOL, V34, P261, DOI 10.1016/j.alcohol.2004.10.004; Drewnowski A, 1997, ANNU REV NUTR, V17, P237, DOI 10.1146/annurev.nutr.17.1.237; ETTENBERG A, 1991, PSYCHOPHARMACOLOGY, V103, P455, DOI 10.1007/BF02244244; Hajnal A, 2004, AM J PHYSIOL-REG I, V286, pR31, DOI 10.1152/ajpregu.00282.2003; Hajnal A, 2002, NEUROREPORT, V13, P2213, DOI 10.1097/00001756-200212030-00010; Hajnal A, 2001, BRAIN RES, V904, P76, DOI 10.1016/S0006-8993(01)02451-9; HAJNAL A, COMMUNICATION; Hemby SE, 1999, J PHARMACOL EXP THER, V288, P274; Hemby SE, 1997, PSYCHOPHARMACOLOGY, V133, P7, DOI 10.1007/s002130050365; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Kanarek RB, 1997, PHARMACOL BIOCHEM BE, V57, P377, DOI 10.1016/S0091-3057(96)00337-1; Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016; Kelley AE, 2003, EUR J NEUROSCI, V18, P2592, DOI 10.1046/j.1460-9568.2003.02991.x; Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5; Kilner RM, 1999, NATURE, V397, P667, DOI 10.1038/17746; Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x; Koob GF, 2006, NEUR ADD; Levine AS, 2003, AM J CLIN NUTR, V78, p834S, DOI 10.1093/ajcn/78.4.834S; LIEBLICH I, 1983, SCIENCE, V221, P871, DOI 10.1126/science.6879185; Malik VS, 2006, AM J CLIN NUTR, V84, P274; MARK GP, 1991, BRAIN RES, V551, P308, DOI 10.1016/0006-8993(91)90946-S; Mateo Y, 2004, EUR J NEUROSCI, V20, P2838, DOI 10.1111/j.1460-9568.2004.03736.x; MEIL WM, 1995, PSYCHOPHARMACOLOGY, V118, P338, DOI 10.1007/BF02245964; Melendez RI, 2002, ALCOHOL CLIN EXP RES, V26, P318; MINTZ S, 1985, SWEETNESS POWER PLAC, P274; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; NADER MA, 1991, PSYCHOPHARMACOLOGY, V105, P169, DOI 10.1007/BF02244304; Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096; Norgren R, 2006, PHYSIOL BEHAV, V89, P531, DOI 10.1016/j.physbeh.2006.05.024; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Pecina S, 2006, NEUROSCIENTIST, V12, P500, DOI 10.1177/1073858406293154; Pelchat ML, 2002, PHYSIOL BEHAV, V76, P347, DOI 10.1016/S0031-9384(02)00757-6; PETTIT HO, 1991, BRAIN RES, V539, P94, DOI 10.1016/0006-8993(91)90690-W; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Popkin BM, 2003, OBES RES, V11, P1325, DOI 10.1038/oby.2003.179; Rada P, 2005, NEUROSCIENCE, V134, P737, DOI 10.1016/j.neuroscience.2005.04.043; Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384; Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Rudski JM, 1997, PHARMACOL BIOCHEM BE, V58, P679, DOI 10.1016/S0091-3057(97)00019-1; Sclafani A, 2004, PHYSIOL BEHAV, V81, P773, DOI 10.1016/j.physbeh.2004.04.031; Scott K, 2005, NEURON, V48, P455, DOI 10.1016/j.neuron.2005.10.015; Sizemore GM, 2000, PSYCHOPHARMACOLOGY, V150, P391, DOI 10.1007/s002130000456; Smith JC, 2002, APPETITE, V38, P155, DOI 10.1006/appe.2001.0467; Spangler R, 2004, MOL BRAIN RES, V124, P134, DOI 10.1016/j.molbrainres.2004.02.013; Steiner J E, 1979, Adv Child Dev Behav, V13, P257, DOI 10.1016/S0065-2407(08)60349-3; Tinbergen, 1951, STUDY INSTINCT; Ulijaszek SJ, 2006, ANNU REV ANTHROPOL, V35, P337, DOI 10.1146/annurev.anthro.35.081705.123301; Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975; Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452; Wang GJ, 2006, P NATL ACAD SCI USA, V103, P15641, DOI 10.1073/pnas.0601977103; Wang GJ, 2004, J ADDICT DIS, V23, P39, DOI 10.1300/J069v23n03_04; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250; Williams G. C., 1966, P307; Williams KL, 2000, ALCOHOL CLIN EXP RES, V24, P980, DOI 10.1111/j.1530-0277.2000.tb04640.x; Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406; WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140; WOOLVERTON WL, 1979, COMMUN PSYCHOPHARMAC, V3, P309; Zittel-Lazarini A, 2007, PSYCHOPHARMACOLOGY, V192, P337, DOI 10.1007/s00213-007-0724-0	78	370	372	1	109	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e698	10.1371/journal.pone.0000698	http://dx.doi.org/10.1371/journal.pone.0000698			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668074	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452300032
J	Man, O; Willhite, DC; Crasto, CJ; Shepherd, GM; Gilad, Y				Man, Orna; Willhite, David C.; Crasto, Chiquito J.; Shepherd, Gordon M.; Gilad, Yoav			A Framework for Exploring Functional Variability in Olfactory Receptor Genes	PLOS ONE			English	Article							SUBSTRATE-SPECIFICITY; ODORANT RECEPTORS; MOLECULAR-BASIS; MOUSE; ACID; PROTEINS; REPERTOIRES; SUPERFAMILY; EXPRESSION; PRIMATES	Background. Olfactory receptors (ORs) are the largest gene family in mammalian genomes. Since nearly all OR genes are orphan receptors, inference of functional similarity or differences between odorant receptors typically relies on sequence comparisons. Based on the alignment of entire coding region sequence, OR genes are classified into families and subfamilies, a classification that is believed to be a proxy for OR gene functional variability. However, the assumption that overall protein sequence diversity is a good proxy for functional properties is untested. Methodology. Here, we propose an alternative sequence-based approach to infer the similarities and differences in OR binding capacity. Our approach is based on similarities and differences in the predicted binding pockets of OR genes, rather than on the entire OR coding region. Conclusions. Interestingly, our approach yields markedly different results compared to the analysis based on the entire OR coding-regions. While neither approach can be tested at this time, the discrepancy between the two calls into question the assumption that the current classification reliably reflects OR gene functional variability.	[Man, Orna] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; [Man, Orna] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; [Willhite, David C.; Crasto, Chiquito J.; Shepherd, Gordon M.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA; [Gilad, Yoav] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	Weizmann Institute of Science; Weizmann Institute of Science; Yale University; University of Chicago	Man, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	orna.man@weizmann.ac.il; gilad@uchicago.edu			NIH [DC00086]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000086] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	GMS, CC, and DCW were supported by NIH grant DC00086 (GMS).	Antikainen NM, 2003, BIOCHEMISTRY-US, V42, P1603, DOI 10.1021/bi0267285; Balasubramanian M, 2002, SCIENCE, V295; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gilad Y, 2005, GENOME RES, V15, P224, DOI 10.1101/gr.2846405; Gilad Y, 2004, PLOS BIOL, V2, P120, DOI 10.1371/journal.pbio.0020005; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Glusman G, 2000, MAMM GENOME, V11, P1016, DOI 10.1007/s003350010196; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Godfrey PA, 2004, P NATL ACAD SCI USA, V101, P2156, DOI 10.1073/pnas.0308051100; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; GRIFF IC, 1995, CELL, V83, P407, DOI 10.1016/0092-8674(95)90118-3; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Katada S, 2005, J NEUROSCI, V25, P1806, DOI 10.1523/jneurosci.4723-04.2005; Kawashima S, 1999, NUCLEIC ACIDS RES, V27, P368, DOI 10.1093/nar/27.1.368; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LANCET D, 1993, P NATL ACAD SCI USA, V90, P3715, DOI 10.1073/pnas.90.8.3715; Lapidot M, 2001, GENOMICS, V71, P296, DOI 10.1006/geno.2000.6431; Laska M, 2000, CHEM SENSES, V25, P47, DOI 10.1093/chemse/25.1.47; Lo LW, 2003, P NATL ACAD SCI USA, V100, P4463, DOI 10.1073/pnas.0737647100; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Man O, 2004, PROTEIN SCI, V13, P240, DOI 10.1110/ps.03296404; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; Mirny LA, 2002, J MOL BIOL, V321, P7, DOI 10.1016/S0022-2836(02)00587-9; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; Niimura Y, 2005, P NATL ACAD SCI USA, V102, P6039, DOI 10.1073/pnas.0501922102; OCONNELL RJ, 1994, CHEM SENSES, V19, P197, DOI 10.1093/chemse/19.3.197; Olender T, 2004, GENOMICS, V83, P361, DOI 10.1016/j.ygeno.2003.08.009; Olender Tsviya, 2004, Genet Mol Res, V3, P545; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Quignon P, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-12-r80; Reed RR, 2004, CELL, V116, P329, DOI 10.1016/S0092-8674(04)00047-9; Rouquier S, 2000, P NATL ACAD SCI USA, V97, P2870, DOI 10.1073/pnas.040580197; SALVADOR S, 2004, DETERMINING NUMBER C, P576; Schneider K, 2003, P NATL ACAD SCI USA, V100, P8601, DOI 10.1073/pnas.1430550100; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Tenenbaum JB, 2000, SCIENCE, V290, P2319, DOI 10.1126/science.290.5500.2319; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zozulya S, 2001, GENOME BIOL, V2	45	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e682	10.1371/journal.pone.0000682	http://dx.doi.org/10.1371/journal.pone.0000682			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668060	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452300018
J	Michos, AG; Syriopoulou, VP; Hadjichristodoulou, C; Daikos, GL; Lagona, E; Douridas, P; Mostrou, G; Theodoridou, M				Michos, Athanasios G.; Syriopoulou, Vassiliki P.; Hadjichristodoulou, Christos; Daikos, George L.; Lagona, Evagelia; Douridas, Panagiotis; Mostrou, Glykeria; Theodoridou, Maria			Aseptic Meningitis in Children: Analysis of 506 Cases	PLOS ONE			English	Article								Background. Non-polio human enteroviruses are the leading cause of aseptic meningitis in children. The role of enterovirus PCR for diagnosis and management of aseptic meningitis has not been fully explored. Methodology/Principal Findings. A retrospective study was conducted to determine the epidemiological, clinical, and laboratory characteristics of aseptic meningitis and to evaluate the role of enterovirus PCR for the diagnosis and management of this clinical entity. The medical records of children who had as discharge diagnosis aseptic or viral meningitis were reviewed. A total of 506 children, median age 5 years, were identified. The annual incidence rate was estimated to be 17/100,000 children less than 14 years of age. Most of the cases occurred during summer (38%) and autumn (24%). The dominant clinical symptoms were fever (98%), headache (94%) and vomiting (67%). Neck stiffness was noted in 60%, and irritation in 46% of the patients. The median number of CSF cell count was 201/mm(3) with polymorphonuclear predominance (>50%) in 58.3% of the cases. Enterovirus RNA was detected in CSF in 47 of 96 (48.9%) children tested. Children with positive enterovirus PCR had shorter hospitalization stay as compared to children who had negative PCR or to children who were not tested (P = 0.01). There were no serious complications or deaths. Conclusions. Enteroviruses accounted for approximately one half of cases of aseptic meningitis. PCR may reduce the length of hospitalization and plays important role in the diagnosis and management of children with aseptic meningitis.	[Michos, Athanasios G.; Syriopoulou, Vassiliki P.; Lagona, Evagelia; Douridas, Panagiotis; Mostrou, Glykeria; Theodoridou, Maria] Univ Athens, Dept Pediat 1, Aghia Sophia Childrens Hosp, Athens, Greece; [Hadjichristodoulou, Christos] Univ Thessaly, Dept Hyg & Epidemiol, Fac Med, Larisa, Greece; [Daikos, George L.] Univ Athens, Laiko Gen Hosp, Dept Propaedeut Med 1, Athens, Greece	National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital; University of Thessaly; Laiko General Hospital; National & Kapodistrian University of Athens	Syriopoulou, VP (corresponding author), Univ Athens, Dept Pediat 1, Aghia Sophia Childrens Hosp, Athens, Greece.	vsyriop@med.uoa.gr	Michos, Athanasios/H-2389-2012; Daikos, George L./ABD-8378-2021	Michos, Athanasios/0000-0003-1745-1118; Hadjichristodoulou, Christos/0000-0002-4769-8376				Ahmed A, 1997, J PEDIATR-US, V131, P393, DOI 10.1016/S0022-3476(97)80064-9; AMIR J, 1991, J PEDIATR-US, V119, P938, DOI 10.1016/S0022-3476(05)83049-5; BERLIN LE, 1993, J INFECT DIS, V168, P888, DOI 10.1093/infdis/168.4.888; Hamilton MS, 1999, PEDIATR INFECT DIS J, V18, P533, DOI 10.1097/00006454-199906000-00011; Ishiko H, 2002, J INFECT DIS, V185, P744, DOI 10.1086/339298; Lee BE, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-68; Marshall GS, 1997, PEDIATR INFECT DIS J, V16, P1086, DOI 10.1097/00006454-199711000-00015; Nigrovic LE, 2000, ARCH PEDIAT ADOL MED, V154, P817, DOI 10.1001/archpedi.154.8.817; Nigrovic LE, 2007, JAMA-J AM MED ASSOC, V297, P52, DOI 10.1001/jama.297.1.52; Ramers C, 2000, JAMA-J AM MED ASSOC, V283, P2680, DOI 10.1001/jama.283.20.2680; RICE SK, 1995, CLIN INFECT DIS, V20, P931, DOI 10.1093/clinids/20.4.931; Robinson CC, 2002, PEDIATR INFECT DIS J, V21, P283, DOI 10.1097/00006454-200204000-00005; Rotbart HA, 1997, PEDIATR INFECT DIS J, V16, P409, DOI 10.1097/00006454-199704000-00014; ROTBART HA, 1995, CLIN INFECT DIS, V20, P971, DOI 10.1093/clinids/20.4.971; SAWYER MH, 1994, PEDIATR INFECT DIS J, V13, P177, DOI 10.1097/00006454-199403000-00002; Sawyer MH, 1999, PEDIATR INFECT DIS J, V18, P1033, DOI 10.1097/00006454-199912000-00002; SCHLESINGER Y, 1994, PEDIATRICS, V94, P157; Siafakas N, 2004, MOL CELL PROBE, V18, P389, DOI 10.1016/j.mcp.2004.06.005; Spicher VM, 2000, CLIN PEDIATR, V39, P203, DOI 10.1177/000992280003900402; STRIKAS RA, 1986, J INFECT DIS, V153, P346, DOI 10.1093/infdis/153.2.346; Syriopoulou VP, 2002, J HOSP INFECT, V51, P275, DOI 10.1053/jhin.2002.1253; van Vliet KE, 1998, J CLIN MICROBIOL, V36, P2652, DOI 10.1128/JCM.36.9.2652-2657.1998; WILDIN S, 1987, AM J DIS CHILD, V141, P454, DOI 10.1001/archpedi.1987.04460040112030	23	90	99	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e674	10.1371/journal.pone.0000674	http://dx.doi.org/10.1371/journal.pone.0000674			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668054	Green Published, gold			2022-12-25	WOS:000207452300012
J	Drisdel, RC; Sharp, D; Henderson, T; Hales, TG; Green, WN				Drisdel, Renaldo C.; Sharp, Douglas; Henderson, Tricia; Hales, Tim G.; Green, William N.			High affinity binding of epibatidine to serotonin type 3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; 5-HT3 RECEPTORS; BLOOD-PRESSURE; FUNCTIONAL EXPRESSION; CHOLINERGIC-RECEPTORS; SUBUNIT ALTERS; POTENT AGONIST; UP-REGULATION; SPINAL-CORD; IN-VITRO	Epibatidine and mecamylamine are ligands used widely in the study of nicotinic acetylcholine receptors (nAChRs) in the central and peripheral nervous systems. In the present study, we find that nicotine blocks only 75% of I-125-epibatidine binding to rat brain membranes, whereas ligands specific for serotonin type 3 receptors (5-HT(3)Rs) block the remaining 25%. I-125-Epibatidine binds with a high affinity to native 5-HT(3)Rs of N1E-115 cells and to receptors composed of only 5-HT3A subunits expressed in HEK cells. In these cells, serotonin, the 5-HT3R-specific antagonist MDL72222, and the 5-HT3R agonist chlorophenylbiguanide readily competed with I-125-epibatidine binding to 5-HT(3)Rs. Nicotine was a poor competitor for I-125-epibatidine binding to 5-HT(3)Rs. However, the noncompetitive nAChR antagonist mecamylamine acted as a potent competitive inhibitor of I-125-epibatidine binding to 5-HT(3)Rs. Epibatidine inhibited serotonin-induced currents mediated by endogenous 5-HT(3)Rs in neuroblastoma cell lines and 5-HT(3)ARs expressed in HEK cells in a competitive manner. Our results demonstrate that 5-HT(3)Rs are previously uncharacterized high affinity epibatidine binding sites in the brain and indicate that epibatidine and mecamylamine act as 5-HT3R antagonists. Previous studies that depended on epibatidine and mecamylamine as nAChR-specific ligands, in particular studies of analgesic properties of epibatidine, may need to be reinterpreted with respect to the potential role of 5-HT(3)Rs.	[Drisdel, Renaldo C.; Green, William N.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; [Hales, Tim G.] George Washington Univ, Med Ctr, Dept Pharmacol & Physiol, Washington, DC 20037 USA; [Sharp, Douglas; Henderson, Tricia; Hales, Tim G.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA	University of Chicago; George Washington University; George Washington University	Green, WN (corresponding author), Univ Chicago, Dept Neurol, 947 E 58th St, Chicago, IL 60637 USA.	wgreen@midway.uchicago.edu			NIDA NIH HHS [P50 DA005010, R01 DA 13602, DA 05010] Funding Source: Medline; NINDS NIH HHS [R01 NS 43782, R01 NS 32693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032693, R01NS043782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013602, P50DA005010] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; ALHAIDER AA, 1991, J NEUROSCI, V11, P1881; Ali Z, 1996, NEUROSCI LETT, V208, P203, DOI 10.1016/0304-3940(95)12600-7; Alkadhi KA, 2001, EXP BIOL MED, V226, P1024, DOI 10.1177/153537020122601109; ALKONDON M, 1995, J PHARMACOL EXP THER, V274, P771; Anuradha K., 2004, Indian Journal of Experimental Biology, V42, P368; BADIO B, 1994, MOL PHARMACOL, V45, P563; Bitner RS, 1998, J NEUROSCI, V18, P5426, DOI 10.1523/JNEUROSCI.18-14-05426.1998; BONHAUS DW, 1995, J PHARMACOL EXP THER, V272, P1199; Boyce S, 2000, PAIN, V85, P443, DOI 10.1016/S0304-3959(99)00303-6; Broad LM, 2002, EUR J PHARMACOL, V452, P137, DOI 10.1016/S0014-2999(02)02273-2; Buisson B, 2000, NEUROPHARMACOLOGY, V39, P2561, DOI 10.1016/S0028-3908(00)00158-1; Butt CM, 2004, J PHARMACOL EXP THER, V308, P591, DOI 10.1124/jpet.103.059758; Connolly CN, 2004, BIOCHEM SOC T, V32, P529, DOI 10.1042/BST0320529; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; Costall B, 2004, CNS NEUROL DISORD-DR, V3, P27, DOI 10.2174/1568007043482624; Cucchiaro G, 2005, J PHARMACOL EXP THER, V313, P389, DOI 10.1124/jpet.104.079368; Curzon P, 1998, J PHARMACOL EXP THER, V287, P847; DAMAJ MI, 1994, BRAIN RES, V664, P34, DOI 10.1016/0006-8993(94)91950-X; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; Davila-Garcia MI, 2003, J NEUROCHEM, V85, P1237, DOI 10.1046/j.1471-4159.2003.01774.x; DECKER MW, 1999, J PHYSL, V92, P221; Dobelis P, 2003, J PHARMACOL EXP THER, V306, P1159, DOI 10.1124/jpet.103.053066; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Eertmoed AL, 1998, METHOD ENZYMOL, V293, P564; Farber L, 2004, SCAND J RHEUMATOL, V33, P2, DOI 10.1080/03009740410006943; Ferezou I, 2002, J NEUROSCI, V22, P7389; Ferreira HS, 2004, BRAIN RES, V1028, P48, DOI 10.1016/j.brainres.2004.08.063; FISHER M, 1994, J PHARMACOL EXP THER, V270, P702; Gerges NZ, 2002, NEUROPHARMACOLOGY, V43, P1070, DOI 10.1016/S0028-3908(02)00283-6; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; Gilbert SD, 2001, PAIN, V89, P159, DOI 10.1016/S0304-3959(00)00358-4; Gnadisch D, 1999, NEUROREPORT, V10, P1631; GRANT KA, 1994, ALCOHOL CLIN EXP RES, V18, P410, DOI 10.1111/j.1530-0277.1994.tb00034.x; Gurley DA, 1998, NEUROSCI LETT, V247, P107, DOI 10.1016/S0304-3940(98)00306-1; HOFFMAN WE, 1978, J PHARMACOL EXP THER, V206, P644; Holladay MW, 1998, J MED CHEM, V41, P407, DOI 10.1021/jm9706224; Hope AG, 1999, MOL PHARMACOL, V55, P1037, DOI 10.1124/mol.55.6.1037; HOUGHTLING RA, 1995, MOL PHARMACOL, V48, P280; IWAMOTO ET, 1993, J PHARMACOL EXP THER, V265, P777; Khan IM, 1998, NEUROPHARMACOLOGY, V37, P1515, DOI 10.1016/S0028-3908(98)00143-9; LAMBERT JJ, 1989, BRIT J PHARMACOL, V97, P27, DOI 10.1111/j.1476-5381.1989.tb11920.x; Lawand NB, 1999, PAIN, V80, P291, DOI 10.1016/S0304-3959(98)00221-8; Lecchi M, 2005, EUR J NEUROSCI, V21, P3182, DOI 10.1111/j.1460-9568.2005.04150.x; LUMMIS SC, 1990, EUR J PHARMACOL, V189, P22; Machu TK, 2001, J PHARMACOL EXP THER, V299, P1112; Macor JE, 2001, BIOORG MED CHEM LETT, V11, P319, DOI 10.1016/S0960-894X(00)00670-3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Marks MJ, 2006, MOL PHARMACOL, V70, P947, DOI 10.1124/mol.106.025338; McCallum S, 2006, PSYCHOPHARMACOLOGY, V184, P314, DOI 10.1007/s00213-005-0076-6; Moore KA, 2002, J APPL PHYSIOL, V92, P2529, DOI 10.1152/japplphysiol.00974.2001; Oortgiesen M, 1997, BRAIN RES, V747, P1, DOI 10.1016/S0006-8993(96)01200-0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Parker SL, 2004, MOL PHARMACOL, V65, P611, DOI 10.1124/mol.65.3.611; Radek RJ, 2004, BRAIN RES BULL, V64, P323, DOI 10.1016/j.brainresbull.2004.08.005; Rashid MH, 2006, PAIN, V125, P125, DOI 10.1016/j.pain.2006.05.011; Rashid MH, 2002, BRAIN RES, V953, P53, DOI 10.1016/S0006-8993(02)03270-5; Reeves DC, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-27; Sacaan AI, 1996, J PHARMACOL EXP THER, V276, P509; SAXENA PR, 1990, J CARDIOVASC PHARM, V15, pS17, DOI 10.1097/00005344-199001001-00004; SEPULVEDA MI, 1994, NEUROPHARMACOLOGY, V33, P493, DOI 10.1016/0028-3908(94)90080-9; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; Stewart A, 2003, NEUROPHARMACOLOGY, V44, P214, DOI 10.1016/S0028-3908(02)00376-3; Stitzel JA, 2000, J PHARMACOL EXP THER, V293, P67; SULLIVAN JP, 1994, J PHARMACOL EXP THER, V271, P624; TSENG CJ, 1993, J PHARMACOL EXP THER, V265, P1511; Ulrich YM, 1997, NEUROPHARMACOLOGY, V36, P1119, DOI 10.1016/S0028-3908(97)00107-X; Wada Y, 1997, BRAIN RES, V759, P313, DOI 10.1016/S0006-8993(97)00366-1; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; Whiteaker P, 2000, BRIT J PHARMACOL, V131, P729, DOI 10.1038/sj.bjp.0703616; Young JM, 2001, CLIN THER, V23, P532, DOI 10.1016/S0149-2918(01)80059-X; Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002; ZHANG L, 1995, NEUROREPORT, V6, P1464, DOI 10.1097/00001756-199507100-00025	73	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9659	9665		10.1074/jbc.M703672200	http://dx.doi.org/10.1074/jbc.M703672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	17702741	Green Published, hybrid			2022-12-25	WOS:000254671600020
J	Corso, S; Migliore, C; Ghiso, E; De Rosa, G; Comoglio, PM; Giordano, S				Corso, S.; Migliore, C.; Ghiso, E.; De Rosa, G.; Comoglio, P. M.; Giordano, S.			Silencing the MET oncogene leads to regression of experimental tumors and metastases	ONCOGENE			English	Article						growth factor receptor; tumor progression; invasion; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; FACTOR-RECEPTOR; INVASIVE GROWTH; C-MET; TYROSINE KINASE; LENTIVIRAL VECTORS; CANCER METASTASIS; DOWN-REGULATION; GENE-TRANSFER	In spite of the established knowledge of the genetic alterations responsible for cancer onset, the genes promoting and maintaining the invasive/metastatic phenotype are still elusive. The MET proto-oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF), senses unfavorable micro-environmental conditions and drives cell invasion and metastasis. MET overexpression, often induced by tumor hypoxia, leads to constitutive activation of the receptor and correlates with poor prognosis. To establish the role of MET in different phases of tumor progression, we developed an inducible lentiviral delivery system of RNA interference. Silencing the endogenous MET gene, overexpressed in tumor cells, resulted in (i) impairment of the execution of the full invasive growth program in vitro, (ii) lack of tumor growth and (iii) decreased generation of experimental metastases in vivo. Notably, silencing MET in already established metastases led to their almost complete regression. This indicates that persistent expression of the MET oncogene is mandatory until the advanced phases of cancer progression.	[Corso, S.; Migliore, C.; Ghiso, E.; Comoglio, P. M.; Giordano, S.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, I-10060 Turin, Italy; [De Rosa, G.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Unit Pathol, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Str Prov 142, I-10060 Turin, Italy.	silvia.giordano@ircc.it	Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503; Migliore, Cristina/0000-0003-3722-2814	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Christensen JG, 2003, CANCER RES, V63, P7345; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corbel SY, 2002, CURR OPIN BIOTECH, V13, P448, DOI 10.1016/S0958-1669(02)00361-0; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIXMAN ED, 1995, ONCOGENE, V10, P237; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Patane S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008-5472.CAN-05-4422; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosario M, 2004, DEV CELL, V7, P3, DOI 10.1016/j.devcel.2004.06.015; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Skibinski G, 2001, IMMUNOLOGY, V102, P506, DOI 10.1046/j.1365-2567.2001.01186.x; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Taulli R, 2005, CANCER GENE THER, V12, P456, DOI 10.1038/sj.cgt.7700815; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Vigna E, 2000, J GENE MED, V2, P308; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	64	103	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					684	693		10.1038/sj.onc.1210697	http://dx.doi.org/10.1038/sj.onc.1210697			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684486				2022-12-25	WOS:000252674900012
J	Franceschini, S; Ilari, A; Verzili, D; Zamparelli, C; Antaramian, A; Rueda, A; Valdivia, HH; Chiancone, E; Colotti, G				Franceschini, Stefano; Ilari, Andrea; Verzili, Daniela; Zamparelli, Carlotta; Antaramian, Anaid; Rueda, Angelica; Valdivia, Hector H.; Chiancone, Emilia; Colotti, Gianni			Molecular basis for the impaired function of the natural F112L sorcin mutant: X-ray crystal structure, calcium affinity, and interaction with annexin VII and the ryanodine receptor	FASEB JOURNAL			English	Article						EF hand heart; PEF proteins channels; excitation-contraction coupling; calcium-induced channel release	HAND PROTEIN FAMILY; MISSENSE MUTATION; DOMAIN-VI; BINDING; HEART; MODULATION; CALPAIN; MUSCLE; DIFFRACTION; RELEASE	The penta-EF hand protein sorcin participates in the modulation of Ca2+-induced calcium-release in the heart through the interaction with several Ca2+ channels such as the ryanodine receptor. The modulating activity is impaired in the recently described natural F112L mutant. The F112 residue is located at the end of the D helix next to Asp113, one of the calcium ligands in the EF3 hand endowed with the highest affinity for the metal. The F112L-sorcin X-ray crystal structure at 2.5 angstrom resolution displays marked alterations in the EF3 hand, where the hydrogen bonding network established by Phe112 is disrupted, and in the EF1 region, which is tilted in both monomers that give rise to the dimer, the stable form of the molecule. In turn, the observed tilt is indicative of an increased flexibility of the N-terminal part of the molecule. The structural alterations result in a 6-fold decrease in calcium affinity with respect to the wild-type protein and to an even larger impairment of the interaction with annexin VII and of the ability of sorcin to interact with and inhibit ryanodine receptors. These results provide a plausible structural and functional framework that helps elucidate the phenotypic alterations of mice overexpressing F112L-sorcin.	[Franceschini, Stefano; Ilari, Andrea; Verzili, Daniela; Chiancone, Emilia; Colotti, Gianni] Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy; [Zamparelli, Carlotta; Chiancone, Emilia] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; [Antaramian, Anaid; Rueda, Angelica; Valdivia, Hector H.] Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; University of Wisconsin System; University of Wisconsin Madison	Colotti, G (corresponding author), Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, P Le A Moro 5, I-00185 Rome, Italy.	gianni.colotti@uniroma1.it	Colotti, Gianni/D-2015-2010; Ilari, Andrea/AAC-7670-2022; Rueda, Angelica/G-4055-2012; Rueda, Angelica/A-1394-2009; Colotti, Gianni/AAG-4918-2019; Rueda, Angelica/AAW-4621-2020; Ilari, Andrea/T-5501-2017	Colotti, Gianni/0000-0002-9913-0635; Ilari, Andrea/0000-0002-7754-399X; Rueda, Angelica/0000-0001-8749-8494; Rueda, Angelica/0000-0001-8749-8494; Ilari, Andrea/0000-0002-7754-399X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-76826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; Blanchard H, 1996, PROTEIN SCI, V5, P535; Brookes AJ, 2000, NUCLEIC ACIDS RES, V28, P356, DOI 10.1093/nar/28.1.356; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; Collis LP, 2007, FASEB J, V21, P475, DOI 10.1096/fj.06-6292com; Colotti G, 2006, BIOCHEMISTRY-US, V45, P12519, DOI 10.1021/bi060416a; DELANO WL, 2002, USERS MANUAL DELANO; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Farrell EF, 2003, J BIOL CHEM, V278, P34660, DOI 10.1074/jbc.M305931200; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; Ilari A, 2002, J MOL BIOL, V317, P447, DOI 10.1006/jmbi.2002.5417; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Matsumoto T, 2005, BASIC RES CARDIOL, V100, P250, DOI 10.1007/s00395-005-0518-7; Mella M, 2003, J BIOL CHEM, V278, P24921, DOI 10.1074/jbc.M213276200; Meyers MB, 2003, J BIOL CHEM, V278, P28865, DOI 10.1074/jbc.M302009200; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; Mohiddin SA, 2002, CIRCULATION, V106, P319; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rueda A, 2006, J PHYSIOL-LONDON, V576, P887, DOI 10.1113/jphysiol.2006.113951; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Seidler T, 2003, CIRC RES, V93, P132, DOI 10.1161/01.RES.0000081596.90205.E2; Smith Godfrey L, 2006, J Cardiovasc Electrophysiol, V17 Suppl 1, pS57, DOI 10.1111/j.1540-8167.2006.00384.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701; YANG XR, 2005, AM J PHYSIOL, V289, pL337	35	27	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2008	22	1					295	306		10.1096/fj.07-8988com	http://dx.doi.org/10.1096/fj.07-8988com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17699613				2022-12-25	WOS:000252309900031
J	Singleton, PA; Salgia, R; Moreno-Vinasco, L; Moitra, J; Sammani, S; Mirzapoiazova, T; Garcia, JGN				Singleton, Patrick A.; Salgia, Ravi; Moreno-Vinasco, Liliana; Moitra, Jaideep; Sammani, Saad; Mirzapoiazova, Tamara; Garcia, Joe G. N.			CD44 regulates hepatocyte growth factor-mediated vascular integrity - Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SIGNAL-TRANSDUCTION; CELL BARRIER ENHANCEMENT; NA+/H+ EXCHANGER NHE1; LIGHT-CHAIN KINASE; ACUTE LUNG INJURY; SPHINGOSINE 1-PHOSPHATE; MARCKS FAMILY; HYALURONAN-CD44 INTERACTION; CYTOSKELETAL REARRANGEMENT; RHO	The preservation of vascular endothelial cell ( EC) barrier integrity is critical to normal vessel homeostasis, with barrier dysfunction being a feature of inflammation, tumor angiogenesis, atherosclerosis, and acute lung injury. Therefore, agents that preserve or restore vascular integrity have important therapeutic implications. In this study, we explored the regulation of hepatocyte growth factor ( HGF)-mediated enhancement of EC barrier function via CD44 isoforms. We observed that HGF promoted c-Met association with CD44v10 and recruitment of c-Met into caveolin-enriched microdomains ( CEM) containing CD44s ( standard form). Treatment of EC with CD44v10-blocking antibodies inhibited HGF-mediated c-Met phosphorylation and c-Met recruitment to CEM. Silencing CD44 expression ( small interfering RNA) attenuated HGF-induced recruitment of c-Met, Tiam1 ( a Rac1 exchange factor), cortactin ( an actin cytoskeletal regulator), and dynamin 2 ( a vesicular regulator) to CEM as well as HGF-induced trans-EC electrical resistance. In addition, silencing Tiam1 or dynamin 2 reduced HGF-induced Rac1 activation, cortactin recruitment to CEM, and EC barrier regulation. We observed that both HGF- and high molecular weight hyaluronan ( CD44 ligand)-mediated protection from lipopolysaccharide-induced pulmonary vascular hyperpermeability was significantly reduced in CD44 knock-out mice, thus validating these in vitro findings in an in vivo murine model of inflammatory lung injury. Taken together, these results suggest that CD44 is an important regulator of HGF/c-Met-mediated in vitro and in vivo barrier enhancement, a process with essential involvement of Tiam1, Rac1, dynamin 2, and cortactin.	Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA	University of Chicago	Garcia, JGN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, 5841 S Maryland Ave,W604, Chicago, IL 60637 USA.	jgarcia@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [F32 HL68472, HL58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, F32HL068472] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; Bannerman DD, 1999, LAB INVEST, V79, P1181; Baumgartner M, 2004, AM J PHYSIOL-CELL PH, V287, pC844, DOI 10.1152/ajpcell.00094.2004; Bourguignon LYW, 2006, J INVEST DERMATOL, V126, P1356, DOI 10.1038/sj.jid.5700260; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cetin S, 2004, SURGERY, V136, P375, DOI 10.1016/j.surg.2004.05.013; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Gee K, 2004, ARCH IMMUNOL THER EX, V52, P13; GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022; Hammond DE, 2004, CURR TOP MICROBIOL, V286, P21; Hippenstiel S, 2000, BLOOD, V95, P3044; HIRANO H, 1994, INT IMMUNOL, V6, P49, DOI 10.1093/intimm/6.1.49; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; Ilangumaran S, 1998, BLOOD, V91, P3901; Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kermorgant S, 2005, CELL CYCLE, V4, P352, DOI 10.4161/cc.4.3.1519; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Luscher TF, 1997, CLIN CARDIOL, V20, P3; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Marhaba R, 2004, J MOL HISTOL, V35, P211; Matsubara M, 2005, SEIKAGAKU, V77, P50; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; Moriez R, 2005, AM J PATHOL, V167, P1071, DOI 10.1016/S0002-9440(10)61196-0; Noma K, 2006, AM J PHYSIOL-CELL PH, V290, pC661, DOI 10.1152/ajpcell.00459.2005; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; PEARSON JD, 1991, RADIOLOGY, V179, P9, DOI 10.1148/radiology.179.1.2006310; Pedersen SF, 2006, PFLUG ARCH EUR J PHY, V452, P249, DOI 10.1007/s00424-006-0044-y; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Selbach M, 2005, TRENDS MICROBIOL, V13, P181, DOI 10.1016/j.tim.2005.02.007; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Su X, 2004, INTENS CARE MED, V30, P133, DOI 10.1007/s00134-003-2001-y; Sundaram M, 2004, BIOCHEM CELL BIOL, V82, P191, DOI 10.1139/o03-087; Taher TEI, 1999, CURR TOP MICROBIOL, V246, P31; Tanabe A, 2006, BIOCHEM BIOPH RES CO, V345, P156, DOI 10.1016/j.bbrc.2006.04.082; Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Trent MS, 2006, J ENDOTOXIN RES, V12, P205, DOI 10.1179/096805106X118825; Triantafilou M, 2005, J ENDOTOXIN RES, V11, P5, DOI 10.1179/096805105225006641; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tzircotis G, 2006, ONCOGENE, V25, P7401, DOI 10.1038/sj.onc.1209724; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC; Yao Q, 2005, J MOL BIOL, V348, P491, DOI 10.1016/j.jmb.2005.02.003; Zhao Y, 2000, J CELL BIOCHEM, V79, P496, DOI 10.1002/1097-4644(20001201)79:3<496::AID-JCB140>3.0.CO;2-5	78	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30643	30657		10.1074/jbc.M702573200	http://dx.doi.org/10.1074/jbc.M702573200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702746	hybrid			2022-12-25	WOS:000250136300032
J	Niknejad, N; Morley, M; Dimitroulakos, J				Niknejad, Nima; Morley, Melissa; Dimitroulakos, Jim			Activation of the integrated stress response regulates lovastatin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; SQUAMOUS-CELL CARCINOMAS; HMG-COA REDUCTASE; PHASE-I; TRANSLATIONAL CONTROL; MEVALONATE PATHWAY; 26S PROTEASOMES; ER STRESS	Lovastatin, a potent inhibitor of mevalonate synthesis, can readily induce apoptosis in a subset of human tumor types including head and neck squamous cell carcinomas (HNSCC). We recently identified activation of transcription factor (ATF) 4 as a lovastatin induced gene in HNSCC cells. ATF4 plays a significant role in regulating cellular responses to a wide variety of stress inducers known as the integrated stress response (ISR). These cell stresses lead to the phosphorylation of eukaryotic initiation factor (eIF) 2 alpha shutting down global protein translation. However, the translation of ATF4 is enhanced. In this study, lovastatin treatment induced eIF2 alpha phosphorylation and inhibited global protein translation. ATF4 expression was induced followed by increased ATF3 andCHOPexpression, targets of ATF4 activity, in SCC25 HNSCC cells. In CHOP (-)/(-) murine embryonic fibroblasts (MEFs), lovastatin- induced apoptosis was attenuated indicating a role for CHOP in this response. Furthermore, the eIF2 alpha kinase GCN2 mediates lovastatin induction of ATF4 and lovastatin- induced apoptosis was also attenuated in GCN2 (-)/(-) MEFs. The pro- drug version of lovastatin has potential proteasome inhibitory activity and recently a variety of well established proteasome inhibitors were shown to activate the ISR. In this study, neither the pro- drug nor the active forms of lovastatin had any significant effect on proteasome activity. Therefore, lovastatin, by targeting mevalonate synthesis, is a potent inducer of the ISR through a novel and as yet unrecognized mechanism.	Univ Ottawa, Ctr Canc Therapeut, Ottawa Reg Canc Ctr, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Dimitroulakos, J (corresponding author), Univ Ottawa, Ctr Canc Therapeut, Ottawa Reg Canc Ctr, Ottawa Hlth Res Inst, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 8L6, Canada.	jdimitroulakos@ohri.ca	Dimitroulakos, Jim/AAK-3398-2020					Alvarez C, 1999, EUR J CELL BIOL, V78, P1; Bence NF, 2005, METHOD ENZYMOL, V399, P481, DOI 10.1016/S0076-6879(05)99033-2; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Crawford LJA, 2006, CANCER RES, V66, P6379, DOI 10.1158/0008-5472.CAN-06-0605; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158; Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Harding HP, 2005, CELL METAB, V2, P361, DOI 10.1016/j.cmet.2005.11.005; Ishii Y, 2007, ANTI-CANCER AGENT ME, V7, P359, DOI 10.2174/187152007780618180; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; Knox JJ, 2005, EUR J CANCER, V41, P523, DOI 10.1016/j.ejca.2004.12.013; Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Liang SH, 2006, BIOCHEM J, V393, P201, DOI 10.1042/BJ20050374; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; Sood R, 2000, GENETICS, V154, P787; Stangl K, 2002, BIOCHEM BIOPH RES CO, V291, P542, DOI 10.1006/bbrc.2002.6476; Thibault A, 1996, CLIN CANCER RES, V2, P483; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007	45	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29748	29756		10.1074/jbc.M705859200	http://dx.doi.org/10.1074/jbc.M705859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699156	hybrid			2022-12-25	WOS:000249981200003
J	Zhang, HM; Im, SC; Waskell, L				Zhang, Haoming; Im, Sang-Choul; Waskell, Lucy			Cytochrome b(5) increases the rate of product formation by cytochrome p450 2B4 and competes with cytochrome p450 reductase for a binding site on cytochrome p450 2B4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ELECTRON-TRANSFER; P450 REDUCTASE; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; SPECTRAL CHARACTERIZATION; PROTEIN INTERACTIONS; NADPH; OXIDATION; COMPLEX	The kinetics of product formation by cytochrome P450 2B4 were compared in the presence of cytochrome b(5) ( cyt b(5)) and NADPH- cyt P450 reductase ( CPR) under conditions in which cytochrome P450 ( cyt P450) underwent a single catalytic cycle with two substrates, benzphetamine and cyclohexane. At a cyt P450: cyt b(5) molar ratio of 1: 1 under single turnover conditions, cyt P450 2B4 catalyzes the oxidation of the substrates, benzphetamine and cyclohexane, with rate constants of 18 +/- 2 and 29 +/- 4.5 s(-1), respectively. Approximately 500 pmol of norbenzphetamine and 58 pmol of cyclohexanol were formed per nmol of cyt P450. In marked contrast, at a cyt P450: CPR molar ratio of 1: 1, cyt P450 2B4 catalyzes the oxidation of benzphetamine congruent to 100- fold (k =0.15 +/- 0.05 s (-1)) and cyclohexane congruent to 10- fold ( k = 2.5 +/- 0.35 s(-1)) more slowly. Four hundred picomoles of norbenzphetamine and 21 pmol of cyclohexanol were formed per nmol of cyt P450. In the presence of equimolar concentrations of cyt P450, cyt b(5), and CPR, product formation is biphasic and occurs with fast and slow rate constants characteristic of catalysis by cyt b(5) and CPR. Increasing the concentration of cyt b5 enhanced the amount of product formed by cyt b(5) while decreasing the amount of product generated by CPR. Under steady- state conditions at all cyt b5: cyt P450 molar ratios examined, cyt b(5) inhibits the rate of NADPH consumption. Nevertheless, at low cyt b(5): cyt P450 molar ratios <= 1: 1, the rate of metabolism of cyclohexane and benzphetamine is enhanced, whereas at higher cyt b(5): cyt P450 molar ratios, cyt b(5) progressively inhibits both NADPH consumption and the rate of metabolism. It is proposed that the ability of cyt b(5) to enhance substrate metabolism by cyt P450 is related to its ability to increase the rate of catalysis and that the inhibitory properties of cyt b(5) are because of its ability to occupy the reductase- binding site on cyt P450 2B4, thereby preventing reduction of ferric cyt P450 and initiation of the catalytic cycle. It is proposed that cyt b(5) and CPR compete for a binding site on cyt P450 2B4.	Univ Michigan, Sch Med, Dept Anesthesiol, Res Serv, Ann Arbor, MI 48105 USA; Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Waskell, L (corresponding author), Univ Michigan, Sch Med, Dept Anesthesiol, Res Serv, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	waskell@umich.edu	Zhang, Haoming/AAE-3749-2020	Zhang, Haoming/0000-0002-8765-4394	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; BACKES WL, 1988, J BIOL CHEM, V263, P247; BHATTACHARYYA AK, 1991, BIOCHEMISTRY-US, V30, P759, DOI 10.1021/bi00217a027; BONFILS C, 1981, J BIOL CHEM, V256, P9457; BOSTERLING B, 1982, J BIOL CHEM, V257, P4375; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Estabrook R W, 1978, Methods Enzymol, V52, P212; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; Guengerich FP, 2005, ARCH BIOCHEM BIOPHYS, V440, P204, DOI 10.1016/j.abb.2005.06.019; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; Ivanov YD, 1999, ARCH BIOCHEM BIOPHYS, V362, P87, DOI 10.1006/abbi.1998.0981; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Loughran PA, 2000, BIOCHEMISTRY-US, V39, P15110, DOI 10.1021/bi001522u; Loughran PA, 2001, ARCH BIOCHEM BIOPHYS, V385, P311, DOI 10.1006/abbi.2000.2136; MIWA GT, 1979, J BIOL CHEM, V254, P5695; Mokashi V, 2003, ARCH BIOCHEM BIOPHYS, V412, P147, DOI 10.1016/S0003-9861(03)00040-7; MORGAN ET, 1984, DRUG METAB DISPOS, V12, P358; OMURA T, 1964, J BIOL CHEM, V239, P2379; OPRIAN DD, 1982, J BIOL CHEM, V257, P8935; POMPON D, 1984, J BIOL CHEM, V259, P5377; Porter TD, 2002, J BIOCHEM MOL TOXIC, V16, P311, DOI 10.1002/jbt.10052; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shimada T, 2005, ARCH BIOCHEM BIOPHYS, V435, P207, DOI 10.1016/j.abb.2004.12.008; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; VELICK SF, 1956, J BIOL CHEM, V221, P265; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Yamaori S, 2003, BIOCHEM PHARMACOL, V66, P2333, DOI 10.1016/j.bcp.2003.08.004; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; Zhang HM, 2003, BIOCHEMISTRY-US, V42, P11594, DOI 10.1021/bi034968u; Zhang HM, 2005, BIOCHEM BIOPH RES CO, V338, P499, DOI 10.1016/j.bbrc.2005.09.022	43	75	79	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29766	29776		10.1074/jbc.M703845200	http://dx.doi.org/10.1074/jbc.M703845200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693640	hybrid			2022-12-25	WOS:000249981200005
J	Mani, AR; Ippolito, S; Moreno, JC; Visser, TJ; Moore, KP				Mani, Ali R.; Ippolito, Silvia; Moreno, Jose C.; Visser, Theo J.; Moore, Kevin P.			The metabolism and dechlorination of chlorotyrosine in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; MYELOPEROXIDASE-CATALYZED OXIDATION; TYROSINE NITRATION; DEFICIENT MICE; HUMAN PLASMA; NITROTYROSINE; PROTEINS; CHLORINATION; SITE; 3-CHLOROTYROSINE	During inflammation, neutrophil- and monocyte-derived myeloperoxidase catalyzes the formation of hypochlorous acid, which can chlorinate tyrosine residues in proteins to form chlorotyrosine. However, little is known of the metabolism and disposition of chlorotyrosine in vivo. Following infusion of deuterium-labeled [D-4] chlorotyrosine into Sprague-Dawley rats, the major urinary metabolites were identified by mass spectrometry. 3-chloro-4-hydroxyphenylacetic acid was identified as the major chlorinated metabolite of chlorotyrosine and accounted for 3.6 +/- 0.3% of infused [D-4] chlorotyrosine. The striking observation was that similar to 40% ( 39 +/- 1%) of infused [D-4] chlorotyrosine was dechlorinated and excreted in the urine as deuterated 4-hydroxyphenylacetic acid, a major metabolite of tyrosine. 1.1 +/- 0.1% of infused [D-4] chlorotyrosine was excreted as [D-4] tyrosine. To determine whether protein-bound chlorotyrosine could undergo dechlorination, chlorinated albumin was incubated with liver homogenate from mutant rats, which did not synthesize albumin. There was similar to 20% decrease in the chlorotyrosine content over 1 h. This study is the first to describe the dechlorination of chlorotyrosine as the major metabolic pathway to eliminate this modified amino acid in vivo.	UCL Royal Free & Univ Coll, Sch Med, Dept Med, London NW3 2PF, England; Erasmus Univ, Ctr Med, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands	University of London; University College London; UCL Medical School; Erasmus University Rotterdam	Moore, KP (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Med, Rowland Hill St, London NW3 2PF, England.	kmoore@medsch.ucl.ac.uk	Visser, Theo J/C-8059-2013; Mani, Alireza/H-3236-2015	Visser, Theo J/0000-0002-6997-284X; Mani, Alireza/0000-0003-0830-2022; Moreno, Jose C./0000-0001-5664-5308	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200; Baldus S, 2001, J CLIN INVEST, V108, P1759; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; COLE JR, 1994, APPL ENVIRON MICROB, V60, P3536, DOI 10.1128/AEM.60.10.3536-3542.1994; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Faleev NG, 2003, BBA-PROTEINS PROTEOM, V1647, P260, DOI 10.1016/S1570-9639(03)00063-3; FELL V, 1978, CLIN CHIM ACTA, V83, P259, DOI 10.1016/0009-8981(78)90114-6; Frost MT, 2000, BIOCHEM J, V345, P453, DOI 10.1042/0264-6021:3450453; Garner CE, 2006, TOXICOL APPL PHARM, V215, P23, DOI 10.1016/j.taap.2006.01.010; Gaut JP, 2002, ANAL BIOCHEM, V300, P252, DOI 10.1006/abio.2001.5469; Gnidehou S, 2004, FASEB J, V18, P1574, DOI 10.1096/fj.04-2023fje; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Irie Y, 2003, P NATL ACAD SCI USA, V100, P5634, DOI 10.1073/pnas.1131756100; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; KAY RR, 1993, P NATL ACAD SCI USA, V90, P487, DOI 10.1073/pnas.90.2.487; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mani AR, 2003, BIOCHEM J, V374, P521, DOI 10.1042/BJ20030670; Mavri-Damelin Demetra, 2007, Int J Biochem Cell Biol, V39, P555, DOI 10.1016/j.biocel.2006.10.007; Moreno JC, 2003, HORM RES, V60, P96, DOI 10.1159/000074509; Moreno JC, 2006, HORM RES, V65, P31; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Quensen JF, 1998, SCIENCE, V280, P722, DOI 10.1126/science.280.5364.722; ROCHE J, 1952, BIOCHIM BIOPHYS ACTA, V9, P161, DOI 10.1016/0006-3002(52)90143-1; Shao BH, 2006, J BIOL CHEM, V281, P9001, DOI 10.1074/jbc.C600011200; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Sun BL, 2002, SCIENCE, V298, P1023, DOI 10.1126/science.1074675; Valverde-R C, 2004, INT REV CYTOL, V234, P143, DOI 10.1016/S0074-7696(04)34004-0; Wilkening S, 2003, DRUG METAB DISPOS, V31, P1035, DOI 10.1124/dmd.31.8.1035; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	35	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29114	29121		10.1074/jbc.M704270200	http://dx.doi.org/10.1074/jbc.M704270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686770	hybrid			2022-12-25	WOS:000249788000006
J	Davis, JA; Handford, PA; Redfield, C				Davis, Jason A.; Handford, Penny A.; Redfield, Christina			The N1317H substitution associated with Leber congenital amaurosis results in impaired interdomain packing in human CRB1 epidermal growth factor-like (EGF) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MODULES; CALCIUM-BINDING; HUMAN FIBRILLIN-1; RETINITIS-PIGMENTOSA; DROSOPHILA-CRUMBS; RETINAL DYSTROPHIES; MOLECULAR-GENETICS; MARFAN-SYNDROME; CHICK RETINA; FACTOR-IX	The calcium-binding epidermal growth factor-like (cbEGF) domain is a widely occurring module in proteins of diverse function. Amino acid substitutions that disrupt its structure or calcium affinity have been associated with various disorders. The extracellular portion of CRB1, the human homologue of Drosophila Crumbs, exhibits a modular domain organization that includes EGF and cbEGF domains. The N1317H substitution in the 19th cbEGF domain of CRB1 is associated with the serious visual disorder Leber congenital amaurosis. We have investigated the structure and Ca2+ binding of recombinant wild-type and N1317H CRB1 fragments ( EGF18-cbEGF19) using NMR and find that Ca2+ binding is altered, resulting in disruption of long range interactions between adjacent EGF domains in CRB1. From these observations, we propose that this substitution affects the structural integrity of CRB1 in the inter-photoreceptor matrix of the retina, where it is expressed. Furthermore, we identify disease-causing substitutions in other cbEGF-containing proteins that are likely to result in similar disruption of interdomain packing, supporting the hypothesis that the tandem cbEGF domain linkages are critical for the structure and function of proteins containing cbEGF domains.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Redfield, C (corresponding author), Univ Oxford, Dept Biochem, S Pk Rd, Oxford OX1 3QU, England.	christina.redfield@bioch.ox.ac.uk		Redfield, Christina/0000-0001-7297-7708	Wellcome Trust [079440] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; BARON M, 1992, PROTEIN SCI, V1, P81; Bernal S, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.7.e89; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169; den Hollander AI, 2004, HUM MUTAT, V24, P355, DOI 10.1002/humu.20093; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767; den Hollander AI, 2001, AM J HUM GENET, V69, P198; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Dmitriev AV, 1999, VISUAL NEUROSCI, V16, P1157, DOI 10.1017/S095252389916615X; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; Hambleton S, 2004, STRUCTURE, V12, P2173, DOI 10.1016/j.str.2004.09.012; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Izaddoost S, 2002, NATURE, V416, P178, DOI 10.1038/nature720; JENSEN SA, 2005, J BIOL CHEM; Johnson K, 2002, CURR BIOL, V12, P1675, DOI 10.1016/S0960-9822(02)01180-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kantardzhieva A, 2006, FEBS J, V273, P1152, DOI 10.1111/j.1742-4658.2006.05140.x; Kantardzhieva A, 2005, INVEST OPHTH VIS SCI, V46, P2192, DOI 10.1167/iovs.04-1417; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Lavallee CR, 2003, J NEUROPHYSIOL, V90, P3654, DOI 10.1152/jn.00736.2003; LI JD, 1994, INVEST OPHTH VIS SCI, V35, P2700; Lotery A J, 2001, Ophthalmic Genet, V22, P163, DOI 10.1076/opge.22.3.163.2222; Lotery AJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P415, DOI 10.1001/archopht.119.3.415; Makarova O, 2003, GENE, V302, P21, DOI 10.1016/S0378111902010843; McKay GJ, 2005, INVEST OPHTH VIS SCI, V46, P322, DOI 10.1167/iovs.04-0734; Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Richard M, 2006, HUM MOL GENET, V15, pR235, DOI 10.1093/hmg/ddl195; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; Suk JY, 2004, J BIOL CHEM, V279, P51258, DOI 10.1074/jbc.M408156200; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; van de Pavert SA, 2004, J CELL SCI, V117, P4169, DOI 10.1242/jcs.01301; van de Pavert SA, 2007, J NEUROSCI, V27, P564, DOI 10.1523/JNEUROSCI.3496-06.2007; van den Hurk JAJM, 2005, MOL VIS, V11, P263; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; YAMAMOTO F, 1992, EXP EYE RES, V54, P685, DOI 10.1016/0014-4835(92)90023-L; YOSHIKAMI S, 1980, NATURE, V286, P395, DOI 10.1038/286395a0	51	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28807	28814		10.1074/jbc.M704015200	http://dx.doi.org/10.1074/jbc.M704015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17660513	hybrid			2022-12-25	WOS:000249642100055
J	Bala, ADS; Spitzer, MW; Takahashi, TT				Bala, Avinash D. S.; Spitzer, Matthew W.; Takahashi, Terry T.			Auditory Spatial Acuity Approximates the Resolving Power of Space-Specific Neurons	PLOS ONE			English	Article							INTERAURAL LEVEL DIFFERENCE; SOUND-LOCALIZATION EXPERIMENTS; BARN OWL; RECEPTIVE-FIELDS; INFERIOR COLLICULUS; TIME DIFFERENCE; BRAIN-STEM; SINGLE NEURONS; VIRTUAL SPACE; NEURAL MAP	The relationship between neuronal acuity and behavioral performance was assessed in the barn owl (Tyto alba), a nocturnal raptor renowned for its ability to localize sounds and for the topographic representation of auditory space found in the midbrain. We measured discrimination of sound-source separation using a newly developed procedure involving the habituation and recovery of the pupillary dilation response. The smallest discriminable change of source location was found to be about two times finer in azimuth than in elevation. Recordings from neurons in its midbrain space map revealed that their spatial tuning, like the spatial discrimination behavior, was also better in azimuth than in elevation by a factor of about two. Because the PDR behavioral assay is mediated by the same circuitry whether discrimination is assessed in azimuth or in elevation, this difference in vertical and horizontal acuity is likely to reflect a true difference in sensory resolution, without additional confounding effects of differences in motor performance in the two dimensions. Our results, therefore, are consistent with the hypothesis that the acuity of the midbrain space map determines auditory spatial discrimination.	[Bala, Avinash D. S.; Spitzer, Matthew W.; Takahashi, Terry T.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; [Spitzer, Matthew W.] Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia	University of Oregon; Monash University	Bala, ADS (corresponding author), Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.	avinash@uoneuro.uoregon.edu	Bala, Avinash/B-7923-2013	Bala, Avinash/0000-0002-8531-5110	National Institute of Deafness and Communication Disorders [DC03925]; Medical Research Foundation of Oregon; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003925] Funding Source: NIH RePORTER	National Institute of Deafness and Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Medical Research Foundation of Oregon; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by grants from the National Institute of Deafness and Communication Disorders (DC03925) and the Medical Research Foundation of Oregon.	Bala ADS, 2003, NATURE, V424, P771, DOI 10.1038/nature01835; Bala ADS, 2000, J COMP PHYSIOL A, V186, P425, DOI 10.1007/s003590050442; BALDI P, 1988, BIOL CYBERN, V59, P313, DOI 10.1007/BF00332921; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Brand A, 2002, NATURE, V417, P543, DOI 10.1038/417543a; Britten KH, 1996, VISUAL NEUROSCI, V13, P87, DOI 10.1017/S095252380000715X; Britten KH, 1999, J NEUROSCI, V19, P5074; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; Carr CE, 1999, NEURAL COMPUT, V11, P1, DOI 10.1162/089976699300016773; COHEN YE, 1995, J NEUROSCI, V15, P5152; DULAC S, 1990, J NEUROPHYSIOL, V63, P131, DOI 10.1152/jn.1990.63.1.131; Eurich CW, 1997, BIOL CYBERN, V76, P357, DOI 10.1007/s004220050349; Euston DR, 2002, J NEUROSCI, V22, P284, DOI 10.1523/JNEUROSCI.22-01-00284.2002; Fairhall AL, 2001, NATURE, V412, P787, DOI 10.1038/35090500; FAREL PB, 1976, J NEUROPHYSIOL, V39, P661, DOI 10.1152/jn.1976.39.4.661; Green DM, 1966, SIGNAL DETECTION THE; Harper NS, 2004, NATURE, V430, P682, DOI 10.1038/nature02768; Keller CH, 1998, HEARING RES, V118, P13, DOI 10.1016/S0378-5955(98)00014-8; KNUDSEN EI, 1978, SCIENCE, V200, P795, DOI 10.1126/science.644324; KNUDSEN EI, 1977, SCIENCE, V198, P1278, DOI 10.1126/science.929202; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P13, DOI 10.1007/BF00663106; KNUDSEN EI, 1993, J NEUROSCI, V13, P2837; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P1, DOI 10.1007/BF00663105; KONISHI M, 1973, AM NAT, V107, P775, DOI 10.1086/282875; MANLEY GA, 1988, J NEUROSCI, V8, P2665; McAlpine D, 2001, NAT NEUROSCI, V4, P396, DOI 10.1038/86049; MOISEFF A, 1983, J NEUROSCI, V3, P2553; Osborne LC, 2005, NATURE, V437, P412, DOI 10.1038/nature03961; Pena JL, 2004, J NEUROSCI, V24, P8907, DOI 10.1523/JNEUROSCI.2924-04.2004; Pena JL, 2001, SCIENCE, V292, P249, DOI 10.1126/science.1059201; Poganiatz I, 2001, J COMP PHYSIOL A, V187, P225, DOI 10.1007/s003590100193; Poganiatz I, 2001, JARO, V2, P1; Recanzone GH, 2000, J NEUROPHYSIOL, V83, P2723, DOI 10.1152/jn.2000.83.5.2723; ROLLS ET, 1989, EUR J NEUROSCI, V1, P53, DOI 10.1111/j.1460-9568.1989.tb00774.x; SAKITT B, 1973, NATURE, V241, P133, DOI 10.1038/241133a0; Shackleton TM, 2003, J NEUROSCI, V23, P716, DOI 10.1523/JNEUROSCI.23-02-00716.2003; Skottun BC, 2001, P NATL ACAD SCI USA, V98, P14050, DOI 10.1073/pnas.241513998; Sokolov EN, 1958, ORIENTING REFLEX EXP, P141; Sparks DL, 2002, NAT REV NEUROSCI, V3, P952, DOI 10.1038/nrn986; Spezio ML, 2003, J NEUROSCI, V23, P4677; Spitzer MW, 2004, J NEUROPHYSIOL, V92, P2051, DOI 10.1152/jn.01235.2003; SULLIVAN WE, 1984, J NEUROSCI, V4, P1787; TAKAHASHI T, 1984, J NEUROSCI, V4, P1781; TAKAHASHI TT, 1992, J COMP PHYSIOL A, V170, P161; TAKAHASHI TT, 1988, J COMP NEUROL, V274, P190, DOI 10.1002/cne.902740206; WAGNER H, 1993, J NEUROSCI, V13, P371; WATHEY JC, 1989, BRAIN BEHAV EVOLUT, V33, P279, DOI 10.1159/000115936	47	30	30	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e675	10.1371/journal.pone.0000675	http://dx.doi.org/10.1371/journal.pone.0000675			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668055	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452300013
J	Jean, L; Thomas, B; Tahiri-Alaoui, A; Shaw, M; Vaux, DJ				Jean, Letitia; Thomas, Benjamin; Tahiri-Alaoui, Abdessamad; Shaw, Michael; Vaux, David J.			Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease	PLOS ONE			English	Article								Neurodegenerative diseases associated with abnormal protein folding and ordered aggregation require an initial trigger which may be infectious, inherited, post-inflammatory or idiopathic. Proteolytic cleavage to generate vulnerable precursors, such as amyloid-beta peptide (A beta) production via beta and gamma secretases in Alzheimer's Disease (AD), is one such trigger, but the proteolytic removal of these fragments is also aetiologically important. The levels of A beta in the central nervous system are regulated by several catabolic proteases, including insulysin (IDE) and neprilysin (NEP). The known association of human acetylcholinesterase (hAChE) with pathological aggregates in AD together with its ability to increase A beta fibrilization prompted us to search for proteolytic triggers that could enhance this process. The hAChE C-terminal domain (T40, AChE(575- 614)) is an exposed amphiphilic alpha-helix involved in enzyme oligomerisation, but it also contains a conformational switch region (CSR) with high propensity for conversion to non-native (hidden) beta-strand, a property associated with amyloidogenicity. A synthetic peptide (AChE(586- 599)) encompassing the CSR region shares homology with A beta and forms beta-sheet amyloid fibrils. We investigated the influence of IDE and NEP proteolysis on the formation and degradation of relevant hAChE beta-sheet species. By combining reverse-phase HPLC and mass spectrometry, we established that the enzyme digestion profiles on T40 versus AChE(586- 599), or versus A beta, differed. Moreover, IDE digestion of T40 triggered the conformational switch from alpha- to beta-structures, resulting in surfactant CSR species that self-assembled into amyloid fibril precursors (oligomers). Crucially, these CSR species significantly increased A beta fibril formation both by seeding the energetically unfavorable formation of amyloid nuclei and by enhancing the rate of amyloid elongation. Hence, these results may offer an explanation for observations that implicate hAChE in the extent of A beta deposition in the brain. Furthermore, this process of heterologous amyloid seeding by a proteolytic fragment from another protein may represent a previously underestimated pathological trigger, implying that the abundance of the major amyloidogenic species (A beta in AD, for example) may not be the only important factor in neurodegeneration.	[Thomas, Benjamin; Vaux, David J.] Univ Oxford, Sir William Dunn Sch Pathol, Cent Prote Facil, Oxford OX1 3RE, England	University of Oxford	Vaux, DJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Cent Prote Facil, S Parks Rd, Oxford OX1 3RE, England.	david.vaux@path.ox.ac.uk		Vaux, David/0000-0002-4901-9795; Jean, Letitia/0000-0002-6450-7148	Synaptica Ltd.; Wellcome Trust	Synaptica Ltd.; Wellcome Trust(Wellcome TrustEuropean Commission)	Funding: This work was supported by a research grant from Synaptica Ltd. and BT was supported by the Wellcome Trust. Synaptica Ltd had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation or review of the manuscript. The company approved the manuscript without modification.	Alvarez A, 1998, J NEUROSCI, V18, P3213; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Bitan G, 2004, ACCOUNTS CHEM RES, V37, P357, DOI 10.1021/ar000214l; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; Bourne Y, 1999, J BIOL CHEM, V274, P30370, DOI 10.1074/jbc.274.43.30370; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Cottingham MG, 2004, LAB INVEST, V84, P523, DOI 10.1038/labinvest.3700054; Cottingham MG, 2003, BIOCHEMISTRY-US, V42, P10863, DOI 10.1021/bi034768i; Cottingham MG, 2002, BIOCHEMISTRY-US, V41, P13539, DOI 10.1021/bi0260334; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Diamant S, 2006, P NATL ACAD SCI USA, V103, P8628, DOI 10.1073/pnas.0602922103; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Dvir H, 2004, EMBO J, V23, P4394, DOI 10.1038/sj.emboj.7600425; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; GEULA C, 1989, BRAIN RES, V498, P185, DOI 10.1016/0006-8993(89)90419-8; Giacobini E, 2002, J NEURAL TRANSM, V109, P1053, DOI 10.1007/s007020200089; Guillozet AL, 1997, ANN NEUROL, V42, P909, DOI 10.1002/ana.410420613; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jaikaran ETAS, 2001, J MOL BIOL, V308, P515, DOI 10.1006/jmbi.2001.4593; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; LIAO J, 1994, J NEUROCHEM, V63, P1446; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Mesulam MM, 2002, NEUROSCIENCE, V110, P627, DOI 10.1016/S0306-4522(01)00613-3; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; Mihara H, 1998, BIOPOLYMERS, V47, P83, DOI 10.1002/(SICI)1097-0282(1998)47:1<83::AID-BIP9>3.0.CO;2-T; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Pedersen JS, 2004, J MOL BIOL, V341, P575, DOI 10.1016/j.jmb.2004.06.020; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PERRY EK, 1978, NEUROPATH APPL NEURO, V4, P273, DOI 10.1111/j.1365-2990.1978.tb00545.x; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Rees T, 2003, NEUROBIOL AGING, V24, P777, DOI 10.1016/S0197-4580(02)00230-0; Rees Tina M., 2005, Current Alzheimer Research, V2, P291, DOI 10.2174/1567205054367847; Saez-Valero J, 1999, J NEUROCHEM, V72, P1600, DOI 10.1046/j.1471-4159.1999.721600.x; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143; Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WRIGHT CI, 1993, ANN NEUROL, V34, P373, DOI 10.1002/ana.410340312; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Yoon S, 2004, PROTEIN SCI, V13, P2149, DOI 10.1110/ps.04790604	64	19	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e652	10.1371/journal.pone.0000652	http://dx.doi.org/10.1371/journal.pone.0000652			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653279	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200021
J	Sangster, TA; Bahrami, A; Wilczek, A; Watanabe, E; Schellenberg, K; McLellan, C; Kelley, A; Kong, SW; Queitsch, C; Lindquist, S				Sangster, Todd A.; Bahrami, Adam; Wilczek, Amity; Watanabe, Etsuko; Schellenberg, Kurt; McLellan, Catherine; Kelley, Alicia; Kong, Sek Won; Queitsch, Christine; Lindquist, Susan			Phenotypic Diversity and Altered Environmental Plasticity in Arabidopsis thaliana with Reduced Hsp90 Levels	PLOS ONE			English	Article								The molecular chaperone HSP90 aids the maturation of a diverse but select set of metastable protein clients, many of which are key to a variety of signal transduction pathways. HSP90 function has been best investigated in animal and fungal systems, where inhibition of the chaperone has exceptionally diverse effects, ranging from reversing oncogenic transformation to preventing the acquisition of drug resistance. Inhibition of HSP90 in the model plant Arabidopsis thaliana uncovers novel morphologies dependent on normally cryptic genetic variation and increases stochastic variation inherent to developmental processes. The biochemical activity of HSP90 is strictly conserved between animals and plants. However, the substrates and pathways dependent on HSP90 in plants are poorly understood. Progress has been impeded by the necessity of reliance on light-sensitive HSP90 inhibitors due to redundancy in the A. thaliana HSP90 gene family. Here we present phenotypic and genome-wide expression analyses of A. thaliana with constitutively reduced HSP90 levels achieved by RNAi targeting. HSP90 reduction affects a variety of quantitative life-history traits, including flowering time and total seed set, increases morphological diversity, and decreases the developmental stability of repeated characters. Several morphologies are synergistically affected by HSP90 and growth temperature. Genome-wide expression analyses also suggest a central role for HSP90 in the genesis and maintenance of plastic responses. The expression results are substantiated by examination of the response of HSP90-reduced plants to attack by caterpillars of the generalist herbivore Trichoplusia ni. HSP90 reduction potentiates a more robust herbivore defense response. In sum, we propose that HSP90 exerts global effects on the environmental responsiveness of plants to many different stimuli. The comprehensive set of HSP90-reduced lines described here is a vital instrument to further examine the role of HSP90 as a central interface between organism, development, and environment.	[Sangster, Todd A.] Univ Chicago, Comm Genet, Chicago, IL 60637 USA; [Sangster, Todd A.; Kelley, Alicia; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Bahrami, Adam; Wilczek, Amity] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; [Watanabe, Etsuko; Schellenberg, Kurt; McLellan, Catherine; Queitsch, Christine] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA; [Kong, Sek Won] Childrens Hosp Boston, Informat Program, Boston, MA USA	University of Chicago; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard University; Harvard University; Boston Children's Hospital	Queitsch, C (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.	queitsch@u.washing-ton.edu	Bahrami, Adam/J-2736-2013	Bahrami, Adam/0000-0003-3039-6854	G. Harold and Lelia Y. Mathers Foundation; Howard Hughes Medical Institute	G. Harold and Lelia Y. Mathers Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute)	Funding: Funding for this project was provided by the G. Harold and Lelia Y. Mathers Foundation to S.L. TAS was supported by a Howard Hughes Medical Institute pre-doctoral fellowship.	ABBOTT RJ, 1989, HEREDITY, V62, P411, DOI 10.1038/hdy.1989.56; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; *AR INF RES, 2007, TAIR7 GEN REL; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Azevedo C, 2006, EMBO J, V25, P2007, DOI 10.1038/sj.emboj.7601084; Bechtold N, 1998, METH MOL B, V82, P259; BHATTARAI KK, 2007, PLANT PHYSL; Bos JIB, 2006, PLANT J, V48, P165, DOI 10.1111/j.1365-313X.2006.02866.x; Campisi L, 1999, PLANT J, V17, P699, DOI 10.1046/j.1365-313X.1999.00409.x; Cao DS, 2003, PLANT J, V33, P107, DOI 10.1046/j.1365-313X.2003.016011.x; Castillo-Davis CI, 2003, BIOINFORMATICS, V19, P891, DOI 10.1093/bioinformatics/btg114; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Cowen LE, 2005, SCIENCE, V309, P2185, DOI 10.1126/science.1118370; Cui J, 2005, P NATL ACAD SCI USA, V102, P1791, DOI 10.1073/pnas.0409450102; Cui JP, 2002, PLANT PHYSIOL, V129, P551, DOI 10.1104/pp.010815; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; Glazebrook J, 2005, ANNU REV PHYTOPATHOL, V43, P205, DOI 10.1146/annurev.phyto.43.040204.135923; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Heil M, 2002, ANN BOT-LONDON, V89, P503, DOI 10.1093/aob/mcf076; HOAGLAND DR, 1950, 347 CAL AGR EXP STA; Holt BF, 2005, SCIENCE, V309, P929, DOI 10.1126/science.1109977; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; Ishiguro S, 2002, EMBO J, V21, P898, DOI 10.1093/emboj/21.5.898; Kanzaki H, 2003, MOL PLANT PATHOL, V4, P383, DOI [10.1046/j.1364-3703.2003.00186.x, 10.1046/J.1364-3703.2003.00186.X]; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; Krishna P, 1997, PLANT MOL BIOL, V33, P457, DOI 10.1023/A:1005709308096; Krishna P, 2001, CELL STRESS CHAPERON, V6, P238, DOI 10.1379/1466-1268(2001)006<0238:THFOPI>2.0.CO;2; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Liu YL, 2004, J BIOL CHEM, V279, P2101, DOI 10.1074/jbc.M310029200; Lu R, 2003, EMBO J, V22, P5690, DOI 10.1093/emboj/cdg546; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Milton CC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000075; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt WB, 2006, HANDB EXP PHARM, V172, P111; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Rutherford SL, 2000, BIOESSAYS, V22, P1095, DOI 10.1002/1521-1878(200012)22:12&lt;1095::AID-BIES7&gt;3.0.CO;2-A; Sangster TA, 2004, BIOESSAYS, V26, P348, DOI 10.1002/bies.20020; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; YABE N, 1994, PLANT CELL PHYSIOL, V35, P1207, DOI 10.1093/oxfordjournals.pcp.a078715; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhao RM, 2007, ADV EXP MED BIOL, V594, P27	53	115	123	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e648	10.1371/journal.pone.0000648	http://dx.doi.org/10.1371/journal.pone.0000648			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653275	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200017
J	Shaish, L; Abelson, A; Rinkevich, B				Shaish, Lee; Abelson, Avigdor; Rinkevich, Baruch			How Plastic Can Phenotypic Plasticity Be? The Branching Coral Stylophora pistillata as a Model System	PLOS ONE			English	Article							REEF-CORAL; POCILLOPORA-DAMICORNIS; PATTERN-FORMATION; GROWTH FORMS; WATER MOTION; ORGANISMS; ORGANIZATION; RESTORATION; COMPETITION; EXPRESSION	Phenotypic plasticity enables multicellular organisms to adjust morphologies and various life history traits to variable environmental challenges. Here, we elucidate fixed and plastic architectural rules for colony astogeny in multiple types of colonial ramets, propagated by cutting from genets of the branching coral Stylophora pistillata from Eilat, the Red Sea. We examined 16 morphometric parameters on 136 one-year old S. pistillata colonies (of seven genotypes), originating from small fragments belonging, each, to one of three single-branch types (single tips, start-up, and advanced bifurcating tips) or to structural preparative manipulations (representing a single or two growth axes). Experiments were guided by the rationale that in colonial forms, complexity of evolving phenotypic plasticity can be associated with a degree of structural modularity, where shapes are approached by erecting iterative growth patterns at different levels of coral-colony organization. Analyses revealed plastic morphometric characters at branch level, and predetermined morphometric traits at colony level (only single trait exhibited plasticity under extreme manipulation state). Therefore, under the experimental manipulations of this study, phenotypic plasticity in S. pistillata appears to be related to branch level of organization, whereas colony traits are controlled by predetermined genetic architectural rules. Each level of organization undergoes its own mode of astogeny. However, depending on the original ramet structure, the spherical 3-D colonial architecture in this species is orchestrated and assembled by both developmental trajectories at the branch level, and traits at the colony level of organization. In nature, branching colonial forms are often subjected to harsh environmental conditions that cause fragmentation of colony into ramets of different sizes and structures. Developmental traits that are plastic, responding to fragment structure and are not predetermine in controlling astogeny, allow formation of species-specific architecture product through integrated but variable developmental routes. This adaptive plasticity or regeneration is an efficient mechanism by which isolated fragments of branching coral species cope with external environmental forces.	[Shaish, Lee; Abelson, Avigdor; Rinkevich, Baruch] Tel Aviv Univ, Dept Zool, Ramat Aviv, Israel; [Shaish, Lee] Natl Inst Oceanog, IL-31080 Haifa, Israel	Tel Aviv University; Israel Oceanographic & Limnological Research Institute	Rinkevich, B (corresponding author), Tel Aviv Univ, Dept Zool, Ramat Aviv, Israel.	buki@ocean.org.il			EC-INCO-DEV; GEF/World Bank; EC collective research	EC-INCO-DEV; GEF/World Bank; EC collective research	Funding: The study was supported by the EC-INCO-DEV (REEFRES project), by the GEF/World Bank (Remediation and Restoration working Group project), and by the EC collective research (CORALZOO) project.	Abraham ER, 2001, MAR BIOL, V138, P503, DOI 10.1007/s002270000479; Ball EE, 2004, NAT REV GENET, V5, P567, DOI 10.1038/nrg1402; BRADSHAW A. D., 1965, ADVANCE GENET, V13, P115, DOI 10.1016/S0065-2660(08)60048-6; BRAZEAU DA, 1988, CORAL REEFS, V7, P139, DOI 10.1007/BF00300973; Bruno JF, 1997, ECOLOGY, V78, P2177, DOI 10.2307/2265954; Callahan HS, 1997, BIOESSAYS, V19, P519, DOI 10.1002/bies.950190611; Cartwright P, 2006, J EXP ZOOL PART B, V306B, P460, DOI 10.1002/jez.b.21106; CLARKE KR, 1993, MAR ECOL PROG SER, V92, P205, DOI 10.3354/meps092205; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; DAUGET JM, 1991, CR ACAD SCI III-VIE, V313, P45; DAUGET JM, 1991, MAR BIOL, V111, P157, DOI 10.1007/BF01986357; Dunn CW, 2005, DEV DYNAM, V234, P835, DOI 10.1002/dvdy.20483; Epstein N, 2001, BASIC APPL ECOL, V2, P219, DOI 10.1078/1439-1791-00045; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Foster A.B., 1983, Coral Reefs, V2, P19, DOI 10.1007/BF00304728; Gateno D, 1998, BIOL BULL, V194, P178, DOI 10.2307/1543048; GRAUS RR, 1976, SCIENCE, V193, P895, DOI 10.1126/science.193.4256.895; Hageman SJ, 2003, INTEGR COMP BIOL, V43, P87, DOI 10.1093/icb/43.1.87; JACKSON JBC, 1979, BIOL SYSTEMATICS COL, V2, P499; Kaandorp JA, 1999, MAR BIOL, V134, P295, DOI 10.1007/s002270050547; Kaandorp JA, 2005, P ROY SOC B-BIOL SCI, V272, P127, DOI 10.1098/rspb.2004.2934; Kaandorp JA, 2001, VIRTUAL LAB, P1; Kim K, 1997, J EXP MAR BIOL ECOL, V215, P49, DOI 10.1016/S0022-0981(97)00015-4; Kizner Z, 2001, ECOL MODEL, V141, P227, DOI 10.1016/S0304-3800(01)00276-9; Lasker HR, 1999, AM ZOOL, V39, P92; Lasker HR, 2003, BIOL BULL-US, V205, P319, DOI 10.2307/1543295; LESSER MP, 1994, J EXP MAR BIOL ECOL, V178, P153, DOI 10.1016/0022-0981(94)90034-5; LIDDLE MJ, 1987, BIOL CONSERV, V42, P1, DOI 10.1016/0006-3207(87)90049-8; Marfenin NN, 1997, HYDROBIOLOGIA, V355, P153, DOI 10.1023/A:1003069831832; Marshall PA, 2000, MAR ECOL PROG SER, V200, P177, DOI 10.3354/meps200177; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; Merks RMH, 2004, J THEOR BIOL, V228, P559, DOI 10.1016/j.jtbi.2004.02.020; MERKS RMH, 2003, THESIS U AMSTERDAM N; MILLER KJ, 1994, MAR ECOL PROG SER, V110, P19, DOI 10.3354/meps110019; Muko S, 2000, B MAR SCI, V66, P225; NAKAMURA T, 2006, P 10 INT COR REEF S, P872; Permata WD, 2005, ZOOL SCI, V22, P1197, DOI 10.2108/zsj.22.1197; Pigliucci M, 1996, TRENDS ECOL EVOL, V11, P168, DOI 10.1016/0169-5347(96)10008-2; PIGLIUCCI M, 1995, ECOLOGY, V76, P2134, DOI 10.2307/1941688; RINKEVICH B, 1985, B MAR SCI, V36, P319; Rinkevich B, 2000, MAR BIOL, V136, P807, DOI 10.1007/s002270000293; RINKEVICH B, 1985, OECOLOGIA, V66, P100, DOI 10.1007/BF00378559; RINKEVICH B, 1986, EXPERIENTIA, V42, P320, DOI 10.1007/BF01942521; Rinkevich B, 2002, ISRAEL J ZOOL, V48, P71, DOI 10.1560/BCPA-UM3A-MKBP-HGL2; RINKEVICH B, 1984, MAR BIOL, V80, P7, DOI 10.1007/BF00393121; RYLAND JS, 1986, PHILOS T ROY SOC B, V313, P53; Sanchez JA, 2004, AM NAT, V163, pE24, DOI 10.1086/382139; Sanchez JA, 2003, P ROY SOC B-BIOL SCI, V270, P2039, DOI 10.1098/rspb.2003.2471; Sebens KP, 1997, J EXP MAR BIOL ECOL, V211, P1, DOI 10.1016/S0022-0981(96)02636-6; Shaish L, 2006, DEV DYNAM, V235, P2111, DOI 10.1002/dvdy.20861; Sokal RR, 1984, BIOMETRY PRINCIPLES; Todd PA, 2004, MAR ECOL PROG SER, V271, P167, DOI 10.3354/meps271167; Underwood A.J., 1981, Oceanography and Marine Biology an Annual Review, V19, P513; VOSBURG F, 1977, P 3 INT COR REEF S, P177; West JM, 1997, BIOL BULL, V192, P279, DOI 10.2307/1542721; Wolpert L, 1996, TRENDS GENET, V12, P359, DOI 10.1016/S0168-9525(96)80019-9	56	45	46	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e644	10.1371/journal.pone.0000644	http://dx.doi.org/10.1371/journal.pone.0000644			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653271	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452200013
J	Lacaille, F; Hiroi, M; Twele, R; Inoshita, T; Umemoto, D; Maniere, G; Marion-Poll, F; Ozaki, M; Francke, W; Cobb, M; Everaerts, C; Tanimura, T; Ferveur, JF				Lacaille, Fabien; Hiroi, Makoto; Twele, Robert; Inoshita, Tsuyoshi; Umemoto, Daisuke; Maniere, Gerard; Marion-Poll, Frederic; Ozaki, Mamiko; Francke, Wittko; Cobb, Matthew; Everaerts, Claude; Tanimura, Teiichi; Ferveur, Jean-Francois			An Inhibitory Sex Pheromone Tastes Bitter for Drosophila Males	PLOS ONE			English	Article								Sexual behavior requires animals to distinguish between the sexes and to respond appropriately to each of them. In Drosophila melanogaster, as in many insects, cuticular hydrocarbons are thought to be involved in sex recognition and in mating behavior, but there is no direct neuronal evidence of their pheromonal effect. Using behavioral and electrophysiological measures of responses to natural and synthetic compounds, we show that Z-7-tricosene, a Drosophila male cuticular hydrocarbon, acts as a sex pheromone and inhibits male-male courtship. These data provide the first direct demonstration that an insect cuticular hydrocarbon is detected as a sex pheromone. Intriguingly, we show that a particular type of gustatory neurons of the labial palps respond both to Z-7-tricosene and to bitter stimuli. Cross-adaptation between Z-7-tricosene and bitter stimuli further indicates that these two very different substances are processed by the same neural pathways. Furthermore, the two substances induced similar behavioral responses both in courtship and feeding tests. We conclude that the inhibitory pheromone tastes bitter to the fly.	[Lacaille, Fabien; Maniere, Gerard; Everaerts, Claude; Ferveur, Jean-Francois] Univ Bourgogne, CNRS, UMR5548, Dijon, France; [Hiroi, Makoto; Marion-Poll, Frederic] INRA, UMR1272, F-78026 Versailles, France; [Twele, Robert; Francke, Wittko] Univ Hamburg, Hamburg, Germany; [Hiroi, Makoto; Inoshita, Tsuyoshi; Tanimura, Teiichi] Kyushu Univ, Grad Sch Sci, Dept Biol, Fukuoka 812, Japan; [Umemoto, Daisuke; Ozaki, Mamiko] Kyoto Inst Technol, Dept Appl Biol, Fac Text Sci, Kyoto 606, Japan; [Cobb, Matthew] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Hamburg; Kyushu University; Kyoto Institute of Technology; University of Manchester	Ferveur, JF (corresponding author), Univ Bourgogne, CNRS, UMR5548, Dijon, France.	jean-francois.ferveur@u-bourgogne.fr	Hiroi, Makoto/B-6834-2008; Frederic, Marion-Poll/I-1358-2019	Hiroi, Makoto/0000-0002-0136-5891; Frederic, Marion-Poll/0000-0001-6824-0180; Cobb, Matthew/0000-0002-8258-4913; Maniere, Gerard/0000-0003-1308-7291				ANTONY C, 1982, J INSECT PHYSIOL, V28, P873, DOI 10.1016/0022-1910(82)90101-9; Billeter JC, 2006, CURR BIOL, V16, pR766, DOI 10.1016/j.cub.2006.08.025; Boll W, 2002, DEVELOPMENT, V129, P5667, DOI 10.1242/dev.00157; Darwin G., 1871, P423; Ferveur JF, 2005, BEHAV GENET, V35, P279, DOI 10.1007/s10519-005-3220-5; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; Ferveur JF, 1996, P ROY SOC B-BIOL SCI, V263, P967, DOI 10.1098/rspb.1996.0143; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Hiroi M, 2004, J NEUROBIOL, V61, P333, DOI 10.1002/neu.20063; HODGSON ES, 1955, SCIENCE, V122, P417, DOI 10.1126/science.122.3166.417-a; Howard RW, 2005, ANNU REV ENTOMOL, V50, P371, DOI 10.1146/annurev.ento.50.071803.130359; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; KIMURA K, 1986, J EXP ZOOL, V239, P393, DOI 10.1002/jez.1402390310; Liberles SD, 2006, NATURE, V442, P645, DOI 10.1038/nature05066; Lin DY, 2005, NATURE, V434, P470, DOI 10.1038/nature03414; Marcillac F, 2005, GENETICS, V171, P1617, DOI 10.1534/genetics.104.033159; Meunier N, 2003, J NEUROBIOL, V56, P139, DOI 10.1002/neu.10235; Moon SJ, 2006, CURR BIOL, V16, P1812, DOI 10.1016/j.cub.2006.07.024; Ozaki M, 2005, SCIENCE, V309, P311, DOI 10.1126/science.1105244; Park SK, 2006, CURR BIOL, V16, P1154, DOI 10.1016/j.cub.2006.04.028; Rezaval C, 2007, EUR J NEUROSCI, V25, P683, DOI 10.1111/j.1460-9568.2007.05317.x; Savarit F, 1999, P NATL ACAD SCI USA, V96, P9015, DOI 10.1073/pnas.96.16.9015; Schmitt U., 1991, Chemoecology, V2, P35, DOI 10.1007/BF01240664; Shanbhag SR, 2001, CELL TISSUE RES, V304, P423, DOI 10.1007/s004410100388; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; Svetec N, 2005, J EXP BIOL, V208, P891, DOI 10.1242/jeb.01454; Thorne N, 2004, CURR BIOL, V14, P1065, DOI 10.1016/j.cub.2004.05.019; Wang ZR, 2004, CELL, V117, P981, DOI 10.1016/j.cell.2004.06.011; Xu A, 2002, CELL TISSUE RES, V307, P381, DOI 10.1007/s00441-002-0524-0; Zufall F, 2000, CHEM SENSES, V25, P473, DOI 10.1093/chemse/25.4.473	31	101	101	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e661	10.1371/journal.pone.0000661	http://dx.doi.org/10.1371/journal.pone.0000661			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710124	Green Published, gold			2022-12-25	WOS:000207455200001
J	Soares, EAJM; Santos, AFA; Sousa, TM; Sprinz, E; Martinez, AMB; Silveira, J; Tanuri, A; Soares, MA				Soares, Esmeralda A. J. M.; Santos, Andre F. A.; Sousa, Thatiana M.; Sprinz, Eduardo; Martinez, Ana M. B.; Silveira, Jussara; Tanuri, Amilcar; Soares, Marcelo A.			Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C	PLOS ONE			English	Article								Background. Subtype C is the most prevalent HIV-1 subtype in the world, mainly in countries with the highest HIV prevalence. However, few studies have evaluated the impact of antiretroviral therapy on this subtype. In southern Brazil, the first developing country to offer free and universal treatment, subtypes B and C co-circulate with equal prevalence, allowing for an extensive evaluation of this issue. Methods and Findings. Viral RNA of 160 HIV-1+ patients was extracted, and the protease and reverse transcriptase genes were sequenced, subtyped and analyzed for ARV mutations. Sequences were grouped by subtype, and matched to type (PI, NRTI and NNRTI) and time of ARV exposure. Statistical analyses were performed to compare differences in the frequency of ARV-associated mutations. There were no significant differences in time of treatment between subtypes B and C groups, although they showed distinct proportions of resistant strains at different intervals for two of three ARV classes. For PI, 26% of subtype B strains were resistant, compared to only 8% in subtype C (p = 0.0288, Fisher's exact test). For NRTI, 54% of subtype B strains were resistant versus 23% of subtype C (p = 0.0012). Differences were significant from 4 years of exposure, and remained so until the last time point analyzed. The differences observed between both subtypes were independent of time under rebound viremia in cases of virologic failure and of the number of HAART regimens used by treated patients. Conclusions. Our results pointed out to a lower rate of accumulation of mutations conferring resistance to ARV in subtype C than in subtype B. These findings are of crucial importance for current initiatives of ARV therapy roll-out in developing countries, where subtype is C prevalent.	[Soares, Esmeralda A. J. M.; Santos, Andre F. A.; Sousa, Thatiana M.; Tanuri, Amilcar; Soares, Marcelo A.] Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil; [Sprinz, Eduardo] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Martinez, Ana M. B.; Silveira, Jussara] Fundacao Univ Fed Rio Grande Sul, Dept Patol, Rio Grande, RS, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul	Soares, MA (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.	masoares@biologia.ufrj.br	Tanuri, Amilcar/AAM-8601-2021; sprinz, eduardo/V-7961-2019; Santos, Andre FA/I-5734-2016; Soares, Marcelo A/G-5662-2010	sprinz, eduardo/0000-0003-4343-8304; 	Brazilian Ministry of Science and Technology (CNPq) [403589/2004-5]; Rio de Janeiro State Science Foundation (FAPERJ) [E-26/171.337/2002]; Brazilian Ministry of Health (PN-DST/AIDS) [322/2005]	Brazilian Ministry of Science and Technology (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro State Science Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Brazilian Ministry of Health (PN-DST/AIDS)	Financial support by the Brazilian Ministry of Science and Technology (CNPq) grant no. 403589/2004-5, Rio de Janeiro State Science Foundation (FAPERJ) grant no. E-26/171.337/2002 and the Brazilian Ministry of Health (PN-DST/AIDS) grant no. 322/2005. The sponsors had no role in any step of the study design, data analysis or manuscript preparation.	Abecasis AB, 2005, AIDS, V19, P1799, DOI 10.1097/01.aids.0000188422.95162.b7; Abecasis AB, 2006, ANTIVIR THER, V11, P581; Arien KK, 2007, NAT REV MICROBIOL, V5, P141, DOI 10.1038/nrmicro1594; Arien KK, 2005, J VIROL, V79, P8979, DOI 10.1128/JVI.79.14.8979-8990.2005; Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/00002030-200301030-00001; Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016; Carmona R, 2005, J CLIN VIROL, V32, P248, DOI 10.1016/j.jcv.2004.11.009; Dumans AT, 2004, J INFECT DIS, V189, P1232, DOI 10.1086/382483; Gonzalez LMF, 2004, ANTIMICROB AGENTS CH, V48, P3552, DOI 10.1128/AAC.48.9.3552-3555.2004; Gonzalez LMF, 2003, ANTIMICROB AGENTS CH, V47, P2817, DOI 10.1128/AAC.47.9.2817-2822.2003; Grossman Z, 2004, AIDS, V18, P909, DOI 10.1097/00002030-200404090-00008; Grossman Z, 2001, AIDS, V15, P1453, DOI 10.1097/00002030-200108170-00001; Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc; Holguin A, 2004, J CLIN VIROL, V31, P215, DOI 10.1016/j.jcv.2004.03.015; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; Johnson Victoria A, 2006, Top HIV Med, V14, P125; Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112; Kantor R, 2006, CURR OPIN INFECT DIS, V19, P594, DOI 10.1097/QCO.0b013e3280109122; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Pieniazek D, 2000, AIDS, V14, P1489, DOI 10.1097/00002030-200007280-00004; Renjifo B, 2004, AIDS, V18, P1629, DOI 10.1097/01.aids.0000131392.68597.34; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100; Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d; Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5; Shankarappa R, 2001, J VIROL, V75, P10479, DOI 10.1128/JVI.75.21.10479-10487.2001; Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4; Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012; Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van de Vijver DA, 2006, JAIDS-J ACQ IMM DEF, V41, P352, DOI 10.1097/01.qai.0000209899.05126.e4; Van Harmelen JH, 1999, AIDS RES HUM RETROV, V15, P395; Vergne L, 2006, J CLIN VIROL, V36, P43, DOI 10.1016/j.jcv.2006.01.012	34	48	50	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e730	10.1371/journal.pone.0000730	http://dx.doi.org/10.1371/journal.pone.0000730			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710130	gold, Green Published, Green Submitted			2022-12-25	WOS:000207455200007
J	Streitz, M; Tesfa, L; Yildirim, V; Yahyazadeh, A; Ulrichs, T; Lenkei, R; Quassem, A; Liebetrau, G; Nomura, L; Maecker, H; Volk, HD; Kern, F				Streitz, Mathias; Tesfa, Lydia; Yildirim, Vedat; Yahyazadeh, Ali; Ulrichs, Timo; Lenkei, Rodica; Quassem, Ali; Liebetrau, Gerd; Nomura, Laurel; Maecker, Holden; Volk, Hans-Dieter; Kern, Florian			Loss of Receptor on Tuberculin-Reactive T-Cells Marks Active Pulmonary Tuberculosis	PLOS ONE			English	Article								Background. Tuberculin-specific T-cell responses have low diagnostic specificity in BCG vaccinated populations. While subunit-antigen (e. g. ESAT-6, CFP-10) based tests are useful for diagnosing latent tuberculosis infection, there is no reliable immunological test for active pulmonary tuberculosis. Notably, all existing immunological tuberculosis-tests are based on T-cell response size, whereas the diagnostic potential of T-cell response quality has never been explored. This includes surface marker expression and functionality of mycobacterial antigen specific T-cells. Methodology/Principal Findings. Flow-cytometry was used to examine over-night antigen-stimulated T-cells from tuberculosis patients and controls. Tuberculin and/or the relatively M. tuberculosis specific ESAT-6 protein were used as stimulants. A set of classic surface markers of T-cell naive/memory differentiation was selected and IFN-gamma production was used to identify T-cells recognizing these antigens. The percentage of tuberculin-specific T-helper-cells lacking the surface receptor CD27, a state associated with advanced differentiation, varied considerably between individuals (from less than 5% to more than 95%). Healthy BCG vaccinated individuals had significantly fewer CD27-negative tuberculin-reactive CD4 T-cells than patients with smear and/or culture positive pulmonary tuberculosis, discriminating these groups with high sensitivity and specificity, whereas individuals with latent tuberculosis infection exhibited levels in between. Conclusions/Significance. Smear and/or culture positive pulmonary tuberculosis can be diagnosed by a rapid and reliable immunological test based on the distribution of CD27 expression on peripheral blood tuberculin specific T-cells. This test works very well even in a BCG vaccinated population. It is simple and will be of great utility in situations where sputum specimens are difficult to obtain or sputum-smear is negative. It will also help avoid unnecessary hospitalization and patient isolation.	[Streitz, Mathias; Tesfa, Lydia; Yildirim, Vedat; Yahyazadeh, Ali; Volk, Hans-Dieter; Kern, Florian] Charite, Charite, Inst Med Immunol, D-13353 Berlin, Germany; [Ulrichs, Timo] Max Planck Inst Infekt Biol, Immunol Abt, Berlin, Germany; [Lenkei, Rodica] St Gorans Univ Hosp, Capio Diagnost AB, Stockholm, Sweden; [Quassem, Ali; Liebetrau, Gerd] Lungenklin Lostau, Lostau, Germany; [Nomura, Laurel; Maecker, Holden] BD Biosci, San Jose, CA USA; [Kern, Florian] Brighton & Sussex Med Sch, Div Med, Brighton, E Sussex, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Saint Goran's Hospital; University of Brighton; University of Sussex	Kern, F (corresponding author), Charite, Charite, Inst Med Immunol, D-13353 Berlin, Germany.	f.kern@bsms.ac.uk	volk, hans-dieter/AAV-8053-2021; Kern, Florian/AAE-6784-2022	volk, hans-dieter/0000-0002-7743-6668; Kern, Florian/0000-0002-0368-8408	Charite-Universitatsmedizin Berlin	Charite-Universitatsmedizin Berlin	The work was funded by Charite-Universitatsmedizin Berlin. The funding source was not involved in study design, data collection, analysis, interpretation, writing the report, or the decision to submit.	Antas PRZ, 2005, T ROY SOC TROP MED H, V99, P699, DOI 10.1016/j.trstmh.2005.05.002; Appay V, 2002, J IMMUNOL, V168, P5954, DOI 10.4049/jimmunol.168.11.5954; Barry SM, 2003, J INFECT DIS, V187, P243, DOI 10.1086/346112; Bienenstock J, 2005, IMMUNOL REV, V206, P22, DOI 10.1111/j.0105-2896.2005.00299.x; Cardoso FLL, 2002, INFECT IMMUN, V70, P6707, DOI 10.1128/IAI.70.12.6707-6714.2002; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hamann D, 1999, IMMUNOL TODAY, V20, P177, DOI 10.1016/S0167-5699(99)01444-9; Hughes AJ, 2005, CLIN EXP IMMUNOL, V142, P132, DOI 10.1111/j.1365-2249.2005.02884.x; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Kern F, 2005, TRENDS IMMUNOL, V26, P477, DOI 10.1016/j.it.2005.07.005; Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1; Lyadova IV, 2004, CLIN EXP IMMUNOL, V138, P21, DOI 10.1111/j.1365-2249.2004.02573.x; Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; Murray RA, 2006, J IMMUNOL, V177, P5647, DOI 10.4049/jimmunol.177.8.5647; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005; Rowland-Jones SL, 2001, IMMUNOL LETT, V79, P15, DOI 10.1016/S0165-2478(01)00261-9; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 2000, CURR TOP MICROBIOL, V251, P167; Tesfa L, 2004, CYTOM PART B-CLIN CY, V60B, P47, DOI 10.1002/cyto.b.20007; TJARNLUND A, 2006, MICROBES INFECT; Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001; Wills MR, 2002, J IMMUNOL, V168, P5455, DOI 10.4049/jimmunol.168.11.5455	29	71	75	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e735	10.1371/journal.pone.0000735	http://dx.doi.org/10.1371/journal.pone.0000735			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710135	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200012
J	Cheng, Z; Ke, Y; Ding, X; Wang, F; Wang, H; Ahmed, K; Liu, Z; Xu, Y; Aikhionbare, F; Yan, H; Liu, J; Xue, Y; Powell, M; Liang, S; Reddy, SE; Hu, R; Huang, H; Jin, C; Yao, X				Cheng, Z.; Ke, Y.; Ding, X.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Xu, Y.; Aikhionbare, F.; Yan, H.; Liu, J.; Xue, Y.; Powell, M.; Liang, S.; Reddy, S. E.; Hu, R.; Huang, H.; Jin, C.; Yao, X.			Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response	ONCOGENE			English	Article						UV irradiation; DNA damage; TIP60; sumoylation; p53	HISTONE ACETYLTRANSFERASE; PROTEIN; P53; ACETYLATION; NUCLEAR; REPAIR	The histone acetyltransferase TIP60 regulates the DNA damage response following genotoxic stress by acetylating histone and remodeling chromatin. However, the molecular mechanisms underlying the TIP60-dependent response to UV-induced DNA damage remain poorly understood. To systematically analyse proteins that regulate TIP60 activity in response to UVirradiation, we performed a proteomic analysis of proteins selectively bound to TIP60 in response to UVirradiation using mass spectrometry and identified a novel regulatory mechanism by which TIP60 orchestrates transcriptional activation of p53-dependent checkpoint response in UV-irradiated cells. The initial step of this pathway involves UV-induced association of TIP60 with SUMO-conjugation enzymes and site-specific sumoylation of TIP60 at lysines 430 and 451 via Ubc9. This sumoylation initiates the relocation of TIP60 from nucleoplasm to the promyelocytic leukemia body, which is essential for the UV-irradiated DNA damage repair response via a p53-dependent pathway. Significantly, inhibition of TIP60 sumoylation by overexpression of non-sumoylatable mutant abrogates the p53-dependent DNA damage response, demonstrating the importance of TIP60 sumoylation in response to UV irradiation. Our biochemical characterization demonstrated that the sumoylation of TIP60 augments its acetyltransferase activity in vitro and in vivo. Thus, this study shed new light on the function and regulation of TIP60 activity in UV-irradiated DNA damage response.	[Cheng, Z.; Ke, Y.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Yan, H.; Liu, J.; Jin, C.; Yao, X.] Hefei Natl Lab, Hefei, Peoples R China; [Ding, X.; Wang, F.; Aikhionbare, F.; Powell, M.; Reddy, S. E.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Ding, X.; Yao, X.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Xu, Y.; Huang, H.] Zhejiang Univ, Dept Hematol, Hangzhou, Peoples R China; [Liang, S.] Hunan Normal Univ, Lab Protein chem, Changsha, Peoples R China; [Hu, R.] Fudan Univ, Dept Endocrinol, Shanghai 200433, Peoples R China	Morehouse School of Medicine; Beijing University of Chinese Medicine; Zhejiang University; Hunan Normal University; Fudan University	Yao, X (corresponding author), Univ Sci & Technol China, Lab Cell Dynam, Hefei 230026, Peoples R China.	yaoxb@ustc.edu.cn	Xue, Yu/G-5929-2011	Xue, Yu/0000-0002-9403-6869; Wang, Hongmei/0000-0002-5881-2488	NCRR NIH HHS [G-12-RR03034] Funding Source: Medline; NIDDK NIH HHS [DK56292] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1718; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHELTER P, 2003, NATURE, V425, P188; Shieh SY, 2000, GENE DEV, V14, P289; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Zhou FF, 2005, FEBS LETT, V579, P3369, DOI 10.1016/j.febslet.2005.04.076	22	50	55	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					931	941		10.1038/sj.onc.1210710	http://dx.doi.org/10.1038/sj.onc.1210710			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17704809				2022-12-25	WOS:000252946300005
J	Peng, ZG; Zhou, MY; Huang, Y; Qiu, JH; Wang, LS; Liao, SH; Dong, S; Chen, GQ				Peng, Z. G.; Zhou, M. Y.; Huang, Y.; Qiu, J. H.; Wang, L. S.; Liao, S. H.; Dong, S.; Chen, G. Q.			Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1 alpha	ONCOGENE			English	Article						hypoxia-inducible factor-1 alpha (HIF-1 alpha); runt-related protein 1 (Runx1); protein-protein interaction; angiogenesis	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; LEUKEMIC-CELL DIFFERENTIATION; STIMULATING FACTOR-RECEPTOR; FUSION PROTEIN; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; OXYGEN-TENSION; ANGIOGENESIS; ALPHA; HEMATOPOIESIS	Angiogenesis and hematopoiesis are closely linked and interactive with each other, but few studies were given to identify possible links between angiogenesis-promoting proteins and hematopoiesis-related transcription factors. Here we investigated the potential relationship of oxygen-sensitive alpha-subunit of angiogenesis-related hypoxia-inducible factor-1 alpha (HIF-1 alpha) with Runt-related protein 1 (Runx1, also known as acute myeloid leukemia-1, AML-1), an important hematopoietic transcription factor. The results demonstrated that Runx1 and HIF-1 alpha proteins directly interacted with each other to a degree, in which Runt homology domain of Runx1 was mainly involved. Leukemia-related abnormal Runx1 fusion protein AML1-ETO, which fuses the N-terminal 177 amino acid residues of the Runx1 protein in frame to ETO (eight-twenty-one) protein, also interacted with HIF-1 alpha protein with greater ability than Runx1 itself. More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1. Vice versa, HIF-1 alpha increased DNA-binding ability and transcriptional activity of Runx1 protein. All these data would shed new insight to understanding Runx1 and HIF-1 alpha-related hematopoietic cell differentiation and angiogenesis.	[Peng, Z. G.; Zhou, M. Y.; Liao, S. H.; Chen, G. Q.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Dept Pathophysiol, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai 200025, Peoples R China; [Huang, Y.; Wang, L. S.; Chen, G. Q.] SJTU SM, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China; [Huang, Y.; Qiu, J. H.; Dong, S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Baylor College of Medicine	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Dept Pathophysiol, Shanghai Inst Biol Sci,Inst Hlth Sci, 280 Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn						Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Desplat V, 2002, STEM CELLS, V20, P347, DOI 10.1634/stemcells.20-4-347; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Kilic M, 2007, ONCOGENE, V26, P2027, DOI 10.1038/sj.onc.1210008; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; SONG LP, 2007, IN PRESS ONCOGENE; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Suda T, 2000, INT J HEMATOL, V71, P99; Werner MH, 1999, NAT MED, V5, P1356, DOI 10.1038/70920; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	37	36	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					839	847		10.1038/sj.onc.1210676	http://dx.doi.org/10.1038/sj.onc.1210676			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684492				2022-12-25	WOS:000252884500013
J	Liu, S; Vinall, RL; Tepper, C; Shi, XB; Xue, LR; Ma, AH; Wang, LY; Fitzgerald, LD; Wu, Z; Gandour-Edwards, R; White, RWD; Kung, HJ				Liu, S.; Vinall, R. L.; Tepper, C.; Shi, X-B; Xue, L. R.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Gandour-Edwards, R.; White, R. W. deVere; Kung, H-J			Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway	ONCOGENE			English	Article						H2-relaxin; GPCR; beta-catenin; Wnt; androgen receptor; prostate cancer	PROSTATE-CANCER CELLS; GLYCOGEN-SYNTHASE KINASE-3; INDEPENDENT GROWTH; NEUROENDOCRINE DIFFERENTIATION; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; COLON-CANCER; H2 RELAXIN; WNT; EXPRESSION	We have previously demonstrated that human H2-relaxin can mediate androgen-independent growth of LNCaP through a mechanism that involves the activation of the androgen receptor (AR) signaling pathway. The goal of the current study is to elucidate the mechanism(s) by which H2-relaxin causes activation of the AR pathway. Our data indicate that there is cross-talk between AR and components of the Wnt signaling pathway. Addition of H2-relaxin to LNCaP cells resulted in increased phosphorylation of protein kinase B (Akt) and inhibitory phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta) with subsequent cytoplasmic accumulation of beta-catenin. Immunoprecipitation and immunocytochemical studies demonstrated that the stabilized b-catenin formed a complex with AR, which was then translocated into the nucleus. Chromatin immunoprecipitation analysis determined that the AR/beta-catenin complex binds to the proximal region of the prostate-specific antigen promoter. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3b and translocation of beta-catenin/AR into the nucleus. Knockdown of beta-catenin levels using a beta-cateninspecific small interfering RNA inhibited H2-relaxin-induced AR activity. The combined data demonstrate that PI3K/Akt and components of the Wnt pathway can facilitate H2-relaxin-mediated activation of the AR pathway.	[Liu, S.; Vinall, R. L.; Tepper, C.; Shi, X-B; Xue, L. R.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Gandour-Edwards, R.; White, R. W. deVere; Kung, H-J] Univ Calif, Ctr Canc, Sacramento, CA USA; [Liu, S.; Tepper, C.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Kung, H-J] Univ Calif, Sch Med, Dept Biochem & Mol Med, Sacramento, CA USA; [Vinall, R. L.; Shi, X-B; Xue, L. R.; White, R. W. deVere] Univ Calif, Sch Med, Dept Urol, Sacramento, CA USA; [Gandour-Edwards, R.] Univ Calif, Sch Med, Dept Pathol, Sacramento, CA USA		White, RWD (corresponding author), Univ Calif Davis, Ctr Canc, UCDMC, Res 3,4645,2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013; Vinall, Ruth/L-7026-2019	Wang, Ling-Yu/0000-0002-1413-817X				Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cronauer MV, 2005, INT J ONCOL, V26, P1033; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; DESANTAGNESE P, 1996, CANCER, V78, P357; Dessauer CW, 2005, ANN NY ACAD SCI, V1041, P272, DOI 10.1196/annals.1282.040; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; Halls ML, 2005, ANN NY ACAD SCI, V1041, P288, DOI 10.1196/annals.1282.042; Halls ML, 2005, ANN NY ACAD SCI, V1041, P292, DOI 10.1196/annals.1282.043; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Ivell R, 2002, SCIENCE, V295, P637, DOI 10.1126/science.1069234; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Nguyen BT, 2003, MOL ENDOCRINOL, V17, P1075, DOI 10.1210/me.2002-0284; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Palejwala S, 1998, ENDOCRINOLOGY, V139, P1208, DOI 10.1210/en.139.3.1208; Pang S, 1997, CANCER RES, V57, P495; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Shi XB, 2004, BJU INT, V94, P996, DOI 10.1111/j.1464-410X.2004.05093.x; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; Song SY, 2004, J CLIN GASTROENTEROL, V38, P252, DOI 10.1097/00004836-200403000-00011; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vinall RL, 2006, ONCOGENE, V25, P2082, DOI 10.1038/sj.onc.1209246; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150	42	35	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					499	505		10.1038/sj.onc.1210671	http://dx.doi.org/10.1038/sj.onc.1210671			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653089				2022-12-25	WOS:000252426100010
J	Watashi, K; Inoue, D; Hijikata, M; Goto, K; Aly, HH; Shimotohno, K				Watashi, Koichi; Inoue, Daisuke; Hijikata, Makoto; Goto, Kaku; Aly, Hussein H.; Shimotohno, Kunitada			Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NONSTRUCTURAL PROTEINS; MEMBRANE ASSOCIATION; MULTIDRUG-RESISTANCE; REPLICATION COMPLEX; CYCLOSPORINE-A; ER-ALPHA; IDENTIFICATION; CYCLOPHILIN; INHIBITION	Hepatitis C virus ( HCV) is a major causative agent of hepatocellular carcinoma. HCV genome replication occurs in the replication complex ( RC) around the endoplasmic reticulum membrane. However, the mechanisms regulating the HCV RC remain widely unknown. Here, we used a chemical biology approach to show that estrogen receptor ( ESR) is functionally associated with HCV replication. We found that tamoxifen suppressed HCV genome replication. Part of ESR alpha resided on the endoplasmic reticulum membranes and interacted with HCV RNA polymerase NS5B. RNA interference- mediated knockdown of endogenous ESR alpha reduced HCV replication. Mechanistic analysis suggested that ESR alpha promoted NS5B association with the RC and that tamoxifen abrogated NS5B- RC association. Thus, ESR alpha regulated the presence of NS5B in the RC and stimulated HCV replication. Moreover, the ability of ESR alpha to regulate NS5B was suggested to serve as a potential novel target for anti-HCV therapeutics.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, 53 Kawaharacho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		Aly, Hussein H/0000-0002-2455-0694				Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Aizaki H, 2004, VIROLOGY, V324, P450, DOI 10.1016/j.virol.2004.03.034; Aly HH, 2007, J HEPATOL, V46, P26, DOI 10.1016/j.jhep.2006.08.018; Bartenschlager R, 2001, ANTIVIR RES, V52, P1, DOI 10.1016/S0166-3542(01)00164-4; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Goto K, 2006, BIOCHEM BIOPH RES CO, V343, P879, DOI 10.1016/j.bbrc.2006.03.059; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hino H, 1999, BIOCHEM BIOPH RES CO, V256, P184, DOI 10.1006/bbrc.1999.0288; Kapadia SB, 2005, P NATL ACAD SCI USA, V102, P2561, DOI 10.1073/pnas.0409834102; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; LIANG TJ, 1993, HEPATOLOGY, V18, P1326, DOI 10.1016/0270-9139(93)90219-D; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LOPES MCF, 1990, CANCER RES, V50, P2753; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Miyanari Y, 2003, J BIOL CHEM, V278, P50301, DOI 10.1074/jbc.M305684200; Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017; Murata T, 2005, VIROLOGY, V340, P105, DOI 10.1016/j.virol.2005.06.015; Murata T, 2005, VIROLOGY, V331, P407, DOI 10.1016/j.virol.2004.10.036; OBRIAN CA, 1988, J NATL CANCER I, V80, P1628, DOI 10.1093/jnci/80.20.1628; OBRIAN CA, 1985, CANCER RES, V45, P2462; RADERER M, 1993, CANCER, V72, P3553, DOI 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449; Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014; Watashi K, 2007, REV MED VIROL, V17, P245, DOI 10.1002/rmv.534; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	46	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32765	32772		10.1074/jbc.M704418200	http://dx.doi.org/10.1074/jbc.M704418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17704057	hybrid			2022-12-25	WOS:000250625400025
J	Capaldi, S; Guariento, M; Saccomani, G; Fessas, D; Perduca, M; Monaco, HL				Capaldi, Stefano; Guariento, Mara; Saccomani, Gianmaria; Fessas, Dimitrios; Perduca, Massimiliano; Monaco, Hugo L.			A single amino acid mutation in zebrafish (Danio rerio) liver bile acid-binding protein can change the stoichiometry of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; CRYSTAL-STRUCTURE; BIOCHEMICAL-CHARACTERIZATION; SEQUENCE; NMR; INSIGHTS; FAMILY; SITE; EVOLUTION; PROGRAM	In all of the liver bile acid-binding proteins (L-BABPs) studied so far, it has been found that the stoichiometry of binding is of two cholate molecules per internal binding site. In this paper, we describe the expression, purification, crystallization, and three-dimensional structure determination of zebrafish ( Danio rerio) L-BABP to 1.5 angstrom resolution, which is currently the highest available for a protein of this family. Since we have found that in zebrafish, the stoichiometry of binding in the protein cavity is of only one cholate molecule per wild type L-BABP, we examined the role of two crucial amino acids present in the binding site. Using site-directed mutagenesis, we have prepared, crystallized, and determined the three-dimensional structure of co-crystals of two mutants. The mutant G55R has the same stoichiometry of binding as the wild type protein, whereas the C91T mutant changes the stoichiometry of binding from one to two ligand molecules in the cavity and therefore appears to be more similar to the other members of the L-BABP family. Based on the presence or absence of a single disulfide bridge, it can be postulated that fish should bind a single cholate molecule, whereas amphibians and higher vertebrates should bind two. Isothermal titration calorimetry has also revealed the presence in the wild type protein and the G55R mutant of an additional binding site, different from the first and probably located on the surface of the molecule.	Univ Verona, Dept Sci & Technol, Biocrystallog Lab, I-37134 Verona, Italy; Univ Milan, Dept Food Sci Technol & Microbiol, I-20133 Milan, Italy	University of Verona; University of Milan	Monaco, HL (corresponding author), Univ Verona, Dept Sci & Technol, Biocrystallog Lab, Ca Vignal 1,Str Le Grazie 15, I-37134 Verona, Italy.	monaco@sci.univr.it	Perduca, Massimiliano/AAS-2666-2020	Perduca, Massimiliano/0000-0001-8291-0523; Monaco, Hugo L./0000-0002-2067-0365; capaldi, stefano/0000-0003-4632-8100				ALREFAI WA, 2007, IN PRESS PHARM RES; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Beringhelli T, 2001, BIOCHEMISTRY-US, V40, P12604, DOI 10.1021/bi011009w; Capaldi S, 2006, PROTEINS, V64, P79, DOI 10.1002/prot.20961; Castronuovo G, 1996, CARBOHYD RES, V287, P127, DOI 10.1016/0008-6215(96)00081-X; CECILIANI F, 1994, COMP BIOCHEM PHYS B, V109, P261, DOI 10.1016/0305-0491(94)90010-8; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cordoba OL, 1999, EUR J BIOCHEM, V265, P832, DOI 10.1046/j.1432-1327.1999.00804.x; Denovan-Wright EM, 2000, BBA-GENE STRUCT EXPR, V1492, P227, DOI 10.1016/S0167-4781(00)00102-0; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P8192, DOI 10.1021/bi034213n; Di Pietro SM, 2001, ARCH BIOCHEM BIOPHYS, V388, P81, DOI 10.1006/abbi.2001.2277; DiPietro SM, 1997, EUR J BIOCHEM, V249, P510; Gill SJ, 1988, BIOCH THERMODYNAMICS; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Jordal AEO, 2006, COMP BIOCHEM PHYS B, V145, P147, DOI 10.1016/j.cbpb.2006.05.007; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kramer W, 2001, J BIOL CHEM, V276, P7291, DOI 10.1074/jbc.M006877200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, INT CCP4 ESRF AECMB, V26, P27; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nichesola D, 2004, BIOCHEMISTRY-US, V43, P14072, DOI 10.1021/bi0489661; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; Odani S, 2001, J BIOCHEM, V129, P69, DOI 10.1093/oxfordjournals.jbchem.a002838; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Press WH, 1989, NUMERICAL RECIPES AR, P521; Ragona L, 2006, J BIOL CHEM, V281, P9697, DOI 10.1074/jbc.M513003200; SANTOME JA, 1998, TREND COMPAR BIOCHEM, V4, P23; Sarropoulou E, 2005, AQUACULTURE, V243, P69, DOI 10.1016/j.aquaculture.2004.10.012; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; SCAPIN G, 1988, FEBS LETT, V240, P196, DOI 10.1016/0014-5793(88)80367-3; Schaap FG, 2002, MOL CELL BIOCHEM, V239, P69, DOI 10.1023/A:1020519011939; SCHIEVANO E, 1994, BIOPOLYMERS, V34, P879, DOI 10.1002/bip.360340707; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tochtrop GP, 2003, BIOCHEMISTRY-US, V42, P11561, DOI 10.1021/bi0346502; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wyman J, 1990, BINDING LINKAGE FUNC, P49; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	45	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31008	31018		10.1074/jbc.M705399200	http://dx.doi.org/10.1074/jbc.M705399200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17670743	hybrid			2022-12-25	WOS:000250136300068
J	Nimonkar, AV; Amitani, I; Baskin, RJ; Kowalczykowski, SC				Nimonkar, Amitabh V.; Amitani, Ichiro; Baskin, Ronald J.; Kowalczykowski, Stephen C.			Single molecule Imaging of Tid1/Rdh54, a rad54 homolog that translocates on duplex DNA and can disrupt joint molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; BRANCH MIGRATION; PROCESSIVE TRANSLOCATION; LOOP FORMATION; PROTEIN; RECOMBINATION; CHROMATIN; COMPLEX	The Saccharomyces cerevisiae Tid1 protein is important for the recombinational repair of double-stranded DNA breaks during meiosis. Tid1 is a member of Swi2/Snf2 family of chromatin remodeling proteins and shares homology with Rad54. Members of this family hydrolyze ATP and promote 1) chromatin remodeling, 2) DNA topology alterations, and 3) displacement of proteins from DNA. All of these activities are presumed to require translocation of the protein on DNA. Here we use single-molecule visualization to provide direct evidence for the ability of Tid1 to translocate on DNA. Tid1 translocation is ATP-dependent, and the velocities are broadly distributed, with the average being 84 +/- 39 base pairs/ s. Translocation is processive, with the average molecule traveling similar to 10,000 base pairs before pausing or dissociating. Many molecules display simple monotonic unidirectional translocation, but the majority display complex translocation behavior comprising intermittent pauses, direction reversals, and velocity changes. Finally, we demonstrate that translocation by Tid1 on DNA can result in disruption of three-stranded DNA structures. The ability of Tid1 translocation to clear DNA of proteins and to migrate recombination intermediates may be of critical importance for DNA repair and chromosome dynamics.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 1 Shields Ave,Briggs Hall,Rm 310, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062653, R01GM064745, R37GM062653] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064745, GM-64745, GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Amitani I, 2006, MOL CELL, V23, P143, DOI 10.1016/j.molcel.2006.05.009; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bugreev DV, 2006, NATURE, V442, P590, DOI 10.1038/nature04889; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chi P, 2006, J BIOL CHEM, V281, P26268, DOI 10.1074/jbc.M602983200; Dresser ME, 1997, GENETICS, V147, P533; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Galletto R, 2006, NATURE, V443, P875, DOI 10.1038/nature05197; Holzen TM, 2006, GENE DEV, V20, P2593, DOI 10.1101/gad.1447106; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Kiianitsa K, 2002, J BIOL CHEM, V277, P46205, DOI 10.1074/jbc.M207967200; Kiianitsa K, 2006, P NATL ACAD SCI USA, V103, P9767, DOI 10.1073/pnas.0604240103; Klein HL, 1997, GENETICS, V147, P1533; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lia G, 2006, MOL CELL, V21, P417, DOI 10.1016/j.molcel.2005.12.013; Massey TH, 2006, MOL CELL, V23, P457, DOI 10.1016/j.molcel.2006.06.019; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; McClure W R, 1980, Methods Enzymol, V64, P277; Mirshad JK, 2003, BIOCHEMISTRY-US, V42, P5937, DOI 10.1021/bi027232q; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Prasad TK, 2007, J MOL BIOL, V369, P940, DOI 10.1016/j.jmb.2007.04.005; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara M, 1997, GENETICS, V147, P1545; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Sugiyama T, 2006, EMBO J, V25, P5539, DOI 10.1038/sj.emboj.7601412; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Thoma NH, 2005, NAT STRUCT MOL BIOL, V12, P350, DOI 10.1038/nsmb919; Zhang YL, 2006, MOL CELL, V24, P559, DOI 10.1016/j.molcel.2006.10.025	42	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30776	30784		10.1074/jbc.M704767200	http://dx.doi.org/10.1074/jbc.M704767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704061	hybrid			2022-12-25	WOS:000250136300046
J	Dong, XY; Patino-Lopez, G; Candotti, F; Shaw, S				Dong, Xiaoyun; Patino-Lopez, Genaro; Candotti, Fabio; Shaw, Stephen			Structure-function analysis of the WIP role in T cell receptor-stimulated NFAT activation - Evidence that WIP-WASP dissociation is not required and that the WIPNH2 terminus is inhibitory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN WASP; ACTIN POLYMERIZATION; INTERACTING PROTEIN; NUCLEAR TRANSLOCATION; MOLECULAR-BASIS; EVH1 DOMAIN; N-WASP; GENE; COMPLEX	WASP and its binding partner WIP play important roles in T cells both in actin polymerization and in interleukin-2 transcription. Aberrations thereof contribute to the pathology of Wiskott-Aldrich syndrome ( WAS). To directly evaluate the cooperativity of WIP and WASP in interleukin-2 transcription, we investigated how the WIP-WASP complex regulates NF-AT-mediated gene transcription. We developed an improved model system for analysis, using WIP and WASP cotransfection into Jurkat cells, in which strong induction of NFAT reporter activation is observed with anti-T cell receptor (TCR) antibody without the phorbol 12-myristate 13-acetate usually used previously. Using this system, our findings contradict a prevailing conceptual model of TCR-induced WIP-WASP dissociation by showing in three ways that the WIP-WASP complex mediates TCR-induced NFAT activation without dissociation. First, phosphorylation of WIP Ser(488) does not cause dissociation of the WIP-WASP complex. Second, WIP-WASP complexes do not dissociate demonstrably after TCR stimulation. Third, a fusion protein of WIP to WASP efficiently mediates NFAT activation. Next, our studies clarify that WIP stabilization of WASP explains otherwise unexpected results in TCR-induced NFAT activation. Finally, we find that the NH2 terminus of WIP is a highly inhibitory region for TCR-mediated transcriptional activation in which at least two elements contribute: the NH2-terminal polyproline and the NH2-terminal actin-binding WH2 domain. This suggests that WIP, like WASP, is subject to autoinhibition. Our data indicate that the WIP-WASP complex plays an important role in WASP stabilization and NFAT activation.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shaw, S (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36,10 Ctr Dr,MSC 1360, Bethesda, MD 20892 USA.	sshaw@nih.gov	Patino-Lopez, Genaro/O-3484-2018; Patiño López, Genaro/GQI-4414-2022	Patino-Lopez, Genaro/0000-0002-8716-722X; Candotti, Fabio/0000-0001-6399-6042	Intramural NIH HHS [Z01 BC009257-31, Z99 CA999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009257, Z01BC010272] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000122] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abo A, 1998, CELL MOL LIFE SCI, V54, P1145, DOI 10.1007/s000180050242; Bauer B, 2000, EUR J IMMUNOL, V30, P3645, DOI 10.1002/1521-4141(200012)30:12<3645::AID-IMMU3645>3.0.CO;2-#; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Cannon JL, 2004, J IMMUNOL, V173, P1658, DOI 10.4049/jimmunol.173.3.1658; Chou HC, 2006, CURR BIOL, V16, P2337, DOI 10.1016/j.cub.2006.10.037; Cianferoni A, 2005, J ALLERGY CLIN IMMUN, V116, P1364, DOI 10.1016/j.jaci.2005.09.006; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Huang W, 2005, J IMMUNOL, V174, P2602, DOI 10.4049/jimmunol.174.5.2602; Imai K, 2003, CURR OPIN ALLERGY CL, V3, P427, DOI 10.1097/01.all.0000104452.09202.9c; Kelly AE, 2006, J BIOL CHEM, V281, P10589, DOI 10.1074/jbc.M507470200; Kettner A, 2004, J EXP MED, V199, P357, DOI 10.1084/jem.20030652; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Koduru S, 2007, BIOCHEM BIOPH RES CO, V353, P875, DOI 10.1016/j.bbrc.2006.12.079; Konno A, 2007, INT IMMUNOL, V19, P185, DOI 10.1093/intimm/dxl135; Meng L, 2007, BIOCHEM BIOPH RES CO, V357, P289, DOI 10.1016/j.bbrc.2007.03.144; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Rajmohan R, 2006, BIOCHEM BIOPH RES CO, V342, P529, DOI 10.1016/j.bbrc.2006.01.160; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Sato M, 2005, FEBS J, V272, P6131, DOI 10.1111/j.1742-4658.2005.05011.x; Sato M, 2001, J IMMUNOL, V167, P4701, DOI 10.4049/jimmunol.167.8.4701; Savoy DN, 2000, J IMMUNOL, V164, P2866, DOI 10.4049/jimmunol.164.6.2866; Sawa M, 2006, BIOCHEM BIOPH RES CO, V340, P709, DOI 10.1016/j.bbrc.2005.12.056; Silvin C, 2001, J BIOL CHEM, V276, P21450, DOI 10.1074/jbc.M010729200; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Stewart DM, 1999, J IMMUNOL, V162, P5019; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; Tsuboi S, 2007, J IMMUNOL, V178, P2987, DOI 10.4049/jimmunol.178.5.2987; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Wada T, 2002, HUM GENE THER, V13, P1039, DOI 10.1089/104303402753812449	33	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30303	30310		10.1074/jbc.M704972200	http://dx.doi.org/10.1074/jbc.M704972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711847	Green Accepted, hybrid			2022-12-25	WOS:000249981200061
J	Rendon, BE; Roger, T; Teneng, I; Zhao, M; Al-Abed, Y; Calandra, T; Mitchell, RA				Rendon, Beatriz E.; Roger, Thierry; Teneng, Ivo; Zhao, Ming; Al-Abed, Yousef; Calandra, Thierry; Mitchell, Robert A.			Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAUTOMERASE ACTIVE-SITE; FACTOR MIF; CANCER CELLS; TUMOR-GROWTH; PROSTATIC ADENOCARCINOMA; IN-VITRO; EXPRESSION; RHO; RAC; ANGIOGENESIS	Macrophage migration inhibitory factor ( MIF) is expressed and secreted in response to mitogens and integrin- dependent cell adhesion. Once released, autocrine MIF promotes the activation of RhoA GTPase leading to cell cycle progression in rodent fibroblasts. We now report that small interfering RNAmediated knockdown of MIF and MIF small molecule antagonism results in a greater than 90% loss of both the migratory and invasive potential of human lung adenocarcinoma cells. Correlating with these phenotypes is a substantial reduction in steady state as well as serum- induced effector binding activity of the Rho GTPase family member, Rac1, in MIF- deficient cells. Conversely, MIF overexpression by adenovirus in human lung adenocarcinoma cells induces a dramatic enhancement of cell migration, and co- expression of a dominant interfering mutant of Rac1 ( Rac1(N17)) completely abrogates this effect. Finally, our results indicate thatMIFdepletion results in defective partitioning of Rac1 to caveolin- containing membrane microdomains, raising the possibility that MIF promotes Rac1 activity and subsequent tumor cell motility through lipid raft stabilization.	Univ Louisville, Mol Targets Program, JG Brown Canc Ctr, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Feinstein Inst Med Res, Med Chem Lab, Manhasset, NY 11030 USA	University of Louisville; University of Louisville; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Northwell Health	Mitchell, RA (corresponding author), Univ Louisville, Mol Targets Program, JG Brown Canc Ctr, Delia Baxter Res Bldg,Suite 204B,580 S Preston St, Louisville, KY 40202 USA.	robert.mitchell@louisville.edu	Calandra, Thierry/D-9017-2015; Roger, Thierry/G-2007-2012	Calandra, Thierry/0000-0003-3051-1285; Roger, Thierry/0000-0002-9358-0109				Abe R, 2001, J IMMUNOL, V166, P747, DOI 10.4049/jimmunol.166.2.747; Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; del Vecchio MT, 2000, PROSTATE, V45, P51, DOI 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Festuccia C, 2005, THROMB HAEMOSTASIS, V93, P964, DOI 10.1160/TH04-09-0637; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Hauck CR, 2001, CANCER RES, V61, P7079; Katanaev VL, 1998, ANAL BIOCHEM, V264, P185, DOI 10.1006/abio.1998.2837; Kayser K, 2003, LUNG CANCER, V42, P171, DOI 10.1016/S0169-5002(03)00289-7; Liao H, 2003, J BIOL CHEM, V278, P76, DOI 10.1074/jbc.M208820200; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; Meyer-Siegler KL, 2002, CANCER-AM CANCER SOC, V94, P1449, DOI 10.1002/cncr.10354; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Minamoto T, 2000, CANCER DETECT PREV, V24, P1; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Nicoletti F, 2005, J NEUROIMMUNOL, V168, P168, DOI 10.1016/j.jneuroim.2005.07.019; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Oka T, 2007, J BIOL CHEM, V282, P2011, DOI 10.1074/jbc.M605153200; Petrenko O, 2003, J BIOL CHEM, V278, P11078, DOI 10.1074/jbc.M211985200; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ren Y, 2006, ONCOGENE, V25, P3501, DOI 10.1038/sj.onc.1209395; Ren Y, 2005, ANN SURG, V242, P55, DOI 10.1097/01.sla.0000168555.97710.bb; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sasaki Y, 2002, INT J MOL MED, V10, P579; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Sun B, 2005, CLIN CANCER RES, V11, P1050; Swant JD, 2005, J BIOL CHEM, V280, P23066, DOI 10.1074/jbc.M500636200; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Tomiyasu M, 2002, CLIN CANCER RES, V8, P3755; White ES, 2003, CLIN CANCER RES, V9, P853; White ES, 2001, J IMMUNOL, V166, P7549, DOI 10.4049/jimmunol.166.12.7549; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	55	94	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29910	29918		10.1074/jbc.M704898200	http://dx.doi.org/10.1074/jbc.M704898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709373	hybrid			2022-12-25	WOS:000249981200020
J	Biswas, SC; Shi, YJ; Sproul, A; Greene, LA				Biswas, Subhas C.; Shi, Yijie; Sproul, Andrew; Greene, Lloyd A.			Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURONAL APOPTOSIS; TERMINAL KINASE ACTIVATION; CELL-CYCLE MOLECULES; C-JUN; SYMPATHETIC NEURONS; TRANSCRIPTION FACTORS; STRESS-RESPONSE; RNA-SYNTHESIS; JNK PATHWAY; DNA-DAMAGE	Bim is a pro-apoptotic member of the Bcl-2 family that is induced and contributes to neuron death in response to nerve growth factor (NGF) deprivation. Past work has revealed that Bim is downstream of multiple independent transcriptional pathways in neurons, including those culminating in activation of the c-Jun, FoxO, and Myb transcription factors. This study addresses the issue of whether the three signaling pathways are redundant with respect to Bim induction or whether they act cooperatively. Examination of the proximal Bim promoter reveals binding sites for FoxO, Mybs, and, as shown here, c-Jun. We find that mutation of any one of these types of sites abolishes induction of a Bim promoter-driven reporter in response to NGF deprivation. Moreover, down-regulation of either c-Jun, FoxOs, or Mybs by short hairpin RNAs blocks induction of Bim promoter-reporter activity triggered by withdrawal of NGF. This was the case for reporters driven by either the proximal promoter or a promoter that also includes additional regulatory elements in the first intron of the Bim gene. Such short hairpin RNAs also suppressed the induction of endogenous Bim protein. These findings thus indicate that the Bim promoter acts as a coincidence detector that optimally responds to the simultaneous activation of three different pro-apoptotic transcriptional pathways. Such a mechanism provides a "fail-safe" that prevents neurons from dying by accidental activation of any single pathway. It also permits neurons to utilize individual pathways such as JNK signaling for other purposes without risk of demise.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Dept Sci Biol, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Biswas, SC (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	scb34@columbia.edu	biswas, subhas/E-7876-2013	Sproul, Andrew/0000-0001-6972-1592				ABBOTT JJ, 2007, NEUROBIOL AGING 0208; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Besirli CG, 2005, J CELL BIOL, V170, P401, DOI 10.1083/jcb.200501138; Biswas SC, 2005, J NEUROSCI, V25, P8349, DOI 10.1523/JNEUROSCI.1570-05.2005; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Biswas SC, 2007, J NEUROSCI, V27, P893, DOI 10.1523/JNEUROSCI.3524-06.2007; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Eriksson M, 2007, J CELL PHYSIOL, V210, P538, DOI 10.1002/jcp.20907; Gilley J, 2005, DNA CELL BIOL, V24, P563, DOI 10.1089/dna.2005.24.563; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA, 2007, BBA-MOL BASIS DIS, V1772, P392, DOI 10.1016/j.bbadis.2006.12.003; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Magrane J, 2005, J NEUROSCI, V25, P10960, DOI 10.1523/JNEUROSCI.1723-05.2005; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Shin DH, 2001, BRAIN RES, V892, P203, DOI 10.1016/S0006-8993(00)03300-X; Shiozawa T, 2004, ONCOGENE, V23, P8603, DOI 10.1038/sj.onc.1207849; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Waetzig V, 2006, PROG NEUROBIOL, V80, P84, DOI 10.1016/j.pneurobio.2006.08.002; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wyttenbach A, 2006, J NEUROCHEM, V96, P1213, DOI 10.1111/j.1471-4159.2005.03676.x; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yao MZ, 2005, J NEUROSCI, V25, P1149, DOI 10.1523/JNEUROSCI.4736-04.2005	36	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29368	29374		10.1074/jbc.M702634200	http://dx.doi.org/10.1074/jbc.M702634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17702754	hybrid			2022-12-25	WOS:000249788000033
J	Kong, M; Bui, TV; Ditsworth, D; Gruber, JJ; Goncharov, D; Krymskaya, VP; Lindsten, T; Thompson, CB				Kong, Mei; Bui, Thi V.; Ditsworth, Dara; Gruber, Josh J.; Goncharov, Dmitry; Krymskaya, Vera P.; Lindsten, Tullia; Thompson, Craig B.			The PP2A-associated protein alpha 4 plays a critical role in the regulation of cell spreading and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SENSITIVE SIGNAL-TRANSDUCTION; RHO-GTPASES; CATALYTIC SUBUNIT; ACTIN CYTOSKELETON; FOCAL ADHESION; GROWTH; YEAST; PHOSPHORYLATION; PATHWAY	Compared with kinases, the role of protein phosphatases in regulating biological functions is less well understood. Here we show that alpha 4, a non-catalytic subunit of the protein phosphatase 2A, plays a major role in the control of cell spreading, migration, and cytoskeletal architecture. Fibroblasts lacking alpha 4 were impaired in their ability to spread and migrate compared with wild-type cells, whereas enforced expression of alpha 4 promoted cell spreading and migration. These effects were not restricted to fibroblasts. Using a T cell-specific alpha 4 transgenic mouse model, increased alpha 4 expression was found to increase lymphocyte motility and chemotaxis. Elevated alpha 4 expression results in an increase in the GTP-bound state of Rac1, and GTP-bound Rac1 was dramatically reduced in alpha 4-deficient cells. A constitutively active mutant of Rac1 rescued the defects of cell spreading and migration caused by alpha 4 deletion, while inhibition of Rac1 blocked the ability of alpha 4 to promote cell migration. Together, these data define a novel role for the protein phosphatase 2A regulatory subunit alpha 4 in the regulation of cell spreading and migration.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 450 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu						Alahari SK, 2002, INT REV CYTOL, V220, P145; Chuang E, 2000, IMMUNITY, V13, P313, DOI 10.1016/S1074-7613(00)00031-5; Cinalli RM, 2005, EUR J IMMUNOL, V35, P786, DOI 10.1002/eji.200425729; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamelers IHL, 2005, J CELL BIOL, V171, P871, DOI 10.1083/jcb.200509172; INUI S, 1995, J IMMUNOL, V154, P2714; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kiely PA, 2006, MOL CELL BIOL, V26, P4041, DOI 10.1128/MCB.01868-05; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Onda M, 1997, GENOMICS, V46, P373, DOI 10.1006/geno.1997.5048; Prickett TD, 2006, J BIOL CHEM, V281, P30503, DOI 10.1074/jbc.M601054200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schneider H, 2006, SCIENCE, V313, P1972, DOI 10.1126/science.1131078; Takahashi K, 2006, J CELL PHYSIOL, V206, P814, DOI 10.1002/jcp.20524; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Wang HM, 2003, MOL CELL BIOL, V23, P3116, DOI 10.1128/MCB.23.9.3116-3125.2003; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	36	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29712	29720		10.1074/jbc.M703159200	http://dx.doi.org/10.1074/jbc.M703159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693407	hybrid			2022-12-25	WOS:000249788000067
J	Long, BM; Badger, MR; Whitney, SM; Price, GD				Long, Benedict M.; Badger, Murray R.; Whitney, Spencer M.; Price, G. Dean			Analysis of carboxysomes from Synechococcus PCC7942 reveals multiple Rubisco complexes with carboxysomal proteins CcmM and CcaA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO2 CONCENTRATING MECHANISM; ARCHAEON METHANOSARCINA-THERMOPHILA; NITRATE ASSIMILATION OPERON; INORGANIC CARBON LIMITATION; STRAIN PCC 7942; CO2-CONCENTRATING MECHANISM; RIBULOSE 1,5-BISPHOSPHATE; HALOTHIOBACILLUS-NEAPOLITANUS; ANHYDRASE ACTIVITY; ACTIVE-SITE	In cyanobacteria, the key enzyme for photosynthetic CO2 fixation, ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco), is bound within proteinaceous polyhedral microcompartments called carboxysomes. Cyanobacteria with Form IB Rubisco produce beta-carboxysomes whose putative shell proteins are encoded by the ccm-type genes. To date, very little is known of the protein-protein interactions that form the basis of beta-carboxysome structure. In an effort to identify such interactions within the carboxysomes of the beta-cyanobacterium Synechococcus sp. PCC7942, we have used polyhistidine-tagging approaches to identify at least three carboxysomal subcomplexes that contain active Rubisco. In addition to the expected L8S8 Rubisco, which is the major component of carboxysomes, we have identified two Rubisco complexes containing the putative shell protein CcmM, one of which also contains the carboxysomal carbonic anhydrase, CcaA. The complex containing CcaA consists of Rubisco and the full-length 58-kDa form of CcmM (M58), whereas the other is made up of Rubisco and a short 35-kDa form of CcmM (M35), which is probably translated independently of M58 via an internal ribosomal entry site within the ccmM gene. We also show that the high CO2-requiring ccmM deletion mutant (Delta ccmM) can achieve nearly normal growth rates at ambient CO2 after complementation with both wild type and chimeric (His(6)-tagged) forms of CcmM. Although a significant amount of independent L8S8 Rubisco is confined to the center of the carboxysome, we speculate that the CcmM-CcaA-Rubisco complex forms an important assembly coordination within the carboxysome shell. A speculative carboxysome structural model is presented.	Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, Canberra, ACT 0200, Australia	Australian National University	Price, GD (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, Bldg 46,Sullivans Creek Rd, Canberra, ACT 0200, Australia.	dean.price@anu.edu.au	Whitney, Spencer M/C-9266-2009; Long, Benedict M/B-3799-2008; Price, G Dean/C-9505-2009	Whitney, Spencer M/0000-0003-2954-2359; Long, Benedict M/0000-0002-4616-2967; Price, G Dean/0000-0001-5906-4912; Badger, Murray/0000-0001-9428-2579				Aichi M, 1997, J BACTERIOL, V179, P4671, DOI 10.1128/jb.179.15.4671-4675.1997; ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; Badger MR, 2006, J EXP BOT, V57, P249, DOI 10.1093/jxb/eri286; Badger MR, 2002, FUNCT PLANT BIOL, V29, P161, DOI 10.1071/PP01213; BADGER MR, 1989, PLANT PHYSIOL, V89, P51, DOI 10.1104/pp.89.1.51; BADGER MR, 1991, CAN J BOT, V69, P974, DOI 10.1139/b91-125; Baker RT, 2005, METHOD ENZYMOL, V398, P540, DOI 10.1016/S0076-6879(05)98044-0; Baker SH, 2000, ARCH MICROBIOL, V173, P278, DOI 10.1007/s002030000141; Berry S, 2005, PLANT BIOLOGY, V7, P342, DOI 10.1055/s-2005-837710; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cannon GC, 2003, CURR MICROBIOL, V46, P115, DOI 10.1007/s00284-002-3825-3; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; Emlyn-Jones D, 2006, PLANT CELL PHYSIOL, V47, P1630, DOI 10.1093/pcp/pcl028; Emlyn-Jones D, 2006, J PHYCOL, V42, P769, DOI 10.1111/j.1529-8817.2006.00236.x; FUKUZAWA H, 1992, P NATL ACAD SCI USA, V89, P4437, DOI 10.1073/pnas.89.10.4437; Gonzales AD, 2005, CAN J BOT, V83, P735, DOI 10.1139/B05-056; Heinhorst S, 2006, J BACTERIOL, V188, P8087, DOI 10.1128/JB.00990-06; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; Long BM, 2005, CAN J BOT, V83, P746, DOI 10.1139/B05-058; Ludwig M, 2000, J PHYCOL, V36, P1109, DOI 10.1046/j.1529-8817.2000.00028.x; Maeda S, 1998, J BACTERIOL, V180, P4080, DOI 10.1128/JB.180.16.4080-4088.1998; MORELL MK, 1994, J BIOL CHEM, V269, P8091; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; PAUL K, 1991, BIOCHEMISTRY-US, V30, P10019, DOI 10.1021/bi00105a029; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRICE GD, 1995, AUST J PLANT PHYSIOL, V22, P285, DOI 10.1071/PP9950285; PRICE GD, 1989, PLANT PHYSIOL, V91, P514, DOI 10.1104/pp.91.2.514; PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784; PRICE GD, 1991, CAN J BOT, V69, P963, DOI 10.1139/b91-124; Price GD, 2004, P NATL ACAD SCI USA, V101, P18228, DOI 10.1073/pnas.0405211101; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; PRICE GD, 1993, J BACTERIOL, V175, P2871, DOI 10.1128/JB.175.10.2871-2879.1993; PRICE GD, 1989, PLANT PHYSIOL, V91, P505, DOI 10.1104/pp.91.2.505; REINHOLD L, 1991, CAN J BOT, V69, P984, DOI 10.1139/b91-126; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Satoh R, 1997, PLANT CELL PHYSIOL, V38, P769, DOI 10.1093/oxfordjournals.pcp.a029234; Sawaya MR, 2006, J BIOL CHEM, V281, P7546, DOI 10.1074/jbc.M510464200; Schmid MF, 2006, J MOL BIOL, V364, P526, DOI 10.1016/j.jmb.2006.09.024; SCHWARZ R, 1995, PLANT PHYSIOL, V108, P183, DOI 10.1104/pp.108.1.183; So AKC, 2002, FUNCT PLANT BIOL, V29, P183, DOI 10.1071/PP01179; So AKC, 2002, PLANTA, V214, P456, DOI 10.1007/s004250100638; So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004; SULTEMEYER D, 1995, PLANTA, V196, P217; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Thomas JC, 2006, P NATL ACAD SCI USA, V103, P18368, DOI 10.1073/pnas.0607718103; Woodger FJ, 2005, PLANT PHYSIOL, V139, P1959, DOI 10.1104/pp.105.069146; Woodger FJ, 2003, PLANT PHYSIOL, V133, P2069, DOI 10.1104/pp.103.029728; YU JW, 1992, PLANT PHYSIOL, V100, P794, DOI 10.1104/pp.100.2.794	53	133	140	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29323	29335		10.1074/jbc.M703896200	http://dx.doi.org/10.1074/jbc.M703896200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675289	hybrid			2022-12-25	WOS:000249788000029
J	Wu, XL; Ge, HF; Gupte, J; Weiszmann, J; Shimamoto, G; Stevens, J; Hawkins, N; Lemon, B; Shen, WY; Xu, J; Veniant, MM; Li, YS; Lindberg, R; Chen, JL; Tian, H; Li, Y				Wu, Xinle; Ge, Hongfei; Gupte, Jamila; Weiszmann, Jennifer; Shimamoto, Grant; Stevens, Jennitte; Hawkins, Nessa; Lemon, Bryan; Shen, Wenyan; Xu, Jing; Veniant, Murielle M.; Li, Yue-Sheng; Lindberg, Richard; Chen, Jin-Long; Tian, Hui; Li, Yang			Co-receptor requirements for fibroblast growth factor-19 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; METABOLIC-RATE; RECEPTOR; KLOTHO; MICE; SPECIFICITY; SUPPRESSION; FAMILY	FGF19 is a unique member of the fibroblast growth factor (FGF) family of secreted proteins that regulates bile acid homeostasis and metabolic state in an endocrine fashion. Here we investigate the cell surface receptors required for signaling by FGF19. We show that beta Klotho, a single-pass transmembrane protein highly expressed in liver and fat, induced ERK1/2 phosphorylation in response to FGF19 treatment and significantly increased the interactions between FGF19 and FGFR4. Interestingly, our results show that alpha Klotho, another Klotho family protein related to beta Klotho, also induced ERK1/2 phosphorylation in response to FGF19 treatment and increased FGF19-FGFR4 interactions in vitro, similar to the effects of beta Klotho. In addition, heparin further enhanced the effects of both beta Klotho and beta Klotho in FGF19 signaling and interaction experiments. These results suggest that a functional FGF19 receptor may consist of FGF receptor (FGFR) and heparan sulfate complexed with either alpha Klotho or beta Klotho.	Amgen Inc, 1120 Vet Blvd, San Francisco, CA 94080 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Li, Y (corresponding author), Amgen Inc, 1120 Vet Blvd, San Francisco, CA 94080 USA.	yangl@amgen.com	LI, Yue/GRS-8071-2022					Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fu L, 2004, ENDOCRINOLOGY, V145, P2594, DOI 10.1210/en.2003-1671; Fukagawa M, 2005, CURR OPIN NEPHROL HY, V14, P325, DOI 10.1097/01.mnh.0000172717.49476.80; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Houten SM, 2006, CELL METAB, V4, P423, DOI 10.1016/j.cmet.2006.11.006; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Ornitz DM, 2001, GENOME BIOL, V2; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	24	110	128	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29069	29072		10.1074/jbc.C700130200	http://dx.doi.org/10.1074/jbc.C700130200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17711860	hybrid			2022-12-25	WOS:000249788000001
J	Brumshtein, B; Greenblatt, HM; Butters, TD; Shaaltiel, Y; Aviezer, D; Silman, I; Futerman, AH; Sussman, JL				Brumshtein, Boris; Greenblatt, Harry M.; Butters, Terry D.; Shaaltiel, Yoseph; Aviezer, David; Silman, Israel; Futerman, Anthony H.; Sussman, Joel L.			Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase - Insights into the mechanism of chemical chaperone action in Gaucher disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISORDERS; X-RAY-STRUCTURE; ENZYME REPLACEMENT; DEFECTIVE ENZYME; INHIBITORS; THERAPY; GLUCOCEREBROSIDASE; HYDROLASES; MUTATIONS; MIGLUSTAT	Gaucher disease is caused by mutations in the gene encoding acid beta-glucosidase ( GlcCerase), resulting in glucosylceramide (GlcCer) accumulation. The only currently available orally administered treatment for Gaucher disease is N-butyl-deoxynojirimycin (Zavesca (TM), NB-DNJ), which partially inhibits GlcCer synthesis, thus reducing levels of GlcCer accumulation. NB-DNJ also acts as a chemical chaperone for GlcCerase, although at a different concentration than that required to completely inhibit GlcCer synthesis. We now report the crystal structures, at 2 A resolution, of complexes of NB-DNJ and N-nonyl-deoxynojirimycin (NN-DNJ) with recombinant human GlcCerase, expressed in cultured plant cells. Both inhibitors bind at the active site of GlcCerase, with the imino sugar moiety making hydrogen bonds to side chains of active site residues. The alkyl chains of NB-DNJ and NN-DNJ are oriented toward the entrance of the active site where they undergo hydrophobic interactions. Based on these structures, we make a number of predictions concerning (i) involvement of loops adjacent to the active site in the catalytic process, (ii) the nature of nucleophilic attack by Glu-340, and (iii) the role of a conserved water molecule located in a solvent cavity adjacent to the active site. Together, these results have significance for understanding the mechanism of action of GlcCerase and the mode of GlcCerase chaperoning by imino sugars.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Protalix Biotherapeut, IL-20100 Carmiel, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; University of Oxford	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115; Sussman, Joel/0000-0003-0306-3878				Alfonso P, 2005, BLOOD CELL MOL DIS, V35, P268, DOI 10.1016/j.bcmd.2005.05.007; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Brady RO, 1998, ARCH NEUROL-CHICAGO, V55, P1055, DOI 10.1001/archneur.55.8.1055; Brumshtein B, 2006, ACTA CRYSTALLOGR D, V62, P1458, DOI 10.1107/S0907444906038303; Butters TD, 2005, GLYCOBIOLOGY, V15, pR43, DOI 10.1093/glycob/cwi076; Caines MEC, 2007, J BIOL CHEM, V282, P14300, DOI 10.1074/jbc.M611455200; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Desnick RJ, 2004, J INHERIT METAB DIS, V27, P385, DOI 10.1023/B:BOLI.0000031101.12838.c6; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERICKSON JS, 1973, J LIPID RES, V14, P133; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Futerman A.H., 2006, GAUCHER DIS; Futerman AH, 2004, TRENDS PHARMACOL SCI, V25, P147, DOI 10.1016/j.tips.2004.01.004; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; Jmoudiak M, 2005, BRIT J HAEMATOL, V129, P178, DOI 10.1111/j.1365-2141.2004.05351.x; Kolter T, 2003, CHEMBIOCHEM, V4, P260, DOI 10.1002/cbic.200390045; Larson SB, 2003, BIOCHEMISTRY-US, V42, P8411, DOI 10.1021/bi034144c; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Lieberman RL, 2007, NAT CHEM BIOL, V3, P101, DOI 10.1038/nchembio850; Liou B, 2006, J BIOL CHEM, V281, P4242, DOI 10.1074/jbc.M511110200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pastores GM, 2003, EXPERT OPIN INV DRUG, V12, P273, DOI 10.1517/13543784.12.2.273; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Sawkar AR, 2006, ACS CHEM BIOL, V1, P235, DOI 10.1021/cb600187q; Sawkar AR, 2005, CHEM BIOL, V12, P1235, DOI 10.1016/j.chembiol.2005.09.007; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Shaaltiel Y, 2007, PLANT BIOTECHNOL J, V5, P579, DOI 10.1111/j.1467-7652.2007.00263.x; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yu L, 2006, BIOORGAN MED CHEM, V14, P7736, DOI 10.1016/j.bmc.2006.08.003	35	98	99	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29052	29058		10.1074/jbc.M705005200	http://dx.doi.org/10.1074/jbc.M705005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666401	hybrid			2022-12-25	WOS:000249642100079
J	Caffaro, CE; Hirschberg, CB; Berninsone, PM				Caffaro, Carolina E.; Hirschberg, Carlos B.; Berninsone, Patricia M.			Functional redundancy between two Caenorhabditis elegans nucleotide sugar transporters with a novel transport mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGALACTOSAMINE; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; FRINGE CONNECTION; GLUCURONIC ACID; C-ELEGANS; IDENTIFICATION; GLYCOSYLATION; GALACTOSE	Transporters of nucleotide sugars regulate the availability of these substrates required for glycosylation reactions in the lumen of the Golgi apparatus and play an important role in the development of multicellular organisms. Caenorhabditis elegans has seven different sugars in its glycoconjugates, although 18 putative nucleotide sugar transporters are encoded in the genome. Among these, SQV-7, SRF-3, and CO3H5.2 exhibit partially overlapping substrate specificity and expression patterns. We now report evidence of functional redundancy between transporters CO3H5.2 and SRF-3. Reducing the activity of the CO3H5.2 gene product by RNA interference (RNAi) in SRF-3 mutants results in oocyte accumulation and abnormal gonad morphology, whereas comparable RNAi treatment of wild type or RNAi hypersensitive C elegans strains does not cause detectable defects. We hypothesize this genetic enhancement to be a mechanism to ensure adequate glycoconjugate biosynthesis required for normal tissue development in multicellular organisms. Furthermore, we show that transporters SRF-3 and CO3H5.2, which are closely related in the phylogenetic tree, share a simultaneous and independent substrate transport mechanism that is different from the competitive one previously demonstrated for transporter SQV-7, which shares a lower amino acid sequence identity with CO3H5.2 and SRF-3. Therefore, different mechanisms for transporting multiple nucleotide sugars may have evolved parallel to transporter amino acid divergence.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA	Boston University; Nevada System of Higher Education (NSHE); University of Nevada Reno	Hirschberg, CB (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM-30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, R37GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Appleford PJ, 2004, MOL MEMBR BIOL, V21, P247, DOI 10.1080/09687680410001712550; Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Bredeston LM, 2005, J BIOL CHEM, V280, P32168, DOI 10.1074/jbc.M507035200; Caffaro CE, 2006, ACCOUNTS CHEM RES, V39, P805, DOI 10.1021/ar0400239; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hoflich J, 2004, J BIOL CHEM, V279, P30440, DOI 10.1074/jbc.M402429200; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Jarriault S, 2005, DEV BIOL, V287, P1, DOI 10.1016/j.ydbio.2005.08.014; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; Nishiwaki K, 2004, NAT CELL BIOL, V6, P31, DOI 10.1038/ncb1079; Nishiwaki K, 1999, GENETICS, V152, P985; Norambuena L, 2002, J BIOL CHEM, V277, P32923, DOI 10.1074/jbc.M204081200; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Xu XJ, 2005, FEBS LETT, V579, P549, DOI 10.1016/j.febslet.2004.12.026	30	12	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27970	27975		10.1074/jbc.M704485200	http://dx.doi.org/10.1074/jbc.M704485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652078	hybrid			2022-12-25	WOS:000249455600046
J	Lafourcade, M; Elezgarai, I; Mato, S; Bakiri, Y; Grandes, P; Manzoni, OJ				Lafourcade, Mathieu; Elezgarai, Izaskun; Mato, Susana; Bakiri, Yamina; Grandes, Pedro; Manzoni, Olivier J.			Molecular Components and Functions of the Endocannabinoid System in Mouse Prefrontal Cortex	PLOS ONE			English	Article								Background. Cannabinoids have deleterious effects on prefrontal cortex (PFC)-mediated functions and multiple evidences link the endogenous cannabinoid (endocannabinoid) system, cannabis use and schizophrenia, a disease in which PFC functions are altered. Nonetheless, the molecular composition and the physiological functions of the endocannabinoid system in the PFC are unknown. Methodology/Principal Findings. Here, using electron microscopy we found that key proteins involved in endocannabinoid signaling are expressed in layers V/VI of the mouse prelimbic area of the PFC: presynaptic cannabinoid CB1 receptors (CB1R) faced postsynaptic mGluR5 while diacylglycerol lipase alpha (DGL-alpha), the enzyme generating the endocannabinoid 2-arachidonoyl-glycerol (2-AG) was expressed in the same dendritic processes as mGluR5. Activation of presynaptic CB1R strongly inhibited evoked excitatory post-synaptic currents. Prolonged synaptic stimulation at 10Hz induced a profound long-term depression (LTD) of layers V/VI excitatory inputs. The endocannabinoid -LTD was presynaptically expressed and depended on the activation of postsynaptic mGluR5, phospholipase C and a rise in postsynaptic Ca2+ as predicted from the localization of the different components of the endocannabinoid system. Blocking the degradation of 2-AG (with URB 602) but not of anandamide (with URB 597) converted subthreshold tetanus to LTD-inducing ones. Moreover, inhibiting the synthesis of 2-AG with Tetrahydrolipstatin, blocked endocannabinoid-mediated LTD. All together, our data show that 2-AG mediates LTD at these synapses. Conclusions/Significance. Our data show that the endocannabinoid -retrograde signaling plays a prominent role in long-term synaptic plasticity at the excitatory synapses of the PFC. Alterations of endocannabinoid -mediated synaptic plasticity may participate to the etiology of PFC-related pathologies.	[Lafourcade, Mathieu; Mato, Susana; Bakiri, Yamina; Manzoni, Olivier J.] INSERM, U862, Equipe Physiopathol Plasticite Synapt, Bordeaux, France; [Elezgarai, Izaskun; Mato, Susana; Grandes, Pedro] Univ Basque Country, Dept Neurosci, Fac Med & Dent, Bilbao, Spain	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Basque Country	Manzoni, OJ (corresponding author), INSERM, U862, Equipe Physiopathol Plasticite Synapt, Bordeaux, France.	manzoni@bordeaux.inserm.fr	Grandes, Pedro/H-7494-2015; Elezgarai, Izaskun/H-7076-2015; Mato, Susana/AAU-3129-2020; Manzoni, Olivier/M-7899-2016; Grandes, Pedro/AAA-1627-2019	Grandes, Pedro/0000-0003-3947-4230; Elezgarai, Izaskun/0000-0003-0880-8058; Mato, Susana/0000-0002-2005-9793; Manzoni, Olivier/0000-0002-5579-6208; Lafourcade, Mathieu/0000-0001-6117-1194	INSERM; Region Aquitaine; ANR 2006 Neurosciences, Neurologie et Psychiatrie [RPV06092GSA]; MCYT [BFI2002-01474]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Region Aquitaine(Region Nouvelle-Aquitaine); ANR 2006 Neurosciences, Neurologie et Psychiatrie(French National Research Agency (ANR)); MCYT(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	Work in O.J.M.'s laboratory is supported by grants from INSERM, Region Aquitaine and "ANR 2006 Neurosciences, Neurologie et Psychiatrie n degrees RPV06092GSA''. P. Grandes' laboratory is supported by MCYT grant BFI2002-01474.	Ade KK, 2007, J NEUROSCI, V27, P2403, DOI 10.1523/JNEUROSCI.2916-06.2007; ANDREASSON S, 1988, LANCET, V1, P1000; Auclair N, 2000, J NEUROPHYSIOL, V83, P3287, DOI 10.1152/jn.2000.83.6.3287; Barbara JG, 2003, EUR J NEUROSCI, V17, P981, DOI 10.1046/j.1460-9568.2003.02533.x; Carelli RM, 2000, BRAIN RES, V866, P44, DOI 10.1016/S0006-8993(00)02217-4; Chang JY, 2000, NEUROSCIENCE, V99, P433, DOI 10.1016/S0306-4522(00)00218-9; Charpier S, 1999, NEUROSCIENCE, V91, P1209, DOI 10.1016/S0306-4522(98)00719-2; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; Chhatwal JP, 2005, NEUROPSYCHOPHARMACOL, V30, P516, DOI 10.1038/sj.npp.1300655; D'Souza DC, 2005, BIOL PSYCHIAT, V57, P594, DOI 10.1016/j.biopsych.2004.12.006; De Marchi Nicola, 2003, Lipids Health Dis, V2, P5, DOI 10.1186/1476-511X-2-5; Dean B, 2001, NEUROSCIENCE, V103, P9, DOI 10.1016/S0306-4522(00)00552-2; Doherty J, 2003, CURR OPIN PHARMACOL, V3, P46, DOI 10.1016/S1471-4892(02)00014-0; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fellous JM, 2003, NEUROSCIENCE, V122, P811, DOI 10.1016/j.neuroscience.2003.08.027; Fortin DA, 2007, CEREB CORTEX, V17, P163, DOI 10.1093/cercor/bhj133; Fourgeaud L, 2004, J NEUROSCI, V24, P6939, DOI 10.1523/JNEUROSCI.0671-04.2004; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Fride E, 2005, CNS NEUROL DISORD-DR, V4, P633, DOI 10.2174/156800705774933069; Giuffrida A, 2004, NEUROPSYCHOPHARMACOL, V29, P2108, DOI 10.1038/sj.npp.1300558; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Haller J, 2005, BEHAV PHARMACOL, V16, P415, DOI 10.1097/00008877-200509000-00014; Hashimotodani Y, 2005, NEURON, V45, P257, DOI 10.1016/j.neuron.2005.01.004; Hashimotodani Y, 2007, J NEUROSCI, V27, P1211, DOI 10.1523/JNEUROSCI.4159-06.2007; Hoffman AF, 2003, J NEUROSCI, V23, P4815; Hoffman AF, 2001, J NEUROPHYSIOL, V85, P72, DOI 10.1152/jn.2001.85.1.72; Howlett AC, 2002, PROSTAG OTH LIPID M, V68-9, P619, DOI 10.1016/S0090-6980(02)00060-6; Jung KM, 2005, MOL PHARMACOL, V68, P1196, DOI 10.1124/mol.105.013961; Katona I, 2006, J NEUROSCI, V26, P5628, DOI 10.1523/JNEUROSCI.0309-06.2006; Kreitzer AC, 2005, J NEUROSCI, V25, P10537, DOI 10.1523/JNEUROSCI.2959-05.2005; Laviolette SR, 2006, CELL MOL LIFE SCI, V63, P1597, DOI 10.1007/s00018-006-6027-5; Laviolette SR, 2006, J NEUROSCI, V26, P6458, DOI 10.1523/JNEUROSCI.0707-06.2006; Leroy S, 2001, AM J MED GENET, V105, P749, DOI 10.1002/ajmg.10038; Leweke FM, 1999, NEUROREPORT, V10, P1665, DOI 10.1097/00001756-199906030-00008; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Makara JK, 2005, NAT NEUROSCI, V8, P1139, DOI 10.1038/nn1521; Makara JK, 2007, NAT NEUROSCI, V10, P134, DOI 10.1038/nn0107-134a; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; Mateos JM, 2000, J NEUROCHEM, V74, P1301; MATHERS DC, 1992, BRIT J PSYCHIAT, V161, P648, DOI 10.1192/bjp.161.5.648; Mato S, 2005, J NEUROSCI, V25, P11619, DOI 10.1523/JNEUROSCI.2294-05.2005; Mato S, 2004, NAT NEUROSCI, V7, P585, DOI 10.1038/nn1251; Melis M, 2004, J NEUROSCI, V24, P10707, DOI 10.1523/JNEUROSCI.3502-04.2004; Myers KM, 2002, NEURON, V36, P340, DOI 10.1016/S0896-6273(02)01017-6; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Piomelli Daniele, 2005, Curr Opin Investig Drugs, V6, P672; Robbe D, 2002, P NATL ACAD SCI USA, V99, P8384, DOI 10.1073/pnas.122149199; Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001; Ronesi J, 2005, J PHYSIOL-LONDON, V562, P245, DOI 10.1113/jphysiol.2004.068460; Safo PK, 2005, NEURON, V48, P647, DOI 10.1016/j.neuron.2005.09.020; Straiker A, 2005, J PHYSIOL-LONDON, V569, P501, DOI 10.1113/jphysiol.2005.091918; Szabo B, 2006, J PHYSIOL-LONDON, V577, P263, DOI 10.1113/jphysiol.2006.119362; Tsai GC, 2002, ANNU REV PHARMACOL, V42, P165, DOI 10.1146/annurev.pharmtox.42.082701.160735; UCHIGASHIMA M, 2007, J NEUROSCI IN PRESS; Ujike H, 2004, J PHARMACOL SCI, V96, P376, DOI 10.1254/jphs.FMJ04003X4; Ujike H, 2002, MOL PSYCHIATR, V7, P515, DOI 10.1038/sj.mp.4001029; Yoshida T, 2006, J NEUROSCI, V26, P4740, DOI 10.1523/JNEUROSCI.0054-06.2006; Zavitsanou K, 2004, PROG NEURO-PSYCHOPH, V28, P355, DOI 10.1016/j.pnpbp.2003.11.005	61	180	181	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e709	10.1371/journal.pone.0000709	http://dx.doi.org/10.1371/journal.pone.0000709			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684555	Green Published, gold			2022-12-25	WOS:000207452400012
J	Jakob, W; Schierwater, B				Jakob, Wolfgang; Schierwater, Bernd			Changing Hydrozoan Bauplans by Silencing Hox-Like Genes	PLOS ONE			English	Article							HYDRACTINIA-SYMBIOLONGICARPUS CNIDARIA; HOMEOBOX GENES; ONCOPELTUS-FASCIATUS; EXPRESSION; MORPHOLINO; ORIGINS; CNOX-2; HYDRA; EVOLUTION; CONSERVATION	Regulatory genes of the Antp class have been a major factor for the invention and radiation of animal bauplans. One of the most diverse animal phyla are the Cnidaria, which are close to the root of metazoan life and which often appear in two distinct generations and a remarkable variety of body forms. Hox-like genes have been known to be involved in axial patterning in the Cnidaria and have been suspected to play roles in the genetic control of many of the observed bauplan changes. Unfortunately RNAi mediated gene silencing studies have not been satisfactory for marine invertebrate organisms thus far. No direct evidence supporting Hox-like gene induced bauplan changes in cnidarians have been documented as of yet. Herein, we report a protocol for RNAi transfection of marine invertebrates and demonstrate that knock downs of Hox-like genes in Cnidaria create substantial bauplan alterations, including the formation of multiple oral poles ("heads'') by Cnox-2 and Cnox-3 inhibition, deformation of the main body axis by Cnox-5 inhibition and duplication of tentacles by Cnox-1 inhibition. All phenotypes observed in the course of the RNAi studies were identical to those obtained by morpholino antisense oligo experiments and are reminiscent of macroevolutionary bauplan changes. The reported protocol will allow routine RNAi studies in marine invertebrates to be established.	[Jakob, Wolfgang; Schierwater, Bernd] Stiftung Tieraerztliche Hsch Hannover, Div Ecol & Evolut, Hannover, Germany; [Schierwater, Bernd] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA	University of Veterinary Medicine Hannover, Foundation; Yale University	Jakob, W (corresponding author), Stiftung Tieraerztliche Hsch Hannover, Div Ecol & Evolut, Hannover, Germany.	wolfgang.jakob@ecolevol.de			DFG [Schi-277/20-1]	DFG(German Research Foundation (DFG))	DFG Schi-277/20-1	AERNE BL, 1995, DEV BIOL, V169, P547, DOI 10.1006/dbio.1995.1168; Amali AA, 2004, DEV DYNAM, V229, P847, DOI 10.1002/dvdy.10454; Blackstone NW, 2003, J EXP ZOOL PART B, V297B, P35, DOI 10.1002/jez.b.00016; Bode HR, 2001, AM ZOOL, V41, P621, DOI 10.1668/0003-1569(2001)041[0621:TROHGI]2.0.CO;2; Boero F, 1997, ITAL J ZOOL, V64, P359, DOI 10.1080/11250009709356223; BOUILLON J, 2006, INTRO HYDROZOA, P591; BOUILLON J, 2000, PHYLOGENY CLASSIFICA, P296; Buchon N, 2006, HEREDITY, V96, P195, DOI 10.1038/sj.hdy.6800789; Cartwright P, 1999, P NATL ACAD SCI USA, V96, P2183, DOI 10.1073/pnas.96.5.2183; Cartwright P, 1999, J EXP ZOOL, V285, P57, DOI 10.1002/(SICI)1097-010X(19990415)285:1<57::AID-JEZ7>3.0.CO;2-P; CARTWRIGHT P, 2006, J EXP ZOOL PART B, V306, P1; Deutsch J, 2005, BIOESSAYS, V27, P673, DOI 10.1002/bies.20260; Endl I, 1999, P NATL ACAD SCI USA, V96, P1445, DOI 10.1073/pnas.96.4.1445; Ferrier DEK, 2001, EVOL DEV, V3, P263, DOI 10.1046/j.1525-142x.2001.003004263.x; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Finnerty JR, 1998, CURR TOP DEV BIOL, V40, P211, DOI 10.1016/S0070-2153(08)60368-3; Finnerty JR, 1997, BIOL BULL-US, V193, P62, DOI 10.2307/1542736; Finnerty JR, 1999, EVOL DEV, V1, P16, DOI 10.1046/j.1525-142x.1999.99010.x; Finnerty JR, 2003, INT J DEV BIOL, V47, P523; Finnerty JR, 2003, EVOL DEV, V5, P331, DOI 10.1046/j.1525-142X.2003.03041.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Galliot B, 2002, INT J DEV BIOL, V46, P39; Gauchat D, 2000, P NATL ACAD SCI USA, V97, P4493, DOI 10.1073/pnas.97.9.4493; HAUENSCHILD C, 1957, Z NATURFORSCH B, V12, P7; HAUENSCHILD C, 1957, Z NATURFORSCH B, V12, P6; HAUENSCHILD C, 1956, Z NATURFORSCH B, V11, P7; Hayward DC, 2001, DEV GENES EVOL, V211, P10; Herke SW, 2005, DEVELOPMENT, V132, P27, DOI 10.1242/dev.01561; Hughes CL, 2000, DEVELOPMENT, V127, P3683; Jakob W, 2004, DEV GENES EVOL, V214, P170, DOI 10.1007/s00427-004-0390-8; Kamm K, 2006, CURR BIOL, V16, P920, DOI 10.1016/j.cub.2006.03.036; Kuhn K, 1996, MOL PHYLOGENET EVOL, V6, P30, DOI 10.1006/mpev.1996.0055; Li M, 2006, CELL RES, V16, P99, DOI 10.1038/sj.cr.7310013; Li YX, 2000, DEV BIOL, V217, P394, DOI 10.1006/dbio.1999.9540; Lohmann JU, 1999, DEV BIOL, V214, P211, DOI 10.1006/dbio.1999.9407; Mokady O, 1998, P NATL ACAD SCI USA, V95, P3673, DOI 10.1073/pnas.95.7.3673; Momose T, 2007, PLOS BIOL, V5, P889, DOI 10.1371/journal.pbio.0050070; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; NAITO M, 1993, FEBS LETT, V333, P271, DOI 10.1016/0014-5793(93)80668-K; Partridge M, 1996, ANTISENSE NUCLEIC A, V6, P169, DOI 10.1089/oli.1.1996.6.169; Ryan JF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000153; SCHIERWATER B, 1989, J MORPHOL, V200, P255, DOI 10.1002/jmor.1052000304; SCHIERWATER B, 1991, J EXP ZOOL, V260, P413, DOI 10.1002/jez.1402600316; Schierwater B, 1998, MOL PHYLOGENET EVOL, V9, P375, DOI 10.1006/mpev.1998.0489; Schubert M, 2006, DEV BIOL, V296, P190, DOI 10.1016/j.ydbio.2006.04.457; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SHENK MA, 1993, DEV BIOL, V160, P108, DOI 10.1006/dbio.1993.1290; SHENK MA, 1993, DEVELOPMENT, V117, P657; Smith KM, 2000, DEVELOPMENT, V127, P4743; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Van Auken K, 2000, P NATL ACAD SCI USA, V97, P4499, DOI 10.1073/pnas.97.9.4499; Wikramanayake AH, 2004, GENESIS, V39, P194, DOI 10.1002/gene.20045; Yamada L, 2003, DEVELOPMENT, V130, P6485, DOI 10.1242/dev.00847; Yanze N, 2001, DEV BIOL, V236, P89, DOI 10.1006/dbio.2001.0299	56	22	23	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e694	10.1371/journal.pone.0000694	http://dx.doi.org/10.1371/journal.pone.0000694			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668071	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452300029
J	Brockhurst, MA				Brockhurst, Michael A.			Population Bottlenecks Promote Cooperation in Bacterial Biofilms	PLOS ONE			English	Article								Population bottlenecks are assumed to play a key role in the maintenance of social traits in microbes. Ecological parameters such as colonisation or disturbances can favour cooperation through causing population bottlenecks that enhance genetic structuring (relatedness). However, the size of the population bottleneck is likely to play a crucial role in determining the success of cooperation. Relatedness is likely to increase with decreasing bottleneck size thus favouring the evolution of cooperation. I used an experimental evolution approach to test this prediction with biofilm formation by the bacterium Pseudomonas fluorescens as the cooperative trait. Replicate populations were exposed to disturbance events every four days under one of six population bottleneck treatments (from 10 3 to 10 8 bacterial cells). In line with predictions, the frequency of evolved cheats within the populations increased with increasing bottleneck size. This result highlights the importance of ecologically mediated population bottlenecks in the maintenance of social traits in microbes.	Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Brockhurst, MA (corresponding author), Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England.	michael.brockhurst@liv.ac.uk	Brockhurst, Michael A/A-6247-2009	Brockhurst, Michael/0000-0003-0362-820X	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	Funding: Funded by the Wellcome Trust through the Research Development Fund of the University of Liverpool.	Brockhurst MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000193; Brockhurst MA, 2007, CURR BIOL, V17, P761, DOI 10.1016/j.cub.2007.02.057; Brockhurst MA, 2006, CURR BIOL, V16, P2030, DOI 10.1016/j.cub.2006.08.068; Brown SP, 2002, TRENDS MICROBIOL, V10, P401, DOI 10.1016/S0966-842X(02)02413-7; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Frank S. A., 1998, FDN SOCIAL EVOLUTION, DOI DOI 10.1515/9780691206820; Fux CA, 2005, TRENDS MICROBIOL, V13, P34, DOI 10.1016/j.tim.2004.11.010; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; HAMILTON WD, 1964, J THEOR BIOL, V7, P17, DOI 10.1016/0022-5193(64)90039-6; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90039-6; HAMILTON WD, 1997, NARROW ROADS GENE LA, V1; Harrison F, 2005, CURR BIOL, V15, P1968, DOI 10.1016/j.cub.2005.09.048; Hodgson DJ, 2002, P ROY SOC B-BIOL SCI, V269, P2277, DOI 10.1098/rspb.2002.2146; MacLean RC, 2006, NATURE, V441, P498, DOI 10.1038/nature04624; MacLean RC, 2004, P NATL ACAD SCI USA, V101, P8072, DOI 10.1073/pnas.0307195101; MAYNARDSMITH J, 2000, BIOESSAYS, V22, P1115; Mitteldorf J, 2000, J THEOR BIOL, V204, P481, DOI 10.1006/jtbi.2000.2007; Parr LA, 1999, NATURE, V399, P647, DOI 10.1038/21345; PETRAITIS PS, 1989, Q REV BIOL, V64, P393, DOI 10.1086/416457; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; Sharp SP, 2005, NATURE, V434, P1127, DOI 10.1038/nature03522; Spiers AJ, 2002, GENETICS, V161, P33; TAYLOR PD, 1992, EVOL ECOL, V6, P352, DOI 10.1007/BF02270971; Velicer GJ, 1998, P NATL ACAD SCI USA, V95, P12376, DOI 10.1073/pnas.95.21.12376; Velicer GJ, 2003, TRENDS MICROBIOL, V11, P330, DOI 10.1016/S0966-842X(03)00152-5; West SA, 2002, SCIENCE, V296, P72, DOI 10.1126/science.1065507; West SA, 2006, NAT REV MICROBIOL, V4, P597, DOI 10.1038/nrmicro1461; WILSON DS, 1992, EVOL ECOL, V6, P331, DOI 10.1007/BF02270969	31	30	32	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e634	10.1371/journal.pone.0000634	http://dx.doi.org/10.1371/journal.pone.0000634			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653261	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452200003
J	Yoo, SY; Kim, Y; Kim, SY; Lee, JS; Ahn, JH				Yoo, So Yeon; Kim, Yunhee; Kim, Soo Young; Lee, Jong Seob; Ahn, Ji Hoon			Control of Flowering Time and Cold Response by a NAC-Domain Protein in Arabidopsis	PLOS ONE			English	Article								Background. Plants must integrate complex signals from environmental and endogenous cues to fine-tune the timing of flowering. Low temperature is one of the most common environmental stresses that affect flowering time; however, molecular mechanisms underlying the cold temperature regulation of flowering time are not fully understood. Methodology/Principal Findings. We report the identification of a novel regulator, LONG VEGETATIVE PHASE 1 (LOV1), that controls flowering time and cold response. An Arabidopsis mutant, long v egetative phase 1-1D (lov1-1D) showing the late-flowering phenotype, was isolated by activation tagging screening. Subsequent analyses demonstrated that the phenotype of the mutant resulted from the overexpression of a NAC-domain protein gene (At2g02450). Both gain-and loss-of-function alleles of LOV1 affected flowering time predominantly under long-day but not short-day conditions, suggesting that LOV1 may act within the photoperiod pathway. The expression of CONSTANS (CO), a floral promoter, was affected by LOV1 level, suggesting that LOV1 controls flowering time by negatively regulating CO expression. The epistatic relationship between CO and LOV1 was consistent with this proposed regulatory pathway. Physiological analyses to elucidate upstream signalling pathways revealed that LOV1 regulates the cold response in plants. Loss of LOV1 function resulted in hypersensitivity to cold temperature, whereas a gain-of-function allele conferred cold tolerance. The freezing tolerance was accompanied by upregulation of cold response genes, COLD-REGULATED 15A (COR15A) and COLD INDUCED 1 (KIN1) without affecting expression of the C-repeat-binding factor/dehydration responsive element-binding factor 1 (CBF/DREB1) family of genes. Conclusions. Our study shows that LOV1 functions as a floral repressor that negatively regulates CO expression under long-day conditions and acts as a common regulator of two intersecting pathways that regulate flowering time and the cold response, respectively. Our results suggest an overlapping pathway for controlling cold stress response and flowering time in plants.	[Kim, Soo Young] Chonnam Natl Univ, Dept Mol Biotechnol, Kwangju, South Korea; [Kim, Soo Young] Chonnam Natl Univ, Kumho Life Sci Lab, Coll Agr & Life Sci, Kwangju, South Korea; [Yoo, So Yeon; Ahn, Ji Hoon] Korea Univ, Plant Signaling Network Res Ctr, Sch Life Sci & Biotechnol, Seoul, South Korea; [Kim, Yunhee; Lee, Jong Seob] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea	Chonnam National University; Chonnam National University; Korea University; Seoul National University (SNU)	Kim, SY (corresponding author), Chonnam Natl Univ, Dept Mol Biotechnol, Kwangju, South Korea.	sooykim@chonnam.ac.kr; jongslee@plaza.snu.ac.kr; jahn@korea.ac.kr	Ahn, Ji Hoon/A-4141-2011	Ahn, Ji Hoon/0000-0003-0347-3922	Crop Functional Genomics Center; Plant Signaling Network Research Center of Korea University; Korea Research Foundation	Crop Functional Genomics Center; Plant Signaling Network Research Center of Korea University; Korea Research Foundation(National Research Foundation of Korea)	Funding: This work was supported by the Crop Functional Genomics Center of the 21C Frontier Program (J.S.L.) and the Plant Signaling Network Research Center of Korea University (J.H.A.). S.Y.Y. was supported by BK21 program and a grant for pre-doctoral students of Korea Research Foundation.	Ahn JH, 2007, PLANT CELL PHYSIOL, V48, P169, DOI 10.1093/pcp/pcl052; Artus NN, 1996, P NATL ACAD SCI USA, V93, P13404, DOI 10.1073/pnas.93.23.13404; Balasubramanian S, 2006, PLOS GENET, V2, P980, DOI 10.1371/journal.pgen.0020106; Blazquez MA, 2003, NAT GENET, V33, P168, DOI 10.1038/ng1085; Boyce JM, 2003, PLANT J, V34, P395, DOI 10.1046/j.1365-313X.2003.01734.x; Cao SQ, 2005, PLANT CELL REP, V24, P683, DOI 10.1007/s00299-005-0061-x; Chen MJ, 2006, PLANT J, V46, P823, DOI 10.1111/j.1365-313X.2006.02740.x; CHOUARD P, 1960, ANNU REV PLANT PHYS, V11, P191, DOI 10.1146/annurev.pp.11.060160.001203; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; Fittinghoff K, 2006, PLANT J, V47, P577, DOI 10.1111/j.1365-313X.2006.02812.x; Henderson IR, 2004, DEVELOPMENT, V131, P3829, DOI 10.1242/dev.01294; Hepworth SR, 2002, EMBO J, V21, P4327, DOI 10.1093/emboj/cdf432; Imaizumi T, 2005, SCIENCE, V309, P293, DOI 10.1126/science.1110586; Imaizumi T, 2006, TRENDS PLANT SCI, V11, P550, DOI 10.1016/j.tplants.2006.09.004; Johnson CH, 2001, ANNU REV PHYSIOL, V63, P695, DOI 10.1146/annurev.physiol.63.1.695; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Knight H, 1999, PLANT CELL, V11, P875, DOI 10.1105/tpc.11.5.875; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; KURKELA S, 1992, PLANT MOL BIOL, V19, P689, DOI 10.1007/BF00026794; KURKELA S, 1990, PLANT MOL BIOL, V15, P137, DOI 10.1007/BF00017731; Laubinger S, 2006, DEVELOPMENT, V133, P3213, DOI 10.1242/dev.02481; Lee JH, 2007, GENE DEV, V21, P397, DOI 10.1101/gad.1518407; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Mizoguchi T, 2005, PLANT CELL, V17, P2255, DOI 10.1105/tpc.105.033464; Olsen AN, 2005, TRENDS PLANT SCI, V10, P79, DOI 10.1016/j.tplants.2004.12.010; Park DH, 1999, SCIENCE, V285, P1579, DOI 10.1126/science.285.5433.1579; Qu LJ, 2006, CURR OPIN PLANT BIOL, V9, P544, DOI 10.1016/j.pbi.2006.07.005; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Sessions A, 2000, SCIENCE, V289, P779, DOI 10.1126/science.289.5480.779; Sharma P, 2005, BIOESSAYS, V27, P1048, DOI 10.1002/bies.20307; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; STONE JM, 1993, P NATL ACAD SCI USA, V90, P7869, DOI 10.1073/pnas.90.16.7869; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Sung S, 2005, ANNU REV PLANT BIOL, V56, P491, DOI 10.1146/annurev.arplant.56.032604.144307; TEUTONICO RA, 1995, MOL BREEDING, V1, P329, DOI 10.1007/BF01248410; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; Yamaguchi-Shinozaki K, 2005, TRENDS PLANT SCI, V10, P88, DOI 10.1016/j.tplants.2004.12.012; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130; Yoo SY, 2005, PLANTA, V221, P523, DOI 10.1007/s00425-004-1466-4; Zhu JH, 2004, P NATL ACAD SCI USA, V101, P9873, DOI 10.1073/pnas.0403166101	49	127	157	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e642	10.1371/journal.pone.0000642	http://dx.doi.org/10.1371/journal.pone.0000642			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653269	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200011
J	Hrus, A; Lau, G; Hutter, H; Schenk, S; Ferralli, J; Brown-Luedi, M; Chiquet-Ehrismann, R; Canevascini, S				Hrus, Ana; Lau, Gordon; Hutter, Harald; Schenk, Susanne; Ferralli, Jacqueline; Brown-Luedi, Marianne; Chiquet-Ehrismann, Ruth; Canevascini, Stefano			C. elegans Agrin Is Expressed in Pharynx, IL1 Neurons and Distal Tip Cells and Does Not Genetically Interact with Genes Involved in Synaptogenesis or Muscle Function	PLOS ONE			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; CAENORHABDITIS-ELEGANS; LEVAMISOLE RESISTANCE; STRUCTURAL PROTEINS; NERVOUS-SYSTEM; BASAL LAMINA; UNC-52 GENE; DYSTROGLYCAN; BINDING; MUSK	Agrin is a basement membrane protein crucial for development and maintenance of the neuromuscular junction in vertebrates. The C. elegans genome harbors a putative agrin gene agr-1. We have cloned the corresponding cDNA to determine the primary structure of the protein and expressed its recombinant fragments to raise specific antibodies. The domain organization of AGR-1 is very similar to the vertebrate orthologues. C. elegans agrin contains a signal sequence for secretion, seven follistatin domains, three EGF-like repeats and two laminin G domains. AGR-1 loss of function mutants did not exhibit any overt phenotypes and did not acquire resistance to the acetylcholine receptor agonist levamisole. Furthermore, crossing them with various mutants for components of the dystrophin-glycoprotein complex with impaired muscle function did not lead to an aggravation of the phenotypes. Promoter-GFP translational fusion as well as immunostaining of worms revealed expression of agrin in buccal epithelium and the protein deposition in the basal lamina of the pharynx. Furthermore, dorsal and ventral IL1 head neurons and distal tip cells of the gonad arms are sources of agrin production, but no expression was detectable in body muscles or in the motoneurons innervating them. Recombinant worm AGR-1 fragment is able to cluster vertebrate dystroglycan in cultured cells, implying a conservation of this interaction, but since neither of these proteins is expressed in muscle of C. elegans, this interaction may be required in different tissues. The connections between muscle cells and the basement membrane, as well as neuromuscular junctions, are structurally distinct between vertebrates and nematodes.	[Hrus, Ana; Lau, Gordon; Schenk, Susanne; Ferralli, Jacqueline; Brown-Luedi, Marianne; Chiquet-Ehrismann, Ruth; Canevascini, Stefano] Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Hutter, Harald] Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada	Friedrich Miescher Institute for Biomedical Research; Novartis; Simon Fraser University	Chiquet-Ehrismann, R (corresponding author), Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, Basel, Switzerland.	Ruth.Chiquet@fmi.ch			Novartis Research Foundation	Novartis Research Foundation	This work was supported by the Novartis Research Foundation.	Ackley BD, 2003, J NEUROSCI, V23, P3577; Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; Avery L, 2003, J EXP BIOL, V206, P2441, DOI 10.1242/jeb.00433; Batchelor CL, 2006, TRENDS CELL BIOL, V16, P198, DOI 10.1016/j.tcb.2006.02.001; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bessereau JL, 2001, NATURE, V413, P70, DOI 10.1038/35092567; Bessou C, 1998, NEUROGENETICS, V2, P61, DOI 10.1007/s100480050053; Bezakova G, 2001, J CELL BIOL, V153, P1453, DOI 10.1083/jcb.153.7.1453; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; BRENNER S, 1974, GENETICS, V77, P71; Brown NH, 2000, MATRIX BIOL, V19, P191, DOI 10.1016/S0945-053X(00)00064-0; Burgess RW, 2002, J NEUROCHEM, V83, P271, DOI 10.1046/j.1471-4159.2002.01102.x; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Campagnola PJ, 2002, BIOPHYS J, V82, P493, DOI 10.1016/S0006-3495(02)75414-3; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; Cheusova T, 2006, GENE DEV, V20, P1800, DOI 10.1101/gad.375206; Chow DK, 2006, EXP GERONTOL, V41, P252, DOI 10.1016/j.exger.2005.12.004; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FISCHER D, 1995, J BIOL CHEM, V270, P3378, DOI 10.1074/jbc.270.7.3378; Fleming JT, 1997, J NEUROSCI, V17, P5843; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Francis MM, 2005, NEURON, V46, P581, DOI 10.1016/j.neuron.2005.04.010; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Gally C, 2004, NATURE, V431, P578, DOI 10.1038/nature02893; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Gieseler K, 1999, NEUROGENETICS, V2, P87, DOI 10.1007/s100480050057; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; Grewal PK, 2003, HUM MOL GENET, V12, pR259, DOI 10.1093/hmg/ddg272; Groffen AJA, 1998, EUR J BIOCHEM, V254, P123, DOI 10.1046/j.1432-1327.1998.2540123.x; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Hobert O, 2003, CURR OPIN NEUROBIOL, V13, P70, DOI 10.1016/S0959-4388(03)00002-3; Hobert O, 2005, WORMBOOK; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hutter H, 2000, SCIENCE, V287, P989, DOI 10.1126/science.287.5455.989; Johnson RP, 2006, DEVELOPMENT, V133, P1911, DOI 10.1242/dev.02363; Jorgensen EM, 2002, NAT REV GENET, V3, P356, DOI 10.1038/nrg794; Kammerer RA, 1999, EMBO J, V18, P6762, DOI 10.1093/emboj/18.23.6762; Kang SH, 2000, MOL BIOL CELL, V11, P3911, DOI 10.1091/mbc.11.11.3911; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Koga M, 1999, DEVELOPMENT, V126, P5387; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; KRAMER JM, 2005, WORMBOOK; Krause M, 1995, METHOD CELL BIOL, V48, P513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee M, 2001, J BIOL CHEM, V276, P36404, DOI 10.1074/jbc.M105795200; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; LEWIS JA, 1980, GENETICS, V95, P905; LHernault SW, 1995, METHOD CELL BIOL, V48, P273; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; MAGILLSOLC C, 1990, J PHYSIOL-PARIS, V84, P78; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; Martin PT, 2003, GLYCOBIOLOGY, V13, p55R, DOI 10.1093/glycob/cwg076; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Merz DC, 2003, DEV BIOL, V256, P173, DOI 10.1016/S0012-1606(03)00014-9; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Millet ACM, 2004, CURR OPIN IMMUNOL, V16, P4, DOI 10.1016/j.coi.2003.11.005; Mullen GP, 1999, MOL BIOL CELL, V10, P3205, DOI 10.1091/mbc.10.10.3205; Neumann FR, 2001, MOL CELL NEUROSCI, V17, P208, DOI 10.1006/mcne.2000.0932; NGUYEN M, 1995, GENETICS, V140, P527; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; Okada K, 2006, SCIENCE, V312, P1802, DOI 10.1126/science.1127142; Pagni M, 2004, NUCLEIC ACIDS RES, V32, pW332, DOI 10.1093/nar/gkh479; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Riddle DL, 1997, C ELEGANS; ROGALSKI TM, 1995, GENETICS, V139, P159; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEDL T, 1997, C ELEGANS, V2, P241; SCOTTON P, 2006, J BIOL CHEM; SMITH MA, 1992, MOL CELL NEUROSCI, V3, P406, DOI 10.1016/1044-7431(92)90052-4; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; SULSTON JE, 1974, GENETICS, V77, P95; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; Tsalik EL, 2003, DEV BIOL, V263, P81, DOI 10.1016/S0012-1606(03)00447-0; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Winzen U, 2003, J BIOL CHEM, V278, P30106, DOI 10.1074/jbc.M212676200; Zhang JP, 2006, FASEB J, V20, P50, DOI 10.1096/fj.04-3303com; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	104	15	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e731	10.1371/journal.pone.0000731	http://dx.doi.org/10.1371/journal.pone.0000731			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710131	Green Submitted, gold, Green Published			2022-12-25	WOS:000207455200008
J	Shieh, JC; Cheng, YC; Su, MC; Moore, M; Choo, Y; Klug, A				Shieh, Jia-Ching; Cheng, Yu-Che; Su, Mao-Chang; Moore, Michael; Choo, Yen; Klug, Aaron			Tailor-Made Zinc-Finger Transcription Factors Activate FLO11 Gene Expression with Phenotypic Consequences in the Yeast Saccharomyces cerevisiae	PLOS ONE			English	Article							DNA-BINDING; INVASIVE GROWTH; MAP KINASE; PSEUDOHYPHAL DIFFERENTIATION; NUCLEIC-ACIDS; PROTEINS; PROMOTER; DESIGN; SEQUENCE; FAMILY	Cys(2)His(2) zinc fingers are eukaryotic DNA-binding motifs, capable of distinguishing different DNA sequences, and are suitable for engineering artificial transcription factors. In this work, we used the budding yeast Saccharomyces cerevisiae to study the ability of tailor-made zinc finger proteins to activate the expression of the FLO11 gene, with phenotypic consequences. Two three-finger peptides were identified, recognizing sites from the 5' UTR of the FLO11 gene with nanomolar DNA-binding affinity. The three-finger domains and their combined six-finger motif, recognizing an 18-bp site, were fused to the activation domain of VP16 or VP64. These transcription factor constructs retained their DNA-binding ability, with the six-finger ones being the highest in affinity. However, when expressed in haploid yeast cells, only one three-finger recombinant transcription factor was able to activate the expression of FLO11 efficiently. Unlike in the wild-type, cells with such transcriptional activation displayed invasive growth and biofilm formation, without any requirement for glucose depletion. The VP16 and VP64 domains appeared to act equally well in the activation of FLO11 expression, with comparable effects in phenotypic alteration. We conclude that the functional activity of tailor-made transcription factors in cells is not easily predicted by the in vitro DNA-binding activity.	[Shieh, Jia-Ching; Cheng, Yu-Che] Chung Shan Med Univ, Dept Biomed Sci, Taichung, Taiwan; [Shieh, Jia-Ching; Moore, Michael; Choo, Yen; Klug, Aaron] MRC, Mol Biol Lab, Cambridge CB2 2QH, England; [Su, Mao-Chang] Chung Shan Med Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Taichung, Taiwan	Chung Shan Medical University; MRC Laboratory Molecular Biology; Chung Shan Medical University; Chung Shan Medical University Hospital	Shieh, JC (corresponding author), Chung Shan Med Univ, Dept Biomed Sci, Taichung, Taiwan.	jcs@csmu.edu.tw		Choo, Yen/0000-0002-3348-9602	Medical Research Council of the United Kingdom; National Science Council, Republic of China [NSC91-2745-P-040-002, NSC 92-2311-B-040-007]; Chung Shan Medical University, Republic of China [CSMU93-OM-B-017]	Medical Research Council of the United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Science Council, Republic of China(Ministry of Science and Technology, Taiwan); Chung Shan Medical University, Republic of China	This work was supported by the Medical Research Council of the United Kingdom and grants from National Science Council (NSC91-2745-P-040-002; NSC 92-2311-B-040-007) of the Republic of China, and Chung Shan Medical University (CSMU93-OM-B-017) of the Republic of China.	Ashworth J, 2006, NATURE, V441, P656, DOI 10.1038/nature04818; Bae KH, 2003, NAT BIOTECHNOL, V21, P275, DOI 10.1038/nbt796; Bartsevich VV, 2003, STEM CELLS, V21, P632, DOI 10.1634/stemcells.21-6-632; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; Bibikova M, 2003, SCIENCE, V300, P764, DOI 10.1126/science.1079512; Blancafort P, 2005, P NATL ACAD SCI USA, V102, P11716, DOI 10.1073/pnas.0501162102; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; Chou S, 2004, CELL, V119, P981, DOI 10.1016/j.cell.2004.11.053; Cullen PJ, 2000, P NATL ACAD SCI USA, V97, P13619, DOI 10.1073/pnas.240345197; Dai QS, 2004, CIRCULATION, V110, P2467, DOI 10.1161/01.CIR.0000145139.53840.49; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fidalgo M, 2006, P NATL ACAD SCI USA, V103, P11228, DOI 10.1073/pnas.0601713103; Gagiano M, 1999, MOL MICROBIOL, V31, P103, DOI 10.1046/j.1365-2958.1999.01151.x; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Guo B, 2000, P NATL ACAD SCI USA, V97, P12158, DOI 10.1073/pnas.220420397; Halme A, 2004, CELL, V116, P405, DOI 10.1016/S0092-8674(04)00118-7; Isalan M, 2001, METHOD ENZYMOL, V340, P593; Isalan M, 2001, NAT BIOTECHNOL, V19, P656, DOI 10.1038/90264; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; Kohler T, 2002, EUKARYOT CELL, V1, P673, DOI 10.1128/EC.1.5.673-686.2002; Lambrechts MG, 1996, P NATL ACAD SCI USA, V93, P8419, DOI 10.1073/pnas.93.16.8419; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Moore M, 2001, P NATL ACAD SCI USA, V98, P1432, DOI 10.1073/pnas.98.4.1432; Moore M, 2001, P NATL ACAD SCI USA, V98, P1437, DOI 10.1073/pnas.98.4.1437; O'Toole GA, 1999, METHOD ENZYMOL, V310, P91; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Palecek SP, 2002, MICROBIOL-SGM, V148, P893, DOI 10.1099/00221287-148-4-893; Papworth M, 2003, P NATL ACAD SCI USA, V100, P1621, DOI 10.1073/pnas.252773399; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Porteus MH, 2003, SCIENCE, V300, P763, DOI 10.1126/science.1078395; Rebar EJ, 2004, EXPERT OPIN INV DRUG, V13, P829, DOI 10.1517/13543784.13.7.829; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; Reynolds TB, 2001, SCIENCE, V291, P878, DOI 10.1126/science.291.5505.878; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Sengupta N, 2007, BIOPHYS CHEM, V125, P59, DOI 10.1016/j.bpc.2006.06.012; Tan WJ, 2004, J VIROL, V78, P1301, DOI 10.1128/JVI.78.3.1301-1313.2004; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Voynov V, 2006, P NATL ACAD SCI USA, V103, P14423, DOI 10.1073/pnas.0606546103	65	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e746	10.1371/journal.pone.0000746	http://dx.doi.org/10.1371/journal.pone.0000746			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710146	Green Published, Green Submitted, gold			2022-12-25	WOS:000207455200023
J	Stoeck, T; Kasper, J; Bunge, J; Leslin, C; Ilyin, V; Epstein, S				Stoeck, Thorsten; Kasper, Jennifer; Bunge, John; Leslin, Chesley; Ilyin, Valya; Epstein, Slava			Protistan Diversity in the Arctic: A Case of Paleoclimate Shaping Modern Biodiversity?	PLOS ONE			English	Article								Background. The impact of climate on biodiversity is indisputable. Climate changes over geological time must have significantly influenced the evolution of biodiversity, ultimately leading to its present pattern. Here we consider the paleoclimate data record, inferring that present-day hot and cold environments should contain, respectively, the largest and the smallest diversity of ancestral lineages of microbial eukaryotes. Methodology/Principal Findings. We investigate this hypothesis by analyzing an original dataset of 18S rRNA gene sequences from Western Greenland in the Arctic, and data from the existing literature on 18S rRNA gene diversity in hydrothermal vent, temperate sediments, and anoxic water column communities. Unexpectedly, the community from the cold environment emerged as one of the richest observed to date in protistan species, and most diverse in ancestral lineages. Conclusions/Significance. This pattern is consistent with natural selection sweeps on aerobic non-psychrophilic microbial eukaryotes repeatedly caused by low temperatures and global anoxia of snowball Earth conditions. It implies that cold refuges persisted through the periods of greenhouse conditions, which agrees with some, although not all, current views on the extent of the past global cooling and warming events. We therefore identify cold environments as promising targets for microbial discovery.	[Leslin, Chesley; Ilyin, Valya; Epstein, Slava] Northeastern Univ, Dept Biol, Boston, MA 02115 USA; [Stoeck, Thorsten; Kasper, Jennifer] Univ Kaiserslautern, Dept Ecol, Kaiserslautern, Germany; [Bunge, John] Cornell Univ, Dept Stat Sci, Ithaca, NY USA; [Epstein, Slava] Northeastern Univ, Ctr Marine Sci, Nahant, MA 01908 USA	Northeastern University; University of Kaiserslautern; Cornell University; Northeastern University	Epstein, S (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.	s.epstein@neu.edu			US NSF [OPP-0214231]; Deutsche Forschungsgemeinschaft [STO414/2-2, STO 414/2-3]	US NSF(National Science Foundation (NSF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This research was supported by the US NSF grant OPP-0214231 to SSE and Deutsche Forschungsgemeinschaft grants STO414/2-2 and STO 414/2-3 to TS. The research was conducted using the computing facilities of the Northeastern University, and resources of the Cornell Theory Center, which receives funding from Cornell University, New York State, federal agencies, foundations, and corporate partners.	Ahlberg A, 2002, GFF, V124, P197, DOI 10.1080/11035890201244197; Akhmanova A, 1999, MOL MICROBIOL, V32, P1103, DOI 10.1046/j.1365-2958.1999.01434.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amaral Zettler Linda A., 2002, Nature (London), V417, P137, DOI 10.1038/417137a; BARGER KJA, 2006, MIXTURES EXPONENTIAL; Behnke A, 2006, APPL ENVIRON MICROB, V72, P3626, DOI 10.1128/AEM.72.5.3626-3636.2006; Bodiselitsch B, 2005, SCIENCE, V308, P239, DOI 10.1126/science.1104657; Cameron A, 2004, J BIOL CHEM, V279, P31429, DOI 10.1074/jbc.M402433200; Chao A, 2002, BIOMETRICS, V58, P531, DOI 10.1111/j.0006-341X.2002.00531.x; Cuny J, 2002, J PHYS OCEANOGR, V32, P627, DOI 10.1175/1520-0485(2002)032<0627:LSBCAT>2.0.CO;2; Dawson SC, 2002, P NATL ACAD SCI USA, V99, P8324, DOI 10.1073/pnas.062169599; Edgcomb VP, 2002, P NATL ACAD SCI USA, V99, P7658, DOI 10.1073/pnas.062186399; ELWOOD HJ, 1985, MOL BIOL EVOL, V2, P399; FISCHER AG, 1960, EVOLUTION, V14, P64, DOI 10.2307/2405923; Fried J, 2002, SYST APPL MICROBIOL, V25, P555, DOI 10.1078/07232020260517706; Gingerich PD, 2006, TRENDS ECOL EVOL, V21, P246, DOI 10.1016/j.tree.2006.03.006; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hong SH, 2006, P NATL ACAD SCI USA, V103, P117, DOI 10.1073/pnas.0507245102; Jenkyns HC, 2004, NATURE, V432, P888, DOI 10.1038/nature03143; Jensen DB, 2003, 55 GRONL NAT, P165; Jeon SO, 2006, APPL ENVIRON MICROB, V72, P6578, DOI 10.1128/AEM.00787-06; Johnson MD, 2004, PROTIST, V155, P347, DOI 10.1078/1434461041844222; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; Kirschvink JL, 2000, P NATL ACAD SCI USA, V97, P1400, DOI 10.1073/pnas.97.4.1400; Kocher TD, 2004, NAT REV GENET, V5, P288, DOI 10.1038/nrg1316; Kuvardina ON, 2002, J EUKARYOT MICROBIOL, V49, P498, DOI 10.1111/j.1550-7408.2002.tb00235.x; Lane D.J., 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.4135/9781446279281.N7; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Lang-Unnasch N, 1998, ANNU REV MICROBIOL, V52, P561, DOI 10.1146/annurev.micro.52.1.561; Lawley B, 2004, APPL ENVIRON MICROB, V70, P5963, DOI 10.1128/AEM.70.10.5963-5972.2004; Leander BS, 2006, PROTIST, V157, P45, DOI 10.1016/j.protis.2005.10.002; Leander BS, 2003, J EUKARYOT MICROBIOL, V50, P334, DOI 10.1111/j.1550-7408.2003.tb00145.x; LEIPE DD, 1994, PHYCOLOGIA, V33, P369, DOI 10.2216/i0031-8884-33-5-369.1; Lomolino MV, 2006, BIOGEOGRAPHY, P845; Lopez-Garcia P, 2001, NATURE, V409, P603, DOI 10.1038/35054537; Lopez-Garcia P, 2003, P NATL ACAD SCI USA, V100, P697, DOI 10.1073/pnas.0235779100; Lopez-Garcia P, 2001, FEMS MICROBIOL ECOL, V36, P193, DOI 10.1016/S0168-6496(01)00133-7; Lovejoy C, 2006, APPL ENVIRON MICROB, V72, P3085, DOI 10.1128/AEM.72.5.3085-3095.2006; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Maidak BL, 2001, NUCLEIC ACIDS RES, V29, P173, DOI 10.1093/nar/29.1.173; Martin AP, 2004, EVOLUTION, V58, P946; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; MILLER SL, 1988, NATURE, V334, P609, DOI 10.1038/334609a0; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Moran K, 2006, NATURE, V441, P601, DOI 10.1038/nature04800; Naviaux RK, 2005, MAR ECOL PROG SER, V301, P9, DOI 10.3354/meps301009; OKELLY CJ, 1993, J EUKARYOT MICROBIOL, V40, P627, DOI 10.1111/j.1550-7408.1993.tb06120.x; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; ROBISONCOX JF, 1995, APPL ENVIRON MICROB, V61, P1240, DOI 10.1128/AEM.61.4.1240-1245.1995; Schrag DP, 2001, NATURE, V409, P306, DOI 10.1038/35053170; Shen TJ, 2003, ECOLOGY, V84, P798, DOI 10.1890/0012-9658(2003)084[0798:PTNONS]2.0.CO;2; Shopsin B, 1999, J CLIN MICROBIOL, V37, P3556, DOI 10.1128/JCM.37.11.3556-3563.1999; Simpson AGB, 1996, SYST PARASITOL, V33, P187, DOI 10.1007/BF01531200; Sluijs A, 2006, NATURE, V441, P610, DOI 10.1038/nature04668; Steenkamp ET, 2006, MOL BIOL EVOL, V23, P93, DOI 10.1093/molbev/msj011; Stoeck T, 2006, PROTIST, V157, P31, DOI 10.1016/j.protis.2005.10.004; Stoeck T, 2003, APPL ENVIRON MICROB, V69, P5656, DOI 10.1128/AEM.69.9.5656-5663.2003; Stoeck T, 2003, APPL ENVIRON MICROB, V69, P2657, DOI 10.1128/AEM.69.5.2657-2663.2003; Suzuki MT, 1996, APPL ENVIRON MICROB, V62, P625, DOI 10.1128/AEM.62.2.625-630.1996; Swofford D.L., 2001, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tripati A, 2005, NATURE, V436, P341, DOI 10.1038/nature03874; Voncken F, 2002, MOL MICROBIOL, V44, P1441, DOI 10.1046/j.1365-2958.2002.02959.x; Wilson PA, 2001, NATURE, V412, P425, DOI 10.1038/35086553; Wuyts J, 2004, NUCLEIC ACIDS RES, V32, pD101, DOI 10.1093/nar/gkh065; Zuendorf A, 2006, FEMS MICROBIOL ECOL, V58, P476, DOI 10.1111/j.1574-6941.2006.00171.x	68	58	59	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e728	10.1371/journal.pone.0000728	http://dx.doi.org/10.1371/journal.pone.0000728			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710128	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200005
J	Tremblay, C; Champoux, F; Voss, P; Bacon, BA; Lepore, F; Theoret, H				Tremblay, Corinne; Champoux, Francois; Voss, Patrice; Bacon, Benoit A.; Lepore, Franco; Theoret, Hugo			Speech and Non-Speech Audio-Visual Illusions: A Developmental Study	PLOS ONE			English	Article							HEARING LIPS; HUMAN BRAIN; PERCEPTION; INTEGRATION	It is well known that simultaneous presentation of incongruent audio and visual stimuli can lead to illusory percepts. Recent data suggest that distinct processes underlie non-specific intersensory speech as opposed to non-speech perception. However, the development of both speech and non-speech intersensory perception across childhood and adolescence remains poorly defined. Thirty-eight observers aged 5 to 19 were tested on the McGurk effect (an audio-visual illusion involving speech), the Illusory Flash effect and the Fusion effect (two audio-visual illusions not involving speech) to investigate the development of audio-visual interactions and contrast speech vs. non-speech developmental patterns. Whereas the strength of audio-visual speech illusions varied as a direct function of maturational level, performance on non-speech illusory tasks appeared to be homogeneous across all ages. These data support the existence of independent maturational processes underlying speech and non-speech audio-visual illusory effects.	[Tremblay, Corinne; Voss, Patrice; Lepore, Franco; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Tremblay, Corinne; Lepore, Franco; Theoret, Hugo] St Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Bacon, Benoit A.] Bishops Univ, Dept Psychol, Sherbrooke, PQ, Canada	Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Bishops University	Theoret, H (corresponding author), Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca	voss, patrice/I-7026-2019	voss, patrice/0000-0001-8698-7130; Theoret, Hugo/0000-0002-7458-8797	Canadian Institutes of Health Research, Fonds de Recherche en Sante du Quebec	Canadian Institutes of Health Research, Fonds de Recherche en Sante du Quebec(Fonds de la Recherche en Sante du QuebecCanadian Institutes of Health Research (CIHR))	This study was funded by the Canadian Institutes of Health Research, Fonds de Recherche en Sante du Quebec. Funders did not contribute to the study or to the mansucript.	Andersen TS, 2004, COGNITIVE BRAIN RES, V21, P301, DOI 10.1016/j.cogbrainres.2004.06.004; Burnham D, 2004, DEV PSYCHOBIOL, V45, P204, DOI 10.1002/dev.20032; Calvert GA, 2000, CURR BIOL, V10, P649, DOI 10.1016/S0960-9822(00)00513-3; Calvert GA, 2001, CEREB CORTEX, V11, P1110, DOI 10.1093/cercor/11.12.1110; Champoux F, 2006, NEUROREPORT, V17, P1607, DOI 10.1097/01.wnr.0000236856.93586.94; Colin C, 2002, CLIN NEUROPHYSIOL, V113, P495, DOI 10.1016/S1388-2457(02)00024-X; DEKLE DJ, 1992, PERCEPT PSYCHOPHYS, V51, P355, DOI 10.3758/BF03211629; Desjardins RN, 2004, DEV PSYCHOBIOL, V45, P187, DOI 10.1002/dev.20033; Frassinetti F, 2002, EXP BRAIN RES, V147, P332, DOI 10.1007/s00221-002-1262-y; Hnath-Chisolm TE, 1998, J SPEECH LANG HEAR R, V41, P94, DOI 10.1044/jslhr.4101.94; Holmes NP, 2005, CURR BIOL, V15, pR762, DOI 10.1016/j.cub.2005.08.058; Kaiser J, 2005, CEREB CORTEX, V15, P646, DOI 10.1093/cercor/bhh166; Lewkowicz DJ, 2002, COGNITIVE BRAIN RES, V14, P41, DOI 10.1016/S0926-6410(02)00060-5; Macaluso E, 2004, NEUROIMAGE, V21, P725, DOI 10.1016/j.neuroimage.2003.09.049; Massaro D.W., 1998, PERCEIVING TALKING F; MASSARO DW, 1990, PSYCHOL SCI, V1, P55, DOI 10.1111/j.1467-9280.1990.tb00068.x; MASSARO DW, 1984, CHILD DEV, V55, P1777, DOI 10.2307/1129925; MASSARO DW, 1986, J EXP CHILD PSYCHOL, V41, P93, DOI 10.1016/0022-0965(86)90053-6; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; Musacchia G, 2006, EXP BRAIN RES, V168, P1, DOI 10.1007/s00221-005-0071-5; Rosenblum LD, 1997, PERCEPT PSYCHOPHYS, V59, P347, DOI 10.3758/BF03211902; Rosenblum LD, 1996, J EXP PSYCHOL HUMAN, V22, P318, DOI 10.1037/0096-1523.22.2.318; Scheier C, 2003, DEVELOPMENTAL SCI, V6, P233, DOI 10.1111/1467-7687.00276; Sekuler R, 1997, NATURE, V385, P308, DOI 10.1038/385308a0; SESTIERI C, 2006, COGN PROCESS, V7, P138; Shams L, 2000, NATURE, V408, P788, DOI 10.1038/35048669; Shams L, 2002, COGNITIVE BRAIN RES, V14, P147, DOI 10.1016/S0926-6410(02)00069-1; Shams L, 2001, NEUROREPORT, V12, P3849, DOI 10.1097/00001756-200112040-00049; Shimojo S, 2001, CURR OPIN NEUROBIOL, V11, P505, DOI 10.1016/S0959-4388(00)00241-5; Stein BE, 2005, EXP BRAIN RES, V166, P305, DOI 10.1007/s00221-005-2372-0; Teder-Salejarvi WA, 2002, COGNITIVE BRAIN RES, V14, P106, DOI 10.1016/S0926-6410(02)00065-4; Tiippana K, 2004, EUR J COGN PSYCHOL, V16, P457, DOI 10.1080/09541440340000268; Tuomainen J, 2005, COGNITION, V96, pB13, DOI 10.1016/j.cognition.2004.10.004; WELCH RB, 1980, PSYCHOL BULL, V88, P638, DOI 10.1037/0033-2909.88.3.638; Welch RB, 1999, PRESENCE-TELEOP VIRT, V8, P574, DOI 10.1162/105474699566387	35	81	81	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e742	10.1371/journal.pone.0000742	http://dx.doi.org/10.1371/journal.pone.0000742			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710142	gold, Green Published, Green Submitted			2022-12-25	WOS:000207455200019
J	Srinivasan, D; Sims, JT; Plattner, R				Srinivasan, D.; Sims, J. T.; Plattner, R.			Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival	ONCOGENE			English	Article						Abl kinases; breast cancer; proliferation; survival; transformation; STAT3	TYROSINE KINASE; INHIBITOR; APOPTOSIS; LEUKEMIA; PATHWAY; TARGETS; GENES; STAT1	Mutant Abl kinases ( such as BCR-Abl) drive the development of leukemia; however little is known regarding whether Abl kinases contribute to the development or progression of solid tumors. We recently demonstrated that endogenous Abl kinases ( c-Abl, Arg) are activated by deregulated ErbB receptors and Src kinases, and drive invasion of aggressive breast cancer cells. In this study, we examined whether activation of endogenous Abl kinases affects transformation, proliferation and survival, which are major contributors to breast cancer development and metastatic progression. Using a pharmacological inhibitor and RNAi, we demonstrate that activation of endogenous Abl kinases dramatically promotes breast cancer cell proliferation and anchorage-independent growth in serum, as well as survival following nutrient deprivation. Activation of Abl kinases mediates phosphorylation of STAT3, and promotes proliferation by accelerating G(1)-> S progression. Moreover, we identify IGF-1R as a novel upstream activator of endogenous Abl kinases, and demonstrate that Abl kinase activation is required for IGF-1-stimulated cell cycle progression in breast cancer cells. Since activation of Abl kinases affects multiple steps of breast cancer development and progression, Abl kinase inhibitors are likely to be effective agents for the treatment of breast cancers containing highly active Abl kinases.	[Srinivasan, D.; Sims, J. T.; Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, 800 Rose St,Combs Res Bldg 209, Lexington, KY 40536 USA.	rplat2@uky.edu			NCI NIH HHS [R01 CA116784] Funding Source: Medline; NCRR NIH HHS [P20 RR20171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116784] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Buettner R, 2002, CLIN CANCER RES, V8, P945; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Liliensiek SJ, 2006, EXP EYE RES, V83, P61, DOI 10.1016/j.exer.2005.11.007; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Nagano K, 2006, ONCOGENE, V25, P493, DOI 10.1038/sj.onc.1208996; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; van Diest PJ, 2004, J CLIN PATHOL, V57, P675, DOI 10.1136/jcp.2003.010777; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Widschwendter A, 2002, CLIN CANCER RES, V8, P3065; Wu J, 1999, BRIT J CANCER, V79, P1572, DOI 10.1038/sj.bjc.6690250	33	86	90	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1095	1105		10.1038/sj.onc.1210714	http://dx.doi.org/10.1038/sj.onc.1210714			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700528				2022-12-25	WOS:000253136700009
J	Engelbert, D; Schnerch, D; Baumgarten, A; Wasch, R				Engelbert, D.; Schnerch, D.; Baumgarten, A.; Waesch, R.			The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells	ONCOGENE			English	Article						Cdh1; anaphase-promoting complex; mitotic exit; genomic instability; ubiquitin-dependent proteolysis	ANAPHASE-PROMOTING COMPLEX; DNA-DAMAGE; CENTROSOME AMPLIFICATION; DEPENDENT PROTEOLYSIS; CYCLIN-E; INSTABILITY; OVEREXPRESSION; DEGRADATION; ACTIVATION; CHECKPOINT	Ensuring precise DNA replication and chromosome segregation is essential during cell division in order to provide genomic stability and avoid malignant growth. Proteolytic control of cell cycle regulators by the anaphase-promoting complex, activated by Cdh1 (APC(Cdh1)), is responsible for a stable G(1) phase after mitotic exit allowing accurate preparation for DNA replication in the following S phase. APCCdh1 target proteins are frequently upregulated in tumor cells and the inactivation of human Cdh1 might interfere with genome integrity by target stabilization. Here we show that APCCdh1 is required for maintaining genomic integrity in primary human cells. Lentiviral-delivered strong and stable suppression of Cdh1 by RNA interference (RNAi) causes aberrant accumulation of several APCCdh1 target proteins, such as cyclin A, B, Aurora A or Plk1, which control accurate and equal distribution of the genetic information to daughter cells. This induces a premature and prolonged S phase, mitotic-entry delay and defects in chromosome separation and cytokinesis. Cell cycle deregulation by stable knockdown of Cdh1 leads to activation of p53/p21 and genomic instability, which is further increased by codepletion of p53. Thus, stabilization of APCCdh1 targets may initiate aberrant DNA replication and chromosome separation, and trigger a p53 response by deregulating G(1) in primary human cells.	[Engelbert, D.; Schnerch, D.; Baumgarten, A.; Waesch, R.] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Wasch, R (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter St 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Holt, Janet E/B-2415-2013; Waesch, Ralph/F-6282-2019					Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Lehman NL, 2006, CELL CYCLE, V5, P1569, DOI 10.4161/cc.5.14.2925; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagao K, 2004, NATURE, V430, P1044, DOI 10.1038/nature02803; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; Park KH, 2005, BREAST CANCER RES, V7, pR238, DOI 10.1186/bcr978; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; VEELKEN H, 1994, HUM GENE THER, V5, P1203, DOI 10.1089/hum.1994.5.10-1203; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	46	90	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					907	917		10.1038/sj.onc.1210703	http://dx.doi.org/10.1038/sj.onc.1210703			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700535	Bronze			2022-12-25	WOS:000252946300003
J	Podar, K; Gouill, SL; Zhang, J; Opferman, JT; Zorn, E; Tai, YT; Hideshima, T; Amiot, M; Chauhan, D; Harousseau, JL; Anderson, KC				Podar, K.; Gouill, S. L.; Zhang, J.; Opferman, J. T.; Zorn, E.; Tai, Y-T; Hideshima, T.; Amiot, M.; Chauhan, D.; Harousseau, J-L; Anderson, K. C.			A pivotal role for Mcl-1 in Bortezomib-induced apoptosis	ONCOGENE			English	Article						Mcl-1; apoptosis; Bortezomib	PROTEASOME INHIBITOR PS-341; MULTIPLE-MYELOMA CELLS; DOWN-REGULATION; IN-VIVO; SURVIVAL; ACTIVATION; GROWTH; BCL-2; PROTEIN; DIFFERENTIATION	Bortezomib is a proteasome inhibitor for the treatment of relapsed/refractory multiple myeloma (MM). Mechanisms of resistance to Bortezomib are undefined. Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic protein, which protects tumor cells against spontaneous and chemotherapy-induced apoptosis. In MM, specific downregulation of Mcl-1 induces apoptosis. Here, we examined the role of Mcl-1 in Bortezomib- and doxorubicin-induced apoptosis. We demonstrate that Bortezomib, but not doxorubicin, triggers caspase-dependent generation of a 28 kDa Mcl-1 fragment, in several MM cell lines, including MM.1S cells. Conversely, transient transfection of MM.1S cells with a previously reported 28 kDa Mcl-1(128-350) fragment, but not with the Mcl-1(1-127) fragment, induces apoptosis. Therefore, both downregulation of full-length antiapoptotic Mcl-1, as well as Bortezomib- induced generation of Mcl-1(128-350) cleaved protein, contribute to MM cell apoptosis. To verify further these findings, we next compared effects triggered by Bortezomib, doxorubicin and melphalan in Mcl-1(wt/wt) and Mcl-1(Delta/null) murine embryonic fibroblasts (MEFs). Our results show that Bortezomib, but not doxorubicin or melphalan, triggers Mcl-1 cleavage in Mcl-1(wt/wt), but not Mcl-1(Delta/null) MEFs and induces sub-G(1) phase cells; caspase-3 and -9, and PARP cleavage as well as morphological signs of apoptosis. Taken together, these results support an important role of Mcl-1 and a Mcl-1 fragment in Bortezomib- induced cell death in general, and in MM in particular. To prevent relapse of MM in patients treated with Bortezomib, we therefore recommend the combination of Bortezomib with agents that induce MM cell death independent of Mcl-1.	[Podar, K.; Gouill, S. L.; Zhang, J.; Tai, Y-T; Hideshima, T.; Chauhan, D.; Anderson, K. C.] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma CtrDept Med Oncol, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02215 USA; [Gouill, S. L.; Amiot, M.; Harousseau, J-L] CHU Nantes, Hotel Dieu, Serv Hematol Clin, F-44035 Nantes 01, France; [Gouill, S. L.; Amiot, M.] INSERM, U 0601, Inst Biol, Quai Moncousu 9, F-44035 Nantes 01, France; [Opferman, J. T.] St Jude Childrens Hosp, Dept Biochem, Memphis, TN 38105 USA; [Zorn, E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Ctr Hematol Oncol,Dept Med, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); St Jude Children's Research Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Podar, K (corresponding author), Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma CtrDept Med Oncol, Dana Farber Canc Inst,Dept Med Oncol, 44 Binney St, Boston, MA 02215 USA.	klaus_podar@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Opferman, Joseph T/M-5331-2018; Amiot, Martine/K-9076-2015	Podar, Klaus/0000-0002-7414-3632; Opferman, Joseph T/0000-0002-1147-5621; le gouill, steven/0000-0001-9840-2128; Amiot, Martine/0000-0003-0428-7355	NATIONAL CANCER INSTITUTE [R01CA050947, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [R0 CA 50947, P0-1 CA 78378, P50 CA 10070] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Chauhan D, 2005, MOL CANCER THER, V4, P686, DOI 10.1158/1535-7163.MCT-04-0338; Chauhan D, 2004, BLOOD, V104, P2458, DOI 10.1182/blood-2004-02-0547; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jang YM, 2004, FEBS LETT, V577, P483, DOI 10.1016/j.febslet.2004.10.053; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; LeBlanc R, 2002, CANCER RES, V62, P4996; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2006, CELL DEATH DIFFER, V13, P1260, DOI 10.1038/sj.cdd.4401978; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Orlowski RZ, 2005, BLOOD, V105, P3058, DOI 10.1182/blood-2004-07-2911; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008-5472.CAN-04-0124; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Rinkenberger JL, 2000, GENE DEV, V14, P23; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; ZAMAI L, 1993, CYTOMETRY, V14, P891, DOI 10.1002/cyto.990140807; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	46	105	111	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					721	731		10.1038/sj.onc.1210679	http://dx.doi.org/10.1038/sj.onc.1210679			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653083				2022-12-25	WOS:000252884500001
J	Gunnarsson, P; Levander, L; Pahlsson, P; Grenegard, M				Gunnarsson, Peter; Levander, Louise; Pahlsson, Peter; Grenegard, Magnus			The acute-phase protein alpha(1)-acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin-like lectins (Siglecs)	FASEB JOURNAL			English	Article						orosomucoid; plasma protein; calcium signaling; carbohydrate; L-selectin; phagocyte	HUMAN ALPHA-1-ACID GLYCOPROTEIN; L-SELECTIN; FUNCTIONAL-ACTIVITY; INHIBITORY MOTIF; ACTIVATION; EXPRESSION; MODULATION; RECEPTORS; SPECIFICITIES; STIMULATION	We studied whether the acute-phase protein alpha(1)-acid glycoprotein (AGP) induces rises in [Ca2+](i) in neutrophils and sought to identify the corresponding AGP receptor (or receptors). We found that AGP elicited a minimal rise in [Ca2+] i in Fura-2-loaded neutrophils, and this response was markedly enhanced by pretreatment with anti-L-selectin antibodies. (The EC50 value of the AGP-induced Ca2+ response was 9 mu g/ml.) Activation of phospholipase-C, Src tyrosine kinases, and PI3 kinases proved to be essential for the AGP-mediated increase in [Ca2+] i, whereas the p38 MAPK and SYK signaling pathways were not involved. Furthermore, antibodies against sialic acid binding, immunoglobulin-like lectin 5 (Siglec-5) and oligosaccharide 3 '- sialyl-lactose both antagonized the AGP-induced response and caused an immediate increase in [Ca2+] i in anti-L-selectin-treated neutrophils, which indicates a signaling capacity of Siglec-5. We used modified forms of AGP (treated with mild periodate or neuraminidase) to establish the importance of sialic acid residues. The modified forms of AGP caused a much smaller rise in [Ca2+] i than did unaltered AGP. Affinity chromatography confirmed that unchanged AGP, but not neuraminidase-treated AGP, bound to Siglec-5. Our report provides the first evidence for a signaling capacity by AGP through a defined receptor. Pre-engagement of L-selectin significantly enhanced this signaling capacity. -Gunnarsson, P., Levander, L., Pahlsson, P., Grenegard, M. The acute- phase protein alpha(1)- acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin- like lectins (Siglecs).	Linkoping Univ, Dept Med & Care, Div Pharmacol, S-58185 Linkoping, Sweden; Linkoping Univ, Dept Biomed & Surg, Div Cell Biol, Linkoping, Sweden	Linkoping University; Linkoping University	Gunnarsson, P (corresponding author), Linkoping Univ, Dept Med & Care, Div Pharmacol, S-58185 Linkoping, Sweden.	petgu@imv.liu.se						ABBASSI O, 1993, BLOOD CELLS, V19, P245; Angata T, 2006, FASEB J, V20, P1964, DOI 10.1096/fj.06-5800com; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Avril T, 2005, J BIOL CHEM, V280, P19843, DOI 10.1074/jbc.M502041200; BORIES PN, 1990, INFLAMMATION, V14, P315, DOI 10.1007/BF00915815; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; BrinkmanVanderLinden ECM, 1996, GLYCOCONJUGATE J, V13, P27, DOI 10.1007/BF01049676; Burelout C, 2004, MOL PHARMACOL, V66, P293, DOI 10.1124/mol.66.2.293; Connolly NP, 2002, BRIT J HAEMATOL, V119, P221, DOI 10.1046/j.1365-2141.2002.03808.x; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; COSTELLO M, 1979, NATURE, V281, P677, DOI 10.1038/281677a0; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; CrockettTorabi E, 1997, AM J PHYSIOL-HEART C, V272, pH1302, DOI 10.1152/ajpheart.1997.272.3.H1302; Erickson-Miller CL, 2003, EXP HEMATOL, V31, P382, DOI 10.1016/S0301-472X(03)00046-8; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Fumagalli L, 2007, J IMMUNOL, V178, P3874, DOI 10.4049/jimmunol.178.6.3874; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jorgensen HG, 1998, BIOMED CHROMATOGR, V12, P343, DOI 10.1002/(SICI)1099-0801(199811/12)12:6<343::AID-BMC760>3.0.CO;2-6; LAINE E, 1990, INFLAMMATION, V14, P1, DOI 10.1007/BF00914025; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; PAWLOWSKI T, 1989, ARTHRITIS RHEUM, V32, P347, DOI 10.1002/anr.1780320319; POS O, 1990, INFLAMMATION, V14, P133, DOI 10.1007/BF00917452; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; SAMELSON LE, 2005, ANNU REV IMMUNOL, V20, P371; Sjogren F, 2000, INFLAMMATION, V24, P21, DOI 10.1023/A:1006983824890; SMITH CD, 1987, J BIOL CHEM, V262, P6121; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Theilgaard-Monch K, 2005, J LEUKOCYTE BIOL, V78, P462, DOI 10.1189/jlb.0105042; Timoshenko AV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P546; VANOSS CJ, 1974, IMMUNOL COMMUN, V3, P321, DOI 10.3109/08820137409061112; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VASSON MP, 1994, CLIN CHIM ACTA, V224, P65, DOI 10.1016/0009-8981(94)90121-X; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Williams JP, 1997, AM J PHYSIOL-GASTR L, V273, pG1031, DOI 10.1152/ajpgi.1997.273.5.G1031; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	46	41	44	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4059	4069		10.1096/fj.07-8534com	http://dx.doi.org/10.1096/fj.07-8534com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17675532				2022-12-25	WOS:000251283500030
J	Godovikova, V; Ritchie, HH				Godovikova, Valentina; Ritchie, Helena H.			Dynamic processing of recombinant dentin sialoprotein-phosphophoryn protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; RAT; DSP; SIALOPHOSPHOPROTEIN; IMMUNOLOCALIZATION; PHOSPHOPROTEIN; TRANSCRIPTS; EXPRESSION; CALCIUM; GENE	Dentin sialoprotein (DSP) and phosphophoryn (PP) are the two noncollagenous proteins classically linked to dentin but more recently found in bone, kidney, and salivary glands. These two proteins are derived from a single copy DSP-PP gene. Although this suggests that the DSP-PP gene is first transcribed into DSP-PP mRNAs, which later undergo processing to yield the DSP and PP proteins, this mechanism has not yet been demonstrated because of the inability to identify a DSP-PP precursor protein from any cell or tissue sample. To study this problem, we utilized a baculovirus expression system to produce recombinant DSP-PP precursor proteins from a DSP-PP240 cDNA, which represents one of several endogenous DSP-PP transcripts that influence various tooth mineralization phases. Our in vitro results demonstrate that DSP-PP240 precursor proteins are produced by this system and are capable of self-processing to yield both DSP and PP proteins. We further demonstrated that purified recombinant DSP-PP240, purified recombinant PP240, and the native highly phosphorylated protein (equivalent to the PP523 isoform) have proteolytic activity. These newly identified tissue proteases may play key roles in tissue modeling during organogenesis.	Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ritchie, HH (corresponding author), Univ Michigan, Sch Dent, Rm 2393,Dental Bldg,1011 N Univ Ave, Ann Arbor, MI 48109 USA.	helenar@umich.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011442] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11442] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRONCKERS ALJJ, 1994, J BONE MINER RES, V9, P833; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Chang SR, 1996, CALCIFIED TISSUE INT, V59, P149, DOI 10.1007/s002239900101; Crossen R., 1996, BACULOVIRUS EXPRESSI; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; Godovikova V, 2006, DEV BIOL, V289, P507, DOI 10.1016/j.ydbio.2005.10.002; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Jo Y, 1999, J BIOCHEM MOL BIOL, V32, P60; LINDE A, 1980, J BIOL CHEM, V255, P5931; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; Linde A., 1985, CHEM BIOL MINERALIZE, P344; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P346, DOI 10.1021/bi00427a047; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; Ritchie H, 1997, BIOCHEM BIOPH RES CO, V231, P425, DOI 10.1006/bbrc.1997.6126; RITCHIE H, 1996, J DENT RES, V75, P153; Ritchie HH, 2000, BBA-GENE STRUCT EXPR, V1493, P27, DOI 10.1016/S0167-4781(00)00150-0; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Ritchie HH, 1997, EUR J ORAL SCI, V105, P405, DOI 10.1111/j.1600-0722.1997.tb02137.x; Ritchie HH, 2001, BBA-GENE STRUCT EXPR, V1520, P212, DOI 10.1016/S0167-4781(01)00274-3; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Veis A, 1985, CHEM BIOL MINERALIZE, P170; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Yamakoshi Y, 2006, J BIOL CHEM, V281, P38235, DOI 10.1074/jbc.M607767200; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	26	16	17	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31341	31348		10.1074/jbc.M702605200	http://dx.doi.org/10.1074/jbc.M702605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17698853	hybrid			2022-12-25	WOS:000250309200023
J	Eichinger, A; Nasreen, A; Kim, HJ; Skerra, A				Eichinger, Andreas; Nasreen, Amber; Kim, Hyun Jin; Skerra, Arne			Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; MOLECULAR-STRUCTURE; CRYSTAL-STRUCTURE; GENETIC-VARIATION; PROGESTERONE; REFINEMENT; EXPRESSION; LIPOCALINS; ALIGNMENT; ERRORS	Human apolipoprotein D(ApoD) occurs in plasma associated with high density lipoprotein. Apart from the involvement in lipid metabolism, its binding activity for progesterone and arachidonic acid plays a role in cancer development and neurological diseases. The crystal structures of free ApoD and its complex with progesterone were determined at 1.8 angstrom resolution and reveal a lipocalin fold. The narrow, mainly uncharged pocket within the typical beta-barrel accommodates progesterone with its acetyl side chain oriented toward the bottom. The cavity adopts essentially the same shape in the absence of progesterone and allows complexation of arachidonic acid as another cognate ligand. Three of the four extended loops at the open end of the beta-barrel expose hydrophobic side chains, which is an unusual feature for lipocalins and probably effects association with the high density lipoprotein particle by mediating insertion into the lipid phase. This mechanism is in line with an unpaired Cys residue in the same surface region that can form a disulfide cross-link with apolipoprotein A-II.	Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Skerra, A (corresponding author), Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany.	skerra@wzw.tum.de	Skerra, Arne/A-2269-2013	Skerra, Arne/0000-0002-5717-498X				ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; AYRAULTJARRIER M, 1963, B SOC CHIM BIOL, V45, P703; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breustedt DA, 2005, J BIOL CHEM, V280, P484, DOI 10.1074/jbc.M410466200; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campanacci V, 2004, FEBS LETT, V562, P183, DOI 10.1016/S0014-5793(04)00199-1; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cianci M, 2001, ACTA CRYSTALLOGR D, V57, P1219, DOI 10.1107/S0907444901009350; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Desai PP, 2002, ATHEROSCLEROSIS, V163, P329, DOI 10.1016/S0021-9150(02)00012-6; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Flower DR, 1996, BIOCHEM J, V318, P1; Gursky O, 2005, CURR OPIN LIPIDOL, V16, P287, DOI 10.1097/01.mol.0000169348.61191.ac; Hall RE, 2004, PROSTATE, V58, P103, DOI 10.1002/pros.10343; Hansen T, 2006, PHARMACOGENOMICS J, V6, P120, DOI 10.1038/sj.tpj.6500350; Helisalmi S, 2004, J NEUROL, V251, P951, DOI 10.1007/s00415-004-0470-8; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahadik SP, 2002, SCHIZOPHR RES, V58, P55, DOI 10.1016/S0920-9964(01)00378-4; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; MILNE RW, 1993, CURR OPIN LIPIDOL, V4, P100, DOI 10.1097/00041433-199304000-00005; Miranda E, 2003, J SURG ONCOL, V83, P99, DOI 10.1002/jso.10245; Nasreen A, 2006, PROTEIN SCI, V15, P190, DOI 10.1110/ps.051775606; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; PEARLMAN WH, 1973, J BIOL CHEM, V248, P5736; Peitsch M C, 1990, New Biol, V2, P197; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X; Tao P, 1999, J MOL MODEL, V5, P189, DOI 10.1007/s008940050118; Thomas EA, 2003, CURR MOL MED, V3, P408, DOI 10.2174/1566524033479681; Vogt M, 2004, CHEMBIOCHEM, V5, P191, DOI 10.1002/cbic.200300703; Vogt M, 2001, J MOL RECOGNIT, V14, P79, DOI 10.1002/1099-1352(200101/02)14:1<79::AID-JMR521>3.0.CO;2-4; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YANG CY, 1994, BIOCHEMISTRY-US, V33, P12451, DOI 10.1021/bi00207a011; Zanotti G, 1998, ACTA CRYSTALLOGR D, V54, P1049, DOI 10.1107/S0907444998002303; Zeng CH, 1996, P NATL ACAD SCI USA, V93, P6626, DOI 10.1073/pnas.93.13.6626; Zhang XJ, 2006, NEUROPSYCHOBIOLOGY, V54, P40, DOI 10.1159/000095740	49	83	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31068	31075		10.1074/jbc.M703552200	http://dx.doi.org/10.1074/jbc.M703552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699160	hybrid			2022-12-25	WOS:000250136300074
J	Deponte, M; Sturm, N; Mittler, S; Harner, M; Mack, H; Becker, K				Deponte, Marcel; Sturm, Nicole; Mittler, Sarah; Harner, Max; Mack, Hildegard; Becker, Katja			Allosteric coupling of two different functional active sites in monomeric Plasmodium falciparum glyoxalase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RANDOM PATHWAY MECHANISM; SACCHAROMYCES-CEREVISIAE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; LEISHMANIA-MAJOR; HUMAN ENZYME; METAL-ION; YEAST; SPECIFICITY	Glyoxalase I (GloI) catalyzes the glutathione-dependent conversion of 2-oxoaldehydes to S-2-hydroxyacylglutathione derivatives. Studies on GloI from diverse organisms such as man, bacteria, yeast, and different parasites show striking differences among these potentially isofunctional enzymes as far as metal content and the number of active sites per subunit are concerned. So far, it is not known whether this structural variability is linked to catalytic or regulatory features in vivo. Here we show that recombinant GloI from the malaria parasite Plasmodium falciparum has a high- and a low-affinity binding site for the diastereomeric hemithioacetals formed by addition of glutathione to methylglyoxal. Both active sites of the monomeric enzyme are functional and have similar k(cat)(app) values. Proteolytic susceptibility studies and detailed analyses of the steady-state kinetics of active-site mutants suggest that both reaction centers can adopt two discrete conformations and are allosterically coupled. As a result of the positive homotropic allosteric coupling, P. falciparum GloI has an increased affinity at low substrate concentrations and an increased activity at higher substrate concentrations. This could also be the case for GloI from yeast and other organisms. Potential physiologically relevant differences between monomeric GloI and homodimeric GloI are discussed. Our results provide a strong basis for drug development strategies and significantly enhance our understanding of GloI kinetics and structure-function relationships. Furthermore, they extend the current knowledge on allosteric regulation of monomeric proteins in general.	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany	University of Munich; Justus Liebig University Giessen	Deponte, M (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	marcel.deponte@gmx.de		Harner, Max/0000-0002-5513-1046; Deponte, Marcel/0000-0003-2141-917X; Mack, Hildegard/0000-0001-7559-1851				Akoachere M, 2005, BIOL CHEM, V386, P41, DOI 10.1515/BC.2005.006; Ariza A, 2006, MOL MICROBIOL, V59, P1239, DOI 10.1111/j.1365-2958.2006.05022.x; ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; Bisswanger H., 2002, ENZYME KINETICS; Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Boyer, 1970, ENZYMES, P341, DOI DOI 10.1016/S1874-6047(08)60170-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; CLIFFE EE, 1961, BIOCHEM J, V79, P475, DOI 10.1042/bj0790475; Clugston SL, 1998, BIOCHEMISTRY-US, V37, P8754, DOI 10.1021/bi972791w; Dakin HD, 1913, J BIOL CHEM, V14, P423; Frickel EM, 2001, J BIOL CHEM, V276, P1845, DOI 10.1074/jbc.M005760200; Gomes RA, 2005, FEBS J, V272, P4521, DOI 10.1111/j.1742-4658.2005.04872.x; HALL SS, 1976, J AM CHEM SOC, V98, P7460, DOI 10.1021/ja00439a077; HAN LPB, 1977, BIOCHEMISTRY-US, V16, P5478, DOI 10.1021/bi00644a013; He MM, 2000, BIOCHEMISTRY-US, V39, P8719, DOI 10.1021/bi000856g; Himo F, 2001, J AM CHEM SOC, V123, P10280, DOI 10.1021/ja010715h; Iozef R, 2003, FEBS LETT, V554, P284, DOI 10.1016/S0014-5793(03)01146-3; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN Y, 1995, J BIOL CHEM, V270, P12957, DOI 10.1074/jbc.270.22.12957; MANNERVIK B, 1974, J BIOL CHEM, V249, P901; Martins AM, 2001, EUR J BIOCHEM, V268, P3930, DOI 10.1046/j.1432-1327.2001.02304.x; Martins AMTBS, 2001, FEBS LETT, V499, P41, DOI 10.1016/S0014-5793(01)02519-4; Miller AG, 2006, J BIOL CHEM, V281, P11864, DOI 10.1074/jbc.M513813200; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; RACKER E, 1951, J BIOL CHEM, V190, P685; RAE C, 1994, BIOCHEMISTRY-US, V33, P3548, DOI 10.1021/bi00178a011; Richter U, 2001, J AM CHEM SOC, V123, P6973, DOI 10.1021/ja0105966; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; SELLIN S, 1982, BIOCHEMISTRY-US, V21, P4850, DOI 10.1021/bi00263a004; Sukdeo N, 2004, BIOCHEM J, V384, P111, DOI 10.1042/BJ20041006; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; VANDERJAGT DL, 1972, BIOCHEMISTRY-US, V11, P3735, DOI 10.1021/bi00770a011; VANDERJAGT DL, 1975, BIOCHEMISTRY-US, V14, P3669, DOI 10.1021/bi00687a024; VANDERJAGT DL, 1989, GLUTATHIONE CHEM B A, P597; VARONCASTELLANO.R, 1995, COMPUTERSIZED DERIVA; Vickers TJ, 2004, P NATL ACAD SCI USA, V101, P13186, DOI 10.1073/pnas.0402918101; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024	42	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28419	28430		10.1074/jbc.M703271200	http://dx.doi.org/10.1074/jbc.M703271200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17664277	hybrid			2022-12-25	WOS:000249642100016
J	Quan, S; Schneider, I; Pan, J; Von Hacht, A; Bardwell, JCA				Quan, Shu; Schneider, Irmhild; Pan, Jonathan; Von Hacht, Annekathrin; Bardwell, James C. A.			The CXXC motif is more than a redox rheostat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI THIOREDOXIN; ACTIVE-SITE; FORMATION INVIVO; IN-VIVO; EFFICIENT CATALYSIS; CRYSTAL-STRUCTURE; DSBA; ISOMERASE; PROTEINS	The CXXCactive-site motif of thiol-disulfide oxidoreductases is thought to act as a redox rheostat, the sequence of which determines its reduction potential and functional properties. We tested this idea by selecting for mutants of the CXXC motif in a reducing oxidoreductase ( thioredoxin) that complement null mutants of a very oxidizing oxidoreductase, DsbA. We found that altering the CXXC motif affected not only the reduction potential of the protein, but also its ability to function as a disulfide isomerase and also impacted its interaction with folding protein substrates and reoxidants. It is surprising that nearly all of our thioredoxin mutants had increased activity in disulfide isomerization in vitro and in vivo. Our results indicate that the CXXC motif has the remarkable ability to confer a large number of very specific properties on thioredoxin-related proteins.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg,Rm 4007,830 N Univ, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	Quan, Shu/O-4562-2015	Quan, Shu/0000-0002-6672-4947	PHS HHS [F007834, F007810] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 2001, J BACTERIOL, V183, P980, DOI 10.1128/JB.183.3.980-988.2001; Britto PJ, 2002, J BIOL CHEM, V277, P29018, DOI 10.1074/jbc.M204263200; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; Carvalho AP, 2006, PROG BIOPHYS MOL BIO, V91, P229, DOI 10.1016/j.pbiomolbio.2005.06.012; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Collet JF, 2002, J BIOL CHEM, V277, P26886, DOI 10.1074/jbc.M203028200; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, DOI DOI 10.1385/1592598900; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Grzyska PK, 2005, BIOCHEMISTRY-US, V44, P3845, DOI 10.1021/bi048746n; Guddat LW, 1997, PROTEIN SCI, V6, P1893, DOI 10.1002/pro.5560060910; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hiniker A, 2005, J BIOL CHEM, V280, P33785, DOI 10.1074/jbc.M505742200; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Inaba K, 2004, J BIOL CHEM, V279, P6761, DOI 10.1074/jbc.M310765200; Iqbalsyah TM, 2006, PROTEIN SCI, V15, P1945, DOI 10.1110/ps.062271506; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MORGAN RS, 1978, INT J PEPT PROT RES, V11, P209; Mossner E, 1998, PROTEIN SCI, V7, P1233; Pal D, 1998, J BIOMOL STRUCT DYN, V15, P1059, DOI 10.1080/07391102.1998.10509001; Pan JL, 2006, PROTEIN SCI, V15, P2217, DOI 10.1110/ps.062268106; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rensing C, 1997, J BACTERIOL, V179, P2769, DOI 10.1128/jb.179.8.2769-2771.1997; Ritz D, 2002, METHOD ENZYMOL, V347, P360; Rozhkova A, 2004, EMBO J, V23, P1709, DOI 10.1038/sj.emboj.7600178; Schultz LW, 1999, ACTA CRYSTALLOGR D, V55, P1533, DOI 10.1107/S0907444999008756; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; Stafford SJ, 1999, FEMS MICROBIOL LETT, V174, P179, DOI 10.1111/j.1574-6968.1999.tb13566.x; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Tapley TL, 2007, J BIOL CHEM, V282, P10263, DOI 10.1074/jbc.M611541200; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zauhar RJ, 2000, BIOPOLYMERS, V53, P233, DOI 10.1002/(SICI)1097-0282(200003)53:3<233::AID-BIP3>3.3.CO;2-W; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200	60	104	105	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28823	28833		10.1074/jbc.M705291200	http://dx.doi.org/10.1074/jbc.M705291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17675287	hybrid			2022-12-25	WOS:000249642100057
J	Moniz, S; Verissimo, F; Matos, P; Brazao, R; Silva, E; Kotevelets, L; Chastre, E; Gespach, C; Jordan, P				Moniz, S.; Verissimo, F.; Matos, P.; Brazao, R.; Silva, E.; Kotevelets, L.; Chastre, E.; Gespach, C.; Jordan, P.			Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2	ONCOGENE			English	Article						cell cycle progression; EGF; ERK MAP kinase pathway; MEK1; WNK protein kinases	CROSS-CASCADE ACTIVATION; WNK KINASES; CYCLE ARREST; PHOSPHORYLATION; RAS; SPAK; MEK1; IDENTIFICATION; EXPRESSION; MUTATIONS	The recently identified subfamily of WNK protein kinases is characterized by a unique sequence variation in the catalytic domain and four related human WNK genes were identified. Here, we describe the cloning and functional analysis of the human family member WNK2. We show that the depletion of endogenous WNK2 expression by RNA interference in human cervical HeLa cancer cells led to the activation of the extracellular signal - regulated kinase ( ERK) 1/ 2 mitogen- activated protein kinases but, in contrast to the depletion of WNK1, had no effect on ERK5. Furthermore, expression of a kinase-dead WNK2- K207M mutant also activated ERK1/ 2 suggesting that WNK2 catalytic activity is required. Depletion of WNK2 expression increased G1/ S progression and potentiated the cellular response to low epidermal growth factor concentrations. The molecular mechanism of ERK1/ 2 activation in WNK2- depleted cells lies downstream of the Raf kinases and involves MEK1 phosphorylation at serine 298 in both HeLa and HT29 colon cancer cells. This modi. cation is linked to the upregulation of MEK1 activity toward ERK1/2. Together, these results provide evidence that WNK2 is involved in the modulation of growth factor - induced cancer cell proliferation through the MEK1/ERK1/2 pathway. The data identify WNK2 as a candidate tumor suppressor gene and suggest a coordinated activity of WNK kinases in the regulation of cell proliferation. ' in ' ' '	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; INSERM, U773, Ctr Rech Biomed Bichat Bequjon CRB3, Paris, France; Univ Paris 07, Paris, France; INSERM U673, Paris, France; Univ Paris 06, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France	Instituto Nacional de Saude Dr. Ricardo Jorge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Avenida,Padre Cruz, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018; Matos, Paulo/F-5245-2012; Matos, Paulo/P-3012-2019	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228; Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gamba G, 2005, AM J PHYSIOL-RENAL, V288, pF245, DOI 10.1152/ajprenal.00311.2004; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104; Ito M, 2001, CANCER RES, V61, P2038; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kostich M, 2002, GENOME BIOL, V3; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Li WQ, 2000, GENE DEV, V14, P895; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Rodriguez-Viciana P, 2005, COLD SH Q B, V70, P461, DOI 10.1101/sqb.2005.70.044; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Verissimo F, 2006, ONCOGENE, V25, P4172, DOI 10.1038/sj.onc.1209449; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	46	64	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6071	6081		10.1038/sj.onc.1210706	http://dx.doi.org/10.1038/sj.onc.1210706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17667937				2022-12-25	WOS:000249277200010
J	Niimura, Y; Nei, M				Niimura, Yoshihito; Nei, Masatoshi			Extensive Gains and Losses of Olfactory Receptor Genes in Mammalian Evolution	PLOS ONE			English	Article								Odor perception in mammals is mediated by a large multigene family of olfactory receptor ( OR) genes. The number of OR genes varies extensively among different species of mammals, and most species have a substantial number of pseudogenes. To gain some insight into the evolutionary dynamics of mammalian OR genes, we identified the entire set of OR genes in platypuses, opossums, cows, dogs, rats, and macaques and studied the evolutionary change of the genes together with those of humans and mice. We found that platypuses and primates have,400 functional OR genes while the other species have 800-1,200 functional OR genes. We then estimated the numbers of gains and losses of OR genes for each branch of the phylogenetic tree of mammals. This analysis showed that (i) gene expansion occurred in the placental lineage each time after it diverged from monotremes and from marsupials and (ii) hundreds of gains and losses of OR genes have occurred in an order-specific manner, making the gene repertoires highly variable among different orders. It appears that the number of OR genes is determined primarily by the functional requirement for each species, but once the number reaches the required level, it fluctuates by random duplication and deletion of genes. This fluctuation seems to have been aided by the stochastic nature of OR gene expression.	[Niimura, Yoshihito] Tokyo Med & Dent Univ, Med Res Inst, Dept Bioinformat, Tokyo, Japan; [Niimura, Yoshihito; Nei, Masatoshi] Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA; [Niimura, Yoshihito; Nei, Masatoshi] Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Tokyo Medical & Dental University (TMDU); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Niimura, Y (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Bioinformat, Tokyo, Japan.	niimura@bioinfo.tmd.ac.jp			US NIH [GM020293]; Ministry of Education, Culture, Sports, Science and Technology, Japan [17710162]; Genome Information Integration Project of the Ministry of Economy; Trade and Industry of Japan; Japan Biological Informatics Consortium; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020293] Funding Source: NIH RePORTER	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Genome Information Integration Project of the Ministry of Economy; Trade and Industry of Japan; Japan Biological Informatics Consortium; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by US NIH grant GM020293 to M.N. and by grant 17710162 from Ministry of Education, Culture, Sports, Science and Technology, Japan and by the Genome Information Integration Project of the Ministry of Economy, Trade and Industry of Japan and the Japan Biological Informatics Consortium to Y.N.	Aloni R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r88; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bargmann CI, 2006, NATURE, V444, P295, DOI 10.1038/nature05402; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Cannarozzi G, 2007, PLOS COMPUT BIOL, V3, P9, DOI 10.1371/journal.pcbi.0030002; Demuth JP, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000085; Gilad Y, 2004, PLOS BIOL, V2, P120, DOI 10.1371/journal.pbio.0020005; Glazko GV, 2003, MOL BIOL EVOL, V20, P424, DOI 10.1093/molbev/msg050; Glusman G, 2000, MAMM GENOME, V11, P1016, DOI 10.1007/s003350010196; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Go Y, 2006, MOL BIOL EVOL, V23, P964, DOI 10.1093/molbev/msj106; GOODMAN M, 1979, SYST ZOOL, V28, P132, DOI 10.2307/2412519; Grus WE, 2005, P NATL ACAD SCI USA, V102, P5767, DOI 10.1073/pnas.0501589102; Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198; Kriegs JO, 2006, PLOS BIOL, V4, P537, DOI 10.1371/journal.pbio.0040091; Kullberg M, 2006, MOL BIOL EVOL, V23, P1493, DOI 10.1093/molbev/msl027; Malnic B, 2004, P NATL ACAD SCI USA, V101, P2584, DOI 10.1073/pnas.0307882100; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Murphy WJ, 2004, TRENDS GENET, V20, P631, DOI 10.1016/j.tig.2004.09.005; Nam J, 2005, MOL BIOL EVOL, V22, P2386, DOI 10.1093/molbev/msi229; Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240; Nei M, 1997, P NATL ACAD SCI USA, V94, P7799, DOI 10.1073/pnas.94.15.7799; NEI M, 2000, MOL EVOLUTION PHYLOG, P175; NEI M, 2007, P NATL ACAD IN PRESS; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; Niimura Y, 2005, GENE, V346, P23, DOI 10.1016/j.gene.2004.09.027; Niimura Y, 2005, P NATL ACAD SCI USA, V102, P6039, DOI 10.1073/pnas.0501922102; Niimura Y, 2005, GENE, V346, P13, DOI 10.1016/j.gene.2004.09.025; Niimura Y, 2003, P NATL ACAD SCI USA, V100, P12235, DOI 10.1073/pnas.1635157100; Niimura Y, 2006, J HUM GENET, V51, P505, DOI 10.1007/s10038-006-0391-8; Nozawa M, 2007, P NATL ACAD SCI USA, V104, P7122, DOI 10.1073/pnas.0702133104; Page RDM, 1997, MOL PHYLOGENET EVOL, V7, P231, DOI 10.1006/mpev.1996.0390; Pettigrew JD, 1999, J EXP BIOL, V202, P1447; Quignon P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r83; Ray A, 2007, NEURON, V53, P353, DOI 10.1016/j.neuron.2006.12.010; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Shepherd GM, 2004, PLOS BIOL, V2, P572, DOI 10.1371/journal.pbio.0020146; Springer MS, 2004, TRENDS ECOL EVOL, V19, P430, DOI 10.1016/j.tree.2004.05.006; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zozulya S, 2001, GENOME BIOL, V2	44	216	223	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e708	10.1371/journal.pone.0000708	http://dx.doi.org/10.1371/journal.pone.0000708			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684554	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452400011
J	Karpathy, SE; Qin, X; Gioia, J; Jiang, HY; Liu, YM; Petrosino, JF; Yerrapragada, S; Fox, GE; Haake, SK; Weinstock, GM; Highlander, SK				Karpathy, Sandor E.; Qin, Xiang; Gioia, Jason; Jiang, Huaiyang; Liu, Yamei; Petrosino, Joseph F.; Yerrapragada, Shailaja; Fox, George E.; Haake, Susan Kinder; Weinstock, George M.; Highlander, Sarah K.			Genome Sequence of Fusobacterium nucleatum Subspecies Polymorphum - a Genetically Tractable Fusobacterium	PLOS ONE			English	Article							HORIZONTAL GENE-TRANSFER; GROUP-I INTRONS; ESCHERICHIA-COLI; PORPHYROMONAS-GINGIVALIS; CLOSTRIDIUM-PERFRINGENS; SHIGELLA-FLEXNERI; BACTERIAL GENOMES; OXIDATIVE STRESS; STREPTOCOCCUS-PYOGENES; SUBGINGIVAL PLAQUE	Fusobacterium nucleatum is a prominent member of the oral microbiota and is a common cause of human infection. F. nucleatum includes five subspecies: polymorphum, nucleatum, vincentii, fusiforme, and animalis. F. nucleatum subsp. polymorphum ATCC 10953 has been well characterized phenotypically and, in contrast to previously sequenced strains, is amenable to gene transfer. We sequenced and annotated the 2,429,698 bp genome of F. nucleatum subsp. polymorphum ATCC 10953. Plasmid pFN3 from the strain was also sequenced and analyzed. When compared to the other two available fusobacterial genomes (F. nucleatum subsp. nucleatum, and F. nucleatum subsp. vincentii) 627 open reading frames unique to F. nucleatum subsp. polymorphum ATCC 10953 were identified. A large percentage of these mapped within one of 28 regions or islands containing five or more genes. Seventeen percent of the clustered proteins that demonstrated similarity were most similar to proteins from the clostridia, with others being most similar to proteins from other gram-positive organisms such as Bacillus and Streptococcus. A ten kilobase region homologous to the Salmonella typhimurium propanediol utilization locus was identified, as was a prophage and integrated conjugal plasmid. The genome contains five composite ribozyme/transposons, similar to the Cd/St IStrons described in Clostridium difficile. IStrons are not present in the other fusobacterial genomes. These findings indicate that F. nucleatum subsp. polymorphum is proficient at horizontal gene transfer and that exchange with the Firmicutes, particularly the Clostridia, is common.	[Karpathy, Sandor E.; Qin, Xiang; Jiang, Huaiyang; Petrosino, Joseph F.; Yerrapragada, Shailaja; Weinstock, George M.; Highlander, Sarah K.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Karpathy, Sandor E.; Weinstock, George M.] Univ Texas Houston, Sch Med, Dept Microbiol & Mol Genet, Houston, TX USA; [Gioia, Jason; Petrosino, Joseph F.; Weinstock, George M.; Highlander, Sarah K.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Liu, Yamei; Fox, George E.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Haake, Susan Kinder] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Houston System; University of Houston; University of California System; University of California Los Angeles	Highlander, SK (corresponding author), Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.	sarahh@bcm.tmc.edu	Willson, richard/AAD-4832-2019; Petrosino, Joseph F./AAF-1621-2019; Weinstock, George M/C-6314-2013	Weinstock, George M/0000-0002-2997-4592	National Institute of Dental and Craniofacial [R01 DE013759]; Susan Kinder Haake [R01 DEO15348]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015348, R01DE013759] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Susan Kinder Haake; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This project was supported by a grant from the National Institute of Dental and Craniofacial Research to George Weinstock. (R01 DE013759). Susan Kinder Haake was supported by R01 DEO15348.	Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997; Bearfield C, 2002, BJOG-INT J OBSTET GY, V109, P527, DOI 10.1016/S1470-0328(02)01349-6; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; Bobik TA, 1997, J BACTERIOL, V179, P6633, DOI 10.1128/jb.179.21.6633-6639.1997; Bolstad AI, 1996, CLIN MICROBIOL REV, V9, P55, DOI 10.1128/CMR.9.1.55; Bradshaw DJ, 1998, INFECT IMMUN, V66, P4729, DOI 10.1128/IAI.66.10.4729-4732.1998; Braun V, 2000, MOL MICROBIOL, V36, P1447, DOI 10.1046/j.1365-2958.2000.01965.x; Brenot A, 2004, INFECT IMMUN, V72, P408, DOI 10.1128/IAI.72.1.408-413.2004; Brook I, 1998, J MED MICROBIOL, V47, P1075, DOI 10.1099/00222615-47-12-1075; Brown L J, 1993, Periodontol 2000, V2, P57; Bruggemann H, 2003, P NATL ACAD SCI USA, V100, P1316, DOI 10.1073/pnas.0335853100; Cahill RJ, 2005, MOL HUM REPROD, V11, P761, DOI 10.1093/molehr/gah234; CARSIOTIS M, 1989, INFECT IMMUN, V57, P3276, DOI 10.1128/IAI.57.11.3276-3280.1989; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; Chaudhry R, 1998, BRIT J NEUROSURG, V12, P127, DOI 10.1080/02688699845258; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Christie PJ, 2004, BBA-MOL CELL RES, V1694, P219, DOI 10.1016/j.bbamcr.2004.02.013; Chryssagi AM, 2001, CLIN RHEUMATOL, V20, P229, DOI 10.1007/s100670170072; CIVEN R, 1995, CLIN INFECT DIS, V20, pS224, DOI 10.1093/clinids/20.Supplement_2.S224; Conrads G, 2002, INT J SYST EVOL MICR, V52, P493, DOI 10.1099/00207713-52-2-493; Demuth DR, 1996, INFECT IMMUN, V64, P1335, DOI 10.1128/IAI.64.4.1335-1341.1996; Desvaux M, 2005, BBA-BIOMEMBRANES, V1713, P92, DOI 10.1016/j.bbamem.2005.05.002; Diaz PI, 2002, MICROBIOL-SGM, V148, P467, DOI 10.1099/00221287-148-2-467; Diaz PI, 2000, FEMS MICROBIOL LETT, V187, P31, DOI 10.1016/S0378-1097(00)00174-9; DZINK JL, 1990, INT J SYST BACTERIOL, V40, P74, DOI 10.1099/00207713-40-1-74; Ebersole JL, 1997, MICROB PATHOGENESIS, V23, P23, DOI 10.1006/mpat.1996.0129; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Feuille F, 1996, INFECT IMMUN, V64, P2095, DOI 10.1128/IAI.64.6.2094-2100.1996; Frias J, 2001, INFECT IMMUN, V69, P3431, DOI 10.1128/IAI.69.5.3431-3434.2001; Gerardo SH, 2002, ORAL MICROBIOL IMMUN, V17, P315; Gmur R, 2006, SYST APPL MICROBIOL, V29, P120, DOI 10.1016/j.syapm.2005.07.011; GOLDSTEIN EJC, 1995, CLIN INFECT DIS, V20, P797, DOI 10.1093/clinids/20.4.797; Griffiths-Jones S, 2003, NUCLEIC ACIDS RES, V31, P439, DOI 10.1093/nar/gkg006; Haake SK, 1997, ARCH ORAL BIOL, V42, P19, DOI 10.1016/S0003-9969(96)00105-7; Haake SK, 2000, J BACTERIOL, V182, P1176, DOI 10.1128/JB.182.4.1176-1180.2000; Han YPW, 2004, INFECT IMMUN, V72, P2272, DOI 10.1128/IAI.72.4.2272-2279.2004; Han YW, 2000, INFECT IMMUN, V68, P3140, DOI 10.1128/IAI.68.6.3140-3146.2000; HASE S, 1977, J BACTERIOL, V129, P9, DOI 10.1128/JB.129.1.9-14.1977; Havlak P, 2004, GENOME RES, V14, P721, DOI 10.1101/gr.2264004; Hayes WS, 1998, GENOME RES, V8, P1154, DOI 10.1101/gr.8.11.1154; Hill G B, 1998, Ann Periodontol, V3, P222, DOI 10.1902/annals.1998.3.1.222; HOLST E, 1994, J CLIN MICROBIOL, V32, P176, DOI 10.1128/JCM.32.1.176-186.1994; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; Jaeger T, 2004, ARCH BIOCHEM BIOPHYS, V423, P182, DOI 10.1016/j.abb.2003.11.021; Jean D, 2004, MICROBIOL-SGM, V150, P1649, DOI 10.1099/mic.0.27017-0; Jewett A, 2000, INFECT IMMUN, V68, P1893, DOI 10.1128/IAI.68.4.1893-1898.2000; JOUSIMIESSOMER H, 1993, CLIN INFECT DIS, V16, pS292, DOI 10.1093/clinids/16.Supplement_4.S292; Kapatral V, 2003, GENOME RES, V13, P1180, DOI 10.1101/gr.566003; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; Karlin S, 1998, CURR OPIN MICROBIOL, V1, P598, DOI 10.1016/S1369-5274(98)80095-7; KAUFMAN J, 1989, INFECT IMMUN, V57, P331, DOI 10.1128/IAI.57.2.331-337.1989; Kersulyte D, 1998, GENE, V223, P175, DOI 10.1016/S0378-1119(98)00164-4; King KY, 2000, J BACTERIOL, V182, P5290, DOI 10.1128/JB.182.19.5290-5299.2000; KOLENBRANDER PE, 1993, J BACTERIOL, V175, P3247, DOI 10.1128/jb.175.11.3247-3252.1993; Kononen E, 2000, ANN MED, V32, P107, DOI 10.3109/07853890009011759; Kuriyama T, 2000, MICROBES INFECT, V2, P1425, DOI 10.1016/S1286-4579(00)01296-X; LAWRENCE JG, 1992, GENETICS, V131, P753; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; LEACH SA, 1966, NATURE, V209, P506, DOI 10.1038/209506a0; Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996; Li KY, 2004, J BACTERIOL, V186, P6800, DOI 10.1128/JB.186.20.6800-6808.2004; LIN ECC, 1996, ESCHERICHIA COLI SAL, P307; LINDAHL L, 1986, ANNU REV GENET, V20, P297; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; MCKAY TL, 1995, PLASMID, V33, P15, DOI 10.1006/plas.1995.1003; McLeod MP, 2004, J BACTERIOL, V186, P5842, DOI 10.1128/JB.186.17.5842-5855.2004; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; Mikamo H, 1999, AM J OBSTET GYNECOL, V180, P378, DOI 10.1016/S0002-9378(99)70217-6; Mikamo H, 1998, AM J OBSTET GYNECOL, V179, P1579, DOI 10.1016/S0002-9378(98)70028-6; Mira A, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-50; Moore W E, 1994, Periodontol 2000, V5, P66, DOI 10.1111/j.1600-0757.1994.tb00019.x; Morris ML, 1996, ORAL MICROBIOL IMMUN, V11, P15, DOI 10.1111/j.1399-302X.1996.tb00331.x; Moszer I, 1999, CURR OPIN MICROBIOL, V2, P524, DOI 10.1016/S1369-5274(99)00011-9; Mrazek J, 1999, ANN NY ACAD SCI, V870, P314, DOI 10.1111/j.1749-6632.1999.tb08893.x; Niederman R, 1997, CRIT REV ORAL BIOL M, V8, P269, DOI 10.1177/10454411970080030301; OZAKI M, 1990, J PERIODONTAL RES, V25, P129, DOI 10.1111/j.1600-0765.1990.tb01034.x; Paster BJ, 2001, J BACTERIOL, V183, P3770, DOI 10.1128/JB.183.12.3770-3783.2001; Philippe H, 2003, CURR OPIN MICROBIOL, V6, P498, DOI 10.1016/j.mib.2003.09.008; Ragan MA, 2001, FEMS MICROBIOL LETT, V201, P187, DOI 10.1111/j.1574-6968.2001.tb10755.x; Ribeiro-Sobrinho AP, 2005, J MED MICROBIOL, V54, P413, DOI 10.1099/jmm.0.45728-0; ROBRISH SA, 1987, J BACTERIOL, V169, P3891, DOI 10.1128/jb.169.9.3891-3897.1987; ROBRISH SA, 1990, J BACTERIOL, V172, P5714, DOI 10.1128/jb.172.10.5714-5723.1990; ROGERS AH, 1991, ORAL MICROBIOL IMMUN, V6, P250, DOI 10.1111/j.1399-302X.1991.tb00486.x; ROGERS AH, 1992, ORAL MICROBIOL IMMUN, V7, P299, DOI 10.1111/j.1399-302X.1992.tb00592.x; Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046; SHENKER BJ, 1995, INFECT IMMUN, V63, P4830, DOI 10.1128/IAI.63.12.4830-4836.1995; Siefert JL, 1997, J MOL EVOL, V45, P467, DOI 10.1007/PL00006251; SUKUPOLVI S, 1990, MICROBIOL REV, V54, P331, DOI 10.1128/MMBR.54.4.331-341.1990; SUZUKI T, 1994, MOL MICROBIOL, V11, P31, DOI 10.1111/j.1365-2958.1994.tb00287.x; TAKADA H, 1988, INFECT IMMUN, V56, P855, DOI 10.1128/IAI.56.4.855-863.1988; Takemoto T, 1997, J CLIN MICROBIOL, V35, P1378, DOI 10.1128/JCM.35.6.1378-1381.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; TUTTLE RS, 1992, ORAL MICROBIOL IMMUN, V7, P78, DOI 10.1111/j.1399-302X.1992.tb00513.x; Ximenez-Fyvie LA, 2000, J CLIN PERIODONTOL, V27, P648, DOI 10.1034/j.1600-051x.2000.027009648.x; Yoshida A, 2005, APPL ENVIRON MICROB, V71, P2372, DOI 10.1128/AEM.71.5.2372-2380.2005; Zhang R, 2004, BIOINFORMATICS, V20, P612, DOI 10.1093/bioinformatics/btg453; Zimmer M, 2002, J BACTERIOL, V184, P4359, DOI 10.1128/JB.184.16.4359-4368.2002	101	49	50	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e659	10.1371/journal.pone.0000659	http://dx.doi.org/10.1371/journal.pone.0000659			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668047	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452300005
J	Garman, R; Rubin, C; Judex, S				Garman, Russell; Rubin, Clinton; Judex, Stefan			Small Oscillatory Accelerations, Independent of Matrix Deformations, Increase Osteoblast Activity and Enhance Bone Morphology	PLOS ONE			English	Article								A range of tissues have the capacity to adapt to mechanical challenges, an attribute presumed to be regulated through deformation of the cell and/or surrounding matrix. In contrast, it is shown here that extremely small oscillatory accelerations, applied as unconstrained motion and inducing negligible deformation, serve as an anabolic stimulus to osteoblasts in vivo. Habitual background loading was removed from the tibiae of 18 female adult mice by hindlimb-unloading. For 20 min/d, 5 d/wk, the left tibia of each mouse was subjected to oscillatory 0.6 g accelerations at 45 Hz while the right tibia served as control. Sham-loaded (n = 9) and normal age-matched control (n = 18) mice provided additional comparisons. Oscillatory accelerations, applied in the absence of weight bearing, resulted in 70% greater bone formation rates in the trabeculae of the metaphysis, but similar levels of bone resorption, when compared to contralateral controls. Quantity and quality of trabecular bone also improved as a result of the acceleration stimulus, as evidenced by a significantly greater bone volume fraction (17%) and connectivity density (33%), and significantly smaller trabecular spacing (-6%) and structural model index (-11%). These in vivo data indicate that mechanosensory elements of resident bone cell populations can perceive and respond to acceleratory signals, and point to an efficient means of introducing intense physical signals into a biologic system without putting the matrix at risk of overloading. In retrospect, acceleration, as opposed to direct mechanical distortion, represents a more generic and safe, and perhaps more fundamental means of transducing physical challenges to the cells and tissues of an organism.	[Garman, Russell; Rubin, Clinton; Judex, Stefan] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Judex, S (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA.	stefan.judex@sunysb.edu			Wallace H. Coulter Foundation; Whitaker Foundation; NASA; NIH	Wallace H. Coulter Foundation; Whitaker Foundation; NASA(National Aeronautics & Space Administration (NASA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding: Financial support from the Wallace H. Coulter Foundation (SJ), Whitaker Foundation (SJ), NASA ( SJ), and NIH (CTR), is gratefully acknowledged. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bacabac RG, 2006, FASEB J, V20, P858, DOI 10.1096/fj.05-4966.com; Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756-3282(96)00028-2; Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021-9290(99)00210-9; FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104; GALILEO G, 1638, DISCORSI DIMONSTRAZI; Garman R, 2007, J ORTHOP RES, V25, P732, DOI 10.1002/jor.20354; Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612; Gross TS, 2002, J BONE MINER RES, V17, P493, DOI 10.1359/jbmr.2002.17.3.493; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Judex S, 2002, FASEB J, V16, P1280, DOI 10.1096/fj.01-0913fje; Judex S, 2004, J BONE MINER RES, V19, P600, DOI 10.1359/JBMR.040101; Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014; Kaab MJ, 1998, J ORTHOP RES, V16, P743, DOI 10.1002/jor.1100160617; LAFORTUNE MA, 1991, J BIOMECH, V24, P877, DOI 10.1016/0021-9290(91)90166-K; MALONE A, 2007, AM J PHYSL CELL PHYS; MCLEOD KJ, 1992, J BONE JOINT SURG AM, V74A, P920, DOI 10.2106/00004623-199274060-00014; Morey-Holton E, 1981, PHYSIOLOGIST, V24, P545; NUNAMAKER DM, 1990, J ORTHOPAED RES, V8, P604, DOI 10.1002/jor.1100080417; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Qin YX, 2003, J BIOMECH, V36, P1427, DOI 10.1016/S0021-9290(03)00127-1; Rubin C, 2002, J BONE MINER RES, V17, P349, DOI 10.1359/jbmr.2002.17.2.349; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756-3282(01)00689-5; Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251; RUBIN CT, 1982, J EXP BIOL, V101, P187; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200; Schaer BLD, 2006, EQUINE VET J, V38, P664, DOI 10.2746/042516406X156389; Spalazzi JP, 2006, J ORTHOP RES, V24, P2001, DOI 10.1002/jor.20260; STEPHENS PR, 1989, AM J VET RES, V50, P1089; TURNER CH, 1994, J BONE MINER RES, V9, P87; Xie LQ, 2006, BONE, V39, P1059, DOI 10.1016/j.bone.2006.05.012; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161	33	51	51	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e653	10.1371/journal.pone.0000653	http://dx.doi.org/10.1371/journal.pone.0000653			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653280	Green Published, gold			2022-12-25	WOS:000207452200022
J	Kelly, KA; Carson, J; McCarthy, JR; Weissleder, R				Kelly, Kimberly A.; Carson, Jonathan; McCarthy, Jason R.; Weissleder, Ralph			Novel Peptide Sequence ("IQ-tag'') with High Affinity for NIR Fluorochromes Allows Protein and Cell Specific Labeling for In Vivo Imaging	PLOS ONE			English	Article								Background. Probes that allow site-specific protein labeling have become critical tools for visualizing biological processes. Methods. Here we used phage display to identify a novel peptide sequence with nanomolar affinity for near infrared (NIR) (benz) indolium fluorochromes. The developed peptide sequence ("IQ-tag'') allows detection of NIR dyes in a wide range of assays including ELISA, flow cytometry, high throughput screens, microscopy, and optical in vivo imaging. Significance. The described method is expected to have broad utility in numerous applications, namely site-specific protein imaging, target identification, cell tracking, and drug development.	[Kelly, Kimberly A.; Carson, Jonathan; McCarthy, Jason R.; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Weissleder, R (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02115 USA.	weissleder@helix.mgh.harvard.edu		/0000-0003-0828-4143	NIH [R24-CA92782, P50-CA86355]; Sandler Foundation; NATIONAL CANCER INSTITUTE [R24CA092782, P50CA086355] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH R24-CA92782 and P50-CA86355, Sandler Foundation (R.W.)	Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Chen I, 2005, CURR OPIN BIOTECH, V16, P35, DOI 10.1016/j.copbio.2004.12.003; Chen I, 2005, NAT METHODS, V2, P99, DOI 10.1038/NMETH735; Farinas J, 1999, J BIOL CHEM, V274, P7603, DOI 10.1074/jbc.274.12.7603; George N, 2004, J AM CHEM SOC, V126, P8896, DOI 10.1021/ja048396s; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; Guignet EG, 2004, NAT BIOTECHNOL, V22, P440, DOI 10.1038/nbt954; Keppler A, 2004, P NATL ACAD SCI USA, V101, P9955, DOI 10.1073/pnas.0401923101; Lisenbee CS, 2003, TRAFFIC, V4, P491, DOI 10.1034/j.1600-0854.2003.00107.x; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Montet X, 2005, CANCER RES, V65, P6330, DOI 10.1158/0008-5472.CAN-05-0382; Ntziachristos V, 2005, NAT BIOTECHNOL, V23, P313, DOI 10.1038/nbt1074; Panchal RG, 2003, P NATL ACAD SCI USA, V100, P15936, DOI 10.1073/pnas.2533915100; SASSO SP, 1994, BBA-PROTEIN STRUCT M, V1207, P74, DOI 10.1016/0167-4838(94)90053-1; Stroffekova K, 2001, PFLUG ARCH EUR J PHY, V442, P859, DOI 10.1007/s004240100619; Tannous BA, 2006, NAT METHODS, V3, P391, DOI 10.1038/NMETH875; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Wilson DS, 2001, P NATL ACAD SCI USA, V98, P3750, DOI 10.1073/pnas.061028198; Yin J, 2004, J AM CHEM SOC, V126, P7754, DOI 10.1021/ja047749k	19	17	18	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e665	10.1371/journal.pone.0000665	http://dx.doi.org/10.1371/journal.pone.0000665			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653285	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452200027
J	Villard, V; Agak, GW; Frank, G; Jafarshad, A; Servis, C; Nebie, I; Sirima, SB; Felger, I; Arevalo-Herrera, M; Herrera, S; Heitz, F; Backer, V; Druilhe, P; Kajava, AV; Corradin, G				Villard, Viviane; Agak, George W.; Frank, Geraldine; Jafarshad, Ali; Servis, Catherine; Nebie, Issa; Sirima, Sodiomon B.; Felger, Ingrid; Arevalo-Herrera, Myriam; Herrera, Socrates; Heitz, Frederic; Baecker, Volker; Druilhe, Pierre; Kajava, Andrey V.; Corradin, Giampietro			Rapid Identification of Malaria Vaccine Candidates Based on alpha-Helical Coiled Coil Protein Motif	PLOS ONE			English	Article								To identify malaria antigens for vaccine development, we selected alpha-helical coiled coil domains of proteins predicted to be present in the parasite erythrocytic stage. The corresponding synthetic peptides are expected to mimic structurally "native" epitopes. Indeed the 95 chemically synthesized peptides were all specifically recognized by human immune sera, though at various prevalence. Peptide specific antibodies were obtained both by affinity-purification from malaria immune sera and by immunization of mice. These antibodies did not show significant cross reactions, i.e., they were specific for the original peptide, reacted with native parasite proteins in infected erythrocytes and several were active in inhibiting in vitro parasite growth. Circular dichroism studies indicated that the selected peptides assumed partial or high alpha-helical content. Thus, we demonstrate that the bioinformatics/chemical synthesis approach described here can lead to the rapid identification of molecules which target biologically active antibodies, thus identifying suitable vaccine candidates. This strategy can be, in principle, extended to vaccine discovery in a wide range of other pathogens.	[Villard, Viviane; Agak, George W.; Frank, Geraldine; Servis, Catherine; Corradin, Giampietro] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; [Jafarshad, Ali; Druilhe, Pierre] Inst Pasteur, Paris, France; [Nebie, Issa; Sirima, Sodiomon B.] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso; [Felger, Ingrid] Swiss Trop Inst, CH-4002 Basel, Switzerland; [Arevalo-Herrera, Myriam; Herrera, Socrates] Univ Valle, Inst Immunol, Cali, Colombia; [Heitz, Frederic; Baecker, Volker; Kajava, Andrey V.] Univ Montpellier, CNRS, CRBM, F-34059 Montpellier, France	University of Lausanne; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Basel; Swiss Tropical & Public Health Institute; Universidad del Valle; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Corradin, G (corresponding author), Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.	giampietro.corradin@unil.ch	Agak, George/AAN-2246-2021; Baecker, Volker/AFT-9035-2022; Kajava, Andrey V/E-1107-2014	Kajava, Andrey V/0000-0002-2342-6886; Agak, George/0000-0002-3356-9864; Felger, Ingrid/0000-0003-1255-2606; Nebie, Issa/0000-0003-3051-3600; SIRIMA, Sodiomon Bienvenu/0000-0002-0972-4211	Swiss National Science Foundation [310000-112244]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Funding: The work was supported by the Swiss National Science Foundation grant 310000-112244.	ALPERS MP, 1992, PAPUA NEW GUINEA MED, V35, P285; Audran R, 2005, INFECT IMMUN, V73, P8017, DOI 10.1128/IAI.73.12.8017-8026.2005; Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Betts JC, 2002, IUBMB LIFE, V53, P239, DOI 10.1080/15216540212651; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Cooke BM, 2006, J CELL BIOL, V172, P899, DOI 10.1083/jcb.200509122; Cooper JA, 1997, MOL IMMUNOL, V34, P433, DOI 10.1016/S0161-5890(97)00056-4; Daubersies P, 2000, NAT MED, V6, P1258, DOI 10.1038/81366; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; FIDOCK DA, 1994, J IMMUNOL, V153, P190; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Guda C, 2005, BIOINFORMATICS, V21, P3963, DOI 10.1093/bioinformatics/bti650; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Hofmann K., 1993, BIOL CHEM HOPPESEYLE, V374; Jafarshad A, 2007, J IMMUNOL, V178, P3099, DOI 10.4049/jimmunol.178.5.3099; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7&lt;1989::AID-IMMU1989&gt;3.0.CO;2-M; Lu SM, 2002, J BIOL CHEM, V277, P23515, DOI 10.1074/jbc.M201981200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Merino EF, 2006, MOL BIOCHEM PARASIT, V149, P10, DOI 10.1016/j.molbiopara.2006.04.002; MOELANS IIMD, 1992, PARASITOL TODAY, V8, P118, DOI 10.1016/0169-4758(92)90278-A; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Rappuoli R, 2003, SCIENCE, V302, P602, DOI 10.1126/science.1092329; Singh S, 2005, INFECT IMMUN, V73, P1235, DOI 10.1128/IAI.73.2.1235-1238.2005; STOUTE JA, 2005, VACCINE; Tripet B, 2006, J STRUCT BIOL, V155, P176, DOI 10.1016/j.jsb.2006.03.019; Vincensini L, 2005, MOL CELL PROTEOMICS, V4, P582, DOI 10.1074/mcp.M400176-MCP200	33	55	116	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e645	10.1371/journal.pone.0000645	http://dx.doi.org/10.1371/journal.pone.0000645			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653272	Green Published, gold			2022-12-25	WOS:000207452200014
J	Henderson, GP; Gan, L; Jensen, GJ				Henderson, Gregory P.; Gan, Lu; Jensen, Grant J.			3-D Ultrastructure of O. tauri: Electron Cryotomography of an Entire Eukaryotic Cell	PLOS ONE			English	Article							NUCLEAR-PORE COMPLEX; MITOCHONDRIAL INNER MEMBRANE; CRYOELECTRON TOMOGRAPHY; 3-DIMENSIONAL STRUCTURE; ARCHITECTURE; MICROSCOPY; ORGANIZATION; DYNAMICS; MAGNETOSOMES; CHLOROPHYTA	The hallmark of eukaryotic cells is their segregation of key biological functions into discrete, membrane-bound organelles. Creating accurate models of their ultrastructural complexity has been difficult in part because of the limited resolution of light microscopy and the artifact-prone nature of conventional electron microscopy. Here we explored the potential of the emerging technology electron cryotomography to produce three-dimensional images of an entire eukaryotic cell in a near-native state. Ostreococcus tauri was chosen as the specimen because as a unicellular picoplankton with just one copy of each organelle, it is the smallest known eukaryote and was therefore likely to yield the highest resolution images. Whole cells were imaged at various stages of the cell cycle, yielding 3-D reconstructions of complete chloroplasts, mitochondria, endoplasmic reticula, Golgi bodies, peroxisomes, microtubules, and putative ribosome distributions in-situ. Surprisingly, the nucleus was seen to open long before mitosis, and while one microtubule (or two in some predivisional cells) was consistently present, no mitotic spindle was ever observed, prompting speculation that a single microtubule might be sufficient to segregate multiple chromosomes.	[Henderson, Gregory P.; Gan, Lu; Jensen, Grant J.] CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Jensen, GJ (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	jensen@caltech.edu	Gan, Lu/F-8317-2011	Gan, Lu/0000-0002-8685-4896	NIH [R01 AI067548, PO1 GM66521]; DOE [DE-FG02-04ER63785]; Searle Scholar Award; Beckman Institute at Caltech; Damon Runyon Cancer Research Foundation [DRG-194007]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066521] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOE(United States Department of Energy (DOE)); Searle Scholar Award; Beckman Institute at Caltech; Damon Runyon Cancer Research Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH grants R01 AI067548 and PO1 GM66521 and DOE grant DE-FG02-04ER63785 to GJJ, a Searle Scholar Award to GJJ, the Beckman Institute at Caltech, and gifts to Caltech from the Gordon and Betty Moore Foundation and Agouron Institute. Lu Gan was supported by a fellowship from the Damon Runyon Cancer Research Foundation (DRG-194007). These sponsors/funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; Al-Amoudi A, 2004, EMBO J, V23, P3583, DOI 10.1038/sj.emboj.7600366; Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808; Briegel A, 2006, MOL MICROBIOL, V62, P5, DOI 10.1111/j.1365-2958.2006.05355.x; Caviston JP, 2006, TRENDS CELL BIOL, V16, P530, DOI 10.1016/j.tcb.2006.08.002; CHRETIENNOTDINET MJ, 1995, PHYCOLOGIA, V34, P285, DOI 10.2216/i0031-8884-34-4-285.1; Comolli LR, 2005, J STRUCT BIOL, V152, P149, DOI 10.1016/j.jsb.2005.08.004; COURTIES C, 1994, NATURE, V370, P255, DOI 10.1038/370255a0; Courties C, 1998, J PHYCOL, V34, P844, DOI 10.1046/j.1529-8817.1998.340844.x; Derelle E, 2006, P NATL ACAD SCI USA, V103, P11647, DOI 10.1073/pnas.0604795103; Drummond SP, 2006, CAN J PHYSIOL PHARM, V84, P423, DOI 10.1139/Y05-148; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Farinas B, 2006, PLANT MOL BIOL, V60, P277, DOI 10.1007/s11103-005-4066-1; Frangakis AS, 2002, P NATL ACAD SCI USA, V99, P14153, DOI 10.1073/pnas.172520299; Frangakis AS, 2001, J STRUCT BIOL, V135, P239, DOI 10.1006/jsbi.2001.4406; Gaietta GM, 2006, P NATL ACAD SCI USA, V103, P17777, DOI 10.1073/pnas.0608509103; Grimm R, 1997, BIOPHYS J, V72, P482, DOI 10.1016/S0006-3495(97)78689-2; Guillard R.R.L., 1975, CULTURE MARINE INVER, P29, DOI [10.1007/978-1-4615-8714-9_3, DOI 10.1007/978-1-4615-8714-9_3]; Henderson GP, 2006, MOL MICROBIOL, V60, P376, DOI 10.1111/j.1365-2958.2006.05113.x; Heymann JB, 2006, J STRUCT BIOL, V153, P312, DOI 10.1016/j.jsb.2005.11.012; Hoog JL, 2007, DEV CELL, V12, P349, DOI 10.1016/j.devcel.2007.01.020; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Iancu CV, 2006, NAT PROTOC, V1, P2813, DOI 10.1038/nprot.2006.432; Iancu CV, 2005, J STRUCT BIOL, V151, P288, DOI 10.1016/j.jsb.2005.07.004; Jensen GJ, 2007, CURR OPIN STRUC BIOL, V17, P260, DOI 10.1016/j.sbi.2007.03.002; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; Komeili A, 2006, SCIENCE, V311, P242, DOI 10.1126/science.1123231; Kurner J, 2005, SCIENCE, V307, P436, DOI 10.1126/science.1104031; Leong PA, 2005, STRUCTURE, V13, P505, DOI 10.1016/j.str.2005.01.015; Lucic V, 2005, ANNU REV BIOCHEM, V74, P833, DOI 10.1146/annurev.biochem.73.011303.074112; Mannella CA, 2006, BBA-MOL BASIS DIS, V1762, P140, DOI 10.1016/j.bbadis.2005.07.001; MANNELLA CA, 1994, MICROSC RES TECHNIQ, V27, P278, DOI 10.1002/jemt.1070270403; Mannella CA, 2001, IUBMB LIFE, V52, P93, DOI 10.1080/15216540152845885; Mannella CA, 2006, BBA-MOL CELL RES, V1763, P542, DOI 10.1016/j.bbamcr.2006.04.006; Marko M, 2007, NAT METHODS, V4, P215, DOI 10.1038/nmeth1014; Mastronarde DN, 1997, J STRUCT BIOL, V120, P343, DOI 10.1006/jsbi.1997.3919; McDonald KL, 2006, BIOTECHNIQUES, V41, P137, DOI 10.2144/000112226; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Mullen RT, 2006, BBA-MOL CELL RES, V1763, P1655, DOI 10.1016/j.bbamcr.2006.09.011; Nevo R, 2007, EMBO J, V26, P1467, DOI 10.1038/sj.emboj.7601594; Nicastro D, 2000, J STRUCT BIOL, V129, P48, DOI 10.1006/jsbi.1999.4204; Palenik B, 2007, P NATL ACAD SCI USA, V104, P7705, DOI 10.1073/pnas.0611046104; Perkins G, 1997, J STRUCT BIOL, V119, P260, DOI 10.1006/jsbi.1997.3885; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Ral JP, 2004, PLANT PHYSIOL, V136, P3333, DOI 10.1104/pp.104.044131; Robbens S, 2005, MOL BIOL EVOL, V22, P589, DOI 10.1093/molbev/msi044; Scheffel A, 2006, NATURE, V440, P110, DOI 10.1038/nature04382; Shibata Y, 2006, CELL, V126, P435, DOI 10.1016/j.cell.2006.07.019; Shimoni E, 2005, PLANT CELL, V17, P2580, DOI 10.1105/tpc.105.035030; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; Stoffler D, 2003, J MOL BIOL, V328, P119, DOI 10.1016/S0022-2836(03)00266-3; STOPPIN V, 1994, PLANT CELL, V6, P1099, DOI 10.1105/tpc.6.8.1099; Storrie B, 2002, TRAFFIC, V3, P521, DOI 10.1034/j.1600-0854.2002.30802.x; Subramaniam S, 2004, ANNU REV BIOPH BIOM, V33, P141, DOI 10.1146/annurev.biophys.33.110502.140339; Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010; van de Meene AML, 2006, ARCH MICROBIOL, V184, P259, DOI 10.1007/s00203-005-0027-y; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Vothknecht UC, 2001, BBA-MOL CELL RES, V1541, P91, DOI 10.1016/S0167-4889(01)00153-7; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wright ER, 2006, J STRUCT BIOL, V153, P241, DOI 10.1016/j.jsb.2005.12.003; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Yoon HS, 2004, MOL BIOL EVOL, V21, P809, DOI 10.1093/molbev/msh075; Zadrag R, 2006, ACTA BIOCHIM POL, V53, P747, DOI 10.18388/abp.2006_3302; Zheng QXS, 2004, J STRUCT BIOL, V147, P91, DOI 10.1016/j.jsb.2004.02.005	65	101	102	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e749	10.1371/journal.pone.0000749	http://dx.doi.org/10.1371/journal.pone.0000749			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710148	Green Published, Green Accepted, Green Submitted, gold			2022-12-25	WOS:000207455200025
J	Spiers, AJ				Spiers, Andrew J.			Wrinkly-Spreader Fitness in the Two-Dimensional Agar Plate Microcosm: Maladaptation, Compensation and Ecological Success	PLOS ONE			English	Article								Bacterial adaptation to new environments often leads to the establishment of new genotypes with significantly altered phenotypes. In the Wrinkly Spreader (WS), ecological success in static liquid microcosms was through the rapid colonisation of the air-liquid interface by the production of a cellulose-based biofilm. Rapid surface spreading was also seen on agar plates, but in this two-dimensional environment the WS appears maladapted and rapidly reverts to the ancestral smooth (SM)-like colony genotype. In this work, the fitness of WS relative to SM in mixed colonies was found to be low, confirming the WS instability on agar plates. By examining defined WS mutants, the maladaptive characteristic was found to be the expression of cellulose. SM-like revertants had a higher growth rate than WS and no longer expressed significant amounts of cellulose, further confirming that the expression of this high-cost polymer was the basis of maladaptation and the target of compensatory mutation in developing colonies. However, examination of the fate of WS-founded populations in either multiple-colony or single mega-colony agar plate microcosms demonstrated that the loss of WS lineages could be reduced under conditions in which the rapid spreading colony phenotype could dominate nutrient and oxygen access more effectively than competing SM/SM-like genotypes. WS-like isolates recovered from such populations showed increased WS phenotype stability as well as changes in the degree of colony spreading, confirming that the WS was adapting to the two-dimensional agar plate microcosm.	[Spiers, Andrew J.] Univ Oxford, Dept Plant Sci, Oxford, England	University of Oxford	Spiers, AJ (corresponding author), Univ Abertay Dundee, Scottish Informat Math Biol & Stat Ctr, Dundee, Scotland.	a.spiers@abertay.ac.uk	Spiers, Andrew/I-3535-2012	Spiers, Andrew/0000-0003-0463-8629	Department of Plant Sciences, University of Oxford; SIMBIOS Centre, University of Abertay Dundee	Department of Plant Sciences, University of Oxford; SIMBIOS Centre, University of Abertay Dundee	Support for this research came from the Department of Plant Sciences, University of Oxford, and the SIMBIOS Centre, University of Abertay Dundee.	Bailey MJ, 1995, MOL ECOL, V4, P755, DOI 10.1111/j.1365-294X.1995.tb00276.x; Bantinaki E, 2007, GENETICS, V176, P441, DOI 10.1534/genetics.106.069906; Ben-Jacob E, 2003, PHILOS T R SOC A, V361, P1283, DOI 10.1098/rsta.2003.1199; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; D'Argenio DA, 2004, MICROBIOL-SGM, V150, P2497, DOI 10.1099/mic.0.27099-0; D'Argenio DA, 2002, J BACTERIOL, V184, P6481, DOI 10.1128/JB.184.23.6481-6489.2002; Elena SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/nrg1088; Fux CA, 2005, TRENDS MICROBIOL, V13, P58, DOI 10.1016/j.tim.2004.11.001; Goymer P, 2006, GENETICS, V173, P515, DOI 10.1534/genetics.106.055863; GOYMER PJ, 2002, THESIS U OXFORD; Grondin A, 1999, ARCH MICROBIOL, V172, P59, DOI 10.1007/s002030050740; HAMILTON WD, 1977, NATURE, V269, P578, DOI 10.1038/269578a0; Jenal U, 2004, CURR OPIN MICROBIOL, V7, P185, DOI 10.1016/j.mib.2004.02.007; KING EO, 1954, J LAB CLIN MED, V44, P301; Knight CG, 2006, NAT GENET, V38, P1015, DOI 10.1038/ng1867; KORONA R, 1994, P NATL ACAD SCI USA, V91, P9037, DOI 10.1073/pnas.91.19.9037; Krebs JR, 1993, INTRO BEHAV ECOLOGY; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1995, SYMP SOC GEN MICROBI, V52, P193; MacLean RC, 2004, P NATL ACAD SCI USA, V101, P8072, DOI 10.1073/pnas.0307195101; Miller J.H., 1972, EXPT MOL GENETICS; Rainey PB, 2000, TRENDS ECOL EVOL, V15, P243, DOI 10.1016/S0169-5347(00)01871-1; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rainey PB, 1996, MOL MICROBIOL, V19, P521, DOI 10.1046/j.1365-2958.1996.391926.x; ROBINSON TP, 1991, J GEN MICROBIOL, V137, P2885, DOI 10.1099/00221287-137-12-2885; Sambrook J., 2002, MOL CLONING LAB MANU; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; SHAPIRO JA, 1995, BIOESSAYS, V17, P597, DOI 10.1002/bies.950170706; Spiers AJ, 2002, GENETICS, V161, P33; Spiers AJ, 2003, MOL MICROBIOL, V50, P15, DOI 10.1046/j.1365-2958.2003.03670.x; Spiers AJ, 2005, MICROBIOL-SGM, V151, P2829, DOI 10.1099/mic.0.27984-0; Ude S, 2006, ENVIRON MICROBIOL, V8, P1997, DOI 10.1111/j.1462-2920.2006.01080.x; WIMPENNY JWT, 1983, J GEN MICROBIOL, V129, P1239	33	9	10	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e740	10.1371/journal.pone.0000740	http://dx.doi.org/10.1371/journal.pone.0000740			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710140	Green Submitted, Green Published, gold			2022-12-25	WOS:000207455200017
J	Fu, YN; Yeh, CL; Cheng, HY; Yang, CH; Tsai, SF; Huang, SF; Chen, YR				Fu, Y-N; Yeh, C-L; Cheng, Hh-Y; Yang, C-H; Tsai, S-F; Huang, S-F; Chen, Y-R			EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy	ONCOGENE			English	Article						EGFR; mutation; src; inhibitor; tyrosine phosphorylation	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; C-SRC; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; MUTATIONS; DOMAIN; ACTIVATION; PATTERNS; COMPLEX	Mutations in epidermal growth factor receptor (EGFR) kinase domain associate with clinical responses to EGFR inhibitors and are frequently observed in non-small cell lung cancer (NSCLC) patients in East Asian populations. Clinically identified EGFR mutations cause constitutive receptor activation. The activating mechanisms were unclear but appeared to be different among EGFR mutants. We found that EGFR mutants had different sensitivity to an Src inhibitor PP2. S768I and L861Q mutants were less sensitive to Src suppression than others. Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. In contrast, cells expressing EGFR-L858R or exon 19 deletion mutants were more sensitive to PP2 than cells expressing wild-type EGFR. Interestingly, EGFR with exon 19-deletion/T790M double mutations, which was resistant to gefitinib, remained sensitive to PP2. Taken together, our data indicate that Src inhibitors might be effective in treating NSCLC harboring specific types of EGFR mutations.	[Fu, Y-N; Yeh, C-L; Cheng, Hh-Y; Yang, C-H; Tsai, S-F; Huang, S-F; Chen, Y-R] Natl Hlth Res Inst, Div Mol Genom Med, Zhunan Town 350, Miaoli Cty, Taiwan; [Tsai, S-F] Natl Yang Ming Univ, Inst Genet Genome Res Ctr, Taipei 112, Taiwan; [Huang, S-F] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital	Chen, YR (corresponding author), Natl Hlth Res Inst, Div Mol Genom Med, 35 Keyan Rd, Zhunan Town 350, Miaoli Cty, Taiwan.	yrchen@nhri.org.tw	Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/CAF-2186-2022; Tsai, Shih-Feng/E-3997-2010; Chen, Yi-Rong/E-3991-2010; Huang, Shiu-Feng Kathy/E-3977-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; 				Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herbst RS, 2003, CLIN CANCER RES, V9, P5813; Hsieh MH, 2006, LUNG CANCER-J IASLC, V53, P311, DOI 10.1016/j.lungcan.2006.06.005; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	26	32	34	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					957	965		10.1038/sj.onc.1210684	http://dx.doi.org/10.1038/sj.onc.1210684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17653080				2022-12-25	WOS:000252946300007
J	Jones, L; Tilli, MT; Assefnia, S; Torre, K; Halama, ED; Parrish, A; Rosen, EM; Furth, PA				Jones, L. P.; Tilli, M. T.; Assefnia, S.; Torre, K.; Halama, E. D.; Parrish, A.; Rosen, E. M.; Furth, P. A.			Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ER alpha-negative and ER alpha-positive mammary preneoplasia and cancer	ONCOGENE			English	Article						breast cancer; mouse model; brca1; estrogen; ER alpha	INSULIN-RECEPTOR SUBSTRATE-2; SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; EPITHELIAL-CELLS; TRANSGENIC MICE; MOUSE MODEL; DUCTAL MORPHOGENESIS; TUMOR-FORMATION; GROWTH; PROGESTERONE	BRCA1 can regulate estrogen receptor-alpha (ER alpha) activity. This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that exposure to increased estrogen or ER alpha collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Longer ductal extension was found in mammary glands of Brca1(f/f;MMTV-Cre) mice during puberty as compared to wild-type mice. Terminal end bud differentiation was impaired in Brca1 mutant mice with preservation of prolactin-induced alveolar differentiation. Exogenous estrogen stimulated an abnormal sustained increase in mammary epithelial cell proliferation and the appearance of ER alpha-negative preneoplasia in postpubertal Brca1 mutant mice. Carcinogenesis was investigated using Brca1(f/f;MMTV-Cre) mice hemizygous for p53. Exogenous estrogen increased the percentage of mice with multiple hyperplastic alveolar nodules. Targeted conditional ER alpha overexpression in mammary epithelial cells of mice that were Brca1 mutant and hemizygous for p53 increased the percentage of mice exhibiting multiple hyperplastic nodules, invasive mammary cancers and cancer multiplicity. Significantly more than half of the preneoplasia and cancers were ER alpha negative even as their initiation was promoted by ER alpha overexpression.	[Jones, L. P.; Tilli, M. T.; Assefnia, S.; Torre, K.; Halama, E. D.; Parrish, A.; Rosen, E. M.; Furth, P. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Furth, PA (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.	paf3@georgetown.edu			DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005024] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112176, T32CA009686] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112176-05, T32 CA009686, R01 CA112176, 2T32CA09686-08, N01-CN-05024, R01CA08000] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Bachelier R, 2005, ONCOL REP, V14, P1117; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Cui XJ, 2003, ONCOGENE, V22, P6937, DOI 10.1038/sj.onc.1206803; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Decensi A, 2003, J MAMMARY GLAND BIOL, V8, P19, DOI 10.1023/A:1025779120649; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; El Etreby MF, 1998, BREAST CANCER RES TR, V51, P149, DOI 10.1023/A:1006078032287; Fan SJ, 2002, CANCER RES, V62, P141; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Frech MS, 2005, CANCER RES, V65, P681; FRECH MS, 2005, BREAST CANC ONLINE, V8; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022; Ginsburg E., 2000, METHODS MAMMARY GLAN, P147; Grimm SL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1520; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Krzysiek Jozef, 2003, Ginekol Pol, V74, P767; Liang YY, 2003, INT J ONCOL, V23, P369; Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milewicz T, 2005, GROWTH HORM IGF RES, V15, P140, DOI 10.1016/j.ghir.2004.12.006; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Raafat AM, 1999, ENDOCRINOLOGY, V140, P2570, DOI 10.1210/en.140.6.2570; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360; Shukla V, 2006, CANCER RES, V66, P7151, DOI 10.1158/0008-5472.CAN-05-4570; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	39	47	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					794	802		10.1038/sj.onc.1210674	http://dx.doi.org/10.1038/sj.onc.1210674			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653086	Green Accepted			2022-12-25	WOS:000252884500008
J	Han, SU; Kwak, TH; Her, KH; Cho, YH; Choi, C; Lee, HJ; Hong, S; Park, YS; Kim, YS; Kim, TA; Kim, SJ				Han, S-U; Kwak, T-H; Her, K. H.; Cho, Y-H; Choi, C.; Lee, H-J; Hong, S.; Park, Y. S.; Kim, Y-S; Kim, T-A; Kim, S-J			CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling	ONCOGENE			English	Article						carcinoembryonic antigen; TGF-beta; Smad3; gastric cancer	BILIARY GLYCOPROTEIN CD66A; CELL-ADHESION MOLECULE-1; HUMAN-TUMOR-MARKER; CARCINOEMBRYONIC ANTIGEN; CEA FAMILY; EXPRESSION; SMAD3; CANCER; TUMORIGENICITY; INHIBITOR	The carcinoembryonic antigen (CEAs) family consists of a large group of evolutionarily and structurally divergent glycoproteins. The transforming growth factor-beta (TGF-beta) signaling pathway has been implicated in the stimulation of CEA secretion in TGF-beta-sensitive colon cells, thereby possibly modulating cell adhesion and differentiation. However, the specific CEAs targeted by TGF-beta signaling or underlying mechanism of the expression of CEAs has not yet been clarified. In this study, we investigated the specific CEAs targeted by the TGF-beta signaling pathway. In nine human gastric cancer cell lines examined, TGF-beta-responsive cell lines showed positive expression of CEAs. Expression patterns of CEA proteins correlated well with the level of CEA (CEACAM5) and CEACAM6 transcripts in these cell lines, but CEACAM1 expression was not observed in all of these cells. To investigate the role of TGF-beta signaling in CEA expression, we selected two TGF-beta unresponsive gastric cancer cell lines; SNU638 cells that contain a mutation in the TGF-beta type II receptor and SNU484 cells that express low to undetectable level of the TGF-beta pathway intermediate protein, Smad3. Restoration of TGF-beta signaling in these cells induced expression of the CEAs and increased activity of both CEA (CEACAM5) and CEACAM6 promoters. CEA expression was observed in the epithelium of the stomach of wild-type mice, but was markedly decreased in Smad3 null mice. These findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.	[Han, S-U; Kwak, T-H; Her, K. H.; Cho, Y-H; Choi, C.; Lee, H-J; Hong, S.; Park, Y. S.; Kim, T-A; Kim, S-J] Natl Canc Inst, Lab Canc Biol & Genet, Natl Inst Hlth, Bethesda, MD 20892 USA; [Lee, H-J] KRIBB, Div Mol Therapeut, Taejon, South Korea; [Kim, Y-S] Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea; [Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Hanyang University; Gachon University	Kim, SJ (corresponding author), Natl Canc Inst, Lab Canc Biol & Genet, Natl Inst Hlth, Bldg 37,Room 5046D,900 Rockville Pike, Bethesda, MD 20892 USA.	kims@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bessa X, 2002, GASTROENTEROLOGY, V122, P1122, DOI 10.1053/gast.2002.32369; CHAKRABARTY S, 1998, CANCER RES, V48, P4059; Chang J, 1997, CANCER RES, V57, P2856; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang J, 1999, J CELL SCI, V112, P4193; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; KAMMERER R, 1994, INT J CANCER, V57, P341, DOI 10.1002/ijc.2910570309; Kammerer R, 2001, J IMMUNOL, V166, P6537, DOI 10.4049/jimmunol.166.11.6537; Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim DY, 2000, J SURG ONCOL, V74, P185, DOI 10.1002/1096-9098(200007)74:3<185::AID-JSO4>3.3.CO;2-S; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; Massague J, 2000, GENE DEV, V14, P627; MYEROFF LL, 1995, CANCER RES, V55, P5545; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Ordonez C, 2000, CANCER RES, V60, P3419; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zimmermann W, 1998, CELL ADHES COMMUN S, V5, P31	33	39	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					675	683		10.1038/sj.onc.1210686	http://dx.doi.org/10.1038/sj.onc.1210686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17653079				2022-12-25	WOS:000252674900011
J	Zigrino, P; Steiger, J; Fox, JW; Loffek, S; Schild, A; Nischt, R; Mauch, C				Zigrino, Paola; Steiger, Julia; Fox, Jay W.; Loeffek, Stefanie; Schild, Alexander; Nischt, Roswitha; Mauch, Cornelia			Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRIN; MATRIX METALLOPROTEINASES; CELL-CELL; INTEGRIN; EXPRESSION; PROTEIN; ADHESION; BINDING; HACAT; MDC9	ADAM-9 belongs to a family of transmembrane, disintegrin-containing metalloproteinases involved in protein ectodomain shedding and cell-cell and cell-matrix interactions. The aim of this study was to analyze the expression of ADAM-9 in skin and to assess the role of this proteolytic/adhesive protein in skin physiology. In normal skin, ADAM-9expression was detected in both the epidermis and dermis and in vitro in keratinocytes and fibroblasts. Here we report that ADAM-9 functions as a cell adhesion molecule via its disintegrin-cysteine-rich domain. Using solid phase binding assays and antibody inhibition experiments, we demonstrated that the recombinant disintegrin-cysteine-rich domain of ADAM-9 specifically interacts with the beta 1 integrin subunit on keratinocytes. This was corroborated by co-immunoprecipitation. In addition, engagement of integrin receptors by the disintegrin-cysteine-rich domain resulted in ERK phosphorylation and increased MMP-9 synthesis. Treatment with the ERK inhibitor PD98059 inhibited MMP-9 induction. Furthermore, the presence of the soluble disintegrin-cysteine-rich domain did not interfere with cell migration on different substrates. However, keratinocytes adhering to the immobilized disintegrin-cysteine-rich domain showed increased motility, which was partially due to the induction of MMP-9 secretion. In summary, our results indicate that the ADAM-9 adhesive domain plays a role in regulating the motility of cells by interaction with beta 1 integrins and modulates MMP synthesis.	Univ Cologne, Dept Dermatol, D-50937 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50937 Cologne, Germany; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Bonn, Inst Phys Chem, D-53115 Bonn, Germany	University of Cologne; University of Cologne; University of Virginia; University of Bonn	Zigrino, P (corresponding author), Univ Cologne, Dept Dermatol, Kerpener Str 62, D-50937 Cologne, Germany.	Paola.Zigrino@uni-koeln.de		Zigrino, Paola/0000-0002-7470-0064				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; BREITKREUTZ D, 1993, DIFFERENTIATION, V54, P201, DOI 10.1111/j.1432-0436.1993.tb01602.x; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Holvoet S, 2003, EXP CELL RES, V290, P108, DOI 10.1016/S0014-4827(03)00293-3; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huang J, 2005, MOL BIOL CELL, V16, P4982, DOI 10.1091/mbc.E05-03-0258; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kamiguti AS, 1998, BRAZ J MED BIOL RES, V31, P853, DOI 10.1590/S0100-879X1998000700001; Kim MH, 2000, J IMMUNOL, V164, P5883, DOI 10.4049/jimmunol.164.11.5883; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; Lafuste P, 2005, MOL BIOL CELL, V16, P861, DOI 10.1091/mbc.e04-03-0226; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LARJAVA H, 1991, AM J MED SCI, V301, P63, DOI 10.1097/00000441-199101000-00012; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; O'Shea C, 2003, INT J CANCER, V105, P754, DOI 10.1002/ijc.11161; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Schlondorff J, 1999, J CELL SCI, V112, P3603; Smyth N, 2000, METH MOL B, V139, P49; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Tousseyn Thomas, 2006, Birth Defects Research, V78, P24, DOI 10.1002/bdrc.20066; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhou M, 2001, BIOCHEM BIOPH RES CO, V280, P574, DOI 10.1006/bbrc.2000.4155; Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	42	45	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30785	30793		10.1074/jbc.M701658200	http://dx.doi.org/10.1074/jbc.M701658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704059	hybrid			2022-12-25	WOS:000250136300047
J	Daugherty, BL; Ward, C; Smith, T; Ritzenthaler, JD; Koval, M				Daugherty, Brandy L.; Ward, Christina; Smith, Tekla; Ritzenthaler, Jeffrey D.; Koval, Michael			Regulation of heterotypic claudin compatibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; EPITHELIAL-CELLS; PERMEABILITY BARRIER; OCCLUDIN; DOMAINS; MICE; MODULATION; EXPRESSION; PEPTIDE; COMPLEX	Tissue barrier function is directly mediated by tight junction transmembrane proteins known as claudins. Cells that form tight junctions typically express multiple claudin isoforms which suggests that heterotypic (head-to-head) binding between different claudin isoforms may play a role in regulating paracellular permeability. However, little is known about motifs that control heterotypic claudin compatibility. We found that although claudin-3 and claudin-4 were heteromerically compatible when expressed in the same cell, they did not heterotypically interact despite having extracellular loop (EL) domains that are highly conserved at the amino acid level. Claudin-1 and -5, which were heterotypically compatible with claudin-3, did not heterotypically bind to claudin-4. In contrast, claudin-4 chimeras containing either the first EL domain or the second EL domain of claudin-3 were able to heterotypically bind to claudin-1, claudin-3, and claudin-5. Moreover, a single point mutation in the first extracellular loop domain of claudin-3 to convert Asn(44) to the corresponding amino acid in claudin-4 (Thr) produced a claudin capable of heterotypic binding to claudin-4 while still retaining the ability to bind to claudin-1 and -5. Thus, control of heterotypic claudin-claudin interactions is sensitive to small changes in the EL domains.	Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA	Emory University	Koval, M (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	mhkoval@emory.edu	Koval, Michael/C-6366-2015	Koval, Michael/0000-0002-5422-5614	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083120, P01HL019737] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL019737-300018, HL083120, P01-HL019737-26, P01 HL019737, R01 HL083120, R01 HL083120-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandre MD, 2005, J CELL SCI, V118, P2683, DOI 10.1242/jcs.02406; Amasheh S, 2005, CELL TISSUE RES, V321, P89, DOI 10.1007/s00441-005-1101-0; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Colegio OR, 2003, AM J PHYSIOL-CELL PH, V284, pC1346, DOI 10.1152/ajpcell.00547.2002; Coyne CB, 2003, AM J PHYSIOL-LUNG C, V285, pL1166, DOI 10.1152/ajplung.00182.2003; Das Sarma J, 2005, CELL COMMUN ADHES, V12, P237, DOI 10.1080/15419060500511875; Everett RS, 2006, MOL PHARMACOL, V69, P492, DOI 10.1124/mol.105.017251; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Haubrich S, 1996, MOL BIOL CELL, V7, P1995, DOI 10.1091/mbc.7.12.1995; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hou JH, 2005, J CELL SCI, V118, P5109, DOI 10.1242/jcs.02631; Kojima S, 2002, J MEMBRANE BIOL, V186, P81, DOI 10.1007/s00232-001-0137-7; Koval M, 2006, CELL COMMUN ADHES, V13, P127, DOI 10.1080/15419060600726209; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Nusrat A, 2005, MOL BIOL CELL, V16, P1725, DOI 10.1091/mbc.E04-06-0465; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Turksen K, 2002, DEVELOPMENT, V129, P1775; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van Itallie CM, 2003, AM J PHYSIOL-RENAL, V285, pF1078, DOI 10.1152/ajprenal.00116.2003; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Wang FS, 2003, AM J RESP CELL MOL, V29, P62, DOI 10.1165/rcmb.2002-0180OC; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yu ASL, 2005, AM J PHYSIOL-CELL PH, V288, pC1231, DOI 10.1152/ajpcell.00581.2004	33	120	123	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30005	30013		10.1074/jbc.M703547200	http://dx.doi.org/10.1074/jbc.M703547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699514	hybrid			2022-12-25	WOS:000249981200030
J	Sugai, R; Takemae, K; Tokuda, H; Nishiyama, KI				Sugai, Rie; Takemae, Kazuhisa; Tokuda, Hajime; Nishiyama, Ken-ichi			Topology inversion of SecG is essential for cytosolic SecA-dependent stimulation of protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; ESCHERICHIA-COLI SECA; PREPROTEIN TRANSLOCASE; CYTOPLASMIC MEMBRANE; PRECURSOR PROTEIN; PLASMA-MEMBRANE; DIMERIC SECA; SECRETORY PROTEINS; CATALYTIC CYCLE; LOW-TEMPERATURE	SecG, a subunit of the protein translocon, undergoes a cycle of topology inversion. To further examine the role of this topology inversion, we analyzed the activity of membrane vesicles carrying a SecG-PhoA fusion protein (SecG-PhoA inverted membrane vesicles (IMVs)). In the absence of externally added SecA, SecG-PhoA IMVs were as active in protein translocation as SecG(+) IMVs per SecA. Consistent with this observation, insertion of membrane-bound SecA into SecG-PhoA IMVs was normally observed. On the other hand, externally added SecA did not affect the activity of SecG-PhoA IMVs, but it caused > 10-fold stimulation of the translocation activity of SecG(+) IMVs, indicating that the topology inversion of SecG, which cannot occur in SecG-PhoA IMVs, is essential for cytosolic SecA-dependent stimulation of protein translocation. SecG-PhoA IMVs generated a 46-kDa fragment of SecA upon trypsin treatment. The accumulation of this membrane-inserted SecA in the SecG-PhoA IMVs was responsible for the loss of the soluble SecA-dependent stimulation. Moreover, fixation of the inverted SecG topology was found to be dependent on soluble SecA. The dual functions of SecG in protein translocation will be discussed.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Nishiyama, KI (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	unishiy@mail.ecc.u-tokyo.ac.jp						AKITA M, 1990, J BIOL CHEM, V265, P8164; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; de Keyzer J, 2005, J BIOL CHEM, V280, P35255, DOI 10.1074/jbc.M506157200; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanada M, 1996, FEBS LETT, V381, P25, DOI 10.1016/0014-5793(96)00066-X; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; Nagamori S, 2000, J BIOCHEM-TOKYO, V128, P129, DOI 10.1093/oxfordjournals.jbchem.a022723; Nagamori S, 2002, J BIOCHEM, V132, P629, DOI 10.1093/oxfordjournals.jbchem.a003266; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; NISHIYAMA K, 1995, BIOCHEM BIOPH RES CO, V217, P217, DOI 10.1006/bbrc.1995.2766; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Nishiyame K, 2005, BBA-GENE STRUCT EXPR, V1729, P166, DOI 10.1016/j.bbaexp.2005.05.003; Oliver D, 1998, J BACTERIOL, V180, P5240, DOI 10.1128/JB.180.19.5240-5242.1998; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Rusch SL, 2007, BBA-BIOMEMBRANES, V1768, P5, DOI 10.1016/j.bbamem.2006.08.013; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Slius EO, 2006, J BACTERIOL, V188, P1188, DOI 10.1128/JB.188.3.1188-1190.2006; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1987, J BIOL CHEM, V262, P2358	58	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29540	29548		10.1074/jbc.M704716200	http://dx.doi.org/10.1074/jbc.M704716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17704542	hybrid			2022-12-25	WOS:000249788000051
J	Fernando, R; Foster, JS; Bible, A; Strom, A; Pestell, RG; Rao, M; Saxton, A; Baek, SJ; Yamaguchi, K; Donnell, R; Cekanova, M; Wimalasena, J				Fernando, Romaine; Foster, James S.; Bible, Amber; Stroem, Anders; Pestell, Richard G.; Rao, Mahadev; Saxton, Arnold; Baek, Seung Joon; Yamaguchi, Kiyoshi; Donnell, Robert; Cekanova, Maria; Wimalasena, Jay			Breast cancer cell proliferation is inhibited by bad - Regulation of CYCLIN D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; CYCLE PROGRESSION; SIGNALING PATHWAY; E-CDK2 ACTIVATION; PHOSPHORYLATION; D1; APOPTOSIS; ESTROGEN; SURVIVAL; PROTEIN	Recent investigations suggest that functions of the proapoptotic BCL2 family members, including BAD, are not limited to regulation of apoptosis. Here we demonstrate that BAD inhibits G(1) to S phase transition in MCF7 breast cancer cells independent of apoptosis. BAD overexpression inhibited G1 transit and cell growth as well as cyclin D1 expression. Inhibition of cyclin D1 expression was mediated through inhibition of transcription activated by AP1. Chromatin immunoprecipitation assays indicated that BAD is localized at the 12-O-tetradecanoylphorbol-13-acetate-response element (TRE) and cAMP-response element (CRE) in the cyclin D1 promoter. This was shown to reflect direct binding interactions of BAD with c-Jun, and this interaction inhibited the activity of AP1 complexes at TRE. BAD did not interact with phosphorylated forms of c-Jun. Our data suggest that inhibitory TRE/CRE-c-Jun-BAD complexes are present at the cyclin D1 promoter in quiescent cells. Estrogen stimulation displaced BAD from TRE/CRE elements in MCF7 cells, whereas BAD overexpression inhibited estrogen-induced cyclin D1 synthesis and cell proliferation. Inhibition of endogenous BAD in MCF7 cells markedly increased the proliferative fraction and DNA synthesis, activated Cdks, and increased cyclin D1 protein levels. This action of BAD required serine residues Ser(75) and Ser(99). Both phosphorylated and unphosphorylated forms of BAD localized to the nuclei of human breast epithelial cells. Thus, we demonstrate a novel role for BAD in cell cycle regulation dependent upon its phosphorylation state and independent of the BAD/BCL2 interaction and apoptosis.	Univ Tennessee, Med Ctr, Grad Sch Med, Knoxville, TN 37920 USA; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA; NCI, Dept Oncol, Natl Inst Hlth, Washington, DC 20057 USA; Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA; Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet; Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Wimalasena, J (corresponding author), Univ Tennessee, Med Ctr, Grad Sch Med, 1924 Alcoa Hwy, Knoxville, TN 37920 USA.	jwimalas@mc.utmck.edu	Cekanova, Maria/M-8085-2017	Cekanova, Maria/0000-0002-9651-1619; Webb, Amber/0000-0002-7431-0533; Saxton, Arnold/0000-0003-3345-5127; Baek, Seung/0000-0001-7866-7778				Ahamed S, 2001, MOL CARCINOGEN, V30, P88, DOI 10.1002/1098-2744(200102)30:2&lt;88::AID-MC1017&gt;3.0.CO;2-E; Alle KM, 1998, CLIN CANCER RES, V4, P847; Altucci L, 1996, ONCOGENE, V12, P2315; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Campo PA, 2002, CELL GROWTH DIFFER, V13, P409; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Crescenzi E, 2001, GYNECOL ONCOL, V81, P184, DOI 10.1006/gyno.2001.6128; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Dees C, 1997, MOL CARCINOGEN, V18, P107, DOI 10.1002/(SICI)1098-2744(199702)18:2<107::AID-MC6>3.0.CO;2-D; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Dumay A, 2006, ONCOGENE, V25, P3196, DOI 10.1038/sj.onc.1209344; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	41	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28864	28873		10.1074/jbc.M700785200	http://dx.doi.org/10.1074/jbc.M700785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17670745	hybrid			2022-12-25	WOS:000249642100061
J	Iwaki, S; Sano, T; Takagi, T; Osumi, M; Kihara, A; Igarashi, Y				Iwaki, Soichiro; Sano, Takamitsu; Takagi, Tomoko; Osumi, Masako; Kihara, Akio; Igarashi, Yasuyuki			Intracellular trafficking pathway of yeast long-chain base kinase Lcb4, from its synthesis to its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS-VACUOLE JUNCTIONS; CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; SPHINGOID BASE; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; SECRETORY PATHWAY; SHUTTLE VECTORS	Sphingoid long-chain base 1-phosphates act as bioactive lipid molecules in eukaryotic cells. In budding yeast, long-chain base 1-phosphates are synthesized mainly by the long-chain base kinase Lcb4. We recently reported that, soon after yeast cells enter into the stationary phase, Lcb4 is rapidly degraded by being delivered to the vacuole in a palmitoylation- and phosphorylation-dependent manner. In this study, we investigated the complete trafficking pathway of Lcb4, from its synthesis to its degradation. After membrane anchoring by palmitoylation at the Golgi apparatus, Lcb4 is delivered to the plasma membrane ( PM) through the late Sec pathway and then to the endoplasmic reticulum ( ER). The yeast ER consists of a cortical network juxtaposed to the PM ( cortical ER) with tubular connections to the nuclear envelope ( nuclear ER). Remarkably, the localization of Lcb4 is restricted to the cortical ER. As the cells reach the stationary phase, G(1) cell cycle arrest initiates Lcb4 degradation and its delivery to the vacuole via the Golgi apparatus. The protein transport pathway from the PM to the ER found in this study has not been previously reported. We speculate that this novel pathway is mediated by the PM-ER contact.	Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Bhiofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Div Biol, Dept Life Sci, Grad Sch Arts & Sci,Meguro Ku, Tokyo 1538902, Japan; Japan Womens Univ, Bunkyo Ku, Electron Microscopy Lab, Open Res Ctr, Tokyo 1128681, Japan; Integrated Imaging Res Support, Chiyoda Ku, Tokyo 1020093, Japan; Hokkaido Univ, Kita Ku, Lab Biomembrane & Biofunct Chem, Fac Adv Life Sci, Sapporo, Hokkaido 0010021, Japan	Hokkaido University; University of Tokyo; Japan Womens University; Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Bhiofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	Sano, Takamitsu/F-9410-2012; KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Baumann NA, 2005, BIOCHEMISTRY-US, V44, P5816, DOI 10.1021/bi048296z; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Brachmann CB, 1998, YEAST, V14, P115; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; de Martin PE, 2005, J CELL SCI, V118, P65, DOI 10.1242/jcs.01583; Dong XW, 2003, MOL CELL BIOL, V23, P6574, DOI 10.1128/MCB.23.18.6574-6584.2003; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Humbel BM, 2001, YEAST, V18, P433, DOI 10.1002/yea.694; Iwaki S, 2005, J BIOL CHEM, V280, P6520, DOI 10.1074/jbc.M410908200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Juschke C, 2005, J CELL BIOL, V169, P613, DOI 10.1083/jcb.200503033; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kihara A, 2005, MOL CELL BIOL, V25, P9189, DOI 10.1128/MCB.25.21.9189-9197.2005; Kihara A, 2004, MOL BIOL CELL, V15, P4949, DOI 10.1091/mbc.E04-06-0458; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kihara A, 2007, PROG LIPID RES, V46, P126, DOI 10.1016/j.plipres.2007.03.001; KONOMI M, 2000, PLANT MORPHOL, V12, P20; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kvam E, 2005, MOL BIOL CELL, V16, P3987, DOI 10.1091/mbc.e05-04-0290; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Li YF, 2004, J BIOL CHEM, V279, P45226, DOI 10.1074/jbc.M407600200; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mao CG, 2000, METHOD ENZYMOL, V311, P223; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sano T, 2005, J BIOL CHEM, V280, P36674, DOI 10.1074/jbc.M503147200; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Takagi T, 2003, J ELECTRON MICROSC, V52, P161, DOI 10.1093/jmicro/52.2.161; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	52	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28485	28492		10.1074/jbc.M701607200	http://dx.doi.org/10.1074/jbc.M701607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686782	Green Published, hybrid			2022-12-25	WOS:000249642100022
J	Bretscher, MS; Clotworthy, M				Bretscher, Mark S.; Clotworthy, Margaret			Using Single loxP Sites to Enhance Homologous Recombination: ts Mutants in Sec1 of Dictyostelium discoideum	PLOS ONE			English	Article								Background. Dictyostelium discoideum amoebae are haploid and, as they share many features with animal cells, should be an ideal creature for studying basic processes such as cell locomotion. Isolation of mutants in this amoeba has largely been limited to non-essential genes: nsfA-the gene for NEM-sensitive factor-remains the only essential gene for which conditional (ts) mutants exist. These ts mutants were generated by gene replacement using a library of mutagenised nsfA containing a selectable marker: transformants were then screened for temperature sensitivity. The success of this approach depended on the high level of homologous recombination prevailing at this locus: similar to 95% of selected clones were homologous recombinants. This is unusually high for Dictyostelium: homologous recombination at other loci is usually much less, usually between 0-30%, making the isolation of ts mutants much more tedious. Methodology/Principal Findings. In trying to make ts mutants in sec1A, homologous recombination was found to be only similar to 25%. A new approach, involving single loxP sites, was investigated. LoxP sites are 34 bp sequences recognised by Cre recombinase and between which this enzyme catalyses recombination. A Dictyostelium line containing a single loxP site adjacent to the 39 end of the sec1A gene was engineered. A sec1A replacement DNA also containing a single loxP site in a homologous position was then introduced into this cell line. In the presence of CRE recombinase, homologous recombination increased to similar to 80% at this locus, presumably largely driven by intermolecular recombination between the two single loxP sites. Conclusions/Significance. A route to increase the rate of homologous recombination at a specific locus, sec1A, is described which enabled the isolation of 30 ts mutants in sec1A. One of these, sec1Ats1, has been studied and found to cease moving at the restrictive temperature. The approach described here may be valuable for enhancing homologous recombination at specified loci and thus for introducing mutations into specific genes in Dictyostelium and other creatures.	[Bretscher, Mark S.; Clotworthy, Margaret] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bretscher, MS (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	msb@mrc-lmb.cam.ac.uk			Medical Research Council; Medical Research Council [MC_U105178788] Funding Source: researchfish; MRC [MC_U105178788] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Medical Research Council.	BRETSCHER MS, 1984, SCIENCE, V224, P681, DOI 10.1126/science.6719108; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Burgoyne RD, 2007, CURR BIOL, V17, pR255, DOI 10.1016/j.cub.2007.02.006; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; CLOTWORTHY M, 2006, STUDIES DICTYOSTELIU; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Faix J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh136; Knecht D, 1995, Methods Mol Biol, V47, P321; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Noegel AA, 2000, J CELL SCI, V113, P759; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Thompson CRL, 2002, DEVELOPMENT, V129, P4185	12	4	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e724	10.1371/journal.pone.0000724	http://dx.doi.org/10.1371/journal.pone.0000724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684569	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452400026
J	Echegoyen, J; Neu, A; Graber, KD; Soltesz, I				Echegoyen, Julio; Neu, Axel; Graber, Kevin D.; Soltesz, Ivan			Homeostatic Plasticity Studied Using In Vivo Hippocampal Activity-Blockade: Synaptic Scaling, Intrinsic Plasticity and Age-Dependence	PLOS ONE			English	Article								Homeostatic plasticity is thought to be important in preventing neuronal circuits from becoming hyper- or hypoactive. However, there is little information concerning homeostatic mechanisms following in vivo manipulations of activity levels. We investigated synaptic scaling and intrinsic plasticity in CA1 pyramidal cells following 2 days of activity-blockade in vivo in adult ( postnatal day 30; P30) and juvenile (P15) rats. Chronic activity-blockade in vivo was achieved using the sustained release of the sodium channel blocker tetrodotoxin (TTX) from the plastic polymer Elvax 40W implanted directly above the hippocampus, followed by electrophysiological assessment in slices in vitro. Three sets of results were in general agreement with previous studies on homeostatic responses to in vitro manipulations of activity. First, Schaffer collateral stimulation-evoked field responses were enhanced after 2 days of in vivo TTX application. Second, miniature excitatory postsynaptic current (mEPSC) amplitudes were potentiated. However, the increase in mEPSC amplitudes occurred only in juveniles, and not in adults, indicating age-dependent effects. Third, intrinsic neuronal excitability increased. In contrast, three sets of results sharply differed from previous reports on homeostatic responses to in vitro manipulations of activity. First, miniature inhibitory postsynaptic current (mIPSC) amplitudes were invariably enhanced. Second, multiplicative scaling of mEPSC and mIPSC amplitudes was absent. Third, the frequencies of adult and juvenile mEPSCs and adult mIPSCs were increased, indicating presynaptic alterations. These results provide new insights into in vivo homeostatic plasticity mechanisms with relevance to memory storage, activity-dependent development and neurological diseases.	[Echegoyen, Julio; Neu, Axel; Soltesz, Ivan] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; [Graber, Kevin D.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	University of California System; University of California Irvine; Stanford University	Echegoyen, J (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA.	jechegoy@uci.edu		Neu, Axel/0000-0001-7045-7194	National Institutes of Health [NS35915 (IS), NS02167 (KDG)]; University of California; Deutsche Forschungsgemeinschaft [NE1185/1-1 (AN)]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS035915, R29NS035915, R01NS035915] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California(University of California System); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by National Institutes of Health Grant NS35915 (IS), NS02167 (KDG); by the University of California Irvine Medical Scientist Training Program (JE); and by Deutsche Forschungsgemeinschaft Grant NE1185/1-1 (AN).	Aizenman CD, 2000, NAT NEUROSCI, V3, P109, DOI 10.1038/72049; Aptowicz CO, 2004, BRAIN RES, V998, P155, DOI 10.1016/j.brainres.2003.11.035; Bacci A, 2001, J NEUROSCI, V21, P6588, DOI 10.1523/JNEUROSCI.21-17-06588.2001; Bausch SB, 2006, J NEUROPHYSIOL, V96, P2151, DOI 10.1152/jn.00355.2006; Burrone J, 2003, CURR OPIN NEUROBIOL, V13, P560, DOI 10.1016/j.conb.2003.09.007; Burrone J, 2002, NATURE, V420, P414, DOI 10.1038/nature01242; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Fan Y, 2005, NAT NEUROSCI, V8, P1542, DOI 10.1038/nn1568; Galvan CD, 2000, J NEUROSCI, V20, P2904; Galvan CD, 2003, EUR J NEUROSCI, V18, P1861, DOI 10.1046/j.1460-9568.2003.02920.x; Golowasch J, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-20-j0004.1999; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Hartman KN, 2006, NAT NEUROSCI, V9, P642, DOI 10.1038/nn1677; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hong SJ, 1997, J NEUROPHYSIOL, V77, P76, DOI 10.1152/jn.1997.77.1.76; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Karmarkar UR, 2006, EUR J NEUROSCI, V23, P1575, DOI 10.1111/j.1460-9568.2006.04692.x; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kirov SA, 2004, NEUROPHARMACOLOGY, V47, P640, DOI 10.1016/j.neuropharm.2004.07.039; Maffei A, 2006, NATURE, V443, P81, DOI 10.1038/nature05079; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; Marder E, 2003, NEURON, V37, P2, DOI 10.1016/S0896-6273(02)01173-X; Marder E, 2002, BIOESSAYS, V24, P1145, DOI 10.1002/bies.10185; Marder E, 2006, NAT REV NEUROSCI, V7, P563, DOI 10.1038/nrn1949; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Moldakarimov SB, 2006, P NATL ACAD SCI USA, V103, P16526, DOI 10.1073/pnas.0607589103; Moulder KL, 2006, J NEUROSCI, V26, P6618, DOI 10.1523/JNEUROSCI.5498-05.2006; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Neu A, 2007, J PHYSIOL-LONDON, V578, P233, DOI 10.1113/jphysiol.2006.115691; Petrak LJ, 2005, J COMP NEUROL, V484, P183, DOI 10.1002/cne.20468; Samsonovich AV, 2006, P NATL ACAD SCI USA, V103, P1569, DOI 10.1073/pnas.0510057103; Santhakumar V, 2004, TRENDS NEUROSCI, V27, P504, DOI 10.1016/j.tins.2004.06.002; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Shepherd JD, 2006, NEURON, V52, P475, DOI 10.1016/j.neuron.2006.08.034; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; SOLTESZ I, 2005, DIVERSITY NEUROANAL; Stemmler M, 1999, NAT NEUROSCI, V2, P521, DOI 10.1038/9173; Sullivan TJ, 2006, NEURAL NETWORKS, V19, P734, DOI 10.1016/j.neunet.2006.05.006; Swanwick CC, 2006, MOL CELL NEUROSCI, V31, P481, DOI 10.1016/j.mcn.2005.11.002; Thiagarajan TC, 2005, NEURON, V47, P725, DOI 10.1016/j.neuron.2005.06.037; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; Trasande CA, 2007, J CLIN NEUROPHYSIOL, V24, P154, DOI 10.1097/WNP.0b013e318033787f; TURRIGIANO G, 1995, J NEUROSCI, V15, P3640; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; Wierenga CJ, 2005, J NEUROSCI, V25, P2895, DOI 10.1523/JNEUROSCI.5217-04.2005; Wierenga CJ, 2006, J NEUROPHYSIOL, V96, P2127, DOI 10.1152/jn.00107.2006; Williams H, 2007, BIOSYSTEMS, V87, P252, DOI 10.1016/j.biosystems.2006.09.020	55	98	99	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e700	10.1371/journal.pone.0000700	http://dx.doi.org/10.1371/journal.pone.0000700			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684547	Green Published, gold			2022-12-25	WOS:000207452400004
J	Orr, A; Dube, MP; Marcadier, J; Jiang, HY; Federico, A; George, S; Seamone, C; Andrews, D; Dubord, P; Holland, S; Provost, S; Mongrain, V; Evans, S; Higgins, B; Bowman, S; Guernsey, D; Samuels, M				Orr, Andrew; Dube, Marie-Pierre; Marcadier, Julien; Jiang, Haiyan; Federico, Antonio; George, Stanley; Seamone, Christopher; Andrews, David; Dubord, Paul; Holland, Simon; Provost, Sylvie; Mongrain, Vanessa; Evans, Susan; Higgins, Brent; Bowman, Sharen; Guernsey, Duane; Samuels, Mark			Mutations in the UBIAD1 Gene, Encoding a Potential Prenyltransferase, Are Causal for Schnyder Crystalline Corneal Dystrophy	PLOS ONE			English	Article							QUANTITATIVE-ANALYSIS; FUNCTIONAL REGIONS; IDENTIFICATION; SEQUENCE; CONSURF; TERE1; ASSOCIATION; PROTEINS; DISEASE; FAMILY	Schnyder crystalline corneal dystrophy (SCCD, MIM 121800) is a rare autosomal dominant disease characterized by progressive opacification of the cornea resulting from the local accumulation of lipids, and associated in some cases with systemic dyslipidemia. Although previous studies of the genetics of SCCD have localized the defective gene to a 1.58 Mbp interval on chromosome 1p, exhaustive sequencing of positional candidate genes has thus far failed to reveal causal mutations. We have ascertained a large multigenerational family in Nova Scotia affected with SCCD in which we have confirmed linkage to the same general area of chromosome 1. Intensive fine mapping in our family revealed a 1.3 Mbp candidate interval overlapping that previously reported. Sequencing of genes in our interval led to the identification of five putative causal mutations in gene UBIAD1, in our family as well as in four other small families of various geographic origins. UBIAD1 encodes a potential prenyltransferase, and is reported to interact physically with apolipoprotein E. UBIAD1 may play a direct role in intracellular cholesterol biochemistry, or may prenylate other proteins regulating cholesterol transport and storage.	[Orr, Andrew; Jiang, Haiyan; Guernsey, Duane; Samuels, Mark] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Orr, Andrew; George, Stanley; Seamone, Christopher; Andrews, David] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada; [Dube, Marie-Pierre; Provost, Sylvie] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada; [Marcadier, Julien; Mongrain, Vanessa; Evans, Susan] Dalhousie Univ, Fac Med, Halifax, NS, Canada; [Federico, Antonio] Univ Siena, Dipartimento Sci Neurol & Comportamento, I-53100 Siena, Italy; [Dubord, Paul; Holland, Simon] Univ British Columbia, Fac Med, Dept Ophthalmol, Vancouver, BC, Canada; [Higgins, Brent; Bowman, Sharen] Canada Inst Marine Biol, Natl Res Council, Halifax, NS, Canada; [Samuels, Mark] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Dalhousie University; Dalhousie University; Universite de Montreal; Dalhousie University; University of Siena; University of British Columbia; National Research Council Canada; Universite de Montreal	Samuels, M (corresponding author), Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.	mark.e.samuels@umontreal.ca	Dubé, Marie-Pierre/B-9364-2008	Dubé, Marie-Pierre/0000-0001-8442-4393; Orr, Andrew/0000-0002-9388-9034	Queen Elizabeth II Health Science Centre; Dalhousie University; IWK Health Centre; Dalhousie Medical Research Foundation; Capital District Health Authority; Genome Atlantic and Genomic Canada; Genome Canada/Genome Atlantic; Fonds de Recherche en Sante du Quebec (FRSQ)	Queen Elizabeth II Health Science Centre; Dalhousie University; IWK Health Centre; Dalhousie Medical Research Foundation; Capital District Health Authority; Genome Atlantic and Genomic Canada; Genome Canada/Genome Atlantic(Genome Canada); Fonds de Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec)	AO was supported by the Queen Elizabeth II Health Science Centre Research Fund. MES was supported by Dalhousie University, the IWK Health Centre, the Dalhousie Medical Research Foundation, the Capital District Health Authority, Genome Atlantic and Genomic Canada. SB was supported by Genome Canada/Genome Atlantic. MPD was supported by the Fonds de Recherche en Sante du Quebec (FRSQ).	Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Aldave AJ, 2005, MOL VIS, V11, P713; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Ashburner M, 1999, GENETICS, V153, P179; BARCHIESI BJ, 1991, SURV OPHTHALMOL, V36, P1, DOI 10.1016/0039-6257(91)90205-T; Battisti C, 1998, AM J MED GENET, V75, P35, DOI 10.1002/(SICI)1096-8628(19980106)75:1<35::AID-AJMG8>3.0.CO;2-P; Brauer L, 2004, J MOL MODEL, V10, P317, DOI 10.1007/s00894-004-0197-6; BRON AJ, 1972, BRIT J OPHTHALMOL, V56, P383, DOI 10.1136/bjo.56.5.383; BRON AJ, 1989, CORNEA, V8, P135; BROWNSTEIN S, 1991, CAN J OPHTHALMOL, V26, P273; Burns R P, 1978, Trans Am Ophthalmol Soc, V76, P184; Crispin S, 2002, PROG RETIN EYE RES, V21, P169, DOI 10.1016/S1350-9462(02)00004-6; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Gaynor PM, 1996, ARTERIOSCL THROM VAS, V16, P992, DOI 10.1161/01.ATV.16.8.992; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Kajinami K, 1988, Nihon Naika Gakkai Zasshi, V77, P1017; Kohnen T, 1997, KLIN MONATSBL AUGENH, V211, P135, DOI 10.1055/s-2008-1035112; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Magnuson VL, 1996, BIOTECHNIQUES, V21, P700, DOI 10.2144/96214rr03; MCCARTHY M, 1994, OPHTHALMOLOGY, V101, P895; McGarvey TW, 2005, J CELL BIOCHEM, V95, P419, DOI 10.1002/jcb.20432; McGarvey TW, 2003, PROSTATE, V54, P144, DOI 10.1002/pros.10174; McGarvey TW, 2001, ONCOGENE, V20, P1042, DOI 10.1038/sj.onc.1204143; Meier U, 1998, KLIN MONATSBL AUGENH, V212, P405, DOI 10.1055/s-2008-1034920; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; OLEYNIKOV YS, 2007, EXCLUSION CHROSOME 1; PALMER M, 1985, ARCH OPHTHALMOL-CHIC, V103, P817, DOI 10.1001/archopht.1985.01050060077030; Pieper U, 2004, NUCLEIC ACIDS RES, V32, pD217, DOI 10.1093/nar/gkh095; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Riebeling P, 2003, OPHTHALMOLOGE, V100, P979, DOI 10.1007/s00347-003-0883-2; Rozen S, 2000, Methods Mol Biol, V132, P365; SAMUELS M, 2007, NEW TECHNOL IN PRESS; SAMUELS ME, 2005, LINKAGE MAPPING ENCY; Schnyder WF., 1929, SCHWEIZ MED WSCHR, V10, P559; Shearman AM, 1996, HUM MOL GENET, V5, P1667, DOI 10.1093/hmg/5.10.1667; Sunyaev S, 2000, TRENDS GENET, V16, P198, DOI 10.1016/S0168-9525(00)01988-0; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Theendakara V, 2004, HUM GENET, V114, P594, DOI 10.1007/s00439-004-1110-1; THIEL HJ, 1977, KLIN MONATSBL AUGENH, V171, P678; Thomas PD, 2004, P NATL ACAD SCI USA, V101, P15398, DOI 10.1073/pnas.0404380101; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Van Went JM., 1924, NIEDERL TIJDSCHR GEN, V68, P2996; WEEKS DE, 1995, AM J HUM GENET, V56, P1506; WEISS JS, 1992, CORNEA, V11, P93, DOI 10.1097/00003226-199203000-00001; WEISS JS, 1992, OPHTHALMOLOGY, V99, P1072; Weiss JS, 1996, OPHTHALMOLOGY, V103, P465; Yamada M, 1998, BRIT J OPHTHALMOL, V82, P444, DOI 10.1136/bjo.82.4.444	54	94	103	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e685	10.1371/journal.pone.0000685	http://dx.doi.org/10.1371/journal.pone.0000685			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668063	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452300021
J	Kwong, LN; Weiss, KR; Haigis, KM; Dove, WF				Kwong, L. N.; Weiss, K. R.; Haigis, K. M.; Dove, W. F.			Atm is a negative regulator of intestinal neoplasia	ONCOGENE			English	Article						gastrointestinal cancer; Atm; Apc; Blm; Lig4; modifier	ATAXIA-TELANGIECTASIA; CANCER PREDISPOSITION; GENOMIC INSTABILITY; TUMOR-FORMATION; TUMORIGENESIS; MOUSE; MICE; APC; PROGRESSION; ADENOMAS	The ataxia telangiectasia-mutated (ATM) gene has been implicated as an early barrier to the growth and progression of incipient solid tumors. Here, we show that germ-line nullizygosity for the mouse Atm gene significantly increases the proliferative index, net growth rate and multiplicity of intestinal adenomas in two distinct models of familial colon cancer: Apc(Min/+) and Apc(1638N/+). These effects of Atm deficiency are quantitatively different from deficiency for either of the genomic stability genes Bloom's syndrome helicase or DNA ligase 4, and the effect of Atm loss on tumor multiplicity is largely independent of the effect of ionizing radiation. Furthermore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by Atm loss. Taken together, these data implicate the Atm gene product as a barrier to dysplastic growth in the early stages of intestinal tumor progression, independent of its effects on genomic stability.	[Kwong, L. N.; Weiss, K. R.; Haigis, K. M.; Dove, W. F.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	dove@oncology.wisc.edu			NCI NIH HHS [T32 CA009135, R37CA63677, CA009135, R37 CA063677, R37 CA063677-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA063677, T32CA009135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos-Landgraf JM, 2007, P NATL ACAD SCI USA, V104, P4036, DOI 10.1073/pnas.0611690104; Bai AHC, 2004, INT J CANCER, V112, P846, DOI 10.1002/ijc.20485; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Grabsch H, 2006, CLIN CANCER RES, V12, P1494, DOI 10.1158/1078-0432.CCR-05-2105; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2004, P NATL ACAD SCI USA, V101, P9769, DOI 10.1073/pnas.0403338101; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; Mann MB, 2005, HUM MOL GENET, V14, P813, DOI 10.1093/hmg/ddi075; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sugai T, 2001, ONCOGENE, V20, P6095, DOI 10.1038/sj.onc.1204731; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397	26	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					1013	1018		10.1038/sj.onc.1210708	http://dx.doi.org/10.1038/sj.onc.1210708			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700532	Green Accepted			2022-12-25	WOS:000252946300013
J	Bruchas, MR; Yang, T; Schreiber, S; DeFino, M; Kwan, SC; Li, S; Chavkin, C				Bruchas, Michael R.; Yang, Tao; Schreiber, Selena; DeFino, Mia; Kwan, Steven C.; Li, Shuang; Chavkin, Charles			Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADMINISTERED NOR-BINALTORPHIMINE; RHESUS-MONKEYS; POTENT; ASTROCYTES; ASSAY; 5'-GUANIDINONALTRINDOLE; PHOSPHORYLATION; ANTINOCICEPTION; IDENTIFICATION; PHARMACOLOGY	Norbinaltorphimine ( NorBNI), guanidinonaltrindole, and atrans-( 3R, 4R)- dimethyl- 4-( 3- hydroxyphenyl) piperidine ( JDTic) are selective kappa opioid receptor ( KOR) antagonists having very long durations of action in vivo despite binding non- covalently in vitro and having only moderately high affinities. Consistent with this, we found that antagonist treatment significantly reduced the subsequent analgesic response of mice to the KOR agonist U50,488 in the tail- withdrawal assay for 14 - 21 days. Receptor protection assays were designed to distinguish between possible explanations for this anomalous effect, and we found that mice pretreated with the readily reversible opioid antagonists naloxone or buprenorphine before norBNI responded strongly in the tail- flick analgesia assay to a subsequent challenge with U50,488 1 week later. Protection by a rapidly cleared reagent indicates that norBNI did not persist at the site of action. In vitro binding of [ H-3] U69,593 to KOR showed that K-d and Bmax values were not significantly affected by prior in vivo norBNI exposure, indicating that the agonist binding site was intact. Consistent with the concept that the long- lasting effects might be caused by a functional disruption of KOR signaling, both norBNI and JDTic were found to stimulate c- Jun N- terminal kinase ( JNK) phosphorylation in HEK293 cells expressing KOR- GFP but not in untransfected cells. Similarly, norBNI increased phospho- JNK in both the striatum and spinal cord in wild type mice but not in KOR knock- out mice. Pretreatment of mice with the JNK inhibitor SP600125 before norBNI attenuated the long acting antagonism. Together, these results suggest that the long duration KOR antagonists disrupt KOR signaling by activating JNK.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280,1959 Pacific Ave NE, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010; Bruchas, Michael/G-7616-2012	Li, Shuang/0000-0003-1684-0031	NIDA NIH HHS [R37 DA011672, F32 DA020430, R01 DA011672-05, K05 DA020570, F32-DA20430, R37-DA11672, R01 DA011672-04, KO5-DA20570, K05 DA020570-01, R01 DA011672, K05 DA020570-02] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA020570, F32DA020430, R37DA011672, R01DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Beardsley PM, 2005, PSYCHOPHARMACOLOGY, V183, P118, DOI 10.1007/s00213-005-0167-4; Beguin C, 2005, BIOORG MED CHEM LETT, V15, P2761, DOI 10.1016/j.bmcl.2005.03.113; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blkbulatov RV, 2007, BIOORG MED CHEM LETT, V17, P2229, DOI 10.1016/j.bmcl.2007.01.100; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Bohn LM, 2000, J NEUROCHEM, V74, P564, DOI 10.1046/j.1471-4159.2000.740564.x; BROADBEAR JH, 1994, PSYCHOPHARMACOLOGY, V115, P311, DOI 10.1007/BF02245071; Bruchas MR, 2006, J BIOL CHEM, V281, P18081, DOI 10.1074/jbc.M513640200; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V267, P1269; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; Clarke S, 2002, EUR J NEUROSCI, V16, P1705, DOI 10.1046/j.1460-9568.2002.02239.x; Dhawan BN, 1996, PHARMACOL REV, V48, P567; HORAN P, 1992, J PHARMACOL EXP THER, V260, P1237; Jewett DC, 1995, BEHAV PHARMACOL, V6, P815; JONES DNC, 1992, EUR J PHARMACOL, V215, P345, DOI 10.1016/0014-2999(92)90055-9; Jones RM, 2000, EUR J PHARMACOL, V396, P49, DOI 10.1016/S0014-2999(00)00208-9; Kam AYF, 2004, J PHARMACOL EXP THER, V310, P301, DOI 10.1124/jpet.104.065078; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Ko MCH, 1999, J PHARMACOL EXP THER, V291, P1113; Kukkonen JP, 1998, BIOCHEM BIOPH RES CO, V243, P41, DOI 10.1006/bbrc.1997.8054; Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; Metcalf MD, 2005, AAPS J, V7, pE704, DOI 10.1208/aapsj070371; Negus SS, 2002, PSYCHOPHARMACOLOGY, V163, P412, DOI 10.1007/s00213-002-1038-x; Piros ET, 1996, NEUROCHEM RES, V21, P1277, DOI 10.1007/BF02532368; PORTOGHESE PS, 1987, J MED CHEM, V30, P238, DOI 10.1021/jm00385a002; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; SADEE W, 1982, J PHARMACOL EXP THER, V223, P157; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Simpson DS, 2007, J MED CHEM, V50, P3596, DOI 10.1021/jm070393d; Smith C, 2006, MOL PHARMACOL, V70, P1264, DOI 10.1124/mol.106.024612; SMITH CB, 1990, PROG CLIN BIOL RES, V328, P65; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Thomas JB, 2004, J MED CHEM, V47, P1070, DOI 10.1021/jm030467v; Thomas JB, 2003, J MED CHEM, V46, P3127, DOI 10.1021/jm030094y; Thomas JB, 2001, J MED CHEM, V44, P2687, DOI 10.1021/jm015521r; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; YOUNG AM, 1984, J PHARMACOL EXP THER, V229, P118; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	46	131	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29803	29811		10.1074/jbc.M705540200	http://dx.doi.org/10.1074/jbc.M705540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702750	Green Accepted, hybrid			2022-12-25	WOS:000249981200009
J	Luo, WB; Wang, YF; Reiser, G				Luo, Weibo; Wang, Yingfei; Reiser, Georg			P24A, a type I transmembrane protein, controls ARF1-dependent resensitization of protease-activated receptor-2 by influence on receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED TRANSPORT VESICLES; ADP-RIBOSYLATION FACTORS; INTRACELLULAR TRAFFICKING; CHEMOKINE GRO/CINC-1; SECRETORY PATHWAY; FAMILY-MEMBERS; RAT ASTROCYTES; GOLGI; MEMBRANE; COATOMER	Protease-activated receptor-2 (PAR- 2), the second member of the G protein-coupled PAR family, is irreversibly activated by trypsin or tryptase and then targeted to lysosomes for degradation. Intracellular presynthesized receptors stored at the Golgi apparatus repopulate the cell surface after trypsin stimulation, thereby leading to rapid resensitization to trypsin signaling. However, the molecular mechanisms of the exocytic trafficking of PAR- 2 from the Golgi apparatus to the plasma membrane remain largely unclear. Here we show that p24A, a type I transmembrane protein, which is a crucial constituent of the Golgi apparatus, associates with PAR- 2 at the Golgi apparatus. The protein interaction occurs between the N-terminal region of p24A (residues 1-105; p24A-GL (GOLD domain with a small linker)) and the second extracellular loop of PAR-2. After receptor activation, PAR- 2 dissociates from p24A. Importantly, we found that ADP-ribosylation factor 1 regulated the dissociation process and initiated PAR- 2 trafficking to the plasma membrane. Conversely, overexpression of the fragment p24A-GL, but not other mutants containing the functional coiled-coil domain of p24A, arrested PAR- 2 at the Golgi apparatus and inhibited receptor trafficking to the plasma membrane, which consequently prevented resensitization of PAR-2. These findings identify a new function of p24A as a regulator of signal-dependent trafficking that regulates the life cycle of PAR- 2, Thus, we reveal a new molecular mechanism underlying resensitization of PAR-2.	Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Otto von Guericke University	Reiser, G (corresponding author), Univ Magdeburg, Fak Med, Inst Neurobiochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	georg.reiser@med.ovgu.de		Luo, Weibo/0000-0002-1992-0320; wang, yingfei/0000-0002-8723-252X				Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Blum R, 1999, J CELL SCI, V112, P537; Blum R, 1996, J BIOL CHEM, V271, P17183, DOI 10.1074/jbc.271.29.17183; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Carney GE, 2004, BIOL CELL, V96, P271, DOI 10.1016/j.biolcel.2004.01.004; Ciufo LF, 2000, J BIOL CHEM, V275, P8382, DOI 10.1074/jbc.275.12.8382; Contreras I, 2004, PLANT J, V38, P685, DOI 10.1111/j.1365-313X.2004.02075.x; Cottrell GS, 2003, BIOCHEM SOC T, V31, P1191; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Dong CM, 2007, BBA-BIOMEMBRANES, V1768, P853, DOI 10.1016/j.bbamem.2006.09.008; Dong CM, 2006, J BIOL CHEM, V281, P38543, DOI 10.1074/jbc.M605734200; Emery G, 2000, J CELL SCI, V113, P2507; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Kaiser C, 2000, P NATL ACAD SCI USA, V97, P3783, DOI 10.1073/pnas.97.8.3783; Luo WB, 2006, J BIOL CHEM, V281, P7927, DOI 10.1074/jbc.M510784200; Luo WB, 2005, BRAIN RES, V1047, P159, DOI 10.1016/j.brainres.2005.04.040; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Paing MM, 2004, J BIOL CHEM, V279, P21938, DOI 10.1074/jbc.M401672200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Satoh AK, 2005, DEVELOPMENT, V132, P1487, DOI 10.1242/dev.01704; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Shen XY, 2006, P NATL ACAD SCI USA, V103, P2635, DOI 10.1073/pnas.0510599103; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Wang YF, 2007, BIOCHEM J, V401, P65, DOI 10.1042/BJ20060732; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	41	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30246	30255		10.1074/jbc.M703205200	http://dx.doi.org/10.1074/jbc.M703205200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693410	hybrid			2022-12-25	WOS:000249981200055
J	Truscott, M; Denault, JB; Goulet, B; Leduy, L; Salvesen, GS; Nepveu, A				Truscott, Mary; Denault, Jean-Bernard; Goulet, Brigitte; Leduy, Lam; Salvesen, Guy S.; Nepveu, Alain			Carboxyl-terminal proteolytic processing of CUX1 by a caspase enables transcriptional activation in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE STIMULATION; CUT HOMEODOMAIN PROTEIN; KAPPA-B ACTIVATION; S-PHASE; DNA-BINDING; HEMATOPOIETIC-CELLS; APOPTOSIS; CLEAVAGE; DIFFERENTIATION; CYCLE	Proteolytic processing at the end of the G(1) phase generates a CUX1 isoform, p110, which functions either as a transcriptional activator or repressor and can accelerate entry into S phase. Here we describe a second proteolytic event that generates an isoform lacking two active repression domains in the COOH terminus. This processing event was inhibited by treatment of cells with synthetic and natural caspase inhibitors. In vitro, several caspases generated a processed isoform that co-migrated with the in vivo generated product. In cells, recombinant CUX1 proteins in which the region of cleavage was deleted or in which Asp residues were mutated to Ala, were not proteolytically processed. Importantly, this processing event was not associated with apoptosis, as assessed by terminal dUTP nick end labeling assay, cytochrome c localization, poly(ADP-ribose) polymerase cleavage, and fluorescence-activated cell sorting. Moreover, processing was observed in S phase but not in early G(1), suggesting that it is regulated through the cell cycle. The functional importance of this processing event was revealed in reporter and cell cycle assays. Arecombinant, processed, CUX1 protein was a more potent transcriptional activator of several cell cycle-related genes and was able to accelerate entry into S phase, whereas mutants that could not be processed were inactive in either assay. Conversely, cells treated with the quinoline-Val Asp-2,6-difluorophenoxymethylketone caspase inhibitor proliferated more slowly and exhibited delayed S phase entry following exit from quiescence. Together, our results identify a substrate of caspases in proliferating cells and suggest a mechanism by which caspases can accelerate cell cycle progression.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	McGill University; McGill University; McGill University; McGill University; Sanford Burnham Prebys Medical Discovery Institute	Nepveu, A (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain.nepveu@mcgill.ca	/AAB-8315-2020; Denault, Jean-Bernard/AAC-5945-2019	Truscott, Mary/0000-0002-2324-6383				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown NM, 2007, J BIOL CHEM, V282, P2144, DOI 10.1074/jbc.M607961200; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Frost V, 2001, ONCOGENE, V20, P2737, DOI 10.1038/sj.onc.1204367; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2002, CANCER RES, V62, P6625; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x; Howcroft TK, 1997, ANAL BIOCHEM, V244, P22, DOI 10.1006/abio.1996.9868; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sansregret L, 2006, MOL CELL BIOL, V26, P2441, DOI 10.1128/MCB.26.6.2441-2455.2006; Santaguida M, 2005, J BIOL CHEM, V280, P32712, DOI 10.1074/jbc.M505417200; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Truscott M, 2004, J BIOL CHEM, V279, P49787, DOI 10.1074/jbc.M409484200; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Yao SL, 1996, CANCER RES, V56, P4551; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	50	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30216	30226		10.1074/jbc.M702328200	http://dx.doi.org/10.1074/jbc.M702328200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17681953	hybrid			2022-12-25	WOS:000249981200052
J	Cheng, XY; Liu, JX; Asuncion-Chin, M; Blaskova, E; Bannister, JP; Dopico, AM; Jaggar, JH				Cheng, Xiaoyang; Liu, Jianxi; Asuncion-Chin, Maria; Blaskova, Eva; Bannister, John P.; Dopico, Alejandro M.; Jaggar, Jonathan H.			A novel Ca(V)1.2 N terminus expressed in smooth muscle cells of resistance size arteries modifies channel regulation by auxiliary subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; ALPHA(1C) SUBUNIT; CA2+ CHANNELS; SUBCELLULAR-LOCALIZATION; LARGE-CONDUCTANCE; BLOOD-PRESSURE; CLONING; HETEROGENEITY	Voltage-dependent L-type Ca2+ (Ca(V)1.2) channels are the principal Ca2+ entry pathway in arterial myocytes. Ca(V)1.2 channels regulate multiple vascular functions and are implicated in the pathogenesis of human disease, including hypertension. However, the molecular identity of Ca(V)1.2 channels expressed in myocytes of myogenic arteries that regulate vascular pressure and blood flow is unknown. Here, we cloned Ca(V)1.2 subunits from resistance size cerebral arteries and demonstrate that myocytes contain a novel, cysteine rich N terminus that is derived from exon 1 (termed "exon 1c"), which is located within CACNA1C, the Ca(V)1.2 gene. Quantitative PCR revealed that exon 1c was predominant in arterial myocytes, but rare in cardiac myocytes, where exon 1a prevailed. When co-expressed with alpha(2)delta subunits, Ca(V)1.2 channels containing the novel exon 1c-derived N terminus exhibited: 1) smaller whole cell current density, 2) more negative voltages of half activation (V-1/2,V-act) and half-inactivation (V-1/2,V-inact), and 3) reduced plasma membrane insertion, when compared with channels containing exon 1b. beta(1b) and beta(2a) subunits caused negative shifts in the V-1/2,V-act and (V1/2,inact) of exon 1b-containing Ca(V)1.2 alpha(1)/alpha(2)delta currents that were larger than those in exon 1c-containing Ca(V)1.2 alpha(1)/alpha(2)delta currents. In contrast, beta(3) similarly shifted V-1/2,V-act and V-1/2,V-inact of currents generated by exon 1b- and exon 1c-containing channels. beta subunits isoform-dependent differences in current inactivation rates were also detected between N-terminal variants. Data indicate that through novel alternative splicing at exon 1, the Ca(V)1.2 N terminus modifies regulation by auxiliary subunits. The novel exon 1c should generate distinct voltage-dependent Ca2+ entry in arterial myocytes, resulting in tissue-specific Ca2+ signaling.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Jaggar, JH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	jjaggar@physio1.utmem.edu	Cheng, Xiaoyang/N-9970-2019; Tuluc, Petronel/C-2527-2011; Cheng, Xiaoyang/M-1257-2017; Cheng, Xiaoyang/A-1729-2012	Cheng, Xiaoyang/0000-0003-1446-2815; Cheng, Xiaoyang/0000-0003-1446-2815; Cheng, Xiaoyang/0000-0003-1446-2815	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077424, R01HL077678, R01HL067061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011560, R37AA011560, R29AA011560] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067061-05, R01 HL077678-03, HL77678, HL77424, R01 HL077424, R01 HL067061, HL67061, R01 HL077678] Funding Source: Medline; NIAAA NIH HHS [R29 AA011560, AA11560, R37 AA011560, R01 AA011560] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Arien H, 2003, J BIOL CHEM, V278, P29231, DOI 10.1074/jbc.M301401200; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Bogdanov Y, 2000, EUR J NEUROSCI, V12, P894, DOI 10.1046/j.1460-9568.2000.00981.x; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Davis MJ, 1999, PHYSIOL REV, V79, P387, DOI 10.1152/physrev.1999.79.2.387; Felix R, 1997, J NEUROSCI, V17, P6884; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gollasch M, 1997, KIDNEY BLOOD PRESS R, V20, P355, DOI 10.1159/000174250; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Jaggar JH, 2005, CIRC RES, V97, P805, DOI 10.1161/01.RES.0000186180.47148.7b; Jaggar JH, 2001, AM J PHYSIOL-CELL PH, V281, pC439, DOI 10.1152/ajpcell.2001.281.2.C439; Klugbauer N, 2003, J BIOENERG BIOMEMBR, V35, P639, DOI 10.1023/B:JOBB.0000008028.41056.58; Kobrinsky E, 2005, J BIOL CHEM, V280, P12474, DOI 10.1074/jbc.M412140200; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Liao P, 2005, CARDIOVASC RES, V68, P197, DOI 10.1016/j.cardiores.2005.06.024; LIU W, 2003, ANN J PHYSL HEART CI, V285, pH97; Lyford GL, 2002, AM J PHYSIOL-CELL PH, V283, pC1001, DOI 10.1152/ajpcell.00140.2002; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Nelson MT, 1990, AM J PHYSIOL, V259, P3; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Pietrzykowski AZ, 2004, J NEUROSCI, V24, P8322, DOI 10.1523/JNEUROSCI.1536-04.2004; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Restituito S, 2001, BIOPHYS J, V81, P89, DOI 10.1016/S0006-3495(01)75682-2; Saada N, 2003, BIOCHEM BIOPH RES CO, V302, P23, DOI 10.1016/S0006-291X(03)00097-4; Saada NI, 2005, CELL CALCIUM, V37, P301, DOI 10.1016/j.ceca.2004.11.003; Sandoval A, 2004, FEBS LETT, V576, P21, DOI 10.1016/j.febslet.2004.08.054; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; Sonkusare S, 2006, VASC PHARMACOL, V44, P131, DOI 10.1016/j.vph.2005.10.005; Stephens GJ, 2000, J PHYSIOL-LONDON, V525, P377, DOI 10.1111/j.1469-7793.2000.t01-1-00377.x; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Tang ZZ, 2007, CELL CALCIUM, V41, P417, DOI 10.1016/j.ceca.2006.08.002; Tang ZZ, 2004, J BIOL CHEM, V279, P44335, DOI 10.1074/jbc.M407023200; TIWARI S, 2006, P NATL ACAD SCI US; Triggle DJ, 2006, CURR PHARM DESIGN, V12, P443, DOI 10.2174/138161206775474503; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138	46	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29211	29221		10.1074/jbc.M610623200	http://dx.doi.org/10.1074/jbc.M610623200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699517	hybrid, Green Accepted			2022-12-25	WOS:000249788000017
J	Suzuki, F; Morishima, S; Tanaka, T; Muramatsu, I				Suzuki, Fumiko; Morishima, Shigeru; Tanaka, Takashi; Muramatsu, Ikunobu			Snapin, a new regulator of receptor signaling, augments alpha(1A)-adrenoceptor-operated calcium influx through TRPC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-C-GAMMA; PC12 CELLS; NEUTRAL ANTAGONISM; POTENTIAL PROTEIN; INVERSE AGONISM; PLASMA-MEMBRANE; CA2+ ENTRY; CHANNELS; SUBTYPES	Activation of G(q)-protein-coupled receptors, including the alpha(1A)-adrenoceptor (alpha(1A)-AR), causes a sustained Ca2+ influx via receptor-operated Ca2+ (ROC) channels, following the transient release of intracellular Ca2+. Transient receptor potential canonical (TRPC) channel is one of the candidate proteins constituting the ROC channels, but the precise mechanism linking receptor activation to increased influx of Ca2+ via TRPCs is not yet fully understood. We identified Snapin as a protein interacting with the C terminus of the alpha(1A)-AR. In receptor-expressing PC12 cells, co-transfection of Snapin augmented alpha(1A)-AR-stimulated sustained increases in intracellular Ca2+ ([Ca2+](i)) via ROC channels. By altering the Snapin binding C-terminal domain of the alpha(1A)-AR or by reducing cellular Snapin with short interfering RNA, the sustained increase in [Ca2+](i) in Snapin-alpha(1A)-AR co-expressing PC12 cells was attenuated. Snapin co-immunoprecipitated with TRPC6 and alpha(1A)-AR, and these interactions were augmented upon alpha(1A)-AR activation, increasing the recruitment of TRPC6 to the cell surface. Our data suggest a new receptor-operated signaling mechanism where Snapin links the alpha(1A)-AR to TRPC6, augmenting Ca2+ influx via ROC channels.	Univ Fukui, Dept Biochem & Bioinformat Sci, Div Pharmacol, Fukui 9101193, Japan	University of Fukui	Muramatsu, I (corresponding author), Univ Fukui, Dept Biochem & Bioinformat Sci, Div Pharmacol, 23-3 Matsuoka Shimoazizuki, Fukui 9101193, Japan.	muramatu@u-fukui.ac.jp						Ambudkar IS, 2006, CELL CALCIUM, V40, P495, DOI 10.1016/j.ceca.2006.08.011; Ambudkar IS, 2006, TRENDS PHARMACOL SCI, V27, P25, DOI 10.1016/j.tips.2005.11.008; Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Dietrich A, 2005, PFLUG ARCH EUR J PHY, V451, P72, DOI 10.1007/s00424-005-1460-0; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fagni L, 2004, SEMIN CELL DEV BIOL, V15, P289, DOI 10.1016/j.semcdb.2003.12.018; Groschner K, 2005, N-S ARCH PHARMACOL, V371, P251, DOI 10.1007/s00210-005-1054-6; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Israilova M, 2004, J PHARMACOL EXP THER, V309, P259, DOI 10.1124/jpet.103.061796; Kida H, 2005, J MEMBRANE BIOL, V208, P55, DOI 10.1007/s00232-005-0819-7; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; Ohta T, 2004, NEUROSCI LETT, V358, P161, DOI 10.1016/j.neulet.2004.01.028; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Redondo PC, 2004, J PHYSIOL-LONDON, V558, P99, DOI 10.1113/jphysiol.2004.064899; Rossier O, 1999, MOL PHARMACOL, V56, P858, DOI 10.1124/mol.56.5.858; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Spassova MA, 2004, BBA-MOL CELL RES, V1742, P9, DOI 10.1016/j.bbamcr.2004.09.001; Suzuki F, 2000, BRIT J PHARMACOL, V129, P1569, DOI 10.1038/sj.bjp.0703242; Suzuki F, 2002, BRIT J PHARMACOL, V135, P600, DOI 10.1038/sj.bjp.0704503; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Taniguchi T, 1999, BRIT J PHARMACOL, V127, P962, DOI 10.1038/sj.bjp.0702609; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Tian JH, 2005, J NEUROSCI, V25, P10546, DOI 10.1523/JNEUROSCI.3275-05.2005; Treves S, 2004, J CELL BIOL, V166, P537, DOI 10.1083/jcb.200404079; Wiktorek M, 1996, BIOCHEM BIOPH RES CO, V224, P645, DOI 10.1006/bbrc.1996.1079; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhong HY, 1999, J NEUROCHEM, V72, P2388, DOI 10.1046/j.1471-4159.1999.0722388.x; Zhu J, 2000, BRIT J PHARMACOL, V131, P546, DOI 10.1038/sj.bjp.0703584	37	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29563	29573		10.1074/jbc.M702063200	http://dx.doi.org/10.1074/jbc.M702063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684020	hybrid			2022-12-25	WOS:000249788000053
J	Bruno, JF; Selig, ER				Bruno, John F.; Selig, Elizabeth R.			Regional Decline of Coral Cover in the Indo-Pacific: Timing, Extent, and Subregional Comparisons	PLOS ONE			English	Article								Background. A number of factors have recently caused mass coral mortality events in all of the world's tropical oceans. However, little is known about the timing, rate or spatial variability of the loss of reef-building corals, especially in the Indo-Pacific, which contains 75% of the world's coral reefs. Methodology/Principle Findings. We compiled and analyzed a coral cover database of 6001 quantitative surveys of 2667 Indo-Pacific coral reefs performed between 1968 and 2004. Surveys conducted during 2003 indicated that coral cover averaged only 22.1% (95% CI: 20.7, 23.4) and just 7 of 390 reefs surveyed that year had coral cover > 60%. Estimated yearly coral cover loss based on annually pooled survey data was approximately 1% over the last twenty years and 2% between 1997 and 2003 (or 3,168 km(2) per year). The annual loss based on repeated measures regression analysis of a subset of reefs that were monitored for multiple years from 1997 to 2004 was 0.72% (n = 476 reefs, 95% CI: 0.36, 1.08). Conclusions/Significance. The rate and extent of coral loss in the Indo-Pacific are greater than expected. Coral cover was also surprisingly uniform among subregions and declined decades earlier than previously assumed, even on some of the Pacific's most intensely managed reefs. These results have significant implications for policy makers and resource managers as they search for successful models to reverse coral loss.	[Bruno, John F.; Selig, Elizabeth R.] Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27515 USA; [Selig, Elizabeth R.] Univ N Carolina, Curriculum Ecol, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bruno, JF (corresponding author), Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27515 USA.	jbruno@unc.edu			National Science Foundation [OCE-0326983]; EPA; University of North Carolina	National Science Foundation(National Science Foundation (NSF)); EPA(United States Environmental Protection Agency); University of North Carolina	This research was funded in part by the National Science Foundation (OCE-0326983 to J.F.B.), an EPA Star Fellowship to E.R.S, and the University of North Carolina at Chapel Hill.	Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; Aronson RB, 2000, NATURE, V405, P36, DOI 10.1038/35011132; Aronson RB, 2001, HYDROBIOLOGIA, V460, P25, DOI 10.1023/A:1013103928980; Aronson RB, 2006, CORAL REEFS, V25, P441, DOI 10.1007/s00338-006-0122-9; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Berkelmans R, 1999, CORAL REEFS, V18, P55, DOI 10.1007/s003380050154; Berkelmans R, 2004, CORAL REEFS, V23, P74, DOI 10.1007/s00338-003-0353-y; Bruno JF, 2001, CORAL REEFS, V20, P127, DOI 10.1007/s003380100151; Bruno JF, 2001, MARINE COMMUNITY ECOLOGY, P201; Bruno JF, 2007, PLOS BIOL, V5, P1220, DOI 10.1371/journal.pbio.0050124; CHESHER RH, 1969, SCIENCE, V165, P280, DOI 10.1126/science.165.3890.280; COLGAN MW, 1987, ECOLOGY, V68, P1592, DOI 10.2307/1939851; Connell JH, 1997, CORAL REEFS, V16, pS101, DOI 10.1007/s003380050246; Connell JH, 1997, ECOL MONOGR, V67, P461, DOI 10.1890/0012-9615(1997)067[0461:AYSOCA]2.0.CO;2; Cote IM, 2005, PHILOS T R SOC B, V360, P385, DOI 10.1098/rstb.2004.1591; Dana T. F., 1979, ATOLL RES B, V228, P1; DONE T, 1992, AM ZOOL, V32, P655; Edmunds PJ, 2007, ECOL MONOGR, V77, P3, DOI 10.1890/05-1081; Edmunds PJ, 2001, P NATL ACAD SCI USA, V98, P5067, DOI 10.1073/pnas.071524598; Endean R., 1973, Atoll Res Bull, VNo. 168, P1; Gardner TA, 2003, SCIENCE, V301, P958, DOI 10.1126/science.1086050; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; GOMEZ ED, 1981, 4TH P INT COR REEF S, V1, P275; Graham NAJ, 2006, P NATL ACAD SCI USA, V103, P8425, DOI 10.1073/pnas.0600693103; Grigg R.W., 1990, P439; Grigg RW, 2005, SCIENCE, V308, P1740; Guinotte JM, 2003, CORAL REEFS, V22, P551, DOI 10.1007/s00338-003-0331-4; HARMELINVIVIEN ML, 1986, CORAL REEFS, V5, P55, DOI 10.1007/BF00270353; Hodgson G, 1999, MAR POLLUT BULL, V38, P345, DOI 10.1016/S0025-326X(99)00002-8; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; Idjadi JA, 2006, MAR ECOL PROG SER, V319, P117, DOI 10.3354/meps319117; Idjadi JA, 2006, CORAL REEFS, V25, P209, DOI 10.1007/s00338-006-0088-7; *ISRS, 2004, EFF TERR RUN SED NUT, P18; Jokiel Paul L., 2004, Pacific Science, V58, P159, DOI 10.1353/psc.2004.0018; Jones GP, 2004, P NATL ACAD SCI USA, V101, P8251, DOI 10.1073/pnas.0401277101; Knowlton N, 2001, P NATL ACAD SCI USA, V98, P5419, DOI 10.1073/pnas.091092998; Lotze HK, 2006, SCIENCE, V312, P1806, DOI 10.1126/science.1128035; Lourey MJ, 2000, MAR ECOL PROG SER, V196, P179, DOI 10.3354/meps196179; Mcmanus JW, 1997, ENVIRON MANAGE, V21, P69, DOI 10.1007/s002679900006; Miller I, 1999, CORAL REEFS, V18, P353, DOI 10.1007/s003380050212; MILLER I, 1997, P 8 INT COR REEF S, V2, P1475; Miller IR, 1996, MAR FRESHWATER RES, V47, P19, DOI 10.1071/MF9960019; MONTEBON ARF, 1997, P 8 INT COR REEF S, V1, P295; Mumby PJ, 2007, P NATL ACAD SCI USA, V104, P8362, DOI 10.1073/pnas.0702602104; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; Ninio R, 2000, MAR ECOL PROG SER, V194, P65, DOI 10.3354/meps194065; Orth RJ, 2006, BIOSCIENCE, V56, P987, DOI 10.1641/0006-3568(2006)56[987:AGCFSE]2.0.CO;2; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Pandolfi JM, 2005, SCIENCE, V307, P1725, DOI 10.1126/science.1104258; Roberts CM, 2002, SCIENCE, V295, P1280, DOI 10.1126/science.1067728; Salvat B, 2002, STATUS CORAL REEFS W, P203; SEBENS KP, 1994, AM ZOOL, V34, P115; Selig ER., 2006, ANALYZING RELATIONSH, P111; Silliman BR, 2005, SCIENCE, V310, P1803, DOI 10.1126/science.1118229; Spalding M, 2002, REEFS RISK SE ASIA, P72; STODDART DR, 1974, 2ND P INT COR REEF S, V2, P473; SWEATMAN H, 2003, 6 AUSTR I MAR SCI; Wilkinson C., 2002, STATUS CORAL REEFS W, P378; Wilkinson CR, 2003, P 7 INT COR REEF S G, V1, P11; Willis BL, 2004, CORAL HEALTH AND DISEASE, P69; Wing SR, 2001, CORAL REEFS, V20, P1	63	814	843	6	201	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e711	10.1371/journal.pone.0000711	http://dx.doi.org/10.1371/journal.pone.0000711			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684557	gold, Green Published			2022-12-25	WOS:000207452400014
J	Ivanov, AI; Bachar, M; Babbin, BA; Adelstein, RS; Nusrat, A; Parkos, CA				Ivanov, Andrei I.; Bachar, Moshe; Babbin, Brian A.; Adelstein, Robert S.; Nusrat, Asma; Parkos, Charles A.			A Unique Role for Nonmuscle Myosin Heavy Chain IIA in Regulation of Epithelial Apical Junctions	PLOS ONE			English	Article							CELL-CELL JUNCTIONS; TIGHT JUNCTIONS; E-CADHERIN; ACTIN POLYMERIZATION; LIGHT-CHAIN; ADHESION; MECHANISM; COMPONENTS; EXPRESSION; DYNAMICS	The integrity and function of the epithelial barrier is dependent on the apical junctional complex (AJC) composed of tight and adherens junctions and regulated by the underlying actin filaments. A major F-actin motor, myosin II, was previously implicated in regulation of the AJC, however direct evidence of the involvement of myosin II in AJC dynamics are lacking and the molecular identity of the myosin II motor that regulates formation and disassembly of apical junctions in mammalian epithelia is unknown. We investigated the role of nonmuscle myosin II (NMMII) heavy chain isoforms, A, B, and C in regulation of epithelial AJC dynamics and function. Expression of the three NMMII isoforms was observed in model intestinal epithelial cell lines, where all isoforms accumulated within the perijunctional F-actin belt. siRNA-mediated downregulation of NMMIIA, but not NMMIIB or NMMIIC expression in SK-CO15 colonic epithelial cells resulted in profound changes of cell morphology and cell-cell adhesions. These changes included acquisition of a fibroblast-like cell shape, defective paracellular barrier, and substantial attenuation of the assembly and disassembly of both adherens and tight junctions. Impaired assembly of the AJC observed after NMMIIA knock-down involved dramatic disorganization of perijunctional actin filaments. These findings provide the first direct non-pharmacological evidence of myosin II-dependent regulation of AJC dynamics in mammalian epithelia and highlight a unique role of NMMIIA in junctional biogenesis.	[Ivanov, Andrei I.; Bachar, Moshe; Babbin, Brian A.; Nusrat, Asma; Parkos, Charles A.] Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; [Adelstein, Robert S.] NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	Emory University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ivanov, AI (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA.	aiivano@emory.edu	Ivanov, Andrei/V-1672-2019	Adelstein, Robert/0000-0002-8683-2144	Crohn's and Colitis Foundation of America; National Institute of Health [DK 61379, DK 72564, HL72124, DK 55679, DK 59888]; Digestive Diseases Minicenter [DK64399]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072124, Z01HL004218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061379, R01DK055679, R29DK055679, R01DK059888, R24DK064399, R01DK072564] Funding Source: NIH RePORTER	Crohn's and Colitis Foundation of America; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Digestive Diseases Minicenter; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a Career Development Award from Crohn's and Colitis Foundation of America (to AII) and by National Institute of Health grants DK 61379, DK 72564 and HL72124 (to CAP), DK 55679, and DK 59888 (to AN) and a Digestive Diseases Minicenter grant DK64399 (epithelial tissue culture and morphology cores).	Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Aijaz S, 2006, INT REV CYTOL, V248, P261, DOI 10.1016/S0074-7696(06)48005-0; Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005; Bao JJ, 2005, J BIOL CHEM, V280, P19594, DOI 10.1074/jbc.M501573200; Bershadsky A, 2004, TRENDS CELL BIOL, V14, P589, DOI 10.1016/j.tcb.2004.09.009; Blaschuk OW, 2002, MOL MEMBR BIOL, V19, P75, DOI 10.1080/09687680210132467; Cai YF, 2006, BIOPHYS J, V91, P3907, DOI 10.1529/biophysj.106.084806; Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; Cramer LP, 2002, CELL MOTIL CYTOSKEL, V51, P27, DOI 10.1002/cm.10013; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; de Rooij J, 2005, J CELL BIOL, V171, P153, DOI 10.1083/jcb.200506152; Gandhi S, 1997, AM J PHYSIOL-RENAL, V272, pF214, DOI 10.1152/ajprenal.1997.272.2.F214; Gloushankova NA, 1998, P NATL ACAD SCI USA, V95, P4362, DOI 10.1073/pnas.95.8.4362; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Goodwin M, 2004, J MOL HISTOL, V35, P839, DOI 10.1007/s10735-004-1833-2; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; Hossain MM, 2005, J BIOL CHEM, V280, P42442, DOI 10.1074/jbc.M509952200; Ivanov AI, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-12; Ivanov AI, 2005, MOL BIOL CELL, V16, P2636, DOI 10.1091/mbc.E05-01-0043; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Jana SS, 2006, J BIOL CHEM, V281, P24662, DOI 10.1074/jbc.M604606200; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Krendel MF, 1999, CELL MOTIL CYTOSKEL, V43, P296, DOI 10.1002/(SICI)1097-0169(1999)43:4<296::AID-CM3>3.0.CO;2-U; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Lecuit T, 2005, TRENDS CELL BIOL, V15, P34, DOI 10.1016/j.tcb.2004.11.007; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; Ma TY, 2000, MICROSC RES TECHNIQ, V51, P156, DOI 10.1002/1097-0029(20001015)51:2<156::AID-JEMT7>3.0.CO;2-J; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; McNeil E, 2006, MOL BIOL CELL, V17, P1922, DOI 10.1091/mbc.E05-07-0650; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Miyake Y, 2006, EXP CELL RES, V312, P1637, DOI 10.1016/j.yexcr.2006.01.031; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Ogita H, 2006, IUBMB LIFE, V58, P334, DOI 10.1080/15216540600719622; Ostap EM, 2002, J MUSCLE RES CELL M, V23, P305, DOI 10.1023/A:1022047102064; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Shewan AM, 2005, MOL BIOL CELL, V16, P4531, DOI 10.1091/mbc.E05-04-0330; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Shu S, 2005, P NATL ACAD SCI USA, V102, P1472, DOI 10.1073/pnas.0409528102; STEVENSON BR, 1994, J CELL SCI, V107, P367; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Weis WI, 2006, J BIOL CHEM, V281, P35593, DOI 10.1074/jbc.R600027200; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yarrow JC, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-5; Zhang JK, 2005, J CELL SCI, V118, P5549, DOI 10.1242/jcs.02639	62	125	128	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e658	10.1371/journal.pone.0000658	http://dx.doi.org/10.1371/journal.pone.0000658			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668046	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452300004
J	Srinivasan, S; Santiago, P; Lubrano, C; Vaisse, C; Conklin, BR				Srinivasan, Supriya; Santiago, Pamela; Lubrano, Cecile; Vaisse, Christian; Conklin, Bruce R.			Engineering the Melanocortin-4 Receptor to Control Constitutive and Ligand-Mediated G(s) Signaling In Vivo	PLOS ONE			English	Article							ENERGY HOMEOSTASIS; OBESITY; MUTATIONS; PROLIFERATION; AGONIST; MC4R; PROOPIOMELANOCORTIN; ACTIVATION; EXPRESSION; SWEET	The molecular and functional diversity of G protein-coupled receptors is essential to many physiological processes. However, this diversity presents a significant challenge to understanding the G protein-mediated signaling events that underlie a specific physiological response. To increase our understanding of these processes, we sought to gain control of the timing and specificity of G(s) signaling in vivo. We used naturally occurring human mutations to develop two G(s)-coupled engineered receptors that respond solely to a synthetic ligand (RASSLs). Our G(s)-coupled RASSLs are based on the melanocortin-4 receptor, a centrally expressed receptor that plays an important role in the regulation of body weight. These RASSLs are not activated by the endogenous hormone alpha-melanocyte-stimulating hormone but respond potently to a selective synthetic ligand, tetrahydroisoquinoline. The RASSL variants reported here differ in their intrinsic basal activities, allowing the separation of the effects of basal signaling from ligand-mediated activation of the G(s) pathway in vivo. These RASSLs can be used to activate G(s) signaling in any tissue, but would be particularly useful for analyzing downstream events that mediate body weight regulation in mice. Our study also demonstrates the use of human genetic variation for protein engineering.	[Srinivasan, Supriya] Univ Calif San Francisco, Dept Physiol, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; [Vaisse, Christian; Conklin, Bruce R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Lubrano, Cecile; Vaisse, Christian] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Srinivasan, S (corresponding author), Univ Calif San Francisco, Dept Physiol, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA.	supriya.srinivasan@ucsf.edu; bconklin@gladstone.ucsf.edu	Vaisse, Christian/F-1067-2011; Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061	National Institutes of Health [HL60664-06]; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060540] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health Grant HL60664-06 (to B. R. C.) and an American Heart Association Postdoctoral Fellowship (to S. S.).	Barb CR, 2004, J ENDOCRINOL, V181, P39, DOI 10.1677/joe.0.1810039; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Challis BG, 2004, P NATL ACAD SCI USA, V101, P4695, DOI 10.1073/pnas.0306931101; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Claeysen S, 2003, J BIOL CHEM, V278, P699, DOI 10.1074/jbc.C200588200; Cone RD, 2000, RECEPTORS, P405; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Gaillard I, 2004, CELL MOL LIFE SCI, V61, P456, DOI 10.1007/s00018-003-3273-7; Goodfellow VS, 2003, CURR TOP MED CHEM, V3, P855, DOI 10.2174/1568026033452212; HAGA T, 2000, G PROTEIN COUPLED RE; Harrold JA, 2003, PEPTIDES, V24, P397, DOI 10.1016/S0196-9781(03)00054-8; Haskell-Luevano C, 2000, PEPTIDES, V21, P49, DOI 10.1016/S0196-9781(99)00167-9; Haskell-Luevano C, 2001, REGUL PEPTIDES, V99, P1, DOI 10.1016/S0167-0115(01)00234-8; Haskell-Luevano C, 2001, BIOCHEMISTRY-US, V40, P6164, DOI 10.1021/bi010025q; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Ho GY, 1999, J BIOL CHEM, V274, P35816, DOI 10.1074/jbc.274.50.35816; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Houshmand P, 2003, CURR OPIN CHEM BIOL, V7, P457, DOI 10.1016/S1367-5931(03)00086-3; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jain RK, 2004, P NATL ACAD SCI USA, V101, P111, DOI 10.1073/pnas.2534352100; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Li ZY, 2002, MOL THER, V5, P420, DOI 10.1006/mthe.2002.0565; Lubrano-Berthelier C, 2003, ANN NY ACAD SCI, V994, P49, DOI 10.1111/j.1749-6632.2003.tb03161.x; Lubrano-Berthelier C, 2003, HUM MOL GENET, V12, P145, DOI 10.1093/hmg/ddg016; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; MacNeil DJ, 2002, EUR J PHARMACOL, V440, P141, DOI 10.1016/S0014-2999(02)01425-5; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; Millington GWM, 2001, NEUROSCIENCE, V108, P437, DOI 10.1016/S0306-4522(01)00428-6; Moldrich RX, 2003, CNS NEUROL DISORD-DR, V2, P109, DOI 10.2174/1568007033482922; Myslivecek J, 2003, GEN PHYSIOL BIOPHYS, V22, P3; Nijenhuis WAJ, 2003, J BIOL CHEM, V278, P22939, DOI 10.1074/jbc.M211326200; Raffin-Sanson ML, 2003, EUR J ENDOCRINOL, V149, P79, DOI 10.1530/eje.0.1490079; Redfern CH, 1999, NAT BIOTECHNOL, V17, P165, DOI 10.1038/6165; Scearce-Levie K, 2001, TRENDS PHARMACOL SCI, V22, P414, DOI 10.1016/S0165-6147(00)01743-0; SCEARCELEVIE K, 2002, SOC NEUROSCIENCE; Sebhat IK, 2002, J MED CHEM, V45, P4589, DOI 10.1021/jm025539h; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shinyama H, 2003, ENDOCRINOLOGY, V144, P1301, DOI 10.1210/en.2002-220931; Small KM, 2001, J BIOL CHEM, V276, P31596, DOI 10.1074/jbc.M102734200; Srinivasan S, 2003, ANN NY ACAD SCI, V994, P225, DOI 10.1111/j.1749-6632.2003.tb03184.x; SRINIVASAN S, 2004, ACTIVATION IN PRESS; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Whitney ML, 2001, J BIOL CHEM, V276, P41191, DOI 10.1074/jbc.M103191200; Yang Suh-Yung, 2000, Korean Journal of Biological Sciences, V4, P39; Yang YK, 2002, J BIOL CHEM, V277, P20328, DOI 10.1074/jbc.M201343200; Yeo GSH, 2003, HUM MOL GENET, V12, P561, DOI 10.1093/hmg/ddg057; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	54	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2007	2	8							e668	10.1371/journal.pone.0000668	http://dx.doi.org/10.1371/journal.pone.0000668			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GK	17668051	gold, Green Published			2022-12-25	WOS:000207452300009
J	Boyles, JG; Storm, JJ				Boyles, Justin G.; Storm, Jonathan J.			The Perils of Picky Eating: Dietary Breadth Is Related to Extinction Risk in Insectivorous Bats	PLOS ONE			English	Article							TROPICAL RAIN-FOREST; FECAL ANALYSIS; RARITY; SPECIALIZATION; CHIROPTERA; PHYLOGENY; FOOD	Several recent papers evaluate the relationship between ecological characteristics and extinction risk in bats. These studies report that extinction risk is negatively related to geographic range size and positively related to habitat specialization. Here, we evaluate the hypothesis that extinction risk is also related to dietary specialization in insectivorous vespertilionid bats using both traditional and phylogenetically-controlled analysis of variance. We collected dietary data and The World Conservation Union (IUCN) rankings for 44 Australian, European, and North American bat species. Our results indicate that species of conservation concern (IUCN ranking near threatened or above) are more likely to have a specialized diet than are species of least concern. Additional analyses show that dietary breadth is not correlated to geographic range size or wing morphology, characteristics previously found to correlate with extinction risk. Therefore, there is likely a direct relationship between dietary specialization and extinction risk; however, the large variation in dietary breadth within species of least concern suggests that diet alone cannot explain extinction risk. Our results may have important implications for the development of predictive models of extinction risk and for the assignment of extinction risk to insectivorous bat species. Similar analyses should be conducted on additional bat families to assess the generality of this relationship between niche breadth and extinction risk.	[Boyles, Justin G.] Indiana State Univ, Ctr N Amer Bat Res & Conservat, Dept Ecol & Organismal Biol, Terre Haute, IN 47809 USA; [Storm, Jonathan J.] Indiana State Univ, Dept Ecol & Organismal Biol, Terre Haute, IN 47809 USA	Indiana State University; Indiana State University	Boyles, JG (corresponding author), Indiana State Univ, Ctr N Amer Bat Res & Conservat, Dept Ecol & Organismal Biol, Terre Haute, IN 47809 USA.	jboyles3@mymail.indstate.edu	Boyles, Justin G/A-5152-2010					ARITA HT, 1993, ECOL APPL, V3, P506, DOI 10.2307/1941919; Boots M, 2002, AM NAT, V159, P706, DOI 10.1086/339996; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Garland T, 1999, AM ZOOL, V39, P374; GARLAND T, 1993, SYST BIOL, V42, P265, DOI 10.2307/2992464; Goulson D, 2005, BIOL CONSERV, V122, P1, DOI 10.1016/j.biocon.2004.06.017; Harcourt AH, 2002, J BIOGEOGR, V29, P445, DOI 10.1046/j.1365-2699.2002.00685.x; Hoofer SR, 2003, ACTA CHIROPTEROL, V5, P1, DOI 10.3161/001.005.s101; HUMPHREY SR, 1975, J MAMMAL, V56, P321, DOI 10.2307/1379364; IUCN, 2012, IUCN RED LIST CATEGO, VSecond; IUCN, 2006, IUCN RED LIST THREAT; Jones KE, 2003, AM NAT, V161, P601, DOI 10.1086/368289; Jonsson T, 2006, ECOL MODEL, V199, P93, DOI 10.1016/j.ecolmodel.2006.06.012; Kotiaho JS, 2005, P NATL ACAD SCI USA, V102, P1963, DOI 10.1073/pnas.0406718102; KUNZ TH, 1983, CAN J ZOOL, V61, P1317, DOI 10.1139/z83-177; KURTA A, 1992, ECOGRAPHY, V15, P257, DOI 10.1111/j.1600-0587.1992.tb00032.x; LAURANCE WF, 1991, CONSERV BIOL, V5, P79, DOI 10.1111/j.1523-1739.1991.tb00390.x; MacArthur R.H., 1972, pvii; Martins E. P., 2004, COMPARE VERSION 4 6B; Mickleburgh SP, 2002, ORYX, V36, P18, DOI 10.1017/S0030605301000011; NORBERG UM, 1987, PHILOS T R SOC B, V316, P337; Purvis A, 2000, BIOESSAYS, V22, P1123, DOI 10.1002/1521-1878(200012)22:12<1123::AID-BIES10>3.0.CO;2-C; Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234; ROBINSON MF, 1993, J ZOOL, V231, P239, DOI 10.1111/j.1469-7998.1993.tb01915.x; Ruedi M, 2001, MOL PHYLOGENET EVOL, V21, P436, DOI 10.1006/mpev.2001.1017; Safi K, 2004, CONSERV BIOL, V18, P1293, DOI 10.1111/j.1523-1739.2004.00155.x; Schoener TW, 2001, NATURE, V412, P183, DOI 10.1038/35084071; Sierro A, 1997, ACTA OECOL, V18, P91, DOI 10.1016/S1146-609X(97)80067-7; Stadelmann B, 2007, MOL PHYLOGENET EVOL, V43, P32, DOI 10.1016/j.ympev.2006.06.019; Stadelmann B, 2004, ACTA CHIROPTEROL, V6, P177, DOI 10.3161/001.006.0201; Walker JS, 2006, BIOL CONSERV, V130, P60, DOI 10.1016/j.biocon.2005.12.002; Williams P, 2005, BIOL CONSERV, V122, P33, DOI 10.1016/j.biocon.2004.06.019; Zar JH, 1999, BIOSTATISTICAL ANAL	33	67	71	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e672	10.1371/journal.pone.0000672	http://dx.doi.org/10.1371/journal.pone.0000672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653286	gold, Green Published			2022-12-25	WOS:000207452200028
J	Catic, A; Fiebiger, E; Korbel, GA; Blom, D; Galardy, PJ; Ploegh, HL				Catic, Andre; Fiebiger, Edda; Korbel, Gregory A.; Blom, Daniel; Galardy, Paul J.; Ploegh, Hidde L.			Screen for ISG15-crossreactive Deubiquitinases	PLOS ONE			English	Article							UBIQUITIN-LIKE PROTEIN; FUNCTIONAL PROTEOMICS; ANTIVIRAL MOLECULE; STIMULATED GENE-15; UBP43 USP18; ATAXIA MICE; ISG15; ENZYME; CONJUGATION; IDENTIFICATION	Background. The family of ubiquitin-like molecules (UbLs) comprises several members, each of which has sequence, structural, or functional similarity to ubiquitin. ISG15 is a homolog of ubiquitin in vertebrates and is strongly upregulated following induction by type I interferon. ISG15 can be covalently attached to proteins, analogous to ubiquitination and with actual support of ubiquitin conjugating factors. Specific proteases are able to reverse modification with ubiquitin or UbLs by hydrolyzing the covalent bond between their C-termini and substrate proteins. The tail regions of ubiquitin and ISG15 are identical and we therefore hypothesized that promiscuous deubiquitinating proteases (DUBs) might exist, capable of recognizing both ubiquitin and ISG15. Results. We have cloned and expressed 22 human DUBs, representing the major clades of the USP protease family. Utilizing suicide inhibitors based on ubiquitin and ISG15, we have identified USP2, USP5 (IsoT1), USP13 (IsoT3), and USP14 as ISG15-reactive proteases, in addition to the bona fide ISG15-specific protease USP18 (UBP43). USP14 is a proteasome-associated DUB, and its ISG15 isopeptidase activity increases when complexed with the proteasome. Conclusions. By evolutionary standards, ISG15 is a newcomer among the UbLs and it apparently not only utilizes the conjugating but also the deconjugating machinery of its more established relative ubiquitin. Functional overlap between these two posttranslational modifiers might therefore be more extensive than previously appreciated and explain the rather innocuous phenotype of ISG15 null mice.	[Galardy, Paul J.] Mayo Clin Pediat & Adolescent Med, Rochester, MN USA; [Catic, Andre] Harvard Univ, Sch Med, Program Immunol, Boston, MA USA; [Catic, Andre; Korbel, Gregory A.; Ploegh, Hidde L.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA; [Fiebiger, Edda] Childrens Hosp, GI Cell Biol, Boston, MA 02115 USA; [Blom, Daniel] Merck, Rahway, NJ USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Boston Children's Hospital; Merck & Company	Galardy, PJ (corresponding author), Mayo Clin Pediat & Adolescent Med, Rochester, MN USA.	Galardy.Paul@mayo.edu; Ploegh@wi.mit.edu	Galardy, Paul/AAE-9297-2019	Catic, Andre/0000-0002-3572-7598	NIH [GM072352-02]; AstraZeneca; Charles A. King Trust; Mayo Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072352] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); Charles A. King Trust; Mayo Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the NIH and from AstraZeneca. E. F. was supported by the Charles A. King Trust. G. A. K. was supported by an NIH postdoctoral fellowship (GM072352-02). P.J.G. is the Harriet H. Samuelsson Clinical Translational Research Scientist and is also supported by the Mayo Foundation.	Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Borodovsky A, 2005, CHEMBIOCHEM, V6, P287, DOI 10.1002/cbic.200400236; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Catic A, 2005, TRENDS BIOCHEM SCI, V30, P600, DOI 10.1016/j.tibs.2005.09.002; Crimmins S, 2006, J NEUROSCI, V26, P11423, DOI 10.1523/JNEUROSCI.3600-06.2006; Dastur A, 2006, J BIOL CHEM, V281, P4334, DOI 10.1074/jbc.M512830200; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Fiebiger E, 2005, J EXP MED, V201, P267, DOI 10.1084/jem.20041384; Fiebiger E, 2002, EMBO J, V21, P1041, DOI 10.1093/emboj/21.5.1041; Gabriel JM, 2002, BIOCHEMISTRY-US, V41, P13755, DOI 10.1021/bi026096m; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guterman A, 2004, CURR PROTEIN PEPT SC, V5, P201, DOI 10.2174/1389203043379756; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hemelaar J, 2004, J PROTEOME RES, V3, P268, DOI 10.1021/pr0341080; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jamaluddin M, 2001, AM J PHYSIOL-LUNG C, V280, pL248, DOI 10.1152/ajplung.2001.280.2.L248; Kessler B, 2003, J BIOL CHEM, V278, P10013, DOI 10.1074/jbc.M211221200; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; KNIGHT E, 1991, J IMMUNOL, V146, P2280; Knobeloch KP, 2005, MOL CELL BIOL, V25, P11030, DOI 10.1128/MCB.25.24.11030-11034.2005; Kroismayr R, 2004, J CELL SCI, V117, P4749, DOI 10.1242/jcs.01338; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lenschow DJ, 2007, P NATL ACAD SCI USA, V104, P1371, DOI 10.1073/pnas.0607038104; Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005; Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005; Liu MJ, 2003, J BIOL CHEM, V278, P1594, DOI 10.1074/jbc.M208123200; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149; MISAGHI S, 2004, J BIOL CHEM; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nakamura M, 1996, J IMMUNOL, V156, P533; Nakamura M, 1998, BIOCHEM J, V330, P683, DOI 10.1042/bj3300683; Narasimhan J, 2005, J BIOL CHEM, V280, P27356, DOI 10.1074/jbc.M502814200; Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103; Osiak A, 2005, MOL CELL BIOL, V25, P6338, DOI 10.1128/MCB.25.15.6338-6345.2005; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Ryu KY, 2006, ANAL BIOCHEM, V353, P153, DOI 10.1016/j.ab.2006.03.038; SCHEID MP, 1975, SCIENCE, V190, P1211, DOI 10.1126/science.1081736; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwer H, 2000, GENOMICS, V65, P44, DOI 10.1006/geno.2000.6148; Segal S, 2003, TRENDS MICROBIOL, V11, P445, DOI 10.1016/S0966-842X(03)00207-5; Soboleva TA, 2004, CURR PROTEIN PEPT SC, V5, P191, DOI 10.2174/1389203043379765; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Takeuchi T, 2006, BIOCHEM BIOPH RES CO, V348, P473, DOI 10.1016/j.bbrc.2006.07.076; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilson SM, 2002, NAT GENET, V32, P420, DOI 10.1038/ng1006; Wong JJY, 2006, P NATL ACAD SCI USA, V103, P10735, DOI 10.1073/pnas.0600397103; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102	69	68	70	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e679	10.1371/journal.pone.0000679	http://dx.doi.org/10.1371/journal.pone.0000679			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653289	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452200031
J	Moradian, MM; Beglaryan, D; Skozylas, JM; Kerikorian, V				Moradian, Mike M.; Beglaryan, Denis; Skozylas, Jill M.; Kerikorian, Varand			Complete Mitochondrial Genome Sequence of Three Tetrahymena Species Reveals Mutation Hot Spots and Accelerated Nonsynonymous Substitutions in Ymf Genes	PLOS ONE			English	Article							DNA; ALIGNMENT; PROGRAM; RATES; THERMOPHILA; EVOLUTION; CLUSTAL; PACKAGE	The ciliate Tetrahymena, a model organism, contains divergent mitochondrial (Mt) genome with unusual properties, where half of its 44 genes still remain without a definitive function. These genes could be categorized into two major groups of KPC (known protein coding) and Ymf (genes without an identified function). To gain insights into the mechanisms underlying gene divergence and molecular evolution of Tetrahymena (T.) Mt genomes, we sequenced three Mt genomes of T. paravorax, T. pigmentosa, and T. malaccensis. These genomes were aligned and the analyses were carried out using several programs that calculate distance, nucleotide substitution (dn/ds), and their rate ratios (omega) on individual codon sites and via a sliding window approach. Comparative genomic analysis indicated a conserved putative transcription control sequence, a GC box, in a region where presumably transcription and replication initiate. We also found distinct features in Mt genome of T. paravorax despite similar genome organization among these similar to 47 kb long linear genomes. Another significant finding was the presence of at least one or more highly variable regions in Ymf genes where majority of substitutions were concentrated. These regions were mutation hotspots where elevated distances and the dn/ds ratios were primarily due to an increase in the number of nonsynonymous substitutions, suggesting relaxed selective constraint. However, in a few Ymf genes, accelerated rates of nonsynonymous substitutions may be due to positive selection. Similarly, on protein level the majority of amino acid replacements occurred in these regions. Ymf genes comprise half of the genes in Tetrahymena Mt genomes, so understanding why they have not been assigned definitive functions is an important aspect of molecular evolution. Importantly, nucleotide substitution types and rates suggest possible reasons for not being able to find homologues for Ymf genes. Additionally, comparative genomic analysis of complete Mt genomes is essential in identifying biologically significant motifs such as control regions.	[Moradian, Mike M.; Beglaryan, Denis; Skozylas, Jill M.; Kerikorian, Varand] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Moradian, MM (corresponding author), Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90024 USA.	mmoradia@ucla.edu			NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding: IGERT training program fellowship from NIH.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; Ballard JWO, 2000, J MOL EVOL, V51, P64, DOI 10.1007/s002390010067; Bleyman Lea K., 1996, P291; Blouin MS, 1998, MOL BIOL EVOL, V15, P1719, DOI 10.1093/oxfordjournals.molbev.a025898; Brunk CF, 2003, NUCLEIC ACIDS RES, V31, P1673, DOI 10.1093/nar/gkg270; BRUNK CF, 1969, EXP CELL RES, V54, P143, DOI 10.1016/0014-4827(69)90225-0; Burger G, 2000, J MOL BIOL, V297, P365, DOI 10.1006/jmbi.2000.3529; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Chiang YC, 2003, AM J BOT, V90, P561, DOI 10.3732/ajb.90.4.561; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; Crandall KA, 1997, NATURE, V387, P667, DOI 10.1038/42628; Dagan T, 2002, MOL BIOL EVOL, V19, P1022, DOI 10.1093/oxfordjournals.molbev.a004161; Denver DR, 2000, SCIENCE, V289, P2342, DOI 10.1126/science.289.5488.2342; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P99; Edqvist J, 2000, J MOL BIOL, V297, P381, DOI 10.1006/jmbi.2000.3530; ENGBERG J, 1990, NUCLEIC ACIDS RES, V18, P6915, DOI 10.1093/nar/18.23.6915; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fares MA, 2004, BIOINFORMATICS, V20, P2867, DOI 10.1093/bioinformatics/bth303; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hu Yin-gang, 2003, Xibei Zhiwu Xuebao, V23, P875; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KORBER B, 2001, HIV SIGNATURE SEQUEN, P55; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LI WH, 1997, MOL EVOLUTION, P216; Lopez R, 2003, NUCLEIC ACIDS RES, V31, P3795, DOI 10.1093/nar/gkg573; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MORIN GB, 1988, CELL, V52, P367, DOI 10.1016/S0092-8674(88)80029-1; MORIN GB, 1988, MOL CELL BIOL, V8, P4450, DOI 10.1128/MCB.8.10.4450; MOUNT DW, 2001, BIOINFORMATICS SEQUE, P96; NANNY DL, 2000, LAB EVOLUTIONARY HIS, P4; NEI M, 1986, MOL BIOL EVOL, V3, P418; ORIAS E, 1976, METHOD CELL BIOL, V8, P247; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Shao RF, 2003, MOL BIOL EVOL, V20, P362, DOI 10.1093/molbev/msg045; Siltberg J, 2002, J EVOLUTION BIOL, V15, P588, DOI 10.1046/j.1420-9101.2002.00416.x; TAJIMA F, 1989, GENETICS, V123, P585; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thorstenson YR, 1998, GENOME RES, V8, P848, DOI 10.1101/gr.8.8.848; Yang ZH, 2000, MOL BIOL EVOL, V17, P32, DOI 10.1093/oxfordjournals.molbev.a026236; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yang ZH, 1998, MOL BIOL EVOL, V15, P1600, DOI 10.1093/oxfordjournals.molbev.a025888; Yokoyama S, 1996, ANNU REV ECOL SYST, V27, P543, DOI 10.1146/annurev.ecolsys.27.1.543; Yu FL, 2005, PLOS GENET, V1, P404, DOI 10.1371/journal.pgen.0010041; Zhang JZ, 2000, J MOL EVOL, V50, P56, DOI 10.1007/s002399910007	54	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e650	10.1371/journal.pone.0000650	http://dx.doi.org/10.1371/journal.pone.0000650			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653277	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452200019
J	Froula, JL; Francino, MP				Froula, Jeffrey L.; Francino, M. Pilar			Selection against Spurious Promoter Motifs Correlates with Translational Efficiency across Bacteria	PLOS ONE			English	Article							MULTIPLE SEQUENCE ALIGNMENT; GENE-EXPRESSION LEVEL; TRANSFER-RNA GENES; ESCHERICHIA-COLI; CODON USAGE; SIGMA(70) SUBUNIT; TRANSCRIPTION; EVOLUTION; PROTEIN; POLYMERASE	Because binding of RNAP to misplaced sites could compromise the efficiency of transcription, natural selection for the optimization of gene expression should regulate the distribution of DNA motifs capable of RNAP-binding across the genome. Here we analyze the distribution of the -10 promoter motifs that bind the sigma(70) subunit of RNAP in 42 bacterial genomes. We show that selection on these motifs operates across the genome, maintaining an over-representation of -10 motifs in regulatory sequences while eliminating them from the nonfunctional and, in most cases, from the protein coding regions. In some genomes, however, -10 sites are over-represented in the coding sequences; these sites could induce pauses effecting regulatory roles throughout the length of a transcriptional unit. For nonfunctional sequences, the extent of motif under-representation varies across genomes in a manner that broadly correlates with the number of tRNA genes, a good indicator of translational speed and growth rate. This suggests that minimizing the time invested in gene transcription is an important selective pressure against spurious binding. However, selection against spurious binding is detectable in the reduced genomes of host-restricted bacteria that grow at slow rates, indicating that components of efficiency other than speed may also be important. Minimizing the number of RNAP molecules per cell required for transcription, and the corresponding energetic expense, may be most relevant in slow growers. These results indicate that genome-level properties affecting the efficiency of transcription and translation can respond in an integrated manner to optimize gene expression. The detection of selection against promoter motifs in nonfunctional regions also confirms previous results indicating that no sequence may evolve free of selective constraints, at least in the relatively small and unstructured genomes of bacteria.	[Froula, Jeffrey L.; Francino, M. Pilar] DOE Joint Genome Inst, Evolutionary Genom Program, Walnut Creek, CA USA	United States Department of Energy (DOE)	Francino, MP (corresponding author), DOE Joint Genome Inst, Evolutionary Genom Program, Walnut Creek, CA USA.	mpfrancino@lbl.gov	Francino, M.Pilar/H-9090-2015	Francino, M.Pilar/0000-0002-4510-5653	US Department of Energy's Office of Science; University of California, Lawrence Berkeley National Laboratory [DE-AC03-76SF00098]	US Department of Energy's Office of Science(United States Department of Energy (DOE)); University of California, Lawrence Berkeley National Laboratory(University of California System)	This work has been performed under the auspices of the US Department of Energy's Office of Science, Biological and Environmental Research Program and by the University of California, Lawrence Berkeley National Laboratory under contract No. DE-AC03-76SF00098.	ALTSCHUL SF, 1985, MOL BIOL EVOL, V2, P526; Babu MM, 2003, TRENDS MICROBIOL, V11, P59, DOI 10.1016/S0966-842X(02)00031-8; BENSON DA, 2005, NUCLEIC ACIDS RES, V38, P33; Brodolin K, 2004, NAT STRUCT MOL BIOL, V11, P551, DOI 10.1038/nsmb768; BULMER M, 1991, GENETICS, V129, P897; Clark MA, 1999, MOL BIOL EVOL, V16, P1586, DOI 10.1093/oxfordjournals.molbev.a026071; Dhandayuthapani S, 1998, GENE, V215, P213, DOI 10.1016/S0378-1119(98)00260-1; Dhiman A, 2000, J BACTERIOL, V182, P5076, DOI 10.1128/JB.182.18.5076-5081.2000; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Hahn MW, 2003, MOL BIOL EVOL, V20, P901, DOI 10.1093/molbev/msg096; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; Herbeck JT, 2003, GENETICS, V165, P1651; Herbeck JT, 2003, MICROBIOL-SGM, V149, P2585, DOI 10.1099/mic.0.26381-0; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huerta AM, 2006, MOL BIOL EVOL, V23, P997, DOI 10.1093/molbev/msk004; Huerta AM, 2003, J MOL BIOL, V333, P261, DOI 10.1016/j.jmb.2003.07.017; Huerta AM, 2006, PLOS GENET, V2, P1740, DOI 10.1371/journal.pgen.0020185; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kanaya S, 1999, GENE, V238, P143, DOI 10.1016/S0378-1119(99)00225-5; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; Lewin B., 2000, GENES; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MAKINO K, 1988, J MOL BIOL, V203, P85, DOI 10.1016/0022-2836(88)90093-9; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; Mooney RA, 2003, GENE DEV, V17, P2839, DOI 10.1101/gad.1142203; Moran NA, 2004, CURR OPIN GENET DEV, V14, P627, DOI 10.1016/j.gde.2004.09.003; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; Moran NA, 2005, J BACTERIOL, V187, P4229, DOI 10.1128/JB.187.12.4229-4237.2005; Moreno-Hagelsieb Gabriel, 2002, Bioinformatics, V18 Suppl 1, pS329; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; Nickels BE, 2004, NAT STRUCT MOL BIOL, V11, P544, DOI 10.1038/nsmb757; Ozoline ON, 1997, NUCLEIC ACIDS RES, V25, P4703, DOI 10.1093/nar/25.23.4703; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Rocha EPC, 2004, GENOME RES, V14, P2279, DOI 10.1101/gr.2896904; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; SHARP PM, 1986, J MOL EVOL, V24, P28, DOI 10.1007/BF02099948; Stone JR, 2001, MOL BIOL EVOL, V18, P1764, DOI 10.1093/oxfordjournals.molbev.a003964; van Ham RCHJ, 2003, P NATL ACAD SCI USA, V100, P581, DOI 10.1073/pnas.0235981100; VARENNE S, 1984, J MOL BIOL, V180, P549, DOI 10.1016/0022-2836(84)90027-5; Vogel J, 2003, NUCLEIC ACIDS RES, V31, P2890, DOI 10.1093/nar/gkg398; Wade JT, 2004, P NATL ACAD SCI USA, V101, P17777, DOI 10.1073/pnas.0404305101; Weiner J, 2000, NUCLEIC ACIDS RES, V28, P4488, DOI 10.1093/nar/28.22.4488; WEISBURG WG, 1985, SCIENCE, V230, P556, DOI 10.1126/science.3931222; Wernegreen JJ, 1999, MOL BIOL EVOL, V16, P83, DOI 10.1093/oxfordjournals.molbev.a026040; Wilcox JL, 2003, MOL MICROBIOL, V48, P1491, DOI 10.1046/j.1365-2958.2003.03522.x	51	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e745	10.1371/journal.pone.0000745	http://dx.doi.org/10.1371/journal.pone.0000745			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710145	gold, Green Published, Green Submitted			2022-12-25	WOS:000207455200022
J	Williamson, P; Halleck, MS; Malowitz, J; Ng, S; Fan, XX; Krahling, S; Remaley, AT; Schlegel, RA				Williamson, Patrick; Halleck, Margaret S.; Malowitz, Jonathan; Ng, Susan; Fan, Xiaoxuan; Krahling, Stephen; Remaley, Alan T.; Schlegel, Robert A.			Transbilayer Phospholipid Movements in ABCA1-Deficient Cells	PLOS ONE			English	Article								Tangier disease is an inherited disorder that results in a deficiency in circulating levels of HDL. Although the disease is known to be caused by mutations in the ABCA1 gene, the mechanism by which lesions in the ABCA1 ATPase effect this outcome is not known. The inability of ABCA1 knockout mice (ABCA1(-/-)) to load cholesterol and phospholipids onto apoA1 led to a proposal that ABCA1 mediates the transbilayer externalization of phospholipids, an activity integral not only to the formation of HDL particles but also to another, distinct process: the recognition and clearance of apoptotic cells by macrophages. Expression of phosphatidylserine (PS) on the surface of both macrophages and their apoptotic targets is required for efficient engulfment of the apoptotic cells, and it has been proposed that ABCA1 is required for transbilayer externalization of PS to the surface of both cell types. To determine whether ABCA1 is responsible for any of the catalytic activities known to control transbilayer phospholipid movements, these activities were measured in cells from ABCA1(-/-) mice and from Tangier individuals as well as ABCA1-expressing HeLa cells. Phospholipid movements in either normal or apoptotic lymphocytes or in macrophages were not inhibited when cells from knockout and wildtype mice or immortalized cells from Tangier individuals vs normal individuals were compared. Exposure of PS on the surface of normal thymocytes, apoptotic thymocytes and elicited peritoneal macrophages from wildtype and knockout mice or B lymphocytes from normal and Tangier individuals, as measured by annexin V binding, was also unchanged. No evidence was found of ABCA1-stimulated active PS export, and spontaneous PS movement to the outer leaflet in the presence or absence of apoA1 was unaffected by the presence or absence of ABCA1. Normal or Tangier B lymphocytes and macrophages were also identical in their ability to serve as targets or phagocytes, respectively, in apoptotic cell clearance assays. No evidence was found to support the suggestion that ABCA1 is involved in transport to the macrophage cell surface of annexins I and II, known to enhance phagocytosis of apoptotic cells. These results show that mutations in ABCA1 do not measurably reduce the rate of transbilayer movements of phospholipids in either the engulfing macrophage or the apoptotic target, thus discounting catalysis of transbilayer movements of phospholipids as the mechanism by which ABCA1 facilitates loading of phospholipids and cholesterol onto apoA1.	[Williamson, Patrick; Malowitz, Jonathan; Ng, Susan] Amherst Coll, Dept Biol, Amherst, MA 01002 USA; [Halleck, Margaret S.; Fan, Xiaoxuan; Krahling, Stephen; Schlegel, Robert A.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Remaley, Alan T.] NHLBI, NIH, Bethesda, MD 20892 USA	Amherst College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Williamson, P (corresponding author), Amherst Coll, Dept Biol, Amherst, MA 01002 USA.	plwilliamson@amherst.edu	Eckhardt, Erik/G-1567-2010		American Heart Association, Pennsylvania; Faculty Research Awards Program of Amherst College; Howard Hughes Medical Institute	American Heart Association, Pennsylvania(American Heart Association); Faculty Research Awards Program of Amherst College; Howard Hughes Medical Institute(Howard Hughes Medical Institute)	Supported by the American Heart Association, Pennsylvania Affiliate (to RAS), the Faculty Research Awards Program of Amherst College (to PLW) and the Howard Hughes Medical Institute through an Undergraduate Biological Sciences Education Program award to Amherst College. Study sponsors had no role in either study design; collection, analysis, and interpretation of the data; writing of the paper; or decision to submit for publication.	Albrecht C, 2005, BLOOD, V106, P542, DOI 10.1182/blood-2004-05-2056; Alder-Baerens N, 2005, J BIOL CHEM, V280, P26321, DOI 10.1074/jbc.M413993200; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Callahan MK, 2003, J LEUKOCYTE BIOL, V74, P846, DOI 10.1189/jlb.0902433; Callahan MK, 2000, CELL DEATH DIFFER, V7, P645, DOI 10.1038/sj.cdd.4400690; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chapman LP, 2003, ENDOCRINOLOGY, V144, P1062, DOI 10.1210/en.2002-220650; Chau PL, 2006, BIOCHEMISTRY-US, V45, P3981, DOI 10.1021/bi052535g; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; ELLIS RE, 1991, GENETICS, V129, P79; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fan XX, 2004, MOL BIOL CELL, V15, P2863, DOI 10.1091/mbc.E03-09-0670; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hamon Y, 2002, BBA-MOL CELL BIOL L, V1585, P64, DOI 10.1016/S1388-1981(02)00325-6; Kielar D, 2001, CLIN CHEM, V47, P2089; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Locher KP, 2004, CURR OPIN STRUC BIOL, V14, P426, DOI 10.1016/j.sbi.2004.06.005; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1999, J LIPID RES, V40, P1769; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schlegel RA, 1999, CELL DEATH DIFFER, V6, P583, DOI 10.1038/sj.cdd.4400529; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3; Zwaal RFA, 2004, BBA-MOL CELL BIOL L, V1636, P119, DOI 10.1016/j.bbalip.2003.07.003	53	28	30	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e729	10.1371/journal.pone.0000729	http://dx.doi.org/10.1371/journal.pone.0000729			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710129	Green Submitted, Green Published, gold			2022-12-25	WOS:000207455200006
J	Gadir, N; Jackson, DN; Lee, E; Foster, DA				Gadir, N.; Jackson, D. N.; Lee, E.; Foster, D. A.			Defective TGF-beta signaling sensitizes human cancer cells to rapamycin	ONCOGENE			English	Article						rapamycin; mTOR; TGF-beta; PKC delta; cancer	GROWTH-FACTOR-BETA; KINASE-C-DELTA; MTOR; INHIBITION; SURVIVAL; RECEPTOR; ARREST; SMAD3; LINES; EXPRESSION	mTOR, the mammalian target of rapamycin, is a critical target of survival signals in many human cancers. In the absence of serum, rapamycin induces apoptosis in MDA-MB-231 human breast cancer cells. However, in the presence of serum, rapamycin induces G1 cell cycle arrest - indicating that a factor( s) in serum suppresses rapamycin-induced apoptosis. We report here that transforming growth factor-beta (TGF-beta) suppresses rapamycin-induced apoptosis in serum-deprived MDA-MB-231 cells in a protein kinase C delta (PKC delta)-dependent manner. Importantly, if TGF-beta signaling or PKCd was suppressed, rapamycin induced apoptosis rather than G1 arrest in the presence of serum. And, if cells were allowed to progress into S phase, rapamycin induced apoptosis in the presence of serum. BT-549 and MDA-MB-468 breast, and SW-480 colon cancer cells have defects in TGF-beta signaling and rapamycin induced apoptosis in these cells in the presence of either serum or TGF-beta. Thus, in the absence of TGF-beta signaling, rapamycin becomes cytotoxic rather than cytostatic. Importantly, this study provides evidence indicating that tumors with defective TGF-beta signaling - common in colon and pancreatic cancers - will be selectively sensitive to rapamycin or other strategies that target mTOR.	[Gadir, N.; Jackson, D. N.; Lee, E.; Foster, D. A.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Borel F, 2002, J CELL SCI, V115, P2829; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Fink SP, 2001, CANCER RES, V61, P256; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; Foster DA, 2006, CURR SIGNAL TRANSD T, V1, P295, DOI 10.2174/157436206778226941; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Popat S, 2005, EUR J CANCER, V41, P2060, DOI 10.1016/j.ejca.2005.04.039; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240-002-0282-1; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	34	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1055	1062		10.1038/sj.onc.1210721	http://dx.doi.org/10.1038/sj.onc.1210721			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700525				2022-12-25	WOS:000253136700004
J	Suprynowicz, FA; Disbrow, GL; Krawczyk, E; Simic, V; Lantzky, K; Schlegel, R				Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.			HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells	ONCOGENE			English	Article						HPV-16 E5 oncoprotein; caveolin-1; ganglioside GM1	EPIDERMAL-GROWTH-FACTOR; E5 PROTEIN; EPITHELIAL-CELLS; PAPILLOMAVIRUS; EXPRESSION; LOCALIZATION; MICRODOMAINS; INHIBIT; SYNAPSE	High-risk human papillomaviruses ( HPVs), especially HPV-16, play a primary role in the pathogenesis of cervical cancer. HPV-16 encodes the E5, E6 and E7 oncoproteins. Although the biological functions of E5 are poorly understood, recent studies indicate that its expression correlates with papillomavirus oncogenicity. In this study we demonstrate that the HPV-16 E5 oncoprotein increases plasma membrane expression of caveolin-1, which is a constituent of lipid rafts and regulator of cell signaling, and that this phenotype is mediated by the C-terminal 10 amino acids of E5. Moreover, E5 ( but not mutant E5) induces a 23- to 40-fold increase in the lipid raft component, ganglioside GM1, on the cell surface and mediates a dramatic increase in caveolin-1/ GM1 association. Since gangliosides strongly inhibit cytotoxic T lymphocytes, block immune synapse formation and are expressed at high levels on the surface of many tumor cells, our results suggest a potential mechanism for immune evasion by the papillomaviruses. Additionally, surface gangliosides are known to enhance proliferative signaling by the epidermal growth factor ( EGF) receptor, providing a possible mechanistic basis for observations that EGF signaling is enhanced in E5-expressing cells. Finally, the upregulation of caveolin-1 and ganglioside GM1 at the plasma membrane of E5-expressing cervical cells provides potential new therapeutic targets and diagnostic markers for high-risk HPV infections.	[Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.] Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20057 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20057 USA.	schleger@georgetown.edu						Ashrafi GH, 2006, INT J CANCER, V119, P2105, DOI 10.1002/ijc.22089; Bacia K, 2004, BIOPHYS J, V87, P1034, DOI 10.1529/biophysj.104.040519; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Bravo IG, 2005, ARCH VIROL, V150, P231, DOI 10.1007/s00705-004-0420-x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cebo C, 2006, J IMMUNOL, V176, P864, DOI 10.4049/jimmunol.176.2.864; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Davis DM, 2004, TRENDS IMMUNOL, V25, P323, DOI 10.1016/j.it.2004.03.007; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; Disbrow GL, 2003, VIROLOGY, V311, P105, DOI 10.1016/S0042-6822(03)00129-6; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Frazer IH, 1996, CURR OPIN IMMUNOL, V8, P484, DOI 10.1016/S0952-7915(96)80035-5; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; McKallip R, 1999, J IMMUNOL, V163, P3718; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Nishio M, 2005, INT J ONCOL, V26, P191; O'Brien PM, 2002, VIRUS RES, V88, P103, DOI 10.1016/S0168-1702(02)00123-5; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Riley RR, 2003, CANCER RES, V63, P4862; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; Shurin GV, 2001, CANCER RES, V61, P363; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Sotgia F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Suprynowicz FA, 2005, VIROLOGY, V332, P102, DOI 10.1016/j.virol.2004.11.011; Suprynowicz FA, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P97; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Vyas YM, 2002, IMMUNOL REV, V189, P161, DOI 10.1034/j.1600-065X.2002.18914.x; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083	40	58	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1071	1078		10.1038/sj.onc.1210725	http://dx.doi.org/10.1038/sj.onc.1210725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704805	Bronze			2022-12-25	WOS:000253136700006
J	Hayes, NVL; Newsam, RJ; Baines, AJ; Gullick, WJ				Hayes, N. V. L.; Newsam, R. J.; Baines, A. J.; Gullick, W. J.			Characterization of the cell membrane-associated products of the Neuregulin 4 gene	ONCOGENE			English	Article						neuregulin 4; growth factor; tyrosine kinase	GROWTH-FACTOR; FACTOR-ALPHA; ISOFORMS; ACTIVATION; SYSTEM; FAMILY	The NRG4 gene is a member of a family of four genes that encode a class of epidermal growth factors. This gene has been reported to express a protein designated here as NRG4A1. We describe here a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide. Both NRG4A1 and NRG4A2 were shown to be expressed on the cell surface, as expected by the presence of a predicted transmembrane sequence, and were modified at a single N-linked glycosylation site in the extracellular domain. Significant stabilization of expression of both proteins was seen in the presence of the proteosome inhibitor MG-132 suggesting that they are normally degraded by this system. N-terminal cleavage was inhibited in both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001). A glycosylated, secreted form of NRG4A1 was detected in the cell medium which showed biological activity in two assays, phosphorylation of the HER4 receptor and stimulation of neurite formation in PC-12 cells stably expressing HER4. Transfection and expression of green fluorescent protein-tagged proteins and immunofluorescent staining with specific anti-peptide antibodies showed that NRG4A1 is localized to membrane ruffles, while NRG4A2 has a more punctate membrane distribution.	[Hayes, N. V. L.; Newsam, R. J.; Gullick, W. J.] Univ Kent, Res Sch Biosci, Canc Biol Lab, Canterbury CT2 7NJ, Kent, England; [Baines, A. J.] Univ Kent, Ctr Biomed Informat, Canterbury CT2 7NJ, Kent, England	University of Kent; University of Kent	Gullick, WJ (corresponding author), Univ Kent, Res Sch Biosci, Canc Biol Lab, Canterbury CT2 7NJ, Kent, England.	w.j.gullick@kent.ac.uk		Baines, Anthony/0000-0003-3068-7811				Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Carteron C, 2006, J CELL SCI, V119, P898, DOI 10.1242/jcs.02799; Dunn M, 2004, J PATHOL, V203, P672, DOI 10.1002/path.1561; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris BZ, 2001, J CELL SCI, V114, P3219; Harrison PJ, 2006, BIOL PSYCHIAT, V60, P132, DOI 10.1016/j.biopsych.2005.11.002; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; ROOBOL A, 1995, J CELL SCI, V108, P1477; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Tastet C, 2003, ELECTROPHORESIS, V24, P1787, DOI 10.1002/elps.200305400; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; von Heijne G, 2006, NAT REV MOL CELL BIO, V7, P909, DOI 10.1038/nrm2063; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Yamada K, 2000, GENE, V255, P15, DOI 10.1016/S0378-1119(00)00309-7	18	22	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					715	720		10.1038/sj.onc.1210689	http://dx.doi.org/10.1038/sj.onc.1210689			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684490	Green Accepted			2022-12-25	WOS:000252674900015
J	Verbrugge, I; de Vries, E; Tait, SWG; Wissink, EHJ; Walczak, H; Verheij, M; Borst, J				Verbrugge, I.; de Vries, E.; Tait, S. W. G.; Wissink, E. H. J.; Walczak, H.; Verheij, M.; Borst, J.			Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway	ONCOGENE			English	Article						apoptosis; DISC; ionizing radiation; mitochondria; TRAIL	IRRADIATION-INDUCED APOPTOSIS; DNA-DAMAGE; CELL-DEATH; CHEMOTHERAPEUTIC DRUGS; CASPASE-8 RECRUITMENT; GAMMA-RADIATION; LIGAND TRAIL; IN-VIVO; ACTIVATION; CD95	In many tumor cell types, ionizing radiation (IR) or DNA-damaging anticancer drugs enhance sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, which is of great clinical interest. We have investigated the molecular mechanism underlying the response to combined modality treatment in p53-mutant Jurkat T leukemic cells overexpressing Bcl-2. These cells are largely resistant to individual treatment with TRAIL or IR, but sensitive to combined treatment, in vitro as well as in vivo. We demonstrate that IR and DNA-damaging anticancer drugs enable TRAIL receptor-2 and CD95/Fas to bypass the mitochondrial pathway for effector caspase activation. This was validated by RNA interference for Bax and Bak and by overexpression of dominant-negative Caspase-9. Improved effector caspase activation was neither caused by altered expression of proapoptotic components nor by impaired activity of inhibitor of apoptosis proteins or nuclear factor-kappa B signaling. Rather, we found that pretreatment of cells with IR caused quantitative and qualitative changes in death receptor signaling. It strongly improved the capacity of ligand-bound receptors to recruit FADD and activate Caspase-8 and -10 in the death-inducing signaling complex, while c-FLIPL levels were unaffected.	[Verbrugge, I.; de Vries, E.; Tait, S. W. G.; Wissink, E. H. J.; Borst, J.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Walczak, H.] German Canc Res Ctr, Div Apoptosis Regulat, D-6900 Heidelberg, Germany; [Verheij, M.] Netherlands Canc Inst, Div Radiotherapy, Amsterdam, Netherlands	Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Verheij, Marcel/O-9652-2018; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009				Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Kitamura T, 1998, INT J HEMATOL, V67, P351; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARINI P, 2005, BMC CANC, V5; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ramp U, 2003, BRIT J CANCER, V88, P1800, DOI 10.1038/sj.bjc.6600984; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Ravi R, 2002, CANCER RES, V62, P1583; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Singh TR, 2003, CANCER RES, V63, P5390; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Werner AB, 2004, J BIOL CHEM, V279, P28771, DOI 10.1074/jbc.M400268200; Wissink EHJ, 2006, RADIOTHER ONCOL, V80, P214, DOI 10.1016/j.radonc.2006.07.030; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	42	34	36	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					574	584		10.1038/sj.onc.1210696	http://dx.doi.org/10.1038/sj.onc.1210696			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684487				2022-12-25	WOS:000252674900002
J	Cascio, S; Bartella, V; Auriemma, A; Johannes, GJ; Russo, A; Giordano, A; Surmacz, E				Cascio, S.; Bartella, V.; Auriemma, A.; Johannes, G. J.; Russo, A.; Giordano, A.; Surmacz, E.			Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1 alpha	ONCOGENE			English	Article						breast cancer; HIF; hyperinsulinemia; leptin	TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR-I; RECEPTOR; OBESITY; PROMOTER; ACTIVATION; INSULIN; HIF-1-ALPHA; PATHWAYS	We reported previously that the obesity hormone leptin is overexpressed in breast cancer biopsies. Here, we investigated molecular mechanisms involved in this process, focusing on conditions that are associated with obesity, that is, hyperinsulinemia and induction of hypoxia. By using quantitative real-time PCR, immunofluorescent detection of proteins and enzyme-linked immunosorbent assays, we found that treatment of MCF-7 breast cancer cells with high doses of insulin or the hypoxia-mimetic agent CoCl2, or culturing the cells under hypoxic conditions significantly increased the expression of leptin mRNA and protein. Notably, the greatest leptin mRNA and protein expression were observed under combined hyperinsulinemia and hypoxia or hypoxia-mimetic treatments. Luciferase reporter assays suggested that increased leptin synthesis could be related to the activation of the leptin gene promoter. DNA affinity precipitation and chromatin immunoprecipitation experiments revealed that insulin, CoCl2 and/or hypoxia treatments augmented nuclear accumulation of hypoxia-inducible factor-1 alpha ( HIF-1 alpha) and increased its interaction with several upstream leptin regulatory sequences, especially with the proximal promoter containing four hypoxia-response elements and three GC-rich regions. By using reverse chromatin precipitation, we determined that loading of HIF-1 alpha on the proximal leptin promoter concurred with the recruitment of p300, the major HIF coactivator, suggesting that the HIF/p300 complex is involved in leptin transcription. The importance of HIF-1 alpha in insulin- and CoCl2-activated leptin mRNA and protein expression was confirmed using RNA interference.	[Cascio, S.; Bartella, V.; Giordano, A.; Surmacz, E.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Cascio, S.; Russo, A.] Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, Palermo, Italy; [Bartella, V.] Univ Calabria, Dept PharmacoBiol, I-87036 Cosenza, Italy; [Auriemma, A.] Univ Verona, Dept Oncol, I-37100 Verona, Italy; [Johannes, G. J.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; University of Calabria; University of Verona; Drexel University	Surmacz, E (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, 1900 N,12th St,Room 446, Philadelphia, PA 19122 USA.	surmacz@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cascio, Sandra/0000-0003-4234-0508				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Calle EE, 2004, ONCOGENE, V23, P6365, DOI 10.1038/sj.onc.1207751; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; De Vos P, 1998, EUR J BIOCHEM, V253, P619, DOI 10.1046/j.1432-1327.1998.2530619.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913; Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472; Garofalo C, 2004, CLIN CANCER RES, V10, P6466, DOI 10.1158/1078-0432.CCR-04-0203; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Gonzalez RR, 2006, J BIOL CHEM, V281, P26320, DOI 10.1074/jbc.M601991200; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Klein S, 2002, GASTROENTEROLOGY, V123, P882, DOI 10.1053/gast.2002.35514; Losso JN, 2005, J AGR FOOD CHEM, V53, P3751, DOI 10.1021/jf0479719; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Meissner U, 2003, BIOCHEM BIOPH RES CO, V303, P707, DOI 10.1016/S0006-291X(03)00401-7; Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Porter GA, 2006, ANN SURG ONCOL, V13, P327, DOI 10.1245/ASO.2006.03.049; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Revillion F, 2006, CLIN CANCER RES, V12, P2088, DOI 10.1158/1078-0432.CCR-05-1904; Snoussi K, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-38; Surmacz E, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1638; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Wauters M, 2000, EUR J ENDOCRINOL, V143, P293, DOI 10.1530/eje.0.1430293; Zhong H, 1999, CANCER RES, V59, P5830	34	71	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					540	547		10.1038/sj.onc.1210660	http://dx.doi.org/10.1038/sj.onc.1210660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653093				2022-12-25	WOS:000252426100014
J	Li, X; Qin, L; Bergenstock, M; Bevelock, LM; Novack, DV; Partridge, NC				Li, Xin; Qin, Ling; Bergenstock, Marika; Bevelock, Laura M.; Novack, Deborah V.; Partridge, Nicola C.			Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B LIGAND; OSTEOCLASTOGENESIS IN-VITRO; BONE-RESORPTION; RECEPTOR ACTIVATOR; PROTEIN-KINASE; OSTEOPROTEGERIN LIGAND; GENE-EXPRESSION; STROMAL CELLS; TNF-ALPHA; DC-STAMP	The clinical findings that alendronate blunted the anabolic effect of human parathyroid hormone ( PTH) on bone formation suggest that active resorption is involved and enhances the anabolic effect. PTH signals via its receptor on the osteoblast membrane, and osteoclasts are impacted indirectly via the products of osteoblasts. Microarray with RNA from rats injected with human PTH or vehicle showed a strong association between the stimulation of monocyte chemoattractant protein-1 ( MCP-1) and the anabolic effects of PTH. PTH rapidly and dramatically stimulated MCP-1 mRNA in the femora of rats receiving daily injections of PTH or in primary osteoblastic and UMR 106-01 cells. The stimulation of MCP-1 mRNA was dose-dependent and a primary response to PTH signaling via the cAMP-dependent protein kinase pathway in vitro. Studies with the mouse monocyte cell line RAW 264.7 and mouse bone marrow proved that osteoblastic MCP-1 can potently recruit osteoclast monocyte precursors and facilitate receptor activator of NF-kappa B ligand-induced osteoclastogenesis and, in particular, enhanced fusion. Our model suggests that PTH-induced osteoblastic expression of MCP-1 is involved in recruitment and differentiation at the stage of multinucleation of osteoclast precursors. This information provides a rationale for increased osteoclast activity in the anabolic effects of PTH in addition to receptor activator of NF-kappa B ligand stimulation to initiate greater bone remodeling.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL)	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln,Res Tower 561, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Partridge, Nicola/0000-0002-5406-4814; Novack, Deborah/0000-0001-7101-5582	NIDDK NIH HHS [DK 48109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CHAKRAVARTHY BR, 1990, BIOCHEM BIOPH RES CO, V171, P1105, DOI 10.1016/0006-291X(90)90798-R; Chen AR, 2005, OBES RES, V13, P1311, DOI 10.1038/oby.2005.159; Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362; CIVITELLI R, 1988, AM J PHYSIOL, V225, pE660; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P153; Dai JC, 2006, BONE, V38, P509, DOI 10.1016/j.bone.2005.10.007; DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756-3282(95)00113-R; Fan X, 2001, AM J PHYSIOL-ENDOC M, V280, pE103, DOI 10.1152/ajpendo.2001.280.1.E103; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Graves DT, 1999, HISTOL HISTOPATHOL, V14, P1347, DOI 10.14670/HH-14.1347; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006-2952(01)00861-9; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259; Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200; Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200; Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838; Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200; Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756-3282(95)00427-0; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Votta BJ, 2000, J CELL PHYSIOL, V183, P196, DOI 10.1002/(SICI)1097-4652(200005)183:2<196::AID-JCP6>3.3.CO;2-#; Weir EC, 1996, J BONE MINER RES, V11, P1474; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Wise GE, 2002, CRIT REV ORAL BIOL M, V13, P323, DOI 10.1177/154411130201300403; Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650; Wuyts A, 1997, METHOD ENZYMOL, V287, P13; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	42	150	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					33098	33106		10.1074/jbc.M611781200	http://dx.doi.org/10.1074/jbc.M611781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17690108	hybrid			2022-12-25	WOS:000250625400058
J	Yao, SYM; Ng, AML; Slugoski, MD; Smith, KM; Mulinta, R; Karpinski, E; Cass, CE; Baldwin, SA; Young, JD				Yao, Sylvia Y. M.; Ng, Amy M. L.; Slugoski, Melissa D.; Smith, Kyla M.; Mulinta, Ras; Karpinski, Edward; Cass, Carol E.; Baldwin, Stephen A.; Young, James D.			Conserved glutamate residues are critically involved in Na+/Nucleoside cotransport by human concentrative nucleoside transporter 1 (hCNT1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NUCLEOSIDE TRANSPORTER; ESCHERICHIA-COLI; FUNCTIONAL EXPRESSION; LACTOSE PERMEASE; NA+/PROLINE TRANSPORTER; SUBSTRATE-TRANSLOCATION; MOLECULAR-CLONING; ACIDIC RESIDUES; PROTEINS HCNT3; CNT FAMILY	Human concentrative nucleoside transporter 1 ( hCNT1), the first discovered of three human members of the SLC28 ( CNT) protein family, is a Na+/nucleoside cotransporter with 650 amino acids. The potential functional roles of 10 conserved aspartate and glutamate residues in hCNT1 were investigated by site-directed mutagenesis and heterologous expression in Xenopus oocytes. Initially, each of the 10 residues was replaced by the corresponding neutral amino acid ( asparagine or glutamine). Five of the resulting mutants showed unchanged Na+-dependent uridine transport activity ( D172N, E338Q, E389Q, E413Q, and D565N) and were not investigated further. Three were retained in intracellular membranes ( D482N, E498Q, and E532Q) and thus could not be assessed functionally. The remaining two ( E308Q and E322Q) were present in normal quantities at cell surfaces but exhibited low intrinsic transport activities. Charge replacement with the alternate acidic amino acid enabled correct processing of D482E and E498D, but not of E532D, to cell surfaces and also yielded partially functional E308D and E322D. Relative to wild-type hCNT1, only D482E exhibited normal transport kinetics, whereas E308D, E308Q, E322D, E322Q, and E498D displayed increased K-50(Na+) and/ or K-m(uridine) values and diminished V-max(Na+) and V-max(uridine) values. E322Q additionally exhibited uridine-gated uncoupled Na+ transport. Together, these findings demonstrate roles for Glu-308, Glu-322, and Glu-498 in Na+/nucleoside cotransport and suggest locations within a common cation/nucleoside translocation pore. Glu-322, the residue having the greatest influence on hCNT1 transport function, exhibited uridine-protected inhibition by p-chloromercuriphenyl sulfonate and 2-aminoethyl methanethiosulfonate when converted to cysteine.	Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Cross Canc Inst, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Astbury Ctr Struct Mol Biol, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Prot Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca	Cass, Carol E/F-5861-2010					Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; Chen NH, 2004, J BIOL CHEM, V279, P5508, DOI 10.1074/jbc.M306294200; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kaback HR, 2005, CR BIOL, V328, P557, DOI 10.1016/j.crvi.2005.03.008; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2004, MOL MEMBR BIOL, V21, P1, DOI 10.1080/0968768031000140836; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Noel J, 2003, BIOCHEMISTRY-US, V42, P15361, DOI 10.1021/bi035296a; Pirch T, 2002, J BIOL CHEM, V277, P8790, DOI 10.1074/jbc.M111008200; POURCHER T, 1993, J BIOL CHEM, V268, P3209; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; Quick M, 2001, J BIOL CHEM, V276, P1728, DOI 10.1074/jbc.M005521200; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; ROTHSTEIN A, 1970, CURRENT TOPICS MEMBR, V1, P135; Slugoski MD, 2007, BIOCHEMISTRY-US, V46, P1684, DOI 10.1021/bi061692s; Smith FM, 2007, MOL MEMBR BIOL, V24, P53, DOI 10.1080/09687860600942534; Smith KM, 2005, J BIOL CHEM, V280, P25436, DOI 10.1074/jbc.M409454200; Smith KM, 2004, J PHYSIOL-LONDON, V558, P807, DOI 10.1113/jphysiol.2004.068189; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Weinglass AB, 2001, BIOCHEMISTRY-US, V40, P769, DOI 10.1021/bi002171m; Xiao GQ, 2001, MOL PHARMACOL, V59, P339, DOI 10.1124/mol.59.2.339; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; Yao SYM, 2000, PRACT APPROACH SER, P47; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Young JD, 2001, CURR TOP MEMBR, V50, P329; Zhang J, 2006, BIOCHEM J, V394, P389, DOI 10.1042/BJ20051476; Zhu QS, 2007, METHODS, V41, P439, DOI 10.1016/j.ymeth.2006.08.004	54	18	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30607	30617		10.1074/jbc.M703285200	http://dx.doi.org/10.1074/jbc.M703285200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704058	hybrid			2022-12-25	WOS:000250136300029
J	Scarchilli, L; Camaioni, A; Bottazzi, B; Negri, V; Doni, A; Deban, L; Bastone, A; Salvatori, G; Mantovani, A; Siracusa, G; Salustri, A				Scarchilli, Laura; Camaioni, Antonella; Bottazzi, Barbara; Negri, Veronica; Doni, Andrea; Deban, Livija; Bastone, Antonio; Salvatori, Giovanni; Mantovani, Alberto; Siracusa, Gregorio; Salustri, Antonietta			PTX3 interacts with inter-alpha-trypsin inhibitor - Implications for hyaluronan organization and cumulus oophorus expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P-COMPONENT; FACTOR-STIMULATED GENE-6; LONG PENTRAXIN PTX3; CELL-OOCYTE COMPLEX; C-REACTIVE PROTEIN; EXTRACELLULAR-MATRIX; HEAVY-CHAINS; IN-VIVO; COVALENT TRANSFER; GRANULOSA-CELLS	Pentraxin 3 (PTX3) and heavy chains (HCs) of inter-alpha-trypsin inhibitor (I alpha I) are essential for hyaluronan ( HA) organization within the extracellular matrix of the cumulus oophorus, which is critical for in vivo oocyte fertilization and female fertility. In this study, we examined the possibility that these molecules interact and cooperate in this function. We show that HCs and PTX3 colocalize in the cumulus matrix and coimmunoprecipitate from cumulus matrix extracts. Coimmunoprecipitation experiments and solid-phase binding assays performed with purified human I alpha I and recombinant PTX3 demonstrate that their interaction is direct and not mediated by other matrix components. PTX3 does not bind to I alpha I subcomponent bikunin and, accordingly, bikunin does not compete for the binding of PTX3 to I alpha I, indicating that PTX3 interacts with I alpha I subcomponent HC only. Recombinant PTX3-specific N-terminal region, but not the PTX3-pentraxin C-terminal domain, showed the same ability as full-length protein to bind to HCs and to enable HA organization and matrix formation by Ptx3(-/-) cumulus cell oocyte complexes cultured in vitro. Furthermore, a monoclonal antibody raised against PTX3 N terminus, which inhibits PTX3/I alpha I interaction, also prevents recombinant full-length PTX3 from restoring a normal phenotype to in vitro-cultured Ptx3(-/-) cumuli. These results indicate that PTX3 directly interacts with HCs of I alpha I and that such interaction is essential for organizing HA in the viscoelastic matrix of cumulus oophorus, highlighting a direct functional link between the two molecules.	Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy; Ist Clin Humanitas, Res Lab Immunol & Inflammat, I-20089 Milan, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; SigmaTau SpA, I-00040 Rome, Italy	University of Rome Tor Vergata; IRCCS Humanitas Research Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Salustri, A (corresponding author), Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy.	salustri@med.uniroma2.it	Camaioni, Antonella/AAB-5294-2020; Mantovani, Alberto/HCI-7449-2022; Camaioni, Antonella/AAB-5285-2020; bottazzi, barbara/ABH-9274-2020	Camaioni, Antonella/0000-0002-7059-2617; Mantovani, Alberto/0000-0001-5578-236X; Camaioni, Antonella/0000-0002-7059-2617; bottazzi, barbara/0000-0002-1930-9257; Doni, Andrea/0000-0001-9203-5814; SALUSTRI, ANTONIETTA/0000-0002-8731-1041				ALMUTLAQ H, 1993, HISTOCHEM J, V25, P219, DOI 10.1007/BF00163818; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Camozzi M, 2006, J BIOL CHEM, V281, P22605, DOI 10.1074/jbc.M601023200; Capon C, 2003, BIOCHIMIE, V85, P101, DOI 10.1016/S0300-9084(03)00066-X; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; CHEN L, 1992, J BIOL CHEM, V267, P12380; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; CHERR GN, 1990, DEV GROWTH DIFFER, V32, P353; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893; EPPIG JJ, 1979, J EXP ZOOL, V208, P111, DOI 10.1002/jez.1402080112; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; Introna M, 1996, BLOOD, V87, P1862; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE GW, 1993, J IMMUNOL, V150, P1804; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MICHALSKI C, 1994, VOX SANG, V67, P329, DOI 10.1111/j.1423-0410.1994.tb01269.x; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nagyova E, 2004, BIOL REPROD, V71, P1838, DOI 10.1095/biolreprod.104.029595; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; POWERS RW, 1995, AM J PHYSIOL, V269, P290; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Russell DL, 2006, SEMIN REPROD MED, V24, P217, DOI 10.1055/s-2006-948551; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1992, DEV BIOL, V151, P541, DOI 10.1016/0012-1606(92)90192-J; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; YUDIN AI, 1988, CELL TISSUE RES, V251, P555, DOI 10.1007/BF00214003; Zahedi K, 1996, J BIOL CHEM, V271, P14897, DOI 10.1074/jbc.271.25.14897; Zahedi K, 1997, J BIOL CHEM, V272, P2143; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	46	118	121	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30161	30170		10.1074/jbc.M703738200	http://dx.doi.org/10.1074/jbc.M703738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17675295	hybrid			2022-12-25	WOS:000249981200046
J	Shi, ML; Foo, SY; Tan, SM; Mitchell, EP; Law, SKA; Lescar, J				Shi, MinLong; Foo, Shen Yun; Tan, Suet-Mien; Mitchell, Edward P.; Law, S. K. Alex; Lescar, Julien			A structural hypothesis for the transition between bent and extended conformations of the leukocyte beta 2 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(L)BETA(2) HYBRID DOMAIN; I-LIKE DOMAIN; CRYSTAL-STRUCTURE; TERMINAL REGION; SUBUNIT; REVEALS; COMPLEX; MODEL; ACTIVATION; EXPRESSION	Integrins mediate cell adhesion in response to activation signals that trigger conformational changes within their ectodomain. It is thought that a compact bent conformation of the molecule represents its physiological low affinity state and extended conformations its active state. We have determined the structure of two integrin fragments of the beta 2 subunit. The first structure, consisting of the plexin-semaphorin-integrin domain, hybrid, integrin-epidermal growth factor 1 ( I-EGF1), and I-EGF2 domains (PHE2), showed an L-shaped conformation with the bend located between the I-EGF1 and I-EGF2 domains. The second structure, which includes, in addition, the I-EGF3 domain, showed an extended conformation. The major reorientation of I-EGF2 with respect to the other domains in the two structures is accompanied by a change of torsion angle of the disulfide bond between Cys(461)-Cys(492) by 180 and the conversion of a short alpha-helix ( residues Ser(468)-Cys(475)) into a flexible coil. Based on the PHE2 structure, we introduced a disulfide bond between the plexin-semaphorin-integrin domain and I-EGF2 domains in the beta 2 subunit. The resultant alpha L beta 2 integrin ( leukocyte function-associated antigen-1) variant was locked in a bent state and could not be detected with the monoclonal antibody KIM127 in Mg2+/EGTA. However, it retained the binding activity to ICAM-1. These results provide a structural hypothesis for our understanding of the transition between the resting and active states of leukocyte function-associated antigen-1.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; European Synchrotron Radiation Facility (ESRF)	Law, SKA (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	alaw@ntu.edu.sg; julien@ntu.edu.sg	shi, minlong/G-8734-2013; Law, Alex/A-2212-2011; Tan, Suet/A-2224-2011	Tan, Suet-Mien/0000-0003-2371-8739				Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Cheng M, 2007, J BIOL CHEM, V282, P18225, DOI 10.1074/jbc.M701386200; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P17; DeLano WL, 2002, PYMOL USERS MANUAL; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Heras B, 2005, ACTA CRYSTALLOGR D, V61, P1173, DOI 10.1107/S0907444905019451; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwasaki K, 2005, J STRUCT BIOL, V150, P259, DOI 10.1016/j.jsb.2005.03.005; Jordan PA, 2005, BLOOD, V105, P1500, DOI 10.1182/blood-2004-02-0608; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Shi ML, 2005, J BIOL CHEM, V280, P30586, DOI 10.1074/jbc.M502525200; Staunton DE, 2006, ADV IMMUNOL, V91, P111, DOI 10.1016/S0065-2776(06)91003-7; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Tan SM, 2001, FEBS LETT, V505, P27, DOI 10.1016/S0014-5793(01)02778-8; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	38	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30198	30206		10.1074/jbc.M701670200	http://dx.doi.org/10.1074/jbc.M701670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17673459	hybrid			2022-12-25	WOS:000249981200050
J	Wang, CG; Rauscher, FJ; Cress, WD; Chen, JD				Wang, Chuangui; Rauscher, Frank J., III; Cress, W. Douglas; Chen, Jiandong			Regulation of E2F1 function by the nuclear corepressor KAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; DNA-DAMAGE; MDM2 INTERACTION; CELL-SURVIVAL; EXPRESSION; P53; APOPTOSIS; REPRESSION; DOMAIN; COLOCALIZES	KAP1 is a nuclear corepressor with conserved domains for RING finger, B boxes, leucine zipper alpha helical coiled- coil region, plant homeo domain finger, and bromo domain. The plant homeo domain finger and bromo domain of KAP1 cooperatively function as a transcription repression domain by recruiting the histone deacetylase complex NuRD and histone H3 lysine 9- specific methyltransferase SETDB1. Here we report that KAP1 binds the E2F1 transcription factor in a retinoblastoma protein ( pRb)- independent fashion and inhibits E2F1 activity. KAP1 stimulates formation of E2F1- HDAC1 complex and inhibits E2F1 acetylation. Ectopic expression of KAP1 represses E2F1 transcription and apoptosis functions independent of pRb. Depletion of endogenous KAP1 in pRb- deficient Saos2 cells by RNA interference increases E2F1 acetylation level, stimulates E2F1 transcriptional activity, and sensitizes apoptosis response to DNA damage. Therefore, KAP1 contributes to the negative regulation of E2F1 and may serve as a partial backup to prevent E2F1- mediated apoptosis in the absence of pRb.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; The Wistar Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, MRC 3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	jiandong.chen@moffitt.org						Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cammas F, 2004, GENE DEV, V18, P2147, DOI 10.1101/gad.302904; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Lu WG, 2002, CANCER RES, V62, P1305; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Okamoto K, 2006, BIOCHEM BIOPH RES CO, V351, P216, DOI 10.1016/j.bbrc.2006.10.022; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Pruschy M, 1999, CELL GROWTH DIFFER, V10, P141; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Weber P, 2002, DEVELOPMENT, V129, P2329; White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	34	73	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29902	29909		10.1074/jbc.M704757200	http://dx.doi.org/10.1074/jbc.M704757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17704056	hybrid			2022-12-25	WOS:000249981200019
J	Fischer, A; Montal, M				Fischer, Audrey; Montal, Mauricio			Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; CLOSTRIDIAL-NEUROTOXINS; SUBSTRATE RECOGNITION; NEUROBLASTOMA-CELLS; SYNAPTOTAGMIN-I; BINDING; RECEPTOR; TOXIN	Clostridial botulinum neurotoxins (BoNTs) exert their neuroparalytic action by arresting synaptic exocytosis. Intoxication requires the disulfide-linked, di-chain protein to undergo conformational changes in response to pH and redox gradients across the endosomal membrane with consequent formation of a protein-conducting channel by the heavy chain (HC) that translocates the light chain (LC) protease into the cytosol. Here, we investigate the role of the disulfide bridge in the dynamics of protein translocation. We utilize a single channel/single molecule assay to characterize in real time the BoNT channel and chaperone activities in Neuro 2A cells under conditions that emulate those prevalent across endosomes. We show that the disulfide bridge must remain intact throughout LC translocation; premature reduction of the disulfide bridge after channel formation arrests translocation. The disulfide bridge must be on the trans compartment to achieve productive translocation of LC; disulfide disruption on the cis compartment or within the bilayer during translocation aborts it. We demonstrate that a peptide linkage between LC and HC in place of a disulfide bridge is insufficient for productive LC translocation. The disulfide linkage, therefore, dictates the outcome of translocation: productive passage of cargo or abortive channel occlusion by cargo. Based on these and previous findings we suggest a sequence of events for BoNT LC translocation to be HC insertion, coupled LC unfolding, and protein conduction through the HC channel in an N to C terminus orientation and ultimate release of the LC from the HC by reduction of the disulfide bridge concomitant with LC refolding in the cytosol.	Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Montal, M (corresponding author), Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mmontal@ucsd.edu	Taylor, Graham/A-4027-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI065359] Funding Source: Medline; NIGMS NIH HHS [T32 GM08326, T32 GM008326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2004, BIOCHEMISTRY-US, V43, P6637, DOI 10.1021/bi036278w; Arndt JW, 2006, BIOCHEMISTRY-US, V45, P3255, DOI 10.1021/bi052518r; Arndt JW, 2005, BIOCHEMISTRY-US, V44, P9574, DOI 10.1021/bi0505924; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Carpaneto A, 1999, EXP BRAIN RES, V124, P193, DOI 10.1007/s002210050614; Chai Q, 2006, NATURE, V444, P1096, DOI 10.1038/nature05411; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; FINKELSTEIN A, 1990, J PHYSIOLOGY PARIS, V84, P188; Fischer A, 2007, P NATL ACAD SCI USA, V104, P10447, DOI 10.1073/pnas.0700046104; Fischer A, 2006, NEUROTOX RES, V9, P93, DOI 10.1007/BF03033926; GAMBALE F, 1988, BIOPHYS J, V53, P771, DOI 10.1016/S0006-3495(88)83157-6; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Ginalski K, 2000, FEBS LETT, V482, P119, DOI 10.1016/S0014-5793(00)01954-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jin RS, 2006, NATURE, V444, P1092, DOI 10.1038/nature05387; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lascola CD, 1998, J NEUROSCI, V18, P1679; Mahrhold S, 2006, FEBS LETT, V580, P2011, DOI 10.1016/j.febslet.2006.02.074; Nishiki T, 1996, NEUROSCI LETT, V208, P105, DOI 10.1016/0304-3940(96)12557-X; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; Simpson LL, 2004, ANNU REV PHARMACOL, V44, P167, DOI 10.1146/annurev.pharmtox.44.101802.121554; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Tsukamoto K, 2005, J BIOL CHEM, V280, P35164, DOI 10.1074/jbc.M507596200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yowler BC, 2002, J BIOL CHEM, V277, P32815, DOI 10.1074/jbc.M205258200	34	112	122	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29604	29611		10.1074/jbc.M703619200	http://dx.doi.org/10.1074/jbc.M703619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17666397	hybrid			2022-12-25	WOS:000249788000057
J	French, AC; Luscher, B; Litchfield, DW				French, Ashley C.; Luscher, Bernhard; Litchfield, David W.			Development of a stabilized form of the regulatory CK2 beta subunit that inhibits cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; II BETA-SUBUNIT; CASEIN KINASE-2; AUTOPHOSPHORYLATION SITE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; PHOSPHORYLATION; EXPRESSION; CYCLE	A number of cancers are characterized by elevated expression of CK2 (formerly casein kinase II), which has been implicated as a key component in cell proliferation and transformation. Two lines of evidence, (a) deregulated expression of CK2 and (b) CK2 beta ubiquitination and degradation of these in a proteasome-dependent manner prompted further investigation of the regulation of CK2 beta protein stability. We demonstrate that mutating six surface-exposed lysine residues to arginine (6KR) to interfere with ubiquitin attachment can stabilize CK2 beta. Examination of 6KR expression in cells revealed increased stability over time and increased its steady-state expression level compared with CK2 beta. In cells, 6KR was no longer sensitive to proteasome inhibition but maintained an elevated expression level. In our studies, 6KR functioned as a normal CK2 regulatory subunit, because it participated in CK2 beta dimerization, associated with catalytic subunits, was autophosphorylated, and formed active, stable CK2 tetramers. The physiological role of CK2 beta stabilization was investigated in cell proliferation assays, which showed a significant decrease in proliferation in cells expressing 6KR compared with CK2 beta. Overall, our results indicate that a stabilized form of CK2 beta can be used to inhibit cell proliferation.	Univ Western Ontario, Schulich Sch Med & Dent, Siebens Drake Med Res Inst, Dept Biochem,Regulatory Biol & Funct Genom Res Gr, London, ON N6A 5C1, Canada; Univ Aachen, Rhein Westfal TH, Klinikum, Inst Biochem, D-52057 Aachen, Germany	Western University (University of Western Ontario); RWTH Aachen University	Litchfield, DW (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Siebens Drake Med Res Inst, Dept Biochem,Regulatory Biol & Funct Genom Res Gr, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Litchfield, David/E-4636-2015; Luscher, Bernhard/A-7330-2011	Litchfield, David/0000-0002-2425-6620; Luscher, Bernhard/0000-0002-9622-8709				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, EUR J BIOCHEM, V218, P515, DOI 10.1111/j.1432-1033.1993.tb18404.x; Boldyreff B, 1996, FEBS LETT, V379, P153, DOI 10.1016/0014-5793(95)01497-7; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lebrin F, 2001, ONCOGENE, V20, P2010, DOI 10.1038/sj.onc.1204307; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Lieberman SL, 2004, DEV BIOL, V268, P271, DOI 10.1016/j.ydbio.2003.12.009; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Litchfield DW, 2001, MOL CELL BIOCHEM, V227, P21, DOI 10.1023/A:1013188101465; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Vilk G, 2002, J CELL BIOCHEM, V84, P84, DOI 10.1002/jcb.1268; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467	48	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29667	29677		10.1074/jbc.M706457200	http://dx.doi.org/10.1074/jbc.M706457200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681943	hybrid			2022-12-25	WOS:000249788000063
J	He, WX; Shi, Q; Hu, XY; Yan, RQ				He, Wanxia; Shi, Qi; Hu, Xiangyou; Yan, Riqiang			The membrane topology of RTN3 and its effect on binding of RTN3 to BACE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; NEURITE OUTGROWTH; ENDOPLASMIC-RETICULUM; AXON REGENERATION; GENE FAMILY; IN-VITRO; NOGO-A; INHIBITOR; IDENTIFICATION	Reticulon 3 (RTN3) has recently been shown to modulate Alzheimer BACE1 activity and to play a role in the formation of dystrophic neurites present in Alzheimer brains. Despite the functional importance of this protein in Alzheimer disease pathogenesis, the functional correlation to the structural domain of RTN3 remained unclear. RTN3 has two long transmembrane domains, but its membrane topology was not known. We report here that the first transmembrane domain dictates membrane integration and its membrane topology. RTN3 adopts a omega-shape structure with two ends facing the cytosolic side. Subtle changes in RTN3 membrane topology can disrupt its binding to BACE1 and its inhibitory effects on BACE1 activity. Thus, the determination of RTN3 membrane topology may provide an important structural basis for our understanding of its cellular functions.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Yan, RQ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	yanr@ccf.org		Yan, Riqiang/0000-0001-7195-7617	NATIONAL INSTITUTE ON AGING [R01AG025493] Funding Source: NIH RePORTER; NIA NIH HHS [AG025493] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; He WX, 2006, J MOL BIOL, V363, P625, DOI 10.1016/j.jmb.2006.07.094; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hu XY, 2007, EMBO J, V26, P2755, DOI 10.1038/sj.emboj.7601707; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Murayama KS, 2006, EUR J NEUROSCI, V24, P1237, DOI 10.1111/j.1460-9568.2006.05005.x; Oertle T, 2003, FASEB J, V17, P1238, DOI 10.1096/fj.02-1166hyp; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Strittmatter SM, 2002, J MOL NEUROSCI, V19, P117, DOI 10.1007/s12031-002-0021-7; Tang BL, 2007, J NEUROCHEM, V100, P314, DOI 10.1111/j.1471-4159.2006.04215.x; Tie JK, 2005, J BIOL CHEM, V280, P16410, DOI 10.1074/jbc.M500765200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Wakana Y, 2005, BIOCHEM BIOPH RES CO, V334, P1198, DOI 10.1016/j.bbrc.2005.07.012; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Yan R, 2006, CELL MOL LIFE SCI, V63, P877, DOI 10.1007/s00018-005-5338-2; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	27	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29144	29151		10.1074/jbc.M704181200	http://dx.doi.org/10.1074/jbc.M704181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699523	hybrid			2022-12-25	WOS:000249788000009
J	Fehr, D; Burr, SE; Gibert, M; d'Alayer, J; Frey, J; Popoff, MR				Fehr, Desiree; Burr, Sarah E.; Gibert, Maryse; d'Alayer, Jacques; Frey, Joachim; Popoff, Michel R.			Aeromonas exoenzyme T of Aeromonas salmonicida is a bifunctional protein that targets the host cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOT; PERFRINGENS IOTA-TOXIN; GTPASE-ACTIVATING PROTEIN; ADP-RIBOSYLATING TOXIN; III SECRETION SYSTEM; SUBSP SALMONICIDA; VIRULENCE; RIBOSYLTRANSFERASE; CLOSTRIDIUM; ACTIN	Type III protein secretion has been shown recently to be important in the virulence of the fish pathogen Aeromonas salmonicida. The ADP-ribosylating toxin Aeromonas exoenzyme T (AexT) is one effector protein targeted for secretion via this system. In this study, we identified muscular and nonmuscular actin as substrates of the ADP-ribosylating activity of AexT. Furthermore, we show that AexT also functions as a GTPase-activating protein ( GAP), displaying GAP activity against monomeric GTPases of the Rho family, specifically Rho, Rac, and Cdc42. Transfection of fish cells with wild type AexT resulted in depolymerization of the actin cytoskeleton and cell rounding. Point mutations within either the GAP or the ADP-ribosylating active sites of AexT (Arg-143 as well as Glu-398 and Glu-401, respectively) abolished enzymatic activity, yet did not prevent actin filament depolymerization. However, inactivation of the two catalytic sites simultaneously did. These results suggest that both the GAP and ADP-ribosylating domains of AexT contribute to its biological activity. This is the first bacterial virulence factor to be described that has a specific actin ADP-ribosylation activity and GAP activity toward Rho, Rac, and Cdc42, both enzymatic activities contributing to actin filament depolymerization.	Univ Bern, Inst Vet Bacteriol, CH-3001 Bern, Switzerland; Inst Pasteur, Unite Bacteries Anaerobies & Toxines, F-75724 Paris 15, France; Inst Pasteur, Plateforme Anal & Microsequencage Prot, F-75724 Paris 15, France	University of Bern; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Frey, J (corresponding author), Univ Bern, Inst Vet Bacteriol, Langgasstr 122,Postfach, CH-3001 Bern, Switzerland.	joachim.frey@vbi.unibe.ch		Burr, Sarah/0000-0002-1780-3403				Barbieri JT, 2005, REV PHYSIOL BIOCH P, V152, P79, DOI 10.1007/s10254-004-0031-7; Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; Belloy L, 2003, MICROBIOL-SGM, V149, P185, DOI 10.1099/mic.0.25864-0; Braman J, 1996, Methods Mol Biol, V57, P31; Braun M, 2002, J BACTERIOL, V184, P1851, DOI 10.1128/JB.184.7.1851-1858.2002; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Burr SE, 2005, MICROBIOL-SGM, V151, P2111, DOI 10.1099/mic.0.27926-0; Burr SE, 2003, DIS AQUAT ORGAN, V57, P167, DOI 10.3354/dao057167; Burr SE, 2003, J BACTERIOL, V185, P6583, DOI 10.1128/JB.185.22.6583-6591.2003; Burr SE, 2002, J BACTERIOL, V184, P5966, DOI 10.1128/JB.184.21.5966-5970.2002; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; Coye LH, 2004, MOL MICROBIOL, V54, P89, DOI 10.1111/j.1365-2958.2004.04262.x; Dacanay A, 2006, MICROBIOL-SGM, V152, P1847, DOI 10.1099/mic.0.28768-0; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Fehr D, 2006, MICROBIOL-SGM, V152, P2809, DOI 10.1099/mic.0.28889-0; Fraylick JE, 2001, INFECT IMMUN, V69, P5318, DOI 10.1128/IAI.69.9.5318-5328.2001; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Ganesan AK, 1999, J BIOL CHEM, V274, P21823, DOI 10.1074/jbc.274.31.21823; Garrity-Ryan L, 2004, INFECT IMMUN, V72, P546, DOI 10.1128/IAI.72.1.546-558.2004; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Hochmann H, 2006, BIOCHEMISTRY-US, V45, P1271, DOI 10.1021/bi051810w; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Lesnick ML, 2001, MOL MICROBIOL, V39, P1464, DOI 10.1046/j.1365-2958.2001.02360.x; Litvak Y, 2007, J BACTERIOL, V189, P2558, DOI 10.1128/JB.01358-06; Maresso A. W., 2006, COMPREHENSIVE SOURCE, P257, DOI [DOI 10.1016/B978-012088445-2/50019-6, 10.1016/B978-012088445-2/50019-6]; Maresso AW, 2004, J BIOL CHEM, V279, P38402, DOI 10.1074/jbc.M405707200; Marvaud JC, 2002, J BIOL CHEM, V277, P43659, DOI 10.1074/jbc.M207828200; Masignani V., 2006, COMPREHENSIVE SOURCE, P213; Mota LJ, 2005, ANN MED, V37, P234, DOI 10.1080/07853890510037329; Nagahama M, 2000, J BACTERIOL, V182, P2096, DOI 10.1128/JB.182.8.2096-2103.2000; NELSON M, 1992, METHOD ENZYMOL, V216, P279; PAWELRAMMINGEN U, 2000, MOL MICROBIOL, V36, P737; Perelle S, 1996, FEBS LETT, V395, P191, DOI 10.1016/0014-5793(96)01035-6; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; Popoff MR, 2000, HANDB EXP PHARM, V145, P275; Popovic M., 2006, COMPREHENSIVE SOURCE, P157; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Sousa S, 2005, NAT CELL BIOL, V7, P954, DOI 10.1038/ncb1308; Stuber K, 2003, J CLIN MICROBIOL, V41, P3854, DOI 10.1128/JCM.41.8.3854-3856.2003; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; Sundin C, 2004, FEMS MICROBIOL LETT, V234, P87, DOI 10.1016/j.femsle.2004.03.014; Tezcan-Merdol D, 2001, MOL MICROBIOL, V39, P606, DOI 10.1046/j.1365-2958.2001.02258.x; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; Vipond R, 1998, INFECT IMMUN, V66, P1990, DOI 10.1128/IAI.66.5.1990-1998.1998; VIRET JF, 1993, BIOTECHNIQUES, V14, P325; WONG KR, 1989, J BACTERIOL, V171, P2523, DOI 10.1128/jb.171.5.2523-2527.1989	51	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28843	28852		10.1074/jbc.M704797200	http://dx.doi.org/10.1074/jbc.M704797200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656370	hybrid			2022-12-25	WOS:000249642100059
J	Vernaleken, A; Veyhl, M; Gorboulev, V; Kottra, G; Palm, D; Burckhardt, BC; Burckhardt, G; Pipkorn, R; Beier, N; van Amsterdam, C; Koepsell, H				Vernaleken, Alexandra; Veyhl, Maike; Gorboulev, Valentin; Kottra, Gabor; Palm, Dieter; Burckhardt, Birgitta-Christina; Burckhardt, Gerhard; Pipkorn, Ruediger; Beier, Norbert; van Amsterdam, Christoph; Koepsell, Hermann			Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D- glucose cotransporter SGLT1 with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ASSOCIATED PROTEIN; XENOPUS-LAEVIS OOCYTES; TRANSPORT MODIFIER RS1; INTESTINAL GLUCOSE; NA+/GLUCOSE COTRANSPORTER; PLASMA-MEMBRANE; SUGAR-TRANSPORT; MESSENGER-RNA; EXPRESSION; CELLS	The human gene RSC1A1 codes for a 67-kDa protein named RS1 that mediates transcriptional and post- transcriptional regulation of Na+-D-glucose cotransporter SGLT1. The post- transcriptional regulation occurs at the trans-Golgi network (TGN). We identified two tripeptides in human RS1 (Gln-Cys-Pro (QCP) and Gln-Ser-Pro (QSP)) that induce posttranscriptional down-regulation of SGLT1 at the TGN leading to 40-50% reduction of SGLT1 in plasma membrane. For effective intracellular concentrations IC50 values of 2.0 nM (QCP) and 0.16 nM (QSP) were estimated. Down-regulation of SGLT1 by tripeptides was attenuated by intracellular monosaccharides including non-metabolized methyl-alpha-D-glucopyranoside and 2-deoxyglucose. In small intestine post- transcriptional regulation of SGLT1 may contribute to glucose-dependent regulation of liver metabolism and intestinal mobility. QCP and QSP are transported by the H+- peptide cotransporter PepT1 that is colocated with SGLT1 in small intestinal enterocytes. Using coexpression of SGLT1 and PepT1 in Xenopus oocytes or polarized Caco-2 cells that contain both transporters we demonstrated that the tripeptides were effective when applied to the extracellular compartment. After a 1-h perfusion of intact rat small intestine with QSP, glucose absorption was reduced by 30%. The data indicate that orally applied tripeptides can be used to down-regulate small intestinal glucose absorption, e. g. in diabetes mellitus.	Univ Wurzburg, Dept Anat & Cell Biol, D-97070 Wurzburg, Germany; Tech Univ Munich, Dept Food & Nutr, D-85350 Freising Weihenstephan, Germany; Univ Gottingen, Inst Physiol & Pathophysiol, D-37073 Gottingen, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Diabet Res Dept Merck KGaA, D-64293 Darmstadt, Germany	University of Wurzburg; Technical University of Munich; University of Gottingen; Helmholtz Association; German Cancer Research Center (DKFZ); Merck KGaA	Koepsell, H (corresponding author), Univ Wurzburg, Dept Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany.	Hermann@Koepsell.de						Asano T, 2004, CURR MED CHEM, V11, P2717, DOI 10.2174/0929867043364360; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Casirola DM, 2006, METABOLISM, V55, P832, DOI 10.1016/j.metabol.2006.02.011; CHANTRET I, 1988, CANCER RES, V48, P1936; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; Coblitz B, 2006, FEBS LETT, V580, P1531, DOI 10.1016/j.febslet.2006.02.014; Conde C, 2006, PLANT PHYSIOL, V141, P1563, DOI 10.1104/pp.106.080804; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; Diez-Sampedro A, 2003, P NATL ACAD SCI USA, V100, P11753, DOI 10.1073/pnas.1733027100; DUBASH J, 2004, BIOORG MED CHEM LETT, V14, P5121; FERRARIS RP, 1989, ANNU REV PHYSIOL, V51, P125, DOI 10.1146/annurev.ph.51.030189.001013; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; Freeman SL, 2006, AM J PHYSIOL-GASTR L, V291, pG439, DOI 10.1152/ajpgi.00079.2006; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; Hirsh AJ, 1998, J BIOL CHEM, V273, P14545, DOI 10.1074/jbc.273.23.14545; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Ishikawa Y, 1997, BBA-MOL CELL RES, V1357, P306, DOI 10.1016/S0167-4889(97)00043-8; Jiang W, 2005, MOL CELL BIOL, V25, P6496, DOI 10.1128/MCB.25.15.6496-6508.2005; Jungermann K, 1999, HEPATO-GASTROENTEROL, V46, P1414; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Katsuno K, 2007, J PHARMACOL EXP THER, V320, P323, DOI 10.1124/jpet.106.110296; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; Khoursandi S, 2004, AM J PHYSIOL-CELL PH, V287, pC1041, DOI 10.1152/ajpcell.00197.2004; Kipp H, 2003, AM J PHYSIOL-CELL PH, V285, pC737, DOI 10.1152/ajpcell.00041.2003; Korn T, 2001, J BIOL CHEM, V276, P45330, DOI 10.1074/jbc.M105975200; Kroiss M, 2006, AM J PHYSIOL-RENAL, V291, pF1201, DOI 10.1152/ajprenal.00067.2006; Lambotte S, 1996, DNA CELL BIOL, V15, P769, DOI 10.1089/dna.1996.15.769; Liu MT, 1999, J NEUROSCI, V19, P10305; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Martin MG, 2000, AM J PHYSIOL-GASTR L, V278, pG591, DOI 10.1152/ajpgi.2000.278.4.G591; Meier JJ, 2002, REGUL PEPTIDES, V107, P1, DOI 10.1016/S0167-0115(02)00039-3; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIYAMOTO K, 1993, BIOCHEM J, V295, P211, DOI 10.1042/bj2950211; Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452; O'Donovan DG, 2004, J CLIN ENDOCR METAB, V89, P3431, DOI 10.1210/jc.2004-0334; Osswald C, 2005, MOL CELL BIOL, V25, P78, DOI 10.1128/MCB.25.1.78-87.2005; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Puntheeranurak T, 2007, BIOCHEMISTRY-US, V46, P2797, DOI 10.1021/bi061917z; RAYBOULD HE, 1995, NEUROGASTROENT MOTIL, V7, P9, DOI 10.1111/j.1365-2982.1995.tb00203.x; Rayner CK, 2001, DIABETES CARE, V24, P371, DOI 10.2337/diacare.24.2.371; Reinhardt J, 1999, BBA-BIOMEMBRANES, V1417, P131, DOI 10.1016/S0005-2736(98)00250-8; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Schmitt BM, 2002, BIOPHYS J, V82, P1345, DOI 10.1016/S0006-3495(02)75490-8; Sharp PA, 1996, GUT, V39, P545, DOI 10.1136/gut.39.4.545; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thorens B, 2004, CURR OPIN CLIN NUTR, V7, P471, DOI 10.1097/01.mco.0000134368.91900.84; Valentin M, 2000, BBA-BIOMEMBRANES, V1468, P367, DOI 10.1016/S0005-2736(00)00277-7; Van de Laar FA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005061; Vayro S, 1999, AM J PHYSIOL-CELL PH, V276, pC1053, DOI 10.1152/ajpcell.1999.276.5.C1053; Vayro S, 2001, EUR J BIOCHEM, V268, P5460, DOI 10.1046/j.0014-2956.2001.02488.x; VEYHL M, 1993, J BIOL CHEM, V268, P25041; Veyhl M, 2003, J MEMBRANE BIOL, V196, P71, DOI 10.1007/s00232-003-0626-y; Veyhl M, 2006, AM J PHYSIOL-RENAL, V291, pF1213, DOI 10.1152/ajprenal.00068.2006; Wang YF, 1997, PHARMACEUT RES, V14, P1563, DOI 10.1023/A:1012174217220; Wideman RD, 2004, HORM METAB RES, V36, P782, DOI 10.1055/s-2004-826164; Zeuthen T, 2002, J PHYSIOL-LONDON, V542, P71, DOI 10.1113/jphysiol.2001.014530; Zhou LB, 2003, J CELL BIOCHEM, V90, P339, DOI 10.1002/jcb.10631	66	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28501	28513		10.1074/jbc.M705416200	http://dx.doi.org/10.1074/jbc.M705416200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686765	hybrid			2022-12-25	WOS:000249642100024
J	Passamaneck, YJ; Hadjantonakis, AK; Di Gregorio, A				Passamaneck, Yale J.; Hadjantonakis, Anna-Katerina; Di Gregorio, Anna			Dynamic and Polarized Muscle Cell Behaviors Accompany Tail Morphogenesis in the Ascidian Ciona intestinalis	PLOS ONE			English	Article								Background. Axial elongation is a key morphogenetic process that serves to shape developing organisms. Tail extension in the ascidian larva represents a striking example of this process, wherein paraxially positioned muscle cells undergo elongation and differentiation independent of the segmentation process that characterizes the formation of paraxial mesoderm in vertebrates. Investigating the cell behaviors underlying the morphogenesis of muscle in ascidians may therefore reveal the evolutionarily conserved mechanisms operating during this process. Methodology/Principle Findings. A live cell imaging approach utilizing subcellularly-localized fluorescent proteins was employed to investigate muscle cell behaviors during tail extension in the ascidian Ciona intestinalis. Changes in the position and morphology of individual muscle cells were analyzed in vivo in wild type embryos undergoing tail extension and in embryos in which muscle development was perturbed. Muscle cells were observed to undergo elongation in the absence of positional reorganization. Furthermore, high-speed high-resolution live imaging revealed that the onset and progression of tail extension were characterized by the presence of dynamic and polarized actin-based protrusive activity at the plasma membrane of individual muscle cells. Conclusions/Significance. Our results demonstrate that in the Ciona muscle, tissue elongation resulted from gradual and coordinated changes in cell geometry and not from changes in cell topology. Proper formation of muscle cells was found to be necessary not only for muscle tissue elongation, but also more generally for completion of tail extension. Based upon the characterized dynamic changes in cell morphology and plasma membrane protrusive activity, a three-phase model is proposed to describe the cell behavior operating during muscle morphogenesis in the ascidian embryo.	[Passamaneck, Yale J.; Di Gregorio, Anna] Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA; [Hadjantonakis, Anna-Katerina] Sloan Kettering Inst, Dev Biol Program, New York, NY USA	Cornell University; Memorial Sloan Kettering Cancer Center	Di Gregorio, A (corresponding author), Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA.	hadj@mskcc.org; and2015@med.cornell.edu	Di Gregorio, Anna/C-4766-2008	Hadjantonakis, Anna-Katerina/0000-0002-7580-5124	March of Dimes Birth Defects Foundation [5-FY03-153]; National Institutes of Health [RO1-HD050704, RO1-HD052115]; Irma T. Hirschl Career Scientist Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD052115] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD050704] Funding Source: NIH RePORTER	March of Dimes Birth Defects Foundation(March of Dimes); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irma T. Hirschl Career Scientist Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Basil O'Connor Starter Scholar Research Award Grant Number 5-FY03-153 from the March of Dimes Birth Defects Foundation, National Institutes of Health RO1-HD050704, Irma T. Hirschl Career Scientist Award to A.D.G, Charles H. Revson postdoctoral fellowship to Y.J.P. and National Institutes of Health RO1-HD052115 to A.-K.H.	Afonin B, 2006, DEV DYNAM, V235, P3268, DOI 10.1002/dvdy.20979; Coisy-Quivy M, 2006, BIOL CELL, V98, P577, DOI 10.1042/BC20060032; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Corbo JC, 1997, DEVELOPMENT, V124, P589; Corbo JC, 2001, CELL, V106, P535, DOI 10.1016/S0092-8674(01)00481-0; Di Gregorio A, 2002, DEV BIOL, V244, P385, DOI 10.1006/dbio.2002.0582; Di Gregorio A, 2006, BIOESSAYS, V28, P874, DOI 10.1002/bies.20453; Erives A, 1998, DEV BIOL, V194, P213, DOI 10.1006/dbio.1997.8810; Fraser ST, 2005, GENESIS, V42, P162, DOI 10.1002/gene.20139; Gibson MC, 2006, NATURE, V442, P1038, DOI 10.1038/nature05014; Hadjantonakis AK, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-33; Hadjantonakis AK, 2003, NAT REV GENET, V4, P613, DOI 10.1038/nrg1126; Jiang D, 2005, CURR BIOL, V15, P79; Kondoh G, 1999, FEBS LETT, V458, P299, DOI 10.1016/S0014-5793(99)01172-2; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Meedel TH, 2007, DEV BIOL, V302, P333, DOI 10.1016/j.ydbio.2006.09.043; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Munro EM, 2002, DEVELOPMENT, V129, P1; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakatani Y, 1999, DEVELOPMENT, V126, P3293; NISHIDA H, 1987, DEV BIOL, V121, P526, DOI 10.1016/0012-1606(87)90188-6; Passamaneck YJ, 2006, MICROSC RES TECHNIQ, V69, P160, DOI 10.1002/jemt.20284; Passamaneck YJ, 2005, DEV DYNAM, V233, P1, DOI 10.1002/dvdy.20300; Plusa B, 2005, NATURE, V434, P391, DOI 10.1038/nature03388; Rhee JM, 2006, GENESIS, V44, P202, DOI 10.1002/dvg.20203; Rhee JM, 2005, GENESIS, V43, P136, DOI 10.1002/gene.20164; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Satoh N., 1994, DEV BIOL ASCIDIANS; SWALLA BJ, 1993, MICROSC RES TECHNIQ, V26, P274, DOI 10.1002/jemt.1070260403; SWALLA BJ, 1990, DEV BIOL, V142, P319, DOI 10.1016/0012-1606(90)90353-K; Tada M, 1998, DEVELOPMENT, V125, P3997; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; WHITTAKER JR, 1977, J EXP ZOOL, V202, P139, DOI 10.1002/jez.1402020202; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Zallen JA, 2004, DEV CELL, V6, P343, DOI 10.1016/S1534-5807(04)00060-7; Zeller RW, 2006, DEV DYNAM, V235, P456, DOI 10.1002/dvdy.20644	37	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e714	10.1371/journal.pone.0000714	http://dx.doi.org/10.1371/journal.pone.0000714			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684560	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452400017
J	Bader, AG; Vogt, PK				Bader, A. G.; Vogt, P. K.			Phosphorylation by Akt disables the anti-oncogenic activity of YB-1	ONCOGENE			English	Article						translation; p50; dbpb; NSEP1; PI3K; mRNA binding	BOX-BINDING PROTEIN-1; COLD-SHOCK DOMAIN; MESSENGER-RNA; CATALYTIC SUBUNIT; BREAST-CANCER; TRANSFORMATION; TRANSCRIPTION; 3-KINASE; KINASE	The Y box-binding protein 1 ( YB-1) is a DNA/ RNA-binding protein that regulates mRNA transcription and translation. It is a major component of free messenger ribonucleoprotein particles and, at higher concentrations, blocks protein synthesis. In chicken embryo fibroblasts, overexpression of YB-1 confers a specific resistance to oncogenic cellular transformation by phosphoinositide 3-kinase ( PI3K) or Akt/ PKB. Recent studies have identified ed YB-1 as a direct substrate of Akt. The functional significance of Akt-mediated phosphorylation remains largely unknown. We generated YB-1 mutants in the Akt phosphorylation consensus sequence to explore the effect of phosphorylated YB-1 in PI3K-induced transformation. In contrast to wild-type YB-1, the phosphomimetic S99E mutant no longer interferes with cellular transformation. This mutant has reduced affinity for the cap of mRNAs and fails to inhibit cap-dependent translation. The data suggest that phosphorylation by Akt disables the inhibitory activity of YB-1 and thereby enhances the translation of transcripts that are necessary for oncogenesis. Overexpression of wild-type YB-1 overrides inactivation by Akt and maintains inhibition of protein synthesis and resistance to transformation.	[Bader, A. G.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Bader, AG (corresponding author), Asuragen Inc, R&D, 2150 Woodward St, Austin, TX 78744 USA.	abader@asuragen.com	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Bader AG, 2006, CURR CANCER THER REV, V2, P31, DOI 10.2174/157339406775471786; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kloks CPAM, 2002, J MOL BIOL, V316, P317, DOI 10.1006/jmbi.2001.5334; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590	19	48	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1179	1182		10.1038/sj.onc.1210719	http://dx.doi.org/10.1038/sj.onc.1210719			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704806				2022-12-25	WOS:000253136700018
J	Baldanzi, G; Cutrupi, S; Chianale, F; Gnocchi, V; Rainero, E; Porporato, P; Filigheddu, N; van Blitterswijk, WJ; Parolini, O; Bussolino, F; Sinigaglia, F; Graziani, A				Baldanzi, G.; Cutrupi, S.; Chianale, F.; Gnocchi, V.; Rainero, E.; Porporato, P.; Filigheddu, N.; van Blitterswijk, W. J.; Parolini, O.; Bussolino, F.; Sinigaglia, F.; Graziani, A.			Diacylglycerol kinase-alpha phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility	ONCOGENE			English	Article						hepatocyte growth factor; Src; diacylglycerol kinase; tyrosine kinase; signal transduction; cell migration	SUBTYPE-SPECIFIC TRANSLOCATION; TYROSINE PHOSPHORYLATION; PROCESSIVE PHOSPHORYLATION; PHOSPHATIDIC-ACID; T-LYMPHOCYTES; V-SRC; PROTEIN; DOMAINS; BINDING; SPECIFICITY	Diacylglycerol (DAG) kinases (Dgk), which phosphorylate DAG to generate phosphatidic acid, act as either positive or negative key regulators of cell signaling. We previously showed that Src mediates growth factors-induced activation of Dgk-alpha, whose activity is required for cell motility, proliferation and angiogenesis. Here, we demonstrate that both hepatocytes growth factor (HGF) stimulation and v-Src transformation induce tyrosine phosphorylation of Dgk-alpha on Y335, through a mechanism requiring its proline-rich C-terminal sequence. Moreover, we show that both proline-rich sequence and phosphorylation of Y335 of Dgk-alpha mediate: (i) its enzymatic activation, (ii) its ability to interact respectively with SH3 and SH2 domains of Src, (iii) its recruitment to the membrane. In addition, we show that phosphorylation of Dgk-alpha on Y335 is required for HGF-induced motility, while its constitutive recruitment at the membrane by myristylation is sufficient to trigger spontaneous motility in absence of HGF. Providing the first evidence that tyrosine phosphorylation of Dgk-alpha is required for growth-factors-induced activation and membrane recruitment, these findings underscore its relevance as a rheostat, whose activation is a threshold to elicit growth factors-induced migratory signaling.	[Baldanzi, G.; Chianale, F.; Gnocchi, V.; Rainero, E.; Porporato, P.; Sinigaglia, F.; Graziani, A.] Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; [Baldanzi, G.; Parolini, O.] Ctr Di Ricerca E Menni, Fond Poliambulanza, Ist Osp, Brescia, Italy; [Cutrupi, S.] Univ Turin, Dept Human & Anim Biol, Turin, Italy; [Filigheddu, N.] Univ Amedeo Avogadro Piemonte Orientale, Dept Clin & Expt Med, Novara, Italy; [van Blitterswijk, W. J.] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; [Bussolino, F.] Univ Turin, Inst Canc Res & Treatment IRCC, Turin, Italy; [Bussolino, F.] Univ Turin, Dept Oncol Sci, Turin, Italy	University of Eastern Piedmont Amedeo Avogadro; Fondazione Poliambulanza di Brescia; University of Turin; University of Eastern Piedmont Amedeo Avogadro; Netherlands Cancer Institute; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin	Graziani, A (corresponding author), Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, V Solaroli 17, I-28100 Novara, Italy.	graziani@med.unipmn.it	cutrupi, santina/AAC-4479-2022; Baldanzi, Gianluca/AAO-7673-2021; Filigheddu, Nicoletta/N-7219-2015; Bussolino, Federico/AES-3951-2022; PAROLINI, ORNELLA/ABI-7862-2020; Graziani, Andrea/AAB-6301-2022; PAROLINI, ORNELLA/C-7946-2013; Porporato, Paolo E./A-9932-2018; graziani, andrea/B-2554-2009; Bussolino, Federico/K-2500-2016	Baldanzi, Gianluca/0000-0002-1370-9903; Filigheddu, Nicoletta/0000-0002-3848-611X; PAROLINI, ORNELLA/0000-0002-5211-6430; Graziani, Andrea/0000-0002-6302-2317; PAROLINI, ORNELLA/0000-0002-5211-6430; Porporato, Paolo E./0000-0001-8519-1552; graziani, andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; CUTRUPI, SANTINA/0000-0002-2358-5852; Rainero, Elena/0000-0003-1402-8701	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Alonso R, 2005, J BIOL CHEM, V280, P28439, DOI 10.1074/jbc.M501112200; Bacchiocchi R, 2005, BLOOD, V106, P2175, DOI 10.1182/blood-2005-01-0316; Baldanzi G, 2004, ONCOGENE, V23, P4828, DOI 10.1038/sj.onc.1207633; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Fukunaga-Takenaka R, 2005, GENES CELLS, V10, P311, DOI 10.1111/j.1365-2443.2005.00842.x; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Olenchock BA, 2006, NAT IMMUNOL, V7, P1174, DOI 10.1038/ni1400; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sanjuan MA, 2003, J IMMUNOL, V170, P2877, DOI 10.4049/jimmunol.170.6.2877; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Yeo MG, 2006, MOL CELL BIOL, V26, P4399, DOI 10.1128/MCB.01147-05; Zha YY, 2006, NAT IMMUNOL, V7, P1166, DOI 10.1038/ni1394; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	35	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					942	956		10.1038/sj.onc.1210717	http://dx.doi.org/10.1038/sj.onc.1210717			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700527				2022-12-25	WOS:000252946300006
J	de Bruijn, DRH; van Dijk, AHA; Willemse, MP; van Kessel, AG				de Bruijn, D. R. H.; van Dijk, A. H. A.; Willemse, M. P.; van Kessel, A. Geurts			The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4	ONCOGENE			English	Article						synovial sarcoma; SSX; LHX4; SS18-SSX; transcription regulation	CHRONIC MYELOGENOUS LEUKEMIA; KRUPPEL-ASSOCIATED BOX; CHROMOSOMAL LOCALIZATION; NUCLEAR-LOCALIZATION; ONCOPROTEIN SYT; FUSION TYPE; HOX GENE; EXPRESSION; TRANSLOCATION; IDENTIFICATION	As a result of the synovial sarcoma-associated t(X; 18) translocation, the SS18 gene on chromosome 18 is fused to either one of the three closely related SSX genes on the X chromosome. The SS18 protein is thought to act as a transcriptional co-activator, whereas the SSX proteins are thought to act as transcriptional corepressors. The main SSX-repression domain is located in its C terminus, a domain that is retained in the respective SS18-SSX fusion proteins. Both the SS18 and SSX proteins lack DNA-binding domains. Previously, we found that the SS18 and SS18-SSX fusion proteins may be tethered to DNA targets via the SS18-interacting protein AF10. Here, we set out to isolate proteins that interact with the SSX C-terminal repression domain using a yeast two-hybrid interaction trap. Of the positive clones isolated, two corresponded to the LIM homeobox protein LHX4, a DNA-binding protein that is involved in transcription regulation. An endogenous interaction was subsequently established in mammalian cells via colocalization and coimmunoprecipitation of the respective proteins. Interestingly, the LHX4 gene was previously found to be deregulated in various human leukemias. In addition, it was previously found that LIM homeobox proteins may bind to and activate the glycoprotein-alpha (CGA) promoter. Using LHX4 chromatin immunoprecipitation and CGA-promoter assays, we found that endogenous LHX4 binds to the CGA promoter and that LHX4-mediated CGA activation is enhanced by the SS18-SSX protein, but not by the SSX protein. Taken together, we conclude that this novel protein - protein interaction may have direct consequences for the (de) regulation of SSX and/or SS18-SSX target genes and, thus, for the development of human synovial sarcomas.	[de Bruijn, D. R. H.; van Dijk, A. H. A.; Willemse, M. P.; van Kessel, A. Geurts] Radboud Univ Nijmegen Med Ctr, Dept Human Genet 855, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Kessel, AG (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Human Genet 855, POB 9101, NL-6500 HB Nijmegen, Netherlands.	a.geurtsvankessel@antrg.umcn.nl	de Bruijn, D.R.H./L-4233-2015; van Kessel, Ad Geurts/A-2810-2010					Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Cronwright G, 2005, CANCER RES, V65, P2207, DOI 10.1158/0008-5472.CAN-04-1882; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; de Bruijn DRH, 2002, GENE CHROMOSOME CANC, V34, P285, DOI 10.1002/gcc.10073; de Bruijn DRH, 2001, CYTOGENET CELL GENET, V92, P310, DOI 10.1159/000056920; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; Dong WF, 1997, DNA CELL BIOL, V16, P671, DOI 10.1089/dna.1997.16.671; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dos Santos NR, 2000, CANCER RES, V60, P1654; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Guillou L, 2004, J CLIN ONCOL, V22, P4040, DOI 10.1200/JCO.2004.11.093; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Howard PW, 2000, J BIOL CHEM, V275, P13336, DOI 10.1074/jbc.275.18.13336; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Ito T, 2004, LAB INVEST, V84, P1484, DOI 10.1038/labinvest.3700174; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Kawamata N, 2002, ONCOGENE, V21, P4983, DOI 10.1038/sj.onc.1205628; Ladanyi M, 2002, CANCER RES, V62, P135; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu YB, 2002, BRAIN RES, V928, P147, DOI 10.1016/S0006-8993(01)03243-7; Machinis K, 2001, AM J HUM GENET, V69, P961, DOI 10.1086/323764; Mischo A, 2006, INT J CANCER, V118, P696, DOI 10.1002/ijc.21352; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2002, INT J CANCER, V98, P640, DOI 10.1002/ijc.10277; Perani M, 2003, ONCOGENE, V22, P8156, DOI 10.1038/sj.onc.1207031; Raetzman LT, 2002, DEVELOPMENT, V129, P4229; Richter K, 2003, HAEMATOLOGICA, V88, P1336; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Saito T, 2006, CANCER RES, V66, P6919, DOI 10.1158/0008-5472.CAN-05-3697; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Taylor BJ, 2005, J IMMUNOTHER, V28, P564, DOI 10.1097/01.cji.0000175685.36239.e5; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806; Wu HK, 1997, BIOCHEM BIOPH RES CO, V233, P806, DOI 10.1006/bbrc.1997.6546; Wu HK, 1996, ONCOGENE, V12, P1205; Yamada S, 2003, INT J RELIAB APPL, V4, P1	56	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					653	662		10.1038/sj.onc.1210688	http://dx.doi.org/10.1038/sj.onc.1210688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667940				2022-12-25	WOS:000252674900009
J	Vitovski, S; Phillips, JS; Sayers, J; Croucher, PI				Vitovski, Srdjan; Phillips, Jennifer S.; Sayers, Jon; Croucher, Peter I.			Investigating the interaction between osteoprotegerin and receptor activator of NF-kappa B or tumor necrosis factor-related apoptosis-inducing ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTOGENESIS-INHIBITORY FACTOR; PROSTATE-CANCER CELLS; KINETIC-ANALYSIS; BONE-RESORPTION; SURVIVAL FACTOR; TNF FAMILY; TRAIL; MEMBER; DIFFERENTIATION; METASTASIS	Osteoprotegerin (OPG) binds the ligand for receptor activator of nuclear factor kappa B (RANKL) to prevent association with its receptor RANK and inhibit osteoclast-mediated bone resorption. OPG has been reported, recently, to inhibit tumor necrosis factor-related apoptosis-induced ligand (TRAIL)-induced tumor cell apoptosis. This raises the possibility that OPG may play a unique role in regulating these two signaling pathways. However, there are little data on the interactions between OPG, RANKL, and TRAIL, and the relative affinity of OPG for these two ligands is unknown. In the present study we examined the ability of OPG to bind native human TRAIL and RANKL under physiological conditions. Native TRAIL was expressed in Escherichia coli, purified to homogeneity, and shown to induce human myeloma cell apoptosis. OPG inhibited native TRAIL from binding the TRAILR1 at 37 degrees C in vitro. Similarly, OPG prevented RANKL from binding to RANK. TRAIL also prevented OPG-mediated inhibition of RANKL from binding RANK. The affinity of OPG for native TRAIL and RANKL at 37 degrees C was determined by plasmon surface resonance analysis. OPG had a binding affinity for TRAIL of 45 nM, whereas the affinity of OPG for RANKL was 23 nM. These data suggest that OPG can bind both RANKL and TRAIL and that the affinity of OPG for these two ligands is of a similar order of magnitude. Furthermore, OPG prevented TRAIL-mediated reductions in cell viability, whereas TRAIL inhibited OPG-mediated inhibition of osteoclastogenesis in vitro. This highlights the pivotal role of OPGin regulating the biology of both RANKL and TRAIL.	Univ Sheffield, Sch Med & Biomed Sci, Sect Inst Inflammat & Immun, Sect Musculoskeletal Sci,Acad Unit Bone Biol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Croucher, PI (corresponding author), Univ Sheffield, Sch Med & Biomed Sci, Sect Inst Inflammat & Immun, Sect Musculoskeletal Sci,Acad Unit Bone Biol, Sheffield S10 2TN, S Yorkshire, England.	p.croucher@sheffield.ac.uk	Sayers, Jon R/AAP-6179-2020; Sayers, Jon R/I-8974-2012	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443; Croucher, Peter/0000-0002-7102-2413				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASKENAZI A, 1999, J CLIN INVEST, V104, P155; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Cha SS, 1999, ACTA CRYSTALLOGR D, V55, P1101, DOI 10.1107/S090744499900164X; Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008-5472.CAN-06-1287; Holen I, 2002, CANCER RES, V62, P1619; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nyambo R, 2004, J BONE MINER RES, V19, P1712, DOI 10.1359/JBMR.040703; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shipman CM, 2003, CANCER RES, V63, P912; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willard D, 2000, PROTEIN EXPRES PURIF, V20, P48, DOI 10.1006/prep.2000.1278; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zauli G, 2004, BLOOD, V104, P2044, DOI 10.1182/blood-2004-03-1196; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586	43	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31601	31609		10.1074/jbc.M706078200	http://dx.doi.org/10.1074/jbc.M706078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17702740	hybrid			2022-12-25	WOS:000250309200052
J	Handschin, C; Chin, S; Li, P; Liu, F; Maratos-Flier, E; LeBrasseur, NK; Yan, Z; Spiegelman, BM				Handschin, Christoph; Chin, Sherry; Li, Ping; Liu, Fenfen; Maratos-Flier, Eleftheria; LeBrasseur, Nathan K.; Yan, Zhen; Spiegelman, Bruce M.			Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1 alpha muscle-specific knock-out animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL BIOGENESIS; SIGNALING PATHWAYS; GENE-EXPRESSION; RECEPTOR-ALPHA; PGC-1 FAMILY; ERR-ALPHA; MECHANISMS; PAX7	The transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) is a key integrator of neuromuscular activity in skeletal muscle. Ectopic expression of PGC-1 alpha in muscle results in increased mitochondrial number and function as well as an increase in oxidative, fatigue-resistant muscle fibers. Whole body PGC-1 alpha knock-out mice have a very complex phenotype but do not have a marked skeletal muscle phenotype. We thus analyzed skeletal muscle-specific PGC-1 alpha knock-out mice to identify a specific role for PGC-1 alpha in skeletal muscle function. These mice exhibit a shift from oxidative type I and IIa toward type IIx and IIb muscle fibers. Moreover, skeletal muscle-specific PGC-1 alpha knock-out animals have reduced endurance capacity and exhibit fiber damage and elevated markers of inflammation following treadmill running. Our data demonstrate a critical role for PGC-1 alpha in maintenance of normal fiber type composition and of muscle fiber integrity following exertion.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; Duke Univ, Med Ctr, Dept Med, Durham, NC 27704 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boston Univ, Sch Med, Diabet & Metab Unit, Boston, MA 02118 USA	Harvard University; Harvard Medical School; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, Smith Bldg,1 Jimmy Fund Way, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Handschin, Christoph/E-6886-2015	Handschin, Christoph/0000-0003-0603-1097; Yan, Zhen/0000-0002-4826-9813; LeBrasseur, Nathan/0000-0002-2002-0418	NIAMS NIH HHS [R01 AR050429, AR050429] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561-12, R01 DK054477, P30 DK040561, DK61562, DK54477] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, R01DK061562, P30DK040561, R56DK054477] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Dalakas MC, 2006, NAT CLIN PRACT RHEUM, V2, P219, DOI 10.1038/ncprheum0140; Disatnik MH, 1998, J NEUROL SCI, V161, P77, DOI 10.1016/S0022-510X(98)00258-5; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; Grundtman Cecilia, 2006, Curr Rheumatol Rep, V8, P188, DOI 10.1007/s11926-996-0024-4; Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C., 2005, DRUG DISCOV TODAY, V2, P151; Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Olguin HC, 2007, J CELL BIOL, V177, P769, DOI 10.1083/jcb.200608122; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Salomonsson S, 2006, AUTOIMMUNITY, V39, P177, DOI 10.1080/08916930600622256; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Timmons JA, 2005, FASEB J, V19, P750, DOI 10.1096/fj.04-1980com; Waters RE, 2004, AM J PHYSIOL-CELL PH, V287, pC1342, DOI 10.1152/ajpcell.00247.2004; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	31	441	477	2	42	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30014	30021		10.1074/jbc.M704817200	http://dx.doi.org/10.1074/jbc.M704817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702743	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000249981200031
J	Merdek, KD; Yang, XQ; Taglienti, CA; Shaw, LM; Mercurio, AM				Merdek, Keith D.; Yang, Xiaoqing; Taglienti, Cherie A.; Shaw, Leslie M.; Mercurio, Arthur M.			Intrinsic signaling functions of the ss 4 integrin intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CALPAIN INHIBITOR CALPEPTIN; BREAST-CARCINOMA CELLS; COLON-CANCER CELLS; NF-KAPPA-B; ALPHA-6-BETA-4 INTEGRIN; ALPHA(6)BETA(4) INTEGRIN; CHEMOTACTIC MIGRATION; NEUROTROPHIC FACTORS; TETRASPANIN CD151	A key issue regarding the role of alpha 6 beta 4 in cancer biology is the mechanism by which this integrin exerts its profound effects on intracellular signaling, including growth factor-mediated signaling. Oneapproach is to evaluate the intrinsic signaling capacity of the unique beta 4 intracellular domain in the absence of contributions from the alpha 6 subunit and tetraspanins and to assess the ability of growth factor receptor signaling to cooperate with this domain. Here, we generated a chimeric receptor composed of the TrkB extracellular domain and the beta 4 transmembrane and intracellular domains. Expression of this chimeric receptor in beta 4-null cancer cells enabled us to assess the signaling potential of the beta 4 intracellular domain alone or in response to dimerization using brain-derived neurotrophic factor, the ligand for TrkB. Dimerization of the beta 4 intracellular domain results in the binding and activation of the tyrosine phosphatase SHP-2 and the activation of Src, events that also occur upon ligation of intact alpha 6 beta 4. In contrast to alpha 6 beta 4 signaling, however, dimerization of the chimeric receptor does not activate either Akt or Erk1/2. Growth factor stimulation induces tyrosine phosphorylation of the chimeric receptor but does not enhance its binding to SHP-2. The chimeric receptor is unable to amplify growth factormediated activation of Akt and Erk1/2, and growth factorstimulated migration. Collectively, these data indicate that the beta 4 intracellular domain has some intrinsic signaling potential, but it cannot mimic the full signaling capacity of alpha 6 beta 4. These data also question the putative role of the beta 4 intracellular domain as an "adaptor" for growth factor receptor signaling.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB-408,364 Plantat St, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu			NATIONAL CANCER INSTITUTE [F32CA117746, R01CA080789] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA117746, R01 CA080789, CA80789] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bertotti A, 2006, J CELL BIOL, V175, P993, DOI 10.1083/jcb.200605114; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; Chao C, 1996, CANCER RES, V56, P4811; Chen M, 2005, ONCOGENE, V24, P5125, DOI 10.1038/sj.onc.1208729; Chung J, 2004, J BIOL CHEM, V279, P32287, DOI 10.1074/jbc.M403809200; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Cowin AJ, 2006, J INVEST DERMATOL, V126, P680, DOI 10.1038/sj.jid.5700142; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Easton JB, 2006, J NEUROCHEM, V97, P834, DOI 10.1111/j.1471-4159.2006.03789.x; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Homan SM, 1998, J CELL SCI, V111, P2717; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Le Naour F, 2006, MOL CELL PROTEOMICS, V5, P845, DOI 10.1074/mcp.M500330-MCP200; Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAKI M, 1989, J BIOL CHEM, V264, P18866; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Owens DM, 2003, J CELL SCI, V116, P3783, DOI 10.1242/jcs.00725; Pouliot N, 2000, EXP CELL RES, V261, P360, DOI 10.1006/excr.2000.5065; PUMA P, 1983, J BIOL CHEM, V258, P3370; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Sariola H, 2001, CELL MOL LIFE SCI, V58, P1061, DOI 10.1007/PL00000921; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; SHAW LM, 1993, J BIOL CHEM, V268, P11401; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Takeda Y, 2007, BLOOD, V109, P1524, DOI 10.1182/blood-2006-08-041970; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	62	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30322	30330		10.1074/jbc.M703156200	http://dx.doi.org/10.1074/jbc.M703156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711859	hybrid			2022-12-25	WOS:000249981200063
J	Verykokakis, M; Papadaki, C; Vorgia, E; Le Gallic, L; Mavrothalassitis, G				Verykokakis, Mihalis; Papadaki, Chara; Vorgia, Elena; Le Gallic, Lionel; Mavrothalassitis, George			The RAS-dependent ERF control of cell proliferation and differentiation is mediated by c-Myc repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; TRANSCRIPTIONAL REPRESSION; NONPERMISSIVE CELLS; MYC/MAX/MAD NETWORK; CYCLE PROGRESSION; HUMAN TROPHOBLAST; GENE-EXPRESSION; BREAST-CANCER; IN-VIVO	The ERF transcriptional repressor is a downstream effector of the RAS/ERK pathway that interacts with and is directly phosphorylated by ERKs in vivo and in vitro. This phosphorylation results in its cytoplasmic export and inactivation, although lack of ERK activity allows its immediate nuclear accumulation and repressor function. Nuclear ERFs arrest cell cycle progression in G(1) and can suppress ras-dependent tumorigenicity. Here we provide evidence that ERF function is mediated by its ability to repress transcription of c-Myc. Promoter reporter assays indicate a DNA binding-dependent and repressor domain-dependent Myc transcriptional repression. Chromatin immunoprecipitations in primary cells suggest that ERF specifically binds on the c-Myc promoter in an E2F4/5-dependent manner and only under conditions that the physiological c-Myc transcription is stopped. Cellular systems overexpressing nuclear ERF exhibit reduced c-Myc mRNA and tumorigenic potential. Elimination of Erf in animal models results in increased c-Myc expression, whereas Erf (-/-) primary fibroblasts fail to down-regulate Myc in response to growth factor withdrawal. Finally, elimination of c-Myc in primary mouse embryo fibroblasts negates the ability of nuclear ERF to suppress proliferation. Thus Erf provides a direct link between the RAS/ERK signaling and the transcriptional regulation of c-Myc and suggests that RAS/ERK attenuation actively regulates cell fate.	Univ Crete, Sch Med, Iraklion 71003, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71003, Crete, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Mavrothalassitis, G (corresponding author), Univ Crete, Sch Med, Iraklion 71003, Crete, Greece.	mavro@imbb.forth.gr		Le Gallic, Lionel/0000-0001-7147-9846; PAPADAKI, CHARA/0000-0002-4591-3757				Bain M, 2003, J GEN VIROL, V84, P41, DOI 10.1099/vir.0.18633-0; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Carroll JS, 2002, CANCER RES, V62, P3126; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dakour J, 1999, PLACENTA, V20, P119, DOI 10.1053/plac.1998.0336; Dang CV, 1999, MOL CELL BIOL, V19, P1; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; de Nigris F, 2001, CANCER RES, V61, P2267; DEAN M, 1986, J BIOL CHEM, V261, P9161; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grill C, 2004, BIOCHEM J, V381, P635, DOI 10.1042/BJ20031688; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; HIRNINGFOLZ U, 1992, CYTOGENET CELL GENET, V61, P289, DOI 10.1159/000133425; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Le Gallic L, 2004, MOL CELL BIOL, V24, P1206, DOI 10.1128/MCB.24.3.1206-1218.2004; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Liu J, 2006, CURR TOP MICROBIOL, V302, P1; MARTINOLI MG, 1992, MOL REPROD DEV, V31, P1, DOI 10.1002/mrd.1080310102; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Papadaki C, 2007, MOL CELL BIOL, V27, P5201, DOI 10.1128/MCB.02237-06; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Perkins KJ, 2007, MOL BIOL CELL, V18, P2864, DOI 10.1091/mbc.E06-12-1069; Polychronopoulos S, 2006, J BIOL CHEM, V281, P25601, DOI 10.1074/jbc.M605185200; Qiu Q, 2004, MOL HUM REPROD, V10, P677, DOI 10.1093/molehr/gah088; QUINN LM, 2004, DEV CAMB, V31, P1411; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rodriguez JL, 2006, BIOCHEM J, V398, P431, DOI 10.1042/BJ20060380; RONCALLI M, 1994, PLACENTA, V15, P399, DOI 10.1016/0143-4004(94)90007-8; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takahashi Y, 2000, GENE DEV, V14, P804; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975; WATSON PH, 1991, CANCER RES, V51, P3996; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Wright E, 2005, J GEN VIROL, V86, P535, DOI 10.1099/vir.0.80352-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	70	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30285	30294		10.1074/jbc.M704428200	http://dx.doi.org/10.1074/jbc.M704428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699159	hybrid			2022-12-25	WOS:000249981200059
J	Xiao, BL; Tian, XX; Xie, WJ; Jones, PP; Cai, ST; Wang, XH; Jiang, DW; Kong, HH; Zhang, L; Chen, KY; Walsh, MP; Cheng, HP; Chen, SRW				Xiao, Bailong; Tian, Xixi; Xie, Wenjun; Jones, Peter P.; Cai, Shitian; Wang, Xianhua; Jiang, Dawei; Kong, Huihui; Zhang, Lin; Chen, Keyun; Walsh, Michael P.; Cheng, Heping; Chen, S. R. Wayne			Functional consequence of protein kinase A-dependent phosphorylation of the cardiac ryanodine receptor - Sensitization of store overload-induced Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; RAT VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM CA2+; HEART-FAILURE; PKA PHOSPHORYLATION; PURKINJE-FIBERS; FAILING HEARTS; SUDDEN-DEATH; CHANNEL; CALCIUM	The phosphorylation of the cardiac Ca2(+)-release channel ( ryanodine receptor, RyR2) by protein kinase A (PKA) has been extensively characterized, but its functional consequence remains poorly defined and controversial. We have previously shown that RyR2 is phosphorylated by PKA at two major sites, serine 2030 and serine 2808, of which Ser-2030 is the major PKA site responding to beta-adrenergic stimulation. Here we investigated the effect of the phosphorylation of RyR2 by PKA on the properties of single channels and on spontaneous Ca2(+) release during sarcoplasmic reticulum Ca2(+) overload, a process we have referred to as store overload-induced Ca2(+) release ( SOICR). We found that PKA activated single RyR2 channels in the presence, but not in the absence, of luminal Ca2(+). On the other hand, PKA had no marked effect on the sensitivity of the RyR2 channel to activation by cytosolic Ca2(+). Importantly, the S2030A mutation, but not mutations of Ser-2808, diminished the effect of PKA on RyR2. Furthermore, a phosphomimetic mutation, S2030D, potentiated the response of RyR2 to luminal Ca2(+) and enhanced the propensity for SOICR in HEK293 cells. In intact rat ventricular myocytes, the activation of PKA by isoproterenol reduced the amplitude and increased the frequency of SOICR. Confocal line-scanning fluorescence microscopy further revealed that the activation of PKA by isoproterenol increased the rate of Ca2(+) release and the propagation velocity of spontaneous Ca2(+) waves, despite reduced wave amplitude and resting cytosolic Ca2(+). Collectively, our data indicate that PKA-dependent phosphorylation enhances the response of RyR2 to luminal Ca2(+) and reduces the threshold for SOICR and that this effect of PKA is largely mediated by phosphorylation at Ser-2030.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China	University of Calgary; University of Calgary; Peking University	Chen, SRW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	swchen@ucalgary.ca	Kong, Huihui/F-9024-2012; Xiao, Bailong/B-6187-2012; Xie, Wenjun/O-4637-2019; Xie, Wenjun/G-3869-2015; Xie, Wenjun/AAD-6881-2021; Jones, Peter P/G-2618-2013; Heping, Cheng/AAE-2680-2019; cheng, heping/A-7299-2011	Xie, Wenjun/0000-0003-0493-062X; Xie, Wenjun/0000-0003-0493-062X; Xie, Wenjun/0000-0003-0493-062X; Heping, Cheng/0000-0002-9604-6702; Jones, Pete/0000-0001-7977-1737				BENKUSKY NA, 2007, IN PRESS CIRC RES; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2003, CIRC RES, V93, P487, DOI 10.1161/01.RES.0000091871.54907.6B; Carter S, 2006, CIRC RES, V98, P1506, DOI 10.1161/01.RES.0000227506.43292.df; Diaz ME, 1997, J PHYSIOL-LONDON, V501, P3, DOI 10.1111/j.1469-7793.1997.003bo.x; Eisner DA, 1998, CARDIOVASC RES, V38, P589, DOI 10.1016/S0008-6363(98)00062-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Ginsburg KS, 2004, J PHYSIOL-LONDON, V556, P463, DOI 10.1113/jphysiol.2003.055384; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; Jiang DW, 2004, P NATL ACAD SCI USA, V101, P13062, DOI 10.1073/pnas.0402388101; Jiang DW, 2005, CIRC RES, V97, P1173, DOI 10.1161/01.RES.0000192146.85173.4b; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; KASS RS, 1982, BIOPHYS J, V38, P259, DOI 10.1016/S0006-3495(82)84557-8; Kubalova Z, 2005, P NATL ACAD SCI USA, V102, P14104, DOI 10.1073/pnas.0504298102; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Obayashi M, 2006, CARDIOVASC RES, V69, P140, DOI 10.1016/j.cardiores.2005.07.010; ORCHARD CH, 1983, NATURE, V304, P735, DOI 10.1038/304735a0; Pogwizd SM, 2004, TRENDS CARDIOVAS MED, V14, P61, DOI 10.1016/j.tcm.2003.12.002; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; Shimoni Y, 2004, J PHYSIOL-LONDON, V555, P345, DOI 10.1113/jphysiol.2003.055590; Song LS, 2001, CIRC RES, V88, P794, DOI 10.1161/hh0801.090461; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; STERN MD, 1983, J GEN PHYSIOL, V82, P119, DOI 10.1085/jgp.82.1.119; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Trafford AW, 2000, CELL CALCIUM, V28, P269, DOI 10.1054/ceca.2000.0156; Uehara A, 2002, PFLUG ARCH EUR J PHY, V444, P202, DOI 10.1007/s00424-002-0791-3; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Viatchenko-Karpinski S, 2001, J PHYSIOL-LONDON, V533, P837, DOI 10.1111/j.1469-7793.2001.t01-1-00837.x; Wehrens XHT, 2006, P NATL ACAD SCI USA, V103, P511, DOI 10.1073/pnas.0510113103; WIER WG, 1983, P NATL ACAD SCI-BIOL, V80, P7367, DOI 10.1073/pnas.80.23.7367; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xiao BL, 2006, BIOCHEM J, V396, P7, DOI 10.1042/BJ20060116; Xiao BL, 2005, CIRC RES, V96, P847, DOI 10.1161/01.RES.0000163276.26083.e8; Xiao BL, 2004, CIRC RES, V94, P487, DOI 10.1161/01.RES.0000115945.89741.22	37	55	58	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30256	30264		10.1074/jbc.M703510200	http://dx.doi.org/10.1074/jbc.M703510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693412	hybrid			2022-12-25	WOS:000249981200056
J	Frigerio, S; Campoli, C; Zorzan, S; Fantoni, LI; Crosatti, C; Drepper, F; Haehnel, W; Cattivelli, L; Morosinotto, T; Bassi, R				Frigerio, Sara; Campoli, Chiara; Zorzan, Simone; Fantoni, Luca Isaia; Crosatti, Cristina; Drepper, Friedel; Haehnel, Wolfgang; Cattivelli, Luigi; Morosinotto, Tomas; Bassi, Roberto			Photosynthetic antenna size in higher plants is controlled by the plastoquinone redox state at the post-transcriptional rather than transcriptional level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING-COMPLEX; PHOTOSYSTEM-II MEMBRANES; CHLOROPHYLL-A-OXYGENASE; CHLAMYDOMONAS-REINHARDTII; ARABIDOPSIS-THALIANA; GENE-EXPRESSION; THYLAKOID MEMBRANES; ENERGY-DISSIPATION; ELECTRON-TRANSFER; PEA-CHLOROPLASTS	We analyze the effect of the plastoquinone redox state on the regulation of the light-harvesting antenna size at transcriptional and post-transcriptional levels. This was approached by studying transcription and accumulation of light-harvesting complexes in wild type versus the barley mutant viridis zb63, which is depleted in photosystem I and where plastoquinone is constitutively reduced. We show that the mRNA level of genes encoding antenna proteins is almost unaffected in the mutant; this stability of messenger level is not a peculiarity of antenna-encoding genes, but it extends to all photosynthesis-related genes. In contrast, analysis of protein accumulation by two-dimensional PAGE shows that the mutant undergoes strong reduction of its antenna size, with individual gene products having different levels of accumulation. We conclude that the plastoquinone redox state plays an important role in the long term regulation of chloroplast protein expression. However, its modulation is active at the post-transcriptional rather than transcriptional level.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, CEA CNRS, UMR 6191, LGBP, F-13288 Marseille, France; CRA Ctr Ric Genom, I-29017 Fiorenzuola Darda, Italy; Univ Modena, Dipartimento Sci Biomed, I-41100 Modena, Italy; Univ Freiburg, Inst Biol Biochem 2, D-79104 Freiburg, Germany; Univ Padua, Dipartimento Biol, I-35131 Padua, Italy	University of Verona; CEA; UDICE-French Research Universities; Aix-Marseille Universite; Universita di Modena e Reggio Emilia; University of Freiburg; University of Padua	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str LeGrazie 15, I-37134 Verona, Italy.	bassi@sci.univr.it	cattivelli, luigi/AAE-7046-2020; Morosinotto, Tomas/AAC-3188-2019	cattivelli, luigi/0000-0002-6067-4600; Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446; Campoli, Chiara/0000-0001-7809-2927; Drepper, Friedel/0000-0002-2043-5795				ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; Arnaud N, 2006, J BIOL CHEM, V281, P23579, DOI 10.1074/jbc.M602135200; Ballottari M, 2004, EUR J BIOCHEM, V271, P4659, DOI 10.1111/j.1432-1033.2004.04426.x; Ballottari M, 2007, J BIOL CHEM, V282, P8947, DOI 10.1074/jbc.M606417200; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; Caffarri S, 2005, PROTEOMICS, V5, P758, DOI 10.1002/pmic.200402008; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Chen YB, 2004, PLANT PHYSIOL, V136, P3737, DOI 10.1104/pp.104.038919; Close TJ, 2004, PLANT PHYSIOL, V134, P960, DOI 10.1104/pp.103.034462; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Dall'Osto L, 2005, PLANT CELL, V17, P1217, DOI 10.1105/tpc.104.030601; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; Durnford DG, 2003, PHYSIOL PLANTARUM, V118, P193, DOI 10.1034/j.1399-3054.2003.00078.x; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; Fujibe T, 2006, BIOSCI BIOTECH BIOCH, V70, P1827, DOI 10.1271/bbb.50673; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Havaux M, 2004, J BIOL CHEM, V279, P13878, DOI 10.1074/jbc.M311154200; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; Jackowski G, 2003, J PHOTOCH PHOTOBIO B, V70, P163, DOI 10.1016/S1011-1344(03)00076-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1102, P53, DOI 10.1016/0167-4838(92)90498-3; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; Masuda T, 2003, PLANT MOL BIOL, V51, P757, DOI 10.1023/A:1022545118212; Mckim SM, 2006, PLANT PHYSIOL BIOCH, V44, P857, DOI 10.1016/j.plaphy.2006.10.018; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Minai L, 2006, PLANT CELL, V18, P159, DOI 10.1105/tpc.105.037705; Morosinotto T, 2006, FEBS J, V273, P4616, DOI 10.1111/j.1742-4658.2006.05465.x; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Mussgnug JH, 2005, PLANT CELL, V17, P3409, DOI 10.1105/tpc.105.035774; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nelson N, 2004, NAT REV MOL CELL BIO, V5, P971, DOI 10.1038/nrm1525; Nielsen VS, 1996, PHYSIOL PLANTARUM, V98, P637, DOI 10.1111/j.1399-3054.1996.tb05721.x; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; Peng LW, 2006, PLANT CELL, V18, P955, DOI 10.1105/tpc.105.037689; PETERGF, 1991, METHODS PLANT BIOCH, P195; Pfannschmidt T, 2001, PHYSIOL PLANTARUM, V112, P1, DOI 10.1034/j.1399-3054.2001.1120101.x; Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058; Sakamoto W, 2003, PLANT CELL, V15, P2843, DOI 10.1105/tpc.017319; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; SIMPSON DJ, 1983, EUR J CELL BIOL, V31, P305; Tullberg A, 2000, PLANT CELL PHYSIOL, V41, P1045, DOI 10.1093/pcp/pcd031; Walters RG, 2005, J EXP BOT, V56, P435, DOI 10.1093/jxb/eri060; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wostrikoff K, 2004, EMBO J, V23, P2696, DOI 10.1038/sj.emboj.7600266; Wostrikoff K, 2007, P NATL ACAD SCI USA, V104, P6466, DOI 10.1073/pnas.0610586104; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827; YU JJ, 1990, PLANT CELL, V2, P315; Zaltsman A, 2005, PLANT J, V42, P609, DOI 10.1111/j.1365-313X.2005.02401.x; Zelisko A, 2005, P NATL ACAD SCI USA, V102, P13699, DOI 10.1073/pnas.0503472102; Zelisko A, 2004, J PLANT PHYSIOL, V161, P1157, DOI 10.1016/j.jplph.2004.01.006	59	55	61	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29457	29469		10.1074/jbc.M705132200	http://dx.doi.org/10.1074/jbc.M705132200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675669	hybrid			2022-12-25	WOS:000249788000043
J	Hlavanda, E; Klement, E; Kokai, E; Vincze, O; Tokesi, N; Orosz, F; Medzihradszky, KF; Dombradi, V; Ovadi, J				Hlavanda, Emma; Klement, Eva; Kokai, Endre; Vincze, Orsolya; Tokesi, Natalia; Orosz, Ferenc; Medzihradszky, Katalin F.; Dombradi, Viktor; Ovadi, Judit			Phosphorylation blocks the activity of tubulin polymerization-promoting protein (TPPP) - Identification of sites targeted by different kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC DISORDER; MASS-SPECTROMETRY; P25; CONSERVATION; MICROTUBULES; ASSEMBLIES; PREDICTION; FAMILIES; DOMAINS	Tubulin polymerization- promoting protein (TPPP), an unfolded brain-specific protein interacts with the tubulin/microtubule system in vitro and in vivo, and is enriched in human pathological brain inclusions. Here we show that TPPP induces tubulin self-assembly into intact frequently bundled microtubules, and that the phosphorylation of specific sites distinctly affects the function of TPPP. In vitro phosphorylation of wild type and the truncated form (Delta 3-43TPPP) of human recombinant TPPP was performed by kinases involved in brain-specific processes. A stoichiometry of 2.9 +/- 0.3, 2.2 +/- 0.3, and 0.9 +/- 0.1 mol P/mol protein with ERK2, cyclin-dependent kinase 5 (Cdk5), and cAMP-dependent protein kinase (PKA), respectively, was revealed for the full-length protein, and 0.4-0.5 mol P/mol protein was detected with all three kinases when the N-terminal tail was deleted. The phosphorylation sites Thr(14), Ser(18), Ser(160) for Cdk5; Ser(18), Ser(160) for ERK2, and Ser(32) for PKA were identified by mass spectrometry. These sites were consistent with the bioinformatic predictions. The three N-terminal sites were also found to be phosphorylated in vivo in TPPP isolated from bovine brain. Affinity binding experiments provided evidence for the direct interaction between TPPP and ERK2. The phosphorylation of TPPP by ERK2 or Cdk5, but not by PKA, perturbed the structural alterations induced by the interaction between TPPP and tubulin without affecting the binding affinity (K-d = 2.5-2.7 mu M) or the stoichiometry (1 mol TPPP/mol tubulin) of the complex. The phosphorylation by ERK2 or Cdk5 resulted in the loss of microtubule-assembling activity of TPPP. The combination of our in vitro and in vivo data suggests that ERK2 can regulate TPPP activity via the phosphorylation of Thr(14) and/or Ser(18) in its unfolded N-terminal tail.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Proteom Res Grp, H-6726 Szeged, Hungary; Univ Debrecen, Res Ctr Mol Med, Dept Med Chem, Hungarian Acad Sci,Cell Biol & Signalling Res Grp, H-4032 Debrecen, Hungary; Eotvos Lorand Univ, Fac Sci, Dept Anat Cell & Dev Biol, H-1117 Budapest, Hungary; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Academy of Sciences; University of Debrecen; Eotvos Lorand University; University of California System; University of California San Francisco	Ovadi, J (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, Karolina 29, H-1113 Budapest, Hungary.	ovadi@enzim.hu		Ovadi, Judit/0000-0002-3420-682X				BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JW, 2006, J PROTEOME RES, V5, P879, DOI 10.1021/pr060048x; Chen JW, 2006, J PROTEOME RES, V5, P888, DOI 10.1021/pr060049p; Collins MO, 2005, J BIOL CHEM, V280, P5972, DOI 10.1074/jbc.M411220200; COVEY TR, 1991, METHODS PROTEIN SEQU, P411; DeGiorgis JA, 2005, J PROTEOME RES, V4, P306, DOI 10.1021/pr0498436; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Hlavanda E, 2002, BIOCHEMISTRY-US, V41, P8657, DOI 10.1021/bi020140g; Jamsa A, 2006, BIOCHEM BIOPH RES CO, V345, P324, DOI 10.1016/j.bbrc.2006.04.032; Kovacs GG, 2004, NEUROBIOL DIS, V17, P155, DOI 10.1016/j.nbd.2004.06.006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; Lehotzky A, 2004, J CELL SCI, V117, P6249, DOI 10.1242/jcs.01550; Lindersson E, 2005, J BIOL CHEM, V280, P5703, DOI 10.1074/jbc.M410409200; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Martin CP, 2002, BBA-MOL BASIS DIS, V1586, P113; Murray AW, 1998, CELL, V92, P157, DOI 10.1016/S0092-8674(00)80910-1; NA GC, 1986, BIOCHEMISTRY-US, V25, P6214, DOI 10.1021/bi00368a057; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Olah J, 2006, FEBS LETT, V580, P5807, DOI 10.1016/j.febslet.2006.09.037; Orosz F, 2004, BIOL CELL, V96, P701, DOI 10.1016/j.biolcel.2004.08.002; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; TAKAHASHI M, 1991, FEBS LETT, V289, P37, DOI 10.1016/0014-5793(91)80903-G; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Thompson AJ, 2003, ANAL CHEM, V75, P3232, DOI 10.1021/ac034134h; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tirian L, 2003, P NATL ACAD SCI USA, V100, P13976, DOI 10.1073/pnas.2436331100; Trinidad JC, 2006, MOL CELL PROTEOMICS, V5, P914, DOI 10.1074/mcp.T500041-MCP200; ULLOA L, 1993, FEBS LETT, V330, P85, DOI 10.1016/0014-5793(93)80925-K; Veeranna GJ, 2000, MOL BRAIN RES, V76, P229, DOI 10.1016/S0169-328X(00)00003-6; Vincze O, 2006, BIOCHEMISTRY-US, V45, P13818, DOI 10.1021/bi061305e; Wang YY, 2007, CHINESE J CHEM, V25, P68, DOI 10.1002/cjoc.200790019; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; WU CW, 1973, BIOCHEMISTRY-US, V12, P1400, DOI 10.1021/bi00731a021	39	51	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29531	29539		10.1074/jbc.M703466200	http://dx.doi.org/10.1074/jbc.M703466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693641	hybrid			2022-12-25	WOS:000249788000050
J	Noguchi, M; Hosoda, K; Fujikura, J; Fujimoto, M; Iwakura, H; Tomita, T; Ishii, T; Arai, N; Hirata, M; Ebihara, K; Masuzaki, H; Itoh, H; Narumiya, S; Nakao, K				Noguchi, Michio; Hosoda, Kiminori; Fujikura, Junji; Fujimoto, Muneya; Iwakura, Hiroshi; Tomita, Tsutomu; Ishii, Takako; Arai, Naoki; Hirata, Masakazu; Ebihara, Ken; Masuzaki, Hiroaki; Itoh, Hiroshi; Narumiya, Shuh; Nakao, Kazuwa			Genetic and pharmacological inhibition of Rho-associated kinase II enhances adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; BINDING PROTEIN-RHO; VENTRAL BODY-WALL; ADIPOCYTE DIFFERENTIATION; PPAR-GAMMA; ROK-ALPHA; ADIPOSE CONVERSION; 3T3-L1 ADIPOCYTES; C/EBP-ALPHA; ROCK-I	Rho-associated kinase (ROCK) regulates reorganization of actin cytoskeleton. During adipogenesis, the structure of filamentous actin is converted from long stress fibers to cortical actin, suggesting that the ROCK is involved in adipogenesis. Two ROCK isoforms have been identified: ROCK-I and ROCK-II. However, pharmacological inhibitors of ROCK cannot distinguish two ROCK isoforms. In the present study, we examined the role of ROCK in adipogenesis and actin cytoskeleton using genetic and pharmacological approaches. Y-27632, which inhibits the activity of both ROCK isoforms, enhanced adipogenesis through the up-regulation of adipogenic transcription factors in 3T3-L1 cells. Furthermore, Y-27632 restored inhibition of adipogenesis by lysophosphatidic acid, which activates Rho. Regarding actin cytoskeleton, Y-27632 disrupted stress fibers in 3T3-L1 preadipocytes. Next, we analyzed adipogenesis of mouse embryonic fibroblasts (MEFs) derived from ROCK-I and ROCK-II knock-out mice, respectively. Adipogenesis of ROCK-II (-/-) MEFs was markedly enhanced compared with wild-type MEFs while that of ROCK-I (-/-) MEFs was not. In contrast to pharmacological approaches, no obvious alteration was found in actin cytoskeleton of ROCK-II(-/-) MEFs compared with wild-type MEFs. In 3T3-L1 cells, knockdown of ROCK-II by RNA interference enhanced the expression of adipogenic transcription factors while that of ROCK-I did not. Moreover, Y-27632 inhibited IRS-1 serine phosphorylation and enhanced Akt phosphorylation in 3T3-L1 preadipocytes. Similarly, Akt phosphorylation in ROCK-II (-/-) MEFs was augmented compared with wild-type MEFs. In conclusion, inhibition of ROCK-II, not ROCK-I, enhances adipogenesis accompanied by the up-regulation of adipogenic transcription factors. Augmentation of insulin signaling may contribute to the enhancement of adipogenesis.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Hosoda, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kaeahara Cho, Kyoto 6068507, Japan.	kh@kuhp.kyoto-u.ac.jp	Fujikura, Junji/AAR-2684-2020	Iwakura, Hiroshi/0000-0001-8033-0736				Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Camp HS, 1997, J BIOL CHEM, V272, P10811; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Farah S, 1998, J BIOL CHEM, V273, P4740, DOI 10.1074/jbc.273.8.4740; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; Furukawa N, 2005, CELL METAB, V2, P119, DOI 10.1016/j.cmet.2005.06.011; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Norisada N, 2004, METABOLISM, V53, P1532, DOI 10.1016/j.metabol.2004.06.020; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Shimokawa H, 1999, CARDIOVASC RES, V43, P1029, DOI 10.1016/S0008-6363(99)00144-3; Simon MF, 2005, J BIOL CHEM, V280, P14656, DOI 10.1074/jbc.M412585200; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Thumkeo D, 2005, GENES CELLS, V10, P825, DOI 10.1111/j.1365-2443.2005.00882.x; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	47	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29574	29583		10.1074/jbc.M705972200	http://dx.doi.org/10.1074/jbc.M705972200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681946	hybrid			2022-12-25	WOS:000249788000054
J	Geisler, DA; Broselid, C; Hederstedt, L; Rasmusson, AG				Geisler, Daniela A.; Broselid, Christian; Hederstedt, Lars; Rasmusson, Allan G.			Ca2+-binding and Ca2+-independent respiratory NADH and NADPH dehydrogenases of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE MITOCHONDRIA; ALTERNATIVE NAD(P)H DEHYDROGENASES; RED BEETROOT MITOCHONDRIA; CALCIUM-BINDING PROTEINS; ESCHERICHIA-COLI; PLANT-MITOCHONDRIA; EXTERNAL NAD(P)H; CYTOPLASMIC PH; CYTOSOLIC NADH	Type II NAD(P)H:quinone oxidoreductases are single polypeptide proteins widespread in the living world. They bypass the first site of respiratory energy conservation, constituted by the type I NADH dehydrogenases. To investigate substrate specificities and Ca2+ binding properties of seven predicted type II NAD(P)H dehydrogenases of Arabidopsis thaliana we have produced them as T7-tagged fusion proteins in Escherichia coli. The NDB1 and NDB2 enzymes were found to bind Ca2+, and a single amino acid substitution in the EF hand motif of NDB1 abolished the Ca2+ binding. NDB2 and NDB4 functionally complemented an E. coli mutant deficient in endogenous type I and type II NADH dehydrogenases. This demonstrates that these two plant enzymes can substitute for the NADH dehydrogenases in the bacterial respiratory chain. Three NDB-type enzymes displayed distinct catalytic profiles with substrate specificities and Ca2+ stimulation being considerably affected by changes in pH and substrate concentrations. Under physiologically relevant conditions, the NDB1 fusion protein acted as a Ca2+-dependent NADPH dehydrogenase. NDB2 and NDB4 fusion proteins were NADH-specific, and NDB2 was stimulated by Ca2+. The observed activity profiles of the NDB-type enzymes provide a fundament for understanding the mitochondrial system for direct oxidation of cytosolic NAD(P)H in plants. Our findings also suggest different modes of regulation and metabolic roles for the analyzed A. thaliana enzymes.	Lund Univ, Dept Cell & Organism Biol, SE-22362 Lund, Sweden	Lund University	Rasmusson, AG (corresponding author), Lund Univ, Dept Cell & Organism Biol, Solvegatan 35B, SE-22362 Lund, Sweden.	Allan.Rasmusson@cob.lu.se		Hederstedt, Lars/0000-0002-6650-6296				ARRON GP, 1980, PLANT PHYSIOL, V65, P591, DOI 10.1104/pp.65.4.591; Bernard L, 2006, FEBS J, V273, P3625, DOI 10.1111/j.1742-4658.2006.05370.x; Bjorklof K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; Carneiro P, 2004, BBA-BIOENERGETICS, V1608, P45, DOI 10.1016/j.bbabio.2003.10.004; Carneiro P, 2007, J MOL BIOL, V368, P1114, DOI 10.1016/j.jmb.2007.02.080; Clifton R, 2005, PLANT MOL BIOL, V58, P193, DOI 10.1007/s11103-005-5514-7; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Duarte M, 2003, BIOCHEM J, V371, P1005, DOI 10.1042/BJ20021374; Duval FD, 2002, PLANT J, V32, P481, DOI 10.1046/j.1365-313X.2002.01409.x; Elhafez D, 2006, PLANT CELL PHYSIOL, V47, P43, DOI 10.1093/pcp/pci221; Escobar MA, 2006, PLANT J, V45, P775, DOI 10.1111/j.1365-313X.2005.02640.x; Escobar MA, 2004, PLANT PHYSIOL, V136, P2710, DOI 10.1104/pp.104.046698; FELLE H, 1986, BIOCHIM BIOPHYS ACTA, V848, P176, DOI 10.1016/0005-2728(86)90039-3; Felle HH, 2000, PLANT PHYSIOL, V124, P1373, DOI 10.1104/pp.124.3.1373; Felle HH, 2001, PLANT BIOLOGY, V3, P577, DOI 10.1055/s-2001-19372; FOX GG, 1995, PLANTA, V195, P324, DOI 10.1007/BF00202588; FREDLUND KM, 1991, PLANT PHYSIOL, V97, P99, DOI 10.1104/pp.97.1.99; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Howitt CA, 1999, J BACTERIOL, V181, P3994, DOI 10.1128/JB.181.13.3994-4003.1999; Igamberdiev AU, 2003, BBA-BIOENERGETICS, V1606, P117, DOI 10.1016/S0005-2728(03)00106-3; JAWOROWSKI A, 1981, BIOCHEMISTRY-US, V20, P2041, DOI 10.1021/bi00510a047; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KROMER S, 1995, ANNU REV PLANT PHYS, V46, P45, DOI 10.1146/annurev.pp.46.060195.000401; LUETHY MH, 1991, PLANT PHYSIOL, V97, P1317, DOI 10.1104/pp.97.4.1317; LUETHY MH, 1995, PLANT PHYSIOL, V107, P443, DOI 10.1016/S0176-1617(11)81768-2; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Matsushita K, 2001, FEMS MICROBIOL LETT, V204, P271, DOI 10.1016/S0378-1097(01)00417-7; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; Melo AMP, 2004, MICROBIOL MOL BIOL R, V68, P603, DOI 10.1128/MMBR.68.4.603-616.2004; Melo AMP, 2001, J BIOL CHEM, V276, P3947, DOI 10.1074/jbc.M008199200; Menz RI, 1996, PLANT PHYSIOL, V112, P607, DOI 10.1104/pp.112.2.607; Michalecka AM, 2004, PLANT J, V37, P415, DOI 10.1046/j.1365-313X.2003.01970.x; Michalecka AM, 2003, PLANT PHYSIOL, V133, P642, DOI 10.1104/pp.103.024208; MOLLER IM, 1981, PHYSIOL PLANTARUM, V53, P413, DOI 10.1111/j.1399-3054.1981.tb02724.x; MOLLER IM, 1981, BIOCHEM J, V194, P487, DOI 10.1042/bj1940487; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; MOLLER IM, 1993, J BIOENERG BIOMEMBR, V25, P377, DOI 10.1007/BF00762463; Moller IM, 1996, PLANT PHYSIOL, V112, P75, DOI 10.1104/pp.112.1.75; MOLLER JM, 1997, PHYSIOL PLANTARUM, V100, P85; Moore CS, 2003, PLANT PHYSIOL, V133, P1968, DOI 10.1104/pp.103.029363; NASH D, 1983, PLANT PHYSIOL, V71, P627, DOI 10.1104/pp.71.3.627; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Overkamp KM, 2000, J BACTERIOL, V182, P2823, DOI 10.1128/JB.182.10.2823-2830.2000; PROCYSHYN RM, 1994, J BIOL CHEM, V269, P1641; Rasmusson AG, 2004, ANNU REV PLANT BIOL, V55, P23, DOI 10.1146/annurev.arplant.55.031903.141720; Rasmusson AG, 2001, PLANT PHYSIOL BIOCH, V39, P1057, DOI 10.1016/S0981-9428(01)01334-1; RASMUSSON AG, 1993, BIOCHIM BIOPHYS ACTA, V1141, P107, DOI 10.1016/0005-2728(93)90196-M; Rasmusson AG, 1999, PLANT J, V20, P79, DOI 10.1046/j.1365-313X.1999.00576.x; Rasmusson AG, 1998, BBA-BIOENERGETICS, V1364, P101, DOI 10.1016/S0005-2728(98)00021-8; Rigoulet M, 2004, MOL CELL BIOCHEM, V256, P73, DOI 10.1023/B:MCBI.0000009888.79484.fd; ROBERTS JKM, 1984, P NATL ACAD SCI-BIOL, V81, P3379, DOI 10.1073/pnas.81.11.3379; ROBERTS TH, 1995, FEBS LETT, V373, P307, DOI 10.1016/0014-5793(95)01059-N; Sakano K, 2001, INT REV CYTOL, V206, P1; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SIEDOW JN, 2000, BIOCH MOL BIOL PLANT, P676; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P217; Svensson AS, 2002, FEBS LETT, V517, P79, DOI 10.1016/S0014-5793(02)02581-4; Svensson AS, 2001, PLANT J, V28, P73, DOI 10.1046/j.1365-313X.2001.01128.x; Trewavas A, 1999, PLANT PHYSIOL, V120, P1, DOI 10.1104/pp.120.1.1; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZOTTINI M, 1993, PLANT PHYSIOL, V102, P579, DOI 10.1104/pp.102.2.579	71	58	62	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28455	28464		10.1074/jbc.M704674200	http://dx.doi.org/10.1074/jbc.M704674200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673460	hybrid			2022-12-25	WOS:000249642100019
J	Hodkinson, PS; Elliott, PA; Lad, Y; McHugh, BJ; MacKinnon, AC; Haslett, C; Sethi, T				Hodkinson, Philip S.; Elliott, Paul. A.; Lad, Yatish; McHugh, Brian J.; MacKinnon, Alison C.; Haslett, Christopher; Sethi, Tariq			Mammalian NOTCH-1 activates beta 1 integrins via the small GTPase R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL STEM-CELLS; ERK MAP KINASE; INTEGRIN ACTIVATION; INTRACELLULAR DOMAIN; VULVAL DEVELOPMENT; SIGNALING PATHWAY; BINDING DOMAIN; GROWTH-FACTOR; MOUSE NOTCH1; RECEPTOR	Notch is a central regulator of important cell fate decisions. Notch activation produces diverse cellular effects suggesting the presence of context-dependent control mechanisms. Genetic studies have demonstrated that Notch and integrin mutations have related phenotypes in key developmental processes such as vascular development and somitogenesis. We show that the intracellular domain of mammalian Notch-1 activates integrins without affecting integrin expression. Integrin activation is dependent on gamma-secretase-mediated intramembranous cleavage of membrane-bound Notch releasing intracellular Notch that activates R-Ras, independent of CSL-transcription. Notch also reverses H-Ras and Raf-mediated integrin suppression without affecting ERK phosphorylation. Membrane-bound Notch mutants that are inefficiently cleaved or intracellular Notch mutants lacking the ankyrin repeat sequence do not activate R-Ras or integrins. Co-expression of Msx2-interacting nuclear target ( MINT) protein with Notch or expression of intracellular Notch-1 truncation mutants lacking the C-terminal transactivation/PEST domain suppresses Notch transcriptional activity without affecting integrin activation. Notch ligand, Delta-like ligand-4, stimulates R-Ras-dependent alpha 5 beta 1 integrin-mediated adhesion, demonstrating the physiological relevance of this pathway. This new CSL-independent Notch/R-Ras pathway provides a molecular mechanism to explain Notch, integrin, and Ras cross-talk during the development of multicellular organisms.	Univ Edinburgh, MRC Ctr Inflammat Res, Queens Med Res Inst, Edinburgh EH16 4SA, Midlothian, Scotland	University of Edinburgh	Sethi, T (corresponding author), 47 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	t.sethi@ed.ac.uk	; Elliott, Tony/M-1057-2015	McHugh, Brian/0000-0003-4747-0643; Elliott, Tony/0000-0002-0715-9431	Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Alberola-Ila J, 2003, IMMUNOL REV, V191, P79, DOI 10.1034/j.1600-065X.2003.00012.x; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Campos LS, 2006, J BIOL CHEM, V281, P5300, DOI 10.1074/jbc.M511886200; Chong SW, 2005, TRENDS CELL BIOL, V15, P453, DOI 10.1016/j.tcb.2005.07.008; Clegg DO, 2003, FRONT BIOSCI-LANDMRK, V8, pD723, DOI 10.2741/1020; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Culi J, 2001, DEVELOPMENT, V128, P299; Darribere T, 2000, BIOL CELL, V92, P5, DOI 10.1016/S0248-4900(00)88760-2; DE SB, 1999, NATURE, V398, P518; deCelis JF, 1996, DEVELOPMENT, V122, P359; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Eagar TN, 2004, IMMUNITY, V20, P407, DOI 10.1016/S1074-7613(04)00081-0; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Endo Y, 2002, DEVELOPMENT, V129, P863; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Furuhjelm J, 2003, J CELL SCI, V116, P3729, DOI 10.1242/jcs.00689; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Julich D, 2005, DEV CELL, V8, P575, DOI 10.1016/j.devcel.2005.01.016; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Komatsu M, 2005, NAT MED, V11, P1346, DOI 10.1038/nm1324; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lad Y, 2006, J BIOL CHEM, V281, P29501, DOI 10.1074/jbc.M513471200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Langdon T, 2006, DEV DYNAM, V235, P998, DOI 10.1002/dvdy.20735; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nagaraj R, 2004, INT J DEV BIOL, V48, P755, DOI 10.1387/ijdb.041881rn; Nagato M, 2005, J NEUROSCI RES, V80, P456, DOI 10.1002/jnr.20442; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Shawber C, 1996, DEVELOPMENT, V122, P3765; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stump G, 2002, MECH DEVELOP, V114, P153, DOI 10.1016/S0925-4773(02)00043-6; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; Sundaram MV, 2004, CURR BIOL, V14, pR311, DOI 10.1016/j.cub.2004.03.052; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Yin ZN, 1997, CELL GROWTH DIFFER, V8, P1339; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; zur Lage P, 1999, DEVELOPMENT, V126, P3149	71	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28991	29001		10.1074/jbc.M703601200	http://dx.doi.org/10.1074/jbc.M703601200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17664272	Green Submitted, hybrid			2022-12-25	WOS:000249642100073
J	Nikolov, EN; Ivanova-Nikolova, TT				Nikolov, Emil N.; Ivanova-Nikolova, Tatyana T.			Dynamic integration of alpha-adrenergic and cholinergic signals in the Atria - Role of G protein-regulated inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; FORM STABLE COMPLEXES; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; COUPLED RECEPTORS; POTASSIUM CHANNELS; ADENYLYL-CYCLASE; GIRK CHANNELS; INHIBITION; CELLS	Numerous heptahelical receptors use activation of heterotrimeric G proteins to convey a multitude of extracellular signals to appropriate effector molecules in the cell. Both high specificity and correct integration of these signals are required for reliable cell function. Yet the molecular machineries that allow each cell to merge information flowing across different receptors are not well understood. Here we demonstrate that G protein-regulated inwardly rectifying K+ (GIRK) channels can operate as dynamic integrators of alpha-adrenergic and cholinergic signals in atrial myocytes. Acting at the last step of the cholinergic signaling cascade, these channels are activated by direct interactions with beta gamma subunits of the inhibitory G proteins (G beta gamma), and efficiently translate M-2 muscarinic acetylcholine receptor (M2R) activation into membrane hyperpolarization. The parallel activation of alpha-adrenergic receptors imposed a distinctive " signature" on the function of M2R-activated GIRK1/4 channels, affecting both the probability of G beta gamma binding to the channel and its desensitization. This modulation of channel function was correlated with a parallel depletion of G beta and protein phosphatase 1 from the oligomeric GIRK1 complexes. Such plasticity of the immediate GIRK signaling environment suggests that multireceptor integration involves large protein networks undergoing dynamic changes upon receptor activation.	E Carolina Univ, Dept Pharmacol & Toxicol, Brody Sch Med, Greenville, NC 27834 USA	University of North Carolina; East Carolina University	Ivanova-Nikolova, TT (corresponding author), E Carolina Univ, Dept Pharmacol & Toxicol, Brody Sch Med, Brody Med Sci Bldg,Rm 6S-11, Greenville, NC 27834 USA.	ivanovanikolovat@ecu.edu						BRAUN AP, 1992, PFLUEGERS ARCH, V421, P43; Brown SG, 2005, AM J PHYSIOL-CELL PH, V289, pC543, DOI 10.1152/ajpcell.00025.2005; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Cho H, 2005, P NATL ACAD SCI USA, V102, P15241, DOI 10.1073/pnas.0408851102; Cho H, 2005, P NATL ACAD SCI USA, V102, P4643, DOI 10.1073/pnas.0408844102; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; Clancy SM, 2005, MOL CELL NEUROSCI, V28, P375, DOI 10.1016/j.mcn.2004.10.009; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ivanova-Nikolova TT, 1998, J GEN PHYSIOL, V112, P199, DOI 10.1085/jgp.112.2.199; Kawano T, 2007, MOL PHARMACOL, V71, P1179, DOI 10.1124/mol.106.032508; Keselman I, 2007, CHANNELS, V1, P113, DOI 10.4161/chan.4321; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Koike-Tani M, 2005, J PHYSIOL-LONDON, V564, P489, DOI 10.1113/jphysiol.2004.079285; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Lei QB, 2003, MOL CELLS, V15, P1; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Nikolov EN, 2004, BIOPHYS J, V87, P3122, DOI 10.1529/biophysj.104.039487; Nikolov EN, 2004, J BIOL CHEM, V279, P23630, DOI 10.1074/jbc.M312861200; Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sadja R, 2003, NEURON, V39, P9, DOI 10.1016/S0896-6273(03)00402-1; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhu WZ, 2005, CIRC RES, V97, P244, DOI 10.1161/01.RES.0000176764.38934.86	36	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28669	28682		10.1074/jbc.M703677200	http://dx.doi.org/10.1074/jbc.M703677200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17684011	hybrid			2022-12-25	WOS:000249642100041
J	Werneburg, NW; Guicciardi, ME; Bronk, SF; Kaufmann, SH; Gores, GJ				Werneburg, Nathan W.; Guicciardi, M. Eugenia; Bronk, Steve F.; Kaufmann, Scott H.; Gores, Gregory J.			Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; BAX-DEPENDENT APOPTOSIS; ALPHA-INDUCED APOPTOSIS; TNF-ALPHA; CELL-DEATH; CHOLANGIOCARCINOMA CELLS; UP-REGULATION; HEPATOCYTE APOPTOSIS; MEDIATED APOPTOSIS	The present studies were performed to determine whether lysosomal permeabilization contributes to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) cytotoxicity and to reconcile a role for lysosomes with prior observations that Bcl-2 family members regulate TRAIL-induced apoptosis. In KMCH cholangiocarcinoma cells stably expressing Mcl-1 small interference RNA ( siRNA), treatment with TRAIL induced a redistribution of the cathepsin B from lysosomes to the cytosol. Pharmacological and small hairpin RNA-targeted inhibition of cathepsin B attenuated TRAIL-mediated apoptosis as assessed by morphological, biochemical, and clonogenic assays. Neither Bid siRNA nor Bak siRNA prevented cathepsin B release. In contrast, treatment of the cells with Bim siRNA or the JNK inhibitor SP600125 attenuated lysosomal permeabilization and cell death. Moreover, Bim and active Bax co-localized to lysosomes in TRAIL-treated cells in a JNK-dependent manner, and Bax siRNA reduced TRAIL-induced lysosomal permeabilization and cell death. Finally, BH3 domain peptides permeabilized isolated lysosomes in the presence of Bax. Collectively, these data suggest that TRAIL can trigger an apoptotic pathway that involves JNK-dependent activation of Bim, which in turn induces Bax-mediated permeabilization of lysosomes.	Mayo Clin, Coll Med, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, 200 1st st SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA69008, R01 CA069008] Funding Source: Medline; NIDDK NIH HHS [DK63947, DK59427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059427, R01DK063947, R56DK059427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAO Y, 1994, CANCER RES, V54, P2468; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Burns TF, 2001, J BIOL CHEM, V276, P37879; Caruso JA, 2006, J BIOL CHEM, V281, P10954, DOI 10.1074/jbc.M508383200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng G, 2006, P NATL ACAD SCI USA, V103, P8499, DOI 10.1073/pnas.0602957103; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Fehrenbacher N, 2004, CANCER RES, V64, P5301, DOI 10.1158/0008-5472.CAN-04-1427; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Feldstein AE, 2006, AM J PHYSIOL-GASTR L, V290, pG1339, DOI 10.1152/ajpgi.00509.2005; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Guicciardi ME, 2007, AM J PHYSIOL-GASTR L, V292, pG1337, DOI 10.1152/ajpgi.00497.2006; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2005, GASTROENTEROLOGY, V129, P269, DOI 10.1053/j.gastro.2005.05.022; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Kagedal K, 2005, INT J EXP PATHOL, V86, P309, DOI 10.1111/j.0959-9673.2005.00442.x; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Malhi H, 2006, J BIOL CHEM, V281, P12093, DOI 10.1074/jbc.M510660200; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Papadakis ES, 2006, FEBS LETT, V580, P1320, DOI 10.1016/j.febslet.2006.01.053; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Sayan BS, 2001, J CELL BIOL, V155, P719, DOI 10.1083/jcb.200106044; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Takada E, 2005, EXP CELL RES, V304, P518, DOI 10.1016/j.yexcr.2004.11.015; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wang YJ, 2006, J BIOL CHEM, V281, P15258, DOI 10.1074/jbc.M512953200; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; YAMADA H, 1984, J BIOCHEM, V95, P1155, DOI 10.1093/oxfordjournals.jbchem.a134704; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zu K, 2005, MOL CANCER THER, V4, P43	61	107	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28960	28970		10.1074/jbc.M705671200	http://dx.doi.org/10.1074/jbc.M705671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686764	hybrid			2022-12-25	WOS:000249642100070
J	Jiang, L; Smith, JN; Anderson, SL; Ma, P; Mizzen, CA; Kelleher, NL				Jiang, Lihua; Smith, Jonell N.; Anderson, Shannon L.; Ma, Ping; Mizzen, Craig A.; Kelleher, Neil L.			Global assessment of combinatorial post-translational modification of core histones in yeast using contemporary mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-CAPTURE DISSOCIATION; SACCHAROMYCES-CEREVISIAE; HAT ACTIVITY; ACETYLATION; METHYLATION; H3; ACETYLTRANSFERASE; TRANSCRIPTION; COMPLEX; GCN5P	A global view of all core histones in yeast is provided by tandem mass spectrometry of intact histones H2A, H2B, H4, and H3. This allowed detailed characterization of > 50 distinct histone forms and their semiquantitative assessment in the deletion mutants gcn5 Delta, spt7 Delta, ahc1 Delta, and rtg2 Delta, affecting the chromatin remodeling complexes SAGA, SLIK, and ADA. The "top down" mass spectrometry approach detected dramatic decreases in acetylation on H3 and H2B in gcn5 Delta cells versus wild type. For H3 in wild type cells, tandem mass spectrometry revealed a direct correlation between increases of Lys(4) trimethylation and the 0, 1, 2, and 3 acetylation states of histone H3. The results show a wide swing from 10 to 80% Lys(4) trimethylation levels on those H3 tails harboring 0 or 3 acetylations, respectively. Reciprocity between these chromatin marks was apparent, since gcn5 Delta cells showed a 30% decrease in trimethylation levels on Lys(4) in addition to a decrease of acetylation levels on H3 in bulk chromatin. Deletion of Set1, the Lys(4) methyltransferase, was associated with the linked disappearance of both Lys(4) methylation and Lys(14) and Lys(18) or Lys(23) acetylation on H3. In sum, we have defined the "basis set" of histone forms present in yeast chromatin using a current mass spectrometric approach that both quickly profiles global changes and directly probes the connectivity of modifications on the same histone.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Stat, Urbana, IL 61801 USA; Univ Illinois, Dept Genom Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews,53 Rodger Adams Lab, Urbana, IL 61801 USA.	kelleher@scs.uiuc.edu	Ma, Ping/M-7746-2015	Ma, Ping/0000-0002-5728-3596	NIGMS NIH HHS [GM 067193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyne MT, 2006, J PROTEOME RES, V5, P248, DOI 10.1021/pr050269n; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; Fingerman IM, 2005, J BIOL CHEM, V280, P28761, DOI 10.1074/jbc.C500097200; Garcia BA, 2007, NAT METHODS, V4, P487, DOI 10.1038/nmeth1052; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lee KK, 2004, BIOCHEM SOC T, V32, P899, DOI 10.1042/BST0320899; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Meng FY, 2002, ANAL CHEM, V74, P2923, DOI 10.1021/ac020049i; Millar CB, 2006, NAT REV MOL CELL BIO, V7, P657, DOI 10.1038/nrm1986; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050; Pesavento JJ, 2004, J AM CHEM SOC, V126, P3386, DOI 10.1021/ja039748i; PESAVENTO JJ, 2007, IN PRESS MOL CELL PR; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1839, DOI 10.1002/(SICI)1097-0231(199611)10:14<1839::AID-RCM718>3.0.CO;2-V; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Siuti N, 2006, J PROTEOME RES, V5, P233, DOI 10.1021/pr050268v; Song OK, 2003, J BIOL CHEM, V278, P38109, DOI 10.1074/jbc.C300355200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Taverna SD, 2007, P NATL ACAD SCI USA, V104, P2086, DOI 10.1073/pnas.0610993104; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Thomas CE, 2006, J PROTEOME RES, V5, P240, DOI 10.1021/pr050266a; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Yuan GC, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r70; Zhang KL, 2004, PROTEOMICS, V4, P3765, DOI 10.1002/pmic.200400819; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zubarev RA, 2004, CURR OPIN BIOTECH, V15, P12, DOI 10.1016/j.copbio.2003.12.002; Zubarev RA, 2000, ANAL CHEM, V72, P563, DOI 10.1021/ac990811p	55	74	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27923	27934		10.1074/jbc.M704194200	http://dx.doi.org/10.1074/jbc.M704194200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652096	hybrid			2022-12-25	WOS:000249455600041
J	Kent, NA; Chambers, AL; Downs, JA				Kent, Nicholas A.; Chambers, Anna L.; Downs, Jessica A.			Dual chromatin remodeling roles for RSC during DNA double strand break induction and repair at the yeast MAT locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE H2A; RECOMBINATION; COMPLEX; DAMAGE; ACCESSIBILITY; NUCLEOSOMES; ADAPTATION; MECHANISM	DNA double strand breaks (DSBs) are potentially serious chromosomal lesions. However, cells sometimes deliberately cleave their own DNA to facilitate certain chromosomal processes, and there is much interest in how such self-inflicted breaks are effectively managed. Eukaryotic DSBs occur in the context of chromatin and the RSC chromatin-remodeling AT Pase complex has been shown to promote DSB repair at the budding yeast MAT locus DSB, created by the HO endonuclease during mating type switching. We show that the role of RSC at MAT is highly specialized. The Rsc1p subunit of RSC directs nucleosome sliding immediately after DSB creation at both MA T and generally and is required for efficient DNA damage-induced histone H2A phosphorylation and strand resection during repair by homologous recombination. However, the Rsc2p and Rsc7p subunits are additionally required to set up a basal MAT locus structure. This RSC-dependent chromatin structure at MA T ensures accessibility to the HO endonuclease. The RSC complex therefore has chromatin remodeling roles both before and after DSB induction at MAT, promoting both DNA cleavage and subsequent repair.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Oxford; University of Cambridge; Cardiff University	Kent, NA (corresponding author), Univ Sussex, Med Res Council Genom Damage & Stability Ctr, Brighton BN1 9RQ, E Sussex, England.	kentn@cardiff.ac.uk	Kent, Nicholas/A-4503-2010	Kent, Nicholas/0000-0002-4114-1307; Downs, Jessica/0000-0002-6600-849X; Chambers, Anna/0000-0001-8133-6240	Wellcome Trust [076258] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Cobb RM, 2006, ADV IMMUNOL, V91, P45, DOI 10.1016/S0065-2776(06)91002-5; Costelloe T, 2006, EXP CELL RES, V312, P2677, DOI 10.1016/j.yexcr.2006.06.031; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fazzio TG, 2003, MOL CELL, V12, P1333, DOI 10.1016/S1097-2765(03)00436-2; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang J, 2004, MOL CELL, V13, P739, DOI 10.1016/S1097-2765(04)00103-0; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Keeney S, 2006, BIOCHEM SOC T, V34, P523, DOI 10.1042/BST0340523; KENT NA, 1995, NUCLEIC ACIDS RES, V23, P3786, DOI 10.1093/nar/23.18.3786; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paques F, 1998, MOL CELL BIOL, V18, P2045, DOI 10.1128/MCB.18.4.2045; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wilson B, 2006, GENETICS, V172, P795, DOI 10.1534/genetics.105.047589; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	30	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27693	27701		10.1074/jbc.M704707200	http://dx.doi.org/10.1074/jbc.M704707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652077	hybrid			2022-12-25	WOS:000249455600017
J	Ling, X; Cheng, QY; Black, JD; Li, FZ				Ling, Xiang; Cheng, Qiuying; Black, Jennifer D.; Li, Fengzhi			Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE VARIANTS; SPINDLE CHECKPOINT; DIVISION; CANCER; ARREST; GENE; TUMORIGENESIS; INTERFERENCE; INHIBITION; CARCINOMAS	It has been previously shown that both survivin and the survivin splice variant survivin-2B are localized in mitochondria. Whereas the mechanism involved in blockade of mitochondria-mediated apoptosis by survivin has been extensively studied, the role of survivin-2B in regulation of apoptosis has not been well defined. In the present study, we report that in addition to mitochondria, survivin-2B is also localized in the microtubule organization center (MTOC) and, in contrast to other survivin isoforms (i.e. survivin and survivin-Delta Ex3), behaves as a proapoptotic molecule. We show that forced expression of survivin-2B blocks tubulin polymerization, ablates mitotic cells, and induces mitochondria-dependent apoptosis. The mitochondria-mediated apoptosis induced by survivin-2B was indicated by Smac release from mitochondria, activation of caspases 9 and 3, and loss of mitochondrial potential, while caspase-8 remained inactive. Further analysis of the mechanism for the mitochondria-associated events of apoptosis induced by forced expression of survivin-2B revealed down-regulation of the pro-survival factor Bcl-2 and up-regulation of the pro-apoptotic factor Bax in mitochondria, while the apoptosis-inducing factor (AIF) remains unchanged. Our studies further showed that taxol (paclitaxel) treatment of cancer cells not only up-regulates survivin but also down-regulates survivin-2B and that forced expression of survivin-2B sensitizes cells to taxol-induced cell growth inhibition and cell death, while silencing of endogenous survivin-2B transcripts by survivin-2B-specific siRNA made cells resistant to taxol treatment. These findings advance our current knowledge about survivin-2B and may help to develop novel approaches for cancer treatment.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Li, Fengzhi/GXF-0115-2022		NCI NIH HHS [P30 CA016056, R01 CA109481, R01 CA109481-03, R01 CA 109481, CA 16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA109481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2004, J CELL BIOCHEM, V92, P656, DOI 10.1002/jcb.20140; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li F, 2005, BRIT J CANCER, V92, P212, DOI 10.1038/sj.bjc.6602340; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li FZ, 2006, AM J PATHOL, V169, P1, DOI 10.2353/ajpath.2006.060121; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 2005, ONCOGENE, V24, P1385, DOI 10.1038/sj.onc.1208330; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Ling X, 2005, LUNG CANCER, V49, P353, DOI 10.1016/j.lungcan.2005.03.037; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; McGuire JJ, 2000, J BIOL CHEM, V275, P13012, DOI 10.1074/jbc.275.17.13012; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Spaulding B, 2006, HISTOPATHOLOGY, V49, P622, DOI 10.1111/j.1365-2559.2006.02556.x; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wu JG, 2005, J BIOL CHEM, V280, P9745, DOI 10.1074/jbc.M409350200; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738; Zhu NX, 2004, ONCOGENE, V23, P7545, DOI 10.1038/sj.onc.1208038	31	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27204	27214		10.1074/jbc.M705161200	http://dx.doi.org/10.1074/jbc.M705161200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17656368	hybrid, Green Accepted			2022-12-25	WOS:000249304900062
J	Johnson, JA; Li, JF; Wei, XR; Lipscomb, J; Bennett, D; Brant, A; Cong, ME; Spira, T; Shafer, RW; Heneine, W				Johnson, Jeffrey A.; Li, Jin-Fen; Wei, Xierong; Lipscomb, Jonathan; Bennett, Diane; Brant, Ashley; Cong, Mian-er; Spira, Thomas; Shafer, Robert W.; Heneine, Walid			Simple PCR Assays Improve the Sensitivity of HIV-1 Subtype B Drug Resistance Testing and Allow Linking of Resistance Mutations	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SINGLE-DOSE NEVIRAPINE; FITNESS; POPULATIONS; PERSISTENCE; MULTIPLE; WOMEN	Background. The success of antiretroviral therapy is known to be compromised by drug-resistant HIV-1 at frequencies detectable by conventional bulk sequencing. Currently, there is a need to assess the clinical consequences of low-frequency drug resistant variants occurring below the detection limit of conventional genotyping. Sensitive detection of drug-resistant subpopulations, however, requires simple and practical methods for routine testing. Methodology. We developed highly-sensitive and simple real-time PCR assays for nine key drug resistance mutations and show that these tests overcome substantial sequence heterogeneity in HIV-1 clinical specimens. We specifically used early wildtype virus samples from the pre-antiretroviral drug era to measure background reactivity and were able to define highly-specific screening cut-offs that are up to 67-fold more sensitive than conventional genotyping. We also demonstrate that sequencing the mutation-specific PCR products provided a direct and novel strategy to further detect and link associated resistance mutations, allowing easy identification of multi-drug-resistant variants. Resistance mutation associations revealed in mutation-specific amplicon sequences were verified by clonal sequencing. Significance. Combined, sensitive real-time PCR testing and mutation-specific amplicon sequencing provides a powerful and simple approach that allows for improved detection and evaluation of HIV-1 drug resistance mutations.	[Johnson, Jeffrey A.; Li, Jin-Fen; Wei, Xierong; Lipscomb, Jonathan; Brant, Ashley; Cong, Mian-er; Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA; [Bennett, Diane] Ctr Dis Control & Prevent, HIV Incidence & Case Surveillance Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA; [Spira, Thomas] Ctr Dis Control & Prevent, Global AIDS Program, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA; [Shafer, Robert W.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Stanford University	Johnson, JA (corresponding author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.	JJohnson1@cdc.gov						Cai FP, 2007, NAT METHODS, V4, P123, DOI 10.1038/nmeth995; Collins JA, 2004, J VIROL, V78, P603, DOI 10.1128/JVI.78.2.603-611.2004; Cong ME, 2007, J VIROL, V81, P3037, DOI 10.1128/JVI.02712-06; Flys T, 2005, J INFECT DIS, V192, P24, DOI 10.1086/430742; Ghosn J, 2006, AIDS, V20, P159, DOI 10.1097/01.aids.0000199820.47703.a0; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; Halvas EK, 2006, J CLIN MICROBIOL, V44, P2612, DOI 10.1128/JCM.00449-06; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Johnson JA, 2005, J INFECT DIS, V192, P16, DOI 10.1086/430741; Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; MELLORS J, 2006, ANTIVIR THER S, V8, pS150; Palmer S, 2006, P NATL ACAD SCI USA, V103, P7094, DOI 10.1073/pnas.0602033103; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Shi CJ, 2004, NAT METHODS, V1, P141, DOI 10.1038/NMETH713; Sturmer M, 2002, J CLIN VIROL, V25, pS65; *US DEP HHS, 2006, GUID US ANT AG HIV 1; Villahermosa ML, 2001, J HUMAN VIROL, V4, P238; Weinstock HS, 2004, J INFECT DIS, V189, P2174, DOI 10.1086/420789	20	59	63	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e638	10.1371/journal.pone.0000638	http://dx.doi.org/10.1371/journal.pone.0000638			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653265	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452200007
J	White, CR; Day, N; Butler, PJ; Martin, GR				White, Craig R.; Day, Norman; Butler, Patrick J.; Martin, Graham R.			Vision and Foraging in Cormorants: More like Herons than Hawks?	PLOS ONE			English	Article								Background. Great cormorants (Phalacrocorax carbo L.) show the highest known foraging yield for a marine predator and they are often perceived to be in conflict with human economic interests. They are generally regarded as visually-guided, pursuit-dive foragers, so it would be expected that cormorants have excellent vision much like aerial predators, such as hawks which detect and pursue prey from a distance. Indeed cormorant eyes appear to show some specific adaptations to the amphibious life style. They are reported to have a highly pliable lens and powerful intraocular muscles which are thought to accommodate for the loss of corneal refractive power that accompanies immersion and ensures a well focussed image on the retina. However, nothing is known of the visual performance of these birds and how this might influence their prey capture technique. Methodology/ Principal Findings. We measured the aquatic visual acuity of great cormorants under a range of viewing conditions (illuminance, target contrast, viewing distance) and found it to be unexpectedly poor. Cormorant visual acuity under a range of viewing conditions is in fact comparable to unaided humans under water, and very inferior to that of aerial predators. We present a prey detectability model based upon the known acuity of cormorants at different illuminances, target contrasts and viewing distances. This shows that cormorants are able to detect individual prey only at close range (less than 1 m). Conclusions/Significance. We conclude that cormorants are not the aquatic equivalent of hawks. Their efficient hunting involves the use of specialised foraging techniques which employ brief short-distance pursuit and/or rapid neck extension to capture prey that is visually detected or flushed only at short range. This technique appears to be driven proximately by the cormorant's limited visual capacities, and is analogous to the foraging techniques employed by herons.	[White, Craig R.; Day, Norman; Butler, Patrick J.; Martin, Graham R.] Univ Birmingham, Sch Biosci, Ctr Ornithol, Birmingham, W Midlands, England	University of Birmingham	Martin, GR (corresponding author), Univ Birmingham, Sch Biosci, Ctr Ornithol, Birmingham, W Midlands, England.	g.r.martin@bham.ac.uk	White, Craig R/F-9062-2010	White, Craig R/0000-0002-0200-2187	UK Natural Environment Research Council [NER/A/2003/00542]	UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	Funding: This research was supported by the UK Natural Environment Research Council: Grant NER/A/2003/00542.	Carss DN, 2003, VOGELWELT, V124, P299; DICKMAN M, 1995, HYDROBIOLOGIA, V312, P27, DOI 10.1007/BF00018884; Engstrom H, 2003, VOGELWELT S, V124, P187; Gaffney MF, 2003, VISION RES, V43, P2053, DOI 10.1016/S0042-6989(03)00304-3; Gislen A, 2003, CURR BIOL, V13, P833, DOI 10.1016/S0960-9822(03)00290-2; GLASSER A, 1996, Q REV BIOL, V79, P475; Gremillet D, 2006, MAR BIOL, V148, P1081, DOI 10.1007/s00227-005-0130-2; Gremillet D, 2005, BIOL LETTERS, V1, P469, DOI 10.1098/rsbl.2005.0356; Gremillet D, 2004, FUNCT ECOL, V18, P793, DOI 10.1111/j.0269-8463.2004.00914.x; HALSEY LG, 2007, BIOL LETT IN PRESS; HESS C, 1913, HDB VERGLEICHENDEN P, P789; Hess Carl, 1909, Archiv fuer Augenheilkunde Wiesbaden, V63; Hliwa P., 2003, VOGELWELT, V124, P217; JABLONSKI PG, 2002, CONDOR, V60, P2633; Jerlov N. G., 1976, MARINE OPTICS; JOHNSGARD P.A., 1993, CORMORANTS DARTERS P; Katzir G, 2003, J EXP BIOL, V206, P833, DOI 10.1242/jeb.00142; Lilliendahl K, 2006, MAR BIOL, V149, P979, DOI 10.1007/s00227-006-0259-7; Lythgoe J.N., 1979, ECOLOGY VISION; MARTIN GR, 1991, BRAIN BEHAV EVOLUT, V37, P65, DOI 10.1159/000114347; Martin GR, 1999, IBIS, V141, P444, DOI 10.1111/j.1474-919X.1999.tb04413.x; MARTIN GR, 1974, VISION RES, V14, P1393, DOI 10.1016/0042-6989(74)90014-5; MCFALLNGAI MJ, 1990, AM ZOOL, V30, P175; ORTA J, 1992, HDB BIRDS WORLD, P00326; REYMOND L, 1987, VISION RES, V27, P1859, DOI 10.1016/0042-6989(87)90114-3; REYMOND L, 1985, VISION RES, V25, P1477, DOI 10.1016/0042-6989(85)90226-3; Ropert-Coudert Y, 2006, MAR BIOL, V149, P415, DOI 10.1007/s00227-005-0242-8; SCHLAER R, 1972, SCIENCE, V176, P920; Strod T, 2004, CURR BIOL, V14, pR376, DOI 10.1016/j.cub.2004.05.009; VANEERDEN MR, 1995, ARDEA, V83, P199; VOISIN C, 1991, HERONS EUROPE; VOSLAMBER B, 1995, ARDEA, V83, P213; Wanless S, 1999, MAR ECOL PROG SER, V188, P219, DOI 10.3354/meps188219; WATANUKI Y, BRIT BIRDS IN PRESS	34	52	54	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e639	10.1371/journal.pone.0000639	http://dx.doi.org/10.1371/journal.pone.0000639			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653266	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200008
J	Rainey, MD; Black, EJ; Zachos, G; Gillespie, DAF				Rainey, M. D.; Black, E. J.; Zachos, G.; Gillespie, D. A. F.			Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G(2) phase	ONCOGENE			English	Article						Chk1; Chk2; DNA damage; G(2)/M checkpoint; mitosis; genome stability	IONIZING-RADIATION; TUMOR-SUPPRESSOR; CHECKPOINT KINASE; CELLS; ACTIVATION; ATM; CANCER; PHOSPHORYLATION; TUMORIGENESIS; INHIBITION	Whether Chk2 contributes to DNA damage- induced arrest in G(2) has been controversial. To investigate this issue further, we generated Chk2-deficient DT40 B-lymphoma cells by gene targeting and compared their cell cycle response to ionizing radiation (IR) with wildtype (WT) and isogenic Chk1-deficient counterparts. After moderate doses of IR (4 Gy), we find that Chk2(-/-) cells which are in G(1) or S phase at the time of irradiation arrest efficiently in G(2). In contrast, Chk2-/- cells which are in G(2) when DNA damage is incurred exhibit an impaired mitotic delay compared to WT, with the result that cells enter mitosis with damaged DNA as judged by the presence of numerous gamma-H2AX foci on condensed chromosomes. Impaired G(2) delay as the result of Chk2 deficiency can be detected at very low doses of radiation (0.1 Gy), and may allow division with spontaneous DNA damage, since a higher proportion of mitotic Chk2-/- cells bear spontaneous gamma-H2AX foci and damaged chromosomes during unperturbed growth compared to WT. The contribution of Chk2 to G(2)/M delay is epistatic to that of Chk1, since Chk1-/- cells exhibit no measurable mitotic delay at any radiation dose tested. We suggest that this function of Chk2 could contribute to tumour suppression, since cell division with low levels of spontaneous damage is likely to promote genetic instability and thus carcinogenesis.	[Gillespie, D. A. F.] Univ Glasgow, Fac Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; [Rainey, M. D.; Black, E. J.; Zachos, G.; Gillespie, D. A. F.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Gillespie, DAF (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Rainey, Michael/0000-0001-9777-873X				Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lukas C, 2001, CANCER RES, V61, P4990; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiromizu T, 2006, GENES CELLS, V11, P477, DOI 10.1111/j.1365-2443.2006.00955.x; Skoufias DA, 2004, MOL CELL, V15, P977, DOI 10.1016/j.molcel.2004.08.018; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	28	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					896	906		10.1038/sj.onc.1210702	http://dx.doi.org/10.1038/sj.onc.1210702			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17684483				2022-12-25	WOS:000252946300002
J	Poncet-Montange, G; Assairi, L; Arold, S; Pochet, S; Labesse, G				Poncet-Montange, Guillaume; Assairi, Liliane; Arold, Stefan; Pochet, Sylvie; Labesse, Gilles			NAD kinases use substrate-assisted catalysis for specific recognition of NAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TARGETS; COMPLEX; ENZYME	Here we describe the crystal structures of the NAD kinase (LmNADK1) from Listeria monocytogenes in complex with its substrate NAD, its product NADP, or two synthesized NAD mimics. We identified one of the NAD mimics, di-adenosine diphosphate, as a new substrate for LmNADK1, whereas we showed that the closely related compound di-5'-thioadenosine is a novel non-natural inhibitor for this enzyme. These structures suggest a mechanism involving substrate- assisted catalysis. Indeed, sequence/structure comparison and directed mutagenesis have previously shown that NAD kinases (NADKs) and the distantly related 6-phosphofructokinases share the same catalytically important GGDGT motif. However, in this study we have shown that these enzymes use the central aspartate of this motif differently. Although this acidic residue chelates the catalytic Mg2+ ion in 6-phosphofructokinases, it activates the phospho-acceptor (NAD) in NADKs. Sequence/structure comparisons suggest that the role of this aspartate would be conserved in NADKs and the related sphingosine and diacylglycerol kinases.	Univ Montpellier I, Ctr Biochim Struct, CNRS, UMR Atelier Bio & Chim Informat Struct 5048, F-34090 Montpellier, France; Univ Montpellier 2, Ctr Biochim Struct, CNRS, UMR Atelier Bio & Chim Informat Struct 5048, F-34090 Montpellier, France; INSERM, U554, F-34090 Montpellier, France; Inst Curie, INSERM, U759, F-91405 Orsay, France; Inst Pasteur, CNRS, URA 2128, Unite Chim Organ, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Labesse, G (corresponding author), Univ Montpellier I, Ctr Biochim Struct, CNRS, UMR Atelier Bio & Chim Informat Struct 5048, 29 Rue Navacelles, F-34090 Montpellier, France.	labesse@cbs.cnrs.fr	Arold, Stefan/T-2612-2019	Labesse, Gilles/0000-0002-6861-3300; Arold, Stefan T/0000-0001-5278-0668; Poncet-Montange, Guillaume/0000-0002-9884-7378				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bakali HMA, 2007, J BIOL CHEM, V282, P19644, DOI 10.1074/jbc.M604852200; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Garavaglia S, 2004, J BIOL CHEM, V279, P40980, DOI 10.1074/jbc.M406586200; Garavaglia S, 2003, J BACTERIOL, V185, P4844, DOI 10.1128/JB.185.16.4844-4850.2003; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Grose JH, 2006, P NATL ACAD SCI USA, V103, P7601, DOI 10.1073/pnas.0602494103; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Kawai S, 2001, EUR J BIOCHEM, V268, P4359, DOI 10.1046/j.1432-1327.2001.02358.x; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; Liu JY, 2005, J MOL BIOL, V354, P289, DOI 10.1016/j.jmb.2005.09.026; McCoy AJ, 2004, ACTA CRYSTALLOGR D, V60, P1220, DOI 10.1107/S0907444904009990; MOFFATT JG, 1964, CAN J CHEM, V42, P599, DOI 10.1139/v64-087; Mori S, 2005, BIOCHEM BIOPH RES CO, V327, P500, DOI 10.1016/j.bbrc.2004.11.163; Pignot M, 2000, EUR J ORG CHEM, V2000, P549; Pucci MJ, 2006, BIOCHEM PHARMACOL, V71, P1066, DOI 10.1016/j.bcp.2005.12.004; Raffaelli N, 2004, BIOCHEMISTRY-US, V43, P7610, DOI 10.1021/bi049650w; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Thanassi JA, 2002, NUCLEIC ACIDS RES, V30, P3152, DOI 10.1093/nar/gkf418; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zalacain M, 2003, J MOL MICROB BIOTECH, V6, P109, DOI 10.1159/000076741	32	35	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2007	282	47					33925	33934		10.1074/jbc.M701394200	http://dx.doi.org/10.1074/jbc.M701394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234FI	17686780	hybrid, Green Published			2022-12-25	WOS:000251145700005
J	Jimenez-Sanchez, M; Cid, VJ; Molina, M				Jimenez-Sanchez, Maria; Cid, Victor J.; Molina, Maria			Retrophosphorylation of mkk1 and mkk2 MAPKKs by the Slt2 MAPK in the yeast cell integrity pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SITE-DIRECTED MUTAGENESIS; SIGNAL-REGULATED KINASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; FEEDBACK PHOSPHORYLATION; SCAFFOLD PROTEIN; ERK ACTIVATION; MEK1; CASCADE	In Saccharomyces cerevisiae, a variety of stresses and aggressions to the cell wall stimulate the activation of the cell wall integrity MAPK pathway, which triggers the expression of a series of genes important for the maintenance of cell wall homeostasis. This MAPK module lies downstream of the Rho1 small GTPase and protein kinase C Pkc1 and consists of MAPKKK Bck1, MAPKKs Mkk1 and Mkk2, and the Slt2 MAPK. In agreement with previous reports suggesting that Mkk1 and Mkk2 were functionally redundant, we show here that both Mkk1 and Mkk2 alone or even chimerical proteins constructed by interchanging their catalytic and regulatory domains are able to efficiently maintain signal transduction through the pathway. Both Mkk1 and Mkk2 are phosphorylated in vivo concomitant to activation of the cell integrity pathway. Interestingly, hyperphosphorylation of the MEKs required not only the upstream components of the pathway, but also a catalytically competent Slt2 MAPK downstream. Active Slt2 purified from yeast extracts was able to phosphorylate Mkk1 and Mkk2 in vitro. We have mapped Ser(50) as a direct phosphorylation target for Slt2 in Mkk2. However, substitution of all (Ser/Thr)-Pro canonical MAPK target sites with alanine did not totally abrogate Slt2-dependent Mkk2 phosphorylation. Mutation or deletion of a conserved MAPK-docking site at the N-terminal extension of Mkk2 precluded its interaction with Slt2 and negatively affected retrophosphorylation. Our data show that the cell wall integrity MAPKKs are targets for their downstream MAPK, suggesting the existence of complex feedback regulatory mechanisms at this	Univ Complutense Madrid, Fac Pharm, Dept Microbiol II, E-28040 Madrid, Spain; Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid	Cid, VJ (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Pza Ramon Cajal S-N, E-28040 Madrid, Spain.	vicjcid@farm.ucm.es	JIMENEZ CID, VICTOR/ABC-4858-2021; CID, VICTOR JIMENEZ/I-1240-2015; Jimenez-Sanchez, Maria/ABH-7666-2020; Molina, Maria/ABE-7186-2021	JIMENEZ CID, VICTOR/0000-0002-3933-2016; CID, VICTOR JIMENEZ/0000-0002-3933-2016; Jimenez-Sanchez, Maria/0000-0002-2287-1582; Molina, Maria/0000-0003-0074-3309				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; AUSUBEL FM, 2007, CURRENT PROTOCOLS MO; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bhattacharyya RP, 2006, SCIENCE, V311, P822, DOI 10.1126/science.1120941; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Byrne KP, 2005, GENOME RES, V15, P1456, DOI 10.1101/gr.3672305; CHEN RE, 2007, BIOCHIM BIOPHYS ACTA, V1771, P353; CHOI KY, 1994, CELL, V78, P499; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; DOHLMAN HG, 2006, SCI STKE; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Flandez M, 2004, J BIOL CHEM, V279, P11027, DOI 10.1074/jbc.M306412200; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Grewal S, 2006, CELL SIGNAL, V18, P123, DOI 10.1016/j.cellsig.2005.04.001; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Maleri S, 2004, MOL CELL BIOL, V24, P9221, DOI 10.1128/MCB.24.20.9221-9238.2004; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Paravicini G, 1996, MOL GEN GENET, V251, P682, DOI 10.1007/s004380050217; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Schwartz MA, 2004, ANNU REV GENET, V38, P725, DOI 10.1146/annurev.genet.39.073003.112634; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; SOLER M, 1995, MOL MICROBIOL, V17, P833, DOI 10.1111/j.1365-2958.1995.mmi_17050833.x; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; van Drogen F, 2002, CURR BIOL, V12, P1698, DOI 10.1016/S0960-9822(02)01186-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	53	35	38	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31174	31185		10.1074/jbc.M706270200	http://dx.doi.org/10.1074/jbc.M706270200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17711850	hybrid			2022-12-25	WOS:000250309200007
J	Collingwood, TS; Smirnova, EV; Bogush, M; Carpino, N; Annan, RS; Tsygankov, AY				Collingwood, Therese S.; Smirnova, Evgeniya V.; Bogush, Marina; Carpino, Nick; Annan, Roland S.; Tsygankov, Alexander Y.			T-cell ubiquitin ligand affects cell death through a functional interaction with apoptosis-inducing factor, a key factor of caspase-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS-SAIMIRI; CONTAINING PROTEIN; DNA-DEGRADATION; FACTOR AIF; MITOCHONDRIAL; LYMPHOCYTES; RELEASE; IDENTIFICATION; INHIBITOR; PATHWAY	The lymphoid protein T-cell ubiquitin ligand (TULA)/suppressor of T-cell receptor signaling (Sts)-2 is associated with c-Cbl and ubiquitylated proteins and has been implicated in the regulation of signaling mediated by protein-tyrosine kinases. The results presented in this report indicate that TULA facilitates T-cell apoptosis independent of either T-cell receptor/CD3-mediated signaling or caspase activity. Mass spectrometry based analysis of protein-protein interactions of TULA demonstrates that TULA binds to the apoptosis-inducing protein AIF, which has previously been shown to function as a key factor of caspase-independent apoptosis. Using RNA interference, we demonstrate that AIF is essential for the apoptotic effect of TULA. Analysis of the subcellular localization of TULA and AIF together with the functional analysis of TULA mutants is consistent with the idea that TULA enhances the apoptotic effect of AIF by facilitating the interactions of AIF with its apoptotic co-factors, which remain to be identified. Overall, our results shed new light on the biological functions of TULA, a recently discovered protein, describing its role as one of very few known functional interactors of AIF.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; GlaxoSmithKline Inc, Proteom & Biol Mass Spectrometry Lab, King Of Prussia, PA 19406 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11738 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tsygankov, AY (corresponding author), Kresge Bldg,Rm 506,3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Smirnova, Evgeniya/ABA-7468-2021; Tsygankov, Alexander Y/K-6205-2017	Smirnova, Evgeniya/0000-0002-9744-952X; 	NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn HJ, 2004, J CELL BIOCHEM, V91, P1043, DOI 10.1002/jcb.20006; Artus C, 2006, ONCOGENE, V25, P5741, DOI 10.1038/sj.onc.1209581; Boisvieux-Ulrich E, 2005, EXP CELL RES, V307, P76, DOI 10.1016/j.yexcr.2005.02.005; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Carpino N, 2002, MOL CELL BIOL, V22, P7491, DOI 10.1128/MCB.22.21.7491-7500.2002; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Ishitsuka K, 2005, ONCOGENE, V24, P5888, DOI 10.1038/sj.onc.1208739; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Panka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pinkoski MJ, 2006, CURR DIRECT AUTOIMMU, V9, P55; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Raymond AD, 2004, VIROLOGY, V324, P60, DOI 10.1016/j.virol.2004.03.021; Skoblenick KJ, 2006, APOPTOSIS, V11, P663, DOI 10.1007/s10495-006-5698-6; Strasser A, 2004, TRENDS IMMUNOL, V25, P610, DOI 10.1016/j.it.2004.08.012; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tiwari M, 2006, CARCINOGENESIS, V27, P2047, DOI 10.1093/carcin/bgl051; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wattenhofer M, 2001, HUM GENET, V108, P140, DOI 10.1007/s004390000453; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687	43	34	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30920	30928		10.1074/jbc.M706870200	http://dx.doi.org/10.1074/jbc.M706870200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17709377	hybrid			2022-12-25	WOS:000250136300060
J	Yao, D; Taguchi, T; Matsumura, T; Pestell, R; Edelstein, D; Giardino, I; Suske, G; Rabbani, N; Thornalley, PJ; Sarthy, VP; Hammes, HP; Brownlee, M				Yao, Dachun; Taguchi, Tetsuya; Matsumura, Takeshi; Pestell, Richard; Edelstein, Diane; Giardino, Ida; Suske, Guntram; Rabbani, Naila; Thornalley, Paul J.; Sarthy, Vijay P.; Hammes, Hans-Peter; Brownlee, Michael			High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 MAJOR PATHWAYS; DIABETIC-RETINOPATHY; HYPERGLYCEMIC DAMAGE; ADVANCED GLYCATION; O-GLYCOSYLATION; GLYOXALASE-I; EXPRESSION; SP1; ACTIVATION; MICE	Methylglyoxal is a highly reactive dicarbonyl degradation product formed from triose phosphates during glycolysis. Methylglyoxal forms stable adducts primarily with arginine residues of intracellular proteins. The biologic role of this covalent modification in regulating cell function is not known. Here we report that in mouse kidney endothelial cells, high glucose causes increased methylglyoxal modification of the corepressor mSin3A. Methylglyoxal modification of mSin3A results in increased recruitment of O-GlcNAc-transferase, with consequent increased modification of Sp3 by O-linked N-acetylglucosamine. This modification of Sp3 causes decreased binding to a glucose-responsive GC-box in the angiopoietin-2 (Ang-2) promoter, resulting in increased Ang-2 expression. Increased Ang-2 expression induced by high glucose increased expression of intracellular adhesion molecule 1 and vascular cell adhesion molecule 1 in cells and in kidneys from diabetic mice and sensitized microvascular endothelial cells to the proinflammatory effects of tumor necrosis factor alpha. This novel mechanism for regulating gene expression may play a role in the pathobiology of diabetic vascular disease.	Albert Einstein Coll Med, Juvenile Diabet Res Fdn Int Ctr Diabet Complicat, Bronx, NY 10461 USA; Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Foggia, Dept Biomed Sci, I-71100 Foggia, Italy; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Warwick, Clin Sci Res Inst, Syst Biol Ctr, Coventry CV2 2DX, W Midlands, England; Univ Warwick, Warwick Med Sch, Prot Damage & Syst Biol Res Grp, Coventry CV2 2DX, W Midlands, England; Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60093 USA; Univ Heidelberg, D-68167 Mannheim, Germany	Yeshiva University; Albert Einstein College of Medicine; Jefferson University; University of Foggia; Philipps University Marburg; University of Warwick; University of Warwick; Northwestern University; Feinberg School of Medicine; Ruprecht Karls University Heidelberg	Brownlee, M (corresponding author), Albert Einstein Coll Med, Juvenile Diabet Res Fdn Int Ctr Diabet Complicat, Bronx, NY 10461 USA.	brownlee@aecom.yu.edu	Hammes, Hans-Peter/S-3719-2019	Suske, Guntram/0000-0002-4807-0513; Thornalley, Paul/0000-0001-7659-443X; Rabbani, Naila/0000-0002-5819-2506				Ahmed N, 2003, BIOCHEM SOC T, V31, P1417; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chakraborty S, 2001, J CELL BIOCHEM, V82, P310, DOI 10.1002/jcb.1165; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Chow FY, 2005, J AM SOC NEPHROL, V16, P1711, DOI 10.1681/ASN.2004070612; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Fingerman IM, 2004, CELL, V117, P690, DOI 10.1016/j.cell.2004.05.021; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Karachalias N, 2003, BIOCHEM SOC T, V31, P1423; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Langley RR, 2003, CANCER RES, V63, P2971; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Navarro JF, 2006, AM J NEPHROL, V26, P562, DOI 10.1159/000098004; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; Rizkalla B, 2005, J HYPERTENS, V23, P153, DOI 10.1097/00004872-200501000-00026; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212; Singh AK, 2004, LAB INVEST, V84, P597, DOI 10.1038/labinvest.3700082; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; Van Herreweghe F, 2002, P NATL ACAD SCI USA, V99, P949, DOI 10.1073/pnas.012432399; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yuan HT, 2002, KIDNEY INT, V61, P2078, DOI 10.1046/j.1523-1755.2002.00381.x	35	175	192	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31038	31045		10.1074/jbc.M704703200	http://dx.doi.org/10.1074/jbc.M704703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17670746	hybrid			2022-12-25	WOS:000250136300071
J	Chen, J; He, R; Minshall, RD; Dinauer, MC; Ye, RD				Chen, Jia; He, Rong; Minshall, Richard D.; Dinauer, Mary C.; Ye, Richard D.			Characterization of a mutation in the Phox homology domain of the NADPH oxidase component p40(phox) identifies a mechanism for negative regulation of superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; LEUKEMIA CELL-LINE; PX DOMAIN; CYTOSOLIC COMPONENT; PROTEIN P40(PHOX); HUMAN NEUTROPHILS; MEMBRANE-BINDING; SH3 DOMAIN; ACTIVATION	The phagocyte oxidase (Phox) protein p40(phox) contains a Phox homology (PX) domain which, when expressed alone, interacts with phosphatidylinositol 3-phosphate (PtdIns ( 3) P). The functions of the PXdomain in p40(phox) localization, association with the cytoskeleton, and superoxide production were examined in transgenic COS-7 cells expressing gp91(phox), p22(phox), p67(phox), and p47(phox) (COSphox cells). Full-length p40(phox) exhibited a cytoplasmic localization pattern in resting cells. Upon stimulation with phorbol 12-myristate 13-acetate or fMet-Leu-Phe, p40(phox) translocated to plasma membrane in a p67(phox)- and p47(phox)-dependent manner. Heterologous expression of p40(phox) markedly enhanced superoxide production in phorbol 12-myristate 13-acetate - and fMet-Leu-Phe- stimulated COSphox cells. Unexpectedly, mutation of Arg-57 in the PX domain to Gln, which abrogated PtdIns (3) P binding, produced a dominant inhibitory effect on agonist-induced superoxide production and membrane translocation of p47(phox) and p67(phox). The mutant p40(phox) (p40R57Q) displayed increased association with actin and moesin and was found enriched in the Triton X-100-insoluble fraction along with p67(phox) and p47(phox). The enhanced cytoskeleton association of p67(phox) and p47(phox) and the dominant inhibitory effect produced by the p40R57Q were alleviated when a second mutation at Asp-289, which eliminated p40(phox) interaction with p67(phox), was introduced. Likewise, cytochalasin B treatment abolished the dominant inhibitory effect of p40R57Q on superoxide production. These findings suggest a dual regulatory mechanism through the PX domain of p40(phox); its interaction with the actin cytoskeleton may stabilize NADPH oxidase in resting cells, and its binding of PtdIns (3) P potentiates superoxide production upon agonist stimulation. Both functions require the association of p40(phox) with p67(phox).	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46020 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,MC868, Chicago, IL 60612 USA.	yer@uic.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, P01HL077806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033503, R56AI033503] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL045635, HL077806] Funding Source: Medline; NIAID NIH HHS [AI033503] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bouin AP, 1998, J BIOL CHEM, V273, P30097, DOI 10.1074/jbc.273.46.30097; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Ellson C, 2006, EMBO J, V25, P4468, DOI 10.1038/sj.emboj.7601346; Ellson CD, 2006, J EXP MED, V203, P1927, DOI 10.1084/jem.20052069; Grogan A, 1997, J CELL SCI, V110, P3071; He R, 2004, J IMMUNOL, V173, P7462, DOI 10.4049/jimmunol.173.12.7462; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Honbou K, 2007, EMBO J, V26, P1176, DOI 10.1038/sj.emboj.7601561; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Lopes LR, 2004, BIOCHEMISTRY-US, V43, P3723, DOI 10.1021/bi035636s; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; Someya A, 1999, J LEUKOCYTE BIOL, V66, P851, DOI 10.1002/jlb.66.5.851; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Suh CI, 2006, J EXP MED, V203, P1915, DOI 10.1084/jem.20052085; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; TUCKER KA, 1987, BLOOD, V70, P372; Ueyama T, 2007, MOL BIOL CELL, V18, P441, DOI 10.1091/mbc.E06-08-0731; Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Zhan Y, 2004, J CELL BIOCHEM, V92, P795, DOI 10.1002/jcb.20084; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	44	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30273	30284		10.1074/jbc.M704416200	http://dx.doi.org/10.1074/jbc.M704416200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698849	hybrid			2022-12-25	WOS:000249981200058
J	Sbodio, JI; Machamer, CE				Sbodio, Juan I.; Machamer, Carolyn E.			Identification of a redox-sensitive cysteine in GCP60 that regulates its interaction with golgin-160	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SULFENIC ACIDS; MOLECULAR CHARACTERIZATION; REVERSIBLE OXIDATION; S-NITROSYLATION; APOPTOSIS; MEMBRANE; COMPLEX; AUTOANTIGENS; EXOCYTOSIS; STEROIDOGENESIS	Golgin-160 is ubiquitously expressed in vertebrates. It localizes to the cytoplasmic side of the Golgi and has a large C-terminal coiled-coil domain. The noncoiled-coil N-terminal head domain contains Golgi targeting information, a cryptic nuclear localization signal, and three caspase cleavage sites. Caspase cleavage of the golgin-160 head domain generates different fragments that can translocate to the nucleus by exposing the nuclear localization signal. We have previously shown that GCP60, a Golgi resident protein, interacts weakly with the golgin160 head domain but has a strong interaction with one of the caspase-generated golgin-160 fragments ( residues 140-311). This preferential interaction increases the Golgi retention of the golgin-160 fragment in cells overexpressing GCP60. Here we studied the interaction of golgin-160-( 140-311) with GCP60 and identified a single cysteine residue in GCP60 ( Cys-463) that is critical for the interaction of the two proteins. Mutation of the cysteine blocked the interaction in vitro and disrupted the ability to retain the golgin-160 fragment at the Golgi in cells. We also found that Cys-463 is redox-sensitive; in its reduced form, interaction with golgin-160 was diminished or abolished, whereas oxidation of the Cys-463 by hydrogen peroxide restored the interaction. In addition, incubation with a nitric oxide donor promoted this interaction in vitro. These findings suggest that nuclear translocation of golgin-160-( 140-311) is a highly coordinated event regulated not only by cleavage of the golgin-160 head but also by the oxidation state of GCP60.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Machamer, CE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 Wolfe St, Baltimore, MD 21205 USA.	machamer@jhmi.edu			NIGMS NIH HHS [GM42522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman V, 2002, GENOME BIOL, V3; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; BUNDIS F, 2003, CELL PHYSIOL BIOCHEM, V17, P1; Cheah JH, 2006, NEURON, V51, P431, DOI 10.1016/j.neuron.2006.07.011; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Forrester MT, 2007, AM J RESP CELL MOL, V36, P135, DOI 10.1165/rcmb.2006-001ED; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Genestra M, 2007, CELL SIGNAL, V19, P1807, DOI 10.1016/j.cellsig.2007.04.009; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hicks SW, 2006, TRAFFIC, V7, P1666, DOI 10.1111/j.1600-0854.2006.00504.x; Hicks SW, 2005, J BIOL CHEM, V280, P28944, DOI 10.1074/jbc.M504937200; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Jacob C, 2006, BIOL CHEM, V387, P1385, DOI 10.1515/BC.2006.174; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Liu J, 2003, J STEROID BIOCHEM, V85, P275, DOI 10.1016/S0960-0760(03)00213-9; Lowe M, 2004, J CELL SCI, V117, P1139, DOI 10.1242/jcs.00950; Lowenstein CJ, 2006, BIOL CHEM, V387, P1377, DOI 10.1515/BC.2006.173; Lu L, 2004, MOL BIOL CELL, V15, P4426, DOI 10.1091/mbc.E03-12-0872; Maag RS, 2005, MOL BIOL CELL, V16, P3019, DOI 10.1091/mbc.E04-11-0971; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Matsushita K, 2005, J CELL BIOL, V170, P73, DOI 10.1083/jcb.200502031; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; Meng TC, 2004, J BIOL CHEM, V279, P37716, DOI 10.1074/jbc.M404606200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Nozawa K, 2005, AUTOIMMUN REV, V4, P35, DOI 10.1016/j.autrev.2004.06.002; Nozawa K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar422; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Reddy JV, 2006, MOL BIOL CELL, V17, P4353, DOI 10.1091/mbc.E06-02-0153; Sbodio JI, 2006, J BIOL CHEM, V281, P27924, DOI 10.1074/jbc.M603276200; Short B, 2005, BBA-MOL CELL RES, V1744, P383, DOI 10.1016/j.bbamcr.2005.02.001; Sohda M, 2001, J BIOL CHEM, V276, P45298, DOI 10.1074/jbc.M108961200; Veal EA, 2007, MOL CELL, V26, P1, DOI 10.1016/j.molcel.2007.03.016; Wang GF, 2006, P NATL ACAD SCI USA, V103, P1295, DOI 10.1073/pnas.0508354103; Williams D, 2006, MOL BIOL CELL, V17, P5346, DOI 10.1091/mbc.E06-05-0386; Yoshino A, 2005, J CELL SCI, V118, P2279, DOI 10.1242/jcs.02358; Zhou Y, 2007, CELL, V129, P163, DOI 10.1016/j.cell.2007.02.037	39	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29874	29881		10.1074/jbc.M705794200	http://dx.doi.org/10.1074/jbc.M705794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711851	hybrid			2022-12-25	WOS:000249981200016
J	Accordi, B; Pillozzi, S; Dell'Orto, MC; Cazzaniga, G; Arcangeli, A; Kronnie, GT; Basso, G				Accordi, Benedetta; Pillozzi, Serena; Dell'Orto, Marta Campo; Cazzaniga, Giovanni; Arcangeli, Annarosa; Kronnie, Geertruy te; Basso, Giuseppe			Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD95 APO-1/FAS SYSTEM; SCATTER FACTOR; IN-VITRO; TYROSINE KINASE; TEL/AML1 FUSION; CELL-LINES; CARCINOMA CELLS; FACTOR HGF/SF; EXPRESSION; INVOLVEMENT	Expression of c-MET, the HGF (hepatocyte growth factor) tyrosine kinase receptor, was investigated in pediatric B-acute lymphoblastic leukemia (ALL) patients. c-MET was found to be expressed in normal B cells and in B-ALL patients with the t(12; 21) TEL-AML1 translocation, but it is not expressed in the most part of B-ALL without the t(12; 21). We also found that c-MET, related to proliferation and protection from apoptosis, is associated with the pro-apoptotic protein FAS in TEL-AML1 B-ALL cells and in normal B lymphocytes. The possible role of this protein complex in drug-induced apoptosis was thus investigated in REH TEL-AML1 B-ALL cell line. REH cells prestimulated with HGF and treated with doxorubicin had shown a higher apoptotic rate than non-HGF-prestimulated ones (p = 0.03). REH cells stimulated with IL-3 and treated with doxorubicin did not undergo apoptosis more than nonstimulated cells, demonstrating that increased proliferation in itself is not directly related to the higher apoptotic sensitivity observed with HGF stimulation. These results indicate that c-MET activation enhances specifically FAS-mediated apoptosis in TEL-AML1 ALL cells and, considering that the c-MET/FAS complex is present only in normal B lymphocytes and in TEL-AML1 leukemias, this implies that it may have an important contribution in cellular homeostasis and in high sensitivity of TEL-AML1 ALL to chemotherapeutic regimens.				benedetta.accordi@unipd.it	pillozzi, serena/K-5876-2016; Kronnie, Geertruy te/L-1014-2016; Cazzaniga, Giovanni/K-6338-2016	pillozzi, serena/0000-0001-8861-8718; /0000-0001-5636-1006; te Kronnie, Geertruy/0000-0001-7143-4795; BASSO, GIUSEPPE/0000-0002-2634-9302; Cazzaniga, Giovanni/0000-0003-2955-4528				Askenasy N, 2005, BLOOD, V105, P1396, DOI 10.1182/blood-2004-06-2364; Basso G, 2001, HAEMATOLOGICA, V86, P675; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Borset M, 1999, LEUKEMIA LYMPHOMA, V32, P249, DOI 10.3109/10428199909167385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Frost BM, 2004, BLOOD, V104, P2452, DOI 10.1182/blood-2003-12-4426; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 1997, CANCER RES, V57, P3823; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; Karawajew L, 1997, LEUKEMIA, V11, P1245, DOI 10.1038/sj.leu.2400746; Kim WH, 2005, AM J PATHOL, V166, P1017, DOI 10.1016/S0002-9440(10)62323-1; Loh ML, 2006, BLOOD, V107, P4508, DOI 10.1182/blood-2005-08-3451; Loh ML, 1998, BLOOD, V92, P4792, DOI 10.1182/blood.V92.12.4792.424k30_4792_4797; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; McHale CM, 2004, AM J HEMATOL, V75, P254, DOI 10.1002/ajh.20030; Mitsiades N, 2001, CANCER RES, V61, P577; Nakamura M, 2007, J HEPATOL, V46, P77, DOI 10.1016/j.jhep.2006.07.032; Pons E, 1998, LEUKEMIA RES, V22, P797, DOI 10.1016/S0145-2126(98)00071-X; Posovszky C, 1999, LEUKEMIA, V13, P400, DOI 10.1038/sj.leu.2401327; Ramakers-van Woerden NL, 2000, BLOOD, V96, P1094; Rasola A, 2004, CANCER RES, V64, P1744, DOI 10.1158/0008-5472.CAN-03-2383; Ravindranath Y, 2003, CURR OPIN ONCOL, V15, P23, DOI 10.1097/00001622-200301000-00004; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Ronen D, 1999, CELL GROWTH DIFFER, V10, P131; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Sakata S, 2003, CELL DEATH DIFFER, V10, P676, DOI 10.1038/sj.cdd.4401215; Shen K, 1997, BIOCHEM BIOPH RES CO, V230, P89, DOI 10.1006/bbrc.1996.5896; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; To C, 2002, EXP CELL RES, V273, P45, DOI 10.1006/excr.2001.5433; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Weimar IS, 1998, EXP HEMATOL, V26, P885; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080; Wuchter C, 2000, BRIT J HAEMATOL, V110, P154, DOI 10.1046/j.1365-2141.2000.02147.x	48	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29384	29393		10.1074/jbc.M706314200	http://dx.doi.org/10.1074/jbc.M706314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17673463	hybrid			2022-12-25	WOS:000249788000035
J	Fujiwara, H; Hayashi, Y; Sanzen, N; Kobayashi, R; Weber, CN; Emoto, T; Futaki, S; Niwa, H; Murray, P; Edgar, D; Sekiguchi, K				Fujiwara, Hironobu; Hayashi, Yoshitaka; Sanzen, Noriko; Kobayashi, Reiko; Weber, Charles N.; Emoto, Tomomi; Futaki, Sugiko; Niwa, Hitoshi; Murray, Patricia; Edgar, David; Sekiguchi, Kiyotoshi			Regulation of mesodermal differentiation of mouse embryonic stem cells by basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN-4; LAMININ ALPHA-5; EPITHELIOMESENCHYMAL TRANSFORMATION; ENDODERM DIFFERENTIATION; MATRIX; CANCER; DYSTROGLYCAN; EPITHELIUM; SURVIVAL; ABSENCE	Basement membranes (BMs) have been implicated in cell fate determination during development. Embryoid bodies (EBs) derived from mouse embryonic stem cells deficient in the laminin gamma 1 chain are incapable of depositing a BM, resulting in failure of primitive ectoderm epithelialization. To elucidate the mechanisms involved in this phenomenon, we compared the gene expression profiles of EBs with or without a BM to identify the genes showing BM-dependent expression. We found that the expressions of marker genes for the epithelial-mesenchymal transition (EMT), including the transcription factor Snai2, were up-regulated in LAMC1(-/-) EBs, whereas restoration of a BM to LAMC1(-/-) EBs suppressed the up-regulation of these genes. Overexpression of Snai2 induced the EMT in control EBs by molecular and morphological criteria, suggesting that suppression of the EMT regulatory genes is involved in BM-dependent epithelialization of primitive ectoderm. Despite the failure of primitive ectoderm epithelialization in BM-deficient EBs, mesodermal differentiation was not compromised, but rather accelerated. Furthermore, at later stages of control EB differentiation, the BM was disrupted at the gastrulation site where mesodermal markers were strongly expressed only in cells that had lost contact with the BM. Taken together, these results indicate that the BM prevents the EMT and precocious differentiation of primitive ectoderm toward mesoderm in EBs, implying that BMs are important for the control of mammalian gastrulation.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Aichi Med Univ, ERATO, Japan Sci & Technol Agcy, Sekiguchi Biomatrix Signaling Project, Aichi 4801195, Japan; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Sch Biomed Sci, Liverpool L69 3GE, Merseyside, England	Osaka University; Aichi Medical University; Japan Science & Technology Agency (JST); University of Liverpool; University of Liverpool	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	hayashiy@riem.nagoya-u.ac.jp; sekiguch@protein.osaka-u.ac.jp	Fujiwara, Hironobu/A-5971-2016; Hayashi, Yoshitaka/I-6168-2014	Fujiwara, Hironobu/0000-0003-0883-3384; Hayashi, Yoshitaka/0000-0002-7557-4303; Murray, Patricia/0000-0003-1316-148X; Sanzen, Noriko/0000-0001-6518-403X	Medical Research Council [G0300296] Funding Source: Medline; MRC [G0300296] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005; Bajanca F, 2006, DEVELOPMENT, V133, P1635, DOI 10.1242/dev.02336; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Blaess S, 2004, J NEUROSCI, V24, P3402, DOI 10.1523/JNEUROSCI.5241-03.2004; BOUCAUT JC, 1984, NATURE, V307, P364, DOI 10.1038/307364a0; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; De Arcangelis A, 1999, DEVELOPMENT, V126, P3957; Duband JL, 1995, ACTA ANAT, V154, P63; Fukumoto S, 2006, J BIOL CHEM, V281, P5008, DOI 10.1074/jbc.M509295200; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Greenlee AR, 2005, TOXICOL IN VITRO, V19, P389, DOI 10.1016/j.tiv.2004.11.002; Gustafsson E, 2000, EXP CELL RES, V261, P52, DOI 10.1006/excr.2000.5042; HAUB O, 1991, DEVELOPMENT, V112, P397; Hay ED, 1995, ACTA ANAT, V154, P8; HAY ED, 1991, CELL BIOL EXTRACELLU, P1; Hayashi Y, 2004, MATRIX BIOL, V23, P47, DOI 10.1016/j.matbio.2004.02.003; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; JONES CM, 1991, DEVELOPMENT, V111, P531; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Murray P, 2004, PHILOS T R SOC B, V359, P1009, DOI 10.1098/rstb.2003.1460; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; NADIJCKA M, 1974, J EMBRYOL EXP MORPH, V32, P675; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Scheele S, 2005, P NATL ACAD SCI USA, V102, P1502, DOI 10.1073/pnas.0405095102; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Verrou C, 1999, BIOL CHEM, V380, P1435, DOI 10.1515/BC.1999.184; Viebahn C, 1995, ACTA ANAT, V154, P79; Viebahn C, 1995, ACTA ANAT, V154, P99; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7	50	41	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29701	29711		10.1074/jbc.M611452200	http://dx.doi.org/10.1074/jbc.M611452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690109	hybrid, Green Published			2022-12-25	WOS:000249788000066
J	Jiang, L; Crews, ST				Jiang, Lan; Crews, Stephen T.			Transcriptional specificity of drosophila dysfusion and the control of tracheal fusion cell gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH-PAS PROTEIN; DNA-BINDING; DIOXIN RECEPTOR; SPINELESS; DOMAIN; EMBRYOGENESIS; LOCALIZATION; ADHESION; NEURONS; TISSUES	The Drosophila Dysfusion basic-helix-loop-helix-PAS ( bHLH-PAS) protein controls the transcription of genes that mediate tracheal fusion. Dysfusion is highly related to the mammalian Nxf protein that has been implicated in nervous system gene regulation. Toward the goal of understanding how Dysfusion controls fusion cell gene expression, the biochemical properties of Dysfusion were investigated using protein interaction experiments, cell culture-based transcription assays, and in vivo transgenic analyses. Dysfusion dimerizes with the Tango bHLH-PAS protein, and together they act as a DNA binding transcriptional activator. Dysfusion/Tango binds multiple NCGTG binding sites, with the following preference: TCGTG > GCGTG > ACGTG > CCGTG. This binding site promiscuity differs from the restricted binding site preferences of other bHLH-PAS/Tango heterodimers. However, it is identical to the binding site preferences of mammalian Nxf/Arnt, indicating that the specificity is evolutionarily conserved. Germ line transformation experiments using a fragment of the CG13196 Dysfusion target gene allowed identification of a fusion cell enhancer. Experiments in which NCGTG sites were mutated individually and in combination revealed that TCGTG sites were required for fusion cell expression but that the single ACGTG and GCGTG sites present were not. Finally, a reporter transgene containing four tandemly arranged TCGTG elements has strong expression in tracheal fusion cells. Transgenic misexpression of dysfusion further revealed that Dysfusion has the ability to activate transcription in multiple cell types, although it does this most effectively in tracheal cells and can only function at mid-embryogenesis and later.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Crews, ST (corresponding author), Fordham Hall CB 3280, Chapel Hill, NC 27599 USA.	steve_crews@unc.edu		Jiang23, Lan/0000-0002-1845-5500	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR021055] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR021055, S10 RR021055-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Chapman-Smith A, 2006, J BIOL CHEM, V281, P12535, DOI 10.1074/jbc.M512145200; CREWS ST, 2003, PAS PROTEINS REGULAT; Crews ST, 2006, GENE DEV, V20, P2773, DOI 10.1101/gad.1487706; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Emmons RB, 1999, DEVELOPMENT, V126, P3937; Estes P, 2001, DEV BIOL, V232, P157, DOI 10.1006/dbio.2001.0174; Gorr TA, 2006, J INSECT PHYSIOL, V52, P349, DOI 10.1016/j.jinsphys.2006.01.002; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; Hester I, 2007, BRAIN RES, V1135, P1, DOI 10.1016/j.brainres.2006.11.083; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jazwinska A, 2004, GENE EXPR PATTERNS, V4, P413, DOI 10.1016/j.modgep.2004.01.003; Jiang L, 2003, MOL CELL BIOL, V23, P5625, DOI 10.1128/MCB.23.16.5625-5637.2003; Jiang L, 2006, MOL CELL BIOL, V26, P6547, DOI 10.1128/MCB.00284-06; Kim MD, 2006, GENE DEV, V20, P2806, DOI 10.1101/gad.1459706; Kinoshita K, 2004, NUCLEIC ACIDS RES, V32, P3169, DOI 10.1093/nar/gkh637; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Manning Gerards, 1993, P609; Manning L, 1999, DEVELOPMENT, V126, P2063; Moser M, 2004, MOL BRAIN RES, V128, P141, DOI 10.1016/j.molbrainres.2004.06.023; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Ooe N, 2004, MOL CELL BIOL, V24, P608, DOI 10.1128/MCB.24.2.608-616.2004; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Pielage J, 2002, DEV BIOL, V249, P283, DOI 10.1006/dbio.2002.0770; Powell-Coffman JA, 2003, PAS PROTEINS: REGULATORS AND SENSORS OF DEVELOPMENT AND PHYSIOLOGY, P51; Samakovlis C, 1996, DEVELOPMENT, V122, P3531; SONNENFELD M, 1997, DEVELOPMENT, V124, P4583; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; Ward MP, 1998, DEVELOPMENT, V125, P1599; WHARTON JKA, 1994, DEVELOPMENT, V120, P3563; Zelzer E, 2000, MECH DEVELOP, V91, P163, DOI 10.1016/S0925-4773(99)00295-6; Zhu Q, 2007, FLY, V1, P55, DOI 10.4161/fly.3892	33	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28659	28668		10.1074/jbc.M703803200	http://dx.doi.org/10.1074/jbc.M703803200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652079	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000249642100040
J	McNally, DJ; Lamoureux, MP; Karlyshev, AV; Fiori, LM; Li, JJ; Thacker, G; Coleman, RA; Khieu, NH; Wren, BW; Brisson, JR; Jarrell, HC; Szymanski, CM				McNally, David J.; Lamoureux, Marc P.; Karlyshev, Andrey V.; Fiori, Laura M.; Li, Jianjun; Thacker, Gillian; Coleman, Russell A.; Khieu, Nam H.; Wren, Brendan W.; Brisson, Jean-Robert; Jarrell, Harold C.; Szymanski, Christine M.			Commonality and biosynthesis of the O-methyl phosphoramidate capsule modification in Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUILLAIN-BARRE-SYNDROME; POLYSACCHARIDE; LIPOOLIGOSACCHARIDE; PATHOGEN; LIPOPOLYSACCHARIDES; IDENTIFICATION; SPECTROMETRY; INFECTIONS; SEROSTRAIN; DIVERSITY	In this study we investigated the commonality and biosynthesis of the O-methyl phosphoramidate (MeOPN) group found on the capsular polysaccharide (CPS) of Campylobacter jejuni. High resolution magic angle spinning NMR spectroscopy was used as a rapid, high throughput means to examine multiple isolates, analyze the cecal contents of colonized chickens, and screen a library of CPS mutants for the presence of MeOPN. Sixty eight percent of C. jejuni strains were found to express the MeOPN with a high prevalence among isolates from enteritis, Guillain Barre , and Miller-Fisher syndrome patients. In contrast, MeOPN was not observed for any of the Campylobacter coli strains examined. The MeOPN was detected on C. jejuni retrieved from cecal contents of colonized chickens demonstrating that the modification is expressed by bacteria inhabiting the avian gastrointestinal tract. In C. jejuni 11168H, the cj1415-cj1418 cluster was shown to be involved in the biosynthesis of MeOPN. Genetic complementation studies and NMR/ mass spectrometric analyses of CPS from this strain also revealed that cj1421 and cj1422 encode MeOPN transferases. Cj1421 adds the MeOPN to C-3 of the beta-D-GalfNAc residue, whereas Cj1422 transfers the MeOPN to C-4 of D-glycero-alpha-L-glucoheptopyranose. CPS produced by the 11168H strain was found to be extensively modified with variable MeOPN, methyl, ethanolamine, and N-glycerol groups. These findings establish the importance of the MeOPN as a diagnostic marker and therapeutic target for C. jejuni and set the groundwork for future studies aimed at the detailed elucidation of the MeOPN biosynthetic pathway.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	National Research Council Canada; University of London; London School of Hygiene & Tropical Medicine	Jarrell, HC (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	harold.jarrell@nrc-cnrc.gc.ca; christine.szymanski@nrc-cnrc.gc.ca	Szymanski, Christine/A-3763-2014; Karlyshev, Andrey/D-2797-2011	Szymanski, Christine/0000-0002-8464-1352; Karlyshev, Andrey/0000-0003-3124-019X	Biotechnology and Biological Sciences Research Council [E20372] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahmed IH, 2002, MICROBIOL-SGM, V148, P1203, DOI 10.1099/00221287-148-4-1203; Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760; Altekruse SF, 1999, EMERG INFECT DIS, V5, P28, DOI 10.3201/eid0501.990104; ASPINALL GO, 1994, INFECT IMMUN, V62, P2122, DOI 10.1128/IAI.62.5.2122-2125.1994; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Champion OL, 2005, P NATL ACAD SCI USA, V102, P16043, DOI 10.1073/pnas.0503252102; Fouts DE, 2005, PLOS BIOL, V3, P72, DOI 10.1371/journal.pbio.0030015; Godschalk PCR, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-32; Gordon RW, 1997, POULTRY SCI, V76, P683, DOI 10.1093/ps/76.5.683; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110; Kanipes MI, 2006, J BACTERIOL, V188, P3273, DOI 10.1128/JB.188.9.3273-3279.2006; Karlyshev AV, 2005, APPL ENVIRON MICROB, V71, P4004, DOI 10.1128/AEM.71.7.4004-4013.2005; Karlyshev AV, 2005, MOL MICROBIOL, V55, P90, DOI 10.1111/j.1365-2958.2004.04374.x; Karlyshev AV, 2000, MOL MICROBIOL, V35, P529, DOI 10.1046/j.1365-2958.2000.01717.x; Li JJ, 2005, RAPID COMMUN MASS SP, V19, P1305, DOI 10.1002/rcm.1927; McKay D, 2001, J CLIN MICROBIOL, V39, P1917, DOI 10.1128/JCM.39.5.1917-1921.2001; McNally DJ, 2006, FEBS J, V273, P3975, DOI 10.1111/j.1742-4658.2006.05401.x; McNally DJ, 2006, CAN J CHEM, V84, P676, DOI 10.1139/V06-028; McNally DJ, 2005, FEBS J, V272, P4407, DOI 10.1111/j.1742-4658.2005.04856.x; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Miller WG, 2005, MICROBIOL-SGM, V151, P337, DOI 10.1099/mic.0.27327-0; MORAN ET, 1980, POULTRY SCI, V59, P1521, DOI 10.3382/ps.0591521; PAOLETTI LC, 1991, J CLIN INVEST, V202, P243; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Penner JL, 1997, J INFECT DIS, V176, pS135, DOI 10.1086/513778; REES JH, 1993, Q J MED, V86, P623, DOI 10.1093/qjmed/86.10.623; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; Rubinstein LJ, 1998, INFECT IMMUN, V66, P5450, DOI 10.1128/IAI.66.11.5450-5456.1998; Serino L, 2002, MOL MICROBIOL, V43, P437, DOI 10.1046/j.1365-2958.2002.02755.x; Silipo A, 2005, J BIOL CHEM, V280, P33660, DOI 10.1074/jbc.M506254200; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; YUKI N, 1995, J NEUROL SCI, V130, P112, DOI 10.1016/0022-510X(95)00045-4	37	75	82	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28566	28576		10.1074/jbc.M704413200	http://dx.doi.org/10.1074/jbc.M704413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17675288	hybrid			2022-12-25	WOS:000249642100031
J	Nagai, H; Sheng, GJ				Nagai, Hiroki; Sheng, Guojun			Cis-Cotranscription of Two Beta Globin Genes during Chicken Primitive Hematopoiesis	PLOS ONE			English	Article								Chicken beta globin locus contains four genes, two of which, rho and epsilon, are expressed from the earliest stage of primitive hematopoiesis. Here we show that the transcription of these two genes in the nucleus engages in "on/off" phases. During each "on" phase, cotranscription of rho and epsilon in cis is favored. We propose that these two chicken beta globin genes are transcribed not by competing for a transcription initiation complex, but in a cooperative way.	[Nagai, Hiroki; Sheng, Guojun] RIKEN, Ctr Dev Biol, Lab Early Embryogenesis, Kobe, Hyogo, Japan	RIKEN	Sheng, GJ (corresponding author), RIKEN, Ctr Dev Biol, Lab Early Embryogenesis, Kobe, Hyogo, Japan.	sheng@cdb.riken.jp	Sheng, Guojun/G-4116-2014; Nagai, Hiroki/GXZ-7815-2022; Sheng, Guojun/G-8746-2013; Sheng, Guojun/I-4900-2015		RIKEN	RIKEN	This work is supported by RIKEN.	DOLAN M, 1981, CELL, V24, P669, DOI 10.1016/0092-8674(81)90093-3; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; Nakazawa F, 2006, BLOOD, V108, P3335, DOI 10.1182/blood-2006-05-021386; Stamatoyannopoulos G, 2005, EXP HEMATOL, V33, P259, DOI 10.1016/j.exphem.2004.11.007; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	7	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e703	10.1371/journal.pone.0000703	http://dx.doi.org/10.1371/journal.pone.0000703			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684550	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452400007
J	Weston, EM; Friday, AE; Lio, P				Weston, Eleanor M.; Friday, Adrian E.; Lio, Pietro			Biometric Evidence that Sexual Selection Has Shaped the Hominin Face	PLOS ONE			English	Article							MALE FACIAL ATTRACTIVENESS; DIMORPHISM; ALLOMETRY; ONTOGENY; PATTERNS; PROPORTIONS; PREFERENCES; SYMMETRY; GROWTH	We consider sex differences in human facial morphology in the context of developmental change. We show that at puberty, the height of the upper face, between the lip and the brow, develops differently in males and females, and that these differences are not explicable in terms of sex differences in body size. We find the same dimorphism in the faces of human ancestors. We propose that the relative shortening in men and lengthening in women of the anterior upper face at puberty is the mechanistic consequence of extreme maxillary rotation during ontogeny. A link between this developmental model and sexual dimorphism is made for the first time, and provides a new set of morphological criteria to sex human crania. This finding has important implications for the role of sexual selection in the evolution of anthropoid faces and for theories of human facial attractiveness.	[Weston, Eleanor M.] UCL, Dept Biol, London, England; [Weston, Eleanor M.; Friday, Adrian E.] Univ Museum Zool, Cambridge, England; [Lio, Pietro] Univ Cambridge, Comp Lab, Cambridge CB2 3QG, England	University of London; University College London; University of Cambridge; University of Cambridge	Weston, EM (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.	e.weston@nhm.ac.uk	P. Lió, Pietro Lio/AAV-3358-2021; van Lent, Laurence/G-5298-2010	P. Lió, Pietro Lio/0000-0002-0540-5053; van Lent, Laurence/0000-0002-9354-0932	European Commission; BBSRC [BB/D522689/1]; Biotechnology and Biological Sciences Research Council [BB/D522689/1, BB/D522689/2] Funding Source: researchfish	European Commission(European CommissionEuropean Commission Joint Research Centre); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was funded by European Commission Marie Curie Fellowship hosted by the Senckenberg Research Institute, Frankfurt, Germany and the Balfour Fund, Department of Zoology, University of Cambridge, UK. EW is a Recognized Researcher on a BBSRC grant reference number BB/D522689/1.	BHAT M, 1985, ANGLE ORTHOD, V55, P269; BJORK A, 1976, MONOGRAPH U MICHIGAN, V6, P61; Broadbent Sr BH, 1975, BOLTON STANDARDS DEN, P166; BROMAGE TG, 1989, J HUM EVOL, V18, P751, DOI 10.1016/0047-2484(89)90088-2; Bulygina E, 2006, AM J PHYS ANTHROPOL, V131, P432, DOI 10.1002/ajpa.20317; CUNNINGHAM MR, 1990, J PERS SOC PSYCHOL, V59, P61, DOI 10.1037/0022-3514.59.1.61; DeBruine LM, 2006, P ROY SOC B-BIOL SCI, V273, P1355, DOI 10.1098/rspb.2005.3445; DEVILLIERS H, 1968, SKULL S AFRICAN NEGR, P342; ENLOW D, 1996, ESSENTIALS FACIAL GR, P303; Ferrario VF, 1998, ANAT REC, V250, P480, DOI 10.1002/(SICI)1097-0185(199804)250:4<480::AID-AR12>3.0.CO;2-K; Hennessy RJ, 2002, AM J PHYS ANTHROPOL, V117, P37, DOI 10.1002/ajpa.10005; Hunt N, 1998, CLIN ORAL SCI, P120; Johnston VS, 2001, EVOL HUM BEHAV, V22, P251, DOI 10.1016/S1090-5138(01)00066-6; LIGTHELMBAKKER ASWMR, 1992, AM J ORTHOD DENTOFAC, V101, P509, DOI 10.1016/0889-5406(92)70124-S; Lockwood CA, 1999, AM J PHYS ANTHROPOL, V108, P97, DOI 10.1002/(SICI)1096-8644(199901)108:1<97::AID-AJPA6>3.0.CO;2-O; Martin R, 1988, ANTHR HDB VERGLEICHE, P742; McCollum MA, 1999, SCIENCE, V284, P301, DOI 10.1126/science.284.5412.301; McCollum MA, 1997, AM J PHYS ANTHROPOL, V102, P377, DOI 10.1002/(SICI)1096-8644(199703)102:3<377::AID-AJPA7>3.0.CO;2-S; McCollum MA, 1997, AM J PHYS ANTHROPOL, V103, P375, DOI 10.1002/(SICI)1096-8644(199707)103:3<375::AID-AJPA7>3.3.CO;2-J; O'Higgins P, 2002, J ZOOL, V257, P255, DOI 10.1017/S0952836902000857; OHIGGINS P, 1990, J ZOOL, V222, P399, DOI 10.1111/j.1469-7998.1990.tb04041.x; Penton-Voak IS, 2001, P ROY SOC B-BIOL SCI, V268, P1617, DOI 10.1098/rspb.2001.1703; Penton-Voak IS, 2001, ADV STUD BEHAV, V30, P219, DOI 10.1016/S0065-3454(01)80008-5; PROFFIT WR, 1983, J DENT RES, V62, P566, DOI 10.1177/00220345830620051201; Rhodes G, 2006, ANNU REV PSYCHOL, V57, P199, DOI 10.1146/annurev.psych.57.102904.190208; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Rightmire GP, 1998, AM J PHYS ANTHROPOL, V106, P61, DOI 10.1002/(SICI)1096-8644(199805)106:1<61::AID-AJPA5>3.3.CO;2-U; Rosas A, 2002, AM J PHYS ANTHROPOL, V117, P236, DOI 10.1002/ajpa.10023; Ruff C, 2002, ANNU REV ANTHROPOL, V31, P211, DOI 10.1146/annurev.anthro.31.040402.085407; Schaefer K, 2004, ANN ANAT, V186, P471, DOI 10.1016/S0940-9602(04)80086-4; Scheib JE, 1999, P ROY SOC B-BIOL SCI, V266, P1913, DOI 10.1098/rspb.1999.0866; Shea B.T., 1985, P175; Shea BT, 1996, AM J PHYS ANTHROPOL, V100, P311; Sokal R.R., 1995, BIOMETRY PRINCIPLES, Vthird; Swaddle JP, 2002, P ROY SOC B-BIOL SCI, V269, P2285, DOI 10.1098/rspb.2002.2165; SYMON D, 1995, CHIC SEX HIST SOC, P80; Thackeray JF, 2000, S AFR ARCHAEOL BULL, V55, P155, DOI 10.2307/3888964; Throckmorton GS, 2000, J ORAL MAXIL SURG, V58, P515, DOI 10.1016/S0278-2391(00)90014-4; URSI WJS, 1993, ANGLE ORTHOD, V63, P47; Vioarsdottir US, 2002, J ANAT, V201, P211; Weston EM, 2004, P ROY SOC B-BIOL SCI, V271, pS416, DOI 10.1098/rsbl.2004.0203; Weston EM, 2003, BIOL J LINN SOC, V80, P625, DOI 10.1111/j.1095-8312.2003.00263.x; WOOD BA, 1991, J ANAT, V174, P185; WOOD BA, 1991, KOOBI FORA RES PROJE, P492; Wood CG, 1996, NATO ADV SCI INST SE, V284, P407	45	160	166	2	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2007	2	8							e710	10.1371/journal.pone.0000710	http://dx.doi.org/10.1371/journal.pone.0000710			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GL	17684556	Green Published, gold			2022-12-25	WOS:000207452400013
J	Coetzee, V; Barrett, L; Greeff, JM; Henzi, SP; Perrett, DI; Wadee, AA				Coetzee, Vinet; Barrett, Louise; Greeff, Jaco M.; Henzi, S. Peter; Perrett, David I.; Wadee, Ahmed A.			Common HLA Alleles Associated with Health, but Not with Facial Attractiveness	PLOS ONE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATING PREFERENCES; MATE CHOICE; NO EVIDENCE; GOOD GENES; HETEROZYGOSITY; SELECTION; EVOLUTION; MEN	Three adaptive hypotheses have been proposed to explain the link between the human leucocyte antigen (HLA) genes, health measures and facial attractiveness: inbreeding avoidance, heterozygote advantage and frequency-dependent selection. This paper reports findings that support a new hypothesis relating HLA to health. We suggest a new method to quantify the level of heterozygosity. HLA heterozygosity did not significantly predict health measures in women, but allele frequency did. Women with more common HLA alleles reported fewer cold and flu bouts per year, fewer illnesses in the previous year and rated themselves healthier than women with rare alleles. To our knowledge, this is the first study to show a positive correlation between HLA allele frequency and general health measures. We propose that certain common HLA alleles confer resistance to prevalent pathogens. Nevertheless, neither HLA heterozygosity nor allele frequency significantly predicted how healthy or attractive men rated the female volunteers. Three non-mutually exclusive explanations are put forward to explain this finding.	[Coetzee, Vinet; Greeff, Jaco M.] Univ Pretoria, Dept Genet, ZA-0002 Pretoria, South Africa; [Barrett, Louise; Henzi, S. Peter] Univ Lethbridge, Dept Psychol, Lethbridge, AB T1K 3M4, Canada; [Perrett, David I.] Univ St Andrews, Dept Psychol, St Andrews, Fife, Scotland; [Wadee, Ahmed A.] Univ Witwatersrand, Dept Immunol, Johannesburg, South Africa	University of Pretoria; University of Lethbridge; University of St Andrews; University of Witwatersrand	Coetzee, V (corresponding author), Univ Pretoria, Dept Genet, ZA-0002 Pretoria, South Africa.	vcoetzee@tuks.co.za	Coetzee, Vinet/F-2155-2011; Greeff, Jaco M/A-5582-2011	Coetzee, Vinet/0000-0003-1716-0804; Henzi, Peter/0000-0001-6175-1674; Perrett, David/0000-0002-6025-0939; Greeff, Jaco/0000-0003-2951-6791	National Research Foundation [2053809]	National Research Foundation	Funding: This material is based, in part, upon work supported by the National Research Foundation under Grant number 2053809 to JMG.	ALMARRI A, 1994, LANCET, V344, P1194, DOI 10.1016/S0140-6736(94)90510-X; Bittles AH, 2001, CLIN GENET, V60, P89, DOI 10.1034/j.1399-0004.2001.600201.x; COOK RD, 1982, RESIDUALS THEIR INFL; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; *EMBL EBI, IMGT HLA SEQ DAT; Freeman-Gallant CR, 2003, MOL ECOL, V12, P3077, DOI 10.1046/j.1365-294X.2003.01968.x; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; HARTL DL, 1987, PRIMER POPULATION GE; Hedrick PW, 1997, AM J HUM GENET, V61, P505, DOI 10.1086/515519; HEDRICK PW, 1987, BIOL J LINN SOC, V31, P311, DOI 10.1111/j.1095-8312.1987.tb01996.x; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Jeffery KJM, 2000, MICROBES INFECT, V2, P1335, DOI 10.1016/S1286-4579(00)01287-9; JIN K, 1995, BIOMETRICS, V51, P1064, DOI 10.2307/2533005; Johnstone RA, 1996, EVOLUTION, V50, P1382, DOI [10.2307/2410876, 10.1111/j.1558-5646.1996.tb03912.x]; KENRICK DT, 1989, SOCIOBIOLOGY SOCIAL, P5; Landry C, 2001, P ROY SOC B-BIOL SCI, V268, P1279, DOI 10.1098/rspb.2001.1659; Lopez-Vazquez A, 2005, HUM IMMUNOL, V66, P285, DOI 10.1016/j.humimm.2005.01.001; MARIEB EN, 1995, HUMAN ANATOMY PHYSL; MITTON JB, 1993, HEREDITY, V71, P59, DOI 10.1038/hdy.1993.107; Neff BD, 2005, MOL ECOL, V14, P19, DOI 10.1111/j.1365-294X.2004.02395.x; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; Paterson S, 1997, P ROY SOC B-BIOL SCI, V264, P1813, DOI 10.1098/rspb.1997.0250; Penn DJ, 1999, AM NAT, V153, P145, DOI 10.1086/303166; POTTS WK, 1993, TRENDS GENET, V9, P408, DOI 10.1016/0168-9525(93)90103-O; Roberts SC, 2005, EVOL HUM BEHAV, V26, P213, DOI 10.1016/j.evolhumbehav.2004.09.002; ROSENBERG LT, 1983, IMMUNOGENETICS, V17, P89, DOI 10.1007/BF00364292; Ryan Michael J., 1997, P179; Statistics South Africa, MORT CAUS DEATH S AF; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornhill R, 2006, EVOL HUM BEHAV, V27, P131, DOI 10.1016/j.evolhumbehav.2005.06.001; Thornhill R, 2003, BEHAV ECOL, V14, P668, DOI 10.1093/beheco/arg043; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; *WHO, MORT PROF; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1978, IMMUNOGENETICS, V6, P253, DOI 10.1007/BF01563915	36	20	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e640	10.1371/journal.pone.0000640	http://dx.doi.org/10.1371/journal.pone.0000640			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653267	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200009
J	Zeidan, YH; Wu, BX; Jenkins, RW; Obeid, LM; Hannun, YA				Zeidan, Youssef H.; Wu, Bill X.; Jenkins, Russell W.; Obeid, Lina M.; Hannun, Yusuf A.			A novel role for protein kinase C delta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury	FASEB JOURNAL			English	Article						ceramide; sphingolipids; apoptosis	RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; HUMAN KERATINOCYTES; SKIN-CANCER; FAS LIGAND; PHOSPHOLIPASE-D; MASS-SPECTROMETRY; CELL CARCINOMA; CYTOCHROME-C; B RADIATION	Multiple studies have addressed the mechanisms by which ultraviolet (UV) light induces cell death, and a few have focused on stress mediators such as acid sphingomyelinase (ASMase) or protein kinase C delta (PKC delta). Based on a recent study that identified a novel mechanism of activation of ASMase through phosphorylation (1), the current study was undertaken to determine the upstream mechanisms regulating ASMase in response to UV and to investigate the role of ASMase and its phosphorylation at S508 as an integral event during UV light-induced cell death. Exposure of MCF-7 breast cancer cells to UV light type C (UVC) transiently activated ASMase with maximal activity detected at 10 min postirradiation. A significant increase in C-16-ceramide was detected concomitant with a decrease in C-16-sphingomyelin. In marked contrast, cells overexpressing the ASMase(S508A) mutant, which could not be phosphorylated, had no change in either ASMase activity or ceramide levels post-UV radiation. Loss of PKC delta by RNA interference or its inhibition by rottlerin blocked ASMase phosphorylation and membrane targeting, thus implicating PKC delta upstream of ASMase activation by UV light. Further investigations revealed that UV radiation altered mitochondrial morphology from elongated tubules to fragmented perinuclear organelles, consistent with the onset of the apoptotic cascade. Importantly, cells overexpressing ASMaseS508A were protected (> 50%) from UV light-induced mitochondrial fragmentation. Mechanistically, the results showed that ASMaseS508A cells had 50% less active Bax than ASMase(WT) cells. These molecular differences culminated in resistance of ASMase(S508) cells to UVC-induced cell death (25%) as compared to ASMaseWT cells (46%). Taken together, this study provides key molecular insights into activation of ASMase in response to UV light, the role of PKC delta in this activation, and the role of ASMase in mediating apoptotic responses. -Zeidan, Y. H., Wu, B. X., Jenkins, R. W., Obeid, L. M., Hannun, Y. A. A novel role for protein kinase c delta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury.	[Zeidan, Youssef H.; Wu, Bill X.; Jenkins, Russell W.; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 175 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Zeidan, Youssef H./H-7578-2019	Zeidan, Youssef H./0000-0002-1951-8585; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA97132] Funding Source: Medline; NCRR NIH HHS [C06 RR018823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Charruyer A, 2005, J BIOL CHEM, V280, P19196, DOI 10.1074/jbc.M412867200; Charruyer A, 2007, BIOCHEM J, V405, P77, DOI 10.1042/BJ20061528; Chaturvedi V, 2005, ONCOGENE, V24, P5299, DOI 10.1038/sj.onc.1208650; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Choi SY, 2006, NAT CELL BIOL, V8, P1255, DOI 10.1038/ncb1487; Chow J, 2005, J CUTAN MED SURG, V9, P289, DOI 10.1007/s10227-005-0109-0; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Faris M, 1998, J IMMUNOL, V160, P134; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FRANCIS B, 2001, SEX ED, V1, P1; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Komatsu M, 2001, BBA-MOL CELL BIOL L, V1533, P47, DOI 10.1016/S1388-1981(01)00139-1; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Magnoni C, 2002, TOXICOL IN VITRO, V16, P349, DOI 10.1016/S0887-2333(02)00024-3; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Morales A, 2004, GLYCOCONJUGATE J, V20, P579; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Radin NS, 2003, BIOORGAN MED CHEM, V11, P2123, DOI 10.1016/S0968-0896(02)00609-0; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Singh IN, 2001, BIOCHEMISTRY-US, V40, P11227, DOI 10.1021/bi010787l; Siskind LJ, 2006, MITOCHONDRION, V6, P118, DOI 10.1016/j.mito.2006.03.002; Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P143, DOI 10.1007/s10863-005-6567-7; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Sitailo LA, 2006, J BIOL CHEM, V281, P29703, DOI 10.1074/jbc.M607351200; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Taha TA, 2005, FASEB J, V19, P482, DOI 10.1096/fj.05-4412fje; Tomassini B, 2002, BIOCHIMIE, V84, P123, DOI 10.1016/S0300-9084(02)01377-9; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; van Montfort BA, 2002, J MASS SPECTROM, V37, P322, DOI 10.1002/jms.288; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zeidan YH, 2007, J BIOL CHEM, V282, P11549, DOI 10.1074/jbc.M609424200; Zeidan YH, 2006, J BIOL CHEM, V281, P24695, DOI 10.1074/jbc.M604713200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	65	59	64	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					183	193		10.1096/fj.07-8967com	http://dx.doi.org/10.1096/fj.07-8967com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	17698617				2022-12-25	WOS:000252309900021
J	Ran, YC; Zhu, H; Liu, MY; Fabian, M; Olson, JS; Aranda, R IV; Phillips, GN; Dooley, DM; Lei, B				Ran, Yanchao; Zhu, Hui; Liu, Mengyao; Fabian, Marian; Olson, John S.; Aranda, Roman, IV; Phillips, George N., Jr.; Dooley, David M.; Lei, Benfang			Bis-methionine Ligation to heme iron in the streptococcal cell surface protein shp facilitates rapid hemin transfer to HtsA of the HtsABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; BINDING-PROTEIN; RECEPTOR HASR; UPTAKE SYSTEM; IDENTIFICATION; HEMOGLOBIN; MEMBRANE; HEMOPHORE; MYOGLOBIN; RESIDUES	The surface protein Shp of Streptococcus pyogenes rapidly transfers its hemin to HtsA, the lipoprotein component of the HtsABC transporter, in a concerted two-step process with one kinetic phase. The structural basis and molecular mechanism of this hemin transfer have been explored by mutagenesis and truncation of Shp. The heme-binding domain of Shp is in the amino-terminal region and is functionally active by itself, although inclusion of the COOH-terminal domain speeds up the process similar to 10-fold. Single alanine replacements of the axial methionine 66 and 153 ligands (Shp(M66A) and Shp(M153A)) cause formation of pentacoordinate hemin-Met complexes. The association equilibrium constants for hemin binding to wild-type, M66A, and M153A Shp are 5,300, 22,000, and 38 mu m(-1), respectively, showing that the Met(153)-Fe bond is critical for high affinity binding and that Met(66) destabilizes hemin binding to facilitate its rapid transfer. Shp(M66A) and Shp(M153A) rapidly bind to hemin-free HtsA (apoHtsA), forming stable transfer intermediates. These intermediates appear to be Shp-hemin-HtsA complexes with one axial ligand from each protein and decay to the products with rate constants of 0.4-3 s(-1). Thus, the M66A and M153A replacements alter the kinetic mechanism and unexpectedly slow down hemin transfer by stabilizing the intermediates. These results, in combination with the structure of the Shp heme-binding domain, allow us to propose a "plug-in" mechanism in which side chains from apoHtsA are inserted into the axial positions of hemin in Shp to extract it from the surface protein and pull it into the transporter active site.	Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77251 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Rice University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lei, B (corresponding author), Montana State Univ, Dept Vet Mol Biol, PO Box 173610, Bozeman, MT 59717 USA.	blei@montana.edu		Lei, Benfang Lei/0000-0001-8133-6021; Olson, John/0000-0002-0760-5403	NCRR NIH HHS [P20 RR020185-010002, P20 RR020185-037582, P20 RR020185-020002, P20 RR020185, P20 RR020185-047743] Funding Source: Medline; NHLBI NIH HHS [HL47020, R01 HL047020] Funding Source: Medline; NIAID NIH HHS [K22 AI057347-02, AI057347, K22 AI057347, K22 AI057347-01] Funding Source: Medline; NIGMS NIH HHS [GM08349, GM35649, R01 GM055807, GM27659, T32 GM008349, R01 GM035649, R01 GM027659, GM55807] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI057347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055807, T32GM008349, R01GM027659, R01GM035649] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1995, J BIOL CHEM, V270, P23268, DOI 10.1074/jbc.270.40.23268; Burkhard KA, 2007, J BIOL CHEM, V282, P15126, DOI 10.1074/jbc.M611121200; Deniau C, 2003, BIOCHEMISTRY-US, V42, P10627, DOI 10.1021/bi030015k; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Eaton W A, 1981, Methods Enzymol, V76, P175; GRIFFITHS E, 1999, IRON INFECT MOL PHYS, P87; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; Izadi-Pruneyre N, 2006, J BIOL CHEM, V281, P25541, DOI 10.1074/jbc.M603698200; Lei BF, 2003, INFECT IMMUN, V71, P5962, DOI 10.1128/IAI.71.10.5962-5969.2003; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Letoffe S, 1999, MOL MICROBIOL, V33, P546, DOI 10.1046/j.1365-2958.1999.01499.x; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Liu XY, 2006, INFECT IMMUN, V74, P1222, DOI 10.1128/IAI.74.2.1222-1232.2006; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Moreira LM, 2006, BIOPHYS CHEM, V124, P62, DOI 10.1016/j.bpc.2006.05.030; NYGAARD TK, 2006, BMC MICROBIOL, V6; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Pettigrew, 1990, CYTOCHROME C EVOLUTI; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Sharp KH, 2007, J BIOL CHEM, V282, P10625, DOI 10.1074/jbc.M700234200; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06	24	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31380	31388		10.1074/jbc.M705967200	http://dx.doi.org/10.1074/jbc.M705967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17699155	hybrid, Green Accepted			2022-12-25	WOS:000250309200028
J	Chen, XM; Polleichtner, G; Kadurin, I; Grunder, S				Chen, Xuanmao; Polleichtner, Georg; Kadurin, Ivan; Gruender, Stefan			Zebrafish acid-sensing ion channel (ASIC) 4, characterization of homo- and heteromeric channels, and identification of regions important for activation by H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARANTULA TOXIN PSALMOTOXIN-1; HIPPOCAMPAL-NEURONS; SENSORY NEURONS; CATION CHANNEL; EXTRACELLULAR CALCIUM; NA+ CHANNELS; ASIC 1A; CURRENTS; SUBUNIT; FAMILY	There are four genes for acid-sensing ion channels (ASICs) in the genome of mammalian species. Whereas ASIC1 to ASIC3 form functional H+-gated Na+ channels, ASIC4 is not gated by H+, and its function is unknown. Zebrafish has two ASIC4 paralogs: zASIC4.1 and zASIC4.2. Whereas zASIC4.1 is gated by extracellular H+, zASIC4.2 is not. This differential response to H+ makes zASIC4 paralogs a good model to study the properties of this ion channel. In this study, we found that surface expression of homomeric zASIC4.2 is higher than that of zASIC4.1. Surface expression of zASIC4.1 was much increased by formation of heteromeric channels, suggesting that zASIC4.1 contributes to heteromeric ASICs in zebrafish neurons. Robust surface expression of H+-insensitive zASIC4.2 suggests that zASIC4.2 functions as a homomer and is gated by an as yet unknown stimulus, different from H+. Moreover, we identified a small region just distal to the first transmembrane domain that is crucial for the differential H+ response of the two paralogs. This post-TM1 domain may have a general role in gating of members of this gene family.	Univ Wurzburg, Dept Physiol 2, D-97070 Wurzburg, Germany	University of Wurzburg	Grunder, S (corresponding author), Univ Wurzburg, Dept Physiol 2, Rontgenring 9, D-97070 Wurzburg, Germany.	stefan.gruender@uni-wuerzburg.de	chen, xuanmao/I-7576-2013; Gründer, Stefan/I-2495-2019; Kadurin, Ivan/F-7759-2012	Gründer, Stefan/0000-0002-7635-9883; Kadurin, Ivan/0000-0002-7720-367X; Chen, Xuanmao/0000-0002-0057-8510				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Bruns JB, 2007, J BIOL CHEM, V282, P6153, DOI 10.1074/jbc.M610636200; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen XM, 2006, J GEN PHYSIOL, V127, P267, DOI 10.1085/jgp.200509409; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chen XM, 2007, J PHYSIOL-LONDON, V579, P657, DOI 10.1113/jphysiol.2006.120733; Chen XM, 2006, NEUROPHARMACOLOGY, V50, P964, DOI 10.1016/j.neuropharm.2006.01.007; Chu XP, 2004, J NEUROSCI, V24, P8678, DOI 10.1523/JNEUROSCI.2844-04.2004; Chu XP, 2003, J PHYSIOL-LONDON, V550, P385, DOI 10.1113/jphysiol.2003.043091; Coric T, 2005, J PHYSIOL-LONDON, V568, P725, DOI 10.1113/jphysiol.2005.087734; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Cottrell GA, 2001, FEBS LETT, V489, P71, DOI 10.1016/S0014-5793(01)02081-6; Grunder S, 2000, NEUROREPORT, V11, P1607; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Meyer A, 2005, BIOESSAYS, V27, P937, DOI 10.1002/bies.20293; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Salinas M, 2006, J PHYSIOL-LONDON, V570, P339, DOI 10.1113/jphysiol.2005.095810; Saugstad JA, 2004, J BIOL CHEM, V279, P55514, DOI 10.1074/jbc.M411849200; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2007, PAIN, V129, P102, DOI 10.1016/j.pain.2006.09.038; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Vukicevic M, 2004, AM J PHYSIOL-CELL PH, V287, pC682, DOI 10.1152/ajpcell.00127.2004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yagi J, 2006, CIRC RES, V99, P501, DOI 10.1161/01.RES.0000238388.79295.4c	40	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30406	30413		10.1074/jbc.M702229200	http://dx.doi.org/10.1074/jbc.M702229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17686779	hybrid, Green Published			2022-12-25	WOS:000250136300008
J	Feng, D; Zhao, X; Soromani, C; Toikkanen, J; Romisch, K; Vembar, SS; Brodsky, JL; Keranen, S; Jantti, J				Feng, Dejiang; Zhao, Xueqiang; Soromani, Christina; Toikkanen, Jaana; Romisch, Karin; Vembar, Shruthi S.; Brodsky, Jeffrey L.; Keranen, Sirkka; Jantti, Jussi			The transmembrane domain is sufficient for sbh1p function, its association with the sec61 complex, and interaction with rtn1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION COMPLEX; MISFOLDED SECRETORY PROTEIN; SIGNAL RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; HETEROLOGOUS PROTEINS; CONDUCTING CHANNEL; ER MEMBRANE; TRANSPORT	The Sec61 protein translocation complex in the endoplasmic reticulum ( ER) membrane is composed of three subunits. The alpha-subunit, called Sec61p in yeast, is a multispanning membrane protein that forms the protein conducting channel. The functions of the smaller, carboxyl-terminally tail-anchored beta subunit Sbh1p, its close homologue Sbh2p, and the gamma subunit Sss1p are not well understood. Here we show that co-translational protein translocation into the ER is reduced in sbh1 Delta sbh2 Delta cells, whereas there is a limited reduction of post-translational tranlocation and no effect on export of a mutant form of alpha-factor precursor for ER-associated degradation in the cytosol. The translocation defect and the temperature-sensitive growth phenotype of sbh1 Delta sbh2 Delta cells were rescued by expression of the transmembrane domain of Sbh1p alone, and the Sbh1p transmembrane domain was sufficient for coimmunoprecipitation with Sec61p and Sss1p. Furthermore, we show that Sbh1p co-precipitates with the ER transmembrane protein Rtn1p. Sbh1p-Rtn1p complexes do not appear to contain Sss1p and Sec61p. Our results define the transmembrane domain as the minimal functional domain of the Sec61 beta homologue Sbh1p in ER translocation, identify a novel interaction partner for Shb1p, and imply that Sbh1p has additional functions that are not directly linked protein translocation in association with the Sec61 complex.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; VTT Biotechnol, FI-02044 Espoo, Finland; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Helsinki; VTT Technical Research Center Finland; University of Cambridge; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jantti, J (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.	jussi.jantti@helsinki.fi	Römisch, Karin/AAO-1210-2021; Vembar, Shruthi Sridhar/AAE-2479-2019	Römisch, Karin/0000-0003-0415-6558; ZHAO, XUEQIANG/0000-0002-4956-6932	NIGMS NIH HHS [GM75061, R01 GM075061-02, R01 GM075061-01A1, R01 GM075061] Funding Source: Medline; Wellcome Trust [042216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075061] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boisrame A, 2002, J CELL SCI, V115, P4947, DOI 10.1242/jcs.00187; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Davydenko SG, 2005, YEAST, V22, P993, DOI 10.1002/yea.1286; De Craene JO, 2006, MOL BIOL CELL, V17, P3009, DOI 10.1091/mbc.e06-01-0080; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Guo W, 2004, TRENDS CELL BIOL, V14, P61, DOI 10.1016/j.tcb.2003.12.008; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Helmers J, 2003, J BIOL CHEM, V278, P23686, DOI 10.1074/jbc.C300180200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; JANTTI J, 1994, J CELL SCI, V107, P3623; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; Kalies KU, 2005, EMBO J, V24, P2284, DOI 10.1038/sj.emboj.7600731; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Rapoport TA, 2004, TRENDS CELL BIOL, V14, P568, DOI 10.1016/j.tcb.2004.09.002; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; RUOHONEN L, 1995, J BIOTECHNOL, V39, P193, DOI 10.1016/0168-1656(95)00024-K; Ruohonen L, 1997, YEAST, V13, P337, DOI 10.1002/(SICI)1097-0061(19970330)13:4<337::AID-YEA98>3.3.CO;2-B; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Tagwerker C, 2006, YEAST, V23, P623, DOI 10.1002/yea.1380; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; Toikkanen JH, 2003, J BIOL CHEM, V278, P20946, DOI 10.1074/jbc.M213111200; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wiederkehr A, 2003, MOL BIOL CELL, V14, P4770, DOI 10.1091/mbc.E03-04-0229; Wiederkehr A, 2004, J CELL BIOL, V167, P875, DOI 10.1083/jcb.200408001; Wilkinson BM, 2001, DEV CELL, V1, P401, DOI 10.1016/S1534-5807(01)00043-0; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	46	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30618	30628		10.1074/jbc.M701840200	http://dx.doi.org/10.1074/jbc.M701840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699516	hybrid, Green Accepted			2022-12-25	WOS:000250136300030
J	Mishra, R; Barthwal, MK; Sondarva, G; Rana, B; Wong, L; Chatterjee, M; Woodgett, JR; Rana, A				Mishra, Rajakishore; Barthwal, Manoj K.; Sondarva, Gautam; Rana, Basabi; Wong, Lucas; Chatterjee, Malay; Woodgett, James R.; Rana, Ajay			Glycogen synthase kinase-3 beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; N-TERMINAL KINASE; MIXED-LINEAGE KINASES; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; ALZHEIMER-DISEASE; CEP-1347 KT7515; GROWTH-FACTOR; BETA-CATENIN; IN-VIVO	Mixed lineage kinase 3 (MLK3) is a mitogen-activated protein kinase kinase kinase member that activates the c-Jun N-terminal kinase (JNK) pathway. Aberrant activation of MLK3 has been implicated in neurodegenerative diseases. Similarly, glycogen synthase kinase (GSK)-3 beta has also been shown to activate JNK and contributetoneuronalapoptosis. Here, we show a functional interaction between MLK3 and GSK-3 beta during nerve growth factor (NGF) withdrawal-induced cell death in PC-12 cells. The protein kinase activities of GSK-3 beta, MLK3, and JNK were increased upon NGF withdrawal, which paralleled increased cell death in NGF-deprived PC-12 cells. NGF withdrawal-induced cell death and MLK3 activation were blocked by a GSK-3 beta-selective inhibitor, kenpaullone. However, the MLK family inhibitor, CEP-11004, although preventing PC-12 cell death, failed to inhibit GSK-3 beta activation, indicating that induction of GSK-3 beta lies upstream of MLK3. In GSK-3 beta-deficient murine embryonic fibroblasts, ultraviolet light was unable to activate MLK3 kinase activity, a defect that was restored upon ectopic expression of GSK-3 beta. The activation of MLK3 by GSK-3 beta occurred via phosphorylation of MLK3 on two amino acid residues, Ser(789) and Ser(793), that are located within the C-terminal regulatory domain of MLK3. Furthermore, the cell death induced by GSK-3 beta was mediated by MLK3 in a manner dependent on its phosphorylation of the specific residues within the C-terminal domain by GSK-3 beta. Taken together, our data provide a direct link between GSK-3 beta and MLK3 activation in a neuronal cell death pathway and identify MLK3 as a direct downstream target of GSK-3 beta. Inhibition of GSK-3 is thus a potential therapeutic strategy for neurodegenerative diseases caused by trophic factor deprivation.	Texas A&M Univ Syst HSC, Dept Internal Med, Cardiovasc & Canc Res Inst, Coll Med, Temple, TX 76504 USA; Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA; Texas A&M Univ Syst HSC, Dept Internal Med, Coll Med, Scott & White Clin, Temple, TX 76504 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Jadavpur Univ, Div Biochem, Dept Pharmaceut Technol, Kolkata 700032, W Bengal, India	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Jadavpur University	Rana, A (corresponding author), Loyola Univ, Dept Pharmacol, Med Ctr, Bldg 102,2160 S 1st Ave, Maywood, IL 60153 USA.	arana@lumc.edu	Mishra, Rajakishore/ABC-3550-2020; Rana, Ajay/ABE-3739-2020; Woodgett, Jim/F-1087-2010	Rana, Ajay/0000-0003-0951-2566; Woodgett, Jim/0000-0003-3731-5797; Mishra, Rajakishore/0000-0002-1735-2411	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055835] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [12043] Funding Source: Medline; NIGMS NIH HHS [R01 GM055835, GM55835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bhat RV, 2002, J ALZHEIMERS DIS, V4, P291, DOI 10.3233/JAD-2002-4404; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; BOZYCZKO JJ, 2001, EMBO J, V77, P849; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hetman M, 2000, J NEUROSCI, V20, P2567; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Imahori K, 1997, J BIOCHEM, V121, P179; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kaneko M, 1997, J MED CHEM, V40, P1863, DOI 10.1021/jm970031d; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Liu SY, 2004, J BIOL CHEM, V279, P51075, DOI 10.1074/jbc.M408607200; Lorigados L, 1998, REV NEUROLOGIA, V26, P744, DOI 10.33588/rn.26153.98023; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Takashima A, 1996, NEUROSCI LETT, V203, P33, DOI 10.1016/0304-3940(95)12257-5; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Wang LH, 2005, J PHARMACOL EXP THER, V312, P1007, DOI 10.1124/jpet.104.077800; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; WOODGETT JR, 2001, SCI STKE, pRE112; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; 2004, NEUROLOGY, V62, P330	56	57	62	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30393	30405		10.1074/jbc.M705895200	http://dx.doi.org/10.1074/jbc.M705895200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17711861	Green Accepted, hybrid			2022-12-25	WOS:000250136300007
J	Gould, SB; Fan, E; Hempel, F; Maier, UG; Kloesgen, RB				Gould, Sven B.; Fan, Enguo; Hempel, Franziska; Maier, Uwe-G.; Kloesgen, Ralf Bernd			Translocation of a phycoerythrin alpha subunit across five biological membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; CRYPTOPHYTE ALGA; COMPLEX; CHLOROPLASTS; PATHWAY; IMPORT; ULTRASTRUCTURE; REQUIREMENTS; LOCALIZATION; MECHANISM	Cryptophytes, unicellular algae, evolved by secondary endosymbiosis and contain plastids surrounded by four membranes. In contrast to cyanobacteria and red algae, their phycobiliproteins do not assemble into phycobilisomes and are located within the thylakoid lumen instead of the stroma. We identified two gene families encoding phycoerythrin alpha and light-harvesting complex proteins from an expressed sequence tag library of the cryptophyte Guillardia theta. The proteins bear a bipartite topogenic signal responsible for the transport of nuclear encoded proteins via the ER into the plastid. Analysis of the phycoerythrin alpha sequences revealed that more than half of them carry an additional, third topogenic signal comprising a twin arginine motif, which is indicative of Tat ( twin arginine transport)specific targeting signals. We performed import studies with several derivatives of one member using a diatom transformation system, as well as intact chloroplasts and thylakoid vesicles isolated from pea. We demonstrated the different targeting properties of each individual part of the tripartite leader and show that phycoerythrin alpha is transported across the thylakoid membrane into the thylakoid lumen and protease-protected. Furthermore, we showed that thylakoid transport of phycoerythrin alpha takes place by the Tat pathway even if the 36 amino acid long bipartite topogenic signal precedes the actual twin arginine signal. This is the first experimental evidence of a protein being targeted across five biological membranes.	Univ Marburg, D-35032 Marburg, Germany; Univ Halle Wittenberg, Inst Biol, D-06120 Halle, Germany	Philipps University Marburg; Martin Luther University Halle Wittenberg	Gould, SB (corresponding author), Univ Melbourne, Sch Bot, Melbourne, Vic 3010, Australia.	sbgould@gmail.com	Gould, Sven B/B-8192-2011	Gould, Sven/0000-0002-2038-8474				ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; Apt KE, 1996, MOL GEN GENET, V252, P572, DOI 10.1007/s004380050264; Berghofer J, 1999, FEBS LETT, V460, P328, DOI 10.1016/S0014-5793(99)01365-4; Bhattacharya D, 2004, BIOESSAYS, V26, P50, DOI 10.1002/bies.10376; Broughton MJ, 2006, GENE, V369, P72, DOI 10.1016/j.gene.2005.10.026; Cavalier-Smith T, 1999, J EUKARYOT MICROBIOL, V46, P347, DOI 10.1111/j.1550-7408.1999.tb04614.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Dabney-Smith C, 2006, J BIOL CHEM, V281, P5476, DOI 10.1074/jbc.M512453200; DeRocher A, 2000, J CELL SCI, V113, P3969; DODGE JD, 1969, ARCH MIKROBIOL, V69, P266, DOI 10.1007/BF00408978; Douglas SE, 1999, J MOL EVOL, V48, P236, DOI 10.1007/PL00006462; DWARTE D, 1983, PROTOPLASMA, V117, P130, DOI 10.1007/BF01288351; Fincher V, 1998, FEBS LETT, V423, P66, DOI 10.1016/S0014-5793(98)00066-0; Frielingsdorf S, 2007, J BIOL CHEM, V282, P24455, DOI 10.1074/jbc.M702630200; GANTT E, 1971, J CELL BIOL, V48, P280, DOI 10.1083/jcb.48.2.280; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gould SB, 2006, MOL BIOL EVOL, V23, P2413, DOI 10.1093/molbev/msl113; Gould SB, 2006, J MOL EVOL, V62, P674, DOI 10.1007/s00239-005-0099-y; Hou B, 2006, J MOL BIOL, V355, P957, DOI 10.1016/j.jmb.2005.11.029; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; KHORTH E, 2005, ENDOCYTOBIOS CELL RE, V15, P549; Kilian O, 2005, PLANT J, V41, P175, DOI 10.1111/j.1365-313X.2004.02294.x; LUDWIG M, 1989, J CELL BIOL, V108, P875, DOI 10.1083/jcb.108.3.875; MacColl R., 1987, PHYCOBILIPROTEINS; Marques JP, 2004, J EXP BOT, V55, P1697, DOI 10.1093/jxb/erh191; Marques JP, 2003, MOL GENET GENOMICS, V269, P381, DOI 10.1007/s00438-003-0846-y; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Molik S, 2001, J BIOL CHEM, V276, P42761, DOI 10.1074/jbc.M106690200; MORSCHEL E, 1977, ARCH MICROBIOL, V113, P83, DOI 10.1007/BF00428585; MOULD RM, 1991, J BIOL CHEM, V266, P17286; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Nassoury N, 2003, J CELL SCI, V116, P2867, DOI 10.1242/jcs.00517; REITH M, 1990, PLANT MOL BIOL, V15, P585, DOI 10.1007/BF00017833; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sommer MS, 2007, MOL BIOL EVOL, V24, P918, DOI 10.1093/molbev/msm008; SPEARBERNSTEIN L, 1985, PROTOPLASMA, V129, P1, DOI 10.1007/BF01282300; Wastl J, 2000, J BIOL CHEM, V275, P23194, DOI 10.1074/jbc.M003125200; WEHRMEYER W, 1970, ARCH MIKROBIOL, V71, P367, DOI 10.1007/BF00417133	40	21	21	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30295	30302		10.1074/jbc.M701869200	http://dx.doi.org/10.1074/jbc.M701869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702756	hybrid			2022-12-25	WOS:000249981200060
J	Greer, EL; Oskoui, PR; Banko, MR; Maniar, JM; Gygi, MP; Gygi, SP; Brunet, A				Greer, Eric L.; Oskoui, Philip R.; Banko, Max R.; Maniar, Jay M.; Gygi, Melanie P.; Gygi, Steven P.; Brunet, Anne			The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; OXIDATIVE-STRESS; LIFE-SPAN; CAENORHABDITIS-ELEGANS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; FACTOR FKHR; INSULIN SENSITIVITY; CALORIC RESTRICTION; NUCLEAR EXCLUSION	The maintenance of homeostasis throughout an organism's life span requires constant adaptation to changes in energy levels. The AMP-activated protein kinase ( AMPK) plays a critical role in the cellular responses to low energy levels by switching off energy-consuming pathways and switching on energy-producing pathways. However, the transcriptional mechanisms by which AMPK acts to adjust cellular energy levels are not entirely characterized. Here, we find that AMPK directly regulates mammalian FOXO3, a member of the FOXO family of Forkhead transcription factors known to promote resistance to oxidative stress, tumor suppression, and longevity. We show that AMPK phosphorylates human FOXO3 at six previously unidentified regulatory sites. Phosphorylation by AMPK leads to the activation of FOXO3 transcriptional activity without affecting FOXO3 subcellular localization. Using a genome-wide microarray analysis, we identify a set of target genes that are regulated by FOXO3 when phosphorylated at these six regulatory sites in mammalian cells. The regulation of FOXO3 by AMPK may play a crucial role in fine tuning gene expression programs that control energy balance and stress resistance in cells throughout life.	Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Stanford University; Stanford University; Harvard University; Harvard Medical School	Brunet, A (corresponding author), 300 Pasteur Dr,Alway M336, Stanford, CA 94305 USA.	anne.brunet@stanford.edu		Greer, Eric/0000-0002-7501-7371	NCI NIH HHS [CA 09302, T32 CA009302] Funding Source: Medline; NIA NIH HHS [AG026648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Barthel A, 2002, ENDOCRINOLOGY, V143, P3183, DOI 10.1210/endo.143.8.8792; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Feng WK, 2006, J BIOL CHEM, V281, P681, DOI 10.1074/jbc.M506956200; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GREER EL, 2007, IN PRESS CURR BIOL; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murakami S, 1996, GENETICS, V143, P1207; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakashima K, 2007, BIOSCI BIOTECH BIOCH, V71, P1650, DOI 10.1271/bbb.70057; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pappa A, 2005, J BIOL CHEM, V280, P27998, DOI 10.1074/jbc.M503698200; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Solaz-Fuster MC, 2006, CELL SIGNAL, V18, P1702, DOI 10.1016/j.cellsig.2006.01.021; Sweet K, 2005, JAMA-J AM MED ASSOC, V294, P2465, DOI 10.1001/jama.294.19.2465; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WEEKES J, 1993, FEBS LETT, V334, P335, DOI 10.1016/0014-5793(93)80706-Z; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Ye B, 2001, P NATL ACAD SCI USA, V98, P2317, DOI 10.1073/pnas.041619198; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	84	595	617	2	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30107	30119		10.1074/jbc.M705325200	http://dx.doi.org/10.1074/jbc.M705325200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17711846	hybrid			2022-12-25	WOS:000249981200041
J	Langlois, S; Maher, AC; Manias, JL; Shao, Q; Kidder, GM; Laird, DW				Langlois, Stephanie; Maher, Amy C.; Manias, Janet L.; Shao, Qing; Kidder, Gerald M.; Laird, Dale W.			Connexin levels regulate keratinocyte differentiation in the epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTO-DIGITAL DYSPLASIA; JUNCTIONAL INTERCELLULAR COMMUNICATION; NEONATAL MICE LACKING; OCULODENTODIGITAL DYSPLASIA; GAP-JUNCTIONS; SKIN DIFFERENTIATION; RETROVIRAL DELIVERY; RAT KERATINOCYTES; GENE DELIVERY; MOUSE SKIN	To understand the role of connexin43 (Cx43) in epidermal differentiation, we reduced Cx43 levels by RNA-mediated interference knockdown and impaired its functional status by over-expressing loss-of-function Cx43 mutants associated with the human disease oculodentodigital dysplasia ( ODDD) in rat epidermal keratinocytes. When Cx43 expression was knocked down by 50-75%, there was a coordinate 55-65% reduction in Cx26 level, gap junction-based dye coupling was reduced by 60%, and transepithelial resistance decreased. Importantly, the overall growth and differentiation of Cx43 knockdown organotypic epidermis was severely impaired as revealed by alterations in the levels of the differentiation markers loricrin and involucrin and by reductions in vital and cornified layer thicknesses. Conversely, although the expression of Cx43 mutants reduced the coupling status of rat epidermal keratinocytes by similar to 80% without altering the levels of endogenous Cx43 or Cx26, their ability to differentiate was not altered. In addition, we used a mouse model of ODDD and found that newborn mice harboring the loss-of-function Cx43(G60S) mutant had slightly reduced Cx43 levels, whereas Cx26 levels, epidermis differentiation, and barrier function remained unaltered. This properly differentiated epidermis was maintained even when Cx43 and Cx26 levels decreased by more than 70% in 3-week-old mutant mice. Our studies indicate that Cx43 and Cx26 collectively co-regulate epidermal differentiation from basal keratinocytes but play a more minimal role in the maintenance of established epidermis. Altogether, these studies provide an explanation as to why the vast majority of ODDD patients, where Cx43 function is highly compromised, do not suffer from skin disease.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg 00077, London, ON N6A 5C1, Canada.	dale.laird@schulich.uwo.ca	Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015	Laird, Dale W/0000-0002-4568-3285; 				Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; BERNARD BA, 1988, J INVEST DERMATOL, V90, P801, DOI 10.1111/1523-1747.ep12462014; Brandner JM, 2004, J INVEST DERMATOL, V122, P1310, DOI 10.1111/j.0022-202X.2004.22529.x; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; BUTTERWECK A, 1994, EUR J CELL BIOL, V65, P152; Choudhry R, 1997, DEV DYNAM, V210, P417, DOI 10.1002/(SICI)1097-0177(199712)210:4<417::AID-AJA6>3.3.CO;2-0; Common JEA, 2002, BIOCHEM BIOPH RES CO, V298, P651, DOI 10.1016/S0006-291X(02)02517-2; Coutinho P, 2003, CELL BIOL INT, V27, P525, DOI 10.1016/S1065-6995(03)00077-5; Di WL, 2005, J CELL SCI, V118, P1505, DOI 10.1242/jcs.01733; Di WL, 2001, CELL COMMUN ADHES, V8, P415, DOI 10.3109/15419060109080763; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Galipeau J, 1999, CANCER RES, V59, P2384; Gemel J, 2004, J CELL SCI, V117, P2469, DOI 10.1242/jcs.01084; Giepmans BNG, 2006, ADV CARDIOL, V42, P41, DOI 10.1159/000092561; Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; Gong XQ, 2007, J BIOL CHEM, V282, P19190, DOI 10.1074/jbc.M609653200; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hirao T, 2001, EXP DERMATOL, V10, P35, DOI 10.1034/j.1600-0625.2001.100105.x; Kelly SC, 2006, EUR J DERMATOL, V16, P241; Kretz M, 2004, EUR J CELL BIOL, V83, P647, DOI 10.1078/0171-9335-00422; Kretz M, 2003, J CELL SCI, V116, P3443, DOI 10.1242/jcs.00638; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Maass K, 2004, MOL BIOL CELL, V15, P4597, DOI 10.1091/mbc.E04-04-0324; Maestrini E, 1996, NAT GENET, V13, P70, DOI 10.1038/ng0596-70; Maher AC, 2005, CELL COMMUN ADHES, V12, P219, DOI 10.1080/15419060500511818; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Plum A, 2001, DEV BIOL, V231, P334, DOI 10.1006/dbio.2000.0148; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Qiu C, 2003, CURR BIOL, V13, P1697, DOI 10.1016/j.cub.2003.09.007; Rabionet R, 2002, TRENDS MOL MED, V8, P205, DOI 10.1016/S1471-4914(02)02327-4; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Richard G, 2005, CLIN DERMATOL, V23, P23, DOI 10.1016/j.clindermatol.2004.09.010; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Richardson RR, 2004, J MED GENET, V41, P60, DOI 10.1136/jmg.2003.012005; RISEK B, 1992, DEVELOPMENT, V116, P639; Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200; Rouan F, 2001, J CELL SCI, V114, P2105; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; Suhonen TM, 2003, EUR J PHARM SCI, V20, P107, DOI 10.1016/S0928-0987(03)00176-3; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Troy TC, 1999, J CELL PHYSIOL, V180, P409, DOI 10.1002/(SICI)1097-4652(199909)180:3<409::AID-JCP12>3.0.CO;2-V; van Steensel MAM, 2005, AM J MED GENET A, V132A, P171, DOI 10.1002/ajmg.a.30412; Vreeburg M, 2007, AM J MED GENET A, V143A, P360, DOI 10.1002/ajmg.a.31558; Wiszniewski L, 2001, CELL COMMUN ADHES, V8, P409, DOI 10.3109/15419060109080762	49	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30171	30180		10.1074/jbc.M703623200	http://dx.doi.org/10.1074/jbc.M703623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693411	hybrid			2022-12-25	WOS:000249981200047
J	Moskvin, OV; Kaplan, S; Gilles-Gonzalez, MA; Gomelsky, M				Moskvin, Oleg V.; Kaplan, Samuel; Gilles-Gonzalez, Marie-Alda; Gomelsky, Mark			Novel heme-based oxygen sensor with a revealing evolutionary history	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; C-TYPE HEME; BLUE-LIGHT; PHOTOSYSTEM FORMATION; CRYSTAL-STRUCTURES; GAF DOMAIN; APPA; PROTEIN; BINDING; PHOTORECEPTOR	To monitor fluctuations in oxygen concentration, cells use sensory proteins often containing heme cofactors. Here, we identify a new class of heme- binding oxygen sensors, reveal their unusual phylogenetic origin, and propose a sensing mode of a member of this class. We show that heme is bound noncovalently to the central region of AppA, an oxygen and light sensor from Rhodobacter sphaeroides. The addition of oxygen to ferrous AppA discoordinated the heme, and subsequent oxygen removal fully restored the heme coordination. In vitro, the extent of heme discoordination increased gradually with the rise in oxygen levels over a broad concentration range. This response correlated well with the gradual decrease in transcription of photosynthesis genes regulated by AppA and its partner repressor PpsR. We conclude that the AppA- PpsR regulatory system functions as an oxygen- dependent transcriptional rheostat. We identified a new domain embedded in the central region of AppA and designated it SCHIC for sensor containing heme instead of cobalamin. A phylogenetic analysis revealed that SCHIC domain proteins form a distinct cluster within a superfamily that includes vitamin B-12- binding proteins and other proteins that may bind other kinds of tetrapyrroles.	Univ Wyoming, Dept Biol Mol, Laramie, WY 82071 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Wyoming; University of Texas System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomelsky, M (corresponding author), Univ Wyoming, Dept Biol Mol, Dept 3944,1000 E Univ Ave, Laramie, WY 82071 USA.	gomelsky@uwyo.edu	gomelsky, mark/F-6209-2010; Moskvin, Oleg/C-5916-2015	Moskvin, Oleg/0000-0003-1499-8900; Gomelsky, Mark/0000-0003-4077-3932	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015640] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15640] Funding Source: Medline; NIGMS NIH HHS [GM15590] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x; Anderson S, 2005, BIOCHEMISTRY-US, V44, P7998, DOI 10.1021/bi0502691; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Braatsch S, 2004, J BACTERIOL, V186, P7726, DOI 10.1128/JB.186.22.7726-7735.2004; Braatsch S, 2002, MOL MICROBIOL, V45, P827, DOI 10.1046/j.1365-2958.2002.03058.x; Cary SPL, 2006, TRENDS BIOCHEM SCI, V31, P231, DOI 10.1016/j.tibs.2006.02.003; CHANG AL, 2001, BIOCHEMISTRY-US, V27, P3410; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; FU RD, 1994, J BACTERIOL, V176, P344, DOI 10.1128/JB.176.2.344-350.1994; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gomelsky L, 2003, MICROBIOL-SGM, V149, P377, DOI 10.1099/mic.0.25972-0; GOMELSKY M, 1995, J BACTERIOL, V177, P4609, DOI 10.1128/jb.177.16.4609-4618.1995; Gomelsky M, 1998, J BIOL CHEM, V273, P35319, DOI 10.1074/jbc.273.52.35319; Gomelsky M, 1997, J BACTERIOL, V179, P128, DOI 10.1128/jb.179.1.128-134.1997; Gomelsky M, 2002, TRENDS BIOCHEM SCI, V27, P497, DOI 10.1016/S0968-0004(02)02181-3; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5; Jung A, 2006, J MOL BIOL, V362, P717, DOI 10.1016/j.jmb.2006.07.024; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Luschinsky Drennan C., 1994, Science, V266, P1669, DOI 10.1126/science.7992050; Masuda S, 2002, CELL, V110, P613, DOI 10.1016/S0092-8674(02)00876-0; Moskvin OV, 2005, J BACTERIOL, V187, P2148, DOI 10.1128/JB.187.6.2148-2156.2005; Pappas CT, 2004, J BACTERIOL, V186, P4748, DOI 10.1128/JB.186.14.4748-4758.2004; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RZHETSKY A, 1992, J MOL EVOL, V35, P367, DOI 10.1007/BF00161174; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sardiwal S, 2005, J MOL BIOL, V353, P929, DOI 10.1016/j.jmb.2005.09.011; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V229, P126, DOI 10.1016/0003-9861(84)90137-1; Yoshioka S, 2005, BIOCHEMISTRY-US, V44, P15406, DOI 10.1021/bi0513352; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	43	53	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28740	28748		10.1074/jbc.M703261200	http://dx.doi.org/10.1074/jbc.M703261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17660296	hybrid			2022-12-25	WOS:000249642100048
J	Liao, X; Wang, W; Chen, S; Wu, Q				Liao, Xudong; Wang, Wei; Chen, Shenghan; Wu, Qingyu			Role of glycosylation in corin zymogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROATRIAL NATRIURETIC PEPTIDE; SERINE-PROTEASE CORIN; INHIBITION; MATRIPTASE; DOMAIN; GENE; ENTEROPEPTIDASE; EXPRESSION; SECRETION; MECHANISM	The cardiac serine protease corin is the pro-atrial natriuretic peptide convertase. Corin is made as a zymogen, which is activated by proteolytic cleavage. Previous studies showed that recombinant human corin expressed in HEK 293 cells was biologically active, but activated corin fragments were not detectashowed that recombinant rat corin was activated in HEK 293 cells, murine HL-1 cardiomyocytes, and rat neonatal cardiomyocytes. In these cells, activated corin represented a small fraction of the total corin molecules. The activation of recombinant rat corin was inhibited by small molecule trypsin inhibitors but not inhibitors for matrix metalloproteinases or cysteine proteases, suggesting that a trypsin-like protease activated corin in these cells. Glycosidase digestion showed that rat and human corin proteins contained substantial N-glycans but little O-glycans. Treatment of HEK 293 cells expressing rat corin with tunicamycin prevented corin activation and inhibited its pro-atrial natriuretic peptide processing activity. Similar effects of tunicamycin on endogenous corin activity were found in HL-1 cells. Mutations altering the two N-glycosylation sites in the protease domain of rat corin prevented its activation in HEK 293 and HL-1 cells. Our results indicate that N-linked oligosaccharides play an important role in corin activation.	Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin, Dept Nephrol, Cleveland, OH 44195 USA; Cleveland Clin, Dept Hypertens, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Wu, Q (corresponding author), Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA.	wuq@ccf.org		Wu, Qingyu/0000-0003-0561-9315				BURNETT JC, 1984, AM J PHYSIOL, V247, pF863, DOI 10.1152/ajprenal.1984.247.5.F863; Burnett JC, 2007, HYPERTENSION, V49, P765, DOI 10.1161/01.HYP.0000258567.67263.96; Calderone A, 2006, J CELL PHYSIOL, V207, P165, DOI 10.1002/jcp.20548; Chan JCY, 2005, P NATL ACAD SCI USA, V102, P785, DOI 10.1073/pnas.0407234102; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Dries DL, 2005, CIRCULATION, V112, P2403, DOI 10.1161/CIRCULATIONAHA.105.568881; GRANGER JP, 1989, AM J PHYSIOL, V257, pH502, DOI 10.1152/ajpheart.1989.257.2.H502; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jiang W, 2005, EUR J PHARMACOL, V507, P153, DOI 10.1016/j.ejphar.2004.11.023; Knappe S, 2003, J BIOL CHEM, V278, P52363, DOI 10.1074/jbc.M309991200; KOHNO M, 1991, J CLIN INVEST, V87, P1999, DOI 10.1172/JCI115228; Langenickel TH, 2004, AM J PHYSIOL-HEART C, V287, pH1516, DOI 10.1152/ajpheart.00947.2003; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liao XD, 2006, FASEB J, V20, P1883, DOI 10.1096/fj.06-5717fje; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; McGrath MF, 2005, TRENDS ENDOCRIN MET, V16, P469, DOI 10.1016/j.tem.2005.10.007; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014; Potter LR, 2005, CELL METAB, V1, P88, DOI 10.1016/j.cmet.2005.01.008; Rame JE, 2007, HYPERTENSION, V49, P857, DOI 10.1161/01.HYP.0000258566.95867.9e; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; Tran KL, 2004, AM J PHYSIOL-HEART C, V287, pH1625, DOI 10.1152/ajpheart.00298.2004; Wu CL, 2003, J BIOL CHEM, V278, P25847, DOI 10.1074/jbc.M301223200; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; Wu QY, 2007, FRONT BIOSCI-LANDMRK, V12, P4179, DOI 10.2741/2379; Wu QY, 2003, CURR TOP DEV BIOL, V54, P167, DOI 10.1016/S0070-2153(03)54009-1; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; Zheng XL, 2002, J BIOL CHEM, V277, P6858, DOI 10.1074/jbc.M109857200	39	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27728	27735		10.1074/jbc.M703687200	http://dx.doi.org/10.1074/jbc.M703687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660514	hybrid			2022-12-25	WOS:000249455600021
J	Nikitina, T; Ghosh, RP; Horowitz-Scherer, RA; Hansen, JC; Grigoryev, SA; Woodcock, CL				Nikitina, Tatiana; Ghosh, Rajarshi P.; Horowitz-Scherer, Rachel A.; Hansen, Jeffrey C.; Grigoryev, Sergei A.; Woodcock, Christopher L.			MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING DOMAIN; NUCLEOSOME CORE PARTICLE; 4-WAY JUNCTION DNA; METHYL-CPG; LINKER HISTONE; MICROCOCCAL NUCLEASE; CRYSTAL-STRUCTURE; PROTEIN MECP2; H1; RESOLUTION	hMeCP2 (human methylated DNA-binding protein 2), mutations of which cause most cases of Rett syndrome (RTT), is involved in the transmission of repressive epigenetic signals encoded by DNA methylation. The present work focuses on the modifications of chromatin architecture induced by MeCP2 and the effects of RTT-causing mutants. hMeCP2 binds to nuclel somes close to the linker DNA entry-exit site and protects similar to 11 bp of linker DNA from micrococcal nuclease. MeCP2 mutants differ in this property; the R106W mutant gives very little extra protection beyond the similar to 146-bp nucleosome core, whereas the large C-terminal truncation R294X reveals wild type behavior. Gel mobility assays show that linker DNA is essential for proper MeCP2 binding to nucleosomes, and electron microscopy visualization shows that the protein induces distinct conformational changes in the linker DNA. When bound to nucleosomes, MeCP2 is in close proximity to histone H3, which exits the nucleosome core close to the proposed MeCP2-binding site. These findings firmly establish nuclecisomal linker DNA as a crucial binding partner of MeCP2 and show that different RTT-causing mutations of MeCP2 are correspondingly defective in different aspects of the interactions that alter chromatin architecture.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Massachusetts, Program Mol & Cell Biol, Amherst, MA 01003 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Colorado State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Woodcock, CL (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	chris@bio.umass.edu		ghosh, rajarshi/0000-0002-0020-6194; ghosh, rajarshi/0000-0003-2348-6333	NIGMS NIH HHS [GM070897, GM45916, GM66834] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066834, R01GM070897, R01GM045916, R29GM045916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams VH, 2007, J BIOL CHEM, V282, P15057, DOI 10.1074/jbc.M700855200; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bharath MMS, 2003, NUCLEIC ACIDS RES, V31, P4264, DOI 10.1093/nar/gkg481; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; Chadwick LH, 2007, CURR OPIN GENET DEV, V17, P121, DOI 10.1016/j.gde.2007.02.003; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; DINGWALL C, 1981, NUCLEIC ACIDS RES, V9, P2659, DOI 10.1093/nar/9.12.2659; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Galvao TC, 2005, NUCLEIC ACIDS RES, V33, P6603, DOI 10.1093/nar/gki971; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P2643, DOI 10.1093/nar/9.12.2643; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; KOCSIS E, 1991, J STRUCT BIOL, V107, P6, DOI 10.1016/1047-8477(91)90025-R; LaSalle JM, 2004, CURR TOP DEV BIOL, V59, P61, DOI 10.1016/S0070-2153(04)59003-8; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luikenhuis S, 2004, P NATL ACAD SCI USA, V101, P6033, DOI 10.1073/pnas.0401626101; McBryant SJ, 2006, CHROMOSOME RES, V14, P39, DOI 10.1007/s10577-006-1025-x; McGowan S, 2006, EMBO J, V25, P3144, DOI 10.1038/sj.emboj.7601201; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Moretti P, 2006, CURR OPIN GENET DEV, V16, P276, DOI 10.1016/j.gde.2006.04.009; Nikitina T, 2007, MOL CELL BIOL, V27, P864, DOI 10.1128/MCB.01593-06; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; Thastrom A, 2004, J MOL BIOL, V338, P695, DOI 10.1016/j.jmb.2004.03.032; Thatcher KN, 2006, EPIGENETICS-US, V1, P24; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Woodcock CL, 1998, METHOD CELL BIOL, V53, P167; Woodward M, 2006, SOFTW TEST VERIF REL, V16, P1, DOI 10.1002/stvr.342; Wu CY, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh121; Young TA, 2007, J MOL BIOL, V368, P1438, DOI 10.1016/j.jmb.2007.02.077	44	88	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28237	28245		10.1074/jbc.M704304200	http://dx.doi.org/10.1074/jbc.M704304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660293	hybrid			2022-12-25	WOS:000249455600073
J	Jiang, SX; Fu, YG; Williams, J; Wood, J; Pandarinathan, L; Avraham, S; Makriyannis, A; Avraham, S; Avraham, HK				Jiang, Shuxian; Fu, Yigong; Williams, John; Wood, JodiAnne; Pandarinathan, Lakshmipathi; Avraham, Shiri; Makriyannis, Alexandros; Avraham, Shalom; Avraham, Hava Karsenty			Expression and Function of Cannabinoid Receptors CB1 and CB2 and Their Cognate Cannabinoid Ligands in Murine Embryonic Stem Cells	PLOS ONE			English	Article								Background. Characterization of intrinsic and extrinsic factors regulating the self-renewal/division and differentiation of stem cells is crucial in determining embryonic stem (ES) cell fate. ES cells differentiate into multiple hematopoietic lineages during embryoid body (EB) formation in vitro, which provides an experimental platform to define the molecular mechanisms controlling germ layer fate determination and tissue formation. Methods and Findings. The cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) are members of the G-protein coupled receptor (GPCR) family, that are activated by endogenous ligands, the endocannabinoids. CB1 receptor expression is abundant in brain while CB2 receptors are mostly expressed in hematopoietic cells. However, the expression and the precise roles of CB1 and CB2 and their cognate ligands in ES cells are not known. We observed significant induction of CB1 and CB2 cannabinoid receptors during the hematopoietic differentiation of murine ES (mES)-derived embryoid bodies. Furthermore, mES cells as well as ES-derived embryoid bodies at days 7 and 14, expressed endocannabinoids, the ligands for both CB1 and CB2. The CB1 and CB2 antagonists (AM251 and AM630, respectively) induced mES cell death, strongly suggesting that endocannabinoids are involved in the survival of mES cells. Treatment of mES cells with the exogenous cannabinoid ligand Delta(9)-THC resulted in the increased hematopoietic differentiation of mES cells, while addition of AM251 or AM630 blocked embryoid body formation derived from the mES cells. In addition, cannabinoid agonists induced the chemotaxis of ES-derived embryoid bodies, which was specifically inhibited by the CB1 and CB2 antagonists. Conclusions. This work has not been addressed previously and yields new information on the function of cannabinoid receptors, CB1 and CB2, as components of a novel pathway regulating murine ES cell differentiation. This study provides insights into cannabinoid system involvement in ES cell survival and hematopoietic differentiation.	[Jiang, Shuxian; Fu, Yigong; Avraham, Shiri; Avraham, Shalom; Avraham, Hava Karsenty] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Expt Med, Boston, MA 02215 USA; [Williams, John; Wood, JodiAnne; Pandarinathan, Lakshmipathi; Makriyannis, Alexandros] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Northeastern University	Avraham, HK (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Expt Med, Boston, MA 02215 USA.	havraham@bidmc.harvard.edu	Makriyannis, Alexandros/GRF-1518-2022	Makriyannis, Alexandros/0000-0003-3272-3687; Avraham, Hava/0000-0002-7545-3640	National Institutes of Health [CA 096805, K18 PAR-02-069];  [PO1-DA 09158];  [R38-DA 03801]; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA009158, R01DA003801, R37DA003801] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Funding: This work was supported by the National Institutes of Health (Grant CA 096805, H.A. a Career Enhancement Award K18 PAR-02-069, H.A.), PO1-DA 09158 (AM) and R38-DA 03801 (AM).	ABADJI V, 1994, J MED CHEM, V37, P1889, DOI 10.1021/jm00038a020; ABEL EL, 1980, MARIJUANA 1 12000 YE, P289; Adams GB, 2003, BLOOD, V101, P45, DOI 10.1182/blood-2002-02-0486; Alger BE, 2004, P NATL ACAD SCI USA, V101, P8512, DOI 10.1073/pnas.0402935101; Bautch VL, 1996, DEV DYNAM, V205, P1; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; Bouaboula M, 1999, MOL PHARMACOL, V55, P473; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Chin CN, 1999, J PHARMACOL EXP THER, V291, P837; Choi K, 1998, DEVELOPMENT, V125, P725; DAAKA Y, 1995, ADV EXP MED BIOL, V373, P91; Downing GJ, 2004, STEM CELLS, V22, P1168, DOI 10.1634/stemcells.2004-0101; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hart C, 2004, STEM CELLS, V22, P580, DOI 10.1634/stemcells.22-4-580; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Hillard CJ, 1999, J PHARMACOL EXP THER, V289, P1427; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Jorda MA, 2002, BLOOD, V99, P2786; Juarez J, 2004, HISTOL HISTOPATHOL, V19, P299, DOI 10.14670/HH-19.299; Kimura T, 2004, BLOOD, V103, P4478, DOI 10.1182/blood-2003-03-0875; Kollet O, 2002, BLOOD, V100, P2778, DOI 10.1182/blood-2002-02-0564; Mahmud N, 2004, BIOL BLOOD MARROW TR, V10, P681, DOI 10.1016/j.bbmt.2004.07.002; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matsuoka S, 2001, BLOOD, V98, P6, DOI 10.1182/blood.V98.1.6; Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5; Molina-Holgado F, 2007, EUR J NEUROSCI, V25, P629, DOI 10.1111/j.1460-9568.2007.05322.x; Nilsson SK, 2004, CURR OPIN HEMATOL, V11, P102, DOI 10.1097/01.moh.0000133651.06863.9c; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Plett PA, 2002, EXP HEMATOL, V30, P1061, DOI 10.1016/S0301-472X(02)00880-9; Quesenberry PJ, 2005, EXP HEMATOL, V33, P9, DOI 10.1016/j.exphem.2004.10.012; Rao M, 2004, DEV BIOL, V275, P269, DOI 10.1016/j.ydbio.2004.08.013; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; Shen W, 2001, EXP HEMATOL, V29, P1439, DOI 10.1016/S0301-472X(01)00741-X; THORSTEN G, 2003, PHARM RES, V47, P269; Viswanathan S, 2002, STEM CELLS, V20, P119, DOI 10.1634/stemcells.20-2-119; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Voermans C, 2001, J HEMATOTH STEM CELL, V10, P725, DOI 10.1089/152581601317210827; WILLIAMS J, 2007, ANAL CHEM IN PRESS; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yanagida E, 2004, CELL CALCIUM, V36, P135, DOI 10.1016/j.ceca.2004.01.022	50	59	59	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e641	10.1371/journal.pone.0000641	http://dx.doi.org/10.1371/journal.pone.0000641			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653268	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452200010
J	Meurens, F; Berri, M; Siggers, RH; Willing, BP; Salmon, H; Van Kessel, AG; Gerdts, V				Meurens, Francois; Berri, Mustapha; Siggers, Richard H.; Willing, Benjamin P.; Salmon, Henri; Van Kessel, Andrew G.; Gerdts, Volker			Commensal Bacteria and Expression of Two Major Intestinal Chemokines, TECK/CCL25 and MEC/CCL28, and Their Receptors	PLOS ONE			English	Article							REGULATORY T-CELLS; EPITHELIAL-CELLS; KAPPA-B; LYMPHOCYTE TRAFFICKING; CCR10 EXPRESSION; FUNCTIONAL-ROLE; CUTTING EDGE; CCL28; RECRUITMENT; TECK	Background. CCL25/TECK and CCL28/MEC are CC chemokines primarily expressed in thymic dendritic cells and mucosal epithelial cells. Their receptors, CCR9 and CCR10, are mainly expressed on T and B lymphocytes. In human, mouse, pig and sheep CCL25 and CCL28 play an important role in the segregation and the compartmentalization of the mucosal immune system. As evidenced by early comparisons of germ-free and conventional animals, the intestinal bacterial microflora has a marked effect on host intestinal immune functions. However, little is known about the impact of bacterial colonization on constitutive and induced chemokine expressions as well as on the generation of anti-inflammatory mechanisms. Methodology/Principal Findings. Therefore, we decided to focus by qPCR on the mRNA expression of two main gut chemokines, CCL25 and CCL28, their receptors CCR9 and CCR10, the Tregs marker Foxp3 and anti-inflammatory cytokines TGF-beta and IL-10 following colonization with different bacterial species within the small intestine. To accomplish this we used an original germ-free neonatal pig model and monoassociated pigs with a representative Gram-negative (Escherichia coli) or Gram-positive (Lactobacillus fermentum) commensal bacteria commonly isolated from the neonatal pig intestine. Our results show a consistent and marked effect of microbial colonization on the mRNA expression of intestinal chemokines, chemokine receptors, Foxp3 and TGF-beta. Moreover, as evidenced by in vitro experiments using two different cell lines, the pattern of regulation of CCL25 and CCL28 expression in the gut appears complex and suggests an additional role for in vivo factors. Conclusions/Significance. Taken together, the results highlight the key role of bacterial microflora in the development of a functional intestinal immune system in an elegant and relevant model for human immune system development.	[Meurens, Francois; Berri, Mustapha; Salmon, Henri] INRA, UR 1282, Nouzilly, France; [Siggers, Richard H.; Willing, Benjamin P.; Van Kessel, Andrew G.] Univ Saskatchewan, Dept Anim & Poultry Sci, Saskatoon, SK S7N 0W0, Canada; [Gerdts, Volker] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 0W0, Canada	INRAE; University of Saskatchewan; University of Saskatchewan	Meurens, F (corresponding author), INRA, UR 1282, Nouzilly, France.	meurens@tours.inra.fr	salmon, henri/B-2605-2010; Meurens, Francois JMA/J-3829-2019; Willing, Benjamin/AAA-9650-2019	Meurens, Francois JMA/0000-0002-0353-4871; Gerdts, Volker/0000-0001-8229-1611	Natural Science and Engineering Research Council of Canada (NSERC); Saskatchewan Health Research Foundation (SHRF); Saskatchewan Agriculture Development Fund Strategic Research Program	Natural Science and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Saskatchewan Health Research Foundation (SHRF); Saskatchewan Agriculture Development Fund Strategic Research Program	This research was supported by the Natural Science and Engineering Research Council of Canada (NSERC), the Saskatchewan Health Research Foundation (SHRF), and the Saskatchewan Agriculture Development Fund Strategic Research Program.	Banham AH, 2006, EUR J IMMUNOL, V36, P2832, DOI 10.1002/eji.200636459; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Bonini JA, 1997, DNA CELL BIOL, V16, P1023, DOI 10.1089/dna.1997.16.1023; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Corthesy B, 2007, J NUTR, V137, p781S, DOI 10.1093/jn/137.3.781S; Eksteen B, 2006, J IMMUNOL, V177, P593, DOI 10.4049/jimmunol.177.1.593; English K, 2006, IMMUNOL LETT, V103, P92, DOI 10.1016/j.imlet.2005.09.011; Ericsson A, 2004, EUR J IMMUNOL, V34, P2720, DOI 10.1002/eji.200425125; Feng NG, 2006, J IMMUNOL, V176, P5749, DOI 10.4049/jimmunol.176.10.5749; FURUSE M, 1994, COMP BIOCHEM PHYS A, V109, P547; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; Hosoe N, 2004, AM J PHYSIOL-GASTR L, V286, pG458, DOI 10.1152/ajpgi.00167.2003; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; Jaimes MC, 2004, J VIROL, V78, P10967, DOI 10.1128/JVI.78.20.10967-10976.2004; KAEFFER B, 1993, EUR J CELL BIOL, V62, P152; Kim CH, 1999, J LEUKOCYTE BIOL, V65, P6, DOI 10.1002/jlb.65.1.6; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Kunkel EJ, 2003, MICROCIRCULATION, V10, P313, DOI 10.1038/sj.mn.7800196; Kunkel EJ, 2003, J CLIN INVEST, V111, P1001, DOI 10.1172/JCI200317244; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Lammers KM, 2005, INFLAMM BOWEL DIS, V11, P447, DOI 10.1097/01.mpa.0000160302.40931.7b; Lazarus NH, 2003, J IMMUNOL, V170, P3799, DOI 10.4049/jimmunol.170.7.3799; Liu CL, 2005, BLOOD, V105, P31, DOI 10.1182/blood-2004-04-1369; Liu CL, 2006, BLOOD, V108, P2531, DOI 10.1182/blood-2006-05-024190; Meurens F, 2007, IMMUNOLOGY, V120, P544, DOI 10.1111/j.1365-2567.2006.02532.x; Meurens F, 2006, VET IMMUNOL IMMUNOP, V113, P313, DOI 10.1016/j.vetimm.2006.05.014; Norment AM, 2000, J IMMUNOL, V164, P639, DOI 10.4049/jimmunol.164.2.639; O'Gorman MT, 2005, CELL IMMUNOL, V238, P87, DOI 10.1016/j.cellimm.2006.02.003; O'Hara AM, 2006, IMMUNOLOGY, V118, P202, DOI 10.1111/j.1365-2567.2006.02358.x; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Pabst O, 2004, J EXP MED, V199, P411, DOI 10.1084/jem.20030996; Pan JL, 2000, J IMMUNOL, V165, P2943, DOI 10.4049/jimmunol.165.6.2943; Pescovitz MD, 1998, HANDBOOK OF INVERTEBRATE IMMUNOLOGY, P373; Petrof EO, 2004, GASTROENTEROLOGY, V127, P1474, DOI 10.1053/j.gastro.2004.09.001; Riedel CU, 2006, WORLD J GASTROENTERO, V12, P3729, DOI 10.3748/wjg.v12.i23.3729; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Seo SH, 1997, J VIROL, V71, P5173, DOI 10.1128/JVI.71.7.5173-5177.1997; Shirkey TW, 2006, EXP BIOL MED, V231, P1333, DOI 10.1177/153537020623100807; Stein JV, 2005, IMMUNOLOGY, V116, P1, DOI 10.1111/j.1365-2567.2005.02183.x; Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451; Tumbleson ME, 1996, ADVANCES IN SWINE IN BIOMEDICAL RESEARCH, VOLS 1 AND 2, P1; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Waidmann M, 2002, GUT, V50, P170, DOI 10.1136/gut.50.2.170; Wang W, 2000, J BIOL CHEM, V275, P22313, DOI 10.1074/jbc.M001461200; WOSTMANN BS, 1996, GERMFREE GNOTOBIOTIC, P195; Wurbel MA, 2000, EUR J IMMUNOL, V30, P262, DOI 10.1002/1521-4141(200001)30:1<262::AID-IMMU262>3.0.CO;2-0; Zaballos A, 1999, J IMMUNOL, V162, P5671; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241; Zhang LY, 2005, J NUTR, V135, P1752, DOI 10.1093/jn/135.7.1752	51	57	60	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2007	2	7							e677	10.1371/journal.pone.0000677	http://dx.doi.org/10.1371/journal.pone.0000677			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GJ	17653288	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452200030
J	Diaz-Uriarte, R; Rueda, OM				Diaz-Uriarte, Ramon; Rueda, Oscar M.			ADaCGH: A Parallelized Web-Based Application and R Package for the Analysis of aCGH Data	PLOS ONE			English	Article								Background. Copy number alterations (CNAs) in genomic DNA have been associated with complex human diseases, including cancer. One of the most common techniques to detect CNAs is array-based comparative genomic hybridization (aCGH). The availability of aCGH platforms and the need for identification of CNAs has resulted in a wealth of methodological studies. Methodology/Principal Findings. ADaCGH is an R package and a web-based application for the analysis of aCGH data. It implements eight methods for detection of CNAs, gains and losses of genomic DNA, including all of the best performing ones from two recent reviews (CBS, GLAD, CGHseg, HMM). For improved speed, we use parallel computing (via MPI). Additional information (GO terms, PubMed citations, KEGG and Reactome pathways) is available for individual genes, and for sets of genes with altered copy numbers. Conclusions/Significance. ADaCGH represents a qualitative increase in the standards of these types of applications: a) all of the best performing algorithms are included, not just one or two; b) we do not limit ourselves to providing a thin layer of CGI on top of existing BioConductor packages, but instead carefully use parallelization, examining different schemes, and are able to achieve significant decreases in user waiting time (factors up to 45x); c) we have added functionality not currently available in some methods, to adapt to recent recommendations (e. g., merging of segmentation results in wavelet-based and CGHseg algorithms); d) we incorporate redundancy, fault-tolerance and checkpointing, which are unique among web-based, parallelized applications; e) all of the code is available under open source licenses, allowing to build upon, copy, and adapt our code for other software projects.	[Diaz-Uriarte, Ramon; Rueda, Oscar M.] Spanish Natl Canc Ctr, Struct Biol & Biocomp Programme, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Diaz-Uriarte, R (corresponding author), Spanish Natl Canc Ctr, Struct Biol & Biocomp Programme, Madrid, Spain.	rdiaz02@gmail.com	Rueda, Oscar/ABF-5479-2020; Diaz-Uriarte, Ramon/M-5517-2013	Rueda, Oscar/0000-0003-0008-4884; Diaz-Uriarte, Ramon/0000-0002-6637-9039	Fundacion de Investigacion Medica Mutua Madrilena; Spanish Ministry of Education and Science (MEC) [TIC2003-09331-C02-02]	Fundacion de Investigacion Medica Mutua Madrilena; Spanish Ministry of Education and Science (MEC)(Spanish Government)	Funding provided by Fundacion de Investigacion Medica Mutua Madrilena and Project TIC2003-09331-C02-02 of the Spanish Ministry of Education and Science (MEC). The funders had no role in design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. Funding used for salaries and equipment.	Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Alibes A, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-9; ANDERSON B, 2006, BMC GENOMICS, V7; BAXTER SM, 2006, PLOS COMPUTATIONAL B, V2; CHARI R, 2006, CANC INFORM, V2; CHEN W, 2005, BMC BIOINFORMATICS, V6; CONDE L, 2007, NUCL ACIDS IN PRESS; Diaz-Uriarte R, 2005, DATA ANALYSIS AND VISUALIZATION IN GENOMICS AND PROTEOMICS, P193, DOI 10.1002/0470094419.ch12; Dongarra J., 2007, CT WATCH QUAT, V3, P1; Dudoit S, 2003, BIOTECHNIQUES, P45; Fogel Karl, 2005, PRODUCING OPEN SOURC; Forozan F, 2000, CANCER RES, V60, P4519; Foster I, 1995, DESIGNING BUILDING P; Fridlyand J, 2004, J MULTIVARIATE ANAL, V90, P132, DOI 10.1016/j.jmva.2004.02.008; Graham P., 2004, HACKERS PAINTERS; Heiskanen MA, 2000, CANCER RES, V60, P799; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Hsu L, 2005, BIOSTATISTICS, V6, P211, DOI 10.1093/biostatistics/kxi004; HUANG J, 2006, BMC BIOINFORMATICS, V7; Huang Jing, 2004, Human Genomics, V1, P287; Hughes C., 2003, PARALLEL DISTRIBUTED; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; KONTOGHIORGHES EJ, 2006, HDB PARALLEL COMPUTI; Lai WR, 2005, BIOINFORMATICS, V21, P3763, DOI 10.1093/bioinformatics/bti611; Lai YL, 2005, COMPUT BIOL CHEM, V29, P47, DOI 10.1016/j.compbiolchem.2004.12.004; Lingjaerde OC, 2005, BIOINFORMATICS, V21, P821, DOI 10.1093/bioinformatics/bti113; LIVA S, 2006, NUCL ACIDS RES, V34; Lockwood WW, 2006, EUR J HUM GENET, V14, P139, DOI 10.1038/sj.ejhg.5201531; Marioni JC, 2006, BIOINFORMATICS, V22, P1144, DOI 10.1093/bioinformatics/btl089; Menten B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-124; Misra A, 2005, CLIN CANCER RES, V11, P2907, DOI 10.1158/1078-0432.CCR-04-0708; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Pacheco Peter., 1997, PARALLEL PROGRAMMING; Picard F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-27; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Price TS, 2005, NUCLEIC ACIDS RES, V33, P3455, DOI 10.1093/nar/gki643; RUEDA OM, 2007, FLEXIBLE AC IN PRESS; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sutter H, 2005, DR DOBBS J, V30, P16; Turek D., 2007, CTWATCH Q, V3, P31; Urban AE, 2006, P NATL ACAD SCI USA, V103, P4534, DOI 10.1073/pnas.0511340103; Van-Roy P., 2004, CONCEPTS TECHNIQUES; Waldo J, 1997, LECT NOTES COMPUT SC, V1222, P49; Willenbrock H, 2005, BIOINFORMATICS, V21, P4084, DOI 10.1093/bioinformatics/bti677; Ylstra B, 2006, NUCLEIC ACIDS RES, V34, P445, DOI 10.1093/nar/gkj456; Yu TW, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-145; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	49	21	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e737	10.1371/journal.pone.0000737	http://dx.doi.org/10.1371/journal.pone.0000737			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710137	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200014
J	Freitas, R; Zhang, GJ; Cohn, MJ				Freitas, Renata; Zhang, GuangJun; Cohn, Martin J.			Biphasic Hoxd Gene Expression in Shark Paired Fins Reveals an Ancient Origin of the Distal Limb Domain	PLOS ONE			English	Article							APICAL ECTODERMAL RIDGE; CONTROL REGION DEFINES; PECTORAL FIN; HOMEOBOX GENES; POLARIZING ACTIVITY; DEVONIAN TETRAPOD; PATTERN-FORMATION; VERTEBRATE; EVOLUTION; ZEBRAFISH	The evolutionary transition of fins to limbs involved development of a new suite of distal skeletal structures, the digits. During tetrapod limb development, genes at the 59 end of the HoxD cluster are expressed in two spatiotemporally distinct phases. In the first phase, Hoxd9-13 are activated sequentially and form nested domains along the anteroposterior axis of the limb. This initial phase patterns the limb from its proximal limit to the middle of the forearm. Later in development, a second wave of transcription results in 59 HoxD gene expression along the distal end of the limb bud, which regulates formation of digits. Studies of zebrafish fins showed that the second phase of Hox expression does not occur, leading to the idea that the origin of digits was driven by addition of the distal Hox expression domain in the earliest tetrapods. Here we test this hypothesis by investigating Hoxd gene expression during paired fin development in the shark Scyliorhinus canicula, a member of the most basal lineage of jawed vertebrates. We report that at early stages, 5' Hoxd genes are expressed in anteroposteriorly nested patterns, consistent with the initial wave of Hoxd transcription in teleost and tetrapod paired appendages. Unexpectedly, a second phase of expression occurs at later stages of shark fin development, in which Hoxd12 and Hoxd13 are re-expressed along the distal margin of the fin buds. This second phase is similar to that observed in tetrapod limbs. The results indicate that a second, distal phase of Hoxd gene expression is not uniquely associated with tetrapod digit development, but is more likely a plesiomorphic condition present the common ancestor of chondrichthyans and osteichthyans. We propose that a temporal extension, rather than de novo activation, of Hoxd expression in the distal part of the fin may have led to the evolution of digits.	[Freitas, Renata; Zhang, GuangJun; Cohn, Martin J.] Univ Florida, Dept Zool, Gainesville, FL 32611 USA; [Cohn, Martin J.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cohn, MJ (corresponding author), Univ Florida, Dept Zool, Canc Genet Res Complex, Gainesville, FL 32611 USA.	cohn@zoo.ufl.edu	Freitas, Renata/I-5917-2013; Zhang, GuangJun/K-2056-2012	Freitas, Renata/0000-0002-0123-7232; Zhang, GuangJun/0000-0002-0839-5161	FCT; University of Oporto; University of Florida; National Institutes of Health (NIH) [HD054554]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD054554] Funding Source: NIH RePORTER	FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); University of Oporto; University of Florida(University of Florida); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	RF received support from FCT, Praxis XXI through the GABBA program of the University of Oporto and from the University of Florida. GZ received support from graduate fellowship from the University of Florida. MJC received support from the University of Florida and from National Institutes of Health (NIH) grant HD054554.	ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; AKIMENKO MA, 1995, DEV BIOL, V170, P243, DOI 10.1006/dbio.1995.1211; AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; BALFOUR M, 1881, P ZOOL SOC LOND, V43, P656; BALLARD WW, 1993, J EXP ZOOL, V267, P318, DOI 10.1002/jez.1402670309; Blom H, 2007, GEODIVERSITAS, V29, P119; Chimal-Monroy J, 2003, DEV BIOL, V257, P292, DOI 10.1016/S0012-1606(03)00066-6; COATES M, 1993, NATURE, V364, P195, DOI 10.1038/364195b0; COATES MI, 1994, DEVELOPMENT, P169; Coates MI, 2003, THEOR BIOSCI, V122, P266; Coates MI, 1996, T ROY SOC EDIN-EARTH, V87, P363, DOI 10.1017/S0263593300006787; Coates MI, 2002, EVOL DEV, V4, P390, DOI 10.1046/j.1525-142X.2002.02026.x; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Dahn RD, 2007, NATURE, V445, P311, DOI 10.1038/nature05436; Davis MC, 2007, NATURE, V447, P473, DOI 10.1038/nature05838; Davis MC, 2004, J MORPHOL, V262, P608, DOI 10.1002/jmor.10264; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Freitas R, 2004, DEV GENES EVOL, V214, P466, DOI 10.1007/s00427-004-0426-0; Freitas R, 2006, NATURE, V442, P1033, DOI 10.1038/nature04984; GONZALEZ F, 2007, DEV BIOL; Grandel H, 2003, THEOR BIOSCI, V122, P288, DOI 10.1007/s12064-003-0058-3; Grandel H, 1998, MECH DEVELOP, V79, P99, DOI 10.1016/S0925-4773(98)00176-2; Grandel H, 2000, DEVELOPMENT, V127, P4169; Haraguchi R, 2000, DEVELOPMENT, V127, P2471; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; KESSEL M, 1993, NATURE, V364, P197, DOI 10.1038/364197a0; Kim CB, 2000, P NATL ACAD SCI USA, V97, P1655, DOI 10.1073/pnas.030539697; Kmita M, 2005, NATURE, V435, P1113, DOI 10.1038/nature03648; Kobayashi D, 2006, DEV GROWTH DIFFER, V48, P283, DOI 10.1111/j.1440-169x.2006.00870.x; Kondo T, 1997, NATURE, V390, P29, DOI 10.1038/36234; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Mabee PM, 2004, J MORPHOL, V261, P334, DOI 10.1002/jmor.10253; Mabee PM, 2000, AM ZOOL, V40, P789, DOI 10.1668/0003-1569(2000)040[0789:DDAPSE]2.0.CO;2; Metscher BD, 1999, DEV BIOL, V210, P1, DOI 10.1006/dbio.1999.9230; Miller RF, 2003, NATURE, V425, P501, DOI 10.1038/nature02001; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NIETO MA, 1996, METHODS AVIAN EMBRYO; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; Perriton CL, 2002, DEV BIOL, V247, P26, DOI 10.1006/dbio.2002.0668; Prohaska SJ, 2004, J MOL EVOL, V58, P212, DOI 10.1007/s00239-003-2545-z; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; Shu DG, 1999, NATURE, V402, P42, DOI 10.1038/46965; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Shubin NH, 2006, NATURE, V440, P764, DOI 10.1038/nature04637; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; Spitz F, 2003, DEV BIOL, V259, P456; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Spitz F, 2001, GENE DEV, V15, P2209, DOI 10.1101/gad.205701; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; Tanaka M, 2002, NATURE, V416, P527, DOI 10.1038/416527a; Tarchini B, 2006, DEV CELL, V10, P93, DOI 10.1016/j.devcel.2005.11.014; THOROGOOD P, 1991, NATO ADV SCI I A-LIF, V205, P347; THOROGOOD P, 1993, NATURE, V364, P196, DOI 10.1038/364196a0; THOROGOOD PV, 1975, J EMBRYOL EXP MORPH, V33, P581; Torok MA, 1998, DEV BIOL, V200, P225, DOI 10.1006/dbio.1998.8956; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; vanderHoeven F, 1996, MECH DEVELOP, V54, P9, DOI 10.1016/0925-4773(95)00455-6; Venkatesh B, 2007, PLOS BIOL, V5, P932, DOI 10.1371/journal.pbio.0050101; VOGEL A, 1995, DEV BIOL, V171, P507, DOI 10.1006/dbio.1995.1300; WOOD A, 1982, ANAT REC, V204, P349, DOI 10.1002/ar.1092040408; Yonei-Tamura S, 1999, DEV BIOL, V211, P133, DOI 10.1006/dbio.1999.9290; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695; Zakany J, 2004, SCIENCE, V304, P1669, DOI 10.1126/science.1096049; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262; ZAKANY J, 2007, DEV BIOL; Zhang XG, 2004, J EVOLUTION BIOL, V17, P1162, DOI 10.1111/j.1420-9101.2004.00741.x; Zhu M, 2002, NATURE, V420, P760, DOI 10.1038/420760a	78	104	107	3	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e754	10.1371/journal.pone.0000754	http://dx.doi.org/10.1371/journal.pone.0000754			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710153	Green Published, gold, Green Submitted			2022-12-25	WOS:000207455200030
